PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Gohla, A; Harhammer, R; Schultz, G				Gohla, A; Harhammer, R; Schultz, G			The G-protein G(13) but not G(12) mediates signaling from lysophosphatidic acid receptor via epidermal growth factor receptor to Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS FIBER FORMATION; BETA-GAMMA-SUBUNITS; TYROSINE PHOSPHORYLATION; FOCAL ADHESIONS; GENE-PRODUCT; RAT-BRAIN; KINASE; ACTIVATION; IDENTIFICATION; P21(RAS)	Lysophosphatidic acid (LPA) utilizes a G-protein-coupled receptor to activate the small GTP-binding protein Rho and to induce rapid remodeling of the actin cytoskeleton, We studied the signal transduction from LPA receptors to Rho activation, Analysis of the G-protein-coupling pattern of LPA receptors by labeling activated G-proteins with [alpha-P-32]GTP azidoanilide revealed interaction with proteins of the G(q), G(i), and G(12) subfamilies, We could show that in COS 7 cells, expression of GTPase-deficient mutants of G alpha(12) and G alpha(13) triggered Rho activation as measured by increased Rho-GTP levels. In Swiss 3T3 cells, incubation with LPA or microinjection of constitutively active mutants of G alpha(12) and G alpha(13) induced formation of actin stress fibers and assembly of focal adhesions in a Rho-dependent manner, Interestingly, the LPA dependent cytoskeletal reorganization was suppressed by microinjected antibodies directed against G alpha(13), whereas G alpha(12)-specific antibodies showed no inhibition, The tyrosine kinase inhibitor tyrphostin A 25 and the epidermal growth factor (EGF) receptor-specific tyrphostin AG 1478 completely blocked actin stress fiber formation caused by LPA or activated G alpha(13) but not the effects of activated G alpha(12). Also, expression of the dominant negative EGF receptor mutant EGFR-CD533 markedly prevented the LPA- and G alpha(13)-induced actin polymerization, Coexpression of EGFR CD533 and activated G alpha(13) in COS-7 cells resulted in decreased Rho-GTP levels compared with expression of activated G alpha(13) alone, These data indicate that in Swiss 3T3 cells, G(13) but not G(12) is involved in the LPA-induced activation of Rho, Moreover, our results suggest an involvement of the EGF receptor in this pathway.	Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin	Schultz, G (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 67-73, D-14195 Berlin, Germany.			Gohla, Antje/0000-0002-7442-1487				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BARRY ST, 1994, J CELL SCI, V107, P2033; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Harhammer R, 1996, FEBS LETT, V399, P211, DOI 10.1016/S0014-5793(96)01327-0; HARHAMMER R, 1994, BIOCHEM J, V303, P135, DOI 10.1042/bj3030135; Harhammer R, 1996, BIOCHEM J, V319, P165, DOI 10.1042/bj3190165; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KALKBRENNER F, 1995, EMBO J, V14, P4728, DOI 10.1002/j.1460-2075.1995.tb00154.x; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; THOMSON FJ, 1994, MOL PHARMACOL, V45, P718; UEDA N, 1994, J BIOL CHEM, V269, P4388; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WOLBRING G, 1994, J BIOL CHEM, V269, P22470	35	232	240	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4653	4659		10.1074/jbc.273.8.4653	http://dx.doi.org/10.1074/jbc.273.8.4653			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468525	hybrid			2022-12-25	WOS:000072115000053
J	Kretz-Remy, C; Bates, EEM; Arrigo, AP				Kretz-Remy, C; Bates, EEM; Arrigo, AP			Amino acid analogs activate NF-kappa B through redox-dependent I kappa B-alpha degradation by the proteasome without apparent I kappa B-alpha phosphorylation - Consequence on HIV-1 long terminal repeat activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; UNFOLDED-PROTEIN-RESPONSE; GLUCOSE-REGULATED PROTEINS; HEAT-SHOCK INDUCTION; TRANSCRIPTION FACTOR; MULTICATALYTIC PROTEINASE; TYROSINE PHOSPHORYLATION; PROTEOLYTIC DEGRADATION; GLUTATHIONE-PEROXIDASE	We report here that amino acid analogs, which activate hsp70 promoter, are powerful transcriptional activators of human immunodeficiency virus 1 (HIV-1) long terminal repeat (LTR), an activation which was impaired when the two kappa B sites present in the LTR were mutated or deleted. Amino acid analogs also stimulated the transcription of a kappa B-controlled reporter gene. Upon treatment with amino acid analogs, the two NF-kappa B subunits (p65 and p50), which are characterized by a relatively long half-life, redistributed into the nucleus where they bound to kappa B elements. This phenomenon, which began to be detectable after 1 h of treatment, was concomitant with the degradation of the short lived inhibitory subunit I kappa B-alpha by the proteasome. However, contrasting with other NF-kappa B inducers that trigger I kappa B-alpha degradation through a phosphorylation step, amino acid analogs did not change I kappa B-alpha isoform composition. Antioxidant conditions inhibited amino acid analog stimulatory action toward NF-kappa B. This suggests that aberrant protein conformation probably generates a prooxidant state that is necessary for I kappa B-alpha proteolysis by the proteasome. Moreover, this activation of NF-kappa B appeared different from that mediated by endoplasmic reticulum overload as it was not inhibited by calcium chelation.	Univ Lyon 1, Ctr Genet Mol & Cellulaire, Lab Stress Cellulaire, CNRS,UMR 5534, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Arrigo, AP (corresponding author), Univ Lyon 1, Ctr Genet Mol & Cellulaire, Lab Stress Cellulaire, CNRS,UMR 5534, 43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.		Kretz-Remy, Carole/J-7850-2019	Kretz-Remy, Carole/0000-0002-9553-5598				ANATHAN J, 1986, SCIENCE, V232, P522; ARRIGO AP, 1993, BIOCHEM BIOPH RES CO, V194, P1387, DOI 10.1006/bbrc.1993.1978; BAUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63; BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; BAUERLE PA, 1988, SCIENCE, V242, P540; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN FL, 1993, MOL CELL BIOL, V13, P5245, DOI 10.1128/MCB.13.9.5245; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Castano JG, 1996, BIOCHEMISTRY-US, V35, P3782, DOI 10.1021/bi952540s; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GARCIA JA, 1994, PROG NUCLEIC ACID RE, V49, P157; GEELEN JLMC, 1988, J GEN VIROL, V69, P2913, DOI 10.1099/0022-1317-69-11-2913; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HIROMI Y, 1986, CELL, V44, P293, DOI 10.1016/0092-8674(86)90763-4; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; KRETZREMY C, 1994, FEBS LETT, V353, P337; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LIM K, 1989, BIOTECHNIQUES, V7, P576; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LYLE R, 1994, GENE, V138, P265, DOI 10.1016/0378-1119(94)90823-0; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIRAULT ME, 1992, MOLECULAR BASIS OF OXIDATIVE DAMAGE BY LEUKOCYTES, P303; MIRAULT ME, 1991, J BIOL CHEM, V266, P20752; MORIMOTO R I, 1990, P1; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Pahl HL, 1996, FEBS LETT, V392, P129, DOI 10.1016/0014-5793(96)00800-9; Pahl HL, 1997, TRENDS CELL BIOL, V7, P50, DOI 10.1016/S0962-8924(96)10050-7; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RE MC, 1989, J VIROL METHODS, V26, P313, DOI 10.1016/0166-0934(89)90113-4; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STANLEY SK, 1990, J IMMUNOL, V145, P1120; STEFFY K, 1991, MICROBIOL REV, V55, P193, DOI 10.1128/MMBR.55.2.193-205.1991; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMAS GP, 1984, MOL CELL BIOL, V4, P1063, DOI 10.1128/MCB.4.6.1063; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; ZABEL U, 1991, J BIOL CHEM, V266, P252	86	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3180	3191		10.1074/jbc.273.6.3180	http://dx.doi.org/10.1074/jbc.273.6.3180			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452429	hybrid			2022-12-25	WOS:000071822300014
J	Kireeva, ML; Lam, SCT; Lau, LF				Kireeva, ML; Lam, SCT; Lau, LF			Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alpha(v)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PHAGE DISPLAY LIBRARY; GROWTH-FACTOR-I; EXTRACELLULAR-MATRIX; ALPHA-V-BETA-3 INTEGRIN; SIGNAL-TRANSDUCTION; EXPRESSION; BINDING; LIGAND; CYCLE	Cyr61 is a member of a family of growth factor-inducible immediate-early gene products thought to act cooperatively with the activities of growth factors, Upon synthesis, Cyr61 is secreted and is predominantly incorporated into the extracellular matrix, Recently, we demonstrated that Cyr61 promotes cell adhesion and migration and augments growth factor-induced DNA synthesis (Kireeva, M, L., Mo, F.-E,, Yang, G, P., and Lau, L, F. (1996) Mol, Cell. Biol. 16, 1326-1334), In the present study, we investigated possible candidate receptor(s) on human umbilical vein endothelial cells (HUVECs) mediating adhesion to Cyr61. Under both serum-containing and serum-free conditions, adhesion of HUVECs to Cyr61 was dose-dependent, saturable, and abolished by affinity-purified anti-Cyr61 antibodies, Cell adhesion to Cyr61 was divalent cation-dependent and specifically inhibited by the peptide RGDS and LM609, a monoclonal antibody against integrin alpha(v) beta(3) Furthermore, purified alpha(v) beta(3) bound directly to an affinity matrix of Cyr61-coupled Sepharose 4B, and this interaction was specifically blocked by anti-Cyr61 antibodies, Additionally, in a solid phase binding assay, soluble Cyr61 bound to immobilized gp, in a dose-dependent manner, and half-saturation binding occurred at approximately 5 nM Cyr61, As expected, the interaction of Cyr61 with immobilized alpha(v) beta(3) was blocked by RGDS and LM609. In sum, these results identified Cyr61 as a novel ligand for alpha(v) beta(3) and indicate that the adhesion of HUVECs to Cyr61 is mediated through interaction with this integrin, The possibility that integrin alpha(v) eta(3) functions as a signaling receptor for Cyr61 accounts for most if not all activities that can be ascribed to Cyr61 to date and suggests a mechanism of action discussed herein.	Univ Illinois, Dept Mol Genet MC 669, Coll Med, Chicago, IL 60607 USA; Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kireeva, ML (corresponding author), Univ Illinois, Dept Mol Genet MC 669, Coll Med, 900 S Ashland Ave, Chicago, IL 60607 USA.		Kireeva, Maria/B-4391-2018	Kireeva, Maria/0000-0003-0527-3182; Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [CA46565] Funding Source: Medline; NHLBI NIH HHS [HL41793] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041793, R01HL041793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTFELD NS, 1993, J BIOL CHEM, V268, P17270; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; CUMMINGS RD, 1992, BIOESSAYS, V14, P849, DOI 10.1002/bies.950141210; DALTON SL, 1995, MOL BIOL CELL, V6, P1781, DOI 10.1091/mbc.6.12.1781; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IUPAC-IUB commission on biochemical nomenclature, 1968, J BIOL CHEM, V243, P3557; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; LAM SCT, 1992, J BIOL CHEM, V267, P5649; LATINKIC BV, 1994, THESIS U ILLINOIS CH; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LESSEY BA, 1992, J CLIN INVEST, V90, P188, DOI 10.1172/JCI115835; Marcinkiewicz C, 1997, BLOOD, V90, P1565, DOI 10.1182/blood.V90.4.1565.1565_1565_1575; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEPP NT, 1994, J INVEST DERMATOL, V103, P295, DOI 10.1111/1523-1747.ep12394617; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; WOODS VL, 1994, ARTHRITIS RHEUM, V37, P537, DOI 10.1002/art.1780370414; Yamada T, 1996, FEBS LETT, V387, P11, DOI 10.1016/0014-5793(96)00409-7; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	57	187	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3090	3096		10.1074/jbc.273.5.3090	http://dx.doi.org/10.1074/jbc.273.5.3090			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446626	hybrid			2022-12-25	WOS:000071736600081
J	Chiariello, E; Roz, L; Albarosa, R; Magnani, I; Finocchiaro, G				Chiariello, E; Roz, L; Albarosa, R; Magnani, I; Finocchiaro, G			PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas	ONCOGENE			English	Article						glioblastoma; chromosome 10; tumor suppressor; mutation	GENE; PATHWAYS; TUMORS	A novel tumor suppressor, PTEN/MMAC1, was recently found on chromosome 10q23 and mutations of this gene mere described in about 20% of primary glioblastomas (GBM) and 60% of GBM cell lines. To define further the relevance of PTEN/MMAC1 mutations in GBM we investigated by SSCP analysis its coding sequence in 44 gliomas, including 41 GBM, and in 21 short-term cultures (15 GBM and six malignant astrocytomas). Loss of heterozygosity (LOH) at 10q23 was present in at least one marker in the vicinity of the PTEN/MMAC1 locus in 59% of the informative GBM (primary tumors and cell cultures). SSCP variant bands were found in seven primary GBM (17%) and in one short-term GBM culture and sequence analysis confirmed the presence of somatic mutations in all these cases (five missense, one splicing mutation and two small deletions). These data indicate that PTEN/MMAC1 is inactivated in a subset of GBM and suggest that the high mutation frequency previously found in GBM established cell lines reflects culture condition artifacts rather than the true mutation frequency in vivo. Other suppressors, located on chromosome 10q, may also have a critical role in glioma tumorigenesis.	Ist Nazl Neurol C Besta, Dept Biochem & Genet, Milan, Italy; Univ Milan, Dept Biol & Genet Med Sci, I-20122 Milan, Italy	IRCCS Istituto Neurologico Besta; University of Milan	Finocchiaro, G (corresponding author), Ist Nazl Neurol C Besta, Dept Biochem & Genet, Milan, Italy.		Finocchiaro, Gaetano/AAG-6791-2020; Roz, Luca/AAB-3889-2019	Roz, Luca/0000-0001-5817-7149; Finocchiaro, Gaetano/0000-0003-3583-4040				Albarosa R, 1996, AM J HUM GENET, V58, P1260; BOGLER O, 1995, GLIA, V15, P308, DOI 10.1002/glia.440150311; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; MAGNANI I, 1994, CANCER GENET CYTOGEN, V75, P77, DOI 10.1016/0165-4608(94)90157-0; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Rhei E, 1997, CANCER RES, V57, P3657; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TENAN M, 1995, INT J CANCER, V62, P115, DOI 10.1002/ijc.2910620121; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; VONDEIMLING A, 1995, GLIA, V15, P328, DOI 10.1002/glia.440150312	20	69	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					541	545		10.1038/sj.onc.1201689	http://dx.doi.org/10.1038/sj.onc.1201689			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484844				2022-12-25	WOS:000071739400013
J	Zhao, Y; Hague, S; Manek, S; Zhang, L; Bicknell, R; Rees, MCP				Zhao, Y; Hague, S; Manek, S; Zhang, L; Bicknell, R; Rees, MCP			PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium	ONCOGENE			English	Article						tamoxifen; adenomedullin; differential PCR display; endometrium; angiogenesis	BREAST-CANCER PATIENTS; GROWTH-FACTOR; POSTMENOPAUSAL WOMEN; HYPOTENSIVE PEPTIDE; CELL-PROLIFERATION; PROMOTER-CONTEXT; POTENTIAL ROLE; EXPRESSION; PREVENTION; PHEOCHROMOCYTOMA	Tamoxifen is currently the most widely used drug for the treatment of breast cancer, but there now exists considerable evidence that tamoxifen can also induce endometrial hyperplasia in pre menopausal women. We have used PCR differential display on primary human endometrial isolates in an attempt to identify genes induced by but not estrogen. Eight such tamoxifen differentially expressed bands were cloned and sequenced, one of which was found to be the peptide adrenomedullin. We have shown that adrenomedullin is a novel growth factor for endothelial cells and is angiogenic in vivo in the chick chorioallantoic membrane assay. Immunohistochemical analysis of endometrial sections have shown that while macrophages in the endometrium express adrenomedullin at a low level, endometrial macrophages of women receiving tamoxifen strongly express adrenomedullin (P=0.008). We postulate that endometrial induction of the angiogenic factor adrenomedullin by tamoxifen is part of the mechanism by which tamoxifen results in endometrial hyperplasia.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynecol, Oxford OX3 9DU, England; Univ Oxford, Inst Mol Med, Imperial Canc Res Fund, Mol Angiogenesis Grp, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Dept Histopathol, Oxford OX3 9DU, England	University of Oxford; University of Oxford; University of Oxford	Rees, MCP (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynecol, Oxford OX3 9DU, England.		zhao, yuan/E-2435-2013	Bicknell, Roy/0000-0002-0941-8919	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FA, 1990, CURRENT PROTOCOLS MO; Barakat RR, 1996, CLIN OBSTET GYNECOL, V39, P629, DOI 10.1097/00003081-199609000-00012; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BUTTA A, 1992, CANCER RES, V52, P4261; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; GAL D, 1991, GYNECOL ONCOL, V42, P120, DOI 10.1016/0090-8258(91)90330-8; HARPER MJK, 1967, J REPROD FERTIL, V13, P101; HUYNH H, 1994, CANCER RES, V54, P3115; ICHIKI Y, 1994, FEBS LETT, V338, P6, DOI 10.1016/0014-5793(94)80106-1; Ishihara T, 1997, LIFE SCI, V60, P1763, DOI 10.1016/S0024-3205(97)00136-7; ISHIMITSU T, 1994, BIOCHEM BIOPH RES CO, V203, P631, DOI 10.1006/bbrc.1994.2229; ISMAIL SM, 1994, J CLIN PATHOL, V47, P827, DOI 10.1136/jcp.47.9.827; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jones RK, 1996, FERTIL STERIL, V66, P81, DOI 10.1016/S0015-0282(16)58391-5; JORDAN VC, 1991, ANN NY ACAD SCI, V622, P439; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; LAHTI E, 1993, OBSTET GYNECOL, V81, P660; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Macri CJ, 1996, AM J OBSTET GYNECOL, V175, P906, DOI 10.1016/S0002-9378(96)80023-8; Maniatis T., 1982, MOL CLONING LAB MANU; MARTINEZ A, 1995, ENDOCRINOLOGY, V136, P4099, DOI 10.1210/en.136.9.4099; Miller MJ, 1996, J BIOL CHEM, V271, P23345; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; Nephew KP, 1996, ENDOCRINOLOGY, V137, P219, DOI 10.1210/en.137.1.219; PEEK MJ, 1988, EXP PATHOL-JENA, V34, P35, DOI 10.1016/S0232-1513(88)80020-3; POWLES TJ, 1990, EUR J CANCER, V26, P680, DOI 10.1016/0277-5379(90)90116-B; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645; SAKAKIBARA K, 1992, AM J OBSTET GYNECOL, V166, P206, DOI 10.1016/0002-9378(92)91860-D; SARTOR BM, 1995, REPROD TOXICOL, V9, P225, DOI 10.1016/0890-6238(95)00003-S; SATOH F, 1995, J CLIN ENDOCR METAB, V80, P1750, DOI 10.1210/jc.80.5.1750; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VU N, 1984, P ANN C RES MED ED, V23, P383; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Withers DJ, 1996, FEBS LETT, V378, P83, DOI 10.1016/0014-5793(95)01427-6; ZHANG L, 1995, J CELL SCI, V108, P323	38	113	121	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					409	415		10.1038/sj.onc.1201768	http://dx.doi.org/10.1038/sj.onc.1201768			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467966				2022-12-25	WOS:000071582100013
J	Eiriksdottir, G; Barkardottir, RB; Agnarsson, BA; Johannesdottir, G; Olafsdottir, K; Egilsson, V; Ingvarsson, S				Eiriksdottir, G; Barkardottir, RB; Agnarsson, BA; Johannesdottir, G; Olafsdottir, K; Egilsson, V; Ingvarsson, S			High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers	ONCOGENE			English	Article						breast cancer; chromosome 17p13; TP53, BRCA2 carriers; LOH	P53 GENE-MUTATIONS; SUPPRESSOR GENE; CANCER PATIENTS; OVARIAN-CANCER; CARCINOMAS; LINKAGE; TP53; IMMUNOHISTOCHEMISTRY; PATHOLOGY; PROGNOSIS	Breast tumours from BRCA1 and BRCA2 mutation carriers are genetically instable and display specific patterns of chromosomal aberrations, suggestive of distinct genetic pathways in tumour progression, The frequency of abnormalities affecting chromosome 17p and the TP53 gene was determined in 27 breast tumours from 26 female patients carrying the Icelandic BRCA2 founder mutation (999del5), Loss of heterozygosity (LOH) was detected in 23 of the 27 tumours (85%), The majority of tumours manifesting LOH had lost a large region on 17p, although a more restricted loss, including the TP53 locus was seen in a few tumours. Positive p53 immunostaining was observed in 18 of 26 tumours (69%), However, mutations in the TP53 gene were detected in only three tumours (11%), including a missense (codon 139) and a nonsense mutation (codon 306) in two tumours with moderate p53 expression and a frameshift deletion (codon 182) in a tumour with no detectable p53 expression, Positive p53 immunostaining, mainly weak, was observed in 16 of the 24 tumours (66%) without TP53 mutation, The high frequency of LOH at chromosome 17p13 suggests that one or more genes from this region are involved in the development of BRCA2-induced breast cancer. The frequent finding of weak overexpression of, presumably wild type p53 protein, suggests an alternative mechanism of TP53 involvement specific to these tumours.	Univ Iceland, Dept Pathol, IS-121 Reykjavik, Iceland; Natl Hosp Iceland, IS-121 Reykjavik, Iceland	University of Iceland; Landspitali National University Hospital	Barkardottir, RB (corresponding author), Univ Iceland, Dept Pathol, POB 1465, IS-121 Reykjavik, Iceland.		Ingvarsson, Sigurdur/E-7448-2011	Ingvarsson, Sigurdur/0000-0003-4125-1714				BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; BHARGAVA V, 1994, MODERN PATHOL, V7, P361; CORNELIS RS, 1994, CANCER RES, V54, P4200; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DENG G, 1994, CANCER RES, V54, P499; EASTON DF, 1993, AM J HUM GENET, V52, P678; ELNAGGAR AK, 1995, INT J CANCER, V64, P196, DOI 10.1002/ijc.2910640309; ELSTON CW, 1987, DIAGNOSTIC HISTOPATH, P300; FISHER CJ, 1994, BRIT J CANCER, V69, P26, DOI 10.1038/bjc.1994.4; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gretarsdottir S, 1996, BRIT J CANCER, V74, P555, DOI 10.1038/bjc.1996.400; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JACQUEMIER J, 1994, BRIT J CANCER, V69, P846, DOI 10.1038/bjc.1994.164; Johannesdottir G, 1996, CANCER RES, V56, P3663; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Lakhani SR, 1997, LANCET, V349, P1505; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LYNCH HT, 1990, BREAST CANCER RES TR, V15, P63, DOI 10.1007/BF01810778; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MERLO GR, 1994, CANCER GENET CYTOGEN, V76, P106, DOI 10.1016/0165-4608(94)90458-8; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SAITOH S, 1994, ONCOGENE, V9, P2869; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; Sobol H, 1997, INT J ONCOL, V10, P349; Soddu S, 1996, MOL CELL BIOL, V16, P487; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; Tirkkonen M, 1997, CANCER RES, V57, P1222; UMEKITA Y, 1994, JPN J CANCER RES, V85, P825, DOI 10.1111/j.1349-7006.1994.tb02954.x; VIGNAL A, 1993, METHODS MOL GENETICS, V1, P211; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; YANDELL DW, 1993, DIAGN MOL PATHOL, V2, P1	42	31	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					21	26		10.1038/sj.onc.1201509	http://dx.doi.org/10.1038/sj.onc.1201509			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467939	Green Published			2022-12-25	WOS:000071236800003
J	Miech, C; Dierks, T; Selmer, T; von Figura, K; Schmidt, B				Miech, C; Dierks, T; Selmer, T; von Figura, K; Schmidt, B			Arylsulfatase from Klebsiella pneumoniae carries a formylglycine generated from a serine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI GENOME; DNA-SEQUENCE; PROTEIN; REGION; ATSA; GENE	Eukaryotic sulfatases share an unusual posttranslational protein modification, which converts a cysteine into alpha-formylglycine. The alpha-formylglycine is essential for the catalytic activity. Klebsiella pneumoniae expresses an inducible arylsulfatase for which the DNA predicts a serine at the position occupied by the alpha-formylglycine residue in eukaryotic sulfatases. Structural analysis showed that the majority of the arylsulfatase polypeptides from K. pneumoniae carries the alpha-formylglycine, whereas the remaining arylsulfatase polypeptides contain the predicted serine residue. This demonstrates the evolutionary conservation between prokaryotes and eukaryotes of this novel protein modification that so far has been found only in sulfatases. alpha-Formylglycine in Klebsiella is generated from a serine and not from a cysteine as in eukaryotes.	Univ Gottingen, Biochem Abt 2, D-37073 Gottingen, Germany	University of Gottingen	Schmidt, B (corresponding author), Univ Gottingen, Biochem Abt 2, Gosslerstr 12D, D-37073 Gottingen, Germany.	bschmidt@ukb2-00.uni-bc.gwdg.de	Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339				BEIL S, 1995, EUR J BIOCHEM, V229, P385, DOI 10.1111/j.1432-1033.1995.0385k.x; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; BROOKS DA, 1995, BIOCHEM J, V307, P457, DOI 10.1042/bj3070457; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; FITZGERALD JW, 1976, BACTERIOL REV, V40, P698, DOI 10.1128/MMBR.40.3.698-721.1976; LUKATELA G, 1998, IN PRESS BIOCHEMISTR; MUROOKA Y, 1990, J BACTERIOL, V172, P2131, DOI 10.1128/jb.172.4.2131-2140.1990; OKAMURA H, 1976, AGR BIOL CHEM TOKYO, V40, P2071, DOI 10.1080/00021369.1976.10862350; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Selmer T, 1996, EUR J BIOCHEM, V238, P341, DOI 10.1111/j.1432-1033.1996.0341z.x; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576	15	72	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4835	4837		10.1074/jbc.273.9.4835	http://dx.doi.org/10.1074/jbc.273.9.4835			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478923	hybrid			2022-12-25	WOS:000072310400007
J	Pessler, F; Hernandez, N				Pessler, F; Hernandez, N			The HIV-1 inducer of short transcripts activates the synthesis of 5,6-dichloro-1-beta-D-benzimidazole-resistant short transcripts in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; C-MYC GENE; PROTEIN-KINASE; ELONGATION; PROMOTERS; ELEMENT; INVITRO; REPEAT	The HIV-1 inducer of short transcripts (IST) is an unusual promoter element that activates the synthesis of short transcripts from the HIV-1 promoter as well as from heterologous promoters. While the DNA sequences constituting IST have been characterized in some detail, little is known about the biochemical mechanisms underlying IST activity. Here, we describe a cell-free transcription assay that faithfully reproduces the synthesis of IST-dependent HIV-1 short transcripts. As in vivo, formation of these short transcripts requires a functional IST element and is repressed in the presence of the viral trans-activator Tat, Short transcript and full-length transcript synthesis respond differently to variations in several reaction parameters, suggesting that the short and full-length transcripts are synthesized by transcription complexes with distinct biochemical properties, In particular, short transcript synthesis is resistant to the action of 5,6-dichloro-1-beta-D-benzimidazole, an inhibitor of transcript elongation. Formation of transcription complexes directed by the IST element may, therefore, not require the activity of a factor inhibited by 5,6-dichloro-1-beta-D-benzimidazole, such as the TFIIH-associated or pTEFb kinases.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	Pessler, F (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.		Stangel, Martin/AAH-5345-2020	Hernandez, Nouria/0000-0003-1465-4585				BENTLEY DL, 1989, GENE DEV, V3, P1179, DOI 10.1101/gad.3.8.1179; Blackburn P, 1982, ENZYMES B, VXV; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KESSLER M, 1992, J VIROL, V66, P4488, DOI 10.1128/JVI.66.7.4488-4496.1992; LASPIA MF, 1993, J MOL BIOL, V232, P732, DOI 10.1006/jmbi.1993.1427; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Okamoto H, 1996, P NATL ACAD SCI USA, V93, P11575, DOI 10.1073/pnas.93.21.11575; Pendergrast PS, 1996, J VIROL, V70, P5025, DOI 10.1128/JVI.70.8.5025-5034.1996; Pendergrast PS, 1997, J VIROL, V71, P910, DOI 10.1128/JVI.71.2.910-917.1997; Pessler F, 1997, MOL CELL BIOL, V17, P3786, DOI 10.1128/MCB.17.7.3786; PIRAS G, 1994, J VIROL, V68, P6170, DOI 10.1128/JVI.68.10.6170-6179.1994; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOOHEY MG, 1989, GENE DEV, V3, P265, DOI 10.1101/gad.3.3.265; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	26	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5375	5384		10.1074/jbc.273.9.5375	http://dx.doi.org/10.1074/jbc.273.9.5375			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478998	hybrid			2022-12-25	WOS:000072310400082
J	Willars, GB; Nahorski, SR; Challiss, RAJ				Willars, GB; Nahorski, SR; Challiss, RAJ			Differential regulation of muscarinic acetylcholine receptor-sensitive polyphosphoinositide pools and consequences for signaling in human neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED PHOSPHOINOSITIDE HYDROLYSIS; PHOSPHOLIPASE-C ISOZYMES; HAMSTER OVARY CELLS; SK-N-SH; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR CA2+; TYROSINE KINASE; GTP ANALOGS; SH-SY5Y	In this study we have quantitatively assessed the basal turnover of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) and M-3-muscarinic receptor-mediated changes in phosphoinositides in the human neuroblastoma cell line, SH-SY5Y. We demonstrate that the polyphosphoinositides represent a minor fraction of the total cellular phosphoinositide pool and that in addition to rapid, sustained increases in [H-3]inositol phosphates dependent upon the extent of receptor activation by carbachol, there are equally rapid and sustained reductions in the levels of polyphosphoinositides. Compared with phosphatidylinositol 4-phosphate (PtdIns(4)P), PtdIns(4,5)P-2 was reduced with less potency by carbachol and recovered faster following agonist removal suggesting protection of PtdIns(4,5)P-2 at the expense of PtdIns(4)P and indicating specific regulatory mechanism(s). This does not involve a pertussis toxin-sensitive G-protein regulation of PtdIns(4)P 5-kinase. Using wortmannin to inhibit PtdIns I-kinase activity, we demonstrate that the immediate consequence of blocking the supply of PtdIns(4)P (and therefore PtdIns(4,5)P-2) is a failure of agonist-mediated phosphoinositide and Ca2+ signaling. The use of wortmannin also indicated that PtdIns is not a substrate for receptor-activated phospholipase C and that 15% of the basal level of PtdIns(4,5)P-2 is in an agonist-insensitive pool. We estimate that the agonist-sensitive pool of PtdIns(4,5)P-2 turns over every 5 s (0.23 fmol/cell/min) during sustained receptor activation by a maximally effective concentration of carbachol, Immediately following agonist addition, PtdIns(4,5)P-2 is consumed >3 times faster (0.76 fmol/cell/min) than during sustained receptor activation which represents, therefore, utilization by a partially desensitized receptor. These data indicate that resynthesis of PtdIns(4,5)P-2 is required to allow full early and sustained phases of receptor signaling Despite the critical dependence of phosphoinositide and Ca2+ signaling on PtdIns(4,5)P-2 resynthesis, we find no evidence that this rate resynthesis is limiting for agonist-mediated responses.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Willars, GB (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, POB 138,Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.		Challiss, R.A. John/A-9412-2008	Challiss, John/0000-0001-5506-2848	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Batty IH, 1996, BIOCHEM J, V317, P347, DOI 10.1042/bj3170347; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLANK JL, 1991, J BIOL CHEM, V266, P18206; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; CHILVERS ER, 1991, BIOCHEM J, V275, P373, DOI 10.1042/bj2750373; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUNG HC, 1995, PFLUG ARCH EUR J PHY, V429, P789, DOI 10.1007/BF00374802; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; CONWAY BR, 1993, MOL PHARMACOL, V43, P286; DOWNES CP, 1986, BIOCHEM J, V234, P199, DOI 10.1042/bj2340199; DOWNES CP, 1989, INOSITOL LIPIDS CELL, P3; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; DRUMMOND AH, 1984, BIOCHEM J, V224, P129, DOI 10.1042/bj2240129; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FISHER SK, 1995, EUR J PHARM-MOLEC PH, V288, P231, DOI 10.1016/0922-4106(95)90035-7; FISHER SK, 1994, NEUROCHEM RES, V19, P549, DOI 10.1007/BF00971329; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HELMS JB, 1991, J BIOL CHEM, V266, P21368; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; JENKINSON S, 1994, MOL PHARMACOL, V46, P1138; KOREH K, 1986, J BIOL CHEM, V261, P88; LAMBERT DG, 1990, BIOCHEM J, V265, P555, DOI 10.1042/bj2650555; LAMBERT DG, 1989, EUR J PHARMACOL, V165, P71, DOI 10.1016/0014-2999(89)90771-1; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NAHORSKI SR, 1991, TRENDS PHARMACOL SCI, V12, P297, DOI 10.1016/0165-6147(91)90581-C; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; NAKANISHI S, 1994, J BIOL CHEM, V269, P6528; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; OKADA T, 1994, J BIOL CHEM, V269, P3563; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Schmidt M, 1996, MOL PHARMACOL, V50, P1038; SMITH CD, 1989, J BIOL CHEM, V264, P3206; STEPHENS L, 1993, BIOCHEM J, V296, P481, DOI 10.1042/bj2960481; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STUBBS EB, 1993, J NEUROCHEM, V60, P1292, DOI 10.1111/j.1471-4159.1993.tb03289.x; VAUGHAN PFT, 1995, GEN PHARMACOL-VASC S, V26, P1191, DOI 10.1016/0306-3623(94)00312-B; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WILLARS GB, 1995, MOL PHARMACOL, V47, P509; WILLARS GB, 1995, BRIT J PHARMACOL, V114, P1133, DOI 10.1111/j.1476-5381.1995.tb13325.x; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; YAMAMOTO K, 1990, BIOCHEM BIOPH RES CO, V168, P466, DOI 10.1016/0006-291X(90)92344-Y; Zhang CY, 1996, MOL PHARMACOL, V50, P864	51	145	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5037	5046		10.1074/jbc.273.9.5037	http://dx.doi.org/10.1074/jbc.273.9.5037			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478953	hybrid			2022-12-25	WOS:000072310400037
J	Elomaa, O; Sankala, M; Pikkarainen, T; Bergmann, U; Tuuttila, A; Raatikainen-Ahokas, A; Sariola, H; Tryggvason, K				Elomaa, O; Sankala, M; Pikkarainen, T; Bergmann, U; Tuuttila, A; Raatikainen-Ahokas, A; Sariola, H; Tryggvason, K			Structure of the human macrophage MARCO receptor and characterization of its bacteria-binding region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; SCAVENGER RECEPTOR; LIGAND-BINDING; ADHESION; COLLAGEN; CLONING; RECOGNITION; EXPRESSION; CONTAINS; PROTEIN	The primary structure of human macrophage receptor with collagenous structure (MARCO) was determined from cDNA clones and shown to be highly similar to that of mouse (Elomaa, O., Kangas, M., Sahlberg, C., Tuukkanen, J., Sormunen, R., Liakka, A., Thesleff, I., Kraal, G., and Tryggvason, H. (1995) Cell 80, 603-609), Features such as potential carbohydrate attachment sites in the extracellular spacer domain III and the interruption of Gly-Xaa-Yaa repeats in the collagenous domain IV were conserved between the two species, However, the human MARCO polypeptide chain lacked the intracellular cysteine present in mouse, as well as two extracellular cysteines that form interchain disulfide bonds in the murine protein, fit situ hybridization showed MARCO to be strongly expressed in macrophages of several tissues of human individuals with sepsis, No expression was observed in other cell types. The bacteria-binding region of MARCO was determined in binding studies with full-length and truncated variants of MARCO, and localized to a region proximal to the cysteine-rich part of the COOH-terminal domain V, The intrachain disulfide bond pattern of domain V was established showing that these bonds are between cysteine pairs C1-C5, C2-C6, and C3-C4.	Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	Karolinska Institutet; University of Helsinki	Tryggvason, K (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden.							ASHKENAS J, 1993, J LIPID RES, V34, P983; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BERGMANN U, 1995, BIOCHEMISTRY-US, V34, P2819, DOI 10.1021/bi00009a011; Bodian DL, 1997, BIOCHEMISTRY-US, V36, P2637, DOI 10.1021/bi962560+; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DOI T, 1993, J BIOL CHEM, V268, P2126; DUNNE DW, 1994, P NATL ACAD SCI USA, V91, P1863, DOI 10.1073/pnas.91.5.1863; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; EMI M, 1993, J BIOL CHEM, V268, P2120; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; GORDON S, 1995, BIOESSAYS, V17, P977, DOI 10.1002/bies.950171111; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HUGHES DA, 1994, IMMUNOL LETT, V43, P7, DOI 10.1016/0165-2478(94)00143-X; HUGHES DA, 1995, EUR J IMMUNOL, V25, P466, DOI 10.1002/eji.1830250224; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MAYER WE, 1995, GENE, V164, P267, DOI 10.1016/0378-1119(95)94092-Z; NAITO M, 1992, AM J PATHOL, V141, P591; Pearson AM, 1996, CURR OPIN IMMUNOL, V8, P20, DOI 10.1016/S0952-7915(96)80100-2; Resnick D, 1996, J BIOL CHEM, V271, P26924, DOI 10.1074/jbc.271.43.26924; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Sambrook J., 2002, MOL CLONING LAB MANU; SUMMERS MD, 1986, TEX AGR EXP STN B, V1555; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TURPIN JA, 1993, MONONUCLEAR PHAGOCYT, P71; vanderLaan LJW, 1997, IMMUNOL LETT, V57, P203, DOI 10.1016/S0165-2478(97)00077-1; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155	32	109	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4530	4538		10.1074/jbc.273.8.4530	http://dx.doi.org/10.1074/jbc.273.8.4530			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468508	hybrid			2022-12-25	WOS:000072115000036
J	Sano, H; Kuroki, Y; Honma, T; Ogasawara, Y; Sohma, H; Voelker, DR; Akino, T				Sano, H; Kuroki, Y; Honma, T; Ogasawara, Y; Sohma, H; Voelker, DR; Akino, T			Analysis of chimeric proteins identifies the regions in the carbohydrate recognition domains of rat lung collectins that are essential for interactions with phospholipids, glycolipids, and alveolar type II cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT-ASSOCIATED PROTEIN; SITE-DIRECTED MUTAGENESIS; APOPROTEIN SP-A; PULMONARY SURFACTANT; HIGH-AFFINITY; PNEUMOCYSTIS-CARINII; SPECIFICALLY BINDS; TERMINAL DOMAIN; SECRETION; PHOSPHATIDYLINOSITOL	Pulmonary surfactant proteins A (SP-A) and D (SP-D) are collectins in the C-type lectin superfamily, SP-A binds to dipalmitoylphosphatidylcholine and galactosylceramide, and it regulates the uptake and secretion of surfactant lipids by alveolar type II cells, In contrast, SP-D binds to phosphatidylinositol (PI) and glucosylceramide (GlcCer). We investigated the functional region in the carbohydrate recognition domain of rat SP-A and SP-D that is involved in binding lipids and interacting with alveolar type II cells by using chimeric proteins, Chimeras ad3, ad4, and ad5 were constructed with SP-A/SP-D splice junctions at Gly(194)/Glu(321), Gln(173)/Thr(300), and Met(134)/Cys(261), respectively, All three chimeras lost SP-A-specific functions, Chimeras ad3, ad4, and ad5 bound to PI with increasing activity, In contrast, chimeras ad3 and ad4 did not bind to GlcCer, whereas ad5 avidly bound this lipid, From these results, we conclude that 1) the SP-A region of Glu(195)-phe(228) is required for lipid and type II cell interactions, 2) the SP-D region of Cys(261)-Phe(355) is required for optimal lipid interactions, and 3) the structural requirement for the binding of SP-D to PI is different from that for GlcCer.	Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 060, Japan; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA	Sapporo Medical University; National Jewish Health	Kuroki, Y (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South-1 West-17, Sapporo, Hokkaido 060, Japan.	kurokiy@sapmed.ac.jp						BrownAugsburger P, 1996, J BIOL CHEM, V271, P13724, DOI 10.1074/jbc.271.23.13724; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; CROUCH E, 1991, AM J PHYSIOL, V260, pL247, DOI 10.1152/ajplung.1991.260.4.L247; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holmskov U, 1997, J BIOL CHEM, V272, P13743, DOI 10.1074/jbc.272.21.13743; Honna T, 1997, BIOCHEMISTRY-US, V36, P7176, DOI 10.1021/bi962967e; KING RJ, 1972, AM J PHYSIOL, V223, P707, DOI 10.1152/ajplegacy.1972.223.3.707; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KUAN SF, 1995, J CLIN INVEST, V95, P2699; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1992, ARCH BIOCHEM BIOPHYS, V299, P261, DOI 10.1016/0003-9861(92)90273-Y; KUROKI Y, 1992, BIOCHEM BIOPH RES CO, V187, P963, DOI 10.1016/0006-291X(92)91291-W; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeVine AM, 1997, J IMMUNOL, V158, P4336; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; MURATA Y, 1993, BIOCHEM J, V291, P71, DOI 10.1042/bj2910071; O'Reilly DR, 1992, BACULOVIRUS EXPRESSI, P139; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OGASAWARA Y, 1995, J BIOL CHEM, V270, P14725, DOI 10.1074/jbc.270.24.14725; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; OGASAWARA Y, 1995, J BIOL CHEM, V270, P19052, DOI 10.1074/jbc.270.32.19052; ORIORDAN DM, 1995, J CLIN INVEST, V95, P2699, DOI 10.1172/JCI117972; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; PISON U, 1992, AM J PHYSIOL, V262, pL412, DOI 10.1152/ajplung.1992.262.4.L412; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; VANIWAARDEN JF, 1992, J BIOL CHEM, V267, P25039; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	48	52	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4783	4789		10.1074/jbc.273.8.4783	http://dx.doi.org/10.1074/jbc.273.8.4783			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468543	hybrid			2022-12-25	WOS:000072115000071
J	Brandsch, M; Thunecke, F; Kullertz, G; Schutkowski, M; Fischer, G; Neubert, K				Brandsch, M; Thunecke, F; Kullertz, G; Schutkowski, M; Fischer, G; Neubert, K			Evidence for the absolute conformational specificity of the intestinal H+/peptide symporter, PEPT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTERS	This study was initiated to determine whether the intestinal H+/peptide symporter PEPT1 differentiates between the peptide bond conformers of substrates, We synthesized a modified dipeptide where the peptide bond is replaced by the isosteric thioxo peptide bond, The Ala-Pro derivative Ala-psi[CS-N]-Pro exists as a mixture of cis and trans conformation in aqueous solution and is characterized by a low cis/trans isomerization rate, The compound was recognized by PEPT1 with high affinity, The K-i value of Ala-psi[CS-N]-Pro for the inhibition of the uptake of radiolabeled glycylsarcosine in Caco-2 cells was 0.30 +/- 0.02 mM, determined in solution with 96% trans conformation, In contrast, the Ri value was 0.51 +/- 0.02 mM when uptake media with 62% trans conformer were used, We conclude that only the trans conformer interacts with the transport system. From our data, a significant affinity of the cis conformer at PEPT1 cannot be derived, In a second approach, conformer-specific uptake of Ala-psi[CS-N]-Pro was studied by analyzing the intracellular content of Caco-2 cells following transport as well as the composition of the extracellular medium using capillary electrophoresis. The percentage of trans conformer that was 62% in the uptake medium increased to 92% inside the cells, This is the first direct evidence that an H+/peptide cotransport system selectively binds and transports the trans conformer of a peptide derivative.	Univ Halle Wittenberg, Inst Biochem, Dept Biochem Biotechnol, D-06120 Halle, Germany; Univ Halle Wittenberg, Biozentrum, D-06120 Halle, Germany; Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Max Planck Society	Brandsch, M (corresponding author), Univ Halle Wittenberg, Inst Biochem, Dept Biochem Biotechnol, Kurt Mothes Str 3, D-06120 Halle, Germany.			Schutkowski, MIke/0000-0003-0919-7076				Adibi SA, 1997, GASTROENTEROLOGY, V113, P332, DOI 10.1016/S0016-5085(97)70112-4; AMIDON GL, 1994, ANNU REV PHARMACOL, V34, P321; Brandsch M, 1997, BBA-BIOMEMBRANES, V1324, P251, DOI 10.1016/S0005-2736(96)00231-3; Daniel H, 1996, J MEMBRANE BIOL, V154, P197, DOI 10.1007/s002329900144; DANIEL H, 1992, J BIOL CHEM, V267, P9565; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; GANAPATHY ME, 1995, J BIOL CHEM, V270, P25672, DOI 10.1074/jbc.270.43.25672; Ganapathy Vadivel, 1994, P1773; Leibach FH, 1996, ANNU REV NUTR, V16, P99, DOI 10.1146/annurev.nu.16.070196.000531; Merker MP, 1996, AM J PHYSIOL-LUNG C, V270, pL251, DOI 10.1152/ajplung.1996.270.2.L251; Ottleben H, 1997, EUR J BIOCHEM, V244, P471, DOI 10.1111/j.1432-1033.1997.00471.x; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; SCHUTKOWSKI M, 1995, BIOCHEMISTRY-US, V34, P13016, DOI 10.1021/bi00040a012; Schutkowski M, 1997, EUR J BIOCHEM, V245, P381, DOI 10.1111/j.1432-1033.1997.00381.x; Thunecke F, 1996, J CHROMATOGR A, V744, P259, DOI 10.1016/0021-9673(96)00241-5; Tsuji A, 1995, PEPTIDE BASED DRUG D, P101; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P186; YAMAZAKI T, 1993, J MED CHEM, V36, P708, DOI 10.1021/jm00058a007; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	19	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3861	3864		10.1074/jbc.273.7.3861	http://dx.doi.org/10.1074/jbc.273.7.3861			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461567	hybrid			2022-12-25	WOS:000072048400009
J	Dibirdik, I; Kristupaitis, D; Kurosaki, T; Tuel-Ahlgren, L; Chu, A; Pond, D; Tuong, D; Luben, R; Uckun, FM				Dibirdik, I; Kristupaitis, D; Kurosaki, T; Tuel-Ahlgren, L; Chu, A; Pond, D; Tuong, D; Luben, R; Uckun, FM			Stimulation of Src family protein-tyrosine kinases as a proximal and mandatory step for SYK kinase-dependent phospholipase C gamma 2 activation in lymphoma B cells exposed to low energy electromagnetic fields	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; OCCUPATIONAL EXPOSURE; CLONAL PROLIFERATION; PHOSPHORYLATION; LEUKEMIA; CANCER; LYN; PRECURSORS; APOPTOSIS	Here, we present evidence that exposure of DT40 lymphoma B cells to low energy electromagnetic field (EMF) results in a tyrosine kinase-dependent activation of phospholipase C gamma 2 (PLC-gamma 2) leading to increased inositol phospholipid turnover, B cells rendered PLC-gamma 2-deficient by targeted disruption of the PLC-gamma 2 gene as well as PLC-gamma 2-deficient cells reconstituted with Src homology domain 2 (SH2) domain mutant PLC-gamma 2 did not show any increase in inositol-1,4,5-trisphosphate levels after EMF exposure, providing direct evidence that PLC-gamma 2 is responsible for EMF-induced stimulation of inositol phospholipid turnover, and its SH2 domains are essential for this function, B cells rendered SYK-deficient by targeted disruption of the syk gene did not show PLC-gamma 2 activation in response to EMF exposure, The C-terminal SH2 domain of SYK kinase is essential for its ability to activate PLC-gamma 2, SYK-deficient cells reconstituted with a C-terminal SH2 domain mutant syk gene failed to elicit increased inositol phospholipid turnover after EMF exposure, whereas SYK deficient cells reconstituted with an N-terminal SH2 domain mutant syk gene showed a normal EMF response, LYN kinase is essential for the initiation of this biochemical signaling cascade, Lymphoma B cells rendered LYN-deficient through targeted disruption of the lyn gene did not elicit enhanced inositol phospholipid turnover after EMF exposure, Introduction of the wild-type (but not a kinase domain mutant) mouse fyn gene into LYN-deficient B cells restored their EMF responsiveness, B cells reconstituted with a SH2 domain mutant fyn gene showed a normal EMF response, whereas no increase in inositol phospholipid turnover in response to EMF was noticed in LYN-deficient cells reconstituted with a SH3 domain mutant fyn gene, Taken together, these results indicate that EMF-induced PLC-gamma 2 activation is mediated by LYN-regulated stimulation of SYK, which acts downstream of LYN kinase and upstream of PLC-gamma 2.	Univ Minnesota, Biotherapy Program, Minneapolis, MN 55417 USA; Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Wayne Hughes Inst, Roseville, NSW 55113, Australia; Kansai Med Univ, Inst Hepat Res, Dept Mol Genet, Osaka 570, Japan	University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Riverside; Kansai Medical University	Uckun, FM (corresponding author), Wayne Hughes Inst, 2665 Long Lake Rd,Suite 330, St Paul, MN 55113 USA.		Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Uckun, Fatih M./0000-0001-9334-183X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007175] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01-ES-07175] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CARTWRIGHT RA, 1989, BRIT J CANCER, V60, P649, DOI 10.1038/bjc.1989.332; DEMERS PA, 1991, AM J EPIDEMIOL, V134, P340, DOI 10.1093/oxfordjournals.aje.a116095; DIBIRDIK I, 1991, BLOOD, V78, P564, DOI 10.1182/blood.V78.3.564.bloodjournal783564; GUENEL P, 1993, BRIT J IND MED, V50, P758; KOBAYASHI H, 1994, ANU RES NAGOYA U HOS, V28, P39; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Linet MS, 1997, NEW ENGL J MED, V337, P1, DOI 10.1056/NEJM199707033370101; Norimura Toshiyuki, 1993, Journal of UOEH, V15, P103; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TORNQVIST S, 1991, British Journal of Industrial Medicine, V48, P597; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1995, J BIOL CHEM, V270, P27666, DOI 10.1074/jbc.270.46.27666; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; UEKUN FM, 1997, BLOOD, V89, P3769; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; Zhang X R, 1995, Nagoya J Med Sci, V58, P157	28	57	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4035	4039		10.1074/jbc.273.7.4035	http://dx.doi.org/10.1074/jbc.273.7.4035			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461594	hybrid			2022-12-25	WOS:000072048400036
J	Mathias, N; Steussy, CN; Goebl, MG				Mathias, N; Steussy, CN; Goebl, MG			An essential domain within Cdc34p is required for binding to a complex containing Cdc4p and Cdc53p in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; YEAST-CELL CYCLE; PROTEOLYTIC PATHWAY; IN-VIVO; UBC3; DEGRADATION; INHIBITOR; TRANSITION; PROTEINS; FAMILY	The CDC34 gene of the yeast Saccharomyces cerevisiae encodes a ubiquitin-conjugating protein that transfers ubiquitin onto substrates to signal rapid degradation via the proteasome, Cdc34p has been implicated in signaling the destruction of a variety of substrates including the cyclin-dependent kinase inhibitor, Sic1p, which must be degraded for cells to enter S-phase, Mutants lacking CDC34 activity fail to degrade Sic1p and fail to enter S-phase, a phenotype that is also shared with cells lacking CDC4 and CDC53 activity, Here we demonstrate that Cdc4p, Cdc34p, and Cdc53p interact in vivo. We have mapped a Cdc4p/Cdc53p-binding region on Cdc34p; this region is essential for S-phase entry and thus the association of these three proteins is required for Sic1p degradation, All three proteins migrate in gel filtration to sizes that greatly exceed their actual size suggesting that they form stable associations with other proteins and we observe Cdc4p, Cdc34p, and Cdc53p fractionating into overlapping families of high molecular weight complexes. Finally, we demonstrate that Cdc4p, Cde34p, and Cdc53p are stable throughout the cell cycle and that Cdc34p permanently resides as part of a complex throughout the cell cycle, This suggests that all Cdc34p substrates are ubiquitinated by a similar high molecular weight complex.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Mathias, N (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	neal@biochem4.iupui.edu						Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Candau R, 1996, J BIOL CHEM, V271, P5237; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; Elbe R, 1992, BIOTECHNIQUES, V13, P18; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOEBL MG, 1994, MOL CELL BIOL, V14, P3022, DOI 10.1128/MCB.14.5.3022; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOLMAN CJ, 1992, EMBO J, V11, P3081, DOI 10.1002/j.1460-2075.1992.tb05380.x; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; LIU Y, 1995, MOL CELL BIOL, V15, P5635; MACKINNEY JD, 1993, GENE DEV, V7, P833; Mathias N, 1996, MOL CELL BIOL, V16, P6634; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; PTAK C, 1994, J BIOL CHEM, V269, P26539; Rose MD., 1990, METHODS YEAST GENETI; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2	42	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4040	4045		10.1074/jbc.273.7.4040	http://dx.doi.org/10.1074/jbc.273.7.4040			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461595	hybrid			2022-12-25	WOS:000072048400037
J	Ribon, V; Herrera, R; Kay, BK; Saltiel, AR				Ribon, V; Herrera, R; Kay, BK; Saltiel, AR			A role for CAP, a novel, multifunctional Src homology 3 domain-containing protein in formation of actin stress fibers and focal adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CELL-ADHESION; TYROSINE PHOSPHORYLATION; SH3 DOMAINS; KINASE; P130(CAS); IDENTIFICATION; CORTACTIN; SUBSTRATE; BINDING; RHO	c-Cbl-associated protein, CAP, was originally cloned from a 3T3-L1 adipocyte cDNA expression library using full-length c-Cbl as a bait, CAP contains a unique structure, with three adjacent Src homology-3 (SH3) domains in the COOH terminus and a region sharing significant sequence similarity with the peptide hormone sorbin, Expression of CAP in NIH-3T3 cells overexpressing the insulin receptor induced the formation of stress fibers and focal adhesions, This effect of CAP expression on the organization of the actin-based cytoskeleton was independent of the type of integrin receptors engaged with extracellular matrix, whereas membrane ruffling and decreased actin stress fibers induced by insulin were not affected by expression of CAP. Immunofluorescence microscopy demonstrated that CAP colocalized with actin stress fibers. Moreover, CAP interacted with the focal adhesion kinase, p125FAK, both in vitro and in vivo through one of the SH3 domains of CAP, The increased formation of stress fibers and focal adhesions in CAP-expressing cells was correlated with decreased tyrosine phosphorylation of p125FAK in growing cells or upon integrin-mediated cell adhesion, These results suggest that CAP may mediate signals for the formation of stress fibers and focal adhesions.	Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Div Cell Biol, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA	Pfizer; University of Michigan System; University of Michigan; University of Wisconsin System; University of Wisconsin Madison	Saltiel, AR (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Div Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				ANDERSON JR, 1990, SCIENCE, V250, P360, DOI 10.1126/science.250.4979.360; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ILIE D, 1995, NATURE, V37, P539; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RIBON V, 1998, IN PRESS MOL CELL BI, V18; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	91	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4073	4080		10.1074/jbc.273.7.4073	http://dx.doi.org/10.1074/jbc.273.7.4073			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461600	hybrid			2022-12-25	WOS:000072048400042
J	Delvig, AA; Robinson, JH				Delvig, AA; Robinson, JH			Different endosomal proteolysis requirements for antigen processing of two T-cell epitopes of the M5 protein from viable Streptococcus pyogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; GROUP-A STREPTOCOCCI; CYSTEINE PROTEINASES; CATHEPSIN-S; RAT-LIVER; MOLECULES; ACIDIFICATION; PROTEASES; COMPLEX; INHIBITION	We studied endosomal proteolysis of the surface fibrillar M5 protein from viable Streptococcus pyogenes as an essential step involved in major histocompatibility complex class II-restricted antigen processing of two immunodominant CD4(+) T-cell epitopes (17-31/E-d and 308-319/A(d)). Intracellular proteolysis of viable streptococci for presentation of 17-31, bound by serine proteinase cleavage sites, was mediated by serine proteinases, whereas processing of soluble recombinant M5 protein required in addition cysteine proteinases. Furthermore, processing of 17-31 was resistant to ammonium chloride and thus was not dependent on endosome acidification. Cysteine and serine proteinase cleavage sites were located adjacent to 308-319, and its processing was dependent on serine, cysteine, and aspartic proteinases, as well as on endosomal acidification. The data suggest that antigen processing of two major T-cell epitopes on streptococcal M5 protein occurred in different endosomal compartments by different classes of intracellular proteinases.	Univ Newcastle Upon Tyne, Sch Med, Sch Microbiol Virol & Immunol Sci, Dept Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Robinson, JH (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Microbiol Virol & Immunol Sci, Dept Immunol, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			von Delwig, Alexei/0000-0003-2978-4761	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRETT AJ, 1975, PROTEASES BIOL CONTR, P467; BENNETT K, 1992, EUR J IMMUNOL, V22, P1519, DOI 10.1002/eji.1830220626; BERG T, 1995, BIOCHEM J, V307, P313, DOI 10.1042/bj3070313; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BROMME D, 1989, BIOCHEM J, V264, P475; Busch R, 1996, CURR OPIN IMMUNOL, V8, P51, DOI 10.1016/S0952-7915(96)80105-1; BUUS S, 1986, J IMMUNOL, V136, P452; CHAIN BM, 1989, CLIN EXP IMMUNOL, V75, P87; Conte MP, 1996, J MED MICROBIOL, V44, P418, DOI 10.1099/00222615-44-6-418; Delvig AA, 1997, BIOCHEM SOC T, V25, pS205, DOI 10.1042/bst025205s; DIMENT S, 1990, J IMMUNOL, V145, P417; FernandezBorja M, 1996, INT IMMUNOL, V8, P625, DOI 10.1093/intimm/8.5.625; FINLAY BB, 1988, BIOCHIMIE, V70, P1089, DOI 10.1016/0300-9084(88)90271-4; HARDING CV, 1997, MHC MOL ANTIGEN PROC; JACQUIERSARLIN MR, 1995, IMMUNOLOGY, V84, P164; KEHOE MA, 1985, INFECT IMMUN, V48, P190, DOI 10.1128/IAI.48.1.190-197.1985; MCCOY K, 1988, J CELL BIOL, V106, P1879, DOI 10.1083/jcb.106.6.1879; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MELLMAN I, 1995, CURR OPIN CELL BIOL, V7, P564, DOI 10.1016/0955-0674(95)80014-X; METZLER DE, 1977, BIOCHEMISTRY-US, P353; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; Pieters J, 1997, CURR OPIN IMMUNOL, V9, P89, DOI 10.1016/S0952-7915(97)80164-1; PINET V, 1995, NATURE, V375, P603, DOI 10.1038/375603a0; PINET V, 1994, J IMMUNOL, V152, P4852; PURI J, 1988, J IMMUNOL, V141, P3313; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; ROBINSON JH, 1991, INFECT IMMUN, V59, P4324, DOI 10.1128/IAI.59.12.4324-4331.1991; ROBINSON JH, 1993, INFECT IMMUN, V61, P1062, DOI 10.1128/IAI.61.3.1062-1068.1993; ROSSITER BA, 1994, EUR J IMMUNOL, V24, P1244, DOI 10.1002/eji.1830240537; STREICHER HZ, 1984, P NATL ACAD SCI-BIOL, V81, P6831, DOI 10.1073/pnas.81.21.6831; TAKAHASHI H, 1989, J IMMUNOL, V142, P2221; TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672; ZIEGLER K, 1994, BBA-BIOMEMBRANES, V1196, P209, DOI 10.1016/0005-2736(94)00228-2	34	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3291	3295		10.1074/jbc.273.6.3291	http://dx.doi.org/10.1074/jbc.273.6.3291			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452445	hybrid			2022-12-25	WOS:000071822300030
J	Lai, A; Gibson, A; Hopkins, CR; Trowbridge, IS				Lai, A; Gibson, A; Hopkins, CR; Trowbridge, IS			Signal-dependent trafficking of beta-amyloid precursor protein-transferrin receptor chimeras in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; MDCK CELLS; CYTOPLASMIC DOMAIN; ENDOCYTIC PATHWAY; EPITHELIAL-CELLS; MEMBRANE; LYSOSOMES; SECRETION; CLEAVAGE; DETERMINANTS	We have investigated the intracellular trafficking of a chimeric molecule consisting of the cytoplasmic domain of the beta-amyloid precursor protein (APP) and the transmembrane region and external domain of the human transferrin receptor (TR) in Madin-Darby canine kidney cells. Newly synthesized APP-TR chimeras are selectively targeted to the basolateral surface by a tyrosine-dependent sorting signal in the APP cytoplasmic tail. APP-TR chimeras are then rapidly internalized from the basolateral surface and a significant fraction (similar to 20-30%) are degraded. Morphological studies show that APP-TR chimeras internalized from the basolateral surface are found in tubulo-vesicular endosomal elements, internal membranes of multivesicular bodies, and lysosomes. APP-TR chimeras are also found in 60-nm diameter vesicles previously shown to selectively deliver wild-type TR to the basolateral surface; this result is consistent with the fact that 90% of internalized chimeras that are not degraded are selectively recycled back to the basolateral surface. APP-TR chimeras internalized from the apical surface are selectively transcytosed to the basolateral surface underscoring the importance of basolateral sorting in the endocytic pathway for maintaining the polarized phenotype. Tyr-653, an important element of the YTSI internalization signal in the APP cytoplasmic domain, is required for basolateral sorting in the biosynthetic and endocytic pathways. However, the structural features for basolateral sorting differ from those required for internalization.	Salk Inst, Dept Canc Biol, San Diego, CA 92186 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92037 USA; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England	Salk Institute; University of California System; University of California San Diego; University of London; University College London	Trowbridge, IS (corresponding author), Salk Inst, Dept Canc Biol, San Diego, CA 92186 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035489] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS35489] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; DeStrooper B, 1995, J BIOL CHEM, V270, P30310, DOI 10.1074/jbc.270.51.30310; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; GOTTLIEB TA, 1986, J CELL BIOL, V102, P1242, DOI 10.1083/jcb.102.4.1242; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HOPKINS CR, 1985, CELL, V40, P199, DOI 10.1016/0092-8674(85)90323-X; HOPKINS CR, 1983, J CELL BIOL, V94, P1265; HUGHES SH, 1990, J REPROD FERTIL, P39; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; LO ACY, 1994, J BIOL CHEM, V269, P30966; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; NORSTEDT C, 1993, J BIOL CHEM, V268, P608; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; ODORIZZI G, 1994, METHOD CELL BIOL, V43, P79; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; OMARY MB, 1981, J BIOL CHEM, V256, P2888; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Yamazaki T, 1996, J CELL SCI, V109, P999	44	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3732	3739		10.1074/jbc.273.6.3732	http://dx.doi.org/10.1074/jbc.273.6.3732			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452505	hybrid			2022-12-25	WOS:000071822300090
J	Ostrowski, J; Roalsvig, T; Hammer, L; Marinier, A; Starrett, JE; Yuo, KL; Reczek, PR				Ostrowski, J; Roalsvig, T; Hammer, L; Marinier, A; Starrett, JE; Yuo, KL; Reczek, PR			Serine 232 and methionine 272 define the ligand binding pocket in retinoic acid receptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; CRYSTAL-STRUCTURE; DOMAIN; ALPHA; GAMMA; RECOGNITION; SITE; BETA	The transcriptional response mediated by retinoic acid involves a complex series of events beginning with ligand recognition by a nuclear receptor. To dissect the amino acid contacts important for receptor-specific ligand recognition, a series of retinoic acid receptor (RAR) mutants were constructed. Transcriptional studies revealed that serine 232 (Ser(232)) in RAR alpha and methionine 272 (Met(272)) in RAR gamma are critical residues for the recognition of their respective receptor-selective analogs. The identification of these key amino acids in the ligand binding pocket is confirmed by the reported crystal structure of RAR gamma. Interestingly, the serine at position 232 in RAR alpha gives an explanation for the observed differences in the affinity of the naturally occurring ligand, all-trans-retinoic acid (t-RA), in this receptor compared with that for the other receptors, since hydrogen bonding would not be permitted between the hydroxyl of serine and the hydrophobic linker of t-RA. Using this model, a molecular mechanism for the transcriptional antagonism of a synthetic analog is suggested that involves an alteration in the structure of the receptor protein in the region around the AF2 domain in helix 12.	Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Cell & Mol Biol, Buffalo, NY 14213 USA; Dept Chem, Candiac, PQ J5R 1J1, Canada; Dept Cent Chem, Wallingford, CT 06492 USA	Bristol-Myers Squibb	Reczek, PR (corresponding author), Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Cell & Mol Biol, 100 Forest Ave, Buffalo, NY 14213 USA.							BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; Driscoll JE, 1996, J BIOL CHEM, V271, P22969, DOI 10.1074/jbc.271.38.22969; GIQUERE V, 1994, ENDOCR REV, V15, P61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; LUPISELLA JA, 1995, J BIOL CHEM, V270, P24884, DOI 10.1074/jbc.270.42.24884; Mangelsdorf David J., 1994, P319; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; Reczek PR, 1995, SKIN PHARMACOL, V8, P292, DOI 10.1159/000211360; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Sasaki T, 1996, BIOL PHARM BULL, V19, P659; SASAKI T, 1995, BIOCHEM BIOPH RES CO, V207, P444, DOI 10.1006/bbrc.1995.1208; STICKLE DF, 1992, J MOL BIOL, V226, P1143, DOI 10.1016/0022-2836(92)91058-W; STROMSTEDT PE, 1990, J BIOL CHEM, V265, P12973; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yu KL, 1996, J MED CHEM, V39, P2411, DOI 10.1021/jm9502293	22	33	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3490	3495		10.1074/jbc.273.6.3490	http://dx.doi.org/10.1074/jbc.273.6.3490			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452473	hybrid			2022-12-25	WOS:000071822300058
J	Wang, L; Darling, J; Zhang, JS; Qian, CP; Hartmann, L; Conover, C; Jenkins, R; Smith, DI				Wang, L; Darling, J; Zhang, JS; Qian, CP; Hartmann, L; Conover, C; Jenkins, R; Smith, DI			Frequent homozygous deletions in the FRA3B region in tumor cell lines still leave the FHIT exons intact	ONCOGENE			English	Article						deletions; tumor cell lines; FRA3B; FHIT	3P14.2 FRAGILE SITE; VIRAL INTEGRATION; TRANSLOCATION BREAKPOINT; CARCINOMA; CANCER; GENE; REPEAT; DNA; HETEROZYGOSITY; AMPLIFICATION	FRA3B at human chromosomal band 3p14.2 is the most active common fragile site in the human genome. The molecular mechanism of fragility at this region remains unknown but does not involve expansion of a trinucleotide or minisatellite repeat as has been observed for several of the cloned rare fragile sites. Deletions and rearrangements at FRA3B have been observed in a number of distinct tumors. The recently identified putative tumor suppressor gene FHIT spans FRA3B, and various groups have reported identifying deletions in this gene in different tumors. Using a high density of PCR amplifiable markers within FRA3B searching for deletions in the FRA3B region, we have analysed 21 tumor cell lines derived from renal cell, pancreatic, and ovarian carcinomas. We found a commonly deleted region in the renal cell and ovarian carcinoma cell lines located in the middle of an HPV16 viral integration site. Despite the presence of deletions in the FRA3B region in most of the cell lines, we did not detect alterations in FHIT exons in any of the cell lines examined. Thus, deletions of 3p14.2 in these carcinoma cell lines may simply reflect instability of the FRA3B region during tumor progression.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55902 USA; Mayo Clin & Mayo Fdn, Dept Med Oncol, Rochester, MN 55902 USA	Mayo Clinic; Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55902 USA.				NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Cohen S, 1997, ONCOGENE, V14, P977, DOI 10.1038/sj.onc.1200917; DRUCK T, 1995, CANCER RES, V55, P5348; Druck T, 1997, CANCER RES, V57, P504; EHLEN T, 1990, ONCOGENE, V5, P219; Fong KM, 1997, CANCER RES, V57, P2256; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Hendricks DT, 1997, CANCER RES, V57, P2112; JENKINS RB, 1993, CANCER GENET CYTOGEN, V71, P76, DOI 10.1016/0165-4608(93)90205-Z; JONES C, 1994, HUM MOL GENET, V3, P2123, DOI 10.1093/hmg/3.12.2123; KAMEL D, 1994, HISTOPATHOLOGY, V25, P339, DOI 10.1111/j.1365-2559.1994.tb01352.x; Kastury K, 1996, CANCER RES, V56, P978; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; Mao L, 1996, CANCER RES, V56, P5128; Mauillon JL, 1996, CANCER RES, V56, P5728; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Panagopoulos I, 1996, CANCER RES, V56, P4871; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; PARADEE W, 1995, GENOMICS, V27, P358, DOI 10.1006/geno.1995.1057; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; POPESCU NC, 1990, HUM GENET, V84, P383; Puget N, 1997, CANCER RES, V57, P828; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; Reiter LT, 1996, NAT GENET, V12, P288, DOI 10.1038/ng0396-288; Shridhar R, 1996, CANCER RES, V56, P4347; Shridhar V, 1997, ONCOGENE, V14, P1269, DOI 10.1038/sj.onc.1201100; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; SMITH PP, 1992, GENE CHROMOSOME CANC, V5, P150, DOI 10.1002/gcc.2870050209; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SUTHERLAND GR, 1985, OXFORD U MONOGRAPHS, V13; Todd S, 1997, CANCER RES, V57, P1344; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P59, DOI 10.1002/(SICI)1098-2264(199706)19:2<59::AID-GCC1>3.3.CO;2-O; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; WAGATSUMA M, 1990, J VIROL, V64, P813, DOI 10.1128/JVI.64.2.813-821.1990; Wang L, 1997, GENOMICS, V41, P485, DOI 10.1006/geno.1997.4690; Wang L, 1996, ONCOGENE, V12, P699; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; YAMAGISAWA K, 1996, CANCER RES, V56, P5579; Yu S, 1997, CELL, V88, P367, DOI 10.1016/S0092-8674(00)81875-9; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; Zimonjic DB, 1997, CANCER RES, V57, P1166	45	33	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					635	642		10.1038/sj.onc.1201576	http://dx.doi.org/10.1038/sj.onc.1201576			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482109				2022-12-25	WOS:000071816600008
J	Rauhala, P; Lin, AMY; Chiueh, CC				Rauhala, P; Lin, AMY; Chiueh, CC			Neuroprotection by S-nitrosoglutathione of brain dopamine neurons from oxidative stress	FASEB JOURNAL			English	Article						hydroxyl radical; lipid peroxidation; nitric oxide; peroxynitrite; Parkinson's disease	LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE RELEASE; GLUTATHIONE; NITROSOTHIOLS; NEUROTOXICITY; PEROXIDATION; ACTIVATION; SUPEROXIDE; INHIBITION; TOXICITY	The proposed anti- and prooxidant effects of nitric oxide (NO) derivatives, such as S-nitrosoglutathione (GSNO) and peroxynitrite, were investigated in the rat nigrostriatal dopaminergic system. Intranigal infusion of freshly prepared GSNO (0-16.8 nmol, i.n.) prevented iron-induced (4.2 nmol, i.n.) oxidative stress and nigral injury, reflected by a decrease in striatal dopamine levels. This neuroprotective effect of GSNO was verified by ex vivo imaging of brain dopamine uptake sites using I-125-labeled RTI-55. In addition, in vitro data indicate that GSNO concentration-dependently inhibited iron-evoked hydroxyl radical generation and brain lipid peroxidation. In this iron-induced oxidant stress model, GSNO was approximately 100-fold more potent than the antioxidant glutathione (GSH). Light-exposed, NO-exhausted GSNO produced neither antioxidative nor neuroprotective effects, which indicates that NO may mediate at least part of GSNO's effects. Moreover, GSNO completely (and GSH only partially) inhibited the weak pro-oxidant effect of peroxynitrite, which produced little injury to nigral neurons in vivo. This study provides relevant in vivo evidence suggesting that nanomol GSNO can protect brain dopamine neurons from iron-induced oxidative stress and degeneration. In conclusion, S-nitrosylation of GSH by NO and oxygen may be part of the antioxidative cellular defense system.	NIMH, Unit Neurodegenerat & Neuroprotect, Clin Sci Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Chiueh, CC (corresponding author), NIMH, Unit Neurodegenerat & Neuroprotect, Clin Sci Lab, NIH, Bldg 10,Rm 3D-41, Bethesda, MD 20892 USA.	chiueh@helix.nih.gov		Rauhala, Pekka/0000-0003-2036-3522	NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002648] Funding Source: NIH RePORTER; NIMH NIH HHS [Z01 MH 02648-04LCS] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRUCKDORFER KR, 1990, BIOCHEM SOC T, V18, P285, DOI 10.1042/bst0180285; Casini A, 1997, HEPATOLOGY, V25, P361; Castagnoli K, 1997, CHEM RES TOXICOL, V10, P364, DOI 10.1021/tx970001d; Chang J, 1996, AM J PHYSIOL-LUNG C, V270, pL931, DOI 10.1152/ajplung.1996.270.6.L931; CHIUEH CC, 1983, J PHARMACOL EXP THER, V225, P529; CHIUEH CC, 1993, ADV NEUROL, V60, P251; CHIUEH CC, 1992, FREE RADICAL BIO MED, V13, P581, DOI 10.1016/0891-5849(92)90151-6; CHIUEH CC, 1995, ANN NY ACAD SCI, V738, P279; CHIUEH CC, 1997, ADV PHARMACOL, V42, P796; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; COOPER AJL, 1993, GLUTATHIONE BRAIN DI, P209; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; DILLARD CJ, 1973, LIPIDS, V8, P183, DOI 10.1007/BF02544632; Do KQ, 1996, NEUROCHEM INT, V29, P213; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gorren ACF, 1996, ARCH BIOCHEM BIOPHYS, V330, P219, DOI 10.1006/abbi.1996.0247; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Gutierrez HH, 1996, FREE RADICAL BIO MED, V21, P43, DOI 10.1016/0891-5849(95)02226-0; Hantraye P, 1996, NAT MED, V2, P1017, DOI 10.1038/nm0996-1017; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O; KIKUGAWA K, 1989, ADV EXP MED BIOL, V266, P345; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; KONOREV EA, 1995, J PHARMACOL EXP THER, V274, P200; Mackenzie GM, 1997, SYNAPSE, V26, P301, DOI 10.1002/(SICI)1098-2396(199707)26:3<301::AID-SYN11>3.0.CO;2-Y; MIKI N, 1977, BIOCHEM BIOPH RES CO, V75, P851, DOI 10.1016/0006-291X(77)91460-7; MOCHIZUKI H, 1994, NEUROSCI LETT, V168, P251, DOI 10.1016/0304-3940(94)90462-6; MOHANAKUMAR KP, 1994, ANN NY ACAD SCI, V738, P392; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PLIUM RC, 1994, PROG INORG CHEM, V41, P599; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; Rauhala P, 1996, FREE RADICAL BIO MED, V21, P391, DOI 10.1016/0891-5849(96)00043-3; Rauhala P, 1996, SYNAPSE, V23, P58, DOI 10.1002/(SICI)1098-2396(199605)23:1<58::AID-SYN7>3.0.CO;2-G; ROTHMAN RB, 1995, J PHARMACOL EXP THER, V274, P385; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Sergent O, 1997, HEPATOLOGY, V25, P122, DOI 10.1002/hep.510250123; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; STRUCK AT, 1995, FEBS LETT, V361, P291, DOI 10.1016/0014-5793(95)00178-C; SUN CJ, 1988, J NEURAL TRANSM, V74, P75, DOI 10.1007/BF01245141; SZIRAKI I, 1998, IN PRESS NEUROSCIENC; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; Wink DA, 1996, ARCH BIOCHEM BIOPHYS, V331, P241, DOI 10.1006/abbi.1996.0304; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813	53	146	148	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1998	12	2					165	173		10.1096/fasebj.12.2.165	http://dx.doi.org/10.1096/fasebj.12.2.165			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472981				2022-12-25	WOS:000071848400004
J	Robinson, NA; Eckert, RL				Robinson, NA; Eckert, RL			Identification of transglutaminase-reactive residues in S100A11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNIFIED CELL-ENVELOPE; CROSS-LINKED ENVELOPE; PLASMA FACTOR-XIIIA; HUMAN EPIDERMAL-KERATINOCYTES; PIG LIVER-ENZYME; STRUCTURAL FEATURES; TISSUE TRANSGLUTAMINASE; LIPOCORTIN-I; ANNEXIN-I; LINKING	The recent finding that S100A11 is a component of the keratinocyte cornified envelope (CE) (Robinson, N. A., Lapic, S., Welter, J. F., and Eckert, R. L. (1997) J. Biol. Chern, 272, 12035-12046) suggests that S100A11 is a transglutaminase (TG) substrate, In the present study we show that S100All forms multimers when cultured keratinocytes are challenged by increased levels of intracellular calcium and that multimer formation is inhibited by the TG inhibitor, cystamine, These S100All multimers appear to be incorporated into the CE, as immunoreactive S100A11 is detected in purified envelopes prepared from cultured cells and from foreskin epidermis, To study S100A11 as a transglutaminase substrate, recombinant human S100All (rhS100A11) was used in a cell-free cross linking system, [C-14]Putrescine, a primary amine, labels rhS100A11 in a TG-dependent manner. Trypsin digestion of [C-14]putrescine-labeled rhS100A11 releases one radiolabeled peptide, Ala(98)-Lys(103). The glutamine residue in this segment, Gln(102), is the site of radiolabel incorporation indicating that Gln(102) functions as an amine acceptor, The ability of S100All to form multimers indicates that it also has a reactive lysine residue that functions as an amine donor, To identify the reactive residue, we compared the high pressure liquid chromatography profile of trypsin-digested rhS100A11 monomer to that of cross-linked rhS100A11, A unique cross linked peptide was purified and identified as Met-Ala-Lys(3)-Ilu-Ser-Ser-Pro-Thr-Glu-Thr-Glu-Arg cross-linked via an Lys(3)-Gln(102) isopeptide bond to Ala-Val-Pro-Ser-Gln(102)-Lys. These studies show that S100All is post-translationally modified by transglutaminase, that it can be cross linked to form multimers, that it is present in CEs from cultured keratinocytes and in vivo epidermis, and that Lys(3) and Gln(102) are specific sites of cross link formation.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol Biophys, Rm E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.				NCI NIH HHS [P30 CA443703] Funding Source: Medline; NIAMS NIH HHS [AR39750] Funding Source: Medline; NIGMS NIH HHS [GM43751] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen BG, 1996, BIOCHEM CELL BIOL, V74, P687, DOI 10.1139/o96-075; ANDO Y, 1989, BIOCHEM BIOPH RES CO, V163, P944, DOI 10.1016/0006-291X(89)92313-9; ANDO Y, 1991, J BIOL CHEM, V266, P1101; BHOWN AS, 1986, ADV METHODS PROTEIN, P208; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; CHAKRAVARTY R, 1990, BIOCHEM J, V271, P25, DOI 10.1042/bj2710025; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GERKE V, 1991, NOVEL CALCIUM BINDIN, P139; GOLDSMITH LA, 1983, J INVEST DERMATOL S, V80, P39; GORMAN JJ, 1984, J BIOL CHEM, V259, P9007; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; GORMAN JJ, 1981, J BIOL CHEM, V256, P2712; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HENSCHEN A, 1986, ADV METHODS PROTEIN, P244; HILT DC, 1991, NOVEL CALCIUM BINDIN, P65; Jensen PH, 1996, J BIOL CHEM, V271, P26892, DOI 10.1074/jbc.271.43.26892; JENSEN PJ, 1995, EXP CELL RES, V217, P65, DOI 10.1006/excr.1995.1064; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KLOTZ AV, 1993, ANAL BIOCHEM, V100, P3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; MOORE KG, 1992, EXP CELL RES, V200, P186, DOI 10.1016/S0014-4827(05)80087-4; NAKA M, 1994, BBA-MOL CELL RES, V1223, P348, DOI 10.1016/0167-4889(94)90094-9; OGAWA H, 1976, J BIOL CHEM, V251, P7281; POLAKOWSKA R, 1991, J INVEST DERMATOL, V96, P285, DOI 10.1111/1523-1747.ep12464554; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Robinson NA, 1996, J INVEST DERMATOL, V107, P101, DOI 10.1111/1523-1747.ep12298323; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; ROBINSON NA, 1991, J BIOCHEM TOXICOL, V6, P171, DOI 10.1002/jbt.2570060303; RORKE EA, 1991, J INVEST DERMATOL, V97, P543, DOI 10.1111/1523-1747.ep12481579; RORKE EA, 1995, EXP CELL RES, V216, P65, DOI 10.1006/excr.1995.1008; ROTHNAGEL JA, 1984, MOL CELL BIOCHEM, V58, P113, DOI 10.1007/BF00240610; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; SIEFRING GE, 1978, BIOCHEMISTRY-US, V17, P2598, DOI 10.1021/bi00606a022; SIMON M, 1988, J BIOL CHEM, V263, P18093; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; SIZEMORE N, 1993, DIFFERENTIATION, V54, P219, DOI 10.1111/j.1432-0436.1993.tb01603.x; Steinert P M, 1995, Cell Death Differ, V2, P33; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; TA BM, 1990, J CELL SCI, V95, P631; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; vandenBos C, 1996, J IMMUNOL, V156, P1247; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; Wicki R, 1996, BIOCHEM BIOPH RES CO, V227, P594, DOI 10.1006/bbrc.1996.1551; YAFFE MB, 1993, J INVEST DERMATOL, V100, P3, DOI 10.1111/1523-1747.ep12349857; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	56	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2721	2728		10.1074/jbc.273.5.2721	http://dx.doi.org/10.1074/jbc.273.5.2721			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446578	hybrid			2022-12-25	WOS:000071736600033
J	Burger, A; Li, H; Zhang, XK; Pienkowska, M; Venanzoni, M; Vournakis, J; Papas, T; Seth, A				Burger, A; Li, H; Zhang, XK; Pienkowska, M; Venanzoni, M; Vournakis, J; Papas, T; Seth, A			Breast cancer genome anatomy: correlation of morphological changes in breast carcinomas with expression of the novel gene product Di12	ONCOGENE			English	Article						gene anatomy; breast cancer; molecular oncology; subtractive cloning; differential display; immunohistochemistry	DIFFERENTIAL DISPLAY; IDENTIFICATION; PROTEINS; BINDING	To determine which genes may be activated or inactivated during breast cancer development, we employed two cloning strategies (subtractive hybridization and differential display) using RNA samples from a human breast tumor and its matching normal breast cell line. Of 950 clones isolated, 102 cDNA inserts were analysed by DNA sequencing and database searching. We found 30 clones that were obviously unidentified, with no significant homology to any listed human gene. We focused upon one of the novel genes, Di12, that is differentially expressed as a 1.35 kb RNA in breast cancer tissues and cell-lines. and in several normal tissues. A full length cDNA of this gene was cloned, and its DIVA sequence revealed an open reading frame of 339 amino acids. Antibodies to the ten N-terminal amino acids were developed to investigate the expression of Di12 in breast cancer cell-lines and tumors. The Di12 protein was found in tissue sections of infiltrating ductal carcinomas (IDCs), but not in benign or normal breast specimens. RT-PCR analysis confirmed expression of Di12 in 80% of infiltrating ductal carcinomas (IDCs). As IDC constitutes similar to 70% of breast cancers seen clinically, the level of Di12 expression may be predictive of disease progression.	Univ Toronto, Womens Coll Hosp, Dept Pathol, Toronto, ON M5S 1B3, Canada; Univ Toronto, Womens Coll Hosp, Lab Lab Med & Pathobiol, Toronto, ON M5S 1B3, Canada; Univ Bradford, Clin Oncol Unit, Bradford BD7 1DP, W Yorkshire, England; Mem Sloan Kettering Canc Inst, New York, NY 10021 USA; Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC 29425 USA; INRCA, Ancona, Italy	University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Bradford; Memorial Sloan Kettering Cancer Center; Medical University of South Carolina; IRCCS INRCA	Seth, A (corresponding author), Univ Toronto, Womens Coll Hosp, Dept Pathol, 76 Grenville St, Toronto, ON M5S 1B3, Canada.							ABTS H, 1991, LEUKEMIA RES, V15, P987, DOI 10.1016/0145-2126(91)90103-Z; ALLRED D, 1990, P ASCO, V9, P23; BERNS EMJJ, 1992, CANCER RES, V52, P1107; Burger AM, 1996, INT J ONCOL, V8, P395; EASTON D, 1993, CANCER SURV, V18, P95; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; IWASE H, 1994, BREAST CANC RES TREA, V33, P83; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAINSBURY JRC, 1987, LANCET, V1, P1398; SALESIOTIS AN, 1995, CANCER LETT, V91, P47, DOI 10.1016/0304-3835(95)03717-B; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SOUBEYRAN I, 1995, BREAST CANCER RES TR, V34, P119, DOI 10.1007/BF00665784; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333	20	29	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					327	333		10.1038/sj.onc.1201517	http://dx.doi.org/10.1038/sj.onc.1201517			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467958				2022-12-25	WOS:000071582100005
J	Queimado, L; Reis, A; Fonseca, I; Martins, C; Lovett, M; Soares, J; Parreira, L				Queimado, L; Reis, A; Fonseca, I; Martins, C; Lovett, M; Soares, J; Parreira, L			A refined localization of two deleted regions in chromosome 6q associated with salivary gland carcinomas	ONCOGENE			English	Article						salivary gland carcinomas; chromosome 6q; loss of heterozygosity (LOH); deletions; histological subtypes	MANGANESE SUPEROXIDE-DISMUTASE; TUMOR-SUPPRESSOR GENE; LONG ARM; BREAST-CARCINOMA; OVARIAN CANCERS; MELANOMA-CELLS; HUMAN GENOME; HETEROZYGOSITY; TUMORIGENICITY; IDENTIFICATION	Deletions within chromosome 6 (6q25 to 6qter) are the most consistent structural change observed in salivary gland carcinomas, To better define the location of these deletions we investigated loss of heterozygosity (LOH) for 23 polymorphic markers within 19 salivary gland carcinomas covering several histological subtypes, LOH was observed in 47% of tumors, confirming previous reports that such losses are frequent and occur in almost all histological subtypes of tumors, The highest frequency of LOH was found at, or distal to, D6S437, Seven tumors had allelic losses for D6S297 and/or D6S37, A second peak of loss was also observed at D6S262 and D6S32, In some tumors we observed LOH in one or the other of these two regions, In other tumors we observed loss of both regions with retention of intervening loci, These data suggest that two small deletions commonly occur, one between D6S262 and D6S32 (estimated to cover less than 1.5 Mb) and another between D6S297 and D6S446 (estimated to cover similar to 2 Mb), These results extend previous studies by sublocalizing the regions of LOH and suggest that inactivation of one or more tumor suppressor genes located in these regions may be an important step in salivary gland carcinogenesis.	Univ Texas, SW Med Ctr, McDermott Ctr, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Otorhinolaryngol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA; Fac Med Lisboa, Inst Histol & Embriol, Lisbon, Portugal; Inst Portugues Oncol Francisco Gentil, Dept Patol Morfol, Lisbon, Portugal; Inst Portugues Oncol Francisco Gentil, Ctr Invest Patobiol Mol, Lisbon, Portugal; Fac Med Lisboa, Inst Histol & Embriol, Lisbon, Portugal	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Universidade de Lisboa; Portuguese Institute of Oncology; Portuguese Institute of Oncology; Universidade de Lisboa	Queimado, L (corresponding author), Univ Texas, SW Med Ctr, McDermott Ctr, NB10106, Dallas, TX 75235 USA.		Queimado, Lurdes/AAY-2545-2021; Fonseca, Isabel/A-7396-2008; Soares, Jorge/C-7429-2015; Queimado, Lurdes/L-7465-2013; Parreira, Leonor/S-2304-2019	Queimado, Lurdes/0000-0002-1106-4873; Fonseca, Isabel/0000-0002-1359-6494; Soares, Jorge/0000-0002-1359-6494; Queimado, Lurdes/0000-0002-1106-4873; Martins, Carmo/0000-0002-7901-7600; Parreira, Leonor/0000-0002-1970-9285				Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Bockmuhl U, 1996, CANCER RES, V56, P5325; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooke IE, 1996, MAMM GENOME, V7, P157, DOI 10.1007/s003359900040; Cooney KA, 1996, CANCER RES, V56, P4150; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1991, CANCER RES, V51, P1020; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; Hankins GR, 1996, ONCOGENE, V12, P2003; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JIN Y, 1994, BRIT J CANCER, V70, P42, DOI 10.1038/bjc.1994.247; Johns MM, 1996, CANCER RES, V56, P1151; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MORITA R, 1991, CANCER RES, V51, P5817; MULLENBACH R, 1989, TRENDS GENET, V5, P391; NORDKVIST A, 1994, GENE CHROMOSOME CANC, V10, P115, DOI 10.1002/gcc.2870100206; Noviello C, 1996, CLIN CANCER RES, V2, P1601; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; SAFFORD SE, 1994, CANCER RES, V54, P4261; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; Sandhu AK, 1996, ONCOGENE, V12, P247; SANDROS J, 1990, CANCER GENET CYTOGEN, V44, P153, DOI 10.1016/0165-4608(90)90042-9; SEIFERT G, 1990, PATHOL RES PRACT, V186, P555, DOI 10.1016/S0344-0338(11)80220-7; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; Simonic I, 1996, HUM GENET, V97, P524; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; TAGUCHI T, 1993, CANCER RES, V53, P4349; Tahara H, 1996, CANCER RES, V56, P599; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WELCH DR, 1994, ONCOGENE, V9, P255	40	41	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					83	88		10.1038/sj.onc.1201480	http://dx.doi.org/10.1038/sj.onc.1201480			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467946				2022-12-25	WOS:000071236800010
J	Rustaeus, S; Stillemark, P; Lindberg, K; Gordon, D; Olofsson, SO				Rustaeus, S; Stillemark, P; Lindberg, K; Gordon, D; Olofsson, SO			The microsomal triglyceride transfer protein catalyzes the post-translational assembly of apolipoprotein B-100 very low density lipoprotein in McA-RH7777 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; HEP G2 CELLS; ENDOPLASMIC-RETICULUM; APO-B; B-100-CONTAINING LIPOPROTEINS; PULSE-CHASE; SECRETION; ABETALIPOPROTEINEMIA; TRANSPORT; MEMBRANE	In cells in which the lipoprotein assembly process had been inactivated by brefeldin A (BFA), membrane-associated apoB-100 disappeared without forming lipoproteins or being secreted, indicating that it was degraded, Reactivation of the assembly process by chasing the cells in the absence of BFA, gave rise to a quantitative recovery of the membrane-associated apoB-100 in the very low density lipoprotein (VLDL) fraction in the medium, These results indicate that the membrane-associated apoB-100 can be converted to VLDL. A new method was developed by which the major amount (88%) of microsomal apoB-100 but not integral membrane proteins could be extracted, The major effect of this method was to increase the recovery of apoB-100 that banded in the LDL and HDL density regions, suggesting that the membrane-associated form of apoB-100 is partially lipidated, We also investigated the role of the microsomal triglyceride transfer protein (MTP) in the assembly of apoB-100 VLDL using a photoactivatable MTP inhibitor (BMS-192951), This compound strongly inhibited the assembly and secretion of apoB-100 VLDL when present during the translation of the protein, To investigate the importance of MTP during the later stages in the assembly process, the cells were preincubated with BFA (to reversibly inhibit the assembly of apoB-100 VLDL) and pulse-labeled (+BFA) and chased (+BFA) for 30 min to obtain full length apoB-100 associated with the microsomal membrane, Inhibition of MTP after the 30-min chase blocked assembly of VLDL, This indicates that MTP is important for the conversion of full-length apoB-100 into VLDL, Results from experiments in which a second chase (-BFA) was introduced before the inactivation of MTP indicated that only early events in this conversion of full-length apoB-100 into VLDL were blocked by the MTP inhibitor, Together these results indicate that there is a MTP-dependent "window" in the VLDL assembly process that occurs after the completion of apoB-100 but before the major amount of lipids is added to the VLDL particle, Thus the assembly of apoB-100 VLDL from membrane-associated apoB-100 involves an early MTP-dependent phase and a late MTP-independent phase, during which the major amount of lipid is added.	Gothenburg Univ, Dept Med Biochem, S-41390 Gothenburg, Sweden; Gothenburg Univ, Wallenberg Lab, S-41390 Gothenburg, Sweden; Bristol Myers Squibb Co, Div Metab Dis, Princeton, NJ 08543 USA	University of Gothenburg; University of Gothenburg; Bristol-Myers Squibb	Olofsson, SO (corresponding author), Gothenburg Univ, Dept Med Biochem, Medicinaregatan 9, S-41390 Gothenburg, Sweden.		Adiels, Martin/C-9278-2011	Andersson, Karin/0000-0002-9475-3040				ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; Benoist F, 1996, EUR J BIOCHEM, V240, P713, DOI 10.1111/j.1432-1033.1996.0713h.x; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; CRESSWELL P, 1997, CURR BIOL, V7, P552; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; Farese RV, 1996, P NATL ACAD SCI USA, V93, P6393, DOI 10.1073/pnas.93.13.6393; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GLICKMAN RM, 1986, P NATL ACAD SCI USA, V83, P5296, DOI 10.1073/pnas.83.14.5296; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; KANE JP, 1980, P NATL ACAD SCI-BIOL, V77, P2465, DOI 10.1073/pnas.77.5.2465; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; KREIBICH G, 1973, J CELL BIOL, V58, P436, DOI 10.1083/jcb.58.2.436; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; Shelness GS, 1996, J LIPID RES, V37, P408; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; Sjoberg A, 1996, J LIPID RES, V37, P275; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTESTEN M, 1985, EUR J BIOCHEM, V149, P461, DOI 10.1111/j.1432-1033.1985.tb08947.x; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277	34	103	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5196	5203		10.1074/jbc.273.9.5196	http://dx.doi.org/10.1074/jbc.273.9.5196			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478974	hybrid			2022-12-25	WOS:000072310400058
J	Shuang, RQ; Zhang, L; Fletcher, A; Groblewski, GE; Pevsner, J; Stuenkel, EL				Shuang, RQ; Zhang, L; Fletcher, A; Groblewski, GE; Pevsner, J; Stuenkel, EL			Regulation of Munc-18 syntaxin 1A interaction by cyclin-dependent kinase 5 in nerve endings	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED PROTEIN-KINASE; UNC-18 GENE ENCODES; MEMBRANE-FUSION; BINDING PROTEIN; SEC1 HOMOLOG; YEAST SEC1; BRAIN; ROP; TRAFFICKING; SPECIFICITY	The Munc-18-syntaxin 1A complex has been postulated to act as a negative control on the regulated exocytotic process because its formation blocks the interaction of syntaxin with vesicle SNARE proteins, However, the formation of this complex is simultaneously essential for the final stages of secretion as evidenced by the necessity of Munc-18's homologues in Saccharomyces cerevisiae (Sec1p), Drosophila (ROP), and Caenorhabditis elegans (Unc-18) for proper secretion in these organisms, As such, any event that regulates the interaction of these two proteins is important for the control of secretion, One candidate for such regulation is cyclin-dependent kinase 5 (Cdk5), a member of the Cdc2 family of cell division cycle kinases that has recently been copurified with Munc-18 from rat brain, The present study shows that Cdk5 bound to its neural specific activator p35 not only binds to Munc-18 but utilizes it as a substrate for phosphorylation, Furthermore, it is demonstrated that Munc-18 that has been phosphorylated by Cdk5 has a significantly reduced affinity for syntaxin Ik Finally, it is shown that Cdk5 can also bind to syntaxin 1A and that a complex of Cdk5, p35, Munc-18, and syntaxin 1A can be fashioned in the absence of ATP and promptly disassembled upon the addition of ATP, These results suggest a model in which p35-activated Cdk5 becomes localized to the Munc-18-syntaxin 1A complex by its affinity for both proteins so that it may phosphorylate Munc-18 and thus permit the positive interaction of syntaxin 1A with upstream protein effecters of the secretory mechanism.	Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Kennedy Krieger Res Inst, Baltimore, MD 21205 USA	University of Michigan System; University of Michigan; Kennedy Krieger Institute	Stuenkel, EL (corresponding author), Univ Michigan, Dept Physiol, 7804 Med Sci 2 Bldg, Ann Arbor, MI 48109 USA.			Stuenkel, Edward/0000-0001-8225-5725	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031888, R01NS036227] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31888, NS36227] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; COWLES CR, 1994, J CELL SCI, V107, P3449; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HODEL A, 1994, J BIOL CHEM, V269, P8623; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; INO H, 1994, BRAIN RES, V661, P196, DOI 10.1016/0006-8993(94)91197-5; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1995, NEUROBIOL AGING, V16, P263, DOI 10.1016/0197-4580(95)00014-6; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; Pevsner J, 1996, J NEUROSCI RES, V45, P89, DOI 10.1002/(SICI)1097-4547(19960715)45:2<89::AID-JNR1>3.3.CO;2-K; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PEVSNER J, 1997, GENE AMST, V183, P7; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHELLER RH, 1995, NEURON, V14, P893; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SHETTY KT, 1995, J NEUROCHEM, V64, P1988; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1993, CELL, V75, P1; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	46	134	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4957	4966		10.1074/jbc.273.9.4957	http://dx.doi.org/10.1074/jbc.273.9.4957			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478941	hybrid			2022-12-25	WOS:000072310400025
J	Ahmad, M; Theofanidis, P; Medford, RM				Ahmad, M; Theofanidis, P; Medford, RM			Role of activating protein-1 in the regulation of the vascular cell adhesion molecule-1 gene expression by tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR AP-1; MOUSE FIBROBLAST CELLS; DNA-BINDING DOMAINS; C-FOS EXPRESSION; ENDOTHELIAL-CELLS; LEUCINE ZIPPERS; NUCLEAR FACTOR; JUN; PROMOTER	Endothelial cell surface expression of VCAM-1 is one of the initial steps in the pathogenesis of atherosclerosis, The inflammatory response transcription factor nuclear factor (NF)-kappa B plays an important role in the regulation of VCAM-1 expression by various stimuli including tumor necrosis factor (TNF)-alpha. Other transcription factors may modulate this response through interaction with NF-kappa B factors. Since c-Fos/c-Jun (activating protein-1 (AP-1)) are expressed in vascular endothelium during proinflammatory conditions, pie investigated the role of AP-1 proteins in the expression of VCAM-1 by TNF-alpha in SV40 immortalized human microvascular endothelial cells (HMEC), TNF-alpha induced expression of both early protooncogenes, c-fos and c-jun. The ability of TNF-alpha to activate the kappa B-motif (kappa L-kappa R)-dependent VCAM-1 promoter-chloramphenicol acetyltransferase (CAT) reporter gene lacking a consensus AP-I element was markedly inhibited by co-transfection of the expression vector encoding c-fos ribozyme, which decreases the level of c-fos by degrading c-fos mRNA, or c-fos or c-jun oligonucleotides. Conversely, co-transfection of c-Fos and c-Jun encoding expression vectors potentiated the p65/NF-kappa B-mediated transactivation of the VCAM-1 promoter-CAT reporter gene, Furthermore the c-Fos encoding expression vector potentiated by a-fold the transactivation activity of a chimeric transcriptional factor Gal/P65 (containing the transactivation domain of p65 and the DNA binding domain of the yeast transcriptional factor Gal-4). Consistent with the promoter studies, curcumin and. NDGA, inhibitors of AP-I activation, markedly inhibited the ability of TNF-alpha to activate the expression of VCAM-1 mRNA levels at concentration that; did not inhibit the activation of NF-kappa B, In gel mobility supershift assays, the antibodies to c-Fos or c-Jun inhibited the binding of TNF-alpha-activated nuclear NF-kappa B to the kappa L-kappa R, suggesting that both e-Fos and c-Jun interacted with NF-kappa B. These results suggest that AP-I proteins may mediate the effect of TNF-alpha in the regulation of VCAM-1 expression through interaction with NF-kappa B factors in endothelial cells.	Emory Univ, Dept Med, Div Cardiol, Sch Med, Atlanta, GA 30322 USA	Emory University	Ahmad, M (corresponding author), Emory Univ, Dept Med, Div Cardiol, Sch Med, 1639 Pierce Dr,WMB 319, Atlanta, GA 30322 USA.	mahmad@emory.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048667] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL48667] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; AHMAD M, 1995, J BIOL CHEM, V270, P8976, DOI 10.1074/jbc.270.15.8976; AHMAD M, 1994, J CELL BIOCHEM, V18, P268; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CASTIGLI E, 1993, J IMMUNOL, V150, P3284; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COLLINS T, 1993, LAB INVEST, V68, P499; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1476; GAMBLE JR, 1991, J IMMUNOL, V146, P1149; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HSIEH HJ, 1993, J CELL PHYSIOL, V154, P143, DOI 10.1002/jcp.1041540118; HUANG TS, 1995, CANCER LETT, V96, P1, DOI 10.1016/0304-3835(95)03918-M; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN JX, 1987, J BIOL CHEM, V262, P11908; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; Sambrook J., 2002, MOL CLONING LAB MANU; SCANLON KJ, 1991, P NATL ACAD SCI USA, V88, P10591, DOI 10.1073/pnas.88.23.10591; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047	50	174	182	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4616	4621		10.1074/jbc.273.8.4616	http://dx.doi.org/10.1074/jbc.273.8.4616			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468519	hybrid			2022-12-25	WOS:000072115000047
J	Arkonac, BM; Foster, LC; Sibinga, NES; Patterson, C; Lai, KH; Tsai, JC; Lee, ME; Perrella, MA; Haber, E				Arkonac, BM; Foster, LC; Sibinga, NES; Patterson, C; Lai, KH; Tsai, JC; Lee, ME; Perrella, MA; Haber, E			Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FACTOR MESSENGER-RNA; FACTOR GENE; ATHEROSCLEROTIC PLAQUES; RECEPTOR EXPRESSION; PHORBOL ESTER; ANGIOGENESIS; EGF; HYPOXIA; INDUCTION	Although several cytokines and growth factors have been shown to regulate vascular endothelial growth factor (VEGF) production, little is known about how VEGF may regulate growth factors that have known mitogenic and chemotactic actions on mesenchymal cells (which are involved in the maturation of the angiogenic process). We investigated the effect of VEGF on heparin-binding epidermal growth factor-like growth factor (HB-EGF) expression in human umbilical vein endothelial cells. HB-EGF mRNA was induced by 8-fold after 2 h of VEGF stimulation, and it returned to base line within 6 h. VEGF did not alter the half-life of HB-EGF mRNA (55 min). Nuclear run-on experiments showed a 4.9-fold increase in HB-EGF gene transcription within 2 h of VEGF stimulation, and Western analysis demonstrated an associated increase in cellular HB-EGF protein. We found that platelet-derived growth factor-BB (PDGF-BB) mRNA was also induced 3-fold after 5 h of VEGF stimulation, whereas neither endothelin 1 nor transforming growth factor-beta 1 was regulated by VEGF. Finally, conditioned medium from VEGF-stimulated endothelial cells produced an increase in DNA synthesis in vascular smooth muscle cells, and this effect was blocked by a neutralizing antibody to PDGF. The induction of HB-EGF an PDGF-BB expression in endothelial cells may represent the mechanism by which VEGF recruits mesenchymal cells to form the medial and adventitial layers of arterioles and venules during the course of angiogenesis.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Kaohsiung Med Coll, Dept Med, Kaohsiung, Taiwan; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Kaohsiung Medical University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Arkonac, BM (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 677 Huntington Ave, Boston, MA 02115 USA.		Sibinga, Nicholas/GOJ-8544-2022	Sibinga, Nicholas/0000-0003-4838-910X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03274, HL03194] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS GF, 1994, J BIOL CHEM, V269, P10112; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BREIER G, 1992, DEVELOPMENT, V114, P521; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; D'Amore P A, 1992, Semin Cancer Biol, V3, P49; DAMORE PA, 1993, GROWTH FACTORS, V8, P61, DOI 10.3109/08977199309029135; DAS SK, 1994, DEVELOPMENT, V120, P1071; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FREEMAN MR, 1995, CANCER RES, V55, P4140; GIAID A, 1995, TRANSPLANTATION, V59, P1308; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; Koolwijk P, 1996, J CELL BIOL, V132, P1177, DOI 10.1083/jcb.132.6.1177; KUZUYA M, 1995, J CELL PHYSIOL, V164, P658, DOI 10.1002/jcp.1041640324; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; MORITA T, 1993, BIOCHEM BIOPH RES CO, V197, P256, DOI 10.1006/bbrc.1993.2469; NEHLS V, 1994, MICROVASC RES, V48, P349, DOI 10.1006/mvre.1994.1061; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; NICOSIA RF, 1995, LAB INVEST, V73, P658; NOMURA M, 1995, J BIOL CHEM, V270, P28316; OBRIEN ER, 1994, AM J PATHOL, V145, P883; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; Ruef J, 1997, CIRC RES, V81, P24, DOI 10.1161/01.RES.81.1.24; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467	50	69	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4400	4405		10.1074/jbc.273.8.4400	http://dx.doi.org/10.1074/jbc.273.8.4400			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468491	hybrid			2022-12-25	WOS:000072115000019
J	Marx, UC; Adermann, K; Bayer, P; Meyer, M; Forssmann, WG; Rosch, P				Marx, UC; Adermann, K; Bayer, P; Meyer, M; Forssmann, WG; Rosch, P			Structure-activity relation of NH2-terminal human parathyroid hormone fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; NUCLEAR-MAGNETIC-RESONANCE; NMR CHEMICAL-SHIFTS; HELIX DIPOLE MODEL; CIRCULAR-DICHROISM; PEPTIDE-FRAGMENTS; AQUEOUS-SOLUTION; ALPHA-HELICES; DYNAMICS CALCULATIONS; H-1-NMR SPECTROSCOPY	Human parathyroid hormone (hPTH) is involved in the regulation of the calcium level in blood. This hormone function is located in the NH2-terminal 34 amino acids of the 84-amino acid peptide hormone and is transduced via the adenylate cyclase and the phosphatidylinositol signaling pathways. it is well known that truncation of the two NH2-terminal amino acids of the hormone leads to complete loss of in vivo normocalcemic function. To correlate loss of calcium level regulatory activity after stepwise NH2-terminal truncation and solution structure, we studied the conformations of fragments hPTH-(2-37), hPTH-(3-37), and hPTH-(4-37) in comparison to hPTH-(1-37) in aqueous buffer solution under near physiological conditions by circular dichroism spectroscopy, two-dimensional nuclear magnetic resonance spectroscopy, and restrained molecular dynamics calculations, All peptides show helical structures and hydrophobic interactions between Leu-15 and Trp-23 that lead to a defined loop region from His-14 to Ser-17. A COOH-terminal helix from Met-18 to at least Leu-28 was found for all peptides. The helical structure in the NH2-terminal part of the peptides was lost in parallel with the NH2-terminal truncation and can be correlated with the loss of calcium regulatory activity.	Univ Bayreuth, Lehrstuhl Biopolymere, D-95440 Bayreuth, Germany; Niedersachs Inst Peptid Forsch, D-30625 Hannover, Germany	University of Bayreuth	Rosch, P (corresponding author), Univ Bayreuth, Lehrstuhl Struktur & Chem Biopolymere, POB 101251, D-95440 Bayreuth, Germany.		Rösch, Paul/I-5445-2014; Bayer, Peter/B-8803-2009	Rösch, Paul/0000-0003-3330-2446; Bayer, Peter/0000-0003-0435-7202; Marx, Ute C./0000-0002-7077-9940				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ABOUSAMRA AB, 1987, J BIOL CHEM, V262, P1129; Atherton E., 1990, SOLID PHASE PEPTIDE; BARDEN JA, 1993, EUR J BIOCHEM, V215, P315, DOI 10.1111/j.1432-1033.1993.tb18037.x; BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1993, X PLOR VERSION 3 1; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo-127-1-83; CHAKRABARTTY A, 1993, BIOCHEMISTRY-US, V32, P5560, DOI 10.1021/bi00072a010; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Chorev Michael, 1994, P139; Coleman Daniel T., 1994, P239; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; Ernst R.R., 1992, ANGEW CHEM, V104, P817; FAIRMAN R, 1989, PROTEINS, V5, P1, DOI 10.1002/prot.340050102; FORSSMANN WG, 1993, PEPTIDE CHEMISTRY 1992, P553; FORSSMANN WG, 1995, PEPTIDES CHEM STRUCT, P225; GANS PJ, 1991, BIOPOLYMERS, V31, P1605, DOI 10.1002/bip.360311315; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Gronwald W, 1996, BIOL CHEM H-S, V377, P175, DOI 10.1515/bchm3.1996.377.3.175; Hock D, 1997, FEBS LETT, V400, P221, DOI 10.1016/S0014-5793(96)01390-7; JIMENEZ MA, 1994, BIOPOLYMERS, V34, P647, DOI 10.1002/bip.360340507; JOUISHOMME H, 1992, ENDOCRINOLOGY, V130, P53, DOI 10.1210/en.130.1.53; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Karle IL, 1996, BIOPOLYMERS, V40, P157, DOI 10.1002/(SICI)1097-0282(1996)40:1<157::AID-BIP7>3.0.CO;2-V; KARLE IL, 1990, BIOCHEMISTRY-US, V29, P6747, DOI 10.1021/bi00481a001; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P976; LANCELIN JM, 1994, FEBS LETT, V343, P261, DOI 10.1016/0014-5793(94)80568-7; Lee MS, 1996, PROTEIN ENG, V9, P15, DOI 10.1093/protein/9.1.15; LOPEZHILKER S, 1992, J LAB CLIN MED, V119, P738; MANNING MC, 1991, BIOPOLYMERS, V31, P569, DOI 10.1002/bip.360310511; MARX UC, 1995, J BIOL CHEM, V270, P15194, DOI 10.1074/jbc.270.25.15194; MILLHAUSER GL, 1995, BIOCHEMISTRY-US, V34, P3873, DOI 10.1021/bi00012a001; MORRISET.JD, 1973, BIOCHEMISTRY-US, V12, P1290, DOI 10.1021/bi00731a008; MORTON CJ, 1994, EUR J BIOCHEM, V219, P97, DOI 10.1111/j.1432-1033.1994.tb19919.x; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; NEUGEBAUER W, 1995, BIOCHEMISTRY-US, V34, P8835, DOI 10.1021/bi00027a035; PARSONS JA, 1973, ENDOCRINOLOGY, V92, P454, DOI 10.1210/endo-92-2-454; Petukhov M, 1996, BIOCHEMISTRY-US, V35, P387, DOI 10.1021/bi9513766; POTTS JT, 1982, ADV PROTEIN CHEM, V35, P323, DOI 10.1016/S0065-3233(08)60471-4; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROSENBLATT M, 1977, J BIOL CHEM, V252, P5847; SAYLE R, 1995, RASMOL VERSION 2 6 M; SCHLUTER KD, 1989, J BIOL CHEM, V264, P11087; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; Segre Gino V., 1994, P213; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SOMJEN D, 1990, BIOCHEM J, V272, P781; SOMJEN D, 1991, BIOCHEM J, V277, P863; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; STICHT H, 1993, EUR J BIOCHEM, V218, P973, DOI 10.1111/j.1432-1033.1993.tb18455.x; STRICKLAND LA, 1993, BIOCHEMISTRY-US, V32, P6050, DOI 10.1021/bi00074a016; TREGEAR GW, 1973, ENDOCRINOLOGY, V93, P1349, DOI 10.1210/endo-93-6-1349; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Woody R. W., 1994, CIRCULAR DICHROISM P, P473; WRAY V, 1994, BIOCHEMISTRY-US, V33, P1684, DOI 10.1021/bi00173a010; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YANG JT, 1986, METHOD ENZYMOL, V130, P208	69	30	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4308	4316		10.1074/jbc.273.8.4308	http://dx.doi.org/10.1074/jbc.273.8.4308			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468478	hybrid			2022-12-25	WOS:000072115000006
J	Sutherland, PJ; Tobin, AE; Rutherford, CL; Price, NPJ				Sutherland, PJ; Tobin, AE; Rutherford, CL; Price, NPJ			Dictyostelium discoideum fatty-acyl amidase II has deacylase activity on Rhizobium nodulation factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPO-OLIGOSACCHARIDE SIGNALS; NOD FACTORS; LINKED OLIGOSACCHARIDES; STRUCTURAL-ANALYSIS; STRAIN NGR234; N-METHYL; ACID; BIOSYNTHESIS; PROTEIN	Dictyostelium discoideum (Amoebidae) secretes cell-lysing enzymes: esterases, amidases, and glycosylases, many of which degrade soil bacteria to provide a source of nutrients, Two of these enzymes, fatty-acyl amidases FAA I and FAA II, act sequentially on the N-linked long chain acyl groups of lipid A, the lipid anchor of Gramnegative bacterial lipopolysaccharide, FAA I selectively hydrolyzes the 3-hydroxymyristoyl group N-linked to the proximal glucosamine residue of de-O-acylated lipid A, Substrate specificity for FAA II is less selective, but does require prior de-N-acylation of the proximal sugar, i.e. bis-N-acylated lipid A is not a substrate, We have synthesized a C-14-labeled substrate analog for FAA II and used this in a novel assay to monitor its purification, Inhibitory studies indicate that FAA II is not a serine protease, but may have a catalytic mechanism similar to metalloprotein de-N-acetylases such as LpxC, Interestingly, rhizobial Nod factor signal oligosaccharides that induce root nodules on leguminous plants have many of the structural requirements for substrate recognition by FAA II, In vitro evidence indicates that Rhizobium fredii Nod factors are selectively de-N-acylated by purified FAA II, suggesting that the enzyme may reduce the N-2-fixing efficiency of Rhizobium-legume symbioses, In contrast, N-methylated Nod factors from transgenic R, fredii carrying the rhizobial nodS gene were resistant to FAA II, suggesting a mechanism by which Nod factors may be protected from enzymatic de-N-acylation, Since FAA II and Nod factors are both secreted, and Nod factors that lack the N-acyl group are unable to induce nodules, dictyostelial FAA II may decrease the efficiency of symbiotic nitrogen fixation in the environment by reducing the available biologically active nodule inducer signal.	SUNY Syracuse, Coll Environm Sci & Forestry, Dept Chem, Syracuse, NY 13210 USA; Virginia Polytech Inst & State Univ, Dept Biol, Blacksburg, VA 24061 USA	State University of New York (SUNY) System; State University of New York (SUNY) College of Environmental Science & Forestry; Virginia Polytechnic Institute & State University	Sutherland, PJ (corresponding author), SUNY Syracuse, Coll Environm Sci & Forestry, Dept Chem, Syracuse, NY 13210 USA.				NIA NIH HHS [AG00678] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ATKINSON EM, 1994, P NATL ACAD SCI USA, V91, P8418, DOI 10.1073/pnas.91.18.8418; BECFERTE MP, 1994, BIOCHEMISTRY-US, V33, P11782, DOI 10.1021/bi00205a014; CARLSON RW, 1994, MOL PLANT MICROBE IN, V7, P684, DOI 10.1094/MPMI-7-0684; DELMONT N, 1993, J BIOL CHEM, V268, P20134; FREEZE HH, 1986, J BIOL CHEM, V261, P127; FREEZE HH, 1983, J BIOL CHEM, V258, P4874; GRAHAM TR, 1988, J BIOL CHEM, V263, P16823; Hyland SA, 1997, J BACTERIOL, V179, P2029, DOI 10.1128/jb.179.6.2029-2037.1997; JABBOURI S, 1995, J BIOL CHEM, V270, P22968, DOI 10.1074/jbc.270.39.22968; KRISHNAN HB, 1992, MOL MICROBIOL, V6, P3321, DOI 10.1111/j.1365-2958.1992.tb02200.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERGAERT P, 1993, P NATL ACAD SCI USA, V90, P1551, DOI 10.1073/pnas.90.4.1551; POUPOT R, 1993, BIOCHEMISTRY-US, V32, P10430, DOI 10.1021/bi00090a019; Price NPJ, 1996, CARBOHYD RES, V289, P115, DOI 10.1016/0008-6215(96)00119-X; PRICE NPJ, 1992, MOL MICROBIOL, V6, P3575, DOI 10.1111/j.1365-2958.1992.tb01793.x; PRICE NPJ, 1995, GLYCOBIOLOGY, V5, P233, DOI 10.1093/glycob/5.2.233; ROHRIG H, 1994, P NATL ACAD SCI USA, V91, P3122, DOI 10.1073/pnas.91.8.3122; ROSNER MR, 1979, J BIOL CHEM, V254, P5926; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; VERRET CR, 1982, J BIOL CHEM, V257, P222; VERRET CR, 1982, J BIOL CHEM, V257, P228	23	5	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4459	4464		10.1074/jbc.273.8.4459	http://dx.doi.org/10.1074/jbc.273.8.4459			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468498	hybrid			2022-12-25	WOS:000072115000026
J	Xu, G; Marshall, CA; Lin, TA; Kwon, G; Munivenkatappa, RB; Hill, JR; Lawrence, JC; McDaniel, ML				Xu, G; Marshall, CA; Lin, TA; Kwon, G; Munivenkatappa, RB; Hill, JR; Lawrence, JC; McDaniel, ML			Insulin mediates glucose-stimulated phosphorylation of PHAS-I by pancreatic beta cells - An insulin-receptor mechanism for autoregulation of protein synthesis by translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTES; GENE-EXPRESSION; MESSENGER-RNA; CYCLIC-AMP; RAT ISLETS; KINASE; BIOSYNTHESIS; RAPAMYCIN; SECRETION; LINE	Although glucose regulates the biosynthesis of a variety of beta cell proteins at the level of translation, the mechanism responsible for this effect is unknown, We demonstrate that incubation of pancreatic islets with elevated glucose levels results in rapid and concentration-dependent phosphorylation of PHAS-I, an inhibitor of mRNA cap-binding protein, eukaryotic initiation factor (eIF)-4E. Our initial approach was to determine if this effect is mediated by the metabolism of glucose and activation of islet cell protein kinases, or whether insulin secreted from the beta cell stimulates phosphorylation of PHAS-I via an insulin-receptor mechanism as described for insulin sensitive cells, In support of the latter mechanism, inhibitors of islet cell protein kinases A and C exert no effect on glucose-stimulated phosphorylation of PHAS-I, whereas the phosphatidylinositol 3-kinase inhibitor, wortmannin, the immunosuppressant, rapamycin, and theophylline, a phosphodiesterase inhibitor, promote marked dephosphorylation of PHAS-I. In addition, exogenous insulin and endogenous insulin secreted by the beta cell line, beta TC6-F7, increase phosphorylation of PHAS-I, suggesting that beta cells of the islet, in part, mediate this effect, Studies with beta cell lines and islets indicate that amino acids are required for glucose or exogenous insulin to stimulate the phosphorylation of PHAS-I, and amino acids alone dose-dependently stimulate the phosphorylation of PHAS-I, which is further enhanced by insulin, Furthermore, rapamycin inhibits by similar to 62% the increase in total protein synthesis stimulated by high glucose concentrations. These results indicate that glucose stimulates PHAS-I phosphorylation via insulin interacting with its own receptor on the beta cell which may serve as an important mechanism for autoregulation of protein synthesis by translation.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA	Washington University (WUSTL); University of Virginia	McDaniel, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol, Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.				NIAMS NIH HHS [AR41189] Funding Source: Medline; NIDDK NIH HHS [DK50628, DK28312] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZICAR041189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; ESCOLAR JC, 1987, J ENDOCRINOL, V115, P225, DOI 10.1677/joe.0.1150225; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GAZZANO H, 1985, BIOCHEM J, V226, P867, DOI 10.1042/bj2260867; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; GRIMALDI KA, 1987, BIOCHEM J, V245, P567, DOI 10.1042/bj2450567; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; ISHIHARA F, 1994, J ENDOCRINOL, V143, P497, DOI 10.1677/joe.0.1430497; KNAACK D, 1994, DIABETES, V43, P1413, DOI 10.2337/diabetes.43.12.1413; Krueger KA, 1997, J BIOL CHEM, V272, P27464, DOI 10.1074/jbc.272.43.27464; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; METZ SA, 1988, DIABETES, V37, P3, DOI 10.2337/diabetes.37.1.3; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; PATTI ME, 1997, DIABETES S1, V46; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PERMUTT MA, 1972, J BIOL CHEM, V247, P1194; PERMUTT MA, 1974, J BIOL CHEM, V249, P2738; Persaud SJ, 1996, BIOCHEM J, V313, P119, DOI 10.1042/bj3130119; PETRITSCH C, 1995, J BIOL CHEM, V270, P26619, DOI 10.1074/jbc.270.44.26619; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; Renstrom E, 1996, J PHYSIOL-LONDON, V494, P41, DOI 10.1113/jphysiol.1996.sp021474; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; Skelly RH, 1996, DIABETES, V45, P37, DOI 10.2337/diabetes.45.1.37; Thompson MG, 1996, BBA-MOL CELL RES, V1311, P37, DOI 10.1016/0167-4889(95)00194-8; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5	40	90	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4485	4491		10.1074/jbc.273.8.4485	http://dx.doi.org/10.1074/jbc.273.8.4485			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468502	hybrid			2022-12-25	WOS:000072115000030
J	DeMattos, RB; Curtiss, LK; Williams, DL				DeMattos, RB; Curtiss, LK; Williams, DL			A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; CENTRAL NERVOUS-SYSTEM; ALZHEIMER-DISEASE; CEREBROSPINAL-FLUID; A-I; PERIPHERAL-TISSUES; NONHUMAN-PRIMATES; E GENOTYPE; EXPRESSION; MOUSE	Within the central nervous system,;apolipoprotein E (apoE) synthesis Is increased in response to nerve injury, a finding that may reflect a role for apoE in neuronal remodeling.,, Recent studies show that apoE3 promotes and apoE4 inhibits neurite outgrowth in cultured neuronal cells, interestingly, these isoform-specific effects are observed only when apoE is presented to cells in the presence of an exogenous lipid source such as rabbit beta-very low density lipoprotein (beta-VLDL, making, it difficult to discern the biologically active form of apoE or to understand the role of the lipid source. In the present study we tested whether a cell-derived lipidated form of apoE can alter neurite outgrowth in the? absence of beta-VLDL by constructing Neuro-2a cell lines expressing high levels of apoE. Our results showed that endogenous apoE3 stimulated neurite outgrowth, whereas the endogenous apoE4 isoform was neutral, Furthermore, beta-VLDL antagonized the stimulatory effects of the endogenous apoE3, Characterization of the secreted apoE3 indicated that the neurite outgrowth-stimulating activity could be recovered,from culture medium with an anti-apoE immunoaffinity column and was present in a poorly lipidated particle with a density between 1.19 and 1.26 g/ml. These results indicated that the biological activity of apoE3 in stimulating neurite outgrowth was inherent in the cell-derived apoE particle and was not dependent on either (a) an interaction of apoE3 with an artificial lipid source or (b) independent actions of apoE3 and beta-VLDL.	SUNY Stony Brook, Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Scripps Research Institute; Scripps Research Institute	Williams, DL (corresponding author), SUNY Stony Brook, Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.				NHLBI NIH HHS [HL 32868, HL 35297] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032868, R01HL035297] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BOYLES JK, 1990, J BIOL CHEM, V265, P17805; CARLSSON J, 1991, CLIN CHIM ACTA, V196, P167, DOI 10.1016/0009-8981(91)90070-S; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAWSON PA, 1986, J BIOL CHEM, V261, P5681; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; GOEDERT M, 1994, NATURE, V372, P45, DOI 10.1038/372045a0; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERSCOVITZ H, 1992, J LIPID RES, V33, P791; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; HUANG DY, 1995, EXP NEUROL, V136, P251, DOI 10.1006/exnr.1995.1101; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Jacobsen L, 1996, J BIOL CHEM, V271, P31379, DOI 10.1074/jbc.271.49.31379; KIM DH, 1996, J BIOL CHEM, V271, P8873; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Narita M, 1997, J NEUROCHEM, V68, P587; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NEWMAN TC, 1985, J BIOL CHEM, V260, P2452; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Puttfarcken PS, 1997, J NEUROCHEM, V68, P760; REYLAND ME, 1991, P NATL ACAD SCI USA, V88, P2375, DOI 10.1073/pnas.88.6.2375; ROHEIM PS, 1979, P NATL ACAD SCI USA, V76, P4646, DOI 10.1073/pnas.76.9.4646; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SHORE V, 1967, BIOCHEMISTRY-US, V6, P1962, DOI 10.1021/bi00859a012; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WILLIAMS DL, 1985, J BIOL CHEM, V260, P2444; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	41	109	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4206	4212		10.1074/jbc.273.7.4206	http://dx.doi.org/10.1074/jbc.273.7.4206			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461617	hybrid			2022-12-25	WOS:000072048400059
J	Gesbert, F; Garbay, C; Bertoglio, J				Gesbert, F; Garbay, C; Bertoglio, J			Interleukin-2 stimulation induces tyrosine phosphorylation of p120-Cbl and CrkL and formation of multimolecular signaling complexes in T lymphocytes and natural killer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-CBL PROTOONCOGENE; EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; IL-2 RECEPTOR; ANTIGEN RECEPTOR; PROTEIN PRODUCT; ADAPTER PROTEIN; SH3 DOMAIN; V-CBL; EGF STIMULATION	Interleukin (IL)-2, a major growth and differentiation factor far T lymphocytes, was found to induce tyrosine phosphorylation of the proto-oncogene products p120-Cbl and CrkL in IL-2-dependent cell lines, We established that, in unstimulated lymphocytes, the Src homology 2 (SH2) and SH3 domain-containing protein Grb2 and the p85 subunit of phosphatidylinositol 3-kinase, associate constitutively with Cbl via their SPPS domains, Furthermore, IL-2 stimulation increased the level of interaction of phosphorylated Cbl with the p85 SH2 domains, and we provide evidence that the preformed Cbl-Grb2 complex recruits the phosphorylated p52 Shc adaptor protein, In addition, we demonstrate that the SH2-SH3-SH3 adaptor protein CrkL is tyrosine-phosphorylated in an IL-2-dependent manner and, via its SH2 domain, associates with a large proportion of phosphorylated Cbl, We also show that p85 is preassociated with the CrkL SH3 domain, Furthermore, the association of CrkL and p85 is increased after IL-2 treatment by a mechanism involving intermediary tyrosine-phosphorylated proteins that remain to be identified, Our results show that CrkL associates independently with Cbl or p85 and suggest that it salse participates in larger complexes containing Cbl and p85. Although the precise roles of Cbl and CrkL remain to be elucidated, their tyrosine phosphorylation, in addition to the multiple protein interactions described here, strongly suggest that Cbl and CrkL may play pivotal roles in the early steps of IL-2 signal transduction.	Fac Pharm Paris 11, INSERM U461, F-92296 Chatenay Malabry, France; Fac Pharm Paris 5, INSERM U266, F-75720 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bertoglio, J (corresponding author), Fac Pharm Paris 11, INSERM U461, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.	j.bertoglio@cep.u-psud.fr		Gesbert, Franck/0000-0002-5800-8385				Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FitzerAttas CJ, 1997, J BIOL CHEM, V272, P8551, DOI 10.1074/jbc.272.13.8551; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HORI T, 1987, BLOOD, V70, P1069; Kanagasundaram V, 1996, BIOCHEM J, V320, P69, DOI 10.1042/bj3200069; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; Kontani K, 1996, J BIOL CHEM, V271, P1534; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Liu YC, 1997, J BIOL CHEM, V272, P168; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Matsuo T, 1996, FEBS LETT, V382, P11, DOI 10.1016/0014-5793(96)00122-6; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MERIDA I, 1991, J IMMUNOL, V147, P2202; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Robertson MJ, 1996, EXP HEMATOL, V24, P406; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Theze J, 1996, IMMUNOL TODAY, V17, P481, DOI 10.1016/0167-5699(96)10057-C; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	58	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3986	3993		10.1074/jbc.273.7.3986	http://dx.doi.org/10.1074/jbc.273.7.3986			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461587	hybrid			2022-12-25	WOS:000072048400029
J	Liberator, P; Anderson, J; Feiglin, M; Sardana, M; Griffin, P; Schmatz, D; Myers, RW				Liberator, P; Anderson, J; Feiglin, M; Sardana, M; Griffin, P; Schmatz, D; Myers, RW			Molecular cloning and functional expression of mannitol-1-phosphatase from the apicomplexan parasite Eimeria tenella	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATIC-ACID-PHOSPHATASE; SITE-DIRECTED MUTAGENESIS; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; MANNITOL CYCLE; ACTIVE-SITE; RAT-LIVER; SEQUENCE; IDENTIFICATION; PROTEINS; ENZYME	A metabolic pathway responsible for the biosynthesis and utilization of mannitol is present in the seven species of Eimeria that infect chickens, but is not in the avian host, Mannitol-l-phosphatase (M1Pase), a key enzyme for mannitol biosynthesis, is a highly substrate-specific phosphatase and, accordingly, represents an attractive chemotherapeutic target, Amino acid sequence of tryptic peptides obtained from biochemically purified Eimeria tenella M1Pase was used to synthesize degenerate oligonucleotide hybridization probes, Using these reagents, a partial genomic clone and full-length cDNA clones have been isolated and characterized, The de deduced amino acid sequence of E. tenella M1Pase shows limited overall homology to members of the phosphohistidine family of phosphatases, This limited homology to other histidine phosphatases does, however, include several conserved residues that have been shown to be essential for their catalytic activity, Kinetic parameters of recombinant M1Pase expressed in bacteria are essentially identical to those of the biochemically purified preparation from E., tenella, Moreover, recombinant M1Pase is subject to active site directed, hydroxylamine-reversible inhibition by the histidine-selective acylating reagent diethyl pyrocarbonate. These results indicate the presence of an essential histidine residue(s) at the M1Pase active site, as predicted for a histidine phosphatase.	Merck Res Labs, Dept Parasite Biochem & Cell Biol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Mol Design & Divers, Rahway, NJ 07065 USA; Merck Res Labs, Dept Biol Chem, West Point, PA 19486 USA	Merck & Company; Merck & Company; Merck & Company	Liberator, P (corresponding author), Merck Res Labs, Dept Parasite Biochem & Cell Biol, POB 2000,Mail Locat R80Y-265, Rahway, NJ 07065 USA.	paul_liberator@merck.com						BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOTHERGILLGILMO.LA, 1990, ADV ENZYMOLOGY RELAT, V62, P227; GRIFFIN PR, 1991, INT J MASS SPECTROM, V111, P131, DOI 10.1016/0168-1176(91)85052-N; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HULT K, 1978, EUR J BIOCHEM, V88, P607, DOI 10.1111/j.1432-1033.1978.tb12487.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lee YH, 1996, BIOCHEMISTRY-US, V35, P6010, DOI 10.1021/bi9600613; Levine N.D., 1982, P1; LIBERATOR PA, 1989, NUCLEIC ACIDS RES, V17, P7104, DOI 10.1093/nar/17.17.7104; LIN K, 1992, J BIOL CHEM, V267, P19163; MCTIGUE JJ, 1978, BIOCHIM BIOPHYS ACTA, V523, P422, DOI 10.1016/0005-2744(78)90044-X; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; OSTANIN K, 1993, J BIOL CHEM, V268, P20778; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; OSTANIN K, 1994, J BIOL CHEM, V269, P8971; OSTROWSKI W, 1978, BIOCHIM BIOPHYS ACTA, V526, P147, DOI 10.1016/0005-2744(78)90299-1; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PILKIS SJ, 1983, J BIOL CHEM, V258, P6135; PILKIS SJ, 1987, J BIOL CHEM, V262, P12672; PROFOUSJUCHELKA H, 1988, MOL BIOCHEM PARASIT, V30, P233, DOI 10.1016/0166-6851(88)90092-8; Rose Z B, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P211; SAINI MS, 1979, BIOCHIM BIOPHYS ACTA, V568, P370, DOI 10.1016/0005-2744(79)90305-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMATZ DM, 1989, MOL BIOCHEM PARASIT, V32, P263, DOI 10.1016/0166-6851(89)90075-3; SCHMATZ DM, 1988, MOL BIOCHEM PARASIT, V29, P29, DOI 10.1016/0166-6851(88)90116-8; SCHMATZ DM, 1989, PARASITOL TODAY, V5, P205, DOI 10.1016/0169-4758(89)90268-8; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; TAULER A, 1990, J BIOL CHEM, V265, P15617; THORNBERRY NA, 1991, J BIOL CHEM, V266, P21657; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27	38	31	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4237	4244		10.1074/jbc.273.7.4237	http://dx.doi.org/10.1074/jbc.273.7.4237			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461622	hybrid			2022-12-25	WOS:000072048400064
J	Huang, L; Grammatikakis, N; Toole, BP				Huang, L; Grammatikakis, N; Toole, BP			Organization of the chick CDC37 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TRANSFORMING PROTEIN; BINDING PROTEIN; HEPARAN-SULFATE; CELL-DIVISION; KINASE; GLYCOSAMINOGLYCANS; LOCALIZATION; REPRESSOR; RECEPTOR; COMPLEX	CDC37 and the chaperone protein, Hsp90, form a complex that binds to several kinases, resulting in stabilization and promotion of their activity. CDC37 also binds DNA and glycosaminoglycans in a sequence-specific manner. In this study, we further characterize chick CDC37 and examine the organization of the CDC37 gene. Chick CDC37 is a similar to 50-kDa protein encoded by an mRNA of similar to 1.7 kilobases. The CDC37 gene is similar to 8.5 kilobases and contains 8 exons and 7 introns of various sizes. The presumptive promoter and 5'-flanking regions contain an E2 box and consensus binding sites for SP1, for the S8 homeodomain protein, and for two zinc finger clusters within the myeloid progenitor transcription factor, MZF1. Particularly striking is a similar to 470-base pair region composed of a highly repetitive 10-11-base pair sequence, (T/C)gCTAT(A/G)GGG(A/T) (where g represents the additional G present in the 11-base pair sequence). This region includes 15 copies of the sequence, TAT-GGGGA, which conforms to the DNA consensus sequence recognized by one of the zinc finger clusters in MZF1. These findings emphasize the potential importance of CDC37 in regulation of cellular behavior during tissue development and reorganization.	Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA	Tufts University	Toole, BP (corresponding author), Tufts Univ, Sch Med, Dept Anat & Cellular Biol, 136 Harrison Ave, Boston, MA 02111 USA.	btoole@infonet.tufts.edu			NICHD NIH HHS [HD23681] Funding Source: Medline; NIDCR NIH HHS [DE05838] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005838] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1982, NATURE, V295, P250, DOI 10.1038/295250a0; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; DEJONG R, 1993, NUCLEIC ACIDS RES, V21, P4711, DOI 10.1093/nar/21.20.4711; Dey B, 1996, MOL BIOL CELL, V7, P1405, DOI 10.1091/mbc.7.9.1405; FERGUSON J, 1986, NUCLEIC ACIDS RES, V14, P6681, DOI 10.1093/nar/14.16.6681; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; GRAMMATIKAKIS N, 1995, J BIOL CHEM, V270, P16198, DOI 10.1074/jbc.270.27.16198; HISCOCK DRR, 1994, J BIOL CHEM, V269, P4539; ISHIHARA M, 1989, J CELL PHYSIOL, V138, P467, DOI 10.1002/jcp.1041380305; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; OCHMAN H, 1988, GENETICS, V120, P621; Ozaki T, 1996, DNA CELL BIOL, V15, P975, DOI 10.1089/dna.1996.15.975; Ozaki T, 1995, DNA CELL BIOL, V14, P1017, DOI 10.1089/dna.1995.14.1017; Ozaki T, 1996, BIOCHEM BIOPH RES CO, V226, P237, DOI 10.1006/bbrc.1996.1339; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; PRATT WB, 1993, J BIOL CHEM, V268, P21455; REED SI, 1980, GENETICS, V95, P561; RIPELLINO JA, 1989, J CELL BIOL, V108, P1899, DOI 10.1083/jcb.108.5.1899; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schutz AR, 1997, J CELL BIOL, V136, P969, DOI 10.1083/jcb.136.5.969; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x	39	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3598	3603		10.1074/jbc.273.6.3598	http://dx.doi.org/10.1074/jbc.273.6.3598			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452487	hybrid			2022-12-25	WOS:000071822300072
J	Reilly, BA; Brostrom, MA; Brostrom, CO				Reilly, BA; Brostrom, MA; Brostrom, CO			Regulation of protein synthesis in ventricular myocytes by vasopressin - The role of sarcoplasmic/endoplasmic reticulum Ca2+ stores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; NUCLEOTIDE EXCHANGE FACTOR; INITIATION-FACTOR 2-ALPHA; VASCULAR SMOOTH-MUSCLE; KINASE-C; RAT-LIVER; TRANSLATIONAL INITIATION; ENDOPLASMIC-RETICULUM; EUKARYOTIC CELLS; PHORBOL ESTER	Protein synthesis in H9c2 ventricular myocytes was subject to rapid inhibition by agents that release Ca2+ from the sarcoplasmic/endoplasmic reticulum, including thapsigargin, ionomycin, caffeine, and arginine vasopressin. Inhibitions were attributable to the suppression of translational initiation and were coupled to the mobilization of cell-associated Ca2+ and the phosphorylation of eIF2 alpha. Ionomycin and thapsigargin produced relatively stringent degrees of Ca2+ mobilization that produced an endoplasmic reticulum (ER) stress response, Translational recovery was associated with the induction of ER chaperones and resistance to translational inhibition by Ca2+-mobilizing agents. Vasopressin at physiologic concentrations mobilized 60% of cell-associated Ca2+ and decreased protein synthesis by 50% within 20-30 min. The inhibition of protein synthesis was exerted through an interaction at the V1 vascular receptor, was imposed at physiologic extracellular Ca2+ concentrations, and became refractory to hormonal washout within 10 min of treatment. Inhibition was found to attenuate after 30 min, with full recovery occurring in 2 h. Translational recovery did not involve an ER stress response but rather was derived from the partial repletion of intracellular Ca2+ stores. Longer exposures to vasopressin were invariably accompanied by increased rates of protein synthesis. Translational inhibition by vasopressin, but not by Ca2+-mobilizing drugs, was both preventable and reversible by treatment with phorbol ester, which reduced the extent of Ca2+ mobilization occurring in response to the hormone. Larger and more prolonged translational inhibitions occurred after down-regulation of protein kinase C. This report provides the first compelling evidence that hormonally induced mobilization of sarcoplasmic/endoplasmic reticulum Ca2+ stores is regulatory upon mRNA translation.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Brostrom, MA (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	brostrom@umdnj.edu						Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; Bogoyevitch MA, 1996, INT J BIOCHEM CELL B, V28, P1, DOI 10.1016/1357-2725(95)00142-5; BRINER VA, 1992, P NATL ACAD SCI USA, V89, P2854, DOI 10.1073/pnas.89.7.2854; BROSTROM CO, 1983, J BIOL CHEM, V258, P4390; BROSTROM CO, 1986, MOL PHARMACOL, V29, P104; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Brostrom CO, 1996, J BIOL CHEM, V271, P24995, DOI 10.1074/jbc.271.40.24995; BROSTROM MA, 1995, J BIOL CHEM, V270, P4127, DOI 10.1074/jbc.270.8.4127; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHIN KV, 1987, J BIOL CHEM, V262, P16509; CHIN KV, 1988, INT J BIOCHEM, V20, P1313, DOI 10.1016/0020-711X(88)90236-4; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CULPEPPER RM, 1985, TXB ENDOCRINOLOGY, P619; DECKER RS, 1995, CIRC RES, V77, P544, DOI 10.1161/01.RES.77.3.544; FISHMAN JB, 1985, J BIOL CHEM, V260, P2641; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; JARVIS WD, 1994, CANCER RES, V54, P1707; JOHNSON JA, 1995, LIFE SCI, V57, P1027, DOI 10.1016/0024-3205(95)02048-N; KIMBALL SR, 1990, J BIOL CHEM, V265, P16794; KIMBALL SR, 1992, AM J PHYSIOL, V263, pE958, DOI 10.1152/ajpendo.1992.263.5.E958; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; LUTZ W, 1991, AM J PHYSIOL, V261, pF1, DOI 10.1152/ajprenal.1991.261.1.F1; MENAYA J, 1988, BIOCHEM J, V254, P773, DOI 10.1042/bj2540773; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Nishioka N, 1995, FEBS LETT, V377, P393, DOI 10.1016/0014-5793(95)01382-2; PALAZZO AJ, 1991, AM J PHYSIOL, V260, pH604, DOI 10.1152/ajpheart.1991.260.2.H604; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; Rakovic S, 1996, CURR BIOL, V6, P989, DOI 10.1016/S0960-9822(02)00643-7; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SCHOPF G, 1986, BIOCHIM BIOPHYS ACTA, V884, P319, DOI 10.1016/0304-4165(86)90180-7; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; THIBONNIER M, 1992, REGUL PEPTIDES, V38, P1, DOI 10.1016/0167-0115(92)90067-5; TRAN K, 1995, MOL CELL BIOCHEM, V151, P69, DOI 10.1007/BF01076898; Tran K, 1995, BBA-LIPID LIPID MET, V1259, P283, DOI 10.1016/0005-2760(95)00175-1; VANDERBENT V, 1994, AM J PHYSIOL, V266, pH597, DOI 10.1152/ajpheart.1994.266.2.H597; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; ZHANG ST, 1995, CIRC RES, V76, P592, DOI 10.1161/01.RES.76.4.592; ZU YJ, 1991, CIRC RES, V69, P239	48	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3747	3755		10.1074/jbc.273.6.3747	http://dx.doi.org/10.1074/jbc.273.6.3747			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452507	hybrid			2022-12-25	WOS:000071822300092
J	Bellanger, JM; Lazaro, JB; Diriong, S; Fernandez, A; Lamb, N; Debant, A				Bellanger, JM; Lazaro, JB; Diriong, S; Fernandez, A; Lamb, N; Debant, A			The two guanine nucleotide exchange factor domains of Trio link the Rac1 and the RhoA pathways in vivo	ONCOGENE			English	Article						Trio; GDP/GTP exchange factor; actin; MAP kinases	ACTIN STRESS FIBERS; BINDING PROTEIN-RHO; CDC42 GTPASES; ACTIVATION; KINASE; RAS; ONCOGENE; TRANSFORMATION; FAMILY	Trio contains two functional guanine nucleotide exchange factors (GEF) domains for the Rho-like GTPases and a serine/threonine kinase domain. In vitro, GEF domain 1(GEFD1) is specifically active on Rac1, while GEF domain 2 (GEFD2) targets RhoA. To determine whether Trio could activate Rad and RhoA in vivo, we measured the effect of Trio on Mitogen Activated Protein Kinase (MAPK) pathways and cytoskeletal rearrangments events mediated by the two GTPases. We show that: (i) the GEFD1 domain of Trio triggers the MAPK pathway leading to Jun kinase (JNK) activation and the production of membrane ruffles; (ii) co-expression of the TrioGEFD1 domain with a dominant-negative form of Rac blocked JNK induction, whereas a dominant-negative form of Cdc42 did not; (iii) a deletion mutant of TrioGEFD1 lacking a region important for exchange activity could not stimulate JNK activity; (iv) in contrast, the TrioGEFD2 domain does not stimulate JNK activity and induces the formation of stress fibers, as does activated RhoA; (v) furthermore, co-expression of both GEF domains induces simultaneously the formation of ruffles and stress fibers. Trio, therefore represents a unique member of the Rho-GEFs family possessing two functional domains of distinct specificities, that allow it to link Rho and Rac signaling pathway in vivo.	CNRS, CRBM, ERS155, F-34033 Montpellier 01, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Debant, A (corresponding author), CNRS, CRBM, ERS155, 1919 Route Mende,BP5051, F-34033 Montpellier 01, France.		Bellanger, Jean-Michel/D-1579-2017; Bellanger, Jean-Michel/S-2103-2019	Bellanger, Jean-Michel/0000-0001-9289-2349				BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CERIONE RA, 1996, CURR OPIN CELL BIOL, V6, P216; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Lamb NJC, 1997, METHOD ENZYMOL, V283, P72; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Leung T, 1996, MOL CELL BIOL, V16, P5313; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1996, J MOL MED-JMM, V74, P563, DOI 10.1007/s001090050060; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; TOMINAGA T, 1993, J CELL BIOL, V120, P1523; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZHENG Y, 1996, J BIOL CHEM, V271, P33269	32	111	112	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					147	152		10.1038/sj.onc.1201532	http://dx.doi.org/10.1038/sj.onc.1201532			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464532				2022-12-25	WOS:000071427100001
J	Edelson, MI; Lau, CC; Colitti, CV; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC				Edelson, MI; Lau, CC; Colitti, CV; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC			A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors	ONCOGENE			English	Article						ovary; cancer; borderline; loss of heterozygosity; chromosome Xq	ANDROGEN-RECEPTOR GENE; HUMAN PROSTATE-CANCER; TERM FOLLOW-UP; X-CHROMOSOME; LINKAGE MAP; MALIGNANCY; MUTATION; CARCINOMAS; HETEROZYGOSITY; PROGRESSION	We have used polymerase chain reaction (PCR) amplification of tandem repeats to study the pattern of allelic loss on chromosome X11.2-q12 in borderline and invasive epithelial ovarian tumors, Using eight microsatellite markers spanning Xq11.2-q12, 41 borderline and 65 invasive ovarian tumors, together with their corresponding normal tissues, were analysed, The highest percentage of loss of heterozygosity (LOH) was observed at the DXS1194 locus in borderline tumors (four of 16 informative cases, 25%) and at the androgen receptor (AR) locus in invasive epithelial ovarian tumors (18 of 47 informative cases, 38%), X chromosome activation studies performed in cases with LOH at the AR locus showed that the allelic loss at the AR locus is not confined to the inactive allele, A one centimorgan region including the AR locus and flanked by the primers DXS1161 and PGK1P1 was identified as the smallest common loss region in both borderline and invasive epithelial ovarian tumors.	Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol, Lab Gynecol Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Texas Childrens Hosp, Div Hematol Oncol, Houston, TX 77030 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Baylor College of Medicine	Mok, SC (corresponding author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol, Lab Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA.				NCI NIH HHS [R01CA63381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; BARAKAT RR, 1994, OBSTET GYN CLIN N AM, V21, P93; BELL DA, 1994, CANCER, V73, P1859, DOI 10.1002/1097-0142(19940401)73:7<1859::AID-CNCR2820730714>3.0.CO;2-L; BOSTWICK DG, 1986, CANCER, V58, P2052, DOI 10.1002/1097-0142(19861101)58:9<2052::AID-CNCR2820580916>3.0.CO;2-5; CASEY AC, 1993, GYNECOL ONCOL, V50, P316, DOI 10.1006/gyno.1993.1218; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; DODSON MK, 1993, CANCER RES, V53, P4456; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; KIM TM, 1994, CANCER RES, V54, P605; LEAKE JF, 1992, CURR OPIN OBSTET GYN, V4, P81; LEAKE JF, 1992, GYNECOL ONCOL, V47, P150, DOI 10.1016/0090-8258(92)90099-5; LOBACCARO JM, 1993, HUM MOL GENET, V2, P1799, DOI 10.1093/hmg/2.11.1799; MOK SCH, 1993, CANCER RES, V53, P1489; NELSON DL, 1995, CYTOGENET CELL GENET, V71, P308; NEWMARK JR, 1992, P NATL ACAD SCI USA, V89, P6319, DOI 10.1073/pnas.89.14.6319; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SCHOENBERG MP, 1994, P ANN M AM ASS CANC, V35, pA1653; SCULLY RE, 1982, B CANCER, V69, P228; Tangir J, 1996, CANCER RES, V56, P2501; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tilley WD, 1996, CLIN CANCER RES, V2, P277; TSAO SW, 1993, GYNECOL ONCOL, V48, P5, DOI 10.1006/gyno.1993.1002; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WEEKS DE, 1995, GENOMICS, V26, P39, DOI 10.1016/0888-7543(95)80080-6; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549	28	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					197	202		10.1038/sj.onc.1201479	http://dx.doi.org/10.1038/sj.onc.1201479			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464537				2022-12-25	WOS:000071427100006
J	Asakura, T; Sasaki, T; Nagano, F; Satoh, A; Obaishi, H; Nishioka, H; Imamura, H; Hotta, K; Tanaka, K; Nakanishi, H; Takai, Y				Asakura, T; Sasaki, T; Nagano, F; Satoh, A; Obaishi, H; Nishioka, H; Imamura, H; Hotta, K; Tanaka, K; Nakanishi, H; Takai, Y			Isolation and characterization of a novel actin filament-binding protein from Saccharomyces cerevisiae	ONCOGENE			English	Article						F-actin; F-actin-binding protein; yeast; ABP140	YEAST SACCHAROMYCES; MEMBRANE INTERACTIONS; CELL-ADHESION; BUD FORMATION; F-ACTIN; CYTOSKELETON; RHO; GTP; MORPHOGENESIS; GENE	We purified a novel actin filament (F-actin)-binding protein from the soluble fraction of Saccharomyces cerevisiae by successive column chromatographies by use of the I-125-labeled F-actin blot overlay method. The purified protein showed a minimum M-r of about 140 kDa on SDS-polyacrylamide gel electrophoresis and we named it ABP140. A search with the partial amino acid sequences of ABP140 against the Saccharomyces Genome Database revealed that the open reading frame of the ABP140 gene (ABP140) corresponded to YOR239W fused with YOR240W by the +1 translational frame shift. The encoded protein consisted of 628 amino acids with a calculated M-r of 71,484. The recombinant protein interacted with F-actin and showed the activity to crosslink F-actin into a bundle. Indirect immunofluorescence study demonstrated that ABP140 was colocalized with both cortical actin patches and cytoplasmic actin cables in intact cells. However, elimination of ABP140 by gene disruption did not show a deleterious effect on cell growth or affect the organization of F-actin. These results indicate that ABP140 is not required for cell growth but may be involved in the reorganization of F-actin in the budding yeast.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 565, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 65122, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 565, Japan.			Nakanishi, Hiroyuki/0000-0002-9765-0266				ADAMS AEM, 1989, SCIENCE, V243, P231, DOI 10.1126/science.2643162; ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; CHIA CP, 1991, CELL MOTIL CYTOSKEL, V18, P164, DOI 10.1002/cm.970180303; COOPER JA, 1982, METHOD ENZYMOL, V85, P182; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gips Sanford J., 1994, Seminars in Cell Biology, V5, P201, DOI 10.1006/scel.1994.1025; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; Madden K, 1992, Trends Cell Biol, V2, P22, DOI 10.1016/0962-8924(92)90140-I; MASUDA T, 1994, J BIOL CHEM, V269, P19713; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SHEMATEK EM, 1980, J BIOL CHEM, V255, P895; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKAISHI K, 1997, IN PRESS J CELL BIOL; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; WELCH MD, 1994, CURR OPIN CELL BIOL, V6, P110, DOI 10.1016/0955-0674(94)90124-4; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Zahner JE, 1996, MOL CELL BIOL, V16, P1857	50	85	92	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					121	130		10.1038/sj.onc.1201487	http://dx.doi.org/10.1038/sj.onc.1201487			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467951				2022-12-25	WOS:000071236800015
J	Blackburn, MR; Datta, SK; Kellems, RE				Blackburn, MR; Datta, SK; Kellems, RE			Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLHOMOCYSTEINE HYDROLASE; MOUSE; 2'-DEOXYADENOSINE; DEOXYADENOSINE; EXPRESSION; APOPTOSIS; RECEPTOR; DEOXYNUCLEOTIDES; INACTIVATION; LYMPHOCYTES	Adenosine deaminase (ADA) deficiency in humans leads to a combined immunodeficiency. The mechanisms involved in the lymphoid specificity of the disease are not fully understood due to the inaccessibility of human tissues for detailed analysis and the absence of an adequate animal model for the disease. We report the use of a two-stage genetic engineering strategy to generate ADA-deficient mice that retain many features associated with ADA deficiency in humans, including a combined immunodeficiency. Severe T and B cell lymphopenia was accompanied by a pronounced accumulation of 2'-deoxyadenosine and dATP in the thymus and spleen, and a marked inhibition of S-adenosylhomocysteine hydrolase in these organs, Accumulation of adenosine was widespread among all tissues examined. ADA-deficient mice also exhibited severe pulmonary insufficiency, bone abnormalities, and kidney pathogenesis. These mice have provided in vivo information into the metabolic basis for the immune phenotype associated with ADA deficiency.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA	University of Texas System; Baylor College of Medicine	Kellems, RE (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin St, Houston, TX 77030 USA.	rkellems@utmmg.med.uth.tmc.edu		Blackburn, Michael/0000-0002-1394-9966	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034130] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R56HD034130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER; NICHD NIH HHS [HD34130, HD07843] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apasov SG, 1997, J IMMUNOL, V158, P5095; BENVENISTE P, 1995, P NATL ACAD SCI USA, V92, P8373, DOI 10.1073/pnas.92.18.8373; BLACKBURN MR, 1995, J BIOL CHEM, V270, P23891, DOI 10.1074/jbc.270.41.23891; Blackburn MR, 1996, J BIOL CHEM, V271, P15203, DOI 10.1074/jbc.271.25.15203; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BLAESE RM, 1995, PEDIATR RES, V33, pS49; BLAESE RM, 1995, METABOLIC MOL BASIS, V3, P3895; Bollinger ME, 1996, NEW ENGL J MED, V334, P1367, DOI 10.1056/NEJM199605233342104; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; CEDERBAUM SD, 1976, J PEDIATR-US, V89, P737, DOI 10.1016/S0022-3476(76)80793-7; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; COLEMAN MS, 1978, J BIOL CHEM, V253, P1619; DOHERTY PJ, 1991, SCAND J IMMUNOL, V33, P405, DOI 10.1111/j.1365-3083.1991.tb01788.x; DONOFRIO J, 1978, J CLIN INVEST, V62, P884, DOI 10.1172/JCI109201; DOOLEY T, 1987, PRENATAL DIAG, V7, P561, DOI 10.1002/pd.1970070806; GAO X, 1994, TERATOLOGY, V49, P1, DOI 10.1002/tera.1420490103; GIBLETT ER, 1972, LANCET, V2, P1067; HERSHFIELD MS, 1979, J CLIN INVEST, V63, P807, DOI 10.1172/JCI109367; HERSHFIELD MS, 1979, J BIOL CHEM, V254, P22; HERSHFIELD MS, 1993, PEDIATR RES, V33, pS35; HERSHFIELD MS, 1995, METABOLIC MOL BASIS, V1, P1725; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; KAMINSKA JE, 1980, J LAB CLIN MED, V96, P141; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; KNUDSEN TB, 1991, BIOL REPROD, V44, P171, DOI 10.1095/biolreprod44.1.171; KNUDSEN TB, 1992, TERATOLOGY, V45, P91, DOI 10.1002/tera.1420450109; LUI X, 1996, CELL, V86, P147; Malanchere E, 1997, EUR J IMMUNOL, V27, P788, DOI 10.1002/eji.1830270330; MIGCHIELSEN AAJ, 1995, NAT GENET, V10, P279, DOI 10.1038/ng0795-279; MORGAN G, 1987, CLIN EXP IMMUNOL, V70, P491; PUFFINBARGER NK, 1995, MOL PHARMACOL, V47, P1126; RATECH H, 1981, CLIN IMMUNOL IMMUNOP, V21, P119, DOI 10.1016/0090-1229(81)90200-2; RATECH H, 1985, AM J PATHOL, V120, P157; Ratter F, 1996, INT IMMUNOL, V8, P1139, DOI 10.1093/intimm/8.7.1139; Resta R, 1997, IMMUNOL TODAY, V18, P371, DOI 10.1016/S0167-5699(97)01047-5; SETO S, 1985, J CLIN INVEST, V75, P377, DOI 10.1172/JCI111710; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; STEHLE JH, 1992, MOL ENDOCRINOL, V6, P384, DOI 10.1210/me.6.3.384; STILES GL, 1992, J BIOL CHEM, V267, P6451; SZONDY Z, 1994, BIOCHEM J, V304, P877, DOI 10.1042/bj3040877; ULLMAN B, 1981, J BIOL CHEM, V256, P848; ULLMAN B, 1978, CELL, V14, P365, DOI 10.1016/0092-8674(78)90122-8; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673	43	136	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5093	5100		10.1074/jbc.273.9.5093	http://dx.doi.org/10.1074/jbc.273.9.5093			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478961	hybrid			2022-12-25	WOS:000072310400045
J	McEwen, DG; Ornitz, DM				McEwen, DG; Ornitz, DM			Regulation of the fibroblast growth factor receptor 3 promoter and intron I enhancer by Sp1 family transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; OSTEONECTIN PROMOTER; FACTOR-BINDING; GENE PROMOTER; LESS PROMOTER; FGF RECEPTOR; BONE-CELLS; ACTIVATION; DNA; EXPRESSION	Fibroblast growth factor receptor 3 (FGFR3) has a complex spatial and temporal pattern of expression and is essential for the normal development of a diverse set of tissues. Recently, mutations have been identified in FGFR3 that result in constitutive tyrosine kinase activity and cause a number of different human skeletal disorders. To examine the regulatory mechanisms governing FGFR3 expression, the promoter for the FGFR3 gene was identified and characterized. It resides in a CpG island, which encompasses the 5' end of the FGFR3 gene and lacks classical cis-regulatory motifs. As little as 100 base pairs of sequence 5' to the initiation site can confer a 20-40-fold increase in transcriptional activity upon a promoter-less vector. The transcriptional activity of these cia-regulatory sequences is further stimulated by elements found within the first intron. Mapping of the enhancer activity found within intron I identified two purine-rich sequence moths between +340 and +395. Electrophoretic mobility shift assays demonstrated that sequences within this region bind members of the Spl family of transcription factors. In a background lacking Spl-like activity, we demonstrate that Spl can enhance transcription of the minimal promoter (which contains five classical Spl sites), whereas both Spl and Sp3 can enhance transcription through the elements found in intron I. Although these transcription factors are ubiquitously expressed, we demonstrate that the sequences between -220 and +609 of the FGFR3 gene are sufficient to promote the tissue-specific expression of a reporter gene in transgenic mice.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Ornitz, DM (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA.			Ornitz, David/0000-0003-1592-7629	NATIONAL CANCER INSTITUTE [R01CA060673] Funding Source: NIH RePORTER; NCI NIH HHS [CA60673] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; CHEN XR, 1992, ONCOGENE, V7, P1805; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISEMANN A, 1991, ONCOGENE, V6, P1195; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HANLEY T, 1991, BIOTECHNIQUES, V10, P56; Iannello RC, 1997, MOL CELL BIOL, V17, P612, DOI 10.1128/MCB.17.2.612; IBARAKI K, 1993, GENE, V130, P225, DOI 10.1016/0378-1119(93)90423-Z; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON SE, 1994, DEV DYNAM, V201, P216, DOI 10.1002/aja.1002010305; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; McEwen DG, 1997, BIOTECHNIQUES, V22, P1068, DOI 10.2144/97226bm12; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; MORGAN WD, 1989, MOL CELL BIOL, V9, P4099, DOI 10.1128/MCB.9.9.4099; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PerezCastro AV, 1997, GENOMICS, V41, P10, DOI 10.1006/geno.1997.4616; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Sambrook J., 2002, MOL CLONING LAB MANU; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; Simon TC, 1997, J BIOL CHEM, V272, P10652; Skaer H, 1997, CURR BIOL, V7, pR238, DOI 10.1016/S0960-9822(06)00110-2; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WILKIE AOM, 1995, CURR BIOL, V5, P500; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; YOUNG MF, 1989, J BIOL CHEM, V264, P450	61	47	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5349	5357		10.1074/jbc.273.9.5349	http://dx.doi.org/10.1074/jbc.273.9.5349			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478995	hybrid			2022-12-25	WOS:000072310400079
J	Bernstein, HS; Coughlin, SR				Bernstein, HS; Coughlin, SR			A mammalian homolog of fission yeast Cdc5 regulates G2 progression and mitotic entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEE1 TYROSINE KINASE; NEGATIVE REGULATION; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; PROTEIN PHOSPHATASE; MITOSIS; PHOSPHORYLATION; INACTIVATION; EXPRESSION; TRANSITION	Progression through G2/M of the mammalian cell division cycle requires the coordinated expression of many gene products, but little is known of the transcriptional regulators involved. Schizosaccharomyces pombe Cdc5 is a putative transcription factor implicated in G2/M transit, me recently identified a cDNA encoding a putative human transcription factor, now designated human Cdc5 (hCdc5), with homology to S. pombe Cdc5. Widespread expression of hCdc5 in human tissues and homology with expressed sequences in other eukaryotes suggested an evolutionarily conserved general function, Nuclear import of hCdc5 upon serum stimulation of mammalian cells suggested a possible role in cell proliferation, We now report that overexpression of hCdc5 in mammalian cells shortened G2 and reduced cell size, A dominant negative mutant of hCdc5 lacking the carboxyl-terminal activation domain slowed G2 progression and delayed entry into mitosis, Thus, hCdc5 is the first transcriptional regulator shown to affect G2 progression and mitotic entry in mammalian cells.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bernstein, HS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, 513 Parnassus Ave,Box 0632, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL103228, R01HL044907, P01HL043821] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03228, HL44907, HL43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernstein HS, 1997, J BIOL CHEM, V272, P5833, DOI 10.1074/jbc.272.9.5833; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; Fleig U N, 1991, Semin Cell Biol, V2, P195; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; Hirayama T, 1996, P NATL ACAD SCI USA, V93, P13371, DOI 10.1073/pnas.93.23.13371; Iavarone A, 1997, NATURE, V387, P417; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KINOSHITA N, 1993, GENE DEV, V7, P1059, DOI 10.1101/gad.7.6.1059; KREK W, 1995, METHOD ENZYMOL, V254, P114; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY A, 1993, CELL CYCLE; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; Okayama H, 1996, ADV CANCER RES, V69, P17, DOI 10.1016/S0065-230X(08)60859-3; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SHIMIZU M, 1995, MOL CELL BIOL, V15, P2882; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0	32	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4666	4671		10.1074/jbc.273.8.4666	http://dx.doi.org/10.1074/jbc.273.8.4666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468527	hybrid			2022-12-25	WOS:000072115000055
J	Frischholz, S; Beier, F; Girkontaite, I; Wagner, K; Poschl, E; Turnay, J; Mayer, U; von der Mark, K				Frischholz, S; Beier, F; Girkontaite, I; Wagner, K; Poschl, E; Turnay, J; Mayer, U; von der Mark, K			Characterization of human type X procollagen and its NC-1 domain expressed as recombinant proteins in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-PLATE CARTILAGE; SCHMID METAPHYSEAL CHONDRODYSPLASIA; SHORT-CHAIN COLLAGEN; ENDOCHONDRAL OSSIFICATION; OSTEOARTHRITIC CARTILAGE; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; TERMINAL DOMAIN; ALGINATE BEADS; CHONDROCYTES	Type X collagen is a short-chain, network-forming collagen found in hypertrophic cartilage in the growth zones of long bones, vertebrae, and ribs. To obtain information about the structure and assembly of mammalian type X collagen, we generated recombinant human type collagen X by stable expression of full-length human alpha 1(X) cDNA in the human embryonal kidney cell line HEK293 and the fibrosarcoma cell line HT1080, Stable clones were obtained secreting recombinant human type X collagen (hrColX) in amounts of 50 mu g/ml with alpha 1(X)-chains of apparent molecular mass of 75 kDa, Pepsin digestion converted the native protein to a molecule migrating as one band at 65 kDa, while bands of 55 and 43 kDa were generated by trypsin digestion, Polyclonal antibodies prepared against purified hrColX reacted specifically with type X collagen in sections of human fetal growth cartilage, Circular dichroism spectra and trypsin/chymotrypsin digestion experiments of hrColX at increasing temperatures indicated triple helical molecules with a reduced melting temperature of 31 degrees C as a result of partial underhydroxylation. Ultrastructural analysis of hrColX by rotary shadowing demonstrated rodlike molecules with a length of 130 nm, assembling into aggregates via the globular noncollagenous (NC)-1 domains as reported for chick type X collagen, NC-1 domains generated by collagenase digestion of hrColX migrated as multimers of apparent mass of 40 kDa on SDS polyacrylamide gel electrophoresis, even after reduction and heat denaturation, and gave rise to monomers of 18-20 kDa after treatment with trichloroacetic acid, The NC-1 domains prepared by collagenase digestion comigrated with NC-1 domains prepared as recombinant protein in HEK293 cells, both in the multimeric and monomeric form. These studies demonstrate the potential of the pCMVsis expression system to produce recombinant triple helical type X collagens in amounts sufficient for further studies on its structural and functional domains.	Univ Erlangen Nurnberg, Inst Expt Med, D-91054 Erlangen, Germany; Univ Complutense Madrid, Fac Chem Sci, Dept Biochem & Mol Biol, Madrid, Spain; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Erlangen Nuremberg; Complutense University of Madrid; Max Planck Society	von der Mark, K (corresponding author), Univ Erlangen Nurnberg, Inst Expt Med, Schwabachanlage 10, D-91054 Erlangen, Germany.	kvdmark@expmed.uni-erlangen.de	Turnay, Javier/K-4551-2014; Girkontaite, Irute/K-9017-2013; Beier, Frank/T-4734-2019; Beier, Frank/G-4595-2013; Turnay, Javier/AAB-1497-2022	Turnay, Javier/0000-0002-6135-2179; Girkontaite, Irute/0000-0002-3659-3202; Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537; Turnay, Javier/0000-0002-6135-2179; Mayer, Ulrike/0000-0003-2328-0052				AIGNER T, 1993, VIRCHOWS ARCH B, V63, P205, DOI 10.1007/BF02899263; AYAD S, 1987, FEBS LETT, V220, P181, DOI 10.1016/0014-5793(87)80899-2; BONAVENTURE J, 1995, HUM GENET, V96, P58, DOI 10.1007/BF00214187; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; CAPASSO O, 1984, EMBO J, V3, P823, DOI 10.1002/j.1460-2075.1984.tb01891.x; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; CHAN D, 1995, J BIOL CHEM, V270, P1747, DOI 10.1074/jbc.270.4.1747; COLOMBATTI A, 1995, J BIOL CHEM, V270, P13105, DOI 10.1074/jbc.270.22.13105; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; Fukuda K, 1997, BIOCHEM BIOPH RES CO, V231, P178, DOI 10.1006/bbrc.1997.6069; GIBSON GJ, 1985, J CELL BIOL, V101, P277, DOI 10.1083/jcb.101.1.277; GIBSON GJ, 1984, J CELL BIOL, V99, P208, DOI 10.1083/jcb.99.1.208; Girkontaite I, 1996, MATRIX BIOL, V15, P231, DOI 10.1016/S0945-053X(96)90114-6; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRANT WT, 1987, J BIOL CHEM, V262, P9844; GRANT WT, 1985, J BIOL CHEM, V260, P3798; GUNSON DE, 1976, IMMUNOLOGY, V31, P577; GUO JF, 1989, CONNECT TISSUE RES, V19, P277, DOI 10.3109/03008208909043901; HARWOOD R, 1976, BIOCHEM J, V156, P81, DOI 10.1042/bj1560081; HAUSELMANN HJ, 1992, MATRIX, V12, P116; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; HOYLAND JA, 1991, BONE MINER, V15, P151, DOI 10.1016/0169-6009(91)90005-K; IYAMA K, 1991, ANAT RECORD, V229, P462, DOI 10.1002/ar.1092290405; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; JIMENEZ SA, 1986, BIOCHEM BIOPH RES CO, V138, P835, DOI 10.1016/S0006-291X(86)80572-1; Kielty Cay M., 1993, P103; KIELTY CM, 1985, BIOCHEM J, V227, P545, DOI 10.1042/bj2270545; KIRSCH T, 1992, DIFFERENTIATION, V52, P89, DOI 10.1111/j.1432-0436.1992.tb00503.x; KIRSCH T, 1990, BIOCHEM J, V265, P453, DOI 10.1042/bj2650453; KIRSCH T, 1991, EUR J BIOCHEM, V196, P575, DOI 10.1111/j.1432-1033.1991.tb15852.x; KIRSCH T, 1992, BONE MINER, V18, P107, DOI 10.1016/0169-6009(92)90851-4; KIRSCH T, 1994, J BIOL CHEM, V269, P11462; KIRSCH T, 1991, FEBS LETT, V294, P149, DOI 10.1016/0014-5793(91)81363-D; KIRSCH T, 1992, FEBS LETT, V310, P143, DOI 10.1016/0014-5793(92)81316-E; KUHN K, 1981, FEBS LETT, V125, P123, DOI 10.1016/0014-5793(81)81012-5; KWAN APL, 1986, FEBS LETT, V206, P267, DOI 10.1016/0014-5793(86)80994-2; KWAN APL, 1986, BIOSCIENCE REP, V6, P155, DOI 10.1007/BF01115001; KWAN APL, 1989, J CELL BIOL, V109, P1849, DOI 10.1083/jcb.109.4.1849; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; MARRIOTT A, 1991, J CELL SCI, V99, P641; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MCINTOSH I, 1995, HUM MUTAT, V5, P121, DOI 10.1002/humu.1380050204; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; MING KK, 1997, J CELL BIOL, V136, P459; MULLER PK, 1974, BIOCHIM BIOPHYS ACTA, V365, P158, DOI 10.1016/0005-2795(74)90260-8; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; QUARTO N, 1985, EUR J BIOCHEM, V147, P397, DOI 10.1111/j.1432-1033.1985.tb08763.x; REGINATO AM, 1988, J BIOL CHEM, V263, P9938; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; REMINGTON MC, 1984, BIOCHEM J, V224, P227, DOI 10.1042/bj2240227; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SCHMID TM, 1984, J ULTRA MOL STRUCT R, V86, P186, DOI 10.1016/S0022-5320(84)80057-X; SCHMID TM, 1985, DEV BIOL, V107, P373, DOI 10.1016/0012-1606(85)90319-7; SCHMID TM, 1990, DEV BIOL, V138, P53, DOI 10.1016/0012-1606(90)90176-J; SCHMID TM, 1984, BIOCHEMISTRY-US, V23, P553, DOI 10.1021/bi00298a024; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; SCHMID TM, 1987, STRUCTURE FUNCTION C, P223; Schmid TM, 1994, EXTRACELLULAR MATRIX, P171; Schulte S, 1998, J BIOL CHEM, V273, P1551, DOI 10.1074/jbc.273.3.1551; SUMMERS TA, 1988, J BIOL CHEM, V263, P581; SWOBODA B, 1989, J CELL BIOL, V109, P1363, DOI 10.1083/jcb.109.3.1363; THOMAS JT, 1991, BIOCHEM J, V280, P617, DOI 10.1042/bj2800617; VONDERMARK K, 1992, ARTHRITIS RHEUM-US, V35, P806, DOI 10.1002/art.1780350715; WALKER GD, 1995, J ORTHOPAED RES, V13, P4, DOI 10.1002/jor.1100130104; WALLIS GA, 1994, AM J HUM GENET, V54, P169; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79	68	50	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4547	4555		10.1074/jbc.273.8.4547	http://dx.doi.org/10.1074/jbc.273.8.4547			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468510	hybrid			2022-12-25	WOS:000072115000038
J	Scholz, A; Truss, M; Beato, M				Scholz, A; Truss, M; Beato, M			Hormone-induced recruitment of Sp1 mediates estrogen activation of the rabbit uteroglobin gene in endometrial epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-DEPENDENT INTERACTION; II PROMOTER INVIVO; TRANSCRIPTION FACTORS; GLUCOCORTICOID RECEPTOR; HYPERSENSITIVE SITES; BINDING-PROTEINS; RESPONSE ELEMENT; MAMMALIAN-CELLS; TFIID COMPLEX; DNA	Steroid hormones activate gene expression by interaction of their receptors with hormone-responsive DNA elements and tissue-specific or ubiquitous factors. To monitor the molecular changes on the promoter of the rabbit uteroglobin gene during early pseudopregnancy in vitro, we have applied the genomic footprinting methodology to endometrial tissue, Estrogen induction results in the simultaneous occupancy of an estrogen-re sponsive element and an adjacent GC/GT box in the promoter, DNA binding assays demonstrate that the corresponding regulatory factors are the ligand-induced estrogen receptor and the ubiquitous transcription factor Sp1, Both factors functionally synergize in primary endometrial cells, showing that the GC/GT box is an essential part of a composite estrogen-responsive unit, However, the estrogen receptor and Sp1 do not bind cooperatively to their sites in vitro, suggesting that other mechanisms might be responsible for the hormone-dependent binding of Sp1 in vivo. Since hormone treatment leads to the appearance of a distinct DNase I-hypersensitive site over the promoter chromatin, an estrogen-induced change in the local chromatin structure could facilitate binding of Sp1 in vivo.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany	Philipps University Marburg	Beato, M (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Emil Mannkopff Str 2, D-35037 Marburg, Germany.	beato@imt.uni-marburg.de	Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARETTINO D, 1994, NUCLEIC ACIDS RES, V22, P541, DOI 10.1093/nar/22.3.541; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BONDY KL, 1993, NUCLEIC ACIDS RES, V21, P5277, DOI 10.1093/nar/21.22.5277; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Eisfeld K, 1997, NUCLEIC ACIDS RES, V25, P3733, DOI 10.1093/nar/25.18.3733; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JANTZEN K, 1987, NUCLEIC ACIDS RES, V15, P4535, DOI 10.1093/nar/15.11.4535; KOK K, 1985, NUCLEIC ACIDS RES, V13, P5189, DOI 10.1093/nar/13.14.5189; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; MULLER H, 1980, EUR J BIOCHEM, V112, P235, DOI 10.1111/j.1432-1033.1980.tb07199.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Saceda M, 1996, ENDOCRINOLOGY, V137, P4322, DOI 10.1210/en.137.10.4322; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SCHAUER M, 1989, P NATL ACAD SCI USA, V86, P1123, DOI 10.1073/pnas.86.4.1123; SCHIPPERS IJ, 1994, EUR J BIOCHEM, V221, P43, DOI 10.1111/j.1432-1033.1994.tb18713.x; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Suske Guntram, 1992, Gene Expression, V2, P339; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; WIJNHOLDS J, 1991, NUCLEIC ACIDS RES, V19, P33, DOI 10.1093/nar/19.1.33; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x	49	52	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4360	4366		10.1074/jbc.273.8.4360	http://dx.doi.org/10.1074/jbc.273.8.4360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468485	hybrid			2022-12-25	WOS:000072115000013
J	Miyake, H; Hanada, N; Nakamura, H; Kagawa, S; Fujiwara, T; Hara, I; Eto, H; Gohji, K; Arakawa, S; Kamidono, S; Saya, H				Miyake, H; Hanada, N; Nakamura, H; Kagawa, S; Fujiwara, T; Hara, I; Eto, H; Gohji, K; Arakawa, S; Kamidono, S; Saya, H			Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer	ONCOGENE			English	Article						Bcl-2; cisplatin; adenoviral-mediated p53 gene transfer; apoptosis; bladder cancer	WILD-TYPE P53; IN-VIVO; LUNG-CANCER; P53-DEPENDENT APOPTOSIS; RECOMBINANT ADENOVIRUS; DNA-BINDING; CARCINOMA; EXPRESSION; THERAPY; RESISTANCE	To investigate the effects of the expression of Bcl-2 protein in bladder cancer on the apoptosis induced by cisplatin or adenoviral-mediated p53 gene (Ad5CMV-p53) transfer, we transfected the bcl-2 gene into KoTCC-1, a human bladder cancer cell line that does not express the Bcl-2 protein. The Bcl-2-transfected KoTCC-1 (KoTCC-1/B) exhibited significantly higher resistance to both cisplatin and Ad5CMV-p53 transfer than did either the parental KoTCC-1 (KoTCC-1/P) or the vector-only transfected cell line (KoTCC-1/C). The flow cytometric analysis of the propidium iodide-stained nuclei and DNA fragmentation analysis after cisplatin or Ad5CMV-p53 treatment revealed DNA degradation in both KoTCC-1/P and KoTCC-1/C, whereas KoTCC1/B showed a marked inhibition of DNA degradation. Following the treatment with cisplatin or Ad5CMV-p53, the accumulation of p53 protein was highly detectable for a long period in KoTCC-1/B compared to that in KoTTC-1/P and KoTCC-1/C. Furthermore, the cisplatin and Ad5CMV-p53 treatments each reduced the volume of the subcutaneous tumors established in nude mice formed by KoTCC-1/P or KoTCC-1/C; in contrast, their reductive effects on the tumors formed by KoTCC-1/B were significantly suppressed. The intraperitoneal tumor cell implantation model revealed that the prognoses of mice injected with KoTCC-1/B were significantly inferior to those of the mice injected with either KoTCC-1/P or KoTCC-1/C after treatment with cisplatin or Ad5CMV-p53. These findings suggest that the expression of Bcl-2 in bladder cancer cells interferes with the therapeutic effects of cisplatin and Ad5CMV-p53 through the inhibition of the apoptotic pathway.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 860, Japan; Kobe Univ, Sch Med, Dept Urol, Kobe, Hyogo 650, Japan; Okayama Univ, Sch Med, Dept Surg 1, Okayama 700, Japan	Kumamoto University; Kobe University; Okayama University	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 860, Japan.		Kagawa, Shunsuke/B-2189-2011; Saya, Hideyuki/J-4325-2013	Kagawa, Shunsuke/0000-0002-3610-8211				ARMSTRONG DK, 1992, CANCER RES, V52, P3418; Bilim V, 1996, J NATL CANCER I, V88, P686, DOI 10.1093/jnci/88.10.686-a; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU G, 1994, J BIOL CHEM, V269, P787; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUJIWARA T, 1994, CANCER RES, V54, P2287; Gallo O, 1996, CLIN CANCER RES, V2, P261; GomezManzano C, 1996, CANCER RES, V56, P694; Graham FL, 1991, METHOD MOL BIOL, P109; Hamada K, 1996, CANCER RES, V56, P3047; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KIM YH, 1992, J IMMUNOL, V149, P17; King ED, 1996, J UROLOGY, V155, P316, DOI 10.1016/S0022-5347(01)66652-7; KYO E, 1993, INT J ONCOL, V3, P265; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIU TJ, 1995, CANCER RES, V55, P3117; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Miyake H, 1997, J UROLOGY, V157, P2351, DOI 10.1016/S0022-5347(01)64779-7; Mujoo K, 1996, ONCOGENE, V12, P1617; Murphy Andrew J. M., 1992, Methods (Orlando), V4, P111, DOI 10.1016/1046-2023(92)90044-9; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; PARK JG, 1987, CANCER RES, V47, P5875; Parker S. L., 1996, CA CANC J CLIN, V65, P5; RAFFO AJ, 1995, CANCER RES, V55, P4438; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; ROUSCULP MD, 1992, HUM GENE THER, V3, P471, DOI 10.1089/hum.1992.3.5-471; STERNBERG CN, 1993, CANCER, V72, P1975, DOI 10.1002/1097-0142(19930915)72:6<1975::AID-CNCR2820720631>3.0.CO;2-I; THRASHER JB, 1993, J UROLOGY, V149, P957, DOI 10.1016/S0022-5347(17)36270-5; Tomita Y, 1996, INT J CANCER, V66, P322, DOI 10.1002/(SICI)1097-0215(19960503)66:3<322::AID-IJC9>3.0.CO;2-0; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG YS, 1993, ONCOGENE, V8, P3427; WELSH MJ, 1994, HUM GENE THER, V5, P209, DOI 10.1089/hum.1994.5.2-209; Werthman PE, 1996, J UROLOGY, V155, P753, DOI 10.1016/S0022-5347(01)66515-7; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	44	112	113	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					933	943		10.1038/sj.onc.1201602	http://dx.doi.org/10.1038/sj.onc.1201602			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484785				2022-12-25	WOS:000072053200013
J	McCormick, KA; Isom, LL; Ragsdale, D; Smith, D; Scheuer, T; Catterall, WA				McCormick, KA; Isom, LL; Ragsdale, D; Smith, D; Scheuer, T; Catterall, WA			Molecular determinants of Na+ channel function in the extracellular domain of the beta 1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; RAT-BRAIN; SKELETAL-MUSCLE; ALPHA-SUBUNIT; AMINO-ACIDS; INACTIVATION; EXPRESSION; PROTEIN; MUTAGENESIS; RECOGNITION	The rat brain voltage-gated Na+ channel is composed of three glycoprotein subunits: the pore-forming cu subunit and two auxiliary subunits, beta 1 and beta 2, which contain immunoglobulin (Ig)-like folds in their extracellular domains, When expressed in Xenopus oocytes, beta 1 modulates the gating properties of the channel-forming type IIA alpha subunit, resulting in an acceleration of inactivation, We have used a combination of deletion, alanine-scanning, site-directed, and chimeric mutagenesis strategies to examine the importance of different structural features of the beta 1 subunit in the modulation of alpha(IIA), function, with an emphasis on the extracellular domain, Deletion analysis revealed that the extracellular domain is required for function, but the intracellular domain is not, The mutation of four putative sites of N-linked glycosylation showed that they are not required for beta 1 function. Mutations of hydrophobic residues in the core beta sheets of the Ig fold disrupted beta 1 function, whereas substitution of amino acid residues in connecting segments had no effect, Mutations of acidic residues in the A/A' strand of the Ig fold reduced the effectiveness of the beta 1 subunit in modulating the rate of inactivation hut did not significantly affect the association of the mutant beta 1 subunit with the alpha(IIA) subunit or its effect on recovery from inactivation, Our data suggest that the Ig fold of the beta 1 extracellular domain serves as a scaffold that presents the charged residues of the A/A' strands for interaction with the pore-forming alpha subunit.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Catterall, WA (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.			Isom, Lori/0000-0002-9479-6729	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025704] Funding Source: NIH RePORTER; NINDS NIH HHS [NS25704] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; BENNETT PB, 1993, FEBS LETT, V326, P21, DOI 10.1016/0014-5793(93)81752-L; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; Chen CF, 1995, PFLUG ARCH EUR J PHY, V431, P186, DOI 10.1007/BF00410190; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FILHIN MT, 1993, J CELL BIOL, V122, P451; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; HUANG XQ, 1994, COMPUT APPL BIOSCI, V10, P227; Isom LL, 1996, NATURE, V383, P307, DOI 10.1038/383307b0; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; JANIN J, 1990, J BIOL CHEM, V265, P16027; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Makita N, 1996, J NEUROSCI, V16, P7117; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; MESSNER DJ, 1986, J BIOL CHEM, V261, P211; MESSNER DJ, 1985, J BIOL CHEM, V260, P597; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PATTON DE, 1994, J BIOL CHEM, V269, P17649; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; TONG JF, 1993, BIOCHEM BIOPH RES CO, V195, P679, DOI 10.1006/bbrc.1993.2099; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; WELLS CA, 1993, J NEUROCHEM, V61, P1987, DOI 10.1111/j.1471-4159.1993.tb07434.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	34	129	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3954	3962		10.1074/jbc.273.7.3954	http://dx.doi.org/10.1074/jbc.273.7.3954			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461582	hybrid			2022-12-25	WOS:000072048400024
J	Olsthoorn, MMA; Petersen, BO; Schlecht, S; Haverkamp, J; Bock, K; Thomas-Oates, JE; Holst, O				Olsthoorn, MMA; Petersen, BO; Schlecht, S; Haverkamp, J; Bock, K; Thomas-Oates, JE; Holst, O			Identification of a novel core type in Salmonella lipopolysaccharide - Complete structural analysis of the core region of the lipopolysaccharide from Salmonella enterica sv. Arizonae 062	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENUS-SPECIFIC EPITOPE; BOMBARDMENT MASS-SPECTROMETRY; MURINE MONOCLONAL-ANTIBODY; MINNESOTA ROUGH MUTANTS; GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; OUTER CORE; CHLAMYDIA LIPOPOLYSACCHARIDE; NMR-SPECTROSCOPY; VIBRIO-CHOLERAE	For the first time, the complete structure of a lipopolysaccharide (LPS) core region from Salmonella enterica has been identified that is different from the Ra core type generally thought to be present in all Salmonella LPS. The LPSs from two rough mutants and the smooth form of S, enterica sv, Arizonae IIIa 062, which all failed to react with an Ra core type-specific monoclonal antibody and were resistant to phage F01, were analyzed after chemical modification using monosaccharide analysis, mass spectrometry, and NMR spectroscopy, In the novel core type, the terminal D-GlcNAc residue present in the Ra core type, is replaced by a D-Glc residue, The O-specific polysaccharide is alpha 1-->4-linked to the second distal Glc residue of the core, Furthermore, phosphoryl substituents attached to 0-4 of L-glycero-D-manno-heptose (Hep) I and II were identified as a-aminoethyl diphosphate (on Hep I) and phosphate (Hep II), GRAPHICS Abbreviations in Structure I are as follows: Hepp, L-glycero-D-manno-heptopyranose; Kdo, 3-deoxy-D-manno-oct-2-ulopyranosonic acid; PPEA, 2-aminoethyl diphosphate; R, O-specific polysaccharide, The presence of this novel core type in LPS of S, enterica should be taken into account in the development of a general antibody-based diagnostic system for Salmonella.	Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, D-23845 Borstel, Germany; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Mass Spectrometry, NL-3508 TB Utrecht, Netherlands; Carlsberg Lab, Dept Chem, DK-2500 Valby, Denmark; Max Planck Inst Immunbiol, D-79108 Freiburg, Germany	Forschungszentrum Borstel; Utrecht University; Max Planck Society	Holst, O (corresponding author), Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, Parkallee 22, D-23845 Borstel, Germany.	oholst@fz-borstel.de						BAX A, 1983, J MAGN RESON, V52, P330, DOI 10.1016/0022-2364(83)90206-8; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BRADE H, 1983, EUR J BIOCHEM, V131, P195, DOI 10.1111/j.1432-1033.1983.tb07249.x; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brull LP, 1997, J AM SOC MASS SPECTR, V8, P43, DOI 10.1016/S1044-0305(96)00134-1; DELL A, 1983, BIOMED MASS SPECTROM, V10, P50, DOI 10.1002/bms.1200100110; DELL A, 1993, GLYCOBIOLOGY PRACTIC, P187; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; Duus JO, 1996, CARBOHYD RES, V288, P25, DOI 10.1016/S0008-6215(96)90773-9; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GALANOS C, 1977, INT REV BIOCH BIOC 2, V14, P238; HAISHIMA Y, 1992, EUR J BIOCHEM, V207, P1129; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HOFINGER A, 1993, CARBOHYD RES, V243, P273, DOI 10.1016/0008-6215(93)87033-O; Holst O, 1996, FEMS IMMUNOL MED MIC, V16, P83, DOI 10.1111/j.1574-695X.1996.tb00126.x; HOLST O, 1995, EUR J BIOCHEM, V229, P194, DOI 10.1111/j.1432-1033.1995.tb20455.x; HOLST O, 1993, EUR J BIOCHEM, V214, P703, DOI 10.1111/j.1432-1033.1993.tb17971.x; HOLST O, 1994, EUR J BIOCHEM, V222, P183, DOI 10.1111/j.1432-1033.1994.tb18856.x; Holst O, 1992, BACTERIAL ENDOTOXIC, VI, P135; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KACA W, 1988, CARBOHYD RES, V179, P289, DOI 10.1016/0008-6215(88)84125-9; KJAER M, 1994, METHODS ENZYMOL, V239, P288; KNIREL YA, 1994, BIOCHEMISTRY-MOSCOW+, V59, P1325; KOVACIK V, 1995, J MASS SPECTROM, V30, P949, DOI 10.1002/jms.1190300704; LERNER L, 1987, CARBOHYD RES, V166, P35, DOI 10.1016/0008-6215(87)80042-3; LOPEZLARA IM, 1995, MOL MICROBIOL, V15, P627, DOI 10.1111/j.1365-2958.1995.tb02372.x; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MCNEIL M, 1983, CARBOHYD RES, V123, P31, DOI 10.1016/0008-6215(83)88378-5; MCNICHOLAS PA, 1987, CARBOHYD RES, V165, P17, DOI 10.1016/0008-6215(87)80073-3; PATIRRE SV, 1996, ANAL CHEM, V68, pA740; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RUCKER SP, 1989, MOL PHYS, V68, P509, DOI 10.1080/00268978900102331; SCHLECHT S, 1986, ZBL BAKT-INT J MED M, V261, P147; SCHLECHT S, 1992, ZBL BAKT-INT J MED M, V277, P288; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TACKEN A, 1986, CARBOHYD RES, V149, P279, DOI 10.1016/S0008-6215(00)90051-X; TSANG RSW, 1991, ZBL BAKT-INT J MED M, V274, P446; TSANG RSW, 1987, INFECT IMMUN, V55, P211, DOI 10.1128/IAI.55.1.211-216.1987; TSANG RSW, 1991, RES MICROBIOL, V142, P521, DOI 10.1016/0923-2508(91)90185-D; TSANG RSW, 1992, ZBL BAKT-INT J MED M, V276, P330, DOI 10.1016/S0934-8840(11)80539-6; TSANG RSW, 1990, RES MICROBIOL, V141, P671, DOI 10.1016/0923-2508(90)90061-T; VINOGRADOV EV, 1992, EUR J BIOCHEM, V210, P491, DOI 10.1111/j.1432-1033.1992.tb17447.x; VINOGRADOV EV, 1994, CARBOHYD RES, V253, P101, DOI 10.1016/0008-6215(94)80058-8; WESTPHAL O, 1952, Z NATURFORSCH B, V7, P148, DOI 10.1515/znb-1952-0303; WHITFIELD C, 1993, ADV MICROB PHYSIOL, V35, P135, DOI 10.1016/S0065-2911(08)60099-5	47	42	44	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3817	3829		10.1074/jbc.273.7.3817	http://dx.doi.org/10.1074/jbc.273.7.3817			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461562	hybrid, Green Submitted			2022-12-25	WOS:000072048400004
J	Capell, A; Grunberg, J; Pesold, B; Diehlmann, A; Citron, M; Nixon, R; Beyreuther, K; Selkoe, DJ; Haass, C				Capell, A; Grunberg, J; Pesold, B; Diehlmann, A; Citron, M; Nixon, R; Beyreuther, K; Selkoe, DJ; Haass, C			The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; IN-VIVO; CAENORHABDITIS-ELEGANS; MISSENSE MUTATIONS; GENE; PEPTIDE	Mutations in the presenilin (PS) genes are linked to early onset familial Alzheimer's disease (FAD). PS-1 proteins are proteolytically processed by an unknown protease to two stable fragments of similar to 30 kDa (N-terminal fragment (NTF)) and similar to 20 kDa (C-terminaI fragment (CTF)) (Thinakaran, G., Borchelt, D. R., Lee, M. K. Slunt, H. H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., Hardy, J., Levey, A. I., Candy, S. E., Jenkins, N. A., Copeland, N. G., Price, D. L., and Sisodia, S. S. (1996) Neuron 17, 181-190). Here we show that the CTF and NTF of PS-1 bind to each other. Fractionating proteins from 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid-extracted membrane preparations by velocity sedimentation reveal a high molecular mass SDS and Triton X-100-sensitive complex of approximately 100-150 kDa. To prove if both proteolytic fragments of PS-1 are bound to the same complex, we performed co-immunoprecipitations using multiple antibodies specific to the CTF and NTF of PS-1. These experiments revealed that both fragments of PS-1 occur as a tightly bound non-covalent complex. Upon overexpression, unclipped wild type PS-1 sediments at a lower molecular weight in glycerol velocity gradients than the endogenous fragments. In contrast, the non-cleavable, PAD-associated PS-1 Delta exon 9 sediments at a molecular weight similar to that observed for the endogenous proteolytic fragments. This result may indicate that the Delta exon 9 mutation generates a mutant protein that exhibits biophysical properties similar to the naturally occurring PS-1 fragments. This could explain the surprising finding that the Delta exon 9 mutation is functionally active, although it cannot be proteolytically processed (Baumeister, R., Leimer, U., Zweckbronner, I., Jakubek, C., Grunberg, J., and Haass, C. (1997) Genes & Function 1, 149-159; Levitan, D., Doyle, T., Brousseau, D., Lee, M., Thinakaran, G., Slunt, H., Sisodia, S., and Greenwald, I, (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 14940-14944). Formation of a high molecular weight complex of PS-1 composed of both endogenous PS-1 fragments may also explain the recent finding that PAD-associated mutations within the N-terminal portion of PS-1 result in the hyperaccumulation not only of the NTF but also of the CTF (Lee, M. K., Borchelt, D. R., Kim, G., Thinakaran, G., Slunt, H. H., Ratovitski, T., Martin, L. J., Kittur, A., Gandy, S., Levey, A. I., Jenkins, N., Copeland, N., Price, D. L., and Sisodia, S. S. (1997) Not. Med 3, 756-760). Moreover, these results provide a model to understand the highly regulated expression and processing of PS proteins.	Cent Inst Mental Hlth, Dept Mol Biol, D-68159 Mannheim, Germany; Zentrum Mol Biol, D-69120 Heidelberg, Germany; Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; NYU, Med Ctr, Dept Psychiat, Orangeburg, NY 10962 USA	Central Institute of Mental Health; Ruprecht Karls University Heidelberg; Harvard University; Harvard Medical School; New York University	Haass, C (corresponding author), Cent Inst Mental Hlth, Dept Mol Biol, J5, D-68159 Mannheim, Germany.							Baumeister R, 1997, Genes Funct, V1, P149; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BURDICK D, 1992, J BIOL CHEM, V267, P546; Capell A, 1997, J NEUROCHEM, V69, P2432; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GRUNBERG J, 1998, IN PRESS BIOCHEMISTR; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Lee MK, 1997, NAT MED, V3, P756, DOI 10.1038/nm0797-756; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	45	301	311	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3205	3211		10.1074/jbc.273.6.3205	http://dx.doi.org/10.1074/jbc.273.6.3205			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452432	hybrid			2022-12-25	WOS:000071822300017
J	Shieh, HL; Chiang, HL				Shieh, HL; Chiang, HL			In vitro reconstitution of glucose-induced targeting of fructose-1,6-bisphosphatase into the vacuole in semi-intact yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-TRANSPORT; ENDOPLASMIC-RETICULUM; SORTING RECEPTOR; SELECTIVE UPTAKE; PLASMA-MEMBRANE; GOLGI MEMBRANES; DEGRADATION; ENDOCYTOSIS; MUTANTS	Fructose-1,6-bisphosphatase (FBPase), the key enzyme in gluconeogenesis in the yeast Saccharomyces cerevisiae, is induced when cells are grown in medium containing poor carbon sources. FBPase is targeted from the cytosol to the vacuole for degradation when glucose-starved yeast cells are replenished with fresh glucose. In this study, we report the reconstitution of the glucose-induced import of FBPase into the vacuole in semi-intact yeast cells using radiolabeled FBPase, an ATP regenerating system and cytosol. The import of FBPase was defined as the fraction of the FBPase that was sequestered inside a membrane-sealed compartment. FBPase import requires ATP hydrolysis and is stimulated by cytosolic proteins. Furthermore, the import of FBPase is a saturable process. FBPase import is low in the glucose-starved cells and is stimulated in the glucose-replenished cells, FBPase accumulates to a higher level in the pep4 cell, suggesting that FBPase is targeted to the vacuole for degradation. Indirect immunofluorescence microscopy studies demonstrate that the imported FBPase is localized to the vacuole in the permeabilized cells. Thus, the glucose-induced targeting of FBPase into the vacuole can be reproduced in our in vitro system.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Chiang, HL (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049267] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM49267] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; Chiang HL, 1996, J BIOL CHEM, V271, P9934, DOI 10.1074/jbc.271.17.9934; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Hoffman M, 1996, GENETICS, V143, P1555; Huang PH, 1997, J CELL BIOL, V136, P803, DOI 10.1083/jcb.136.4.803; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES EW, 1991, J BIOL CHEM, V266, P7963; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LAI K, 1995, J BIOL CHEM, V270, P2525, DOI 10.1074/jbc.270.6.2525; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; Murdock D. G., 1994, CELLULAR PROTEOLYTIC, P115; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; RAYMOND CK, 1992, INT REV CYTOL, V139, P59, DOI 10.1016/S0074-7696(08)61410-2; RIBALLO E, 1995, J BACTERIOL, V177, P5622, DOI 10.1128/jb.177.19.5622-5627.1995; RITTENHOUSE J, 1986, J BIOL CHEM, V261, P3939; ROGERS DT, 1988, J BIOL CHEM, V263, P6051; ROTHMAN JE, 1987, J BIOL CHEM, V262, P12502; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SCANDEL K, 1994, MOL CELL BIOL, V14, P7245; SCHLENSTEDT G, 1993, J CELL BIOL, V123, P785, DOI 10.1083/jcb.123.4.785; SCHMITT M, 1995, EMBO J, V14, P3434, DOI 10.1002/j.1460-2075.1995.tb07349.x; Scott SV, 1995, J CELL BIOL, V131, P1727, DOI 10.1083/jcb.131.6.1727; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; TUTTLE DL, 1995, J CELL SCI, V108, P25; VanDenHazel HB, 1996, YEAST, V12, P1, DOI 10.1002/(SICI)1097-0061(199601)12:1<1::AID-YEA902>3.0.CO;2-N; VEENHUIS M, 1983, ARCH MICROBIOL, V134, P193, DOI 10.1007/BF00407757; VIDA TA, 1990, J CELL BIOL, V111, P2871, DOI 10.1083/jcb.111.6.2871; YOSHIHISA T, 1990, J BIOL CHEM, V265, P22418; Zhang JW, 1996, J CELL BIOL, V132, P325, DOI 10.1083/jcb.132.3.325	46	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3381	3387		10.1074/jbc.273.6.3381	http://dx.doi.org/10.1074/jbc.273.6.3381			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452458	hybrid			2022-12-25	WOS:000071822300043
J	Sundaram, M; Sivaprasadarao, A; DeSousa, MM; Findlay, JBC				Sundaram, M; Sivaprasadarao, A; DeSousa, MM; Findlay, JBC			The transfer of retinol from serum retinol-binding protein to cellular retinol-binding protein is mediated by a membrane receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIAL-CELLS; VITAMIN-A; TRANSPORT PROTEINS; ESCHERICHIA-COLI; PLASMA; PURIFICATION; BOVINE	The hypothesis that the cellular uptake of retinol involves the specific interaction of a plasma membrane receptor with serum retinol-binding protein (RBP) at the extracellular surface followed by ligand transfer to cytoplasmic cellular retinol-binding protein (CRBP) has been investigated. The experimental system consisted of the [H-3]retinol-RBP complex, Escherichia coli-expressed recombinant apo-CRBP containing the 10 amino acid long streptavidin-binding peptide sequence at its C terminus (designated as CRBP Strep) and permeabilized human placental membranes, [H-3]Retinol transfer from REP to CRBP-Strep was monitored by measuring the radioactivity associated with CRBP-Strep retained by an immobilized streptavidin resin. Using this assay system, we have demonstrated that optimal retinol uptake is achieved with holo-RBP, the membrane receptor and apo-CRBP. The effects are specific: other binding proteins, including beta-lactoglobulin and serum albumin, despite their ability to bind retinol, failed to substitute for either REP or apo-CRBP. The process is facilitated by membranes containing the native receptor suggesting that this protein is an important component in the transfer mechanism. Taken together, the data suggest that the REP receptor, through specific interactions with the binding proteins, participates (either directly or via associated proteins) in the mechanism which mediates the transfer of retinol from extracellular REP to intracellular CRBP.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Dept Pharmacol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Sivaprasadarao, A (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.	a.sivaprasadarao@leeds.ac.uk	Sousa, Monica/K-4367-2013	Sousa, Monica/0000-0002-4524-2260; Sivaprasadarao, Asipu/0000-0002-6755-3502				BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BOOTH AG, 1980, PLACENTA, V1, P327, DOI 10.1016/S0143-4004(80)80034-8; CHEN CC, 1977, J BIOL CHEM, V252, P5216; CHEN WYJ, 1986, BIOCHEM SOC T, V14, P925, DOI 10.1042/bst0140925; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COLANTUONI V, 1983, NUCLEIC ACIDS RES, V11, P7769, DOI 10.1093/nar/11.22.7769; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; HELLER J, 1975, J BIOL CHEM, V250, P3613; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATARESE V, 1993, J BIOL CHEM, V268, P18859; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NOY N, 1990, BIOCHEMISTRY-US, V29, P3613; ONG DE, 1994, NUTR REV, V52, P524; OTTONELLO S, 1987, J BIOL CHEM, V262, P3975; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; RASK L, 1976, J BIOL CHEM, V251, P6360; SANI BP, 1979, BIOCHEM BIOPH RES CO, V91, P502, DOI 10.1016/0006-291X(79)91550-X; SCHMIDT TGM, 1993, PROTEIN ENG, V6, P109, DOI 10.1093/protein/6.1.109; SENOO H, 1990, J LIPID RES, V31, P1229; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9641, DOI 10.1021/bi00451a015; SIVAPRASADARAO A, 1993, BIOCHEM SOC T, V21, P619, DOI 10.1042/bst0210619; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P571; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SIVAPRASADARAO A, 1994, BIOCHEM J, V300, P437, DOI 10.1042/bj3000437; SIVAPRASADARAO A, 1994, BIOCHEM J, V302, P245, DOI 10.1042/bj3020245; SIVAPRASADARAO A, 1993, BIOCHEM J, V296, P209, DOI 10.1042/bj2960209; Sivaprasadarao A., 1994, Vitamin A in health and disease., P87	33	90	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3336	3342		10.1074/jbc.273.6.3336	http://dx.doi.org/10.1074/jbc.273.6.3336			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452451	hybrid			2022-12-25	WOS:000071822300036
J	Tanaka, T; Kohno, T; Kinoshita, S; Mukai, H; Itoh, H; Ohya, M; Miyazawa, T; Higashijima, T; Wakamatsu, K				Tanaka, T; Kohno, T; Kinoshita, S; Mukai, H; Itoh, H; Ohya, M; Miyazawa, T; Higashijima, T; Wakamatsu, K			alpha helix content of G protein or subunit is decreased upon activation by receptor mimetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; BETA-ADRENERGIC-RECEPTOR; HETEROTRIMERIC G-PROTEIN; CRYSTAL-STRUCTURE; SECONDARY STRUCTURE; SYNTHETIC PEPTIDES; CIRCULAR-DICHROISM; WASP VENOM; BOUND CONFORMATION; ADENYLATE-CYCLASE	To elucidate the mechanism whereby liganded receptor molecules enhance nucleotide exchange of GTP-binding regulatory proteins (G proteins), changes in the secondary structure of the recombinant G(i1) alpha subunit (G(i1)alpha) upon binding with receptor mimetics, compound 48/80 and mastoparan, were analyzed by circular dichroism spectroscopy. Compound 48/80 enhanced the initial rate of GTP gamma S binding to soluble G(i1)alpha 2.6-fold with an EC50 of 30 mu g/ml. With the same EC50, the mimetic decreased the magnitude of ellipticity, which is ascribed to a reduction in a helix content of the G(i1)alpha by 7%. Likewise, mastoparan also enhanced the rate of GTP gamma S binding by 3.0-fold and decreased the magnitude of ellipticity of G(i1)alpha similar to compound 48/80. In corresponding experiments using a K349P-G(i1)alpha, a G(i1)alpha counterpart of the une mutant in G(s) alpha in which Pro was substituted for Lys(349), enhancement of the GTP gamma S binding rate by both activators was quite small. In addition, compound 48/80 showed a negligible effect on the circular dichroism spectrum of the mutant. On the other hand, a proteolytic fragment of G(i1)alpha lacking the N-terminal 29 residues was activated and showed decreased ellipticity upon interaction with the compound, as did the wild-type C(i1)alpha. Taken together, our results strongly suggest that the activator-induced unwinding of the alpha helix of the G protein alpha subunit is mechanically coupled to the enhanced release of bound GDP from the alpha subunit.	Gunma Univ, Fac Engn, Dept Biochem Sci, Kiryu, Gumma 376, Japan; Mitsubishi Kasei Inst Life Sci, Tokyo 194, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 305, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Kanagawa 226, Japan; Prot Engn Res Inst, Osaka 565, Japan; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; RIKEN, Inst Phys & Chem Res, Wako, Saitama 35101, Japan	Gunma University; University of Tsukuba; Tokyo Institute of Technology; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; RIKEN	Wakamatsu, K (corresponding author), Gunma Univ, Fac Engn, Dept Biochem Sci, Kiryu, Gumma 376, Japan.	wakamats@bce.gunma-u.ac.jp	Wakamatsu, Kaori/AAQ-9690-2020	Wakamatsu, Kaori/0000-0003-1412-5691				BOURNE HR, 1995, SCIENCE, V270, P933, DOI 10.1126/science.270.5238.933; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; HAGA T, 1977, P NATL ACAD SCI USA, V74, P2016, DOI 10.1073/pnas.74.5.2016; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; ITOH H, 1991, J BIOL CHEM, V266, P16226; KATSU T, 1983, FEBS LETT, V151, P219, DOI 10.1016/0014-5793(83)80073-8; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1991, METHOD ENZYMOL, V195, P202; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; ROBISHAW JD, 1986, P NATL ACAD SCI USA, V83, P1251, DOI 10.1073/pnas.83.5.1251; ROSS EM, 1994, METHOD ENZYMOL, V237, P26; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; SAITO K, 1984, CHEM PHARM BULL, V32, P2187; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SUKUMAR M, 1992, J BIOL CHEM, V267, P21421; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TAYLOR JM, 1994, CELL SIGNAL, V6, P841, DOI 10.1016/0898-6568(94)90017-5; TOMITA U, 1991, J BIOCHEM-TOKYO, V109, P184, DOI 10.1093/oxfordjournals.jbchem.a123342; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P5654, DOI 10.1021/bi00139a032; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0	53	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3247	3252		10.1074/jbc.273.6.3247	http://dx.doi.org/10.1074/jbc.273.6.3247			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452438	hybrid			2022-12-25	WOS:000071822300023
J	Ye, Q; Koltchine, VV; Mihic, SJ; Mascia, MP; Wick, MJ; Finn, SE; Harrison, NL; Harris, RA				Ye, Q; Koltchine, VV; Mihic, SJ; Mascia, MP; Wick, MJ; Finn, SE; Harrison, NL; Harris, RA			Enhancement of glycine receptor function by ethanol is inversely correlated with molecular volume at position alpha 267	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELINATED NERVE; SODIUM CURRENTS; PROTEIN; ACID; INHIBITION; ALCOHOLS; NEURONS; BRAIN; ANESTHETICS; SUPERFAMILY	Glycine and gamma-aminobutyric acid (GABA)(A) receptors are members of the "superfamily" of ion channels, and are sensitive to allosteric modulation by n-alcohols such as ethanol and butanol. We recently demonstrated that the mutation of Ser-267 to Ile in the alpha 1 subunit abolished ethanol regulation of glycine receptors (Gly-R). In the present study, a pair of chimeric receptors was studied, in which a 45-amino acid domain comprising transmembrane domains 2 and 3 was exchanged between the Gly-R alpha 1 and gamma-aminobutyric acid rho 1 subunits. Detailed pharmacologic analysis of these chimeras confirmed that this domain of the Gly-R confers enhancement of recep tor function by ethanol and butanol. An extensive series of mutations at Ser-267 in the Gly-R alpha 1 subunit was also prepared, and the resulting homomeric receptors were expressed and tested for sensitivity to glycine, and allosteric modulation by alcohols. All of the mutant receptors expressed successfully in Xenopus oocytes. Mutation of Ser-267 to small amino acid residues such as Gly or Ala produced receptors in which glycine responses were potentiated by ethanol. As we have reported previously, the mutant Gly-R alpha 1 (Ser-267 --> Ile) was completely insensitive to ethanol; mutation of Ser-267 to Val had a similar effect. Mutation of Ser-267 to large residues such as His, Cys, or Tyr resulted in inhibition of Gly-R function by ethanol. These results demonstrate that the size of the amino acid residue at position alpha 267 plays a crucial role in determining the functional consequences of allosteric modulation of the Gly-R by alcohols.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Alcohol Res Ctr, Denver, CO 80262 USA; Univ Chicago, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Chicago; University of Chicago; Wake Forest University; Wake Forest Baptist Medical Center	Harris, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th St, Denver, CO 80262 USA.				NIAAA NIH HHS [AA 03527, AA 11428, AA 06399] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011428, R37AA006399, R01AA006399, P50AA003527] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AGUAYO LG, 1994, J PHARMACOL EXP THER, V270, P61; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BETZ H, 1991, TRENDS NEUROSCI, V14, P458, DOI 10.1016/0166-2236(91)90045-V; CELENTANO JJ, 1988, BRAIN RES, V455, P377, DOI 10.1016/0006-8993(88)90098-4; COURTNEY KR, 1975, J PHARMACOL EXP THER, V195, P225; CURRY S, 1991, BRIT J PHARMACOL, V102, P167, DOI 10.1111/j.1476-5381.1991.tb12148.x; DEITRICH RA, 1989, PHARMACOL REV, V41, P491; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DILDYMAYFIELD JE, 1995, J NEUROSCI, V15, P3162; ENGBLOM AC, 1991, J NEUROCHEM, V57, P384, DOI 10.1111/j.1471-4159.1991.tb03764.x; Gready JE, 1997, PROTEIN SCI, V6, P983, DOI 10.1002/pro.5560060504; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Koltchine VV, 1996, NEUROPHARMACOLOGY, V35, P1445, DOI 10.1016/S0028-3908(96)00088-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LI CY, 1994, P NATL ACAD SCI USA, V91, P8200, DOI 10.1073/pnas.91.17.8200; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LOVINGER DM, 1993, NEUROSCI LETT, V159, P83, DOI 10.1016/0304-3940(93)90804-T; Mascia MP, 1996, BRIT J PHARMACOL, V119, P1331, DOI 10.1111/j.1476-5381.1996.tb16042.x; Mascia MP, 1996, MOL PHARMACOL, V50, P402; MCCLAVE JT, 1979, STATISTICS, P492; Mihic S.J., 1996, PHARMACOLOGICAL EFFE, P51; Mihic SJ, 1996, J PHARMACOL EXP THER, V277, P411; MIHIC SJ, 1994, EUR J PHARM-MOLEC PH, V268, P209; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Mihic SJ, 1996, BIOTECHNIQUES, V20, P802; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; SAMSON HH, 1992, TRENDS PHARMACOL SCI, V13, P206, DOI 10.1016/0165-6147(92)90065-E; STRICHARTZ GR, 1973, J GEN PHYSIOL, V62, P37, DOI 10.1085/jgp.62.1.37; VANDENBERG RJ, 1994, HDB MEMBRANE CHANNEL, P317; WILLIAMS KL, 1995, PHARMACOL BIOCHEM BE, V50, P199, DOI 10.1016/0091-3057(94)00288-T; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; [No title captured]	34	116	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3314	3319		10.1074/jbc.273.6.3314	http://dx.doi.org/10.1074/jbc.273.6.3314			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452448	hybrid			2022-12-25	WOS:000071822300033
J	Ferreira, F; Ebner, C; Kramer, B; Casari, G; Briza, P; Kungl, AJ; Grimm, R; Jahn-Schmid, B; Breiteneder, H; Kraft, D; Breitenbach, M; Rheinberger, H; Scheiner, O				Ferreira, F; Ebner, C; Kramer, B; Casari, G; Briza, P; Kungl, AJ; Grimm, R; Jahn-Schmid, B; Breiteneder, H; Kraft, D; Breitenbach, M; Rheinberger, H; Scheiner, O			Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy	FASEB JOURNAL			English	Article						major birch pollen allergen; Bet v 1 mutants; IgE binding epitopes; allergen-specific T cell clones; hypoallergens	BIRCH POLLEN ALLERGEN; T-CELL CLONES; BET-V-I; 4 RECOMBINANT ISOFORMS; MAJOR ALLERGEN; INTERLEUKIN-4 PRODUCTION; PROTEIN ANTIGENICITY; OVERLAPPING PEPTIDES; ESCHERICHIA-COLI; ATOPIC PATIENTS	Specific immunotherapy is an efficient treatment for patients suffering from type I allergy. The mechanisms underlying successful immunotherapy are assumed to operate at the level of T helper cells, leading to a modulation of the immune response to allergens. During immunotherapy, increasing doses of allergens are given on a regular basis, and the beneficial effects for the patient depend on the concentration of allergen used. On the other hand, the risk of IgE-mediated anaphylactic side effects also increase with the amount of allergen applied per injection. Therefore, we have proposed the use of hypoallergenic (low IgE binding activity) forms of allergens for immunotherapy. We evaluated by site-directed mutagenesis the contributions of individual amino acid residues/positions for IgE binding to Bet v 1, the major allergen of birch pollen. We found that IgE binding to Bet v 1 depended on at least six amino acid residues/positions. Immunoblot analyses and inhibition experiments showed that the multiple-point Bet v 1 mutant exhibited extremely low reactivity with serum IgE from birch pollen-allergic patients. In vivo (skin prick) tests showed that the potency of the multiple-point mutant to induce typical urticarial type I reactions in pollen-allergic patients was significantly lower than for wild-type Bet v 1. Proliferation assays of allergen-specific T cell clones demonstrated that these six amino acid exchanges in the Bet v 1 sequence did not influence T cell recognition. Thus, the Bet v I six-point mutant displayed significantly reduced IgE binding activity, but conserved T cell activating capacity, which is necessary for immunomodulation. The approach described here may be generally applied to produce allergen variants to be used in a safe therapy form of immediate-type allergies.	Salzburg Univ, Inst Genet & Allgemeine Biol, A-5020 Salzburg, Austria; European Mol Biol Lab, D-69012 Heidelberg, Germany; Novartis Forschungsinst, A-1235 Vienna, Austria; Hewlett Packard Analyt Grp, D-76337 Waldbronn, Germany; Univ Vienna, Inst Allgemeine & Expt Pathol, A-1090 Vienna, Austria	Salzburg University; European Molecular Biology Laboratory (EMBL); Novartis; Hewlett-Packard; University of Vienna	Ferreira, F (corresponding author), Salzburg Univ, Inst Genet & Allgemeine Biol, Hellbrunnerstr 34, A-5020 Salzburg, Austria.	fatima.ferreira@mh.sbg.ac.at	Briza, Peter/D-7309-2012; Ferreira, Fatima/E-4889-2011; Ferreira, Fatima/AAB-4321-2019	Briza, Peter/0000-0002-4941-6782; Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Kungl, Andreas/0000-0003-3362-797X				BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CARBALLIDO JM, 1992, EUR J IMMUNOL, V22, P135; CASARI G, 1995, NAT STRUCT BIOL, V2, P171, DOI 10.1038/nsb0295-171; DREBORG S, 1985, ALLERGY S4, V40, P55; Duro G, 1997, INT ARCH ALLERGY IMM, V112, P348, DOI 10.1159/000237479; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J IMMUNOL, V154, P1932; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; Faber C, 1996, J BIOL CHEM, V271, P19243, DOI 10.1074/jbc.271.32.19243; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; IPSEN H, 1989, EPITOPES ATOPIC ALLE, P3; JACOBS S, 1959, NATURE, V183, P262, DOI 10.1038/183262a0; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kungl AJ, 1996, BIOCHEM BIOPH RES CO, V223, P187, DOI 10.1006/bbrc.1996.0867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laffer S, 1996, MOL IMMUNOL, V33, P417, DOI 10.1016/0161-5890(95)00152-2; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; MARINI F, 1993, NUCLEIC ACIDS RES, V21, P2277, DOI 10.1093/nar/21.9.2277; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PETERSEN A, 1994, CLIN EXP ALLERGY, V24, P250, DOI 10.1111/j.1365-2222.1994.tb00227.x; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Rothbard J B, 1989, Int Immunol, V1, P479, DOI 10.1093/intimm/1.5.479; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; SCHENK S, 1994, EUR J BIOCHEM, V224, P717, DOI 10.1111/j.1432-1033.1994.00717.x; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; SILVANOVICH A, 1991, J BIOL CHEM, V266, P1204; Smith AM, 1997, CLIN EXP ALLERGY, V27, P593, DOI 10.1111/j.1365-2222.1997.tb00750.x; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Smith AM, 1997, INT ARCH ALLERGY IMM, V113, P99, DOI 10.1159/000237517; STAIGER CJ, 1993, PLANT J, V4, P631, DOI 10.1046/j.1365-313X.1993.04040631.x; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUPHIOGLU C, 1995, CLIN EXP ALLERGY, V25, P853, DOI 10.1111/j.1365-2222.1995.tb00028.x; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; VANREGENMORTEL MHV, 1989, IMMUNOL TODAY, V10, P266, DOI 10.1016/0167-5699(89)90140-0; VANREGENMORTEL MHV, 1986, TRENDS BIOCHEM SCI, V11, P36, DOI 10.1016/0968-0004(86)90230-6; Vrtala S, 1997, INT ARCH ALLERGY IMM, V113, P246, DOI 10.1159/000237560; WEISS C, 1993, J BIOL CHEM, V268, P19574; WESTHOF E, 1984, NATURE, V311, P123, DOI 10.1038/311123a0; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	57	235	263	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1998	12	2					231	242		10.1096/fasebj.12.2.231	http://dx.doi.org/10.1096/fasebj.12.2.231			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472988	Bronze			2022-12-25	WOS:000071848400011
J	Gitt, MA; Colnot, C; Poirier, F; Nani, KJ; Barondes, SH; Leffler, H				Gitt, MA; Colnot, C; Poirier, F; Nani, KJ; Barondes, SH; Leffler, H			Galectin-4 and galectin-6 are two closely related lectins expressed in mouse gastrointestinal tract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTINS; ADHERENS JUNCTION PROTEIN; RAT SMALL-INTESTINE; CRYSTAL-STRUCTURE; GENE FAMILY; S-LECTIN; LACTOSE; SEQUENCE; CLONING; MEMBER	Galectins are a family of carbohydrate-binding proteins that share a conserved sequence and affinity for beta-galactosides. Some, such as galectin-1, are isolated as dimers and have a single carbohydrate recognition domain (CRD) in each monomer, whereas others, such as galectin-4, are isolated as monomers and have two CRDs in a single polypeptide chain. In the course of studying mouse colon mRNA for galectin-4, we detected a related mRNA that encodes a new galectin that also has two CRDs in a single peptide chain. The new galectin, galectin-6, lacks a 24-amino acid stretch in the link region between the two CRDs that is present in galectin-4. Otherwise, these two galectins have 83% amino acid identity. Expression of both galectin-4 and galectin-6 is confined to the epithelial cells of the embryonic and adult gastrointestinal tract. Galectin-4 is expressed at about equal levels in colon and small intestine but much less in stomach, whereas galectin-6 is expressed at about equal levels throughout the gastrointestinal tract.	Univ Calif San Francisco, Ctr Neurobiol & Psychiat, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Inst Cochin Genet Mol, U257 INSERM, F-75014 Paris, France	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Leffler, H (corresponding author), Inst Med Microbiol, Dept Clin Immunol, Solvegatan 23, S-22362 Lund, Sweden.		Colnot, Celine/D-4997-2017; Leffler, Hakon/A-2416-2019	Colnot, Celine/0000-0001-8423-8718; Leffler, Hakon/0000-0003-4482-8945	NHLBI NIH HHS [HL38627] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038627] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; BARILA D, 1995, BBA-GENE STRUCT EXPR, V1263, P133, DOI 10.1016/0167-4781(95)00090-4; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; CHIU ML, 1992, J CELL BIOL, V119, P1689, DOI 10.1083/jcb.119.6.1689; CHIU ML, 1994, J BIOL CHEM, V269, P31770; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOWLIS D, 1995, DEV DYNAM, V203, P241, DOI 10.1002/aja.1002030211; Gitt MA, 1998, J BIOL CHEM, V273, P2961, DOI 10.1074/jbc.273.5.2961; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; Huflejt ME, 1997, J BIOL CHEM, V272, P14294, DOI 10.1074/jbc.272.22.14294; KLION AD, 1994, MOL BIOCHEM PARASIT, V65, P305, DOI 10.1016/0166-6851(94)90081-7; Leffler H, 1997, TRENDS GLYCOSCI GLYC, V9, P9, DOI 10.4052/tigg.9.9; Leonidas DD, 1995, STRUCTURE, V3, P1379, DOI 10.1016/S0969-2126(01)00275-1; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; MADARA JL, 1981, DEV BIOL, V86, P170, DOI 10.1016/0012-1606(81)90327-4; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; MAGNALDO T, 1995, DEV BIOL, V168, P259, DOI 10.1006/dbio.1995.1078; ODA Y, 1993, J BIOL CHEM, V268, P5929; POIRIER F, 1992, DEVELOPMENT, V115, P143; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; TARDY F, 1995, FEBS LETT, V359, P169, DOI 10.1016/0014-5793(95)00025-5; Tureci O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/jbc.272.10.6416; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; WASANO K, 1995, CELL TISSUE RES, V281, P77, DOI 10.1007/BF00307960	30	91	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2954	2960		10.1074/jbc.273.5.2954	http://dx.doi.org/10.1074/jbc.273.5.2954			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446608	hybrid			2022-12-25	WOS:000071736600063
J	Vega, MC; Walsh, SB; Mantle, TJ; Coll, M				Vega, MC; Walsh, SB; Mantle, TJ; Coll, M			The three-dimensional structure of Cys-47-modified mouse liver glutathione S-transferase P1-1 - Carboxymethylation dramatically decreases the affinity for glutathione and is associated with a loss of electron density in the alpha B-3(10)B region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-PI; 3-DIMENSIONAL STRUCTURE; CATALYTIC MECHANISM; HUMAN PLACENTA; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURES; GSH TRANSFERASE; RAT; INACTIVATION; COMPLEX	The three-dimensional structure of mouse liver glutathione S-transferase P1-1 carboxymethylated at Cys-47 and its complex with S-(p-nitrobenzyl)glutathione have been determined by x-ray diffraction analysis, The structure of the modified enzyme described here is the first structural report for a P-i class glutathione S-transferase with no glutathione, glutathione S-conjugate, or inhibitor bound, It shows that part of the active site area, which includes helix alpha B and helix 3(10)B, is disordered. However, the environment of Tyr-7, an essential residue for the catalytic reaction, remains unchanged, The position of the sulfur atom of glutathione is occupied in the ligand-free enzyme by a water molecule that is at H-bond distance from Tyr-7, We do not find any structural evidence for a tyrosinate form, and therefore our results suggest that Tyr-7 is not acting as a general base abstracting the proton from the thiol group of glutathione, The binding of the inhibitor S-(p-nitrobenzyl)glutathione to the carboxymethylated enzyme results in a partial restructuring of the disordered area. The modification of Cys-47 sterically hinders structural organization of this region, and although it does not prevent glutathione binding, it significantly reduces the affinity, A detailed kinetic study of the modified enzyme indicates that the carboxymethylation increases the K-m for glutathione by 3 orders of magnitude, although the enzyme can function efficiently under saturating conditions.	CSIC, Ctr Invest & Desenvolupament, Dept Mol & Cellular Biol, ES-08034 Barcelona, Spain; Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland	Consejo Superior de Investigaciones Cientificas (CSIC); Trinity College Dublin	Coll, M (corresponding author), CSIC, Ctr Invest & Desenvolupament, Dept Mol & Cellular Biol, Jordi Girona 18-26, ES-08034 Barcelona, Spain.	mcccri@cid.csic.es	Coll, Miquel/L-5999-2014; Vega, M. Cristina/C-3640-2011	Coll, Miquel/0000-0003-4471-8674; Vega, M. Cristina/0000-0003-0628-8378	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; ATKINS WM, 1993, J BIOL CHEM, V268, P19188; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; CACCURI AM, 1992, ARCH BIOCHEM BIOPHYS, V297, P119, DOI 10.1016/0003-9861(92)90648-G; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; DIRR H, 1994, J MOL BIOL, V243, P72, DOI 10.1006/jmbi.1994.1631; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; HAYES JD, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P3; JI XH, 1994, BIOCHEMISTRY-US, V33, P1043, DOI 10.1021/bi00171a002; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LoBello M, 1997, BIOCHEMISTRY-US, V36, P6207, DOI 10.1021/bi962813z; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MEYER DJ, 1993, BIOCHEM J, V293, P351, DOI 10.1042/bj2930351; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NISHIHARA T, 1991, BIOCHEM BIOPH RES CO, V174, P580, DOI 10.1016/0006-291X(91)91456-M; Oakley AJ, 1997, BIOCHEMISTRY-US, V36, P576, DOI 10.1021/bi962316i; Orozco M, 1997, PROTEINS, V28, P530, DOI 10.1002/(SICI)1097-0134(199708)28:4<530::AID-PROT7>3.3.CO;2-U; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; PHILLIPS MF, 1993, BIOCHEM J, V294, P57, DOI 10.1042/bj2940057; PHILLIPS MF, 1992, THESIS U DUBLIN DUBL; RAGHUNATHAN S, 1994, J MOL BIOL, V238, P815, DOI 10.1006/jmbi.1994.1336; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; ROUSELL A, 1991, SILICON GRAPHICS DIR; SHEN H, 1991, ARCH BIOCHEM BIOPHYS, V286, P178, DOI 10.1016/0003-9861(91)90025-E; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; STEIGEMANN W, 1991, PROTEIN VERSION 3 1; TAMAI K, 1990, BIOCHEM BIOPH RES CO, V167, P331, DOI 10.1016/0006-291X(90)91769-O; TAMAI K, 1991, BIOCHEM BIOPH RES CO, V179, P790, DOI 10.1016/0006-291X(91)91886-H; TURK D, 1996, MAIN 96; WALSH SB, 1995, BIOCH SOC T, V23; Widersten M, 1996, BIOCHEMISTRY-US, V35, P7731, DOI 10.1021/bi9601619; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8	43	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2844	2850		10.1074/jbc.273.5.2844	http://dx.doi.org/10.1074/jbc.273.5.2844			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446594	hybrid			2022-12-25	WOS:000071736600049
J	Ronai, Z; Yang, YM; Fuchs, SY; Adler, V; Sardana, M; Herlyn, M				Ronai, Z; Yang, YM; Fuchs, SY; Adler, V; Sardana, M; Herlyn, M			ATF2 confers radiation resistance to human melanoma cells	ONCOGENE			English	Article						ATF2; melanoma; radiation resistance; UV	JUN-NH2-TERMINAL KINASE ACTIVATION; ELEMENT-BINDING PROTEIN; TRANSCRIPTION FACTOR-II; ULTRAVIOLET-IRRADIATION; EXPRESSION; JUN; MEDIATE; FAMILY; CREB; IDENTIFICATION	We have previously identifed a U.V.-response element (URE; TGACAACA) and its bound proteins, members of the AP1 and ATF transcription factor families, in melanoma cells, Using a mutant form of cylic AMP response element binding (CREB), we found that CREB-associated-URE-bound proteins conferred characteristic melanoma phenotypes, including radiation resistance (Oncogene 12:2223, 1996). In the present study,ve sought to determine which of the CREB-associated proteins confers radiation resistance on human melanoma cells, To this end we purified and identified via microsequencing ATF2 as a major URE-boundand CREB-associated protein in MeWo cells - a late stage human melanoma cell line, To determine the contribution of ATF2 to radiation resistance, MeWo cells mere transfected with ATF2 cDNA lacking the trans-activation domain (ATF2(Delta 1-195)). MeWo cells that stably express ATF2(Delta 1-195) showed weaker transcriptional activities and an altered pattern of homo/ hetero dimers. ATF2(Delta 1-195) clones exhibited up to tenfold lower resistance to irradiation by either U.V. or X-rays. The degree of resistance to radiation in the ATF2(Delta 1-195) expressing clones could be increased upon transient transfection with ATF2(wt), but not with phosphorylation-defective mutant ATF2(69,71). Similarly, transfection of ATF2(wt) to WM3211, an early stage human melanoma cells line, increased resistance to radiation, Finally, changes elicited through ATF2(Delta 1-195) also led to reduced drug resistance, as shown for MMC, araC and cis-platinum. Our results suggest that ATF2 is a regulator of radiation and drug resistance in melanomas, and that tumor targeted ATF2 modulators may be useful sensitizers in the treatment of tumors of this type.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Merck Sharp & Dohme, W Point, NY USA; Wistar Inst, Mol & Cellular Biol Program, W Point, NY USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, Box 1130,1 Gustave Levy Pl, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA51995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051995, R01CA051995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; CHATTON B, 1994, ONCOGENE, V9, P375; Dhar V, 1996, CELL GROWTH DIFFER, V7, P841; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; GRINJORGENSEN CM, 1992, CUTANEOUS MELANOMA, P27; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HERLYN M, 1992, CUTANEOUS MELANOMA, P82; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KIM SJ, 1992, NATURE, V358, P31; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; KRASILNIKOV M, UNPUB; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Loganzo Frank Jr., 1994, Molecular and Cellular Differentiation, V2, P23; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; MAEKAWA T, 1991, ONCOGENE, V6, P627; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; RONAI ZA, 1990, CANCER RES, V50, P5374; RUTBERG SE, 1992, NUCLEIC ACIDS RES, V20, P1815, DOI 10.1093/nar/20.7.1815; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; RUTBERG SE, 1992, NUCLEIC ACIDS RES, V20, P4305, DOI 10.1093/nar/20.16.4305; SCHMID P, 1995, CARCINOGENESIS, V16, P1499, DOI 10.1093/carcin/16.7.1499; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; *WHO, 1994, ENV HLTH CRIT, P15; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358; YANG YM, 1995, MOL CARCINOGEN, V14, P111, DOI 10.1002/mc.2940140207; YANG YM, 1993, MOL CARCINOGEN, V7, P36, DOI 10.1002/mc.2940070107; YANG YM, 1993, CELL GROWTH DIFFER, V4, P595; Yang YM, 1996, ONCOGENE, V12, P2223; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	37	68	70	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					523	531		10.1038/sj.onc.1201566	http://dx.doi.org/10.1038/sj.onc.1201566			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484842				2022-12-25	WOS:000071739400011
J	Wang, XY; Smith, DI; Frederick, L; James, CD				Wang, XY; Smith, DI; Frederick, L; James, CD			Analysis of EGF receptor amplicons reveals amplification of multiple expressed sequences	ONCOGENE			English	Article						EST; amplicon; EGFR; glioblastoma	EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CANCER; DEAD BOX GENE; INDEPENDENT AMPLIFICATION; AMPLIFIED REGIONS; MALIGNANT GLIOMAS; CARCINOMA-CELLS; PROTO-ONCOGENE; N-MYC; COAMPLIFICATION	In this study we have examined the epidermal growth factor receptor gene (EGFR) region for the amplification of novel expressed sequences in 28 glioblastoma tumors and two cell lines with EGFR gene amplification. Southern analysis with expressed sequence tag (EST) probes revealed instances of amplification for 11 of 13 loci investigated. Northern blot analysis with the same probes indicated that three ESTs identified transcripts that are over-expressed in cell lines having corresponding sequence amplification. The determination of increased dosage and transcript levels for multiple expressed sequences raises the possibility that there are genes in addition to EGFR whose elevated expression contribute to the biologic behavior of tumors with amplification of this region.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA	Mayo Clinic	James, CD (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA.		James, Charles D/E-2721-2012	James, Charles D/0000-0002-1027-203X	NATIONAL CANCER INSTITUTE [R01CA055728, R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55728, CA-48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Bieche I, 1996, CANCER RES, V56, P3886; Bringuier PP, 1996, ONCOGENE, V12, P1747; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; ELKAHLOUN AG, 1996, CANCER, V17, P205; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; George RE, 1996, ONCOGENE, V12, P1583; HALEY J, 1987, ONCOGENE RES, V1, P375; JAMES CD, 1988, CANCER RES, V48, P5546; KAWASAKI K, 1988, JPN J CANCER RES, V79, P1174, DOI 10.1111/j.1349-7006.1988.tb01542.x; MANOHAR CF, 1995, GENE CHROMOSOME CANC, V14, P196, DOI 10.1002/gcc.2870140307; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; Reifenberger G, 1996, CANCER RES, V56, P5141; Reiter JL, 1996, GENOMICS, V32, P97, DOI 10.1006/geno.1996.0081; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TANIGAMI A, 1992, GENOMICS, V13, P21, DOI 10.1016/0888-7543(92)90196-Y; Tanner MM, 1996, CANCER RES, V56, P3441; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899	23	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					191	195		10.1038/sj.onc.1201476	http://dx.doi.org/10.1038/sj.onc.1201476			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464536				2022-12-25	WOS:000071427100005
J	Hu, XQ; Singh, N; Mukhopadhyay, D; Akbarali, HI				Hu, XQ; Singh, N; Mukhopadhyay, D; Akbarali, HI			Modulation of voltage-dependent Ca2+ channels in rabbit colonic smooth muscle cells by c-Src and focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; ANGIOTENSIN-II; SH3 DOMAIN; FACTOR RECEPTOR; FACTOR BB; ASSOCIATION; ACTIVATION; FAMILY; PP125(FAK)	There is emerging evidence indicating that smooth muscle contraction and Ca2+ influx through voltage-dependent L-type Ca2+ channels are regulated by tyrosine kinases; however, the specific kinases involved are largely unknown, In rabbit colonic muscularis mucosae cells, tyrosine-phosphorylated proteins of similar to 60 and 125 kDa were observed served in immunoblots using an anti-phosphotyrosine antibody and were identified as c-Src and focal adhesion kinase (FAK) by immunoblotting with specific antibodies, FAK co-immunoprecipitated with c-Src, and the phosphorylation of the c-Src.FAK complex was markedly enhanced by platelet-derived growth factor (PDGF) BE. The presence of activated c-Src in unstimulated cells was identified in cell lysates by immunoblotting with an antibody recognizing the autophosphorylated site (P416Y). In whole-cell patch-clamp studies, intracellular dialysis of a Src substrate peptide and anti-c-Src and anti-FAK antibodies suppressed Ca2+ currents by 60, 62, and 43%, respectively, In contrast, intracellular dialysis of an anti-mouse IgG or anti-Kv1.5 antibody did not inhibit Ca2+ currents, Co-dialysis of anti-cSrc and anti-FAK antibodies inhibited Ca2+ currents (63%) equivalent to dialysis with the anti-c-Src antibody alone, PDGF-BB enhanced Ca2+ currents by 43%, which was abolished by the anti-c-Src and anti-FAK antibodies, Neither the MER inhibitor PD 098059 nor an anti-Ras antibody inhibited basal Ca2+ currents or PDGF-stimulated Ca2+ currents, The alpha(1C) subunit of the L-type Ca2+ channel co-immunoprecipitated with anti-c-Src and anti-phosphotyrosine antibodies, indicating direct association of c-Src kinase with the Ca2+ channel, These data suggest that c-Src and FAK, but not the Ras/mitogen-activated protein kinase cascade, modulate basal Ca2+ channel activity and mediate the PDGF-induced enhancement of L-type Ca2+ currents in differentiated smooth muscle cells.	Harvard Univ, Sch Med, Beth Israel Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Med Ctr, Div Pathol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Akbarali, HI (corresponding author), Harvard Univ, Sch Med, Beth Israel Med Ctr, Div Gastroenterol, 330 Brookline Ave, Boston, MA 02215 USA.		Akbarali, Hamid I/B-3236-2012; Akbarali, Hamid/Q-9344-2019	Singh, Namita/0000-0002-6782-4288; Akbarali, Hamid/0000-0003-1423-0774	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046367, R29DK046367] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-46367] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DISALVO J, 1993, BIOCHEM BIOPH RES CO, V190, P968, DOI 10.1006/bbrc.1993.1144; DISALVO J, 1989, J BIOL CHEM, V264, P10773; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hatakeyama N, 1996, AM J PHYSIOL-CELL PH, V270, pC1780, DOI 10.1152/ajpcell.1996.270.6.C1780; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; KURIYAMA H, 1995, PHARMACOL REV, V47, P387; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEDUC I, 1995, J BIOL CHEM, V270, P4401, DOI 10.1074/jbc.270.9.4401; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Ma HP, 1996, J CLIN INVEST, V97, P2332, DOI 10.1172/JCI118676; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PAVALKO FM, 1995, AM J PHYSIOL-CELL PH, V268, pC563, DOI 10.1152/ajpcell.1995.268.3.C563; POLTE TR, 1994, J CELL BIOCHEM, V55, P106, DOI 10.1002/jcb.240550113; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHOELSON SE, 1989, J BIOL CHEM, V264, P7831; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wijetunge S, 1996, FEBS LETT, V399, P63, DOI 10.1016/S0014-5793(96)01177-5; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	37	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5337	5342		10.1074/jbc.273.9.5337	http://dx.doi.org/10.1074/jbc.273.9.5337			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478993	hybrid			2022-12-25	WOS:000072310400077
J	Ratner, JN; Balasubramanian, B; Corden, J; Warren, SL; Bregman, DB				Ratner, JN; Balasubramanian, B; Corden, J; Warren, SL; Bregman, DB			Ultraviolet radiation-induced ubiquitination and proteasomal degradation of the large subunit of RNA polymerase II - Implications for transcription-coupled DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; INVITRO TRANSCRIPTION; ALPHA-AMANITIN; ACTIVE GENES; KAPPA-B; PHOSPHORYLATION; PROTEIN; CELLS; ELONGATION; ENCODES	We have shown previously that UV radiation and other DNA-damaging agents induce the ubiquitination of a portion of the RNA polymerase II large subunit (Pol II LS), In the present study UV irradiation of repair competent fibroblasts induced a transient reduction of the Pol II LS level; new protein synthesis restored Pol II LS to the base-line level within 16-24 h. In repair-deficient xeroderma pigmentosum cells, UV radiation-induced ubiquitination of Pol II LS was followed by a sustained reduction of Pol II LS level, In both normal and xeroderma pigmentosum cells, the ubiquitinated Pol II LS had a hyperphosphorylated COOH-terminal domain (CTD), which is characteristic of elongating Pol II, The portion of Pol II LS whose steady-state level diminished most quickly had a relatively hypophosphorylated CTD, The ubiquitinated residues did not map to the CTD, Importantly, UV-induced reduction of Pol II LS level in repair-competent or -deficient cells was inhibited by the proteasome inhibitors lactacystin or MG132. These data demonstrate that UV-induced ubiquitination of Pol II LS is followed by its degradation in the proteasome, These results suggest, contrary to a current model of transcription-coupled DNA repair, that elongating Pol II complexes which arrest at intragenic DNA lesions may be aborted rather than resuming elongation after repair takes place.	Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; NeXstar Pharmaceut, Boulder, CO 80301 USA	Yeshiva University; Albert Einstein College of Medicine; Johns Hopkins University	Ratner, JN (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, 1300 Morris Pk Ave,F717N, Bronx, NY 10461 USA.	bregman@aecom.yu.edu			NATIONAL CANCER INSTITUTE [K08CA073549] Funding Source: NIH RePORTER; NCI NIH HHS [CA73549] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BARTOLOMEI MS, 1987, MOL CELL BIOL, V7, P586, DOI 10.1128/MCB.7.2.586; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CHEN YH, 1991, P NATL ACAD SCI USA, V88, P9583, DOI 10.1073/pnas.88.21.9583; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Coin F., 1997, Mutation Research, V379, pS33, DOI 10.1016/S0027-5107(97)82704-2; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; Dahmus ME, 1996, METHOD ENZYMOL, V273, P185; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DALLEY BK, 1993, GENETICS, V133, P237; Damgaard J, 1996, BIOCHEM BIOPH RES CO, V227, P677, DOI 10.1006/bbrc.1996.1568; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Donahue BA, 1996, J BIOL CHEM, V271, P10588, DOI 10.1074/jbc.271.18.10588; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; Ikehata H, 1997, MOL CELL BIOL, V17, P1484, DOI 10.1128/MCB.17.3.1484; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KONTERMANN RE, 1995, BIOL CHEM H-S, V376, P473, DOI 10.1515/bchm3.1995.376.8.473; Maki CG, 1996, CANCER RES, V56, P2649; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; Verhage RA, 1997, MOL GEN GENET, V254, P284, DOI 10.1007/s004380050417; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; Weeda G, 1997, NUCLEIC ACIDS RES, V25, P2274, DOI 10.1093/nar/25.12.2274; WINTZERITH M, 1992, NUCLEIC ACIDS RES, V20, P910, DOI 10.1093/nar/20.4.910; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZHANG J, 1991, J BIOL CHEM, V266, P2290	56	188	190	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5184	5189		10.1074/jbc.273.9.5184	http://dx.doi.org/10.1074/jbc.273.9.5184			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478972	hybrid			2022-12-25	WOS:000072310400056
J	Yamaguchi, K; Kinosaki, M; Goto, M; Kobayashi, F; Tsuda, E; Morinaga, T; Higashio, K				Yamaguchi, K; Kinosaki, M; Goto, M; Kobayashi, F; Tsuda, E; Morinaga, T; Higashio, K			Characterization of structural domains of human osteoclastogenesis inhibitory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH-DOMAIN; CELL-SURFACE; CONTAINING RECEPTOR; SOLUBLE FORM; APOPTOSIS; PROTEIN; FAS; DIFFERENTIATION; MODULATION; PROTECTION	Osteoclastogenesis inhibitory factor (OCIF) is a heparin-binding secretary glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) family. OCIF is present both as a similar to 60-kDa monomer and a disulfide-linked homodimer, We attempted to characterize the seven structural domains of OCIF by determining the capabilities of various OCIF mutants to inhibit osteoclastogenesis, to interact with heparin, and to form dimers. We also examined a potential of domains 5 and 6, death domain homologous regions (DDHs), for inducing cell death by expressing OCIF/Fas fusion proteins, Our results show that: (i) the N-terminal portion of OCIF containing domains 1-4, which have structural similarity to the extracellular domains of the TNFR family proteins, is sufficient to inhibit osteoclastogenesis; (ii) a heparin-binding site is located in domain 7, and affinity for heparin does not correlate with the inhibitory activity; (iii) Cys-400 in domain 7 is the residue responsible for dimer formation; and (iv) the C-terminal portion containing domains 5 and 6, DDHs, has a high potential for mediating a cytotoxic signal when it is expressed in cells as an OCIF/Fas fusion protein in which the transmembrane region of Fas is inserted in front of DDHs.				fvbd7042@mb.infoweb.or.jp						ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAMBERS TJ, 1991, VITAM HORM, V46, P41; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; HARTMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; SANDSTROM J, 1994, J BIOL CHEM, V269, P19163; Schreiber M, 1996, J BIOL CHEM, V271, P13333, DOI 10.1074/jbc.271.23.13333; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH C, 1991, CYTOKINE, V3, P448; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; SUDA T, 1995, BONE, V17, pS87, DOI 10.1016/8756-3282(95)00185-G; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603; YASUDA H, 1998, IN PRESS ENDOCRINOLO; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	29	180	205	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5117	5123		10.1074/jbc.273.9.5117	http://dx.doi.org/10.1074/jbc.273.9.5117			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478964	hybrid			2022-12-25	WOS:000072310400048
J	Holtz-Heppelmann, CJ; Algeciras, A; Badley, AD; Paya, CV				Holtz-Heppelmann, CJ; Algeciras, A; Badley, AD; Paya, CV			Transcriptional regulation of the human FasL promoter-enhancer region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA GENE; HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-MEDIATED CYTOTOXICITY; RECEPTOR TRANSGENIC MICE; NF-KAPPA-B; T-CELLS; LYMPHOPROLIFERATIVE SYNDROME; ALLOGRAFT-REJECTION; LIGAND EXPRESSION; INDUCED APOPTOSIS	The human FasL enhancer region was cloned and functionally characterized in transformed and primary T cells, Within the 2.3 kilobase pairs of the FasL, untranslated region, the distal 3' 300-base pair portion contains a single transcription initiation site and confers basal and inducible transcriptional activity. Stimuli that increase [Ca2+](i) such as CD3 cross-linking or ionomycin, but not activation of protein kinase C, were found to induce FasL enhancer transcription in a cyclosporin-sensitive manner. Moreover, calcineurin and NFAT, but not AP1, were identified as necessary and sufficient effectors in driving FasL, transcription through an NFAT cis-acting motif (GGAAA), Additional modes of T cell activation such as CD4 cross-linking were also found to induce NFAT binding to the FasL enhancer region and to functionally transactivate its transcription, These results indicate that the induction of FasL gene transcription in T cells after CD3 or CD4 activation is selectively mediated by calcineurin and NFAT.	Mayo Clin & Mayo Fdn, Div Expt Pathol, Dept Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Paya, CV (corresponding author), Mayo Clin & Mayo Fdn, Div Expt Pathol, Dept Expt Pathol, 200 1st St SW,Guggenheim 501, Rochester, MN 55905 USA.		badley, andrew d/O-9022-2014	Badley, Andrew/0000-0001-7796-7680				Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; Badley AD, 1996, J VIROL, V70, P199, DOI 10.1128/JVI.70.1.199-206.1996; Badley AD, 1997, J EXP MED, V185, P55, DOI 10.1084/jem.185.1.55; BALDARI CT, 1995, EUR J IMMUNOL, V25, P1843, DOI 10.1002/eji.1830250708; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; Eischen CM, 1996, J IMMUNOL, V156, P2693; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GOLDFELD AE, 1994, J EXP MED, V180, P763, DOI 10.1084/jem.180.2.763; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Latinis KM, 1997, J IMMUNOL, V158, P4602; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCELHINNY JA, 1995, J VIROL, V69, P1500, DOI 10.1128/JVI.69.3.1500-1509.1995; Mitra D, 1996, IMMUNOLOGY, V87, P581, DOI 10.1046/j.1365-2567.1996.510589.x; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OYAIZU N, 1995, J CLIN IMMUNOL, V15, P217, DOI 10.1007/BF01540879; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; Seino K, 1996, INT IMMUNOL, V8, P1347, DOI 10.1093/intimm/8.9.1347; SEKIGAWA I, 1995, J CLIN IMMUNOL, V15, P312, DOI 10.1007/BF01541321; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Sytwu HK, 1996, IMMUNITY, V5, P17, DOI 10.1016/S1074-7613(00)80306-4; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; TWIGG HL, 1992, J IMMUNOL, V149, P1462; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wu JG, 1996, J CLIN INVEST, V98, P1107, DOI 10.1172/JCI118892; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673	51	136	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4416	4423		10.1074/jbc.273.8.4416	http://dx.doi.org/10.1074/jbc.273.8.4416			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468493	hybrid			2022-12-25	WOS:000072115000021
J	Kim, A; Kim, J; Martin, BM; Dunaway-Mariano, D				Kim, A; Kim, J; Martin, BM; Dunaway-Mariano, D			Isolation and characterization of the carbon-phosphorus bond-forming enzyme phosphoenolpyruvate mutase from the mollusk Mytilus edulis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-C BOND; TRYPANOSOMA-CRUZI; STREPTOMYCES-HYGROSCOPICUS; TETRAHYMENA-PYRIFORMIS; NUCLEOTIDE-SEQUENCE; EPIMASTIGOTE FORMS; BIOSYNTHETIC GENES; BIALAPHOS SF-1293; APLYSIA-KURODAI; PHOSPHOMUTASE	The enzyme phosphoenolpyruvate mutase was purified to homogeneity from the mollusk Mytilus edulis. The subunit size of the native homotetramer was determined to be 34,000 Da, The steady state kinetic constants for catalysis of the conversion of phosphonopyruvate to phosphoenolpyruvate at pH 7.5 and 25 degrees C were measured at k(cat) = 34 s(-1), phosphonopyruvate K-m = 3 mu M, and Mg2+ K-m = 4 mu M. The enzyme displayed a broad specificity for divalent metal ion activation; Co2+, Mn2+, Zn2+, and Ni2+ are activators, whereas Ca2+ is not. Analysis of the pH dependence of the Mg2+-activated mutase-catalyzed reaction of phosphonopyruvate revealed one residue that must be protonated (apparent pK(a) = 8.3) and a second residue that must be unprotonated (apparent pK(a) = 7.7) for maximal catalytic activity.	Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA; NIMH, Mol Neurogenet Unit, Clin Neurosci Branch, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland College Park; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Dunaway-Mariano, D (corresponding author), Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA.		Kim, Jaebong/AAV-1986-2021	Kim, Jaebong/0000-0003-1609-338X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028688] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28688] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE S, 1991, J BIOL CHEM, V266, P9939; ALHADELFF JA, 1970, J BIOCH, V9, P4866; BARRY RJ, 1988, BIOCHEM BIOPH RES CO, V153, P177, DOI 10.1016/S0006-291X(88)81205-1; BAUMANN H, 1992, BIOCHEMISTRY-US, V31, P4081, DOI 10.1021/bi00131a026; BOWMAN E, 1988, J AM CHEM SOC, V110, P5575, DOI 10.1021/ja00224a054; BOWMAN ED, 1990, BIOCHEMISTRY-US, V29, P7059, DOI 10.1021/bi00482a016; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleland W W, 1979, Methods Enzymol, V63, P103; DELEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; HAMMERSCHMIDT F, 1991, J ORG CHEM, V56, P2364, DOI 10.1021/jo00007a022; HARA O, 1991, J GEN MICROBIOL, V137, P351, DOI 10.1099/00221287-137-2-351; HARD K, 1993, BIOCHEMISTRY-US, V32, P766, DOI 10.1021/bi00054a005; HIDAKA T, 1989, J ANTIBIOT, V42, P491, DOI 10.7164/antibiotics.42.491; HIDAKA T, 1989, J AM CHEM SOC, V111, P8012, DOI 10.1021/ja00202a051; HIDAKA T, 1992, J ANTIBIOT, V45, P1977, DOI 10.7164/antibiotics.45.1977; HIDAKA T, 1995, MOL GEN GENET, V249, P274, DOI 10.1007/BF00290527; HILDERBRAND RL, 1983, ROLES PHOSPHONATES L; KAHAN FM, 1974, ANN NY ACAD SCI, V235, P364, DOI 10.1111/j.1749-6632.1974.tb43277.x; KENNEDY KE, 1970, SCIENCE, V168, P989, DOI 10.1126/science.168.3934.989; KILBY PM, 1991, NATURWISSENSCHAFTEN, V78, P514, DOI 10.1007/BF01131402; MASTELERZ P, 1984, NATURAL PRODUCTS CHE, P171; MATSUBARA T, 1990, BIOCHIM BIOPHYS ACTA, V1042, P280, DOI 10.1016/0005-2760(90)90154-P; NAKASHITA H, 1992, J BACTERIOL, V174, P6857, DOI 10.1128/JB.174.21.6857-6861.1992; NAKASHITA H, 1991, AGR BIOL CHEM TOKYO, V55, P2825, DOI 10.1080/00021369.1991.10871050; OGAWA Y, 1973, Scientific Reports of Meiji Seika Kaisha, V13, P42; PREVIATO JO, 1995, J BIOL CHEM, V270, P7241, DOI 10.1074/jbc.270.13.7241; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; SEIDEL HM, 1992, BIOCHEMISTRY-US, V31, P2598, DOI 10.1021/bi00124a021; SEIDEL HM, 1988, NATURE, V335, P457, DOI 10.1038/335457a0; STEINER S, 1973, J BACTERIOL, V116, P1199, DOI 10.1128/JB.116.3.1199-1211.1973; WASSEF MK, 1977, BIOCHIM BIOPHYS ACTA, V922, P78; WHITE RW, 1970, BIOCHEM J, V116, P767, DOI 10.1042/bj1160767; YAMADA S, 1995, J BIOCHEM-TOKYO, V117, P794, DOI 10.1093/oxfordjournals.jbchem.a124778	33	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4443	4448		10.1074/jbc.273.8.4443	http://dx.doi.org/10.1074/jbc.273.8.4443			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468496	hybrid			2022-12-25	WOS:000072115000024
J	Larsen, M; Ressler, SJ; Lu, B; Gerdes, MJ; McBride, L; Dang, TD; Rowley, DR				Larsen, M; Ressler, SJ; Lu, B; Gerdes, MJ; McBride, L; Dang, TD; Rowley, DR			Molecular cloning and expression of ps20 growth inhibitor - A novel WAP-type "four-disulfide core" domain protein expressed in smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-MESENCHYMAL INTERACTIONS; UROGENITAL SINUS MESENCHYME; ELASTASE-SPECIFIC INHIBITOR; RODENT URINARY-BLADDER; CELL-SURFACE; DIFFERENTIAL EXPRESSION; PROSTATIC DEVELOPMENT; CULTURED FIBROBLASTS; NEGATIVE REGULATION; ENDOTHELIAL-CELLS	We previously reported the purification of ps20 (Rowley, D. R,, Dang, T, D., Larsen, IM,, Gerdes, M. J,, McBride, L., and Lu, B, (1995) J. Biol. Chem. 270, 22058-22065), a urogenital sinus mesenchymal cell, secreted protein having growth-inhibitory properties, We report here cloning of the 1.03-kilobase rat ps20 cDNA clone from the PS-1 (adult rat prostate smooth muscle) cDNA library. Partial clones were obtained by nested polymerase chain reaction with degenerate primers, and full-length ps20 cDNA clones were isolated by plaque hybridization. Sequence analysis revealed that ps20 protein contains a WAP-type "four-disulfide core" motif and is a novel member of the WAP signature protein family composed primarily of secreted serine protease inhibitors. Native ps20 immunoprecipitated from smooth muscle cells and recombinant ps20 both resolved on SDS-polyacrylamide gel electrophoresis with apparent molecular mass of 27-29 kDa under reducing conditions and 21-23 kDa under non-reducing conditions, respectively, Stable ps20-transfectant COS-7 cell lines secreted ps20 and were growth-inhibited relative to mock transfectants. In addition, COS-7 and prostate carcinoma PC-3 cells were growth-inhibited by bacterially expressed ps20, Northern analysis indicated differential expression by tissue with highest, expression in the heart, Immunohistochemical localization of ps20 protein showed cell-specific expression by both visceral and vascular smooth muscle in all tissues, including the prostate gland. These results indicate ps20 is a novel growth-regulatory member of the WAP signature family expressed by smooth muscle cells.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Program Mol & Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Rowley, DR (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	drowley@bcm.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA058093, P50CA058204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045909] Funding Source: NIH RePORTER; NCI NIH HHS [CA58093, CA58204] Funding Source: Medline; NIDDK NIH HHS [DK45909] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANGELLOZNICOUD P, 1995, ENDOCRINOLOGY, V136, P5485, DOI 10.1210/en.136.12.5485; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CUNHA GR, 1983, J CELL BIOL, V96, P1662, DOI 10.1083/jcb.96.6.1662; CUNHA GR, 1972, ANAT REC, V172, P179, DOI 10.1002/ar.1091720206; CUNHA GR, 1980, ENDOCRINOLOGY, V107, P1767, DOI 10.1210/endo-107-6-1767; DEAR TN, 1988, CANCER RES, V48, P5203; DEAR TN, 1991, BIOCHEM BIOPH RES CO, V176, P247, DOI 10.1016/0006-291X(91)90916-U; DOW KE, 1983, CELL TISSUE RES, V231, P83; FREY P, 1979, P NATL ACAD SCI USA, V76, P6294, DOI 10.1073/pnas.76.12.6294; GEOURJON C, 1993, COMPUT APPL BIOSCI, V9, P87; Gerdes MJ, 1996, ENDOCRINOLOGY, V137, P864, DOI 10.1210/en.137.3.864; GERDES MJ, 1998, IN PRESS J HISTOCHEM; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HASLAM SZ, 1991, ENDOCRINOLOGY, V129, P2017, DOI 10.1210/endo-129-4-2017; HEINZEL R, 1986, EUR J BIOCHEM, V160, P61, DOI 10.1111/j.1432-1033.1986.tb09940.x; HENNIGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P2677, DOI 10.1093/nar/10.8.2677; JAHNKE GD, 1994, ENDOCRINOLOGY, V135, P2022, DOI 10.1210/en.135.5.2022; KATO I, 1979, FED PROC, V38, P832; KIRCHHOFF C, 1991, BIOL REPROD, V45, P350, DOI 10.1095/biolreprod45.2.350; KNOTH K, 1988, NUCLEIC ACIDS RES, V16, P109; Koolwijk P, 1996, J CELL BIOL, V132, P1177, DOI 10.1083/jcb.132.6.1177; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; KUROKI J, 1995, J BIOL CHEM, V270, P22428, DOI 10.1074/jbc.270.38.22428; KYPRIANOU N, 1988, ENDOCRINOLOGY, V123, P2124, DOI 10.1210/endo-123-4-2124; LACROIX B, 1984, DIFFERENTIATION, V28, P129, DOI 10.1111/j.1432-0436.1984.tb00276.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAJMUDAR G, 1994, MOL CARCINOGEN, V11, P29, DOI 10.1002/mc.2940110106; NEUBAUER BL, 1983, J CELL BIOL, V96, P1671, DOI 10.1083/jcb.96.6.1671; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PONGOR S, 1994, NUCLEIC ACIDS RES, V22, P3610; POST M, 1984, BIOCHIM BIOPHYS ACTA, V793, P297, DOI 10.1016/0005-2760(84)90332-1; ROWLEY DR, 1992, IN VITRO CELL DEV-AN, V28A, P29; ROWLEY DR, 1995, J BIOL CHEM, V270, P22058, DOI 10.1074/jbc.270.37.22058; ROWLEY DR, 1987, CANCER RES, V47, P2955; Rugarli EI, 1996, HUM MOL GENET, V5, P1109, DOI 10.1093/hmg/5.8.1109; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAWYER RH, 1984, DEV BIOL, V101, P8, DOI 10.1016/0012-1606(84)90111-8; SHEUG S, 1996, P NATL ACAD SCI USA, V93, P11669; SMITH BT, 1983, P NATL ACAD SCI-BIOL, V80, P1951, DOI 10.1073/pnas.80.7.1951; SMITH BT, 1979, SCIENCE, V204, P1094, DOI 10.1126/science.582216; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Thompson K, 1996, J CELL PHYSIOL, V166, P495, DOI 10.1002/(SICI)1097-4652(199603)166:3<495::AID-JCP4>3.0.CO;2-K; THORSEN S, 1987, FUNDAMENTAL CLIN FIB, P83; Tsunemi M, 1996, BIOCHEMISTRY-US, V35, P11570, DOI 10.1021/bi960900l; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; WILSON MJ, 1995, MICROSC RES TECHNIQ, V30, P305, DOI 10.1002/jemt.1070300406; ZHANG M, 1995, CANCER RES, V55, P2537	56	62	65	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4574	4584		10.1074/jbc.273.8.4574	http://dx.doi.org/10.1074/jbc.273.8.4574			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468514	hybrid			2022-12-25	WOS:000072115000042
J	Murthy, KS; Makhlouf, GM				Murthy, KS; Makhlouf, GM			Coexpression of ligand-gated P-2X and G protein-coupled P-2Y receptors in smooth muscle - Preferential activation of P-2Y receptors coupled to phospholipase C (PLC)-beta 1 via and the PLC-beta 3 via G beta gamma(i3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANES; INTESTINAL MUSCLE; ION CHANNELS; EXTRACELLULAR ATP; FUNCTIONAL EXPRESSION; NUCLEOTIDE RECEPTOR; SIGNAL-TRANSDUCTION; GUANINE-NUCLEOTIDES; MOLECULAR-CLONING; ADENYLYL-CYCLASE	P-2 receptor subtypes and their signaling mechanisms were characterized in dispersed smooth muscle cells. UTP and ATP stimulated inositol 1,4,5-triphosphate formation, Ca2+ release, and contraction that were abolished by U-73122 and guanosine 5'-O-(3-thio) diphosphate, and partly inhibited (50-60%) by pertussis toxin (PTX). ATP analogs (adenosine 5'-(alpha,beta-methylene)triphosphate, adenosine 5'-(beta, gamma-methylene)triphosphate, and 2-methylthio-ATP) stimulated Ca2+ influx and contraction that were abolished by nifedipine and in Ca2+-free medium, Micromolar concentrations of ATP stimulated both Ca2+ influx and Ca2+ release. ATP and UTP activated G(q/11) and G(i3) in gastric and aortic smooth muscle and heart membranes, G(q/11) and G(i1) acid/or G(i2) in liver membranes, and G(o) and G(i1-3) in brain membranes. Phosphoinositide hydrolysis stimulated by ATP and UTP was mediated concurrently by G alpha(q/11)-dependent activation of phospholipase (PL) C-beta 1 and G beta gamma(i3)-dependent activation of PLC-beta 3. Phosphoinositide hydrolysis was partially inhibited by PTX or by antibodies to G alpha(q/11), G(beta), PLC-beta 1, or PLC-beta 3, and completely inhibited by the following combinations (PLC-beta 1 and PLC-beta 3 antibodies; G alpha(q/11) and G(beta) antibodies; PLC-beta 1 and G(beta) antibodies; PTX with either PLC-beta 1 or G alpha(q/11) antibody). The pattern of responses implied that P-2Y2 receptors in visceral, and probably vascular, smooth muscle are coupled to PLC-beta 1 via G alpha(q/11) and to PLC-beta 3 via G beta gamma(i3). These receptors co-exist with ligand-gated P-2X1 receptors activated by ATP analogs and high levels of ATP.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Makhlouf, GM (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, POB 980711, Richmond, VA 23298 USA.				NIDDK NIH HHS [DK-28300] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028300] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akbar GKM, 1996, J BIOL CHEM, V271, P18363, DOI 10.1074/jbc.271.31.18363; BITAR KN, 1986, J BIOL CHEM, V261, P6591; BITAR KN, 1982, NATURE, V297, P72, DOI 10.1038/297072a0; BITAR KN, 1982, SCIENCE, V216, P531, DOI 10.1126/science.6176025; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Collo G, 1996, J NEUROSCI, V16, P2495; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; COWEN DS, 1990, BIOCHIM BIOPHYS ACTA, V1053, P195, DOI 10.1016/0167-4889(90)90014-5; CRACK BE, 1994, BRIT J PHARMACOL, V113, P1432, DOI 10.1111/j.1476-5381.1994.tb17157.x; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GERWINS P, 1992, J BIOL CHEM, V267, P16081; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; Harden TK, 1997, TRENDS PHARMACOL SCI, V18, P43, DOI 10.1016/S0165-6147(97)89795-7; IRVING HR, 1987, J BIOL CHEM, V262, P3440; KUEMMERLE JF, 1992, AM J PHYSIOL, V263, pG269, DOI 10.1152/ajpgi.1992.263.2.G269; KUEMMERLE JF, 1992, MOL PHARMACOL, V42, P1090; LANZAROWSKI ER, 1994, AM J PHYSIOL, V266, pC406; LAZAROWSKI ER, 1994, J BIOL CHEM, V269, P11830; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; MORINI G, 1993, J PHARMACOL EXP THER, V264, P598; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; Murthy KS, 1997, J BIOL CHEM, V272, P21317, DOI 10.1074/jbc.272.34.21317; Murthy KS, 1996, MOL PHARMACOL, V50, P870; MURTHY KS, 1995, AM J PHYSIOL-CELL PH, V269, pC969, DOI 10.1152/ajpcell.1995.269.4.C969; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; MURTHY KS, 1995, J PHARMACOL EXP THER, V274, P300; MURTHY KS, 1993, AM J PHYSIOL, V265, pG660, DOI 10.1152/ajpgi.1993.265.4.G660; Najbar AT, 1996, BRIT J PHARMACOL, V118, P537, DOI 10.1111/j.1476-5381.1996.tb15435.x; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; OKOMOTO T, 1992, FEBS LETT, V305, P125; PACAUD P, 1995, AM J PHYSIOL-HEART C, V269, pH30, DOI 10.1152/ajpheart.1995.269.1.H30; Post SR, 1996, J BIOL CHEM, V271, P2029, DOI 10.1074/jbc.271.4.2029; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; SIMON J, 1995, PHARMACOL TOXICOL, V76, P302, DOI 10.1111/j.1600-0773.1995.tb00151.x; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; Todorov LD, 1997, NATURE, V387, P76, DOI 10.1038/387076a0; TREZISE DJ, 1995, N-S ARCH PHARMACOL, V351, P603; UHING RJ, 1986, J BIOL CHEM, V261, P2140; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; Webb TE, 1996, MOL PHARMACOL, V50, P258; Webb TE, 1996, BIOCHEM BIOPH RES CO, V219, P105, DOI 10.1006/bbrc.1996.0189; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	57	84	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4695	4704		10.1074/jbc.273.8.4695	http://dx.doi.org/10.1074/jbc.273.8.4695			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468531	hybrid			2022-12-25	WOS:000072115000059
J	Wegner, SA; Ehrenberg, PK; Chang, G; Dayhoff, DE; Sleeker, AL; Michael, NL				Wegner, SA; Ehrenberg, PK; Chang, G; Dayhoff, DE; Sleeker, AL; Michael, NL			Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7-TRANSMEMBRANE DOMAIN RECEPTOR; HIV-1 ENTRY; TROPIC HIV-1; INFECTION; CLONING; MIP-1-ALPHA; MIP-1-BETA; FUSION; RANTES; CELLS	CXCR4 is both a chemokine receptor and entry co-preceptor for T cell lime-adapted human immunodeficiency virus type 1. The genomic organization and promoter function for the entire transcription unit of CXCR4 were determined, The gene contains 2 exons of 103 and 1563 base pairs (bp) interrupted by a 2132-bp intron precisely between codons 5 and 6 of the coding sequences. a transcription start site was identified 88 bp upstream of the initiation codon, and a polyadenylate addition sits was identified 22 bp 3' to a polyadenylation signal, Transient expression assays defined a minimal promoter at positions -114 to +43 relative to the transcription start site. This region contains a TATA box, a nuclear respiratory factor-1 (NRF-1) site, and two GC boxes. Specific factor binding to the NRF-1 site and GC boxes were demonstrated by gel mobility shifts and DNase I footprinting. Site-directed mutagenesis showed that the NRF-1 site is crucial for promoter activity providing the first evidence for the regulation of a signal transduction gene by NRF-1. Sequences between -691 and -191 repress CXCR4 promoter activity. Further study of these regulatory elements will be important to understanding how CXCR4 functions as both a chemokine receptor and human immunodeficiency virus type 1 entry co-receptor.	Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD 20850 USA; Henry M Jackson Fdn, Rockville, MD 20850 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc	Michael, NL (corresponding author), Walter Reed Army Inst Res, Div Retrovirol, 1600 E Gude Dr, Rockville, MD 20850 USA.	nmichael@pasteur.hjf.org		Ehrenberg, Philip/0000-0002-8695-4301				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, NATURE, V388, P238, DOI 10.1038/40789; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRUNAK S, 1991, J MOL BIOL, V220, P49, DOI 10.1016/0022-2836(91)90380-O; Clapham PR, 1997, NATURE, V388, P230, DOI 10.1038/40758; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; GRANELLIPIPERNO A, 1995, P NATL ACAD SCI USA, V92, P10944, DOI 10.1073/pnas.92.24.10944; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160; MICHAEL NL, 1995, J VIROL, V69, P6758, DOI 10.1128/JVI.69.11.6758-6769.1995; MICHAEL NL, 1994, J VIROL, V68, P3163, DOI 10.1128/JVI.68.5.3163-3174.1994; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; MICHAEL NL, 1994, J VIROL, V68, P979, DOI 10.1128/JVI.68.2.979-987.1994; Moriuchi M, 1997, J IMMUNOL, V159, P4322; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; REESE MG, 1996, P PAC S BIOC KON HAW, P74; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAMPSON M, 1996, BIOCHEMISTRY-US, V35, P3362; SAMPSON M, 1996, NATURE, V382, P722; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZOUBAK S, 1999, GENE AMST, V174, P95	48	96	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4754	4760		10.1074/jbc.273.8.4754	http://dx.doi.org/10.1074/jbc.273.8.4754			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468539	hybrid			2022-12-25	WOS:000072115000067
J	Aguado, B; Campbell, RD				Aguado, B; Campbell, RD			Characterization of a human lysophosphatidic acid acyltransferase that is encoded by a gene located in the class III region of the human major histocompatibility complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; GLYCOSYLATION END-PRODUCTS; PHOSPHATIDIC-ACID; 1-ACYLGLYCEROPHOSPHORYLCHOLINE ACYLTRANSFERASE; 1-ACYL-SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; 1-ACYLGLYCEROLPHOSPHATE ACYLTRANSFERASE; PROTEIN; RECEPTOR; IDENTIFICATION; SPECIFICITIES	Sequence analysis of cDNA clones corresponding to a number of genes located in the class III region of the human major histocompatibility complex (MHC), in the chromosome band 6p21.3, has shown that the G15 gene encodes a 283-amino acid polypeptide with significant homology over the entire polypeptide with the enzyme lysophosphatidic acid acyltransferase (LPAAT) from different yeast, plant, and bacterial species, The amino acid sequence of the MHC-encoded human LPAAT (hLPAAT alpha) is 48% identical to the recently described hLPAAT (Eberhardt, C., Gray, P. W., and Tjoelker, L. W. (1991) J, Biol. Chem. 272, 20299 - 20305), which is encoded by a gene located on chromosome 9p34.3, LPAAT is the enzyme that in lipid metabolism converts lysophosphatidic acid (LPA) into phosphatidic acid (PA), The expression of the hEPAAT alpha polypeptide in the baculovirus system and in mammalian cells has shown that it is an intracellular protein that contains LPAAT activity. Cell extracts from insect cells overexpressing hLPAAT alpha were analyzed in different LPAAT enzymatic assays using as substrates, different acyl acceptors and acyl donors, These cell extracts were found to contain up to 5-fold more LPAAT activity compared with control cell extracts, indicating that the hLPAAT alpha specifically converts LPA into PA, incorporating different acyl-CoAs with different affinities, The hLPAAT alpha polypeptide expressed in the mammalian Chinese hamster ovary cell Pine was found, by confocal immunofluorescence, to be localized in the endoplasmic reticulum, Due to the known role of EPA anti PA in intracellular signaling and inflammation, the hLPAAT alpha gene represents a candidate gene for some MHC-associated diseases.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England	University of Oxford	Campbell, RD (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.		Aguado, Begoña/R-4496-2019	Aguado, Begona/0000-0003-4043-6944	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUADO B, 1995, GENOMICS, V25, P650, DOI 10.1016/0888-7543(95)80007-9; Aguado B, 1996, HLA MHC GENES MOL FU, P39; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; Bell RM, 1983, ENZYMES, V16, P87; BRISTOW J, 1993, J CELL BIOL, V122, P265, DOI 10.1083/jcb.122.1.265; BURSTEN S, 1994, CIRC SHOCK, V44, P14; BURSTEN SL, 1992, AM J PHYSIOL, V262, pC328, DOI 10.1152/ajpcell.1992.262.2.C328; BURSTEN SL, 1991, J BIOL CHEM, V266, P20732; CAMPBELL RD, 1997, IMMUNOL TODAY, V18; COLEMAN J, 1992, MOL GEN GENET, V232, P295, DOI 10.1007/BF00280009; COLEMAN RA, 1983, ENZYMES, V16, P605; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Eberhardt C, 1997, J BIOL CHEM, V272, P20299, DOI 10.1074/jbc.272.32.20299; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; JALINK K, 1994, BBA-REV CANCER, V1198, P185, DOI 10.1016/0304-419X(94)90013-2; Katsanis N, 1996, GENOMICS, V35, P101, DOI 10.1006/geno.1996.0328; KENDALL E, 1990, NUCLEIC ACIDS RES, V18, P7251, DOI 10.1093/nar/18.24.7251; Khanna A, 1996, BIOCHEM J, V319, P81, DOI 10.1042/bj3190081; KNUTZON DS, 1995, PLANT PHYSIOL, V109, P999, DOI 10.1104/pp.109.3.999; LANDS WEM, 1982, J BIOL CHEM, V257, P4968; LASSNER MW, 1995, PLANT PHYSIOL, V109, P1389, DOI 10.1104/pp.109.4.1389; LIVINGSTONE C, 1989, NUCLEIC ACIDS RES, V17, P2366, DOI 10.1093/nar/17.6.2366; Lodish H., 1995, MOL CELL BIOL; LUTTINGER AL, 1991, NEW BIOL, V3, P687; MIKI Y, 1977, EUR J BIOCHEM, V81, P433, DOI 10.1111/j.1432-1033.1977.tb11968.x; MIN J, 1995, GENOMICS, V30, P149, DOI 10.1006/geno.1995.9891; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; NEEPER M, 1992, J BIOL CHEM, V267, P14998; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROST B, 1995, PROTEIN SCI, V4, P521; Singer J. W., 1994, EXPERT OPIN INV DRUG, V3, P631; STADEN R, 1987, NUCLEIC ACID PROTEIN, P173; Stamps AC, 1997, BIOCHEM J, V326, P455, DOI 10.1042/bj3260455; SUGAYA K, 1994, GENOMICS, V23, P408, DOI 10.1006/geno.1994.1517; SWARTLEY JS, 1995, MOL MICROBIOL, V18, P401, DOI 10.1111/j.1365-2958.1995.mmi_18030401.x; TOU JS, 1991, BIOCHEM J, V280, P625, DOI 10.1042/bj2800625; Voet D., 1995, BIOCHEMISTRY; West J, 1997, DNA CELL BIOL, V16, P691, DOI 10.1089/dna.1997.16.691; YAMASHIT.S, 1973, EUR J BIOCHEM, V38, P25, DOI 10.1111/j.1432-1033.1973.tb03028.x; YAMASHITA S, 1975, P NATL ACAD SCI USA, V72, P600, DOI 10.1073/pnas.72.2.600; Yamashita S, 1981, Methods Enzymol, V71 Pt C, P528	44	85	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4096	4105		10.1074/jbc.273.7.4096	http://dx.doi.org/10.1074/jbc.273.7.4096			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461603	hybrid			2022-12-25	WOS:000072048400045
J	Yan, H; Piazza, F; Krishnan, K; Pine, R; Krolewski, JJ				Yan, H; Piazza, F; Krishnan, K; Pine, R; Krolewski, JJ			Definition of the interferon-alpha receptor-binding domain on the TYK2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; SIGNAL-TRANSDUCTION; JAK FAMILY; PHOSPHORYLATION; P135(TYK2); SUBUNIT; CELLS; FORM; ASSOCIATION; ACTIVATION	Interferons and cytokines modulate gene expression via a simple, direct signaling pathway containing receptors, JAK tyrosine kinases, and STAT transcription factors, The interferon-alpha pathway is a model for these cascades. Two receptors, IFNaR1 and IFNaR2, associate exclusively in a constitutive manner with two JAK proteins, TYK2 and JAK1, respectively; Defining the molecular interface between JAK proteins and their receptors is critical to understanding the signaling pathway and may contribute to the development of novel therapeutics. This report defines the IFNaR1 interaction domain on TYK2. In vitro binding studies demonstrate that the amino-terminal half of TYK2, which is similar to 600 amino acids long and contains JAK homology (JH) domains 3-7, comprises the maximal binding domain for IFNaR1, A fragment containing amino acids 171-601 (JH3-6) also binds IFNaR1, but with reduced affinity. Glutathione S-transferase-TYK2 fusion proteins approximating either the JH6 or JH3 domain affinity-precipitate IFNaR1, suggesting that these are major sites of interaction within the larger binding domain. TYK2 amino acids 1-601 act in a dominant manner to inhibit the transcription of an interferon-alpha-dependent reporter gene, presumably by displacing endogenous TYK2 from the receptor, This same fragment inhibits interferon-alpha-dependent tyrosine phosphorylation of TYK2, STAT1, and STAT2.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Irving Comprehens Canc Ctr, New York, NY 10032 USA; Publ Hlth Res Inst, New York, NY 10016 USA	Columbia University; Columbia University	Krolewski, JJ (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.	jjk5@columbia.edu			NATIONAL CANCER INSTITUTE [R01CA056862] Funding Source: NIH RePORTER; NCI NIH HHS [CA56862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; Davis E, 1996, LEUKEMIA, V10, P543; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HARPUR AG, 1992, ONCOGENE, V7, P1347; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; Krishnan K, 1996, ONCOGENE, V13, P125; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yan H, 1996, MOL CELL BIOL, V16, P2074; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	36	37	37	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4046	4051		10.1074/jbc.273.7.4046	http://dx.doi.org/10.1074/jbc.273.7.4046			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461596	hybrid			2022-12-25	WOS:000072048400038
J	Yu, NJ; Spremulli, LL				Yu, NJ; Spremulli, LL			Regulation of the activity of chloroplast translational initiation factor 3 by NH2- and COOH-terminal extensions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-3 DOMAINS; EUGLENA-GRACILIS; MESSENGER-RNA; FACTOR IF3; CHLAMYDOMONAS-REINHARDTII; FACTOR-III; PROKARYOTIC TRANSLATION; COMPLEX FORMS; SH3 DOMAINS; IN-VITRO	The mature form of the chloroplast translational initiation factor 3 (IF3(chl)) from Euglena gracilis consists of an internal region homologous to prokaryotic IF3 flanked by long NH2- and COOH-terminal extensions. Sequences in these extensions reduce the activity of the homology domain in promoting initiation complex formation with chloroplast mRNAs and 30 S ribosomal sub units. A series of deletions of the NH2- and COOH-terminal extensions of IF3(chl) were constructed and tested for their effects on the activity of the homology domain. About half of the inhibitory effect arises from sequences within 9 residues of the junction between the NH2-terminal extension and the homology domain. The remaining inhibitory effect is the result of sequences in the COOH-terminal extension. The equilibrium constant governing the binding of the homology domain of IF3(chl) to 30 S subunits is estimated to be 1.3 x 10(7) M-1. Sequences close to the junction of the NH2-terminal extension and the homology domain reduce this binding constant about 10-fold. Sequences in the COOH-terminal extension have a similar negative effect. The negative effects of these two regions are cumulative, resulting in a 100-fold reduction of the binding constant. The 9 residues at the NH2-terminal extension effectively prevent the proofreading activity of IF3(chl). The entire COOH-terminal extension reduces the proofreading ability by about half. These results are discussed in terms of the proposed three-dimensional structure of the homology domain of IF3(chl).	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Res Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Spremulli, LL (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.	Linda_Spremulli@unc.edu			NIGMS NIH HHS [GM24963] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024963] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BERKHOUT B, 1986, BIOCHIM BIOPHYS ACTA, V866, P144, DOI 10.1016/0167-4781(86)90111-9; BETTS L, 1994, J BIOL CHEM, V269, P26456; BIOU V, 1995, EMBO J, V14, P4056, DOI 10.1002/j.1460-2075.1995.tb00077.x; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; BUTLER JS, 1987, P NATL ACAD SCI USA, V84, P4022, DOI 10.1073/pnas.84.12.4022; CANONACO MA, 1989, EUR J BIOCHEM, V182, P501, DOI 10.1111/j.1432-1033.1989.tb14856.x; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; DESMIT MH, 1994, J MOL BIOL, V235, P173, DOI 10.1016/S0022-2836(05)80024-5; DOTTAVIOMARTIN D, 1979, FEBS LETT, V97, P105, DOI 10.1016/0014-5793(79)80062-9; FORTIER PL, 1994, BIOCHIMIE, V76, P376, DOI 10.1016/0300-9084(94)90111-2; GARCIA C, 1995, J MOL BIOL, V254, P247, DOI 10.1006/jmbi.1995.0615; GARCIA C, 1995, EUR J BIOCHEM, V228, P395, DOI 10.1111/j.1432-1033.1995.tb20276.x; GOLD JC, 1985, J BIOL CHEM, V260, P4897; GRAVES MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P192, DOI 10.1016/0003-9861(83)90516-7; GUALERZI C, 1979, J BIOL CHEM, V254, P44; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; GUALERZI CO, 1990, RIBOSOME, P281; HARTZ D, 1989, GENE DEV, V3, P1899, DOI 10.1101/gad.3.12a.1899; HARTZ D, 1990, GENE DEV, V4, P1790, DOI 10.1101/gad.4.10.1790; Hauser CR, 1996, J BIOL CHEM, V271, P1486, DOI 10.1074/jbc.271.3.1486; Hirose T, 1996, EMBO J, V15, P1687, DOI 10.1002/j.1460-2075.1996.tb00514.x; KINI RM, 1995, BIOCHEM BIOPH RES CO, V212, P1115, DOI 10.1006/bbrc.1995.2084; KOO JS, 1994, J BIOL CHEM, V269, P7494; KRAUS BL, 1988, PLANT PHYSIOL, V88, P993, DOI 10.1104/pp.88.4.993; KYCIA JH, 1995, BIOCHEMISTRY-US, V34, P6183, DOI 10.1021/bi00018a022; LAMMI M, 1987, FEBS LETT, V215, P115, DOI 10.1016/0014-5793(87)80124-2; Lin Q, 1996, PLANT MOL BIOL, V32, P937, DOI 10.1007/BF00020490; LIN Q, 1994, J BIOL CHEM, V269, P9436; MA L, 1990, J BIOL CHEM, V265, P13560; MA L, 1992, ARCH BIOCHEM BIOPHYS, V267, P18356; Mangroo D, 1995, BIOCHEM CELL BIOL, V73, P1023, DOI 10.1139/o95-109; MCCARTHY JEG, 1994, TRENDS GENET, V10, P402, DOI 10.1016/0168-9525(94)90057-4; MORTON CJ, 1994, CURR BIOL, V4, P615, DOI 10.1016/S0960-9822(00)00134-2; PACI M, 1984, J BIOL CHEM, V259, P9628; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Pon C L, 1979, Methods Enzymol, V60, P230; PON CL, 1974, P NATL ACAD SCI USA, V71, P4950, DOI 10.1073/pnas.71.12.4950; RISULEO G, 1976, EUR J BIOCHEM, V67, P603, DOI 10.1111/j.1432-1033.1976.tb10726.x; SAKAMOTO W, 1994, PLANT J, V6, P503, DOI 10.1046/j.1365-313X.1994.6040503.x; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STAUB JM, 1994, PLANT J, V6, P547, DOI 10.1046/j.1365-313X.1994.6040547.x; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Sussman JK, 1996, MOL MICROBIOL, V21, P347, DOI 10.1046/j.1365-2958.1996.6371354.x; TEANA A, 1996, J MOL BIOL, V256, P667; VANKNIPPENBERG PH, 1990, RIBOSOME, P265; WANG CC, 1989, NUCLEIC ACIDS RES, V17, P9735, DOI 10.1093/nar/17.23.9735; WANG CC, 1991, J BIOL CHEM, V266, P17079; WEIEL J, 1978, FEBS LETT, V87, P103, DOI 10.1016/0014-5793(78)80144-6; WU HY, 1995, CURR GENET, V27, P263, DOI 10.1007/BF00326159; ZERGES W, 1994, MOL CELL BIOL, V14, P5268, DOI 10.1128/MCB.14.8.5268	53	11	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3871	3877		10.1074/jbc.273.7.3871	http://dx.doi.org/10.1074/jbc.273.7.3871			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461569	hybrid			2022-12-25	WOS:000072048400011
J	Corey, SJ; Dombrosky-Ferlan, PM; Zuo, S; Krohn, E; Donnenberg, AD; Zorich, P; Romero, G; Takata, M; Kurosaki, T				Corey, SJ; Dombrosky-Ferlan, PM; Zuo, S; Krohn, E; Donnenberg, AD; Zorich, P; Romero, G; Takata, M; Kurosaki, T			Requirement of Src kinase Lyn for induction of DNA synthesis by granulocyte colony-stimulating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; NECROSIS-FACTOR-ALPHA; FACTOR-RECEPTOR; SIGNAL-TRANSDUCTION; AUTOIMMUNE-DISEASE; LEUKEMIA-CELLS; DEFICIENT MICE; GM-CSF; ACTIVATION; FAMILY	Treatment of cells with granulocyte colony-stimulating factor (G-CSF) leads to tyrosine phosphorylation of cellular proteins, G-CSF stimulates both the activation of protein tyrosine kinases Lyn, Jak1, and Jak2 and the association of these enzymes with the G-CSF receptor, Wild-type, lyn-deficient, and syk-deficient chicken B lymphocyte cell lines were transfected with the human G-CSF receptor, and stable transfectants were studied, G-CSF-dependent tyrosyl phosphorylation of Jak1 and Jak2 occurred in all three cell lines, Wild-type and syk-deficient transfectants responded to G-CSF in a dose-responsive fashion with increased thymidine incorporation, but none of the clones of lyn-deficient transfectants did, Ectopic expression of Lyn, but not that of c-Src, in the lyn-deficient cells restored their mitogenic responsiveness to G-CSF, Ectopic expression in wild-type cells of the kinase inactive form of Lyn, but not of the kinase-inactive form of Jak2, inhibited thymidine incorporation in response to G-CSF. These studies show that the absence of Lyn results in the loss of mitogenic signaling in the G-CSF signaling pathway and that activation of Jak1 or Jak2 is not sufficient to cause mitogenesis.	Childrens Hosp Pittsburgh, Div Hematol Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Amer Cyanamid Co, Div Cardiovasc Med, Pearl River, NY 10965 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Corey, SJ (corresponding author), Childrens Hosp Pittsburgh, Div Hematol Oncol, 3705 5th Ave, Pittsburgh, PA 15213 USA.	corey@med.pitt.edu		Takata, Minoru/0000-0002-4926-3675	NHLBI NIH HHS [HL02303] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIMARU K, 1992, ARCH BIOCHEM BIOPHYS, V298, P703, DOI 10.1016/0003-9861(92)90469-D; BOLEN JB, 1991, ADV CANCER RES, V57, P103; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DEMETRI GD, 1991, BLOOD, V78, P2791; DHAR A, 1991, J BIOL CHEM, V266, P18797; DONG F, 1995, BLOOD, V85, P902, DOI 10.1182/blood.V85.4.902.bloodjournal854902; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; EVANS JPM, 1990, BLOOD, V75, P88; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LI Y, 1995, J IMMUNOL, V155, P2165; LIESCHKE GJ, 1994, BLOOD, V84, P1737; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NICOLA NA, 1985, J CELL PHYSIOL, V124, P313, DOI 10.1002/jcp.1041240222; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TIAN SS, 1994, BLOOD, V84, P1760; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Wilkinson L., 1990, SYSTAT SYSTEM STAT; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	39	88	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3230	3235		10.1074/jbc.273.6.3230	http://dx.doi.org/10.1074/jbc.273.6.3230			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452436	hybrid			2022-12-25	WOS:000071822300021
J	Dai, RM; Chen, EY; Longo, DL; Gorbea, CM; Li, CCH				Dai, RM; Chen, EY; Longo, DL; Gorbea, CM; Li, CCH			Involvement of valosin-containing protein, an ATPase co-purified with I kappa B alpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOMA CELL-LINES; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; PRECURSOR PROTEIN; ESCHERICHIA-COLI; RAT-LIVER; SIGNAL; PROTEOLYSIS; ACTIVATION; SUBUNIT	The inactivation of the prototype NF-kappa B inhibitor, I kappa B alpha, occurs through a series of ordered processes including phosphorylation, ubiquitin conjugation, and proteasome-mediated degradation. We identify valosin-containing protein (VCP), an AAA (ATPases associated with a variety of cellular activities) family member, that co-precipitates with I kappa B alpha immune complexes, The ubiquitinated I kappa B alpha conjugates readily associate with VCP both in vivo and in vitro, and this complex appears dissociated from NF-kappa B. In ultracentrifugation analysis, physically associated VCP and ubiquitinated I kappa B alpha complexes sediment in the 19 S fractions, while the unmodified I kappa B alpha sediments in the 4.5 S fractions deficient in VCP, Phosphorylation and ubiquitination of I kappa B alpha are critical for VCP binding, which in turn is necessary but not sufficient for I kappa B alpha degradation; while the N-terminal domain of I kappa B alpha is required in all three reactions, both N- and C-terminal domains are required in degradation, Further, VCP co-purifies with the 26 S proteasome on two-dimensional gels and co-immunoprecipitates with subunits of the 26 S proteasome. Our results suggest that VCP may provide a physical and functional link between I kappa B alpha and the 26 S proteasome and play an important role in the proteasome-mediated degradation of I kappa B alpha.	NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; NIA, NIH, Gerontol Res Ctr, Baltimore, MD 21224 USA; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Utah System of Higher Education; University of Utah	Li, CCH (corresponding author), NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA.		Longo, Dan L./F-6022-2011					ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; AKIYAMA K, 1995, FEBS LETT, V363, P151, DOI 10.1016/0014-5793(95)00304-R; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BECKWITH M, 1990, J NATL CANCER I, V82, P501, DOI 10.1093/jnci/82.6.501; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; COUX L, 1996, ANN REV BIOCH, V65, P801; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; DEVERAUX Q, 1995, J BIOL CHEM, V270, P23726, DOI 10.1074/jbc.270.40.23726; DEVEREAUX Q, 1994, J BIOL CHEM, V26, P7059; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DUBIEL W, 1994, BIOL CHEM H-S, V375, P237, DOI 10.1515/bchm3.1994.375.4.237; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EGERTON M, 1994, J BIOL CHEM, V269, P11435; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LI CCH, 1994, J BIOL CHEM, V269, P30089; OCONNOR PM, 1993, CANCER RES, V53, P4776; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871	58	272	282	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3562	3573		10.1074/jbc.273.6.3562	http://dx.doi.org/10.1074/jbc.273.6.3562			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452483	hybrid			2022-12-25	WOS:000071822300068
J	Dominguez, DI; Ryabova, LA; Pooggin, MM; Schmidt-Puchta, W; Futterer, J; Hohn, T				Dominguez, DI; Ryabova, LA; Pooggin, MM; Schmidt-Puchta, W; Futterer, J; Hohn, T			Ribosome shunting in cauliflower mosaic virus - Identification of an essential, and sufficient structural element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCISTRONIC MESSENGER-RNA; ENCEPHALOMYOCARDITIS VIRUS; PROTEIN-SYNTHESIS; TRANSLATION; INITIATION; SEQUENCE; PLANTS; CODONS; CELLS; CAULIMOVIRUS	A wheat germ cell-free system was used to study details of ribosome shunting promoted by the cauliflower mosaic virus 35 S RNA leader. By testing a dicistronic construct with the leader placed between two coding regions, we confirmed that the 35 S RNA leader does not include an internal ribosome entry site of the type observed with picornavirus RNAs. A reporter gene fused to the leader was shown to be expressed by ribosomes that had followed the bypass route (shunted) and, with lower efficiency, by ribosomes that had scanned through the whole region. Stem section 1, the most stable of the three stem sections of the leader, was shown to be an important structural element for shunting. Mutations that abolished formation of this stem section drastically reduced reporter gene expression, whereas complementary mutations that restored stem section 1 also restored shunting. A micro-leader capable of shunting consisting of stem section 1 and flanking sequences could be defined. A small open reading frame preceding stem section 1 enhances shunting.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; ETH Zurich, CH-8902 Zurich, Switzerland	Friedrich Miescher Institute for Biomedical Research; Swiss Federal Institutes of Technology Domain; ETH Zurich	Hohn, T (corresponding author), Friedrich Miescher Inst, CH-4002 Basel, Switzerland.			Pooggin, Mikhail/0000-0003-2308-393X				ALTMANN M, 1994, BIOCHIMIE PARIS, V76, P835; BAUGHMAN G, 1988, VIROLOGY, V167, P125, DOI 10.1016/0042-6822(88)90061-X; BONNEVILLE JM, 1989, CELL, V59, P1135, DOI 10.1016/0092-8674(89)90769-1; BONNEVILLE JM, 1993, REVERSE TRANSCRIPTAS, P357; Browning K. S., 1996, POST TRANSCRIPTIONAL, P107; Cao JH, 1996, MOL CELL BIOL, V16, P7109; CURRAN J, 1989, EMBO J, V8, P521, DOI 10.1002/j.1460-2075.1989.tb03406.x; CURRAN J, 1988, EMBO J, V7, P2869, DOI 10.1002/j.1460-2075.1988.tb03143.x; DIXON LK, 1984, EMBO J, V3, P2731, DOI 10.1002/j.1460-2075.1984.tb02203.x; Dominguez DI, 1996, VIROLOGY, V226, P374, DOI 10.1006/viro.1996.0665; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; FUTTERER J, 1988, NUCLEIC ACIDS RES, V16, P8377, DOI 10.1093/nar/16.17.8377; FUTTERER J, 1990, EMBO J, V9, P1697, DOI 10.1002/j.1460-2075.1990.tb08293.x; Futterer J, 1989, Virus Genes, V3, P45, DOI 10.1007/BF00301986; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; Futterer J, 1996, J VIROL, V70, P2999; GEBALLE AP, 1995, TRANSLATIONAL CONTRO, P173; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; GORDON K, 1992, PLANT J, V2, P809, DOI 10.1046/j.1365-313X.1992.t01-17-00999.x; HemmingsMieszczak M, 1997, J MOL BIOL, V267, P1075, DOI 10.1006/jmbi.1997.0929; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HOHN T, 1989, UCLA S MOL CELLULAR, V101, P153; HULL R, 1984, PLANT MOL BIOL, V3, P121, DOI 10.1007/BF00016059; Jackson RJ, 1995, CURR TOP MICROBIOL, V203, P1; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; JOSHI B, 1994, J BIOL CHEM, V269, P2048; KISSLASZLO Z, 1995, EMBO J, V14, P3552, DOI 10.1002/j.1460-2075.1995.tb07361.x; KissLaszlo Z, 1996, TRENDS MICROBIOL, V4, P480, DOI 10.1016/S0966-842X(97)82909-5; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LI J, 1996, THESIS U GIESSEN GIE; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MESNARD J, 1996, VIROLOGY, V213, P1; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; ROBERTS BE, 1973, P NATL ACAD SCI USA, V70, P2330, DOI 10.1073/pnas.70.8.2330; ROTHNIE HM, 1994, ADV VIRUS RES, V44, P1, DOI 10.1016/S0065-3527(08)60327-9; ROTHNIE HM, 1994, EMBO J, V13, P2200, DOI 10.1002/j.1460-2075.1994.tb06497.x; Sachs AB, 1997, TRENDS BIOCHEM SCI, V22, P189, DOI 10.1016/S0968-0004(97)01051-7; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SANFACON H, 1990, NATURE, V346, P81, DOI 10.1038/346081a0; SchmidtPuchta W, 1997, NUCLEIC ACIDS RES, V25, P2854, DOI 10.1093/nar/25.14.2854; SCHOLTHOF HB, 1992, J VIROL, V66, P3131, DOI 10.1128/JVI.66.5.3131-3139.1992; SIMPSON GG, 1995, EMBO J, V14, P4540, DOI 10.1002/j.1460-2075.1995.tb00133.x; THOMAS AAM, 1992, NEW BIOL, V4, P404; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; ZUCKER M, 1989, SCIENCE, V244, P48	50	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3669	3678		10.1074/jbc.273.6.3669	http://dx.doi.org/10.1074/jbc.273.6.3669			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452497	hybrid			2022-12-25	WOS:000071822300082
J	Vanden Berghe, W; Plaisance, S; Boone, E; De Bosscher, K; Schmitz, ML; Fiers, W; Haegeman, G				Vanden Berghe, W; Plaisance, S; Boone, E; De Bosscher, K; Schmitz, ML; Fiers, W; Haegeman, G			p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor kappa B p65 transactivation mediated by tumor necrosis factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; INTERLEUKIN-6 GENE-EXPRESSION; TRANSCRIPTION FACTOR; HUMAN-FIBROBLASTS; CYCLIC-AMP; CELL-LINES; IN-VIVO; INDUCTION; PROMOTER; DNA	Interleukin-6 (IL-6) is a pleiotropic cytokine, which is involved in inflammatory and immune responses, acute phase reactions, and hematopoiesis. In the mouse fibrosarcoma cell line L929, the nuclear factor (NF)-kappa B plays a crucial role in IL-6 gene expression mediated by tumor necrosis factor (TNF). The levels of the activated factor do not, however, correlate with the variations of IL-6 gene transcription; therefore, other factors and/or regulatory mechanisms presumably modulate the levels of IL-6 mRNA production, Upon analysis of various deletion and point-mutated variants of the human IL-6 gene promoter coupled to a reporter gene, we screened for possible cooperating transcription factors. Even the smallest deletion variant, containing almost exclusively a NF-kappa B-responsive sequence preceding the IL-6 minimal promoter, as well as a recombinant construction containing multiple kappa B-motifs, could still be stimulated with TNF. We observed that the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 was able to repress TNF-stimulated expression of the IL-6 gene, as well as of a kappa B-dependent reporter gene construct, without affecting the levels of NF-kappa B binding to DNA. Furthermore, we clearly show that, using a nuclear Gal4 "one-hybrid" system, the MAPK inhibitors SB203580 and PD0980589 have a direct repressive effect on the transactivation potential of the p65 kappa B subunit. Therefore, we conclude that, in addition to cytoplasmic activation and DNA binding of NF-kappa B, the p38 and extracellular signal-regulated kinase MAPK pathways act as necessary cooperative mechanisms to regulate TNF-induced IL-6 gene expression by modulating the transactivation machinery.	Univ Ghent, Mol Biol Lab, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, Mol Biol Lab, Ghent, Belgium; German Canc Res Ctr, Dept Immunochem, D-69120 Heidelberg, Germany	Ghent University; Helmholtz Association; German Cancer Research Center (DKFZ)	Haegeman, G (corresponding author), Univ Ghent, Mol Biol Lab, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	chrish@mb.rug.ac.be	Plaisance, Stephane/B-3488-2009; Plaisance, Stephane/ABI-6307-2020; Berghe, Wim Vanden/S-6425-2018; Schmitz, M. Lienhard/D-9328-2017; Vanden Berghe, Wim/HGE-4696-2022	Plaisance, Stephane/0000-0002-1651-241X; Plaisance, Stephane/0000-0002-1651-241X; Berghe, Wim Vanden/0000-0003-0161-7355; Schmitz, M. Lienhard/0000-0002-6984-7192; De Bosscher, Karolien/0000-0001-5059-9718				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bellier S, 1997, MOL CELL BIOL, V17, P1434, DOI 10.1128/MCB.17.3.1434; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAEGEMAN G, 1986, EUR J BIOCHEM, V159, P625, DOI 10.1111/j.1432-1033.1986.tb09931.x; HAEGEMAN G, 1995, SIGNALLING MECH TRAN, P375; HIRANO T, 1992, RES IMMUNOL, V143, P689; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Keller Evan T., 1996, Frontiers in Bioscience (online), V1, pD340; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PATESTOS NP, 1993, BIOCHIMIE, V75, P1007, DOI 10.1016/0300-9084(93)90153-J; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VANHAESEBROECK B, 1992, J IMMUNOL, V148, P2785; VANHOENACKER P, 1994, EUR CYTOKINE NETW, V5, P283; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	47	593	600	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3285	3290		10.1074/jbc.273.6.3285	http://dx.doi.org/10.1074/jbc.273.6.3285			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452444	hybrid			2022-12-25	WOS:000071822300029
J	Wang, J; Riedel, H				Wang, J; Riedel, H			Insulin-like growth factor-I receptor and insulin receptor association with a Src homology-2 domain-containing putative adapter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; SIGNAL-TRANSDUCTION; SH2 DOMAIN; GLUT4 TRANSLOCATION; 2-HYBRID SYSTEM; BINDING-SITES; PROTEINS P85; GRB-IR; KINASE; CELLS	Insulin receptor (IR) and the related insulin-like growth factor-I (IGF-I) receptor (IGF-IR) mediate a variety of metabolic and mitogenic cellular responses, some of which may involve unidentified receptor tar gets, A Src homology-a (SH2) domain-coding region of a mouse protein was cloned based on its interaction with IR. It was designated mSH2-B based on its high similarity to an earlier reported rat sequence SH2-B. A role of mSH2-B in IGF-I and insulin action was suggested by the interaction of the SH2 domain with activated IGF-IR and IR catalytic fragments but not with an inactive IR catalytic fragment in the yeast two-hybrid system in vivo and by the hormone-dependent association of a glutathione S-transferase (GST) SH2 domain fusion protein of mSH2-B with both receptors in cell extracts, A comparison of IGF-IR and IR mutants lacking individual Tyr autophosphorylation sites for association with GST; mSH2-B showed that homologous juxtamembrane (IR960/IGF-IR950) and C-terminal (IR1322/IGF-IR1316) receptor motifs were required. Synthetic phosphopeptides representing IR960 and IR1322 competed for GST mSH2-B binding to the receptor, suggesting that both motifs participate in the association with mSH2-B. Antibodies raised against GST mSH2-B identified a cellular protein of 92 kDa that was not found to be phosphorylated on Tyr. It co-immunoprecipitated with IGF-IR or IR, which was strictly dependent on receptor activation, IR and IGF IR Tyr phosphorylation motifs were not identified in the complete SH2-B primary structure, suggesting that it may participate as an adapter rather than a substrate in the IGF-I and insulin signaling pathways.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA; Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48202 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Mol Biol Sect, Boston, MA 02215 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Riedel, H (corresponding author), Wayne State Univ, Dept Biol Sci, 2171 BSB,5047 Gullen Mall, Detroit, MI 48202 USA.	hriedel@sun.science.wayne.edu						ANDO A, 1992, J BIOL CHEM, V267, P12788; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Carel K, 1996, ENDOCRINOLOGY, V137, P2362, DOI 10.1210/en.137.6.2362; CARTER WG, 1995, BIOCHEMISTRY-US, V34, P9488, DOI 10.1021/bi00029a025; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN DI, 1995, MOL CELL BIOL, V15, P4711; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; JHUN BH, 1995, BIOCHEMISTRY-US, V34, P7996, DOI 10.1021/bi00025a005; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KAN M, 1995, DIABETES, V44, P1081, DOI 10.2337/diabetes.44.9.1081; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; Krook A, 1996, J BIOL CHEM, V271, P7134, DOI 10.1074/jbc.271.12.7134; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; MYERS MG, 1991, J BIOL CHEM, V266, P10616; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Najjar SM, 1997, BIOCHEMISTRY-US, V36, P6827, DOI 10.1021/bi962634h; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; RIEDEL H, 1994, J VIROL, V68, P411, DOI 10.1128/JVI.68.1.411-424.1994; Rocchi S, 1996, ENDOCRINOLOGY, V137, P4944, DOI 10.1210/en.137.11.4944; RUBIN R, 1995, LAB INVEST, V73, P311; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; Smith RM, 1997, INT REV CYTOL, V173, P243; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; UDDIN S, 1995, J BIOL CHEM, V270, P7712, DOI 10.1074/jbc.270.13.7712; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163	48	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3136	3139		10.1074/jbc.273.6.3136	http://dx.doi.org/10.1074/jbc.273.6.3136			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452421	hybrid			2022-12-25	WOS:000071822300006
J	Worby, CA; Vega, QC; Chao, HHJ; Seasholtz, AF; Thompson, RC; Dixon, JE				Worby, CA; Vega, QC; Chao, HHJ; Seasholtz, AF; Thompson, RC; Dixon, JE			Identification and characterization of GFR alpha-3, a novel co-receptor belonging to the glial cell line-derived neurotrophic receptor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RET PROTOONCOGENE; TYROSINE KINASE; MICE LACKING; GDNF; NEURONS; EXPRESSION; MUTATIONS; PHOSPHATIDYLINOSITOL; SUPERFAMILY; SURVIVAL	A new family of neuronal survival factors comprised of glial cell line-derived neurotrophic factor (GDNF) and neurturin has recently been described (Kotzbauer, P. T., Lampe, P. A., Heuckeroth, R. O., Golden, J. P., Creedon, D. J., Johnson, E. M., Jr., and Milbrandt, J. (1997) Nature 384, 467-470), These molecules, which are related to transforming growth factor-beta, are important in embryogenesis and in the survival of distinct neuronal populations, These molecules signal through a novel receptor system that includes the Ret receptor tyrosine kinase, a ligand (i.e. GDNF or neurturin), and an accessory glycosyl-phosphatidylinositol-linked molecule that is responsible for high affinity binding of the ligand, Two accessory molecules denoted GDNF family receptor 1 and 2 (GFR alpha-1 and GFR alpha-2) have been described that function in GDNF and neurturin signaling complexes, We have identified a novel co-receptor belonging to this family based on similarity to GFR alpha-1, which we have named GFR alpha-3. GFR alpha-3 displays 33% amino acid identity with GFR alpha-1 and 36% identity with GFR alpha-2. Despite the similarity of GFR alpha-3 to GFR alpha-1 and GFR alpha-2, it is unable to activate Ret in conjunction with GDNF, suggesting that there are likely additional undiscovered ligands and/or Ret-like receptors to be identified, GFR alpha-3 is anchored to the cell membrane by a phosphatidylinositol-specific phospholipase C-resistant glycosyl-phosphatidylinositol linkage, GFR alpha-3 is highly expressed by embryonic day 11 but is not appreciably expressed in the adult mouse, In situ hybridization analyses demonstrate that GFR alpha-3 is located in dorsal root ganglia and the superior cervical sympathetic ganglion. Comparison of the expression patterns of GFR alpha-3 and Ret suggests that these molecules could form a receptor pair and interact with GDNF family members to play unique roles in development.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Reprod Sci Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dixon, JE (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.				PHS HHS [18024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EBENDAL T, 1995, J NEUROSCI RES, V40, P276, DOI 10.1002/jnr.490400217; FATEMI SH, 1987, J BIOL CHEM, V262, P4728; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KEEGAN CE, 1994, ENDOCRINOLOGY, V134, P2547, DOI 10.1210/en.134.6.2547; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LOW MG, 1986, TRENDS BIOCHEM SCI, V11, P212, DOI 10.1016/0968-0004(86)90009-5; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1997, J NEUROSCI, V17, P3554; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619	37	86	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3502	3508		10.1074/jbc.273.6.3502	http://dx.doi.org/10.1074/jbc.273.6.3502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452475	hybrid			2022-12-25	WOS:000071822300060
J	Yu, ZB; Su, LC; Hoglinger, O; Jaramillo, ML; Banville, D; Shen, SH				Yu, ZB; Su, LC; Hoglinger, O; Jaramillo, ML; Banville, D; Shen, SH			SHP-1 associates with both platelet-derived growth factor receptor and the p85 subunit of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GTPASE-ACTIVATING PROTEIN; SRC HOMOLOGY-2 DOMAINS; PHOSPHOTYROSINE PHOSPHATASE; MITOGENIC SIGNAL; SYP PHOSPHATASE; BETA-SUBUNIT; PHOSPHORYLATION; KINASE; INSULIN	The Src homology 2 (SH2)-containing protein tyrosine phosphatase 1, SHP-1, is highly expressed in all hematopoietic cells as well as in many non-hematopoietic cells, particularly in some malignant epithelial cell lines. In hematopoietic cells, SHP-1 negatively regulates multiple cytokine receptor pathways. The precise function and the targets of SHP-1 in non-hematopoietic cells, however, are largely unknown. Here we demonstrate that SHP-1 associates with both the tyrosine-phosphorylated platelet-derived growth factor (PDGF) receptor and the p85 subunit of phosphatidylinositol 3-kinase in MCF-7 and TRMP cells. Through the use of mutant PDGF receptors and performing peptide competition for immunoprecipitation, it was determined that SHP-1 independently associates with the PDGF receptor and p85 and that its N-terminal SH2 domain is directly responsible for the interactions. Overexpression of SHP-1 in TRMP cells transfected with the PDGF receptor markedly inhibited PDGF-induced c-fos promoter activation, whereas the expression of three catalytically inactive SHP-1 mutants increased the c-fos promoter activation in response to PDGF stimulation. These results indicate that SHP-1 might negatively regulate PDGF receptor-mediated signaling in these cells. Identification of the association of SHP-1 with the PDGF receptor and p85 in MCF-7 and TRMP cells furthers our understanding of the function of SHP-1 in non-hematopoietic cells.	Natl Res Council Canada, Biotechnol Res Inst, Pharmaceut Sector, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada	National Research Council Canada; McGill University	Shen, SH (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Pharmaceut Sector, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.							Adachi M, 1996, CELL, V85, P15; Allard JD, 1996, DEVELOPMENT, V122, P1137; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; Cossette LJ, 1996, EXP CELL RES, V223, P459, DOI 10.1006/excr.1996.0102; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DeMali KA, 1997, J BIOL CHEM, V272, P9011; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Liu L, 1997, J BIOL CHEM, V272, P10998; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; Manie SN, 1997, J BIOL CHEM, V272, P15636, DOI 10.1074/jbc.272.25.15636; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; REEVES SA, 1995, EUR J BIOCHEM, V233, P55, DOI 10.1111/j.1432-1033.1995.055_1.x; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHEN SH, 1991, J BIOL CHEM, V266, P1058; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tailor P, 1996, EUR J BIOCHEM, V237, P736, DOI 10.1111/j.1432-1033.1996.0736p.x; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; UCHIDA T, 1993, J BIOL CHEM, V268, P11845; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	50	80	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3687	3694		10.1074/jbc.273.6.3687	http://dx.doi.org/10.1074/jbc.273.6.3687			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452499	hybrid			2022-12-25	WOS:000071822300084
J	Hellbach, S; Gartner, P; Deicke, J; Fischer, D; Hassan, AHS; Almeida, OFX				Hellbach, S; Gartner, P; Deicke, J; Fischer, D; Hassan, AHS; Almeida, OFX			Inherent glucocorticoid response potential of isolated hypothalamic neuroendocrine neurons	FASEB JOURNAL			English	Article						corticotropin-releasing hormone; arginine vasopressin; beta-endorphin; dexamethasone; glucocorticoid feedback	CORTICOTROPIN-RELEASING HORMONE; FACTOR GENE-EXPRESSION; CENTRAL-NERVOUS-SYSTEM; PARAVENTRICULAR NUCLEUS; MESSENGER-RNA; RAT-BRAIN; VASOPRESSIN EXPRESSION; ARGININE-VASOPRESSIN; FACTOR SECRETION; INHIBITION	Within the broader framework of facilitating investigations into the inherent responses of restricted neuronal phenotypes devoid of their in vivo afferents, serum- and steroid-free cultures enriched in corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), and beta-endorphin (beta-END) peptidergic neurons were prepared from the hypothalamic paraventricular (PVN: CRH and AVP) and/or arcuate (ARC: beta-END) nuclei of juvenile male rats, The functional viability of these ARC/PVN cultures was verified by their ability to synthesize and secrete CRH, AVP, and beta-END under basal and depolarizing (veratridine) conditions in vitro. Peptide secretion was shown to be Ca2+ and Na+ dependent in that it was blocked in the presence of veraspamil and tetrodotoxin, respectively. Exposure of ARC/PVN cocultures to the glucocorticoid dexamethasone (DEX) resulted in a dose-dependent increase of CRH secretion and an inhibition of AVP and beta-END; the CRH responses deviated strikingly from predictions based on in vivo experiments. Steroid withdrawal or treatment with the glucocorticoid receptor antagonist RU38486 reversed these trends. Opposite effects of DEX on CRH secretion were observed in cultures consisting of PVN cells only. Supported by studies using an opioid receptor agonist (morphine) and antagonist (naloxone), these observations demonstrate that ARC-derived (beta-END) neurons modulate the responses of PVN neurons to DEX.	Max Planck Inst Psychiat, Dept Neuroendocrinol, Neuroadaptat Grp, D-80804 Munich, Germany	Max Planck Society	Almeida, OFX (corresponding author), Max Planck Inst Psychiat, Dept Neuroendocrinol, Neuroadaptat Grp, Kraepelinstr 2-10, D-80804 Munich, Germany.	osa@mpipsykl.mpg.de	Almeida, Osborne F.X. F/E-8402-2010	Almeida, Osborne F.X. F/0000-0001-7331-6928				AHIMA RS, 1991, ENDOCRINOLOGY, V129, P226, DOI 10.1210/endo-129-1-226; ALMEIDA OFX, 1992, BRAIN RES, V571, P189, DOI 10.1016/0006-8993(92)90654-R; ALMEIDA OFX, 1993, CIBA F SYMP, V172, P151; ANTONI FA, 1993, FRONT NEUROENDOCRIN, V14, P76, DOI 10.1006/frne.1993.1004; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEAULIEU S, 1988, MOL ENDOCRINOL, V2, P727, DOI 10.1210/mend-2-8-727; BERTINI LT, 1991, NEUROSCIENCE, V42, P237, DOI 10.1016/0306-4522(91)90161-G; BERTINI LT, 1993, NEUROENDOCRINOLOGY, V57, P716, DOI 10.1159/000126430; BRADY LS, 1992, NEUROENDOCRINOLOGY, V55, P121, DOI 10.1159/000126107; BUCKINGHAM JC, 1986, NEUROENDOCRINOLOGY, V42, P148, DOI 10.1159/000124266; CALOGERO AE, 1988, J CLIN INVEST, V82, P767, DOI 10.1172/JCI113677; Calogero AE, 1995, ANN NY ACAD SCI, V771, P31, DOI 10.1111/j.1749-6632.1995.tb44668.x; DALLMAN MF, 1994, ANN NY ACAD SCI, V746, P22; DAVIS LG, 1986, P NATL ACAD SCI USA, V83, P1145, DOI 10.1073/pnas.83.4.1145; DEKLOET ER, 1993, CELL MOL NEUROBIOL, V13, P433, DOI 10.1007/BF00711582; FELDMAN S, 1995, NEUROSCI BIOBEHAV R, V19, P235, DOI 10.1016/0149-7634(94)00062-6; FINK G, 1988, J PHYSIOL-LONDON, V401, P329, DOI 10.1113/jphysiol.1988.sp017165; HERMAN JP, 1995, J COMP NEUROL, V363, P15, DOI 10.1002/cne.903630103; HERMAN JP, 1995, J NEUROENDOCRINOL, V7, P475, DOI 10.1111/j.1365-2826.1995.tb00784.x; IMAKI T, 1995, J CLIN INVEST, V96, P231, DOI 10.1172/JCI118026; IXART G, 1991, EXP BRAIN RES, V87, P153; JOELS M, 1991, J STEROID BIOCHEM, V40, P83, DOI 10.1016/0960-0760(91)90170-A; JONES MT, 1988, PHYSIOL REV, V68, P743, DOI 10.1152/physrev.1988.68.3.743; Karalis K, 1996, NAT MED, V2, P556, DOI 10.1038/nm0596-556; KOVACS KJ, 1987, NEUROENDOCRINOLOGY, V46, P365, DOI 10.1159/000124846; LEVINE S, 1994, ANN NY ACAD SCI, V76, P275; LIPOSITS Z, 1990, PROG HISTOCHEM CYTOC, V21, P1; Liu X, 1995, NEUROENDOCRINOLOGY, V62, P628, DOI 10.1159/000127059; Malkoski SP, 1997, MOL CELL ENDOCRINOL, V127, P189, DOI 10.1016/S0303-7207(96)04004-X; MCDOWELL J, 1987, BRAIN RES REV, V12, P397, DOI 10.1016/0165-0173(87)90006-3; NIKOLARAKIS KE, 1987, NEUROSCIENCE, V23, P143, DOI 10.1016/0306-4522(87)90278-8; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; ORCHINIK M, 1994, ANN NY ACAD SCI, V746, P101; PATCHEV VK, 1995, FASEB J, V9, P419, DOI 10.1096/fasebj.9.5.7896013; Patchev VK, 1996, J NEUROSCI, V16, P7077; PATCHEV VK, 1991, NEUROENDOCRINOLOGY, V54, P111, DOI 10.1159/000125859; PICH EM, 1993, NEUROSCIENCE, V55, P695, DOI 10.1016/0306-4522(93)90435-I; PLOTSKY PM, 1986, REGUL PEPTIDES, V16, P235, DOI 10.1016/0167-0115(86)90022-4; PLOTSKY PM, 1991, J NEUROENDOCRINOL, V3, P1, DOI 10.1111/j.1365-2826.1991.tb00231.x; ROSENFELD P, 1993, CELL MOL NEUROBIOL, V13, P295, DOI 10.1007/BF00711575; RUNDLE SE, 1988, NEUROENDOCRINOLOGY, V47, P374, DOI 10.1159/000124941; SAPOLSKY RM, 1990, BIOL PSYCHIAT, V27, P937, DOI 10.1016/0006-3223(90)90032-W; SAWCHENKO PE, 1992, CIBA F SYMP, V168, P16; SAWCHENKO PE, 1987, BRAIN RES, V403, P213, DOI 10.1016/0006-8993(87)90058-8; SCHILLING K, 1991, NEUROENDOCRINOLOGY, V53, P528, DOI 10.1159/000125768; Schmidt ED, 1997, J NEUROENDOCRINOL, V9, P69, DOI 10.1046/j.1365-2826.1997.00618.x; SPENCER RL, 1990, BRAIN RES, V514, P37, DOI 10.1016/0006-8993(90)90433-C; SZE PY, 1995, J STEROID BIOCHEM, V55, P185, DOI 10.1016/0960-0760(95)00178-3; SZOT P, 1993, DEV BRAIN RES, V73, P177, DOI 10.1016/0165-3806(93)90136-X; TIXIERVIDAL A, 1994, ANN NY ACAD SCI, V733, P56, DOI 10.1111/j.1749-6632.1994.tb17256.x; TSAGARAKIS S, 1990, NEUROENDOCRINOLOGY, V51, P599, DOI 10.1159/000125397; Walker CD, 1997, J NEUROENDOCRINOL, V9, P25, DOI 10.1046/j.1365-2826.1997.00544.x; Wang GJ, 1996, ENDOCRINOLOGY, V137, P379, DOI 10.1210/en.137.1.379; WHITNALL MH, 1993, PROG NEUROBIOL, V40, P573, DOI 10.1016/0301-0082(93)90035-Q	54	13	14	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1998	12	2					199	207		10.1096/fasebj.12.2.199	http://dx.doi.org/10.1096/fasebj.12.2.199			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472985				2022-12-25	WOS:000071848400008
J	Skrzypek, MS; Nagiec, MM; Lester, RL; Dickson, RC				Skrzypek, MS; Nagiec, MM; Lester, RL; Dickson, RC			Inhibition of amino acid transport by sphingoid long chain bases in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN CATABOLITE REPRESSION; PROTEIN-KINASE-C; TRANSLATIONAL CONTROL; BAKERS-YEAST; PERMEASES; SPHINGOLIPIDS; CERAMIDE; GENE; METABOLISM; STRAINS	Sphingoid long chain bases have many effects on cells including inhibition or stimulation of growth, The physiological significance of these effects is unknown in most cases, To bean to understand how these compounds inhibit growth, we have studied Saccharomyces cerevisiae cells. Growth of tryptophan (Trp(-)) auxotrophs was more strongly inhibited by phytosphingosine (PHS) than was growth of Trp(+) strains, suggesting that PHS diminishes tryptophan uptake and starves cells for this amino acid, This hypothesis is supported by data showing that growth inhibition is relieved by increasing concentrations of tryptophan in the culture medium and by multiple copies of the TAT2 gene, encoding a high affinity tryptophan transporter, Measurement of tryptophan uptake shows that it is inhibited by PHS. Finally, PHS treatment induces the general control response, indicating starvation for amino acids, Multiple copies of TAT2 do not protect cells against two other cationic lipids, stearylamine, and sphingosine, indicating that the effect of PHS on tryptophan utilization is specific, Other data demonstrate that PHS reduces uptake of leucine, histidine, and proline by specific transporters, Our data suggest that PHS targets proteins in the amino acid transporter family but not other distantly related membrane transporters, including those necessary for uptake of adenine and uracil.	Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Dickson, RC (corresponding author), Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA.	bobd@pop.uky.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41302] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; COURCHESNE WE, 1983, MOL CELL BIOL, V3, P672, DOI 10.1128/MCB.3.4.672; Ella KM, 1997, ARCH BIOCHEM BIOPHYS, V340, P101, DOI 10.1006/abbi.1997.9897; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GIETZ RD, 1992, NUCLEIC ACIDS RES, V8, P1425; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HEITMAN J, 1993, MOL CELL BIOL, V13, P5010, DOI 10.1128/MCB.13.8.5010; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HORAK J, 1986, BIOCHIM BIOPHYS ACTA, V864, P223, DOI 10.1016/0304-4157(86)90001-8; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; JAUNIAUX JC, 1987, EUR J BIOCHEM, V164, P601, DOI 10.1111/j.1432-1033.1987.tb11169.x; JOHNSTON SA, 1982, P NATL ACAD SCI USA, V79, P6871; LESTER RL, 1993, ADV LIPID RES, V26, P253; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MERRILL AHJ, 1996, LIPID 2 MESSENGERS, V8, P205; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; NELISSEN B, 1995, FEBS LETT, V377, P22; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; ROSE M, 1983, METHOD ENZYMOL, V101, P167; SCHMIDT A, 1994, MOL CELL BIOL, V14, P6597, DOI 10.1128/MCB.14.10.6597; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH SW, 1974, J BIOL CHEM, V249, P3395; SOPHIANOPOULOU V, 1995, FEMS MICROBIOL REV, V16, P53, DOI 10.1016/0168-6445(94)00091-C; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; STEINER S, 1969, P NATL ACAD SCI USA, V64, P1042, DOI 10.1073/pnas.64.3.1042; WIAME JM, 1985, ADV MICROB PHYSIOL, V26, P1, DOI 10.1016/S0065-2911(08)60394-X; WILSON E, 1986, J BIOL CHEM, V261, P2616	36	73	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2829	2834		10.1074/jbc.273.5.2829	http://dx.doi.org/10.1074/jbc.273.5.2829			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446592	hybrid			2022-12-25	WOS:000071736600047
J	Wang, ZG; Ackerman, SH				Wang, ZG; Ackerman, SH			Mutational studies with Atp12p, a protein required for assembly of the mitochondrial F-1-ATPase in yeast - Identification of domains important for Atp12p function and oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; F1-ATPASE; SYNTHASE; SUBUNIT; GENES; F1; DISRUPTION; MECHANISM	The Atp12p protein of Saccharomyces cerevisiae is required for assembly of the F-1 moiety of the mitochondrial ATP synthase, The current work has used mutant forms of Atp12p in an effort to learn about amino acids and/or domains that are important for the action of the protein, In one set of studies, the mutant atp12 genes were cloned and sequenced from 13 independent isolates of chemically mutagenized yeast, Of the 10 different mutant alleles that were identified, 9 (8 nonsense and 1 frameshift) lead to the early termination of the protein. A single missense mutation that substitutes lysine for Glu-289 was identified in two of the atp12 strains. Analysis of several Atp12p variants, each with different substitutions at Glu-289, showed that the functional activity of Atp12p is compromised when non-acidic residues are introduced at position 289 in the sequence, In other work, deletion analysis led to the assignment of two domains in Atp12p; the functional domain of the protein was mapped to the sequence between Gln-181 and Val-306, and a structural domain (Asp-307 through Gln-325) was identified that confers Atp12p the ability to oligomerize with other proteins in mitochondria.	Wayne State Univ, Sch Med, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Ackerman, SH (corresponding author), Wayne State Univ, Sch Med, Dept Surg, Detroit, MI 48201 USA.	sackerm@med.wayne.edu			NIGMS NIH HHS [GM48157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048157] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; BIANCHET M, 1994, BBA-BIOENERGETICS, V1187, P163, DOI 10.1016/0005-2728(94)90103-1; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BURNS DJ, 1986, J BIOL CHEM, V261, P2066; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; Clarke AR, 1996, CURR OPIN STRUC BIOL, V6, P43, DOI 10.1016/S0959-440X(96)80093-5; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUTAI M, 1988, J BIOENERG BIOMEMBR, V20, P41, DOI 10.1007/BF00762137; GIRAUD MF, 1994, EUR J BIOCHEM, V222, P851, DOI 10.1111/j.1432-1033.1994.tb18932.x; GUELIN E, 1993, J BIOL CHEM, V268, P161; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU; MUKHOPADHYAY A, 1994, FEBS LETT, V343, P160, DOI 10.1016/0014-5793(94)80310-2; PAUL MF, 1994, J BIOL CHEM, V269, P26158; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; RICHARME G, 1982, BIOCHEM BIOPH RES CO, V105, P476, DOI 10.1016/0006-291X(82)91459-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; TAKEDA M, 1985, J BIOL CHEM, V260, P5458; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; Wang ZG, 1996, J BIOL CHEM, V271, P4887; WHITE M, 1995, ARCH BIOCHEM BIOPHYS, V319, P299, DOI 10.1006/abbi.1995.1296; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	36	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2993	3002		10.1074/jbc.273.5.2993	http://dx.doi.org/10.1074/jbc.273.5.2993			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446613	hybrid			2022-12-25	WOS:000071736600068
J	Gazzeri, S; Gouyer, V; Vourc'h, C; Brambilla, C; Brambilla, E				Gazzeri, S; Gouyer, V; Vourc'h, C; Brambilla, C; Brambilla, E			Mechanisms of p16(INK4A) inactivation in non small-cell lung cancers	ONCOGENE			English	Article						p16(INK4A); lung cancer; protein expression; mutation methylation; homozygous deletion	KINASE-4 INHIBITOR GENE; TUMOR-SUPPRESSOR GENE; RB PROTEIN; SOMATIC MUTATIONS; CYCLE INHIBITION; P18 GENES; IN-VITRO; EXPRESSION; CARCINOMA; GROWTH	The cyclin-dependent kinase inhibitor p16 (p16(INK4A)/CDKN2/MTS1) is a potent inhibitor of the cyclin D-dependent phosphorylation of the retinoblastoma gene (Rb) product, the inactivation of which induces loss of Rb-dependent G1 arrest through inappropriate phosphorylation of the Rb protein. To analyse the role of po16(INK4A) as a tumor suppressor in the genesis of non small cell lung cancers (NSCLC) and correlate loss of p16(INK4A) protein expression to genetic or epigenetic mechanisms, we have performed a comprehensive study of p16 status in a series of 43 NSCLC. To this end, we have investigated p16(INK4A) protein expression with immunohistochemistry, deletions of the gene by FISH, and determined the methylation status of exon 1 alpha using a PCR-based methylation assay. Finally, possible mutations were studied by SSCP and subsequent sequencing, Twenty one of the 43 (49%) NSCLC studied exhibited an absence of p16(INK4A) nuclear staining. Of these, three (14%) had frameshift or missense mutations, seven (33%) displayed methylation of exon1 alpha and 10 (48%) displayed homozygous deletions, In total, 95% of the tumors with p16(INK4A) negative staining carried one of these three alternative genetic or epigenetic alterations. Furthermore, a high degree of chromosome 9 polysomy was found (58%) in those tumors with p16(INK4A) inactivation. Taken together these results suggest that deregulation of the p16 gene locus is a frequently occurring event in NSCLC through distinct mechanisms including rare point mutations, promotor methylation and frequent homozygous deletions. Furthermore, our data show that immunohistochemistry is a rapid and an accurate technique for screening of p16(INK4A) gene inactivation events that result in loss of protein expression.	Inst Albert Bonniot, Grp Rech Canc Poumon, F-38706 La Tronche, France; Inst Albert Bonniot, INSERM, U309, DYOGEN, F-38706 La Tronche, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Inst Albert Bonniot, Grp Rech Canc Poumon, F-38706 La Tronche, France.		Vourc'h, Claire/AAE-3119-2022; gazzeri, sylvie/U-4669-2019; VOURC'H, Claire/L-9319-2013; Brambilla, Elisabeth MP/L-8796-2013; Gouyer, Valérie/R-4984-2018; gazzeri, sylvie/M-1961-2013; VOURC'H, Claire/AAG-8576-2021	gazzeri, sylvie/0000-0001-5817-1839; VOURC'H, Claire/0000-0002-7276-9359; Gouyer, Valérie/0000-0002-4223-7060; gazzeri, sylvie/0000-0001-5817-1839; VOURC'H, Claire/0000-0002-7276-9359				ARAP W, 1995, CANCER RES, V55, P1351; BRAMBILLA E, 1992, HUM PATHOL, V23, P993, DOI 10.1016/0046-8177(92)90260-A; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; DEVOS S, 1995, GENE CHROMOSOME CANC, V14, P164; DURO D, 1995, ONCOGENE, V11, P21; GERADTS J, 1995, CANCER RES, V55, P6006; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GOUYER V, 1994, INT J CANCER, V58, P818, DOI 10.1002/ijc.2910580612; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; Hittelman WN, 1996, J CELL BIOCHEM, P57; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JIN X, 1995, CANCER RES, V55, P3520; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kratzke RA, 1996, CANCER RES, V56, P3415; LI Y, 1994, CANCER RES, V54, P6078; Liggett WH, 1996, CANCER RES, V56, P4119; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; Marchetti A, 1997, J PATHOL, V181, P178, DOI 10.1002/(SICI)1096-9896(199702)181:2<178::AID-PATH741>3.0.CO;2-5; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAKAGAWA K, 1995, ONCOGENE, V11, P1843; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Packenham JP, 1995, CLIN CANCER RES, V1, P687; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, CELL, V83, P993; QUESNEL B, 1995, BRIT J CANCER, V72, P351, DOI 10.1038/bjc.1995.337; Reed AL, 1996, CANCER RES, V56, P3630; ROCCHI M, 1991, GENOMICS, V9, P517, DOI 10.1016/0888-7543(91)90419-F; Rusin MR, 1996, INT J CANCER, V65, P734, DOI 10.1002/(SICI)1097-0215(19960315)65:6<734::AID-IJC4>3.0.CO;2-#; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; STONE S, 1995, CANCER RES, V55, P2988; TAM SW, 1994, CANCER RES, V54, P5816; *WHO CLASS, 1981, HIST TYP LUNG TUM; Wiest JS, 1997, CANCER RES, V57, P1	46	154	161	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	1998	16	4					497	504		10.1038/sj.onc.1201559	http://dx.doi.org/10.1038/sj.onc.1201559			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484839				2022-12-25	WOS:000071739400008
J	Pitkanen, K; Haapajarvi, T; Laiho, M				Pitkanen, K; Haapajarvi, T; Laiho, M			UVC-induction of p53 activation and accumulation is dependent on cell cycle and pathways involving protein synthesis and phosphorylation	ONCOGENE			English	Article						transcriptional regulation; DNA damage; post-transcriptional modification; staurosporine	TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; DNA-BINDING FUNCTION; CASEIN KINASE-II; DAMAGING AGENTS; IN-VITRO; TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA PROTEIN; POTENT INHIBITOR; MAMMALIAN-CELLS	Transcriptional activation and stabilization of p53 is a major response of mammalian cells to U.V.-light induced genetic damages, and possibly responsible for cell damage control. We have studied here by gel mobility shift and immunoblotting assays the activation and accumulation of p53 by U.V.C. and its dependency on cell cycle, protein synthesis and protein phosphorylation. In G(0)/G(1) synchronized cells U.V.C.-induced p53 DNA-binding activity, but not its accumulation, whereas both events took place in G(1)/S and S-phase cells. The kinetics of p53 activation by U.V.C. were slow requiring at least 1 h and slowly increasing thereafter with full activation observed at 6 h. Treatment of cells with cycloheximide (CHX) prevented the activation of p53 in all phases of the cell cycle and its accumulation in G(1)/S and S. However, removing CHX-block allowed full activation and accumulation of p53 with fast kinetics even if 4 h had lapsed since the initial U.V.C. insult. This suggests that the protein synthesis-dependent signal initiating p53 activation by U.V.C. remains continuous in the cells, The requirement of protein phosphorylation as mediator of p53 activation by U.V.C. was studied by using chemical protein kinase inhibitors. Of the tested inhibitors, only staurosporine, a known inhibitor of protein kinase C (PKC) and various other kinases, inhibited both p53 activation and accumulation, whereas specific PKC inhibitors, tyrosine kinase inhibitors and a serine/threonine kinase inhibitor did not. PKC-mediation of the p53 U.V.-response was further ruled out by the reactivity of the activated p53 to C-terminal antibody PAb 421. Kinetic studies shelved that staurosporine-mediated inhibition of p53 function is an early event in cell damage response, Thus dual, kinetically different events, de novo protein synthesis and staurosporine-inhibited protein phosphorylation are required for p53 activation and accumulation in all phases of the cell cycle, Notably, in the absence of U.V.-induced accumulation in G(0)/G(1) cells, p53 activation is still subject to inhibition of protein synthesis.	Univ Helsinki, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland	University of Helsinki	Laiho, M (corresponding author), Univ Helsinki, Dept Virol, Haartman Inst, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.							ADDISON C, 1990, ONCOGENE, V5, P423; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAKALKIN, 1994, P NATL ACAD SCI US, V1, P413; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Bond J, 1996, ONCOGENE, V13, P2097; BRUNO S, 1992, CANCER RES, V52, P470; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; DEFFIE A, 1995, MOL CELL BIOL, V15, P3926; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FRITSCHE M, 1993, ONCOGENE, V8, P307; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lane DP, 1996, ONCOGENE, V12, P2461; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; MIYASHITA T, 1995, CELL, V80, P293; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PRICE BD, 1993, ONCOGENE, V8, P3055; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SMITH ML, 1995, ONCOGENE, V10, P1053; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TARUNINA M, 1993, ONCOGENE, V8, P3165; TISHLER RB, 1993, CANCER RES, V53, P2212; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	75	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					459	469		10.1038/sj.onc.1201528	http://dx.doi.org/10.1038/sj.onc.1201528			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484835	Bronze			2022-12-25	WOS:000071739400004
J	Landgren, E; Schiller, P; Cao, YH; Claesson-Welsh, L				Landgren, E; Schiller, P; Cao, YH; Claesson-Welsh, L			Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1	ONCOGENE			English	Article						VEGF; PLGF; endothelial cells; migration; proliferation	TYROSINE KINASE; SIGNAL-TRANSDUCTION; IN-VIVO; VASCULAR ENDOTHELIUM; RECEPTOR; VEGF; ANGIOGENESIS; BINDING; FLK-1; KDR	Vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) are structurally related growth factors for endothelial cells. VEGF binds to the related receptor tyrosine kinases Fit 1 and KDR/Flk 1 with high affinity, whereas PlGF binds only to Fit 1. Ligand-stimulated KDR is known to transduce signals for cellular activity such as proliferation and migration, whereas weak or no responses have been recorded for Fit 1. We examined VEGF and PIGF for their capacity to stimulate signal transduction in porcine aortic endothelial cells expressing Fit 1 or KDR. VEGF had essentially no effect on Fit 1 expressing cells, but induced DNA synthesis and migration of KDR expressing cells. PlGF on the other hand induced DNA synthesis but not migration of the Fit 1 cells. In agreement, MAP kinase, examined as a marker for DNA synthesis, was activated both by VEGF-stimulation of the KDR cells and by PlGF-stimulation of the Fit 1 cells. In contrast, phospholipase C-gamma (PLC-gamma), was tyrosine phosphorylated only in VEGF stimulated KDR cells, and not in the PlGF-stimulated Fit 1 cells, which is in agreement with a role for PLC-gamma in cellular migration. We furthermore examined induction of protein levels of plasminogen activator (PA), which was evident in the PlGF-stimulated Fit 1 cells, but not in the VEGF-stimulated KDR cells. These data show that Fit 1 is able to mediate an array-of biological signals when appropriately stimulated and that the pattern of responses of PlGF-stimulation of Fit 1 is distinct from the pattern of responses to VEGF-stimulation of KDR.	Biomed Ctr, Dept Med & Physiol Chem, S-75123 Uppsala, Sweden; Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden	Karolinska Institutet	Claesson-Welsh, L (corresponding author), Biomed Ctr, Dept Med & Physiol Chem, Box 575, S-75123 Uppsala, Sweden.			Claesson-Welsh, Lena/0000-0003-4275-2000; Schiller, Petter/0000-0002-1790-3711				AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; Landgren E, 1996, EXP CELL RES, V223, P405, DOI 10.1006/excr.1996.0095; MAGLIONE D, 1993, ONCOGENE, V8, P925; Maniatis T., 1982, MOL CLONING LAB MANU; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; OBERG C, 1994, GROWTH FACTORS, V10, P115, DOI 10.3109/08977199409010985; PARK JE, 1994, J BIOL CHEM, V269, P25646; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TESSLER S, 1994, J BIOL CHEM, V269, P12456; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WENNSTROM S, 1994, ONCOGENE, V9, P651; WILKIE AOM, 1995, CURR BIOL, V5, P500	39	143	145	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					359	367		10.1038/sj.onc.1201545	http://dx.doi.org/10.1038/sj.onc.1201545			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467961	Bronze			2022-12-25	WOS:000071582100008
J	Baskakov, I; Bolen, DW				Baskakov, I; Bolen, DW			Forcing thermodynamically unfolded proteins to fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSACTIVATION DOMAIN; CONFORMATION; DNA; RIBONUCLEASE-T1; ISOMERIZATION; SOLUBILITY; OSMOLYTE; BINDING; ALPHA	A growing number of biologically important proteins have been identified as fully unfolded or partially disordered, Thus, an intriguing question is whether such proteins can be forced to fold by adding solutes found in the cells of some organisms, Nature has not ignored the powerful effect that the solution can have on protein stability and has developed the strategy of using specific solutes (called organic osmolytes) to maintain the structure and function cellular proteins in organisms exposed to denaturing environmental stresses (Yancey, P. H., Clark, M. E., Hand, S. C., Bowlus, R. D., and Somero, G. N. (1982) Science 217, 1214-1222), Here, we illustrate the extraordinary capability of one such osmolyte, trimethylamine N-oxide (TMAO), to force two thermodynamically unfolded proteins to fold to nativelike species having significant functional activity, In one of these examples, TMAO is shown to increase the population of native state relative to the denatured ensemble by nearly five orders of magnitude, The ability of TMAO to force thermodynamically unstable proteins to fold presents an opportunity for structure determination and functional studies of an important emerging class of proteins that have little or no structure without the presence of TMAO.	Univ Texas, Med Branch, Sealy Ctr Struct Biol, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Bolen, DW (corresponding author), Univ Texas, Med Branch, Sealy Ctr Struct Biol, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.	wbolen@hbcg.utmb.edu			PHS HHS [49760] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; BUCHE A, 1993, J BIOMOL STRUCT DYN, V11, P95, DOI 10.1080/07391102.1993.10508712; Cho HS, 1996, PROTEIN SCI, V5, P262; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GAST K, 1995, BIOCHEMISTRY-US, V34, P13211, DOI 10.1021/bi00040a037; HOY MV, 1993, CELL, V72, P587; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3053, DOI 10.1021/bi00464a023; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; LIN TY, 1994, BIOCHEMISTRY-US, V33, P12695, DOI 10.1021/bi00208a021; MUCKE M, 1992, BIOCHEMISTRY-US, V31, P7848; Nelson JC, 1997, SCIENCE, V277, P1793, DOI 10.1126/science.277.5333.1793; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; OOBATAKE M, 1979, J BIOCHEM-TOKYO, V86, P65; PACE C N, 1975, Critical Reviews in Biochemistry, V3, P1, DOI 10.3109/10409237509102551; PACE CN, 1988, J BIOL CHEM, V263, P11820; Pan B, 1997, PROTEIN SCI, V6, P1237, DOI 10.1002/pro.5560060612; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SHORTLE D, 1989, BIOCHEMISTRY-US, V28, P936, DOI 10.1021/bi00429a003; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TIMASHEFF SN, 1970, ACCOUNTS CHEM RES, V3, P62, DOI 10.1021/ar50026a004; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Zurdo J, 1997, BIOCHEMISTRY-US, V36, P9625, DOI 10.1021/bi9702400	31	304	315	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4831	4834		10.1074/jbc.273.9.4831	http://dx.doi.org/10.1074/jbc.273.9.4831			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478922	hybrid			2022-12-25	WOS:000072310400006
J	Kulzer, R; Pils, T; Kappl, R; Huttermann, J; Knappe, J				Kulzer, R; Pils, T; Kappl, R; Huttermann, J; Knappe, J			Reconstitution and characterization of the polynuclear iron-sulfur cluster in pyruvate formate-lyase-activating enzyme - Molecular properties of the holoenzyme form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RIBONUCLEOTIDE REDUCTASE; ESCHERICHIA-COLI; PROTEIN; GLYCINE-734; ACONITASE; FE3S4	The glycyl radical (Gly-734) contained in the active form of pyruvate formate-lyase (PFL) of Escherichia coli is generated by the S-adenosylmethionine-dependent pyruvate formate-lyase-activating enzyme (PFL activase), A 5'-deoxyadenosyl radical intermediate produced by the activase has been suggested as the species that abstracts the pro-S hydrogen of the glycine 734 residue in PFL (Frey, M., Rothe, M., Wagner, A. F. V., and Knappe, J. (1994) J. Biol. Chem. 269, 12432-12437). To enable mechanistic investigations of this system we have worked out a convenient large scale preparation of functionally competent PFL activase from its apoform, The previously inferred metallic cofactor was identified as redox-interconvertible polynuclear iron-sulfur cluster, most probably of the [4Fe-4S] type, according to W-visible and EPR spectroscopic information, Cys --> Ser replacements by site-directed mutagenesis determined Cys-29, Cys-33, and Cys-36 to be essential to yield active holoenzyme, Gel filtration chromatography showed a monomeric structure (28 kDa) for both the apoenzyme and holoenzyme form, The iron-sulfur cluster complement proved to be a prerequisite for effective binding of adenosylmethionine, which induces a characteristic shift of the EPR signal shape of the reduced enzyme form ([4Fe-4S](+)) from axial to rhombic symmetry.	Univ Heidelberg, Inst Biol Chem, D-69120 Heidelberg, Germany; Univ Saarland, Inst Biophys & Phys Grundlagen Med, D-66421 Homburg, Germany	Ruprecht Karls University Heidelberg; Saarland University	Knappe, J (corresponding author), Univ Heidelberg, Inst Biol Chem, Neuenheimer Feld 501, D-69120 Heidelberg, Germany.	knappe@sun0.urz.uni-heidelberg.de		Kappl, Reinhard/0000-0003-0223-6642				Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broderick JB, 1997, J AM CHEM SOC, V119, P7396, DOI 10.1021/ja9711425; CONRADT H, 1984, ARCH BIOCHEM BIOPHYS, V228, P133, DOI 10.1016/0003-9861(84)90054-7; DEPAMPHILIS BV, 1974, J AM CHEM SOC, V96, P4159, DOI 10.1021/ja00820a017; FREY M, 1994, J BIOL CHEM, V269, P12432; Guianvarc'h D, 1997, BIOCHEM BIOPH RES CO, V236, P402, DOI 10.1006/bbrc.1997.6952; HAGEN KS, 1983, J AM CHEM SOC, V105, P3905, DOI 10.1021/ja00350a028; KING TE, 1967, METHOD ENZYMOL, V10, P634; KNAPPE J, 1990, FEMS MICROBIOL LETT, V75, P383, DOI 10.1111/j.1574-6968.1990.tb04108.x; KNAPPE J, 1974, EUR J BIOCHEM, V50, P253, DOI 10.1111/j.1432-1033.1974.tb03894.x; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; KNAPPE J, 1993, BIOCHEM SOC T, V21, P731, DOI 10.1042/bst0210731; Knappe J, 1975, Methods Enzymol, V41, P508; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; PARAST CV, 1995, BIOCHEMISTRY-US, V34, P2393, DOI 10.1021/bi00008a001; Penefsky H S, 1979, Methods Enzymol, V56, P527; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; RODEL W, 1988, EUR J BIOCHEM, V177, P151; SANYAL I, 1994, BIOCHEMISTRY-US, V33, P3625, DOI 10.1021/bi00178a020; SAYERS JR, 1991, DIRECTED MUTAGENESIS, P49; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; SURERUS KK, 1989, P NATL ACAD SCI USA, V86, P9846, DOI 10.1073/pnas.86.24.9846; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WONG KK, 1993, BIOCHEMISTRY-US, V32, P14102, DOI 10.1021/bi00214a005; YOUNG P, 1994, J BIOL CHEM, V269, P27815	28	125	125	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4897	4903		10.1074/jbc.273.9.4897	http://dx.doi.org/10.1074/jbc.273.9.4897			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478932	hybrid			2022-12-25	WOS:000072310400016
J	Mustafa, SB; Olson, MS				Mustafa, SB; Olson, MS			Expression of nitric-oxide synthase in rat Kupffer cells is regulated by cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CYCLIC-AMP; BACTERIAL LIPOPOLYSACCHARIDE; TRANSCRIPTION FACTORS; ENDOTHELIAL-CELLS; PROTEIN-SYNTHESIS; GENE-EXPRESSION; MESSENGER-RNA; ACTIVATION; INDUCTION	Treatment of cultured rat Kupffer cells with lipopolysaccharide (LPS) resulted in a time-dependent increase in the expression of the inducible isoform of nitric-oxide synthase (iNOS). Agents that elevated intracellular cAMP levels (e.g, forskolin, dibutyryl cAMP, cholera toxin, and isoproterenol) markedly decreased nitrite production and iNOS protein formation by LPS-stimulated Kupffer cells, Furthermore, inhibition of LPS-induced nitrite formation and iNOS protein levels by these agents was enhanced in the presence of the phosphodiesterase inhibitor 5-isobutyl-1-methylxanthine. Forskolin, the most potent inhibitor of LPS-induced nitrite formation by Kupffer cells, decreased iNOS mRNA levels in a time-dependent manner. Time course studies indicated that forskolin was most effective at inhibiting LPS-induced nitrite formation and iNOS mRNA levels by Kupffer cells when added before LPS. Message stability studies established that forskolin did not enhance the rate of decay of LPS-induced iNOS mRNA Nuclear run-on assays revealed that forskolin decreased LPS-induced transcription of the iNOS gene, Treatment of Kupffer cells with LPS induced the translocation of the p65 subunit of nuclear factor kappa B (NF-kappa B) into the nucleus, and this process was abolished by forskolin, In addition, the LPS-dependent degradation of I kappa B alpha was not observed in forskolin-treated cells; the levels of the p65 subunit of NF-kappa B were minimal in the nucleus at the same time. Also, we observed that forskolin induced transcription of the I kappa B alpha gene in a time-dependent manner and in addition up-regulated LPS-induced I kappa B alpha mRNA levels. Taken together, this study indicates that the attenuation of LPS-induced iNOS formation in Kupffer cells by elevated intracellular cAMP levels occurs by preventing the degradation of I kappa B alpha which suppresses the activation of NF-kappa B and inhibits the onset of transcription of the iNOS gene.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Olson, MS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NIDDK NIH HHS [DK-33538] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033538] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bellezzo JM, 1996, AM J PHYSIOL-GASTR L, V270, pG956, DOI 10.1152/ajpgi.1996.270.6.G956; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BULUT V, 1993, BIOCHEM BIOPH RES CO, V195, P1134, DOI 10.1006/bbrc.1993.2162; CHAO W, 1990, J BIOL CHEM, V265, P17576; CURRAN RD, 1990, ANN SURG, V212, P462, DOI 10.1097/00000658-199010000-00009; Eberhardt W, 1996, BIOCHEM BIOPH RES CO, V223, P752, DOI 10.1006/bbrc.1996.0968; Essani NA, 1996, J IMMUNOL, V156, P2956; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Grisham MB, 1996, METHOD ENZYMOL, V268, P237; HARBRECHT BG, 1995, ENDOTHELIUM, V3, pS95; Ikeda K, 1996, PHYSIOL CHEM PHYS, V28, P239; Jeon YJ, 1996, MOL PHARMACOL, V50, P334; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; KNOOK DL, 1976, EXP CELL RES, V99, P444, DOI 10.1016/0014-4827(76)90605-4; KOIDE M, 1993, J BIOL CHEM, V268, P24959; KUNZ D, 1994, BIOCHEM J, V304, P337, DOI 10.1042/bj3040337; Kurose I, 1997, J CLIN INVEST, V99, P867, DOI 10.1172/JCI119251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKIN DL, 1995, HEPATOLOGY, V22, P223, DOI 10.1002/hep.1840220133; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; Minghetti L, 1997, GLIA, V19, P152, DOI 10.1002/(SICI)1098-1136(199702)19:2<152::AID-GLIA6>3.0.CO;2-2; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUSTAFA SB, 1996, HEPATOLOGY, V23, P1662; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NeuschwanderTetri BA, 1996, BIOCHEM J, V320, P1005, DOI 10.1042/bj3201005; Nisoli E, 1997, ENDOCRINOLOGY, V138, P676, DOI 10.1210/en.138.2.676; NUSSLER AK, 1995, HEPATOLOGY, V21, P1552, DOI 10.1016/0270-9139(95)90459-X; Oddis CV, 1995, AM J PHYSIOL-HEART C, V269, pH2044, DOI 10.1152/ajpheart.1995.269.6.H2044; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pang LH, 1997, BIOCHEM PHARMACOL, V53, P493, DOI 10.1016/S0006-2952(96)00737-X; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Szabo C, 1997, IMMUNOLOGY, V90, P95, DOI 10.1046/j.1365-2567.1997.00137.x; SZABO C, 1993, CIRC RES, V73, P991, DOI 10.1161/01.RES.73.6.991; TRANTHI TA, 1995, HEPATOLOGY, V22, P613, DOI 10.1016/0270-9139(95)90587-1; WANG MH, 1994, J BIOL CHEM, V269, P14027; West M A, 1996, New Horiz, V4, P168; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	45	91	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5073	5080		10.1074/jbc.273.9.5073	http://dx.doi.org/10.1074/jbc.273.9.5073			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478958	hybrid			2022-12-25	WOS:000072310400042
J	Bae, YS; Cantley, LG; Chen, CS; Kim, SR; Kwon, KS; Rhee, SG				Bae, YS; Cantley, LG; Chen, CS; Kim, SR; Kwon, KS; Rhee, SG			Activation of phospholipase C-gamma by phosphatidylinositol 3,4,5-trisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOINOSITIDE-3 KINASE; 3-KINASE; SYSTEM; PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE; PHOSPHATES; WORTMANNIN; RECEPTOR; DOMAINS; CLONING	Signal transduction across cell membranes often involves the activation of both phosphatidylinositol (PI)-specific phospholipase C (PLC) and phosphoinositide 3-kinase (PI 3-kinase). Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2), a substrate for both enzymes, is converted to phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P-3) by the action of PI 3-kinase. Here, we show that PI(3,4,5)P-3 activates purified PLC-gamma isozymes by interacting with their Src homology 2 domains, Furthermore, the expression of an activated catalytic subunit of PI 3-kinase in COS-7 cells resulted in an increase in inositol phosphate formation, whereas platelet-derived growth factor-induced PLC activation in NIH 3T3 cells was markedly inhibited by the specific PI 3-kinase inhibitor LY294002. These results suggest that receptors coupled to PI 3-kinase may activate PLC-gamma isozymes indirectly, in the absence of PLC-gamma tyrosine phosphorylation, through the generation of PI(3,4,5)P-3.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Beth Israel Hosp, Dept Med, Boston, MA 02115 USA; Univ Kentucky, Coll Pharm, Div Med Chem & Pharmaceut, Lexington, KY 40506 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Kentucky	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 3,Rm 122,3 Ctr Dr,MSC 0320, Bethesda, MD 20892 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053448] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48871] Funding Source: Medline; NIGMS NIH HHS [GM53448] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER S, 1995, MOL BIOL CELL, V6, P1145; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COCKCROFT S, 1992, BIOCHEM J, V288, P1; Cunningham E, 1996, P NATL ACAD SCI USA, V93, P6589, DOI 10.1073/pnas.93.13.6589; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; FALASCA M, 1998, IN PRESS EMBO J; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANISHI S, 1994, J BIOL CHEM, V269, P6528; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PARK D, 1992, J BIOL CHEM, V267, P16048; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOKER A, 1994, J BIOL CHEM, V269, P32358; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; WHETTON AD, 1986, EMBO J, V5, P3281, DOI 10.1002/j.1460-2075.1986.tb04640.x	34	292	296	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4465	4469		10.1074/jbc.273.8.4465	http://dx.doi.org/10.1074/jbc.273.8.4465			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468499	hybrid			2022-12-25	WOS:000072115000027
J	Knodler, LA; Sekyere, EO; Stewart, TS; Schofield, PJ; Edwards, MR				Knodler, LA; Sekyere, EO; Stewart, TS; Schofield, PJ; Edwards, MR			Cloning and expression of a prokaryotic enzyme, arginine deiminase, from a primitive eukaryote Giardia intestinalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT GLUTAMATE-DEHYDROGENASE; TRICHOMONAS-VAGINALIS; MYCOPLASMA-ARGININI; NUCLEOTIDE-SEQUENCE; LAMBLIA; GENE; METABOLISM; PATHWAY; LOCALIZATION; CATABOLISM	Arginine deiminase (EC 3.5.3.6) catalyzes the irreversible catabolisn: of arginine to citrulline in the arginine dihydrolase pathway, This pathway has been regarded as restricted to prokaryotic organisms but if an important source of energy to the primitive protozoan Giardia intestinalis. In this paper we report the cloning and expression of the arginine deiminase gene from this parasite, Degenerate oligonucleotides based on amino acid sequences of tryptic peptides from the purified protein were used to amplify a portion of the arginine deiminase gene. This was then used as a probe to screen HindIII and PstI "mini" libraries to obtain two overlapping clones that contained the arginine deiminase gene, The open reading frame encoded 581 amino acids including all of the tryptic peptides that were sequenced and corresponded to a molecular mass of 67 kDa. Northern blot analysis identified a single 1.8-kilobase transcript in both trophozoites and encysting cells. Arginine deiminase was successfully expressed in Escherichia coli and purified to homogeneity. The recombinant protein was found to have characteristics comparable with those of the native enzyme.	Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Edwards, MR (corresponding author), Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia.	m.edwards@unsw.edu.au		Knodler, Leigh/0000-0002-3028-2198				BAUR H, 1989, EUR J BIOCHEM, V179, P53, DOI 10.1111/j.1432-1033.1989.tb14520.x; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; EDWARDS MR, 1992, MOL BIOCHEM PARASIT, V53, P97, DOI 10.1016/0166-6851(92)90011-8; HARASAWA R, 1992, MICROBIOL IMMUNOL, V36, P661, DOI 10.1111/j.1348-0421.1992.tb02068.x; KABNICK KS, 1991, AM SCI, V79, P34; Knodler LA, 1997, EXP PARASITOL, V85, P77, DOI 10.1006/expr.1996.4099; KNODLER LA, 1995, MICROBIOL-UK, V141, P2063, DOI 10.1099/13500872-141-9-2063; KNODLER LA, 1994, EXP PARASITOL, V79, P117, DOI 10.1006/expr.1994.1071; KONDO K, 1990, MOL GEN GENET, V221, P81, DOI 10.1007/BF00280371; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSTEAD D, 1983, MOL BIOCHEM PARASIT, V8, P241, DOI 10.1016/0166-6851(83)90046-4; MISAWA S, 1994, J BIOTECHNOL, V36, P145, DOI 10.1016/0168-1656(94)90050-7; OHNO T, 1990, INFECT IMMUN, V58, P3788, DOI 10.1128/IAI.58.11.3788-3795.1990; PEATTIE DA, 1989, J CELL BIOL, V109, P2323, DOI 10.1083/jcb.109.5.2323; Que XC, 1996, MOL BIOCHEM PARASIT, V81, P101, DOI 10.1016/0166-6851(96)02698-9; SCHOFIELD PJ, 1992, MOL BIOCHEM PARASIT, V51, P29, DOI 10.1016/0166-6851(92)90197-R; SCHOFIELD PJ, 1991, MOL BIOCHEM PARASIT, V45, P39, DOI 10.1016/0166-6851(91)90025-2; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; UPCROFT JA, 1993, INT J PARASITOL, V23, P609, DOI 10.1016/0020-7519(93)90167-W; YARLETT N, 1994, J EUKARYOT MICROBIOL, V41, P554, DOI 10.1111/j.1550-7408.1994.tb01516.x; YEE J, 1992, J BIOL CHEM, V267, P7539; YEE J, 1994, SYST APPL MICROBIOL, V16, P759, DOI 10.1016/S0723-2020(11)80350-4	22	66	69	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4470	4477		10.1074/jbc.273.8.4470	http://dx.doi.org/10.1074/jbc.273.8.4470			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468500	hybrid			2022-12-25	WOS:000072115000028
J	Martin, DA; Siegel, RM; Zheng, LX; Lenardo, MJ				Martin, DA; Siegel, RM; Zheng, LX; Lenardo, MJ			Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACH alpha 1) death signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOPROLIFERATIVE SYNDROME; INDUCED APOPTOSIS; CRYSTAL-STRUCTURE; CD95 FAS/APO-1; T-CELLS; PROTEASE; RECEPTOR; FAS; PROTEINS; DOMAIN	Many forms of apoptosis, including that caused by the death receptor CD95/Fas/APO-1, depend on the activation of caspases, which are proteases that cleave specific intracellular proteins to cause orderly cellular disintegration. The requirements for activating these. crucial enzymatic mediators of death are not well understood. Using molecular chimeras with either CD8 or Tac, we find that oligomerization at the cell membrane powerfully induces caspase-8 autoactivation and apoptosis. Death induction was abrogated by the z-VAD-fmk, z-IETD-fmk, or p35 enzyme inhibitors or by a mutation in the active site cysteine but was surprisingly unaffected by death inhibitor Bcl-2, Amino acid substitutions that prevent the proteolytic separation of the caspase from its membrane-associated domain completely blocked apoptosis. Thus, oligomerization at the membrane is sufficient for caspase-8 autoactivation, but apoptosis could involve a death signal conveyed by the proteolytic release of the enzyme into the cytoplasm.	NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lenardo, MJ (corresponding author), NIAID, Immunol Lab, NIH, Rm 11N311,Bldg 10,10 Ctr Dr,MSC1892, Bethesda, MD 20892 USA.	lenardo@nih.gov	Siegel, Richard/C-7592-2009	Siegel, Richard/0000-0001-5953-9893				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brinkmann U, 1997, APOPTOSIS, V2, P192, DOI 10.1023/A:1026468532413; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hu SM, 1997, J BIOL CHEM, V272, P9621; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; LACAL PM, 1988, ONCOGENE, V2, P533; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEMON SA, 1995, J IMMUNOL, V155, P4644; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Sneller MC, 1997, BLOOD, V89, P1341, DOI 10.1182/blood.V89.4.1341; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Tomita Y, 1996, INT J CANCER, V68, P132, DOI 10.1002/(SICI)1097-0215(19960927)68:1<132::AID-IJC23>3.0.CO;2-C; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	32	314	336	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4345	4349		10.1074/jbc.273.8.4345	http://dx.doi.org/10.1074/jbc.273.8.4345			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468483	hybrid			2022-12-25	WOS:000072115000011
J	English, JM; Pearson, G; Baer, R; Cobb, MH				English, JM; Pearson, G; Baer, R; Cobb, MH			Identification of substrates and regulators of mitogen-activated protein kinase ERK5 using chimeric protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; PHOSPHORYLATION SITES; MYC; PATHWAYS; CASCADES; INSULIN; FAMILY; YEAST; CELLS; AUTOPHOSPHORYLATION	Extracellular signal-regulated protein kinase 5 (ERK5) is a recently discovered orphan mitogen-activated protein kinase for which no substrates or strong activators have? been described. Two ERK5 chimeras were created as a novel approach to discover its substrates and upstream regulators, One chimeric protein contained the N-terminal domain of the ERK5 catalytic core (subdomains I-IV) and the C-terminal domain of the ERK2 catalytic core (subdomains V-XI), This chimera a was highly responsive to stimuli that regulate ERK2 in vitro and in cells, A second chimeric protein consisted of the N-terminal domain of ERK2 (subdomains I-IV) and the C-terminal domain of the ERK5 catalytic core (subdomains V-XI). This chimera was activated in bacteria by coexpression with a constitutively active mutant of MEK1. Using the activated chimera, we identified three in vitro substrates of ERK5, Assaying ERK5 activity in immune complexes with one of these substrates, c-Myc, wet determined that the ERK5 catalytic domain is activated by V-12 H-Ras and to a lesser extent by phorbol ester but not by constitutively active mutants of Raf-1. Thus, ERK5 is a target of a novel Ras effector pathway that may communicate with c-Myc.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL CANCER INSTITUTE [T32CA066187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA66187] Funding Source: Medline; NIDDK NIH HHS [DK34128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Cheng M, 1996, J BIOL CHEM, V271, P12057, DOI 10.1074/jbc.271.20.12057; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LEWIS TS, IN PRESS ADV CANC RE; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; Moriguchi T, 1996, Adv Pharmacol, V36, P121, DOI 10.1016/S1054-3589(08)60579-7; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; XIA Y, 1994, ONCOGENE, V9, P1437; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	64	134	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3854	3860		10.1074/jbc.273.7.3854	http://dx.doi.org/10.1074/jbc.273.7.3854			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461566	hybrid			2022-12-25	WOS:000072048400008
J	Hata, K; Ito, T; Takeshige, K; Sumimoto, H				Hata, K; Ito, T; Takeshige, K; Sumimoto, H			Anionic amphiphile-independent activation of the phagocyte NADPH oxidase in a cell-free system by p47(phox) and p67(phox), both in C terminally truncated forms - Implication for regulatory Src homology 3 domain-mediated interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; SUPEROXIDE PRODUCTION; SH3 DOMAINS; COMPONENT P47(PHOX); PROTEIN-KINASE; P67-PHOX; BINDING; COMPLEX	Anionic amphiphiles, such as arachidonate, activate the superoxide-producing phagocyte NADPH oxidase in a cell-free system with human neutrophil membrane, which contains cytochrome b(558) comprising gp91(phox) and p22(phox), and three cytosolic proteins: p47(phox) and p67(phox), each harboring two SH3 domains, and the small GTPase Rac. Here we show that, even without the amphiphiles, the oxidase is activated in vitro by a C terminally truncated p47(phox)., retaining the N-terminal and the two SH3 domains, and the N terminus of p67(phox). When either truncated p47(phox) or, p67(phox) is replaced by the respective full-length one, the activation absolutely requires the amphiphiles. The results indicate that both p47(phox) and p67(phox) are the primary targets of the amphiphiles, and that their C-terminal regions play negative regulatory roles. We also find that the truncated p47(phox), but not the full-length one, can bind to p22(phox), a binding required for the oxidase activation. The N-terminal SH3 domain of p47(phox) is responsible for the binding not only to p22(phox), but also to the p47(phox) C terminus. Thus the SH3 domain is accessible in the active p47(phox) but is normally masked in the full-length one probably via intramolecularly interacting with the C terminus. The present findings support our previous proposal of regulatory SH3 domain-mediated interactions.	Kyushu Univ, Sch Med, Dept Biochem, Higashi Ku, Fukuoka 81282, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 108, Japan	Kyushu University; University of Tokyo	Sumimoto, H (corresponding author), Kyushu Univ, Sch Med, Dept Biochem, Higashi Ku, 3-1-1 Maidashi, Fukuoka 81282, Japan.	hsumi@mailserver.med.kyushu-u.ac.jp		Ito, Takashi/0000-0001-6097-2803				Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHEN JK, 1995, ANGEW CHEM INT EDIT, V34, P953, DOI 10.1002/anie.199509531; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CROSS AR, 1990, FREE RADICAL BIO MED, V8, P71, DOI 10.1016/0891-5849(90)90147-B; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FINAN P, 1994, J BIOL CHEM, V269, P13752; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; JONES OTG, 1994, BIOESSAYS, V16, P919, DOI 10.1002/bies.950161211; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; Nguyen JT, 1997, NAT STRUCT BIOL, V4, P256, DOI 10.1038/nsb0497-256; NISHIMOTO Y, 1997, J BIOL CHEM, V272, P18834; Park JW, 1997, J BIOL CHEM, V272, P11035; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Roos D, 1996, BLOOD, V87, P1663; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH RM, 1991, BLOOD, V77, P673; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Sumimoto H, 1997, MEMBRANE PROTEINS - STRUCTURE, FUNCTION AND EXPRESSION CONTROL: INTERNATIONAL SYMPOSIUM, P235; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Wang DS, 1996, P NATL ACAD SCI USA, V93, P13182, DOI 10.1073/pnas.93.23.13182; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	40	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4232	4236		10.1074/jbc.273.7.4232	http://dx.doi.org/10.1074/jbc.273.7.4232			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461621	hybrid			2022-12-25	WOS:000072048400063
J	Spangler, NJ; Meyers, MR; Gierke, KL; Kerby, RL; Roberts, GP; Ludden, PW				Spangler, NJ; Meyers, MR; Gierke, KL; Kerby, RL; Roberts, GP; Ludden, PW			Substitution of valine for histidine 265 in carbon monoxide dehydrogenase from Rhodospirillum rubrum affects activity and spectroscopic states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; CLOSTRIDIUM-THERMOACETICUM; COA SYNTHASE; NICKEL; SITE; IDENTIFICATION; ACTIVATION; SEQUENCE; CLUSTER; CYANIDE	In carbon monoxide dehydrogenase (CODH) from Rhodospirillum rubrum, histidine 265 was replaced with valine by site-directed mutagenesis of the cooS gene, The altered form of CODH (H265V) had a low nickel content and a dramatically reduced level of catalytic activity, Although treatment with NiCl2 and CoCl2 increased the activity of H265V CODH by severalfold, activity levels remained more than 1000-fold lower than that of wild-type CODH. Histidine 265 was not essential for the formation and stability of the Fe4S4 clusters, The K-m and K-D for CO as well as the K-D for cyanide were relatively unchanged as a result of the amino acid substitution in CODH. The time-dependent reduction of the [Fe4S4](2+) clusters by CO occurred on a time scale of hours, suggesting that, as a consequence of the mutation, a rate-limiting step had been introduced prior to the transfer of electrons from CO to the cubanes in centers B and C. EPR spectra of H265V CODH lacked the g(av) = 1.86 and g(av) = 1.87 signals characteristic of reduced forms of the active site (center C) of wild-type CODH, This indicates that the electronic properties of center C have been modified possibly by the disruption or alteration of the ligand-mediated interaction between the nickel site and Fe4S4 chromophore.	Univ Wisconsin, Dept Biochem, Coll Agr & Life Sci, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Coll Agr & Life Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ludden, PW (corresponding author), Univ Wisconsin, Dept Biochem, Coll Agr & Life Sci, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053228] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53228] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson ME, 1996, BIOCHEMISTRY-US, V35, P8371, DOI 10.1021/bi952902w; ANDERSON ME, 1993, J AM CHEM SOC, V115, P12204, DOI 10.1021/ja00078a085; BONAM D, 1988, P NATL ACAD SCI USA, V85, P31, DOI 10.1073/pnas.85.1.31; BONAM D, 1987, J BIOL CHEM, V262, P2980; BONAM D, 1984, J BACTERIOL, V159, P693, DOI 10.1128/JB.159.2.693-699.1984; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EGGEN RIL, 1991, J BIOL CHEM, V266, P6883; ENSIGN SA, 1990, BIOCHEMISTRY-US, V29, P2162, DOI 10.1021/bi00460a029; ENSIGN SA, 1989, BIOCHEMISTRY-US, V28, P4973, DOI 10.1021/bi00438a011; ENSIGN SA, 1989, BIOCHEMISTRY-US, V28, P4968, DOI 10.1021/bi00438a010; ENSIGN SA, 1995, BIOCHEMISTRY-US, V34, P5372, DOI 10.1021/bi00016a008; ENSIGN SA, 1991, J BIOL CHEM, V266, P18395; Hu ZG, 1996, J AM CHEM SOC, V118, P830, DOI 10.1021/ja9528386; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; Kerby RL, 1997, J BACTERIOL, V179, P2259, DOI 10.1128/jb.179.7.2259-2266.1997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MaupinFurlow JA, 1996, J BACTERIOL, V178, P6849, DOI 10.1128/jb.178.23.6849-6856.1996; MORTON TA, 1991, J BIOL CHEM, V266, P23824; Ragsdale SW, 1996, CHEM REV, V96, P2515, DOI 10.1021/cr950058+; Seravalli J, 1997, BIOCHEMISTRY-US, V36, P11241, DOI 10.1021/bi970590m; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spangler NJ, 1996, J BIOL CHEM, V271, P7973, DOI 10.1074/jbc.271.14.7973; STEPHENS PJ, 1989, J BIOL CHEM, V264, P16347; TAN GO, 1992, P NATL ACAD SCI USA, V89, P4427, DOI 10.1073/pnas.89.10.4427; XIA JQ, 1995, BIOCHEMISTRY-US, V34, P6037, DOI 10.1021/bi00018a005; Zhang YP, 1996, J BACTERIOL, V178, P2948, DOI 10.1128/jb.178.10.2948-2953.1996	28	27	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4059	4064		10.1074/jbc.273.7.4059	http://dx.doi.org/10.1074/jbc.273.7.4059			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461598	hybrid			2022-12-25	WOS:000072048400040
J	Turner, PR; Mefford, S; Bambino, T; Nissenson, RA				Turner, PR; Mefford, S; Bambino, T; Nissenson, RA			Transmembrane residues together with the amino terminus limit the response of the parathyroid hormone (PTH) 2 receptor to PTH-related peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-LINKED RECEPTOR; EXPRESSION; ACTIVATION; BINDING	The mechanisms of ligand binding and receptor activation for G-protein-coupled receptors in the secretin/parathyroid hormone (PTH) receptor subfamily are not understood, The PTH1 receptor (PTH1R) signals in response to both PTH and parathyroid hormone-related peptide (PTHrP), whereas the PTH2 receptor (PTH2R) responds only to PTB, not to PTHrP, To locate PTHrP discriminatory domains in the PTH2R, we generated PTH1R/PTH2R chimeras in which the extracellular ami no-terminal domains were exchanged. Production of cAMP in response to 1 mu M PTHrP or PTH was identical in cells expressing the PTH1R with the PTH2R amino terminus and in cells expressing the PTH2R with the PTH1R amino terminus. The ability of the chimeric receptor with the PTH2R amino terminus to respond fully to PTHrP showed that the body of the PTH2R, must contain sites that limit the response to PTHrP. Mutations to PTH1R sequence were therefore made in each of the seven transmembrane domains of the PTH2R. Mutations in transmembrane domains 3 and 7 resulted in receptors able to respond to PTHrP Thus, residues in more than one domain form a barrier or filter, allowing the receptor to discriminate between different ligands.	Univ Calif San Francisco, Vet Affairs Med Ctr, Endocrine Unit, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco	Turner, PR (corresponding author), Univ Calif San Francisco, Vet Affairs Med Ctr, Endocrine Unit, 111N,4150 Clement St, San Francisco, CA 94121 USA.				NIDDK NIH HHS [DK 35323] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035323] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Behar V, 1996, ENDOCRINOLOGY, V137, P2748, DOI 10.1210/en.137.7.2748; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Mizobe T, 1996, J BIOL CHEM, V271, P2387, DOI 10.1074/jbc.271.5.2387; NISSENSON RA, 1985, CANCER RES, V45, P5358; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Schipani E, 1997, MOL ENDOCRINOL, V11, P851, DOI 10.1210/me.11.7.851; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Usdin TB, 1997, ENDOCRINOLOGY, V138, P831, DOI 10.1210/en.138.2.831; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	16	47	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3830	3837		10.1074/jbc.273.7.3830	http://dx.doi.org/10.1074/jbc.273.7.3830			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461563	hybrid			2022-12-25	WOS:000072048400005
J	Caspi, S; Halimi, M; Yanai, A; Ben Sasson, S; Taraboulos, A; Gabizon, R				Caspi, S; Halimi, M; Yanai, A; Ben Sasson, S; Taraboulos, A; Gabizon, R			The anti-prion activity of Congo red - Putative mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB DISEASE; NEURO-BLASTOMA CELLS; CULTURED-CELLS; CONFORMATIONAL TRANSITIONS; NEUROBLASTOMA-CELLS; AGENT REPLICATION; PRP ACCUMULATION; SCRAPIE PRIONS; INCUBATION PERIOD; PROTEIN	PrPSc, an abnormal conformational isoform of the normal prion protein, PrPC, is the only known component of the prion, a proteinacious agent that causes fatal neurodegenerative disorders in humans and other animals. The hallmark properties of PrPSc are its insolubility in nondenaturing detergents and its resistance to digestion by proteases. Anions such as Congo red (CR) have been shown to reduce the accumulation of PrPSc in a neuroblastoma cell line permanently infected with prions as well as to delay disease onset in rodents when administrated prophylactically. The mechanism by which such anti prion agents operate is unknown. We show here that in vitro incubation with CR renders native PrPSc resistant to denaturation by boiling SDS, This resulted from PrPSc conformation, since neither the properties of PrPC nor those of predenatured PrPSc were changed by the addition of CR. CR-PrPSc could only be denatured by the addition of acidic 3 M guanidine thiocyanate. Since in vitro conversion experiments have suggested that partial denaturation may be required for PrPSc to serve as template in the PrPC --> PrPSc conversion, we propose that CR inhibits prion propagation by overstabilizing the conformation of PrPSc molecules.	Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, Dept Expt Med & Canc Res, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Gabizon, R (corresponding author), Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel.	gabizonr@hadassah.org.il		Yanai, Anat/0000-0002-0792-6901				BALDWIN MA, 1995, J BIOL CHEM, V270, P19197, DOI 10.1074/jbc.270.33.19197; BARRY RA, 1986, J INFECT DIS, V154, P518, DOI 10.1093/infdis/154.3.518; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1994, ANN NY ACAD SCI, V724, P290, DOI 10.1111/j.1749-6632.1994.tb38918.x; CAUGHEY B, 1994, PHILOS T R SOC B, V343, P399, DOI 10.1098/rstb.1994.0035; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CAUGHEY B, 1993, J VIROL, V67, P6270, DOI 10.1128/JVI.67.10.6270-6272.1993; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Edenhofer F, 1996, J VIROL, V70, P4724, DOI 10.1128/JVI.70.7.4724-4728.1996; EHLERS B, 1984, J GEN VIROL, V65, P1325, DOI 10.1099/0022-1317-65-8-1325; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GABIZON R, 1988, J BIOL CHEM, V263, P4950; GABIZON R, 1987, P NATL ACAD SCI USA, V84, P4017, DOI 10.1073/pnas.84.12.4017; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; Harrison PM, 1997, CURR OPIN STRUC BIOL, V7, P53, DOI 10.1016/S0959-440X(97)80007-3; INGROSSO L, 1995, J VIROL, V69, P506, DOI 10.1128/JVI.69.1.506-508.1995; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Lindquist S, 1995, COLD SPRING HARB SYM, V60, P451, DOI 10.1101/SQB.1995.060.01.050; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OESCH B, 1994, PHILOS T R SOC B, V343, P443, DOI 10.1098/rstb.1994.0042; Ovadia H, 1996, J BIOL CHEM, V271, P16856, DOI 10.1074/jbc.271.28.16856; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; POCCHIARI M, 1987, J GEN VIROL, V68, P219, DOI 10.1099/0022-1317-68-1-219; PRIOLA SA, 1994, INFECT AGENT DIS, V3, P54; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1996, CURR TOP MICROBIOL, V207, P1; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P2793, DOI 10.1073/pnas.90.7.2793; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; Safar J, 1996, CURR TOP MICROBIOL, V207, P69; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; SNOW AD, 1990, LAB INVEST, V63, P601; Tagliavini F, 1997, SCIENCE, V276, P1119, DOI 10.1126/science.276.5315.1119; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TASHIMA T, 1986, BRAIN RES, V399, P80, DOI 10.1016/0006-8993(86)90602-5; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Wille H, 1996, J MOL BIOL, V259, P608, DOI 10.1006/jmbi.1996.0343	52	112	119	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3484	3489		10.1074/jbc.273.6.3484	http://dx.doi.org/10.1074/jbc.273.6.3484			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452472	hybrid			2022-12-25	WOS:000071822300057
J	Redwood, C; Davies, SL; Wells, NJ; Fry, AM; Hickson, ID				Redwood, C; Davies, SL; Wells, NJ; Fry, AM; Hickson, ID			Casein kinase II stabilizes the activity of human topoisomerase II alpha in a phosphorylation-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; CYCLE-DEPENDENT PHOSPHORYLATION; DNA TOPOISOMERASE; CELL-CYCLE; IN-VITRO; SACCHAROMYCES-CEREVISIAE; MOLECULAR-COMPLEX; GROWTH-STATE; YEAST TOP2; M-PHASE	Previous reports have indicated that topoisomerase II (topo II) co-purifies with and is a substrate for casein kinase II. We have carried out a detailed study of the effect that purified casein kinase II has on the activity of purified recombinant human topo II alpha. Co-incubation of topo II alpha and casein kinase II led to an apparent activation of the topo II alpha; however, in experiments in which topo II alpha was preincubated at 37 degrees C with or without native casein kinase II prior to assaying for decatenation activity, it emerged that the kinase was exerting its "activating" function via a decrease in the rate of topo II alpha enzyme inactivation during the incubation period. This stabilization of topo II alpha by casein kinase II was ATP-independent and was observed in both mutated and truncated derivatives of topo II alpha lacking the major casein kinase II phospho-acceptor sites, indicating the lack of a requirement for phosphorylation. Consistent with a nonenzymatic role for casein kinase II, stoichiometric quantities of kinase were required for topo II alpha stabilization. These data indicate that casein kinase II plays a significant role in regulating human topo II alpha protein action via stabilization against thermal inactivation.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford	Hickson, ID (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England.	hickson@icrf.icnet.uk	Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X				ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI N, 1992, NUCLEIC ACIDS RES, V20, P5297, DOI 10.1093/nar/20.20.5297; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; AUSTIN CA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P283, DOI 10.1016/0167-4781(93)90215-Y; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21328; DANDREA MR, 1994, APPL IMMUNOHISTOCHEM, V2, P177; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; FILHOL O, 1992, J BIOL CHEM, V267, P20577; GOSWAMI P, 1996, MOL CELL BIOL, V116, P1500; GOTO T, 1984, EMBO J, V3, P1737; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; Ishida R, 1996, J BIOL CHEM, V271, P30077, DOI 10.1074/jbc.271.47.30077; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; Jensen S, 1996, MOL GEN GENET, V252, P79, DOI 10.1007/BF02173207; KIMURA K, 1994, J BIOL CHEM, V269, P1173; Kimura K, 1996, J BIOL CHEM, V271, P10990, DOI 10.1074/jbc.271.18.10990; KORDIYAK GJ, 1994, BIOCHEMISTRY-US, V33, P13484, DOI 10.1021/bi00249a037; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; PARK SH, 1993, BIOCHEM BIOPH RES CO, V193, P787, DOI 10.1006/bbrc.1993.1694; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SANDER M, 1984, P NATL ACAD SCI-BIOL, V81, P6938, DOI 10.1073/pnas.81.22.6938; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; Turley H, 1997, BRIT J CANCER, V75, P1340, DOI 10.1038/bjc.1997.227; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VASSETZKY YS, 1994, MOL CELL BIOL, V14, P6962, DOI 10.1128/MCB.14.10.6962; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WELLS NJ, 1995, J BIOL CHEM, V270, P28357; WELLS NJ, 1995, EUR J BIOCHEM, V231, P491, DOI 10.1111/j.1432-1033.1995.tb20723.x; WELLS NJ, 1994, J BIOL CHEM, V269, P29746; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209	50	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3635	3642		10.1074/jbc.273.6.3635	http://dx.doi.org/10.1074/jbc.273.6.3635			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452492	hybrid			2022-12-25	WOS:000071822300077
J	Reverter, D; Ventura, S; Villegas, V; Vendrell, J; Aviles, FX				Reverter, D; Ventura, S; Villegas, V; Vendrell, J; Aviles, FX			Overexpression of human procarboxypeptidase A2 in Pichia pastoris and detailed characterization of its activation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-A; 3-DIMENSIONAL STRUCTURE; EXPRESSION; SECRETION; PROTEINS; CLONING; PANCREAS; ENZYME; GENES	The cDNA of human procarboxypeptidase A2 has been overexpressed in the methylotrophic yeast Pichia pastoris and secreted into the culture medium by means of the alpha-mating factor signal sequence, yielding a major protein of identical size and N-terminal sequence as the wild-type form, Two other forms containing the proenzyme have also been overexpressed: one of them resulted from an incomplete processing of the signal peptide, whereas the other was a glycosylated derivative. Recombinant procarboxypeptidase A2 was purified to homogeneity, and it was shown that its mature active form displays functional properties similar to those of the enzyme directly isolated from human pancreas, The overall yield was similar to 250 mg of proenzyme or 180 mg of mature enzyme/liter of cell culture. The proteolysis-promoted activation process of the recombinant proenzyme has been studied in detail. During maturation by trypsin, the increase in activity of the enzyme is a rapid and monotonic event, which reflects the rate of the proteolytic release of the inhibitory pro-segment and the weaker nature of its interactions with the enzyme moiety compared with procarboxypeptidases of the A1 type, Three main forms of the pro-segment (96, 94, and 92 amino acids), with no inhibitory capability in the severed state, and a single mature carboxypeptidase A2 are produced during this process. No further proteolysis of these pro-segments by the generated carboxypeptidase A2 occurs, in contrast with observations made in other procarboxypeptidases (A1 and B), This differential behavior is a result of the extreme specificity of carboxypeptidase A2.	Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Unitat Ciencies, Bellaterra 08193, Spain; Univ Autonoma Barcelona, Inst Biol Fonamental, Bellaterra 08193, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona	Aviles, FX (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Unitat Ciencies, Bellaterra 08193, Spain.	FX.Aviles@blues.uab.es	Ventura, Salvador/C-7021-2008; Vendrell, Josep/A-6731-2010; Aviles, Francesc Xavier/F-3482-2019; Villegas, Sandra/ABF-8206-2021; Villegas, Sandra/D-8789-2011; Reverter, David/H-5360-2015; Ventura, Salvador/AAY-3170-2021; Avilés, Francesc Xavier/A-2664-2015	Ventura, Salvador/0000-0002-9652-6351; Vendrell, Josep/0000-0002-9378-4742; Aviles, Francesc Xavier/0000-0002-1399-6789; Villegas, Sandra/0000-0001-8644-4304; Villegas, Sandra/0000-0001-8644-4304; Reverter, David/0000-0002-5347-0992; Ventura, Salvador/0000-0002-9652-6351; Avilés, Francesc Xavier/0000-0002-1399-6789				AULD DS, 1987, NEW COMPR BIOCH, V16, P201; AVILES FX, 1993, EUR J BIOCHEM, V211, P391; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; BURGOS FJ, 1991, BIOCHEMISTRY-US, V30, P4092; CATASUS L, 1995, J BIOL CHEM, V270, P6651, DOI 10.1074/jbc.270.12.6651; COLL M, 1991, EMBO J, V9, P1; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; FAMMING Z, 1991, J BIOL CHEM, V266, P24606; GARDELL SJ, 1988, J BIOL CHEM, V263, P17828; GOMISRUTH FX, 1995, EMBO J, V14, P4387, DOI 10.1002/j.1460-2075.1995.tb00117.x; GUASCH A, 1992, J MOL BIOL, V224, P141, DOI 10.1016/0022-2836(92)90581-4; HUENNEKENS FM, 1994, TRENDS BIOTECHNOL, V12, P234, DOI 10.1016/0167-7799(94)90122-8; KJELDSEN T, 1996, GENE, V170, P97; Laethem RM, 1996, ARCH BIOCHEM BIOPHYS, V332, P8, DOI 10.1006/abbi.1996.0310; NEURATH H, 1986, J CELL BIOCHEM, V32, P35, DOI 10.1002/jcb.240320105; NORMANT E, 1995, J BIOL CHEM, V270, P20543, DOI 10.1074/jbc.270.35.20543; Ohi H, 1996, YEAST, V12, P31, DOI 10.1002/(SICI)1097-0061(199601)12:1<31::AID-YEA877>3.0.CO;2-S; OPPEZZO O, 1994, EUR J BIOCHEM, V222, P55, DOI 10.1111/j.1432-1033.1994.tb18841.x; PASCUAL R, 1989, EUR J BIOCHEM, V179, P609, DOI 10.1111/j.1432-1033.1989.tb14590.x; Phillips MA, 1996, BIOCHEMISTRY-US, V35, P6771, DOI 10.1021/bi960113o; PUIGSERVER A, 1986, MOL CELLULAR BASIS D, P235; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; Rowsell S, 1997, STRUCTURE, V5, P337, DOI 10.1016/S0969-2126(97)00191-3; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Skidgel R. A., 1996, ZINC METALLOPROTEASE, P241; Song LX, 1997, J BIOL CHEM, V272, P10543; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; VEDVICK T, 1991, J IND MICROBIOL, V7, P197, DOI 10.1007/BF01575883; VENDRELL J, 1986, J CHROMATOGR, V358, P401, DOI 10.1016/S0021-9673(01)90354-1; VENDRELL J, 1990, J BIOL CHEM, V265, P6949; VENDRELL J, 1993, INNOVATIONS PROTEASE, P279; VILLEGAS V, 1995, BIOCHEMISTRY-US, V34, P15105, DOI 10.1021/bi00046a017; VILLEGAS V, 1995, PROTEIN SCI, V4, P1792, DOI 10.1002/pro.5560040914; VILLEGAS V, 1995, THESIS U AUTONOMA BA; VITOLS KS, 1995, CANCER RES, V55, P478; Vozza LA, 1996, BIO-TECHNOL, V14, P77, DOI 10.1038/nbt0196-77; WAGNER SL, 1992, BIOCHEM BIOPH RES CO, V196, P1139; Zhu A, 1995, ARCH BIOCHEM BIOPHYS, V324, P65, DOI 10.1006/abbi.1995.9928	39	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3535	3541		10.1074/jbc.273.6.3535	http://dx.doi.org/10.1074/jbc.273.6.3535			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452479	hybrid			2022-12-25	WOS:000071822300064
J	Fahraeus, R; Lain, S; Ball, KL; Lane, DP				Fahraeus, R; Lain, S; Ball, KL; Lane, DP			Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule	ONCOGENE			English	Article						p16(INK4a); cyclin dependent kinases 4 and 6; cell cycle; peptide delivery; tumour suppressor	PROVIRUS INSERTIONAL MUTAGENESIS; RETINOBLASTOMA GENE-PRODUCT; REPLICATIVE SENESCENCE; TRANSCRIPTION FACTOR; PRB PHOSPHORYLATION; CDK INHIBITORS; HUMAN HEAD; WILD-TYPE; CELL; PROTEIN	We have previously shown that a 20 amino acid peptide derived from the third ankyrin-like repeat of the p16(CDKN2/INK4a) (p16) tumour suppressor protein (residues 84-103 of the human p16 protein) can bind to cdk4 and cdk6 and inhibit cdk4-cyclin D1 kinase activity in vitro as well as block cell cycle progression through G1. Substitution of two valine residues corresponding to amino acids 95 and 96 (V95A and V96A) of the p16 peptide reduces the binding to cdk4 and cdk6 and increases its IC0.5 for kinase inhibition approximately threefold when linked to the Antennapedia homeodomain carrier sequence. The same mutations increase the IC0.5 approximately fivefold in the p16 protein. Substitution of aspartic acid 92 by alanine instead increases the binding of the peptide to cdk4 and cdk6 and the kinase inhibitory activity. The p16 peptide blocks S-phase entry in nonsynchronized human HaCaT cells by approximately 90% at a 24 mu M concentration. The V95A and V96A double substitution minimizes the cell cycle inhibitory capacity of the peptide whereas the D92A substitution increases its capacity to block cell cycle progression. A deletion series of the p16 derived peptide shows that a 10 residue peptide still retains cdk4-cyclin D1 kinase and cell cycle inhibitory activity. The p16 peptide inhibited S-phase entry in five cell lines tested, varying between 47-75%, but had only a limited (11%) inhibitory effect in the pRb negative Saos-2 cells at a concentration of 24 mu M. Like the full length p16 protein, the p16 peptide does not inhibit cyclin E dependent cdk2 kinase activity in vitro. These data suggest that acute inhibition of CDK-cyclin D activity by a peptide derived from the INK4 family mill stop cells in late G1 in a pRb dependent fashion.	Univ Dundee, Dept Biochem, CRC, Cell Transformat Grp, Dundee DD1 4HN, Scotland	University of Dundee	Fahraeus, R (corresponding author), Univ Dundee, Dept Biochem, CRC, Cell Transformat Grp, Dundee DD1 4HN, Scotland.		Lane, David P/C-4920-2008; fahraeus, robin/K-8726-2014; Lain, Sonia/B-6980-2014	Lain, Sonia/0000-0001-9693-5246; Lane, David/0000-0003-0551-3545; , robin/0000-0003-0402-8492				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BALL K, 1997, CURR BIOL, V7, P81; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN F, 1995, MOL CELL BIOL, V15, P2681; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; EINHORN S, 1994, BLOOD, V84, P297; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNA Z, 1993, ONCOGENE, V8, P1661; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HERBERT J, 1994, BLOOD, V84, P4038; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Ichimura K, 1996, ONCOGENE, V13, P1065; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KATHIB ZA, 1993, CANCER RES, V53, P5535; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAMMIE GA, 1991, ONCOGENE, V6, P439; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Loughran O, 1996, ONCOGENE, V13, P561; LOUGHRAN O, 1994, CANCER RES, V54, P5045; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OTTERSON GA, 1995, ONCOGENE, V11, P1211; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Parry D, 1996, MOL CELL BIOL, V16, P3844; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; QUELLE DE, 1995, ONCOGENE, V11, P635; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Reifenberger G, 1996, CANCER RES, V56, P5141; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1973, CELL, V73, P1056; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; TREMBLAY PJ, 1992, J VIROL, V66, P1344, DOI 10.1128/JVI.66.3.1344-1353.1992; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577	61	76	79	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					587	596		10.1038/sj.onc.1201580	http://dx.doi.org/10.1038/sj.onc.1201580			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482104				2022-12-25	WOS:000071816600003
J	Tamarit, J; Cabiscol, E; Ros, J				Tamarit, J; Cabiscol, E; Ros, J			Identification of the major oxidatively damaged proteins in Escherichia coli cells exposed to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-CATALYZED OXIDATION; ELONGATION-FACTOR-G; HYDROGEN-PEROXIDE; RNASE-E; IRON; ENZYME; IONS; DEHYDROGENASES; ACCUMULATION; INACTIVATION	In the present study we have analyzed protein oxidation on Escherichia coli when these cells were submitted to different stress conditions such as hydrogen peroxide, superoxide-generating compounds, and iron overloading, Carbonyl groups on oxidized cell proteins were examined by Western blot immunoassay. When anaerobically grown E, coli cells were exposed to hydrogen peroxide stress, alcohol dehydrogenase E, elongation factor G, the heat shock protein DNA K, oligopeptide-binding protein A, enolase, and the outer membrane protein A were identified as the major protein targets, A similar immunostained band pattern was found when cells were shifted from anaerobic to aerobic conditions in the presence of different concentrations of iron; it is relevant to note that oxidation of outer membrane protein C, not observed in peroxide stress conditions, was clearly detected as the concentration of iron was increased in the culture media, The hydrogen peroxide stress performed under aerobic conditions affected the beta-subunit of F0F1-ATPase; the rest of the oxidized protein pattern was very similar to that found for anaerobic conditions, with the exception of alcohol dehydrogenase E, a protein not synthesized aerobically, Cells submitted to superoxide stress using menadione showed a more specific pattern in which elongation factor G and the beta-subunit of F0F1-ATPase were affected significantly, When paraquat was used, although the degree of oxidative damage was lower, the same two modified proteins were detected, and DNA K was also clearly damaged, Cell. viability was affected to different extents depending on the type of stress exerted, The results described in this paper provide data about the in vivo effects of oxidative stress on protein oxidation and give insights into understanding how such modifications can affect cellular functions.	Univ Lleida, Dept Ciencies Med Basiques, Fac Med, Lleida 25198, Spain	Universitat de Lleida	Ros, J (corresponding author), Univ Lleida, Dept Ciencies Med Basiques, Fac Med, Avda Rovira Roure 44, Lleida 25198, Spain.	joaquim.ros@cmb.udl.es	ROS, Joaquim/ABG-7487-2020; Ros, Joaquim/A-7507-2010; Tamarit, Jordi/C-6316-2008; Cabiscol, Elisa/A-4584-2009	ROS, Joaquim/0000-0003-0901-8648; Tamarit, Jordi/0000-0003-3227-6928; Cabiscol, Elisa/0000-0003-2795-7999				AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Ayala A, 1996, J BIOL CHEM, V271, P23105, DOI 10.1074/jbc.271.38.23105; Belogrudov GI, 1996, ARCH BIOCHEM BIOPHYS, V335, P131, DOI 10.1006/abbi.1996.0490; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; CABISCOL E, 1994, J BIOL CHEM, V269, P6592; CARNEY JM, 1991, J MOL NEUROSCI, V3, P47, DOI 10.1007/BF02896848; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CRAWFORD DR, 1994, ENVIRON HEALTH PERSP, V102, P25, DOI 10.2307/3432208; Crawford DR, 1997, FREE RADICAL BIO MED, V22, P551, DOI 10.1016/S0891-5849(96)00380-2; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Dean RT, 1997, BIOCHEM J, V324, P1; DEAN RT, 1993, TRENDS BIOCHEM SCI, V18, P437, DOI 10.1016/0968-0004(93)90145-D; Demple B., 1996, REGULATION GENE EXPR, P433; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; GonzalezFlecha B, 1997, J BACTERIOL, V179, P382, DOI 10.1128/jb.179.2.382-388.1997; GONZALEZFLECHA B, 1995, J BIOL CHEM, V270, P13681, DOI 10.1074/jbc.270.23.13681; GREENBERG JT, 1989, J BACTERIOL, V171, P3933, DOI 10.1128/jb.171.7.3933-3939.1989; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HASSAN HM, 1979, ARCH BIOCHEM BIOPHYS, V196, P385, DOI 10.1016/0003-9861(79)90289-3; HOLMSEN H, 1977, J BIOL CHEM, V252, P1752; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; IIDA H, 1985, NATURE, V315, P688, DOI 10.1038/315688a0; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LIPPE G, 1991, BIOCHEM BIOPH RES CO, V181, P764, DOI 10.1016/0006-291X(91)91256-C; MAITRA PK, 1971, J BIOL CHEM, V246, P475; MCPHEDRAN P, 1961, J BACTERIOL, V81, P852, DOI 10.1128/JB.81.6.852-857.1961; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; MISRA TK, 1979, J BIOL CHEM, V254, P1154; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; OLIVER CN, 1987, J AM GERIATR SOC, V35, P947, DOI 10.1111/j.1532-5415.1987.tb02297.x; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; SCHNAITMAN CA, 1981, MANUAL METHODS GENER, P52; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SHACTER E, 1994, FREE RADICAL BIO MED, V17, P429, DOI 10.1016/0891-5849(94)90169-4; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STADTMAN ER, 1991, J BIOL CHEM, V266, P17201; STARKE PE, 1985, J BIOL CHEM, V260, P99; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; VERHOEVEN AJM, 1985, J BIOL CHEM, V260, P2621; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	56	216	223	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3027	3032		10.1074/jbc.273.5.3027	http://dx.doi.org/10.1074/jbc.273.5.3027			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446617	hybrid, Green Published			2022-12-25	WOS:000071736600072
J	Young, KC; Shi, GY; Wu, DH; Chang, LC; Chang, BI; Ou, CP; Wu, HL				Young, KC; Shi, GY; Wu, DH; Chang, LC; Chang, BI; Ou, CP; Wu, HL			Plasminogen activation by streptokinase via a unique mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX; BINDING; MICROPLASMINOGEN; FRAGMENTS; CLEAVAGE; AFFINITY; ANTIBODY; PROTEINS; ACID	The mechanism of human plasminogen (HPlg) activation by streptokinase (SK)-type activator was investigated with recombinant truncated SR peptides. An enzyme substrate intermediate of HPlg SK HPlg ternary complex was demonstrated by a sandwich-binding experiment. Formation of the ternary complex was saturable, HPlg-specific, and inhibited by 6-aminocaproic acid. Three interaction sites between SK and HPlg were demonstrated. SK-(220-414) bound to HPlg with two binding sites: one to the micro-HPlg region, the catalytic domain of HPlg, and one to the kringle 1-5 region, with K-d values of 1.50 x 10(-7) and 2.44 x 10(-6) M, respectively. SK-(16-251) bound to a single site on the kringle 1-5 region of HPlg with a K-d of 4.09 x 10(-7) M. SK-(220-414) and SK-(16-251) competed for binding on the same or nearby location on the human kringle 1-5 domain. Combination of SK-(220-414) and SK-(16-251), but not either peptide alone, could effectively activate HPlg. In addition, SK-(16-251) dose-dependently enhanced the activation of HPlg by SK-(16-414), while the HPlg activation by SK-(16-414) was inhibited by SK-(220-414). We conclude that the HPlg that binds to the COOH-terminal domains of SK functions as an enzyme to catalyze the conversion of substrate HPlg that binds to the NH2-terminal domain of SK to human plasmin.	Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Med Technol, Tainan 70101, Taiwan	National Cheng Kung University; National Cheng Kung University	Wu, HL (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 70101, Taiwan.		Young, Kung-Chia/G-1529-2011					ALKJAERSIG N, 1959, J BIOL CHEM, V234, P832; BAJAJ SP, 1977, J BIOL CHEM, V252, P492; BROCKWAY WJ, 1972, ARCH BIOCHEM BIOPHYS, V151, P194, DOI 10.1016/0003-9861(72)90488-2; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DAMASCHUN G, 1992, EUR BIOPHYS J BIOPHY, V20, P355; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; DAVIES MC, 1964, J BIOL CHEM, V239, P2651; DAWSON KM, 1994, BIOCHEMISTRY-US, V33, P12042, DOI 10.1021/bi00206a005; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; GONZALEZGRONOW M, 1978, J BIOL CHEM, V253, P1090; JACKSON KW, 1982, BIOCHEMISTRY-US, V21, P6620, DOI 10.1021/bi00269a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING CM, 1965, J BIOL CHEM, V240, P4213; LING CM, 1967, J BIOL CHEM, V242, P1419; MARKUS G, 1976, J BIOL CHEM, V251, P6495; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; NAGENDRA K, 1974, J BIOL CHEM, V249, P4851; Nihalani D, 1995, BIOCHEM BIOPH RES CO, V217, P1245, DOI 10.1006/bbrc.1995.2902; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REDDY KNN, 1988, ENZYME, V40, P79, DOI 10.1159/000469149; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; REED GL, 1993, J IMMUNOL, V150, P4407; SCHICK LA, 1973, BIOCHEMISTRY-US, V12, P4315, DOI 10.1021/bi00746a003; SCHICK LA, 1974, BIOCHEM BIOPH RES CO, V57, P47, DOI 10.1016/S0006-291X(74)80355-4; SHI GY, 1994, BIOCHEM J, V304, P235, DOI 10.1042/bj3040235; SHI GY, 1988, J BIOL CHEM, V263, P17071; SHI GY, 1993, BIOCHEM BIOPH RES CO, V195, P192, DOI 10.1006/bbrc.1993.2029; SHI GY, 1990, THROMB RES, V58, P317, DOI 10.1016/0049-3848(90)90101-H; SUMMARIA L, 1987, THROMB HAEMOSTASIS, V58, P772; SUMMARIA L, 1982, BIOCHEMISTRY-US, V21, P2056, DOI 10.1021/bi00538a012; SUMMARIA L, 1974, J BIOL CHEM, V249, P4760; TEUTEN AJ, 1993, BIOCHEM J, V290, P313, DOI 10.1042/bj2900313; Tillett WS, 1933, J EXP MED, V58, P485, DOI 10.1084/jem.58.4.485; TOMAR RH, 1971, BIOCHEM J, V125, P793, DOI 10.1042/bj1250793; WANG JY, 1995, PROTEIN SCI, V4, P1758, DOI 10.1002/pro.5560040911; WANG JY, 1995, PROTEIN SCI, V4, P1768, DOI 10.1002/pro.5560040912; WOHL RC, 1980, J BIOL CHEM, V255, P2005; WU HL, 1992, BIOCHEM BIOPH RES CO, V188, P703, DOI 10.1016/0006-291X(92)91113-5; WU HL, 1990, J BIOL CHEM, V265, P19658; WULF RJ, 1969, CAN J BIOCHEM CELL B, V47, P927, DOI 10.1139/o69-145; YOUNG KC, 1995, J BIOL CHEM, V270, P29601, DOI 10.1074/jbc.270.49.29601	41	56	58	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3110	3116		10.1074/jbc.273.5.3110	http://dx.doi.org/10.1074/jbc.273.5.3110			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446629	hybrid			2022-12-25	WOS:000071736600084
J	Martinez, JD; Craven, MT; Pennington, ME				Martinez, JD; Craven, MT; Pennington, ME			Selective binding of different p53 response elements by p53 containing complexes	ONCOGENE			English	Article						p53; DNA binding; EMSA	TRANSFORMATION; MUTATIONS; SUPPRESSION; MUTANT; GENE	The p53 tumor suppressor protein binds two copies of a ten base pair motif that is degenerate in eight out of ten bases and conforms to the sequence, 5'PuPuPuC(A/T)(T/A)GPyPyPy-3'. As a consequence of this high degree of degeneracy, p53 response elements show a great deal of variation and it has been speculated that the variation aids in the selective activation of p53 responsive genes by specific stimuli. Here, we examined the DNA binding characteristics of several different p53 protein complexes present in nuclear extracts prepared from a cell line expressing the murine temperature sensitive p53 protein, p53(val135). Interestingly, the complexes exhibited a distinct preference for binding to some p53 response elements and not others, A critical determinant of this specificity was the sequence at the center of the ten base pair motif and alteration of a single base within this region mas sufficient to alter the set of complexes that associated with the oligonucleotide, In addition, thermal denaturation experiments demonstrated that some complexes could bind DIVA even though the p53(val135) protein had a mutant conformation, Our results are consistent with the hypothesis that p53 can distinguish between various response elements and suggest that this selectivity is manifested, in part, by the sequence of the motif and conformation of the p53 protein.	Univ Arizona, Dept Radiat Oncol, Tucson, AZ 85724 USA	University of Arizona	Martinez, JD (corresponding author), Univ Arizona, Dept Radiat Oncol, Tucson, AZ 85724 USA.				NCI NIH HHS [CA64842, CA-23074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064842, P30CA023074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Park DJ, 1996, MOL CARCINOGEN, V16, P101, DOI 10.1002/(SICI)1098-2744(199606)16:2<101::AID-MC6>3.0.CO;2-L; Smith ML, 1996, AM J PATHOL, V148, P1019; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	19	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					453	458		10.1038/sj.onc.1201565	http://dx.doi.org/10.1038/sj.onc.1201565			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484834				2022-12-25	WOS:000071739400003
J	Fang, BL; Ji, L; Bouvet, M; Roth, JA				Fang, BL; Ji, L; Bouvet, M; Roth, JA			Evaluation of GAL4/TATA in vivo - Induction of transgene expression by adenovirally mediated gene codelivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT ADENOVIRUS; MAMMALIAN-CELLS; GAL4-VP16; SYSTEM; GAL4; TRANSCRIPTION; THERAPY; YEAST; MICE; P53	A synthetic GAL4-responsive promoter consisting of five GAL4-binding sites and a TATA box (GAL4/TATA) was evaluated for its transcriptional activity in an adenoviral backbone using luciferase as the reporter, Basal luciferase activities in vitro were the same for cells infected with either adenovirus-containing luciferase cDNA driven by GAL4/TATA (Ad/GT-Luc) or adenovirus-containing luciferase cDNA not driven by a promoter (Ad/PO-Luc), In vitro induction of GAL4/TATA by coinfection of cells with adenovirus expressing the GAL4/VP16 fusion protein (Ad/3-phosphoglycerate kinase (PGK)-GV16) was dose-dependent and reached as high as 4 x 10(4)- to 9 x 10(4)-fold above basal levels when GAL4/TATA and GAL4/VP16 were delivered at a ratio of 10:1, In vivo studies in Balb/c mice showed no detectable luciferase activities in liver or other tissues examined in mice infused with either Ad/GT-Luc or Ad/PO-Luc, High levels of luciferase activity were, however, elicited when animals were infused with Ad/GT-Luc and Ad/PGK-GV16, Together, these results suggest that combination of the GAL4 gene regulatory system with adenovirally mediated in vivo gene delivery may be applicable to the in vivo evaluation of promoter activities and in vivo targeting of gene expression.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Introgen Therapeut Inc, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fang, BL (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Box 109,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAND AH, 1993, DEVELOPMENT, V118, P401; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; CHANG CB, 1993, MOL CELL BIOL, V13, P7469, DOI 10.1128/MCB.13.12.7469; Fang B, 1996, GENE THER, V3, P217; FANG B, 1994, GENE THER, V1, P247; Fang BL, 1997, J VIROL, V71, P4798, DOI 10.1128/JVI.71.6.4798-4803.1997; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HUYGHE BG, 1995, HUM GENE THER, V6, P1403, DOI 10.1089/hum.1995.6.11-1403; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; Oligino T, 1996, GENE THER, V3, P892; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sadowski I, 1995, Genet Eng (N Y), V17, P119; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; ZHANG WW, 1994, CANCER GENE THER, V1, P5	17	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4972	4975		10.1074/jbc.273.9.4972	http://dx.doi.org/10.1074/jbc.273.9.4972			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478943	hybrid			2022-12-25	WOS:000072310400027
J	Garner, J; Durrer, P; Kitchen, J; Brunner, J; Crooke, E				Garner, J; Durrer, P; Kitchen, J; Brunner, J; Crooke, E			Membrane-mediated release of nucleotide from all initiator of chromosomal replication, Escherichia coli DnaA, occurs with insertion of a distinct region of the protein into the lipid bilayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; ANIONIC PHOSPHOLIPIDS; ACIDIC PHOSPHOLIPIDS; ORIGIN; BINDING; DOMAIN; DIACYLGLYCEROL; QUANTITIES; ATP	DnaA protein, the initiator protein of E. coli chromosomal replication, can be rejuvenated from an inactive ADP form to active ATP-DnaA protein by acidic phospholipids in a fluid bilayer. Cross-linking studies with the photoactivable phospholipid analog 1-O-hexadecanoyl-2-O-[9-[[[2-[I-125]iodo-4-(trifluoromethyl-3H-diazirin-3-yl)benzyl]oxy]carbonyl]nonanoyl]-sn-glycero-3-phosphocholine reveal insertion of DnaA protein into the hydrophobic region of the bilayer; this insertion is accompanied by membrane-mediated dissociation of the tightly bound allosteric nucleotides ADP and ATP. Photolabeling of DnaA protein occurred with membrane properties that resembled those needed for reactivation of ADP-DnaA protein; efficient labeling of DnaA protein was observed only when the lipid analog was incorporated into anionic vesicles and the temperature during treatment was above the gel to Liquid crystalline phase transition. Predominant hydrophobic photolabeling was localized within a single region of DnaA protein, a region that contains putative amphipathic helices and has been shown to contain information essential for functional interaction with membranes.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; ETH Zurich, Dept Biochem, CH-8092 Zurich, Switzerland	Georgetown University; Swiss Federal Institutes of Technology Domain; ETH Zurich	Crooke, E (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.				NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049700] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16042-20] Funding Source: Medline; NIGMS NIH HHS [R01-GM49700, R01 GM049700] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; CROOKE E, 1993, J MOL BIOL, V233, P16, DOI 10.1006/jmbi.1993.1481; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CROOKE E, 1992, J BIOL CHEM, V267, P16779; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; DURRER P, 1995, J BIOL CHEM, V270, P17575, DOI 10.1074/jbc.270.29.17575; Garner J, 1996, EMBO J, V15, P3477, DOI 10.1002/j.1460-2075.1996.tb00714.x; Gennis R. B., 1989, BIOMEMBRANES MOL STR, DOI [10.1007/978-1-4757-2065-5, DOI 10.1007/978-1-4757-2065-5]; HEACOCK PN, 1987, J BIOL CHEM, V262, P13044; HEACOCK PN, 1989, J BIOL CHEM, V264, P14972; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; KOGOMA T, 1983, EMBO J, V2, P463, DOI 10.1002/j.1460-2075.1983.tb01445.x; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MESSER W, 1996, INITIATION CHROMOSOM, P1579; Mizushima T, 1996, J BIOL CHEM, V271, P3633; ORR JW, 1992, J BIOL CHEM, V267, P15263; ROTH A, 1995, EMBO J, V14, P2106, DOI 10.1002/j.1460-2075.1995.tb07202.x; SAKAKIBARA Y, 1982, MOL GEN GENET, V186, P87, DOI 10.1007/BF00422917; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schaper S, 1997, PROTEINS, V28, P1; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SEKIMIZU K, 1988, J BIOL CHEM, V263, P1724; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; WEBER T, 1995, J AM CHEM SOC, V117, P3084, DOI 10.1021/ja00116a013; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783; YUNG BYM, 1990, J BIOL CHEM, V265, P1282; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202; YUNG BYM, 1989, J BIOL CHEM, V264, P6146	38	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5167	5173		10.1074/jbc.273.9.5167	http://dx.doi.org/10.1074/jbc.273.9.5167			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478970	hybrid			2022-12-25	WOS:000072310400054
J	Breen, JJ; Agulnick, AD; Westphal, S; Dawid, IB				Breen, JJ; Agulnick, AD; Westphal, S; Dawid, IB			Interactions between LIM domains and the LIM domain-binding protein Ldb1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX GENE; SYNERGISTIC ACTIVATION; ORGANIZER; XENOPUS; HOMEODOMAIN; DIFFERENTIATION; TRANSCRIPTION; REQUIREMENT; SPECIFICITY; ELEGANS	LIM domains mediate protein-protein interactions and, within LIM-homeodomain proteins, act as negative regulators of the transcriptional activation function of the protein, The recently described protein Ldb1 (also known as NLI; LIM domain-binding protein) binds LIM domains in vitro and synergizes with the LIM-homeodomain protein Xlim-1 in frog embryo microinjection experiments. Hn this study we localized the transcriptional activation domain of Xlim-1 to its carboxyl-terminal region, and characterized the interactions of the amino-terminally located LIM domains with Ldb1. Ldb1 binds LIM domains through its carboxyl-terminal region, and can form homodimers via its amino-terminal region. Optimal binding to Ldb1 required tandem LIM domains, while single domains could bind at lower but clearly reasonable efficiency. In animal explant experiments, synergism of Ldb1 with Xlim-1 in the activation of downstream genes required both the region containing the dimerization domain of Ldb1 and time region containing the LIM-binding domain. The role of Ldb1 may be to recruit other transcriptional activators depending on the promoter context and LIM-homeodomain partner involved.	NICHD, Genet Mol Lab, NIH, Bethesda, MD 20892 USA; NICHD, Lab Mammalian Genes & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dawid, IB (corresponding author), NICHD, Genet Mol Lab, NIH, Bldg 6B,Rm 413, Bethesda, MD 20892 USA.							Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; LICHTSTEINER S, 1995, EMBO J, V14, P3937, DOI 10.1002/j.1460-2075.1995.tb00065.x; MENZEL R, 1989, ANAL BIOCHEM, V181, P40, DOI 10.1016/0003-2697(89)90391-6; MOEHLE CM, 1991, MOL CELL BIOL, V11, P2723, DOI 10.1128/MCB.11.5.2723; PANNESE M, 1995, DEVELOPMENT, V121, P707; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; RICHTER K, 1990, New Biologist, V2, P556; SANCHEZGARCIA I, 1995, ONCOGENE, V10, P1301; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; TAIRA M, 1995, TRENDS GENET, V11, P431, DOI 10.1016/S0168-9525(00)89139-8; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934	33	82	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4712	4717		10.1074/jbc.273.8.4712	http://dx.doi.org/10.1074/jbc.273.8.4712			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468533	hybrid			2022-12-25	WOS:000072115000061
J	Isobe, K; Ito, S; Hosaka, H; Iwamura, Y; Kondo, H; Kagawa, Y; Hayashi, JI				Isobe, K; Ito, S; Hosaka, H; Iwamura, Y; Kondo, H; Kagawa, Y; Hayashi, JI			Nuclear-recessive mutations of factors involved in mitochondrial translation are responsible for age-related respiration deficiency of human skin fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA DELETIONS; HUMAN BRAIN; HUMAN-CELLS; GENOME; DYSFUNCTION; SENESCENCE; INTEGRITY; INCREASE; DISEASE	We addressed the question of whether both mitochondrial and cytoplasmic translation activities decreased simultaneously in human skin fibroblasts with the age of the donors and found that the age-related reduction was limited to mitochondrial translation. Then, to determine which genome, mitochondrial or nuclear, was responsible for this age-related, mitochondria-specific reduction, pure nuclear transfer was carried out from mitochondrial DNA (mtDNA)-less HeLa cells to four fibroblast lines, two from aged subjects, one from a fetus, and one from a patient with cardiomyopathy, and their nuclear hybrid clones were isolated. A normal fibroblast line from the fetus and a respiration-deficient fibroblast line from the patient were used as a positive and a negative control, respectively, Subsequently, the mitochondrial translation and respiration properties of the nuclear hybrid clones were compared, A negative control experiment showed that this procedure could be used to isolate even nuclear hybrids expressing overall mitochondrial respiration deficiency, whereas no respiration deficiencies were observed in any nuclear hybrids irrespective of whether their mtDNAs were exclusively derived from aged or fetal donors. These observations suggest that nuclear recessive mutations of factors involved in mitochondrial translation but not mtDNA mutations are responsible for age-related respiration deficiency of human fibroblasts.	Univ Tsukuba, Inst Biol Sci, Ibaraki, Osaka 305, Japan; Ibaraki Prefectural Univ Hlth Sci, Ctr Arts & Humanities, Ibaraki, Osaka 30003, Japan; Tokyo Metropolitan Inst Gerontol, Dept Biol, Tokyo 103, Japan; Jichi Med Sch, Dept Biochem, Minami Kawachi, Tochigi 32904, Japan	University of Tsukuba; Tokyo Metropolitan Institute of Gerontology; Jichi Medical University	Hayashi, JI (corresponding author), Univ Tsukuba, Inst Biol Sci, Ibaraki, Osaka 305, Japan.	jih45@sakura.cc.tsukuba.ac.jp						ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; GOLDSTEIN S, 1982, J CELL PHYSIOL, V112, P419, DOI 10.1002/jcp.1041120316; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAYASHI JI, 1986, CANCER RES, V46, P4001; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1994, J BIOL CHEM, V269, P19060; HAYASHI JI, 1994, J BIOL CHEM, V269, P6878; HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B; Inoue K, 1997, J BIOL CHEM, V272, P15510, DOI 10.1074/jbc.272.24.15510; Isobe K, 1997, J BIOL CHEM, V272, P12606, DOI 10.1074/jbc.272.19.12606; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; Kubota N, 1997, RADIAT RES, V148, P395, DOI 10.2307/3579525; Laderman KA, 1996, J BIOL CHEM, V271, P15891, DOI 10.1074/jbc.271.27.15891; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; MIQUEL J, 1991, ARCH GERONTOL GERIAT, V12, P99, DOI 10.1016/0167-4943(91)90022-I; MIYABAYASHI S, 1984, BRAIN DEV-JPN, V6, P362, DOI 10.1016/S0387-7604(84)80112-6; REIS RJS, 1983, J BIOL CHEM, V258, P9078; ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; SOONG NW, 1992, NAT GENET, V2, P318; Takai D, 1997, J BIOL CHEM, V272, P6028, DOI 10.1074/jbc.272.9.6028; TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769; TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; YEN TC, 1991, BIOCHEM BIOPH RES CO, V178, P124, DOI 10.1016/0006-291X(91)91788-E	33	52	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4601	4606		10.1074/jbc.273.8.4601	http://dx.doi.org/10.1074/jbc.273.8.4601			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468517	hybrid			2022-12-25	WOS:000072115000045
J	Laurberg, M; Mansilla, F; Clark, BFC; Knudsen, CR				Laurberg, M; Mansilla, F; Clark, BFC; Knudsen, CR			Investigation of functional aspects of the N-terminal region of elongation factor Tu from Escherichia coli using a protein engineering approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-EF-TU; AMINOACYL-TRANSFER-RNA; CRYSTAL-STRUCTURE; STEP PURIFICATION; TERNARY COMPLEX; GTPASE; EFFECTOR; BINDING; DNA	The function of the N-terminal region of elongation factor Tu is still unexplained, Until recently, it has not been visible in electron density maps from xray crystallography studies, but the presence of several well conserved basic residues suggest that this part of the molecule is of structural importance for the factor to function properly, In this study, two lysines at positions 4 and 9 were mutated separately to alanine or glutamate, The resulting four point mutants were expressed and purified using the pGEX system, The untagged products were characterized with regard to guanine-nucleotide interaction, intrinsic GTPase activity, and binding of aminoacyl-tRNA (aa-tRNA), The results show that Lys(9) is especially strongly involved in the association with guanine nucleotides and the binding of aa-tRNA. Also Lys(4) plays a role in the association of GDP and GTP and is also of some importance in aa-tRNA binding, Our results are discussed in structural terms with the conclusion that a complex network of interactions across the interface between domains 1 and 2 with Lys(9) being a key residue seems to be important for the fine tuning of the dimensions of the cleft accommodating the acceptor end of aa-tRNA as well as delineating the structure of the effector region.	Aarhus Univ, Biostruct Chem IMSB, DK-8000 Aarhus C, Denmark; Lund Univ, S-22100 Lund, Sweden	Aarhus University; Lund University	Knudsen, CR (corresponding author), Aarhus Univ, Biostruct Chem IMSB, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	crk@imsb.au.dk		Knudsen, Charlotte/0000-0003-2356-4821				Abel K, 1996, STRUCTURE, V4, P1153, DOI 10.1016/S0969-2126(96)00123-2; ANDERSEN C, 1994, EUR J BIOCHEM, V220, P739, DOI 10.1111/j.1432-1033.1994.tb18674.x; ANTONSSON B, 1984, EUR J BIOCHEM, V141, P483, DOI 10.1111/j.1432-1033.1984.tb08218.x; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; Knudsen CR, 1995, PROTEIN ENG, V8, P1267, DOI 10.1093/protein/8.12.1267; KNUDSEN CR, 1995, EUR J BIOCHEM, V228, P176; KNUDSEN CR, 1992, BIOCHEM INT, V28, P353; Mansilla F, 1997, PROTEIN ENG, V10, P927, DOI 10.1093/protein/10.8.927; Miller D L, 1974, Methods Enzymol, V30, P219; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Nissen P, 1996, BIOCHIMIE, V78, P921, DOI 10.1016/S0300-9084(97)86714-4; PARMEGGIANI A, 1981, MOL CELL BIOCHEM, V35, P129, DOI 10.1007/BF02357085; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPRINZL M, 1994, TRENDS BIOCHEM SCI, V19, P245, DOI 10.1016/0968-0004(94)90149-X; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; von der Haar F, 1979, Methods Enzymol, V59, P257	24	10	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4387	4391		10.1074/jbc.273.8.4387	http://dx.doi.org/10.1074/jbc.273.8.4387			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468489	hybrid			2022-12-25	WOS:000072115000017
J	Yamauchi, E; Kiyonami, R; Kanai, M; Taniguchi, H				Yamauchi, E; Kiyonami, R; Kanai, M; Taniguchi, H			The C-terminal conserved domain of MARCKS is phosphorylated in vivo by proline-directed protein kinase - Application of ion trap mass spectrometry to the determination of protein phosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE MARCKS; CELLULAR SUBSTRATE; FAMILY; CALMODULIN; PEPTIDES; BINDING; CLONING; GAP-43; 80-KDA; BRAIN	MARCKS, the major protein kinase C substrate in various cells and tissues, binds to calmodulin, acidic membrane phospholipids, and actin filaments, and these in teractions are regulated by protein phosphorylation. We have previously shown that MARCKS purified from bovine brain is phosphorylated not only by protein kinase C but also by so-called proline-directed protein kinases in the well conserved N-terminal half of the molecule (Taniguchi, H., Manenti, S., Suzuki, M., and Titani, K. (1994) J, Biol, Chem, 269, 18299-18302), Although the presence of other phosphorylation sites in the C-terminal peptide was also noticed, the ambiguity in the C-terminal domain of the bovine protein hampered a more detailed analysis, In the present study, we analyzed MARCKS purified from rat brain by electrospray ionization/ion trap mass spectrometry, The results obtained revealed two additional novel phosphorylation sites in the C-terminal region, Both phosphorylation sites (Ser(291) and Ser(299)) are immediately followed by proline, suggesting that these sites are also phosphorylated by the proline-directed protein kinase(s), Since Ser(299) is within the C-terminal domain, which is well conserved among various species, the function of the domain, whatever it is, seems to be controlled by phosphorylation.	Fujita Hlth Univ, Inst Comprehens Med Sci, Div Biomed Polymer Sci, Aichi 47011, Japan; Nagoya City Univ, Fac Pharmaceut Sci, Dept Biol Chem, Mizuho Ku, Nagoya, Aichi 467, Japan; ThermoQuest KK, Shibuya Ku, Tokyo 151, Japan	Fujita Health University; Nagoya City University	Taniguchi, H (corresponding author), Fujita Hlth Univ, Inst Comprehens Med Sci, Div Biomed Polymer Sci, Aichi 47011, Japan.		Kanai, Motomu/J-6807-2016; Taniguchi, Hisaaki/I-9171-2012	Kanai, Motomu/0000-0003-1977-7648; 				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HERGET T, 1992, EUR J BIOCHEM, V209, P7, DOI 10.1111/j.1432-1033.1992.tb17255.x; HILLENKAMP F, 1990, METHOD ENZYMOL, V193, P280, DOI 10.1016/0076-6879(90)93420-P; KIM JY, 1994, J BIOL CHEM, V269, P28214; LABATE ME, 1989, NEURON, V3, P299, DOI 10.1016/0896-6273(89)90254-7; MANENTI S, 1992, J BIOL CHEM, V267, P22310; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TANIGUCHI H, 1994, J BIOL CHEM, V269, P18299; TANIGUCHI H, 1994, J BIOL CHEM, V269, P22481; Yates JR, 1996, METHOD ENZYMOL, V271, P351	20	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4367	4371		10.1074/jbc.273.8.4367	http://dx.doi.org/10.1074/jbc.273.8.4367			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468486	hybrid			2022-12-25	WOS:000072115000014
J	Brown, MR; Graf, R; Swiderek, KM; Fendley, D; Stracker, TH; Champagne, DE; Lea, AO				Brown, MR; Graf, R; Swiderek, KM; Fendley, D; Stracker, TH; Champagne, DE; Lea, AO			Identification of a steroidogenic neurohormone in female mosquitoes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; AEDES-AEGYPTI; MICROSEQUENCE ANALYSIS; PEPTIDES; PROTEINS; VITELLOGENIN; HORMONE; SYSTEM	In the female mosquito, Aedes aegypti, neurohormones are released from the brain in response to a blood meal and stimulate the ovaries to secrete ecdysteroid hormones, which modulate yolk protein synthesis in the fat body. Neuropeptides with this bioactivity were isolated from head extracts, and partial sequences from these peptides when aligned gave a 31-residue sequence at the amino terminus. Oligonucleotide primers for this sequence were used to amplify with the polymerase chain reaction a genomic DNA product that hybridized to a clone from a head cDNA library. The cDNA encodes a 149-residue preprohormone that is processed into an 86-residue peptide, as indicated by the mass value obtained from the native peptide, with the expected amino-terminal sequence, After modification, the cDNA for the putative neurohormone was expressed in a bacterial system, and the purified peptide had high specific activity in bioassays, thus confirming that it is a steroidogenic gonadotropin, the first to be identified for invertebrates.	Univ Georgia, Dept Entomol, Athens, GA 30602 USA; Univ Zurich Hosp, Dept Chirurg, CH-8091 Zurich, Switzerland; City Hope Natl Med Ctr, Div Immunol, Duarte, CA 91010 USA	University System of Georgia; University of Georgia; University of Zurich; University Zurich Hospital; City of Hope	Brown, MR (corresponding author), Univ Georgia, Dept Entomol, Athens, GA 30602 USA.		Stracker, Travis H/I-2815-2015	Stracker, Travis H/0000-0002-8650-2081; Graf, Rolf/0000-0001-7449-7302	NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033108] Funding Source: NIH RePORTER; NCI NIH HHS [CA33572] Funding Source: Medline; NIAID NIH HHS [AI33108, AI17927, R01 AI033108] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWN MR, 1988, J COMP NEUROL, V270, P606, DOI 10.1002/cne.902700413; DAVIS MT, 1995, J AM SOC MASS SPECTR, V6, P571, DOI 10.1016/1044-0305(95)00192-G; DEITSCH KW, 1995, INSECT BIOCHEM MOLEC, V25, P449, DOI 10.1016/0965-1748(94)00082-A; FOURNIER B, 1994, BBA-MOL CELL RES, V1220, P181, DOI 10.1016/0167-4889(94)90133-3; Girardie J, 1996, J INSECT PHYSIOL, V42, P107, DOI 10.1016/0022-1910(95)00092-5; Girardie J, 1996, J INSECT PHYSIOL, V42, P215, DOI 10.1016/0022-1910(95)00097-6; GIRARDIE J, 1993, MOL COMP PHYSL, V12, P67; Graf R, 1997, INSECT MOL BIOL, V6, P151, DOI 10.1111/j.1365-2583.1997.tb00083.x; HAWKE DH, 1985, ANAL BIOCHEM, V147, P315, DOI 10.1016/0003-2697(85)90278-7; Hua YJ, 1997, ARCH INSECT BIOCHEM, V35, P125, DOI 10.1002/(SICI)1520-6327(1997)35:1/2<125::AID-ARCH11>3.3.CO;2-A; ISHIZAKI H, 1994, INT J DEV BIOL, V38, P301; Kim AJ, 1997, P NATL ACAD SCI USA, V94, P1130, DOI 10.1073/pnas.94.4.1130; KINGAN TG, 1989, ANAL BIOCHEM, V183, P283, DOI 10.1016/0003-2697(89)90481-8; Klowden MJ, 1997, ARCH INSECT BIOCHEM, V35, P491, DOI 10.1002/(SICI)1520-6327(1997)35:4<491::AID-ARCH10>3.3.CO;2-5; KOLLER CN, 1991, J INSECT PHYSIOL, V37, P703, DOI 10.1016/0022-1910(91)90048-5; LEA AO, 1967, J INSECT PHYSIOL, V13, P419, DOI 10.1016/0022-1910(67)90082-0; LEA AO, 1972, GENERAL COMPAR END S, V3, P602; MASLER EP, 1995, EUR J ENTOMOL, V92, P113; MATSUMOTO S, 1989, INSECT BIOCHEM, V19, P651, DOI 10.1016/0020-1790(89)90100-5; MUEHLEISEN DP, 1994, EXPERIENTIA, V50, P159, DOI 10.1007/BF01984956; Raikhel A.S., 1992, Advances in Disease Vector Research, V9, P1; Sambrook J, 1989, MOL CLONING LABORATO, p1 25; SHIVELY JE, 1987, ANAL BIOCHEM, V163, P517, DOI 10.1016/0003-2697(87)90257-0; Swiderek KM, 1996, METHOD ENZYMOL, V271, P68; WHEELOCK GD, 1991, J CHROMATOGR, V542, P508, DOI 10.1016/S0021-9673(01)88785-9	25	124	128	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3967	3971		10.1074/jbc.273.7.3967	http://dx.doi.org/10.1074/jbc.273.7.3967			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461584	hybrid			2022-12-25	WOS:000072048400026
J	Kundra, A; Kornfeld, S				Kundra, A; Kornfeld, S			Wortmannin retards the movement of the mannose 6-phosphate/insulin-like growth factor II receptor and its ligand out of endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; SYNTHESIZED LYSOSOMAL-ENZYMES; TRANS-GOLGI NETWORK; 6-PHOSPHATE RECEPTOR; ENDOCYTIC PATHWAY; PHOSPHOINOSITIDE 3-KINASE; CYTOPLASMIC DOMAIN; CELLS; TRAFFICKING; BIOGENESIS	The effect of wortmannin on the trafficking of the mannose 6-phosphate/insulin-like growth factor II receptor (Man-6-P/IGF-II receptor) and its ligand beta-glucuronidase has been determined in murine L cells and normal rat kidney cells, The drug induced a 90% decrease in the steady-slate level of the Man-6-P/IGF-II receptor at the plasma membrane without affecting the rate of internalization, indicating that the return of receptor from endosomes to the plasma membrane is retarded. Wortmannin also slowed the movement of receptor from endosomes to the trans-Golgi network by about 60%, Such a kinetic block would dramatically reduce the number of Man-6-P/IGF-II receptors in the trans-Golgi network, which could account for the previously described hypersecretion of procathepsin D induced by wortmannin, In addition, the drug slowed delivery of endocytosed beta-glucuronidase from endosomes to dense lysosomes. These data, taken together with the published reports of others, indicate that wortmannin inhibits membrane trafficking out of multiple compartments of the endosomal system and suggest a role for phosphatidylinositol 3-kinase in regulating these processes.	Washington Univ, Sch Med, Div Hematol, St Louis, MO 63110 USA	Washington University (WUSTL)	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Div Hematol, 660 S Euclid Ave,Box 8125, St Louis, MO 63110 USA.				NATIONAL CANCER INSTITUTE [R37CA008759, R01CA008759] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08759-30] Funding Source: Medline; NHLBI NIH HHS [T32 HL07088] Funding Source: Medline; NIGMS NIH HHS [T32 GM07200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BENNETT G, 1981, J CELL BIOL, V88, P1, DOI 10.1083/jcb.88.1.1; BRAULKE T, 1987, J CELL BIOL, V104, P1735, DOI 10.1083/jcb.104.6.1735; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Gaffet P, 1997, J BIOL CHEM, V272, P24170, DOI 10.1074/jbc.272.39.24170; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRIFFITHS G, 1990, J CELL SCI, V95, P441; HANSEN SH, 1995, J BIOL CHEM, V270, P28425; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; JADOT M, 1992, J BIOL CHEM, V267, P11069; JIN M, 1989, J BIOL CHEM, V264, P7675; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; Korner C, 1996, MOL CELL ENDOCRINOL, V118, P201, DOI 10.1016/0303-7207(96)03785-9; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; Nakajima Y, 1997, MOL BIOL CELL, V8, P577, DOI 10.1091/mbc.8.4.577; NATOWICZ M, 1982, J BIOL CHEM, V257, P4412; OKADA T, 1994, J BIOL CHEM, V269, P3568; Reaves BJ, 1996, J CELL SCI, V109, P749; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P533; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; TAIT JF, 1981, J BIOL CHEM, V256, P1086; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WILSON RB, 1993, J BIOL CHEM, V268, P25357	46	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3848	3853		10.1074/jbc.273.7.3848	http://dx.doi.org/10.1074/jbc.273.7.3848			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461565	hybrid			2022-12-25	WOS:000072048400007
J	Hartmann, R; Norby, PL; Martensen, PM; Jorgensen, P; James, MC; Jacobsen, C; Moestrup, SK; Clemens, MJ; Justesen, J				Hartmann, R; Norby, PL; Martensen, PM; Jorgensen, P; James, MC; Jacobsen, C; Moestrup, SK; Clemens, MJ; Justesen, J			Activation of 2 '-5 ' oligoadenylate synthetase by single-stranded and double-stranded RNA aptamers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS-1; TREATED HELA-CELLS; PROTEIN-KINASE; 2',5'-OLIGO(A) POLYMERASE; RESPONSE ELEMENT; BINDING DOMAIN; VAI RNA; INTERFERON; RECOGNITION; LIGANDS	A number of small RNA molecules that are high affinity ligands for the 46-kDa form of human 2'-5' oligoadenylate synthetase have been identified by the SELEX method, Surface plasmon resonance analysis indicates that these RNAs bind to the enzyme with dissociation constants in the nanomolar range, Competition experiments indicate that the binding site for the small RNAs on the 2'-5' oligoadenylate synthetase molecule at least partially overlaps that for the synthetic double-stranded RNA, poly(I). poly(C). Several of the RNAs function as potent activators of 2'-5' oligoadenylate synthetase in vitro, although there is no correlation between binding affinity and ability to activate, The RNA aptamers having the strongest activation potential appear to have few base-paired regions. This suggests that 2'-5' oligoadenylate synthetase, which has previously been believed to be activated only by double-stranded RNA, can also be activated by RNA ligands with little secondary structure, Since 2'-5' oligoadenylate synthetase possesses no homology to other known RNA-binding proteins, the development of small specific ligands by SELEX should facilitate studies of RNA-protein interactions and may reveal novel features of the structure-function relationships involving this enzyme.	Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark; Univ London St Georges Hosp, Sch Med, Dept Cellular & Mol Sci, Div Biochem, London SW17 0RE, England; Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark	Aarhus University; St Georges University London; Aarhus University	Justesen, J (corresponding author), Aarhus Univ, Dept Mol & Struct Biol, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.	jj@mbio.aau.dk	Martensen, Pia/I-3996-2012; Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019	Moestrup, Søren Kragh/0000-0003-3862-2107; Hartmann, Rune/0000-0003-1159-066X; Martensen, Pia Moller/0000-0002-1259-0226				BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHEBATH J, 1992, INTERFERON PRINCIPLE, P225; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CLEMENS MJ, 1984, TRANSCRIPTION TRANSL, P270; DESAI SY, 1995, J BIOL CHEM, V270, P3454, DOI 10.1074/jbc.270.7.3454; FERBUS D, 1984, MOL CELL BIOCHEM, V62, P51; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GUNNERY S, 1990, P NATL ACAD SCI USA, V87, P8687, DOI 10.1073/pnas.87.22.8687; JOHNSTON MI, 1984, MECH PRODUCTION ACTI, P189; JUSTESEN J, 1992, ANAL BIOCHEM, V207, P90, DOI 10.1016/0003-2697(92)90506-3; JUSTESEN J, 1980, NUCLEIC ACIDS RES, V8, P3073, DOI 10.1093/nar/8.14.3073; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; KING CA, 1991, BACULOVIRUS EXPRESSI; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; Lund AH, 1996, NUCLEIC ACIDS RES, V24, P800, DOI 10.1093/nar/24.4.800; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MELLITS KH, 1990, NUCLEIC ACIDS RES, V18, P5401, DOI 10.1093/nar/18.18.5401; MINKS MA, 1980, J BIOL CHEM, V255, P6403; MINKS MA, 1979, J BIOL CHEM, V254, P180; MORDECHAI E, 1995, VIROLOGY, V206, P913, DOI 10.1006/viro.1995.1014; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PETERSON ET, 1994, J MOL BIOL, V242, P186, DOI 10.1006/jmbi.1994.1571; PRATT G, 1988, NUCLEIC ACIDS RES, V16, P3497, DOI 10.1093/nar/16.8.3497; SAUNDERS ME, 1985, EMBO J, V4, P1761, DOI 10.1002/j.1460-2075.1985.tb03848.x; SCHNEIDER D, 1992, J MOL BIOL, V228, P862, DOI 10.1016/0022-2836(92)90870-P; SENGUPTA DN, 1989, NUCLEIC ACIDS RES, V17, P969, DOI 10.1093/nar/17.3.969; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TUERK C, 1993, GENE, V137, P33, DOI 10.1016/0378-1119(93)90248-2; Zuker M, 1994, Methods Mol Biol, V25, P267	36	71	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3236	3246		10.1074/jbc.273.6.3236	http://dx.doi.org/10.1074/jbc.273.6.3236			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452437	hybrid			2022-12-25	WOS:000071822300022
J	Iordanov, MS; Magun, BE				Iordanov, MS; Magun, BE			Loss of cellular K+ mimics ribotoxic stress - Inhibition of protein synthesis and activation of the stress kinases SEK1/MKK4, stress-activated protein kinase c-Jun NH2-terminal kinase 1, and p38/HOG1 by palytoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION PATHWAYS; ARACHIDONIC-ACID METABOLISM; TUMOR PROMOTER PALYTOXIN; MAMMALIAN SODIUM-PUMP; PROSTAGLANDIN PRODUCTION; MOUSE SKIN; CELLS; INDUCTION; FOS	The tumor promoter palytoxin has been found to activate the stress-activated protein kinase/c-Jun NH2-terminal kinase 1 (SAPK/JNK1), and it also potentiates, as demonstrated here, the p38/HOG1 mitogen-activated protein kinase and the upstream activator of SAPK/JNK1, SEK1/MKK4. In search of possible mechanisms for both the cytotoxicity and the activation of stress kinases by palytoxin, we found that palytoxin is a potent inhibitor of cellular protein synthesis. The inhibition of translation by palytoxin does not result from its direct binding to the translational apparatus. We have previously demonstrated that ribotoxic stressors (Iordanov, M. S., Pribnow, D., Magun, J. L., Dinh, T.-H., Pearson, J. A., Chen, S. L.-Y., and Magun, B. E. (1997) Mol. Cell. Biol. 17, 3373-3381) signal the activation of SAPK/JNK1 by binding to or covalently modifying 28 S rRNA in ribosomes that are active at the time of exposure to the stressor, Palytoxin acted as a ribotoxic stressor, inasmuch as it required actively translating ribosomes at the time of exposure to activate SAPK/JNK1. Palytoxin has been shown to augment ion fluxes by binding to the Na+/K+-ATPase in the plasma membrane of cells. To determine whether altered fluxes of either Na+ or K+ could be responsible for the effects of palytoxin on translation and on activation of SAPK/JNK1, cells were exposed to palytoxin in modified culture medium in which a major portion of the Na+ was replaced by either K+ or by choline(+). The substitution of Na+ by K+ strongly inhibited the ability of palytoxin both to inhibit protein translation and to activate SAPK/JNK1, whereas the substitution of Na+ by choline(+) did not. These results suggest that palytoxin-induced efflux of cellular K+ mimics ribotoxic stress by provoking both translational inhibition and activation of protein kinases associated with cellular defense against stress.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University	Magun, BE (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA.	magunb@OHSU.edu			NCI NIH HHS [CA-39360] Funding Source: Medline; NIEHS NIH HHS [ES-08456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AIZU E, 1990, EUR J PHARMACOL, V182, P19; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FISCHER SM, 1980, ARACHIDONIC ACID MET; Fujiki H, 1983, Princess Takamatsu Symp, V14, P37; FUJIKI H, 1986, CARCINOGENESIS, V7, P707, DOI 10.1093/carcin/7.5.707; FURSTENBERGER G, 1981, P NATL ACAD SCI-BIOL, V78, P7722, DOI 10.1073/pnas.78.12.7722; FURSTENBERGER G, 1994, CARCINOGENESIS, V15, P2823, DOI 10.1093/carcin/15.12.2823; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HABERMANN E, 1989, TOXICON, V27, P1171, DOI 10.1016/0041-0101(89)90026-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; Kuroki DW, 1996, CANCER RES, V56, P637; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAZZARO M, 1987, ENDOCRINOLOGY, V120, P1338, DOI 10.1210/endo-120-4-1338; LEVINE L, 1986, PROSTAGLANDINS, V31, P669, DOI 10.1016/0090-6980(86)90173-5; LEVINE L, 1986, CARCINOGENESIS, V7, P99, DOI 10.1093/carcin/7.1.99; LEVINE L, 1991, PROSTAG OTH LIPID M, V41, P7, DOI 10.1016/0090-6980(91)90100-T; LEWIS JG, 1987, CARCINOGENESIS, V8, P889, DOI 10.1093/carcin/8.7.889; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MAGUN BE, 1995, CELL GROWTH DIFFER, V6, P891; Marks F, 1995, TOXICOL LETT, V82-3, P907, DOI 10.1016/0378-4274(95)03529-X; MARTINSGREEN M, 1994, CANCER RES, V54, P4334; MCGAUGHEY C, 1983, J TOXICOL ENV HEALTH, V11, P467, DOI 10.1080/15287398309530359; Michiel D F, 1992, Semin Cancer Biol, V3, P3; OHUCHI K, 1985, BIOCHIM BIOPHYS ACTA, V834, P42, DOI 10.1016/0005-2760(85)90174-2; PESTKA S, 1971, ANNU REV MICROBIOL, V25, P487, DOI 10.1146/annurev.mi.25.100171.002415; Redondo J, 1996, MOL PHARMACOL, V49, P49; Rodland KD, 1997, MOL ENDOCRINOL, V11, P281, DOI 10.1210/me.11.3.281; RODRIGUEZFONSECA C, 1995, J MOL BIOL, V247, P224, DOI 10.1006/jmbi.1994.0135; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHEINERBOBIS G, 1994, MOL PHARMACOL, V45, P1132; SCHOOF RA, 1986, INT J IMMUNOPHARMACO, V8, P455, DOI 10.1016/0192-0561(86)90132-3; SCRIBNER JD, 1972, EUR J CANCER, V8, P617, DOI 10.1016/0014-2964(72)90142-9; SEGAL A, 1978, CANCER RES, V38, P921; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANBOGELEN RA, 1990, P NATL ACAD SCI USA, V87, P5589, DOI 10.1073/pnas.87.15.5589; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vazquez D., 1979, INHIBITORS PROTEIN B; WATTENBERG EV, 1989, J BIOL CHEM, V264, P213; WATTENBERG EV, 1987, CANCER RES, V47, P4618; WATTENBERG EV, 1989, J BIOL CHEM, V264, P14668; WATTENBERG EV, 1989, CANCER RES, V49, P5837; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WOOL IG, 1992, TRENDS BIOCHEM SCI, V17, P266, DOI 10.1016/0968-0004(92)90407-Z; YAN MH, 1994, NATURE, V372, P798	51	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3528	3534		10.1074/jbc.273.6.3528	http://dx.doi.org/10.1074/jbc.273.6.3528			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452478	hybrid			2022-12-25	WOS:000071822300063
J	Shimabukuro, M; Zhou, YT; Lee, Y; Unger, RH				Shimabukuro, M; Zhou, YT; Lee, Y; Unger, RH			Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; INSULIN-RESISTANCE; OBESITY; LIPOTOXICITY; PATHOGENESIS; BIOSYNTHESIS; SECRETION; DEPLETION; CS-045; ACIDS	The thiazolidinedione compound troglitazone, which is used to treat non-insulin-dependent diabetes mellitus (NIDDM) in man, is also effective in the adipogenic NIDDM of Zucker diabetic fatty (ZDF) rats, To test the "lipotoxicity hypothesis," which attributes the beta cell dysfunction of adipogenic NIDDM to an excessive accumulation of fat in the pancreatic islets, we sought to determine if troglitazone-mediated amelioration of beta cell function in islets of ZDF rats might be associated with a reduction in their elevated triglyceride (TG) content. Troglitazone (10 mu M) in the culture medium reduced the TG content of ZDF rats by 52%; this was reflected by decreased esterification and increased oxidation of [H-3]palmitate, Glycerol-3-phosphate acyltransferase mRNA fell by 57% and acyl-CoA synthetase mRNA by 67% (brain isoform) and 38% (liver isoform), all consistent with the effects of troglitazone on TG metabolism, The 52% decrease in islet TG was accompanied by >30- and 2-fold improvements in glucose- and arginine-stimulated insulin secretion, respectively. We conclude that troglitazone exerts direct lipopenic activity in normal islets and in islets of obese prediabetic ZDF rats; in the latter, this correlated with improvement in beta cell function, The results are consistent with the lipotoxicity hypothesis for adipogenic diabetes.	Univ Texas, SW Med Ctr, Ctr Diabet Res, Gifford Labs, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Vet Adm Med Ctr, Dallas, TX 75216 USA	Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Unger, RH (corresponding author), Univ Texas, SW Med Ctr, Ctr Diabet Res, Gifford Labs, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Shimabukuro, Michio/0000-0001-7835-7665	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK002700, R01DK002700] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02700-37] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAPITO K, 1992, ACTA DIABETOL, V28, P193, DOI 10.1007/BF00778997; ELKS ML, 1993, ENDOCRINOLOGY, V133, P208, DOI 10.1210/en.133.1.208; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; Hirose H, 1996, J BIOL CHEM, V271, P5633, DOI 10.1074/jbc.271.10.5633; Iida M, 1996, BIOCHEM BIOPH RES CO, V222, P19, DOI 10.1006/bbrc.1996.0691; IWAOTO Y, 1994, DIABETES CARE, V14, P1083; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; McDaniel ML, 1996, P SOC EXP BIOL MED, V211, P24; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; NABER SP, 1980, DIABETOLOGIA, V19, P439, DOI 10.1007/BF00281823; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; OHNEDA M, 1995, DIABETOLOGIA, V38, P173, DOI 10.1007/BF00400091; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Shimabukuro M, 1997, J CLIN INVEST, V100, P1750, DOI 10.1172/JCI119700; Shimabukuro M, 1997, J CLIN INVEST, V100, P290, DOI 10.1172/JCI119534; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Sreenan S, 1996, AM J PHYSIOL-ENDOC M, V271, pE742, DOI 10.1152/ajpendo.1996.271.4.E742; Unger RH, 1997, TRENDS ENDOCRIN MET, V8, P276, DOI 10.1016/S1043-2760(97)00094-5; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; YOSHIOKA S, 1993, METABOLISM, V42, P75, DOI 10.1016/0026-0495(93)90175-N; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	26	214	226	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3547	3550		10.1074/jbc.273.6.3547	http://dx.doi.org/10.1074/jbc.273.6.3547			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452481	hybrid			2022-12-25	WOS:000071822300066
J	Barabe, F; Gilbert, C; Liao, N; Bourgoin, SG; Naccache, PH				Barabe, F; Gilbert, C; Liao, N; Bourgoin, SG; Naccache, PH			Crystal-induced neutrophil activation VI. Involvement of Fc gamma RIIIB (CD16) and CD11b in response to inflammatory microcrystals	FASEB JOURNAL			English	Article						tyrosine phosphorylation; inflammation; gout; signal transduction; opsonin receptors	MONOSODIUM URATE CRYSTALS; PROTEIN-TYROSINE KINASE; C-CBL PROTOONCOGENE; CALCIUM PYROPHOSPHATE CRYSTALS; RECEPTOR-MEDIATED PHAGOCYTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; COMPLEMENT RECEPTOR-TYPE-3; SIGNALING PATHWAYS; RESPIRATORY BURST; EGF STIMULATION	The inflammatory reaction associated with the deposition of monosodium urate (MSU) crystals in synovial spaces is known to be due to interactions with polymorphonuclear neutrophils mediated by presently unidentified surface structures. In this study, we have observed that antibodies directed against CD16 (VIFcRIII) and CD11b (VIM12) selectively and potently inhibit the activation of neutrophils by MSU crystals. The responses affected include the stimulation of tyrosine phosphorylation, activation of the tyrosine kinase syk, tyrosine phosphorylation of the proto-oncogene Cbl, mobilization of calcium, and stimulation of the activity of phospholipase D and of the production of superoxide anions, Tyrosine phosphorylation responses to MSU crystals develop during the Me2SO4-induced differentiation of HC-60 cells in parallel with the surface expression of CD16, These data strongly support the hypothesis that inflammatory microcrystals interact opportunistically with CD16 initially, and that the signal transduction pathways activated thereby depend on CD11b, An examination of the relevance of the hypothesis that an uncontrolled activation of CD16/CD11b may play a role in inflammatory reactions associated with a dysregulation of neutrophil function (other than crystal arthropathies) appears warranted on the basis of the present results.	CHUL, Ctr Rech, Ctr Rech Rhumatol & Immunol, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med, Ste Foy, PQ G1K 7P4, Canada; Univ Laval, Fac Med, Dept Physiol, Ste Foy, PQ G1K 7P4, Canada	Laval University; Laval University; Laval University	Naccache, PH (corresponding author), CHUL, Ctr Rech, Ctr Rech Rhumatol & Immunol, Room T1-49,2705 Blvd Laurier, Ste Foy, PQ G1V 4G2, Canada.	paul.naccache@crchul.ulaval.ca		Bourgoin, Sylvain/0000-0001-9779-0368; Gilbert, Caroline/0000-0003-2722-1180				ABRAMSON S, 1982, ARTHRITIS RHEUM, V25, P174, DOI 10.1002/art.1780250210; AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; AlShami A, 1997, J IMMUNOL METHODS, V202, P183, DOI 10.1016/S0022-1759(97)00004-5; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOMALASKI JS, 1990, J IMMUNOL, V145, P3391; BURT HM, 1993, MOL PHARMACOL, V43, P30; BURT HM, 1994, J LEUKOCYTE BIOL, V55, P112, DOI 10.1002/jlb.55.1.112; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DEMEDICIS R, 1983, EUR J RHEUMATOL INFL, V6, P143; DIGIOVINE FS, 1991, J CLIN INVEST, V87, P1375, DOI 10.1172/JCI115142; DIGIOVINE FS, 1987, J IMMUNOL, V138, P3213; EDBERG JC, 1994, J IMMUNOL, V152, P5826; FAIRES JS, 1962, LANCET, V2, P682; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Galon J, 1996, J IMMUNOL, V157, P1184; GAUDRY M, 1993, J CLIN INVEST, V91, P1649, DOI 10.1172/JCI116373; GINSBERG MH, 1977, ARTHRITIS RHEUM, V20, P1538, DOI 10.1002/art.1780200815; GORDON TP, 1988, INFLAMMATION BASIC P, P775; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUERNE PA, 1989, ARTHRITIS RHEUM-US, V32, P1443, DOI 10.1002/anr.1780321114; HACHICHA M, 1995, J EXP MED, V182, P2019, DOI 10.1084/jem.182.6.2019; HOFFMEYER F, 1995, J IMMUNOL, V155, P4016; HULETT MD, 1995, ADV IMMUNOL, V57, P1; INDIK ZK, 1995, BLOOD, V85, P1175, DOI 10.1182/blood.V85.5.1175.bloodjournal8551175; INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389; JAQUES BC, 1982, ARTHRITIS RHEUM-US, V25, P508, DOI 10.1002/art.1780250504; KOBAYASHI K, 1995, J BIOCHEM, V117, P1156, DOI 10.1093/oxfordjournals.jbchem.a124838; KRAUSS JC, 1994, J IMMUNOL, V153, P1769; KUSUNOKI T, 1994, J LEUKOCYTE BIOL, V55, P735, DOI 10.1002/jlb.55.6.735; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MACKENZIE SJ, 1995, BIOCHEM J, V306, P519, DOI 10.1042/bj3060519; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; Matsuo T, 1996, FEBS LETT, V382, P11, DOI 10.1016/0014-5793(96)00122-6; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MILLER EJ, 1993, J RHEUMATOL, V20, P1250; NACCACHE PH, 1993, ARTHRITIS RHEUM, V36, P117, DOI 10.1002/art.1780360119; NACCACHE PH, 1990, BLOOD, V76, P2098; NACCACHE PH, 1991, ARTHRITIS RHEUM, V34, P333, DOI 10.1002/art.1780340311; ONELLO E, 1991, J IMMUNOL, V146, P4289; ORTIZBRAVO E, 1993, ARTHRITIS RHEUM-US, V36, P1274, DOI 10.1002/art.1780360912; PETTY HR, 1993, J LEUKOCYTE BIOL, V54, P492, DOI 10.1002/jlb.54.5.492; POO H, 1995, J MOL BIOL, V247, P597; POUBELLE PE, 1987, BIOCHEM BIOPH RES CO, V149, P649, DOI 10.1016/0006-291X(87)90417-7; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROBERGE CJ, 1993, J CLIN INVEST, V92, P1722, DOI 10.1172/JCI116759; Roberge CJ, 1996, J LEUKOCYTE BIOL, V59, P864, DOI 10.1002/jlb.59.6.864; ROBERGE CJ, 1994, J IMMUNOL, V152, P5485; ROCHARVEILLER M, 1990, BIOMED PHARMACOTHER, V44, P467, DOI 10.1016/0753-3322(90)90207-P; ROLLET E, 1994, J IMMUNOL, V153, P353; SALMON JE, 1995, J CLIN INVEST, V95, P2877, DOI 10.1172/JCI117994; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SCHUMACHER HR, 1975, ARTHRITIS RHEUM, V18, P783, DOI 10.1002/art.1780180723; SEEGMILLER JE, 1962, JAMA-J AM MED ASSOC, V180, P125; SEHGAL G, 1993, J IMMUNOL, V150, P4571; SERHAN CN, 1984, PROSTAG OTH LIPID M, V27, P563, DOI 10.1016/0090-6980(84)90092-3; SIMCHOWITZ L, 1982, ARTHRITIS RHEUM, V25, P181, DOI 10.1002/art.1780250211; STOCKL J, 1995, J IMMUNOL, V154, P5452; STROHMEIER GR, 1995, J LEUKOCYTE BIOL, V58, P415, DOI 10.1002/jlb.58.4.415; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TERKELTAUB R, 1991, ARTHRITIS RHEUM, V34, P894, DOI 10.1002/art.1780340716; TERKELTAUB RA, 1990, J IMMUNOL, V144, P2719; TERKELTAUB RA, 1995, ANN RHEUM DIS, V54, P79, DOI 10.1136/ard.54.2.79; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Uddin S, 1996, BIOCHEM BIOPH RES CO, V225, P833, DOI 10.1006/bbrc.1996.1259; Unkeless J C, 1995, Semin Immunol, V7, P37, DOI 10.1016/1044-5323(95)90006-3; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407; ZHOU MJ, 1993, J IMMUNOL, V150, P3030	72	71	72	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1998	12	2					209	220		10.1096/fasebj.12.2.209	http://dx.doi.org/10.1096/fasebj.12.2.209			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472986				2022-12-25	WOS:000071848400009
J	English, JA; Hemphill, KM; Paul, IA				English, JA; Hemphill, KM; Paul, IA			LP-BM5 infection impairs acquisition, but not performance, of active avoidance responding in C57B1/6 mice	FASEB JOURNAL			English	Article						animal model; AIDS; dementia; learning; memory; retention	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AIDS DEMENTIA COMPLEX; IMMUNE-DEFICIENCY-SYNDROME; QUINOLINIC ACID; HIV-1 INFECTION; BRAIN; VIRUS; NEUROPATHOLOGY; LOCALIZATION; EXPRESSION	LP-BM5 murine leukemia virus infection causes an AIDS-like syndrome-murine acquired immunodeficiency syndrome-in C57Bl/6 mice and impairs spatial learning in the Morris water maze without gross motor impairment. We used a shuttle shock-avoidance procedure to examine the effects of LP-BM5 infection on learning and retention of avoidance behavior. Thirty mice were inoculated with LP-BM5; 30 received vehicle (DMEM) injections. Fifteen LP-BM5 and 15 DMEM mice were trained in avoidance 7 wk after inoculation; retention of the avoidance response was tested 4 wk later. The remaining mice were trained 11 wk after inoculation, In animals trained 7 wk after inoculation, the groups performed similarly, with a marginally significant tendency for LP-BM5-infected animals to make more avoidance responses. This group difference was sig nificant when animals were retested at 11 wk. However, LP-BM5 animals trained 11 wk after inoculation made significantly fewer avoidance responses than controls trained at the same time. We conclude that in later stages of disease, LP-BM5 impairs response acquisition, but not performance, in the active avoidance procedure. Results extend the use of the LP-BM5-infected mouse as a model of AIDS dementia complex.	Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	English, JA (corresponding author), Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Box 127,2500 N State St, Jackson, MS 39216 USA.				NIMH NIH HHS [MH53228] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053228] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 1994, DIAGN STAT MAN MENT, V4th ed.; ANDERS KH, 1986, AM J PATHOL, V124, P537; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; EPSTEIN L G, 1984, AIDS Research, V1, P447; HA JH, 1995, J NEUROCHEM, V64, P1896; HARTLEY JW, 1989, J VIROL, V63, P1223, DOI 10.1128/JVI.63.3.1223-1231.1989; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; HO DD, 1989, ANN INTERN MED, V111, P400, DOI 10.7326/0003-4819-111-5-400; HOLSCHER C, 1994, BEHAV BRAIN RES, V63, P187, DOI 10.1016/0166-4328(94)90090-6; JOHNSON RT, 1988, FASEB J, V2, P2970, DOI 10.1096/fasebj.2.14.2846395; KESEBERG U, 1995, BEHAV BRAIN RES, V67, P255, DOI 10.1016/0166-4328(94)00156-A; KLINKEN SP, 1988, J IMMUNOL, V140, P1123; KLINMAN DM, 1989, J IMMUNOL, V142, P1144; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; Nishida K, 1996, J NEUROCHEM, V66, P433; PAUL IA, 1993, AM COL NEUROPSYCHOPH, P139; POPOLI P, 1994, BRAIN RES BULL, V35, P329, DOI 10.1016/0361-9230(94)90109-0; POWER C, 1993, ANN NEUROL, V34, P339, DOI 10.1002/ana.410340307; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; Sei Y, 1996, J NEUROCHEM, V66, P296; SEI Y, 1992, FASEB J, V6, P3008, DOI 10.1096/fasebj.6.11.1644264; SHUSTER GM, 1992, EUR J PHARMACOL, V224, P97; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; WEINBERGER SB, 1992, BEHAV GENET, V22, P177, DOI 10.1007/BF01066996; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089	28	11	11	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1998	12	2					175	179		10.1096/fasebj.12.2.175	http://dx.doi.org/10.1096/fasebj.12.2.175			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472982				2022-12-25	WOS:000071848400005
J	Nichols, BL; Eldering, J; Avery, S; Hahn, D; Quaroni, A; Sterchi, E				Nichols, BL; Eldering, J; Avery, S; Hahn, D; Quaroni, A; Sterchi, E			Human small intestinal maltase-glucoamylase cDNA cloning - Homology to sucrase-isomaltase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; LYSOSOMAL ALPHA-GLUCOSIDASE; BRUSH-BORDER MEMBRANE; NEUTRAL MALTASE; MOLECULAR-CLONING; AMINOPEPTIDASE-N; SUCKLING RAT; EXPRESSION; COMPLEX; GENE	It has been hypothesized that human mucosal glucoamylase (EC 3.2.1.20 and 3.2.1.3) activity serves as an alternate pathway for starch digestion when luminal cu-amylase activity is reduced because of immaturity or malnutrition and that maltase-glucoamylase plays a unique role in the digestion of malted dietary oligosaccharides used in food manufacturing, As a first step toward the testing of this hypothesis, we have cloned human small intestinal maltase-glucoamylase cDNA to permit study of the individual catalytic and binding sites for maltose and starch enzyme hydrolase activities in subsequent expression experiments, Human maltase-glucoamylase was purified by immunoisolation and partially sequenced, Maltase-glucoamylase cDNA was amplified from human intestinal RNA using degenerate and gene-specific primers with the reverse transcription-polymerase chain reaction. The 6,513-base pair cDNA contains an open reading frame that encodes a 1,857-amino acid protein (molecular mass 209,702 Da). Maltase-glucoamylase has two catalytic sites identical to those of sucrase-isomaltase, but the proteins are only 59% homologous, Both are members of glycosyl hydrolase family 31, which has a variety of substrate specificities, Our findings suggest that divergences in the carbohydrate binding sequences must determine the substrate specificities for the four different enzyme activities that share a conserved catalytic site.	Baylor Coll Med, Dept Pediat, Childrens Nutr Res Ctr, USDA, Houston, TX 77030 USA; Cornell Univ, Sch Vet Med, Dept Physiol, Ithaca, NY 14853 USA; Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland	Baylor College of Medicine; United States Department of Agriculture (USDA); Cornell University; University of Bern	Nichols, BL (corresponding author), Baylor Coll Med, Dept Pediat, Childrens Nutr Res Ctr, USDA, 1100 Bates St, Houston, TX 77030 USA.							ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; AURICCHIO S, 1965, BIOCHIM BIOPHYS ACTA, V96, P498, DOI 10.1016/0005-2787(65)90566-6; AZAD MAK, 1990, PEDIATR RES, V28, P166, DOI 10.1203/00006450-199028020-00017; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BAYER DP, 1989, BIOCHEM J, V263, P647; CHANDRASENA G, 1994, GENE, V150, P355, DOI 10.1016/0378-1119(94)90452-9; CHANTRET I, 1992, BIOCHEM J, V285, P915, DOI 10.1042/bj2850915; COWELL GM, 1986, BIOCHEM J, V237, P455, DOI 10.1042/bj2370455; DANIELSEN EM, 1994, BIOCHEMISTRY-US, V33, P1599, DOI 10.1021/bi00172a041; DANIELSEN EM, 1983, BIOCHEM J, V210, P389, DOI 10.1042/bj2100389; DANUS VO, 1970, J PEDIATR-US, V77, P334; DOHMEN RJ, 1990, GENE, V95, P111, DOI 10.1016/0378-1119(90)90421-M; EGGERMONT E, 1981, TXB GASTROENTEROLOGY, P966; FORSTNER G, 1982, CAN J BIOCHEM CELL B, V60, P1007, DOI 10.1139/o82-129; FORSTNER G, 1979, BIOCHIM BIOPHYS ACTA, V586, P250, DOI 10.1016/0304-4165(79)90097-7; GALAND G, 1986, COMP BIOCHEM PHYS A, V85, P109, DOI 10.1016/0300-9629(86)90470-6; GALLUSER M, 1991, J COMP PHYSIOL B, V161, P357; Genetic Computer Group, 1994, PROGR MAN WISC PACK; HASSID WZ, 1957, CARBOHYDRATES CHEM B, P501; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HENIKOFF S, 1994, J MOL BIOL, V243, P574, DOI 10.1016/0022-2836(94)90032-9; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; HOEFSLOOT LH, 1988, EMBO J, V7, P1697, DOI 10.1002/j.1460-2075.1988.tb02998.x; HU CB, 1987, BIOCHIM BIOPHYS ACTA, V896, P275, DOI 10.1016/0005-2736(87)90188-X; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; IWANAMI S, 1995, BIOSCI BIOTECH BIOCH, V59, P459, DOI 10.1271/bbb.59.459; JAMES WPT, 1971, ARCH DIS CHILD, V46, P218, DOI 10.1136/adc.46.246.218; KELLY JJ, 1973, J BIOL CHEM, V248, P8216; KELLY JJ, 1973, BIOCHIM BIOPHYS ACTA, V315, P113, DOI 10.1016/0005-2744(73)90135-6; KIMURA A, 1992, BIOSCI BIOTECH BIOCH, V56, P1368, DOI 10.1271/bbb.56.1368; LAWRENCE CB, 1989, SAM SOFTWARE PACKAGE; LEBENTHAL E, 1994, J PEDIATR-US, V124, P541, DOI 10.1016/S0022-3476(05)83131-2; LEE L, 1990, BIOCHEM CELL BIOL, V68, P1103, DOI 10.1139/o90-165; LEE L, 1983, CAN J BIOCHEM, V62, P36; NAIM HY, 1988, J BIOL CHEM, V263, P19709; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NOREN O, 1986, J BIOL CHEM, V261, P2306; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRINSLOO JG, 1971, ARCH DIS CHILD, V46, P474, DOI 10.1136/adc.46.248.474; QUARONI A, 1992, INT J CANCER, V51, P404, DOI 10.1002/ijc.2910510312; QUARONI A, 1974, J BIOL CHEM, V249, P6424; QUEZADACALVILLO R, 1993, AM J PHYSIOL, V265, pG1150, DOI 10.1152/ajpgi.1993.265.6.G1150; REISS U, 1981, ARCH BIOCHEM BIOPHYS, V209, P342, DOI 10.1016/0003-9861(81)90290-3; ROSSITER MA, 1974, ACTA PAEDIATR SCAND, V63, P389, DOI 10.1111/j.1651-2227.1974.tb04815.x; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SEMENZA G, 1989, METABOLIC BASIS INHE, V2, P2975; SHULMAN RJ, 1983, J PEDIATR-US, V103, P23, DOI 10.1016/S0022-3476(83)80769-0; SORENSEN SH, 1982, EUR J BIOCHEM, V126, P559, DOI 10.1111/j.1432-1033.1982.tb06817.x; Sugimoto M, 1996, J BIOCHEM, V119, P500; Tibbot BK, 1996, PLANT MOL BIOL, V30, P229, DOI 10.1007/BF00020110; WHISTLER RL, 1957, CARBOHYDRATES CHEM B, P644; WOLF H, 1988, COMPUT APPL BIOSCI, V4, P187	53	91	97	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3076	3081		10.1074/jbc.273.5.3076	http://dx.doi.org/10.1074/jbc.273.5.3076			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446624	hybrid			2022-12-25	WOS:000071736600079
J	Erhardt, JA; Pittman, RN				Erhardt, JA; Pittman, RN			p21(WAF1) induces permanent growth arrest and enhances differentiation, but does not alter apoptosis in PC12 cells	ONCOGENE			English	Article						p21(WAF1); PC12; NGF; apoptosis; differentiation; proliferation	CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; IN-VIVO; TERMINAL DIFFERENTIATION; SYMPATHETIC NEURONS; TUMOR SUPPRESSION; HUMAN FIBROBLASTS; PROTEIN-KINASES; G(1) ARREST; P21	p21(WAF1) cyclin-dependent kinase inhibitor has been implicated in the control of proliferation, differentiation, and death in, various cell lines, To further examine p21 regulation of the transitions between these cellular processes, an inducible p21 vector (lac operon system) was transfected into the rat pheochromocytoma (PC12) neural cell line, Induction of p21 led to permanent growth arrest, as evidenced by cell counts, FACS analysis, and thymidine incorporation, This arrest was maintained, even after removal of the inducing signal (IPTG). Northern analysis revealed that endogenous p21 mRNA increased following IPTG removal, which may be responsible for the continued growth arrest despite the decrease in ectopic p21 expression, p21 overexpression did not directly lead to a differentiated phenotype; however, differentiation in response to nerve growth factor (NGF) was greatly accelerated. To examine effects on cell, death, and specifically test the hypothesis that apoptosis caused by withdrawal of trophic support results from inappropriate entry into cell cycle, serum was removed from proliferating and p21-arrested PC12 cells, The rate of apoptotic death was not affected by p21, nor was it effective in altering the extent of death following other apoptotic stimuli.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Erhardt, JA (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.				AHRQ HHS [HS32465] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ATTARDI D, 1996, EMBO J, V15, P3696; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Buchkovich K, 1994, MOL BIOL CELL, V5, P1226; Chen J, 1996, ONCOGENE, V13, P1395; CHEN YQ, 1995, CANCER RES, V55, P4536; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FERRARI G, 1995, J NEUROSCI, V15, P2857; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Givol I, 1995, ONCOGENE, V11, P2609; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GRANA X, 1995, ONCOGENE, V11, P211; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUO K, 1995, MOL CELL BIOL, V15, P3823; GUPTA M, 1987, BRAIN RES BULL, V18, P555, DOI 10.1016/0361-9230(87)90119-5; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HUPPI K, 1994, ONCOGENE, V9, P3017; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; Mills JC, 1997, EXP CELL RES, V231, P337, DOI 10.1006/excr.1997.3474; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Poluha W, 1996, MOL CELL BIOL, V16, P1335; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; STEIN GS, 1994, CELL BIOL LAB HDB, P282; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Teng KK, 1994, CELL BIOL LAB HDB, P218; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanGrunsven LA, 1996, ONCOGENE, V12, P855; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Woodgett JR, 1996, CANCER SURV, V27, P127; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAN GZ, 1995, J NEUROSCI, V15, P6200; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG BW, 1996, CURR BIOL, V6, P606	67	53	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					443	451		10.1038/sj.onc.1201577	http://dx.doi.org/10.1038/sj.onc.1201577			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484833				2022-12-25	WOS:000071739400002
J	Sekiguchi, T; Hunter, T				Sekiguchi, T; Hunter, T			Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHKZ1 cells	ONCOGENE			English	Article						cell cycle; PCNA; tetracycline	DEPENDENT-KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; P53-MEDIATED G(1) ARREST; DNA-REPLICATION; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; HUMAN FIBROBLASTS; PHASE-TRANSITION; NUCLEAR ANTIGEN; BINDING DOMAINS	p21(cip1/waf1/sdil) is universal cyclin-Cdk kinase inhibitor that has two functional domains; one binds and inhibits cyclin-Cdk activity and the other binds PCNA and thereby inhibits elongation by DNA polymerase. When transiently expressed in hamster BHK21 cells we found that human p21 was able to cause cell cycle arrest in G1 phase; this arrest was counteracted by coexpression of E2F-1 or SV40 large T antigen. To study the effect of p21 overexpression in vivo, BHK21 cell clones inducibly expressing human p21 (Tet-p21) driven by the tetracycline (Tet)-repressible promoter were established. The maximum induced p21 levels in the absence of Tet were estimated to be ten times that of endogenous hamster p21. As p21 levels rose following removal of Tet, p21-associated histone H1 kinase activity was increased and concomitantly cell growth and DNA synthesis were reduced. Tet-p21 BHK21 cells became arrested in G1 phase and lost colony forming ability irreversibly 2-4 days after removal of Tet. The induction of cyclin E- and cyclin A-associated kinase activities was diminished when G0-synchronized Tet-p21 BHK21 cells mere serum stimulated in the absence of Tet. Increased binding of p21 to PCNA and cyclin D1-Cdk4 was detected in induced cells. Overexpression of p21 led to cell death in BHK21 cells at 39.5 degrees C within 4 days.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	Salk Institute	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, CA14195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; ARIGA H, 1983, J VIROL, V48, P481, DOI 10.1128/JVI.48.2.481-491.1983; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen IT, 1996, ONCOGENE, V12, P595; CHEN IT, 1995, ONCOGENE, V11, P1931; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CRISTOFALO VJ, 1989, EXP GERONTOL, V24, P367, DOI 10.1016/0531-5565(89)90044-2; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Ezhevsky SA, 1996, MOL BIOL CELL, V7, P553, DOI 10.1091/mbc.7.4.553; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fotedar R, 1996, ONCOGENE, V12, P2155; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOUBIN F, 1995, ONCOGENE, V10, P2281; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kobayashi T, 1995, ONCOGENE, V11, P2311; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin JY, 1996, MOL CELL BIOL, V16, P1786; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOGUCHI E, 1993, BIOCHEM BIOPH RES CO, V197, P1524, DOI 10.1006/bbrc.1993.2650; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1987, EXP CELL RES, V169, P395, DOI 10.1016/0014-4827(87)90200-X; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; Sekiguchi T, 1996, GENES CELLS, V1, P687, DOI 10.1046/j.1365-2443.1996.00259.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Tsao YP, 1995, BIOCHEM J, V312, P693, DOI 10.1042/bj3120693; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	71	52	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					369	380		10.1038/sj.onc.1201539	http://dx.doi.org/10.1038/sj.onc.1201539			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467962				2022-12-25	WOS:000071582100009
J	Jackson, P; Mastrangelo, I; Reed, M; Tegtmeyer, P; Yardley, G; Barrett, J				Jackson, P; Mastrangelo, I; Reed, M; Tegtmeyer, P; Yardley, G; Barrett, J			Synergistic transcriptional activation of the MCK promoter by p53: tetramers link separated DNA response elements by DNA looping	ONCOGENE			English	Article						p53; MCK; transcription; DNA looping	TATA-BINDING PROTEIN; GENE; IDENTIFICATION; ENHANCER; SEQUENCE; DOMAINS; MUTANT; SITES; TRANSACTIVATION; SUPPRESSION	The WAF1, Cyclin G and muscle creatine kinase (MCK) genes, all contain multiple copies of the consensus p53-binding element within their regulatory regions, We examined the role of these elements in transactivation of the muscle creatine kinase (MCK) gene by p53, The MCK promoter possesses distal (-3182 to -3133) and proximal (-177 to -81) p53-binding elements within which residues -3182 to -3151 (distal) and -176 to -149 (proximal) show homology to the consensus p53-binding site, Using promoter deletion studies, we find that both proximal and distal elements are required for high level, synergistic transcriptional activation in vivo. Electron microscopy indicates that p53-p53 interactions link proximal and distal p53-binding elements and cause looping out of intervening DNA, suggesting that this DNA sequence may be dispensable for synergy, This idea was confirmed by progressive deletion of the DNA between p53-binding elements, Synergism persisted with spacing reduced to only 150 bp, Tetramerization-deficient p53 mutants were defective for transcriptional activation but still capable of synergy, Our results provide evidence for a model by which high level transcriptional activation of promoters with multiple p53 response elements is achieved.	Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; SUNY Stony Brook, Med Ctr, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Jackson, P (corresponding author), Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia.				NCI NIH HHS [CA-18808, CA-28148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018808, R37CA018808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BURATOWSKI S, 1995, SCIENCE, V270, P1773, DOI 10.1126/science.270.5243.1773; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; JACKSON P, 1995, GENE EXPRESSION, V5, P19; JACKSON P, 1993, ONCOGENE, V8, P589; Jackson P, 1997, FEBS LETT, V406, P271, DOI 10.1016/S0014-5793(97)00283-4; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MAYR GA, 1995, CANCER RES, V55, P2410; Momand J, 1997, J CELL BIOCHEM, V64, P343; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; Reed Michael, 1993, Gene Expression, V3, P95; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YUAN JN, 1993, BIOCHEM BIOPH RES CO, V192, P662; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	47	30	30	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					283	292		10.1038/sj.onc.1201491	http://dx.doi.org/10.1038/sj.onc.1201491			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464547				2022-12-25	WOS:000071427100016
J	Wagner, P; Fuchs, A; Gotz, C; Nastainczyk, W; Montenarh, M				Wagner, P; Fuchs, A; Gotz, C; Nastainczyk, W; Montenarh, M			Fine mapping and regulation of the association of p53 with p34(cdc2)	ONCOGENE			English	Article						p53; growth suppressor protein; protein kinase p34(cdc2)	CASEIN KINASE-II; CELL-CYCLE CONTROL; TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; FISSION YEAST; DNA-BINDING; TMS1 PROTEIN; PHOSPHORYLATION SITES; GROWTH ARREST; MUTANT	In vivo p53 is multiply phosphorylated by different protein kinases suggesting a central role for phosphorylation in modulating p53 function. In addition, p53 was found to be associated with two protein kinases, p34(cdc2) and protein kinase CK2. Here we report the precise mapping of the interaction sites of p53-p34(cdc2) complexes. The p34(cdc2) binding site on human p53 maps to one distinct C-terminal site LQIRGRERFE (aa 330-339) close to the corresponding phosphorylation site at serine 315. In order to test whether phosphorylation of p53 might influence the binding of p53 to p34(cdc2) phosphorylation mutants of the C-terminus of p53, which mimick permanent phosphorylation, were tested on their ability to bind to p34(cdc2) in vitro. Substitution of serine 315 (the p34(cdc2) phosphorylation site) with aspartic acid had only little effect on complex formation whereas an exchange of serine 392 (the protein kinase CK2 phosphorylation site) to aspartic acid resulted in a significant reduced relative binding affinity of p53 to p34(cdc2). The same result was obtained when the C-terminus of p53 was phosphorylated by purified protein kinase CK2 prior to examination of complex formation. In addition, the specificity of the complex formation has been checked by competition experiments with full length p53 proteins and the influence of cyclin B on complex formation was examined.	Univ Saarlandes, D-66421 Homburg, Germany	Saarland University	Wagner, P (corresponding author), Univ Saarlandes, Bldg 44, D-66421 Homburg, Germany.		Montenarh, Mathias/AAB-6689-2020					APPEL K, 1995, ONCOGENE, V11, P1971; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DAMICO D, 1992, ONCOGENE, V7, P339; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1994, ONCOGENE, V9, P3249; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARLOW E, 1981, J VIROL, V398, P61; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hecker D, 1996, ONCOGENE, V12, P953; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; KASTAN MB, 1993, ADV EXP MED BIOL, V339, P291; KRAISS S, 1990, ONCOGENE, V5, P845; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; LIU FS, 1994, OBSTET GYNECOL, V83, P118; LORENZ A, 1992, INT J ONCOL, V1, P571; MEEK DW, 1992, BIOCHEM J, V287, P1; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NISHIDA N, 1993, CANCER RES, V53, P368; SCHNEIDER E, 1995, HYBRIDOMA, V14, P329, DOI 10.1089/hyb.1995.14.329; SELTER H, 1994, INT J BIOCHEM, V26, P145, DOI 10.1016/0020-711X(94)90139-2; STURZBECHER HW, 1990, ONCOGENE, V5, P795; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WAGNER P, 1993, EUR J BIOCHEM, V217, P731, DOI 10.1111/j.1432-1033.1993.tb18299.x; WAGNER P, 1991, ONCOGENE, V6, P1539; Wagner P, 1995, FEBS LETT, V377, P155, DOI 10.1016/0014-5793(95)01329-6; WAGNER P, 1994, HYBRIDOMA, V13, P527, DOI 10.1089/hyb.1994.13.527; WAGNER P, 1995, INT J ONCOL, V7, P171; WAGNER P, 1994, INT J ONCOL, V4, P987; WAGNER P, 1994, INT J ONCOL, V4, P491; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0	49	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					105	111		10.1038/sj.onc.1201510	http://dx.doi.org/10.1038/sj.onc.1201510			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467949				2022-12-25	WOS:000071236800013
J	Waltz, SE; Toms, CLV; McDowell, SA; Clay, LA; Muraoka, RS; Air, EL; Sun, WY; Thomas, MB; Degen, SJF				Waltz, SE; Toms, CLV; McDowell, SA; Clay, LA; Muraoka, RS; Air, EL; Sun, WY; Thomas, MB; Degen, SJF			Characterization of the mouse Ron/Stk receptor tyrosine kinase gene	ONCOGENE			English	Article						Ron; Stk; hepatocyte growth factor-like protein receptor	MACROPHAGE-STIMULATING PROTEIN; HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; MOLECULAR-CLONING; CONSTITUTIVE ACTIVATION; MET; EXPRESSION; RON; MSP; STK	In an effort to understand the mechanisms governing the regulation of the mouse Ron receptor gene, a mouse genomic library was screened and overlapping clones coding for the Ron gene and flanking DNA were identified, Continuous DNA sequence was obtained for approximately 16.4 kilobases, The gene, from the initiator methionine to the polyadenylation site, is contained within 13 244 basepairs and contains 19 exons, Primer extension analyses were performed to determine the transcription start site of the mouse Ron transcript, Multiple transcription start sites were found which also appear to be used in transfected reporter constructs containing Ron 5' flanking DNA, To determine the location of sites which may be critical for the function of the Ron gene promoter, a series of chimeric genes containing serial deletions of the Ron gene promoter fused to the coding sequences for the chloramphenicol acetyl-transferase gene were constructed, Transient transfection analyses of these hybrid genes into various cell lines demonstrated that two regions of the Ron gene promoter, encompassing nucleotides -585 to -465 and from -465 to -285, are important for expression of this transcript in CMT-93 cells, Further analysis of the Ron promoter utilizing gel mobility shift analyses suggests that regions encompassing nucleotides -585 to -508 and nucleotides -375 to -285 appear to bind specific proteins which may be involved in the negative and positive regulation, respectively, of the mouse Ron gene.	Univ Cincinnati, Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45221 USA; Univ Cincinnati, Grad Program Dev Biol, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Degen, SJF (corresponding author), Univ Cincinnati, Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45221 USA.		Toms, Christy/L-4472-2013	Toms, Christy/0000-0003-4305-6357; Waltz, Susan/0000-0003-3572-4642	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009466] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07382] Funding Source: Medline; NIDDK NIH HHS [DK47003, DK09466] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERKNER KL, 1985, NUCLEIC ACIDS RES, V13, P841, DOI 10.1093/nar/13.3.841; BEZERRA JA, 1993, PROTEIN SCI, V2, P666; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Collesi C, 1996, MOL CELL BIOL, V16, P5518; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CORRELL PH, 1997, GENES FUNCTION, V1, P1; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DEGEN SJF, 1991, BIOCHEMISTRY-US, V30, P9781, DOI 10.1021/bi00104a030; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P6165, DOI 10.1021/bi00393a033; DEGEN SJF, 1992, GENOMICS, V13, P1368, DOI 10.1016/0888-7543(92)90073-2; DELGATTO F, 1995, BBA-GENE STRUCT EXPR, V1263, P93, DOI 10.1016/0167-4781(95)00082-R; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; Gambarotta G, 1996, ONCOGENE, V13, P1911; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HAN S, 1993, HEPATOCYTE GROWTH FA, P81; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; IWAMA A, 1995, BLOOD, V86, P3394, DOI 10.1182/blood.V86.9.3394.bloodjournal8693394; KRAYEV AS, 1982, NUCLEIC ACIDS RES, V10, P7461, DOI 10.1093/nar/10.23.7461; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QUANTIN B, 1995, DEV DYNAM, V204, P383, DOI 10.1002/aja.1002040405; RONSIN C, 1993, ONCOGENE, V8, P1195; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SHIMAMOTO A, 1993, FEBS LETT, V333, P61, DOI 10.1016/0014-5793(93)80375-5; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SKEEL A, 1994, J IMMUNOL, V152, P4618; Waltz SE, 1996, J BIOL CHEM, V271, P9024, DOI 10.1074/jbc.271.15.9024; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; ZHEN Z, 1994, ONCOGENE, V9, P1691	44	30	33	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					27	42		10.1038/sj.onc.1201508	http://dx.doi.org/10.1038/sj.onc.1201508			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467940				2022-12-25	WOS:000071236800004
J	Chang, DJ; Ji, C; Kim, KK; Casinghino, S; McCarthy, TL; Centrella, M				Chang, DJ; Ji, C; Kim, KK; Casinghino, S; McCarthy, TL; Centrella, M			Reduction in transforming growth factor beta receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT BONE; OSTEOPOROSIS; PHENOTYPE; CULTURES; COMPLEX; GENE	Glucocorticoid in excess suppresses bone formation in. vivo and disrupts bone matrix protein synthesis by osteoblasts in vitro, In contrast, transforming growth factor beta (TGF-beta) potently enhances bone matrix apposition. The rat TGF-beta type I receptor gene promoter contains cis-acting elements for transcription factor CBFa1, which increases in parallel with osteoblast differentiation, Here we present molecular data linking these events. We show that previously unexplained effects of glucocorticoid on bone loss may be mediated in part by suppression of CBFa1, with a resultant decrease in the expression and activity of the TGF-beta type I receptor on matrix-producing bone cells.	Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA	Yale University	Centrella, M (corresponding author), Yale Univ, Sch Med, Dept Surg Plast Surg, 333 Cedar St,POB 208041, New Haven, CT 06520 USA.				NIAMS NIH HHS [AR39201] Funding Source: Medline; NIDDK NIH HHS [DK47421] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039201, R29AR039201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047421] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER RA, 1994, ENDOCRIN METAB CLIN, V23, P641, DOI 10.1016/S0889-8529(18)30090-2; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; BELLOWS CG, 1987, ENDOCRINOLOGY, V121, P1985, DOI 10.1210/endo-121-6-1985; Centrella M, 1997, J CELL BIOCHEM, V67, P528, DOI 10.1002/(SICI)1097-4644(19971215)67:4<528::AID-JCB10>3.3.CO;2-5; Centrella M, 1996, ANN NY ACAD SCI, V785, P224, DOI 10.1111/j.1749-6632.1996.tb56267.x; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; Centrella M, 1996, J BIOL CHEM, V271, P18616, DOI 10.1074/jbc.271.31.18616; CENTRELLA M, 1995, HORMONAL REGULATION, P211; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; ITO Y, 1997, ONCOGENES TRANSCRIPT, V2, P107; Ji CH, 1996, J CELL BIOCHEM, V63, P478; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lukert Barbara P., 1996, P278; MAJORS J, 1983, P NATL ACAD SCI USA, V80, P5066; Meyers S, 1996, ONCOGENE, V13, P303; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Rodan GA, 1997, CELL, V89, P677, DOI 10.1016/S0092-8674(00)80249-4; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x	24	150	153	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4892	4896		10.1074/jbc.273.9.4892	http://dx.doi.org/10.1074/jbc.273.9.4892			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478931	hybrid			2022-12-25	WOS:000072310400015
J	Hazen, SL; d'Avignon, A; Anderson, MM; Hsu, FF; Heinecke, JW				Hazen, SL; d'Avignon, A; Anderson, MM; Hsu, FF; Heinecke, JW			Human neutrophils employ the myeloperoxidase hydrogen peroxide chloride system to oxidize alpha-amino acids to a family of reactive aldehydes - Mechanistic studies identifying labile intermediates along the reaction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; DEFICIENT MICE; OXIDATION; OXIDANTS; AUTOANTIBODIES; CHLORINATION; EOSINOPHILS; GENERATION; EPITOPES; TAURINE	We have recently demonstrated that neutrophils oxidize nearly all of the amino acids commonly found in plasma to a corresponding family of aldehydes in high yield. The reaction is mediated by hypochlorous acid (HOCl), the major oxidant generated by the myeloperoxidase-H2O2-Cl- system of phagocytes, We now present evidence for the underlying mechanism of this reaction, including the structural requirements and reaction intermediates formed, Utilizing mass spectrometry and isotopically labeled amino acids, we rule out hydrogen atom abstraction from the alpha-carbon as the initial event in aldehyde formation during amino acid oxidation, a pathway known to occur with ionizing radiation, Aldehyde generation from amino acids required the presence of an alpha-amino moiety; beta- and epsilon-amino acids did not form aldehydes upon oxidation by either the myeloperoxidase system or HOCl, generating stable monochloramines instead, UV difference spectroscopy, high pressure liquid chromatography, and multinuclear (H-1,N-15) NMR spectroscopy established that the conversion of alpha-amino acids into aldehydes begins with generation of an unstable alpha-monochloramine, which subsequently decomposes to yield an aldehyde, Precursor product relationships between alpha-amino acid and alpha-monochloramine, and alpha-monochloramine and aldehyde were confirmed by high pressure liquid chromatography purification of the reaction intermediate and subsequent H-1 and N-15 NMR spectroscopy. Collectively, these results detail the chemical mechanism and reaction intermediates generated during conversion of amino acids into aldehydes by myeloperoxidase-generated HOCl.	Washington Univ, Dept Mol Biol & Pharmacol, Div Atherosclerosis Nutr & Lipid Res, St Louis, MO 63110 USA; Washington Univ, Dept Med, St Louis, MO 63110 USA; Washington Univ, Dept Chem, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Heinecke, JW (corresponding author), Washington Univ, Dept Mol Biol & Pharmacol, Div Atherosclerosis Nutr & Lipid Res, Box 8046,660 S Euclid Ave, St Louis, MO 63110 USA.	heinecke@im.wustl.edu	Hazen, Stanley L/ABD-5845-2021	Hsu, Fong-Fu/0000-0001-5368-0183	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015013, R01AG012293] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00954] Funding Source: Medline; NIA NIH HHS [R01 AG12293, R01 AG15013] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBRICH J, 1982, P NATL ACAD SCI USA, V78, P210; Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BASS DA, 1985, CECIL TXB MED, P1011; Dakin HD, 1906, J BIOL CHEM, V1, P171; Dakin HD, 1908, J BIOL CHEM, V5, P409; Dakin HD, 1908, J BIOL CHEM, V4, P63; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; FURUKAWA J, 1963, POLYM ALDEHYDES OXIM, P43; GARRISON WARREN M., 1968, CURR TOP RADIAT RES, VVol. 4-4, P43; GARRISON WM, 1964, RADIATION RES      S, V4, P158; GRISHAM MB, 1984, J BIOL CHEM, V259, P6575; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1997, J BIOL CHEM, V272, P16990, DOI 10.1074/jbc.272.27.16990; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HAZEN SL, 1998, IN PRESS BIOCHEMISTR; KETTLE AJ, 1994, METHOD ENZYMOL, V233, P502; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P447; KNAPP DR, 1979, HDB ANAL DERIVATIZAT, P485; LINDER M, 1992, NUTR BIOCH METABOLIS, P98; MAXWELL CR, 1955, RADIAT RES, V2, P431, DOI 10.2307/3570188; MAYENO AN, 1989, J BIOL CHEM, V264, P5660; MONNIER VM, 1991, GERONTOLOGY, V37, P152; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; RAPER, 1932, BIOCH J, V266, P2000; ROWBOTTOM J, 1955, J BIOL CHEM, V212, P877; Schauenstein E, 1978, Ciba Found Symp, P225; SHARPLESS NE, 1955, RADIAT RES, V2, P135, DOI 10.2307/3570317; SHRINER RL, 1980, SYSTEMATIC IDENTIFIC, P161; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1991, P NATL ACAD SCI USA, V87, P389; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; SWALLOW AJ, 1960, RAD CHEM ORGANIC COM, P200; TEST ST, 1984, J CLIN INVEST, V74, P1341, DOI 10.1172/JCI111544; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1995, J BIOL CHEM, V270, P2906, DOI 10.1074/jbc.270.7.2906; THOMAS EL, 1985, J BIOL CHEM, V260, P3321; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; ZGLICZYNSKI JM, 1971, BIOCHIM BIOPHYS ACTA, V235, P419, DOI 10.1016/0005-2744(71)90281-6	42	160	173	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4997	5005		10.1074/jbc.273.9.4997	http://dx.doi.org/10.1074/jbc.273.9.4997			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478947	hybrid			2022-12-25	WOS:000072310400031
J	Pei, L				Pei, L			Genomic organization and identification of an enhancer element containing binding sites for multiple proteins in rat pituitary tumor-transforming gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; EMBRYONIC-DEVELOPMENT; CELL-DIFFERENTIATION; EGR FAMILY; EXPRESSION; PROMOTER; SP1; HOX-1.4; DOMAINS; TESTIS	The rat pituitary tumor transforming gene (PTTG) genomic structure was characterized in this study. Northern blot analysis showed that PTTG mRNA is highly expressed in testicular cell lines. Transfection of testicular cell lines with fusion constructs containing various portions of PTTG 5'-flanking sequences linked to luciferase showed that at least 745 base-pair (bp(s)) 5'-flanking sequences are required for PTTG transcriptional activation. DNaseI footprinting assays indicated that nuclear protein(s) from testicular cell lines interacts with PTTG 5'-flanking sequence between -509 and -624 bp, including two consensus Spl binding sites. Western and Southwestern blot analysis showed that three nuclear proteins in addition to Spl protein specifically interact with this DNA sequence and that two of these proteins are testicular cell-specific. Deletion of this 115-bp sequence from PTTG promoter resulted in complete loss of promoter function. Site-directed mutagenesis within the Spl consensus sequences indicated that the Spl binding sites are not critical components of the enhancer sequence for PTTG trancriptional activation in testicular cell lines. Finally, the 115-bp enhancer sequence was shown to be able to activate transcription from a heterologous promoter. These results suggest that PTTG transcriptional activation in testicular cell lines involves interactions of multiple nuclear factors with the PTTG 5' enhancer sequence.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Endocrinol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pei, L (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Endocrinol, 8700 Beverly Blvd,D-3066, Los Angeles, CA 90048 USA.	Pei@CSMC.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002346] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-02346] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DITTMER J, 1994, J BIOL CHEM, V269, P21428; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; GARRETT JE, 1989, MOL CELL BIOL, V9, P4381, DOI 10.1128/MCB.9.10.4381; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MULLER M, 1991, MOL ENDOCRINOL, V5, P1498, DOI 10.1210/mend-5-10-1498; PATWARDHAN S, 1991, ONCOGENE, V6, P917; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PROPST F, 1988, ONCOGENE, V2, P227; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; WATRIN F, 1993, DEV BIOL, V156, P136, DOI 10.1006/dbio.1993.1064; WILKINSON MF, 1990, DEV BIOL, V141, P451, DOI 10.1016/0012-1606(90)90400-D; WOLGEMUTH DJ, 1991, ANN NY ACAD SCI, V637, P300, DOI 10.1111/j.1749-6632.1991.tb27317.x; WOLGEMUTH DJ, 1987, P NATL ACAD SCI USA, V84, P5813, DOI 10.1073/pnas.84.16.5813; WOLGEMUTH DJ, 1986, EMBO J, V5, P1229, DOI 10.1002/j.1460-2075.1986.tb04351.x; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YU CY, 1991, J BIOL CHEM, V266, P8907; ZHANG DE, 1994, J BIOL CHEM, V269, P11425	29	33	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5219	5225		10.1074/jbc.273.9.5219	http://dx.doi.org/10.1074/jbc.273.9.5219			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478977	hybrid			2022-12-25	WOS:000072310400061
J	Banghart, LR; Chamberlain, CW; Velarde, J; Korobko, IV; Ogg, SL; Jack, LJW; Vakharia, VN; Mather, IH				Banghart, LR; Chamberlain, CW; Velarde, J; Korobko, IV; Ogg, SL; Jack, LJW; Vakharia, VN; Mather, IH			Butyrophilin is expressed in mammary epithelial cells from a single-sized messenger RNA as a type I membrane glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-GLOBULE-MEMBRANE; MILK LIPID GLOBULES; IMMUNOGLOBULIN SUPERFAMILY; BOVINE BUTYROPHILIN; ENDOPLASMIC-RETICULUM; APICAL GLYCOPROTEIN; CYTOPLASMIC DOMAIN; XANTHINE-OXIDASE; PROTEIN; SURFACE	We investigated the expression of butyrophilin in eukaryotic cells with a view to determining the number of mRNA species, the incorporation of the peptide chain into microsomes, and the topology of the processed protein in biological membranes, Butyrophilin is synthesized from a single sized mRNA in both bovine and murine lactating mammary tissue and associates with microsomal membranes with a type I topology (N-exo.C-cyto) via a single hydrophobic anchor in the middle of the sequence. Several isoelectric variants of the protein were detected in cellular membranes from lactating bovine mammary tissue and in the milk-fat-globule membrane. We found no evidence for soluble forms of butyrophilin in postmicrosomal supernatants, The 66-kDa protein appears to be subjected to limited proteolysis, giving rise to a 62-kDa fragment lacking the C terminus and to other more minor fragments of lower M-r, in the milk-fat-globule membrane. Antipeptide antibodies to epitopes within the N- nd C-terminal domains were used to show that butyrophilin retains a type I topology in plasma membranes when expressed in insect cells from a baculovirus vector, and in secreted milk-fat globules, These data do not agree with previous suggestions that butyrophilin may exist in cytoplasmic soluble forms, or be reorganized in the plane of the lipid bilayer during secretion in lipid droplets from mammary cells. The results are discussed with reference to the role butyrophilin may play as the principal scaffold for the assembly of a complex with xanthine oxidase and other proteins that functions in the budding and release of milk-fat globules from the apical surface during lactation.	Univ Maryland, Dept Anim & Avian Sci, College Pk, MD 20742 USA; Univ Maryland, Agr Biotechnol Ctr, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Mather, IH (corresponding author), Univ Maryland, Dept Anim & Avian Sci, College Pk, MD 20742 USA.	im2@umail.umd.edu		Vakharia, Vikram/0000-0002-0955-3010	FOGARTY INTERNATIONAL CENTER [F06TW001508] Funding Source: NIH RePORTER; FIC NIH HHS [FO6TWO1508-01] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		BANGHART LR, 1992, MOL BIOL CELL, V3, pA208; BELLINI M, 1993, EMBO J, V12, P107, DOI 10.1002/j.1460-2075.1993.tb05636.x; BUCHHEIM W, 1982, NATURWISSENSCHAFTEN, V69, P505, DOI 10.1007/BF00365826; BUCHHEIM W, 1988, BIOL HUMAN MILK, V15, P27; Davey HW, 1997, GENE, V199, P57, DOI 10.1016/S0378-1119(97)00346-6; DEENEY JT, 1985, EUR J CELL BIOL, V38, P16; DYLEWSKI DP, 1984, EUR J CELL BIOL, V35, P99; FRANKE WW, 1981, J CELL BIOL, V89, P485, DOI 10.1083/jcb.89.3.485; FREUDENSTEIN C, 1979, EXP CELL RES, V118, P277, DOI 10.1016/0014-4827(79)90153-8; GARDINIER MV, 1992, J NEUROSCI RES, V33, P177, DOI 10.1002/jnr.490330123; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; Heid HW, 1996, BIOCHEM J, V320, P1025, DOI 10.1042/bj3201025; HEID HW, 1983, BIOCHIM BIOPHYS ACTA, V728, P228, DOI 10.1016/0005-2736(83)90476-5; HINK WF, 1991, IN VITRO CELL DEV B, V27, P397, DOI 10.1007/BF02630959; Ishii T, 1995, BBA-GEN SUBJECTS, V1245, P285, DOI 10.1016/0304-4165(95)00102-6; JACK LJW, 1990, J BIOL CHEM, V265, P14481; JARASCH ED, 1981, CELL, V25, P67, DOI 10.1016/0092-8674(81)90232-4; Jensen R. G., 1995, HDB MILK COMPOSITION, P5; Keenan T. W., 1988, Fundamentals of dairy chemistry., P511; KEON BH, 1994, BBA-LIPID LIPID MET, V1215, P327, DOI 10.1016/0005-2760(94)90061-2; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LINSLEY PS, 1994, PROTEIN SCI, V3, P1341, DOI 10.1002/pro.5560030820; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mather I. H., 1987, The mammary gland. Development, regulation, and function., P217; MATHER IH, 1975, J MEMBRANE BIOL, V21, P65, DOI 10.1007/BF01941062; MATHER IH, 1993, J DAIRY SCI, V76, P3832, DOI 10.3168/jds.S0022-0302(93)77726-7; MATHER IH, 1978, BIOCHIM BIOPHYS ACTA, V514, P25, DOI 10.1016/0005-2736(78)90074-3; MATHER IH, 1980, EUR J BIOCHEM, V110, P327, DOI 10.1111/j.1432-1033.1980.tb04871.x; MELANCON P, 1986, EMBO J, V5, P1551, DOI 10.1002/j.1460-2075.1986.tb04396.x; MONDY BL, 1993, PROTOPLASMA, V177, P32, DOI 10.1007/BF01403396; NEIRA LM, 1990, PROTOPLASMA, V159, P168, DOI 10.1007/BF01322599; NIELSEN CS, 1977, BIOCHIM BIOPHYS ACTA, V466, P496, DOI 10.1016/0005-2736(77)90342-X; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Ogg SL, 1996, MAMM GENOME, V7, P900, DOI 10.1007/s003359900265; PACIOTTI GF, 1992, PROG NEUROENDOCRINIM, V5, P21; PATTON S, 1986, LIPIDS, V21, P170, DOI 10.1007/BF02534441; PATTON S, 1975, BIOCHIM BIOPHYS ACTA, V415, P273, DOI 10.1016/0304-4157(75)90011-8; PINTODASILVA P, 1980, EXP CELL RES, V125, P127, DOI 10.1016/0014-4827(80)90197-4; Ruddy DA, 1997, GENOME RES, V7, P441, DOI 10.1101/gr.7.5.441; SATO T, 1995, J BIOCHEM-TOKYO, V117, P147, DOI 10.1093/oxfordjournals.jbchem.a124702; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TaziAhnini R, 1997, IMMUNOGENETICS, V47, P55, DOI 10.1007/s002510050326; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERNET C, 1993, J MOL EVOL, V37, P600; WARD WR, 1975, ARCH BIOCHEM BIOPHYS, V169, P695; WELSCH U, 1988, HISTOCHEMISTRY, V88, P357; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WOODING FBP, 1975, CELL TISSUE RES, V165, P113, DOI 10.1007/BF00222804; ZERBAN H, 1978, CELL BIOL INT REP, V2, P87, DOI 10.1016/0309-1651(78)90088-7; ZERIAL M, 1986, EMBO J, V5, P1543, DOI 10.1002/j.1460-2075.1986.tb04395.x; [No title captured]	54	53	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4171	4179		10.1074/jbc.273.7.4171	http://dx.doi.org/10.1074/jbc.273.7.4171			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461613	hybrid			2022-12-25	WOS:000072048400055
J	Yao, GQ; Sun, BH; Hammond, EE; Spencer, EN; Horowitz, MC; Insogna, KL; Weir, EC				Yao, GQ; Sun, BH; Hammond, EE; Spencer, EN; Horowitz, MC; Insogna, KL; Weir, EC			The cell-surface form of colony-stimulating factor-1 is regulated by osteotropic agents and supports formation of multinucleated osteoclast-like cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I CSF-1; OP OP MOUSE; PARATHYROID-HORMONE; OSTEOBLASTIC CELLS; MOLECULAR-CLONING; MESSENGER-RNA; BONE-RESORPTION; C-FMS; EXPRESSION; RECEPTORS	Colony-stimulating factor-1 (CSF-1) is a hematopoietic growth factor that is released by osteoblasts and is recognized to play a critical role in bone remodeling in vivo and in vitro. CSF-1 is synthesized as a soluble or cell-surface protein. It is unclear, however, whether human osteoblasts express both molecular forms of CSF-1, and whether these isoforms can independently mediate osteoclastogenesis. In the present study, using a combination of quantitative reverse transcriptase polymerase chain reaction, flow cytometry, and Western immunoblot analysis, we have demonstrated that human osteoblast-like cells as well as primary human osteoblasts express the cell-surface form of CSF-1 both constitutively and in response to parathyroid hormone and tumor necrosis factor. Furthermore, using an in vitro coculture system, we have shown that cell-surface CSF-1 alone is sufficient to support osteoclast formation. These findings may be especially significant in view of evidence that direct cell-to-cell contact is critical for osteoclast formation, and suggest that differential regulation of expression of the CSF-1 isoforms may influence osteoclast function modulated by osteotropic hormones.	Yale Univ, Sch Med, Comparat Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Orthopaed & Rehabil, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Weir, EC (corresponding author), Yale Univ, Sch Med, Comparat Med Sect, POB 208016, New Haven, CT 06520 USA.	eleanor.weir@yale.edu		Insogna, Karl/0000-0001-6973-5679	NIAMS NIH HHS [AR39571] Funding Source: Medline; NIDDK NIH HHS [DK45228, DK50859] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050859, R01DK045228] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONIOLICORBOZ V, 1992, ENDOCRINOLOGY, V130, P437; BARON R, 1983, BONE HISTOMORPHOMETR, P31; BEGG SK, 1993, J EXP MED, V177, P237, DOI 10.1084/jem.177.1.237; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIVITELLI R, 1994, J BONE MINER RES, V9, P1407; DAITER E, 1992, J CLIN ENDOCR METAB, V74, P850, DOI 10.1210/jc.74.4.850; DIVIACCO S, 1992, GENE, V122, P3013; ELFORD PR, 1987, CALCIFIED TISSUE INT, V41, P151, DOI 10.1007/BF02563795; ELIAS JA, 1995, ENDOCRINOLOGY, V136, P489, DOI 10.1210/en.136.2.489; Felix R, 1996, J CELL PHYSIOL, V166, P311, DOI 10.1002/(SICI)1097-4652(199602)166:2<311::AID-JCP9>3.0.CO;2-S; FELIX R, 1989, CALCIFIED TISSUE INT, V44, P356, DOI 10.1007/BF02556317; HATTERSLEY G, 1991, BIOCHEM BIOPH RES CO, V177, P526, DOI 10.1016/0006-291X(91)92015-C; HOFSTETTER W, 1992, P NATL ACAD SCI USA, V89, P9637, DOI 10.1073/pnas.89.20.9637; HUME DA, 1995, J INTERF CYTOK RES, V15, P279, DOI 10.1089/jir.1995.15.279; JIN CF, 1994, PCR METH APPL, V3, P252; Kaplan DL, 1996, J CELL PHYSIOL, V168, P199; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; MAHAFFEY JE, 1979, J BIOL CHEM, V254, P6496; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; MOROHASHI T, 1994, J BONE MINER RES, V9, P401; PAMPFER S, 1991, MOL ENDOCRINOL, V5, P1931, DOI 10.1210/mend-5-12-1931; Perkins SL, 1995, AM J PHYSIOL-ENDOC M, V269, pE1024, DOI 10.1152/ajpendo.1995.269.6.E1024; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RETTENMIER CW, 1988, MOL CELL BIOL, V8, P5026, DOI 10.1128/MCB.8.11.5026; RETTENMIER CW, 1989, CURR TOP MICROBIOL, V149, P129; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; ROULEAU MF, 1988, ENDOCRINOLOGY, V123, P187, DOI 10.1210/endo-123-1-187; Rubin J, 1996, CALCIFIED TISSUE INT, V59, P291, DOI 10.1007/s002239900125; Sarma U, 1996, BLOOD, V88, P2531, DOI 10.1182/blood.V88.7.2531.bloodjournal8872531; SHADLE PJ, 1989, J CELL BIOCHEM, V40, P91, DOI 10.1002/jcb.240400110; SHIINAISHIMI Y, 1986, BIOCHEM BIOPH RES CO, V134, P400, DOI 10.1016/0006-291X(86)90577-2; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; TAKAHASHI N, 1991, ENDOCRINOLOGY, V128, P1792, DOI 10.1210/endo-128-4-1792; TAKAHASHI N, 1991, J BONE MINER RES, V6, P977; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; WEIR EC, 1993, J BONE MINER RES, V8, P1507; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WIKTORJEDRZEJCZAK W, 1982, J EXP MED, V156, P1516, DOI 10.1084/jem.156.5.1516; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; Yao GQ, 1996, BIOCHEM PHARMACOL, V51, P431, DOI 10.1016/0006-2952(95)02198-1; YAO GQ, 1995, VIRUS GENES, V9, P247, DOI 10.1007/BF01702880	44	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4119	4128		10.1074/jbc.273.7.4119	http://dx.doi.org/10.1074/jbc.273.7.4119			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461606	hybrid			2022-12-25	WOS:000072048400048
J	Barylko, B; Binns, D; Lin, KM; Atkinson, MAL; Jameson, DM; Yin, HL; Albanesi, JP				Barylko, B; Binns, D; Lin, KM; Atkinson, MAL; Jameson, DM; Yin, HL; Albanesi, JP			Synergistic activation of dynamin GTPase by Grb2 and phosphoinositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; CRYSTAL-STRUCTURE; ACIDIC PHOSPHOLIPIDS; MICROTUBULES; BINDING; KINASE; PHOSPHORYLATION; ENDOCYTOSIS; SUBUNITS; VESICLES	Hydrolysis of GTP by dynamin is essential for budding clathrin-coated vesicles from the plasma membrane. Two distinct domains of dynamin are implicated in the interactions with dynamin GTPase activators. Microtubules and Grb2 bind to the carboxyl-terminal proline/arginine-rich domain (PRD), whereas phosphoinositides bind to the pleckstrin homology (PH) domain. In this study we tested the effect of different phosphoinositides on dynamin GTPase activity and found that the best activator is phosphatidylinositol 4,5-bisphosphate followed by 1-O-(1,2-di-O-palmitoyl-sn-glycerol-3-benzyloxyphosphoryl)-D-myo-inositol 3,4,5-triphosphate. Phosphatidylinositol 4-phosphate was a weak activator and phosphatidylinositol 3,4-bisphosphate did not activate GTPase at all. We then addressed the question of whether both domains of dynamin, PRD and PH, can be engaged simultaneously, and determined the effects of dual occupancy on dynamin GTPase activity. We found that Grb2 and phosphatidylinositol 4,5-bisphosphate together increased the dynamin GTPase activity up to 4-fold higher than that obtained by these activators tested separately, and also reduced the dynamin concentration required for half-maximal activities by 3-fold. These results indicate that both stimulators can bind to dynamin simultaneously resulting in superactivation of dynamin GTPase activity. We propose that SH3-containing proteins such as Grb2 bind to the dynamin PRD to target it to clathrin-coated pits and prime it for superactivation by phosphoinositides.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, Hlth Sci Ctr, Tyler, TX 75708 USA; Univ Hawaii, Dept Biochem & Biophys, Honolulu, HI 96822 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT); University of Hawaii System	Albanesi, JP (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031430] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM5112] Funding Source: Medline; NINDS NIH HHS [NS31430] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohn E. J., 1943, PROTEINS AMINO ACIDS; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P59; Earnest S, 1996, FEBS LETT, V396, P62, DOI 10.1016/0014-5793(96)01074-5; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HOOD LE, 1984, IMMUNOLOGY, P48; KORN ED, 1982, METHOD ENZYMOL, V85, P357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; McClure SJ, 1996, MOL MEMBR BIOL, V13, P189, DOI 10.3109/09687689609160598; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VALLEE RB, 1995, TRENDS CELL BIOL, V5, P43, DOI 10.1016/S0962-8924(00)88937-0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P357; Woscholski R, 1997, J BIOL CHEM, V272, P9625; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	47	109	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3791	3797		10.1074/jbc.273.6.3791	http://dx.doi.org/10.1074/jbc.273.6.3791			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452513	hybrid			2022-12-25	WOS:000071822300098
J	Brasier, AR; Jamaluddin, M; Casola, A; Duan, WL; Shen, Q; Garafalo, RP				Brasier, AR; Jamaluddin, M; Casola, A; Duan, WL; Shen, Q; Garafalo, RP			A promoter recruitment mechanism for tumor necrosis factor-alpha-induced interleukin-8 transcription in type II pulmonary epithelial cells - Dependence of nuclear abundance of Rel A, NF-kappa B1 and c-Rel transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RESPIRATORY SYNCYTIAL VIRUS; UBIQUITIN-PROTEASOME PATHWAY; TATA-BINDING PROTEIN; GENE-EXPRESSION; MMTV PROMOTER; IN-VIVO; ACTIVATION; DNA; INFECTION	The alveolar macrophage-derived peptide tumor necrosis factor-alpha (TNF alpha) initiates pulmonary inflammation through its ability to stimulate interleukin-8 (IL-8) synthesis in alveolar epithelial cells through an incompletely described transcriptional mechanism. In this study, we use the technique of ligation-mediated polymerase chain reaction (LMPCR) to record changes in transcription factor occupancy of the IL-8 promoter after TNF alpha stimulation of A549 human alveolar cells. Using dimethylsulfate/LMPCR, no detectable proteins bind the TATA box in unstimulated cells. By contrast, TNF alpha rapidly induces protection of G residues at -79 and -80 coincident with endogenous IL-8 gene transcription. Using DNase I/LMPCR, we observe inducible protection of nucleotides -60 to -99 (the TNF response element) and nucleotides -3 to -32 (containing the TATA box). Surprisingly, extensive TATA box protection is only seen after TNF alpha stimulation Using a two-step microaffinity isolation/Western immunoblot DNA binding assay, we observe that the NF-kappa B subunits Rel A, NF-kappa B1, and c-Rel inducibly bind the TNF response element; these proteins undergo rapid TNF alpha-inducible increases in nuclear abundance as a consequence of I kappa B alpha proteolysis. Furthermore, the peptide aldehyde N-acetyl-Leu-Leu-norleucinal, an agent that blocks both I kappa B alpha proteolysis and NF-kappa B subunit translocation, abrogates recombinant human TNF alpha-inducible IL-8 gene transcription. These studies demonstrate that IL-8 is activated by a promoter recruitment mechanism in alveolar epithelial cells, where NF-kappa B subunit translocation is required for (and coincident with) binding of the constitutively active TATA box-binding proteins.	Univ Texas, Med Branch, Div Endocrinol, Dept Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Brasier, AR (corresponding author), Univ Texas, Med Branch, Div Endocrinol, Dept Med, MRB 8-138,301 Univ Blvd, Galveston, TX 77555 USA.	arbrasie@utmb.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015939, R01AI040218] Funding Source: NIH RePORTER; NIAID NIH HHS [1 R01 AI40218-01A1, AI/HL 15939-14A1] Funding Source: Medline; NICHD NIH HHS [R30HD 27841] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARNOLD R, 1994, IMMUNOLOGY, V82, P126; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; Beato M, 1996, J MOL MED, V74, P711, DOI 10.1007/s001090050076; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEUTLER B, 1995, J INVEST MED, V43, P227; BRASIER AR, 1994, J BIOL CHEM, V269, P10341; BRASIER AR, 1991, METHODS NEUROSCIENCE, P108; BRASIER AR, 1990, CURRENT PROTOCOLS MO; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHOI AMK, 1992, FEBS LETT, V309, P327, DOI 10.1016/0014-5793(92)80799-M; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; ECKMANN L, 1993, INFECT IMMUN, V61, P4569, DOI 10.1128/IAI.61.11.4569-4574.1993; Garofalo R, 1996, J VIROL, V70, P8773, DOI 10.1128/JVI.70.12.8773-8781.1996; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; Han YQ, 1997, J BIOL CHEM, V272, P9825; HAYES PJ, 1994, J MED VIROL, V42, P323, DOI 10.1002/jmv.1890420402; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jamaluddin M, 1996, J VIROL, V70, P1554, DOI 10.1128/JVI.70.3.1554-1563.1996; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; Khair OA, 1996, EUR RESPIR J, V9, P1913, DOI 10.1183/09031936.96.09091913; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KWON J, 1994, AM J PHYSIOL, V267, pL398; Li JY, 1996, MOL ENDOCRINOL, V10, P252, DOI 10.1210/me.10.3.252; LI Z, 1989, GENE DEV, V3, P1814, DOI 10.1101/gad.3.11.1814; Liu L, 1996, AM J RESP CELL MOL, V15, P771, DOI 10.1165/ajrcmb.15.6.8969272; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MASSION PP, 1994, J CLIN INVEST, V93, P26, DOI 10.1172/JCI116954; MUELLER P R, 1991, Methods (Orlando), V2, P20, DOI 10.1016/S1046-2023(05)80122-7; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STADNYK AW, 1994, FASEB J, V8, P1041, DOI 10.1096/fasebj.8.13.7926369; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506	56	149	153	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3551	3561		10.1074/jbc.273.6.3551	http://dx.doi.org/10.1074/jbc.273.6.3551			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452482	hybrid			2022-12-25	WOS:000071822300067
J	Justice, MC; Hsu, MJ; Tse, B; Ku, T; Balkovec, J; Schmatz, D; Nielsen, J				Justice, MC; Hsu, MJ; Tse, B; Ku, T; Balkovec, J; Schmatz, D; Nielsen, J			Elongation factor 2 as a novel target for selective inhibition of fungal protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SHUTTLE VECTORS; EF-G; TRANSLATION; RESISTANT; SYSTEM; GDP	Elongation factor 2 (EF2) is an essential protein catalyzing ribosomal translocation during protein synthesis and is highly conserved in all eukaryotes. It is largely interchangeable in translation systems reconstituted from such divergent organisms as human, wheat, and fungi, We have identified the sordarins as selective inhibitors of fungal protein synthesis acting via a specific interaction with EF2 despite the high degree of amino acid sequence homology exhibited by EF2s from various eukaryotes, In vitro reconstitution assays using purified components from human, yeast, and plant cells demonstrate that sordarin sensitivity is dependent on fungal EF2, Genetic analysis of sordarin-resistant mutants of Saccharomyces cerevisiae shows that resistance to the inhibitor is linked to the genes EFT1 and EFT2 that encode EF2, Sordarin blocks ribosomal translocation by stabilizing the fungal EF2-ribosome complex in a manner similar to that of fusidic acid, The fungal specificity of the sordarins, along with a detailed understanding of its mechanism of action, make EF2 an attractive antifungal target, These findings are of particular significance due to the need for new antifungal agents.	Merck Res Labs, Dept Basic Anim Sci Res, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Nielsen, J (corresponding author), Merck Res Labs, Dept Basic Anim Sci Res, Rahway, NJ 07065 USA.	jennifer_nielsen_kahn@merck.com						BELFIELD GP, 1993, MOL MICROBIOL, V9, P411, DOI 10.1111/j.1365-2958.1993.tb01702.x; BODLEY JW, 1970, FEBS LETT, V11, P153, DOI 10.1016/0014-5793(70)80516-6; COLLINS JF, 1971, J BIOL CHEM, V246, P1049; COVAL SJ, 1995, J ANTIBIOT, V48, P1171, DOI 10.7164/antibiotics.48.1171; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Czworkowski J, 1996, PROG NUCLEIC ACID RE, V54, P293, DOI 10.1016/S0079-6603(08)60366-9; Evarsson A., 1994, EMBO J, V13, P3669; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HAUSER D, 1971, HELV CHIM ACTA, V54, P1178, DOI 10.1002/hlca.19710540427; HUSSAIN I, 1986, GENE, V46, P13, DOI 10.1016/0378-1119(86)90162-9; Johanson U, 1996, J MOL BIOL, V258, P420, DOI 10.1006/jmbi.1996.0259; JOHANSON U, 1994, GENE, V143, P55, DOI 10.1016/0378-1119(94)90604-1; JURNAK F, 1994, STRUCTURE, V2, P785, DOI 10.1016/S0969-2126(94)00078-6; LAUER SJ, 1984, J BIOL CHEM, V259, P1644; PHAN LD, 1993, J BIOL CHEM, V268, P8665; Sambrook J., 2002, MOL CLONING LAB MANU; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; Skogerson L, 1979, Methods Enzymol, V60, P676	19	134	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3148	3151		10.1074/jbc.273.6.3148	http://dx.doi.org/10.1074/jbc.273.6.3148			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452424	hybrid			2022-12-25	WOS:000071822300009
J	Siddiqui, AA; Garland, JR; Dalton, MB; Sinensky, M				Siddiqui, AA; Garland, JR; Dalton, MB; Sinensky, M			Evidence for a high affinity, saturable, prenylation-dependent p21(Ha-ras) binding site in plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYBASIC DOMAIN; RAS PROTEINS; PURIFICATION; PALMITOYLATION; INSULIN	Oncogenic p21(ras) proteins can only exert their stimulation of cellular proliferation when plasma membrane-associated. This membrane association has an absolute requirement for post-translational modification with isoprenoids. The mechanism by which isoprenoids participate in the specific association of p21(ras) with plasma membranes is the subject of this report. We present in vitro evidence for a plasma membrane binding protein for p21(ras) that can recognize the isoprenoid substituent and, therefore, may facilitate the localization of p21(ras).	E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA	East Tennessee State University	Sinensky, M (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Box 70581, Johnson City, TN 37614 USA.	sinensky@etsu-tn.edu						Bylund D.B., 1990, METHODS NEUROTRANSMI, P1; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CAMP LA, 1993, J BIOL CHEM, V268, P22566; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; FLEISCHER S, 1975, METHOD ENZYMOL, V3, P299; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GHOMASCHI F, 1995, BIOCHEMISTRY-US, V35, P11910; Goalstone ML, 1996, J BIOL CHEM, V271, P27585, DOI 10.1074/jbc.271.44.27585; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KHOSRAVIFAR R, 1995, METHOD ENZYMOL, V255, P56; Kilic F, 1997, J BIOL CHEM, V272, P5298, DOI 10.1074/jbc.272.8.5298; LOWE PN, 1990, ONCOGENE, V5, P1045; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PFENNING MA, 1990, METHODS NEUROTRANSMI, P156; PORFIRI E, 1995, METHOD ENZYMOL, V255, P13; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; SIDDIQUI AA, 1985, J HELMINTHOL, V59, P263, DOI 10.1017/S0022149X00008063; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Summers MD, 1987, MANUAL METHODS BACUL; TAN EW, 1991, J BIOL CHEM, V266, P10719; WHITTENBERGER B, 1977, P NATL ACAD SCI USA, V74, P2251, DOI 10.1073/pnas.74.6.2251; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	29	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3712	3717		10.1074/jbc.273.6.3712	http://dx.doi.org/10.1074/jbc.273.6.3712			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452502	hybrid			2022-12-25	WOS:000071822300087
J	Kadrmas, JL; Raetz, CRH				Kadrmas, JL; Raetz, CRH			Enzymatic synthesis of lipopolysaccharide in Escherichia coli - Purification and properties of heptosyltransferase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; T7 RNA-POLYMERASE; SALMONELLA-TYPHIMURIUM; LIPID-A; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; ANTIBACTERIAL AGENTS; CLONED GENES; BIOSYNTHESIS; EXPRESSION; ENDOTOXIN	Heptosyltransferase I, encoded by the rfaC(waaC) gene of Escherichia coli, is thought to add L-glycero-D-manno-heptose to the inner 3-deoxy-D-manno-octulosonic acid (Kdo) residue of the lipopolysaccharide core. Lipopolysaccharide isolated from mutants defective in rfaC lack heptose and all other sugars distal to heptose. The putative donor, ADP-L-glycero-D-manno-heptose, has never been fully characterized and is not readily available, In cell extracts, the analog ADP-mannose can serve as an alternative donor for RfaC-catalyzed glycosylation of the acceptor, Kdo(2)-lipid IVA. Using a T7 promoter construct that overexpresses RfaC similar to 15,000-fold, the enzyme has been purified to near homogeneity. NH2-terminal sequencing confirms that the purified enzyme is the rfaC gene product. The subunit molecular mass is 36 kDa, Enzymatic activity is dependent upon the presence of Triton X-100 and is maximal at pH 7.5. The apparent K-m (determined at near saturating concentrations of the second substrate) is 1.5 mM for ADP-mannose and 4.5 mu M for Kdo(2)-lipid IVA. Chemical hydrolysis of the RfaC reaction product at 100 degrees C in the presence of sodium acetate and 1% sodium dodecyl sulfate generates fragments consistent with the inner Kdo residue of Kdo(2)-lipid IVA as the site of mannosylation, The analog, Kdo-lipid IVA, functions as an acceptor, but is mannosylated at less than 1% the rate of Kdo(2)-lipid IVA. The purified enzyme displays no activity with ADP-glucose, GDP-mannose, UDP-glucose, or UDP-galactose. Mannosylation of Kdo(2)-lipid IVA catalyzed by RfaC proceeds in high yield and may be useful for the synthesis of lipopolysaccharide analogs. Pure RfaC can also be used together with Kdo(2)-[4'P-32]lipid IVA to assay for the physiological donor (presumably ADP-L-glycero-D-manno-heptose) in a crude, low molecular weight fraction isolated from wild type cells.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007105, R37GM051796, R01GM051796] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07105, GM-51796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BEHUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BOWMAN HG, 1968, GENET RES, V12, P169; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAROFF M, 1991, J BIOL CHEM, V266, P18543; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; CREEGER ES, 1979, J BIOL CHEM, V254, P804; DANKERT M, 1964, BIOCHEM BIOPH RES CO, V14, P358, DOI 10.1016/S0006-291X(64)80010-3; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DING L, 1994, J BIOL CHEM, V269, P24384; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; GRUNDSTROM T, 1980, J BACTERIOL, V143, P1127; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HAMPTON RY, 1992, METHOD ENZYMOL, V209, P466; HAVEKES L, 1977, J BACTERIOL, V129, P1; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kadrmas JL, 1997, FASEB J, V11, pA1421; KONTROHR T, 1981, J BIOL CHEM, V256, P7715; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN V, 1973, EUR J BIOCHEM, V32, P268, DOI 10.1111/j.1432-1033.1973.tb02607.x; Makela P. H., 1984, HDB ENDOTOXIN, P59; Miller J.H., 1972, EXPT MOL GENETICS; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; NISHIMURA A, 1992, MICROBIOL REV, V56, P137, DOI 10.1128/MMBR.56.1.137-151.1992; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; PASSERON S, 1964, BIOCHIM BIOPHYS ACTA, V89, P372, DOI 10.1016/0926-6569(64)90233-0; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; REEVES PR, 1994, BACTERIAL CELL WALL, V27, P281; RICK PD, 1977, J BIOL CHEM, V252, P4895; RICK PD, 1987, ESCHERICHIA COLI SAL, V1, P648; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; ROANTREE RJ, 1977, J GEN MICROBIOL, V103, P223, DOI 10.1099/00221287-103-2-223; RONCERO C, 1992, J BACTERIOL, V174, P3250, DOI 10.1128/jb.174.10.3250-3260.1992; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SANDERSON KE, 1974, CAN J MICROBIOL, V20, P1127, DOI 10.1139/m74-175; SANDERSON KE, 1988, MICROBIOL REV, V52, P485, DOI 10.1128/MMBR.52.4.485-532.1988; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SCHNAITMAN CA, 1991, J BACTERIOL, V173, P7410, DOI 10.1128/jb.173.23.7410-7411.1991; SIRISENA DM, 1992, J BIOL CHEM, V267, P18874; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; STRAIN SM, 1983, J BIOL CHEM, V258, P3466; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WALENGA RW, 1980, J BIOL CHEM, V255, P4257; White KA, 1997, J BIOL CHEM, V272, P16555, DOI 10.1074/jbc.272.26.16555	54	61	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2799	2807		10.1074/jbc.273.5.2799	http://dx.doi.org/10.1074/jbc.273.5.2799			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446588	hybrid			2022-12-25	WOS:000071736600043
J	Gaudin, P; Maoret, JJ; Couvineau, A; Rouyer-Fessard, C; Laburthe, M				Gaudin, P; Maoret, JJ; Couvineau, A; Rouyer-Fessard, C; Laburthe, M			Constitutive activation of the human vasoactive intestinal peptide 1 receptor, a member of the new class II family of G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAGON-LIKE PEPTIDE-1; HORMONE (PTH)/PTH-RELATED PEPTIDE; TERMINAL EXTRACELLULAR DOMAIN; VIP RECEPTOR; THYROTROPIN-RECEPTOR; ADENYLATE-CYCLASE; LIGAND-BINDING; SECRETIN; MUTATION; MUTAGENESIS	The human vasoactive intestinal peptide (VIP) 1 receptor belongs to the new class II subfamily of G protein-coupled receptors, Specific change by mutagenesis of a strictly conserved histidine into arginine at position 178 of the human VIP1 receptor resulted in its constitutive activation with respect to cAMP production. Transfection of the H178R mutant into COS cells resulted in a 3.5-fold increase in the cAMP level as compared with cells transfected with the wild type receptor or the vector alone. This increase was proportional to the amount of transfected cDNA The H178R mutant exhibited an otherwise normal cAMP response to VIP as well as a dissociation constant similar to that of the wild type receptor. Other mutants at position 178 such as H178K, H178A, and H178D were not constitutively activated. They were otherwise expressed at the cell surface of transfected nonpermeabilized cells. Double mutants were then constructed in which the H178R mutation was associated with a point mutation in the the N-terminal extracellular domain that totally abolished VIP binding or VIP-stimulated cAMP production, i.e. E36A or D68A. The corresponding double mutants H178R/E36A and H178R/D68A were no longer constitutively activated, A control double mutant (H178R/D132A) with an unaltered dissociation constant for VIP and cAMP response to VIP was still constitutively activated. Our findings demonstrate that constitutive activation of the VIP1 receptor by mutation of His(178) into R requires the functional integrity of the N-terminal extracellular VIP binding domain. They might provide interesting generalities about the activation process of G protein-coupled receptors.	Fac Med Xavier Bichat, INSERM, U410, F-75870 Paris 18, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Laburthe, M (corresponding author), Fac Med Xavier Bichat, INSERM, U410, BP 416, F-75870 Paris 18, France.	laburthe@bichat.inserm.fr	couvineau, alain/T-3466-2019; couvineau, alain/G-3641-2013; LABURTHE, Marc/C-1875-2012	couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168; 				BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; BIRNBAUMER M, 1995, J RECEPT SIGNAL TR R, V15, P131, DOI 10.3109/10799899509045213; BRADFORD M, 1979, ANAL BIOCHEM, V78, P248; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; Couvineau A, 1996, BIOCHEMISTRY-US, V35, P1745, DOI 10.1021/bi952022h; Couvineau A, 1996, J BIOL CHEM, V271, P12795, DOI 10.1074/jbc.271.22.12795; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; COUVINEAU A, 1986, J BIOL CHEM, V261, P14882; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Graziano MP, 1996, RECEPTOR CHANNEL, V4, P9; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; HAGER J, 1995, NAT GENET, V9, P299, DOI 10.1038/ng0395-299; HAMMAN J, 1995, J IMMUNOL, V155, P1942; Heller RS, 1996, BIOCHEM BIOPH RES CO, V223, P624, DOI 10.1006/bbrc.1996.0945; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; HOUSSAMI S, 1994, ENDOCRINOLOGY, V135, P183, DOI 10.1210/en.135.1.183; Huang ZM, 1996, J BIOL CHEM, V271, P33382, DOI 10.1074/jbc.271.52.33382; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; LABURTHE M, 1978, P NATL ACAD SCI USA, V75, P2772, DOI 10.1073/pnas.75.6.2772; LABURTHE M, 1987, J BIOL CHEM, V262, P10180; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; LABURTHE M, 1993, HDB EXPT PHARM, V106, P133; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICOLE P, 1996, REGUL PEPTIDES, V64, P139; PARMA J, 1994, MOL CELL ENDOCRINOL, V100, P159, DOI 10.1016/0303-7207(94)90296-8; REN Q, 1993, J BIOL CHEM, V268, P16483; SAMMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Spalding TA, 1995, J PHARMACOL EXP THER, V275, P1274; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Unson CG, 1996, P NATL ACAD SCI USA, V93, P310, DOI 10.1073/pnas.93.1.310; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895; Wilmen A, 1996, FEBS LETT, V398, P43, DOI 10.1016/S0014-5793(96)01214-8; ZHANG ML, 1995, BIOCHEM BIOPH RES CO, V211, P205, DOI 10.1006/bbrc.1995.1797	47	53	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4990	4996		10.1074/jbc.273.9.4990	http://dx.doi.org/10.1074/jbc.273.9.4990			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478946	hybrid			2022-12-25	WOS:000072310400030
J	Plonk, SG; Park, SK; Exton, JH				Plonk, SG; Park, SK; Exton, JH			The alpha-subunit of the heterotrimeric G protein G(13) activates a phospholipase D isozyme by a pathway requiring Rho family GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COS-7 CELLS; G-ALPHA(12); MUTANT; IDENTIFICATION; TRANSFORMATION; FIBROBLASTS; SUBFAMILY; EXCHANGE; KINASE; RAC	G(13) belongs to the G(12) family of heterotrimeric G proteins, whose effecters are poorly defined. The present study was designed to test if phospholipase D (PLD) is regulated by G(13) and if Rho-type small GTPases are involved. Expression of the constitutively active Q226L mutant of the alpha-subunit of G(13) in COS-7 cells stimulated the activity of a rat brain phospholipase D isozyme (rPLD1) co-expressed in the cells. Wild type G alpha(13) was ineffective unless the cells were incubated with AlF4-. rPLD1 was previously shown to be activated by constitutively active V14RhoA in COS-7 cells (Park, S. K., Provost, J. J., Bae, C. D., Ho, W. T., and Exton, J. H. (1997) J. Biol. Chem. 272, 29263-29272). When the endogenous Rho proteins of the cells were inactivated by treatment with C3 exoenzyme from Clostridium botulinum, the ability of G alpha(13)Q226L to activate rPLD1 was greatly attenuated. Co-transfection of dominant negative N19RhoA and N17Rac-1, but not N17Cdc42Hs or N17Ras, also inhibited the activation. Expression of constitutively active G alpha(q) in COS-7 cells also activated rPLD1, but constitutively active forms of G alpha(i2) and G alpha(s) were without effect. These findings support an effector role for PLD in G(13) signaling and demonstrate a requirement for Rho GTPases in this response.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA	Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.	john.exton@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047448] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47448, DK 07563] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Harhammer R, 1996, BIOCHEM J, V319, P165, DOI 10.1042/bj3190165; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Liscovitch M, 1996, CHEM PHYS LIPIDS, V80, P37, DOI 10.1016/0009-3084(96)02544-3; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MILLIGAN G, 1992, FEBS LETT, V297, P186, DOI 10.1016/0014-5793(92)80357-M; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; WU DQ, 1992, J BIOL CHEM, V267, P1811; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	34	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4823	4826		10.1074/jbc.273.9.4823	http://dx.doi.org/10.1074/jbc.273.9.4823			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478920	hybrid			2022-12-25	WOS:000072310400004
J	Sullam, PM; Hyun, WC; Szollosi, J; Dong, JF; Foss, WM; Lopez, JA				Sullam, PM; Hyun, WC; Szollosi, J; Dong, JF; Foss, WM; Lopez, JA			Physical proximity and functional interplay of the glycoprotein Ib-IX-V complex and the Fc receptor Fc gamma RIIA on the platelet plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; VIRIDANS GROUP STREPTOCOCCI; IMMUNOGLOBULIN-G; CELL-SURFACES; VONWILLEBRAND-FACTOR; FLOW-CYTOMETRY; FACTOR BINDING; AGGREGATION; ACTIVATION; THROMBOCYTOPENIA	Although the glycoprotein (GP) Ib-IX-V complex and Fc gamma RIIA are distinct platelet membrane receptors, previous studies have suggested that these structures may be co-localized. To determine more directly the proximity of GP Ib-IX-V and Fc gamma RIIA, we assessed the effects of anti-GP Ib alpha monoclonal antibodies on Fc gamma RIIA-mediated platelet aggregation and on the direct binding of polymeric IgG to human platelets. In addition, we directly examined the proximity of Fc gamma RII and GP Ib-IX-V using flow cytometric fluorescence energy transfer and immunoprecipitation studies. Preincubation of platelets with either of two monoclonal antibodies (AN51 or SZ2) directed against GP Ib alpha completely blocked platelet aggregation by polymeric IgG. Similarly, these antibodies totally inhibited platelet aggregation by two strains of viridans group streptococci known to induce aggregation via Fc gamma RIIA, In addition, AN51 and SZ2 significantly reduced the binding of polymeric IgG to washed fixed platelets, When assessed by flow cytometry, significant levels of bidirectional energy transfer were detected between Fc gamma RIIA and GP Ib alpha, indicating a physical proximity of less than 10 nm between these receptors, This energy transfer was not due to high receptor density, because no homoassociative energy transfer was seen, Moreover, immunoprecipitation of Fc gamma RIIA from platelet lysates also co-precipitated GP Ib alpha. These results indicate that GP Ib alpha and Fc gamma RIIA are co-localized on the platelet membrane and that this association is not random.	Vet Affairs Med Ctr, Div Infect Dis 111W, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Ctr Canc, Lab Cell Anal, San Francisco, CA 94143 USA; Debrecen Univ Med, Sch Med, Dept Biophys & Cell Biol, H-4012 Debrecen, Hungary; Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Debrecen; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Sullam, PM (corresponding author), Vet Affairs Med Ctr, Div Infect Dis 111W, 4150 Clement St, San Francisco, CA 94121 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041513] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02463] Funding Source: Medline; NIAID NIH HHS [AI41513, AI32506] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADELMAN B, 1989, J LAB CLIN MED, V113, P204; ANDERSON CL, 1995, SEMIN THROMB HEMOST, V21, P1, DOI 10.1055/s-2007-1000374; Andrews RK, 1996, BIOCHEMISTRY-US, V35, P12629, DOI 10.1021/bi960704e; BECKER RC, 1994, CORONARY ARTERY DIS, V5, P339, DOI 10.1097/00019501-199404000-00010; BENE L, 1994, EUR J IMMUNOL, V24, P2115, DOI 10.1002/eji.1830240928; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; CHONG BH, 1989, BRIT J HAEMATOL, V73, P235, DOI 10.1111/j.1365-2141.1989.tb00258.x; CORASH L, 1990, BLOOD CELLS, V16, P97; DU XP, 1994, J BIOL CHEM, V269, P18287; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; FORD I, 1993, BRIT J HAEMATOL, V84, P95, DOI 10.1111/j.1365-2141.1993.tb03030.x; Ford I, 1997, BRIT J HAEMATOL, V97, P737, DOI 10.1046/j.1365-2141.1997.1342950.x; Harlow E., 1988, ANTIBODIES LAB MANUA; JUNG SM, 1983, BIOCHIM BIOPHYS ACTA, V761, P152, DOI 10.1016/0304-4165(83)90224-6; KARAS SP, 1982, BLOOD, V60, P1277; KOKSCH M, 1995, J IMMUNOL METHODS, V187, P53, DOI 10.1016/0022-1759(95)00166-8; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; LIEGLER T, 1991, P NATL ACAD SCI USA, V88, P6755, DOI 10.1073/pnas.88.15.6755; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MATYUS L, 1992, J PHOTOCH PHOTOBIO B, V12, P323, DOI 10.1016/1011-1344(92)85039-W; MOORE A, 1978, J CLIN INVEST, V62, P1053, DOI 10.1172/JCI109210; ODA A, 1995, THROMB HAEMOSTASIS, V74, P736; RAZDAN K, 1994, BIOCHEM J, V302, P681, DOI 10.1042/bj3020681; ROSENFELD SI, 1985, J CLIN INVEST, V76, P2317, DOI 10.1172/JCI112242; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SULLAM PM, 1988, INFECT IMMUN, V56, P2907, DOI 10.1128/IAI.56.11.2907-2911.1988; SULLAM PM, 1987, INFECT IMMUN, V55, P1743, DOI 10.1128/IAI.55.8.1743-1750.1987; SZOLLOSI J, 1987, P NATL ACAD SCI USA, V84, P7246, DOI 10.1073/pnas.84.20.7246; SZOLLOSI J, 1984, CYTOMETRY, V5, P210, DOI 10.1002/cyto.990050216; TOMIYAMA Y, 1992, BLOOD, V80, P2261; TRON L, 1984, BIOPHYS J, V45, P939, DOI 10.1016/S0006-3495(84)84240-X; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471	32	117	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5331	5336		10.1074/jbc.273.9.5331	http://dx.doi.org/10.1074/jbc.273.9.5331			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478992	hybrid			2022-12-25	WOS:000072310400076
J	Witt, H; Malatesta, F; Nicoletti, F; Brunori, M; Ludwig, B				Witt, H; Malatesta, F; Nicoletti, F; Brunori, M; Ludwig, B			Tryptophan 121 of subunit II is the electron entry site to cytochrome-c oxidase in Paracoccus denitrificans - Involvement of a hydrophobic patch in the docking reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2.8 ANGSTROM; BINDING; KINETICS; IDENTIFICATION; RESIDUES; PROTEINS; MUTANTS; ENZYME; GENE	To investigate the contribution of hydrophobic residues to the molecular recognition of cytochrome c with cytochrome oxidase, we mutated several hydrophobic amino acids exposed on subunit II of the Paracoccus denitrificans oxidase, K-M and k(cat) values and the bimolecular rate constant were determined under steady-or presteady-state conditions, respectively, We present evidence that Trp-121 which is surrounded by a hydrophobic patch is the electron entry site to oxidase. Mutations in this cluster do not affect the binding of cytochrome c as the K-M remains largely unchanged, Rather, the k(cat) is reduced, proposing that these hydrophobic residues are required for a fine tuning of the redox partners in the initial collisional complex to obtain a configuration optimal for electron transfer.	Biozentrum, Inst Biochem, D-60439 Frankfurt, Germany; Univ Aquila, Dept Basic & Appl Biol, I-67100 Laquila, Italy; Univ Rome La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Rome La Sapienza, CNR, Ctr Biol Mol, I-00185 Rome, Italy	University of L'Aquila; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Ludwig, B (corresponding author), Biozentrum, Inst Biochem, N200 1-OG,Marie Curie Str 9, D-60439 Frankfurt, Germany.	ludwig@em.uni-frankfurt.de	Malatesta, Francesco/AAT-4757-2020	Brunori, Maurizio/0000-0002-7795-1635				Bendall D. S., 1996, P43; BUSE G, 1978, H-S Z PHYSIOL CHEM, V359, P1011; CAFFREY MS, 1994, BIOCHIMIE, V76, P622, DOI 10.1016/0300-9084(94)90139-2; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; Davidson VL, 1996, BIOCHEMISTRY-US, V35, P14035, DOI 10.1021/bi961577p; DEGIER JWL, 1994, MOL MICROBIOL, V13, P183, DOI 10.1111/j.1365-2958.1994.tb00414.x; ERREDE B, 1976, P NATL ACAD SCI USA, V73, P113, DOI 10.1073/pnas.73.1.113; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; GARBER EAE, 1990, BIOCHIM BIOPHYS ACTA, V1015, P279, DOI 10.1016/0005-2728(90)90032-Y; GERHUS E, 1990, J BACTERIOL, V172, P2392, DOI 10.1128/jb.172.5.2392-2400.1990; HARRIS TK, 1994, BIOCHEMISTRY-US, V33, P12600, DOI 10.1021/bi00208a010; HENDLER RW, 1991, BIOPHYS J, V60, P415, DOI 10.1016/S0006-3495(91)82067-7; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; LAPPALAINEN P, 1995, BIOCHEMISTRY-US, V34, P5824, DOI 10.1021/bi00017a014; LUDWIG B, 1986, METHOD ENZYMOL, V126, P153; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4552, DOI 10.1021/bi00068a010; MILLETT F, 1983, BIOCHEMISTRY-US, V22, P546, DOI 10.1021/bi00272a004; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Overholtzer MH, 1996, J BIOL CHEM, V271, P7719, DOI 10.1074/jbc.271.13.7719; RICHTER OMH, 1994, J BIOL CHEM, V269, P23079; RIEDER R, 1980, J BIOL CHEM, V255, P4732; STAUDENMAYER N, 1977, BIOCHEMISTRY-US, V16, P600, DOI 10.1021/bi00623a007; STEINRUCKE P, 1991, J BIOL CHEM, V266, P7676; TOLLIN G, 1991, ARCH BIOCHEM BIOPHYS, V287, P1, DOI 10.1016/0003-9861(91)90380-2; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975; WITT H, 1995, BBA-BIOENERGETICS, V1230, P74, DOI 10.1016/0005-2728(95)00050-S; Witt H, 1998, EUR J BIOCHEM, V251, P367, DOI 10.1046/j.1432-1327.1998.2510367.x	32	91	91	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5132	5136		10.1074/jbc.273.9.5132	http://dx.doi.org/10.1074/jbc.273.9.5132			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478966	hybrid			2022-12-25	WOS:000072310400050
J	Chow, JC; Condorelli, G; Smith, RJ				Chow, JC; Condorelli, G; Smith, RJ			Insulin-like growth factor-1 receptor internalization regulates signaling via the Shc/mitogen-activated protein kinase pathway, but not the insulin receptor substrate-1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I-RECEPTOR; MEDIATED ENDOCYTOSIS; PHOSPHATIDYLINOSITOL 3'-KINASE; TYROSINE PHOSPHORYLATION; SKELETAL-MUSCLE; SHC PROTEINS; TRANSDUCTION; CELLS; SRC; ASSOCIATION	Insulin like growth factor-I (IGF-I) receptors activate divergent signaling pathways by phosphorylation multiple cellular proteins, including insulin receptor substrate-1 (IRS-1) and the Shc proteins. Following hormone binding, IGF-I receptors cluster into clathrin-coated pits and are internalized via an endocytotic mechanism, This study investigates the relationship between IGF-I receptor internalization and signaling via IRS-1 and Shc. A mutation in the C terminus of the IGF-I receptor decreased both the rate of receptor internalization and IGF-I-stimulated Shc phosphorylation by more than 50%, but did not affect IRS-1 phosphorylation. Low temperature (15 degrees C) decreased IGF-I receptor internalization and completely inhibited Shc phosphorylation. Although receptor and IRS-1 phosphorylation were decreased in accordance with delayed binding kinetics at 15 degrees C, the ratio of IRS-1 to receptor phosphorylation was increased more than 2-fold. Dansylcadaverine de creased receptor internalization and Shc phosphorylation, but did not change receptor or IRS-1 phosphorylation, Consistent with these findings, dansylcadaverine inhibited IGF-I stimulated Shc-Grb2 association, mitogen activated protein kinase phosphorylation, and p90 ribosomal S6 kinase activation, but did not affect the association of phosphatidylinositide 3-kinase with IRS-1 or activation of p70 S6 kinase, These data support the concept that Shc/mitogen-activated protein kinase pathway activation requires IGF-I receptor internalization, whereas the IRS-1 pathway is activated by both cell surface and endosomal receptors.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Smith, RJ (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.		Condorelli, Gerolama/AAC-3472-2022	Condorelli, Gerolama/0000-0003-0177-8829	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043038, P30DK036836, T32DK007260] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43038, DK07260, DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADASHI EY, 1988, ENDOCRINOLOGY, V122, P194, DOI 10.1210/endo-122-1-194; Aronson D, 1997, J CLIN INVEST, V99, P1251, DOI 10.1172/JCI119282; Bevan AP, 1996, TRENDS ENDOCRIN MET, V7, P13, DOI 10.1016/1043-2760(95)00179-4; BEVAN AP, 1995, J BIOL CHEM, V270, P10784, DOI 10.1074/jbc.270.18.10784; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CARPENTIER JL, 1994, DIABETOLOGIA, V37, pS117, DOI 10.1007/BF00400835; CARPENTIER JL, 1994, ANN NY ACAD SCI, V733, P266, DOI 10.1111/j.1749-6632.1994.tb17276.x; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CONDORELLI G, 1994, FRONT ENDOCRINOL, V9, P373; CONDORELLI G, 1994, J BIOL CHEM, V269, P8510; Dardevet D, 1996, ENDOCRINOLOGY, V137, P4087, DOI 10.1210/en.137.10.4087; DAVIES PJA, 1984, DIABETES CARE, V7, P35; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; FURLANETTO RW, 1988, ENDOCRINOLOGY, V122, P2044, DOI 10.1210/endo-122-5-2044; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HSU D, 1994, ENDOCRINOLOGY, V134, P744, DOI 10.1210/en.134.2.744; HSU D, 1993, ENDOCRINOLOGY, V133, P1247, DOI 10.1210/en.133.3.1247; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAMPS MP, 1988, ONCOGENE, V2, P305; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; LUND KA, 1990, J BIOL CHEM, V265, P15713; MOEHLYROSEN D, 1995, SCIENCE, V268, P247; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NORIEGA AG, 1980, J CELL BIOL, V85, P839; OLEFSKY JM, 1982, J BIOL CHEM, V257, P8667; PEAVY DE, 1984, ENDOCRINOLOGY, V114, P753, DOI 10.1210/endo-114-3-753; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1997, TRENDS BIOCHEM SCI, V21, P312; SMITH RJ, 1996, EXP CLIN ENDOCR S2, V104, P42; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	49	139	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4672	4680		10.1074/jbc.273.8.4672	http://dx.doi.org/10.1074/jbc.273.8.4672			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468528	hybrid			2022-12-25	WOS:000072115000056
J	Byrne, JA; Nourse, CR; Basset, P; Gunning, P				Byrne, JA; Nourse, CR; Basset, P; Gunning, P			Identification of homo- and heteromeric interactions between members of the breast carcinoma-associated D52 protein family using the yeast two-hybrid system	ONCOGENE			English	Article						D52-like proteins; coiled-coil domain; yeast two-hybrid system; in vitro translation; GST pull-down assay	EXPRESSION; SEQUENCE; ALIGNMENT; CLONING	The hD52 gene was originally identified through its elevated expression level in human breast carcinoma. Cloning of D52 homologues from other species has indicated that D52 may play roles in calcium-mediated signal transduction and cell proliferation. Two human homologues of hD52, hD53 and hD54, have also been identified, demonstrating the existence of a novel gene/protein family. Since D52-like protein sequences are all predicted to contain a coiled-coil domain, we used the yeast two-hybrid system and glutathione S-transferase pull-down assays to investigate whether homo- and/or heteromeric interactions occur between D52-like proteins. Analyses of yeast strains co-transfected with paired D52-like constructs indicated that D52-like fusion proteins interact in homo- and heteromeric fashions through their predicted coiled-coil domains. Similarly, extensive two-hybrid screenings of a human breast carcinoma expression library identified hD53 and hD52 as potential interactors for both hD52 and hD53 baits. Thus, D52-like proteins appear to exert and/or regulate their activities through specific interactions with other D52-like proteins, which in turn may be intrinsic to potential roles of these molecules in controlling cell proliferation.	Childrens Med Res Inst, Cell Biol Unit, Westmead, NSW 2145, Australia; Univ Sydney, Dept Paediat & Child Hlth, Westmead, NSW 2145, Australia; CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France; New Childrens Hosp, Oncol Res Unit, Westmead, NSW 2145, Australia	Children's Medical Research Institute - Australia; University of Sydney; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Sydney	Byrne, JA (corresponding author), Childrens Med Res Inst, Cell Biol Unit, Westmead, NSW 2145, Australia.		Gunning, Peter W/E-9058-2010	Byrne, Jennifer Anne/0000-0002-8923-0587; Gunning, Peter/0000-0003-0833-3128				ALLEN JB, 1995, TRENDS BIOCHEM SCI, V20, P511, DOI 10.1016/S0968-0004(00)89119-7; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V1; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V3; BYRNE JA, 1995, CANCER RES, V55, P2896; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; Chen SL, 1996, ONCOGENE, V12, P741; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Parente JA, 1996, J BIOL CHEM, V271, P20096, DOI 10.1074/jbc.271.33.20096; Proux V, 1996, J BIOL CHEM, V271, P30790, DOI 10.1074/jbc.271.48.30790; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	17	67	74	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					873	881		10.1038/sj.onc.1201604	http://dx.doi.org/10.1038/sj.onc.1201604			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484778				2022-12-25	WOS:000072053200006
J	Inoue, D; Reid, M; Lum, L; Kratzschmar, J; Weskamp, G; Myung, YM; Baron, R; Blobel, CP				Inoue, D; Reid, M; Lum, L; Kratzschmar, J; Weskamp, G; Myung, YM; Baron, R; Blobel, CP			Cloning and initial characterization of mouse meltrin beta and analysis of the expression of four metalloprotease-disintegrins in bone cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-EGG FUSION; PROTEIN; DIFFERENTIATION; OSTEOCLAST; DOMAIN; FAMILY; GENE; ACID; IDENTIFICATION; RECEPTOR	Here Ne report the cloning and initial biochemical characterization of the mouse metalloprotease/disintegrin/cysteine-rich (MDC) protein meltrin beta and the analysis of the mRNA expression of four MDC genes (meltrin alpha, meltrin beta, mdc9, and mdc15) in bone cells, including osteoclasts and osteoblasts. Like most other MDC proteins, the predicted meltrin beta protein consists of a signal sequence, prodomain, metalloprotease domain with a predicted catalytic site, disintegrin domain, cysteine-rich region, epidermal growth factor repeat, transmembrane domain, and cytoplasmic domain with putative signaling motifs, such as potential SH3 ligand domains. Northern blot analysis indicates that meltrin beta is widely expressed, with the highest expression in bone, heart, and lung. RNase protection studies revealed expression of all four MDC genes analyzed here in osteoblasts, whereas only mdc9 and mdc15 mRNAs were detectable in osteoclast like cells generated in vitro. Treatment of primary osteoblasts with 10 nM calcitriol increased meltrin beta expression more than 3-fold, and both meltrin alpha and meltrin beta expression is apparently regulated in a differentiation associated manner in a mouse osteoblastic cell line, MC3T3E1. Collectively, these results suggest that meltrin alpha and meltrin beta may play a role in osteoblast differentiation and/or function but are not likely to be involved in osteoclast fusion.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Yale Univ, Sch Med, Dept Orthopaed & Cell Biol, New Haven, CT 06510 USA	Memorial Sloan Kettering Cancer Center; Yale University	Blobel, CP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, Box 368,1275 York Ave, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM051988] Funding Source: NIH RePORTER; NCI NIH HHS [NCI-P30-CA-08748] Funding Source: Medline; NIGMS NIH HHS [R55GM51988] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfandari D, 1997, DEV BIOL, V182, P314, DOI 10.1006/dbio.1996.8458; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRETIEN M, 1995, P ASSOC AM PHYSICIAN, V107, P47; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; EVANS JP, 1995, J CELL SCI, V108, P3267; FAMBROUGH D, 1996, P NATL ACAD SCI USA, V93, P13223; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; KRATZSCHMAR J, 1991, GENE, V105, P229, DOI 10.1016/0378-1119(91)90155-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Podbilewicz B, 1996, MOL BIOL CELL, V7, P1877, DOI 10.1091/mbc.7.12.1877; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Shilling FM, 1997, DEV BIOL, V186, P155, DOI 10.1006/dbio.1997.8586; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; YAMIN M, 1994, ENDOCRINOLOGY, V135, P2635, DOI 10.1210/en.135.6.2635; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110	47	90	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4180	4187		10.1074/jbc.273.7.4180	http://dx.doi.org/10.1074/jbc.273.7.4180			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461614	hybrid			2022-12-25	WOS:000072048400056
J	Auchus, RJ; Lee, TC; Miller, WL				Auchus, RJ; Lee, TC; Miller, WL			Cytochrome b(5) augments the 17,20-lyase activity of human P450c17 without direct electron transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN CLEAVAGE; RAT-LIVER MICROSOMES; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; YEAST-CELLS; NADPH-P450 REDUCTASE; CATALYTIC ACTIVITIES; APOCYTOCHROME B(5); MESSENGER-RNA; PIG TESTIS	In the biosynthesis of steroid hormones, P450c17 is the single enzyme that catalyzes both the 17 alpha-hydroxylation of al-carbon steroids and the 17,20-lyase activity that cleaves the C-17,-C-20,, bond to produce C-19, sex steroids. Cytochrome b(5), augments the 17,20-lyase activity of cytochrome P450c17 in vitro, but this has not been demonstrated in membranes, and the mechanism of this action is unknown. We expressed human P450c17, human P450-oxidoreductase (OR), and/or human cytochrome b(5) in Saccharomyces cerevisiae and analyzed the 17 alpha-hydroxylase and 17,20-lyase activities of the resulting yeast microsomes. Yeast expressing only P450c17 have 17 alpha-hydroxylase and trace 17,20 lyase activities toward both Delta(4) and Delta(5) steroids. Coexpression of human OR with P450c17 increases the V-max,,, of both the 17 alpha-hydroxylase and 17,20-lyase reactions B-fold; coexpression of human b(5), with P450c17 also increases the V-max,, of the 17,20-lyase reactions but not of the 17 alpha-hydroxylase reactions. Simultaneous expression of human b(5), with P450c17 and OR, or addition of purified human b(5), to microsomes from yeast coexpressing human P450c17 and OR, further increases the V-max,, of the 17,20-lyase reaction without altering 17 alpha-hydroxylase activity. Genetically engineered yeast and mixing experiments demonstrate that OR is both necessary and sufficient for microsomal 17,20-lyase activity. Addition of purified human holo-b(5),, apo-b(5),, or cytochrome c to microsomes containing both human P450c17 and OR demonstrate that the stimulatory action of b(5), does not require electron transfer from b(5), to P450c17. These data suggest that human b(5), acts principally as an allosteric effector that interacts primarily with the P450c17 OR complex to stimulate 17,20-lyase activity.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Miller, WL (corresponding author), Univ Calif San Francisco, Dept Pediat, Bldg MR-IV,Box 0978, San Francisco, CA 94143 USA.		Miller, Walter L/J-3696-2012		NICHD NIH HHS [U54-HD34449] Funding Source: Medline; NIDDK NIH HHS [DK37922, DK42154] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD034449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042154, R01DK037922] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P5425, DOI 10.1073/pnas.87.14.5425; BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; BARNES HJ, 1994, ARCH BIOCHEM BIOPHYS, V315, P489, DOI 10.1006/abbi.1994.1530; CHUNG BC, 1987, P NATL ACAD SCI USA, V84, P407, DOI 10.1073/pnas.84.2.407; Conley AJ, 1997, BIOL REPROD, V56, P789, DOI 10.1095/biolreprod56.4.789; CUTLER GB, 1978, ENDOCRINOLOGY, V103, P2112, DOI 10.1210/endo-103-6-2112; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; Falzone CJ, 1996, BIOCHEMISTRY-US, V35, P6519, DOI 10.1021/bi960501q; Geller DH, 1997, NAT GENET, V17, P201, DOI 10.1038/ng1097-201; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILLETTE JR, 1957, J PHARMACOL EXP THER, V119, P532; GIORDANO SJ, 1994, HUM GENET, V93, P568; HADFIELD C, 1986, GENE, V45, P149, DOI 10.1016/0378-1119(86)90249-0; HALL PF, 1985, VITAM HORM, V42, P315; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HIGUCHI A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P240, DOI 10.1016/0005-2760(91)90064-O; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; KATAGIRI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P343, DOI 10.1006/abbi.1995.1173; KOMINAMI S, 1992, J STEROID BIOCHEM, V42, P57, DOI 10.1016/0960-0760(92)90011-7; KUMA F, 1976, ARCH BIOCHEM BIOPHYS, V172, P600, DOI 10.1016/0003-9861(76)90113-2; LeeRobichaud P, 1997, BIOCHEM J, V321, P857, DOI 10.1042/bj3210857; LIN D, 1991, J BIOL CHEM, V266, P15992; LIN D, 1993, ENDOCRINOLOGY, V132, P2498, DOI 10.1210/en.132.6.2498; MILLER WL, 1989, ANNU REV GENET, V23, P371, DOI 10.1146/annurev.ge.23.120189.002103; Miller WL, 1997, STEROIDS, V62, P133, DOI 10.1016/S0039-128X(96)00172-9; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; Modi S, 1997, BIOCHEMISTRY-US, V36, P4461, DOI 10.1021/bi962633p; Muskett FW, 1996, J MOL BIOL, V258, P172, DOI 10.1006/jmbi.1996.0241; NAKAJIN S, 1981, J BIOL CHEM, V256, P3871; NAKAJIN S, 1985, BIOCHEM BIOPH RES CO, V132, P708, DOI 10.1016/0006-291X(85)91190-8; OMURA T, 1964, J BIOL CHEM, V239, P2370; ONODA M, 1982, BIOCHEM BIOPH RES CO, V108, P454, DOI 10.1016/0006-291X(82)90850-6; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; PARIKH A, 1997, NAT BIOTECHNOL, V15, P346; PEYRONNEAU MA, 1993, EUR J BIOCHEM, V218, P355, DOI 10.1111/j.1432-1033.1993.tb18384.x; POMPON D, 1987, BIOCHEMISTRY-US, V26, P6429, DOI 10.1021/bi00394a020; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; POMPON D, 1984, J BIOL CHEM, V259, P5377; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SAKAKI T, 1989, DNA-J MOLEC CELL BIO, V8, P409, DOI 10.1089/dna.1.1989.8.409; SHET MS, 1994, ARCH BIOCHEM BIOPHYS, V311, P402, DOI 10.1006/abbi.1994.1255; Storch EM, 1996, BIOCHEMISTRY-US, V35, P11596, DOI 10.1021/bi960598g; SWART P, 1993, J CLIN ENDOCR METAB, V77, P98, DOI 10.1210/jc.77.1.98; TAGASHIRA H, 1995, BIOCHEMISTRY-US, V34, P10939, DOI 10.1021/bi00034a028; TRUAN G, 1994, GENE, V142, P123, DOI 10.1016/0378-1119(94)90366-2; TRUAN G, 1993, GENE, V125, P49, DOI 10.1016/0378-1119(93)90744-N; URBAN P, 1993, BIOCHEM SOC T, V21, P1028, DOI 10.1042/bst0211028; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Yamazaki H, 1997, ARCH BIOCHEM BIOPHYS, V342, P329, DOI 10.1006/abbi.1997.0125; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438; YANAGIBASHI K, 1986, J BIOL CHEM, V261, P8429; YOO M, 1988, BIOCHEM BIOPH RES CO, V156, P576, DOI 10.1016/S0006-291X(88)80881-7; ZHANG LH, 1995, P NATL ACAD SCI USA, V92, P10619, DOI 10.1073/pnas.92.23.10619	54	436	446	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3158	3165		10.1074/jbc.273.6.3158	http://dx.doi.org/10.1074/jbc.273.6.3158			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452426	hybrid			2022-12-25	WOS:000071822300011
J	Domanski, P; Nadeau, OW; Platanias, LC; Fish, E; Kellum, M; Pitha, P; Colamonici, OR				Domanski, P; Nadeau, OW; Platanias, LC; Fish, E; Kellum, M; Pitha, P; Colamonici, OR			Differential use of the beta(L) subunit of the type I interferon (IFN) receptor determines signaling specificity for IFN alpha 2 and IFN beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE CYTOPLASMIC DOMAIN; ALPHA RECEPTOR; TARGETED DISRUPTION; TYROSINE KINASE; BINDING; GENE; TRANSDUCTION; EXPRESSION; CLONING; CELLS	The signaling specificity for cytokines that have common receptor subunits is achieved by the presence of additional cytokine-specific receptor components. In the type I interferon (IFN) family, all 14 subtypes of IFN alpha, IFN beta, and IFN omega bind to the same alpha and beta(L), subunits of the type I IFN-R, yet differences in signaling and biological effects exist among them. Our data demonstrate that IFN alpha 2 and IFN beta utilize different regions of the beta(L), subunit for signaling, Thus, in contrast to other cytokine systems, signal diversity in the type I IFN system can be accomplished within the same receptor complex by utilizing different regions of the same receptor subunits.	Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA; Univ Illinois, Dept Med, Hematol Oncol Sect, Chicago, IL 60607 USA; W Side Vet Affairs Hosp, Chicago, IL 60607 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Toronto; Johns Hopkins University; Johns Hopkins Medicine	Colamonici, OR (corresponding author), Univ Tennessee, Dept Pathol, 899 Madison Ave,M-576, Memphis, TN 38163 USA.				NCI NIH HHS [CA73381, CA55079] Funding Source: Medline; NIGMS NIH HHS [GM54709] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073381, R01CA055079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZAN JF, 1990, CELL, V61, P753, DOI 10.1016/0092-8674(90)90182-E; BENOIT P, 1993, J IMMUNOL, V150, P707; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; CHEUNG SC, 1991, J IMMUNOL, V146, P121; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1995, J BIOL CHEM, V270, P8188, DOI 10.1074/jbc.270.14.8188; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COOK JR, 1996, J BIOL CHEM, V271, P13488; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; GROUP AR, 1989, J NEUROL NEUROSUR PS, V52, P566; JOHNSON K P, 1990, Neurology, V40, P261; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platanias LC, 1996, J BIOL CHEM, V271, P23630, DOI 10.1074/jbc.271.39.23630; Rani MRS, 1996, J BIOL CHEM, V271, P22878, DOI 10.1074/jbc.271.37.22878; SCHINDLER S, 1995, ANNU REV BIOCHEM, V64, P621; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; Yan H, 1996, MOL CELL BIOL, V16, P2074	36	71	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3144	3147		10.1074/jbc.273.6.3144	http://dx.doi.org/10.1074/jbc.273.6.3144			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452423	hybrid			2022-12-25	WOS:000071822300008
J	Haas, TL; Davis, SJ; Madri, JA				Haas, TL; Davis, SJ; Madri, JA			Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGELATINASE-A; GROWTH-FACTOR; ANGIOGENESIS INVITRO; VITRO ANGIOGENESIS; TISSUE INHIBITOR; GENE-EXPRESSION; TUBE FORMATION; MEMBRANE; ACTIVATION; MODULATION	Matrix metalloproteinases (MMPs) are hypothesized to play a key role in the processes of endothelial cell migration and matrix remodeling during angiogenesis. We utilized an in vitro model of microvascular endothelial cell angiogenesis, cells cultured within a collagen matrix, to investigate the MMP profile of endothelial cells undergoing angiogenesis. We demonstrated by gelatin zymography that monolayer cultures (two-dimensional) of endothelial cells constitutively expressed low levels of latent MMP-2, but that culture in a three-dimensional collagen matrix increased the total amount of MMP-2 mRNA and protein, Furthermore, 51% of total MMP-2 protein was activated in the three-dimensional culture lysates, compared with 3.5% in two-dimensional culture, The mRNA and protein of MT1-MMP, the putative activator of MMP-2, were up-regulated in endothelial cells cultured in three-dimensional as compared with two dimensional culture, Treatment of cultures with MMP inhibitors blocked activation of MMP-2 and inhibited formation of endothelial cell networks within the collagen gel, Induction of MT1-MMP and MMP-2 appeared to be specific to collagen, inasmuch as culture of the endothelial cells on top of, or within, a Matrigel(R) matrix neither increased total MMP-2 nor increased activation of MMP-2. These results suggest that MT1-MMP activation of MMP-2 occurs in endothelial cells undergoing angiogenesis, that this activation has a functional role in endothelial cell organization, and that specific matrix interactions may be critical for the increased expression of MT1-MMP and MMP-2.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Yale University	Madri, JA (corresponding author), Yale Univ, Sch Med, Dept Pathol, LH115,310 Cedar St, New Haven, CT 06510 USA.	joseph.madri@yale.edu	Haas, Tara/F-6788-2013	Haas, Tara/0000-0001-8559-9574	NHLBI NIH HHS [R01 HL-5108] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1992, CANCER RES, V52, P4540; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CANFIELD AE, 1995, J CELL SCI, V108, P797; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Clark, 1996, MOL CELLULAR BIOL WO, P355; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; CORNELIUS LA, 1995, J INVEST DERMATOL, V105, P170, DOI 10.1111/1523-1747.ep12317080; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; Foda HD, 1996, LAB INVEST, V74, P538; Folkman J, 1997, EXS, V79, P1; Gilles C, 1997, LAB INVEST, V76, P651; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; JACKSON CJ, 1994, CELL BIOL INT, V18, P859, DOI 10.1006/cbir.1994.1122; Jendraschak E, 1996, SEMIN CANCER BIOL, V7, P139, DOI 10.1006/scbi.1996.0019; JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; LEWALLE JM, 1995, J CELL PHYSIOL, V165, P475, DOI 10.1002/jcp.1041650305; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; MADRI JA, 1983, J CELL BIOL, V97, P153, DOI 10.1083/jcb.97.1.153; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MADRI JA, 1986, J HISTOCHEM CYTOCHEM, V34, P85, DOI 10.1177/34.1.2416801; MARX M, 1994, J CLIN INVEST, V93, P131, DOI 10.1172/JCI116936; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MERWIN JR, 1990, J CELL PHYSIOL, V142, P117, DOI 10.1002/jcp.1041420115; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MONTESANO R, 1992, EUR J CLIN INVEST, V22, P504, DOI 10.1111/j.1365-2362.1992.tb01498.x; Okumura Y, 1997, FEBS LETT, V402, P181, DOI 10.1016/S0014-5793(96)01523-2; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Pepper MS, 1997, ARTERIOSCL THROM VAS, V17, P605, DOI 10.1161/01.ATV.17.4.605; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; Senger DR, 1996, AM J PATHOL, V149, P293; SHATTIL SJ, 1995, THROMB HAEMOSTASIS, V74, P149; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132	47	294	309	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3604	3610		10.1074/jbc.273.6.3604	http://dx.doi.org/10.1074/jbc.273.6.3604			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452488	hybrid			2022-12-25	WOS:000071822300073
J	Ratovitski, EA; Kotzbauer, PT; Milbrandt, J; Lowenstein, CJ; Burrow, CR				Ratovitski, EA; Kotzbauer, PT; Milbrandt, J; Lowenstein, CJ; Burrow, CR			Midkine induces tumor cell proliferation and binds to a high affinity signaling receptor associated with JAK tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; EMBRYONAL CARCINOMA-CELLS; ACID-RESPONSIVE GENE; EPITHELIAL-MESENCHYMAL INTERACTIONS; I INTERFERON RECEPTOR; N-SYNDECAN SYNDECAN-3; RETINOIC ACID; LIGAND-BINDING; HB-GAM; DIFFERENTIAL EXPRESSION	The G401 cell line derived from a rhabdoid tumor of the kidney secretes the heparin-binding growth factors midkine and pleiotrophin. Both proteins act as mitogens for diverse cells, but only midkine serves as an autocrine mitogen for G401 tumor cells. We show that midkine specifically binds a protein or complex of molecular mass greater than 200 kDa with high affinity (K-d = 0.07 +/- 0.01 nM). Midkine, but not pleiotrophin, stimulates tyrosine phosphorylation of several cellular proteins with molecular mass of 100, 130, and 200+ kDa. Upon midkine binding, the midkine-receptor complex associates with the Janus tyrosine kinases, JAK1 and JAK2. MK stimulates tyrosine phosphorylation of JAK1, JAK2, and STAT1 alpha. Our initial characterization of the midkine receptor suggests that midkine autocrine stimulation of tumor cell proliferation is mediated by a cell-surface receptor which in turn might activate the JAK/STAT pathway.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA	Johns Hopkins University; Johns Hopkins University; Washington University (WUSTL); Icahn School of Medicine at Mount Sinai	Ratovitski, EA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, 972 Rutland Ave,950 Ross Bldg, Baltimore, MD 21205 USA.	erat@welchlink.welch.jhu.edu		Lowenstein, Charles/0000-0003-0485-7514; Milbrandt, Jeffrey/0000-0002-5477-7689	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052315] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL52315, R01 HL5361] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; CHERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOWDY SF, 1991, J CELL PHYSIOL, V147, P248, DOI 10.1002/jcp.1041470209; EKBLOM P, 1992, KIDNEY PHYSL PATHOPH, P475; ELENIUS K, 1994, J CELL SCI, V107, P2975; GARVER RI, 1994, CANCER, V74, P1584, DOI 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V; GARVER RI, 1993, AM J RESP CELL MOL, V9, P463, DOI 10.1165/ajrcmb/9.5.463; GARVIN AJ, 1993, AM J PATHOL, V142, P375; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; KADOMATSU K, 1990, J CELL BIOL, V110, P607, DOI 10.1083/jcb.110.3.607; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KAREY KP, 1988, IN VITRO CELL DEV B, V24, P1107; KIKUCHI S, 1993, NEUROSCI LETT, V160, P9, DOI 10.1016/0304-3940(93)90904-Y; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOJIMA S, 1995, J BIOL CHEM, V270, P9590, DOI 10.1074/jbc.270.16.9590; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; KUO MD, 1992, BIOCHEM BIOPH RES CO, V182, P188, DOI 10.1016/S0006-291X(05)80129-9; KUO MD, 1990, J BIOL CHEM, V265, P18749; Kurtz A, 1995, CRIT REV ONCOGENESIS, V6, P151; LANGER JA, 1986, J BIOL CHEM, V261, P9801; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LI YS, 1992, BIOCHEM BIOPH RES CO, V184, P427, DOI 10.1016/0006-291X(92)91211-8; LI YS, 1993, BIOCHEM BIOPH RES CO, V195, P1089, DOI 10.1006/bbrc.1993.2156; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; Mehler MF, 1997, TRENDS NEUROSCI, V20, P357, DOI 10.1016/S0166-2236(96)01045-4; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MICHIKAWA M, 1993, J NEUROSCI RES, V35, P530, DOI 10.1002/jnr.490350509; MICHIKAWA M, 1993, BIOCHEM BIOPH RES CO, V192, P1312, DOI 10.1006/bbrc.1993.1559; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; MITSIADIS TA, 1995, J CELL BIOL, V129, P267, DOI 10.1083/jcb.129.1.267; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; MURAMATSU T, 1994, DEV GROWTH DIFFER, V36, P1; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; NAKAMOTO M, 1992, J BIOCHEM-TOKYO, V112, P346, DOI 10.1093/oxfordjournals.jbchem.a123903; NURCOMBE V, 1992, DEVELOPMENT, V116, P1175; RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SATOH J, 1993, DEV BRAIN RES, V75, P201, DOI 10.1016/0165-3806(93)90024-5; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHWABE M, 1988, EUR J IMMUNOL, V18, P2009, DOI 10.1002/eji.1830181221; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKE M, 1994, J BIOCHEM-TOKYO, V116, P1063, DOI 10.1093/oxfordjournals.jbchem.a124628; TOMOMURA M, 1990, J BIOL CHEM, V265, P10765; TSUTSUI J, 1991, BIOCHEM BIOPH RES CO, V176, P792, DOI 10.1016/S0006-291X(05)80255-4; TSUTSUI J, 1993, CANCER RES, V53, P1281; VANDERWINDEN J, 1932, ANAT EMBRYOL, V186, P387; WELLER A, 1991, DEV BIOL, V144, P248, DOI 10.1016/0012-1606(91)90419-4; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	61	54	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3654	3660		10.1074/jbc.273.6.3654	http://dx.doi.org/10.1074/jbc.273.6.3654			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452495	hybrid			2022-12-25	WOS:000071822300080
J	Schmid-Alliana, A; Menou, L; Manie, S; Schmid-Antomarchi, H; Millet, MA; Giuriato, S; Ferrua, B; Rossi, B				Schmid-Alliana, A; Menou, L; Manie, S; Schmid-Antomarchi, H; Millet, MA; Giuriato, S; Ferrua, B; Rossi, B			Microtubule integrity regulates Src-like and extracellular signal-regulated kinase activities in human pro-monocytic cells - Importance for interleukin-1 production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; EPIDERMAL GROWTH-FACTOR; TYROSINE-PHOSPHORYLATION; ENDOTHELIAL-CELLS; PLASMA-MEMBRANE; TRANSDUCTION; MACROPHAGES; INHIBITOR; FAMILY	We have demonstrated previously that microtubule depolymerization by colchicine in human monocytes induces selective production of interleukin-1 (IL-1) (Manie, S., Schmid-Alliana, A., Kubar, J., Ferrua, B., and Rossi, B. (1993) J. Biol. Chem. 268, 13675-13681), Here, we provide evidence that disruption of the microtubule structure rapidly triggers extracellular signal-regulated kinase (ERK) activation, whereas it was without effect on SAPK2 activity, which is commonly acknowledged to control pro-inflammatory cytokine production, This process involves the activation of the entire cascade including Ras, Raf-1, MEK1/2, ERK1, and ERK2, Activation of ERKs is followed by their nuclear translocation, Although other SAPK congeners might be activated upon microtubule depolymerization, the activation of ERK1 and ERK2 is mandatory for IL-1 production as shown by the blocking effect of PD 98059, a specific MEK1/2 inhibitor, Additionally, we provide evidence that microtubule disruption also induces the activation of c-Src and Hck activities, The importance of Src kinases in the mediation of the colchicine effect is underscored by the fact that CP 118556, a specific inhibitor of Src like kinase, abrogates both the colchicine-induced ERK activation and IL-1 production. This is the first evidence that ERK activation is an absolute prerequisite for induction of this cytokine, Altogether, our data lend support to a model where the status of microtubule integrity controls the level of Src activities that subsequently activate the ERK kinase cascade, thus leading to IL-1 production.	Fac Med Pasteur, INSERM, U364, F-06107 Nice 02, France; Fac Med Pasteur, Parasitol Lab, Grp Rech Immunopathol Leishmaniose, F-06107 Nice 02, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Rossi, B (corresponding author), Fac Med Pasteur, INSERM, U364, Ave Valombrose, F-06107 Nice 02, France.	rossi@unice.fr	Giuriato, Sylvie/A-9113-2010; SCHMID-ALLIANA, Annie/P-4366-2016; Manie, Serge/ABC-8331-2021	Giuriato, Sylvie/0000-0003-3274-3397; SCHMID-ALLIANA, Annie/0000-0003-2321-7408; manie, serge/0000-0002-9168-1977				AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALLEN NN, 1991, AM J PHYSIOL, V261, pL315; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BURDERING BMT, 1991, EMBO J, V10, P1103; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DING A, 1993, J IMMUNOL, V151, P5596; DING AH, 1990, J EXP MED, V171, P715, DOI 10.1084/jem.171.3.715; DOGLIO A, 1988, BIOCHEM J, V238, P123; FERRUA B, 1988, J IMMUNOL METHODS, V114, P41, DOI 10.1016/0022-1759(88)90151-2; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; INGBER DE, 1993, CELL, V75, P1249, DOI 10.1016/0092-8674(93)90612-T; JASPER JR, 1995, J PHARMACOL EXP THER, V274, P937; KATAGIRI K, 1993, J IMMUNOL, V150, P585; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MANIE S, 1993, J BIOL CHEM, V268, P13675; MANIE S, 1993, EUR CYTOKINE NETW, V4, P51; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; MOLONY L, 1991, EXP CELL RES, V196, P40, DOI 10.1016/0014-4827(91)90454-3; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; PARK JH, 1993, BLOOD, V82, P2470; Park RK, 1996, J BIOL CHEM, V271, P13342, DOI 10.1074/jbc.271.23.13342; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; ROBERGE CJ, 1993, J CLIN INVEST, V92, P1722, DOI 10.1172/JCI116759; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SchmidAntomarchi H, 1996, EUR J IMMUNOL, V26, P717, DOI 10.1002/eji.1830260331; SETH A, 1992, J BIOL CHEM, V267, P24796; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; WINSTON BW, 1995, J BIOL CHEM, V270, P27391, DOI 10.1074/jbc.270.46.27391; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	47	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3394	3400		10.1074/jbc.273.6.3394	http://dx.doi.org/10.1074/jbc.273.6.3394			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452460	hybrid			2022-12-25	WOS:000071822300045
J	Guerrero, C; Fernandez-Medarde, A; Rojas, JM; de Mora, JF; Esteban, LM; Santos, E				Guerrero, C; Fernandez-Medarde, A; Rojas, JM; de Mora, JF; Esteban, LM; Santos, E			Transformation suppressor activity of C3G is independent of its CDC25-homology domain	ONCOGENE			English	Article						malignant transformation; focus formation; C3G; Ras; Raf; Sis	GUANINE-NUCLEOTIDE EXCHANGE; DEPENDENT ACTIVATION; RAS P21; H-RAS; R-RAS; CEREVISIAE CDC25; POINT MUTATIONS; SEVENLESS GENE; SH3 DOMAIN; PH DOMAIN	The guanine nucleotide releasing protein C3G was initially identified as a Crk SH3-binding protein and recently shown to exhibit exchange activity on Rap1 proteins. Overexpression in NIH3T3 cells of a full-length C3G cDNA isolated from human placenta markedly reduced the focus forming activity of cotransfected, malignantly activated, ras oncogenes (5-7-fold). C3G also had a reverting effect on sis-mediated transformation, decreasing the number of c-sis-induced foci by a factor of 5-10-fold. The observed inhibitory effect of C3G on focus-forming activity of Ras and Sis was always higher than that observed with Rap1A, a known target of C3G. The inhibition of focus formation observed in the presence of C3G was not due to toxic effects on cell viability, since transfected C3G cells exhibited the same survival and growth rates as untransfected NIH3T3 cells or cells transfected with plasmid vector alone. Surprisingly, as opposed to Rap1A, which has no effect on Raf-1 oncogene-mediated transformation, C3G also reduced dramatically (6-8-fold) the number of v-raf-induced foci in transfected NIH3T3 cells. The inhibitory effect on Raf-induced transformation suggests that C3G has other functional targets in addition to Rap1. A C3G mutant (C3G Delta Cat) lacking the catalytic domain (CDC25-H) but retaining the rest of the N-terminal sequences, including the Crk-binding domain, exhibited similar ability than full length C3G to inhibit focus formation. In contrast, a C3G mutant (C3G Cat), containing the catalytic domain only but lacking the rest of the N-terminal sequences, did not have any inhibitory effect on transformation mediated by the oncogenes tested. The C3G-derived gene products overexpressed in our transfected cell lines localized to the cytoplasm and did not change the basal MAPK or JNK activity of those cell lines nor their ability to activate the kinases in response to agonists. Our results suggest that the N-terminal region of C3G, and not its catalytic domain, may be responsible for the inhibitory effects observed.	NCI, Cellular & Mol Biol Lab, DBS, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Santos, E (corresponding author), NCI, Cellular & Mol Biol Lab, DBS, NIH, Bldg 37, Bethesda, MD 20892 USA.		Rojas, José M/D-3718-2018; Rojas, José M./AAA-3354-2021; Guerrero, Carmen/F-1776-2010; Fernández-Medarde, Alberto/B-3839-2017; de Mora, Jaime Font/H-6304-2015; de Mora, Jaime Font/AAK-7591-2021	Rojas, José M/0000-0002-5383-3482; Rojas, José M./0000-0002-7547-2825; Guerrero, Carmen/0000-0002-8747-6831; Fernández-Medarde, Alberto/0000-0002-1230-5501; de Mora, Jaime Font/0000-0002-6816-2095; de Mora, Jaime Font/0000-0002-6816-2095				BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN LP, 1993, DEV GENET, V14, P339, DOI 10.1002/dvg.1020140503; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1994, ONCOGENE, V9, P685; CUADRADO A, 1993, ONCOGENE, V8, P2443; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; Fam NP, 1997, GENOMICS, V39, P118, DOI 10.1006/geno.1996.4484; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FELLER SM, 1995, ONCOGENE, V10, P1465; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Greulich H, 1996, CELL GROWTH DIFFER, V7, P1443; Guerrero C, 1996, ONCOGENE, V12, P1097; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; JACQUET E, 1992, J BIOL CHEM, V267, P24181; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAEZ R, 1994, ONCOGENE, V9, P2977; SAKODA T, 1992, ONCOGENE, V7, P1705; SCHELESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	53	36	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					613	624		10.1038/sj.onc.1201569	http://dx.doi.org/10.1038/sj.onc.1201569			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482107				2022-12-25	WOS:000071816600006
J	De Angelis, J; Gastel, J; Klein, DC; Cole, PA				De Angelis, J; Gastel, J; Klein, DC; Cole, PA			Kinetic analysis of the catalytic mechanism of serotonin N-acetyltransferase (EC 2.3.1.87)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-ENZYME INTERMEDIATE; PINEAL-GLAND; ESCHERICHIA-COLI; COENZYME-A; EXPRESSION; RHYTHM; SITE; RAT	Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT, EC 2.3.1.87) is the penultimate enzyme in melatonin biosynthesis. This enzyme is of special biological interest because large changes in its activity drive the large night/day rhythm in circulating melatonin in vertebrates, In this study the kinetic mechanism of AANAT action was studied using bacterially expressed glutathione S-transferase (GST)-AANAT fusion protein, The enzymologic behavior of GST-AANAT and cleaved AANAT was essentially identical, Two-substrate kinetic analysis generated an intersecting line pattern characteristic of a ternary complex mechanism, The dead end inhibitor analog desulfo-CoA was competitive versus acetyl-CoA and noncompetitive versus tryptamine. Tryptophol was not an alternative substrate but was a dead end competitive inhibitor versus tryptamine and an uncompetitive inhibitor versus acetyl-CoA, indicative of an ordered binding mechanism requiring binding of acetyl-CoA first, N-Acetyl-tryptamine, a reaction product, was a noncompetitive inhibitor versus tryptamine and uncompetitive with respect to acetyl-CoA, Taken together these results support an ordered BiBi ternary complex (sequential) kinetic mechanism for AANAT and provide a framework for inhibitor design.	Rockefeller Univ, Bioorgan Chem Lab, New York, NY 10021 USA; NICHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA	Rockefeller University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Cole, PA (corresponding author), Rockefeller Univ, Bioorgan Chem Lab, 1230 York Ave, New York, NY 10021 USA.			Klein, David/0000-0002-1792-5806				ARENDT J, 1996, MELATONIN MAMMALIAN; BERGES DA, 1986, J BIOL CHEM, V261, P6160; Bernard M, 1997, J NEUROCHEM, V68, P213; BORJIGIN J, 1995, NATURE, V378, P783, DOI 10.1038/378783a0; CHENN HG, 1992, BIOCHEM PHARMACOL, V43, P2255; Cleland W W, 1979, Methods Enzymol, V63, P103; COLUCCI WJ, 1988, BIOORG CHEM, V16, P307, DOI 10.1016/0045-2068(88)90018-1; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; Coon SL, 1996, GENOMICS, V34, P76, DOI 10.1006/geno.1996.0243; DEGUCHI T, 1975, J NEUROCHEM, V24, P1083, DOI 10.1111/j.1471-4159.1975.tb03682.x; DUPRET JM, 1992, J BIOL CHEM, V267, P7381; FAJARDO N, 1992, J PINEAL RES, V13, P80, DOI 10.1111/j.1600-079X.1992.tb00058.x; Gehring AM, 1996, BIOCHEMISTRY-US, V35, P579, DOI 10.1021/bi952275a; JENCKS WP, 1972, J BIOL CHEM, V247, P3756; JENKINS DL, 1985, J BIOL CHEM, V260, P4748; KLEIN DC, 1970, SCIENCE, V169, P1093, DOI 10.1126/science.169.3950.1093; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; Klein DC, 1996, TRENDS ENDOCRIN MET, V7, P106, DOI 10.1016/1043-2760(96)00033-1; MORRISSEY JJ, 1977, BIOCHEM BIOPH RES CO, V77, P118, DOI 10.1016/S0006-291X(77)80172-1; RIDDLE B, 1971, J BIOL CHEM, V246, P3250; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Roseboom PH, 1996, ENDOCRINOLOGY, V137, P3033, DOI 10.1210/en.137.7.3033; Segel IH, 1975, ENZYME KINETICS BEHA; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363; SIM E, 1992, BIOCHEM SOC T, V20, P304, DOI 10.1042/bst0200304; SOBER HA, 1970, HDB BIOCH SELECTED D, pJ184; THOMAS KB, 1990, ANAL BIOCHEM, V184, P228, DOI 10.1016/0003-2697(90)90673-W; VATSIS KP, 1995, PHARMACOGENETICS, V5, P1, DOI 10.1097/00008571-199502000-00001; VOISIN P, 1984, J BIOL CHEM, V259, P913; WEBER WW, 1967, MOL PHARMACOL, V3, P266; WOLFE MS, 1995, BRAIN RES, V669, P100, DOI 10.1016/0006-8993(94)01267-L; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	32	108	109	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3045	3050		10.1074/jbc.273.5.3045	http://dx.doi.org/10.1074/jbc.273.5.3045			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446620	hybrid			2022-12-25	WOS:000071736600075
J	Bednarek, AK; Chu, YL; Aldaz, CM				Bednarek, AK; Chu, YL; Aldaz, CM			Constitutive telomerase activity in cells with tissue-renewing potential from estrogen-regulated rat tissues	ONCOGENE			English	Article						telomerase; stem cells; estrogen; proliferation	IMMORTAL CELLS; DIFFERENTIATION; CANCER; LINES; PROGRESSION; PROSTATE; SKIN	To investigate the role of telomerase in estrogen-regulated rodent tissues, we assayed the activity levels of this enzyme and measured cell proliferation and indicators of cellularity in vagina, mammary gland, and uterus from virgin, pregnant, ovariectomized, and ovariectomized estradiol-treated rats. No association was observed between telomerase activity and increased cell proliferation. Telomerase activity was significantly higher (P=0.003) in vagina obtained from ovariectomized rats (very low proliferation) than in vagina from ovariectomized and estradiol-treated rats (high proliferation, high differentiation). The high telomerase levels observed in vagina from ovariectomized rats indicates that the same epithelial compartment (i.e., basal layer) that has the potential to reconstitute the epithelium also contains the cells that express telomerase. The lower telomerase activity in the keratinized (differentiated) vagina was probably due to dilution of the number of telomerase-producing cells by the terminally differentiated non-telomerase-producing cells. Similar results were observed in uterus from ovariectomized ver sus ovariectomized and estradiol-treated rats. Telomerase activity was highest in uterus from pregnant rats. Telomerase levels in samples from total mammary gland fat pads varied considerably between groups and appeared to be representative of the amount of epithelium present in the sample. Interestingly, when mammary gland samples from the same animals were obtained from pure epithelial organoid preparations, no differences in telomerase activity could be distinguished between animals or groups. Overall these data suggest that telomerase activity, particularly in rat vagina and uterus, appears to be associated with a cell subpopulation showing proliferative and tissue reconstitution potential and not directly associated with proliferation status per se.	Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Aldaz, CM (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Res, Sci Pk, Smithville, TX 78957 USA.		Bednarek, Andrzej K./S-9664-2016; Aldaz, C. Marcelo/E-7868-2011	Bednarek, Andrzej K./0000-0002-4570-4154; Aldaz, C. Marcelo/0000-0002-2453-2939	NATIONAL CANCER INSTITUTE [R01CA059967] Funding Source: NIH RePORTER; NCI NIH HHS [CA59967] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanell J, 1996, CANCER RES, V56, P1503; ALDAZ CM, 1992, CANCER RES, V52, P4791; BEDNAREK A, 1995, CANCER RES, V55, P4566; Bestilny LJ, 1996, CANCER RES, V56, P3796; CHADENEAU C, 1995, ONCOGENE, V11, P893; CHADENEAU C, 1995, CANCER RES, V55, P2533; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Holt SE, 1996, MOL CELL BIOL, V16, P2932; HORVAT B, 1995, EXP CELL RES, V199, P234; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 1997, CANCER RES, V57, P610; Meeker AK, 1996, ENDOCRINOLOGY, V137, P5743, DOI 10.1210/en.137.12.5743; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Sommerfeld HJ, 1996, CANCER RES, V56, P218; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Yasumoto S, 1996, ONCOGENE, V13, P433	19	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					381	385		10.1038/sj.onc.1201553	http://dx.doi.org/10.1038/sj.onc.1201553			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467963				2022-12-25	WOS:000071582100010
J	Kon, H; Sonoda, Y; Kumabe, T; Yoshimoto, T; Sekiya, T; Murakami, Y				Kon, H; Sonoda, Y; Kumabe, T; Yoshimoto, T; Sekiya, T; Murakami, Y			Structural and functional evidence for the presence of tumor suppressor genes on the short arm of chromosome 10 in human gliomas	ONCOGENE			English	Article						glioma; tumor suppressor gene; chromosome 10p; loss of heterozygosity; chromosome transfer	CANCER CELL-LINE; GLIOBLASTOMA-MULTIFORME; MALIGNANT PHENOTYPE; BRAIN-TUMORS; HETEROZYGOSITY; DELETION; AMPLIFICATION; ASTROCYTOMA; PROGRESSION; REGION	Loss of heterozygosity (LOH) observed at polymorphic loci on both arms of chromosome 10 in many human gliomas suggests the presence of multiple tumor suppressor genes on this chromosome. Recently, the PTEN/MMAC1 gene on 10q23 was isolated as one of these putative glioma suppressors. To determine the subchromosomal localization of others, we analysed 79 gliomas for LOH using 30 polymorphic microsatellite markers on the short arm and 10 markers on the long arm of chromosome 10. Twenty tumors showed LOH at all the loci examined, while 17 others showed LOH at loci on a portion of chromosome 10. Deletion mapping of the latters demonstrated that two distinct regions, encompassing genetic distances of 5.6 cM on 10p15 and 5.5 cM on 10p14, were lost frequently. Introduction of chromosomal fragments 10p14-p15, which included the entire region on 10p15 and a portion of that on 10p14 assigned by deletion mapping, into the human glioblastoma cell line T98G through microcell-mediated chromosome transfer markedly suppressed colony forming ability in soft agar compared with parental T98G cells. The combined results of structural and functional analyses strongly suggest that aberrations of the tumor suppressor gene(s) within chromosomal region 10p14-p15 are involved in development of human gliomas.	Natl Canc Ctr, Res Inst, Div Oncogene, Chuo Ku, Tokyo 104, Japan; Tohoku Univ, Sch Med, Dept Neurosurg, Aoba Ku, Sendai, Miyagi 980, Japan	National Cancer Center - Japan; Tohoku University	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Div Oncogene, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 104, Japan.			Sonoda, Yukihiko/0000-0001-7651-1374				Albarosa R, 1996, AM J HUM GENET, V58, P1260; BERGERHEIM U, 1989, CANCER RES, V49, P1390; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; DOWDY SF, 1987, SCIENCE, V236, P175; FOURNIER REK, 1981, P NATL ACAD SCI-BIOL, V78, P6349, DOI 10.1073/pnas.78.10.6349; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1992, CANCER RES, V52, P674; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRANT R, 1995, NEUROLOGY, V45, P929, DOI 10.1212/WNL.45.5.929; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HE J, 1994, GENE CHROMOSOME CANC, V11, P91, DOI 10.1002/gcc.2870110205; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; HUNTER SB, 1995, J NEUROPATH EXP NEUR, V54, P57, DOI 10.1097/00005072-199501000-00007; IITTMANN M, 1996, CANCER RES, V56, P2143; IZUMOTO S, 1995, CANCER LETT, V97, P241, DOI 10.1016/0304-3835(95)03981-2; JAMES CD, 1988, CANCER RES, V48, P5546; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARLBOM AE, 1993, HUM GENET, V92, P169; Kimmelman AC, 1996, GENOMICS, V34, P250, DOI 10.1006/geno.1996.0277; Kleihues P., 1993, WHO INT HISTOLOGICAL, V2nd ed.; Konig JJ, 1996, HUM PATHOL, V27, P720, DOI 10.1016/S0046-8177(96)90404-9; KUMABE T, 1992, ONCOGENE, V7, P627; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; Murakami YS, 1996, CANCER RES, V56, P2157; MURAKAMI YS, 1995, CANCER RES, V55, P3389; PERHOUSE MA, 1993, CANCER RES, V53, P5043; RASHEED BKA, 1995, ONCOGENE, V10, P2243; REMPEL SA, 1993, CANCER RES, V53, P2386; SONODA Y, 1995, CANCER RES, V55, P2166; Sonoda Y, 1996, JPN J CANCER RES, V87, P363, DOI 10.1111/j.1349-7006.1996.tb00231.x; SONODA Y, 1995, ONCOGENE, V11, P2145; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816	43	55	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					257	263		10.1038/sj.onc.1201488	http://dx.doi.org/10.1038/sj.onc.1201488			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464544				2022-12-25	WOS:000071427100013
J	Li, AC; Guidez, FRB; Collier, JG; Glass, CK				Li, AC; Guidez, FRB; Collier, JG; Glass, CK			The macrosialin promoter directs high levels of transcriptional activity in macrophages dependent on combinatorial interactions between PU.1 and c-Jun	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; LOW-DENSITY-LIPOPROTEIN; PROTEIN-KINASE-C; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; CELL-SURFACE EXPRESSION; SCAVENGER RECEPTOR; INTERFERON-GAMMA; DIFFERENTIAL EXPRESSION; SEQUENCE SIMILARITY; HEMATOPOIETIC-CELLS	Macrosialin is a transmembrane glycoprotein that is highly expressed in macrophages. In the present studies, macrosialin mRNA levels are shown to be markedly up-regulated during macrophage differentiation of bone marrow progenitor cells in response to macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. To investigate the mechanisms responsible for regulation of macrosialin expression, we have isolated the macrosialin gene and performed an initial analysis of its transcriptional regulatory elements. The macrosialin promoter and 7.0 kilobase pairs of 5'-flanking information direct high levels of reporter gene activity in monocyte/macrophage-like cells, but little or no expression in nonmyeloid cells. This pattern of expression is dependent on regulatory elements located between -7.0 and -2.5 kilobase pairs from the transcriptional start site that exhibit strong enhancer activity in macrophages and repressor activity in nonmyeloid cells. Analysis of the proximal macrosialin promoter indicates that combinatorial interactions between at least four classes of transcriptional activators, including PU.1/Spi-1 and members of the AP-1 family are required for basal promoter function. PU.1/Spi-1 and c-Jun act synergistically to activate the macrosialin promoter in a nonmyeloid cell line, suggesting that combinatorial interactions between these proteins are involved in regulating macrosialin expression during macrophage differentiation.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Cardiol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Glass, CK (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.	cglass@ucsd.edu	Glass, Christopher/AAI-3933-2021; Guidez, Fabien/P-4220-2019; Guidez, Fabien/B-3750-2009	Glass, Christopher/0000-0003-4344-3592; Guidez, Fabien/0000-0003-1380-4473; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003625, P50HL014197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K12AG000353] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14197, 1K08HL03625-01] Funding Source: Medline; NIA NIH HHS [2K12AG00353-09] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKESON AL, 1991, J LIPID RES, V32, P1699; ATHANASOU NA, 1986, J PATHOL, V150, P239, DOI 10.1002/path.1711500403; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN JW, 1988, J BIOL CHEM, V263, P8754; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; COLLINS SJ, 1987, BLOOD, V70, P1233; daSilva RP, 1996, BIOCHEM SOC T, V24, P220, DOI 10.1042/bst0240220; DATTA R, 1992, BLOOD, V79, P904; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRACH J, 1994, CANCER RES, V54, P1746; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; FAMBROUGH DM, 1988, J CELL BIOL, V106, P61, DOI 10.1083/jcb.106.1.61; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; GENG YJ, 1992, J CLIN INVEST, V89, P1322, DOI 10.1172/JCI115718; GORDON S, 1995, CURR OPIN IMMUNOL, V7, P24, DOI 10.1016/0952-7915(95)80025-5; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; HOLNESS CL, 1993, BLOOD, V81, P1607; HORVAI A, 1995, P NATL ACAD SCI USA, V92, P5391, DOI 10.1073/pnas.92.12.5391; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hsu HY, 1996, J BIOL CHEM, V271, P7767, DOI 10.1074/jbc.271.13.7767; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; MOULTON KS, 1992, P NATL ACAD SCI USA, V89, P8102, DOI 10.1073/pnas.89.17.8102; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PAJL HL, 1993, J BIOL CHEM, V268, P5014; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PULFORD KAF, 1990, INT IMMUNOL, V2, P973, DOI 10.1093/intimm/2.10.973; RABINOWITZ S, 1989, J CELL SCI, V93, P623; RABINOWITZ SS, 1991, J EXP MED, V174, P827, DOI 10.1084/jem.174.4.827; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; RAY D, 1990, ONCOGENE, V5, P663; ROUSSEL MF, 1994, J CELL SCI, P105; SAITO N, 1991, AM J PATHOL, V139, P1053; SAITOH O, 1992, J BIOL CHEM, V267, P5700; Schreyer SA, 1996, J BIOL CHEM, V271, P26174, DOI 10.1074/jbc.271.42.26174; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SMITH MJ, 1987, J CELL SCI, V87, P113; STROBL H, 1995, BRIT J HAEMATOL, V90, P774, DOI 10.1111/j.1365-2141.1995.tb05195.x; WARNKE RA, 1989, AM J PATHOL, V135, P1089; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; YOUNG HA, 1995, J LEUKOCYTE BIOL, V58, P373, DOI 10.1002/jlb.58.4.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	58	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5389	5399		10.1074/jbc.273.9.5389	http://dx.doi.org/10.1074/jbc.273.9.5389			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9479000	hybrid			2022-12-25	WOS:000072310400084
J	Martens, JS; Reiner, NE; Herrera-Velit, P; Steinbrecher, UP				Martens, JS; Reiner, NE; Herrera-Velit, P; Steinbrecher, UP			Phosphatidylinositol 3-kinase is involved in the induction of macrophage growth by oxidized low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; HERITABLE HYPERLIPIDEMIC RABBIT; COLONY-STIMULATING FACTORS; PLATELET-ACTIVATING-FACTOR; ENDOTHELIAL-CELLS; HUMAN-MONOCYTES; PROTEIN-KINASE; LINE THP-1; ATHEROSCLEROSIS; LDL	Early atherosclerotic lesions are characterized by the presence of cholesterol-rich, macrophage-derived foam cells. It has recently been shown that macrophage proliferation occurs during the development of early lesions and that oxidized low density lipoprotein (LDL) stimulates macrophage growth, Possible mechanisms for this induction of macrophage growth include potentiation of mitogenic signal transduction by a component of oxidized LDL following internalization and degradation, interaction with integral plasma membrane proteins coupled to signaling pathways, or direct or indirect activation of growth factor receptors on the cell surface (e.g. GM-CSF receptor) through an autocrine/paracrine mechanism, The present study was undertaken to characterize some of the early intracellular signaling events by which oxidized LDL mediates macrophage cell growth. Extensively oxidized LDL increased protein-tyrosine phosphorylation and caused a 2-fold increase in phosphatidylinositol (PI) 3-kinase activity in phorbol ester-pretreated THP-1 cells (a human monocyte-like cell line). Similar concentrations of native LDL had no effect. Oxidized LDL also stimulated growth of resident mouse peritoneal macrophages, and this effect was reduced by 40-50% in cells treated with PI 3-kinase inhibitors (100 nM wortmannin or 20 mu M LY294002), These results suggest that PI 3-kinase mediates part of the mitogenic effect of oxidized LDL, but parallel pathways involving other receptors and signal transduction pathways are likely also involved.	Univ British Columbia, Dept Med, Div Gastroenterol, Vancouver, BC V5Z 4E3, Canada; Univ British Columbia, Dept Med, Div Infect Dis, Vancouver, BC V5Z 4E3, Canada	University of British Columbia; University of British Columbia	Steinbrecher, UP (corresponding author), Univ British Columbia, Dept Med, Div Gastroenterol, 3300-950 W 10th Ave, Vancouver, BC V5Z 4E3, Canada.	usteinbr@unixg.ubc.ca		Herrera, Patricia/0000-0001-8754-9335				AagaardTillery KM, 1996, J IMMUNOL, V156, P4543; BERLINER JA, 1993, ADV EXP MED BIOL, V351, P13; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; Claus R, 1996, BIOCHEMISTRY-US, V35, P4911, DOI 10.1021/bi952036n; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Deigner HP, 1996, FEBS LETT, V385, P149, DOI 10.1016/0014-5793(96)00371-7; FOWLER S, 1979, LAB INVEST, V41, P372; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GERRITY RG, 1981, AM J PATHOL, V103, P181; GERRITY RG, 1985, SWINE BIOMEDICAL RES, P1497; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HerreraVelit P, 1996, J IMMUNOL, V156, P1157; Iwama A., 1995, Clinical and Experimental Pharmacology and Physiology, V22, pS318, DOI 10.1111/j.1440-1681.1995.tb02935.x; KATSUDA S, 1993, AM J PATHOL, V142, P1787; KIM JA, 1994, ARTERIOSCLER THROMB, V14, P427, DOI 10.1161/01.ATV.14.3.427; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; Kusuhara M, 1997, ARTERIOSCL THROM VAS, V17, P141, DOI 10.1161/01.ATV.17.1.141; Lougheed M, 1997, J BIOL CHEM, V272, P12938, DOI 10.1074/jbc.272.20.12938; Miki S, 1996, FEBS LETT, V399, P241, DOI 10.1016/S0014-5793(96)01332-4; NATARAJAN V, 1995, J LIPID RES, V36, P2005; OKADA T, 1994, J BIOL CHEM, V269, P3563; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PLIEMAN CM, 1993, J MOL CELL BIOL, V13, P5877; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; REKHTER MD, 1995, AM J PATHOL, V147, P668; RESINK TJ, 1992, ARTERIOSCLER THROMB, V12, P278, DOI 10.1161/01.ATV.12.3.278; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sakai M, 1996, J BIOL CHEM, V271, P27346, DOI 10.1074/jbc.271.44.27346; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SASAHARA M, 1994, J CLIN INVEST, V94, P155, DOI 10.1172/JCI117301; SCHWARTZ D, 1994, J CLIN INVEST, V94, P1968, DOI 10.1172/JCI117548; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Shattil SJ, 1997, J CLIN INVEST, V100, P1, DOI 10.1172/JCI119500; SPARROW CP, 1992, J CLIN INVEST, V89, P1885, DOI 10.1172/JCI115793; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VENABLE ME, 1993, J LIPID RES, V34, P691; VIA DP, 1989, J LIPID RES, V30, P1515; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331; YUSOFF P, 1994, GROWTH FACTORS, V10, P181, DOI 10.3109/08977199409000236	56	79	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4915	4920		10.1074/jbc.273.9.4915	http://dx.doi.org/10.1074/jbc.273.9.4915			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478935	hybrid			2022-12-25	WOS:000072310400019
J	Fieschi, F; Torrents, E; Toulokhonova, L; Jordan, A; Hellman, U; Barbe, J; Gibert, I; Karlsson, M; Sjoberg, BM				Fieschi, F; Torrents, E; Toulokhonova, L; Jordan, A; Hellman, U; Barbe, J; Gibert, I; Karlsson, M; Sjoberg, BM			The manganese-containing ribonucleotide reductase of Corynebacterium ammoniagenes is a class Ib enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; BACILLUS-SUBTILIS; BREVIBACTERIUM-AMMONIAGENES; NRDEF ENZYME; CLONING; PROTEIN; ENTEROBACTERIACEAE; THIOREDOXIN; EXPRESSION	Ribonucleotide reductases (RNRs) are key enzymes in living cells that provide the precursors of DNA synthesis, The three characterized classes of RNRs differ by their metal cofactor and their stable organic radical. We have purified to near homogeneity the enzymatically active Mn-containing RNR of Corynebacterium ammoniagenes, previously claimed to represent a fourth RNR class, N-terminal and internal peptide sequence analyses clearly indicate that the C. ammoniagenes RNR is a class Ib enzyme. In parallel, we have cloned a 10-kilobase pair fragment from C. ammoniagenes genomic DNA, using primers specific for the known class Ib RNR, The cloned class Ib locus contains the nrdHIEF genes typical for class Ib RNR operon, The deduced amino acid sequences of the nrdE and nrdF genes matched the peptides from the active enzyme, demonstrating that C. ammoniagenes RNR is composed of R1E and R2F components typical of class Ib. We also show that the Mn-containing RNR has a specificity for the NrdH-redoxin and a response to allosteric effecters that are typical of class Ib RNRs. Electron paramagnetic resonance and atomic absorption analyses confirm the presence of Mn as a cofactor and show, for the first time, insignificant amounts of iron and cobalt found in the other classes of RNR. Our discovery that C. ammoniagenes RNR is a class Ib enzyme and possesses all the highly conserved amino acid side chains that are known to ligate two ferric ions in other class I RNRs evokes new, challenging questions about the control of the metal site specificity in RNR. The cloning of the entire NrdHIEF locus of C, ammoniagenes will facilitate further studies along these lines.	Univ Stockholm, Dept Biol Mol, S-10691 Stockholm, Sweden; Autonomous Univ Barcelona, Fac Sci, Dept Genet & Microbiol, E-08193 Barcelona, Spain; Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden	Stockholm University; Autonomous University of Barcelona; Ludwig Institute for Cancer Research	Sjoberg, BM (corresponding author), Univ Stockholm, Dept Biol Mol, S-10691 Stockholm, Sweden.	Britt-Marie.Sjoberg@molbio.su.se	Torrents, Eduard/C-7184-2008; jordan, albert/ABC-8229-2020; jordan, albert/K-4678-2014; Gibert, Isidre/L-9834-2014; Fieschi, Franck/W-2748-2019	Torrents, Eduard/0000-0002-3010-1609; jordan, albert/0000-0002-3970-8693; jordan, albert/0000-0002-3970-8693; Gibert, Isidre/0000-0003-1442-2258; FIESCHI, Franck/0000-0003-1194-8107; Sjoberg, Britt-Marie/0000-0001-5953-3360				ATTA M, 1992, J BIOL CHEM, V267, P20682; Bathe B, 1996, MOL GEN GENET, V252, P255, DOI 10.1007/s004380050227; Boldt YR, 1997, BIOCHEMISTRY-US, V36, P2147, DOI 10.1021/bi962362i; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; Eliasson R, 1996, J BIOL CHEM, V271, P26582, DOI 10.1074/jbc.271.43.26582; FraOsto da Silva Williams, 1991, BIOL CHEM ELEMENTS I; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FURUYA A, 1976, MICROBIAL PRODUCTION, P125; Griepenburg U, 1996, FREE RADICAL RES, V24, P473, DOI 10.3109/10715769609088046; Hellman U, 1997, SPRING LAB MAN, P97; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HOCH JA, 1991, METHOD ENZYMOL, V204, P305; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; JORDAN A, 1994, J BACTERIOL, V176, P3420, DOI 10.1128/jb.176.11.3420-3427.1994; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; Jordan A, 1996, MOL MICROBIOL, V19, P777, DOI 10.1046/j.1365-2958.1996.424950.x; Jordan A, 1995, GENE, V167, P75, DOI 10.1016/0378-1119(95)00656-7; Jordan A, 1997, J BIOL CHEM, V272, P18044, DOI 10.1074/jbc.272.29.18044; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LUNN CA, 1984, J BIOL CHEM, V259, P469; MALUMBRES M, 1993, GENE, V134, P15, DOI 10.1016/0378-1119(93)90169-4; MORIYA S, 1985, NUCLEIC ACIDS RES, V13, P2251, DOI 10.1093/nar/13.7.2251; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; OKA T, 1968, J BACTERIOL, V96, P1760, DOI 10.1128/JB.96.5.1760-1767.1968; Patek M, 1996, MICROBIOL-SGM, V142, P1297, DOI 10.1099/13500872-142-5-1297; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PLONZIG J, 1987, ARCH MICROBIOL, V146, P396, DOI 10.1007/BF00410942; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIMPFFWEILAND G, 1981, BIOCHEM BIOPH RES CO, V102, P1276, DOI 10.1016/S0006-291X(81)80149-0; Schmidt M, 1996, J BIOL INORG CHEM, V1, P532, DOI 10.1007/s007750050089; Scotti C, 1996, MICROBIOL-SGM, V142, P2995, DOI 10.1099/13500872-142-11-2995; Sjoberg BM, 1997, STRUCT BOND, V88, P139; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; Thelander L, 1978, Methods Enzymol, V51, P227; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WEBLEY DM, 1962, J GEN MICROBIOL, V29, P179, DOI 10.1099/00221287-29-1-179; WILLING A, 1988, EUR J BIOCHEM, V170, P603, DOI 10.1111/j.1432-1033.1988.tb13740.x; WILLING A, 1988, EUR J BIOCHEM, V175, P167, DOI 10.1111/j.1432-1033.1988.tb14179.x; YANG FD, 1994, J BACTERIOL, V176, P6738, DOI 10.1128/JB.176.21.6738-6743.1994; Yang FD, 1997, J BACTERIOL, V179, P6408, DOI 10.1128/jb.179.20.6408-6415.1997	49	45	47	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4329	4337		10.1074/jbc.273.8.4329	http://dx.doi.org/10.1074/jbc.273.8.4329			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468481	hybrid, Green Published			2022-12-25	WOS:000072115000009
J	Librizzi, MD; Brenowitz, M; Willis, IM				Librizzi, MD; Brenowitz, M; Willis, IM			The TATA element and its context affect the cooperative interaction of TATA-binding protein with the TFIIB-related factor, TFIIIB70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TRANSCRIPTION FACTOR-IIIB; CRYSTAL-STRUCTURE; MINOR-GROOVE; BOX COMPLEX; IN-VIVO; YEAST; DNA; TBP; PROMOTER	We have conducted a quantitative thermodynamic study of the effects of the TATA element and TATA-flanking sequences on the assembly of complexes containing TATA-binding protein (TBP) and the TFIIB-related factor, TFIIIB70. TBP binds to the sequence TATAAAAG in the context of the yeast U6 gene (yU6 hybrid TATA) or the adenovirus major late promoter (AdMLP) with different affinities demonstrating that the sequence context of a TATA element contributes to TBP binding, We also determined the cooperative free energies of formation of TBP.TFIIIB70.DNA complexes on the yU6 TATA element, the yU6 hybrid TATA element and a nonconsensus TATA element, The yU6 hybrid TATA displayed a moderate, less than 5-fold, increase in TBP affinity similar to the 3-fold increase observed for the AdMLP. In contrast, the nonconsensus and yU6 TATAs increased the affinity of TBP for DNA 12- and 17-fold, respectively. Since the TBP-TFIIIB70 cooperativity is greater on lower affinity TATA boxes and most polymerase III genes contain low affinity "TATA boxes," we conclude that the cooperative binding of TFIIIB70 and TBP to DNA represents an important driving force in the assembly of polymerase III-specific transcription complexes, An effect of the sequences surrounding the TATA box was also observed on TBP-TFIIIB70 cooperativity, The mechanistic implications of the thermodynamic linkage between DNA sequence and binding cooperativity are discussed.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Willis, IM (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	willis@aecom.yu.edu		Willis, Ian/0000-0001-6599-2395	NIGMS NIH HHS [GM51506, GM42728, GM07491] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051506, R01GM042728] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1983, J MOL BIOL, V170, P223, DOI 10.1016/S0022-2836(83)80234-4; BRENOWITZ M, 1993, FOOTPRINTING TECHNIQ, P1; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CHOISNE N, 1998, IN PRESS PLANT MOL B; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; Daugherty MA, 1997, FASEB J, V11, pA1207; GAILLARD C, 1990, NUCLEIC ACIDS RES, V18, P378, DOI 10.1093/nar/18.2.378; GARBER ME, 1994, MOL CELL BIOL, V14, P339, DOI 10.1128/MCB.14.1.339; GERLACH VL, 1995, MOL CELL BIOL, V15, P1455; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; Huang WB, 1996, NUCLEIC ACIDS RES, V24, P1158, DOI 10.1093/nar/24.6.1158; Huet J, 1997, J BIOL CHEM, V272, P18341, DOI 10.1074/jbc.272.29.18341; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; Kosa PF, 1997, P NATL ACAD SCI USA, V94, P6042, DOI 10.1073/pnas.94.12.6042; Librizzi MD, 1996, J BIOL CHEM, V271, P32695, DOI 10.1074/jbc.271.51.32695; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; Nikolov DB, 1996, P NATL ACAD SCI USA, V93, P4862, DOI 10.1073/pnas.93.10.4862; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; PETRI V, 1995, BIOCHEMISTRY-US, V34, P9977, DOI 10.1021/bi00031a020; PETRI V, 1996, FASEB J, V10, pA1123; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; ROBERTS S, 1995, GENE DEV, V9, P832, DOI 10.1101/gad.9.7.832; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; STARR DB, 1995, J MOL BIOL, V250, P434; VERRIJZER CP, 1996, TRENDS BIOCHEM SCI, V21, P325; Wang Y, 1996, NUCLEIC ACIDS RES, V24, P3100, DOI 10.1093/nar/24.15.3100; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890	37	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4563	4568		10.1074/jbc.273.8.4563	http://dx.doi.org/10.1074/jbc.273.8.4563			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468512	hybrid			2022-12-25	WOS:000072115000040
J	Hsu, CY; Yung, BYM				Hsu, CY; Yung, BYM			Down-regulation of nucleophosmin/B23 during retinoic acid-induced differentiation of human promyelocytic leukemia HL-60 cells	ONCOGENE			English	Article						nucleophosmin/B23; retinoic acid; HL-60 differentiation	NUCLEOLAR PHOSPHOPROTEIN B23; NUCLEAR MATRIX PROTEIN; HELA-CELLS; RNA-SYNTHESIS; TRANSCRIPTIONAL REGULATION; ACTINOMYCIN-D; NUMATRIN B23; TUMOR-CELLS; C-MYC; GROWTH	Human promyelocytic leukemia HL-60 cells were induced to undergo granulocytic differentiation by treatment with retinoic acid (RA, 10 mu M, 1-5 days). The steady-state level of nucleophosmin/B23 mRNA decreased during the RA-induced differentiation. There was also decrease in the level of total cellular nucleophosmin/B23 protein during the RA-induced differentiation. Stabilization and nuclear run-on assays indicate that the decrease in nucleophosmin/B23 mRNA in RA-treated HL-60 cells was transcriptionally regulated. Unlike c-myc mRNA, there was virtually no decline of nucleophosmin/B23 mRNA during the growth arrest by serum-starvation. The decrease in nucleophosmin/B23 mRNA expression in HL-60 cells subsequent to retinoic acid treatment can thus be attributed to cellular differentiation rather than the growth arrest induced by RA. Nucleophosmin/B23 antisense oligomer treatment significantly potentiated RA-induced cellular differentiation. Results of this study suggest that nucleophosmin/B23 is one of the key elements in the down-regulation of nucleolar function for cellular differentiation.	Chang Gung Med & Engn Coll, Dept Pharmacol, Canc Biochem Lab, Tao Yuan 333, Taiwan; Natl Yang Ming Univ, Grad Inst Pharmacol, Taipei, Taiwan	National Yang Ming Chiao Tung University	Yung, BYM (corresponding author), Chang Gung Med & Engn Coll, Dept Pharmacol, Canc Biochem Lab, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.			Yung, Benjamin Yat Ming/0000-0003-0093-3196				ADACHI Y, 1993, J BIOL CHEM, V268, P13930; BECKMANN R, 1992, EUR J BIOCHEM, V210, P45, DOI 10.1111/j.1432-1033.1992.tb17388.x; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREITMAN TR, 1980, EXP CELL RES, V126, P494, DOI 10.1016/0014-4827(80)90296-7; CHAN PK, 1989, CANCER RES, V49, P3271; CHAN PK, 1992, EXP CELL RES, V203, P174, DOI 10.1016/0014-4827(92)90053-B; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Cho SK, 1996, J BIOL CHEM, V271, P3238, DOI 10.1074/jbc.271.6.3238; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOU YH, 1995, BIOCHEM BIOPH RES CO, V217, P313, DOI 10.1006/bbrc.1995.2779; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FONAGY A, 1992, CANCER RES, V52, P5250; GROSSO LE, 1985, CANCER RES, V45, P847; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITINGER N, 1993, J CELL BIOCHEM, V52, P153, DOI 10.1002/jcb.240520207; LI XZ, 1989, BIOCHEM BIOPH RES CO, V163, P72, DOI 10.1016/0006-291X(89)92100-1; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; PATTERSON SD, 1995, J BIOL CHEM, V270, P9429, DOI 10.1074/jbc.270.16.9429; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; TSIFTSOGLOU AS, 1985, INT J CELL CLONING, V3, P349, DOI 10.1002/stem.5530030602; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; WU MH, 1995, BIOCHEM J, V305, P987, DOI 10.1042/bj3050987; YonedaKato N, 1996, ONCOGENE, V12, P265; YUNG BY, 1990, CANCER RES, V50, P5987; YUNG BYM, 1990, INT J CANCER, V46, P272, DOI 10.1002/ijc.2910460222; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8; YUNG BYM, 1986, CANCER RES, V46, P922; YUNG BYM, 1992, INT J CANCER, V52, P317, DOI 10.1002/ijc.2910520227	43	57	57	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					915	923		10.1038/sj.onc.1201615	http://dx.doi.org/10.1038/sj.onc.1201615			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484783				2022-12-25	WOS:000072053200011
J	Svedberg, H; Chylicki, K; Baldetorp, B; Rauscher, FJ; Gullberg, U				Svedberg, H; Chylicki, K; Baldetorp, B; Rauscher, FJ; Gullberg, U			Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program	ONCOGENE			English	Article						WT1; leukemia; differentiation; hematopoiesis; U937	ZINC FINGER PROTEIN; I RECEPTOR GENE; SUPPRESSOR GENE; RETINOIC ACID; MYELOID-LEUKEMIA; ADHESION MOLECULES; PROMOTER ACTIVITY; FLOW-CYTOMETRY; U-937 CELLS; PRODUCT	The Wilms tumor gene, WT1, encodes a zinc-finger DNA binding protein which is thought to function as a tissue specific transcription factor, regulating cell growth and differentiation, High expression of WT1 has been detected in a range of acute leukemias. To elucidate a role for WT1 in leukemogenesis, we transfected the monoblastic cell line U937, which lacks detectable levels of endogenous WT1, with two isoforms of WT1, We showed that, in contrast to U937 control cells, cells constitutively expressing either of the isoforms, WT1(-KTS) or WT1(+KTS), did not respond to differentiation induction by retinoic acid or vitamin D3, as judged by the capacity to reduce nitro blue tetrazolium and morphology. Although U937 cells expressing WT1 were hampered in their ability to differentiate on incubation with retinoic acid and vitamin D3, the induced G1/G0-accumulation was similar to differentiating control cells treated with inducers, Furthermore, distinct effects on the maturation process were indicated by downregulation of the myeloid cell surface makers CD13 and CD15, while the upregulation of CD14 and CD11c on WT1 transfected cells was similar to control cells upon incubation with retinoic acid and vitamin D3, Taken together our results demonstrate that a constitutive expression of WT1 in the leukemic cell line U937 leads to impairment of differentiation responses, indicating that a high expression of WT1 can contribute to the differentiation block of acute leukemia.	Lund Univ, Dept Hematol, S-22185 Lund, Sweden; Lund Univ, Dept Oncol, S-22185 Lund, Sweden; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	Lund University; Lund University; The Wistar Institute	Gullberg, U (corresponding author), Lund Univ, Dept Hematol, S-22185 Lund, Sweden.		Baldetorp, Bo/HDM-9924-2022					Algar EM, 1996, ONCOGENE, V12, P1005; Baird PN, 1997, EXP HEMATOL, V25, P312; BALDETORP B, 1989, CYTOMETRY, V10, P695, DOI 10.1002/cyto.990100605; BALDETORP B, 1992, CYTOMETRY, V13, P577, DOI 10.1002/cyto.990130605; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARLOS TM, 1994, BLOOD, V84, P2068; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EHINGER M, 1995, CELL GROWTH DIFFER, V6, P9; Ehinger M, 1996, BLOOD, V87, P1064, DOI 10.1182/blood.V87.3.1064.bloodjournal8731064; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FRAIZER GC, 1995, BLOOD, V86, P4704, DOI 10.1182/blood.V86.12.4704.bloodjournal86124704; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOODYER P, 1995, ONCOGENE, V10, P1125; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Hewitt SM, 1996, J BIOL CHEM, V271, P8588, DOI 10.1074/jbc.271.15.8588; HEWITT SM, 1995, CANCER RES, V55, P5386; Inoue K, 1997, BLOOD, V89, P1405, DOI 10.1182/blood.V89.4.1405; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kudoh T, 1996, ONCOGENE, V13, P1431; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; LUO XN, 1995, ONCOGENE, V11, P743; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MIWA H, 1992, LEUKEMIA, V6, P405; MORRIS JF, 1991, ONCOGENE, V6, P2339; OBERG F, 1993, J IMMUNOL, V150, P3487; Olsson I, 1996, EUR J HAEMATOL, V57, P1; OLSSON I, 1983, CANCER RES, V43, P5862; OLSSON IL, 1982, CANCER RES, V42, P3924; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Patmasiriwat P, 1996, LEUKEMIA, V10, P1127; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SEKIYA M, 1994, BLOOD, V83, P1876; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; STOCKS SC, 1990, BIOCHEM J, V268, P275, DOI 10.1042/bj2680275; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878	55	71	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	1998	16	7					925	932		10.1038/sj.onc.1201613	http://dx.doi.org/10.1038/sj.onc.1201613			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484784				2022-12-25	WOS:000072053200012
J	Underwood, KW; Jacobs, NL; Howley, A; Liscum, L				Underwood, KW; Jacobs, NL; Howley, A; Liscum, L			Evidence for a cholesterol transport pathway from lysosomes to endoplasmic reticulum that is independent of the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HAMSTER OVARY CELLS; ACYL-COENZYME-A; INTRACELLULAR CHOLESTEROL; CULTURED FIBROBLASTS; HEPATOMA-CELLS; GOLGI-COMPLEX; BREFELDIN-A; ESTERIFICATION; MACROPHAGES	We have studied the movement of low density lipoprotein (LDL)-derived cholesterol in cultured Chinese hamster ovary cells, Our hypothesis is that when LDL cholesterol is effluxed from lysosomes, the bulk of LDL cholesterol is mobilized to the plasma membrane, while another pathway delivers LDL cholesterol from lysosomes to acyl-CoA/cholesterol acyltransferase (ACAT) in the endoplasmic reticulum. Three lines of evidence support this model, First, LDL cholesterol transport to ACAT can be blocked without inhibiting the movement of cholesterol from lysosomes to plasma membrane or from plasma membrane to endoplasmic reticulum, Second, LDL cholesterol transport to ACAT is normal in a Chinese hamster ovary mutant with defective plasma membrane-to-ACAT movement, Third, LDL cholesterol is not diluted by the plasma. membrane cholesterol pool before reaching ACAT, Our evidence supports a vesicular model of cholesterol transport from lysosomes to the endoplasmic reticulum that is independent; of the plasma membrane.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Liscum, L (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049564, T32DK007542, P30DK034928] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34928, DK49564, DK07542] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; COXEY RA, 1993, J LIPID RES, V34, P1165; DAHL NK, 1992, J BIOL CHEM, V267, P4889; DAHL NK, 1994, J LIPID RES, V35, P1839; DEKRUIJFF B, 1990, BIOSCIENCE REP, V10, P127; FAUST JR, 1977, J BIOL CHEM, V252, P4861; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HARMALA AS, 1994, BBA-LIPID LIPID MET, V1211, P317, DOI 10.1016/0005-2760(94)90156-2; Jacobs NL, 1997, J LIPID RES, V38, P1973; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KINSKY SC, 1970, ANNU REV PHARMACOLOG, V10, P119, DOI 10.1146/annurev.pa.10.040170.001003; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORTING HC, 1994, LIFE SCI, V55, P533, DOI 10.1016/0024-3205(94)00746-2; LANGE Y, 1983, J BIOL CHEM, V258, P5130; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; LANGE Y, 1995, J LIPID RES, V36, P1092; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1991, J LIPID RES, V32, P329; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; NORMAN AW, 1972, J BIOL CHEM, V247, P1918; PORN MI, 1995, BIOCHEM J, V308, P269; RALSTON E, 1993, J CELL BIOL, V120, P399, DOI 10.1083/jcb.120.2.399; RIDGWAY ND, 1995, J BIOL CHEM, V270, P8023, DOI 10.1074/jbc.270.14.8023; RODRIGUEZLAFRASSE C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P123, DOI 10.1016/0005-2760(90)90284-5; Skiba PJ, 1996, J BIOL CHEM, V271, P13392, DOI 10.1074/jbc.271.23.13392; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; TABAS I, 1988, J BIOL CHEM, V263, P1266; TABAS I, 1994, J BIOL CHEM, V269, P22547; Underwood KW, 1996, J LIPID RES, V37, P1556; WARNOCK DE, 1993, J BIOL CHEM, V268, P10145; XU XX, 1991, J BIOL CHEM, V266, P17040	41	137	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4266	4274		10.1074/jbc.273.7.4266	http://dx.doi.org/10.1074/jbc.273.7.4266			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461625	hybrid			2022-12-25	WOS:000072048400067
J	Makhina, EN; Nichols, CG				Makhina, EN; Nichols, CG			Independent trafficking of K-ATP channel subunits to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFONYLUREA RECEPTOR; ENDOPLASMIC-RETICULUM; POTASSIUM CHANNELS; PROTEIN; EXPRESSION; CLONING; CELLS	K-ATP channels are unique in requiring two distinct subunits (Kir6.2, a potassium channel subunit) and SUR1 (an ABC protein) for generation of functional channels, To examine the cellular trafficking of K-ATP channel subunits, green fluorescent protein (GFP) was tagged to the cytoplasmic N or C terminus of SUR1 and Kir6.2 subunits and to the C terminus of a dimeric fusion between SUR1 and Kir6.2 (SUR1-Kir6.2). AU tagged constructs generated functional channels with essentially normal properties when coexpressed with the relevant other subunit. GFP-tagged Kir6.2 (Kir6.2-GFP) showed perinuclear and plasma membrane fluorescence patterns when expressed alone or with SUR1, and a very similar pattern was observed when channel-forming SUR1-Kir6.2-GFP was expressed on its own. In contrast, whereas SUR1 (SUR1-GFP) also showed a perinuclear and plasma membrane fluorescence pattern when expressed alone, an apparently cytoplasmic fluorescence was observed when coexpressed with Kir6.2 subunits, The results indicate that Kir6.2 subunits traffic to the plasma membrane in the presence or absence of SUR1, in contradiction to the hypothesis that homomeric Kir6.2 channels are not observed because SUR1 is required as a chaperone to guide Kir6.2 subunits through the secretory pathway.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Nichols, CG (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Nichols, Colin/D-6336-2012		NHLBI NIH HHS [HL54171, HL451231] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054171] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ammala C, 1996, NATURE, V379, P545, DOI 10.1038/379545a0; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MAKHINA EN, 1997, BIOPHYS J, V72, P253; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; OZANNE SE, 1995, DIABETOLOGIA, V38, P277; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; Salinas M, 1997, J BIOL CHEM, V272, P8774, DOI 10.1074/jbc.272.13.8774; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; SHYNG SL, 1997, J GEN PHYSIOL, V110, P654; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0	23	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3369	3374		10.1074/jbc.273.6.3369	http://dx.doi.org/10.1074/jbc.273.6.3369			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452456	hybrid			2022-12-25	WOS:000071822300041
J	Schultz, RA; Swoap, SJ; McDaniel, LD; Zhang, BQ; Koon, EC; Garry, DJ; Li, K; Williams, RS				Schultz, RA; Swoap, SJ; McDaniel, LD; Zhang, BQ; Koon, EC; Garry, DJ; Li, K; Williams, RS			Differential expression of mitochondrial DNA replication factors in mammalian tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; CONTRACTILE ACTIVITY; POLYMERASE-GAMMA; STRIATED-MUSCLE; GENE-EXPRESSION; SKELETAL-MUSCLE; NUCLEAR; CLONING; SSB; RNA	Mitochondrial biogenesis and mitochondrial DNA (mtDNA) replication are regulated during development and in response to physiological stresses, but the regulatory events that control the abundance of mtDNA in cells of higher eukaryotes have not been defined at a molecular level, In this study, we observed that expression of the catalytic subunit of DNA polymerase gamma (POL gamma(CAT)) mRNA varies little among different tissues and is not increased by continuous neural activation of skeletal muscle, a potent stimulus to mitochondrial bio genesis, Increased copy number for the POL gamma locus in a human cell line bearing a partial duplication of chromosome 15 increased the abundance of POL gamma(CAT) mRNA without up-regulation of mtDNA, In contrast, expression of mitochondrial single-stranded DNA-binding (mtSSB) mRNA is regulated coordinately with variations in the abundance of mtDNA among tissues of mammalian organisms and is up-regulated in association with the enhanced mitochondrial biogenesis that characterizes early postnatal development of the heart and the adaptive response of skeletal myofibers to motor nerve stimulation, In addition, we noted that expression of mtSSB is concentrated within perinuclear mitochondria that constitute active sites of mtDNA replication, We conclude that constitutive expression of the gene encoding the catalytic subunit of mitochondrial DNA polymerase is sufficient to support physiological variations in mtDNA replication among specialized cell types, whereas expression of the mtSSB gene is controlled by molecular mechanisms acting to regulate mtDNA replication or stability in mammalian cells.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Biol Oncol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Williams, RS (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, NB11-200, Dallas, TX 75235 USA.				NATIONAL CANCER INSTITUTE [R01CA052121] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054794, P01HL006296] Funding Source: NIH RePORTER; NCI NIH HHS [CA52121] Funding Source: Medline; NHLBI NIH HHS [HL54794, HL06296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANNEX BH, 1990, MOL CELL BIOL, V10, P5671, DOI 10.1128/MCB.10.11.5671; ANNEX BH, 1991, AM J PHYSIOL, V260, pC266, DOI 10.1152/ajpcell.1991.260.2.C266; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883; Davis AF, 1996, NUCLEIC ACIDS RES, V24, P2753, DOI 10.1093/nar/24.14.2753; FOURY F, 1989, J BIOL CHEM, V264, P20552; GHRIR R, 1991, ARCH BIOCHEM BIOPHYS, V291, P395, DOI 10.1016/0003-9861(91)90152-9; HOKE GD, 1990, ARCH BIOCHEM BIOPHYS, V282, P116, DOI 10.1016/0003-9861(90)90094-F; ORDWAY GA, 1993, AM J PHYSIOL, V265, pC1511, DOI 10.1152/ajpcell.1993.265.6.C1511; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Saltin B, 2010, COMPR PHYSIOL, P555; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; Walker RL, 1997, GENOMICS, V40, P376, DOI 10.1006/geno.1996.4580; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WILLIAMS RS, 1986, J BIOL CHEM, V261, P2390; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481	22	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3447	3451		10.1074/jbc.273.6.3447	http://dx.doi.org/10.1074/jbc.273.6.3447			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452467	hybrid			2022-12-25	WOS:000071822300052
J	Hemminki, A; Hoglund, P; Pukkala, E; Salovaara, R; Jarvinen, H; Norio, R; Aaltonen, LA				Hemminki, A; Hoglund, P; Pukkala, E; Salovaara, R; Jarvinen, H; Norio, R; Aaltonen, LA			Intestinal cancer in patients with a germline mutation in the down-regulated in adenoma (DRA) gene	ONCOGENE			English	Article						DRA; CLD; cancer; neoplasia; tumor suppressor	CONGENITAL CHLORIDE DIARRHEA; LINKAGE DISEQUILIBRIUM; CYSTIC-FIBROSIS; MUCOSA; COLON; GROWTH; CARCINOMA; ENCODES	A recent study has revealed that germline mutations of the down-regulated in adenoma (DRA) gene are a likely cause of a recessive intestinal absorption defect, congenital chloride diarrhea, This finding was in accordance with previous works showing that DRA encodes a sodium independent transporter for sulfate and oxalate, Although DRA was originally reported as a candidate tumor suppressor, these studies have questioned the relevance of DRA in cancer. To evaluate whether further studies on the role of DRA in tumorigenesis are still of interest, we examined whether individuals carrying germline DRA mutations have an excess of intestinal cancer, Cancer status of 229 members of 36 Finnish congenital chloride diarrhea families (44 homozygous patients, 70 heterozygous parents, and 115 grandparents at 50% risk of being a DRA mutation carrier) was checked at the Finnish Cancer Registry and the risk of intestinal cancer was found slightly elevated (standardized incidence ratio 3.4, 95% confidence interval 1.4-7.0, P<0.05). While this result does not unambiguously demonstrate an increased intestinal cancer risk in DRA mutation carriers, it should promote further studies to determine the possible role of DRA in cancer.	Univ Helsinki, Dept Med Genet, Helsinki 00014, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, Helsinki 00014, Finland; Finnish Canc Registry, Helsinki 00171, Finland; Univ Helsinki, Cent Hosp, Dept Surg 2, Helsinki 00250, Finland; Family Fed Finland, Dept Med Genet, Helsinki 00101, Finland	University of Helsinki; University of Helsinki; Finnish Cancer Registry; University of Helsinki; Helsinki University Central Hospital; Family Federation of Finland	Aaltonen, LA (corresponding author), Univ Helsinki, Dept Med Genet, Haartmaninkatu 3,POB 21, Helsinki 00014, Finland.		Aaltonen, Lauri/A-5375-2010	Aaltonen, Lauri/0000-0001-6839-4286	NATIONAL CANCER INSTITUTE [U01CA067941, R01CA067941] Funding Source: NIH RePORTER; NCI NIH HHS [CA67941] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham EH, 1996, NAT MED, V2, P593, DOI 10.1038/nm0596-593; FILIPE MI, 1974, CANCER-AM CANCER SOC, V34, P282, DOI 10.1002/1097-0142(197408)34:2<282::AID-CNCR2820340211>3.0.CO;2-W; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HOGLUND P, 1995, AM J HUM GENET, V57, P95; HOGLUND P, 1994, AM J HUM GENET, V55, P747; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; KYLLONEN LEJ, 1987, ANN CHIR GYNAECOL FE, V76, P185; LAPIS K, 1990, Tokai Journal of Experimental and Clinical Medicine, V15, P155; Mckusick V.A., 1994, MENDELIAN INHERITANC; NAKAMURA N, 1981, CANCER RES, V41, P278; NEGLIA JP, 1995, NEW ENGL J MED, V332, P494, DOI 10.1056/NEJM199502233320803; NORIO R, 1971, Clinical Genetics, V2, P182; PUKKALA E, 1992, USE RECORD LINKAGE S, P125; PUKKALA E, 1987, CANC SOC FINLAND PUB, V37; ROBINSON J, 1984, J CELL BIOL, V98, P946, DOI 10.1083/jcb.98.3.946; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; SHAMSUDDIN AKM, 1981, J NATL CANCER I, V66, P413; SILBERG DG, 1995, J BIOL CHEM, V270, P11897, DOI 10.1074/jbc.270.20.11897; TAGUCHI T, 1994, GENOMICS, V20, P146, DOI 10.1006/geno.1994.1148; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; VONDIPPE P, 1982, J BIOL CHEM, V257, P4381; YAMORI T, 1987, CANCER RES, V47, P2741	24	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					681	684		10.1038/sj.onc.1201538	http://dx.doi.org/10.1038/sj.onc.1201538			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482116				2022-12-25	WOS:000071816600015
J	Ahmed, M; Dusanter-Fourt, I; Bernard, M; Mayeux, P; Hawley, RG; Bennardo, T; Novault, S; Bonnet, ML; Gisselbrecht, S; Varet, B; Turhan, AG				Ahmed, M; Dusanter-Fourt, I; Bernard, M; Mayeux, P; Hawley, RG; Bennardo, T; Novault, S; Bonnet, ML; Gisselbrecht, S; Varet, B; Turhan, AG			BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line	ONCOGENE			English	Article						BCR-ABL; apoptosis; EpoR	DNA-BINDING ACTIVITY; CHRONIC MYELOGENOUS LEUKEMIA; FACTOR-DEPENDENT CELLS; TYROSINE KINASE; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; POSITIVE CELLS; SH2 DOMAIN; TRANSFORMATION	The interleukin-3 dependent murine Ba/F3 cell line has been widely used as an experimental model of cell transformation by BCR-ABL oncogenes as assessed by induction of growth-factor-independence and inhibition of apoptosis in vitro. The signaling pathways used by BCR-ABL oncogenes to exert these effects are unknown, To gain insights into this phenomenon, we have introduced the p190- and p210-encoding BCR-ABL oncogenes as well as the constitutively activated oncogenic murine erythropoietin receptor (cEpoR) into Ba/F3 and compared the behavior of individual clones in response to apoptotic stimuli, Both p210 and p190 BCR-ABL vectors induced IL-3-independent growth and the same result was obtained with the cEpo-R vector, Individual clones of Ba/F3 cells expressing BCR-ABL exhibited significant resistance to apoptosis induced by either etoposide, serum deprivation or growth-factor withdrawal. In contrast, Ba/F3 cells expressing the constitutively active cEpoR behaved like parental Ba/F3 cells undergoing apoptosis when similarly treated with etoposide or upon serum deprivation, Bc12 and Bas levels were similar in all BCR-ABL and cEpoR-transfected clones, However, in band-shift assays, nuclear extracts from growth-factor-independent Ba/F3 clones expressing cEpoR had no detectable STAT activity as opposed to the constitutive STAT activation detected in all Ba/F3 clones expressing p210 or p190 BCR-ABL. Our results indicate that although both constitutively activated cEpoR and BCR-ABL oncogenes induce growth-factor independence in Ba/F3 cells, only BCR-ABL is able to protect cells from etoposide and serum-deprivation-induced apoptosis and induce a strong constitutive activation of STAT factors, suggesting a role for these molecules in the anti-apoptotic activity of BCR-ABL.	Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Hop Necker Enfants Malad, CNRS, URA 1461, F-75743 Paris, France; Hop Necker Enfants Malad, Serv Hematol Adulte, F-75743 Paris, France; Hop Cochin, ICGM, INSERM, U363, F-75674 Paris, France; Toronto Hosp, Oncol Gene Therapy Program, Toronto, ON M5G 2M1, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Turhan, AG (corresponding author), Inst Gustave Roussy, INSERM, U362, PR-1 Rue Camille Desmoulins, F-94805 Villejuif, France.		Dusanter-Fourt, Isabelle/P-4558-2017	Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Hawley, Robert/0000-0003-3512-5818; TURHAN, Ali/0000-0002-4861-0137				BEDI A, 1994, BLOOD, V83, P2038; Bright JJ, 1997, J IMMUNOL, V159, P175; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; EAVES CJ, 1987, CHRONIC MYELOID LEUK, V1, P931; Esteve P, 1995, ONCOGENE, V11, P2657; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HAWLEY RG, 1994, GENE THER, V1, P136; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; ISSAAD C, 1994, BLOOD, V84, P3447; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LANEUVILLE P, 1994, CANCER RES, V54, P1360; LONGMORE GD, 1994, MOL CELL BIOL, V14, P2266, DOI 10.1128/MCB.14.4.2266; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OFarrell AM, 1996, BLOOD, V87, P3655, DOI 10.1182/blood.V87.9.3655.bloodjournal8793655; OKUDA K, 1994, J BIOL CHEM, V269, P24602; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; SIRARD C, 1994, BLOOD, V83, P1575; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	48	23	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					489	496		10.1038/sj.onc.1201556	http://dx.doi.org/10.1038/sj.onc.1201556			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484838				2022-12-25	WOS:000071739400007
J	Andersson, E; Hellman, L; Gullberg, U; Olsson, I				Andersson, E; Hellman, L; Gullberg, U; Olsson, I			The role of the propeptide for processing and sorting of human myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA HL-60 CELLS; HUMAN RECOMBINANT MYELOPEROXIDASE; HUMAN CATHEPSIN-G; LINE RBL; PROGENITOR-CELL; BREFELDIN-A; BIOSYNTHESIS; GRANULES; HEME; SITE	Myeloperoxidase (MPO), stored in azurophil granules of neutrophils, is critical for an optimal oxygen-dependent microbicidal activity of these cells. Pro-MPO goes through a stepwise proteolytic trimming with elimination of an amino-terminal propeptide to yield one heavy and one light polypeptide chain. The propeptide of MPO may have a role in retention and folding of the nascent protein into its tertiary structure or in targeting of pro-MPO for processing and storage in granules, A propeptide-deleted pro-MPO mutant (MPO Delta pro) was constructed to determine if deletion of the propeptide interferes with processing and targeting after transfection to the myeloid 32D cell line. Transfection of full-length cDNA for human MPO results in normal processing and targeting of MPO to cytoplasmic dense organelles. Although the efficiency of incorporation was lower for MPO Delta pro, both pro-MPO and MPO Delta pro showed heme incorporation indicating that the propeptide is not critical for this process. Deletion of the propeptide results in synthesis of a protein that lacks processing into mature two-chain forms but rather is degraded intracellularly or secreted, The finding of continued degradation of MPO Delta pro in the presence of lysosomotrophic agents or brefeldin A rules out that the observed degradation takes place after transfer to granules, Intracellular pro-MPO has high mannose oligosaccharide side chains, whereas stored mature MPO was found to have both high mannose and complex oligosaccharide side chains as judged by only partial sensitivity to endoglycosidase H. The propeptide may normally interfere with the generation of certain complex oligosaccharide chain(s) supported by the finding of high mannose side chains in secreted pro-MPO and lack of them in MPO Delta pro that contained complex oligosaccharide side chains only. In conclusion, elimination of the propeptide of pro-MPO blocks the maturation process and abolishes accumulation of the final product in granules suggesting a critical role of the propeptide for late processing of pro-MPO and targeting for storage in granules.	Univ Lund Hosp, Res Dept 2, Dept Hematol, S-22185 Lund, Sweden; Univ Uppsala, Ctr Biomed, Dept Immunol & Med Microbiol, S-75123 Uppsala, Sweden	Lund University; Skane University Hospital; Uppsala University	Olsson, I (corresponding author), Univ Lund Hosp, Res Dept 2, Dept Hematol, E Blocket, S-22185 Lund, Sweden.	inge.olsson@hematologi.lu.se						AKIN DT, 1987, ARCH BIOCHEM BIOPHYS, V255, P428, DOI 10.1016/0003-9861(87)90411-5; AKIN DT, 1986, J BIOL CHEM, V261, P8370; ANDREWS PC, 1981, J BIOL CHEM, V256, P4211; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BRETZ R, 1977, EUR J BIOCHEM, V77, P181, DOI 10.1111/j.1432-1033.1977.tb11656.x; CASTANEDA VL, 1992, EXP HEMATOL, V20, P916; CONNER GE, 1992, J BIOL CHEM, V267, P21738; CULLY J, 1989, EXP CELL RES, V180, P440, DOI 10.1016/0014-4827(89)90070-0; GARWICZ D, 1995, J BIOL CHEM, V270, P28413; Garwicz D, 1997, J LEUKOCYTE BIOL, V61, P113, DOI 10.1002/jlb.61.1.113; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; GULLBERG U, 1994, J BIOL CHEM, V269, P25219; Gullberg U, 1997, EUR J HAEMATOL, V58, P137; HASHINAKA K, 1988, BIOCHEMISTRY-US, V27, P5906, DOI 10.1021/bi00416a013; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HASILIK A, 1984, EMBO J, V3, P2671, DOI 10.1002/j.1460-2075.1984.tb02192.x; HULTBERG B, 1976, BIOCHEM J, V155, P599, DOI 10.1042/bj1550599; JACQUET A, 1991, ARCH BIOCHEM BIOPHYS, V291, P132, DOI 10.1016/0003-9861(91)90115-Y; JACQUET A, 1992, FEBS LETT, V302, P189, DOI 10.1016/0014-5793(92)80437-L; KLEBANOFF SJ, 1992, INFLAMMATION BASIC P; KOEFFLER HP, 1985, BLOOD, V65, P484; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; LINDMARK A, 1990, BLOOD, V76, P2374; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIU L, 1995, BLOOD, V85, P1095, DOI 10.1182/blood.V85.4.1095.bloodjournal8541095; LIU LD, 1995, J IMMUNOL METHODS, V181, P253, DOI 10.1016/0022-1759(95)00009-Y; MOGUILEVSKY N, 1991, EUR J BIOCHEM, V197, P605, DOI 10.1111/j.1432-1033.1991.tb15950.x; NAUSEEF WM, 1988, EUR J HAEMATOL, V40, P97; NAUSEEF WM, 1986, BLOOD, V67, P865; Nauseef WM, 1996, J BIOL CHEM, V271, P9546, DOI 10.1074/jbc.271.16.9546; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NAUSEEF WM, 1987, BLOOD, V70, P1143; NAUSEEF WM, 1992, BLOOD, V80, P2622; OLSSON I, 1984, BIOCHEM J, V223, P911, DOI 10.1042/bj2230911; OLSSON I, 1972, SCAND J HAEMATOL, V9, P483; PINNIX IB, 1994, ARCH BIOCHEM BIOPHYS, V312, P447, DOI 10.1006/abbi.1994.1331; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; STROMBERG K, 1986, EUR J CELL BIOL, V39, P424; TAYLOR KL, 1992, J BIOL CHEM, V267, P25282; TAYLOR KL, 1992, BIOCHEM BIOPH RES CO, V187, P1572, DOI 10.1016/0006-291X(92)90482-Z; VALTIERI M, 1987, J IMMUNOL, V138, P3829; YAMADA M, 1982, J BIOL CHEM, V257, P5980; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	44	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4747	4753		10.1074/jbc.273.8.4747	http://dx.doi.org/10.1074/jbc.273.8.4747			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468538	hybrid			2022-12-25	WOS:000072115000066
J	Lain, B; Yanez, A; Iriarte, A; Martinez-Carrion, M				Lain, B; Yanez, A; Iriarte, A; Martinez-Carrion, M			Aminotransferase variants as probes for the role of the N-terminal region of a mature protein in mitochondrial precursor import and processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE TRANSLATION SYSTEM; ASPARTATE-AMINOTRANSFERASE; YEAST MITOCHONDRIA; RAT-LIVER; PHOSPHOLIPID-VESICLES; MOLECULAR CHAPERONES; PROTEOLYTIC CLEAVAGE; TARGETING SEQUENCES; STRUCTURAL FEATURES; PEPTIDASE	Of the two homologous isozymes of aspartate aminotransferase that are also nearly identical in their folded structures, only the mitochondrial form (mAAT) is synthesized as a precursor (pmAAT). After its in vitro synthesis in rabbit reticulocyte lysate, it can also be efficiently imported into isolated rat liver mitochondria, where it is processed to its native form by removal of the N-terminal presequence. The homologous cytosolic isoenzyme (cAAT) is not imported into mitochondria, even after fusion of the mitochondrial presequence from pmAAT to its N-terminal end. Substitution of the 30-residue N-terminal peptide of the mature portion of pmAAT with the corresponding sequence from the homologous, import-incompetent cytosolic isozyme (pc-mAAT) does not prevent import but reduces substantially its processing in the matrix. A detectable amount of the pcmAAT chimera is found associated with the inner mitochondrial membrane. Single and double substitution mutants of Trp-5 and Trp-6 at the N-terminal end of the mature protein are imported into mitochondria with efficiency similar to that of wild type. However, replacement of Trp-5 with proline, or of both tryptophans with either alanine (W5A/W6A mutant) or valine and aline (W5V/W6A mutant), allows import but interferes with the correct processing of the imported protein despite the presence of an intact cleavage site for the processing peptidase. Similar cleavage results were obtained using newly synthesized proteins and mitochondrial matrix extracts. These results indicate that translocation and processing for a precursor are independent events and that sequences C-terminal to the cleavage site are indeed important for the correct maturation of pmAAT in the matrix, probably because of their contribution to the conformation and flexibility of the peptide region surrounding the cleavage site required for efficient processing. The same region from the mature component of the passenger protein to complete its translocation into the matrix.	Univ Missouri, Sch Biol Sci, Div Biochem & Mol Biol, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Martinez-Carrion, M (corresponding author), Univ Missouri, Sch Biol Sci, Div Biochem & Mol Biol, Kansas City, MO 64110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38412] Funding Source: Medline; NIGMS NIH HHS [GM-38341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI F, 1989, J BIOL CHEM, V264, P4782; ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P403; ARRETZ M, 1994, J BIOL CHEM, V269, P4959; Artigues A, 1997, J BIOL CHEM, V272, P16852, DOI 10.1074/jbc.272.27.16852; Artigues A, 1997, TECH PROT CHEM, V8, P481, DOI 10.1016/S1080-8914(97)80048-8; Berezov A, 1996, ARCH BIOCHEM BIOPHYS, V336, P173, DOI 10.1006/abbi.1996.0546; BEREZOV A, 1994, J BIOL CHEM, V269, P22222; CHRISTEN P, 1985, TRANSAMINASES, V2, P173; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HORWICH AL, 1985, P NATL ACAD SCI USA, V82, P4930, DOI 10.1073/pnas.82.15.4930; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; HUYNH QK, 1981, J BIOCHEM-TOKYO, V90, P863, DOI 10.1093/oxfordjournals.jbchem.a133543; IRIARTE A, 1984, CHEM BIOL ASPECTS B, P269; JAUSSI R, 1985, J BIOL CHEM, V260, P6060; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIN B, 1994, J BIOL CHEM, V269, P15588; LAIN B, 1995, J BIOL CHEM, V270, P24732, DOI 10.1074/jbc.270.42.24732; LALORAYA S, 1995, MOL CELL BIOL, V15, P7098; LIN LN, 1985, BIOCHEMISTRY-US, V24, P6533, DOI 10.1021/bi00344a034; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTINEZCARRION M, 1990, ANN NY ACAD SCI, V585, P346, DOI 10.1111/j.1749-6632.1990.tb28067.x; MATOUSCHEK A, 1995, P NATL ACAD SCI USA, V92, P6319, DOI 10.1073/pnas.92.14.6319; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MATTINGLY JR, 1993, J BIOL CHEM, V268, P26320; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; NGUYEN M, 1987, J CELL BIOL, V104, P1193, DOI 10.1083/jcb.104.5.1193; NIIDOME T, 1994, J BIOL CHEM, V269, P24719; OBARU K, 1986, J BIOL CHEM, V261, P6976; Ogishima T, 1995, J BIOL CHEM, V270, P30322, DOI 10.1074/jbc.270.51.30322; OU WJ, 1994, J BIOL CHEM, V269, P24673; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; PARSONS DF, 1967, METHOD ENZYMOL, V10, P443; PAVEPREUX M, 1988, J BIOL CHEM, V263, P17459; PFANNER N, 1995, CURR BIOL, V5, P132; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; RILERS M, 1988, CELL, V52, P481; ROISE D, 1988, J BIOL CHEM, V263, P4509; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SRINIVASAN M, 1995, J BIOL CHEM, V270, P1191, DOI 10.1074/jbc.270.3.1191; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; THORNTON K, 1993, J BIOL CHEM, V268, P19906; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VASSAROTTI A, 1987, J BIOL CHEM, V262, P411; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Voos W, 1996, EMBO J, V15, P2668, DOI 10.1002/j.1460-2075.1996.tb00627.x; WALTNER M, 1995, J BIOL CHEM, V270, P26311, DOI 10.1074/jbc.270.44.26311; YANG M, 1991, J BIOL CHEM, V266, P6416	58	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4406	4415		10.1074/jbc.273.8.4406	http://dx.doi.org/10.1074/jbc.273.8.4406			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468492	hybrid			2022-12-25	WOS:000072115000020
J	Cover, CM; Hsieh, SJ; Tran, SH; Hallden, G; Kim, GS; Bjeldanes, LF; Firestone, GL				Cover, CM; Hsieh, SJ; Tran, SH; Hallden, G; Kim, GS; Bjeldanes, LF; Firestone, GL			Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G(1) cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURALLY OCCURRING INDOLES; DIETARY INDOLE-3-CARBINOL; ESTRADIOL METABOLISM; GENE-EXPRESSION; GROWTH-FACTOR; INDUCTION; RAT; PROGRESSION; TAMOXIFEN; BINDING	Indole-3-carbinol (I3C), a naturally occurring component of Brassica vegetables such as cabbage, broccoli, and Brussels sprouts, has been shown to reduce the incidence of spontaneous and carcinogen-induced mammary tumors, Treatment of cultured human MGF7 breast cancer cells with I36 reversibly suppresses the incorporation of [H-3]thymidine without affecting cell viability or estro,aem receptor (ER) responsiveness, Flow cytometry of propidium iodide stained cells revealed that I3C induces a G(1) cell cycle arrest, Concurrent with the I3C-induced growth inhibition, Northern blot and Western blot analyses demonstrated that I3C selectively abolished the expression of cyclin-dependent kinase 6 (CDK6) in a dose-and time-dependent manner. Furthermore, I3C inhibited the endogenous retinoblastoma protein phosphorylation and CDK6 phosphorylation of retinoblastoma in vi;ro to the same extent, After the MCF7 cells reached their maximal growth arrest, the levels of the p21 and p27 CDK inhibitors increased by 50%, The antiestrogen tamoxifen also suppressed MCF7 cell DNA synthesis but had no effect on CDK6 expression, while a combination of I3C and tamoxifen inhibited MCF7 cell growth more stringently than either agent alone. The I3C-mediated cell cycle arrest and repression of CDK6 production were also observed in estrogen receptor-deficient MDA-MB-231 human breast cancer cells, which demonstrates that this indole can suppress the growth of mammary tumor cells independent of estrogen receptor signaling Thus, our observations have uncovered a previously undefined antiproliferative pathway for I3C that implicates CDK6 as a target for cell cycle control in human breast cancer cells, Moreover, our results establish for the first time that CDK6 gene expression can be inhibited in response to an extracellular antiproliferative signal.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 LSA, Berkeley, CA 94720 USA.	glfire@mendel.berkeley.edu		Hsieh, S. Jean/0000-0002-2716-4609	NCI NIH HHS [CA-09041] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALDWIN WS, 1992, CHEM-BIOL INTERACT, V83, P155, DOI 10.1016/0009-2797(92)90043-K; BARDON S, 1984, MOL CELL ENDOCRINOL, V35, P89, DOI 10.1016/0303-7207(84)90004-2; Bergan R, 1996, CLIN EXP METASTAS, V14, P389, DOI 10.1007/BF00123398; Birt DF, 1996, PROG CLIN BIOL RES, V395, P223; BJELDANES LF, 1991, P NATL ACAD SCI USA, V88, P9543, DOI 10.1073/pnas.88.21.9543; BRADFIELD CA, 1984, FOOD CHEM TOXICOL, V22, P977, DOI 10.1016/0278-6915(84)90147-9; BRADLOW HL, 1994, CANCER EPIDEM BIOMAR, V3, P591; BRADLOW HL, 1991, CARCINOGENESIS, V12, P1571, DOI 10.1093/carcin/12.9.1571; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHEN YH, 1995, J BIOL CHEM, V270, P22548, DOI 10.1074/jbc.270.38.22548; Costello JF, 1997, CANCER RES, V57, P1250; DE KC, 1991, CHEM-BIOL INTERACT, V80, P303; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; Forbes JF, 1997, SEMIN ONCOL, V24, pS5; Freudenheim JL, 1996, JNCI-J NATL CANCER I, V88, P340, DOI 10.1093/jnci/88.6.340; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; GROSE KR, 1992, CHEM RES TOXICOL, V5, P188, DOI 10.1021/tx00026a007; GRUBBS CJ, 1995, ANTICANCER RES, V15, P709; Hamel PA, 1997, CANCER INVEST, V15, P143, DOI 10.3109/07357909709115767; Hartmann A, 1997, TRENDS GENET, V13, P27, DOI 10.1016/S0168-9525(96)10043-3; Hirokawa M, 1996, IMMUNOL LETT, V50, P95, DOI 10.1016/0165-2478(96)02526-6; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; ISHIDA T, 1995, J IMMUNOL, V155, P5527; JELLINCK PH, 1993, BIOCHEM PHARMACOL, V45, P1129, DOI 10.1016/0006-2952(93)90258-X; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kwon TK, 1996, CELL GROWTH DIFFER, V7, P1305; LEGHA SS, 1988, ANN INTERN MED, V109, P219, DOI 10.7326/0003-4819-109-3-219; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LIU H, 1994, JNCI-J NATL CANCER I, V86, P1758, DOI 10.1093/jnci/86.23.1758; LOUB WD, 1975, J NATL CANCER I, V54, P985; MCDANELL R, 1989, FOOD CHEM TOXICOL, V27, P289, DOI 10.1016/0278-6915(89)90130-0; Meier CA, 1997, J RECEPT SIGNAL TR R, V17, P319, DOI 10.3109/10799899709036612; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHNOVICZ JJ, 1990, J NATL CANCER I, V82, P947, DOI 10.1093/jnci/82.11.947; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORSE MA, 1990, CANCER RES, V50, P2613; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Musgrove EA, 1997, MOL ENDOCRINOL, V11, P54, DOI 10.1210/me.11.1.54; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Norberg T, 1996, ACTA ONCOL, V35, P96, DOI 10.3109/02841869609083980; Pennisi E, 1996, SCIENCE, V273, P1171, DOI 10.1126/science.273.5279.1171; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POWL, 1997, SEMIN ONCOL S1, V24, P48; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; SCHUURING E, 1992, ONCOGENE, V7, P355; SHARMA S, 1994, CANCER RES, V54, P5848; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERTZER HG, 1984, CHEM-BIOL INTERACT, V48, P81, DOI 10.1016/0009-2797(84)90008-5; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Strobl JS, 1995, GEN PHARMACOL, V26, P1643, DOI 10.1016/0306-3623(95)00062-3; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; TIWARI RK, 1994, J NATL CANCER I, V86, P126, DOI 10.1093/jnci/86.2.126; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang QM, 1997, CANCER RES, V57, P2851; WATTENBERG LW, 1978, CANCER RES, V38, P1410; WATTENBERG LW, 1990, BASIC LIFE SCI, V52, P155; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIEBE VJ, 1993, CRIT REV ONCOL HEMAT, V14, P173, DOI 10.1016/1040-8428(93)90008-R; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65	68	223	231	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3838	3847		10.1074/jbc.273.7.3838	http://dx.doi.org/10.1074/jbc.273.7.3838			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461564	hybrid			2022-12-25	WOS:000072048400006
J	Kordula, T; Rydel, RE; Brigham, EF; Horn, F; Heinrich, PC; Travis, J				Kordula, T; Rydel, RE; Brigham, EF; Horn, F; Heinrich, PC; Travis, J			Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate alpha(1)-antichymotrypsin expression in human cortical astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE PATIENTS; NECROSIS-FACTOR-ALPHA; ACUTE-PHASE RESPONSE; INFLAMMATORY CYTOKINES; CEREBROSPINAL-FLUID; TRANSGENIC MICE; NERVOUS-SYSTEM; CELLS; TRANSCRIPTION; BRAIN	alpha(1)-Antichymotrypsin (ACT) is an acute phase protein expressed in the brain which specifically colocalizes with amyloid-beta during Alzheimer's disease, We analyzed ACT synthesis in cultured human cortical astrocytes in response to various cytokines and growth factors. Oncostatin M (OSM) and interleukin (IL)-1 beta were potent stimulators of ACT mRNA expression, whereas tumor necrosis factor-alpha had modest activity, and IL-6 and leukemia inhibitory factor (LIF) were ineffective. The finding that OSM, but not LIF or IL-6, stimulated ACT expression suggests that human astrocytes express a "specific" OSM receptor, but not IL-6 or LIF receptors, However, cotreatment of human, astrocytes with soluble IL-6 receptor (sIL-6R).IL-6 complex did result In potent stimulation of ACT expression. When the human ACT gene was cloned, two elements binding STAT1 and STAT3 (signal transducer and activator of transcription) in response to OSM or IL-6.sIL-6R complexes could be identified and characterized, Taken together, these findings indicate that OSM or IL-6.sIL-6 complexes may regulate ACT expression in human astrocytes and thus directly or indirectly contribute to title pathogenesis of Alzheimer's disease.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Jagiellonian Univ, Inst Mol Biol, PL-31120 Krakow, Poland; Athena Neurosci Inc, S San Francisco, CA 94080 USA; Rhein Westfal TH Aachen, Inst Biochem, D-5100 Aachen, Germany	University System of Georgia; University of Georgia; Jagiellonian University; RWTH Aachen University	Travis, J (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Life Sci Bldg, Athens, GA 30602 USA.	JTravis@uga.cc.uga.edu			NHLBI NIH HHS [HL37090, HL26148] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL137090, R01HL037090, R01HL026148, R37HL037090] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ALOISI F, 1994, J IMMUNOL, V152, P5022; ATSUMI T, 1995, ACTA HAEMATOL-BASEL, V94, P90; Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BENVENISTE JA, 1992, AM J PHYSIOL, V263, pC1; BlumDegen D, 1995, NEUROSCI LETT, V202, P17, DOI 10.1016/0304-3940(95)12192-7; BRETT FM, 1995, J NEUROPATH EXP NEUR, V54, P766, DOI 10.1097/00005072-199511000-00003; CADMAN ED, 1994, J NEUROCHEM, V63, P980; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; CICHY J, 1995, J CLIN INVEST, V95, P2729, DOI 10.1172/JCI117975; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIELING JTM, 1994, CYTOKINE, V6, P376, DOI 10.1016/1043-4666(94)90061-2; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HUELL M, 1995, ACTA NEUROPATHOL, V89, P544; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Koj A, 1985, ACUTE PHASE RESPONSE, P139; Kordula T, 1996, BIOCHEM J, V313, P1019, DOI 10.1042/bj3131019; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; LEE SC, 1993, J IMMUNOL, V150, P2659; Lieb K, 1996, J NEUROCHEM, V67, P2039; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; MERILL JE, 1992, J IMMUNOTHER, V12, P167; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MURAKAMIMORI K, 1995, J CLIN INVEST, V96, P1319, DOI 10.1172/JCI118167; NAEMURA JR, 1993, LYMPHOKINE CYTOK RES, V12, P187; OWENS T, 1994, IMMUNOL TODAY, V15, P566, DOI 10.1016/0167-5699(94)90218-6; PASTERNACK JM, 1989, AM J PATHOL, V135, P827; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J., 2002, MOL CLONING LAB MANU; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SCHERRER K, 1962, BIOCHEM BIOPH RES CO, V7, P486, DOI 10.1016/0006-291X(62)90341-8; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; STRAUSS S, 1992, LAB INVEST, V66, P223; THOMA B, 1994, J BIOL CHEM, V269, P6215; VADENABEELE P, 1991, IMMUNOL TODAY, V12, P217; WAAGE A, 1989, J EXP MED, V170, P1859, DOI 10.1084/jem.170.6.1859; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	55	103	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4112	4118		10.1074/jbc.273.7.4112	http://dx.doi.org/10.1074/jbc.273.7.4112			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461605	hybrid			2022-12-25	WOS:000072048400047
J	Noel, LS; Champion, BR; Holley, CL; Simmons, CJ; Morris, DC; Payne, JA; Lean, JM; Chambers, TJ; Zaman, G; Lanyon, LE; Suva, LJ; Miller, LR				Noel, LS; Champion, BR; Holley, CL; Simmons, CJ; Morris, DC; Payne, JA; Lean, JM; Chambers, TJ; Zaman, G; Lanyon, LE; Suva, LJ; Miller, LR			RoBo-1, a novel member of the urokinase plasminogen activator receptor/CD59/Ly-6/snake toxin family selectively expressed in rat bone and growth plate cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE A(2) INHIBITOR; CANCELLOUS BONE; MECHANICAL STIMULATION; OSTEOGENIC RESPONSE; OVARIECTOMIZED RATS; GENE-EXPRESSION; THAILAND COBRA; MESSENGER-RNA; RECEPTOR; PROTEINS	Using differential display polymerase chain reaction, we cloned a novel cDNA named RoBo-1 from rat tibia, RoBo-1 is abundantly expressed in bone, including the hypertrophic chondrocytes of the growth plate where cartilage is remodeled into bone. RoBo-1 mRNA expression increased in response to two modulators of bone metabolism, estradiol and intermittent mechanical loading, suggesting a role in bone homeostasis. The 1.6-kilobase cDNA encodes a 240-amino acid protein with a cysteine spacing pattern, suggesting that RoBo-1 is a novel member of the urokinase plasminogen activator a receptor/Cd59/Ly-6/snake toxin family. Furthermore, the C-terminal contains glycosyl-phosphatidylinositol attachment site, suggesting that it is a cell surface protein similar to other mammalian members of this family, The strongest homology of RoBo-1 is to the snake serum-derived phospholipase A2 inhibitors, which uniquely contain two of the cysteine domains but are secreted proteins, interestingly, RoBo-1 is likely the first membrane-anchored member of this family containing two cysteine domains. Thus, the tissue specificity, responsiveness bane protective mediators, along with its relationship to the multifunctional urokinase plasminogen activator receptor/CD59/Ly-6/snake toxin family suggests that RoBo-1 may play a novel role in the growth or remodeling of bone.	Glaxo Wellcome Inc, Res, Dept Mol Pharmacol, Res Triangle Pk, NC 27709 USA; Univ London St Georges Hosp, Sch Med, Dept Histopathol, London SW17 0RE, England; Univ London Royal Vet Coll, London NW1 0TU, England; Harvard Univ, Beth Israel Hosp, Div Bone & Mineral Metab, Beth Israel Deaconess Med Ctr,Med Sch, Boston, MA 02215 USA	GlaxoSmithKline; St Georges University London; University of London; University of London Royal Veterinary College; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Miller, LR (corresponding author), Glaxo Wellcome Inc, Res, Dept Mol Pharmacol, Rm 3-3084,5 Moore Dr, Res Triangle Pk, NC 27709 USA.	LRM11241@glaxowellcome.com	Holley, Christopher/ABB-6677-2020; Holley, Christopher/T-1312-2019	Holley, Christopher/0000-0002-2870-3352; Suva, Larry/0000-0002-2892-9757				Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104; BIKLE DD, 1994, AM J PHYSIOL-ENDOC M, V267, pE822, DOI 10.1152/ajpendo.1994.267.6.E822; Canalis E, 1996, REGULATION BONE REMO, P29; CASEY JR, 1994, BLOOD, V84, P1151; CHOW JWM, 1993, AM J PHYSIOL, V265, pE340, DOI 10.1152/ajpendo.1993.265.2.E340; FORTESDIAS CL, 1994, J BIOL CHEM, V269, P15646; FROST HM, 1988, CALCIFIED TISSUE INT, V42, P145, DOI 10.1007/BF02556327; HENDRIKS W, 1987, NUCLEIC ACIDS RES, V15, P9093, DOI 10.1093/nar/15.21.9093; HORTON WE, 1988, EXP CELL RES, V178, P457, DOI 10.1016/0014-4827(88)90414-4; Jagger CJ, 1996, J CLIN INVEST, V98, P2351, DOI 10.1172/JCI119047; LEAN JM, 1995, AM J PHYSIOL-ENDOC M, V268, pE318, DOI 10.1152/ajpendo.1995.268.2.E318; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NORRDIN RW, 1990, PROSTAG LEUKOTR ESS, V41, P139, DOI 10.1016/0952-3278(90)90081-U; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V200, P784, DOI 10.1006/bbrc.1994.1519; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V204, P1212, DOI 10.1006/bbrc.1994.2592; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; PLOUG M, 1993, J BIOL CHEM, V268, P17539; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; RAWLINSON SCF, 1991, J BONE MINER RES, V6, P1345; RIEK RP, 1995, J THEOR BIOL, V172, P245; SALIH MA, 1993, BONE MINER, V23, P285, DOI 10.1016/S0169-6009(08)80104-3; SCHWARTZ Z, 1988, ENDOCRINOLOGY, V122, P2191, DOI 10.1210/endo-122-5-2191; SCHWARTZ Z, 1992, BONE, V13, P51, DOI 10.1016/8756-3282(92)90361-Y; SUVA LJ, 1993, J BONE MINER RES, V8, P379; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TORRANCE AG, 1994, CALCIFIED TISSUE INT, V54, P241, DOI 10.1007/BF00301686; WRONSKI TJ, 1988, ENDOCRINOLOGY, V123, P681, DOI 10.1210/endo-123-2-681; Zaman G, 1997, J BONE MINER RES, V12, P769, DOI 10.1359/jbmr.1997.12.5.769; [No title captured]	31	35	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3878	3883		10.1074/jbc.273.7.3878	http://dx.doi.org/10.1074/jbc.273.7.3878			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461570	hybrid			2022-12-25	WOS:000072048400012
J	Zrihan-Licht, S; Deng, BJ; Yarden, Y; McShan, G; Keydar, I; Avraham, H				Zrihan-Licht, S; Deng, BJ; Yarden, Y; McShan, G; Keydar, I; Avraham, H			Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-TYROSINE KINASES; MAMMARY-TUMORS; C-SRC; C-ERBB-2 PROTEIN; TRANSGENIC MICE; NEU RECEPTOR; EXPRESSION; GENE; INDUCTION	Substantial evidence exists supporting direct roles for ErbB-2/neu and Src kinase activation in breast cancer, The Csk homologous kinase (CHK) is a recently identified tyrosine kinase which, like Csk, phosphorylates the C-terminal tyrosine of Src kinases, resulting in inactivation of these enzymes, Recently, we observed that CHK is associated with the ErbB-2/neu receptor upon heregulin stimulation of breast cancer cells, Here, we report that CHK expression was observed in 70 out of 80 primary breast cancer specimens but not in normal breast tissues (0/19), Confocal microscopy analysis revealed colocalization of CHK with ErbB-2 in these primary specimens (6/6), In addition, we observed that the cytoplasmic domain of the ErbB-2/neu receptor is sufficient for its interaction with the CHKSH2 domain, Phosphopeptide inhibition of the in vitro interaction of CHKSH2 or native CHK with ErbB-2/neu, as well as site-directed mutagenesis of ErbB-2/neu, indicated that CHKSH2 binds to Tyr(1253) of ErbB-2/neu, Interestingly, autophosphorylation at this site confers oncogenicity to this receptor, Moreover, CHK was able to down-regulate ErbB-2/neu-activated Src kinases, Overexpression of CHK in MCF-7 breast cancer cells markedly inhibited cell growth and proliferative response to heregulin as well as decreased colony formation in soft agar, These studies indicate that CHK binds, via its SH2 domain, to Tyr(1253) Of the activated ErbB-2/neu and down-regulates the ErbB-2/neu-mediated activation of Src kinases, thereby inhibiting breast cancer cell growth, These data strongly suggest that CHK is a novel negative growth regulator in human breast cancer.	Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02115 USA; Weizmann Inst Sci, Dept Chem Immunol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Ramat Aviv, Israel	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Weizmann Institute of Science; Tel Aviv University	Avraham, H (corresponding author), Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.		YARDEN, YOSEF/K-1467-2012	Avraham, Hava/0000-0002-7545-3640	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELOFF MD, 1996, CURR OPIN ONCOL, V8, P447; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BISHOP JM, 1995, GENE DEV, V9, P1309, DOI 10.1101/gad.9.11.1309; Blackwood M. Anne, 1996, Current Opinion in Oncology, V8, P449; BOLEN JB, 1993, ONCOGENE, V8, P2025; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; CANCE WG, 1995, BREAST CANCER RES TR, V35, P105, DOI 10.1007/BF00694751; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; COHEN JA, 1989, ONCOGENE, V4, P81; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Davidson D, 1997, J BIOL CHEM, V272, P1355, DOI 10.1074/jbc.272.2.1355; ELROYSTEIN O, 1990, P NATL ACAD SCI USA, V87, P6743, DOI 10.1073/pnas.87.17.6743; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HAMAGUCHI I, 1994, ONCOGENE, V9, P3371; Hirao A, 1997, EMBO J, V16, P2342, DOI 10.1093/emboj/16.9.2342; Hoskins Kent, 1995, Current Opinion in Oncology, V7, P495, DOI 10.1097/00001622-199511000-00003; JHUN BH, 1995, J BIOL CHEM, V270, P9661, DOI 10.1074/jbc.270.16.9661; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KUO SS, 1994, J NEUROSCI RES, V38, P705, DOI 10.1002/jnr.490380613; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; MCVICAR DW, 1994, ONCOGENE, V9, P2037; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN G, 1993, P NATL ACAD SCI USA, V9, P1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1990, REGULATORY MECH BREA, P25; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; ZHAU HE, 1990, MOL CARCINOGEN, V3, P254, DOI 10.1002/mc.2940030503; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	47	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4065	4072		10.1074/jbc.273.7.4065	http://dx.doi.org/10.1074/jbc.273.7.4065			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461599	hybrid			2022-12-25	WOS:000072048400041
J	Brazil, BT; Ybarra, J; Horowitz, PM				Brazil, BT; Ybarra, J; Horowitz, PM			Divalent cations can induce the exposure of GroEL hydrophobic surfaces and strengthen GroEL hydrophobic binding interactions - Novel effects of Zn2+ GroEL interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; CHAPERONIN GROEL; PROTEINS; ATP; OLIGOMER	Fluorescent and non-fluorescent probes have been used to show that divalent cations (Ca2+, Mg2+, Mn2+, and Zn2+) significantly increase hydrophobic exposure on GroEL, whereas monovalent cations (K+ and Na+) have little effect, Zn2+ always induced the largest amount of hydrophobic exposure on GroEL, By using a new method based on interactions of GroEL with octyl-Sepharose, it was demonstrated that Zn2+ binding strengthens GroEL hydrophobic binding interactions and increases the efficiency of substrate release upon the addition of MgATP and GroES. The binding of 4,4'-bis(1-anilino-8-naphthalenesulfonic acid) to GroEL in the presence of Zn2+ has a K-d congruent to 1 mu M, which is similar to that observed previously for the GroEL 4,4'-bis(1-anilino-8-naphthalenesulfonic acid) complex, Urea denaturation, sedimentation velocity ultracentrifugation, and electron microscopy revealed that the quaternary structure of GroEL in the presence of Zn2+ had a stability and morphology equivalent to unliganded GroEL. In contrast, circular dichroism suggested some loss in both alpha-helical and beta-sheet secondary structure in the presence of Zn2+. These data suggest that divalent cations can modulate the amount of hydrophobic surface presented by GroEL, Furthermore, the influence of Zn2+ on GroEL hydrophobic surface exposure as well as substrate binding and release appears to be distinct from the stabilizing effects of Mg2+ on GroEL quaternary structure.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Horowitz, PM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA.	Horowitz@bioc09.uthscsa.edu			NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Brazil BT, 1997, J BIOL CHEM, V272, P5105, DOI 10.1074/jbc.272.8.5105; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; FLYNN GC, 1993, P NATL ACAD SCI USA, V90, P10826, DOI 10.1073/pnas.90.22.10826; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GOROVITS BM, 1995, J BIOL CHEM, V270, P28551, DOI 10.1074/jbc.270.48.28551; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; ZAHN R, 1994, J MOL BIOL, V242, P165, DOI 10.1006/jmbi.1994.1567; ZAHN R, 1994, J MOL BIOL, V242, P150, DOI 10.1006/jmbi.1994.1566	26	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3257	3263		10.1074/jbc.273.6.3257	http://dx.doi.org/10.1074/jbc.273.6.3257			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452440	hybrid			2022-12-25	WOS:000071822300025
J	Jurata, LW; Pfaff, SL; Gill, GN				Jurata, LW; Pfaff, SL; Gill, GN			The nuclear LIM domain interactor NLI mediates homo- and heterodimerization of LIM domain transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; HOMEOBOX GENE LHX3; NEUROENDOCRINE TISSUES; TRANSGENIC MICE; INSULIN GENE; EXPRESSION; CELL; HOMEODOMAIN; PROTEIN; RHOMBOTIN	LIM domain-containing transcription factors are required for embryonic survival and for the determination of many cell types. The combinatorial expression of the LIM homeodomain proteins Isl1, Isl2, Lhx1, and Lhx3 in subsets of developing motor neurons correlates with the future organization of these neurons into motor columns with distinct innervation targets, implying a functional role for LIM homeodomain protein combinations in the specification of neuronal identity, NLI is a widely expressed, dimeric protein that has been shown to specifically interact with the LIM domains of LIM domain-containing transcription factors, The present studies demonstrate that NLI mediates home-and heteromeric complex formation between LIM domain transcription factors, requiring both the N-terminal dimerization and C-terminal LIM interaction domains of NLI, Although the interaction between most LIM homeodomain proteins is dependent on NLI, a direct interaction between the LIM domains of Lhx3 and the homeodomains of Isl1 and Isl2 was also observed. This interaction was disrupted by NLI, demonstrating that the conformational state of Lhx3-Isl1/Isl2 complexes is modified by NLI, Evidence indicating that NLI facilitates long range enhancer-promoter interactions suggests that NLI-dependent LIM domain transcription factor complexes are involved in communication between transcriptional control elements.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute	Gill, GN (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 13149, DK 07541] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Appel B, 1995, DEVELOPMENT, V121, P4117; Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHEN CA, 1990, CURRENT PROTOCOLS MO; DANDOYDRON F, 1993, EXP CELL RES, V209, P58, DOI 10.1006/excr.1993.1285; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DONG JL, 1991, MOL ENDOCRINOL, V5, P1633, DOI 10.1210/mend-5-11-1633; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; Johnson JD, 1997, MOL CELL BIOL, V17, P3488, DOI 10.1128/MCB.17.7.3488; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LUNDGREN SE, 1995, DEVELOPMENT, V121, P1769; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; Morcillo P, 1997, GENE DEV, V11, P2729, DOI 10.1101/gad.11.20.2729; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; SEIDAH NG, 1994, DNA CELL BIOL, V13, P1163, DOI 10.1089/dna.1994.13.1163; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; Thor S, 1997, NEURON, V18, P397, DOI 10.1016/S0896-6273(00)81241-6; TOSNEY KW, 1995, BIOESSAYS, V17, P379, DOI 10.1002/bies.950170503; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; Yamashita T, 1997, GENOMICS, V44, P144, DOI 10.1006/geno.1997.4852; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	40	138	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3152	3157		10.1074/jbc.273.6.3152	http://dx.doi.org/10.1074/jbc.273.6.3152			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452425	hybrid			2022-12-25	WOS:000071822300010
J	Reynolds, MG; Roos, DS				Reynolds, MG; Roos, DS			A biochemical and genetic model for parasite resistance to antifolates - Toxoplasma gondii provides insights into pyrimethamine and cycloguanil resistance in Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTASE-THYMIDYLATE SYNTHASE; DIHYDROFOLATE-REDUCTASE; ESCHERICHIA-COLI; POINT MUTATIONS; HUMAN MALARIA; DRUG-RESISTANCE; HETEROLOGOUS EXPRESSION; DEFICIENT MUTANT; SYNTHETASE GENE; MOLECULAR-BASIS	We have exploited the experimental accessibility of the protozoan parasite Toxoplasma gondii and its similarity to Plasmodium falciparum to investigate the influence of specific dihydrofolate reductase polymorphisms known from field isolates of drug-resistant malaria. By engineering appropriate recombinant shuttle vectors, it is feasible to examine mutations by transient or stable transformation of T. gondii parasites, in bacterial and yeast complementation assays, and through biochemical analysis of purified enzyme, A series of mutant alleles that mirror P. falciparum variants reveals that the key mutation Asn-108 (Asn-83 in T. gondii) probably confers resistance to pyrimethamine by affecting critical interactions in the ternary complex, Mutations such as Arg-59 (T. gondii 36) have limited effect in isolation, but in combination with other mutations they enhance the competitive ability of folate by increasing the speed of product turnover. Val-16 (T. gondii 10) confers low level resistance to cycloguanil but hypersensitivity to pyrimethamine, This mutation precludes Asn-108, probably because compression of the folate binding pocket introduced by this combination is incompatible with enzyme function. These studies permit detailed biochemical, kinetic, and structural analysis of drug resistance mutations and reconstruction of the probable phylogeny of antifolate resistance in malaria.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Roos, DS (corresponding author), Univ Penn, Dept Biol, 415 S Univ Ave, Philadelphia, PA 19104 USA.	droos@sas.upenn.edu		Reynolds, Mary/0000-0001-7882-4614; Roos, David Siker/0000-0001-6725-4089	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028724, R37AI028724] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28724] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACCANARI DP, 1982, BIOCHEMISTRY-US, V21, P5068, DOI 10.1021/bi00263a034; BACCANARI DP, 1981, BIOCHEMISTRY-US, V20, P1710, DOI 10.1021/bi00510a002; BASCO LK, 1995, MOL BIOCHEM PARASIT, V69, P135, DOI 10.1016/0166-6851(94)00207-4; BASCO LK, 1994, AM J TROP MED HYG, V50, P193, DOI 10.4269/ajtmh.1994.50.193; BROOKS RG, 1987, ANTIMICROB AGENTS AN, V2, P267; BROWN KA, 1992, FARADAY DISCUSS, V93, P217, DOI 10.1039/fd9929300217; BZIK DJ, 1987, P NATL ACAD SCI USA, V84, P8360, DOI 10.1073/pnas.84.23.8360; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHEN GX, 1987, MOL PHARMACOL, V31, P430; CHENG Q, 1994, MOL BIOCHEM PARASIT, V65, P361, DOI 10.1016/0166-6851(94)90087-6; Cowman AF, 1995, AUST NZ J MED, V25, P837, DOI 10.1111/j.1445-5994.1995.tb02889.x; COWMAN AF, 1988, P NATL ACAD SCI USA, V85, P9109, DOI 10.1073/pnas.85.23.9109; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; DONALD RGK, 1994, MOL BIOCHEM PARASIT, V63, P243, DOI 10.1016/0166-6851(94)90060-4; DONALD RGK, 1993, P NATL ACAD SCI USA, V90, P11703, DOI 10.1073/pnas.90.24.11703; EYLES DON E., 1955, ANTIBIOT AND CHEMOTHER, V5, P529; EYLES DON E., 1955, ANTIBIOT AND CHEMOTHER, V5, P731; FILMAN DJ, 1982, J BIOL CHEM, V257, P13663; FOOTE SJ, 1990, P NATL ACAD SCI USA, V87, P3014, DOI 10.1073/pnas.87.8.3014; HALL SJ, 1991, MOL BIOCHEM PARASIT, V45, P317, DOI 10.1016/0166-6851(91)90100-K; HekmatNejad M, 1997, EXP PARASITOL, V85, P303, DOI 10.1006/expr.1997.4145; HILLCOAT BL, 1967, ANAL BIOCHEM, V21, P178, DOI 10.1016/0003-2697(67)90179-0; HITCHINGS GH, 1983, INHIBITION FOLATE ME, P1; HOLFELS E, 1994, ANTIMICROB AGENTS CH, V38, P1392, DOI 10.1128/AAC.38.6.1392; HOWELL EE, 1988, J BACTERIOL, V170, P3040, DOI 10.1128/jb.170.7.3040-3045.1988; HYDE JE, 1990, PHARMACOL THERAPEUT, V48, P45, DOI 10.1016/0163-7258(90)90017-V; ITZSCH MH, 1993, J EUKARYOT MICROBIOL, V40, P24; IVANETICH KM, 1990, EXP PARASITOL, V70, P367, DOI 10.1016/0014-4894(90)90119-W; KNIGHTON DR, 1994, NAT STRUCT BIOL, V1, P186, DOI 10.1038/nsb0394-186; Le Bras Jacques, 1996, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V190, P471; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; LEVINE ND, 1988, J PROTOZOOL, V35, P518, DOI 10.1111/j.1550-7408.1988.tb04141.x; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; PENNER MH, 1987, J BIOL CHEM, V262, P15908; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; PETERSON DS, 1990, P NATL ACAD SCI USA, V87, P3018, DOI 10.1073/pnas.87.8.3018; PFEFFERKORN ER, 1977, J PROTOZOOL, V24, P449, DOI 10.1111/j.1550-7408.1977.tb04774.x; Prapunwattana P, 1996, MOL BIOCHEM PARASIT, V83, P93, DOI 10.1016/S0166-6851(96)02756-9; Reeder JC, 1996, AM J TROP MED HYG, V55, P209, DOI 10.4269/ajtmh.1996.55.209; REYES P, 1982, MOL BIOCHEM PARASIT, V5, P275, DOI 10.1016/0166-6851(82)90035-4; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; ROOS DS, 1993, J BIOL CHEM, V268, P6269; SANO G, 1994, MOL BIOCHEM PARASIT, V63, P265, DOI 10.1016/0166-6851(94)90062-0; SCHWARTZMAN JD, 1981, J PARASITOL, V67, P150, DOI 10.2307/3280627; SINGER S, 1985, J BACTERIOL, V164, P470, DOI 10.1128/JB.164.1.470-472.1985; SIRAWARAPORN W, 1993, J BIOL CHEM, V268, P21637; Sirawaraporn W, 1997, P NATL ACAD SCI USA, V94, P1124, DOI 10.1073/pnas.94.4.1124; SIRAWARAPORN W, 1990, BIOCHEMISTRY-US, V29, P10779, DOI 10.1021/bi00500a009; SNEWIN VA, 1989, GENE, V76, P41, DOI 10.1016/0378-1119(89)90006-1; STONE SR, 1986, BIOCHIM BIOPHYS ACTA, V869, P275, DOI 10.1016/0167-4838(86)90067-1; TANAKA M, 1990, MOL BIOCHEM PARASIT, V39, P127, DOI 10.1016/0166-6851(90)90015-E; TENANTFLOWERS M, 1991, AIDS, V5, P311, DOI 10.1097/00002030-199103000-00011; THAITHONG S, 1992, MOL BIOCHEM PARASIT, V52, P149, DOI 10.1016/0166-6851(92)90047-N; THILLET J, 1990, BIOCHEMISTRY-US, V29, P5195, DOI 10.1021/bi00473a028; Trujillo M, 1996, BIOCHEMISTRY-US, V35, P6366, DOI 10.1021/bi952923q; vanderWel AM, 1997, J EXP MED, V185, P1499, DOI 10.1084/jem.185.8.1499; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; Zindrou S, 1996, EXP PARASITOL, V84, P56, DOI 10.1006/expr.1996.0089; ZOLG JW, 1989, MOL BIOCHEM PARASIT, V36, P253, DOI 10.1016/0166-6851(89)90173-4	62	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3461	3469		10.1074/jbc.273.6.3461	http://dx.doi.org/10.1074/jbc.273.6.3461			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452469	hybrid			2022-12-25	WOS:000071822300054
J	Xie, Z; Price, DH				Xie, Z; Price, DH			Unusual nucleic acid binding properties of factor 2, an RNA polymerase II transcript release factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR COUPLING FACTOR; ELONGATION COMPLEXES; DEPENDENT ATPASE; TERMINATION; GENE; DNA; DROSOPHILA; PURIFICATION; EXPRESSION; ETHIDIUM	Drosophila factor 2, an RNA polymerase II transcript release factor, exhibits a DNA-dependent ATPase activity (Xie, Z., and Price D. H. (1997) J. Biol. Chem. 272, 31902-31907). We examined the nucleic acid requirement and found that only double-stranded DNA (dsDNA) effectively activated the ATPase. Single-stranded DNA (ssDNA) not only failed to activate the ATPase, but suppressed the dsDNA-dependent ATPase. Gel mobility shift assays showed that factor 2 formed stable complexes with dsDNA or ssDNA in the absence of ATP. However, in the presence of ATP, the interaction of factor 2 with dsDNA was destabilized, while the ssDNA-factor 2 complexes were not affected. The interaction of factor 2 with dsDNA was sensitive to increasing salt concentrations and was competed by ssDNA. In both cases, loss of binding of factor 2 to dsDNA was mirrored by a decrease in ATPase and transcript release activity, suggesting that the interaction of factor 2 with dsDNA is important in coupling the ATPase with the transcript release activity. Although the properties of factor 2 suggested that it might have helicase activity, we were unable to detect any DNA unwinding activity associated with factor 2.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Price, DH (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X	NIGMS NIH HHS [R01-GM35500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMANN M, 1990, CELL, V60, P85, DOI 10.1016/0092-8674(90)90718-T; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; Deng L, 1996, J BIOL CHEM, V271, P29386, DOI 10.1074/jbc.271.46.29386; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; Guzder SN, 1996, J BIOL CHEM, V271, P18314, DOI 10.1074/jbc.271.31.18314; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HANAWALT PC, 1994, CURR BIOL, V4, P18; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MATSON SW, 1986, J BIOL CHEM, V261, P169; PECK LJ, 1981, NATURE, V292, P375, DOI 10.1038/292375a0; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; PRICE DH, 1987, J BIOL CHEM, V262, P3244; PULLEYBLANK DE, 1975, J MOL BIOL, V91, P1, DOI 10.1016/0022-2836(75)90368-X; RHODES D, 1981, NATURE, V292, P378, DOI 10.1038/292378a0; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SPENCER CA, 1990, ONCOGENE, V5, P777; Tong J, 1996, J BACTERIOL, V178, P2695, DOI 10.1128/jb.178.9.2695-2700.1996; WANG JC, 1974, J MOL BIOL, V89, P783, DOI 10.1016/0022-2836(74)90053-9; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; Xie Z, 1997, J BIOL CHEM, V272, P31902, DOI 10.1074/jbc.272.50.31902; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	32	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3771	3777		10.1074/jbc.273.6.3771	http://dx.doi.org/10.1074/jbc.273.6.3771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452510	hybrid			2022-12-25	WOS:000071822300095
J	Laursen, NB; Kessler, R; Frohli, E; Klemenz, R				Laursen, NB; Kessler, R; Frohli, E; Klemenz, R			Effects of ras transformation on the induction of the IL-1 receptor related T1 gene in response to mitogens, anisomycin, IL-1 and TNF alpha	ONCOGENE			English	Article						anisomycin; IL-1R family; IL-1; TNF alpha; MAP kinases; SB203580; signal transduction pathway; ras oncogene	ACTIVATED PROTEIN-KINASE; MURINE ST2 GENE; RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; SIGNAL-TRANSDUCTION PATHWAYS; TUMOR-NECROSIS-FACTOR; NIH 3T3 FIBROBLASTS; HEAT-SHOCK PROTEINS; MAP KINASE; INTERLEUKIN-1 RECEPTOR; C-JUN	The T1 gene gives rise to two transcripts encoding a 62 kDa membrane-bound and a 37 kDa secreted protein with similarity to the type I IL-1 receptor. It is weakly expressed in proliferating but not in resting fibroblasts and is strongly induced during the entry of quiescent cells into the cell cycle. Here we show that the T1 gene is also transcriptionally activated in response to the treatment of fibroblasts with cycloheximide and anisomycin. These protein synthesis inhibitors are known to stimulate the JNK and p38/RK signal transduction pathways. We provide evidence that anisomycin triggers T1 gene induction through the stimulation of the p38/RK MAP kinase. This observation is in line with our finding that physiological activators of the p38/RK pathway, the proinflammatory cytokines IL-1 and TNF alpha, stimulate T1 gene expression efficiently. Growth factor mediated T1 gene induction is a delayed early event, requiring ongoing protein synthesis. In contrast, anisomycin induces T1 gene expression at concentrations which block translation completely. Thus, transcriptional induction of the T1 gene via the p38/RK pathway is an immediate early event not requiring de novo protein synthesis. The T1 gene is strongly induced by various mitogens in quiescent NIH3T3 fibroblasts but not in ras transformed NIH3T3 cells. In contrast, all of the three tested agent which activate the p38/RK pathway, IL-1, TNF alpha, and anisomycin led to strong T1 gene expression in normal and ras transformed NIH3T3 cells alike. Thus, the T1 gene can be induced through the activation of at least two MAP kinase pathways: signaling through the ERK pathway can occur in normal but not in ras transformed NIH3T3 cells, whereas the signaling through the p38/RK pathway is not affected by ras transformation.	Univ Zurich Hosp, Dept Pathol, Div Canc Res, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Klemenz, R (corresponding author), Univ Zurich Hosp, Dept Pathol, Div Canc Res, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.							ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P240; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; AOYAMA A, 1993, CRIT REV ONCOGENESIS, V4, P53; BERGERS G, 1994, EMBO J, V13, P1176, DOI 10.1002/j.1460-2075.1994.tb06367.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CANO E, 1995, J CELL SCI, V108, P3599; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRETE P, 1990, RADIAT RES, V121, P320, DOI 10.2307/3577783; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DANESCU J, 1995, FEBS LETT, V367, P89, DOI 10.1016/0014-5793(95)00542-H; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Gachter T, 1996, J BIOL CHEM, V271, P124; Gayle MA, 1996, J BIOL CHEM, V271, P5784, DOI 10.1074/jbc.271.10.5784; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KALOUSEK MB, 1994, J BIOL CHEM, V269, P6866; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; KUMAR S, 1995, J BIOL CHEM, V270, P27905, DOI 10.1074/jbc.270.46.27905; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1991, GENES INDUCED SERUM, P257; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Parnet P, 1996, J BIOL CHEM, V271, P3967; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; REIKERSTORFER A, 1995, J BIOL CHEM, V270, P17645, DOI 10.1074/jbc.270.30.17645; ROSSLER U, 1993, ONCOGENE, V8, P609; ROSSLER U, 1995, DEV BIOL, V168, P86, DOI 10.1006/dbio.1995.1063; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SIMS JE, 1995, CYTOKINE, V7, P483, DOI 10.1006/cyto.1995.0066; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SYMONS JA, 1995, P NATL ACAD SCI USA, V92, P1714, DOI 10.1073/pnas.92.5.1714; TAKAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P194, DOI 10.1016/0167-4889(93)90009-E; TOMINAGA S, 1992, BIOCHIM BIOPHYS ACTA, V1171, P215, DOI 10.1016/0167-4781(92)90125-J; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; TOMINAGA S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P1, DOI 10.1016/0167-4781(91)90029-L; TRUB T, 1994, P NATL ACAD SCI USA, V91, P3896, DOI 10.1073/pnas.91.9.3896; TSONIS PA, 1988, NUCLEIC ACIDS RES, V16, P7745, DOI 10.1093/nar/16.15.7745; WERENSKIOLD AK, 1992, EUR J BIOCHEM, V204, P1041, DOI 10.1111/j.1432-1033.1992.tb16726.x; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U; YANAGISAWA K, 1992, FEBS LETT, V302, P51, DOI 10.1016/0014-5793(92)80282-L; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	69	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					575	586		10.1038/sj.onc.1201522	http://dx.doi.org/10.1038/sj.onc.1201522			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482103	Bronze			2022-12-25	WOS:000071816600002
J	Fujiwara, T; Takami, N; Misumi, Y; Ikehara, Y				Fujiwara, T; Takami, N; Misumi, Y; Ikehara, Y			Nordihydroguaiaretic acid blocks protein transport in the secretory pathway causing redistribution of Golgi proteins into the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; DIPEPTIDYL PEPTIDASE-IV; BREFELDIN-A CAUSES; INTRACELLULAR-TRANSPORT; ORGANELLE STRUCTURE; GUANINE-NUCLEOTIDE; MEMBRANE-PROTEIN; NETWORK; COMPLEX; EXPRESSION	We have investigated the effect of nordihydroguaiaretic acid (NDGA), an inhibitor of lipoxygenase, on the intracellular protein transport and the structure of the Golgi complex. Pulse-chase experiments and immuno-electron microscopy showed that NDGA strongly inhibits the transport of newly synthesized secretory proteins to the Golgi complex resulting in their accumulation in the endoplasmic reticulum (ER). Despite their retention in the ER, oligosaccharides of secretory and ED-resident proteins were processed to endoglycosidase H-resistant forms, raising the possibility that oligosaccharide-processing enzymes are redistributed from the Golgi to the ER. Morphological observations further revealed that a-mannosidase II (a cis/medial-Golgi marker), but not TGN38 (a trans-Golgi network marker), rapidly redistributes to the ER in the presence of NDGA, resulting in the disappearance of the characteristic Golgi structure. Upon removal of the drug, the Golgi complex was reassembled into the normal structure as judged by perinuclear staining of alpha-mannosidase II and by restoration of the secretion. These effects of NDGA are quite similar to those of brefeldin A. However, unlike brefeldin A, NDGA did not cause a dissociation of beta-coatomer protein, a subunit of coatomer, from the Golgi membrane. On the contrary, NDGA exerted the stabilizing effect on beta-coatomer protein/membrane interaction against the dissociation caused by brefeldin A and ATP depletion. Taken together, these results indicate that NDGA is a potent agent disrupting the structure and function of the Golgi complex with a mechanism different from those known for other drugs reported so far.	Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 81480, Japan; Fukuoka Univ, Sch Med, Radioistope Lab, Jonan Ku, Fukuoka 81480, Japan	Fukuoka University; Fukuoka University	Ikehara, Y (corresponding author), Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 81480, Japan.	mm031321@cc.fukuoka-u.ac.jp						ARMOUR CL, 1981, EUR J PHARMACOL, V72, P93, DOI 10.1016/0014-2999(81)90302-2; BALCH WE, 1986, J BIOL CHEM, V261, P4681; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; CARMANKRZAN M, 1993, J NEUROSCI RES, V34, P225, DOI 10.1002/jnr.490340210; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1992, BIOCHEM BIOPH RES CO, V185, P776, DOI 10.1016/0006-291X(92)91693-K; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HIROSE S, 1988, J BIOL CHEM, V263, P7426; HORRUM MA, 1987, AGE, V10, P58, DOI 10.1007/BF02432287; KINOUCHI T, 1995, BIOCHEM BIOPH RES CO, V209, P841, DOI 10.1006/bbrc.1995.1576; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIM J, 1996, ANN OTO RHINOL LARYN, V105, P916; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MORRIS HR, 1979, BRIT J PHARMACOL, V66, P452; ODA K, 1990, BIOCHEM J, V265, P161, DOI 10.1042/bj2650161; OGATA S, 1989, J BIOL CHEM, V264, P3596; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PARDINI RS, 1970, BIOCHEM PHARMACOL, V19, P2695, DOI 10.1016/0006-2952(70)90095-X; PAVANI M, 1994, BIOCHEM PHARMACOL, V48, P1935, DOI 10.1016/0006-2952(94)90592-4; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PERSSON R, 1988, J CELL BIOL, V107, P2503, DOI 10.1083/jcb.107.6.2503; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; SEGUCHI T, 1992, J BIOL CHEM, V267, P11626; SIMONS K, 1987, EMBO J, V6, P2241, DOI 10.1002/j.1460-2075.1987.tb02496.x; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Tagaya M, 1996, J BIOCHEM, V119, P863; TAGAYA M, 1993, FEBS LETT, V324, P210; TAKAMI N, 1988, J BIOL CHEM, V263, P3016; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; TSUJI E, 1992, BIOCHEMISTRY-US, V31, P11921, DOI 10.1021/bi00162a035; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; Yamaguchi T, 1997, J BIOL CHEM, V272, P25260, DOI 10.1074/jbc.272.40.25260	57	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3068	3075		10.1074/jbc.273.5.3068	http://dx.doi.org/10.1074/jbc.273.5.3068			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446623	hybrid			2022-12-25	WOS:000071736600078
J	Hofmann, A; Escherich, A; Lewit-Bentley, A; Benz, J; Raguenes-Nicol, C; Russo-Marie, F; Gerke, V; Moroder, L; Huber, R				Hofmann, A; Escherich, A; Lewit-Bentley, A; Benz, J; Raguenes-Nicol, C; Russo-Marie, F; Gerke, V; Moroder, L; Huber, R			Interactions of benzodiazepine derivatives with annexins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-STRUCTURE; MEMBRANE-BINDING; CALCIUM; VESICLES; PROTEIN; CRYSTAL; REPLICATION; INHIBITION; CHANNELS; INVITRO	Human annexins III and V, members of the annexin family of calcium-and membrane-binding proteins, were complexed within the crystals with BDA452, a new 1,4-benzodiazepine derivative by soaking and co-crystallization methods, The crystal structures of the complexes were analyzed by x-ray crystallography and refined to 2.3- and 3.0-Angstrom resolution, BDA452 binds to a cleft which is located close to the N-terminus opposite to the membrane binding side of the proteins. Biophysical studies of the interactions of various benzodiazepine derivatives with annexins were performed to analyze the binding of benzodiazepines to annexins and their effects on the annexin-induced calcium influx into phosphatidylserine/phosphatidylethanolamine liposomes, Different effects were observed with a variety of benzodiazepines and different annexins depending on both the ligand and the protein, Almost opposite effects on annexin function are elicited by BDA250 and diazepam, its 7-chloro-derivative. We conclude that benzodiazepines modulate the calcium influx activity of annexins allosterically by stabilizing or destabilizing the conducting state of peripherally bound annexins in agreement with suggestions by Kaneko.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Abt Bioorgan Chem, D-82152 Martinsried, Germany; Ctr Univ Paris Sud, LURE, F-91405 Orsay, France; Inst Cochin Genet Mol, U332, INSERM, F-75014 Paris, France; Univ Munster, Inst Med Biochem, D-48149 Munster, Germany	Max Planck Society; Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Munster	Hofmann, A (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18A, D-82152 Martinsried, Germany.		Hofmann, Andreas/M-9870-2019; Hofmann, Andreas/B-9515-2008; Raguenes-Nicol, Celine/I-2693-2015	Hofmann, Andreas/0000-0003-4408-5467; Hofmann, Andreas/0000-0003-4408-5467; Raguenes-Nicol, Celine/0000-0001-8428-9558; Moroder, Luis/0000-0001-9570-5713				Arispe N, 1996, BIOPHYS J, V71, P1764, DOI 10.1016/S0006-3495(96)79377-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Benz J, 1996, J MOL BIOL, V260, P638, DOI 10.1006/jmbi.1996.0426; BERENDES R, 1993, SCIENCE, V262, P427, DOI 10.1126/science.7692599; BERENDES R, 1993, FEBS LETT, V317, P131, DOI 10.1016/0014-5793(93)81507-V; BOCK MG, 1989, J MED CHEM, V32, P13, DOI 10.1021/jm00121a004; BONDINELL WE, 1993, Patent No. 00095; BRISSON A, 1991, J MOL BIOL, V220, P199, DOI 10.1016/0022-2836(91)90002-N; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; BURGER A, 1993, FEBS LETT, V329, P25, DOI 10.1016/0014-5793(93)80185-W; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; Eghbali M, 1997, NATURE, V388, P71, DOI 10.1038/40404; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FavierPerron B, 1996, BIOCHEMISTRY-US, V35, P1740, DOI 10.1021/bi952092o; FORTH W, 1996, ALLGEMEINE SPEZIELLE, P304; Garcia DA, 1997, BBA-BIOMEMBRANES, V1324, P76, DOI 10.1016/S0005-2736(96)00210-6; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; *GEN COMP GROUP, 1996, WISC PACK VERS 9 0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofmann A, 1997, BBA-BIOMEMBRANES, V1330, P254, DOI 10.1016/S0005-2736(97)00150-8; Hommer DW, 1987, PSYCHOPHARMACOLOGY 3, P977; HSU MC, 1991, SCIENCE, V254, P1799, DOI 10.1126/science.1763331; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaneko N, 1997, J MOL BIOL, V274, P16, DOI 10.1006/jmbi.1997.1375; KANEKO N, 1994, DRUG DEVELOP RES, V33, P429, DOI 10.1002/ddr.430330406; KORNECKI E, 1984, SCIENCE, V226, P1454, DOI 10.1126/science.6150550; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; LASKOWSKI RA, 1994, PROCHECK PROGRAMS CH; LESLIE AGW, 1994, MOSFLM VERSION 5 20; Liu L, 1997, FASEB J, V11, P3227; MEERS P, 1991, BIOCHEMISTRY-US, V30, P2903, DOI 10.1021/bi00225a025; Meers P., 1996, ANNEXINS MOL STRUCTU, P97; MINOR W, 1993, XDISPLAYF PROGRAMME; MUTSCHLER E, 1986, ARZNEIMITTELWIRKUNGE, P145; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; OTWINOVSKI Z, 1993, P CCP4 STUDY WEEKEND; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; Perron B, 1997, J BIOL CHEM, V272, P11321; PLAGER DA, 1994, BIOCHEMISTRY-US, V33, P13239, DOI 10.1021/bi00249a010; RANG HP, 1991, PHARMACOLOGY, P634; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; ROJAS E, 1990, J BIOL CHEM, V265, P21207; ROMER D, 1982, NATURE, V298, P759, DOI 10.1038/298759a0; Seemann J, 1996, MOL BIOL CELL, V7, P1359, DOI 10.1091/mbc.7.9.1359; STERNBACH LH, 1979, J MED CHEM, V22, P1, DOI 10.1021/jm00187a001; SWAIRJO MA, 1994, BIOCHEMISTRY-US, V33, P10944, DOI 10.1021/bi00202a013; THIEL C, 1991, J BIOL CHEM, V266, P14732; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281; WILSCHUT J, 1980, BIOCHEMISTRY-US, V19, P6011, DOI 10.1021/bi00567a011	55	24	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2885	2894		10.1074/jbc.273.5.2885	http://dx.doi.org/10.1074/jbc.273.5.2885			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446599	hybrid			2022-12-25	WOS:000071736600054
J	Jarpe, MB; Knall, C; Mitchell, FM; Buhl, AM; Duzic, E; Johnson, GL				Jarpe, MB; Knall, C; Mitchell, FM; Buhl, AM; Duzic, E; Johnson, GL			[D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]substance P acts as a biased agonist toward neuropeptide and chemokine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; ACTIVATED PROTEIN-KINASE; SWISS 3T3 CELLS; STRESS FIBER FORMATION; LUNG-CANCER CELLS; SUBSTANCE-P; INVERSE AGONISTS; TYROSINE KINASE; IN-VITRO; BOMBESIN	Substance P derivatives are potential therapeutic compounds for the treatment of small cell lung cancer and can cause apoptosis in small cell lung cancer cells in culture. These peptides act as broad spectrum neuropeptide antagonists, blocking calcium mobilization induced by gastrin-releasing peptide, bradykinin, cholecystokinin, and other neuropeptides. We show that [D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]substance P has unique agonist activities in addition to this described antagonist function, At doses that block calcium mobilization by neuropeptides, this peptide causes activation of c-Jun N-terminal kinase and cytoskeletal changes in Swiss 3T3 fibroblasts and stimulates migration and calcium flux in human neutrophils. Activation of c-Jun N-terminal kinase is dependent on the expression of the gastrin-releasing peptide receptor in rat 1A fibroblasts, demonstrating that the responses to the peptide are receptor-mediated. me hypothesize that [D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]substance P acts as a biased agonist on neuropeptide and related receptors, activating certain guanine nucleotide-binding proteins through the receptor, but not others.	Natl Jewish Med & Res Ctr, Program Mol Signal Transduct, Div Basic Sci, Denver, CO 80206 USA; Cadus Pharmaceut, Tarrytown, NY 10591 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Jarpe, MB (corresponding author), Natl Jewish Med & Res Ctr, Program Mol Signal Transduct, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.	jarpem@njc.org			NATIONAL CANCER INSTITUTE [P50CA058187, F32CA073037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER; NCI NIH HHS [CA73037, CA58187] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY SJ, 1984, BRIT J PHARMACOL, V82, P441, DOI 10.1111/j.1476-5381.1984.tb10779.x; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BUNN PA, 1994, CANCER RES, V54, P3602; BURBACH JPH, 1992, EUR J PHARM-MOLEC PH, V227, P1, DOI 10.1016/0922-4106(92)90136-J; Cadwallader K, 1997, BIOCHEM J, V321, P795, DOI 10.1042/bj3210795; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DUZIC E, 1992, J BIOL CHEM, V267, P9844; FAURE M, 1994, J BIOL CHEM, V269, P7851; Fruh T, 1996, BIOORG MED CHEM LETT, V6, P2323, DOI 10.1016/0960-894X(96)00421-0; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; GU XH, 1991, BIOCHEM BIOPH RES CO, V179, P1991; HAWCOCK AB, 1982, EUR J PHARMACOL, V80, P135, DOI 10.1016/0014-2999(82)90189-3; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P188, DOI 10.1016/S0165-6147(00)89020-3; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P25970; LETTERIO JJ, 1986, SCIENCE, V234, P1117, DOI 10.1126/science.3465038; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; PONG L, 1993, BIOCHEM J, V289, P283; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; REEVE JG, 1994, BIOCHEM BIOPH RES CO, V199, P1313, DOI 10.1006/bbrc.1994.1374; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; Seckl MJ, 1996, J BIOL CHEM, V271, P29453, DOI 10.1074/jbc.271.46.29453; SERRA MC, 1988, J IMMUNOL, V141, P2118; SETHI T, 1992, CANCER RES, V52, pS2737; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; TAKENOUCHI T, 1995, PEPTIDES, V16, P1019, DOI 10.1016/0196-9781(95)00084-W; TSOU K, 1985, EUR J PHARMACOL, V110, P155, DOI 10.1016/0014-2999(85)90047-0; Wang JL, 1996, BIOCHEM J, V320, P87, DOI 10.1042/bj3200087; WOLL PJ, 1988, P NATL ACAD SCI USA, V85, P1859, DOI 10.1073/pnas.85.6.1859; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	42	83	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3097	3104		10.1074/jbc.273.5.3097	http://dx.doi.org/10.1074/jbc.273.5.3097			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446627	hybrid			2022-12-25	WOS:000071736600082
J	Caruana, G; Cambareri, AC; Gonda, TJ; Ashman, LK				Caruana, G; Cambareri, AC; Gonda, TJ; Ashman, LK			Transformation of NIH3T3 fibroblasts by the c-Kit receptor tyrosine kinase: effect of receptor density and ligand-requirement	ONCOGENE			English	Article						c-Kit; SLF; transformation; anchorage independence; receptor density	STEM-CELL FACTOR; COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR; EGF RECEPTOR; MAST-CELLS; SIGNAL-TRANSDUCTION; PROTO-ONCOGENE; NEURONAL DIFFERENTIATION; MONOCLONAL-ANTIBODIES	Ectopic expression of the normal murine receptor tyrosine kinase, c-Kit, in NIH3T3 cells induced many phenotypic changes characteristic of transformation including anchorage-independent growth, focus formation and tumorigenicity in nude mice, Although transformation was largely dependent on the presence of recombinant murine Steel Factor (SLF), the ligand to the c-Kit receptor, anchorage independent growth did occur at a low frequency in the absence of added factor, and this could not be inhibited by neutralising antibodies or by SLF anti-sense mRNA, Clones from factor-independent colonies in semi-solid agar displayed a narrow range of c-Kit surface protein levels (4.3-6.4 x 10(4) receptors/cell) which was relatively high compared with the pool from which they were derived, Analysis of a larger series of random clones derived from adherent cultures expressing different levels of c-Kit demonstrated a positive correlation between SLF-dependent, anchorage-independent growth and c-Kit protein and mRNA expression levels (respectively, R-S = 0.58, P < 0.01; and R-S = 0.53, P < 0.01) with consistent colony formation observed with clones having > 2.5 x 10(4) receptors/cell, Interestingly, two of the three clones expressing the highest levels of c-Kit protein and mRNA produced few or no colonies in the presence or absence of SLF, Sequential overexpression of human c-KIT in NIH3T3 cells using a dihydrofolate reductase (DHFR)-encoding vector and gene co-amplification through methotrexate selection, which resulted in pools expressing up to 1.5 x 10(5) receptors/cell, confirmed that high receptor densities resulted in a decrease in colony numbers, Thus, analysis of clonal and selected populations has indicated that an optimal level of c-Kit is required for transformation of NIH3T3 cells in the presence of SLF, and that some ligand-independent transformation occurs.	Inst Med & Vet Sci, Div Haematol, Leukaemia Res Unit, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Div Human Immunol, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia	Ashman, LK (corresponding author), Inst Med & Vet Sci, Div Haematol, Leukaemia Res Unit, Box 14,Rundle Mall PO, Adelaide, SA 5000, Australia.		ASHMAN, LEONIE/G-7631-2013; Gonda, Thomas J/A-3620-2012	ASHMAN, LEONIE/0000-0003-3559-3611; 				ALEXANDER WS, 1991, EMBO J, V10, P3683, DOI 10.1002/j.1460-2075.1991.tb04936.x; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ASHMAN LK, 1988, LEUKEMIA RES, V12, P923, DOI 10.1016/0145-2126(88)90020-3; AYLETT G, 1995, LEUCOCYTE TYPING V W, V2, P1917; BERNSTEIN A, 1991, SEMIN HEMATOL, V28, P138; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CARUANA G, 1993, EXP HEMATOL, V21, P761; CHOO KH, 1986, DNA-J MOLEC CELL BIO, V5, P529, DOI 10.1089/dna.1.1986.5.529; COLE SR, 1989, IMMUNOL CELL BIOL, V67, P377, DOI 10.1038/icb.1989.54; Cole SR, 1996, LEUKEMIA, V10, P288; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; FERRAO P, 1997, IN PRESS BLOOD, V90; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GRAHAM FL, 1980, INTRO MACROMOLECULES, P3; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERBST R, 1995, ONCOGENE, V10, P369; HIBI K, 1991, ONCOGENE, V6, P2291; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; IRANI AMA, 1992, BLOOD, V80, P3009; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; JOZAKI K, 1991, EXP HEMATOL, V19, P185; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; KERN JA, 1990, CANCER RES, V50, P5184; KISS C, 1993, LEUKEMIA, V7, P235; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LERNER NB, 1991, BLOOD, V77, P1876; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LIU E, 1992, ONCOGENE, V7, P1027; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MAYRHOFER G, 1987, IMMUNOL CELL BIOL, V65, P241, DOI 10.1038/icb.1987.27; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OCONNOR CG, 1982, J IMMUNOL METHODS, V54, P267, DOI 10.1016/0022-1759(82)90068-0; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; QUI F, 1988, EMBO J, V7, P1003; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; RIEDEL H, 1987, SCIENCE, V236, P197, DOI 10.1126/science.3494307; ROSNET O, 1991, ONCOGENE, V6, P1641; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SASAKI K, 1995, BLOOD, V85, P1220, DOI 10.1182/blood.V85.5.1220.bloodjournal8551220; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Zar JH., 1999, BIOSTAT ANAL	60	24	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					179	190		10.1038/sj.onc.1201494	http://dx.doi.org/10.1038/sj.onc.1201494			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464535				2022-12-25	WOS:000071427100004
J	Brickman, YG; Ford, MD; Gallagher, JT; Nurcombe, V; Bartlett, PF; Turnbull, JE				Brickman, YG; Ford, MD; Gallagher, JT; Nurcombe, V; Bartlett, PF; Turnbull, JE			Structural modification of fibroblast growth factor-binding heparan sulfate at a determinative stage of neural development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDURONATE 2-SULFATE RESIDUES; FACTOR RECEPTOR; MOLECULAR-ORGANIZATION; PRECURSOR CELLS; FINE-STRUCTURE; HIGH-AFFINITY; FGF-2; PROTEOGLYCANS; SEQUENCE; DEPOLYMERIZATION	Heparan sulfate (HS) glycosaminoglycans are essential modulators of fibroblast growth factor (FGF) activity and appear to act by coupling particular forms of FGF to appropriate FGF receptors, During neural development, one particular HS proteoglycan is able to rapidly switch its potentiating activity from FGF-2, as neural precursor cell proliferation occurs, to FGF-1, as neuronal differentiation occurs, Using various analytical techniques, including chemical and enzymatic cleavage, low pressure chromatography, and strong anion-exchange high performance Liquid chromatography, we have analyzed the different HSs expressed during these crucial developmental stages, There are distinct alterations in patterns of 6-O-sulfation, total chain length, and the number of sulfated domains of the HS from the more mature embryonic brain, These changes correlate with a switch in the ability of the HS to potentiate the actions of FGF-1 in triggering: cell differentiation It thus appears that each HS pool is designed to function in the modulation of an intricate interaction with a specific growth factor and its cognate receptor, and suggests tightly regulated expression of specific, bioactive disaccharide sequences, The data can be used to construct a simple model of controlled variations in HS chain structure which have functional consequences at a crucial stage of neuronal maturation.	Univ Melbourne, Dept Anat & Cell Biol, Melbourne, Vic 3052, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Manchester, CRC, Dept Med Oncol, Christie Res Ctr, Manchester M20 4BX, Lancs, England	University of Melbourne; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Manchester	Brickman, YG (corresponding author), Monash Univ, Alfred Hosp, Dept Med, Dept Neurosci,Van Cleef Roet Ctr Nervous Dis, Commercial Rd, Prahran, Vic 3181, Australia.		Bartlett, Perry/F-3813-2012					BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BIENKOWSKI MJ, 1984, J BIOL CHEM, V259, P2989; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BRICKMAN YG, 1995, J BIOL CHEM, V270, P24941, DOI 10.1074/jbc.270.42.24941; BRICKMAN YG, 1997, IN PRESS GLYCOBIOLOG, V7; CHALLACOMBE JF, 1995, NEUROCHEM RES, V20, P253, DOI 10.1007/BF00969540; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FORD MD, 1994, NEUROREPORT, V5, P565, DOI 10.1097/00001756-199401000-00008; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HISCOCK DRR, 1995, BBA-GEN SUBJECTS, V1244, P104, DOI 10.1016/0304-4165(94)00206-D; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P451, DOI 10.1093/glycob/4.4.451; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; Joseph SJ, 1996, DEVELOPMENT, V122, P3443; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KATO M, 1994, J BIOL CHEM, V269, P18881; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; LINHARDT R, 1991, BIOCHEMISTRY-US, V29, P2611; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MURPHY M, 1990, J NEUROSCI RES, V25, P463, DOI 10.1002/jnr.490250404; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PYE DA, 1995, BBA-MOL CELL RES, V1266, P235, DOI 10.1016/0167-4889(95)00012-H; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; Turnbulll Jeremy E., 1993, V19, P253; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	47	157	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4350	4359		10.1074/jbc.273.8.4350	http://dx.doi.org/10.1074/jbc.273.8.4350			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468484	hybrid			2022-12-25	WOS:000072115000012
J	Natochin, M; Artemyev, NO				Natochin, M; Artemyev, NO			Substitution of transducin Ser(202) by Asp abolishes G-protein/RGS interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; ALPHA-SUBUNITS; MECHANISM; BINDING; FAMILY; HYDROLYSIS; DOMAIN; GAIP; RGS4	Known RGS proteins stimulate GTPase activity of G(i) and G(q) family members, but do not interact with G(s) alpha and G(12)alpha. To determine the role of specific G alpha residues for RGS protein recognition, six RGS contact residues of chimeric transducin alpha-subunit (G(t) alpha) corresponding to the residues that differ between G(i) alpha and G(s) alpha have been replaced by G(s) alpha residues, The ability of human retinal RGS (hRGSr) to bind mutant G(t) alpha subunits and accelerate their GTPase activity was investigated Substitutions Thr(178) --> Ser, Ile(181) --> Phe, and Lys(205) --> Arg of G(t) alpha did not alter its interaction with hRGSr. The Lys(176) --> Leu mutant had the same affinity for hRGSr as G(t) alpha, but the maximal GTPase stimulation by hRGSr was reduced by similar to 2.5-fold, The substitution His(209) --> Gln led to a 3-fold decrease in the affinity of hRGSr for the G(t) alpha mutant without significantly affecting the maximal GTPase enhancement. The Ser(202) --> Asp mutation abolished G(t) alpha recognition by hRGSr. A counteracting replacement of Glu(129) by Ala in hRGSr did not restore the interaction of hRGSr with the G(t) alpha Ser(202) --> Asp mutant. Our data suggest that the Ser residue at position 202 of G(t) alpha is critical for the specificity of RGS proteins toward G(i) and G(q) families of G-proteins. Consequently, the corresponding residue, Asp(229) of G(s) alpha, is likely responsible for the inability of RGS proteins to interact with G(s) alpha.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, 5-660 Bowen Sci Bldg, Iowa City, IA 52242 USA.			Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [EY-10843] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Natochin M, 1997, FEBS LETT, V411, P179, DOI 10.1016/S0014-5793(97)00687-X; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; NATOCHIN M, 1998, IN PRESS J BIOL CHEM, V273; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039	26	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4300	4303		10.1074/jbc.273.8.4300	http://dx.doi.org/10.1074/jbc.273.8.4300			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468476	hybrid			2022-12-25	WOS:000072115000004
J	Muranjan, M; Nussenzweig, V; Tomlinson, S				Muranjan, M; Nussenzweig, V; Tomlinson, S			Characterization of the human serum trypanosome toxin, haptoglobin-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; 21-KDA PROTEIN; GENE; BRUCEI; IDENTIFICATION; COMPLEX; PLASMA; TUMORS	Haptoglobin-related protein (HPR) is a serum protein that is > 90% homologous to the acute-phase reactant haptoglobin (Hp). Haptoglobin binds and removes free hemoglobin (Hb) from the circulation, Hpr levels are elevated with tumor progression in the serum of some cancer patients, but the relevance of this observation is not understood. HPR is an integral part of two distinct high molecular weight complexes (trypanosome lytic factor 1 (TLF1) and TLF2) that are lytic for the African parasite Tryanosoma brucei brucei. Previous data indicate that HPR represents the toxic component of both trypanosoma lytic factors. It has been proposed that after uptake by the parasite, Hb bound to HPR causes lysis in a peroxidase-dependent process, We report that the molecular architecture of HPR in normal human serum is different from that of Rp and that HPR does not bind Hb in normal human serum. Immunodepletion of all detectable Hb from TLF1 does not deplete TLF1 of HPR or trypanolytic activity, suggesting that; the mechanism of parasite lysis is Hb-independent.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA	New York University	Tomlinson, S (corresponding author), NYU, Med Ctr, Dept Pathol, MSB 127,550 1st Ave, New York, NY 10016 USA.	tomlis01@popmail.med.nyu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040206, R21AI040206] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40206] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENSI G, 1985, EMBO J, V4, P119, DOI 10.1002/j.1460-2075.1985.tb02325.x; BOWMAN BH, 1982, ADV HUM GENET, V12, P189; FAWCETT HAC, 1990, BIOCHIM BIOPHYS ACTA, V1048, P187, DOI 10.1016/0167-4781(90)90055-7; GRUNDNERCULEMANN E, 1993, J CANCER RES CLIN, V119, P685, DOI 10.1007/BF01215988; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAWKING F, 1973, T ROY SOC TROP MED H, V67, P501, DOI 10.1016/0035-9203(73)90081-3; HWANG PK, 1980, J BIOL CHEM, V255, P3038; JENNINGS FW, 1983, T ROY SOC TROP MED H, V77, P693, DOI 10.1016/0035-9203(83)90207-9; KUHAJDA FP, 1989, NEW ENGL J MED, V321, P636, DOI 10.1056/NEJM198909073211003; KUHAJDA FP, 1989, P NATL ACAD SCI USA, V86, P1188, DOI 10.1073/pnas.86.4.1188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; MAEDA N, 1985, J BIOL CHEM, V260, P6698; MCEVOY SM, 1988, J BIOL CHEM, V263, P15740; OH SK, 1992, HYBRIDOMA, V11, P1, DOI 10.1089/hyb.1992.11.1; PINTERA J, 1971, BIOCH GENETIC CLINIC; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; Raper J, 1996, J EXP MED, V183, P1023, DOI 10.1084/jem.183.3.1023; SEED JR, 1990, J PROTOZOOL, V37, P393, DOI 10.1111/j.1550-7408.1990.tb01163.x; SHALITIN C, 1991, INT J CANCER, V49, P861, DOI 10.1002/ijc.2910490610; SMITH AB, 1995, P NATL ACAD SCI USA, V92, P10262, DOI 10.1073/pnas.92.22.10262; SMITH AB, 1995, SCIENCE, V268, P284, DOI 10.1126/science.7716520; Tabak S, 1996, DNA CELL BIOL, V15, P1001, DOI 10.1089/dna.1996.15.1001; TOMLINSON S, 1995, MOL BIOCHEM PARASIT, V70, P131, DOI 10.1016/0166-6851(95)00019-W; Tomlinson S, 1997, MOL BIOCHEM PARASIT, V86, P117, DOI 10.1016/S0166-6851(97)90013-X	25	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3884	3887		10.1074/jbc.273.7.3884	http://dx.doi.org/10.1074/jbc.273.7.3884			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461571	hybrid			2022-12-25	WOS:000072048400013
J	Ralton, JE; McConville, MJ				Ralton, JE; McConville, MJ			Delineation of three pathways of glycosylphosphatidylinositol biosynthesis in Leishmania mexicana - Precursors from different pathways are assembled on distinct pools of phosphatidylinositol and undergo fatty acid remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMASTIGOTE SURFACE PROTEASE; MEMBRANE ANCHORS; GLYCOSYL-PHOSPHATIDYLINOSITOLS; GLYCOINOSITOL-PHOSPHOLIPIDS; AFRICAN TRYPANOSOMES; GLUCOSAMINYL PHOSPHATIDYLINOSITOL; INOSITOL ACYLATION; MYRISTIC ACID; LIPOPHOSPHOGLYCAN; GLYCOLIPIDS	Glycosylphosphatidylinositol (GPI) glycolipids are major cell surface constituents in the Leishmania parasites. Distinct classes of GPI are present as membrane anchors for several surface glycoproteins and an abundant lipophosphoglycan as well as being the major glycolipids (GIPLs) in the plasma membrane. In this study we have identified putative precursors for the protein and lipophosphoglycan anchors and delineated the complete pathway for GIPL biosynthesis in Leishmania mexicana promastigotes. Based on the structural analyses of these GPI intermediates and their kinetics of labeling in vivo and in cell-free systems, we provide evidence that the GIPLs are the products of an independent biosynthetic pathway rather than being excess precursors of the anchor pathways, First, we show that the similar glycan head groups of the GIPL and protein/lipophosphoglycan anchor precursors are assembled on two distinct pools of PI corresponding to 1-O-(C18:0)alkyl-2-stearoyl-PI and 1-O-(C24:0/C26:0)-2-stearoyl-PI, respectively, These PI species account for 20 and 1% of the total PI pool, respectively, indicating a remarkable specificity in their selection, Second, analysis of the flux of intermediates through these pathways in vivo and in a cell-free system suggests that the GIPL and anchor pathways are independently regulated. We also show that GIPL biosynthesis requires fatty acid remodeling, in which the sn-2 stearoyl chains are replaced with myristoyl or lauroyl chains, Fatty acid remodeling is dependent on CoA and ATP and occurs on pre-existing but not on de novo synthesized GIPLs. We suggest that the compartmentalization of different GPI pathways may be important in regulating the species and stage-specific expression of different GPI structures in these parasites.	Univ Melbourne, Dept Biochem, Parkville, Vic 3052, Australia	University of Melbourne	McConville, MJ (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia.							BABR V, 1993, MOL BIOCHEM PARASIT, V58, P107; BAUXBAUM LU, 1994, J BIOL CHEM, V269, P30212; BUTOKOFER P, 1992, EUR J BIOCHEM, V208, P677; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; DOERING TL, 1994, P NATL ACAD SCI USA, V91, P9735, DOI 10.1073/pnas.91.21.9735; DOERING TL, 1994, BIOCHEM J, V299, P741, DOI 10.1042/bj2990741; DOERING TL, 1993, J BIOL CHEM, V268, P9215; DOERING TL, 1991, SCIENCE, V252, P1851, DOI 10.1126/science.1829548; Doerrler WT, 1996, J BIOL CHEM, V271, P27031, DOI 10.1074/jbc.271.43.27031; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; GEROLD P, 1994, J BIOL CHEM, V269, P2597; Giorgione JR, 1996, P NATL ACAD SCI USA, V93, P11634, DOI 10.1073/pnas.93.21.11634; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Heise N, 1996, J BIOL CHEM, V271, P16877, DOI 10.1074/jbc.271.28.16877; ILG T, 1992, J BIOL CHEM, V267, P6834; Ma DQ, 1996, BIOCHEM BIOPH RES CO, V227, P885, DOI 10.1006/bbrc.1996.1600; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1995, BIOCHEM J, V310, P807, DOI 10.1042/bj3100807; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1993, J BIOL CHEM, V268, P15595; MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; MENON AK, 1990, J BIOL CHEM, V265, P9033; PROUDFOOT L, 1995, BIOCHEM J, V308, P45, DOI 10.1042/bj3080045; PROUDFOOT L, 1995, EUR J IMMUNOL, V25, P745, DOI 10.1002/eji.1830250318; REDMAN CA, 1995, BIOCHEM J, V311, P495, DOI 10.1042/bj3110495; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SCHNEIDER P, 1993, ANAL BIOCHEM, V210, P106, DOI 10.1006/abio.1993.1158; SEVLEVER D, 1995, EUR J BIOCHEM, V233, P384, DOI 10.1111/j.1432-1033.1995.384_1.x; Singh N, 1996, J BIOL CHEM, V271, P12879, DOI 10.1074/jbc.271.22.12879; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; Smith TK, 1997, BIOCHEM J, V326, P393, DOI 10.1042/bj3260393; Smith TK, 1996, J BIOL CHEM, V271, P6476, DOI 10.1074/jbc.271.11.6476; STEVENS VL, 1995, BIOCHEM J, V310, P361, DOI 10.1042/bj3100361; Tachado SD, 1997, P NATL ACAD SCI USA, V94, P4022, DOI 10.1073/pnas.94.8.4022; TAKEDA J, 1995, TRENDS BIOCHEM SCI, V20, P367, DOI 10.1016/S0968-0004(00)89078-7; TOMAVO S, 1992, J BIOL CHEM, V267, P21446; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; VANTHOF W, 1995, J BIOL CHEM, V270, P24150; WINTER G, 1994, J CELL SCI, V107, P2471	44	97	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4245	4257		10.1074/jbc.273.7.4245	http://dx.doi.org/10.1074/jbc.273.7.4245			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461623	hybrid			2022-12-25	WOS:000072048400065
J	Vorgia, P; Zannis, VI; Kardassis, D				Vorgia, P; Zannis, VI; Kardassis, D			A short proximal promoter and the distal hepatic control region-1 (HCR-1) contribute to the liver specificity of the human apolipoprotein C-II gene - Hepatic enhancement by HCR-1 requires two proximal hormone response elements which have different binding specificities for orphan receptors HNF-4, ARP-1, and EAR-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOCIII GENE; TRANSCRIPTIONAL ACTIVATION; INTESTINAL TRANSCRIPTION; TRANSGENIC MICE; MESSENGER-RNA; B GENE; APO-B; A-I; EXPRESSION; DNA	We have identified the regulatory elements, some of the factors and potential regulatory mechanisms which determine the tissue specificity of the human apoC-II gene. The -545/+18 apoC-II promoter directs high levels of expression of the reporter CAT gene in cells of hepatic origin (NepG2), low levels of expression in cells of intestinal origin (CaCo-2) and basal expression in HeLa cells, Deletion analysis identified negative regulatory elements within the -545/-388 region and positive regulatory elements within the -388/-55 region. Linkage of different apoC-II promoter segments to the hepatic control region-1 (HCR-1) enhanced the promoter activity 2.5-11-fold in HepG2 cells but did not affect its activity in CaCo-2 or COS-1 cells. DNase I footprinting analysis using rat liver nuclear extracts identified five protected regions within the -545/+18 apoC-II promoter as follows: CIIA (-74/-44), CIIB (-102/-81), CIIC (-159/-116), CIID (-288/-265), and CIIE (-497/-462), Elements CIIB and CIIC: contain hormone response elements. CIIB is recognized by hepatic nuclear factor-4 (HNF-4) but not ARP-I or EAR-2, whereas CIIC is recognized by ARP-1 and EAR-2 but not by HNF-4, HNF-4 transactivated the apoC-II promoter or the apoC-II promoter linked. to the HCR-1 in COS-1 cells, A double mutation in elements CIIB and CIIC that eliminated binding of HNF-4 or ARP-1 and EAR-2, respectively, to these sites abolished the enhancer activity of HCR-1. The combined data suggest that the apoC-II: promoter/HCR-1. cluster can direct expression In cells of hepatic origin and that optimal enhancer activity requires synergistic interactions between factors bound Let the distal HCR-1 and nuclear receptors bound to the two proximal hormone response elements.	Univ Crete, Dept Med, Biochem Sect, Div Basic Sci, Heraklion 71110, Crete, Greece; Inst Mol Biol & Biotechnol, Heraklion 71110, Crete, Greece	University of Crete	Kardassis, D (corresponding author), Univ Crete, Dept Med, Biochem Sect, Div Basic Sci, POB 1393, Heraklion 71110, Crete, Greece.		Vorgia, Pelagia/ABK-2455-2022; VORGIA, PELAGIA/W-8793-2018	Vorgia, Pelagia/0000-0002-7061-146X; 	NHLBI NIH HHS [HL-33952] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033952] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN CM, 1995, J BIOL CHEM, V270, P26278, DOI 10.1074/jbc.270.44.26278; ALLAN CM, 1995, GENOMICS, V28, P291, DOI 10.1006/geno.1995.1144; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; DANG Q, 1995, J BIOL CHEM, V270, P22577, DOI 10.1074/jbc.270.38.22577; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; JACKSON RL, 1977, P NATL ACAD SCI USA, V74, P1942, DOI 10.1073/pnas.74.5.1942; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; KARDASSIS D, 1990, MOL CELL BIOL, V10, P2653, DOI 10.1128/MCB.10.6.2653; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LENICH C, 1988, J LIPID RES, V29, P755; LUSIS AJ, 1986, P NATL ACAD SCI USA, V83, P3929, DOI 10.1073/pnas.83.11.3929; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; Malik S, 1996, MOL CELL BIOL, V16, P1824; MANGELSDORF DJ, 1994, RETINOIDS BIOL CHEM, V8, P319; METZGER S, 1993, J BIOL CHEM, V268, P16831; MILLER AL, 1973, J BIOL CHEM, V248, P3359; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; OGAMI K, 1990, J BIOL CHEM, V265, P9808; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SAYER F, 1995, SCIENCE, V270, P1825; SAYER F, 1995, SCIENCE, V270, P1783; SCHACHTER NS, 1993, J LIPID RES, V34, P1699; SCHACHTER NS, 1994, J CLIN INVEST, V93, P1688; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRONCHE F, 1994, LIVER GENE EXPRESSIO, P157; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WEI CF, 1985, J BIOL CHEM, V260, P5211; WU AL, 1979, J BIOL CHEM, V254, P7316; ZANNIS VI, 1993, ADV HUM GENET, V21, P145; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	55	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4188	4196		10.1074/jbc.273.7.4188	http://dx.doi.org/10.1074/jbc.273.7.4188			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461615	hybrid			2022-12-25	WOS:000072048400057
J	Yang, CZ; Heimberg, H; D'Souza-Schorey, C; Mueckler, MM; Stahl, PD				Yang, CZ; Heimberg, H; D'Souza-Schorey, C; Mueckler, MM; Stahl, PD			Subcellular distribution and differential expression of endogenous ADP-ribosylation factor 6 in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; GUANINE-NUCLEOTIDE; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; PHOSPHOLIPASE-D; BREFELDIN-A; ARF; LOCALIZATION; MECHANISM; TRANSPORT	ADP-ribosylation factor (ARF) 6 has been shown to play a role in vesicular transport; however, the expression and subcellular localization of the endogenous protein have not been clearly delineated, In this study, an ARF6-specific monoclonal antibody was raised and used to examine the subcellular distribution and expression of ARF6 in various tissues and during the differentiation of several well characterized cell types, We found that ARF6 localizes in both the cytosol and membranes of all tissues and cells tested, Moreover, ARF6 in 3T3-L1 adipocytes is principally localized on the plasma membrane, but substantial amounts are detected in the cytosolic and intracellular membrane fractions, We observed an increased expression of ARF6 during the differentiation of B lymphocytes to plasmocytes, However, the expression of ARF6 decreased during adipogenesis and monocyte differentiation. In contrast, the expression of other ARFs, detected by the monoclonal antibody 1D9, did not significantly change during differentiation of the aforementioned cell types, Taken together, our results indicate that ARF6 is a broadly expressed, differentially regulated GTPase that is present in cytoplasm and on both cell-surface and intracellular membranes and whose functions may include tissue-specific effects on vesicular trafficking during cellular differentiation.	Washington Univ, Sch Med, Dept Physiol & Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL)	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Physiol & Cell Biol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Mueckler, Mike M/F-6115-2012; Stahl, Philip/D-6315-2012	Heimberg, Harry/0000-0003-1954-7375	NIDDK NIH HHS [DK38495, DRTC DK2057] Funding Source: Medline; NIGMS NIH HHS [GM42259] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038495, K08DK002057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDINI G, 1995, P NATL ACAD SCI USA, V92, P4284, DOI 10.1073/pnas.92.10.4284; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KITAGAWA K, 1989, BIOCHIM BIOPHYS ACTA, V1014, P83, DOI 10.1016/0167-4889(89)90244-9; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MARIDONNEAUPARINI I, 1991, J CLIN INVEST, V87, P901, DOI 10.1172/JCI115096; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; Shisheva A, 1997, BIOCHEMISTRY-US, V36, P6564, DOI 10.1021/bi970202g; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; YANG CZ, 1992, BIOCHEM BIOPH RES CO, V182, P1499, DOI 10.1016/0006-291X(92)91903-4	28	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4006	4011		10.1074/jbc.273.7.4006	http://dx.doi.org/10.1074/jbc.273.7.4006			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461590	hybrid			2022-12-25	WOS:000072048400032
J	Chang, WSW; Lomas, DA				Chang, WSW; Lomas, DA			Latent alpha(1)-antichymotrypsin - A molecular explanation for the inactivation of alpha(1)-antichymotrypsin in chronic bronchitis and emphysema	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; HUMAN ALPHA-1-PROTEINASE INHIBITOR; HUMAN ALPHA-1-ANTICHYMOTRYPSIN; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; REACTIVE CENTER; HUMAN-PLASMA; PURIFICATION; LOOP; CLEAVAGE	alpha(1)-Antichymotrypsin is an acute phase protein that protects the tissues from damage by proteolytic enzymes, but previous studies have shown that alpha(1)-antichymotrypsin within the lungs of patients with chronic bronchitis and emphysema is intact but inactive as an inhibitor. Ammonium sulfate fractionation followed by blue Sepharose and DNA-Sepharose chromatography was used to isolate small amounts of intact, monomeric but inactive alpha(1)-antichymotrypsin from the plasma of 30 healthy blood donors. This species had a higher DNA binding affinity with more anodal electrophoretic mobility than native alpha(1)-antichymotrypsin and was conformationally stable against thermal denaturation, 8 M urea, and 7 M guanidinium chloride. The protein was unable to accept synthetic reactive loop peptides, and the reactive loop was resistant to proteolytic cleavage at the P-5-P-4 bond but could be cleaved between P-1' and P-3'. These data suggest that this new alpha(1)-antichymotrypsin species was in a conformation similar to those of the crystallographically determined latent serpins, plasminogen activator inhibitor-1 and antithrombin. alpha(1)-Antichymotrypsin from lung lavage migrated with the same electrophoretic mobility as the putative latent alpha(1)-antichymotrypsin, suggesting that this is the inactive conformation described previously in the lungs of patients with chronic bronchitis and emphysema. This conformational transition of alpha(1)-antichymotrypsin, from an active to an inactive state, within the lung may play an important role in the pathogenesis of chronic lung disease.	Univ Cambridge, Ctr Mrc, Dept Haematol, Cambridge CB2 2QH, England; Univ Cambridge, Ctr Mrc, Dept Med, Cambridge CB2 2QH, England	University of Cambridge; University of Cambridge	Lomas, DA (corresponding author), Univ Cambridge, Ctr Mrc, Dept Haematol, Hills Rd, Cambridge CB2 2QH, England.	dal16@cam.ac.uk	Chang, Wun-Shaing Wayne/C-1202-2010		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARONSEN KF, 1972, SCAND J CLIN LAB INV, V29, P127, DOI 10.3109/00365517209102760; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BERMAN G, 1986, J BIOL CHEM, V261, P14095; CALVERLEY PMA, 1995, CHRONIC OBSTRUCTIVE; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chang WSW, 1996, BIOCHEM J, V314, P647, DOI 10.1042/bj3140647; CICHY J, 1995, J CLIN INVEST, V95, P2729, DOI 10.1172/JCI117975; GAFFAR SA, 1980, J BIOL CHEM, V255, P8334; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HEIMBURG.N, 1965, CLIN CHIM ACTA, V12, P116, DOI 10.1016/0009-8981(65)90118-X; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; KILPATRICK L, 1991, J IMMUNOL, V146, P2388; KRESS LF, 1984, COMP BIOCHEM PHYS B, V77, P431, DOI 10.1016/0305-0491(84)90255-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE A, 1981, BIOCHIM BIOPHYS ACTA, V668, P429, DOI 10.1016/0005-2795(81)90177-X; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEVIN EG, 1987, BLOOD, V70, P1090; LINDMARK B, 1989, BIOCHIM BIOPHYS ACTA, V997, P90, DOI 10.1016/0167-4838(89)90139-8; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; LOMAS DA, 1995, J BIOL CHEM, V270, P23437, DOI 10.1074/jbc.270.40.23437; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MORII M, 1983, BIOCHEM BIOPH RES CO, V111, P438, DOI 10.1016/0006-291X(83)90325-X; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MUNCH M, 1991, FEBS LETT, V295, P102, DOI 10.1016/0014-5793(91)81395-O; NAIDOO N, 1995, J BIOL CHEM, V270, P14548, DOI 10.1074/jbc.270.24.14548; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; POTEMPA J, 1991, J BIOL CHEM, V266, P21482; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; STOCKLEY RA, 1992, BOICH PULMONARY EMPH, P47; TRAVIS J, 1978, BIOCHEMISTRY-US, V17, P5647, DOI 10.1021/bi00619a010; TRAVIS J, 1981, METHOD ENZYMOL, V80, P765; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TRAVIS J, 1978, BIOCHEMISTRY-US, V17, P5651, DOI 10.1021/bi00619a011; TUCKER HM, 1995, NAT STRUCT BIOL, V2, P442, DOI 10.1038/nsb0695-442; Wardell MR, 1997, BIOCHEMISTRY-US, V36, P13133, DOI 10.1021/bi970664u; WEEKE B, 1973, SCAND J IMMUNOL, V2, P37, DOI 10.1111/j.1365-3083.1973.tb03777.x; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251	49	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3695	3701		10.1074/jbc.273.6.3695	http://dx.doi.org/10.1074/jbc.273.6.3695			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452500	hybrid			2022-12-25	WOS:000071822300085
J	Schreiber, M; Wei, AG; Yuan, A; Gaut, J; Saito, M; Salkoff, L				Schreiber, M; Wei, AG; Yuan, A; Gaut, J; Saito, M; Salkoff, L			Slo3, a novel pH-sensitive K+ channel from mammalian spermatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; INTRACELLULAR PH; ZONA-PELLUCIDA; ACROSOMAL EXOCYTOSIS; SKELETAL-MUSCLE; CA2+ CHANNELS; BETA-SUBUNIT; MOUSE SPERM; CONDUCTANCE; CELLS	Potassium channels have evolved to play specialized roles in both excitable and inexcitable tissues, Here we describe the cloning and expression of Slo3, a novel potassium channel abundantly expressed in mammalian spermatocytes. Slo3 represents a new and unique type of potassium channel regulated by both intracellular pH and membrane voltage, Reverse transcription-polymerase chain reaction, Northern analysis, and in situ hybridization show that Slo3 is primarily expressed in testis in both mouse and human, Because of its sensitivity to both pH and voltage, Slo3 could be involved in sperm capacitation and/or the acrosome reaction, essential steps in fertilization where changes in both intracellular pH and membrane potential are Imo cvn to occur, The protein sequence of mSlo3 (the mouse Slo3 homologue) is similar to Slo1, the large conductance, calcium-and voltage-gated potassium channel. These results suggest that Slo channels comprise a multigene family, defined by a combination of sensitivity to voltage and a variety of intracellular factors, Northern analysis from human testis indicates that a Slo3 homologue is present in humans and conserved with regard to sequence, transcript size, and tissue distribution, Because of its high testis-specific expression, pharmacological agents that target human Slo3 channels may be useful in both the study of fertilization as well as in the control or enhancement of fertility.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Salkoff, L (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, Box 8108,660 S Euclid Ave, St Louis, MO 63110 USA.	salkoffl@thalamus.wustl.edu	Gaut, Joseph/ABD-4600-2021; Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Yuan, Alex/0000-0003-0191-8035				ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; Arnoult C, 1996, J CELL BIOL, V134, P637, DOI 10.1083/jcb.134.3.637; ART JJ, 1995, J GEN PHYSIOL, V105, P49, DOI 10.1085/jgp.105.1.49; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BABCOCK DF, 1987, J BIOL CHEM, V262, P15041; BABCOCK DF, 1983, P NATL ACAD SCI-BIOL, V80, P1327, DOI 10.1073/pnas.80.5.1327; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Chan HC, 1997, BBA-BIOMEMBRANES, V1323, P117, DOI 10.1016/S0005-2736(96)00127-7; COOK SP, 1993, J BIOL CHEM, V268, P22402; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; DWORETZKY SI, 1994, MOL BRAIN RES, V27, P189, DOI 10.1016/0169-328X(94)90203-8; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; FLORMAN HM, 1994, DEV BIOL, V165, P152, DOI 10.1006/dbio.1994.1242; FLORMAN HM, 1992, DEV BIOL, V152, P304, DOI 10.1016/0012-1606(92)90137-6; Fuchs P A, 1992, Curr Opin Neurobiol, V2, P457, DOI 10.1016/0959-4388(92)90180-S; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; Knaus HG, 1996, J NEUROSCI, V16, P955; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAURIDO C, 1991, J GEN PHYSIOL, V98, P1025, DOI 10.1085/jgp.98.5.1025; Lievano A, 1996, FEBS LETT, V388, P150, DOI 10.1016/0014-5793(96)00515-7; MARTY A, 1981, NATURE, V291, P497, DOI 10.1038/291497a0; MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V269, pH767, DOI 10.1152/ajpheart.1995.269.3.H767; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; NEELY A, 1992, J PHYSIOL-LONDON, V453, P97, DOI 10.1113/jphysiol.1992.sp019220; PALLOTTA BS, 1981, NATURE, V293, P471, DOI 10.1038/293471a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PETERSEN OH, 1984, NATURE, V307, P693, DOI 10.1038/307693a0; Santi CM, 1996, AM J PHYSIOL-CELL PH, V271, pC1583, DOI 10.1152/ajpcell.1996.271.5.C1583; SASAKI S, 1992, BIOCHIM BIOPHYS ACTA, V1137, P45, DOI 10.1016/0167-4889(92)90098-V; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; SUZUKI M, 1994, NATURE, V367, P642, DOI 10.1038/367642a0; TABCHARANI JA, 1989, BIOCHIM BIOPHYS ACTA, V982, P62, DOI 10.1016/0005-2736(89)90174-0; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; VREDENBURGHWILBERG WL, 1995, MOL REPROD DEV, V40, P490, DOI 10.1002/mrd.1080400413; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; WALENSKY LD, 1995, J CELL BIOL, V130, P857, DOI 10.1083/jcb.130.4.857; Wallner M, 1996, P NATL ACAD SCI USA, V93, P14922, DOI 10.1073/pnas.93.25.14922; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; Zeng Y, 1996, DEV BIOL, V173, P510, DOI 10.1006/dbio.1996.0044	50	173	187	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3509	3516		10.1074/jbc.273.6.3509	http://dx.doi.org/10.1074/jbc.273.6.3509			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452476	hybrid			2022-12-25	WOS:000071822300061
J	Zuscik, MJ; Porter, JE; Gaivin, R; Perez, DM				Zuscik, MJ; Porter, JE; Gaivin, R; Perez, DM			Identification of a conserved switch residue responsible for selective constitutive activation of the beta(2)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-H EXCHANGE; BETA-ADRENERGIC-RECEPTOR; TERNARY COMPLEX MODEL; ADENYLATE-CYCLASE; G-PROTEIN; AFFINITY; BINDING; TRANSIENTS; PATHWAYS; STATE	A cysteine-to-phenylalanine mutation of residue 116 in the third transmembrane domain of the beta(2)-adrenergic receptor caused selective constitutive activation of Na+/H+ exchange through a pathway not involving cAMP. This selectivity was identified by comparing binding and signaling characteristics of wild-type (WT) versus C116F mutant receptors transiently transfected into COS-1 cells, Indicating constitutive activity, ligand binding to the C116F mutant showed a 78-fold higher than WT affinity for isoproterenol and a 40-fold lower than WT affinity for ICI 118551, Although agonist-independent activation of cAMP production was not exhibited by the C116F mutant, a constitutive stimulation of the Na+/H+ exchanger (NHE1) was observed. This was identified by measuring either basal intracellular pH (pH(i)) or rate of pH(i) recovery from cellular acid load. Due to a higher rate of H+ efflux through NHE1, C116F transfectants exhibited a significantly higher pH(i) (7.42) than did WT transfectants (7.1). Furthermore, the rate of pH(i) recovery from acid load facilitated by NHE1 was 8.1-fold faster in mutant transfectants than in WT transfectants. The lower rate seen in the WT case was stimulated by epinephrine, and the higher rate seen in the mutant case was inhibited by ICI 118551. These findings, which show that a C116F mutation of the beta(2)-adrenergic receptor evokes selective constitutive coupling to NHE1 over cAMP, form the basis of our prediction that multiple and distinct activation states can exist in G protein-coupled receptors.	Cleveland Clin Fdn, Dept Mol Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Perez, DM (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, 9500 Euclid Ave,FF3-01, Cleveland, OH 44195 USA.	perexd@cesmtp.ccf.org		Zuscik, Michael/0000-0003-0461-8708	PHS HHS [R01152544] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Acharya S, 1996, J BIOL CHEM, V271, P25406, DOI 10.1074/jbc.271.41.25406; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BENOS DJ, 1982, AM J PHYSIOL, V242, pC131, DOI 10.1152/ajpcell.1982.242.3.C131; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYLUND DB, 1992, FASEB J, V6, P832, DOI 10.1096/fasebj.6.3.1346768; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; FRASER CM, 1988, P NATL ACAD SCI USA, V85, P5478, DOI 10.1073/pnas.85.15.5478; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HARDMAN JG, 1996, PHARMACOL BASIS THER, P125; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA B, 1991, TRENDS CARDIOVAS MED, V1, P189, DOI 10.1016/1050-1738(91)90036-E; KOHMOTO O, 1990, CIRC RES, V66, P622, DOI 10.1161/01.RES.66.3.622; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Noda K, 1996, BIOCHEMISTRY-US, V35, P16435, DOI 10.1021/bi961593m; NODA K, 1994, J BIOL CHEM, V269, P6743; Perez DM, 1996, MOL PHARMACOL, V49, P112; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PEREZ DM, 1993, MOL PHARMACOL, V44, P784; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1991, J BIOL CHEM, V266, P5; STROSBERG AD, 1993, PROTEIN SCI, V2, P1198, DOI 10.1002/pro.5560020802; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721	34	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3401	3407		10.1074/jbc.273.6.3401	http://dx.doi.org/10.1074/jbc.273.6.3401			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452461	hybrid			2022-12-25	WOS:000071822300046
J	Klugbauer, S; Demidchik, EP; Lengfelder, E; Rabes, HM				Klugbauer, S; Demidchik, EP; Lengfelder, E; Rabes, HM			Molecular analysis of new subtypes of ELE/RET rearrangements, their reciprocal transcripts and breakpoints in papillary thyroid carcinomas of children after Chernobyl	ONCOGENE			English	Article						RET oncogene; RT-PCR; reciprocal transcript; breakpoint; Chernobyl	RET PROTOONCOGENE; RET/PTC ONCOGENE; REACTOR ACCIDENT; ACTIVATION; CANCER; GENES; FORM	A high prevalence of RET rearrangements is found in papillary thyroid carcinomas (PTC) of children from Belarus after the Chernobyl reactor accident. The ELE/RET rearrangement (PTC3) is prevailing. Aberrant types of ELE/RET rearrangement have been found with a truncated ELE1 gene: As compared with the common form (PTC3r1) one aberrant type is shorter by one 144 bp exon (PTC3r2) (three cases); in the second atypic form (PTC3r3) the ELE1 part is 18 bp shorter than in PTC3r1. In agreement with the observation that the oncogenic RET is generated by a paracentric inversion at chromosome 10, we found not only ELE/RET, but also RET/ELE transcripts in these tumors. Sequencing of the breakpoint regions at the genomic DNA level revealed DNA modifications that might be relevant for illegitimate recombination after DNA doublestrand breaks. The high prevalence of ELE/RET rearrangements and various subtypes appears to be typical for radiation-induced thyroid carcinomas of children after the Chernobyl reactor accident.	Univ Munich, Inst Pathol, D-80337 Munich, Germany; Med High Sch Minsk, Chair Oncol, Minsk, BELARUS; Univ Munich, Inst Radiat Biol, Munich, Germany	University of Munich; University of Munich	Rabes, HM (corresponding author), Univ Munich, Inst Pathol, Thalkirchner Str 36, D-80337 Munich, Germany.							BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; BONGARZONE I, 1997, IN PRESS GENOMICS; Fugazzola L, 1996, ONCOGENE, V13, P1093; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1996, ONCOGENE, V13, P1099; Klugbauer S, 1995, ONCOGENE, V11, P2459; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; Nikiforov YE, 1997, CANCER RES, V57, P1690; RABES HM, 1997, IN PRESS VERH DTSCH; RUDIGER NS, 1995, NUCLEIC ACIDS RES, V23, P256, DOI 10.1093/nar/23.2.256; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; TSUZUKI T, 1995, ONCOGENE, V10, P191	16	58	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	1998	16	5					671	675		10.1038/sj.onc.1201526	http://dx.doi.org/10.1038/sj.onc.1201526			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482114				2022-12-25	WOS:000071816600013
J	Bevans, CG; Kordel, M; Rhee, SK; Harris, AL				Bevans, CG; Kordel, M; Rhee, SK; Harris, AL			Isoform composition of connexin channels determines selectivity among second messengers and uncharged molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION CHANNELS; MARIE-TOOTH DISEASE; CROSS-LINKING; HORIZONTAL CELLS; HELA-CELLS; UNITARY CONDUCTANCE; XENOPUS-OOCYTES; LIPID BILAYERS; RAT-LIVER; PROTEINS	Intercellular connexin channels (gap junction channels) have long been thought to mediate molecular signaling between cells, but the nature of the signaling has been unclear. This study shows that connexin channels from native tissue have selective permeabilities, partially based on pore diameter, that discriminate among cytoplasmic second messenger molecules, Permeability was assessed by measurement of selective loss/retention of tracers from liposomes containing reconstituted connexin channels. The tracers employed were tritiated cyclic nucleotides and a series of oligomaltosaccharides derivatized with a small uncharged fluorescent moiety, The data define different size cut-off limits for permeability through homomeric connexin-32 channels and through heteromeric connexin-32/connexin-26 channels, Connexin-26 contributes to a narrowed pore, Both cAMP and cGMP were permeable through the homomeric connexin-32 channels. cAMP was permeable through only a fraction of the heteromeric channels, Surprisingly, cGMP was permeable through a substantially greater fraction of the heteromeric channels than was cAMP. The data suggest that isoform stoichiometry and/or arrangement within a connexin channel determines whether cyclic nucleotides can permeate, and which ones, This is the first evidence for connexin-specific selectivity among biological signaling molecules.	Johns Hopkins Univ, Thomas C Jenkins Dept Biophys, Baltimore, MD 21218 USA; Gesell Biotechnol Forsch mbH, Dept Enzyme Technol, D-38124 Braunschweig, Germany; Yeungnam Univ, Dept Biochem, Kyongsan 712749, South Korea	Johns Hopkins University; Gesellschaft fur Biotechnologische Forschung mbH; Yeungnam University	Harris, AL (corresponding author), Johns Hopkins Univ, Thomas C Jenkins Dept Biophys, Baltimore, MD 21218 USA.		Bevans, Carville/C-6651-2009	Bevans, Carville/0000-0001-7389-2124; Harris, Andrew/0000-0002-3782-0550	NIGMS NIH HHS [GM36044] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036044] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TS, 1983, J CELL BIOL, V96, P204, DOI 10.1083/jcb.96.1.204; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; Bevans C. G., 1995, Biophysical Journal, V68, pA204; Bevans C. G., 1995, Molecular Biology of the Cell, V6, p190A; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; Brink PR, 1997, AM J PHYSIOL-CELL PH, V273, pC1386, DOI 10.1152/ajpcell.1997.273.4.C1386; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; BUEHLER LK, 1995, BIOPHYS J, V68, P1767, DOI 10.1016/S0006-3495(95)80353-X; BUKAUSKAS FF, 1995, BIOPHYS J, V68, P2289, DOI 10.1016/S0006-3495(95)80411-X; BUKAUSKAS FF, 1995, PFLUG ARCH EUR J PHY, V429, P870, DOI 10.1007/BF00374812; Cao F., 1994, Molecular Biology of the Cell, V5, p198A; CASCIO M, 1995, J BIOL CHEM, V270, P18643, DOI 10.1074/jbc.270.31.18643; Chanson M., 1994, Journal of Physiology (Cambridge), V479P, p117P; CHEN YH, 1996, AM J PHYSIOL, V39, pC276; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; Donaldson P, 1997, HISTOL HISTOPATHOL, V12, P219; DOWNER NW, 1985, BIOPHYS J, V47, P285, DOI 10.1016/S0006-3495(85)83918-7; EBIHARA L, 1995, BIOPHYS J, V68, P1796, DOI 10.1016/S0006-3495(95)80356-5; EBIHARA L, 1993, J GEN PHYSIOL, V102, P59, DOI 10.1085/jgp.102.1.59; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; EHIHARA L, 1996, BIOPHYS J, V71, P742; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; FALLON RF, 1981, J CELL BIOL, V90, P521, DOI 10.1083/jcb.90.2.521; FRENCH AD, 1979, BAKERS DIG, V53, P39; FRENCH AD, 1978, J JPN SOC STARCH SCI, V25, P171, DOI 10.5458/jag1972.25.171; Ghosh S., 1995, Molecular Biology of the Cell, V6, p189A; Gingalewski C, 1996, J CELL PHYSIOL, V166, P461; GOLDIN SM, 1978, J BIOL CHEM, V253, P2575; GOLIGER JA, 1994, DEV DYNAM, V200, P1, DOI 10.1002/aja.1002000102; GOODENOU.DA, 1974, J CELL BIOL, V61, P557, DOI 10.1083/jcb.61.2.557; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; GUPTA VK, 1994, INVEST OPHTH VIS SCI, V35, P3747; HARRIS AL, 1989, J MEMBRANE BIOL, V109, P243, DOI 10.1007/BF01870281; HARRIS RM, 1992, DATABASE, V15, P69; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HENNEMANN H, 1992, EUR J CELL BIOL, V58, P81; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; HOGER JH, 1985, J BIOL CHEM, V260, P6932; JANSSENTIMMEN U, 1986, CARCINOGENESIS, V7, P1475, DOI 10.1093/carcin/7.9.1475; JEFFREY GA, 1978, MOL STRUCTURE DIFFRA, P183; Jiang JX, 1996, P NATL ACAD SCI USA, V93, P1287, DOI 10.1073/pnas.93.3.1287; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KORDEL M, 1993, BIOPHYS J, V64, pA192; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KURAOKA A, 1993, J HISTOCHEM CYTOCHEM, V41, P971, DOI 10.1177/41.7.8390496; KWAK BR, 1995, MOL BIOL CELL, V6, P1707, DOI 10.1091/mbc.6.12.1707; KWAK BR, 1995, PFLUG ARCH EUR J PHY, V430, P770, DOI 10.1007/BF00386175; LAWRENCE TS, 1978, NATURE, V272, P501, DOI 10.1038/272501a0; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; LUDWIG FR, 1985, EUR J BIOCHEM, V151, P83, DOI 10.1111/j.1432-1033.1985.tb09071.x; MAKOWSKI L, 1977, J CELL BIOL, V74, P629, DOI 10.1083/jcb.74.2.629; MAKOWSKI L, 1984, J MOL BIOL, V174, P449, DOI 10.1016/0022-2836(84)90331-0; MALCHOW RP, 1993, J NEUROSCI RES, V35, P237, DOI 10.1002/jnr.490350303; MESNIL M, 1995, CANCER RES, V55, P629; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MORENO AP, 1992, BIOPHYS J, V62, P51, DOI 10.1016/S0006-3495(92)81775-7; MORENO AP, 1994, BIOPHYS J, V67, P113, DOI 10.1016/S0006-3495(94)80460-6; MURRAY SA, 1984, J CELL BIOL, V98, P1710, DOI 10.1083/jcb.98.5.1710; NEVEU MJ, 1994, J CELL SCI, V107, P83; NEVEU MJ, 1994, MOL CARCINOGEN, V11, P145, DOI 10.1002/mc.2940110305; NICHOLSON B, 1987, NATURE, V329, P732, DOI 10.1038/329732a0; NICHOLSON BJ, 1988, MODERN CELL BIOL, V7, P207; Oh S, 1997, NEURON, V19, P927, DOI 10.1016/S0896-6273(00)80973-3; OLLIVON M, 1986, ANAL BIOCHEM, V152, P262, DOI 10.1016/0003-2697(86)90408-2; PAUL DL, 1995, CURR OPIN CELL BIOL, V7, P665, DOI 10.1016/0955-0674(95)80108-1; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; PERICAKVANCE MA, 1995, HUM HERED, V45, P121, DOI 10.1159/000154272; Perkins G, 1997, BIOPHYS J, V72, P533, DOI 10.1016/S0006-3495(97)78693-4; PICCOLINO M, 1984, J NEUROSCI, V4, P2477; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; RISEK B, 1995, J CELL SCI, V108, P1017; RIVKIN RB, 1981, LIMNOL OCEANOGR, V26, P780, DOI 10.4319/lo.1981.26.4.0780; SOSINSKY G, 1995, P NATL ACAD SCI USA, V92, P9210, DOI 10.1073/pnas.92.20.9210; SOUMARMON A, 1986, BIOCHIM BIOPHYS ACTA, V860, P109, DOI 10.1016/0005-2736(86)90504-3; Spray David C., 1994, P195; STAROS JV, 1989, METHOD ENZYMOL, V172, P609; STAUFFER KA, 1995, J BIOL CHEM, V270, P6768; Suchyna Thomas M., 1994, Molecular Biology of the Cell, V5, p199A; TAKENSKWAK BR, 1992, PFLUG ARCH EUR J PHY, V422, P198, DOI 10.1007/BF00370421; Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039; Trexler EB, 1996, P NATL ACAD SCI USA, V93, P5836, DOI 10.1073/pnas.93.12.5836; Unger VM, 1997, NAT STRUCT BIOL, V4, P39, DOI 10.1038/nsb0197-39; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; VEENSTRA RD, 1995, CIRC RES, V77, P1156, DOI 10.1161/01.RES.77.6.1156; Veenstra RD, 1996, BIOPHYS J, V70, P1082, DOI 10.1016/S0006-3495(96)79654-6; Veenstra RD, 1996, J BIOENERG BIOMEMBR, V28, P327, DOI 10.1007/BF02110109; VEENSTRA RD, 1994, CIRC RES, V75, P483, DOI 10.1161/01.RES.75.3.483; White TW, 1996, J BIOENERG BIOMEMBR, V28, P339, DOI 10.1007/BF02110110; WILCOX MD, 1992, BIOCHEMISTRY-US, V31, P10458, DOI 10.1021/bi00158a007; Yamasaki H, 1995, MUTAT RES-FUND MOL M, V333, P181, DOI 10.1016/0027-5107(95)00144-1; ZAMBROWICZ EB, 1993, BIOPHYS J, V65, P1093, DOI 10.1016/S0006-3495(93)81148-2; ZHANG JT, 1994, J MEMBRANE BIOL, V139, P15; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391; Zhou XW, 1997, BIOPHYS J, V72, P1946, DOI 10.1016/S0006-3495(97)78840-4	98	255	266	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2808	2816		10.1074/jbc.273.5.2808	http://dx.doi.org/10.1074/jbc.273.5.2808			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446589	hybrid			2022-12-25	WOS:000071736600044
J	Meyer, SC; Sanan, DA; Fox, JEB				Meyer, SC; Sanan, DA; Fox, JEB			Role of actin-binding protein in insertion of adhesion receptors into the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IB-IX COMPLEX; DYSTROPHIN-ASSOCIATED PROTEINS; 4.1(-) HEREDITARY ELLIPTOCYTOSIS; PLATELET GLYCOPROTEIN-IB; VON-WILLEBRAND-FACTOR; GLYCOPHORIN-C; CYTOPLASMIC DOMAIN; ERYTHROCYTE-MEMBRANE; MUSCULAR-DYSTROPHIES; EXTRACELLULAR-MATRIX	The goal of this study was to determine whether actin-binding protein (ABP) regulates membrane composition, ABP-deficient and ABP-containing cells were transfected with the cDNAs coding for glycoprotein (GP) Ib-IX, a platelet receptor that interacts with ABP, Most of the GP Ib-IX remained inside the ABP-deficient cells, When ABP was present, functional GP Ib-IX was inserted into the membrane, GP Ib-IX lacking the domain that interacts with ABP also showed increased membrane insertion in ABP-expressing cells. Furthermore, a fragment of ABP that lacks the dimerization and GP Ib-IX-binding sites restored the spreading of the cells and increased the amount of GP Ib-IX in the membrane, Finally, expression of ABP also increased endogenous beta(1) integrin in the membrane, These results indicate that 1) ABP maintains the properties of the cell such that adhesion receptors can be efficiently expressed in the membrane; 2) increased receptor expression is accompanied by increased ability of the cell to spread; and 3) ABP exerts its effect by a mechanism that does not appear to involve direct cross-linking of actin filaments or direct interaction with receptors.	Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol FF 20, Cleveland, OH 44195 USA; Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA	Cleveland Clinic Foundation; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; The J David Gladstone Institutes	Fox, JEB (corresponding author), Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol FF 20, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030657, R37HL030657, R23HL030657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AAKHUS AM, 1992, THROMB HAEMOSTASIS, V67, P252; ALLOISIO N, 1993, BLOOD, V82, P1323, DOI 10.1182/blood.V82.4.1323.bloodjournal8241323; ALLOISIO N, 1985, BIOCHIM BIOPHYS ACTA, V816, P57, DOI 10.1016/0005-2736(85)90392-X; ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BERNDT MC, 1984, PROG HEMOST THROMB, V7, P111; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; MATSUMURA K, 1993, FEBS LETT, V320, P276, DOI 10.1016/0014-5793(93)80602-Q; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MEYER S, 1993, J BIOL CHEM, V268, P20555; MEYER SC, 1995, J BIOL CHEM, V270, P14693, DOI 10.1074/jbc.270.24.14693; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; REID ME, 1990, BLOOD, V75, P2229; REID ME, 1989, RED CELL, P553; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SOLUM NO, 1983, BIOCHIM BIOPHYS ACTA, V729, P53, DOI 10.1016/0005-2736(83)90455-8; SONDAG D, 1987, BRIT J HAEMATOL, V65, P43, DOI 10.1111/j.1365-2141.1987.tb06133.x; STUPACK DG, 1991, SCAND J IMMUNOL, V34, P761, DOI 10.1111/j.1365-3083.1991.tb01601.x; TRUGLIA JA, 1981, BIOCHEM BIOPH RES CO, V100, P814, DOI 10.1016/S0006-291X(81)80247-1; VENEZIA ND, 1992, J CLIN INVEST, V90, P1713, DOI 10.1172/JCI116044; WEIHING RR, 1988, BIOCHEMISTRY-US, V27, P1865, DOI 10.1021/bi00406a011; ZHANG J, 1992, J BIOL CHEM, V267, P4686	48	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3013	3020		10.1074/jbc.273.5.3013	http://dx.doi.org/10.1074/jbc.273.5.3013			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446615	hybrid			2022-12-25	WOS:000071736600070
J	Colitti, CV; Rodabaugh, KJ; Welch, WR; Berkowitz, RS; Mok, SC				Colitti, CV; Rodabaugh, KJ; Welch, WR; Berkowitz, RS; Mok, SC			A novel 4 cM minimal deletion unit on chromosome 6q25.1-q25.2 associated with high grade invasive epithelial ovarian carcinomas	ONCOGENE			English	Article						ovary; cancer; loss of heterozygosity; chromosome 6	HUMAN BORDERLINE; BREAST-CANCER; FREQUENT LOSS; ALLELE LOSS; LONG ARM; HETEROZYGOSITY; 6Q; TUMORS; ALLELOTYPE; REGION	Detailed deletion mapping of chromosome 6q has shown that the highest percentage of loss of heterozygosity (LOH) is located at 6q25-q27 and suggested that an ovarian cancer associated tumor suppressor gene may reside in this region. To further define the smallest region of common loss, we used 12 tandem repeat markers spanning a region no more than 18 cM, located between 6q25.1 and 6q26, to examine allelic loss in 54 fresh and paraffin embedded invasive ovarian epithelial tumor tissues. Loss of heterozygosity was observed more frequently at the loci defined by marker D6S473 (14 of 32 informative cases, 44%) and marker D6S448 (17 of 40 informative cases, 43%). Detailed mapping of chromosome 6q25-q26 in these tumor samples identified a 4 cM minimal region of LOH between markers D6S473 and D6S448 (6q25.1-q25.2). Loss of heterozygosity at DGS473 correlated significantly both with serous versus non-serous ovarian tumors (P=0.040) and with high grade versus low grade specimens (P=0.023). The results suggest that a 4 chi deletion unit located at 6q25.1-q25.2 may contain the putative tumor suppressor gene which may play a role in the development and progression of human invasive epithelial ovarian carcinomas (IEOC).	Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mok, SC (corresponding author), Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA069291, R01CA069453, R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA69453, R01CA63381, R01CA69291] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CLIBY W, 1993, CANCER RES, V53, P2393; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooke IE, 1996, MAMM GENOME, V7, P157, DOI 10.1007/s003359900040; DEVILEE P, 1991, ONCOGENE, V6, P1705; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; EHLEN T, 1990, ONCOGENE, V5, P219; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; IWASE H, 1995, BRIT J CANCER, V71, P448, DOI 10.1038/bjc.1995.91; LEARY JA, 1993, INT J GYNECOL CANCER, V3, P293, DOI 10.1046/j.1525-1438.1993.03050293.x; LEE JH, 1990, CANCER RES, V50, P2724; Lee WC, 1996, CANCER RES, V56, P4297; MERLO A, 1994, CANCER RES, V54, P2322; MILLIKIN D, 1991, CANCER RES, V51, P5449; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SAITO S, 1992, CANCER RES, V52, P5815; SATO T, 1991, CANCER RES, V51, P5118; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; VOLZ A, 1994, GENOMICS, V21, P464, DOI 10.1006/geno.1994.1302; Wertheim I, 1996, ONCOGENE, V12, P2147; ZHENG JP, 1991, CANCER RES, V51, P4045	28	39	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					555	559		10.1038/sj.onc.1201523	http://dx.doi.org/10.1038/sj.onc.1201523			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484846				2022-12-25	WOS:000071739400015
J	Rampalli, AM; Gao, CY; Chauthaiwale, VM; Zelenka, PS				Rampalli, AM; Gao, CY; Chauthaiwale, VM; Zelenka, PS			pRb and p107 regulate E2F activity during lens fiber cell differentiation	ONCOGENE			English	Article						differentiation; cell cycle; tumor suppressors; lens; E2F; transcription factors	TRANSCRIPTION FACTOR E2F; B-MYB TRANSCRIPTION; RETINOBLASTOMA PROTEIN; CYCLE REGULATION; IN-VIVO; TRANSGENIC MICE; FACTOR DRTF1/E2F; GENE FAMILY; MOUSE LENS; EXPRESSION	During growth arrest and differentiation, activity of the E2F family of transcription factors is inhibited by interactions with pRb and the related proteins, p107 and p130. To determine which members of the E2F and pRb families may contribute to growth arrest as lens epithelial cells differentiate into fiber cells, we examined the expression of individual E2F species and characterized the E2F protein complexes formed in rat lens epithelia and fibers. RT/PCR detected all five known members of the E2F family in lens epithelial cells, but only E2F-1, E2F-3, and E2F-5 in fiber cells. Proteins extracted from lens epithelia of newborn rats formed at least two specific complexes with an E2F consensus oligonucleotide. Proteins from lens fiber cells formed three specific complexes, one of which comigrated with an epithelial cell complex. Incubation of epithelial and fiber cell extracts with an antibody specific for p107 demonstrated that two fiber cell complexes and one epithelial cell complex contained p107. Although the remaining fiber cell complex did not react with antibodies to pRb or p130 in this assay, a strong reaction with pRb antibody was observed when the electromobility shifted complexes were subsequently immunoblotted (shift/Western assay). Immunocytochemistry confirmed that pRb protein is present in the nuclei of both epithelial cells and fiber cells. Immunoblotting of whole cell extracts with pRb antibody showed multiple, phosphorylated forms of pRb in the epithelial cells, but predominantly hypophosphorylated pRb in the fiber cells. None of the complexes formed with E2F were recognized exclusively by the p130 antibody, although the previously identified p107 complexes reacted weakly. The absence of p130/E2F complexes was correlated with the presence of multiple ubiquitinated forms of p130, especially in the fiber cells. Thus, although p130/E2F complexes are implicated in the terminal differentiation of many cell types, in differentiating lens fiber cells pRb and p107 seem to be the primary regulators of E2F activity.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Zelenka, PS (corresponding author), NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA.							ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BASSNETT S, 1992, DEV DYNAM, V194, P85, DOI 10.1002/aja.1001940202; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CORBEIL HB, 1995, ONCOGENE, V11, P909; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRIDOVICHKEIL JL, 1993, CELL GROWTH DIFFER, V4, P679; Fromm L, 1996, ONCOGENE, V12, P69; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GAO CY, 1995, DEV BIOL, V169, P185, DOI 10.1006/dbio.1995.1136; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HEIBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERZINGER T, 1995, ONCOGENE, V10, P2079; HEY HY, 1997, IN PRESS DEV DYNAM; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; ITOH A, 1995, CELL MOL BIOL RES, V41, P147; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG HP, 1994, ONCOGENE, V9, P3397; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; KUWABARA T, 1974, INVEST OPHTH VISUAL, V13, P973; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PEARSON BE, 1991, MOL CELL BIOL, V11, P2181; PERSONS BJ, 1970, EXP EYE RES, V9, P144, DOI 10.1016/S0014-4835(70)80069-0; PIATIGORSKY J, 1992, ADV DEV BIOCH, V1, P211; RINAUDO JAS, 1992, EXP CELL RES, V199, P147, DOI 10.1016/0014-4827(92)90472-K; Sambrook J., 2002, MOL CLONING LAB MANU; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VRENSEN GFJM, 1991, EXP EYE RES, V52, P647, DOI 10.1016/0014-4835(91)90017-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wells JM, 1997, J BIOL CHEM, V272, P4483, DOI 10.1074/jbc.272.7.4483; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; ZHANG YH, 1995, ONCOGENE, V10, P2085; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	73	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					399	408		10.1038/sj.onc.1201546	http://dx.doi.org/10.1038/sj.onc.1201546			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467965				2022-12-25	WOS:000071582100012
J	Stoneley, M; Paulin, FEM; Le Quesne, JPC; Chappell, SA; Willis, AE				Stoneley, M; Paulin, FEM; Le Quesne, JPC; Chappell, SA; Willis, AE			C-Myc 5 ' untranslated region contains an internal ribosome entry segment	ONCOGENE			English	Article						internal ribosome entry segment (IRES); c-myc 5 ' UTR; internal initiation; translation	MESSENGER-RNA; TRANSLATIONAL CONTROL; BURKITT-LYMPHOMA; PROMOTER USAGE; INITIATION; GENE; CELLS; ONCOGENE; TRANSLOCATION; EFFICIENCY	Translation in eukaryotic cells is generally initiated by ribosome scanning from the 5' end of the capped mRNA. However, initiation of translation may also occur by a mechanism which is independent of the cap structure and in this case ribosomes are directed to the start codon by an internal ribosome entry segment (IRES). Picornaviruses represent the paradigm for this mechanism, but only a few examples exist which show that this mechanism is used by eukaryotic cells. In this report we show data which demonstrate that the 5' UTR of the proto-oncogene c-myc contains an IRES. When a dicistronic reporter vector, with c-myc 5' UTR inserted between the two cistrons, was transfected into both HepG2 and HeLa cells, the translation of the downstream cistron was increased by 50-fold, demonstrating that translational regulation of c-myc is mediated through cap-independent mechanisms. This is the first example of a proto-oncogene regulated in this manner and suggests that aberrant translational regulation of c-myc is likely to play a role in tumorigenesis.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Le Quesne, John/0000-0003-3552-7446; Willis, Anne/0000-0002-1470-8531				AUSUBEL RM, 1987, CURRENT PROTOCOLS MO; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BORMAN A, 1992, VIROLOGY, V188, P685, DOI 10.1016/0042-6822(92)90523-R; BORMAN AM, 1995, NUCLEIC ACIDS RES, V23, P3656, DOI 10.1093/nar/23.18.3656; BUTNICK NZ, 1985, MOL CELL BIOL, V5, P3009, DOI 10.1128/MCB.5.11.3009; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; GRAY NK, 1994, MOL BIOL REP, V19, P195, DOI 10.1007/BF00986961; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Jackson RJ, 1995, CURR TOP MICROBIOL, V203, P1; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; Jackson RJ, 1995, RNA, V1, P985; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; NILSEN TW, 1984, MOL CELL BIOL, V4, P2235, DOI 10.1128/MCB.4.10.2235; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; Paulin FEM, 1996, ONCOGENE, V13, P505; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; West MJ, 1995, ONCOGENE, V11, P2515; WINNEPENNINCKX B, 1995, BIOTECHNIQUES, V18, P1060; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; ZUKER M, 1989, METHOD ENZYMOL, P262	30	281	300	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					423	428		10.1038/sj.onc.1201763	http://dx.doi.org/10.1038/sj.onc.1201763			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467968				2022-12-25	WOS:000071582100015
J	Wiggan, O; Taniguchi-Sidle, A; Hamel, PA				Wiggan, O; Taniguchi-Sidle, A; Hamel, PA			Interaction of the pRB-family proteins with factors containing paired-like homeodomains	ONCOGENE			English	Article						mhox; paired-like homeodomain; PGX-3; pRB	EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTION FACTOR E2F; C-MET RECEPTOR; RETINOBLASTOMA PROTEIN; TYROSINE KINASE; DNA-BINDING; HUMAN PAPILLOMAVIRUSES; TERMINAL SEQUENCES; CRYSTAL-STRUCTURE; GENE-EXPRESSION	The specific loss of pRB or p107 together with p130 disrupts the normal development of only a very limited spectrum of tissues. These developmental defects have been attributed primarily to deregulation of E2F activity and consequent uncontrolled proliferation. We hypothesized, however, that the tissue-specific nature of these defects may also reflect deregulation of pRB-family associated factors that are specifically involved in determining cell fate. We report here that the pRB-family members interact with transcription factors which contain paired-like homeodomains such as MHox, Chx10 and Pax-3. The interaction between the pRB-family and the paired-like homeodomain proteins was initially identified in a yeast two-hybrid screen where the N-terminal portion of p130 was used to isolate interacting factors from an embryonic mouse library. This interaction was confirmed by in vitro binding and co-immunoprecipitation assays. We show further that coexpression of Pax-3 dependent pRB, p107 or p130 with Pax-3 causes repression of activated transcription from the c-met promoter. These data demonstrate that the pRB-family proteins can modulate the activity of factors which specifically control cell fate and/or differentiation as well as controlling cell cycle regulators.	Univ Toronto, Dept Pathol, Toronto, ON M5S 1A8, Canada	University of Toronto	Hamel, PA (corresponding author), Univ Toronto, Dept Pathol, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.							BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BUCK V, 1995, ONCOGENE, V11, P31; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; CHALEPAKIS G, 1994, NUCLEIC ACIDS RES, V22, P3131, DOI 10.1093/nar/22.15.3131; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CORBEIL HB, 1995, ONCOGENE, V11, P909; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; Daston G, 1996, DEVELOPMENT, V122, P1017; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; ERNST H, 1991, MOL CELL BIOL, V11, P3735, DOI 10.1128/MCB.11.7.3735; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWLEY PM, 1991, COLD SPRING HARB SYM, V56, P149; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; HUNT T, 1989, NATURE, V342, P483, DOI 10.1038/342483a0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; PRUITT SC, 1992, DEVELOPMENT, V116, P573; Rao MV, 1996, MOL CELL BIOL, V16, P3909; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SHERR C, 1996, 12 ANN M ONC FRED MA; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; SLACK RS, 1993, ONCOGENE, V8, P1585; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Yang XM, 1996, DEVELOPMENT, V122, P2163; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZHAO GQ, 1993, P NATL ACAD SCI USA, V90, P8633, DOI 10.1073/pnas.90.18.8633	85	69	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					227	236		10.1038/sj.onc.1201534	http://dx.doi.org/10.1038/sj.onc.1201534			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464541	Green Published			2022-12-25	WOS:000071427100010
J	Dahia, PLM; Aguiar, RCT; Honegger, J; Fahlbush, R; Jordan, S; Lowe, DG; Lu, X; Clayton, R; Besser, GM; Grossman, AB				Dahia, PLM; Aguiar, RCT; Honegger, J; Fahlbush, R; Jordan, S; Lowe, DG; Lu, X; Clayton, R; Besser, GM; Grossman, AB			Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours	ONCOGENE			English	Article						Cushing's disease; ACTH-tumour; p27-kip1; mutation; carcinoid; cell cycle inhibitor; pituitary tumour	DEPENDENT KINASE INHIBITOR; HUMAN PITUITARY-TUMORS; GROWTH-FACTOR-BETA; RETINOBLASTOMA GENE; P27(KIP1) GENE; CDK INHIBITOR; MICE LACKING; CELL-CYCLE; P27; G1	The molecular mechanisms leading to Cushing's disease are unclear, Inhibitors of cyclin-cyclin dependent kinase (CDK) complexes are regulators of the cell cycle and may function as tumour suppressor genes, many of which have been involved in the pathogenesis of several human malignancies, A member of this family, the p27/kip1 gene, maps to chromosome 12p13 and encodes an inhibitor of several cyclin-CDK complexes; these control the progression of the cell cycle from G1 to S-phase, Complete lack of p27/kip1 function, as occurs in the p27/kip1 'knockout' mouse, produces a complex phenotype associated with the development of pituitary tumours, specifically those of the intermediate lobe corticotrophs, We therefore investigated whether structural and functional abnormalities of the p27/kip1 gene and loss at the chromosome 12p13 region were present in human corticotrophin (ACTH)-secreting pituitary tumours, We studied 21 pituitary tumours, of which 20 were ACTH-secreting (two of these had biochemical and histological features of 'intermediate-lobe' tumours and one was malignant) while the remaining tumour was a prolactinoma; three ectopic secretors of ACTH (two bronchial and one thymic carcinoid); and a non-secretory thymic carcinoid, The whole coding region of the p27/kip1 gene was screened for mutations by PGR-SSCP analysis and/or direct sequencing, while tumour mRNA expression was analysed by means of a semi-quantitative duplex PGR, Three polymorphic microsatellite markers of the 12p13 region were used to assess loss of heterozygosity (LOH) in 12 samples, Finally, tumour p27/kip1 protein expression was assessed by immunohistochemistry using a monoclonal antibody in 12 samples suitable for analysis, No sequence abnormalities were found in any of the samples other than a previously-described polymorphism, No LOH was observed in the tumours analysed, p27/kip1 mRNA expression was similar in tumour samples in comparison with normal pituitaries, Seven of the eight corticotroph tumours analysed by immunohistochemistry stained positive for p27/kip1, including the intermediate lobe, The only malignant pituitary tumour in the original series showed an absence of staining for p27/kip1, In addition, the three carcinoid tumours studied were negative on immunohistochemistry. Of a further three malignant pituitary tumours assessed, two (including a prolactinoma) were essentially negative, while the third was moderately positive, We conclude that mutations of the p27/kip1 gene, deletions of the 12p13 area or changes in expression, are not a general feature of corticotroph tumours, even those with intermediate lobe characteristics, However, other mechanisms of p27/kip1 inactivation, such as an abnormality at the post-translational level, may be related to more aggressive histological subtypes of ACTH-secreting and possibly other pituitary tumours.	St Bartholomews Hosp, Dept Endocrinol, London, England; St Bartholomews Hosp, Dept Pathol, London, England; Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA; Univ Erlangen Nurnberg, Neurochirurg Klin, D-8520 Erlangen, Germany; St Marys Hosp, Ludwig Inst Canc Res, London, England; Univ Keele, Postgrad Med Sch, Dept Med, Stoke On Trent, Staffs, England	University of London; Queen Mary University London; University of London; Queen Mary University London; Harvard University; Dana-Farber Cancer Institute; University of Erlangen Nuremberg; Imperial College London; Ludwig Institute for Cancer Research; Keele University	Grossman, AB (corresponding author), St Bartholomews Hosp, Dept Endocrinol, London, England.			Lu, Xin/0000-0002-6587-1152				BATES AS, 1995, CLIN ENDOCRINOL, V42, P663, DOI 10.1111/j.1365-2265.1995.tb02697.x; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CRYNS VL, 1993, J CLIN ENDOCR METAB, V77, P644, DOI 10.1210/jc.77.3.644; Dahia PLM, 1996, J CLIN ENDOCR METAB, V81, P1768, DOI 10.1210/jc.81.5.1768; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; HALE AC, 1988, CLIN ENDOCRINOL, V28, P215, DOI 10.1111/j.1365-2265.1988.tb03658.x; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERMAN V, 1993, J CLIN ENDOCR METAB, V77, P50, DOI 10.1210/jc.77.1.50; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LEVY A, 1994, CLIN ENDOCRINOL, V41, P809, DOI 10.1111/j.1365-2265.1994.tb02797.x; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lloyd RV, 1997, AM J PATHOL, V150, P401; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NORTON AJ, 1994, J PATHOL, V173, P371, DOI 10.1002/path.1711730413; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Qian X, 1996, ENDOCRINOLOGY, V137, P3051, DOI 10.1210/en.137.7.3051; Ravitz MJ, 1996, J CELL PHYSIOL, V168, P510, DOI 10.1002/(SICI)1097-4652(199609)168:3<510::AID-JCP3>3.0.CO;2-S; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Spirin KS, 1996, CANCER RES, V56, P2400; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Woloschak M, 1996, INT J CANCER, V67, P16, DOI 10.1002/(SICI)1097-0215(19960703)67:1<16::AID-IJC4>3.0.CO;2-2	34	91	98	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					69	76		10.1038/sj.onc.1201516	http://dx.doi.org/10.1038/sj.onc.1201516			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467944				2022-12-25	WOS:000071236800008
J	De Reggi, M; Gharib, B; Patard, L; Stoven, V				De Reggi, M; Gharib, B; Patard, L; Stoven, V			Lithostathine, the presumed pancreatic stone inhibitor, does not interact specifically with calcium carbonate crystals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC CALCIFYING PANCREATITIS; AMINO-ACID SEQUENCE; REG PROTEIN; LIQUID-CHROMATOGRAPHY; REGENERATING GENE; THREAD PROTEIN; MESSENGER-RNA; EXPRESSION; PRODUCT; GROWTH	Lithostathine (pancreatic stone protein, Peg protein) is, in addition to albumin, the major nonenzymatic protein of the pancreatic juice. It has been assumed to inhibit calcium carbonate precipitation and therefore to prevent stone formation in the pancreatic ducts. This function is, however, debatable, The assumption is based on the inhibition of in vitro crystal nucleation and growth by lithostathine, Considering that these phenomena occur only under certain critical conditions, we re-examined the question using a protein preparation where the purity and folding have been tested by mass spectroscopy and NMR in the absence of nonprotein contaminants, Under these conditions, we showed conclusively that lithostathine does not inhibit calcium carbonate nucleation and crystal growth, We demonstrated that previous findings on the alleged inhibition can be attributed to the uncontrolled presence of salts in the protein preparation used, Moreover, the affinity of lithostathine to calcite crystals, expressed as the half-life of bound iodinated protein in the presence of unlabeled competitor, was significantly lower than that of bovine serum albumin (8.8 and 11.2 h, respectively). Using glass microspheres instead of crystals did not significantly change the half-life of bound lithostathine (8.0 h), These findings are incompatible with the hypothesis of a specific interaction of lithostathine with calcium carbonate crystals, In conclusion, considering that components of pancreatic juice such as NaCl and phosphate ions are powerful inhibitors of calcium carbonate crystal growth, the mechanism of stone formation in pancreatic ducts must be reconsidered, The presence in normal pancreatic juice of small amounts of the 133-residue isoform of lithostathine (PSP-S-1), which precipitates at physiological pH, should be noted, and the possibility should be considered that they form micro-precipitates that aggregate and are progressively calcified.	INSERM, U399, F-13385 Marseille 5, France; Ecole Polytech, CNRS, URA 1308, Synth Organ Lab,Lab Resonance Magnet Nucl, F-91128 Palaiseau, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris	De Reggi, M (corresponding author), INSERM, U399, 27 Blvd Jean Moulin, F-13385 Marseille 5, France.							BACHRA BN, 1963, ARCH BIOCHEM BIOPHYS, V103, P124, DOI 10.1016/0003-9861(63)90018-3; Baeza N, 1996, DIABETES METAB, V22, P229; BARTOLI C, 1993, FEBS LETT, V327, P289, DOI 10.1016/0014-5793(93)81006-L; BERNARD JP, 1995, GUT, V36, P630, DOI 10.1136/gut.36.4.630; BERNARD JP, 1992, GASTROENTEROLOGY, V103, P1277, DOI 10.1016/0016-5085(92)91516-7; Bertrand JA, 1996, EMBO J, V15, P2678, DOI 10.1002/j.1460-2075.1996.tb00628.x; Bimmler D, 1997, J BIOL CHEM, V272, P3073, DOI 10.1074/jbc.272.5.3073; *CIB GEIG, 1985, GEIG SCI TABL, P662; DECARO A, 1979, BIOCHEM BIOPH RES CO, V87, P1176, DOI 10.1016/S0006-291X(79)80031-5; DECARO AM, 1987, EUR J BIOCHEM, V168, P201; DEREGGI M, 1995, EUR J BIOCHEM, V230, P503; FredjReygrobellet D, 1996, OPHTHALMIC RES, V28, P130, DOI 10.1159/000267885; Geider S, 1996, J BIOL CHEM, V271, P26302, DOI 10.1074/jbc.271.42.26302; HANEIN D, 1993, LANGMUIR, V9, P1058, DOI 10.1021/la00028a030; HAY DI, 1986, CALCIFIED TISSUE INT, V39, P151, DOI 10.1007/BF02555111; KIMURA N, 1992, CANCER, V70, P1857, DOI 10.1002/1097-0142(19921001)70:7<1857::AID-CNCR2820700708>3.0.CO;2-8; MARIANI A, 1995, GUT, V36, P622, DOI 10.1136/gut.36.4.622; MONTALTO G, 1986, BIOCHEM J, V238, P227, DOI 10.1042/bj2380227; Moriscot C, 1996, PEDIATR RES, V39, P349, DOI 10.1203/00006450-199602000-00026; OKIDO M, 1992, HEPATOLOGY, V15, P1079, DOI 10.1002/hep.1840150618; Patard L, 1996, PROTEIN ENG, V9, P949, DOI 10.1093/protein/9.11.949; PERFETTI R, 1994, TRANSPLANT P, V26, P733; ROUQUIER S, 1991, J BIOL CHEM, V266, P786; SARLES H, 1992, B ACAD NAT MED PARIS, V176, P153; SARLES H, 1974, GASTROENTEROLOGY, V66, P604, DOI 10.1016/s0016-5085(74)80050-8; SOKAL RR, 1981, BIOMETRY, P454; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; WATANABE T, 1990, J BIOL CHEM, V265, P7432; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; Zenilman ME, 1996, SURGERY, V119, P576, DOI 10.1016/S0039-6060(96)80270-4; Zenilman ME, 1996, GASTROENTEROLOGY, V110, P1208, DOI 10.1053/gast.1996.v110.pm8613011	31	32	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4967	4971		10.1074/jbc.273.9.4967	http://dx.doi.org/10.1074/jbc.273.9.4967			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478942	hybrid			2022-12-25	WOS:000072310400026
J	Genestier, L; Prigent, AF; Paillot, R; Quemeneur, L; Durand, I; Banchereau, J; Revillard, JP; Bonnefoy-Berard, N				Genestier, L; Prigent, AF; Paillot, R; Quemeneur, L; Durand, I; Banchereau, J; Revillard, JP; Bonnefoy-Berard, N			Caspase-dependent ceramide production in Fas- and HLA class I-mediated peripheral T cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RESONANCE ENERGY-TRANSFER; ICE-LIKE PROTEASE; ICE/CED-3 PROTEASE; PHOSPHOLIPASE-C; RECEPTOR SUPERFAMILY; MOLECULAR-CLONING; SURFACE ANTIGEN; DEATH; PATHWAY	We recently demonstrated that the engagement of HLA class I alpha 1 domain induced Fas-independent apoptosis in human T and B lymphocytes. We analyzed the signaling pathway involved in HLA class I-mediated apoptosis in comparison with Fas (APO-1, CD95)-dependent apoptosis. The mouse mAb90 or the rat YTH862 monoclonal antibodies which bind the human HLA class I alpha 1 domain induced the production of ceramide which was blocked by addition of the phosphatidylcholine-dependent phospholipase C inhibitor, D609. Furthermore, HLA class I-mediated apoptosis involved at least two different caspases, an interleukin-1 converting enzyme-like protease and another protease inhibited by the CPP32-like protease inhibitor Ac-DEVD-CHO. Despite similarity between Fas and HLA class I signaling pathways, we failed to demonstrate any physical association between these two molecules. We also report that the pan-caspase inhibitory peptide zVAD-fmk, but not Ac-DEVD-CHO and Ac-YVAD-CHO, inhibited decrease of mitochondrial transmembrane potential and generation of ceramide induced by anti-HLA class I and anti-Fas monoclonal antibodies, whereas all three peptides efficiently inhibited apoptosis. Altogether these results suggest that signaling through Fas and HLA class I involve caspase(s), targeted by zVAD-fmk, which act upstream of ceramide generation and mitochondrial events, whereas interleukin-1 converting enzyme-like and CPP32-like proteases act downstream of the mitochondria.	Hop Edouard Herriot, INSERM, Immunol Lab, U80,UCBL, F-69437 Lyon, France; Inst Natl Sci Appl Lyon, Lab Biochem & Pharmacol, U352, INSERM, F-69621 Villeurbanne, France; Schering Plough, Lab Immunol Res, F-69571 Dardilly, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; Merck & Company	Bonnefoy-Berard, N (corresponding author), Hop Edouard Herriot, INSERM, Immunol Lab, U80,UCBL, F-69437 Lyon, France.	bonnefoy@inserm.lyon151.fr	Bonnefoy, Nathalie/J-2536-2012; Genestier, Laurent/H-6443-2016	Bonnefoy, Nathalie/0000-0003-4814-6722; Genestier, Laurent/0000-0002-0527-4583; PAILLOT, Romain/0000-0003-3081-2037				ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BEIER DC, 1994, J IMMUNOL, V152, P3862; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FOURNEL S, 1995, FEBS LETT, V367, P188, DOI 10.1016/0014-5793(95)00532-E; Genestier L, 1997, BLOOD, V90, P3629, DOI 10.1182/blood.V90.9.3629; Genestier L, 1997, BLOOD, V90, P726, DOI 10.1182/blood.V90.2.726.726_726_735; GORVEL JP, 1989, J CELL BIOL, V108, P2193, DOI 10.1083/jcb.108.6.2193; GOTTSCHALK AR, 1995, EUR J IMMUNOL, V25, P1032, DOI 10.1002/eji.1830250426; GRIBBEN JG, 1995, P NATL ACAD SCI USA, V92, P811, DOI 10.1073/pnas.92.3.811; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Klaus SJ, 1996, J IMMUNOL, V156, P2743; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Mollereau B, 1996, J IMMUNOL, V156, P3184; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OEHM A, 1992, J BIOL CHEM, V267, P10709; PENNINGTON MW, 1994, PEPTIDE RES, V7, P72; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; PREISS J, 1986, J BIOL CHEM, V261, P8597; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHOWRONSKI EW, 1996, CELL DEATH DIFFER, V3, P171; Skov S, 1997, J IMMUNOL, V158, P3189; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SZOLLOSI J, 1987, P NATL ACAD SCI USA, V84, P7246, DOI 10.1073/pnas.84.20.7246; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TSHERNING T, 1994, SCAND J IMMUNOL, V39, P117; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESSELBORG S, 1993, EUR J IMMUNOL, V23, P2707, DOI 10.1002/eji.1830231050; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WOODLE SE, 1997, J IMMUNOL, V158, P2156; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	57	64	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5060	5066		10.1074/jbc.273.9.5060	http://dx.doi.org/10.1074/jbc.273.9.5060			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478956	hybrid			2022-12-25	WOS:000072310400040
J	Nagai, T; Igarashi, K; Akasaka, J; Furuyama, K; Fujita, H; Hayashi, N; Yamamoto, M; Sassa, S				Nagai, T; Igarashi, K; Akasaka, J; Furuyama, K; Fujita, H; Hayashi, N; Yamamoto, M; Sassa, S			Regulation of NF-E2 activity in erythroleukemia cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NF-E2; PORPHOBILINOGEN DEAMINASE GENE; LEUCINE ZIPPER PROTEIN; SUBSTRATE RECOGNITION; ERYTHROID PROMOTER; EXPRESSION; KINASE; IDENTIFICATION; HEMATOPOIESIS; ACTIVATION	The erythroid transcription factor NF-ES is an obligate heterodimer composed of two different subunits (p45 and p18), each containing a basic region-leucine zipper DNA binding domain, and it plays a critical role in erythroid differentiation as an enhancer-binding protein for expression of the beta-globin gene. We show here that dimethyl sulfoxide treatment of wild-type murine erythroleukemia cells, but not a mutant clone of dimethyl sulfoxide-resistant cells, increases NF-E2 activity significantly, which involves both up-regulation of DNA binding and transactivation activities, Both activities were reduced markedly by treatment of cells with a-aminopurine but not by genistein, Activation of the Ras-Raf-MAP kinase signaling cascade increased NF-E2 activity significantly, but this was suppressed when MafK was overexpressed, Domain analysis revealed an activation domain in the NH2-terminal region of p45 and a suppression domain in the basic region-leucine zipper of MafK. These findings indicate that induction of NF-ES activity is essential for erythroid differentiation of murine erythroleukemia cells, and serine/threonine phosphorylation may be involved in this process. In addition, they also suggest that a MafK homodimer can suppress transcription, not only by competition for the DNA binding site, but also by direct inhibition of transcription, Hence, MafK may function as an active transcription repressor.	Rockefeller Univ, New York, NY 10021 USA; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan; Tohoku Univ, Sch Med, Sendai, Miyagi 980, Japan	Rockefeller University; University of Tsukuba; University of Tsukuba; Tohoku University	Sassa, S (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.		Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Furuyama, Kazumichi/0000-0002-1376-4080; Igarashi, Kazuhiko/0000-0002-2470-2475	NIDDK NIH HHS [DK32890] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032890] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHANG CS, 1982, J BIOL CHEM, V257, P3650; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; EISEN H, 1978, P277; FUJITA H, 1991, BIOCHIM BIOPHYS ACTA, V1090, P311, DOI 10.1016/0167-4781(91)90195-R; FUJITA H, 1991, J BIOL CHEM, V266, P17494; GARINGO AD, 1995, J BIOL CHEM, V270, P9169, DOI 10.1074/jbc.270.16.9169; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; IGARASHI K, 1995, J BIOL CHEM, V270, P7915; KISHI A, 1993, BIOCHEM BIOPH RES CO, V192, P1131, DOI 10.1006/bbrc.1993.1534; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LU SJ, 1995, CANCER RES, V55, P1139; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MEGURO K, 1995, BLOOD, V86, P940; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; OHTA Y, 1976, P NATL ACAD SCI USA, V73, P1232, DOI 10.1073/pnas.73.4.1232; SASSA S, 1983, REGULATION HEMOGLOBI, P359; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	32	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5358	5365		10.1074/jbc.273.9.5358	http://dx.doi.org/10.1074/jbc.273.9.5358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478996	hybrid			2022-12-25	WOS:000072310400080
J	Zhang, ZQ; Simons, AM; Prabhu, VP; Chen, JH				Zhang, ZQ; Simons, AM; Prabhu, VP; Chen, JH			Strand exchange protein 1 (Sep1) from Saccharomyces cerevisiae does not promote branch migration in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UVSX PROTEIN; RECA PROTEIN; IN-VITRO; DNA; RECOMBINATION; GENE; EXONUCLEASE; CELLS; XRN1; BETA	It has been shown in vitro that Saccharomyces cerevisiae strand exchange protein 1 (Sep1) promotes the transfer of one strand of a linear duplex DNA to a homologous single-stranded DNA circle, Sep1 also has an exonuclease active on DNA and RNA. By using exonuclease III-treated linear duplex DNA with various lengths of single-stranded tail as well as Ca2+ to inhibit the exonuclease activity of Sep1, we show that the processivity of exonuclease activity of Sep1 is greater than previously reported. The results in this work also demonstrate that the joint molecule between the linear duplex and single-stranded circle observed from the Sep1-promoted strand transfer reaction is just the pairing between the long single-stranded tail of the linear duplex DNA (generated by the exonuclease activity of Sep1) and the single-stranded circular DNA. When a synthetic Holliday junction was used as substrate, branch migration facilitated by Sep1 could not be detected. Finally, using electron microscopy no alpha-structure, a joint molecule with displaced single-stranded DNA tail that indicates branch migration could be observed. The results imply that Sep1 cannot promote branch migration in vitro. Further investigation is needed to determine the role of Sep1 in recombination in vivo.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	University of Delaware	Chen, JH (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.		Chen, Junghuei/B-5217-2011					BASHKIROV VI, 1995, CHROMOSOMA, V104, P215, DOI 10.1007/s004120050110; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; CHEN JH, 1994, GENE DEV, V8, P1356, DOI 10.1101/gad.8.11.1356; Davis R.W., 1971, METHODS ENZYMOL, V21, P413; DYKSTRA CC, 1991, MOL CELL BIOL, V11, P2583, DOI 10.1128/MCB.11.5.2583; DYKSTRA CC, 1990, J BIOL CHEM, V265, P10968; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; GRIFFITH J, 1985, J BIOL CHEM, V260, P4484; HEYER WD, 1988, J BIOL CHEM, V263, P15189; HEYER WD, 1995, MOL CELL BIOL, V15, P2728; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; INTERTHAL H, 1995, EMBO J, V14, P1057, DOI 10.1002/j.1460-2075.1995.tb07088.x; JOHNSON AW, 1994, J BIOL CHEM, V269, P3664; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; JOHNSON AW, 1994, J BIOL CHEM, V269, P3673; KASLIN E, 1994, J BIOL CHEM, V269, P14103; KASLIN E, 1994, J BIOL CHEM, V269, P14094; KERSEY S, 1991, TRENDS CELL BIOL, V1, P110; KIM JM, 1990, GENETICS, V126, P799; KIPLING D, 1991, NUCLEIC ACIDS RES, V19, P1385, DOI 10.1093/nar/19.7.1385; KMIEC EB, 1994, J BIOL CHEM, V269, P10163; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KOLODNER R, 1994, MOL MICROBIOL, V11, P23, DOI 10.1111/j.1365-2958.1994.tb00286.x; LARIMER FW, 1992, GENE, V120, P51, DOI 10.1016/0378-1119(92)90008-D; LAVERY PE, 1992, J BIOL CHEM, V267, P9307; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; MUNIYAPPA K, 1986, J BIOL CHEM, V261, P7472; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PEREZMORGA DL, 1993, NUCLEIC ACIDS RES, V21, P1327, DOI 10.1093/nar/21.5.1327; Sambrook J., 2002, MOL CLONING LAB MANU; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; STEVENS A, 1980, J BIOL CHEM, V255, P3080; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; TISHKOFF DX, 1995, GENETICS, V139, P495; YU X, 1993, J MOL BIOL, V232, P1, DOI 10.1006/jmbi.1993.1363	36	2	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4950	4956		10.1074/jbc.273.9.4950	http://dx.doi.org/10.1074/jbc.273.9.4950			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478940	Green Published, hybrid			2022-12-25	WOS:000072310400024
J	Frenkel, C; Peters, JS; Tieman, DM; Tiznado, ME; Handa, AK				Frenkel, C; Peters, JS; Tieman, DM; Tiznado, ME; Handa, AK			Pectin methylesterase regulates methanol and ethanol accumulation in ripening tomato (Lycopersicon esculentum) fruit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOL-DEHYDROGENASE; METHYL ESTERASE; EXPRESSION; GENE	We provide genetic evidence that the production of methanol in tomato fruit is regulated by pectin methylesterase (PME, EC 3.1.1.11), an enzyme that catalyzes demethoxylation of pectins, The role of PME in methanol production in tomato fruit was examined by relating the tissue methanol content to the PME enzymatic activity in wild-type Rutgers and isogenic PME antisense fruits with lowered PME activity, In the wild-type, fruit development and ripening were accompanied by an increase in the abundance of PME protein and activity and a corresponding ripening-related increase in methanol content, In the PME antisense pericarp, the level of methanol was greatly reduced in unripe fruit, and diminished methanol content persisted throughout the ripening process, The close correlation between PME activity and levels of methanol in fruit tissues from wildtype and a PME antisense mutant indicates that PME is the primary biosynthetic pathway for methanol production in tomato fruit, Interestingly, ethanol levels that were low and unchanged during ripening of wild-type tomatoes increased progressively with the ripening of PME antisense fruit, In vitro studies indicate that methanol is a competitive inhibitor of the tomato alcohol dehydrogenase (ADH, EC 1.1.1.1) activity suggesting that ADH-catalyzed production of ethanol may be arrested by methanol accumulation in the wild-type but not in the PME mutant where methanol levels remain low.	Rutgers State Univ, Dept Plant Sci, New Brunswick, NJ 08901 USA; Purdue Univ, Dept Hort, W Lafayette, IN 47907 USA	Rutgers State University New Brunswick; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Frenkel, C (corresponding author), Rutgers State Univ, Dept Plant Sci, 59 Dudley Rd, New Brunswick, NJ 08901 USA.							BICSAK TA, 1982, ARCH BIOCHEM BIOPHYS, V216, P605, DOI 10.1016/0003-9861(82)90250-8; BIGGS MS, 1989, PLANT PHYSIOL, V89, P117, DOI 10.1104/pp.89.1.117; DAVIES DD, 1980, BIOCH PLANTS COMPREH, V2, P581, DOI DOI 10.1016/B978-0-12-675402-5.50020-9; FISCHER RL, 1991, ANNU REV PLANT PHYS, V42, P675, DOI 10.1146/annurev.pp.42.060191.003331; GAFFE J, 1994, PLANT PHYSIOL, V105, P199, DOI 10.1104/pp.105.1.199; GOLDBERG R, 1984, PHYSIOL PLANTARUM, V61, P58, DOI 10.1111/j.1399-3054.1984.tb06100.x; HARRIMAN RW, 1991, PLANT PHYSIOL, V97, P80, DOI 10.1104/pp.97.1.80; KIMMERER TW, 1982, PLANT PHYSIOL, V69, P840, DOI 10.1104/pp.69.4.840; LONGHURST TJ, 1990, J FOOD BIOCHEM, V14, P421, DOI 10.1111/j.1745-4514.1990.tb00804.x; MOUSTACAS AM, 1986, EUR J BIOCHEM, V155, P191, DOI 10.1111/j.1432-1033.1986.tb09476.x; NEMECEKMARSHALL M, 1995, PLANT PHYSIOL, V108, P1359, DOI 10.1104/pp.108.4.1359; NURSTEN HE, 1967, CHEM IND-LONDON, P486; OBENDORF RL, 1990, J EXP BOT, V41, P489, DOI 10.1093/jxb/41.4.489; Sajjaanantakul T., 1991, CHEM TECHNOLOGY PECT, P135; TIEMAN DM, 1992, PLANT CELL, V4, P667, DOI 10.1105/tpc.4.6.667; TIEMAN DM, 1994, PLANT PHYSIOL, V106, P429, DOI 10.1104/pp.106.2.429; WOOD PJ, 1971, ANAL BIOCHEM, V39, P418, DOI 10.1016/0003-2697(71)90432-5	17	87	91	4	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4293	4295		10.1074/jbc.273.8.4293	http://dx.doi.org/10.1074/jbc.273.8.4293			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468474	hybrid			2022-12-25	WOS:000072115000002
J	Jacob, KK; Sap, J; Stanley, FM				Jacob, KK; Sap, J; Stanley, FM			Receptor-like protein-tyrosine phosphatase alpha specifically inhibits insulin-increased prolactin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; R-PTP-KAPPA; PHOSPHATIDYLINOSITOL 3-KINASE; RAS ACTIVATION; DOMAIN; SIGNAL; KINASE; PATHWAYS; GRB2; STIMULATION	A physiologically relevant response to insulin, stimulation of prolactin promoter activity in GH4 pituitary cells, was used as an assay to study the specificity of protein-tyrosine phosphatase function. Receptor-like protein-tyrosine phosphatase alpha (RPTP alpha) blocks the effect of insulin to increase prolactin gene expression but potentiates the effects of epidermal growth factor and cAMP on prolactin promoter activity. RPTP alpha was the only protein-tyrosine phosphatase tested that did this, Thus, the effect of RPTP alpha on prolactin-chloramphenicol acetyltransferase (CAT) promoter activity is specific by two criteria. A number of potential RPTP alpha targets were ruled out by finding (a) that they are not affected or (b) that they are not on the pathway to insulin-increased prolactin-CAT activity, The negative effect of RPTP alpha on insulin activation of the prolactin promoter is not due to reduced phosphorylation or kinase activity of the insulin receptor or to reduced phosphorylation of insulin. receptor substrate-1 or Shc. Inhibitor studies suggest that insulin-increased prolactin gene expression is mediated by a Ras-like GTPase but is not mitogen-activated protein kinase dependent. Experiments with inhibitors of phosphatidylinositol 3-kinase suggest that insulin-increased prolactin-CAT expression is phosphatidylinositol 3-kinase-independent. These results suggest that RPTP alpha may be a physiological regulator of insulin action.	NYU, Med Ctr, Dept Med, New York, NY 10016 USA; NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University; New York University	Stanley, FM (corresponding author), NYU, Med Ctr, Dept Med, TH 450,550 1st Ave, New York, NY 10016 USA.			Stanley, Frederick/0000-0002-3684-2168	NCI NIH HHS [R29CA68365] Funding Source: Medline; NIDDK NIH HHS [DK43365] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA068365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043365] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alarcon CM, 1996, GENE DEV, V10, P279, DOI 10.1101/gad.10.3.279; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BRUDER J, 1992, GENE DEV, V6, P546; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; GOLDSTEIN BJ, 1992, J CELL BIOCHEM, V48, P33, DOI 10.1002/jcb.240480107; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; IRANMANESH A, 1990, J CLIN ENDOCR METAB, V71, P73, DOI 10.1210/jcem-71-1-73; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; JACOB K, 1995, J BIOL CHEM, V270, P2773; JACOB KK, 1995, MOL CELL ENDOCRINOL, V109, P175, DOI 10.1016/0303-7207(95)03500-7; JACOB KK, 1994, J BIOL CHEM, V269, P25515; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Myers MG, 1996, MOL CELL BIOL, V16, P4147; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; PRAGER D, 1988, ENDOCRINOLOGY, V122, P2946, DOI 10.1210/endo-122-6-2946; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SAP J, 1994, MOL CELL BIOL, V14, P1; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STANLEY F, 1988, J BIOL CHEM, V263, P13444; STANLEY F, 1989, MOL ENDOCRINOL, V3, P1627, DOI 10.1210/mend-3-10-1627; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SU J, 1994, J BIOL CHEM, V269, P18731; TESONE M, 1985, MOL CELL ENDOCRINOL, V43, P135, DOI 10.1016/0303-7207(85)90076-0; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	50	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4800	4809		10.1074/jbc.273.8.4800	http://dx.doi.org/10.1074/jbc.273.8.4800			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468545	hybrid			2022-12-25	WOS:000072115000073
J	Lin, JC; Naujokas, M; Zhu, H; Nolet, S; Park, M				Lin, JC; Naujokas, M; Zhu, H; Nolet, S; Park, M			Intron-exon structure of the MET gene and cloning of an alternatively-spliced Met isoform reveals frequent exon-skipping of a single large internal exon	ONCOGENE			English	Article						MET receptor tyrosine kinase; genomic structure; alternative splicing; exon-skipping; hepatocyte growth factor receptor	HEPATOCYTE GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; TYROSINE KINASE RECEPTOR; C-MET; SCATTER FACTOR; PROTOONCOGENE PRODUCT; FACTOR/SCATTER FACTOR; HGF RECEPTOR; EXPRESSION; OVEREXPRESSION	Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional factor that stimulates epithelial cell mitogenesis, motility, invasion, and morphogenesis. Its receptor is encoded by the MET proto-oncogene, a transmembrane receptor tyrosine kinase. Several studies have suggested a role for MET as a dominant oncogene in tumor development and progression. Conversely, MET is located at a region on chromosome 7q31 frequently deleted in carcinomas, suggesting that recessive mutations in MET may exist in certain cancers. To facilitate a search for mutations in MET, we have obtained the intron-exon structure of the human MET gene. We present the genomic structure of the first member of the Met receptor family to be characterized. Interestingly, MET contains a large second exon of 1214 nucleotides. We show that this exon, containing the AUG for the Met receptor, is frequently skipped in normal human tissues and cell lines, and corresponds to a ubiquitously expressed 7 kb Met transcript. This transcript yields no detectable protein product in vivo. Thus, unlike other genes, in which alternative splicing often gives rise to proteins,vith distinct activities, exon-skipping of MET exon 2 is predicted to decrease the abundance of a Met mRNA encoding a functional Met receptor.	McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; McGill Univ, Dept Biochem, Montreal, PQ, Canada	McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Dept Med, Montreal, PQ, Canada.							BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIORDANO S, 1989, ONCOGENE, V4, P1983; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; JUCKER M, 1994, LEUKEMIA RES, V18, P7, DOI 10.1016/0145-2126(94)90003-5; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE CC, 1995, J BIOL CHEM, V270, P507, DOI 10.1074/jbc.270.2.507; Lin JC, 1996, ONCOGENE, V13, P2001; LIU C, 1992, ONCOGENE, V7, P181; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Maniatis T., 1992, MOL CLONING LAB MANU; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MOTOYAMA T, 1979, Acta Medica et Biologica, V27, P49; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PIAO XH, 1994, BLOOD, V83, P476; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1995, CANCER RES, V55, P1963; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RONSIN C, 1993, ONCOGENE, V8, P1195; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Scotlandi K, 1996, AM J PATHOL, V149, P1209; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Sterner DA, 1996, P NATL ACAD SCI USA, V93, P15081, DOI 10.1073/pnas.93.26.15081; TAKAHASHI S, 1995, CANCER RES, V55, P4114; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Yang XM, 1996, DEVELOPMENT, V122, P2163; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Yonemura Y, 1996, INT J ONCOL, V8, P555; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370	51	23	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					833	842		10.1038/sj.onc.1201599	http://dx.doi.org/10.1038/sj.onc.1201599			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484774				2022-12-25	WOS:000072053200002
J	Marathe, S; Schissel, SL; Yellin, MJ; Beatini, N; Mintzer, R; Williams, KJ; Tabas, I				Marathe, S; Schissel, SL; Yellin, MJ; Beatini, N; Mintzer, R; Williams, KJ; Tabas, I			Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase - Implication for early atherogenesis and ceramide-mediated cell signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN ACID SPHINGOMYELINASE; NIEMANN-PICK DISEASE; MATRIX METALLOPROTEINASES; ATHEROSCLEROTIC LESIONS; MACROPHAGE UPTAKE; PLASMA-MEMBRANE; DEFICIENT MICE; PROPOSED ROLE; CHOLESTEROL	We recently reported that macrophages and fibroblasts secrete a Zn2+-dependent sphingomyelinase (S-SMase), which, like lysosomal SMase, is a product of the acid SMase gene. S-SMase may cause subendothelial retention and aggregation of lipoproteins during athero genesis, and the acid SMase gene has been implicated in ceramide-mediated cell signaling, especially involving apoptosis of endothelial cells, Because of the central importance of the endothelium in each of these pro cesses, we now sought to examine the secretion and regulation of S-SMase by vascular endothelial cells, Herein we show that cultured human coronary artery and umbilical vein endothelial cells secrete massive amounts of S-SMase (up to 20-fold more than macrophages). Moreover, whereas S-SMase secreted by macrophages and fibroblasts is almost totally dependent on the addition of exogenous Zn2+, endothelium-derived S-SMase was partially active even in the absence of added Zn2+. Secretion of S-SMase by endothelial cells occurred both apically and basolaterally, suggesting an endothelial contribution to both serum and arterial wall SMase. When endothelial cells were incubated with inflammatory cytokines, such as interleukin-1 beta and interferon-gamma, S-SMase secretion by endothelial cells was increased 2-3-fold above the already high level of basal secretion, whereas lysosomal SMase activity was decreased. The mechanism of interleukin-1 beta-stimulated secretion appears to be through increased routing of a SMase precursor protein through the secretory pathway. In summary, endothelial cells are a rich and regulatable source of enzymatically active S-SMase, suggesting physiologic and pathophysiologic roles for this enzyme.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Berlex Biosci, Richmond, CA 94804 USA; Thomas Jefferson Univ, Div Endocrinol Diabet & Metab Dis, Dorrance H Hamilton Res Labs, Philadelphia, PA 19107 USA	Columbia University; Columbia University; Jefferson University	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	iat1@columbia.edu		Yellin, Michael/0000-0002-1164-7614; Williams, Kevin Jon/0000-0002-0000-2159	NHLBI NIH HHS [HL39703, HL56984, HL38956] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039703, R29HL038956, P50HL056984, R01HL038956] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD TY, 1985, J LIPID RES, V26, P1160; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOTTALICO LA, 1993, J BIOL CHEM, V268, P8569; CALLAHAN JW, 1983, J NEUROSCI RES, V10, P151, DOI 10.1002/jnr.490100205; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CORNICELLI JA, 1983, ARTERIOSCLEROSIS, V3, P560, DOI 10.1161/01.ATV.3.6.560; COUSINS RJ, 1988, FASEB J, V2, P2884, DOI 10.1096/fasebj.2.13.2458983; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DONANGELO CM, 1981, CLIN CHIM ACTA, V113, P201, DOI 10.1016/0009-8981(81)90154-6; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; FOGELMAN AM, 1981, J LIPID RES, V22, P1131; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HOFF HF, 1985, ANN NY ACAD SCI, V454, P183, DOI 10.1111/j.1749-6632.1985.tb11857.x; HOFF HF, 1990, EUR HEART J, V11, P105, DOI 10.1093/eurheartj/11.suppl_E.105; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; LIBBY P, 1991, LAB INVEST, V64, P5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mantovani A, 1997, THROMB HAEMOSTASIS, V78, P406; MAROUDAS A, 1988, BIOPHYS CHEM, V32, P257, DOI 10.1016/0301-4622(88)87012-1; MENDIS S, 1989, BIOL TRACE ELEM RES, V22, P251, DOI 10.1007/BF02916613; Menkin V, 1934, AM J PATHOL, V10, P193; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MILANINO R, 1988, AGENTS ACTIONS, V24, P365, DOI 10.1007/BF02028295; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; OKWU AK, 1994, J LIPID RES, V35, P644; Perregaux DG, 1996, J BIOL CHEM, V271, P29830, DOI 10.1074/jbc.271.47.29830; POBER JS, 1991, ADV IMMUNOL, V50, P261; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SMITH EB, 1979, ADV EXP MED BIOL, V115, P245; SORBI D, 1993, KIDNEY INT, V44, P1266, DOI 10.1038/ki.1993.378; SPENCE MW, 1993, ADV LIPID RES, V26, P3; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; SRIPADA PK, 1987, J LIPID RES, V28, P710; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1993, J BIOL CHEM, V268, P20419; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; TAPPER H, 1992, BIOCHEM J, V281, P245, DOI 10.1042/bj2810245; URADE R, 1988, BIOCHIM BIOPHYS ACTA, V946, P151, DOI 10.1016/0005-2736(88)90468-3; VARKI A, 1983, J BIOL CHEM, V258, P2808; Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; XU XX, 1991, J BIOL CHEM, V266, P24849; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857; Zhang P, 1997, J BIOL CHEM, V272, P9609	65	199	209	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4081	4088		10.1074/jbc.273.7.4081	http://dx.doi.org/10.1074/jbc.273.7.4081			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461601	hybrid			2022-12-25	WOS:000072048400043
J	Palaniappan, C; Kim, JK; Wisniewski, M; Fay, PJ; Bambara, RA				Palaniappan, C; Kim, JK; Wisniewski, M; Fay, PJ; Bambara, RA			Control of initiation of viral plus strand DNA synthesis by HIV reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE LEUKEMIA-VIRUS; SEQUENCE FEATURES IMPORTANT; RNASE-H; POLYPURINE TRACT; CLEAVAGE SPECIFICITY; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; RIBONUCLEASE-H; POLYMERASE	Human immunodeficiency virus reverse transcribes its single-stranded RNA genome making a DNA copy. As synthesis proceeds, the RNA is simultaneously degraded to oligomers; one of these, the polypurine tract, primers synthesis of a plus strand DNA. The viral reverse transcriptase (Ra) degrades all of the non-polypurine tract oligomers, We show that until ie other DNA polymerases the retroviral RT can bind either end of an annealed RNA primer, the 5'-end for degradation and the 3'-end for synthesis, The competition between the two binding modes at any primer determines whether it will be extended or degraded. The 5'-end binding can be suppressed in at least two ways, The sequence of the primer can be such that a region at the 5'-end is unannealed or a DNA primer can be annealed just adjacent to the 5'-end of the RNA primer. This promotes binding of RT to the RNA 3'-end, allowing a primer that; would normally be degraded to be extended. implications for human immunodeficiency virus replication and antiviral therapy are discussed.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Dept Med, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, POB 712,601 Elmwood Ave, Rochester, NY 14642 USA.				NCI NIH HHS [CA 11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOONE LR, 1993, REVERSE TRANSCRIPTAS, P119; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; Fedoroff OY, 1997, J MOL BIOL, V269, P225, DOI 10.1006/jmbi.1997.1024; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; Fuentes GM, 1996, NUCLEIC ACIDS RES, V24, P1719, DOI 10.1093/nar/24.9.1719; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUNGNES O, 1992, VIROLOGY, V190, P440, DOI 10.1016/0042-6822(92)91230-R; HUNGNES O, 1991, ARCH VIROL, V116, P133, DOI 10.1007/BF01319237; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; Klarmann GJ, 1997, J VIROL, V71, P9259, DOI 10.1128/JVI.71.12.9259-9269.1997; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; Leis J, 1993, REVERSE TRANSCRIPTAS, P33; LITVAK S, 1996, RETROVIRAL REVERSE T, P83; Lu YN, 1997, J BIOL CHEM, V272, P14523, DOI 10.1074/jbc.272.23.14523; MILLER MD, 1995, J VIROL, V69, P3938, DOI 10.1128/JVI.69.6.3938-3944.1995; MIZRAHI V, 1989, BIOCHEMISTRY-US, V28, P9088, DOI 10.1021/bi00449a020; Palaniappan C, 1997, J BIOL CHEM, V272, P11157, DOI 10.1074/jbc.272.17.11157; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; RANDOLPH CA, 1994, J BIOL CHEM, V269, P19207; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; Rausch JW, 1997, J BIOL CHEM, V272, P8602, DOI 10.1074/jbc.272.13.8602; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; SALAZAR M, 1993, BIOCHEMISTRY-US, V32, P4207, DOI 10.1021/bi00067a007; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; Schultz SJ, 1996, J VIROL, V70, P8630, DOI 10.1128/JVI.70.12.8630-8638.1996; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; TELESNITSKY A, 1993, EMBO J, V12, P4433, DOI 10.1002/j.1460-2075.1993.tb06128.x; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343	48	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3808	3816		10.1074/jbc.273.7.3808	http://dx.doi.org/10.1074/jbc.273.7.3808			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461561	hybrid			2022-12-25	WOS:000072048400003
J	Haltiwanger, RS; Grove, K; Philipsberg, GA				Haltiwanger, RS; Grove, K; Philipsberg, GA			Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATION; PHOSPHORYLATION; BINDING; IDENTIFICATION; GLCNACYLATION; TRANSCRIPTION; GLYCOPROTEINS; PURIFICATION	O-Linked N-acetylglucosamine (O-GlcNAc) is a ubiquitous and abundant post-translational modification found on nuclear and cytoplasmic proteins and is thought to be a dynamically regulated modification much like phosphorylation. In this study we have demonstrated that O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc), a potent in vitro inhibitor of the enzyme responsible for the removal of O-GlcNAc from proteins (peptide O-GlcNAc-beta-N-acetylglucosaminidase), can be used to increase O-GlcNAc levels on nuclear and cytoplasmic proteins in vivo. Overall, PUGNAc caused approximately a 2-fold increase in O-GlcNAc levels in the human colon cancer cells, HT29, although the effects on individual proteins varied, The increase appeared to be the result of the direct inhibition of the peptide O-GlcNAc-beta-N-acetylglucosaminidase since neither the O-GlcNAc transferase nor UDP-GlcNAc levels were affected by the treatment. O-GlcNAc levels in other cell lines tested (NIH 3T3, CV-1, and HeLa) were also affected by PUGNAc, although the effects on HeLa cells were minimal. At the concentrations tested, PUGNAc was non-toxic and had no affect on the growth rate of any of the cell lines examined, Interestingly, we demonstrated that an increase in O-GlcNAc levels on the transcription factor Sp1 resulted in a reciprocal decrease in its level of phosphorylation, supporting the hypothesis that O-GlcNAc competes with phosphate on some proteins, These studies demonstrate that PUGNAc is an effective inhibitor of O-GlcNAc turnover within cells and can be used to selectively alter the extent of O-GlcNAc on cellular proteins.	SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Haltiwanger, RS (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048666] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48666] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; DONG DLY, 1994, J BIOL CHEM, V269, P19321; FELIN M, 1994, J CELL BIOCHEM, V56, P527, DOI 10.1002/jcb.240560413; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Haltiwanger RS, 1997, J BIOL CHEM, V272, P8752, DOI 10.1074/jbc.272.13.8752; Haltiwanger RS, 1997, BIOCHEM BIOPH RES CO, V231, P237, DOI 10.1006/bbrc.1997.6110; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HORSCH M, 1991, EUR J BIOCHEM, V197, P815, DOI 10.1111/j.1432-1033.1991.tb15976.x; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lubas WA, 1997, J BIOL CHEM, V272, P9316; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; Shaw P, 1996, ONCOGENE, V12, P921; SNOW DM, 1996, MOL BIOL CELL, V6, pA357; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WICE BM, 1985, J BIOL CHEM, V260, P139	29	230	255	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3611	3617		10.1074/jbc.273.6.3611	http://dx.doi.org/10.1074/jbc.273.6.3611			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452489	hybrid			2022-12-25	WOS:000071822300074
J	Marcu, MG; Zhang, L; Elzagallaai, A; Trifaro, JM				Marcu, MG; Zhang, L; Elzagallaai, A; Trifaro, JM			Localization by segmental deletion analysis and functional characterization of a third actin-binding site in domain 5 of scinderin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN CELL SCINDERIN; FILAMENT-SEVERING PROTEIN; BOVINE ADRENAL-MEDULLA; PERMEABILIZED PLATELETS; RECOMBINANT SCINDERIN; PLASMA GELSOLIN; CALCIUM; EXPRESSION; PURIFICATION; EXOCYTOSIS	Scinderin is a Ca2+-dependent actin filament severing protein present in a variety of secretory cells. Previous work suggests that scinderin-evoked cortical F-actin disassembly is required for secretion because local disassembly of cortical cytoskeleton allows secretory vesicle exocytosis (Vitale, M. L., Rodriguez Del Castillo, A., Tchakarov, L., and Trifaro, J.-M. (1991) J. Cell Biol. 113, 1057-1067). Scinderin has six domains each containing three internal sequence motifs, two actin, and two phosphatidylinositol disphosphate-binding sites in domains 1 and 2. In this paper we report the presence of another actin-binding site at the NH2-terminal of domain 5 (Sc511-518). This site binds actin in a Ca2+-independent manner and a recombinant fragment (Sc5-6 or Sc502-715) containing this site binds to actin-DNase-I-Sepharose 4B beads, co-sediments with actin and is able to nucleate actin assembly. Recombinant Sc(L)5-6, a fusion protein devoid of the actin-binding site (Sc519-715), did not exhibit these properties, Moreover, Sc-ABP(3), a peptide constructed with sequence (RLFQVRRNLASIT) identical to Sc511-523 blocked the binding of Sc5-6 to actin. Sc5-6 and Sc-ABP(3) also prevented the actin severing activity of recombinant full-length scinderin (r-Sc) and inhibited the potentiation by r-Sc of Ca2+-evoked release of serotonin from permeabilized platelets. On the other hand, Sc(L)5-6 failed to block the effect of r-Sc on platelet serotonin release. Sc1-4,6, a construct devoid of domain 5, was able to sever but unable to nucleate actin, indicating that an actin nucleation site of scinderin was in domain 5. The results suggest that scinderin, in addition to binding actin on sites present in domains 1 and 2, must bind actin on a third site in domain 5 to sever and nucleate actin effectively.	Univ Ottawa, Fac Med, Dept Pharmacol, Secretory Proc Res Program, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Trifaro, JM (corresponding author), Univ Ottawa, Fac Med, Dept Pharmacol, Secretory Proc Res Program, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.							ASHINO N, 1987, J BIOCHEM-TOKYO, V101, P609, DOI 10.1093/jb/101.3.609; BADER MF, 1986, J CELL BIOL, V102, P643; BRETSCHER A, 1979, P NATL ACAD SCI USA, V76, P2321, DOI 10.1073/pnas.76.5.2321; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; DELCASTILLO AR, 1992, J CELL BIOL, V119, P797, DOI 10.1083/jcb.119.4.797; DELCASTILLO AR, 1990, EMBO J, V9, P43, DOI 10.1002/j.1460-2075.1990.tb08078.x; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; EDMONDS CG, 1990, METHOD ENZYMOL, V193, P412, DOI 10.1016/0076-6879(90)93430-S; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FECHHEIMER M, 1984, J BIOL CHEM, V259, P4514; HASLAM RJ, 1984, BIOCHEM J, V222, P351, DOI 10.1042/bj2220351; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; LAPETINA EG, 1985, J BIOL CHEM, V260, P7078; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; MAEKAWA S, 1990, J BIOL CHEM, V265, P10940; Marcu MG, 1996, BLOOD, V87, P20; MARCU MG, 1994, MOL CELL BIOCHEM, V141, P153, DOI 10.1007/BF00926179; MATSUDAIRA P, 1985, NATURE, V315, P248, DOI 10.1038/315248a0; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NAKAMURA S, 1994, J BIOL CHEM, V269, P5890; POPE B, 1995, BIOCHEMISTRY-US, V34, P1583, DOI 10.1021/bi00005a014; SAKURAI T, 1990, NEUROSCIENCE, V38, P743, DOI 10.1016/0306-4522(90)90067-E; SAKURAI T, 1991, J BIOL CHEM, V266, P15979; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; TCHAKAROV L, 1990, FEBS LETT, V268, P209, DOI 10.1016/0014-5793(90)81010-L; TRIFARO JM, 1985, CAN J BIOCHEM CELL B, V63, P661, DOI 10.1139/o85-084; TRIFARO JM, 1992, MOL NEUROBIOL, V6, P339, DOI 10.1007/BF02757940; TRIFARO JM, 1995, PHARM SCI PERSPECTIV, P282; TRIFARO JM, 1989, J CELL BIOL, V109, P274; VanTroys M, 1996, FEBS LETT, V397, P191, DOI 10.1016/S0014-5793(96)01086-1; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YU FX, 1991, J BIOL CHEM, V266, P19269; Zhang L, 1996, NEURON, V17, P287, DOI 10.1016/S0896-6273(00)80160-9	38	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3661	3668		10.1074/jbc.273.6.3661	http://dx.doi.org/10.1074/jbc.273.6.3661			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452496	hybrid			2022-12-25	WOS:000071822300081
J	Sutherland, C; Waltner-Law, M; Gnudi, L; Kahn, BB; Granner, DK				Sutherland, C; Waltner-Law, M; Gnudi, L; Kahn, BB; Granner, DK			Activation of the Ras mitogen-activated protein kinase ribosomal protein kinase pathway is not required for the repression of phosphoenolpyruvate carboxykinase gene transcription by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; DEPENDENT ACTIVATION; EXPRESSION; CAMP; PHOSPHORYLATION; CONVERGENCE; INHIBITION; SEQUENCE; CASCADE	Phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the first committed step in hepatic gluconeogenesis. Glucagon and glucocorticoids stimulate PEPCK gene transcription, whereas insulin has a dominant inhibitory effect. We have shown that inhibitors of 1-phosphatidylinositol 3-kinase (PI 3-kinase) block this action of insulin, In contrast, three distinct agents, all of which prevent activation of p42/p44 mitogen-activated protein (MAP) kinase, have no effect on the regulation of PEPCK transcription by insulin. However, a subsequent report has suggested that this pathway is involved in the inhibition of cAMP induced PEPCK gene transcription by insulin, To address these conflicting data, we re-examined the Ras MAP kinase pathway, not only with respect to regulation of PEPCK gene transcription, but also for regulation of PI 3-kinase and p42/p44 MAP kinase, Overexpression of constitutively active Ras (V61) (or Raf-1 (RafCAAX)) partially represses PEPCK transcription in hepatoma cells. However, an inhibitor of MAP kinase kinase blocks this action of RafCAAX but has no effect on regulation of PEPCK gene transcription by insulin. Second, the action of a dominant negative Ras (N17Ras) on PEPCK gene transcription correlates more closely with the inhibition of PI 3-kinase than with the inhibition of p42/p44 MAP kinase. Third, insulin cannot activate p42/p44 MAP kinase in the presence of cAMP even though cAMP-induced PEPCK gene transcription is inhibited by insulin. This data confirms that the Pas MAP kinase pathway is not required for the regulation of PEPCK gene transcription by insulin and demonstrates the importance of employing multiple techniques when investigating the function of signaling pathways.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol & Metab, Diabet Unit, Boston, MA 02215 USA	Vanderbilt University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 707 Light Hall, Nashville, TN 37232 USA.			Sutherland, Calum/0000-0003-4398-7434; gnudi, luigi/0000-0002-6353-630X	NIDDK NIH HHS [R01 DK043051, DK20593, DK43051, DK35107] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, R01DK043051, R37DK043051, R01DK035107, R37DK035107, P60DK020593] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHU DTW, 1986, J BIOL CHEM, V261, P6848; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Gines P, 1996, HEPATOLOGY, V23, P1167; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sutherland C, 1997, DIABETES, V46, P17, DOI 10.2337/diabetes.46.1.17; Sutherland C, 1996, PHILOS T ROY SOC B, V351, P191, DOI 10.1098/rstb.1996.0016; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; TEBBEY PW, 1995, BIOCHEM BIOPH RES CO, V215, P1006, DOI 10.1006/bbrc.1995.2564; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	36	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3198	3204		10.1074/jbc.273.6.3198	http://dx.doi.org/10.1074/jbc.273.6.3198			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452431	hybrid			2022-12-25	WOS:000071822300016
J	Eng, C; Myers, SM; Kogon, MD; Sanicola, M; Hession, C; Cate, RL; Mulligan, LM				Eng, C; Myers, SM; Kogon, MD; Sanicola, M; Hession, C; Cate, RL; Mulligan, LM			Genomic structure and chromosomal localization of the human GDNFR-alpha gene	ONCOGENE			English	Article						RET; GFR alpha-1; GDNF; Exon-intron; 10q	MICE LACKING GDNF; MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; NEOPLASIA TYPE 2B; RET PROTOONCOGENE; DISEASE PHENOTYPE; POINT MUTATION; MEN 2A; RECEPTOR; FMTC	GDNFR-alpha is a glycosyl-phosphotidylinositol-linked receptor for glial cell line-derived neurotrophic factor (GDNF), GDNF binds to GDNFR-alpha and this complex, in turn, is believed to interact with the RET receptor tyrosine kinase to effect downstream signalling. GDNFR-alpha belongs to a novel gene family without strong homology to known genes. Thus, little information has been available to help predict genomic structure or location of this gene. In this study, the genomic organization of human GDNFR-alpha was delineated through a combination of PAC clone characterization, long distance PCR and sequence analyses. Exon-intron boundaries were defined by comparing the size and sequence of the genomic PCR products to those predicted by the cDNA sequence. The human GDNFR-alpha gene comprises 9 exons. GDNFR-alpha PAC clones were used for FISH analysis to map this gene to 10q26.	Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Richard & Sara Smith Labs, Boston, MA 02115 USA; Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Paediat, Kingston, ON K7L 3N6, Canada; Biogen Inc, Dept Mol Biol, Cambridge, MA 02142 USA	Harvard University; Dana-Farber Cancer Institute; University of Cambridge; Queens University - Canada; Queens University - Canada; Biogen	Eng, C (corresponding author), Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Richard & Sara Smith Labs, SM822 1 Jimmy Fund Way, Boston, MA 02115 USA.			Eng, Charis/0000-0002-3693-5145				Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BOLINO A, 1995, ONCOGENE, V10, P2415; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Ivanchuk SM, 1996, HUM MOL GENET, V5, P2023, DOI 10.1093/hmg/5.12.2023; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Leong S, 1981, ADV THYROID NEOPLASI, P95; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Moore DD, 1995, GLOB MOB SURV; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0	30	10	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					597	601		10.1038/sj.onc.1201573	http://dx.doi.org/10.1038/sj.onc.1201573			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482105				2022-12-25	WOS:000071816600004
J	Coda, L; Salcini, AE; Confalonieri, S; Pelicci, G; Sorkina, T; Sorkin, A; Pelicci, PG; Di Fiore, PP				Coda, L; Salcini, AE; Confalonieri, S; Pelicci, G; Sorkina, T; Sorkin, A; Pelicci, PG; Di Fiore, PP			Eps15R is a tyrosine kinase substrate with characteristics of a docking protein possibly involved in coated pits-mediated internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ASYMMETRIC LOCALIZATION; TRANSFORMING ACTIVITY; ACTIN CYTOSKELETON; BINDING DOMAIN; SH3 DOMAIN; GENE; NUMB; DROSOPHILA; CONFERS	eps15R was identified because of its relatedness to eps15, a gene encoding a tyrosine kinase substrate bearing a novel protein-protein interaction domain, called EH, In this paper, we report a biochemical characterization of the eps15R gene product(s). In NIH-3T3 cells, three proteins of 125, 108, and 76 kDa were specifically recognized by anti-eps15R sera, The 125-kDa species is a bona fide product of the eps15R gene, whereas p108 and p76 are most likely products of alternative splicing events. Eps15R protein(s) are tyrosine-phosphorylated following epidermal growth factor receptor activation in NIH-3T3 cells overexpressing the receptor, even at low levels of receptor occupancy, thus behaving as physiological substrates, A role for eps15R in clathrin-mediated endocytosis is suggested by its localization in plasma membrane-coated pits and in vivo association to the coated pits' adapter protein AP-2. Finally, we demonstrate that a sizable fraction of eps15R exists in the cell as a complex with eps15 and that its EH domains exhibit binding specificities that are partially distinct from those of eps15, We propose that eps15 and eps15R are multifunctional binding proteins that serve pleiotropic functions within the cell.	Ist Europeo Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Parma, Ist Patol Speciale Med, I-43100 Parma, Italy; Univ Bari, Ist Microbiol, I-70124 Bari, Italy	IRCCS European Institute of Oncology (IEO); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Parma; Universita degli Studi di Bari Aldo Moro	Di Fiore, PP (corresponding author), Ist Europeo Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Confalonieri, Stefano/AAQ-6786-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Pelicci, Giuliana/AAA-8921-2022; Di Fiore, Pier Paolo/K-2130-2012; Salcini, Anna Elisabetta/G-4472-2017	Confalonieri, Stefano/0000-0001-6886-9851; Pelicci, Giuliana/0000-0003-0986-8255; Di Fiore, Pier Paolo/0000-0002-2252-0950; Sorkin, Alexander/0000-0002-4446-1920; Salcini, Anna Elisabetta/0000-0001-5828-2512	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046817] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46817] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVANTAGGIATO V, 1995, ONCOGENE, V11, P1191; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Iannolo G, 1997, CANCER RES, V57, P240; Matoskova B, 1996, ONCOGENE, V12, P2679; Matoskova B, 1996, ONCOGENE, V12, P2563; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SPANA EP, 1995, DEVELOPMENT, V121, P3489; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Tan PK, 1996, J CELL BIOL, V135, P1789, DOI 10.1083/jcb.135.6.1789; Tang HY, 1996, MOL CELL BIOL, V16, P4897; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; vanDelft S, 1997, J BIOL CHEM, V272, P14013, DOI 10.1074/jbc.272.22.14013; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WONG WT, 1994, ONCOGENE, V9, P1591; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	34	70	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3003	3012		10.1074/jbc.273.5.3003	http://dx.doi.org/10.1074/jbc.273.5.3003			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446614	hybrid			2022-12-25	WOS:000071736600069
J	Fernandes, ND; Kolattukudy, PE				Fernandes, ND; Kolattukudy, PE			A newly identified methyl-branched chain fatty acid synthesizing enzyme from Mycobacterium tuberculosis var. bovis BCG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; MULTIFUNCTIONAL ENZYME; SYNTHASE; PURIFICATION; GENE; BIOSYNTHESIS; PROTEINS; CLONING	Mycobacterium bovis BCG produces a variety of methyl-branched fatty acids. They include C-28 to C-32 mycocerosic acids esterified to phthiocerol and phenolphthiocerol and the shorter (C-22 to C-26) mycocerosic acids esterified to phthiocerol. A mycocerosic acid synthase gene-disrupted mutant was still able to produce the shorter mycocerosic acids. The enzyme short chain mycocerosic acid synthase (SMAS), that catalyzes the synthesis of such acids, was purified using anion exchange and red-agarose chromatography. Gel filtration showed the native enzyme to be a 537-kDa protein. Since SDS-polyacrylamide gel electrophoresis of the purified enzyme showed a 280-, 170-, and 100-kDa protein and they cross-reacted with antibodies prepared against the 280- or 100-kDa protein, this enzyme is composed of the three subunits or two 280-kDa monomers with an unusual susceptibility to a proteolytic nick. SMAS utilizes methylmalonyl-CoA with C-12 to C-20 acyl CoA as primers and with either NADH or NADPH as the reductant to synthesize the short mycocerosic acids. The K-m values for NADH and NADPH were 93 and 90 mu M, respectively. Antibodies raised against either the 280- or 100-kDa protein inhibited the incorporation of methylmalonyl-CoA into fatty acids by SMAS, The enzyme is not immunologically closely related to mycocerosic acid synthase or fatty acid synthase.	Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA	Ohio State University; Ohio State University; Ohio State University	Kolattukudy, PE (corresponding author), Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA.		kolattukudy, pappachan e/A-1350-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035272] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35272] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS AW, 1984, FATTY ACID METABOLIS, P29; Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; Azad AK, 1996, P NATL ACAD SCI USA, V93, P4787, DOI 10.1073/pnas.93.10.4787; BESRA GS, 1992, BIOCHEMISTRY-US, V31, P9832, DOI 10.1021/bi00155a040; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; BUCKNER JS, 1976, BIOCHEMISTRY-US, V15, P1948, DOI 10.1021/bi00654a024; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Fernandes ND, 1996, GENE, V170, P95, DOI 10.1016/0378-1119(95)00842-X; Fernandes ND, 1997, J BACTERIOL, V179, P7538, DOI 10.1128/jb.179.23.7538-7543.1997; HARLOW E, 1989, ANTIBODIES LAB MANUA, P103; Hart CA, 1996, J MED MICROBIOL, V44, P1, DOI 10.1099/00222615-44-1-1; HUNTER SW, 1983, J BIOL CHEM, V258, P481; KIKUCHI S, 1992, ARCH BIOCHEM BIOPHYS, V295, P318, DOI 10.1016/0003-9861(92)90524-Z; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATHUR M, 1992, J BIOL CHEM, V267, P19388; MINNIKIN DE, 1982, BIOL MYCOBACTERIA, V1, P95; NAJIMA H, 1996, WHO REPORT, P27; PETERSON DO, 1977, J BIOL CHEM, V252, P5735; RAFIDINARIVO E, 1982, BIOCHIM BIOPHYS ACTA, V711, P266, DOI 10.1016/0005-2760(82)90035-2; RAINWATER DL, 1985, J BIOL CHEM, V260, P616; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WHEELER PR, 1990, J GEN MICROBIOL, V136, P211, DOI 10.1099/00221287-136-1-211	24	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2823	2828		10.1074/jbc.273.5.2823	http://dx.doi.org/10.1074/jbc.273.5.2823			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446591	hybrid			2022-12-25	WOS:000071736600046
J	Boumans, H; Grivell, LA; Berden, JA				Boumans, H; Grivell, LA; Berden, JA			The respiratory chain in yeast behaves as a single functional unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C OXIDOREDUCTASE; MITOCHONDRIAL ELECTRON-TRANSPORT; 17-KDA SUBUNIT-VI; SACCHAROMYCES-CEREVISIAE; LATERAL DIFFUSION; PLASTOQUINONE COMPARTMENTATION; PARACOCCUS-DENITRIFICANS; REACTION CENTERS; BC1 COMPLEX; UBIQUINOL	Inhibitor titrations using antimycin have been used to study the pool behavior of ubiquinone and cytochrome c in the respiratory chain of the yeast Saccharomyces cerevisiae, If present in a homogeneous pool, these carriers should be able to diffuse freely through or along the membrane respectively and accept and subsequently donate electrons to an infinite number of the respective respiratory complex, However, we show that under physiological conditions neither ubiquinone nor cyto chrome c exhibits pool behavior, implying that the respiratory chain in yeast is one functional unit, Pool behavior can be introduced for both small carriers by adding chaotropic agents to the reaction medium. We conclude that these agents disrupt the interaction between the respiratory complexes, thereby causing them to become randomly arranged in the membrane, In such a situation, ubiquinone and cytochrome c become mobile carriers, shuttling between the large respiratory complexes. Furthermore, we conclude from the respiratory activities found for different substrates that the respiratory units in yeast vary in composition with respect to the ubiquinone reducing enzyme, All units contain the cytochrome chain, supplemented with either succinate dehydrogenase or the internal or the external NADH dehydrogenase. This implies that when only one substrate is available, only a certain fraction of the cytochrome chain is used in respiration, The molecular organization of the respiratory chain in yeast is compared with that of higher eukaryotes and to the electron transfer systems of photosynthetic membranes, Differences between the organization of the respiratory chain of yeast and that of higher eukaryotes are discussed in terms of the ability of yeast to radically alter its metabolism in response to change of the available carbon source.	Univ Amsterdam, EC Slater Inst, Bioctr, Dept Mol Cell Biol, NL-1018 TV Amsterdam, Netherlands; Univ Amsterdam, Bioctr, Dept Mol Cell Biol, Mol Biol Sect, NL-1018 TV Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam	Berden, JA (corresponding author), Univ Amsterdam, EC Slater Inst, Bioctr, Dept Mol Cell Biol, Plantage Muidergracht 12, NL-1018 TV Amsterdam, Netherlands.							BEATTIE DS, 1992, ARCH BIOCHEM BIOPHYS, V292, P499, DOI 10.1016/0003-9861(92)90022-O; BERRY EA, 1985, J BIOL CHEM, V260, P2458; BONNEFOY N, 1994, P NATL ACAD SCI USA, V91, P11978, DOI 10.1073/pnas.91.25.11978; Bonnefoy N, 1996, MOL GEN GENET, V251, P204; BOUSQUET I, 1991, EMBO J, V10, P2023, DOI 10.1002/j.1460-2075.1991.tb07732.x; Brasseur G, 1997, EUR J BIOCHEM, V246, P103, DOI 10.1111/j.1432-1033.1997.t01-1-00103.x; Bruel C, 1996, J BIOENERG BIOMEMBR, V28, P59; BRYLA J, 1969, BIOCHIM BIOPHYS ACTA, V189, P317; CHAZOTTE B, 1989, J BIOL CHEM, V264, P4978; DEGIER JWL, 1994, MOL MICROBIOL, V13, P183, DOI 10.1111/j.1365-2958.1994.tb00414.x; DEVRIES S, 1988, EUR J BIOCHEM, V176, P377; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; GUPTE S, 1984, P NATL ACAD SCI-BIOL, V81, P2606, DOI 10.1073/pnas.81.9.2606; GUPTE SS, 1988, J BIOL CHEM, V263, P5241; GUPTE SS, 1988, J BIOL CHEM, V263, P5248; HEMRIKA W, 1993, EUR J BIOCHEM, V215, P601, DOI 10.1111/j.1432-1033.1993.tb18071.x; HERON C, 1978, BIOCHEM J, V174, P791, DOI 10.1042/bj1740791; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; JOLIOT P, 1992, BIOCHIM BIOPHYS ACTA, V1101, P1, DOI 10.1016/0167-4838(92)90460-U; JOLIOT P, 1993, BIOCHIM BIOPHYS ACTA, V1141, P151, DOI 10.1016/0005-2728(93)90039-I; JOLIOT P, 1989, BIOCHIM BIOPHYS ACTA, V975, P336, DOI 10.1016/S0005-2728(89)80341-X; KROGER A, 1973, EUR J BIOCHEM, V39, P313, DOI 10.1111/j.1432-1033.1973.tb03129.x; LAVERGNE J, 1992, BIOCHIM BIOPHYS ACTA, V1101, P13, DOI 10.1016/0167-4838(92)90461-L; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PEARCE DA, 1995, P NATL ACAD SCI USA, V92, P3735, DOI 10.1073/pnas.92.9.3735; PRIETO S, 1992, EUR J BIOCHEM, V208, P487, DOI 10.1111/j.1432-1033.1992.tb17212.x; RAGAN CI, 1978, BIOCHEM J, V174, P783, DOI 10.1042/bj1740783; RAGAN CI, 1985, BIOCHIM BIOPHYS ACTA, V811, P13; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; ROSEN D, 1980, BIOCHEMISTRY-US, V19, P5687, DOI 10.1021/bi00566a004; SCHNEIDER H, 1980, J BIOL CHEM, V255, P3748; SCHNEIDER H, 1982, FUNCTION QUINONES EN, P125; SCHOPPINK PJ, 1989, BIOCHIM BIOPHYS ACTA, V974, P192, DOI 10.1016/S0005-2728(89)80372-X; SCHOPPINK PJ, 1988, EUR J BIOCHEM, V173, P115, DOI 10.1111/j.1432-1033.1988.tb13974.x; SONE N, 1987, J BIOL CHEM, V262, P15386; WALLACE PG, 1994, ANAL BIOCHEM, V222, P404, DOI 10.1006/abio.1994.1509	37	129	136	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4872	4877		10.1074/jbc.273.9.4872	http://dx.doi.org/10.1074/jbc.273.9.4872			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478928	hybrid			2022-12-25	WOS:000072310400012
J	McLaurin, J; Franklin, T; Fraser, PE; Chakrabartty, A				McLaurin, J; Franklin, T; Fraser, PE; Chakrabartty, A			Structural transitions associated with the interaction of Alzheimer beta-amyloid peptides with gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; FIBRIL FORMATION; DISEASE; PROTEIN; MEMBRANES; CELLS; NEUROTOXICITY; CONFORMATION; PATHOGENESIS; SUBSTITUTION	Alzheimer's disease is characterized pathologically by the presence of neurofibrillary tangles and amyloid plaques. The principal component of the plaque is the beta-amyloid peptide (A beta), a 39-43-resiure peptide. The conformational change required for the conversion of soluble peptide into amyloid fabrils is modulated by pH, A beta concentration, addition of kinetic and thermodynamic enhancers, and alterations in the primary sequence of A beta. We report here the ability of gangliosides to induce an alpha-helical structure in A beta and thereby diminish fibrillogenesis, Circular dichroism and a fluorescence dye release assay data indicate that gangliosides interact with and induce alpha-helix formation in A beta. We find that the sialic acid moiety of gangliosides is necessary for the induction of alpha-helical structure. Differences in the amount and the position of the sialic acid on the carbohydrate backbone also affect the conformational switch. The A beta-ganglioside interaction at pH 7.0, monitored by CD, is stable over time and resistant to high concentrations of NaCl. The induction of alpha-helical structure is greater with A beta 1-40 than A beta 1-42. The ability of gangliosides to sequester A beta from fibril formation was also evaluated by electron microscopy.	Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5G 2M9, Canada	University of Toronto; University of Toronto	Chakrabartty, A (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Chakrabartty, Avi/0000-0001-7002-8381				ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Avdulov NA, 1997, J NEUROCHEM, V68, P2086; Barlett G.R., 1959, J BIOL CHEM, V234, P466; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; Blanc EM, 1997, J NEUROCHEM, V68, P1870; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; FRASER PE, 1994, J MOL BIOL, V244, P64, DOI 10.1006/jmbi.1994.1704; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P883; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KOHN LD, 1980, STRUCTURE FUNCTION G, P333; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MAESTRE GE, 1992, BRAIN RES, V599, P64, DOI 10.1016/0006-8993(92)90853-2; MAESTRE GE, 1993, BRAIN RES, V621, P145, DOI 10.1016/0006-8993(93)90311-A; McLaurin J, 1997, EUR J BIOCHEM, V245, P355, DOI 10.1111/j.1432-1033.1997.t01-2-00355.x; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; MCLEAN LR, 1990, BIOCHIM BIOPHYS ACTA, V1024, P1, DOI 10.1016/0005-2736(90)90201-X; MULLER WE, 1995, BRAIN RES, V674, P133, DOI 10.1016/0006-8993(94)01463-R; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Pillot T, 1996, J BIOL CHEM, V271, P28757, DOI 10.1074/jbc.271.46.28757; RAHMANN H, 1992, NEUROCHEM INT, V20, P323, DOI 10.1016/0197-0186(92)90047-U; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; ROTH GS, 1995, TRENDS NEUROSCI, V18, P203, DOI 10.1016/0166-2236(95)93902-A; SARTI P, 1990, BIOCHEM J, V267, P413, DOI 10.1042/bj2670413; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SNOW AD, 1988, AM J PATHOL, V133, P456; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; SOTO C, 1995, NEUROSCI LETT, V186, P115, DOI 10.1016/0304-3940(95)11299-C; TATE B, 1992, B CLIN NEUROSCI, V56, P131; TERRY RD, 1994, PROG BRAIN RES, V101, P383; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; TETTAMANTI G, 1993, ADV LIPID RES, V25, P235; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; WEIGEL J, 1990, ACTA NEUROPATHOL, V81, P116; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; YAMAGUCHI H, 1989, AM J PATHOL, V135, P593; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062	49	153	156	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4506	4515		10.1074/jbc.273.8.4506	http://dx.doi.org/10.1074/jbc.273.8.4506			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468505	hybrid			2022-12-25	WOS:000072115000033
J	Nakamura, T; Jamieson, GA; Okuma, M; Kambayashi, J; Tandon, NN				Nakamura, T; Jamieson, GA; Okuma, M; Kambayashi, J; Tandon, NN			Platelet adhesion to native type I collagen fibrils - Role of GPVI in divalent cation-dependent and -independent adhesion and thromboxane A(2) generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACKING GLYCOPROTEIN-IV; INDUCED AGGREGATION; DEFICIENCY; BLOOD; CD36; PATIENT; SUBENDOTHELIUM; IDENTIFICATION; INHIBITION; RECEPTOR	Three glycoproteins (GPs), namely GPIa-IIa, GPVI, and GPIV, have been recently implicated in platelet-collagen adhesive interactions, We have employed antibodies to these GPs to investigate further their role in platelet adhesion to immobilized monomeric and polymeric fibrillar collagen under static conditions in the presence and the absence of Mg2+, In the presence of Mg2+, each antibody inhibited platelet adhesion to fibrillar collagen from 70 to 85%, especially during the early phase (<15 min), but the inhibitory effects diminished dramatically to 25% or less by 60 min, Combination of anti-GPVI with anti-GPIa-IIa antibodies completely inhibited platelet adhesion at 60 min, Anti-GPIV and anti-GPIa-IIa or anti-GPVI antibodies in combinations were more effective in inhibiting adhesion than was anti-GPIa-IIa or anti-GPVI alone, In the absence of Mg2+, anti-GPVI completely inhibited adhesion at 60 min, while anti-GPIV antibody inhibited adhesion by about 50% and minimal effects were seen with anti-GPIa-IIa, suggesting that GPIa-IIa does not play a significant role in the divalent cation-independent platelet adhesion to immobilized fibrillar collagen, Under either divalent cation-dependent or -independent conditions, platelets adhered to fibrillar collagen were able to secrete contents of both alpha-granules and dense granules and generate thromboxane A(2) (TXA(2)), but platelets adhering to acid soluble monomeric collagen neither secreted their granular contents nor generated TXA(2). Although anti-GPVI antibodies were not able to inhibit Mg2+-dependent adhesion, they completely inhibited TXA(2) generation under both divalent cation-dependent and -independent conditions. With the other antibodies, TXA(2) generation corresponded with the amount of adhesion observed, These results suggest that GPVI is directly associated with the TXA(2) generating system during platelet collagen interaction.	Otsuka Amer Pharmaceut Inc, Maryland Res Labs, Rockville, MD 20850 USA; Amer Red Cross, Rockville, MD 20855 USA; Takashima Gen Hosp, Shiga 52011, Japan	American Red Cross	Nakamura, T (corresponding author), Otsuka Amer Pharmaceut Inc, Maryland Res Labs, 9900 Med Ctr Dr, Rockville, MD 20850 USA.							ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P1; BRASS LF, 1974, J CLIN INVEST, V54, P1480, DOI 10.1172/JCI107896; Chiang TM, 1997, J CLIN INVEST, V100, P514, DOI 10.1172/JCI119560; COLLER BS, 1989, BLOOD, V74, P182; DECKMYN H, 1990, THROMB HAEMOSTASIS, V64, P74; DIAZRICART M, 1993, BLOOD, V82, P491; HANDA M, 1995, THROMB HAEMOSTASIS, V73, P521; JAFFE R, 1974, J CLIN INVEST, V53, P875, DOI 10.1172/JCI107628; KEHREL B, 1988, BLOOD, V71, P1074; Matsuno K, 1996, BRIT J HAEMATOL, V92, P960, DOI 10.1046/j.1365-2141.1996.422962.x; MCKEOWN L, 1994, BLOOD, V83, P2866, DOI 10.1182/blood.V83.10.2866.2866; MOROI M, 1992, BIOCHIM BIOPHYS ACTA, V1137, P1, DOI 10.1016/0167-4889(92)90092-P; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON L F, 1991, Biochemical Society Transactions, V19, p439S; MUGGLI R, 1973, Thrombosis Research, V3, P715, DOI 10.1016/0049-3848(73)90018-2; NIEUWENHUIS HK, 1986, BLOOD, V68, P692; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; PACKHAM MA, 1984, THROMB HAEMOSTASIS, V51, P140; PETRONI A, 1995, THROMB RES, V78, P151, DOI 10.1016/0049-3848(95)00043-7; RYO R, 1992, AM J HEMATOL, V39, P25, DOI 10.1002/ajh.2830390107; SAELMAN EUM, 1994, BLOOD, V83, P3240, DOI 10.1182/blood.V83.11.3240.bloodjournal83113240; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SANTORO SA, 1988, MOL BASIS PLATELET A, P291; SUGIYAMA T, 1987, BLOOD, V69, P1712; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANDON NN, 1991, BLOOD, V78, P2809; YAMAMOTO N, 1990, BLOOD, V76, P1698; ZIJENAH LS, 1990, BIOCHEM J, V268, P481, DOI 10.1042/bj2680481; ZUCKER WH, 1974, AM J PATHOL, V77, P255	31	70	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4338	4344		10.1074/jbc.273.8.4338	http://dx.doi.org/10.1074/jbc.273.8.4338			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468482	hybrid			2022-12-25	WOS:000072115000010
J	Ulrix, W; Swinnen, JV; Heyns, W; Verhoeven, G				Ulrix, W; Swinnen, JV; Heyns, W; Verhoeven, G			Identification of the phosphatidic acid phosphatase type 2a isozyme as an androgen-regulated gene in the human prostatic adenocarcinoma cell line LNCaP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; MESSENGER-RNA; CANCER CELLS; ENDOPLASMIC-RETICULUM; PHOSPHOHYDROLASE; RECEPTOR; PROTEIN; DIFFERENTIATION; PROLIFERATION; EXPRESSION	Differential display wars used to identify novel and androgen-regulated genes in the human prostatic adenocarcinoma cell line LNCaP. A 322-base pair cDNA fragment that, was consistently induced by the synthetic androgen R1881 revealed 100% homology with the human phosphatidic acid phosphatase type 2a isozyme very recently reported by Kai Et al; (PAP-2a; Kai., Wa., Wada, I., Imai, S.-i., Sakane, F., and Kanoh, H. (1997) J. Biol. Chem. 272, 24572-24578). The fragment was used to clone the corresponding cDNA from a human prostate library. The deduced amino acid sequence confirmed the identity with human PAP-2a. The inducibility of PAP-2a mRNA by androgens was confirmed by Northern blot hybridization, The effect was time-and dose-dependent Math a maximal stimulation (4-fold) after 24 h of treatment with 10(-9) M R1881. The steroid specificity of PAP-2a mRNA regulation was found to be in agreement with the aberrant ligand specificity of the mutated androgen receptor in LNCaP cells, supporting the involvement of the androgen receptor in the induction process. Furthermore, low basal levels of PAP-2a mRNA and absence of androgen inducibility were observed in the poorly differentiated and androgen receptor-negative cell lines PC-3 and DU-145. Induction of PaP-2a mRNA was not affected by the protein synthesis inhibitor cycloheximide and was accompanied by a marked increase in PAP-2 activity as measured by the conversion of phosphatidic acid into diacylglycerol in membrane fractions of LNCaP. Comparison of the expression of PAP-2a mRNA in 50 different human tissues revealed ubiquitous expression. The highest levels, however, were observed in the prostate, Since PAP-2 plays a pivotal role in the control of signal transduction by lipid mediators such as phosphatidate, lysophosphatidate, and ceramide-1-phosphate, the ability off androgens to stimulate the expression and activity of this enzyme in prostatic cells may provide an important opportunity for cross-talk between signaling pathways involving lipid mediators and androgens.	Catholic Univ Louvain, Fac Med, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium	KU Leuven; Universite Catholique Louvain	Verhoeven, G (corresponding author), LEGENDO, Herestr 49, B-3000 Louvain, Belgium.	guido.verhoeven@med.kuleuven.ac.be	Swinnen, Johannes V/AAA-2214-2022	Swinnen, Johannes V/0000-0002-7720-5077				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barila D, 1996, J BIOL CHEM, V271, P29928, DOI 10.1074/jbc.271.47.29928; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; Brindley DN, 1996, CHEM PHYS LIPIDS, V80, P45, DOI 10.1016/0009-3084(96)02545-5; BRINDLEY DN, 1988, PHOSPHATIDATE PHOSPH, V1, P21; CARTER HB, 1990, PROSTATE, V16, P39; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; DAVIES P, 1995, J ENDOCRINOL, V131, P5; EGAWA K, 1995, FEBS LETT, V372, P74, DOI 10.1016/0014-5793(95)00957-B; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Esquenet M, 1996, PROSTATE, V28, P182, DOI 10.1002/(SICI)1097-0045(199603)28:3<182::AID-PROS5>3.0.CO;2-H; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; HOER A, 1994, ARCH PHARM, V349, P653; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; KAIGHN ME, 1979, INVEST UROL, V17, P16; KANOH H, 1992, J BIOL CHEM, V267, P25309; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KOKONTIS J, 1994, CANCER RES, V54, P1566; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; MCCONNELL JD, 1991, J ANDROL, V12, P356; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; NEGRICESI P, 1994, J STEROID BIOCHEM, V51, P89, DOI 10.1016/0960-0760(94)90119-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SCHUURMANS ALG, 1988, INT J CANCER, V42, P917, DOI 10.1002/ijc.2910420622; SOZZANI S, 1992, J BIOL CHEM, V267, P20481; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; SUGIMOTO K, 1994, J STEROID BIOCHEM, V51, P167, DOI 10.1016/0960-0760(94)90090-6; SWILNNEN JV, 1997, CANCER RES, V57, P1086; SWINNEN JV, 1994, MOL CELL ENDOCRINOL, V104, P153, DOI 10.1016/0303-7207(94)90118-X; Swinnen JV, 1996, ENDOCRINOLOGY, V137, P4468, DOI 10.1210/en.137.10.4468; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VERHOEVEN G, 1995, INT J ANDROL, V18, P23, DOI 10.1111/j.1365-2605.1995.tb00931.x; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WILDING G, 1990, PROSTATE, V16, P15, DOI 10.1002/pros.2990160103; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0	44	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4660	4665		10.1074/jbc.273.8.4660	http://dx.doi.org/10.1074/jbc.273.8.4660			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468526	hybrid			2022-12-25	WOS:000072115000054
J	Saberan-Djoneidi, D; Picart, R; Escalier, D; Gelman, M; Barret, A; Tougard, C; Glowinski, J; Levi-Strauss, M				Saberan-Djoneidi, D; Picart, R; Escalier, D; Gelman, M; Barret, A; Tougard, C; Glowinski, J; Levi-Strauss, M			A 21-kDa polypeptide belonging to a new family of proteins is expressed in the Golgi apparatus of neural and germ cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESENCEPHALIC DOPAMINERGIC-NEURONS; MEMBRANE-PROTEINS; MESSENGER-RNA; GENE; RECEPTORS; SPERM; RESISTANCE; SEQUENCES; PEPTIDES; VESICLES	We have isolated a full-length murine clone corresponding to the rat neuronal p1A75 partial cDNA (Sutcliffe, J. G., Milner, R. J., Shinnick, T. M., and Bloom, F, E. (1983) Cell 33, 671-682). It encodes a 185-residue polypeptide that displays 56% identity with p19, a protein selectively expressed in the Golgi apparatus of neural cells (Saberan-Djoneidi, D., Marey-Semper, I., Picart, R., Studler, J.-M., Tougard, C., Glowinski, J., and Levi-Strauss, M. (1995) J. Biol. Chem. 270, 1888-1893). An antibody directed against the recombinant polypeptide allowed us to demonstrate the existence of the natural 21-kDa protein (p21) in brain and its prominent juxtanuclear Golgi-like localization in cultured neurons. Ultrastructural observation of cultured neurons and analysis of transfected COS cells revealed a specific labeling of the Golgi apparatus, suggesting, as for p19, the presence of a Golgi targeting signal in its primary sequence. Surprisingly, p21, which is much more strongly expressed in the olfactory epithelium than p19, is also present in the Golgi complex of spermatocytes and in the flagellar middle piece of late spermatids.	Coll France, INSERM, U114, Chaire Neuropharmacol, F-75005 Paris, France; Coll France, INSERM, U36, Grp Biol Cellule Neuroendocrine, F-75005 Paris, France; Hop Necker Enfants Malad, INSERM, U25, F-75743 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Saberan-Djoneidi, D (corresponding author), INSERM, U406, 27 Bd Jean Moulin, F-13385 Marseille 5, France.		Saberan-Djoneidi, Delara/AAD-7820-2022	Saberan-Djoneidi, Delara/0000-0002-2757-6419				BALZI E, 1994, J BIOL CHEM, V269, P2206; BRINKLEY BR, 1967, J CELL BIOL, V35, P279, DOI 10.1083/jcb.35.1.279; BURGAYA F, 1995, EUR J NEUROSCI, V7, P1810, DOI 10.1111/j.1460-9568.1995.tb00700.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHENDAYAG A, 1995, P NATL ACAD SCI USA, V92, P11039, DOI 10.1073/pnas.92.24.11039; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DENISDONINI S, 1984, NATURE, V307, P641, DOI 10.1038/307641a0; DIPORZIO U, 1980, NATURE, V288, P370, DOI 10.1038/288370a0; DIRIONG S, 1994, HUM GENET, V93, P703; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUNDIN LG, 1993, GENOMICS, V16, P1, DOI 10.1006/geno.1993.1133; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; OTTIGER HP, 1990, J NEUROSCI, V10, P3135; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; PRASAD R, 1995, CURR GENET, V27, P320, DOI 10.1007/BF00352101; Russell L.D., 1990, HISTOLOGICAL HISTOPA, P120; SABERANDJONEIDI D, 1995, J BIOL CHEM, V270, P1888, DOI 10.1074/jbc.270.4.1888; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; STUDLER JM, 1993, EUR J NEUROSCI, V5, P614, DOI 10.1111/j.1460-9568.1993.tb00527.x; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; SUTCLIFFE JG, 1983, CELL, V33, P671, DOI 10.1016/0092-8674(83)90010-7; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TOUGARD C, 1986, AM J ANAT, V175, P161, DOI 10.1002/aja.1001750206; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; VANDERHAEGHEN P, 1993, J CELL BIOL, V123, P1441, DOI 10.1083/jcb.123.6.1441; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALENSKY LD, 1995, MOL MED, V1, P130, DOI 10.1007/BF03401561	37	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3909	3914		10.1074/jbc.273.7.3909	http://dx.doi.org/10.1074/jbc.273.7.3909			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461575	hybrid			2022-12-25	WOS:000072048400017
J	Kamitani, T; Nguyen, HP; Kito, K; Fukuda-Kamitani, T; Yeh, ETH				Kamitani, T; Nguyen, HP; Kito, K; Fukuda-Kamitani, T; Yeh, ETH			Covalent modification of PML by the sentrin family of ubiquitin-like proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RAR-ALPHA; TRANSLOCATION; SUPPRESSOR; TRANSFORMATION; LOCALIZATION; T(15-17); GROWTH; CELLS; GENE	PML, a RING finger protein with tumor suppressor activity, has been implicated in the pathogenesis of acute promyelocytic leukemia that arises following a reciprocal chromosomal translocation that fuses the PML gene with the retinoic acid receptor alpha (RAR alpha) gene. Immunocytochemical analysis has demonstrated that PML is co-localized with a novel ubiquitin-like protein in the nuclear bodies, which could be disrupted by the PML-RAR alpha: fusion protein. The physical nature of this co-localization is unknown. Using a COS cell expression system, we show that PML is covalently modified by all three members of the sentrin family of ubiquitin-like proteins. Covalent modification of PML requires the conserved Gly residue near the C termini of sentrin proteins. Sentrinization of PML is highly specific because neither NEDD8 nor ubiquitin could modify PML. Similar specificity is also observed for the covalent modification of RanGAP1 by the sentrin member of ubiquitin-like proteins, These observations highlight the fine substrate specificity of the sentrinization pathway. In acute promyelocytic leukemia, two forms of PML-RAR alpha fusion proteins have been reported, Remarkably, both forms of PML-RAR alpha fusion proteins could not be sentrinized, Thus differential sentrinization of PML and PML-RAR alpha could play an important role in regulating the biological function of PML and in the pathogenesis of acute promyelocytic leukemia.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Mol Med, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Yeh, ETH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Mol Med, 6431 Fannin,Suite 4-200, Houston, TX 77030 USA.		Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boddy MN, 1996, ONCOGENE, V13, P971; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mannen H, 1996, BIOCHEM BIOPH RES CO, V222, P178, DOI 10.1006/bbrc.1996.0717; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Okura T, 1996, J IMMUNOL, V157, P4277; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	19	180	184	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3117	3120		10.1074/jbc.273.6.3117	http://dx.doi.org/10.1074/jbc.273.6.3117			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452416	hybrid			2022-12-25	WOS:000071822300001
J	Low, SH; Roche, PA; Anderson, HA; van Ijzendoorn, SCD; Zhang, M; Mostov, KE; Weimbs, T				Low, SH; Roche, PA; Anderson, HA; van Ijzendoorn, SCD; Zhang, M; Mostov, KE; Weimbs, T			Targeting of SNAP-23 and SNAP-25 in polarized epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; SYNAPTOSOMAL-ASSOCIATED PROTEIN; NERVE GROWTH-FACTOR; POLYMERIC IMMUNOGLOBULIN RECEPTOR; SYNTAXIN-BINDING PROTEIN; PRIMARY CILIA; CLOSTRIDIAL NEUROTOXINS; BASOLATERAL TRANSPORT; NONNEURONAL TISSUES; NEURITE OUTGROWTH	SNAP-23 is the ubiquitously expressed homologue of the neuronal SNAP-25, which functions in synaptic vesicle fusion, We have investigated the subcellular localization of SNAP-23 in polarized epithelial cells, In hepatocyte-derived HepG2 cells and in Madin-Darby canine kidney (MDCK) cells, the majority of SNAP-23 was present at both the basolateral and apical plasma membrane domains with little intracellular localization, This suggests that SNAP-23 does not function in intracellular fusion events but rather as a general plasma membrane t-SNARE, Canine SNAP-23 is efficiently cleaved by the botulinum neurotoxin E, suggesting that it is the toxin-sensitive factor previously found to be involved in plasma membrane fusion in MDCK cells, The localization of SNAP-25 in transfected MDCK cells was studied for comparison and was found to be identical to SNAP-23 with the exception that SNAP-25 was transported to the primary cilia protruding from the apical plasma membrane, which suggests that subtle differences in the targeting signals of both proteins exist. In contrast to its behavior in neurons, the distribution of SNAP-25 in MDCK cells remained unaltered by treatment with dibutyryl cAMP or forskolin, which, however, caused an increased growth of the primary cilia, Finally, we found that SNAP-23/25 and syntaxin 1A, when coexpressed in MDCK cells, do not stably interact with each other but are independently targeted to the plasma membrane and lysosomes, respectively.	Univ Calif San Francisco, Dept Anat, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, Inst Cardiovasc Res, San Francisco, CA 94143 USA; NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Univ Groningen, Dept Physiol Chem, NL-9713 AV Groningen, Netherlands	University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Groningen	Weimbs, T (corresponding author), Univ Calif San Francisco, Dept Anat, Inst Cardiovasc Res, 513 Parnassus Ave, San Francisco, CA 94143 USA.	weimbs@itsa.ucsf.edu		Roche, Paul/0000-0002-8949-9172; Weimbs, Thomas/0000-0001-9423-5561; mostov, keith/0000-0002-8123-6247	NIAID NIH HHS [R01 AI25144, AI36953, AI39161] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039161, R01AI025144, R01AI036953] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn J, 1996, J BIOL CHEM, V271, P6917, DOI 10.1074/jbc.271.12.6917; Apodaca G, 1996, EMBO J, V15, P1471, DOI 10.1002/j.1460-2075.1996.tb00491.x; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; BINZ T, 1994, J BIOL CHEM, V269, P1617; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Brandstatter JH, 1996, EUR J NEUROSCI, V8, P823, DOI 10.1111/j.1460-9568.1996.tb01268.x; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Calakos N, 1996, PHYSIOL REV, V76, P1; CASANOVA JE, 1991, J BIOL CHEM, V266, P24428; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; DEHOOP MJ, 1993, J CELL SCI, P85; EKER P, 1994, J BIOL CHEM, V269, P18607; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; Gu HH, 1996, J BIOL CHEM, V271, P18100, DOI 10.1074/jbc.271.30.18100; GUNDERSEN GG, 1984, CELL, V38, P779, DOI 10.1016/0092-8674(84)90273-3; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HESS DT, 1992, J NEUROSCI, V12, P4634; HohneZell B, 1996, FEBS LETT, V394, P109, DOI 10.1016/0014-5793(96)00931-3; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; LOW SH, 1991, J BIOL CHEM, V266, P13391; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; Mostov KE, 1995, COLD SPRING HARB SYM, V60, P775, DOI 10.1101/SQB.1995.060.01.083; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; OYLER GA, 1991, P NATL ACAD SCI USA, V88, P5247, DOI 10.1073/pnas.88.12.5247; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Pelham HRB, 1995, COLD SPRING HARB SYM, V60, P105, DOI 10.1101/SQB.1995.060.01.013; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; POOLE CA, 1985, CELL MOTIL CYTOSKEL, V5, P175, DOI 10.1002/cm.970050302; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; RICHTERLANDSBERG C, 1986, J CELL BIOL, V102, P821, DOI 10.1083/jcb.102.3.821; ROTH KE, 1988, J CELL SCI, V89, P457; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; SANNA PP, 1991, DEV BRAIN RES, V59, P104, DOI 10.1016/0165-3806(91)90035-H; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; ULLRICH B, 1994, J PHYSIOL-PARIS, V88, P249, DOI 10.1016/0928-4257(94)90088-4; Valentich J D, 1981, Ann N Y Acad Sci, V372, P384, DOI 10.1111/j.1749-6632.1981.tb15490.x; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Wheatley DN, 1995, PATHOBIOLOGY, V63, P222, DOI 10.1159/000163955; Wheatley DN, 1996, CELL BIOL INT, V20, P73, DOI 10.1006/cbir.1996.0011; ZAAL KJM, 1994, EUR J CELL BIOL, V63, P10	63	90	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3422	3430		10.1074/jbc.273.6.3422	http://dx.doi.org/10.1074/jbc.273.6.3422			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452464	hybrid			2022-12-25	WOS:000071822300049
J	Martina, JA; Daniotti, JL; Maccioni, HJF				Martina, JA; Daniotti, JL; Maccioni, HJF			Influence of N-glycosylation and N-glycan trimming on the activity and intracellular traffic of GD3 synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-SUGAR PYROPHOSPHATASE; SITE-DIRECTED MUTAGENESIS; MOLECULAR-CLONING; MOUSE-BRAIN; RAT RETINA; EXPRESSION; GANGLIOSIDES; PROTEINS; CELLS; PHOSPHORYLATION	GD3 synthase (ST8Sia I) transfers a sialic acid in alpha-2-->8 linkage to the sialic acid moiety of GM3 to form the ganglioside GD3. The cDNAs of GD3 synthases predict several putative N-glycosylation sites. In this work we have examined the occupancy of these sites in a chicken GD3 synthase and how they affect its activity and intracellular traffic. COS-7 cells were transfected with an influenza virus hemagglutinin (HA) epitope-tagged form of GD3 synthase (GD3 synthase-HA). Cells acquired GD3 synthase activity, cell surface GD3 immunoexpression, and GD3 synthase-HA immunoreactivity in the Golgi complex, In Western blots, a main GD3 synthase-HA band of 47 kDa was detected, which was radioactive upon metabolic labeling with [2-H-3] mannose. Tunicamycin prevented the incorporation of [2-H-3]mannose into GD3 synthase-HA, blocked the enzyme activity, and promoted a reduction of the enzyme molecular mass of 6-7 kDa. Timed deglycosylation with N-glycosidase F showed that all three potential N-glycosylation sites of GD3 synthase-HA were glycosylated. The deglycosylated forms were enzymatically more unstable than the native form. Tunicamycin treatment of cells led to retention of GD3 synthase-HA immunoreactivity in the endoplasmic reticulum (ER). Castanospermine and deoxynojirimycin, inhibitors of the ER-processing enzymes Lu-glucosidases I and II, also prevented the exit from the ER but did not essentially affect the enzyme specific activity. 1-Deoxymannojirimycin and swainsonine, inhibitors of mannosidases, did not affect either the enzyme activity or the Golgi localization, Results indicate that (a) N-glycosylation is necessary for GD3 synthase to attain and to maintain a catalytically active folding, and for exiting the ER; and (b) N-glycan trimming in the ER, while not required for enzyme activity, is necessary for proper trafficking of GD3 synthase to the Golgi complex.	Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC,CONICET, RA-5000 Cordoba, Argentina	National University of Cordoba	Maccioni, HJF (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC,CONICET, AP 4,CC 61, RA-5000 Cordoba, Argentina.		Martina, Jose A/C-2772-2013	Martina, Jose/0000-0001-5814-8807				Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Daniotti JL, 1997, INT J DEV NEUROSCI, V15, P767, DOI 10.1016/S0736-5748(97)00027-0; Daniotti JL, 1997, NEUROCHEM INT, V31, P11, DOI 10.1016/S0197-0186(97)00002-8; DeAngelis DA, 1996, J NEUROCHEM, V67, P943; FAST DG, 1993, BIOCHIM BIOPHYS ACTA, V1202, P325, DOI 10.1016/0167-4838(93)90023-K; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; Glombitza GJ, 1997, J BIOL CHEM, V272, P5199, DOI 10.1074/jbc.272.8.5199; GU XB, 1995, J NEUROCHEM, V64, P2295; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HARAGUCHI M, 1995, BIOCHEM J, V312, P273, DOI 10.1042/bj3120273; Kaetzel DM, 1996, BBA-PROTEIN STRUCT M, V1298, P250, DOI 10.1016/S0167-4838(96)00136-7; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LABRIOLA C, 1995, J CELL BIOL, V130, P771, DOI 10.1083/jcb.130.4.771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martina JA, 1996, J NEUROSCI RES, V46, P485, DOI 10.1002/(SICI)1097-4547(19961115)46:4<485::AID-JNR10>3.0.CO;2-Y; MARTINA JA, 1995, J NEUROCHEM, V64, P1274; Maxzud MK, 1997, NEUROCHEM RES, V22, P455, DOI 10.1023/A:1027311811334; MAXZUD MK, 1995, J BIOL CHEM, V270, P20207, DOI 10.1074/jbc.270.34.20207; MOORE SEH, 1993, J BIOL CHEM, V268, P3809; Nagai K, 1997, GLYCOBIOLOGY, V7, P769, DOI 10.1093/glycob/7.6.769; Nguyen TT, 1996, J NEUROCHEM, V67, P645; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; PANZETTA P, 1980, J NEUROCHEM, V35, P100, DOI 10.1111/j.1471-4159.1980.tb12494.x; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SCHEIDELER MA, 1986, J NEUROCHEM, V46, P1639, DOI 10.1111/j.1471-4159.1986.tb01787.x; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; WEITZ G, 1992, J BIOL CHEM, V267, P10039; Yamamoto A, 1996, J NEUROCHEM, V66, P26; Yamamoto A, 1996, GLYCOCONJUGATE J, V13, P471, DOI 10.1007/BF00731480; YAMASHIRO S, 1993, CANCER RES, V53, P5395; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x; ZENG GC, 1995, P NATL ACAD SCI USA, V92, P8670, DOI 10.1073/pnas.92.19.8670; Zeng GC, 1996, BIOCHEM BIOPH RES CO, V226, P319, DOI 10.1006/bbrc.1996.1354	35	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3725	3731		10.1074/jbc.273.6.3725	http://dx.doi.org/10.1074/jbc.273.6.3725			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452504	hybrid			2022-12-25	WOS:000071822300089
J	Na, SY; Kim, HJ; Lee, SK; Choi, HS; Na, DS; Lee, MO; Chung, M; Moore, DD; Lee, JW				Na, SY; Kim, HJ; Lee, SK; Choi, HS; Na, DS; Lee, MO; Chung, M; Moore, DD; Lee, JW			I kappa B beta interacts with the retinoid X receptor and inhibits retinoid-dependent transactivation in lipopolysaccharide-treated cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; PROTEINS; ACTIVATION; FAMILY	To elucidate the molecular action of the NF kappa B inhibitor I kappa B beta, we isolated a number of I kappa B beta interactors using the yeast two-hybrid system, These include the retinoid X receptor (RXR), whose interaction with I kappa B beta is significantly stimulated by the RXR ligand g-cis-retinoic acid, as shown in the yeast system as well as the glutathione S-transferase pull down assays. RXR is a nuclear protein, whereas I kappa B beta accumulates in the nucleus only in cells stimulated with lipopolysaccharide or other inducers that result in prolonged activation of NF kappa beta. Consistent with this, cotransfection with I kappa B beta specifically repressed the 9-cis-RA-induced transcriptional activities of RXR in an lipopolysaccharide-dependent manner. These results suggest a novel I kappa B beta-mediated antagonism between the signaling pathways of NF kappa B and RXR.	Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Univ Ulsan, Coll Med, Dept Biochem, Seoul 138040, South Korea; Yonsei Univ, Coll Med, Dept Microbiol, Seoul 120752, South Korea; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Chonnam National University; Chonnam National University; Chonnam National University; University of Ulsan; Yonsei University; Yonsei University Health System; Harvard University; Massachusetts General Hospital	Lee, JW (corresponding author), Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea.	jlee@chonnam.chonnam.ac.kr			NIDDK NIH HHS [R01 DK43382] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043382] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GOLLNICK H, 1987, Dermatologica (Basel), V175, P182; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; Moore DD, 1995, GLOB MOB SURV; ORFANOS CE, 1983, BRIT J DERMATOL, V109, P55; ORFANOS CE, 1987, DRUGS, V34, P459, DOI 10.2165/00003495-198734040-00003; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Weil R, 1997, J BIOL CHEM, V272, P9942	24	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3212	3215		10.1074/jbc.273.6.3212	http://dx.doi.org/10.1074/jbc.273.6.3212			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452433	hybrid			2022-12-25	WOS:000071822300018
J	Bertrand, F; Atfi, A; Cadoret, A; L'Allemain, G; Robin, H; Lascols, O; Capeau, J; Cherqui, G				Bertrand, F; Atfi, A; Cadoret, A; L'Allemain, G; Robin, H; Lascols, O; Capeau, J; Cherqui, G			A role for nuclear factor kappa B in the antiapoptotic function of insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; RECEPTOR TYROSINE RESIDUE-1162; CASEIN KINASE-II; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; CELL-DEATH; SUPPRESSES APOPTOSIS; SIGNALING PATHWAY; GLUCOSE-TRANSPORT; EPITHELIAL-CELLS	We previously reported that insulin activates nuclear factor kappa B (NF-kappa B) in Chinese hamster ovary (CHO)-R cells overexpressing wild-type insulin receptors (IRs) through a pathway requiring IR tyrosine kinase and Raf-1 kinase activities, We now investigated whether the activation of NF-kappa B by insulin could serve an antiapoptotic function. Insulin (10(-9)-10(-7) M) inhibited apoptosis induced by serum withdrawal in CHO-R cells in a concentration-dependent manner. Insulin antiapoptotic signaling: (i) was dependent on IR number and IR tyrosine kinase activity since it was reduced in parental CHO cells and was abolished in CHO-YB cells overexpressing IRs mutated at Tyr(1162/1163); (ii) was, like insulin activation of NF-KB, dependent on Raf-1 but not on mitogen activated protein kinase activity since both processes were decreased by the dominant-negative Raf-1 mutant Raf-C4 whereas they persisted in mitogen-activated protein kinase-depleted cells; and (iii) required NF-kappa B activation since it was decreased by proteasome inhibitors and the dominant-negative I kappa B-alpha (A32/36) mutant and was mimicked by overexpression of the NF-KB c-Rel subunit, We also show that insulin antiapoptotic signaling but not insulin activation of NF-kappa B involved phosphatidylinositol 3-kinase (PI 3-kinase), as supported by the inhibition of the former but not of the latter process by the PI S-kinase inhibitor LY294002. Inhibition of both NF-kappa B and PI 3-kinase totally abolished insulin antiapoptotic signaling, Thus insulin exerts a specific antiapoptotic function which is dependent on IR tyrosine kinase activity and is mediated by both a Raf-1-dependent pathway that leads to NF-kappa B activation and a PI 3-kinase-dependent pathway.	Fac Med St Antoine, INSERM U402, Inst Fed Rech 65, Biol Cellulaire Lab, F-75571 Paris 12, France; Hop St Antoine, Inst Fed Rech 65, INSERM U482, F-75571 Paris, France; Fac Sci, F-06108 Nice, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Cherqui, G (corresponding author), Fac Med St Antoine, INSERM U402, Inst Fed Rech 65, Biol Cellulaire Lab, 27 Rue Chaligny, F-75571 Paris 12, France.		Cadoret, Axelle/L-2529-2017	Cadoret, Axelle/0000-0002-4283-6864				Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Chappell D, 1997, CELL DEATH DIFFER, V4, P105, DOI 10.1038/sj.cdd.4400219; CHERQUI G, 1990, J BIOL CHEM, V265, P21254; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DESBOIS C, 1992, J BIOL CHEM, V267, P13488; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GRILLI M, 1993, INT REV CYTOL, V143, P1; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KAUFMANZEH A, 1997, NATURE, V385, P5444; KOONG AC, 1994, CANCER RES, V54, P5273; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; Menke AL, 1997, CANCER RES, V57, P1353; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Miller TM, 1997, J BIOL CHEM, V272, P9847; Minshall C, 1996, J IMMUNOL, V156, P939; MUNOZ E, 1994, J VIROL, V68, P8035; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; OWENLYNCH PJ, 1995, J BIOL CHEM, V270, P5956, DOI 10.1074/jbc.270.11.5956; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Parrizas M, 1997, J BIOL CHEM, V272, P154; RAMPALLI AM, 1995, CELL GROWTH DIFFER, V6, P945; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rudin CM, 1997, ANNU REV MED, V48, P267; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zamorano J, 1996, J IMMUNOL, V157, P4926; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	70	94	94	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2931	2938		10.1074/jbc.273.5.2931	http://dx.doi.org/10.1074/jbc.273.5.2931			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446605	hybrid			2022-12-25	WOS:000071736600060
J	Gitt, MA; Xia, YR; Atchison, RE; Lusis, AJ; Barondes, SH; Leffler, H				Gitt, MA; Xia, YR; Atchison, RE; Lusis, AJ; Barondes, SH; Leffler, H			Sequence, structure, and chromosomal mapping of the mouse Lgals6 gene, encoding galectin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING-PROTEIN; LEYDEN CRYSTAL PROTEIN; NEGATIVE GROWTH-FACTOR; S-LAC LECTIN; NUCLEOTIDE-SEQUENCE; 2 MEMBERS; FAMILY; EXPRESSION; DNA; ORGANIZATION	In the accompanying paper (Gitt, M, A., Colnot, C., Poirier, F., and Barondes, S. H., and Leffler, H. (1998) J. Biol. Chem. 273, 2954-2960), we reported that mouse gastrointestinal tract specifically expresses two closely related galectins, galectins-4 and -6, each with two carbohydrate recognition domains in the same peptide. Here, we report the isolation, characterization, and chromosomal mapping of the complete mouse Lgals6 gene, which encodes galectin-6, and of a fragment of a distinct gene, Lgals4, which encodes galectin-4, The coding sequence of galectin-6 is specified by eight exons. The upstream region contains two putative promoters. Both Lgals6 and the closely related Lgals4 are clustered together about 3.2 centimorgans proximal to the apoE gene on mouse chromosome 7. The syntenic human region is 19q13.1-13.3.	Univ Calif San Francisco, Dept Psychiat, Ctr Neurobiol & Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol & Mol Genet, Los Angeles, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Leffler, H (corresponding author), Inst Med Microbiol, Dept Clin Immunol, Solvegatan 23, S-22362 Lund, Sweden.		Leffler, Hakon/A-2416-2019	Leffler, Hakon/0000-0003-4482-8945	NHLBI NIH HHS [HL38627] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038627] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSUBEL FM, 1992, CURRENT PROTOCOLS S, V20; BALDINI A, 1993, GENOMICS, V15, P216, DOI 10.1006/geno.1993.1039; BARBAS JA, 1988, EMBO J, V7, P625, DOI 10.1002/j.1460-2075.1988.tb02856.x; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARLSSON P, 1989, GENE, V77, P113, DOI 10.1016/0378-1119(89)90365-X; CASASNOVAS JM, 1987, NUCLEIC ACIDS RES, V15, P8899, DOI 10.1093/nar/15.21.8899; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CHIARIOTTI L, 1991, BIOCHIM BIOPHYS ACTA, V1089, P54, DOI 10.1016/0167-4781(91)90084-Y; Dyer KD, 1997, GENOMICS, V40, P217, DOI 10.1006/geno.1996.4590; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; Gitt MA, 1998, J BIOL CHEM, V273, P2954, DOI 10.1074/jbc.273.5.2954; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; GRITZMACHER CA, 1992, BIOCHEMISTRY-US, V31, P9533, DOI 10.1021/bi00155a004; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Hurlin PJ, 1995, ONCOGENE, V11, P2487; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Leffler H, 1997, TRENDS GLYCOSCI GLYC, V9, P9, DOI 10.4052/tigg.9.9; LEITH IR, 1988, NUCLEIC ACIDS RES, V16, P8277, DOI 10.1093/nar/16.17.8277; Leonidas DD, 1995, STRUCTURE, V3, P1379, DOI 10.1016/S0969-2126(01)00275-1; LIAO, 1994, P NATL ACAD SCI US, V91, P1428; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; Maniatis T., 1982, MOL CLONING LAB MANU; MASTRIANNI DM, 1992, GENOMICS, V13, P240, DOI 10.1016/0888-7543(92)90237-M; McCrea Kirk W., 1993, Biotechniques, V15, P843; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MEHRABIAN M, 1993, GENOMICS, V15, P418, DOI 10.1006/geno.1993.1078; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; ODA Y, 1993, J BIOL CHEM, V268, P5929; OHYAMA Y, 1988, J BIOCHEM-TOKYO, V104, P173, DOI 10.1093/oxfordjournals.jbchem.a122436; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Raimond J, 1997, MAMM GENOME, V8, P706, DOI 10.1007/s003359900548; ROSENBERG IM, 1993, J BIOL CHEM, V268, P12393; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLOVYEV VV, 1995, P 3 INT C INT SYST M, P367; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; TABOURY JA, 1985, NUCLEIC ACIDS RES, V13, P4469, DOI 10.1093/nar/13.12.4469; Tureci O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/jbc.272.10.6416; VOSS PG, 1994, GLYCOCONJUGATE J, V11, P353, DOI 10.1007/BF00731209; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; WARDEN CH, 1993, GENOMICS, V18, P295, DOI 10.1006/geno.1993.1469; WATSON ML, 1990, J EXP MED, V172, P263, DOI 10.1084/jem.172.1.263; WHEELER MB, 1992, MOL CELL BIOL, V12, P3531, DOI 10.1128/MCB.12.8.3531; WINGENDER E, 1994, J BIOTECHNOL, V35, P273, DOI 10.1016/0168-1656(94)90041-8	52	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2961	2970		10.1074/jbc.273.5.2961	http://dx.doi.org/10.1074/jbc.273.5.2961			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446609	hybrid			2022-12-25	WOS:000071736600064
J	Bergemann, AD; Zhang, L; Chiang, MK; Brambilla, R; Klein, R; Flanagan, JG				Bergemann, AD; Zhang, L; Chiang, MK; Brambilla, R; Klein, R; Flanagan, JG			Ephrin-B3, a ligand for the receptor EphB3, expressed at the midline of the developing neural tube	ONCOGENE			English	Article						Eph; ephrin; receptor; kinase; development; neural	PROTEIN-TYROSINE KINASE; GROWTH-FACTOR; FLOOR PLATE; KIT-LIGAND; TRANSMEMBRANE LIGANDS; MOLECULAR-CLONING; COMMISSURAL AXONS; MESSENGER-RNAS; NERVOUS-SYSTEM; IN-VITRO	The ephrins are a family of ligands that bind to Eph family receptor tyrosine kinases, and have been implicated in axon guidance and other patterning processes during vertebrate development. We describe here the identification and characterization of murine ephrin-B3. The cDNA encodes a 340 amino acid transmembrane molecule, most closely related to the two other known transmembrane ligands, ephrin-B1 and ephrin-B2. In addition to homology in their extracellular receptor binding domains, these transmembrane ligands share striking homology between their cytoplasmic domains, with 31 of the last 34 amino acids of ephrin-B3 being identical to ephrin-B2, suggesting functional interactions of the cytoplasmic tail. While most Eph family ligands are promiscuous in their interactions with Eph receptors, binding studies with the five receptors known to bind other transmembrane ligands only revealed a high affinity interaction of ephrin-B3 with EphB3, with a dissociation constant of approximately 1 nM. In situ hybridization of mouse embryos showed ephrin-B3 is expressed prominently at the dorsal and ventral midline of the neural tube, particularly in the floor plate, a structure with key functions in patterning the nervous system. The isolation of this ligand may help to elucidate the molecular basis of patterning activities at the neural tube midline.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany	Harvard University; Harvard Medical School; European Molecular Biology Laboratory (EMBL)	Flanagan, JG (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.		Klein, Ruediger/C-6147-2008; Flanagan, John/AAM-2995-2020; Brambilla, Riccardo/A-6082-2010	Klein, Ruediger/0000-0002-3109-0163; Brambilla, Riccardo/0000-0003-3569-5706; Bergemann, Andrew/0000-0002-0027-7662	NICHD NIH HHS [HD29417] Funding Source: Medline; NIDDK NIH HHS [DK45580] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD029417, R01HD029417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045580] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brambilla R, 1996, MOL CELL NEUROSCI, V8, P199, DOI 10.1006/mcne.1996.0057; BRAMBILLA R, 1996, MOL CELL NEUROSCI, V6, P487; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CIOSSEK T, 1995, ONCOGENE, V10, P97; CIOSSEK T, 1995, ONCOGENE, V11, P2085; COLAMARINO SA, 1995, ANNU REV NEUROSCI, V18, P497, DOI 10.1146/annurev.ne.18.030195.002433; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Donoghue MJ, 1996, MOL CELL NEUROSCI, V8, P185, DOI 10.1006/mcne.1996.0056; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Flanagan JG, 1997, CELL, V90, P403; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FLANAGAN JG, IN PRESS ANN REV NEU, V21; FLETCHER FA, 1994, GENOMICS, V24, P127, DOI 10.1006/geno.1994.1589; Gale NW, 1996, ONCOGENE, V13, P1343; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GANJU P, 1994, ONCOGENE, V9, P1613; Gao PP, 1996, P NATL ACAD SCI USA, V93, P11161, DOI 10.1073/pnas.93.20.11161; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; Kilpatrick TJ, 1996, MOL CELL NEUROSCI, V7, P62, DOI 10.1006/mcne.1996.0005; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Nicola NA, 1996, GROWTH FACTORS, V13, P141, DOI 10.3109/08977199609034574; NIETO MA, 1992, DEVELOPMENT, V116, P1137; Ohta K, 1996, MECH DEVELOP, V54, P59, DOI 10.1016/0925-4773(95)00461-0; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SAJJADI FG, 1993, ONCOGENE, V8, P1807; Sakano S, 1996, ONCOGENE, V13, P813; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SMITH A, 1997, CURRENT BIOL; SOANS C, 1994, ONCOGENE, V9, P3353; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Stoeckli ET, 1997, NEURON, V18, P209, DOI 10.1016/S0896-6273(00)80262-7; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WU Q, 1995, DEVELOPMENT, V121, P4005; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Zhang JH, 1996, J NEUROSCI, V16, P7182; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117	69	62	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	1998	16	4					471	480		10.1038/sj.onc.1201557	http://dx.doi.org/10.1038/sj.onc.1201557			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484836				2022-12-25	WOS:000071739400005
J	Cambier, N; Chopra, R; Strasser, A; Metcalf, D; Elefanty, AG				Cambier, N; Chopra, R; Strasser, A; Metcalf, D; Elefanty, AG			BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner	ONCOGENE			English	Article						BCR-ABL oncogene; apoptosis	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR P53; V-ABL; PHILADELPHIA-CHROMOSOME; PROGENITOR CELLS; CLONAL ANALYSIS; RAS ONCOGENE; BLAST CRISIS; DNA-DAMAGE	The hallmark of chronic myeloid leukemia (CML) is the chimeric tyrosine kinase oncogene bcp - abl. Since expression of bcr - abl mRNA frequently increases with disease progression and a duplication of the Philadelphia chromosome (harbouring the bcr - abl hybrid locus) represents the most frequent karyotypic abnormality in acute phase CML, we hypothesized that the level of BCR - ABL protein may affect the disease phenotype. Therefore, the biological effects of high and low levels of BCR - ABL expression were compared in growth factor-dependent and -independent myeloid and lymphoid cell lines. Our results demonstrated that low levels of BCR - ABL were sufficient to render these cell lines growth factor independent and tumorigenic, but higher levels were mandatory for additional protection against apoptotic stimuli. The provision of growth factor or an activated ras oncogene did not afford the same degree of protection as high levels of BCR - ABL and there were qualitative differences between the survival signals mediated by BCR - ABL and Bcl-2. These results have enabled us to establish a dose-dependent hierarchy of BCR - ABL induced biological effects, thus distinguishing the activation of pathways mediating protection from cytokine withdrawal from those protecting against other apoptotic stimuli.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute	Elefanty, AG (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, PO Royal Melbourne Hosp, Parkville, Vic 3050, Australia.		Elefanty, Andrew G/A-6066-2008; Strasser, Andreas/C-7581-2013	Strasser, Andreas/0000-0002-5020-4891; Elefanty, Andrew/0000-0001-6448-8314	NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Albrecht T, 1996, BRIT J HAEMATOL, V95, P501, DOI 10.1046/j.1365-2141.1996.d01-1934.x; AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; ANDREWS DF, 1987, LEUKEMIA, V1, P718; ANTONIOU M, 1993, J CELL BIOL, V123, P1055, DOI 10.1083/jcb.123.5.1055; BAKER DA, 1994, LEUKEMIA, V8, P1970; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BOSWELL HS, 1990, EXP HEMATOL, V18, P452; CEROTTINI JC, 1974, J EXP MED, V140, P703, DOI 10.1084/jem.140.3.703; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUMENIL D, 1994, EXP HEMATOL, V22, P178; ELEFANTY AG, 1992, BLOOD, V79, P1271; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GAIGER A, 1995, BLOOD, V86, P2371, DOI 10.1182/blood.V86.6.2371.bloodjournal8662371; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; GROFFEN J, 1987, CHRONIC MYELOID LEUK, P983; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hariharan I K, 1988, Oncogene Res, V3, P387; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Ihle JN, 1996, ADV CANCER RES, V68, P23, DOI 10.1016/S0065-230X(08)60351-6; JACOB MC, 1991, CYTOMETRY, V12, P550, DOI 10.1002/cyto.990120612; KANTARJIAN HM, 1987, AM J MED, V83, P445, DOI 10.1016/0002-9343(87)90754-6; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KEATING A, 1987, CHRONIC MYELOID LEUK, P1021; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; METCALF D, 1988, LEUKEMIA, V2, P216; METCALF D, 1979, INT J CANCER, V24, P616, DOI 10.1002/ijc.2910240515; METCALF D, 1995, LEUKEMIA, V9, P1556; METCALF D, 1977, RECENT RESULTS CANC, V61, P120; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nishii K, 1996, ONCOGENE, V13, P2225; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; SAKAI N, 1994, EXP CELL RES, V215, P131, DOI 10.1006/excr.1994.1324; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854; Zhu JY, 1996, BLOOD, V87, P4368, DOI 10.1182/blood.V87.10.4368.bloodjournal87104368	74	98	101	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					335	348		10.1038/sj.onc.1201490	http://dx.doi.org/10.1038/sj.onc.1201490			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467959				2022-12-25	WOS:000071582100006
J	Steegenga, WT; Riteco, N; Jochemsen, AG; Fallaux, FJ; Bos, JL				Steegenga, WT; Riteco, N; Jochemsen, AG; Fallaux, FJ; Bos, JL			The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells	ONCOGENE			English	Article						p53; adenovirus; E1A; large E1B; E4orf6	HUMAN PAPILLOMAVIRUS TYPE-16; TRANSFORMED-CELLS; EARLY REGION-4; TUMOR-ANTIGEN; E6 ONCOPROTEIN; CELLULAR P53; WILD-TYPE; TRANSCRIPTIONAL REPRESSION; BINDING PROTEIN; EXPRESSION	It has recently been shown that an adenovirus mutant lacking expression of the large E1B protein (Delta E1B) selectively replicates in p53 deficient cells. However, apart from the large E1B protein the adenovirus early region encodes the E1A and E4orf6 proteins which also have been reported to affect p53 expression as well as its functioning. After infection with wild-type adenovirus we observed a dramatic decrease in wild-type p53 expression while no down-regulation of p53 could be detected after infection with the Delta E1B virus. The different effects of the wild-type and Delta E1B adenovirus on p53 expression were not only found in cells expressing wild-type p53 but mere also observed when tumor cells expressing highly stabilized mutant p53 were infected with these two viruses. Infection with different adenovirus mutants indicated the importance of a direct interaction between p53 and the large E1B protein for reduced p53 expression after infection. Moreover, coexpression of the E4orf6 protein was found to be required for this phenomenon, while expression of E1A is dispensable. Tn addition, we provide evidence that p53 is actively degraded in wild-type adenovirus-infected cells but not in Delta E1B-infected cells.	Univ Utrecht, Physiol Chem Lab, NL-3508 TA Utrecht, Netherlands; Leiden Univ, Sylvius Labs, Mol Carcinogenesis Lab, NL-2300 RA Leiden, Netherlands	Utrecht University; Leiden University; Leiden University - Excl LUMC	Steegenga, WT (corresponding author), Univ Utrecht, Physiol Chem Lab, POB 80042, NL-3508 TA Utrecht, Netherlands.							Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRAHAM FL, 1991, GENE TRANSFER EXPRES; GRAND RJA, 1995, VIROLOGY, V210, P323, DOI 10.1006/viro.1995.1349; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grand RJA, 1996, VIROLOGY, V218, P23, DOI 10.1006/viro.1996.0162; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JOCHEMSEN AG, 1987, EMBO J, V6, P3399, DOI 10.1002/j.1460-2075.1987.tb02663.x; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAK I, 1988, VIROLOGY, V163, P201, DOI 10.1016/0042-6822(88)90248-6; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Marcellus RC, 1996, J VIROL, V70, P6207, DOI 10.1128/JVI.70.9.6207-6215.1996; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; STEEGENGA WT, 1995, ONCOGENE, V11, P49; STEEGENGA WT, 1995, VIROLOGY, V212, P543, DOI 10.1006/viro.1995.1512; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; STRATFORDPERRIC.LD, 1991, HUMAN GENE TRANSFER; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; VANDENHEUVEL SJL, 1993, J VIROL, V67, P5226, DOI 10.1128/JVI.67.9.5226-5234.1993; VOJTESEK B, 1993, J CELL SCI, V105, P607; WEINBERG DH, 1983, P NATL ACAD SCI-BIOL, V80, P5383, DOI 10.1073/pnas.80.17.5383; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	53	144	150	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					349	357		10.1038/sj.onc.1201540	http://dx.doi.org/10.1038/sj.onc.1201540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467960				2022-12-25	WOS:000071582100007
J	Bellocq, A; Suberville, S; Philippe, C; Bertrand, F; Perez, J; Fouqueray, B; Cherqui, G; Baud, L				Bellocq, A; Suberville, S; Philippe, C; Bertrand, F; Perez, J; Fouqueray, B; Cherqui, G; Baud, L			Low environmental pH is responsible for the induction of nitric-oxide synthase in macrophages - Evidence for involvement of nuclear factor-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR NF-KAPPA; RENAL EPITHELIAL-CELLS; MESSENGER-RNA LEVELS; TRANSCRIPTION FACTOR; PERITONEAL-MACROPHAGES; PROTEASOME PATHWAY; INTERFERON-GAMMA; MAMMALIAN-CELLS; DNA-BINDING; LIPOPOLYSACCHARIDE	Stimulation of macrophages with endotoxin and/or cytokines is responsible for the expression of the inducible isoform of nitric oxide synthase (MOS). Because macrophages are exposed to low pH within the microenvironment of inflammatory lesions, the potential role of acidic pH as an additional regulator of iNOS was investigated, Substitution of the culture medium of rat peritoneal macrophages at pH 7.4 with medium at pH 7.0 up-regulated iNOS activity, as reflected by a 2.5-fold increase in nitrite accumulation, The increase in iNOS activity was associated with a similar increase in iNOS mRNA expression that reflected an increase in iNOS mRNA synthesis rather than stability, Low environmental pH-induced iNOS gene transcription involved the activation of nuclear factor-kappa B (NF-kappa B) transcription factor since exposure of macrophages to low environmental pH both increased NF-kappa B binding activity in the nucleus and enhanced NF-kappa B-driven reporter gene expression, In addition, treatment of macrophages with pyrrolidine dithiocarbamate or n-acetyl-leucinyl-leucinyl-norleucinal, two drugs preventing NF-kappa B translocation to the nucleus, canceled low pH-induced nitrite accumulation, The overall mechanism required the synthesis of tumor necrosis factor alpha (TNF alpha). Indeed, 1) elevated TNF alpha bioactivity was observed in the medium of macrophages exposed to pH 7.0, and 2) incubation of macrophages with a neutralizing anti-TNF alpha antibody impaired both NF-kappa B activation and nitrite accumulation in response to acid challenge, In summary, exposure of macrophages to acidic microenvironment in inflammatory lesions leads to the up-regulation of iNOS activity through the activation of NF-kappa B.	Hop Tenon, INSERM, U64, F-75020 Paris, France; Hop St Antoine, INSERM, U402, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Baud, L (corresponding author), Hop Tenon, INSERM, U64, 4 Rue Chine, F-75020 Paris, France.	laurent.baud@tnn.ap-hop-paris.fr		BELLOCQ, Agnes/0000-0002-9297-7534				ALARD P, 1993, BIOTECHNIQUES, V15, P730; Bailey JL, 1996, J CLIN INVEST, V97, P1447, DOI 10.1172/JCI118566; BAUD L, 1988, J CELL PHYSIOL, V136, P355, DOI 10.1002/jcp.1041360220; BAUD L, 1989, AM J PHYSIOL, V257, pC232, DOI 10.1152/ajpcell.1989.257.2.C232; BAYDOUN AR, 1994, BRIT J PHARMACOL, V112, P487, DOI 10.1111/j.1476-5381.1994.tb13099.x; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BOUTARD V, 1995, J IMMUNOL, V155, P2077; BRYANT RE, 1980, J INFECT DIS, V142, P594, DOI 10.1093/infdis/142.4.594; CHESROWN SE, 1994, BIOCHEM BIOPH RES CO, V200, P126, DOI 10.1006/bbrc.1994.1424; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DOUVDEVANI A, 1995, KIDNEY INT, V47, P1537, DOI 10.1038/ki.1995.217; GAO J, 1977, J BIOL CHEM, V272, P1226; GHIGO D, 1988, J BIOL CHEM, V263, P19437; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; KAISER S, 1991, J BIOL CHEM, V266, P9397; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LIU SF, 1993, BIOCHEM BIOPH RES CO, V196, P1208, DOI 10.1006/bbrc.1993.2380; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MELLERGARD P, 1994, AM J PHYSIOL, V267, pC581, DOI 10.1152/ajpcell.1994.267.2.C581; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OCONNELL MA, 1995, J BIOL CHEM, V270, P7399, DOI 10.1074/jbc.270.13.7399; PHILIPPE C, 1993, AM J PATHOL, V143, P1713; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SELDEN RF, 1996, CURRENT PROTOCOLS MO; Spink J, 1997, J BIOL CHEM, V272, P24417, DOI 10.1074/jbc.272.39.24417; SWALLOW CJ, 1991, J EXP MED, V174, P1009, DOI 10.1084/jem.174.5.1009; WEINBERG JM, 1991, KIDNEY INT, V39, P476, DOI 10.1038/ki.1991.58; WRIGHT J, 1986, J CLIN INVEST, V77, P782, DOI 10.1172/JCI112375; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YAMAJI Y, 1994, J CLIN INVEST, V94, P1297, DOI 10.1172/JCI117448; Yaqoob M, 1996, KIDNEY INT, V49, P1314, DOI 10.1038/ki.1996.187; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804	38	172	179	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5086	5092		10.1074/jbc.273.9.5086	http://dx.doi.org/10.1074/jbc.273.9.5086			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478960	hybrid			2022-12-25	WOS:000072310400044
J	Kanda, Y; Mitani, K; Kurokawa, M; Yamagata, T; Yazaki, Y; Hirai, H				Kanda, Y; Mitani, K; Kurokawa, M; Yamagata, T; Yazaki, Y; Hirai, H			Overexpression of the MEN/ELL protein, an RNA polymerase II elongation factor, results in transformation of Rat1 cells with dependence on the lysine-rich region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; C-FOS; CHROMOSOME-TRANSLOCATION; DROSOPHILA-TRITHORAX; MYELOID-LEUKEMIA; GENE; TRANSCRIPTION; CLONING; T(11-19)(Q23-P13.1); ONCOGENE	The MEN gene (also called ELL) encodes an RNA polymerase II elongation factor that has been implicated in t(11;19)(q23;p13.1) translocation in myeloid leukemias. The function of another elongation factor, elongin, is known to be inhibited by VHL tumor suppressor protein in vitro, suggesting the possible relationship of aberrant transcriptional elongation to oncogenesis. We overexpressed the MEN protein in Rat1 fibroblasts to evaluate its transforming activity, MEN-overexpressing cells acquired the capacity for anchorage-independent growth, In addition, the growth factor requirement was decreased in these cells, However, cells expressing a deletion mutant of MEN lacking the lysine-rich region did not exhibit such biological abilities, c-Fos protein expression and AP-1 activity were elevated in the MEN-expressing cells, which might be part of the mechanism responsible for the transformation, The c-fos mRNA, the expression of which is known to be regulated partly at the stage of transcriptional elongation, appeared earlier in the MEN-expressing cells than in cells transfected with an empty vector or the deletion mutant lacking the lysine-rich region after stimulation with epidermal growth factor, The RNA polymerase II elongation factor MEN may play an important role in the regulation of cell proliferation.	Univ Tokyo, Fac Med, Dept Cell Therapy & Transplantat Med, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo; University of Tokyo	Hirai, H (corresponding author), Univ Tokyo, Fac Med, Dept Cell Therapy & Transplantat Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.							Ausubel FM, 1992, CURRENT PROTOCOLS MO; BALSALOBRE A, 1995, ONCOGENE, V11, P455; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Kanda Y, 1997, INT J HEMATOL, V66, P189; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PRASAD R, 1993, CANCER RES, V53, P5624; REINES D, 1994, TRANSCRIPTION MECHAN, P263; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDERSCHAULIES J, 1987, EUR J IMMUNOL, V17, P713, DOI 10.1002/eji.1830170521; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1997, J BIOL CHEM, V272, P22355, DOI 10.1074/jbc.272.35.22355; TAN SY, 1994, J BIOL CHEM, V269, P25684; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Thirman MJ, 1997, P NATL ACAD SCI USA, V94, P1408, DOI 10.1073/pnas.94.4.1408; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9	25	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5248	5252		10.1074/jbc.273.9.5248	http://dx.doi.org/10.1074/jbc.273.9.5248			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478981	hybrid			2022-12-25	WOS:000072310400065
J	Petruska, J; Hartenstine, MJ; Goodman, MF				Petruska, J; Hartenstine, MJ; Goodman, MF			Analysis of strand slippage in DNA polymerase expansions of CAG/CTG triplet repeats associated with neurodegenerative disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; TRINUCLEOTIDE REPEATS; MUTATIONS; CTG	Lengthy expansions of trinucleotide repeats are found in DNA of patients suffering severe neurodegenerative age-related diseases, Using a synthetic self-priming DNA, containing CAG and CTG repeats implicated in Huntington's disease and several other neurological disorders, we measure the equilibrium distribution of hairpin folding and generate triplet repeat expansions by polymerase-catalyzed extensions of the hairpin folds, Expansions occur by slippage in steps of two CAG triplets when the self priming sequence (CTG)(16)(CAG)(4) is extended with proofreading-defective Klenow fragment (KF exo(-)) from Escherichia coli DNA polymerase I. Slippage by two triplets is 20 times more frequent than by one triplet, in accordance with our finding that hairpin loops with even numbers of triplets are 1-2 kcal/mol more stable than their odd-numbered counterparts, By measuring triplet repeat expansions as they evolve over time, individual rate constants for expansion from 4 to 18 CAG repeats are obtained, An empirical expression is derived from the data, enabling the prediction of slippage rates from the ratio of hairpin CTG/CTG interactions to CAG/CTG interactions, Slippage is initiated internally in the hairpin folds in preference to melting inward from the 3' terminus, The same triplet expansions are obtained using proofreading-proficient KF exo(+), provided 10-100-fold higher dNTP concentrations are present to counteract the effect of 3'-exonucleolytic proofreading.	Univ So Calif, Hedco Mol Biol Labs, Dept Biol Sci, Los Angeles, CA 90089 USA	University of Southern California	Petruska, J (corresponding author), Univ So Calif, Hedco Mol Biol Labs, Dept Biol Sci, Los Angeles, CA 90089 USA.				NIA NIH HHS [AG 11398] Funding Source: Medline; NIGMS NIH HHS [GM 21422] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021422, R37GM021422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011398] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BEHNKRAPPA A, 1994, HUM MUTAT, V3, P19, DOI 10.1002/humu.1380030104; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; Cossee M, 1997, P NATL ACAD SCI USA, V94, P7452, DOI 10.1073/pnas.94.14.7452; DARLOW JM, 1995, GENETICS, V141, P825; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; GACY AM, 1995, CELL, V81, P533; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; Ji JP, 1996, NUCLEIC ACIDS RES, V24, P2835, DOI 10.1093/nar/24.14.2835; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; SMITH GK, 1995, NUCLEIC ACIDS RES, V23, P4303; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; YU A, 1995, NUCLEIC ACIDS RES, V23, P4055, DOI 10.1093/nar/23.20.4055	22	89	94	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5204	5210		10.1074/jbc.273.9.5204	http://dx.doi.org/10.1074/jbc.273.9.5204			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478975	hybrid			2022-12-25	WOS:000072310400059
J	Xie, WF; Kondo, S; Sandell, LJ				Xie, WF; Kondo, S; Sandell, LJ			Regulation of the mouse cartilage-derived retinoic acid-sensitive protein gene by the transcription factor AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALIGNANT MELANOMA; CLONING; DIFFERENTIATION; ACTIVATION; EXPRESSION; BINDING; CELLS; MIA	The expression of cartilage-derived retinoic acid-sensitive protein (CD-RAP) is initiated at the beginning of chondrogenesis and continues throughout the cartilage development, In chondrocytes, CD-RAP is down-regulated by retinoic acid, To understand the molecular mechanism underlying this regulation and the cell-specific expression, the deletion constructs of the mouse CD-RAP promoter were transfected into chondrocytes and a melanoma cell line, The results revealed a domain that demonstrated high levels of expression specifically in chondrocytes. In this functional domain, we show that a cis-acting element, 5'-GCCTGAGGC-3', binds to the trans-acting factor protein AP-2, Mutation of the AP-2 site on the CD-RAP promoter led to decreased transcription in C5.18 chondrocytes, indicating that this site may act as an activator of transcription, In contrast, increased concentration of AP-2, stimulated by retinoic acid, led to decreased transcription of the CD RAP promoter, an effect that was abolished by mutation of the AP-2 binding site, The effect of AP-2 was further examined by co-transfection of C5.18 and HepG2 cells with the CD-RAP promoter constructs and an AP-2 expression plasmid, In a dose-dependent manner, cotransfection with AP-2 elevated and then decreased CD-RAP promoter activity, Taken together, these results suggest that AP-2 is involved in the biphasic regulation of CD-RAP transcription.	Univ Washington, Dept Orthopaed, Seattle, WA 98108 USA; Univ Washington, Dept Biochem, Seattle, WA 98108 USA; Vet Adm Puget Sound Hlth Care Syst, Seattle, WA 98108 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Sandell, LJ (corresponding author), Washington Univ, Sch Med, Dept Orthopaed Surg, Yalem Res Bldg,Room 704,216 S Kingshighway, St Louis, MO 63110 USA.	sandelll@msnotes.wustl.edu			PHS HHS [R0136994] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BLESCH A, 1994, CANCER RES, V54, P5695; BOGDAHN U, 1989, CANCER RES, V49, P5358; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Bosserhoff AK, 1997, DEV DYNAM, V208, P516, DOI 10.1002/(SICI)1097-0177(199704)208:4<516::AID-AJA7>3.0.CO;2-L; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; COVERT J, 1995, VET IMMUNOL IMMUNOP, V49, P39, DOI 10.1016/0165-2427(95)05451-B; Dietz UH, 1996, J BIOL CHEM, V271, P3311, DOI 10.1074/jbc.271.6.3311; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GRIGORIADIS AE, 1989, ENDOCRINOLOGY, V125, P2103, DOI 10.1210/endo-125-4-2103; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IWAMOTO M, 1993, EXP CELL RES, V205, P213, DOI 10.1006/excr.1993.1079; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KOCHHAR DM, 1967, ACTA PATHOL MIC SC, V70, P398; KONDO S, 1998, ORTHOP T, V21, P28; KUETTNER KE, 1982, J CELL BIOL, V93, P743, DOI 10.1083/jcb.93.3.743; LANGMAN J, 1967, J COMP NEUROL, V131, P15, DOI 10.1002/cne.901310103; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; Mangelsdorf David J., 1994, P319; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MOSER M, 1995, DEVELOPMENT, V121, P2779; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SNAPE AM, 1991, DEVELOPMENT, V113, P283; TAMARIN A, 1984, J EMBRYOL EXP MORPH, V84, P105; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	34	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5026	5032		10.1074/jbc.273.9.5026	http://dx.doi.org/10.1074/jbc.273.9.5026			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478951	hybrid			2022-12-25	WOS:000072310400035
J	Coombs, GS; Bergstrom, RC; Madison, EL; Corey, DR				Coombs, GS; Bergstrom, RC; Madison, EL; Corey, DR			Directing sequence-specific proteolysis to new targets - The influence of loop size and targets sequence on selective proteolysis by tissue-type plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL NUCLEASE; SUBSTRATE-SPECIFICITY; OMEGA-LOOP; SITE; PROTEIN; IDENTIFICATION; MUTAGENESIS; EXPRESSION; CATALYSIS; MECHANISM	We have previously used substrate phage display to identify peptide sequences that are efficiently and selectively cleaved by tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA), We demonstrate that this information can be used to direct selective proteolysis to new protein targets, Sequences that were labile to selective cleavage by t-PA or u-PA when in the context of a peptide were introduced into the 43-52 (or Omega) loop of staphylococcal nuclease, Both t-PA and u-PA hydrolyze the engineered proteins at the inserted target sequences, and K-m values for protein cleavage were reduced up to 200-fold relative to values for cleavage of analogous sequences within 15 residue peptides, Variation of loop size surrounding a target sequence affects the efficiency of t-PA approximately 5-fold more strongly than that of trypsin, suggesting that cleavage by t-PA is more dependent on target site mobility, Cleavage of proteins by t-PA and u-PA is sequence selective, u-PA is 47-fold more active than t-PA for cleavage of a sequence known to be u-PA selective within small peptide substrates, whereas t-PA is 230-fold more active toward a t-PA-selective sequence.	Scripps Res Inst, Dept Vasc Biol VB1, La Jolla, CA 92037 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	Scripps Research Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Corey, DR (corresponding author), Scripps Res Inst, Dept Vasc Biol VB1, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Corey@howie.swmed.edu		Coombs, Gary/0000-0002-0711-185X	NHLBI NIH HHS [P01 HL31950, R01 HL52475] Funding Source: Medline; NIGMS NIH HHS [T32GM08203] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R01HL052475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008203] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDISSERI DM, 1991, BIOCHEMISTRY-US, V30, P3628, DOI 10.1021/bi00229a006; BUNTON CA, 1960, J CHEM SOC, P3293, DOI 10.1039/jr9600003293; CHAPMAN KT, 1993, J MED CHEM, V36, P4293, DOI 10.1021/jm00078a019; CHATTERJEE S, 1995, J MOL BIOL, V245, P311, DOI 10.1006/jmbi.1994.0025; Coombs GS, 1996, J BIOL CHEM, V271, P4461; CUATRECA.P, 1967, J BIOL CHEM, V242, P1541; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; GUTHRIE JP, 1977, J AM CHEM SOC, V99, P3391; HALE SP, 1993, BIOCHEMISTRY-US, V32, P7479, DOI 10.1021/bi00080a020; HAMILTON RT, 1991, MOL REPROD DEV, V30, P285, DOI 10.1002/mrd.1080300402; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; JUDICE JK, 1993, SCIENCE, V261, P1578, DOI 10.1126/science.8103944; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Ke SH, 1997, J BIOL CHEM, V272, P16603, DOI 10.1074/jbc.272.26.16603; Ke SH, 1997, J BIOL CHEM, V272, P20456, DOI 10.1074/jbc.272.33.20456; KUMAMOTO J, 1956, J AM CHEM SOC, V78, P4858, DOI 10.1021/ja01600a012; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; Niedbala M J, 1993, Agents Actions Suppl, V42, P179; POOLE LB, 1991, BIOCHEMISTRY-US, V30, P3621, DOI 10.1021/bi00229a005; RYPNIEWSKI WR, 1994, PROTEIN ENG, V7, P57, DOI 10.1093/protein/7.1.57; SERPERSU EH, 1987, BIOCHEMISTRY-US, V26, P1289, DOI 10.1021/bi00379a014; SHORTLE D, 1986, J CELL BIOCHEM, V30, P281, DOI 10.1002/jcb.240300402; Sim R B, 1993, Int Rev Immunol, V10, P65, DOI 10.3109/08830189309051172; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; TAKAHARA M, 1985, J BIOL CHEM, V260, P2670; TANIUCHI H, 1967, P NATL ACAD SCI USA, V58, P1235, DOI 10.1073/pnas.58.3.1235; TANIUCHI H, 1968, J BIOL CHEM, V243, P4778; Taylor J. R., 1982, INTRO ERROR ANAL STU; TORCHIA DA, 1989, BIOCHEMISTRY-US, V28, P5509, DOI 10.1021/bi00439a028; Werb Z, 1992, Matrix Suppl, V1, P337	38	27	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4323	4328		10.1074/jbc.273.8.4323	http://dx.doi.org/10.1074/jbc.273.8.4323			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468480	hybrid			2022-12-25	WOS:000072115000008
J	Hoffman, GR; Nassar, N; Oswald, RE; Cerione, RA				Hoffman, GR; Nassar, N; Oswald, RE; Cerione, RA			Fluoride activation of the Rho family GTP-binding protein Cdc42Hs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; GS-ALPHA; TRANSDUCIN; MECHANISM; DOMAIN; IDENTIFICATION; KINASE; SPECTROSCOPY; HYDROLYSIS; MUTATIONS	Aluminum tetrafluoride (AlF4-) activation of heterotrimeric G-protein alpha-subunits is a well established aspect of the biochemistry of these proteins; however, until recently it has been thought that AlF4- does not mediate effects on the Ras superfamily of low molecular weight GTP-binding proteins. Recent work demonstrating aluminum fluoride-induced complex formation between Ras and its GTPase-activating proteins (RasGAP and NF1) has provided important insights into the mechanism of GAP-stimulated GTP hydrolysis. We have characterized the AlF4--induced complex formation between the GDP-bound form of the Rho subfamily G-protein Cdc42Hs and a limit functional domain of the Cdc42-GAP using a variety of biochemical techniques. Our results indicate that the apparent affinity of GAP for the AlF4--mediated complex ids similar to the affinity observed for the activated (GTP-bound) form of Cdc42 and that beryllium (Be) can replace aluminum in mediating fluoride-induced complex formation. Additionally, the AlF4--induced interaction is weakened significantly by the catalytically compromised GAP(R305A) mutant, indicating that this arginine is critical in transition state stabilization. Unlike Ras, we find that AlF4- and BeF3- mediate complex formation between Cdc42Hs.GDP and downstream target/effector molecules, indicating that there are important differences in the mechanism of effector binding between the Ras and Rho subfamily G-proteins.	Cornell Univ, Dept Pharmacol, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Dept Pharmacol, Ithaca, NY 14853 USA.				NEI NIH HHS [EY06429] Funding Source: Medline; NIGMS NIH HHS [GM47458] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; AHMED S, 1994, J BIOL CHEM, V269, P17642; ANTONNY B, 1992, J BIOL CHEM, V267, P6710; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DARWISH AA, 1981, J LIQ CHROMATOGR, V4, P1511, DOI 10.1080/01483918108064826; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HART MJ, 1991, J BIOL CHEM, V266, P20840; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDOP C, 1984, J BIOL CHEM, V259, P696	35	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4392	4399		10.1074/jbc.273.8.4392	http://dx.doi.org/10.1074/jbc.273.8.4392			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468490	hybrid			2022-12-25	WOS:000072115000018
J	Ishikawa, K; Matera, KM; Zhou, H; Fujii, H; Sato, M; Yoshimura, T; Ikeda-Saito, M; Yoshida, T				Ishikawa, K; Matera, KM; Zhou, H; Fujii, H; Sato, M; Yoshimura, T; Ikeda-Saito, M; Yoshida, T			Identification of histidine 45 as the axial heme iron ligand of heme oxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; CARBON-MONOXIDE; ESCHERICHIA-COLI; CATALYTIC SITE; DEGRADATION; EXPRESSION; COMPLEX; CDNA; SYSTEM; PURIFICATION	A truncated, soluble, and enzymatically active form of human heme oxygenase-2 (Delta HHO2) was expressed in Escherichia coli, To identify the axial heme ligand of HO-2, His-45 to Ala (Delta H45A) and His-152 to Ala (Delta H152A) mutants have been prepared using this expression system. Delta H45A could form a 1:1 complex with hemin but was completely devoid of the heme degradation activity, A 5-coordinate-type ferrous NO EPR spectrum was ob served for the heme-Delta H45A complex, The Delta H152A mutant was expressed as an inclusion body and was recovered from the lysis pellet by dissolution in urea followed by dialysis. The solubilized fraction obtained, however, was composed of a mixture of a functional enzyme and an inactive fraction. The inactive fraction was removed by Sephadex G-75 column chromatography since it eluted out of the column at the void volume, The gel filtration-purified Delta H152A exhibited spectroscopic and enzymatic properties identical to those of wild-type. We conclude, in contrast to the previous reports (McCoubrey and Maines (1993) Arch. Biochem. Biophys. 302, 402-408; McCoubrey, W, K., Jr., Huang, T, J., and Maines, M. (1997) J. Biol, Chem. 272, 12568-12574), that His 45, but not His-152, in heme oxygenase isoform-a is the proximal ligand of the heme and is essential for the heme degradation activity of the enzyme, His-152 appears to play a structural role in stabilization of the heme oxygenase protein.	Yamagata Univ, Sch Med, Dept Biochem, Yamagata 99023, Japan; Yamagata Univ, Sch Med, Cent Lab Res & Educ, Yamagata 99023, Japan; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Yamagata Techonopolis Fdn, Inst Life Support Technol, Yamagata 990, Japan	Yamagata University; Yamagata University; Case Western Reserve University	Yoshida, T (corresponding author), Yamagata Univ, Sch Med, Dept Biochem, Yamagata 99023, Japan.		Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015		NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051588] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05659] Funding Source: Medline; NIGMS NIH HHS [GM51588] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNE B, 1987, MOL PHARMACOL, V32, P497; HARGROVE M, 1994, BIOCHEMISTRY-US, V33, P11676; ISHIKAWA K, 1991, EUR J BIOCHEM, V202, P161, DOI 10.1111/j.1432-1033.1991.tb16357.x; ISHIKAWA K, 1995, J BIOL CHEM, V270, P6345, DOI 10.1074/jbc.270.11.6345; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; KIKUCHI G, 1980, TRENDS BIOCHEM SCI, V5, P323, DOI 10.1016/0968-0004(80)90141-3; KON H, 1975, BIOCHIM BIOPHYS ACTA, V379, P103, DOI 10.1016/0005-2795(75)90012-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MARSTON FAO, 1984, BIO-TECHNOL, V2, P800, DOI 10.1038/nbt0984-800; Matera KM, 1997, BIOCHEMISTRY-US, V36, P4909, DOI 10.1021/bi962321m; MCCOUBREY WK, 1993, ARCH BIOCHEM BIOPHYS, V302, P402, DOI 10.1006/abbi.1993.1231; MCCOUBREY WK, 1992, ARCH BIOCHEM BIOPHYS, V295, P13, DOI 10.1016/0003-9861(92)90481-B; McCoubrey WK, 1997, J BIOL CHEM, V272, P12568, DOI 10.1074/jbc.272.19.12568; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; NOGUCHI M, 1983, J BIOCHEM, V93, P1027, DOI 10.1093/oxfordjournals.jbchem.a134226; ROTENBERG MO, 1990, J BIOL CHEM, V265, P7501; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SPRINGER BA, 1994, CHEM REV, V94, P69; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Wilks A, 1996, BIOCHEMISTRY-US, V35, P930, DOI 10.1021/bi952405f; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YOSHIDA T, 1991, EUR J BIOCHEM, V199, P729, DOI 10.1111/j.1432-1033.1991.tb16177.x; YOSHIDA T, 1978, J BIOL CHEM, V253, P4230; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x	33	19	19	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4317	4322		10.1074/jbc.273.8.4317	http://dx.doi.org/10.1074/jbc.273.8.4317			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468479	hybrid			2022-12-25	WOS:000072115000007
J	Tibbs, GR; Liu, DT; Leypold, BG; Sigelbaum, SA				Tibbs, GR; Liu, DT; Leypold, BG; Sigelbaum, SA			A state-independent interaction between ligand and a conserved arginine residue in cyclic nucleotide-gated channels reveals a functional polarity of the cyclic nucleotide binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; AMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; REGULATORY SUBUNIT; POTASSIUM CHANNEL; K+ CHANNEL; ARABIDOPSIS-THALIANA; MOLECULAR MECHANISM; ION-CHANNEL; CAMP	Activation of cyclic nucleotide-gated channels is thought to involve two distinct steps: a recognition event in which a ligand binds to the channel and a conformational change that both opens the channel and increases the affinity of the channel for an agonist, Sequence similarity with the cyclic nucleotide binding sites of cAMP- and cGMP-dependent protein kinases and the bacterial catabolite activating protein (CAP) suggests that the channel ligand binding site consists of a beta-roll and three alpha-helices, Recent evidence has demonstrated that the third (or C) alpha-helix moves relative to the agonist upon channel activation, forming additional favorable contacts with the purine ring, Here we ask if channel activation also involves structural changes in the beta-roll by investigating the contribution of a conserved arginine residue that, in CAP and the kinases, forms an important ionic interaction with the cyclized phosphate of the bound ligand, Mutations that conserve, neutralize, or reverse the charge on this arginine decreased the apparent affinity for ligand over four orders of magnitude but had little effect on the ability of bound ligand to open the channel, These data indicate that the cyclized phosphate of the nucleotide approaches to within 2-4 Angstrom of the arginine, forming a favorable ionic bond that is largely unaltered upon activation, Thus, the binding site appears to be polarized into two distinct structural and functional domains: the beta-roll stabilizes the ligand in a state-independent manner, whereas the C-helix selectively stabilizes the ligand in the open state of the channel. It is likely that these distinct contributions of the nucleotide/C-helix and nucleotide/beta-roll interactions may also be a general feature of the mechanism of activation of other cyclic nucleotide-binding proteins.	Columbia Univ, Dept Pharmacol, Ctr Neurobiol & Behav, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute	Tibbs, GR (corresponding author), Columbia Univ, Dept Pharmacol, Ctr Neurobiol & Behav, 722 W 168th St, New York, NY 10032 USA.							AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; ALTENHOFEN W, 1991, P NATL ACAD SCI USA, V88, P9868, DOI 10.1073/pnas.88.21.9868; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BELDUZ AO, 1993, NUCLEIC ACIDS RES, V21, P1827, DOI 10.1093/nar/21.8.1827; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; BUBIS J, 1988, J BIOL CHEM, V263, P9668; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; COSSART P, 1982, NUCLEIC ACIDS RES, V10, P1363, DOI 10.1093/nar/10.4.1363; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; DOSTMANN WRG, 1991, BIOCHEMISTRY-US, V30, P8710, DOI 10.1021/bi00099a032; Gaymard F, 1996, J BIOL CHEM, V271, P22863, DOI 10.1074/jbc.271.37.22863; Gordon SE, 1997, NEURON, V19, P431, DOI 10.1016/S0896-6273(00)80951-4; GORDON SE, 1995, NEURON, V14, P857, DOI 10.1016/0896-6273(95)90229-5; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; GRONENBORN AM, 1988, BIOCHEM J, V253, P801, DOI 10.1042/bj2530801; GRONENBORN AM, 1982, BIOCHEMISTRY-US, V21, P4040, DOI 10.1021/bi00260a020; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Kramer RH, 1996, J NEUROSCI, V16, P1285; KUMAR VD, 1992, BIOCHEMISTRY-US, V31, P4643, DOI 10.1021/bi00134a015; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOORE J, 1992, J BACTERIOL, V174, P8030, DOI 10.1128/JB.174.24.8030-8035.1992; OGREID D, 1988, J BIOL CHEM, V263, P17397; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; Scott SP, 1996, PROTEIN ENG, V9, P333, DOI 10.1093/protein/9.4.333; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SHEN NV, 1993, NEURON, V11, P67; STEINBERG RA, 1991, J BIOL CHEM, V266, P3547; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Tibbs GR, 1997, NATURE, V386, P612, DOI 10.1038/386612a0; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; TU LW, 1995, BIOPHYS J, V68, P147, DOI 10.1016/S0006-3495(95)80169-4; Varnum MD, 1997, SCIENCE, V278, P110, DOI 10.1126/science.278.5335.110; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	44	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4497	4505		10.1074/jbc.273.8.4497	http://dx.doi.org/10.1074/jbc.273.8.4497			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468504	hybrid			2022-12-25	WOS:000072115000032
J	Welsh, M; Zhou, SY; Frantz, JD; Trub, T; Reedquist, KA; Karlsson, T; Miyazaki, M; Cantley, LC; Band, H; Shoelson, SE				Welsh, M; Zhou, SY; Frantz, JD; Trub, T; Reedquist, KA; Karlsson, T; Miyazaki, M; Cantley, LC; Band, H; Shoelson, SE			Stimulation through the T cell receptor leads to interactions between SHB and several signaling proteins	ONCOGENE			English	Article						Shb; Jurkat T cells; T cell receptor; p36/38; SH2 domain; PTB domain	ANTIGEN RECEPTOR; TYROSINE KINASE; ZETA-CHAIN; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOLIPASE C-GAMMA-1; ADAPTER PROTEIN; ACTIVATION; DOMAIN; PHOSPHOTYROSINE; ASSOCIATION	Shb is a recently described Src homology 2 (SH2) domain-containing adaptor protein. Here we show that Shb is expressed in lymphoid tissues, and is recruited into signaling complexes upon activation of Jurkat T cells. Grb2 binds proline-rich motifs in Shb via its SH3 domains, As a result, a number of proteins detected in anti-Shb and anti-Grb2 immunoprecipitates are shared, including phosphoproteins of 22, 36/38, 55/57 and 70 kDa. Shb-association with p22, which represents the T cell receptor associated zeta chain, occurs through the Shb SH2 domain. The central region of Shb binds p36/38. Since this interaction was inhibited by phosphotyrosine, this region of Shb is likely to contain a non-SH2 PTB (phosphotyrosine binding) domain. The Shb PTB domain tvas found to preferentially bind the sequence Asp-Asp-X-pTyr when incubated with a phosphopeptide library, A peptide corresponding to a phosphorylation site in 34 kDa Lnk inhibited association between Shb and p36/38. Overexpression of Shb in Jurkat cells led to increased basal phosphorylation of Shb-associated p36/38 and p70 proteins, Inactivation of the Shb SH2 domain by an R522K mutation resulted in a reduced stimulation of tyrosine phosphorylation of several proteins in response to CD3 crosslinking when expressed in Jurkat cells. Together, our results show three distinct domains of Shb all participate in the formulation of multimeric signaling complexes in activated T cells. These results indicate that the Shb protein functions in T cell receptor signaling.	Uppsala Univ, Dept Med Cell Biol, Uppsala, Sweden; Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Brigham & Womens Hosp, Div Rheumatol & Immunol, Lymphocyte Biol Sect, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Hosp, Div Signal Transduct, Boston, MA USA	Uppsala University; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Welsh, M (corresponding author), Biomedicum, Dept Med Cell Biol, Box 571, S-75123 Uppsala, Sweden.		Welsh, Michael/AAF-8564-2020; Miyazaki, Masaya/F-8520-2012; Cantley, Lewis C/D-1800-2014	Welsh, Michael/0000-0002-5467-9755; Miyazaki, Masaya/0000-0003-4031-7224; Cantley, Lewis C/0000-0002-1298-7653	NIAMS NIH HHS [AR36308] Funding Source: Medline; NIDDK NIH HHS [DK36836, DK45943] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK045943] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUDAY L, 1994, J BIOL CHEM, V269, P9019; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; KARLSSON T, 1995, ONCOGENE, V10, P1475; Karlsson T, 1996, ONCOGENE, V13, P955; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; THOMPSON PA, 1992, ONCOGENE, V7, P719; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; TRUB T, 1995, J BIOL CHEM, V270, P18205; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WELSH M, 1994, ONCOGENE, V9, P19; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407	28	50	55	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					891	901		10.1038/sj.onc.1201607	http://dx.doi.org/10.1038/sj.onc.1201607			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484780				2022-12-25	WOS:000072053200008
J	Brink, R; Lodish, HF				Brink, R; Lodish, HF			Tumor necrosis factor receptor (TNFR)-associated factor 2A (TRAF2A), a TRAF2 splice variant with an extended RING finger domain that inhibits TNFR2-mediated NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER; CELL-DEATH; CYTOPLASMIC DOMAIN; SIGNALING PROTEINS; INDUCED APOPTOSIS; FACTOR FAMILY; CONTAINS 2; CD40; INTERACTS	We describe here the identification and characterization of tumor necrosis factor receptor (TNFR)-associated factor 2A (TRAF2A), a splice variant of the TRAF2 molecule utilized for signal transduction by members of the TNFR family. TRAF2A and TRAF2 cDNAs are identical in sequence with the exception of an extra 21 base pairs of sequence encoding a 7-amino acid insert within the TRAF2A RING finger domain. TRAF2A mRNA expression is regulated in a tissue-specific manner, with relative TRAF2A mRNA levels being highest in spleen and lowest in brain. TRAF2A protein is capable of binding to the cytoplasmic domain of TNFR2 (p75) and is detectable in T-lymphoma cells stably transfected with the TRAF2A cDNA. Unlike TRAF2, TRAF2A has a short half-life (similar to 100 min) in these cells and is expressed at only low levels in transiently transfected COS-7 cells. However, TRAF2A levels in transiently transfected COS-7 cells approach those of TRAF2 upon coexpression with TRAF1 and/or TRAF2, indicating that TRAF2A stability is regulated by the binding of other TRAF family proteins. Also in contrast to TRAF2, TRAF2A is unable to stimulate NF-kappa B activity when overexpressed in 293 cells and acts as a dominant inhibitor of TNFR2-dependent NF-kappa B activation. TRAF2A thus represents a novel signal transduction protein, the expression of which can act to inhibit TRAF2-dependent NF-kappa B activation.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	Brink, R (corresponding author), Centenary Inst Canc Med & Cell Biol, Locked Bag 6, Newtown, NSW 2042, Australia.	R.Brink@centenary.usyd.edu.au	Brink, Robert/B-7910-2010	Brink, Robert/0000-0002-9586-3655	NATIONAL CANCER INSTITUTE [R01CA063260] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-63260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	37	60	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4129	4134		10.1074/jbc.273.7.4129	http://dx.doi.org/10.1074/jbc.273.7.4129			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461607	hybrid			2022-12-25	WOS:000072048400049
J	Gupta, SK; Lysko, PG; Pillarisetti, K; Ohlstein, E; Stadel, JM				Gupta, SK; Lysko, PG; Pillarisetti, K; Ohlstein, E; Stadel, JM			Chemokine receptors in human endothelial cells - Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; PLATELET FACTOR-IV; X-C CHEMOKINE; MOLECULAR-CLONING; IMMUNODEFICIENCY-VIRUS; HIV-1 ENTRY; LYMPHOCYTE CHEMOATTRACTANT; CHROMOSOMAL LOCALIZATION; INTERLEUKIN-8 RECEPTORS; FOAM CELLS	Chemokines play an important role in the regulation of endothelial cell (EC) function, including proliferation, migration and differentiation during angiogenesis, and re-endothelialization after injury. In this study, reverse transcriptase-polymerase chain reaction was used to reveal expression of various CXC and CC chemokine receptors in human umbilical vein EC, Northern analysis showed. that CXCR4 was selectively expressed in vascular EC, but not in smooth muscle cells. Compared with other chemokines, stromal cell derived factor-1 alpha (SDF-1 alpha), the known CXCR4 ligand, was an efficacious chemoattractant. for EC, causing the migration of similar to 40% input cells with an EC50 of 10-20 nM., Of the chemokines tested, only SDF-1 alpha induced a rapid, though variable mobilization of intracellular Ca2+ in EC. Experiments with actinomycin D demonstrated that CXCR4 transcripts were short-lived, indicating a rapid mRNA turnover. Interferon-gamma (IFN-gamma) caused a pronounced downregulation of CXCR4 mRNA in a concentration-and time-dependent manner, In a striking functional correlation, IFN-gamma treatment also attenuated the chemotactic response of EC to SDF-1 alpha, IL-1 beta, tumor necrosis factor-al and lipopolysaccharide produced a time course-dependent biphasic effect on CXCR4 transcription Expression of CXCR4 in EC is significant, more so as it and several CC chemokine receptors have been shown to serve as fusion ca-receptors along with CD4 during human immunodeficiency virus infection. Taken together, these findings provide evidence of chemokine receptor expression in EC and offer an explanation for the action of chemokines like SDF-1 alpha on the vascular endothelium.	SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA	GlaxoSmithKline	Gupta, SK (corresponding author), SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, Mail Code UW2511, King Of Prussia, PA 19406 USA.							Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; CORBEIL J, 1995, IMMUNOL CELL BIOL, V73, P140, DOI 10.1038/icb.1995.22; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GERRITY RG, 1981, AM J PATHOL, V103, P181; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; GUPTA SK, 1994, J CELL BIOL, V127, P1121, DOI 10.1083/jcb.127.4.1121; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; GUPTA SK, 1993, GENE, V124, P287, DOI 10.1016/0378-1119(93)90407-T; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOCH AE, 1995, SCIENCE, V268, P448, DOI 10.1126/science.268.5209.448; LABRANCHE CC, 1994, J VIROL, V68, P5509, DOI 10.1128/JVI.68.9.5509-5522.1994; LEE J, 1992, J BIOL CHEM, V267, P16283; LLOYD AR, 1995, J BIOL CHEM, V270, P28188; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; LYSKO PG, 1994, STROKE, V25, P2476, DOI 10.1161/01.STR.25.12.2476; MACIAG T, 1988, ENDOTHELIAL CELLS, V2, P3; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MOSES AV, 1993, P NATL ACAD SCI USA, V90, P10474, DOI 10.1073/pnas.90.22.10474; Murray HW, 1996, INTENS CARE MED, V22, pS456, DOI 10.1007/BF01743724; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Rot A, 1996, J LEUKOCYTE BIOL, V59, P39, DOI 10.1002/jlb.59.1.39; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SCHONBECK U, 1995, J IMMUNOL, V154, P2375; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Sica A, 1997, J EXP MED, V185, P969, DOI 10.1084/jem.185.5.969; STARY HC, 1987, ATHEROSCLEROSIS, V64, P91, DOI 10.1016/0021-9150(87)90234-6; STEFFAN AM, 1992, P NATL ACAD SCI USA, V89, P1582, DOI 10.1073/pnas.89.5.1582; STOECKLE M Y, 1990, New Biologist, V2, P313; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; Tangirala RK, 1997, J BIOL CHEM, V272, P8050, DOI 10.1074/jbc.272.12.8050; WATSON CA, 1995, SCIENCE, V268, P447, DOI 10.1126/science.7716553	54	384	402	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4282	4287		10.1074/jbc.273.7.4282	http://dx.doi.org/10.1074/jbc.273.7.4282			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461627	hybrid			2022-12-25	WOS:000072048400069
J	Ichimura, T; Bonventre, JV; Bailly, V; Wei, H; Hession, CA; Cate, RL; Sanicola, M				Ichimura, T; Bonventre, JV; Bailly, V; Wei, H; Hession, CA; Cate, RL; Sanicola, M			Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING GDNF; RHINOVIRUS RECEPTOR; GROWTH-FACTOR; EXPRESSION; MADCAM-1; FAILURE; VIMENTIN; ANTIGEN; CLONING; BINDING	We report the identification of rat and human cDNAs for a type 1 membrane protein that contains a novel six-cysteine immunoglobulin-like domain and a mucin domain; it is named kidney injury molecule-1 (KIM-1). Structurally, KIM-1 is a member of the immunoglobulin gene superfamily most reminiscent of mucosal addressin cell adhesion molecule 1 (MAdCAM-1). Human KIM-1 exhibits homology to a monkey gene, hepatitis A virus cell receptor 1 (HAVcr-1), which was identified recently as a receptor for the hepatitis A virus, KIM-1 mRNA and protein are expressed at a low level in normal kidney but are increased dramatically in postischemic kidney, In situ hybridization and immunohistochemistry revealed that KIM-1 is expressed in proliferating bromodeoxyuridine-positive and dedifferentiated vimentin-positive epithelial cells in regenerating proximal tubules, Structure and expression data suggest that KIM-1 is an epithelial cell adhesion molecule up-regulated in the cells, which are dedifferentiated and undergoing replication, KIM-1 may play an important role in the restoration of the morphological integrity and function to postischemic kidney.	Biogen Inc, Cambridge Ctr 14, Cambridge, MA 01242 USA; Massachusetts Gen Hosp East, Renal Unit, Med Serv, Boston, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02129 USA	Biogen; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Sanicola, M (corresponding author), Biogen Inc, Cambridge Ctr 14, Cambridge, MA 01242 USA.		Wilson, Matthew H/K-3193-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039773, R01DK039773] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39773] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barclay A.N., 1993, LEUCOCYTE ANTIGEN FA; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOLIGORSKY MS, 1993, P NATL ACAD SCI USA, V90, P5700, DOI 10.1073/pnas.90.12.5700; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HAMMERMAN MR, 1994, J AM SOC NEPHROL, V5, P1; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; ICHIMURA T, 1995, AM J PHYSIOL-RENAL, V269, pF653, DOI 10.1152/ajprenal.1995.269.5.F653; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Kaplan G, 1996, EMBO J, V15, P4282, DOI 10.1002/j.1460-2075.1996.tb00803.x; KELLY KJ, 1994, P NATL ACAD SCI USA, V91, P812, DOI 10.1073/pnas.91.2.812; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; MALIS CD, 1983, AM J PHYSIOL, V245, pF735, DOI 10.1152/ajprenal.1983.245.6.F735; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Muller U, 1997, CELL, V88, P603, DOI 10.1016/S0092-8674(00)81903-0; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; SHI SR, 1993, J HISTOCHEM CYTOCHEM, V41, P1599, DOI 10.1177/41.11.7691930; SHIMIZU Y, 1993, NATURE, V366, P630, DOI 10.1038/366630a0; Shyjan AM, 1996, J IMMUNOL, V156, P2851; SIGEL MB, 1983, METHOD ENZYMOL, V93, P3; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907; VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613, DOI 10.1152/ajpgi.1995.269.5.G613; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALLIN A, 1992, LAB INVEST, V66, P474; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214	42	894	984	3	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4135	4142		10.1074/jbc.273.7.4135	http://dx.doi.org/10.1074/jbc.273.7.4135			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461608	hybrid			2022-12-25	WOS:000072048400050
J	Munch-Petersen, B; Piskur, J; Sondergaard, L				Munch-Petersen, B; Piskur, J; Sondergaard, L			Four deoxynucleoside kinase activities from Drosophila melanogaster are contained within a single monomeric enzyme, a new multifunctional deoxynucleoside kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYMIDINE KINASE; DEOXYGUANOSINE KINASE; DEOXYCYTIDINE KINASE; CELL-CYCLE; AFFINITY-CHROMATOGRAPHY; SUBSTRATE-SPECIFICITY; MOLECULAR-FORMS; DNA POLYMERASE; CLONING; EXPRESSION	In mammalian cells, there are three pyrimidine nucleoside salvage enzymes with the capacity to phosphorylate all four deoxynucleosides, the two thymidine kinase isoenzymes, TK1 and TK2, and two deoxycytidine kinase, dCK. TK1 is cell cycle-regulated; TK2 is expressed constitutively and can phosphorylate deoxycytidine to the same extent as thymidine. dCK phosphorylates deoxycytidine, deoxyadenosine, and deoxyguanosine, but not thymidine. In addition, the three kinases can phosphorylate a number of medically important analogs. In cultured Drosophila melanogaster embryonic cells, only one pyrimidine deoxynucleoside kinase was present, This kinase was purified and showed a broad substrate specificity, since it was able to phosphorylate all four deoxynucleosides with high efficiency, as compared with the kinases in mammalian cells. Additionally, a number of nucleoside analogs such as arabinofuranosyl pyrimidines, deoxyuridine, and 5'-fluorodeoxyuridine, were phosphorylated. There was negligible 3'-azidothymidine and no dTMP phosphorylation. The enzyme was active as a monomer of about 30 kDA. We suggest the name D. melanogaster deoxynucleoside kinase for this multifunctional kinase. The substrate specificity, size, and other characteristics show that this enzyme is more related to human TK2 than to the other mammalian deoxyribonucleoside kinases, but is unique with respect to the capacity to phosphorylate all four deoxynucleosides.	Roskilde Univ, Dept Chem & Life Sci, DK-4000 Roskilde, Denmark; Tech Univ Denmark, Dept Microbiol, DK-2800 Lyngby, Denmark; Univ Copenhagen, Dept Genet, DK-1353 Copenhagen, Denmark	Roskilde University; Technical University of Denmark; University of Copenhagen	Munch-Petersen, B (corresponding author), Roskilde Univ, Dept Chem & Life Sci, POB 260, DK-4000 Roskilde, Denmark.							ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6; BLACK ME, 1991, MOL MICROBIOL, V5, P373, DOI 10.1111/j.1365-2958.1991.tb02119.x; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHAW HD, 1983, P NATL ACAD SCI-BIOL, V80, P5588, DOI 10.1073/pnas.80.18.5588; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; EGER K, 1993, PHARMACEUT RES, V10, P771, DOI 10.1023/A:1018980304519; GOWER WR, 1979, J BIOL CHEM, V254, P2180; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P5328, DOI 10.1021/bi00183a041; Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454; Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258; KAGUNI LS, 1983, P NATL ACAD SCI-BIOL, V80, P2221, DOI 10.1073/pnas.80.8.2221; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; KIT S, 1974, BIOCHEM GENET, V11, P231, DOI 10.1007/BF00486058; KOWAL EP, 1976, PREP BIOCHEM, V6, P369, DOI 10.1080/00327487608061625; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM FK, 1988, BIOCHEM CELL BIOL, V66, P318, DOI 10.1139/o88-041; MUNCHPETERSEN B, 1993, J BIOL CHEM, V268, P15621; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; Sondergaard L, 1996, BIOTECHNOL TECH, V10, P161, DOI 10.1007/BF00158939; WANG LY, 1993, J BIOL CHEM, V268, P22847; Wang LY, 1996, FEBS LETT, V390, P39, DOI 10.1016/0014-5793(96)00623-0; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764	26	87	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3926	3931		10.1074/jbc.273.7.3926	http://dx.doi.org/10.1074/jbc.273.7.3926			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461577	hybrid			2022-12-25	WOS:000072048400019
J	Hill, JR; Kwon, G; Marshall, CK; McDaniel, ML				Hill, JR; Kwon, G; Marshall, CK; McDaniel, ML			Hyperglycemic levels of glucose inhibit interleukin 1 release from RAW 264.7 murine macrophages by activation of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET CELL TUMOR; DIABETIC RATS; LINES; IDENTIFICATION; GLYCOLYSIS; METABOLISM; GLUTAMINE; GLOMERULI; INSULIN; ENZYME	Diabetic patients with hyperglycemia (high blood glucose) have frequent and persistent bacterial infections linked to significantly diminished bactericidal activity and macrophage function, Interleukin-1 (IL-1), released primarily from activated macrophages, is a key mediator of effective host defense against microorganisms. We observe that hyperglycemic levels of D-glucose (8-20 mM) inhibit the release of IL-1 by lipopolysaccharide-stimulated RAW 264.7 murine macrophage cells. An inhibitor of glucose transport and metabolism, 2-deoxyglucose, prevents this inhibition of IL-1 release, High levels (8-20 mM) of fructose and mannose (but not galactose or L-glucose) also inhibit the release of IL-1 activity, suggesting that metabolism is required for IL-1 inhibition. Immunoprecipitation and activity measurements demonstrate that high glucose levels block the release of IL-1 but do not inhibit IL-1 production, High glucose levels (20 mM) increase protein kinase C (PKC) activity, and inhibitors of PKC block the inhibitory effects of glucose. Phorbol 12-myristate 13-acetate, an agonist of PKC, mimics glucose-induced inhibition of IL-1 release. These results demonstrate that high glucose levels inhibit IL-1 release (but not production) by RAW 264.7 murine macrophages, and this inhibition is mediated by PKC activation. These studies suggest that persistent infections in hyperglycemic patients may be due to an inhibition of IL-1 release from macrophages.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL)	McDaniel, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol, 660 S Euclid Ave,Box 8118, St Louis, MO 63110 USA.				NIDDK NIH HHS [F32 DK-08748, DK-06181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008748, R01DK006181, R56DK006181] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bessman Alice N., 1992, Journal of Diabetes and its Complications, V6, P258, DOI 10.1016/1056-8727(92)90062-P; BHATHENA SJ, 1982, DIABETES, V31, P521, DOI 10.2337/diabetes.31.6.521; BUSTOS R, 1992, BIOCHEM J, V282, P299, DOI 10.1042/bj2820299; CALAME W, 1995, J INFECTION, V30, P227, DOI 10.1016/S0163-4453(95)90762-9; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CRAVEN PA, 1994, J CLIN INVEST, V93, P311, DOI 10.1172/JCI116961; CRAVEN PA, 1990, DIABETES, V39, P667, DOI 10.2337/diabetes.39.6.667; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DOUVDEVANI A, 1992, PERITON DIALYSIS INT, V13, P112; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; GILKES AF, 1994, BIOCHEM BIOPH RES CO, V204, P1318, DOI 10.1006/bbrc.1994.2607; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Hill JR, 1996, J BIOL CHEM, V271, P22672, DOI 10.1074/jbc.271.37.22672; Hill JR, 1996, ANAL BIOCHEM, V236, P14, DOI 10.1006/abio.1996.0125; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; JONES CA, 1982, P SOC EXP BIOL MED, V170, P298; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; MAYHAN WG, 1995, AM J PHYSIOL-HEART C, V269, pH1297, DOI 10.1152/ajpheart.1995.269.4.H1297; MILLER DK, 1993, ANN NY ACAD SCI, V696, P133; NEWSHOLME P, 1986, BIOCHEM J, V239, P121, DOI 10.1042/bj2390121; NIELSON CP, 1989, DIABETES, V38, P1031, DOI 10.2337/diabetes.38.8.1031; ORLINSKA U, 1993, J CELL PHYSIOL, V157, P201, DOI 10.1002/jcp.1041570126; POTTER LR, 1994, J BIOL CHEM, V269, P14636; RALPH P, 1977, J IMMUNOL, V119, P950; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; RAYFIELD EJ, 1982, AM J MED, V72, P439, DOI 10.1016/0002-9343(82)90511-3; RUBARTELLI A, 1991, BIOCHEM SOC T, V19, P255, DOI 10.1042/bst0190255; SCHACHTELE C, 1988, BIOCHEM BIOPH RES CO, V151, P542, DOI 10.1016/0006-291X(88)90628-6; SHARMA K, 1995, BIOCHEM BIOPH RES CO, V207, P80, DOI 10.1006/bbrc.1995.1156; SMITHERMAN KO, 1995, MED CLIN N AM, V79, P53, DOI 10.1016/S0025-7125(16)30084-0; WHEAT LJ, 1980, DIABETES CARE, V3, P187, DOI 10.2337/diacare.3.1.187; WILLIAMS B, 1992, DIABETES, V41, P1464, DOI 10.2337/diabetes.41.11.1464; WU GY, 1991, BIOCHIM BIOPHYS ACTA, V1115, P166, DOI 10.1016/0304-4165(91)90026-D	37	28	28	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3308	3313		10.1074/jbc.273.6.3308	http://dx.doi.org/10.1074/jbc.273.6.3308			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452447	hybrid			2022-12-25	WOS:000071822300032
J	Jonassen, T; Proft, M; Randez-Gil, F; Schultz, JR; Marbois, BN; Entian, KD; Clarke, CF				Jonassen, T; Proft, M; Randez-Gil, F; Schultz, JR; Marbois, BN; Entian, KD; Clarke, CF			Yeast clk-1 homologue (Coq7/Cat5) is a mitochondrial protein in coenzyme Q synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; UBIQUINONE BIOSYNTHESIS; CAENORHABDITIS-ELEGANS; GLUCOSE REPRESSION; GLUCONEOGENIC ENZYMES; ENDOPLASMIC-RETICULUM; HYDROPHOBIC MOMENT; HYDROGEN-PEROXIDE	Mutations in the clk-1 gene result in slower development and increased life span in Caenorhabditis elegans. The Saccharomyces cerevisiae homologue COQ7/CAT5 is essential for several metabolic pathways including ubiquinone biosynthesis, respiration, and gluconeogenic gene activation. We show here that Coq7p/Cat5p is a mitochondrial inner membrane protein directly involved in ubiquinone biosynthesis, and that the defect in gluconeogenic gene activation in coq7/cat5 null mutants is a general consequence of a defect in respiration. These results obtained in the yeast model suggest that the effects on development and life span in C. elegans clk-1 mutants may relate to changes in the amount of ubiquinone, an essential electron transport component and a lipid soluble antioxidant.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Goethe Univ Frankfurt, Biozentrum, Inst Mikrobiol, D-60439 Frankfurt, Germany	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Goethe University Frankfurt	Clarke, CF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 405 Hilgard Ave, Los Angeles, CA 90095 USA.	cathy@ewald.mbi.ucla.edu	Randez-Gil, Francisca/H-2868-2012; Entian, Karl-Dieter/D-3080-2011; Proft, Markus/K-2323-2014	Randez-Gil, Francisca/0000-0001-8217-3156; Proft, Markus/0000-0002-6788-5830	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07185, GM45952] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; ANDREE P, 1996, THESIS KAROLINSKA I, P9; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; ASHER E B, 1989, Molecular and General Genetics, V215, P517, DOI 10.1007/BF00427051; Austriaco NR, 1996, YEAST, V12, P623, DOI 10.1002/(SICI)1097-0061(19960615)12:7<623::AID-YEA968>3.0.CO;2-G; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; Barkovich RJ, 1997, J BIOL CHEM, V272, P9182; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; BROWN TA, 1995, J BACTERIOL, V177, P1380, DOI 10.1128/jb.177.5.1380-1382.1995; CALDER KM, 1991, MOL MICROBIOL, V5, P1769, DOI 10.1111/j.1365-2958.1991.tb01926.x; CARLSON M, 1981, GENETICS, V98, P25; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHEN WJ, 1987, CELL, V49, P651, DOI 10.1016/0092-8674(87)90541-1; CIRIACY M, 1975, MOL GEN GENET, V138, P157, DOI 10.1007/BF02428119; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; Dibrov E, 1997, J BIOL CHEM, V272, P9175; DIXON GH, 1959, BIOCHEM J, V72, pP3; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ENTIAN KD, 1992, TRENDS BIOCHEM SCI, V17, P506, DOI 10.1016/0968-0004(92)90341-6; ENTIAN KD, 1982, J BACTERIOL, V151, P1123, DOI 10.1128/JB.151.3.1123-1128.1982; ERNSTER L, 1993, CLIN INVESTIGATOR, V71, pS60, DOI 10.1007/BF00226842; ESTORNELL E, 1992, FEBS LETT, V311, P107, DOI 10.1016/0014-5793(92)81378-Y; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; Forman HJ, 1997, FASEB J, V11, P374, DOI 10.1096/fasebj.11.5.9141504; ForsmarkAndree P, 1997, FREE RADICAL BIO MED, V22, P391, DOI 10.1016/S0891-5849(96)00330-9; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Glinn MA, 1997, BBA-BIOENERGETICS, V1318, P246, DOI 10.1016/S0005-2728(96)00142-9; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; HANSEN RJ, 1976, ANAL BIOCHEM, V74, P576, DOI 10.1016/0003-2697(76)90240-2; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HEDGES D, 1995, MOL CELL BIOL, V15, P1915; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; Johnston M., 1992, MOL CELLULAR BIOL YE, P193; Jonassen T, 1996, ARCH BIOCHEM BIOPHYS, V330, P285, DOI 10.1006/abbi.1996.0255; KAGAN V, 1990, BIOCHEM BIOPH RES CO, V169, P851, DOI 10.1016/0006-291X(90)91971-T; KAGAN VE, 1996, HDB ANTIOXIDANTS, P157; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Lemmon MA., 1992, CURR OPIN STRUC BIOL, V2, P511; LENAZ G, 1993, CLIN INVESTIGATOR, V71, pS66; Lithgow GJ, 1996, BIOESSAYS, V18, P809, DOI 10.1002/bies.950181007; MARBOIS BN, 1994, GENE, V138, P213; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Murakami S, 1996, GENETICS, V143, P1207; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NAKAI T, 1995, MOL CELL BIOL, V15, P4441; NEIGEBORN L, 1984, GENETICS, V108, P845; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; OHASHI A, 1982, J BIOL CHEM, V257, P3042; POON WW, 1995, ARCH BIOCHEM BIOPHYS, V320, P305, DOI 10.1016/0003-9861(95)90014-4; Poon WW, 1997, MOL ASPECTS MED, V18, pS121; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; PROFT M, 1997, THESIS JW GOETHE U F; RandezGil F, 1997, MOL CELL BIOL, V17, P2502, DOI 10.1128/MCB.17.5.2502; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; SantosOcana C, 1995, J BIOENERG BIOMEMBR, V27, P597, DOI 10.1007/BF02111657; SIKORSKI RS, 1989, GENETICS, V122, P19; SIPPEL CJ, 1983, J BIOL CHEM, V258, P1057; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1986, J BIOL CHEM, V261, P7163; TZAGOLOFF A, 1975, J BACTERIOL, V122, P826, DOI 10.1128/JB.122.3.826-831.1975; WONG A, 1995, GENETICS, V139, P1247; WONG S, 1986, BIOCHEMISTRY-US, V25, P6294, DOI 10.1021/bi00368a069; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; Yu BP, 1996, ANN NY ACAD SCI, V786, P1, DOI 10.1111/j.1749-6632.1996.tb39047.x; ZIMMERMANN FK, 1977, MOL GEN GENET, V151, P95, DOI 10.1007/BF00446918; [No title captured]	87	103	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3351	3357		10.1074/jbc.273.6.3351	http://dx.doi.org/10.1074/jbc.273.6.3351			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452453	hybrid			2022-12-25	WOS:000071822300038
J	Kim, MJ; Min, DS; Ryu, SH; Suh, PG				Kim, MJ; Min, DS; Ryu, SH; Suh, PG			A cytosolic, G alpha(q)- and beta gamma-insensitive splice variant of phospholipase C-beta 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNIT; DROSOPHILA-MELANOGASTER; INOSITOL TRISPHOSPHATE; BOVINE CEREBELLUM; HUMAN PLATELETS; GROWTH-FACTOR; NORPA GENE; C ISOZYME; ACTIVATION; PURIFICATION	Phospholipase C (PLC)-beta 4 has been considered to be a mammalian homolog of the NorpA PLC, which is responsible for visual signal transduction in Drosophila. We reported previously the cloning of a cDNA encoding rat phospholipase C-beta 4 (PLC-beta 4) (Kim, M.J., Bahk, Y.Y., Min, D.S., Lee, S.J., Ryu, S.H., and Suh, P.-G. (1993) Biochem. Biophys. Res. Commun. 194, 706-712), We report now the isolation and characterization of a splice variant (PLC-beta 4b). PLC-beta 4b is identical to the 130-kDa PLC-beta 4 (PLC-beta 4a) except that the carboxyl-terminal 162 amino acids of PLC-beta 4a are replaced by 10 distinct amino acids, The existence of PLC-beta 4b transcripts in the rat brain was demonstrated by reverse transcription-polymerase chain reaction analysis. Immunological analysis using polyclonal antibody specific for PLC-beta 4b revealed that this splice variant exists in rat brain cytosol. To investigate functional differences between the two forms of PLC-beta 4, transient expression studies in COS-7 cells were conducted, We found that PLC-beta 4a was localized mainly in the particulate fraction of the cell, and it could be activated by G alpha(q), whereas PLC-beta 4b was localized exclusively in the soluble fraction, and it could not be activated by G alpha(q). In addition, both PLC-beta 4a and PLC-beta 4b were not activated by G-protein beta gamma-subunits purified from rat brain. These results suggest that PLC-beta 4b may be regulated by a mechanism different from that of PLC-beta 4a, and therefore it may play a distinct role in PLC mediated signal transduction.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH)	Suh, PG (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea.	pgs@pop.postech.ac.kr	Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048				BAHK YY, 1994, J BIOL CHEM, V269, P8240; BANNO Y, 1994, FEBS LETT, V340, P185, DOI 10.1016/0014-5793(94)80134-7; BANNO Y, 1995, J BIOL CHEM, V270, P4318, DOI 10.1074/jbc.270.9.4318; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BOYER JL, 1994, J BIOL CHEM, V269, P2814; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; FERREIRA PA, 1994, J BIOL CHEM, V269, P3129; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; JHON DY, 1993, J BIOL CHEM, V268, P6654; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P14598, DOI 10.1073/pnas.93.25.14598; JIANG HP, 1994, J BIOL CHEM, V269, P7593; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; KIM MJ, 1993, BIOCHEM BIOPH RES CO, V194, P706, DOI 10.1006/bbrc.1993.1879; KIM S, 1995, J BIOL CHEM, V270, P14376, DOI 10.1074/jbc.270.24.14376; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEE CW, 1994, J BIOL CHEM, V269, P25335; LEE SB, 1993, J BIOL CHEM, V268, P25952; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MCKAY RR, 1995, J BIOL CHEM, V270, P13271, DOI 10.1074/jbc.270.22.13271; MIN DS, 1993, FEBS LETT, V331, P38, DOI 10.1016/0014-5793(93)80293-4; MIN DS, 1993, J BIOL CHEM, V268, P12207; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARK DG, 1993, J BIOL CHEM, V268, P3710; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROUSTAN P, 1995, NEUROREPORT, V6, P1837, DOI 10.1097/00001756-199510020-00004; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; UEDA N, 1994, J BIOL CHEM, V269, P4388; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1993, J BIOL CHEM, V268, P3704; WU DQ, 1992, J BIOL CHEM, V267, P1811; YEO EJ, 1994, J BIOL CHEM, V269, P27823	45	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3618	3624		10.1074/jbc.273.6.3618	http://dx.doi.org/10.1074/jbc.273.6.3618			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452490	hybrid			2022-12-25	WOS:000071822300075
J	Nadanaka, S; Clement, A; Masayama, K; Faissner, A; Sugahara, K				Nadanaka, S; Clement, A; Masayama, K; Faissner, A; Sugahara, K			Characteristic hexasaccharide sequences in octasaccharides derived from shark cartilage chondroitin sulfate D with a neurite outgrowth promoting activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; HEPARAN-SULFATE; FLAVOBACTERIUM-HEPARINUM; MONOCLONAL-ANTIBODIES; STRUCTURAL-ANALYSIS; OLIGOSACCHARIDES; PROTEOGLYCANS; ABC; SPECTROSCOPY; TETRASACCHARIDES	A mouse brain chondroitin sulfate (CS) proteoglycan, DSD-1-PG, bears the DSD-1 epitope and has neurite out-growth promoting properties. Shark cartilage CS-C inhibits the interactions between the DSD-1-specific monoclonal antibody 473HD and the CS chains of the DSD-1-PG, which is expressed on the mouse glial cells (Faissner, A., Clement, A., Lochter, A., Streit, A., Mandl, C., and Schachner, M. (1994) J. Cell Biol. 126, 783-799), On the other hand, several hexasaccharides isolated from commercial shark cartilage CS-D, which contains a higher proportion of characteristic D units (GlcUA(2-sulfate)beta 1-3GalNAc(6-sulfate)) as compared with CS-C, has the A-D tetrasaccharide sequence composed of an A disaccharide unit (GlcUA beta 1-3GalNAc(4-sulfate)) and a D disaccharide unit (Nadanaka, S. and Sugahara, K. (1997) Glycobiology 7, 253-263). In this study, the biological activities and the structure of shark cartilage CS-D were investigated. CS-D inhibited the interactions between monoclonal antibody 473HD and DSD-1-PG and also promoted neurite outgrowth of embryonic day 18 hippocampal neurons. Eight octasaccharide fractions were isolated from CS-D after partial digestion with bacterial chondroitinase ABC by means of gel filtration chromatography and anion-exchange high performance liquid chromotography to investigate the frequency and the arrangement of the A-D tetrasaccharide unit in the polymer sequence. Structural analysis performed by a combination of enzymatic digestions with 500-MHz H-1 NMR spectroscopy demonstrated that the isolated octasaccharides shared the common core structure Delta HexA alpha 1-3GalNAc beta 1-4(GlcUA beta 1-3GalNAc)(3) with four, five, and six sulfate esters at various hydroxyl groups in different combinations, In the structure, Delta HexA and GlcUA represent 4-deoxy-alpha-L-threo-hex-4-enepyranosyluronic acid and glucuronic acid, respectively. No D-D tetrasaccharide sequence was found, and discrete D disaccharide units were demonstrated exclusively as A-D tetrasaccharide units in either an A-D-A or an A-D-C hexasaccharide sequence in the five octasaccharides that represented about 5.0% (w/w) of the starting polysaccharides (C denotes the disaccharide GlcUA beta 1-3GalNAc(6-sulfate)). It remains to be determined whether such characteristic hexasaccharide sequences present in shark cartilage CS-D serve as functional domain structures recognized by some protein ligands.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 658, Japan; Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany	Kobe Pharmaceutical University; Ruprecht Karls University Heidelberg	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 658, Japan.		Faissner, Andreas/A-5314-2008	Faissner, Andreas/0000-0002-2211-8259				BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; DAVIDSON S, 1990, J BIOL CHEM, V265, P12324; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; Goslin K., 1991, CULTURING NERVE CELL, P251; Gotz B, 1996, J CELL BIOL, V132, P681, DOI 10.1083/jcb.132.4.681; Hamai A, 1997, J BIOL CHEM, V272, P9123; HARDINGHAM TE, 1994, CARBOHYD RES, V255, P241, DOI 10.1016/S0008-6215(00)90982-0; HARRIS MJ, 1970, CARBOHYD RES, V15, P57, DOI 10.1016/S0008-6215(00)80294-3; JANDIK KA, 1994, GLYCOBIOLOGY, V4, P289, DOI 10.1093/glycob/4.3.289; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MARK M P, 1990, International Journal of Developmental Biology, V34, P191; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; MICHELACCI YM, 1987, BIOCHIM BIOPHYS ACTA, V923, P291, DOI 10.1016/0304-4165(87)90016-X; Nadanaka S, 1997, GLYCOBIOLOGY, V7, P253, DOI 10.1093/glycob/7.2.253; NADANAKA S, 1997, GLYCONJUGATE J, V14, pS15; SORRELL JM, 1993, MATRIX, V13, P351, DOI 10.1016/S0934-8832(11)80040-5; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; Sugahara K, 1996, GLYCOCONJUGATE J, V13, P609, DOI 10.1007/BF00731449; Sugahara K, 1996, EUR J BIOCHEM, V239, P871, DOI 10.1111/j.1432-1033.1996.0871u.x; Sugahara K, 1996, EUR J BIOCHEM, V239, P865, DOI 10.1111/j.1432-1033.1996.0865u.x; SUZUKI S, 1960, J BIOL CHEM, V235, P3580; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4; YOSHIDA K, 1995, GLYCOCONJUGATE J, V12, P488	33	144	152	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3296	3307		10.1074/jbc.273.6.3296	http://dx.doi.org/10.1074/jbc.273.6.3296			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452446	hybrid			2022-12-25	WOS:000071822300031
J	Gandrillon, O; Samarut, J				Gandrillon, O; Samarut, J			Role of the different RAR isoforms in controlling the erythrocytic differentiation sequence. Interference with the v-erbA and p135(gap-myb-ets) nuclear oncogenes	ONCOGENE			English	Article						nuclear hormone receptors; erythroleukemia; viral transformation	RETINOIC ACID RECEPTORS; AVIAN ERYTHROBLASTOSIS VIRUS; ETS FUSION ONCOPROTEIN; LEUKEMIA-VIRUS; TRANSCRIPTIONAL ACTIVATION; PROGENITOR CELLS; THYROID-HORMONE; MYELOID CELLS; TARGET-CELLS; SELF-RENEWAL	Little is known as to how the nuclear oncogenes v-erbA and p135(gag-myb-ets) do transform cells. The elucidation of their molecular mechanisms of action requires the identification of relevant target genes. We analysed the possibility for the RAR beta gene to represent such a target gene. We first show that the RAR beta gene induction is a specific and direct process, requiring the continous presence of retinoids and under the control of the RAR alpha isoform exclusively. We then show that the expression of either the v-erbA or the p135(gag-myb-ets) oncogene is not sufficient to block the RAR beta gene induction. We confirmed the loss of RARE gene response in certain cell lines but we discarded the possibility that this lass might represent a necessary step for cell lines immortalization. We further show that the RAR alpha isoform activation is necessary and sufficient to induce the growth inhibition and the differentiation stimulation characteristic for the commitment-inducing ability of retinoids in chicken erythrocytic progenitor cells. We therefore propose a model showing that RAR alpha but not RAR beta is the key mediator for commitment to differentiation and that it should control two different set of genes whose expression is differentially affected by the v-erbA and the p135(gag-myb-ets) oncogenes.	Ecole Normale Super Lyon, Dept Biol Mol & Cellulaire, F-69364 Lyon 7, France	Ecole Normale Superieure de Lyon (ENS de LYON)	Gandrillon, O (corresponding author), Ecole Normale Super Lyon, Dept Biol Mol & Cellulaire, 46 Allee Italie, F-69364 Lyon 7, France.		Samarut, Jacques/AAD-2587-2019					ALMOUSTAFA AE, 1994, CELL GROWTH DIFFER, V5, P863; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; Botling J, 1996, CELL GROWTH DIFFER, V7, P1239; CassarMalek I, 1997, ONCOGENE, V14, P1099, DOI 10.1038/sj.onc.1200928; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1995, INT J ONCOL, V6, P215; Geisen C, 1997, CANCER RES, V57, P1460; Gianni M, 1996, BLOOD, V87, P1520, DOI 10.1182/blood.V87.4.1520.bloodjournal8741520; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HERMANN T, 1993, ONCOGENE, V8, P55; Inaba M, 1996, J CLIN INVEST, V97, P1804, DOI 10.1172/JCI118610; Jing YK, 1996, FASEB J, V10, P1064, DOI 10.1096/fasebj.10.9.8801168; KRAUT N, 1995, ONCOGENE, V10, P1027; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEWIS JB, 1980, CELL, V21, P303, DOI 10.1016/0092-8674(80)90138-5; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; Mills KJ, 1996, CELL GROWTH DIFFER, V7, P327; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PAIN B, 1990, New Biologist, V2, P284; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; Rascle A, 1996, MOL CELL BIOL, V16, P6338; REICHERT U, 1993, MOL BIOL THERAPEUTIC, V5, P117; Rogers MB, 1996, CELL GROWTH DIFFER, V7, P115; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Rusten LS, 1996, BLOOD, V87, P1728; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHARIF M, 1992, ONCOGENE, V7, P953; SPANJAARD RA, 1995, J BIOL CHEM, V270, P17429, DOI 10.1074/jbc.270.29.17429; WOODS C, 1995, ENDOCRINOLOGY, V136, P85, DOI 10.1210/en.136.1.85; XIAO JH, 1995, J BIOL CHEM, V270, P3001, DOI 10.1074/jbc.270.7.3001; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	51	13	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	1998	16	5					563	574		10.1038/sj.onc.1201550	http://dx.doi.org/10.1038/sj.onc.1201550			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482102				2022-12-25	WOS:000071816600001
J	Prost, S; Bellamy, COC; Cunningham, DS; Harrison, DJ				Prost, S; Bellamy, COC; Cunningham, DS; Harrison, DJ			Altered DNA repair and dysregulation of p53 in IRF-1 null hepatocytes	FASEB JOURNAL			English	Article						liver; cell cycle; apoptosis; UV irradiation; cell proliferation	NUCLEOTIDE EXCISION-REPAIR; CELL-GROWTH INHIBITION; LI-FRAUMENI SYNDROME; TUMOR-SUPPRESSOR; UV; APOPTOSIS; DAMAGE; INDUCTION; PHOSPHORYLATION; RADIATION	The tumor suppressor proteins IRF-1 and p53 are involved in response pathways after DNA damage. In different cell types, IRF-1 and p53 can cooperate to produce cell cycle arrest (embryo fibroblasts) or can independently trigger apoptosis (lymphoid cells). p53 may also regulate DNA repair, but there is no information on IRF-1 and repair. The cell lineage dependency of these effects precludes extrapolation of findings to other tissues of relevance to human cancer. Here, we report the consequences of IRF-1 deficiency for apoptosis, cell cycle arrest, and DNA repair in primary hepatocytes after DNA damage and extend previous work on the role of p53 in hepatocytes. IRF-1-deficient hepatocytes showed reduced DNA repair activity compared with wild-type, as assessed by unscheduled DNA synthesis after UV irradiation (10J/m(2)) and by host reactivation of a UV-damaged reporter construct. p53-deficient hepatocytes also showed reduced unscheduled DNA synthesis after UV, but there was no impairment of specific repair in host reactivation assays. IRF-1 deficiency did not affect the p53-dependent G(1)/S arrest after UV irradiation. Hepatocyte apoptosis after UV treatment, previously reported to be independent of p53, was also independent of IRF-1. However, IRF-1 deficiency produced dysregulation of p53, manifested as increased transactivation of a p53-reporter plasmid in undamaged hepatocytes, and accelerated p53 stabilization after DNA damage. Hence, in hepatocytes, IRF-1 is not required for growth arrest or apoptosis after DNA damage, but the results suggest for the first time a role in DNA repair regulation.	Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Prost, S (corresponding author), Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	s.prost@ed.ac.uk		prost, sandrine/0000-0002-0140-7115; harrison, david/0000-0001-9041-9988				ABRAHAMS PJ, 1995, MUTAT RES-DNA REPAIR, V336, P169, DOI 10.1016/0921-8777(94)00049-C; Bellamy COC, 1997, J PATHOL, V183, P177, DOI 10.1002/(SICI)1096-9896(199710)183:2<177::AID-PATH909>3.0.CO;2-E; Bellamy COC, 1997, FASEB J, V11, P591, DOI 10.1096/fasebj.11.7.9212083; Bellamy COC, 1997, BRIT MED BULL, V53, P522; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; HARPER JW, 1993, CELL, V75, P805; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; Li G, 1996, AM J PATHOL, V148, P1113; Li G, 1997, AM J PATHOL, V150, P1457; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lohrum M, 1996, ONCOGENE, V13, P2527; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MacCallum DE, 1996, ONCOGENE, V13, P2575; MARX J, 1994, SCIENCE, V266, P1321, DOI 10.1126/science.7973719; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; McDonald E, 1996, CANCER RES, V56, P2250; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Scheidtmann KH, 1996, INT J ONCOL, V9, P1277; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHIVJI MK, 1995, CURR BIOL, V4, P1062; SMITH ML, 1995, ONCOGENE, V10, P1053; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIGUCHI T, 1995, J CANC RES CLIN ONCO, V121, P416; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; ZHANG W, 1994, CANCER RES, V54, P4448	38	28	29	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1998	12	2					181	188		10.1096/fasebj.12.2.181	http://dx.doi.org/10.1096/fasebj.12.2.181			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472983				2022-12-25	WOS:000071848400006
J	Flynn, P; Mellor, H; Palmer, R; Panayotou, G; Parker, PJ				Flynn, P; Mellor, H; Palmer, R; Panayotou, G; Parker, PJ			Multiple interactions of PRK1 with RhoA - Functional assignment of the HR1 repeat motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-D ACTIVITY; GTP-BINDING PROTEIN; AMINO-TERMINAL REGION; ZIPPER-LIKE SEQUENCES; PUTATIVE TARGET; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; HA-RAS; ACTIVATION; FAMILY	PRK1 (PKN) is a serine/threonine kinase that has been shown to be activated by RhoA (Amano, M., Mukai, H., One, Y., Chihara, K., Matsui, T., Hamajima, Y., Okawa, K., Iwamatsu, A., and Kaibuchi, K. (1996) Science 271, 648-650), Detailed analysis of the PRK1 region involved in RhoA binding has revealed that two homologous sequences within the HR1 domain (HR1a and HR1b) both bind to RhoA; the third repeat within this domain, HR1c(PRK1), does not bind RhoA, The related HR1 motif is also found to confer RhoA binding activity to the only other fully cloned member of this kinase family, PRK2, Furthermore, the predictive value of this motif is established for an HR1a sequence derived from a Caenorhabditis elegans open reading frame encoding a protein kinase of unknown function, Interestingly, the HR1a(PRK1) and HR1b(PRK1) subdomains are shown to display a distinctive nucleotide dependence for RhoA binding, HR1a(PRK1) is entirely GTP-dependent, while HR1b(PRK1) binds both GTP-and GDP-bound forms of RhoA. This distinction indicates that there are two sites of contact between RhoA and PRK1, one contact through a region that is conformationally dependent upon the nucleotide-bound state of RhoA and one that is not, Analysis of binding to Rho/Rac chimera provides evidence for a HR1a(PRK1) but not HR1b(PRK1) interaction in the central third of Rho, Additionally, it is observed that the V14RhoA mutant binds HR1a but does not bind HR1b, This distinct binding behavior corroborates the conclusion that there are independent contacts on RhoA for the HR1a(PRK1) and HR1b(PRK1) motifs.	Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England; UCL, Ludwig Inst Canc Res, London W1P 8BT, England	Cancer Research UK; Ludwig Institute for Cancer Research; University of London; University College London	Parker, PJ (corresponding author), Imperial Canc Res Fund, Prot Phosphorylat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Parker, Peter j/D-5192-2013	Mellor, Harry/0000-0003-3894-0623; parker, peter/0000-0002-6218-2933				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BALBOA MA, 1995, J BIOL CHEM, V270, P29843; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; ISHIZAKI T, 1996, EMBO J, V15, P4885; JONSSON U, 1991, BIOTECHNIQUES, V11, P520; Kitagawa M, 1996, BIOCHEM BIOPH RES CO, V220, P963, DOI 10.1006/bbrc.1996.0515; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; OHGUCHI K, 1995, BIOCHEM BIOPH RES CO, V211, P306, DOI 10.1006/bbrc.1995.1811; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PALMER RH, 1994, FEBS LETT, V356, P5, DOI 10.1016/0014-5793(94)01202-4; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; Ponting CP, 1996, PROTEIN SCI, V5, P162; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Schlenstedt G, 1996, FEBS LETT, V389, P75, DOI 10.1016/0014-5793(96)00583-2; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Shimooku K, 1996, FEBS LETT, V387, P141, DOI 10.1016/0014-5793(96)00483-8; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOLONTE C, 1992, J BIOL CHEM, V267, P21663; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Yokozeki T, 1996, J NEUROCHEM, V66, P1234; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	43	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2698	2705		10.1074/jbc.273.5.2698	http://dx.doi.org/10.1074/jbc.273.5.2698			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446575	hybrid			2022-12-25	WOS:000071736600030
J	Mohanty, BK; Sahoo, T; Bastia, D				Mohanty, BK; Sahoo, T; Bastia, D			Mechanistic studies on the impact of transcription on sequence-specific termination of DNA replication and vice versa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; TRANSCRIBING POLYMERASE; POLAR CONTRAHELICASE; BINDING PROTEIN; TUS PROTEIN; FORK; ARREST; IDENTIFICATION	Since DNA replication and transcription often temporally and spatially overlap each other, the impact of one process on the other is of considerable interest. We have reported previously that transcription is impeded at the replication termini of Escherichia coli and Bacillus subtilis in a polar mode and that, when transcription is allowed to invade a replication terminus from the permissive direction, arrest of replication fork at the terminus is abrogated. In the present report, we have addressed four significant questions pertaining to the mechanism of transcription impedance by the replication terminator proteins, Is transcription arrested at the replication terminus or does RNA polymerase dissociate from the DNA causing authentic transcription termination? How does transcription cause abrogation of replication fork arrest at the terminus? Are the points of arrest of the replication fork and transcription the same or are these different? Are eukaryotic RNA polymerases also arrested at prokaryotic replication termini? Our results show that replication terminator proteins of E, coli and B. subtilis arrest but do not terminate transcription, Passage of an RNA transcript through the replication terminus causes the dissociation of the terminator protein from the terminus DNA, thus causing abrogation of replication fork arrest. DNA and RNA chain elongation are arrested at different locations on the terminator sites, Finally, although bacterial replication terminator proteins blocked yeast RNA polymerases in a polar fashion, a yeast transcription terminator protein (Reb1p) was unable to block T7 RNA polymerase and E, coli DnaB helicase.	Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA	Duke University	Bastia, D (corresponding author), Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA.	bastia@abacus.mc.duke.edu						Bastia D, 1997, Genet Eng (N Y), V19, P101; BASTIA D, 1996, EUKARYOTIC DNA REPLI, P177; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BRUAND C, 1990, GENETICS BIOTECHNOLO, V3, P117; BUSSIERE DE, 1995, CELL, V80, P651; CARRIGAN CM, 1991, J MOL BIOL, V222, P197, DOI 10.1016/0022-2836(91)90206-L; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; DHAR V, 1988, MOL CELL BIOL, V8, P4958, DOI 10.1128/MCB.8.11.4958; DILLIN A, 1995, TRENDS BIOCHEM SCI, V20, P231, DOI 10.1016/S0968-0004(00)89023-4; FRANKS AH, 1995, MOL MICROBIOL, V17, P13, DOI 10.1111/j.1365-2958.1995.mmi_17010013.x; FURTH ME, 1978, J MOL BIOL, V126, P195, DOI 10.1016/0022-2836(78)90359-5; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1992, ANNU REV MICROBIOL, V46, P603, DOI 10.1146/annurev.micro.46.1.603; Kamada K, 1996, NATURE, V383, P598, DOI 10.1038/383598a0; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KAUL S, 1994, P NATL ACAD SCI USA, V91, P11143, DOI 10.1073/pnas.91.23.11143; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOBAYASHI T, 1992, MOL GEN GENET, V233, P355, DOI 10.1007/BF00265431; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; LANG WH, 1994, CELL, V79, P527, DOI 10.1016/0092-8674(94)90261-5; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEVINE A, 1995, MOL MICROBIOL, V15, P287, DOI 10.1111/j.1365-2958.1995.tb02243.x; LEWIS PJ, 1989, J BACTERIOL, V171, P1402, DOI 10.1128/jb.171.3.1402-1408.1989; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; Manna AC, 1996, CELL, V87, P881, DOI 10.1016/S0092-8674(00)81995-9; Manna AC, 1996, P NATL ACAD SCI USA, V93, P3253, DOI 10.1073/pnas.93.8.3253; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; Messer W, 1997, MOL MICROBIOL, V24, P1, DOI 10.1046/j.1365-2958.1997.3171678.x; Miller A, 1997, SCIENCE, V275, P1655, DOI 10.1126/science.275.5306.1655; Mohanty BK, 1996, EMBO J, V15, P2530, DOI 10.1002/j.1460-2075.1996.tb00610.x; Pai KS, 1996, EMBO J, V15, P3164, DOI 10.1002/j.1460-2075.1996.tb00679.x; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; RICHARDSON JP, 1966, J MOL BIOL, V21, P115, DOI 10.1016/0022-2836(66)90083-0; ROCKLEIN BA, 1992, MOL MICROBIOL, V6, P1655, DOI 10.1111/j.1365-2958.1992.tb00890.x; SAHOO T, 1995, J BIOL CHEM, V270, P29138, DOI 10.1074/jbc.270.49.29138; SAHOO T, 1995, EMBO J, V14, P619, DOI 10.1002/j.1460-2075.1995.tb07038.x; SISTA PR, 1989, P NATL ACAD SCI USA, V86, P3026, DOI 10.1073/pnas.86.9.3026; SMITH MT, 1992, J MOL BIOL, V227, P648, DOI 10.1016/0022-2836(92)90214-5; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816; YOUNG PA, 1994, J MOL BIOL, V240, P275, DOI 10.1006/jmbi.1994.1444	54	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3051	3059		10.1074/jbc.273.5.3051	http://dx.doi.org/10.1074/jbc.273.5.3051			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446621	hybrid			2022-12-25	WOS:000071736600076
J	Cayrol, C; Knibiehler, M; Ducommun, B				Cayrol, C; Knibiehler, M; Ducommun, B			p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells	ONCOGENE			English	Article						cell cycle; cyclin-dependent kinase; growth arrest; p21(CIP1/WAF1); PCNA	DEPENDENT-KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; C-TERMINAL REGION; NUCLEAR ANTIGEN; DNA-REPLICATION; TUMOR SUPPRESSION; P21(WAF1/CIP1); PROTEIN; EXPRESSION; P21(CIP1)	A unique feature of p21 that distinguishes it from the other cyclin-dependent kinase (CDK) inhibitors is its ability to associate with the proliferating cell nuclear antigen (PCNA), an auxiliary factor for DNA polymerases delta and epsilon. While it is now well established that inhibition of cyclin/CDK complexes by p21 can result in G1 cell cycle arrest, the consequences of p21/PCNA interaction on cell cycle progression have not yet been determined. Here, we show, using a tetracycline-regulated system, that expression of wild-type p21 in p53-deficient DLD1 human colon cancer cells inhibits DNA synthesis and causes G1 and G2 cell cycle arrest. Similar effects are observed in cells expressing p21(CDK-) mutant impaired in the interaction with CDKs, but not in cells expressing p21(PCNA-), a mutant deficient for the interaction with PCNA. Analysis of cells treated with a p21-derived PCNA-binding peptide provides additional evidence that the growth inhibitory effects of p21 and p21(CDK-) result from their ability to bind to PCNA. Our results suggest that p21 might inhibit cell cycle progression by two independent mechanisms, inhibition of cyclin/CDK complexes, and inhibition of PCNA function resulting in both G1 and G2 arrest.	Univ Toulouse 3, CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Ducommun, B (corresponding author), Univ Toulouse 3, CNRS, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.		CAYROL, Corinne/C-2106-2011; DUCOMMUN, Bernard/B-3208-2008	CAYROL, Corinne/0000-0002-7813-4397; DUCOMMUN, Bernard/0000-0002-7126-8368				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARBOULE N, 1995, INT J CANCER, V63, P611, DOI 10.1002/ijc.2910630502; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; CHEN YQ, 1995, CANCER RES, V55, P4536; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fotedar R, 1996, ONCOGENE, V12, P2155; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOUBIN F, 1995, ONCOGENE, V10, P2281; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JUNG JM, 1995, ONCOGENE, V11, P2021; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Knibiehler M, 1996, FEBS LETT, V391, P66, DOI 10.1016/0014-5793(96)00702-8; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Savio M, 1996, ONCOGENE, V13, P1591; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; Tournier S, 1996, MOL BIOL CELL, V7, P651, DOI 10.1091/mbc.7.4.651; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZAKUT R, 1995, ONCOGENE, V11, P393	49	309	316	3	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					311	320		10.1038/sj.onc.1201543	http://dx.doi.org/10.1038/sj.onc.1201543			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467956	Bronze			2022-12-25	WOS:000071582100003
J	Alblas, J; Slager-Davidov, R; Steenbergh, PH; Sussenbach, JS; van der Burg, B				Alblas, J; Slager-Davidov, R; Steenbergh, PH; Sussenbach, JS; van der Burg, B			The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells	ONCOGENE			English	Article						Erk; Jun kinase; AP1; MCF7; phorbol ester; cell cycle	ACTIVATED PROTEIN-KINASES; ESTROGEN-RECEPTOR ACTIVITY; C-JUN; GROWTH-FACTOR; GENE-EXPRESSION; REGULATORY ELEMENTS; CARCINOMA-CELLS; FOS PROTEINS; DIFFERENTIATION; PROLIFERATION	In MCF7 breast cancer cells, mitogen-activated protein (MAP) kinase (i.e. Erk-1/2) is activated by the mitogen insulin, but also by the growth inhibiting agent TPA, though with very different kinetics, Insulin induces a relatively transient activation of Erk2 ( < 15 min), whereas TPA is able to induce a prolonged activation of Erk2 ( > 6 h), Expression of immediate-early genes of the c-fos and c-jun families, whose transcription and activation are regulated by MAP kinases, is differentially induced by insulin and TPA, Whereas insulin stimulates prolonged induction of c-jun, but not of junB mRNA, resulting in c-jun expression during the entire G(1) period, the growth inhibitor TPA induces junB much longer than c-jun. Inhibition of the Erk2 pathway by PD98059, specific for the upstream MAP kinase kinase (MEK1), abolishes TPA-stimulated junB but not insulin-induced c-jun, In agreement with this, insulin readily stimulates Jun kinase (JNK), whereas TPA does not, Furthermore, insulin-induced pRB hyperphosphorylation at the G(1)-S transition and S-phase entry is insensitive to MAP kinase inhibition by PD98059, On the other hand, PD98059 reverts the inhibitory effect of TPA on cell cycle entry as web as on pRB hyperphosphorylation, indicating that Erk effecters function as inhibitors of proliferation in MCF7 cells.	Univ Utrecht, Physiol Chem Lab, Stratenum, NL-3584 CG Utrecht, Netherlands; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Alblas, J (corresponding author), Univ Utrecht Hosp, Dept Pulm Dis, Room G03550,POB 85500, NL-3508 GA Utrecht, Netherlands.			Alblas, Jacqueline/0000-0002-2996-9697				ABE M, 1986, J CELL PHYSIOL, V126, P126, DOI 10.1002/jcp.1041260117; ALKHALAF M, 1992, MOL ENDOCRINOL, V6, P1625, DOI 10.1210/me.6.10.1625; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284; CARTER R, 1991, ONCOGENE, V6, P229; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DEGROOT RP, 1991, CELL GROWTH DIFFER, V2, P631; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HASHIMOTO M, 1993, ENDOCRINOLOGY, V133, P1934, DOI 10.1210/en.133.5.1934; HERBER B, 1994, ONCOGENE, V9, P1295; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHARBANDA S, 1994, CELL GROWTH DIFFER, V5, P259; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUKAS J, 1994, ONCOGENE, V9, P707; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAYO MW, 1994, ONCOGENE, V9, P1999; MELAMED D, 1993, CELL GROWTH DIFFER, V4, P689; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NISHINA Y, 1993, EXP CELL RES, V208, P492, DOI 10.1006/excr.1993.1271; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; REDNER RL, 1992, ONCOGENE, V7, P43; RUPPRECHT HD, 1993, AM J PHY SL, V265, P351; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHLINGENSIEPEN KH, 1993, DEV GENET, V14, P305, DOI 10.1002/dvg.1020140408; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; VALETTE A, 1987, CANCER RES, V47, P1615; VANDERBURG B, 1990, CANCER RES, V50, P7770; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; VANDERBURG B, 1990, MOL ENDOCRINOL, V4, P1720, DOI 10.1210/mend-4-11-1720; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; VANZOELEN EJJ, 1993, GROWTH FACTORS PRACT, P13; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030	63	73	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					131	139		10.1038/sj.onc.1201485	http://dx.doi.org/10.1038/sj.onc.1201485			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467952				2022-12-25	WOS:000071236800016
J	Caricasole, AAD; van Schaik, RHN; Zeinstra, LM; Wierikx, CDJ; van Gurp, RJHLM; van den Pol, M; Looijenga, LHJ; Oosterhuis, JW; Pera, MF; Ward, A; de Bruijn, D; Kramer, P; de Jong, FH; van den Eijnden-van Raaij, AJM				Caricasole, AAD; van Schaik, RHN; Zeinstra, LM; Wierikx, CDJ; van Gurp, RJHLM; van den Pol, M; Looijenga, LHJ; Oosterhuis, JW; Pera, MF; Ward, A; de Bruijn, D; Kramer, P; de Jong, FH; van den Eijnden-van Raaij, AJM			Human growth-differentiation factor 3 (hGDF3): developmental regulation in human teratocarcinoma cell lines and expression in primary testicular germ cell tumours	ONCOGENE			English	Article						teratocarcinoma; germ cell tumour; TGF beta; embryonal carcinoma	EMBRYONAL CARCINOMA-CELLS; BETA SUPERFAMILY; ADULT TESTIS; ACTIVIN-A; TUMORS; RECEPTORS; MEMBERS	We describe the cloning and initial characterization of a novel cDNA from human embryonal carcinoma CEC) cells, This cDNA, which we named human growth differentiation factor 3 (hGDF3), encodes the homologue of mouse GDF3, a TGF beta superfamily member belonging to the Growth/Differentiation Factors. We have analysed the expression of hGDF3 in human embryonal carcinoma cell lines and in primary testicular germ cell tumours of adolescents and adults (TGCTs), Expression of hGDF3 in human EC cell lines is stem cell-specific, is down-regulated upon RA-mediated differentiation and is increased upon culture of the cells in the presence of activin A, In TGCTs, hGDF3 expression is low in seminomas, while expression in non-seminomas is readily detectable and appears to be associated with the EC and yolk sac components in the tumours, We have also mapped the hGDF3 locus to the short arm of human chromosome 12, a region consistently overrepresented in human testicular germ cell rumours, Thus, hGDF3 represents an embryonal carcinoma stem cell-associated marker both in vitro and in vivo.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Erasmus Univ, Dept Endocrinol & Reprod, NL-3000 DR Rotterdam, Netherlands; Acad Hosp Rotterdam, Dr Daniel Den Hoed Canc Ctr, Expt Pathooncol Lab, NL-3075 EA Rotterdam, Netherlands; Monash Univ, Med Ctr, Inst Reprod & Dev, Clayton, Vic 3168, Australia; Univ Bath, Sch Biol & Biochem, Bath BA2 7AY, Avon, England; Dept Human Genet, NL-6500 HB Nijmegen, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Monash University; University of Bath	Caricasole, AAD (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.		PERA, MARTIN/A-9812-2012; De Jong, Frank H/A-9876-2011; de Bruijn, D.R.H./L-4233-2015; van Schaik, Ron H.N./G-6816-2013; Looijenga, Leendert/B-8145-2019	PERA, MARTIN/0000-0001-6239-0428; De Jong, Frank H/0000-0003-3578-1065; Looijenga, Leendert/0000-0002-8146-1911; Ward, Andrew/0000-0001-8311-5695				ANDREWS P, 1987, TERATOCARCINOMAS EMB; ANDREWS PW, 1994, LAB INVEST, V71, P243; BAARENDS WM, 1995, ENDOCRINOLOGY, V136, P5614, DOI 10.1210/en.136.12.5614; CARICASOLE A, 1993, NUCLEIC ACIDS RES, V21, P1873, DOI 10.1093/nar/21.8.1873; DAMJANOV I, 1993, LAB INVEST, V68, P220; DEJONG B, 1990, CANCER GENET CYTOGEN, V48, P143, DOI 10.1016/0165-4608(90)90115-Q; DEJONG FH, 1993, BIOCHEM BIOPH RES CO, V192, P1334, DOI 10.1006/bbrc.1993.1562; DEJONG FH, 1994, FRONTIERS ENDOCRINOL, V3; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Innis MA, 1990, PCR PROTOCOLS GUIDE; JONES CM, 1992, MOL ENDOCRINOL, V6, P1961, DOI 10.1210/me.6.11.1961; KEITZ ATV, 1994, UROLOGY, V5, P28; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; MCPHERRON AC, 1993, J BIOL CHEM, V268, P3444; Mosselman S, 1996, P NATL ACAD SCI USA, V93, P2884, DOI 10.1073/pnas.93.7.2884; MUMMERY CL, 1990, CELL DIFFER DEV, V30, P195, DOI 10.1016/0922-3371(90)90139-N; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; PERA MF, 1988, DIFFERENTIATION, V39, P139, DOI 10.1111/j.1432-0436.1988.tb00089.x; PERA MF, 1987, INT J CANCER, V40, P334, DOI 10.1002/ijc.2910400309; Sambrook J., 2002, MOL CLONING LAB MANU; SHIOZAKI M, 1992, P NATL ACAD SCI USA, V89, P1553, DOI 10.1073/pnas.89.5.1553; SINKE RJ, 1992, GENOMICS, V12, P206, DOI 10.1016/0888-7543(92)90367-2; VANDENEIJNDENVANRAAIJ AJM, 1991, MECH DEVELOP, V33, P157, DOI 10.1016/0925-4773(91)90082-H; VANSCHAIK RHN, 1997, IN PRESS BR J CANC; ZHANG J, 1989, HUM GENET, V83, P359, DOI 10.1007/BF00291381	26	51	80	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					95	103		10.1038/sj.onc.1201515	http://dx.doi.org/10.1038/sj.onc.1201515			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467948				2022-12-25	WOS:000071236800012
J	Lawler, JF; Yin, M; Diehl, AM; Roberts, E; Chatterjee, S				Lawler, JF; Yin, M; Diehl, AM; Roberts, E; Chatterjee, S			Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; HUMAN FIBROBLASTS; ACTIVATION; CERAMIDE; CELLS; TURNOVER; VESICLES	The mechanism by which genes involved in cholesterol biosynthesis and import are preferentially up-regulated in response to sterol depletion was elucidated with the cloning of sterol regulatory element binding protein-1 (SREBP-1), SREBP-1 is a transcription factor whose entry into the nucleus is gated by sterol-regulated proteolysis. We have investigated the role of tumor necrosis factor-alpha (TNF-alpha) as a mediator of SREBP-1 maturation in human hepatocytes. TNF-alpha is capable of inducing SREBP-1 maturation in a time-and dose-dependent manner that is consistent with the kinetics of TNF-alpha-mediated activation of neutral sphingomyelinase (N-SMase). Antibodies to N-SMase inhibit TNF-alpha-induced SREBP-1 maturation suggesting that N-SMase is a necessary component of this signal transduction pathway, Ceramide, a product of sphingomyelin hydrolysis, is also capable of inducing SREBP-1 maturation, The mature form of SREBP-1 generated by TNF-alpha, sphingomyelinase or ceramide treatment translocates to the nucleus and binds the sterol regulatory element. This promotes transcription of the gene upstream of the sterol regulatory element. A unique finding of our studies is that ceramide stimulated SREBP-1 maturation even in the presence of cholesterol and 25-hydroxycholesterol both of which are known suppressors of SREBP-1 maturation, Our findings indicate that ceramide-mediated maturation of SREBP-1 maturation is a novel sterol-independent mechanism by which cholesterol homeostasis may be regulated.	Johns Hopkins Univ, Sch Med, Dept Pediat, Lipid Res Atherosclerosis Unit, Baltimore, MD 21287 USA; Univ Toronto, Toronto, ON M5G 1X8, Canada	Johns Hopkins University; University of Toronto	Chatterjee, S (corresponding author), Johns Hopkins Hosp, CMSC-604,600 N Wolfe St, Baltimore, MD 21287 USA.				NHLBI NIH HHS [P50-HL47212] Funding Source: Medline; NIDDK NIH HHS [R0-1 DK-31722] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031722] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; CHAN G, 1995, EUR J IMMUNOL, V25, P1999, DOI 10.1002/eji.1830250730; CHATTERJEE S, 1993, J BIOL CHEM, V268, P3401; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CLEJAN S, 1984, J BIOL CHEM, V259, P823; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; KAN C, 1991, BIOCHEMISTRY-US, V30, P10746; KIM MY, 1991, J BIOL CHEM, V266, P484; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8	23	130	134	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5053	5059		10.1074/jbc.273.9.5053	http://dx.doi.org/10.1074/jbc.273.9.5053			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478955	hybrid			2022-12-25	WOS:000072310400039
J	Lewis, SD; Lucas, BJ; Brady, SF; Sisko, JT; Cutrona, KJ; Sanderson, PEJ; Freidinger, RM; Mao, SS; Gardell, SJ; Shafer, JA				Lewis, SD; Lucas, BJ; Brady, SF; Sisko, JT; Cutrona, KJ; Sanderson, PEJ; Freidinger, RM; Mao, SS; Gardell, SJ; Shafer, JA			Characterization of the two-step pathway for inhibition of thrombin by alpha-ketoamide transition state analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ARG CHLOROMETHYLKETONE; CYCLOTHEONAMIDE-A; CRYSTAL-STRUCTURE; BINDING INHIBITION; SLOW-BINDING; DESCRIBES; KINETICS	The interaction of thrombin with several potent and selective alpha-ketoamide transition state analogs was characterized. L-370,518 (H-N-Me-D-Phe-Pro-t-4-aminocyclohexylglycyl N-methylcarboxamide) a potent (K-i = 90 pd and selective (>10(4)-fold versus trypsin) ketoamide thrombin inhibitor was shown to bind thrombin via a two-step reaction wherein the initially formed thrombin-inhibitor complex (EI1) rearranges to a more stable, final complex (EI2). A novel sequential stopped-Row analysis showed that k(-1), the rate constant for dissociation of EI1, was comparable to k(2), the rate constant for conversion of EI1 to EI2 (0.049 and 0.035 s(-1), respectively) indicating that formation of the initial complex EI1 is partially rate controlling. Replacement of the N-terminal methylamino group in L-370,518 with a hydrogen (L-372,051) resulted in a 44-fold loss in potency (K-i = 4 nM) largely due to an increase in k(-1). Consequently in the reaction of L-372,051 with thrombin formation of EI1 was not rate controlling. Replacement of the P1' N-methylcarboxamide group of L-370,518 with an azetidylcarboxamido (L-372,228) produced a 58-fold increase in the value of the equilibrium constant (K(-)1) for dissociation of EI1. Nevertheless, L-372,228 was a 2-fold more potent thrombin inhibitor (K-i = 40 pM) than L-370,518 due to its 18-fold higher k(2) and 10-fold lower k(-2) values. The desketoamide analogs of L-370,518 and L-372,051, namely L-371,912 and L-372,011, inhibited thrombin via a one-step process. The K-i value for L-371,912 and the K-1 value for its alpha-ketoamide analog, L-370,518, were similar (5 and 14 nM, respectively). Likewise, the K-i value for L-372,011 and the K-1 value for its alpha-ketoamide analog, L-372,051, were similar (330 and 285 nM, respectively). These observations are consistent with the view that the alpha-ketoamides L-370,518 and L-372,051 form initial complexes with thrombin that are similar to the complexes formed by their desketoamide analogs, and in a second step the alpha-ketoamides react with the active site serine residue of thrombin to form a more stable hemiketal adduct.	Merck Res Labs, Dept Biol Chem, W Point, PA 19486 USA; Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA	Merck & Company; Merck & Company	Lewis, SD (corresponding author), Merck Res Labs, Dept Biol Chem, WP 42-300,Sumneytown Pike, W Point, PA 19486 USA.							BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; BRADY SF, 1995, BIOORGAN MED CHEM, V3, P1063, DOI 10.1016/0968-0896(95)00105-P; BRADY SF, 1995, PEPTIDES CHEM STRUCT, P331; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHEN ZG, 1995, ARCH BIOCHEM BIOPHYS, V322, P198, DOI 10.1006/abbi.1995.1452; Cutrona KJ, 1996, TETRAHEDRON LETT, V37, P5045, DOI 10.1016/0040-4039(96)01013-1; FUSETANI N, 1990, J AM CHEM SOC, V112, P7053, DOI 10.1021/ja00175a045; HAGIHARA M, 1992, J AM CHEM SOC, V114, P6570, DOI 10.1021/ja00042a053; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; LEWIS SD, 1993, THROMB RES, V70, P173, DOI 10.1016/0049-3848(93)90158-K; LEWIS SD, 1995, THROMB HAEMOSTASIS, V74, P1107; Lyle TA, 1997, BIOORG MED CHEM LETT, V7, P67, DOI 10.1016/S0960-894X(96)00583-5; MARYANOFF BE, 1995, J AM CHEM SOC, V117, P1225, DOI 10.1021/ja00109a006; MARYANOFF BE, 1993, P NATL ACAD SCI USA, V90, P8048, DOI 10.1073/pnas.90.17.8048; MEHDI S, 1993, BIOORG CHEM, V21, P249, DOI 10.1006/bioo.1993.1021; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Sculley MJ, 1996, BBA-PROTEIN STRUCT M, V1298, P78, DOI 10.1016/S0167-4838(96)00118-5; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; Williams J W, 1979, Methods Enzymol, V63, P437; WIPF P, 1993, J ORG CHEM, V58, P5592, DOI 10.1021/jo00073a010	24	19	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4843	4854		10.1074/jbc.273.9.4843	http://dx.doi.org/10.1074/jbc.273.9.4843			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478925	hybrid			2022-12-25	WOS:000072310400009
J	Borsch-Haubold, AG; Bartoli, F; Asselin, J; Dudler, T; Kramer, RM; Apitz-Castro, R; Watson, SP; Gelb, MH				Borsch-Haubold, AG; Bartoli, F; Asselin, J; Dudler, T; Kramer, RM; Apitz-Castro, R; Watson, SP; Gelb, MH			Identification of the phosphorylation sites of cytosolic phospholipase A(2) in agonist-stimulated human platelets and HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR; MAP KINASE; DEPENDENT PHOSPHORYLATION; ARACHIDONIC-ACID; NUCLEAR-ENVELOPE; THROMBIN; TRANSLOCATION; INHIBITION; MEMBRANE	The present study identifies the phosphorylation sites of the 85-kDa cytosolic phospholipase A(2) (cPLA(2)) in human platelets and HeLa cells, Tryptic digests of P-32-phosphorylated and -immunoprecipitated cPLA(2) were analyzed by microbore high performance liquid chromatography and two-dimensional phosphopeptide mapping against synthetic phosphopeptide standards, Thrombin stimulated significant phosphorylation of platelet cPLA(2) at two sites, Ser-505 and Ser-727. Exclusive phosphorylation on these two sites was also seen in collagen-stimulated platelets and HeLa cells stimulated with interferon-alpha or arsenite; no tyrosine phosphorylation was detected. The inhibitor of the 38-kDa stress-activated protein kinase (p38(mapk)), SB 203580, reduced phosphorylation of both Ser-505 and Ser-727 by 50 and 60%, respectively, in thrombin-stimulated platelets. An additional p38(mapk) inhibitor SB 202190 also partially (60%) inhibited the phosphorylation of cPLA(2) in arsenite-stimulated HeLa cells, These studies extend the previous work on the identification of multiple phosphorylation sites on cPLA(2) expressed in a baculovirus/insect cell system to cPLA(2) in mammalian cells stimulated with physiological agonists, They also underscore the necessity of high resolution phosphopeptide mapping combined with microbore high performance liquid chromatography for quantification of phosphorylation levels, which has lead to the conclusion that Ser-505 and Ser-727 are common phosphorylation sites on cPLA(2) in different mammalian cells stimulated with multiple agonists.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; IVIC, Ctr Biofis & Bioquim, Lab Thrombosis, Caracas, Venezuela; Lilly Res Labs, Indianapolis, IN 46285 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Oxford; Venezuelan Institute Science Research; Eli Lilly	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.		Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423; gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL50040] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25885, DOI 10.1074/jbc.270.43.25885; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; Flati V, 1996, EMBO J, V15, P1566, DOI 10.1002/j.1460-2075.1996.tb00501.x; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KAST R, 1993, J BIOL CHEM, V268, P16795; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAMER RM, 1994, SIGNAL ACTIVATED PHO, P13; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIU LL, 1993, CELL, V72, P269; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; QIU ZH, 1994, J BIOL CHEM, V269, P19480; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SMITH MC, 1988, J BIOL CHEM, V263, P7211; VANDERGEER P, 1993, PROTEIN PHOSPHORYLAT, P35; XING MZ, 1994, J BIOL CHEM, V269, P3117	35	137	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4449	4458		10.1074/jbc.273.8.4449	http://dx.doi.org/10.1074/jbc.273.8.4449			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468497	hybrid			2022-12-25	WOS:000072115000025
J	Ferre, S; Torvinen, M; Antoniou, K; Irenius, E; Civelli, O; Arenas, E; Fredholm, BB; Fuxe, K				Ferre, S; Torvinen, M; Antoniou, K; Irenius, E; Civelli, O; Arenas, E; Fredholm, BB; Fuxe, K			Adenosine A(1) receptor-mediated modulation of dopamine D-1 receptors in stably cotransfected fibroblast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERTUSSIS TOXIN; ADENYLATE-CYCLASE; PROTEIN-KINASE; BINDING; RAT; HIPPOCAMPUS; CLONING; BRAIN; CAMP	The antagonistic interactions between adenosine A(1) and dopamine D-1 receptors were studied in a mouse Ltk(-) cell hue stably cotransfected with human adenosine A(1) receptor and dopamine D-1 receptor cDNAs, In membrane preparations, both the adenosine A(1) receptor agonist N-6-cyclopentyladenosine and the GTP analogue guanyl-5'-yl imidodiphospate induced a decrease in the proportion of dopamine D-1 receptors in a high affinity state, In the cotransfect-ed cells, the adenosine A(1) agonist induced a concentration-dependent inhibition of dopamine-induced cAMP accumulation, Blockade of adenosine A(1) receptor signal transduction with the adenosine A(1) receptor antagonist 1,3-dipropyl-8-cyclopentylxanthine or with pertussis toxin pretreatment increased both basal and dopamine-stimulated cAMP levels, indicating the existence of tonic adenosine A(1) receptor activation, Pretreatment with pertussis toxin also counteracted the effects of low concentrations of the A(1) agonist on D-1 receptor-agonist binding The results suggest that adenosine A(1) receptors antagonistically modulate dopamine D-1 receptors at the level of receptor binding and the generation of second messengers.	Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Biochem & Mol Biophys, S-17177 Stockholm, Sweden; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of California System; University of California Irvine	Ferre, S (corresponding author), Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden.		Civelli, Olivier/A-8392-2012; Ferre, Sergi/K-6115-2014; Arenas, Ernest/AAO-5231-2020	Ferre, Sergi/0000-0002-1747-1779; Arenas, Ernest/0000-0003-0197-6577; Fuxe, Kjell/0000-0001-8491-4288				ABBRACCHIO MP, 1987, PHARMACOL RES COMMUN, V19, P275, DOI 10.1016/0031-6989(87)90085-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTE TE, 1984, J BIOL CHEM, V259, P8693; CUNHA RA, 1995, NEUROREPORT, V6, P1583, DOI 10.1097/00001756-199507310-00029; Dasgupta S, 1996, EUR J PHARMACOL, V316, P325, DOI 10.1016/S0014-2999(96)00665-6; Ferre S, 1996, EUR J NEUROSCI, V8, P1545, DOI 10.1111/j.1460-9568.1996.tb01617.x; FERRE S, 1994, NEUROREPORT, V6, P73, DOI 10.1097/00001756-199412300-00020; FERRE S, 1992, NEUROSCIENCE, V51, P501, DOI 10.1016/0306-4522(92)90291-9; Ferre S, 1997, TRENDS NEUROSCI, V20, P482, DOI 10.1016/S0166-2236(97)01096-5; FERRE S, 1991, P NATL ACAD SCI USA, V88, P7238, DOI 10.1073/pnas.88.16.7238; FREDHOLM BB, 1989, EUR J PHARM-MOLEC PH, V172, P249, DOI 10.1016/0922-4106(89)90055-2; HERVE D, 1992, NEUROSCIENCE, V46, P687, DOI 10.1016/0306-4522(92)90155-U; HSIA JA, 1984, J BIOL CHEM, V259, P1086; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; KUROSE H, 1983, J BIOL CHEM, V258, P4870; LIBERT F, 1992, BIOCHEM BIOPH RES CO, V187, P919, DOI 10.1016/0006-291X(92)91285-X; LIU YF, 1992, MOL ENDOCRINOL, V6, P1815, DOI 10.1210/me.6.11.1815; NORDSTEDT C, 1990, ANAL BIOCHEM, V189, P231, DOI 10.1016/0003-2697(90)90113-N; TOWNSENDNICHOLSON A, 1992, MOL BRAIN RES, V16, P365, DOI 10.1016/0169-328X(92)90248-A; UHLER MD, 1987, J BIOL CHEM, V262, P15202; ZOLI M, 1993, MOL NEUROBIOL, V7, P293, DOI 10.1007/BF02769180	21	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4718	4724		10.1074/jbc.273.8.4718	http://dx.doi.org/10.1074/jbc.273.8.4718			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468534	hybrid			2022-12-25	WOS:000072115000062
J	Klann, E; Roberson, ED; Knapp, LT; Sweatt, JD				Klann, E; Roberson, ED; Knapp, LT; Sweatt, JD			A role for superoxide in protein kinase C activation and induction of long-term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; FREE-RADICALS; SYNAPTIC TRANSMISSION; PERSISTENT ACTIVATION; RETROGRADE MESSENGER; HIPPOCAMPAL SLICES; ARACHIDONIC-ACID; PHOSPHORYLATION; MAINTENANCE; RAT	The induction of several forms of long-term potentiation (LTP) of synaptic transmission in the CA1 region of the mammalian hippocampus is dependent on N-methyl-D-aspartate receptor activation and the subsequent activation of protein kinase C (PKC), but the mechanisms that underlie the regulation of PKC in this context are largely unknown. It is known that reactive oxygen species, including superoxide, are produced by N-methyl-D-aspartate receptor activation in neurons, and recent studies have suggested that some reactive oxygen species can modulate PKC in vitro. Thus, we have investigated the role of superoxide in both the induction of LTP and the activation of PKC during LTP. We found that incubation of hippocampal slices with superoxide scavengers inhibited the induction of LTP. The effects of superoxide on LTP induction may involve PKC, as we observed that superoxide was required for appropriate modulation of PKC activation during the induction of LTP. In this respect, superoxide appears to work in conjunction with nitric oxide, which was required for a portion of the LTP-associated changes in PKC activity as well. Our observations indicate that superoxide and nitric oxide together regulate PKC in a physiologic context and that this type of regulation occurs during the induction of LTP in the hippocampus.	Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15260 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor College of Medicine	Klann, E (corresponding author), Univ Pittsburgh, Dept Neurosci, 446 Crawford Hall, Pittsburgh, PA 15260 USA.		Roberson, Erik/A-5718-2009	Roberson, Erik/0000-0002-1810-9763; Sweatt, J. David/0000-0003-3567-485X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034007, R01NS034007, R37NS034007, F32NS008950] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48186] Funding Source: Medline; NINDS NIH HHS [NS34007, NS08950] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; Chen SJ, 1997, BRAIN RES, V749, P181, DOI 10.1016/S0006-8993(96)01159-6; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DIONISI O, 1975, BIOCHIM BIOPHYS ACTA, V403, P292, DOI 10.1016/0005-2744(75)90059-5; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; GIBSON QH, 1957, J PHYSIOL-LONDON, V136, P507, DOI 10.1113/jphysiol.1957.sp005777; GONZALEZ A, 1993, ANAL BIOCHEM, V215, P184, DOI 10.1006/abio.1993.1574; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HVALBY O, 1994, P NATL ACAD SCI USA, V91, P4761, DOI 10.1073/pnas.91.11.4761; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LARSSON R, 1988, J BIOL CHEM, V263, P17452; LARSSON R, 1989, CANCER RES, V49, P5627; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; LYNCH MA, 1991, BIOCHEM SOC T, V19, P391, DOI 10.1042/bst0190391; LYNCH MA, 1989, NEUROSCIENCE, V30, P693, DOI 10.1016/0306-4522(89)90162-0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; Osten P, 1996, J NEUROSCI, V16, P2444; OTANI S, 1993, BRAIN RES, V613, P1, DOI 10.1016/0006-8993(93)90446-T; PALUMBO EJ, 1992, BIOCHEM BIOPH RES CO, V187, P1439, DOI 10.1016/0006-291X(92)90463-U; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; PELLEGRINIGIAMPIETRO DE, 1988, J NEUROCHEM, V51, P1960, DOI 10.1111/j.1471-4159.1988.tb01187.x; PELLMAR TC, 1991, NEUROSCIENCE, V44, P353, DOI 10.1016/0306-4522(91)90060-2; PELLMAR TC, 1992, BRAIN RES, V569, P189, DOI 10.1016/0006-8993(92)90630-R; POU S, 1992, J BIOL CHEM, V267, P24173; RADI R, 1991, J BIOL CHEM, V266, P4244; RAMAKERS GMJ, 1995, J BIOL CHEM, V270, P13892, DOI 10.1074/jbc.270.23.13892; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SUZUKI T, 1992, BIOCHEM BIOPH RES CO, V189, P1515, DOI 10.1016/0006-291X(92)90247-I; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; WILLIAMS JH, 1989, NEUROSCI LETT, V107, P301, DOI 10.1016/0304-3940(89)90835-5	55	151	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4516	4522		10.1074/jbc.273.8.4516	http://dx.doi.org/10.1074/jbc.273.8.4516			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468506	hybrid			2022-12-25	WOS:000072115000034
J	Weis, MA; Wilkin, DJ; Kim, HJ; Wilcox, WR; Lachman, RS; Rimoin, DL; Cohn, DH; Eyre, DR				Weis, MA; Wilkin, DJ; Kim, HJ; Wilcox, WR; Lachman, RS; Rimoin, DL; Cohn, DH; Eyre, DR			Structurally abnormal type II collagen in a severe form of Kniest dysplasia caused by an exon 24 skipping mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LETHAL OSTEOGENESIS IMPERFECTA; CROSS-LINKING SITES; TRIPLE-HELIX; SPONDYLOEPIPHYSEAL DYSPLASIA; PRO-ALPHA-1(I) CHAIN; ALTER CLEAVAGE; N-PROTEINASE; AMINO-ACIDS; XI COLLAGEN; CARTILAGE	Type II collagen mutations have been identified in a phenotypic continuum of chondrodysplasias that range widely in clinical severity. They include achondrogenesis type II, hypochondrogenesis, spondyloepiphyseal dysplasia congenita, spondyloepimetaphyseal dysplasia, Kniest dysplasia, and Stickler syndrome. We report here results that define the underlying genetic defect and consequent altered structure of assembled type II collagen in a neonatal lethal form of Kniest dysplasia, Electrophoresis of a cyanogen bromide (CNBr) (CB) digest of sternal cartilage revealed an alpha 1(II)CB11 peptide doublet and a slightly retarded mobility for all major CB peptides, which implied post-translational overmodification. Further peptide mapping and sequence analysis of CB11 revealed equal amounts of a normal alpha 1(II) sequence and a chain lacking the 18 residues (361-378 of the triple helical domain) corresponding to exon 24. Sequence analysis of an amplified genomic DNA fragment identified a G to A transition in the +5 position of the splice donor consensus sequence of intron 24 in one allele. Cartilage matrix analysis showed that the short alpha 1(II) chain was present in collagen molecules that had become cross-linked into fibrils. Trypsin digestion of the pepsin-extracted native type II collagen selectively cleaved the normal length alpha 1(II) chains within the exon 24 domain, These findings support a hypothesis that normal and short alpha-chains had combined to form hetero trimeric molecules in which the chains were in register in both directions from the deletion site, accommodated effectively by a loop out of the normal chain exon 24 domain. Such an accommodation, with potential overall shortening of the helical domain and hence misalignment of intermolecular relationships within fibrils, offers a common molecular mechanism by which a group of different mutations might act to produce the Kniest phenotype.	Univ Washington, Dept Orthopaed, Orthopaed Res Labs, Seattle, WA 98195 USA; Cedars Sinai Med Ctr, Burns & Allen Cedars Sinai Res Inst, Steven Spielberg Pediat Res Ctr, Ahmanson Dept Pediat, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Radiol, Los Angeles, CA 90048 USA; Ajou Univ, Coll Med, Dept Med Genet, Suwon 441749, South Korea	University of Washington; University of Washington Seattle; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Ajou University	Eyre, DR (corresponding author), Univ Washington, Dept Orthopaed, Orthopaed Res Labs, POB 356500, Seattle, WA 98195 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD022657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037318, R37AR037318, R01AR036794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016219] Funding Source: NIH RePORTER; NIAMS NIH HHS [R37 AR037318, AR37318, R01 AR036794] Funding Source: Medline; NICHD NIH HHS [HD22657] Funding Source: Medline; NIGMS NIH HHS [GM16219] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BALDWIN CT, 1989, J CLIN INVEST, V81, P521; BATEMAN JF, 1986, ANAL BIOCHEM, V154, P338, DOI 10.1016/0003-2697(86)90534-8; BOGAERT R, 1992, J BIOL CHEM, V267, P22522; BOGAERT R, 1994, AM J HUM GENET, V55, P1128; Byers Peter H., 1993, P317; Chen LP, 1996, J ORTHOPAED RES, V14, P712, DOI 10.1002/jor.1100140506; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; CHIPMAN SD, 1992, J BONE MINER RES, V7, P793; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Diab M, 1996, BIOCHEM J, V314, P327, DOI 10.1042/bj3140327; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; EYRE D, 1987, METHOD ENZYMOL, V144, P115; EYRE D R, 1990, P188; EYRE DR, 1984, ANAL BIOCHEM, V137, P380, DOI 10.1016/0003-2697(84)90101-5; EYRE DR, 1975, BIOCHEM J, V151, P595, DOI 10.1042/bj1510595; FERNANDES RJ, 1995, T ORTHO RES SOC, V20, P30; Fertala A, 1996, J BIOL CHEM, V271, P14864, DOI 10.1074/jbc.271.25.14864; HORTON WA, 1979, PEDIATR RES, V13, P1266, DOI 10.1203/00006450-197911000-00012; Horton William A., 1993, P641; KNIEST W, 1952, Z Kinderheilkd, V70, P633, DOI 10.1007/BF00438870; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LACHMAN RS, 1975, AM J ROENTGENOL, V123, P805, DOI 10.2214/ajr.123.4.805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; LIGHTFOOT SJ, 1994, J BIOL CHEM, V269, P30352; MILLER EJ, 1972, BIOCHEMISTRY-US, V11, P4903, DOI 10.1021/bi00776a005; Mundlos S, 1996, J BIOL CHEM, V271, P21068, DOI 10.1074/jbc.271.35.21068; POOLE AR, 1988, J CLIN INVEST, V81, P579, DOI 10.1172/JCI113356; PROCKOP DJ, 1990, J BIOL CHEM, V265, P15349; RIMOIN DL, 1975, ADV HUM GENET, V5, P1; RIMOIN DL, 1996, PRINCIPLES PRACTICE, P2779; SOKOLOV B P, 1988, Biokhimiya, V53, P1828; SPRANGER J, 1994, EUR J PEDIATR, V153, P56, DOI 10.1007/BF01959208; Spranger J, 1997, AM J MED GENET, V69, P79, DOI 10.1002/(SICI)1096-8628(19970303)69:1<79::AID-AJMG15>3.0.CO;2-L; STEGEMANN H, 1958, H-S Z PHYSIOL CHEM, V311, P41, DOI 10.1515/bchm2.1958.311.1.41; TILLER GE, 1995, AM J HUM GENET, V56, P388; WALLIS GA, 1992, J BIOL CHEM, V267, P25529; WILKIN DJ, 1994, HUM MOL GENET, V3, P1999; WILLING MC, 1988, J BIOL CHEM, V263, P8398; Winterpacht A, 1996, J MED GENET, V33, P649, DOI 10.1136/jmg.33.8.649; WINTERPACHT A, 1994, HUM MOL GENET, V3, P1891, DOI 10.1093/hmg/3.10.1891; WINTERPACHT A, 1993, NAT GENET, V3, P323, DOI 10.1038/ng0493-323; WU JJ, 1995, J BIOL CHEM, V270, P18865, DOI 10.1074/jbc.270.32.18865; WU JJ, 1984, BIOCHEMISTRY-US, V23, P1850, DOI 10.1021/bi00303a041	45	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4761	4768		10.1074/jbc.273.8.4761	http://dx.doi.org/10.1074/jbc.273.8.4761			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468540	hybrid			2022-12-25	WOS:000072115000068
J	Santolini, J; Haraux, F; Sigalat, C; Munier, L; Andre, F				Santolini, J; Haraux, F; Sigalat, C; Munier, L; Andre, F			Interrelation between high and low affinity tentoxin binding sites in chloroplast F-1-ATPase revealed by synthetic analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; COUPLING FACTOR-I; ATP SYNTHASE; SPINACH CHLOROPLAST; ELECTRON-MICROSCOPY; CYCLIC TETRAPEPTIDE; SUBUNITS; ROTATION; CF1; MITOCHONDRIA	Eight synthetic analogues of tentoxin (cyclo-(L-N-Me-Glu(1)-L-Leu(2)-N-Me Delta(z)Phe(3)-Gly(4))) modified in residues 1, 2, and 3 were checked for their ability to inhibit and reactivate the ATPase activity of the activated soluble part of chloroplast ATP synthase. The data were consistent with a model involving two binding sites of different affinities for the toxins. The occupancy of the high affinity site (or tight site) gave rise to an inactive complex, whereas filling both sites (tight + loose) gave rise to a complex of variable activity, dependent on the toxin analogue. Competition experiments between tentoxin and nonreactivating analogues allowed discrimination between the absence of binding and a nonproductive binding to the site of lower affinity (or loose site). The affinity for the loose site was not affected significantly by the modifications of the tentoxin molecule, whereas the affinity for the tight site was found notably changed. Increasing the size of side chain 1 or 2 and introducing a net electrical charge both resulted in a decrease of affinity for the tight site, but the second change dominated the first one. The activity of different ternary complexes enzyme-tentoxin-analogue depended on the nature of the toxin bound on each site and not only on that bound on the loose site. This demonstrates that the reactivation process results from an interaction, direct or not, between these two binding sites. Possible molecular mechanisms are discussed.	CEA Saclay, Sect Bioenerget, Dept Biol Cellulaire & Mol, F-91191 Gif Sur Yvette, France; CEA Saclay, DBCM, CNRS, URA 2096, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS)	Andre, F (corresponding author), CEA Saclay, Sect Bioenerget, Dept Biol Cellulaire & Mol, Batiment 532, F-91191 Gif Sur Yvette, France.	andre@dsvidf.cea.fr	ANDRE, François/E-5555-2015	Santolini, Jerome/0000-0001-8919-112X				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; AVNI A, 1992, SCIENCE, V257, P1245, DOI 10.1126/science.1387730; BERGER G, 1987, J LIQ CHROMATOGR, V10, P1507, DOI 10.1080/01483918708066783; BOEKEMA EJ, 1990, BIOCHIM BIOPHYS ACTA, V1020, P49, DOI 10.1016/0005-2728(90)90092-I; BOEKEMA EJ, 1986, BIOCHIM BIOPHYS ACTA, V851, P353, DOI 10.1016/0005-2728(86)90071-X; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; DAHSE I, 1994, J PLANT PHYSIOL, V143, P615, DOI 10.1016/S0176-1617(11)81147-8; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DURBIN RD, 1977, PHYTOPATHOLOGY, V67, P602, DOI 10.1094/Phyto-67-602; FROMME P, 1992, Z NATURFORSCH C, V47, P239; HU NM, 1993, J BIOL CHEM, V268, P8536; LIEBERMANN B, 1983, Z ALLG MIKROBIOL, V23, P503, DOI 10.1002/jobm.3630230810; MEYER W L, 1971, Tetrahedron Letters, V25, P2357; MUSIER KM, 1987, BIOCHEMISTRY-US, V26, P5982, DOI 10.1021/bi00393a006; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Pinet E, 1996, FEBS LETT, V395, P217, DOI 10.1016/0014-5793(96)01043-5; Pinet E, 1996, BIOCHEMISTRY-US, V35, P12804, DOI 10.1021/bi960955n; PINET E, 1995, BIOPOLYMERS, V36, P135, DOI 10.1002/bip.360360204; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SIGALAT C, 1995, FEBS LETT, V368, P253, DOI 10.1016/0014-5793(95)00664-U; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Sokolov M, 1996, BIOCHEMISTRY-US, V35, P1242, DOI 10.1021/bi9511189; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V504, P136, DOI 10.1016/0005-2728(78)90012-9; STEELE JA, 1976, P NATL ACAD SCI USA, V73, P2245, DOI 10.1073/pnas.73.7.2245; STEELE JA, 1978, BIOCHEM BIOPH RES CO, V84, P215, DOI 10.1016/0006-291X(78)90284-X; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V501, P72, DOI 10.1016/0005-2728(78)90096-8; vanRaaij MJ, 1996, P NATL ACAD SCI USA, V93, P6913, DOI 10.1073/pnas.93.14.6913; VIK SB, 1994, J BIOL CHEM, V269, P30364; WANG JH, 1987, BIOCHEMISTRY-US, V26, P5527, DOI 10.1021/bi00391a047; YOSHIMURA H, 1990, ULTRAMICROSCOPY, V32, P265, DOI 10.1016/0304-3991(90)90004-6	33	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3343	3350		10.1074/jbc.273.6.3343	http://dx.doi.org/10.1074/jbc.273.6.3343			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452452	hybrid			2022-12-25	WOS:000071822300037
J	Pacini, F; Vivaldi, A; Santoro, M; Fedele, M; Fusco, A; Romei, C; Basolo, F; Pinchera, A				Pacini, F; Vivaldi, A; Santoro, M; Fedele, M; Fusco, A; Romei, C; Basolo, F; Pinchera, A			Simian virus 40-like DNA sequences in human papillary thyroid carcinomas	ONCOGENE			English	Article						SV40; thyroid cancer; autoimmune thyroiditis; oncogene	LARGE T-ANTIGEN; TRANSGENIC MICE; CHOROID-PLEXUS; RET ONCOGENE; CANCER; TUMORS; CELLS; EXPRESSION; RADIATION; EXPOSURE	Sequences of the SV40 virus, a virus of Asian macaques, have been found in human tumors, such as pleural mesotheliomas, ependimomas and choroid plexus tumors, Transgenic mice carrying the SV40 large T gene under the transcriptional control of the thyroglobulin gene promoter, develop thyroid dedifferentiation and follicular thyroid cell proliferation, leading to thyroid hyperplasia and adenocarcinomas. On these bases we investigated the presence of SV40 DNA sequences in 69 samples of papillary thyroid carcinomas (PTC) and in other thyroid and non-thyroid carcinomas, as well as in benign thyroid diseases. By Southern blot and PCR amplification followed by sequence analysis, we found the presence of SV40-related sequences integrated in the tumoral DNA of three cases of PTC. At least the 203 bp fragment of the aminoterminus of large T antigen, the 294 bp fragment of the VP1 gene and the 483 bp entire regulatory region were present in the tumoral DNA of these patients. SV40 sequences were not found in tissues other than PTC. Our results demonstrate that, in addition to previous findings in mesotheliomas and brain tumors, SV40 is somehow linked to papillary thyroid carcinoma. Although our data do not demonstrate a causative role in the development of PTC, this possibility must be considered and requires further studies.	Univ Pisa, Ist Endocrinol Metodol Clin & Med Lavoro, I-56124 Pisa, Italy; Univ Pisa, Ist Anat Patol, I-56124 Pisa, Italy; Univ Naples Federico II, CNR, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Ist Nazl Tumori, I-80131 Naples, Italy; Univ Reggio Calabria, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Pisa; University of Pisa; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria	Pacini, F (corresponding author), Univ Pisa, Ist Endocrinol Metodol Clin & Med Lavoro, Via Paradisa 2, I-56124 Pisa, Italy.		Basolo, Fulvio/AAC-2727-2019; Fedele, Monica/C-1417-2015	Basolo, Fulvio/0000-0003-1657-5020; Fedele, Monica/0000-0002-9171-1312; Fusco, Alfredo/0000-0003-3332-5197				ARTHUR RR, 1989, PROG MED VIROL, V36, P42; BALKANY C, 1995, THYROID, V5, P47, DOI 10.1089/thy.1995.5.47; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; Bond JA, 1996, INT J CANCER, V67, P563, DOI 10.1002/(SICI)1097-0215(19960807)67:4<563::AID-IJC16>3.0.CO;2-8; CARBONE M, 1994, ONCOGENE, V9, P1781; CIAMPOLILLO A, 1989, LANCET, V1, P1096; Cristaudo A., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P29; DAS BC, 1992, J MED VIROL, V36, P239, DOI 10.1002/jmv.1890360402; FEIGENBAUM L, 1992, J VIROL, V66, P1176, DOI 10.1128/JVI.66.2.1176-1182.1992; GALANTI MR, 1995, INT J CANCER, V61, P615, DOI 10.1002/ijc.2910610506; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; LEDENT C, 1995, ONCOGENE, V10, P1789; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; Martini F, 1996, CANCER RES, V56, P4820; MELNICK JL, 1962, P SOC EXP BIOL MED, V109, P965, DOI 10.3181/00379727-109-27392; MILLER RW, 1995, ENVIRON HEALTH PERSP, V103, P41, DOI 10.2307/3432343; MORRIS JA, 1961, P SOC EXP BIOL MED, V108, P56, DOI 10.3181/00379727-108-26843; Pettersson B, 1996, INT J CANCER, V65, P13, DOI 10.1002/(SICI)1097-0215(19960103)65:1&lt;13::AID-IJC3&gt;3.0.CO;2-4; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1995, EUR J ENDOCRINOL, V133, P513, DOI 10.1530/eje.0.1330513; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1994, ONCOGENE, V9, P509; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; SORIANO F, 1974, NATURE, V249, P421, DOI 10.1038/249421a0; TAKAHASHI MH, 1995, BRIT J CANCER, V72, P813, DOI 10.1038/bjc.1995.418; WILLIAMS ED, 1979, CLIN ENDOCRINOL META, V8, P193, DOI 10.1016/S0300-595X(79)80017-1; WILLIAMS ED, 1995, J ENDOCRINOL INVEST, V18, P144, DOI 10.1007/BF03349725	31	48	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	1998	16	5					665	669		10.1038/sj.onc.1201552	http://dx.doi.org/10.1038/sj.onc.1201552			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482113				2022-12-25	WOS:000071816600012
J	Mironov, A; Luini, A; Mironov, A				Mironov, A; Luini, A; Mironov, A			A synthetic model of intra-Golgi traffic	FASEB JOURNAL			English	Article						intra-Golgi transport; cistern maturation; lateral diffusion; Golgi enzyme recycling	CYTOPLASMIC MEMBRANES; TRANSPORT VESICLES; APPARATUS; COMPLEX; PROTEIN; CELL; ELEMENTS	We present a hypothesis on the mechanisms used by cells to transport cargo through the secretory system. We propose that at least three basic processes coordinately participate in membrane traffic: cisternal maturation-progression, controlled cargo diffusion along transient membrane continuities between different compartments, and a mostly retrograde vesicle-mediated transport. A 'synthetic' model based on the combination of these mechanisms can explain both the progression of supramolecular aggregates through the secretory pathway and the fast intra-Golgi transport of conventional cargoes. Analysis of the existing literature shows that the available data are consistent with the proposed model.	Mario Negri Sud Inst, Mol Neurobiol Lab, I-66030 Chieti, Italy	Consorzio Mario Negri Sud	Luini, A (corresponding author), Mario Negri Sud Inst, Mol Neurobiol Lab, Via Nazl, I-66030 Chieti, Italy.	mironov@cmns.mnegri.it; luini@cmns.mnegri.it	Luini, Alberto/L-1372-2013	Luini, Alberto/0000-0002-8729-2549; Mironov, Aleksandr/0000-0002-1497-328X				Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; CLAUDE A, 1970, J CELL BIOL, V47, P745, DOI 10.1083/jcb.47.3.745; CLERMONT Y, 1994, ANAT REC, V240, P469, DOI 10.1002/ar.1092400405; DAHAN S, 1994, J CELL BIOL, V127, P1859, DOI 10.1083/jcb.127.6.1859; LEBLOND CP, 1989, ANAT REC, V224, P123, DOI 10.1002/ar.1092240204; Mironov AA, 1997, J CELL BIOL, V138, P481, DOI 10.1083/jcb.138.3.481; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; RABOUILLE C, 1995, J CELL SCI, V108, P1617; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; ROTHMAN JE, 1984, J CELL BIOL, V99, P248, DOI 10.1083/jcb.99.1.248; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sonnichsen B, 1996, J CELL BIOL, V134, P1411, DOI 10.1083/jcb.134.6.1411; STINCHCOMBE JC, 1995, J CELL BIOL, V131, P1387, DOI 10.1083/jcb.131.6.1387; Tanaka K, 1992, Hum Cell, V5, P211; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39	17	29	32	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1998	12	2					249	252						4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472990				2022-12-25	WOS:000071848400013
J	Muciaccia, B; Uccini, S; Filippini, A; Ziparo, E; Paraire, F; Baroni, CD; Stefanini, M				Muciaccia, B; Uccini, S; Filippini, A; Ziparo, E; Paraire, F; Baroni, CD; Stefanini, M			Presence and cellular distribution of HIV in the testes of seropositive subjects: an evaluation by in situ PCR hybridization	FASEB JOURNAL			English	Article						testis; stem cell infection; AIDS; germ cell	HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY-SYNDROME; POLYMERASE CHAIN-REACTION; SERTOLI CELLS; ARTIFICIAL-INSEMINATION; HTLV-III; PREEJACULATORY FLUID; SEMINIFEROUS TUBULES; SEXUAL TRANSMISSION; TESTICULAR ATROPHY	Cellular distribution of HIV-1 proviral DNA has been studied, by in situ PCR hybridization, in the testes of infected men who died at various stages of the disease. In seropositive asymptomatic subjects, HIV-1 proviral DNA was present in the nuclei of germ cells at all stages of their differentiation. The presence of provirus did not induce germ cell damage, was associated with normal spermatogenesis, and was not accompanied by morphologic signs of immune response. The observed HIV hybridization pattern of germ cells suggests clonal infection. Mechanisms responsible for HIV penetration in testicular germ cells remain to be clarified; however, the possibility of a direct infection of the germ cells by cell-free virus is suggested. In the testes of AIDS-deceased men, histologic features of hypoplasia with arrested spermatogenesis were evident, and few infected spermatogonia and spermatocytes were observed. The whale of these data demonstrates that the testis is a site of early viral localization that fails to elicit an immunological response, and that HIV-seropositive men produce infected spermatozoa that are released in the genital tract.	Univ Roma La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, Chair Pathol 2, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, Immunopathol Sect, I-00161 Rome, Italy; Univ Roma La Sapienza, Ist Pasteur Fdn Cenci Bolognetti, I-00161 Rome, Italy; Hop Poincare, Lab Pathol & Forens Med, Garches, France	Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP	Muciaccia, B (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, Via Antonio Scarpa 14, I-00161 Rome, Italy.	mstefanini@axrma.uniromal.it		Ziparo, Elio/0000-0002-8776-3515; filippini, antonio/0000-0001-8453-287X				ANDERSON DJ, 1991, LANCET, V338, P573, DOI 10.1016/0140-6736(91)91139-L; ARANETA MRG, 1995, JAMA-J AM MED ASSOC, V273, P854, DOI 10.1001/jama.273.11.854; BACCETTI B, 1991, J SUBMICR CYTOL PATH, V23, P339; BACCETTI B, 1994, J CELL BIOL, V127, P903, DOI 10.1083/jcb.127.4.903; BAGASRA O, 1994, AIDS, V8, P1669, DOI 10.1097/00002030-199412000-00005; BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BORZY MS, 1988, J ACQ IMMUN DEF SYND, V1, P419; Brogi A, 1996, AIDS RES HUM RETROV, V12, P483, DOI 10.1089/aid.1996.12.483; BROGI A, 1995, J SUBMICR CYTOL PATH, V27, P565; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CHABON AB, 1987, UROLOGY, V29, P658, DOI 10.1016/0090-4295(87)90118-X; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; DALTON ADA, 1991, J PATHOL, V163, P47, DOI 10.1002/path.1711630109; DASILVA M, 1990, AM J CLIN PATHOL, V93, P196, DOI 10.1093/ajcp/93.2.196; DECESARIS P, 1992, BIOCHEM BIOPH RES CO, V186, P1639; DEPAEPE ME, 1989, HUM PATHOL, V20, P210, DOI 10.1016/0046-8177(89)90125-1; DEPAEPE ME, 1989, HUM PATHOL, V20, P572, DOI 10.1016/0046-8177(89)90246-3; DUSSAIX E, 1993, RES VIROLOGY, V144, P487, DOI 10.1016/S0923-2516(06)80064-6; Dym M, 1970, Biology Reprod., V3, P308; FANTINI J, 1993, P NATL ACAD SCI USA, V90, P2700, DOI 10.1073/pnas.90.7.2700; FILIPPINI A, 1989, GAMETE RES, V23, P367, DOI 10.1002/mrd.1120230402; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; GRAY F, 1992, J NEUROPATH EXP NEUR, V51, P177, DOI 10.1097/00005072-199203000-00007; GUINAN ME, 1995, JAMA-J AM MED ASSOC, V273, P890; HAASE AT, 1990, P NATL ACAD SCI USA, V87, P4971, DOI 10.1073/pnas.87.13.4971; HAMED KA, 1993, J INFECT DIS, V167, P798, DOI 10.1093/infdis/167.4.798; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HEAD JR, 1985, TRANSPLANTATION, V40, P269, DOI 10.1097/00007890-198509000-00010; HEAD JR, 1983, TRANSPLANTATION, V36, P423, DOI 10.1097/00007890-198310000-00014; HERMO L, 1976, AM J ANAT, V145, P467, DOI 10.1002/aja.1001450406; HERMO L, 1978, BIOL REPROD, V19, P92, DOI 10.1095/biolreprod19.1.92; HO DD, 1984, SCIENCE, V226, P451, DOI 10.1126/science.6208608; ILARIA G, 1992, LANCET, V340, P1469, DOI 10.1016/0140-6736(92)92658-3; JACKSON DP, 1991, PCR PRACTICAL APPROA, P29; KIESSLING AA, 1987, P NATL ACAD SCI USA, V84, P8667, DOI 10.1073/pnas.84.23.8667; KRIEGER JN, 1995, J UROLOGY, V154, P1035, DOI 10.1016/S0022-5347(01)66969-6; KRIEGER JN, 1991, J INFECT DIS, V163, P386, DOI 10.1093/infdis/163.2.386; LECATSAS G, 1985, P SOC EXP BIOL MED, V178, P653; MARX JL, 1989, SCIENCE, V245, P30, DOI 10.1126/science.2740912; Meistrich M., 1989, HISTONES OTHER BASIC, P165; MERMIN JH, 1991, J INFECT DIS, V164, P769, DOI 10.1093/infdis/164.4.769; Mostad SB, 1996, AIDS, V10, P1305, DOI 10.1097/00002030-199610000-00001; NUOVO GJ, 1994, AM J PATHOL, V144, P1142; NUOVO GJ, 1992, PCR IN SITU HYBRIDIZ; OLeary JJ, 1996, J PATHOL, V178, P11; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PORTIS JL, 1987, J VIROL, V61, P1037, DOI 10.1128/JVI.61.4.1037-1044.1987; PUDNEY J, 1991, AM J PATHOL, V139, P149; PUDNEY J, 1992, LANCET, V340, P1470, DOI 10.1016/0140-6736(92)92659-4; RICCIOLI A, 1995, P NATL ACAD SCI USA, V92, P5808, DOI 10.1073/pnas.92.13.5808; ROGERS C, 1988, HISTOPATHOLOGY, V12, P659, DOI 10.1111/j.1365-2559.1988.tb01990.x; Sanberg PR, 1996, NAT BIOTECHNOL, V14, P1692, DOI 10.1038/nbt1296-1692; SCOFIELD VL, 1994, AIDS, V8, P1733, DOI 10.1097/00002030-199412000-00018; Sewart G, 1996, LANCET, V347, P970, DOI 10.1016/S0140-6736(96)91457-9; SMABROOK J, 1989, MOL CLONING LAB MANU; STEWART GJ, 1985, LANCET, V2, P581; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; TINDALL B, 1992, AIDS, V6, P949, DOI 10.1097/00002030-199209000-00006; TUNG KSK, 1980, IMMUNOLOGICAL ASPECT, P33; VANVOORHIS BJ, 1991, FERTIL STERIL, V55, P588; VERNAZZA PL, 1994, AIDS, V8, P1325, DOI 10.1097/00002030-199409000-00017; VIDAL F, 1993, HUM REPROD, V8, P1740, DOI 10.1093/oxfordjournals.humrep.a137926; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAGURY D, 1984, SCIENCE, V226, P449, DOI 10.1126/science.6208607	68	46	52	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1998	12	2					151	163		10.1096/fasebj.12.2.151	http://dx.doi.org/10.1096/fasebj.12.2.151			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472980				2022-12-25	WOS:000071848400003
J	Rivera, DL; Olister, SM; Liu, X; Thompson, JH; Zhang, XJ; Pennline, K; Azuero, R; Clark, DA; Miller, MJS				Rivera, DL; Olister, SM; Liu, X; Thompson, JH; Zhang, XJ; Pennline, K; Azuero, R; Clark, DA; Miller, MJS			Interleukin-10 attenuates experimental fetal growth restriction and demise	FASEB JOURNAL			English	Article						TNF-alpha; nitric oxide; IL-10; TUNEL; placenta; cellular infiltration	TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE SYNTHASE; FACTOR-ALPHA; AMNIOTIC-FLUID; CYTOKINE PRODUCTION; TROPHOBLAST CELLS; INTERFERON-GAMMA; PLACENTAL CELLS; T-CELLS; MACROPHAGES	Premature labor, fetal demise, and fetal growth restriction are accompanied by indices of inflammation or infection of the uteroplacental unit. To understand whether these events are causally related, we established an animal model of fetal demise and growth restriction and evaluated the potential utility of the anti-inflammatory cytokine interleukin-10 (IL-10). We administered low-dose endotoxin (lipopolysaccharide, or LPS, 100 mu g/kg, i.p.) to third trimester rats (gestational days 14-20). (Control rats received normal saline. A third group received IL-10 (100 mu g/kg; s.c.) concomitantly with LPS for 7 prenatal days. Cytokine gene expression (IL-10 and TNF-alpha) was evaluated by RT-PCR and tissue levels (TNF-alpha) were determined by ELISA. Apoptosis was evaluated by TdT-mediated dUTP nick end labeling immunohistochemistry, and nitric oxide (NO) levels were quantified by microelectrode electrochemical detection in explants in culture media. LPS exposure resulted in 43% fetal demise and reduced the size of the surviving fetuses. Placental weight was not altered by LPS. IL-10 attenuated the LPS-induced fetal death rate (to 22%) and growth restriction (P<0.05). in normal rats, IL-10 did not affect fetus size or the incidence of resorptions, although placental size was marginally smaller. Increased uterine TNF-alpha content and NO release and apoptosis of uterine epithelia and muscularis were hallmarks of the LPS model. All were normalized by IL-10. IL-10 may represent a new therapeutic option for the treatment of a variety of perinatal complications. Benefit may result from the suppression of TNF-a-and NO-mediated cell death.	Louisiana State Univ, Med Ctr, Dept Pediat, New Orleans, LA 70112 USA; Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA	Louisiana State University System; Merck & Company; Schering Plough Corporation	Miller, MJS (corresponding author), Louisiana State Univ, Med Ctr, Dept Pediat, 1542 Tulane Ave, New Orleans, LA 70112 USA.	mmiller@mail.peds.lsumc.edu			PHS HHS [R01 31885] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBINA JE, 1993, J IMMUNOL, V150, P5080; ARAI T, 1995, BIOCHEM BIOPH RES CO, V213, P600, DOI 10.1006/bbrc.1995.2174; ATHANASSAKIS I, 1987, J IMMUNOL, V138, P37; BECHEREL PA, 1995, EUR J IMMUNOL, V25, P2992, DOI 10.1002/eji.1830251042; BERKOWITZ RS, 1988, AM J OBSTET GYNECOL, V158, P199, DOI 10.1016/0002-9378(88)90810-1; Bingisser P, 1996, AM J RESP CELL MOL, V15, P64, DOI 10.1165/ajrcmb.15.1.8679223; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; Bour ES, 1996, AM J PATHOL, V148, P485; CADET P, 1995, AM J OBSTET GYNECOL, V173, P25, DOI 10.1016/0002-9378(95)90164-7; CENDI E, 1993, EUR J IMMUNOL, V23, P1034; CHAOUAT G, 1995, J IMMUNOL, V154, P4261; CHEDA S, 1996, PEDIATR RES, V40, P475; CUI S, 1993, CANCER RES, V54, P2462; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; DEKOSSODO S, 1992, J EXP MED, V176, P1259, DOI 10.1084/jem.176.5.1259; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; GENDRON RL, 1990, J REPROD FERTIL, V90, P395, DOI 10.1530/jrf.0.0900395; Geng YJ, 1996, CANCER RES, V56, P866; GREIG PC, 1995, AM J OBSTET GYNECOL, V173, P1223, DOI 10.1016/0002-9378(95)91358-0; HEYBORNE KD, 1992, AM J OBSTET GYNECOL, V167, P920, DOI 10.1016/S0002-9378(12)80012-3; HEYBORNE KD, 1994, AM J OBSTET GYNECOL, V171, P55, DOI 10.1016/S0002-9378(94)70077-X; HUNT JS, 1989, J REPROD IMMUNOL, V16, P1, DOI 10.1016/0165-0378(89)90002-8; HUNT JS, 1988, J IMMUNOL, V140, P1293; HUNZIKER RD, 1986, CRC CR REV IMMUNOL, V6, P245; INOUE T, 1994, HUM REPROD, V9, P2411, DOI 10.1093/oxfordjournals.humrep.a138460; JAATTELA M, 1988, LAB INVEST, V58, P48; LAHAM N, 1994, EUR J ENDOCRINOL, V131, P607, DOI 10.1530/eje.0.1310607; LIU XP, 1990, J ELECTROANAL CHEM, V295, P15; Lyall F, 1996, PLACENTA, V17, P165, DOI 10.1016/S0143-4004(96)80009-9; MACNEIL IA, 1990, J IMMUNOL, V145, P4167; MALEFYT RD, 1991, J EXP MED, V174, P1209; MARCHANT A, 1994, EUR J IMMUNOL, V24, P1167, DOI 10.1002/eji.1830240524; MCDUFFIE RS, 1992, AM J OBSTET GYNECOL, V167, P1583, DOI 10.1016/0002-9378(92)91745-V; Miller MJS, 1996, FREE RADICAL BIO MED, V21, P619, DOI 10.1016/0891-5849(96)00171-2; MOWBRAY J, 1993, IMMUNOLOGY PREGNANCY; MYERS SA, 1982, AM J PHYSIOL, V243, P4404; PAMPFER S, 1994, J REPROD FERTIL, V101, P199, DOI 10.1530/jrf.0.1010199; PENG TCC, 1992, P 39 ANN M SOC GYN I; PHILPOTT KL, 1988, IMMUNOLOGY, V64, P479; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; Ribbons KA, 1997, EUR J PHARMACOL, V323, P245, DOI 10.1016/S0014-2999(97)00017-4; SANDOVAL M, 1995, MEDIAT INFLAMM, V4, P248, DOI 10.1155/S0962935195000391; SILEN ML, 1989, AM J PATHOL, V135, P239; STALLMACH T, 1995, LAB INVEST, V73, P384; YELAVARTHI KK, 1991, J IMMUNOL, V146, P3840; YUI J, 1994, PLACENTA, V15, P819, DOI 10.1016/S0143-4004(05)80184-5	46	110	117	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1998	12	2					189	197		10.1096/fasebj.12.2.189	http://dx.doi.org/10.1096/fasebj.12.2.189			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472984	Bronze			2022-12-25	WOS:000071848400007
J	Berry, H; Debat, H; Garde, VL				Berry, H; Debat, H; Garde, VL			Oxygen concentration determines regiospecificity in soybean lipoxygenase-1 reaction via a branched kinetic scheme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; STEADY-STATE KINETICS; LINOLEIC-ACID; OXIDATION; HYDROPEROXIDES; PEROXIDATION; CATALYSIS; MECHANISM; RADICALS; CAROTENE	The effect of oxygen concentration on the regiospecificity of the soybean lipoxygenase-l dioxygenation reaction was studied, At low oxygen concentrations (<5 mu M), a dramatic change in the regiospecificity of the enzyme was observed with the hydroperoxy-octadecadienoic acid (HPOD) 13:9 ratio closer to 50:50 instead of the generally reported 95:5. This alteration of regiospecificity is not an isolated phenomenon, since it occurs during a reaction carried out under "classical" conditions, i.e. in a buffer saturated with air before the reaction. beta-carotene bleaching and electronic paramagnetic resonance findings provided evidence that substrate-derived free radical species are released from the enzyme. The kinetic scheme proposed by Schilstra et al, (Schilstra, M. J., Veldink, G. A. & Vliegenthart, J. F. G. (1994) Biochemistry 33, 3974-3979) was thus expanded to account for the observed variations in specificity, The equations describing the branched scheme show two different kinetic pathways: a fully enzymatic one leading to a regioisomeric composition of 13-HPOD:9-HPOD = 95:5, and a semienzymatic one leading to a regio-isomeric composition of 13-HPOD:9-HPOD = 50:50, The ratio between the two different pathways depends on oxygen concentration, which thus determines the overall specificity of the reaction.	Univ Cergy Pontoise, Dept Life Sci, F-95302 Cergy Pontoise, France; Univ Technol Compiegne, Lab Enzyme Technol, CNRS, UPRES A 6022, F-60205 Compiegne, France	CY Cergy Paris Universite; Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne	Garde, VL (corresponding author), Univ Cergy Pontoise, Dept Life Sci, 2 Ave Adolphe Chauvin, F-95302 Cergy Pontoise, France.	larreta@u-cergy.fr	Berry, Hugues/C-2321-2011; larreta garde, veronique/E-9356-2013	Berry, Hugues/0000-0003-3470-683X; larreta garde, veronique/0000-0003-3500-1364; DEBAT, Helene/0000-0003-0020-2748				AOSHIMA H, 1977, BIOCHIM BIOPHYS ACTA, V486, P121; ARAI H, 1995, LIPIDS, V30, P135, DOI 10.1007/BF02538266; Axelrod B., 1981, METH ENZYMOL, V441, P451, DOI [10.1016/0076-6879(81)71055-3, DOI 10.1016/0076-6879(81)71055-3]; CHRISTOPHER JP, 1972, BIOCHIM BIOPHYS ACTA, V289, P81; DEGROOT JJM, 1975, BIOCHIM BIOPHYS ACTA, V377, P71, DOI 10.1016/0005-2744(75)90287-9; EGMOND MR, 1976, EUR J BIOCHEM, V61, P93, DOI 10.1111/j.1432-1033.1976.tb10001.x; FRANKEL E N, 1980, Progress in Lipid Research, V19, P1, DOI 10.1016/0163-7827(80)90006-5; GALEY JB, 1988, BIOCHEMISTRY-US, V27, P1058, DOI 10.1021/bi00403a031; GARDNER HW, 1989, BIOCHIM BIOPHYS ACTA, V1001, P274, DOI 10.1016/0005-2760(89)90111-2; GARDNER HW, 1989, FREE RADICAL BIO MED, V7, P65, DOI 10.1016/0891-5849(89)90102-0; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; GARSSEN GJ, 1971, BIOCHEM J, V122, P327, DOI 10.1042/bj1220327; GIBIAN MJ, 1976, BIOCHEMISTRY-US, V15, P4209, DOI 10.1021/bi00664a012; Glickman MH, 1996, BIOCHEMISTRY-US, V35, P12882, DOI 10.1021/bi960985q; GLICKMAN MH, 1995, BIOCHEMISTRY-US, V34, P14077, DOI 10.1021/bi00043a013; HONN KV, 1994, CANCER METAST REV, V13, P365, DOI 10.1007/BF00666105; Jones GD, 1996, BIOCHEMISTRY-US, V35, P7197, DOI 10.1021/bi952425h; KUHN H, 1986, ADV ENZYMOL RAMB, V58, P273; LUDWIG P, 1987, EUR J BIOCHEM, V61, P93; NELSON MJ, 1994, BIOCHEMISTRY-US, V33, P4966, DOI 10.1021/bi00182a027; NIKOLAEV V, 1990, BIOCHEM BIOPH RES CO, V170, P491, DOI 10.1016/0006-291X(90)92118-J; PORTER NA, 1984, J AM CHEM SOC, V106, P2626, DOI 10.1021/ja00321a022; POURPLANCHE C, 1994, J BIOL CHEM, V269, P31585; POURPLANCHE C, 1991, ANAL BIOCHEM, V198, P160, DOI 10.1016/0003-2697(91)90522-U; RAMADOSS CS, 1978, ARCH BIOCHEM BIOPHYS, V190, P549, DOI 10.1016/0003-9861(78)90309-0; ROGINSKII VA, 1990, MOL BIOL+, V24, P1262; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHEWE T, 1991, TRENDS BIOCHEM SCI, V16, P369, DOI 10.1016/0968-0004(91)90153-M; SCHILSTRA MJ, 1994, BIOCHEMISTRY-US, V33, P3974, DOI 10.1021/bi00179a025; SCHILSTRA MJ, 1993, BIOCHEMISTRY-US, V32, P7686, DOI 10.1021/bi00081a012; SCHNURR K, 1995, BIOCHIM BIOPHYS ACTA, V1254, P109; SCHONEICH C, 1992, ARCH BIOCHEM BIOPHYS, V292, P456, DOI 10.1016/0003-9861(92)90016-P; WANG ZX, 1993, BIOCHEMISTRY-US, V32, P1500, DOI 10.1021/bi00057a014; ZAMORA R, 1988, NAHRUNG, V32, P965, DOI 10.1002/food.19880321013	34	35	35	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2769	2776		10.1074/jbc.273.5.2769	http://dx.doi.org/10.1074/jbc.273.5.2769			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446584	Green Published, hybrid			2022-12-25	WOS:000071736600039
J	Ogata, H; Inoue, N; Podolsky, DK				Ogata, H; Inoue, N; Podolsky, DK			Identification of a goblet cell-specific enhancer element in the rat intestinal trefoil factor gene promoter bound by a goblet cell nuclear protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC SPASMOLYTIC POLYPEPTIDE; EPIDERMAL GROWTH-FACTOR; SUCRASE-ISOMALTASE GENE; MOLECULAR-CLONING; BINDING-PROTEINS; REPORTER GENE; DNA-BINDING; P-DOMAIN; EXPRESSION; PS2	Intestinal trefoil factor (ITF) is selectively expressed in goblet cells of the small and large intestinal mucosa. Detailed analysis of the rat ITF (RITF) promoter was undertaken by transient transfection and gel mobility shift assays (GMSAs) using the goblet cell-like LS174T colon cancer-derived cell line. Various lengths of wild-type or mutant constructs of the 5'-flanking region were linked to the pXP2 reporter gene luciferase. Expression of -118 RITF was significantly decreased compared with -154 RITF, and transfection with an 18-base pair construct (-141 to -124) resulted in more than 5-fold greater expression than transfection with the promoterless pXP2 gene construct alone. Using various synthetic oligonucleotide mutants, GMSAs revealed that only a 9-base pair sequence (CCCCTCCCC) in this element was required for specific binding, overlapping but distinct from a Spl-like element. GMSA demonstrated that this element was specifically bound by nuclear proteins from intestinal cells with a goblet cell-like phenotype. These studies demonstrate that a 9-base pair element (goblet cell response element) between -154 and -118 in the RITF promoter gene is a cis-active element bound by a distinct nuclear transcription factor and is capable of directing intestine and goblet cell-specific expression.	Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Podolsky, DK (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, Fruit St, Boston, MA 02114 USA.	Podolsky.Daniel@mgh.harvard.edu	Ogata, H/B-3964-2014		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, R01DK046906] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43351, DK46906] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596; BOLL W, 1991, AM J HUM GENET, V48, P889; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARR MD, 1992, BIOCHEMISTRY-US, V31, P1998, DOI 10.1021/bi00122a015; CHANTRET I, 1992, BIOCHEM J, V285, P915, DOI 10.1042/bj2850915; CHINERY R, 1992, BIOCHEM J, V285, P5, DOI 10.1042/bj2850005; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; HAUSER F, 1992, J BIOL CHEM, V267, P24620; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; JEFFREY GP, 1994, GASTROENTEROLOGY, V106, P336, DOI 10.1016/0016-5085(94)90590-8; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; JORGENSEN KH, 1982, REGUL PEPTIDES, V3, P207, DOI 10.1016/0167-0115(82)90126-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KINDON H, 1995, GASTROENTEROLOGY, V109, P516, DOI 10.1016/0016-5085(95)90340-2; LEFEBVRE O, 1993, J CELL BIOL, V122, P191, DOI 10.1083/jcb.122.1.191; MASHIMO H, 1995, BIOCHEM BIOPH RES CO, V210, P31, DOI 10.1006/bbrc.1995.1623; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; MILLAN JL, 1987, NUCLEIC ACIDS RES, V15, P10599, DOI 10.1093/nar/15.24.10599; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; OLSEN J, 1989, FEBS LETT, V251, P275, DOI 10.1016/0014-5793(89)81470-X; PHILLIPS TE, 1988, GASTROENTEROLOGY, V94, P1390, DOI 10.1016/0016-5085(88)90678-6; PLAYFORD RJ, 1995, GASTROENTEROLOGY, V108, P108, DOI 10.1016/0016-5085(95)90014-4; PODOLSKY DK, 1993, J BIOL CHEM, V268, P6694; QUARONI A, 1979, J CELL BIOL, V80, P245; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; SANDS BE, 1995, J BIOL CHEM, V270, P9353, DOI 10.1074/jbc.270.16.9353; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEIB T, 1995, BIOCHEM BIOPH RES CO, V214, P195, DOI 10.1006/bbrc.1995.2274; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; THIM L, 1988, BIOCHEM J, V253, P309; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; TOMITA M, 1995, BIOCHEM J, V311, P293, DOI 10.1042/bj3110293; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; WRIGHT NA, 1990, J PATHOL, V162, P279, DOI 10.1002/path.1711620402	42	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3060	3067		10.1074/jbc.273.5.3060	http://dx.doi.org/10.1074/jbc.273.5.3060			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446622	hybrid			2022-12-25	WOS:000071736600077
J	Alric, S; Froeschle, A; Piquemal, D; Carnac, G; Bonnieu, A				Alric, S; Froeschle, A; Piquemal, D; Carnac, G; Bonnieu, A			Functional specificity of the two retinoic acid receptor RAR and RXR families in myogenesis	ONCOGENE			English	Article						myogenesis; retinoic acid; RAR; RXR; dominant negative; MyoD	INDUCED GRANULOCYTIC DIFFERENTIATION; EMBRYONAL CARCINOMA-CELLS; NUCLEAR HORMONE RECEPTORS; X-RECEPTOR; MUTANT MICE; SIGNALING PATHWAYS; RESPONSE ELEMENT; THYROID-HORMONE; GENE-REGULATION; MUSCLE-CELLS	In C2 myoblasts, retinoic acid (RA) is an efficient inducer of both growth arrest and differentiation. These RA effects are mediated through at least two classes of retinoic acid receptors (RARs and RXRs), which belong to the nuclear receptor superfamily. To determine the role played by each RAR or RXR family in this model system, we have analysed the effects of RA in C2 myoblasts expressing a dominant negative RAR (dnRAR) or a dominant negative RXR (dnRXR), The stable expression of dnRAR or dnRXR in C2 cells delays the RA-induced growth arrest and differentiation, an effect which is more pronounced in C2-dnRXR myoblasts, Furthermore, the RA-inducible expression of MyoD gene is lost in C2-dnRXR but not in C2-dnRAR cells, indicating that each family of retinoid receptors RAR and RXR may regulate distinct subsets of RA-responsive genes. Finally, using C2 cell lines with different retinoid responsiveness, we provided evidence for a link between the RXR and MyoD families in the process of myogenic differentiation, These results illustrate a critical role for RA-receptors in RA-control of C2 myogenesis and provide tools for studying the function of RA and its receptors during vertebrate development.	INRA, Lab Differenciat Cellulaire & Croissance, F-34060 Montpellier 1, France; Univ Montpellier 2, INSERM, U431, F-34095 Montpellier, France; CNRS, CRBM, Cell Biol Unit, F-34033 Montpellier, France	INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Bonnieu, A (corresponding author), INRA, Lab Differenciat Cellulaire & Croissance, Pl Viala, F-34060 Montpellier 1, France.		Bonnieu, Anne/ABA-7182-2020; Carnac, Gilles/N-6744-2018	Piquemal, David/0000-0002-5870-4276; Carnac, Gilles/0000-0002-3518-8774				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; CARNAC G, 1993, ENDOCRINOLOGY, V133, P2171, DOI 10.1210/en.133.5.2171; CARNAC G, 1993, ONCOGENE, V8, P3103; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN YP, 1991, ROUX ARCH DEV BIOL, V200, P162, DOI 10.1007/BF00190236; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10056, DOI 10.1073/pnas.89.21.10056; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DE LUCA LM, 1991, FASEB J, V5, P2924; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; DOWNES M, 1994, ENDOCRINOLOGY, V134, P2658, DOI 10.1210/en.134.6.2658; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Froeschle A, 1996, ONCOGENE, V12, P411; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRIGNANI F, 1995, CANCER RES, V55, P440; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Gudas Lorraine J., 1994, P443; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; Hofmann Clementine, 1994, P387; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kastner P, 1997, DEVELOPMENT, V124, P313; Kastner P, 1996, GENE DEV, V10, P80, DOI 10.1101/gad.10.1.80; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KONIECZNY SF, 1989, ONCOGENE, V4, P473; Krezel W, 1996, P NATL ACAD SCI USA, V93, P9010, DOI 10.1073/pnas.93.17.9010; KRUYT FAE, 1992, DIFFERENTIATION, V49, P27, DOI 10.1111/j.1432-0436.1992.tb00766.x; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOHNES D, 1995, J STEROID BIOCHEM, V53, P475, DOI 10.1016/0960-0760(95)00094-G; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; MONTARRAS D, 1991, NEW BIOL, V3, P592; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NILSEN DA, 1983, P NATL ACAD SCI USA, V80, P5198; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SIVE HL, 1991, GENE DEV, V5, P1321, DOI 10.1101/gad.5.8.1321; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; Sucov HM, 1995, DEVELOPMENT, V121, P3997; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TAPSCOTT SJ, 1989, SCIENCE, V245, P532, DOI 10.1126/science.2547249; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WAGNER M, 1992, DEVELOPMENT, V116, P55; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	82	22	22	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					273	282		10.1038/sj.onc.1201484	http://dx.doi.org/10.1038/sj.onc.1201484			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464546				2022-12-25	WOS:000071427100015
J	Blackshear, PE; Goldsworthy, SM; Foley, JF; McAllister, KA; Bennett, LM; Collins, NK; Bunch, DO; Brown, P; Wiseman, RW; Davis, BJ				Blackshear, PE; Goldsworthy, SM; Foley, JF; McAllister, KA; Bennett, LM; Collins, NK; Bunch, DO; Brown, P; Wiseman, RW; Davis, BJ			Brca1 and Brca2 expression patterns in mitotic and meiotic cells of mice.	ONCOGENE			English	Article						Brca1; Brca2; mitosis; meiosis	BREAST-CANCER; SPERMATOGENIC CELLS; EPITHELIAL-CELLS; MESSENGER-RNA; GENE; DIFFERENTIATION; SUSCEPTIBILITY; TISSUES	The mouse homologues of the breast cancer susceptibility genes, Brca1 and Brca2, are expressed in a cell cycle-dependent fashion in vitro and appear to be regulated by similar or overlapping pathways, Therefore, we compared the non isotopic in situ hybridization expression patterns of Brca1 and Brca2 mRNA in vivo in mitotic and meiotic cells during mouse embryogenesis, mammary gland development, and in adult tissues including testes, ovaries, and hormonally altered ovaries, Brca1 and Brca2 are expressed concordantly in proliferating cells of embryos, and the mammary gland undergoing morphogenesis and in most adult tissues, The expression pattern of Brca1 and Brca2 correlates with the localization of proliferating cell nuclear antigen, an indicator of proliferative activity, In the ovary, Brca1 and Brca2 exhibited a comparable hormone-independent pattern of expression in oocytes, granulosa cells and thecal cells of developing follicles, In the testes, Brca1 and Brca2 were expressed in mitotic spermatogonia and early meiotic prophase spermatocytes, Northern analyses of prepubertal mouse testes revealed that the time course of Brca2 expression was delayed in spermatogonia relative to Brca1. Thus, while Brca1 and Brca2 share concordant cell-specific patterns of expression in most proliferating tissues, these observations suggest that they may have distinct roles during meiosis.	NIEHS, Res Triangle Pk, NC 27709 USA; Pathol Associates Int, Durham, NC 27713 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Blackshear, PE (corresponding author), NIEHS, POB 12233, Res Triangle Pk, NC 27709 USA.			Bunch, Donna/0000-0002-3638-0522; Foley, Julie/0000-0001-9726-2821				BELIVE AR, 1977, J CELL BIOL, V74, P68; CLEVELAND DW, 1990, CELL, V60, P701, DOI 10.1016/0092-8674(90)90083-Q; Connor F, 1997, HUM MOL GENET, V6, P291, DOI 10.1093/hmg/6.2.291; DANIEL CWA, 1987, POSTNATAL DEV RODENT; FOLEY J, 1993, ENVIRON HEALTH PERSP, V101, P199, DOI 10.2307/3431868; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; KURIYAMA R, 1992, BIOESSAYS, V14, P81, DOI 10.1002/bies.950140203; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; McAllister KA, 1997, CANCER RES, V57, P3121; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OBRIEN DA, 1989, ENDOCRINOLOGY, V125, P2973, DOI 10.1210/endo-125-6-2973; Phillips KW, 1997, LAB INVEST, V76, P419; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Smith H S, 1991, Basic Life Sci, V57, P329; Stratton MR, 1996, HUM MOL GENET, V5, P1515, DOI 10.1093/hmg/5.Supplement_1.1515; Vaughn JP, 1996, CANCER RES, V56, P4590; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WELCH JE, 1995, DEV GENET, V16, P179, DOI 10.1002/dvg.1020160210; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Zabludoff SD, 1996, ONCOGENE, V13, P649	30	79	80	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					61	68		10.1038/sj.onc.1201506	http://dx.doi.org/10.1038/sj.onc.1201506			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467943				2022-12-25	WOS:000071236800007
J	Engelward, BP; Allan, JM; Dreslin, AJ; Kelly, JD; Wu, MM; Gold, B; Samson, LD				Engelward, BP; Allan, JM; Dreslin, AJ; Kelly, JD; Wu, MM; Gold, B; Samson, LD			A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID EXCHANGES; CHINESE-HAMSTER CELLS; DNA-POLYMERASE-BETA; ULTRAVIOLET-LIGHT; THYMOCYTE APOPTOSIS; ALKYLATING-AGENTS; S-PHASE; DAMAGE; CYCLE; MOUSE	DNA-damaging agents produce a plethora of cellular responses that include p53 induction, cell cycle arrest, and apoptosis, It is generally assumed that it is the DNA damage produced by these agents that triggers such responses, but there is limited direct evidence to support this assumption, Here, we used DNA alkylation repair proficient and deficient isogenic mouse cell lines to demonstrate that the signal to trigger p53 induction, cell cycle arrest, and apoptosis in response to alkylating agents does emanate from DNA damage. Moreover, we established that 3-methyladenine, a relatively minor DNA lesion produced by most methylating agents (which form mainly 7-methylguanine), can specifically induce sister chromatid exchange, chromatid and chromosome gaps and breaks, S phase arrest, the accumulation of p53, and apoptosis, This study was made possible by the generation of 3-methyladenine DNA glycosylase null mutant cells by targeted homologous recombination and by the chemical synthesis of a methylating agent that almost exclusively produces 3-methyladenine DNA lesions, The combined use of these two experimental tools has defined the biological consequences of 3-methyladenine, a DNA lesion produced by endogenous cellular metabolites, environmental carcinogens, and chemotherapeutic alkylating agents.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Samson, LD (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.		Allan, James/B-4448-2009	Allan, James/0000-0002-7580-5087	NATIONAL CANCER INSTITUTE [R01CA055042, P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES003926] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA55042, CA36727] Funding Source: Medline; NIEHS NIH HHS [P01 ES03926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEAN CL, 1993, MUTAT RES, V292, P3, DOI 10.1016/0165-1161(93)90003-I; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; BENDER MA, 1973, MUTAT RES, V20, P387, DOI 10.1016/0027-5107(73)90060-2; BERANEK DT, 1980, CARCINOGENESIS, V1, P595, DOI 10.1093/carcin/1.7.595; BIANCHINI F, 1993, CARCINOGENESIS, V14, P1677, DOI 10.1093/carcin/14.8.1677; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DASHWOOD RH, 1988, CARCINOGENESIS, V9, P427, DOI 10.1093/carcin/9.3.427; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DOSANJH MK, 1994, P NATL ACAD SCI USA, V91, P1024, DOI 10.1073/pnas.91.3.1024; DOUBLIE S, 1998, IN PRESS NATURE; Encell L, 1996, CHEM RES TOXICOL, V9, P563, DOI 10.1021/tx9501849; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; EVANS HJ, 1969, PROC R SOC SER B-BIO, V173, P491, DOI 10.1098/rspb.1969.0073; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; ISHII Y, 1980, MUTAT RES, V79, P19, DOI 10.1016/0165-1218(80)90144-5; KAINA B, 1991, CARCINOGENESIS, V12, P1857; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Ljungman M, 1996, ONCOGENE, V13, P823; Longhese MP, 1996, MOL CELL BIOL, V16, P3235; MEYN RE, 1984, PHARMACOL THERAPEUT, V24, P147, DOI 10.1016/0163-7258(84)90032-9; MORRIS SM, 1991, ENVIRON MOL MUTAGEN, V18, P139, DOI 10.1002/em.2850180210; NATARAJAN AT, 1984, CHROMOSOMA, V90, P120, DOI 10.1007/BF00292448; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OCONNOR TR, 1990, EMBO J, V9, P3337, DOI 10.1002/j.1460-2075.1990.tb07534.x; PAINTER RB, 1980, MUTAT RES, V70, P337, DOI 10.1016/0027-5107(80)90023-8; PAINTER RB, 1985, MUTAT RES, V145, P63, DOI 10.1016/0167-8817(85)90041-0; PAINTER RB, 1975, RADIAT RES, V64, P648, DOI 10.2307/3574254; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SAVATIER P, 1994, ONCOGENE, V9, P809; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Spratt TE, 1997, BIOCHEMISTRY-US, V36, P13292, DOI 10.1021/bi971253g; Tominaga Y, 1997, CARCINOGENESIS, V18, P889, DOI 10.1093/carcin/18.5.889; WATANABE I, 1974, RADIAT RES, V58, P541, DOI 10.2307/3573922; WOLFF S, 1974, MUTAT RES, V25, P73, DOI 10.1016/0165-1218(74)90082-2; YAGI T, 1984, CARCINOGENESIS, V5, P593, DOI 10.1093/carcin/5.5.593; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; ZHANG Y, 1993, BIOCHEMISTRY-US, V32, P7954, DOI 10.1021/bi00082a017	49	113	116	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5412	5418		10.1074/jbc.273.9.5412	http://dx.doi.org/10.1074/jbc.273.9.5412			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9479003	hybrid			2022-12-25	WOS:000072310400087
J	Hallier, M; Lerga, A; Barnache, S; Tavitian, A; Moreau-Gachelin, F				Hallier, M; Lerga, A; Barnache, S; Tavitian, A; Moreau-Gachelin, F			The transcription factor Spi-1/PU.1 interacts with the potential splicing factor TLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; HUMAN MYELOID-LEUKEMIA; CHROMOSOMAL TRANSLOCATION; ACTIVATION DOMAIN; FACTOR PU.1; FUSION; CHOP; LIPOSARCOMA; INVITRO; SITE	Spi-1/PU.1 is an Ets protein deregulated by insertional mutagenesis during the murine Friend erythroleukemia. The overexpression of the normal protein in a proerythroblastic cell prevents its terminal differentiation. In normal hematopoiesis Spi-1/PU.1 is a transcription factor that plays a key role in normal myeloid and B lymphoid differentiation. Moreover, Spi-1/PU.1 binds RNA and interferes in vitro with the splicing process. Here we report that Spi-1 interacts in vivo with TLS (translocated in liposarcoma), a RNA-binding protein involved in human tumor-specific chromosomal translocations. This interaction appears functionally relevant, since TLS is capable of reducing the abilities of Spi-1/PU.1 to bind DNA and to transactivate the expression of a reporter gene. In addition, we observe that TLS is potentially a splicing factor. It promotes the use of the distal 5' splice site during the E1A pre-mRNA splicing. This effect is counterpoised in vivo by Spi-1. These data suggest that alteration of pre-mRNA alternative splicing by Spi-1 could be involved in the transformation of an erythroblastic cell.	Inst Curie, INSERM, U248, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Moreau-Gachelin, F (corresponding author), Inst Curie, INSERM, U248, 26 Rue Ulm, F-75248 Paris 05, France.	framoreau@curie.fr	Hallier, Marc/L-2031-2015					CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELGADO MD, 1994, ONCOGENE, V9, P1723; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; Hackl W, 1996, J MOL BIOL, V264, P843, DOI 10.1006/jmbi.1996.0681; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAYGALLET D, 1995, ONCOGENE, V11, P303; SCHMITT P, 1987, CELL, V50, P31, DOI 10.1016/0092-8674(87)90659-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; TAMBOURIN P, 1983, P NATL ACAD SCI-BIOL, V80, P6269, DOI 10.1073/pnas.80.20.6269; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	23	116	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4838	4842		10.1074/jbc.273.9.4838	http://dx.doi.org/10.1074/jbc.273.9.4838			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478924	hybrid			2022-12-25	WOS:000072310400008
J	Sugano, M; Makino, N; Sawada, S; Otsuka, S; Watanabe, M; Okamoto, H; Kamada, M; Mizushima, A				Sugano, M; Makino, N; Sawada, S; Otsuka, S; Watanabe, M; Okamoto, H; Kamada, M; Mizushima, A			Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; LIPID TRANSFER PROTEIN; MESSENGER-RNA; FAMILIAL HYPERALPHALIPOPROTEINEMIA; COMBINED HYPERLIPIDEMIA; TRANSGENIC MICE; PLASMA; RECEPTOR; GENE; DEFICIENCY	Cholesteryl ester transfer protein (CETP) is the enzyme that facilitates the transfer of cholesteryl ester from high density lipoprotein (HDL) to apolipoprotein B (apoB)-containing lipoproteins, However, the exact role of CETP in the development of atherosclerosis has not been determined, In the present study, we examined the effect of the suppression of increased plasma CETP by intravenous injection with antisense oligodeoxynucleotides (ODNs) against CETP targeted to the liver on the development of atherosclerosis in rabbits fed a cholesterol diet, The ODNs against rabbit CETP were coupled to asialoglycoprotein (ASOR) carrier molecules, which serve as an important method to regulate liver gene expression, Twenty-two male Japanese White rabbits were used in the experiment, Eighteen animals were fed a standard rabbit chow supplemented with 0.3% cholesterol throughout the experiment for 16 weeks, At 8 weeks, they were divided into three groups (six animals in each group), among which the plasma total and HDL cholesterol concentrations did not significantly change, The central group received nothing, the sense group were injected with the sense ODNs complex, and the antisense group were injected with the antisense ODNs complex, respectively, for subsequent 8 weeks, ASOR poly(L-lysine) ODNs complex were injected via the ear veins twice a week, Four animals were fed a standard rabbit diet for 16 weeks, The total cholesterol concentrations and the CETP mass in the animals injected with antisense ODNs were all significantly decreased in 12 and 16 weeks compared with those injected with sense ODNs and the control animals, The HDL cholesterol concentrations measured by the precipitation assay did not significantly change among the groups fed a cholesterol diet, and triglyceride concentrations did not significantly change in the four groups, However, at the end of the study, when the HDL cholesterol concentrations were measured after the isolation by ultracentrifugation and a column chromotography, they were significantly higher in the animals injected with antisense ODNs than in the animals injected with sense ODNs and in the control animals, A reduction of CETP mRNA and an increase of LDL receptor mRNA in the liver were observed in the animals injected with antisense ODNs compared with those injected with sense ODNs and the control animals, Aortic cholesterol contents and the aortic percentage lesion to total surface area were significantly lower in the animals injected with antisense ODNs than in the animals injected with sense ODNs and in the control animals, These findings showed for the first time that suppression of increased plasma CETP by the injection with antisense ODNs against CETP coupled to ASOR carrier molecules targeted to the liver could thus inhibit the atherosclerosis possibly by decreasing the plasma LDL + very low density lipoprotein (VLDL) cholesterol in cholesterol-fed rabbits.	Kyushu Univ, Med Inst Bioregulat, Dept Bioclimatol & Med, Oita 874, Japan; Japan Tobacco Inc, Cent Pharmaceut Res Inst, Osaka 56911, Japan	Kyushu University; Japan Tobacco Inc.	Sugano, M (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Bioclimatol & Med, 4546 Tsurumihara, Oita 874, Japan.			Mizushima, Atsushi/0000-0002-1256-1919				CHIOU HC, 1994, NUCLEIC ACIDS RES, V22, P5439, DOI 10.1093/nar/22.24.5439; CHOWDHURY NR, 1993, J BIOL CHEM, V268, P11265; FOGER B, 1995, J MOL MED, V73, P369; Foger B, 1996, ARTERIOSCL THROM VAS, V16, P1430, DOI 10.1161/01.ATV.16.12.1430; Guerin M, 1996, ARTERIOSCL THROM VAS, V16, P763, DOI 10.1161/01.ATV.16.6.763; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; HESLER CB, 1987, J BIOL CHEM, V262, P2275; HIRANO K, 1995, ARTERIOSCL THROM VAS, V15, P1849, DOI 10.1161/01.ATV.15.11.1849; HIRANO KI, 1995, ANN NY ACAD SCI, V748, P599; IKEWAKI K, 1995, J CLIN INVEST, V96, P1573, DOI 10.1172/JCI118196; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; ISHIDA BY, 1987, J LIPID RES, V28, P778; JIANG XC, 1993, J BIOL CHEM, V268, P27406; KATO H, 1989, J BIOL CHEM, V264, P4082; Kinoshita M, 1996, ATHEROSCLEROSIS, V120, P75, DOI 10.1016/0021-9150(95)05684-X; KOIZUMI J, 1985, ATHEROSCLEROSIS, V58, P175, DOI 10.1016/0021-9150(85)90064-4; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; McPherson R, 1997, ARTERIOSCL THROM VAS, V17, P203, DOI 10.1161/01.ATV.17.1.203; NAGASHIMA M, 1988, J LIPID RES, V29, P1643; Oliveira HCF, 1997, ARTERIOSCL THROM VAS, V17, P1045, DOI 10.1161/01.ATV.17.6.1045; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; SAITO F, 1984, METABOLISM, V33, P629, DOI 10.1016/0026-0495(84)90061-1; Sugano M, 1996, J BIOL CHEM, V271, P19080, DOI 10.1074/jbc.271.32.19080; SUGANO M, 1986, ARTERIOSCLEROSIS, V6, P237, DOI 10.1161/01.ATV.6.2.237; SUGANO M, 1996, BIOCHIM BIOPHYS ACTA, V127, P123; TALL AR, 1986, J LIPID RES, V27, P361; TALL AR, 1995, J INTERN MED, V237, P5, DOI 10.1111/j.1365-2796.1995.tb01133.x; TATO F, 1995, THROMB VASC BIOL, V15, P112; WHITLOCK ME, 1989, J CLIN INVEST, V84, P129, DOI 10.1172/JCI114132; WU GY, 1988, J BIOL CHEM, V263, P14621; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YAMASHITA S, 1995, ANN NY ACAD SCI, V748, P606; Zhong SB, 1996, J CLIN INVEST, V97, P2917, DOI 10.1172/JCI118751	34	206	219	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5033	5036		10.1074/jbc.273.9.5033	http://dx.doi.org/10.1074/jbc.273.9.5033			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478952	hybrid			2022-12-25	WOS:000072310400036
J	Tsuga, H; Kameyama, K; Haga, T; Honma, T; Lameh, J; Sadee, W				Tsuga, H; Kameyama, K; Haga, T; Honma, T; Lameh, J; Sadee, W			Internalization and down-regulation of human muscarinic acetylcholine receptor m2 subtypes - Role of third intracellular m2 loop and G protein-coupled receptor kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINERGIC RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; PHOSPHORYLATION SITES; BETA-ARRESTIN; WILD-TYPE; DESENSITIZATION; SEQUESTRATION; MUTANT; BINDING	Internalization and down-regulation of human muscarinic acetylcholine m2 receptors (hm2 receptors) and a hm2 receptor mutant lacking a central part of the third intracellular loop (I3-del m2 receptor) were examined in Chinese hamster ovary (CHO-K1) cells stably expressing these receptors and G protein-coupled receptor kinase 2 (GRK2). Agonist-induced internalization of up to 80-90% of hm2 receptors was demonstrated by measuring loss of [H-3]N-methylscopolamine binding sites from the cell surface, and transfer of [H-3]quinuclidinyl benzilate binding sites from the plasma membrane into the light-vesicle fractions separated by sucrose density gradient centrifugation. Additionally, translocation of hm2 receptors with endocytic vesicles were visualized by immunofluorescence confocal microscopy. Agonist-induced down-regulation of up to 60-70% of hm2 receptors was demonstrated by determining the loss of [H-3]quinuclidinyl benzilate binding sites in the cells. The half-time (t(1/2)) of internalization and down-regulation in the presence of 10(-4) nn carbamylcholine was estimated to be 9.5 min and 2.3 h, respectively. The rates of both internalization and down-regulation of hm2 receptors in the presence of 10(-6) M or lower concentrations of carbamylcholine were markedly increased by coexpression of GRK2. Agonist-induced internalization of I3-del m2 receptors was barely detectable upon incubation of cells for 1 h, but agonist-induced down-regulation of up to 40-50% of I3-del m2 receptors occurred upon incubation with 10(-4) M carbamylcholine for 16 h. However, the rate of down-regulation was lower compared with wild type receptors (t(1/2) = 9.9 versus 2.3 h). These results indicate that rapid internalization of hm2 receptors is facilitated by their phosphorylation with GRK2 and does not occur in the absence of the third intracellular loop, but downregulation of hm2 receptors may occur through both GRK2-facilitating pathway and third intracellular loop-independent pathways.	Natl Inst Ind Hlth, Dept Occupat Dis, Tama Ku, Kanagawa 214, Japan; Univ Tokyo, Fac Med, Dept Neurochem, Bunkyo Ku, Tokyo 113, Japan; Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA	University of Tokyo; University of California System; University of California San Francisco	Tsuga, H (corresponding author), Natl Inst Ind Hlth, Dept Occupat Dis, Tama Ku, 6-21-1 Nagao, Kanagawa 214, Japan.				NIDA NIH HHS [DA04166] Funding Source: Medline; NIGMS NIH HHS [GM43102] Funding Source: Medline; NIMH NIH HHS [MH00996] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K21MH000996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004166] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Diviani D, 1996, J BIOL CHEM, V271, P5049; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAGA T, 1994, J NEUROCHEM, V63, P400; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; ISHII K, 1994, J BIOL CHEM, V269, P1125; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; KAMEYAMA K, 1994, EUR J BIOCHEM, V226, P267, DOI 10.1111/j.1432-1033.1994.tb20050.x; KONG GH, 1994, J BIOL CHEM, V269, P13084; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; MORO O, 1993, J BIOL CHEM, V268, P6862; Nagayama Y, 1996, J BIOL CHEM, V271, P10143, DOI 10.1074/jbc.271.17.10143; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Slowiejko DM, 1996, J NEUROCHEM, V66, P186; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; Tiberi M, 1996, J BIOL CHEM, V271, P3771; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; TSUGA H, 1994, J BIOL CHEM, V269, P32522	37	72	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5323	5330		10.1074/jbc.273.9.5323	http://dx.doi.org/10.1074/jbc.273.9.5323			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478991	hybrid			2022-12-25	WOS:000072310400075
J	Vidal, M; Montiel, JL; Cussac, D; Cornille, F; Duchesne, M; Parker, F; Tocque, B; Roques, BP; Garbay, C				Vidal, M; Montiel, JL; Cussac, D; Cornille, F; Duchesne, M; Parker, F; Tocque, B; Roques, BP; Garbay, C			Differential interactions of the growth factor receptor-bound protein a N-SH3 domain with son of sevenless and dynamin - Potential role in the Ras-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SH3 DOMAIN; MAP KINASE PHOSPHORYLATION; TYROSINE KINASES; GRB2 ADAPTER; BINDING; TRANSDUCTION; PEPTIDE; ASSOCIATION; ENDOCYTOSIS; ACTIVATION	In this paper, we show that the 36-45 surface-exposed sequence WYKAELNGKD of growth factor receptor-bound protein 2 (Grb2) N-SH3 domain inhibits the interaction between Grb2 and a 97-kDa protein identified as dynamin. Moreover, the peptide GPPPQVPSRPNR from dynamin also blocks the binding of dynamin to the proline-rich recognition platform of Grb2. Mutations in the 36-45 motif show that Glu-40 is critical for dynamin recognition. These observations were confirmed by immunoprecipitation experiments, carried out using ER 22 cells. It was also observed that the proline-rich peptide from dynamin was unable to dissociate the Grb2.Sos complex, whereas the proline-rich peptide from Son of sevenless (Sos) inhibited Grb2.dynamin interaction. A time-dependent stimulation of epidermal growth factor receptor overexpressing clone 22 (ER 22) cells by epidermal growth factor resulted in an immediate increase of the Grb2.Sos complex and a concomitant decrease in Grb2.dynamin. This suggests that the recruitment of Grb2.Sos to the membrane, triggered by epidermal growth factor stimulation, activates the Ras-dependent signaling and simultaneously enhances free dynamin levels, leading to both receptor internalization and endocytotic processes.	Univ Paris 05, UFR Sci Pharmaceut & Biol, U266 INSERM URA D1500 CNRS, Dept Pharmacochim Mol & Struct, F-75270 Paris 06, France; Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, F-94403 Vitry Sur Seine, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Sanofi-Aventis; Sanofi France	Roques, BP (corresponding author), Univ Paris 05, UFR Sci Pharmaceut & Biol, U266 INSERM URA D1500 CNRS, Dept Pharmacochim Mol & Struct, 4,Ave de Observ, F-75270 Paris 06, France.		Vidal, Michel/ABA-3396-2020	Montiel Hernandez, Jose Luis/0000-0002-6258-7092; Vidal, Michel/0000-0002-4858-1591				ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BUDAY L, 1995, ONCOGENE, V11, P1327; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; HERMANSON GT, 1992, IMMOBILIZED AFFINITY, V53; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; KELLY RB, 1995, NATURE, V374, P116, DOI 10.1038/374116a0; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; LOWE PN, 1994, CELL SIGNAL, V6, P109, DOI 10.1016/0898-6568(94)90067-1; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MIKI H, 1994, J BIOL CHEM, V269, P5489; MONTIEL JL, 1997, PROTEIN PEPTIDE LETT, V38, P1389; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Parker F, 1996, MOL CELL BIOL, V16, P2561; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; Romero F, 1996, MOL CELL BIOL, V16, P37; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; YANG YS, 1994, EMBO J, V13, P1270, DOI 10.1002/j.1460-2075.1994.tb06379.x; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	45	40	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5343	5348		10.1074/jbc.273.9.5343	http://dx.doi.org/10.1074/jbc.273.9.5343			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478994	hybrid			2022-12-25	WOS:000072310400078
J	Yoshioka, K; Matsumura, F; Akedo, H; Itoh, K				Yoshioka, K; Matsumura, F; Akedo, H; Itoh, K			Small GTP-binding protein Rho stimulates the actomyosin system, leading to invasion of tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; ASCITES HEPATOMA-CELLS; ACTIN STRESS FIBERS; MYOSIN LIGHT-CHAIN; ADP-RIBOSYLATION; PUTATIVE TARGET; SMOOTH-MUSCLE; GENE-PRODUCT; SERINE/THREONINE KINASE; LYSOPHOSPHATIDIC-ACID	We have shown previously that Rho plays a pivotal role in 1-oleoyl-lysophosphatidic acid (LPA)-dependent invasion of rat hepatoma cells (MM1). Herein we made stable transfectants of MM1 expressing active and Botulinum exoenzyme C3 (C3)-sensitive (Val(14)), or active and C3-insensitive (Val(14)/Ile(41)) forms of human RhoA, Both transfectants showed greatly promoted invasive ability in vitro in the absence of LPA as well as in vivo, adherence to the dish with scattered shape, and enhanced phosphorylation level of 20-kDa myosin light chain (MLC20), A specific MLC kinase inhibitor (KT5926) could inhibit their invasion and the phosphorylation level of MLC20, Stable active RhoA transfectants of W1 cells (low invasive counterpart of MM1) also demonstrated promoted invasive ability in, vitro and in vivo, and enhanced phosphorylation level of MLC20. C3 treatment inhibited the invasiveness of the Val(14) RhoA transfectant but not that of the Val(14)/Ile(41) RhoA transfectant. LPA enhanced the invasiveness of both transfectants, and this enhancement was abolished by the C3 treatment, These results suggested that 1) the Rho signaling pathway and actomyosin system were linked in the transmigration of tumor cells, and 2) expressed active RhoA enhanced LPA-induced tumor cell invasion via the activation of endogenous RhoA pathway, indicating a positive feedback mechanism in the activation of RhoA.	Osaka Med Ctr Canc & Cardiovasc Dis, Dept Tumor Biochem, Higashinari Ku, Osaka 537, Japan; Rutgers State Univ, Dept Biochem & Mol Biol, Piscataway, NJ 08854 USA	Osaka Medical Center for Cancer & Cardiovascular Diseases; Rutgers State University New Brunswick	Yoshioka, K (corresponding author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Tumor Biochem, Higashinari Ku, 1-3-3 Nakamichi, Osaka 537, Japan.			Matsumura, Fumio/0000-0002-8204-153X; Itoh, Kazuyuki/0000-0002-0761-0499				AKEDO H, 1989, INVAS METAST, V9, P134; AKEDO H, 1986, CANCER RES, V46, P2416; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; FIDLER IJ, 1991, BRIT MED BULL, V47, P157, DOI 10.1093/oxfordjournals.bmb.a072453; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Gong MC, 1997, J BIOL CHEM, V272, P10704; HIRATA K, 1992, J BIOL CHEM, V267, P8719; IMAMURA F, 1991, JPN J CANCER RES, V82, P493, DOI 10.1111/j.1349-7006.1991.tb01877.x; Imamura F, 1996, INT J CANCER, V65, P627, DOI 10.1002/(SICI)1097-0215(19960301)65:5<627::AID-IJC12>3.0.CO;2-4; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; ITOH K, 1992, BIOCHIM BIOPHYS ACTA, V1136, P52, DOI 10.1016/0167-4889(92)90084-O; ITOH K, 1996, MOL BIOL CELL, V7, P234; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MORII N, 1995, METHOD ENZYMOL, V256, P196; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NICOLSON GL, 1989, INVAS METAST, V9, P102; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NODA M, 1995, FEBS LETT, V367, P246, DOI 10.1016/0014-5793(95)00573-R; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAUBMAN MB, 1987, J CELL BIOL, V104, P1505, DOI 10.1083/jcb.104.6.1505; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; YAMAKITA Y, 1996, MOL BIOL CELL, V7, P198; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YOSHIOKA K, 1995, FEBS LETT, V372, P25, DOI 10.1016/0014-5793(95)00937-5; ZETTER BR, 1990, NEW ENGL J MED, V322, P605	55	149	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5146	5154		10.1074/jbc.273.9.5146	http://dx.doi.org/10.1074/jbc.273.9.5146			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478968	hybrid			2022-12-25	WOS:000072310400052
J	Kassam, G; Choi, KS; Ghuman, J; Kang, HM; Fitzpatrick, SL; Zackson, T; Zackson, S; Toba, M; Shinomiya, A; Waisman, DM				Kassam, G; Choi, KS; Ghuman, J; Kang, HM; Fitzpatrick, SL; Zackson, T; Zackson, S; Toba, M; Shinomiya, A; Waisman, DM			The role of annexin II tetramer in the activation of plasminogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT EXOCYTOSIS; ENDOTHELIAL-CELL RECEPTOR; T-PA; EXTRACELLULAR-MATRIX; FIBRIN ENHANCEMENT; CHROMAFFIN CELLS; LYMPHOMA-CELLS; CALPACTIN-I; BINDING; SURFACE	Annexin II tetramer (AIIt) is a major Ca2+-binding protein of endothelial cells which has been shown to exist on both the intracellular and extracellular surfaces of the plasma membrane. In this report, Eve demonstrate that AIIt stimulates the activation of plasminogen by facilitating the tissue plasminogen activator (t-PA)-dependent conversion of plasminogen to plasmin, Fluid-phase AIIt stimulated the rate of activation of [Glu]plasminogen about 341-fold compared with an approximate 6-fold stimulation by annexin II. AIIt bound to [Glu]plasminogen(S741C-fluorescein) with a K-d of 1.26 +/- 0.04 mu M (mean +/- S.D., n = 3) and this interaction resulted in a large conformational change in [Glu]plasminogen. Kinetic analysis established that AIIt produces a large increase of about 190-fold in the k(cat, app) and a small increase in the K-m,K- app which resulted in a 90-fold increase in the catalytic efficiency (k(cat)/K-m) of t-PA for [Glu]plasminogen. AIIt also stimulated the t-PA-dependent activation of [Lys]plasminogen about 28-fold. Furthermore, other annexins such as annexin I, V, or VI did not produce comparable activation of t-PA-dependent conversion of [Glu]plasminogen to plasmin, The stimulation of the activation of [Glu]plasminogen by AIIt was Ca2+-independent and inhibited by epsilon-aminocaproic acid. AIIt bound to human 293 cells potentiated t-PA-dependent plasminogen activation, AIIt that was bound to phospholipid vesicles or heparin also stimulated the activation of [Glu]plasminogen 5- or 11-fold, respectively. Furthermore, immunofluorescence labeling of nonpermeabilized HUVEC revealed a punctated distribution of AIIt subunits on the cell surface, These results therefore identify AIIt as a potent in vitro activator of plasminogen.	Univ Calgary, Fac Med, Dept Med Biochem, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Med Biochem, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			shinomiya, aya/0000-0003-3969-7290; Waisman, David/0000-0002-5097-9662				ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; Bellagamba C, 1997, J BIOL CHEM, V272, P3195, DOI 10.1074/jbc.272.6.3195; Bock PE, 1996, J BIOL CHEM, V271, P1072, DOI 10.1074/jbc.271.2.1072; Borza DB, 1997, J BIOL CHEM, V272, P5718, DOI 10.1074/jbc.272.9.5718; BURGOYNE RD, 1990, BIOCHEM SOC T, V18, P1101, DOI 10.1042/bst0181101; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; ChasserotGolaz S, 1996, J CELL BIOL, V133, P1217, DOI 10.1083/jcb.133.6.1217; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; DEVRIES C, 1990, J BIOL CHEM, V265, P13547; DRAPIER JC, 1979, BIOCHIMIE, V61, P463, DOI 10.1016/S0300-9084(79)80202-3; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FEARS R, 1990, BIOCHEM J, V266, P693, DOI 10.1042/bj2660693; FISCHER BE, 1992, BLOOD COAGUL FIBRIN, V3, P197; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY JR, 1986, J BIOL CHEM, V261, P485; HAJJAR KA, 1995, THROMB HAEMOSTASIS, V74, P294; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2176; Jost M, 1997, J CELL SCI, V110, P221; Kang HM, 1997, BIOCHEMISTRY-US, V36, P2041, DOI 10.1021/bi962569b; Kassam G, 1997, J BIOL CHEM, V272, P15093, DOI 10.1074/jbc.272.24.15093; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; LIJNEN HR, 1995, BAILLIERE CLIN HAEM, V8, P277, DOI 10.1016/S0950-3536(05)80268-9; LIJNEN HR, 1990, THROMB HAEMOSTASIS, V64, P61; LIN JJ, 1995, CLIN NEPHROL, V44, P310; LIU L, 1995, BBA-LIPID LIPID MET, V1259, P166, DOI 10.1016/0005-2760(95)00159-A; MAGNUSSON S, 1996, PROTEOLYSIS PHYSL RE, V11, P203; Markus G, 1996, FIBRINOLYSIS, V10, P75, DOI 10.1016/S0268-9499(96)80082-8; MOSER TL, 1993, J BIOL CHEM, V268, P18917; NIEUWENHUIZEN W, 1983, BIOCHIM BIOPHYS ACTA, V748, P86, DOI 10.1016/0167-4838(83)90030-4; NIEUWENHUIZEN W, 1982, EUR J BIOCHEM, V704, P461; Nilius B, 1996, J BIOL CHEM, V271, P30631, DOI 10.1074/jbc.271.48.30631; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; SAEZ CT, 1995, BIOCHEMISTRY-US, V34, P2496, DOI 10.1021/bi00008a013; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; STACK S, 1990, BIOCHEMISTRY-US, V29, P4966, DOI 10.1021/bi00472a029; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; SUENSON E, 1990, J BIOL CHEM, V265, P22228; TRESSLER RJ, 1993, J CELL BIOCHEM, V53, P265, DOI 10.1002/jcb.240530311; TRESSLER RJ, 1994, EXP CELL RES, V215, P395, DOI 10.1006/excr.1994.1358; VANELDIK LJ, 1984, BIOCHEM BIOPH RES CO, V124, P752, DOI 10.1016/0006-291X(84)91022-2; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WRIGHT JF, 1994, BIOCHEM BIOPH RES CO, V198, P983, DOI 10.1006/bbrc.1994.1140; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064	48	133	142	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4790	4799		10.1074/jbc.273.8.4790	http://dx.doi.org/10.1074/jbc.273.8.4790			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468544	hybrid			2022-12-25	WOS:000072115000072
J	Monte, D; DeWitte, F; Hum, DW				Monte, D; DeWitte, F; Hum, DW			Regulation of the human P450scc gene by steroidogenic factor 1 is mediated by CBP/p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E1A-ASSOCIATED PROTEIN P300; CHAIN-CLEAVAGE ENZYME; NUCLEAR RECEPTOR; FACTOR-I; TRANSCRIPTION FACTOR; ADENOVIRUS E1A; GRANULOSA-CELLS; COACTIVATOR CBP; KEY REGULATOR; LEYDIG-CELLS	Regulation of the human CYP11A gene encoding cytochrome P450scc, which catalyzes the first step of steroid synthesis, is regulated by many trans-acting transcription factors including steroidogenic factor 1 (SF-l), Transfection experiments in human adrenal NCI-H295 cells demonstrate regulation of the P450scc gene promoter region that contains several putative SF-1 binding sites, Cotransfection of SF-l with a luciferase reporter construct containing the P450scc gene 5'-flanking region from nucleotides -1676 to +49 increased promoter activity, and deletion of the nucleotide sequence from position -1676 to -1620, which removes a putative cAMP response element (CRE), did not affect the stimulatory response to SF-l, As well, further deletion of the promoter region to nucleotide -110, which contains only one SF-1 binding site, still retained the ability to respond to exogenous SF-1, However, mutation of the remaining site which abolished SF-1 protein/DNA interaction also abrogated any functional response to the factor, All the P450scc reporter constructs which responded to SF-l were further stimulated by exogenous p300 and CREB-binding protein (CBP), suggesting interaction between SF-l and p300/CBP, As well, mutation of the binding site that abrogated the response to SF-l also abolished the response to p300 and CBP, Cotransfection of the adenovirus E1A oncoprotein, which has been shown to interact with p300/CBP and interfere with its function, decreased the stimulatory effect of SF-l and p300/CBP, Cotransfection of a mutated E1A protein, RG2, which does not interact with p300/CBP, did not alter the stimulatory effect of SF-l and p300/CBP on the P450scc promoter, Deletion of the region from amino acid residues 2-67 in E1A, which has been postulated to interact with p300/CBP, also abolished the inhibitory effect of E1A, whereas deletion of the region from residues 120 to 140 had no effect, Two regions of CBP from amino acids 1 to 451 and from 1460 to 1891 were demonstrated to interact with SF-l in vitro, Coexpression of fragments of the p300 protein fused to the VP16 protein in the presence of SF-l and the -110 P450scc reporter construct indicated in vivo the interaction of two regions of p300 with SF-1, thus confirming the in vitro results, Taken together these results indicate that regulation of the human P450scc gene by SF-1 is mediated by p300/CBP, Due to the many putative roles of SF-l to regulate many genes, its interaction with p300/CBP is potentially a key component effecting important physiological processes.	CHUL, Mol Endocrinol Lab, Ctr Rech, St Foy, PQ G1V 4G2, Canada; Univ Laval, St Foy, PQ G1V 4G2, Canada	Laval University; Laval University	Hum, DW (corresponding author), CHUL, Mol Endocrinol Lab, Ctr Rech, 2705 Boul Laurier, St Foy, PQ G1V 4G2, Canada.			monte, didier/0000-0002-0613-6203				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN CT, 1995, DNA CELL BIOL, V14, P803, DOI 10.1089/dna.1995.14.803; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Giuili G, 1997, DEVELOPMENT, V124, P1799; GUO IC, 1994, J BIOL CHEM, V269, P6362; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HANUKOGLU I, 1989, FOLLICULAR DEV OVULA, P233; HATANO O, 1994, DEVELOPMENT, V120, P2787; HONDA S, 1993, J BIOL CHEM, V268, P7494; HUM DW, 1993, ENDOCRINOLOGY, V132, P546, DOI 10.1210/en.132.2.546; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; INOUE H, 1991, EUR J BIOCHEM, V195, P563, DOI 10.1111/j.1432-1033.1991.tb15738.x; INOUE H, 1988, EUR J BIOCHEM, V171, P435, DOI 10.1111/j.1432-1033.1988.tb13808.x; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Lapointe J, 1996, CANCER RES, V56, P4586; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; LeersSucheta S, 1997, J BIOL CHEM, V272, P7960, DOI 10.1074/jbc.272.12.7960; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; MELLON SH, 1993, BRAIN RES, V629, P283, DOI 10.1016/0006-8993(93)91332-M; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; Morohashi KI, 1996, FASEB J, V10, P1569, DOI 10.1096/fasebj.10.14.9002548; Parker KL, 1996, TRENDS ENDOCRIN MET, V7, P203, DOI 10.1016/1043-2760(96)00105-1; RAINEY WE, 1994, MOL CELL ENDOCRINOL, V100, P45, DOI 10.1016/0303-7207(94)90277-1; Rodriguez H, 1997, J CLIN ENDOCR METAB, V82, P365, DOI 10.1210/jc.82.2.365; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SIMPSON ER, 1990, MOL CELL ENDOCRINOL, V70, pC25, DOI 10.1016/0303-7207(90)90151-W; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; STAELS B, 1993, MOL ENDOCRINOL, V7, P423, DOI 10.1210/me.7.3.423; TAKAYAMA K, 1994, J BIOCHEM-TOKYO, V116, P193, DOI 10.1093/oxfordjournals.jbchem.a124493; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WATANABE N, 1994, EUR J BIOCHEM, V222, P825, DOI 10.1111/j.1432-1033.1994.tb18929.x; Waterman MR, 1986, CYTOCHROME P450 STRU, P345; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang PL, 1997, MOL ENDOCRINOL, V11, P891, DOI 10.1210/me.11.7.891; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147	72	128	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4585	4591		10.1074/jbc.273.8.4585	http://dx.doi.org/10.1074/jbc.273.8.4585			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468515	hybrid			2022-12-25	WOS:000072115000043
J	Furukawa, K; Fritze, CE; Gerace, L				Furukawa, K; Fritze, CE; Gerace, L			The major nuclear envelope targeting domain of LAP2 coincides with its lamin binding region but is distinct from its chromatin interaction domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; INTEGRAL MEMBRANE-PROTEINS; CHICKEN HEPATIC LECTIN; B-RECEPTOR; INNER MEMBRANE; PORE COMPLEX; CDNA CLONING; PHOSPHORYLATION; CHROMOSOMES; CELLS	LAP2 is an integral protein of the inner nuclear membrane which binds lamins and chromosomes and is suggested to have an important role in nuclear envelope organization. In a previous study we identified an internal 76-amino acid region of LAPS which is required for stable targeting of the protein to the nuclear envelope. Here, we have mapped the lamin binding region of LAPS and demonstrate that it coincides with this nuclear envelope targeting domain. In contrast, we found that the portion of LAPS involved in binding to chromosomes resides in a separate region of the protein near its NH2 terminus. The minimal lamin binding region of LAPS is capable of conferring stable nuclear envelope localization when attached to the transmembrane and partial lumenal domains of a protein that shows no nuclear envelope targeting activity. This directly supports the notion that a major mechanism for localization of integral membrane proteins at the inner nuclear membrane involves binding to lamins, which would constrain diffusion through the continuous nuclear envelope/endoplasmic reticulum membrane system.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Gerace, L (corresponding author), Scripps Res Inst, Dept Cell Biol, Mail Drop IMM-10,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.							ADAM SA, 1992, METHOD ENZYMOL, V219, P97; AsheryPadan R, 1997, J BIOL CHEM, V272, P2493; Berger R, 1996, GENOME RES, V6, P361, DOI 10.1101/gr.6.5.361; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; BURKE B, 1990, EXP CELL RES, V186, P169, DOI 10.1016/0014-4827(90)90223-W; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; DRICKAMER K, 1982, J BIOL CHEM, V257, P5156; DRICKAMER K, 1981, J BIOL CHEM, V256, P5827; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; Furukawa K, 1997, BIOCHEM BIOPH RES CO, V238, P240, DOI 10.1006/bbrc.1997.7235; FURUKAWA K, 1995, EMBO J, V14, P1626, DOI 10.1002/j.1460-2075.1995.tb07151.x; FURUKAWA K, 1993, EMBO J, V12, P97, DOI 10.1002/j.1460-2075.1993.tb05635.x; GEORGATOS SD, 1994, CURR OPIN CELL BIOL, V6, P347, DOI 10.1016/0955-0674(94)90025-6; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; Gerace Larry, 1994, Trends in Cell Biology, V4, P127, DOI 10.1016/0962-8924(94)90067-1; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; HARRIS CA, 1994, P NATL ACAD SCI USA, V91, P6283, DOI 10.1073/pnas.91.14.6283; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOGER TH, 1991, EXP CELL RES, V197, P280, DOI 10.1016/0014-4827(91)90434-V; Lourim David, 1994, Trends in Cell Biology, V4, P314, DOI 10.1016/0962-8924(94)90228-3; Manilal S, 1996, HUM MOL GENET, V5, P801, DOI 10.1093/hmg/5.6.801; Marshall ICB, 1997, TRENDS CELL BIOL, V7, P69, DOI 10.1016/S0962-8924(96)10047-7; MARTIN L, 1995, J BIOL CHEM, V270, P8822, DOI 10.1074/jbc.270.15.8822; Nagano A, 1996, NAT GENET, V12, P254, DOI 10.1038/ng0396-254; NIGG E A, 1992, Current Opinion in Cell Biology, V4, P105, DOI 10.1016/0955-0674(92)90066-L; Nikolakaki E, 1997, J BIOL CHEM, V272, P6208, DOI 10.1074/jbc.272.10.6208; PADAN R, 1990, J BIOL CHEM, V265, P7808; POWELL L, 1990, J CELL BIOL, V111, P2225, DOI 10.1083/jcb.111.6.2225; REYNOLDS A, 1993, PROTOCOLS OPINIONS M; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; SMITH S, 1993, J CELL BIOL, V120, P631, DOI 10.1083/jcb.120.3.631; SOULLAM B, 1993, J CELL BIOL, V120, P1093, DOI 10.1083/jcb.120.5.1093; SOULLAM B, 1995, J CELL BIOL, V130, P15, DOI 10.1083/jcb.130.1.15; Spann TP, 1997, J CELL BIOL, V136, P1201, DOI 10.1083/jcb.136.6.1201; TANIURA H, 1995, J CELL BIOL, V131, P33, DOI 10.1083/jcb.131.1.33; Wiese C, 1993, CURR OPIN CELL BIOL, V5, P387, DOI 10.1016/0955-0674(93)90002-8; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; Yang L, 1997, J CELL BIOL, V139, P1077, DOI 10.1083/jcb.139.5.1077; Yang L, 1997, J CELL BIOL, V137, P1199, DOI 10.1083/jcb.137.6.1199; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983; YUAN J, 1991, J BIOL CHEM, V266, P9211	48	99	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4213	4219		10.1074/jbc.273.7.4213	http://dx.doi.org/10.1074/jbc.273.7.4213			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461618	hybrid			2022-12-25	WOS:000072048400060
J	Iyer, S; Woo, J; Cornejo, MC; Gao, L; McCoubrey, W; Maines, M; Buelow, R				Iyer, S; Woo, J; Cornejo, MC; Gao, L; McCoubrey, W; Maines, M; Buelow, R			Characterization and biological significance of immunosuppressive peptide D2702.75-84(E -> V) binding protein - Isolation of heme oxygenase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART GRAFT-SURVIVAL; TOXIC LYMPHOCYTES-T; UNCONJUGATED BILIRUBIN; ALLOGRAFT SURVIVAL; CELL RECEPTOR; RAT-LIVER; IN-VITRO; MESSENGER; DOMAIN; BRAIN	This is the first report on peptidic inhibitors of heme oxygenase, Such peptides were originally developed from the immunomodulatory peptide 2702.75-84 which corresponds to amino acid residues 75 to 84 of the alpha(1)-helix of HLA-B2702 (2702.75-84) and has been shown to be immunosuppressive in vitro and in vivo, lit vitro, 2702.75-84 inhibited cytotoxic T-and natural killer cell-mediated target cell lysis, and in vivo peptide therapy resulted in prolongation of heart and skin allograft survival in mice, The peptide was also shown to bind to heat shock protein 70, However, D-enantiomers of 2702.75-84 and derivatives thereof, while still being immunosuppressive, did not bind to heat shock protein 70, This study was designed to identify proteins binding to peptide D2702.75-84(E --> V) (rvnlrialry) consisting of D-amino acids, Compared with 2702.75-84 (RENLRIALRY), glutamic acid residue 76 (E) was replaced with valine (V), Affinity chromatography using immobilized D2702.75-84(E --> V) and mouse and human cell extracts, resulted in the isolation of heme oxygenase-l (HO-1), Peptide D2702.75-84 inhibited HO activity in vitro in a dose dependent manner, Similar to what has been observed with other inhibitors of HO, administration of peptide into mice resulted in an up-regulation of HO-1 mRNA and protein, as well as enzyme activity in liver, spleen and kidney, Other peptides derived from 2702.75-84 with similar immunomodulatory activity displayed similar effects, In contrast, inactive derivatives of 2702.75-84 had no effect on HO activity, Therefore, the immunosuppressive effects of the described immunomodulatory peptides are similar to those of cobalt-protoporphyrin, a known up-regulator of HO-1, Our results suggest that HO-1 modulation may be a novel mechanism of immunomodulation.	SangStat Med Corp, Menlo Park, CA 94025 USA; Univ Rochester, Sch Med, Dept Biochem Biophys & Environm Med, Rochester, NY 14642 USA	University of Rochester	Buelow, R (corresponding author), SangStat Med Corp, 1505 Adams Dr, Menlo Park, CA 94025 USA.				NIEHS NIH HHS [ES03968] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003968] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agarwal A, 1996, TRANSPLANTATION, V61, P93, DOI 10.1097/00007890-199601150-00019; BRIINE B, 1987, MOL PHARMACOL, V32, P497; BUELOW R, 1995, TRANSPLANTATION, V59, P455; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAYBERGER C, 1993, TRANSPLANT P, V25, P477; CLAYBERGER C, 1987, NATURE, V330, P763, DOI 10.1038/330763a0; CUTURI MC, 1995, TRANSPLANTATION, V59, P661, DOI 10.1097/00007890-199503150-00003; Degerman E, 1996, BIOCHEM SOC T, V24, P1010, DOI 10.1042/bst0241010; DIAZ JA, 1995, ARCH SURG, V130; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; Finn JT, 1996, ANNU REV PHYSIOL, V58, P395, DOI 10.1146/annurev.ph.58.030196.002143; Gao L, 1996, J HEART LUNG TRANSPL, V15, P78; Haga Y, 1996, BBA-MOL BASIS DIS, V1316, P29, DOI 10.1016/0925-4439(96)00004-X; Haga Y, 1996, DIGEST DIS SCI, V41, P1468, DOI 10.1007/BF02088574; HAGA Y, 1992, CLIN BIOCHEM, V25, P277, DOI 10.1016/0009-9120(92)80033-D; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; KWAK JY, 1991, BIOCHIM BIOPHYS ACTA, V1076, P369, DOI 10.1016/0167-4838(91)90478-I; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lincoln T M, 1995, Adv Pharmacol, V34, P305; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1975, J BIOL CHEM, V250, P4171; MAINES MD, 1986, J BIOL CHEM, V261, P411; MAINES MD, 1977, J BIOL CHEM, V252, P219; MAINES MD, 1992, HEME OXYGENASE CLIN, P276; NAKAGAMI T, 1993, BIOCHIM BIOPHYS ACTA, V1158, P189, DOI 10.1016/0304-4165(93)90013-X; NISCO S, 1994, J IMMUNOL, V152, P3786; NOESSNER E, 1996, J EXP MED, V183, P339; OLSON CA, 1989, P NATL ACAD SCI USA, V86, P1031, DOI 10.1073/pnas.86.3.1031; PARHAM P, 1987, NATURE, V325, P625, DOI 10.1038/325625a0; Pratt J R, 1996, Transpl Immunol, V4, P72, DOI 10.1016/S0966-3274(96)80041-4; ROTENBERG MO, 1991, ARCH BIOCHEM BIOPHYS, V290, P336, DOI 10.1016/0003-9861(91)90549-X; Sambrook J., 2002, MOL CLONING LAB MANU; SANO K, 1985, PEDIATR RES, V19, P587, DOI 10.1203/00006450-198506000-00017; SARDANA MK, 1987, P NATL ACAD SCI USA, V84, P2464, DOI 10.1073/pnas.84.8.2464; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SIGAL LJ, 1994, J IMMUNOL METHODS, V177, P261, DOI 10.1016/0022-1759(94)90164-3; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUN Y, 1990, J BIOL CHEM, V265, P8212; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Woo J, 1997, TRANSPLANTATION, V64, P1460, DOI 10.1097/00007890-199711270-00015; WOO J, 1995, TRANSPLANTATION, V60, P1156, DOI 10.1097/00007890-199511270-00017; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	45	47	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2692	2697		10.1074/jbc.273.5.2692	http://dx.doi.org/10.1074/jbc.273.5.2692			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446574	hybrid			2022-12-25	WOS:000071736600029
J	Girard, L; Jolicoeur, P				Girard, L; Jolicoeur, P			A full-length Notch1 allele is dispensable for transformation associated with a provirally activated truncated Notch1 allele in Moloney MuLV-infected MMTVD/myc transgenic mice	ONCOGENE			English	Article						Notch1; transgenic mice; targeted mutagenesis; retrovirus; MuLV	DROSOPHILA NOTCH; INSERTIONAL MUTAGENESIS; HUMAN HOMOLOG; C-ELEGANS; GENE; RECEPTOR; MYOGENESIS; NEOPLASMS; LIN-12; DOMAIN	The Notch1 gene was previously found to be targetted by provirus insertion in a high proportion of T-cell lymphomas arising in Moloney MuLV-inoculated MMTVD/myc transgenic mice, Proviral activation of Notch1 was associated with overexpression of truncated Notch1, deleted of the sequences coding for the extracellular domain, The high levels of truncated Notch1 RNA and proteins in these tumors are thought to be involved in the oncogenic transformation, However, in addition to these truncated RNA and proteins, high level expression of full-length Notch1 RNA and proteins was also observed in several tumors, suggesting that they could also contribute to the transformation process, To test this hypothesis, me used a genetic approach and studied MMTVD/myc transgenic mice in which one of the Notch1 alleles was mutated by targeted mutagenesis (Notch(+/-) mice). Heterozygote (Notch1(+/-)) and wild-type (Notch1(+/+)) transgenic mice were inoculated with Moloney MuLV and the frequency of Notch1 rearrangements was compared between both groups. Notch1 was rearranged at similar frequencies in both groups, indicating that the full-length Notch1 allele is dispensable in tumors harboring an activated Notch1 allele.	Clin Res Inst Montreal, Mol Biol Lab, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3J 3J7, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3G 1A4, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University	Jolicoeur, P (corresponding author), Clin Res Inst Montreal, Mol Biol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.							ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Christensen S, 1996, DEVELOPMENT, V122, P1373; CONLON RA, 1995, DEVELOPMENT, V121, P1533; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; HANNA Z, 1993, ONCOGENE, V8, P1661; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; KENYON C, 1995, CELL, V82, P171, DOI 10.1016/0092-8674(95)90302-X; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; NYE JS, 1994, DEVELOPMENT, V120, P2421; PAQUETTE Y, 1992, MOL CELL BIOL, V12, P3522, DOI 10.1128/MCB.12.8.3522; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8	24	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	1998	16	4					517	522		10.1038/sj.onc.1201562	http://dx.doi.org/10.1038/sj.onc.1201562			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484841	Green Submitted			2022-12-25	WOS:000071739400010
J	Reunanen, N; Westermarck, J; Hakkinen, L; Holmstrom, TH; Elo, I; Eriksson, JE; Kahari, VM				Reunanen, N; Westermarck, J; Hakkinen, L; Holmstrom, TH; Elo, I; Eriksson, JE; Kahari, VM			Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; INHIBITS COLLAGEN; MAP KINASE; CELLS; PHOSPHORYLATION; JUN; SUPPRESSION; INDUCTION; AP-1; INTERLEUKIN-1	Inflammatory cytokines tumor necrosis factor-alpha and interleukin-1 trigger the ceramide signaling pathway, initiated by neutral sphingomyelinase-elicited hydrolysis of cell membrane phospholipid sphingomyelin to ceramide, a new lipid second messenger. Here, we show that triggering the ceramide pathway by sphingomyelinase or C-2- and C-6-ceramide enhances collagenase-1 (matrix metalloproteinase-1; MMP-1) gene expression by fibroblasts. C-2-ceramide activates three distinct mitogen-activated protein kinases (MAPKs) in dermal fibroblasts, Le. extracellular signal-regulated kinase 1/2 (ERK1/2), stress-activated protein kinase/Jun N-terminal-kinase (SAPK/JNK), and p38. Stimulation of MMP-1 promoter activity by C-2-ceramide is dependent on the presence of a functional AP-1 cis-element and is entirely inhibited by overexpression of MAPK inhibitor, dual specificity phosphatase CL100 (MAPK phosphatase-1). Activation of MMP-1 promoter by C-2-ceramide is also effectively inhibited by kinase-deficient forms of ERK1/2 kinase (MEK1/2) activator Raf-1, ERK1 and ERK2, SAPK/JNK activator SEK1, or SAPK beta, In addition, ceramide-dependent induction of MMP-1 expression is potently prevented by PD 98059, a selective inhibitor of MEK1 activation, and by specific p38 inhibitor SB 203580. These results show that triggering the ceramide signaling pathway activates MMP-1 gene expression via three distinct MAPK pathways, i.e. ERK1/2, SAPK/JNK and p38, and suggest that targeted modulation of the ceramide signaling pathway may offer a novel therapeutic approach for inhibiting collagenolytic activity, e.g. in inflammatory disorders.	Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, Dept Periodontol, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Dermatol, FIN-20520 Turku, Finland; Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland	University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; Abo Akademi University	Kahari, VM (corresponding author), Univ Turku, MediCity Res Lab, Tykistokatu 6, FIN-20520 Turku, Finland.	velkah@utu.fi	Kähäri, Veli-Matti/E-5144-2011; Westermarck, Jukka/AAL-6464-2020; Kahari, Veli-Matti/T-4925-2019; Hakkinen, Lari/B-2228-2016	Kähäri, Veli-Matti/0000-0003-2421-9368; Westermarck, Jukka/0000-0001-7478-3018; Kahari, Veli-Matti/0000-0003-2421-9368; 				ALESSI DR, 1993, ONCOGENE, V8, P2015; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BARBARA JAJ, 1994, EMBO J, V13, P843, DOI 10.1002/j.1460-2075.1994.tb06327.x; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRUDER T, 1993, GENE DEV, V6, P545; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRISCH SM, 1990, ONCOGENE, V5, P75; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; JOSEPH CK, 1994, J BIOL CHEM, V269, P17606; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; Kahari VM, 1997, EXP DERMATOL, V6, P199, DOI 10.1111/j.1600-0625.1997.tb00164.x; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LAULEDERKIND SJF, 1995, J EXP MED, V182, P599, DOI 10.1084/jem.182.2.599; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MAUVIEL A, 1988, FEBS LETT, V236, P47, DOI 10.1016/0014-5793(88)80283-7; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; Pierce RA, 1996, J CLIN INVEST, V97, P1890, DOI 10.1172/JCI118620; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rapala KT, 1996, EXPERIENTIA, V52, P70, DOI 10.1007/BF01922419; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SAUS J, 1988, J BIOL CHEM, V263, P6742; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTERMARCK J, 1995, J INVEST DERMATOL, V105, P197, DOI 10.1111/1523-1747.ep12317114; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; WESTERMARCK J, 1994, CELL GROWTH DIFFER, V5, P1205; YAN MH, 1994, NATURE, V372, P798; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	55	192	199	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5137	5145		10.1074/jbc.273.9.5137	http://dx.doi.org/10.1074/jbc.273.9.5137			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478967	hybrid			2022-12-25	WOS:000072310400051
J	Vaingankar, SM; Martins-Green, M				Vaingankar, SM; Martins-Green, M			Thrombin activation of the 9E3/CEF4 chemokine involves tyrosine kinases including c-src and the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; SMOOTH-MUSCLE CELLS; MICROVASCULAR ENDOTHELIAL-CELLS; PROTEIN ALPHA-SUBUNITS; HUMAN PLATELETS; V-SRC; PHOSPHOINOSITIDE TURNOVER; SIGNALING PATHWAYS; EGF RECEPTOR; TGF-ALPHA	The 9E3/CEF4 gene codes for a chemokine that is highly homologous to human interleukin-8 and melanoma growth-stimulating activity/gro alpha. These chemokines belong to a family of molecular mediators that are importantly involved in inflammation, wound healing, tumor development, and viral entry into cells. On the chorioallantoic membrane the 9E3 protein is chemotactic for monocyte/macrophages and lymphocytes and is angiogenic. In cultured chicken embryo fibroblasts, which have many of the properties of wound fibroblasts, the gene is stimulated by a variety of agents including oncogenes, growth factors, phorbol esters, and thrombin, The strong stimulation of 9E3 by thrombin in culture correlates well with the observation that in young chicks this gene is stimulated to very high levels in fibroblasts upon wounding and remains high throughout wound repair, Activation of 9E3 by thrombin: (i) occurs very rapidly, one minute exposure to thrombin is sufficient to initiate the signals necessary for gene activation; (ii) is independent of mitogenesis; (iii) operates through the proteolytically activated receptor for thrombin; (iv) is mediated by tyrosine kinases, including c-src and the epidermal growth factor (EGF) receptor, rather than Ser/Thr kinases such as protein kinase C and protein kinase A. Inhibition of either c-src or the EGF receptor tyrosine kinase inhibits the stimulation of 9E3 by thrombin. We show here for the first time that activation of the EGF receptor through a cell-surface receptor that does not have tyrosine kinase activity can lead to expression of an immediate early response gene which encodes for a secreted protein, a chemokine. This rapidly activated tyrosine kinase pathway may be a general stress response by which in vivo a localized cell population reacts to emergency situations such as viral infection, wounding, or tumor growth.	Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside	Martins-Green, M (corresponding author), Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA.	mmgreen@ucracl.ucr.edu			NIGMS NIH HHS [GM48436] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048436] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAFFY G, 1994, J BIOL CHEM, V269, P8483; BARKER K, 1990, MOL CELL BIOL, V10, P3813, DOI 10.1128/MCB.10.7.3813; BARKER K, 1989, J VIROL, V63, P2929, DOI 10.1128/JVI.63.7.2929-2935.1989; BARKER KA, 1993, J VIROL, V67, P3528, DOI 10.1128/JVI.67.6.3528-3533.1993; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BISSELL MJ, 1977, J SUPRAMOL STR CELL, V6, P1, DOI 10.1002/jss.400060102; Bojovic B, 1996, J BIOL CHEM, V271, P22528, DOI 10.1074/jbc.271.37.22528; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CARVETH HJ, 1992, SEMIN THROMB HEMOST, V18, P126, DOI 10.1055/s-2007-1002417; CHEN LB, 1976, EXP CELL RES, V101, P41, DOI 10.1016/0014-4827(76)90409-2; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; CONSTANTINOU A, 1995, P SOC EXP BIOL MED, V208, P109; COUGHLIN SR, 1992, COLD SPRING HARB SYM, V57, P149, DOI 10.1101/SQB.1992.057.01.019; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; CROWLEY MR, 1994, J CARDIOVASC PHARM, V23, P806, DOI 10.1097/00005344-199405000-00017; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DERYNCK R, 1990, BIOCHEMISTRY-US, V29, P10225, DOI 10.1021/bi00496a011; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; ERIKSON RL, 1988, COLD SPRING HARB SYM, V53, P143, DOI 10.1101/SQB.1988.053.01.020; FALET H, 1994, FEBS LETT, V345, P87, DOI 10.1016/0014-5793(94)00414-5; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GONNEVILLE L, 1991, ONCOGENE, V6, P1825; GRABHAM P, 1995, J NEUROCHEM, V64, P583; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HEWLETT EL, 1983, INFECT IMMUN, V41, P137, DOI 10.1128/IAI.41.1.137-144.1983; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Iorio P, 1996, FEBS LETT, V381, P244, DOI 10.1016/0014-5793(96)00117-2; ISHII K, 1994, J BIOL CHEM, V269, P1125; IZUMI H, 1994, EXP CELL RES, V214, P654, DOI 10.1006/excr.1994.1303; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KIM DW, 1994, J CELL PHYSIOL, V160, P573, DOI 10.1002/jcp.1041600321; KIM DW, 1991, J CELL BIOL, V115, P16; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; LAPETINA EG, 1990, FEBS LETT, V268, P400, DOI 10.1016/0014-5793(90)81293-W; Lerner DJ, 1996, J BIOL CHEM, V271, P13943, DOI 10.1074/jbc.271.24.13943; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIEBENHOFF U, 1993, BIOCHEM J, V295, P41, DOI 10.1042/bj2950041; Lin ZW, 1996, P NATL ACAD SCI USA, V93, P2582, DOI 10.1073/pnas.93.6.2582; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MARTINSGREEN M, 1991, CELL REGUL, V2, P739, DOI 10.1091/mbc.2.9.739; MartinsGreen M, 1996, CYTOKINE, V8, P448, DOI 10.1006/cyto.1996.0061; MARTINSGREEN M, 1990, J CELL BIOL, V110, P581, DOI 10.1083/jcb.110.3.581; MARTINSGREEN M, 1992, J CELL SCI, V101, P701; MARTINSGREEN M, 1997, CYTOKINE GROWTH F R, V8, P219; MARTINSGREEN M, 1998, IN PRESS CYTOKINE; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; Molloy CJ, 1996, J CLIN INVEST, V97, P1173, DOI 10.1172/JCI118531; MOYERS JS, 1995, BIOCHEM J, V305, P411, DOI 10.1042/bj3050411; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PRIESCHL EE, 1995, INT ARCH ALLERGY IMM, V107, P475, DOI 10.1159/000237089; QURESHI SA, 1991, ONCOGENE, V6, P995; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; SHERRY B, 1991, CURR OPIN IMMUNOL, V3, P56, DOI 10.1016/0952-7915(91)90077-E; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SIEWEKE MH, 1989, CANCER RES, V49, P6419; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; STIERNBERG J, 1984, J CELL PHYSIOL, V120, P289, DOI 10.1002/jcp.1041200305; STIERNBERG J, 1993, THROMB HAEMOSTASIS, V70, P158; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; Ueno A, 1996, IMMUNOLOGY, V88, P76, DOI 10.1046/j.1365-2567.1996.d01-635.x; VAINGANKAR S, 1995, MOL BIOL CELL, V6, P84; Vaingankar SM, 1996, MOL BIOL CELL, V7, P52; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x; YOSHIMURA M, 1995, J BIOL CHEM, V270, P2298, DOI 10.1074/jbc.270.5.2298; ZIMMERMAN BJ, 1994, AM J PHYSIOL, V267, pH1049, DOI 10.1152/ajpheart.1994.267.3.H1049; ZIMMERMAN GA, 1986, ANN NY ACAD SCI, V485, P349, DOI 10.1111/j.1749-6632.1986.tb34596.x	83	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5226	5234		10.1074/jbc.273.9.5226	http://dx.doi.org/10.1074/jbc.273.9.5226			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478978	hybrid			2022-12-25	WOS:000072310400062
J	Conus, NM; Hemmings, BA; Pearson, RB				Conus, NM; Hemmings, BA; Pearson, RB			Differential regulation by calcium reveals distinct signaling requirements for the activation of Akt and p70(S6k)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; S6 KINASE; PHOSPHATASE INHIBITORS; GROWTH-FACTOR; WORTMANNIN; INSULIN; TARGET; DOMAIN; CA-2+	Activation of the phosphatidylinositol 3-kinase (PI3K) plays an important role in the mitogenic response of many cell types. Recently, two serine/threonine kinases Akt and p70(S6k) have been identified as physiological targets of FI3K. Observations that expression of activated forms elf Akt led to the activation of p70(S6k) implied Akt might mediate mitogenic signaling through activation of p70(S6k). TO clarify the relationship between signaling through these two kinases, we have examined their regulation by various mitogenic stimuli. In this study we have focused on the role of calcium in the regulation of each kinase in Balb/c-3T3 fibroblasts. Depletion of intracellular calcium stores by EGTA pretreatment has no effect on growth factor-induced Akt activation but completely abolishes p70(S6k) stimulation. Increase of intracellular calcium induced by ionomycin or thapsigargin results in a full activation of p70(S6k), whereas little or no activation of Akt is observed. Furthermore, although PI3k in anti-phosphotyrosine immunoprecipitates is only very weakly activated by ionomycin, the calcium-induced stimulation of p70(S6k) is completely inhibited by the specific FISH inhibitor wortmannin. We conclude Akt and p70(S6k) Ii, on separate signaling pathways, Activation of signaling to Akt is insufficient for the activation of p70(S6k), which can be achieved independently of Akt. p70(S6k) requires a separate calcium-dependent and wortmannin-sensitive process that is likely to be independent of type, I-A PI3K family members.	Royal Melbourne Inst Technol, Trescowthick Res Labs, Melbourne, Vic 3000, Australia; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Royal Melbourne Institute of Technology (RMIT); Friedrich Miescher Institute for Biomedical Research	Pearson, RB (corresponding author), Royal Melbourne Inst Technol, Trescowthick Res Labs, Locked Bag 1,A Beckett St, Melbourne, Vic 3000, Australia.		Pearson, Richard Bruce/I-1451-2013	Pearson, Richard Bruce/0000-0001-5919-5090				AHMED NN, 1993, ONCOGENE, V8, P1957; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ettinger SL, 1996, J BIOL CHEM, V271, P14514, DOI 10.1074/jbc.271.24.14514; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LANE HA, 1991, METHOD ENZYMOL, V200, P269; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SUSA M, 1992, J BIOL CHEM, V267, P6905; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TWOMEY B, 1990, BIOCHEM BIOPH RES CO, V171, P1087, DOI 10.1016/0006-291X(90)90795-O; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WAHL M, 1993, MOL BIOL CELL, V4, P293, DOI 10.1091/mbc.4.3.293; WELTERS P, 1994, P NATL ACAD SCI USA, V91, P11398, DOI 10.1073/pnas.91.24.11398; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wymann MP, 1996, MOL CELL BIOL, V16, P1722	52	96	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4776	4782		10.1074/jbc.273.8.4776	http://dx.doi.org/10.1074/jbc.273.8.4776			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468542	hybrid			2022-12-25	WOS:000072115000070
J	Forbes, BE; Turner, D; Hodge, SJ; McNeil, KA; Forsberg, G; Wallace, JC				Forbes, BE; Turner, D; Hodge, SJ; McNeil, KA; Forsberg, G; Wallace, JC			Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II; SEQUENCE; SERUM; CELLS; MITOGENESIS; COMPLEX; IGFBP-3; CLONING	We have investigated which region(s) of bovine insulin-like growth factor binding protein-2 (bIGFBP-2) interact with insulin-like growth factors (IGFs) using C-terminally truncated forms of bIGFBP-2. Initially to aid in mutant design, we defined the disulfide bonding pattern of bIGFBP-2 C-terminal region using enzymatic digestion, The pattern is Cys(186)-Cys(220), CyS231-CyS242, and Cys(244)-Cys(265). I, addition, cyanogen bromide cleavage of bIGFBP-2 revealed that the N-and C-terminal cysteine-rich domains were not linked by disulfide bonds, Taking the disulfide bonding pattern into consideration, C-terminal truncation mutants were designed and expressed in COS-1 mammalian cells, Following IGF binding assays, a region between residues 222 and 236 was identified as important in IGF binding, Specifically, mutants truncated by 14, 36, and 48 residues from the C terminus bound IGFs to the same extent as wild type (WT) bIGFBP-2. Removal of 63 residues resulted in a greatly reduced (up to 80-fold) ability to bind IGF compared with WT bIGFBP-2. Interestingly this mutant lacked the IGF-II binding preference of WT bIGFBP-2. Residues 236-270 also appeared to play a role in determining IGF binding specificity as their removal resulted in mutants with higher IGF-II binding affinity.	Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Cooperat Res Ctr Tissue Growth & Repair, Adelaide, SA 5005, Australia	University of Adelaide	Forbes, BE (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.		, John/AAP-5150-2020; Forbes, Briony/R-1838-2019	Forbes, Briony/0000-0003-4360-9927				ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; Baxter Robert C., 1995, Progress in Growth Factor Research, V6, P215, DOI 10.1016/0955-2235(95)00004-6; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; BRINKMAN A, 1991, MOL ENDOCRINOL, V5, P987, DOI 10.1210/mend-5-7-987; BRINKMAN A, 1991, FEBS LETT, V291, P264, DOI 10.1016/0014-5793(91)81298-M; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CLACKSON T, 1993, PCR PRACTICAL APPROA, P201; FORBES B, 1990, J ENDOCRINOL, V126, P497, DOI 10.1677/joe.0.1260497; FRANCIS GL, 1988, BIOCHEM J, V251, P95, DOI 10.1042/bj2510095; GOCKERMAN A, 1995, CIRC RES, V76, P514, DOI 10.1161/01.RES.76.4.514; GUIDICE LC, 1990, J CLIN ENDOCRINOLOGY, V71, P806; Heding A, 1996, J BIOL CHEM, V271, P13948, DOI 10.1074/jbc.271.24.13948; Hobba GD, 1996, J BIOL CHEM, V271, P30529, DOI 10.1074/jbc.271.48.30529; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landale EC, 1995, GROWTH FACTORS, V12, P245, DOI 10.3109/08977199509028963; LEE CY, 1995, ENDOCRINOLOGY, V136, P668, DOI 10.1210/en.136.2.668; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OCRANT I, 1992, ENDOCRINOLOGY, V131, P221, DOI 10.1210/en.131.1.221; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULLER AGP, 1993, GROWTH REGULAT, V3, P32; SOMMER A, 1991, MODERN CONCEPTS INSU, P715; UPTON Z, 1990, J MOL ENDOCRINOL, V5, P77, DOI 10.1677/jme.0.0050077; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7; WHYATT LM, 1993, MOL CELL BIOL, V13, P7971, DOI 10.1128/MCB.13.12.7971; ZAPF J, 1995, EUR J ENDOCRINOL, V132, P645, DOI 10.1530/eje.0.1320645	31	69	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4647	4652		10.1074/jbc.273.8.4647	http://dx.doi.org/10.1074/jbc.273.8.4647			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468524	hybrid			2022-12-25	WOS:000072115000052
J	Petti, LM; Irusta, PM; DiMaio, D				Petti, LM; Irusta, PM; DiMaio, D			Oncogenic activation of the PDGF beta receptor by the transmembrane domain of p185(neu)	ONCOGENE			English	Article						growth factor receptor; cell transformation; tyrosine phosphorylation	GROWTH-FACTOR RECEPTOR; PAPILLOMAVIRUS-E5 TRANSFORMING PROTEIN; CHRONIC MYELOMONOCYTIC LEUKEMIA; TYROSINE KINASE-ACTIVITY; SIMIAN SARCOMA-VIRUS; SIGNAL-TRANSDUCTION; TUMORIGENIC TRANSFORMATION; INSULIN-RECEPTOR; POINT MUTATION; E5 PROTEIN	We replaced the transmembrane domain of the wild type murine PDGF beta receptor with that of p185(neu*), the oncogenic form of p185(neu), thereby generating a constitutively activated chimeric receptor PR/neu*. Unlike the wild type PDGF beta receptor or a Chimeric receptor containing the transmembrane domain of wild type p185(neu) (PR/neu), PR/neu* induced morphologic transformation, focus formation, and tumorigenicity in mouse C127 fibroblasts. Expression of PR/neu* in mouse Ba/F3 hematopoietic cells, which normally depend on IL-3 for survival and sustained proliferation, induced proliferation in the absence of IL-3. The PR/neu chimera conferred limited IL-3-independent growth of Ba/F3 cells. Only PR/neu* and not PR/neu displayed significantly increased levels of phosphotyrosine compared to the wild type PDGF receptor in C127 and Ba/F3 cells. In addition, PR/neu* immune complexes displayed increased levels of kinase activity in vitro compared to immune complexes of the wild type receptor. Furthermore, novel tyrosine phosphorylated proteins of approximately 60 kDa appeared to specifically complex with PR/neu*, suggesting that PR/neu* may activate distinct signaling pathways. We speculate that the p185(neu*) transmembrane domain in the context of the PDGF beta receptor facilitates receptor homodimerization, thereby inducing tyrosine autophosphorylation followed by association with important signaling substrates and transforming activity. Thus, PR/neu* should be a useful reagent for further characterizing activation and signaling mechanisms of the PDGF beta receptor.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA	Yale University	Petti, LM (corresponding author), Albany Med Coll, Dept Microbiol Immunol & Mol Genet, A-68,47 New Scotland Ave, Albany, NY 12208 USA.				NATIONAL CANCER INSTITUTE [R37CA037157, P01CA016038, R01CA037157] Funding Source: NIH RePORTER; NCI NIH HHS [CA16038, CA37157] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CAO HN, 1992, J BIOL CHEM, V267, P20489; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; ESCOBEDO JA, MOL CELL BIOL, V10, P3858; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; LEE AW, 1992, J BIOL CHEM, V267, P16472; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; LEPTAK C, 1991, J VIROL, V66, P1833; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; RIESE DJ, 1995, ONCOGENE, V10, P1431; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; YAMADA K, 1992, J BIOL CHEM, V267, P12452; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	43	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					843	851		10.1038/sj.onc.1201590	http://dx.doi.org/10.1038/sj.onc.1201590			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484775				2022-12-25	WOS:000072053200003
J	Lim, YH; Yoshimura, T; Kurokawa, Y; Esaki, N; Soda, K				Lim, YH; Yoshimura, T; Kurokawa, Y; Esaki, N; Soda, K			Nonstereospecific transamination catalyzed by pyridoxal phosphate-dependent amino acid racemases of broad substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOSTABLE ALANINE RACEMASE; GLUTAMATE RACEMASE; BACILLUS-STEAROTHERMOPHILUS; ESCHERICHIA-COLI; REACTION-MECHANISM; AEROMONAS-CAVIAE; PURIFICATION; GENE; AMINOTRANSFERASE; RACEMIZATION	Pyridoxal 5'-phosphate-dependent amino acid racemases of broad substrate specificity catalyze transamination as a side reaction. We studied the stereospecificities for hydrogen abstraction from C-4' of the bound pyridoxamine 5'-phosphate during transamination from pyridoxamine 5'-phosphate to pyruvate catalyzed by three amino acid racemases of broad substrate specificity. When the enzymes were incubated with (4'S)- or (4'R)-[4'-H-3]pyridoxamine 5'-phosphate in the presence of pyruvate, tritium was released into the solvent from both pyridoxamine 5'-phosphates. Thus, these enzymes abstract a hydrogen nonstereospecifically from C-4' of the coenzyme in contrast to the other pyridoxal 5'-phosphate-dependent enzymes so far studied, which catalyze the stereospecific hydrogen removal. Amino acid racemase of broad substrate specificity from Pseudomonas putida produced D-and L-glutamate from alpha-ketoglutarate through the transamination with L-ornithine. Be cause glutamate does not serve as a substrate for racemization, the enzyme catalyzed the nonstereospecific overall transamination between L-ornithine and alpha-ketoglutarate, The cleavage and formation of the C-H bond at C-4' of the coenzyme and C-2 of the substrate thus occurs nonstereospecifically on both sides of the plane of the coenzyme-substrate complex intermediate, Amino acid racemase of broad substrate specificity is the first example of a pyridoxal enzyme catalyzing nonstereospecific transamination.	Kyoto Univ, Chem Res Inst, Microbial Biochem Lab, Kyoto 611, Japan; Kansai Univ, Fac Engn, Dept Biotechnol, Osaka 564, Japan	Kyoto University; Kansai University	Esaki, N (corresponding author), Kyoto Univ, Chem Res Inst, Microbial Biochem Lab, Kyoto 611, Japan.	esaki@scl.kyoto-u.ac.jp						AHMED SA, 1986, BIOCHEMISTRY-US, V25, P385, DOI 10.1021/bi00350a017; ALBERY WJ, 1986, BIOCHEMISTRY-US, V25, P2572, DOI 10.1021/bi00357a043; ASADA Y, 1981, BIOCHEMISTRY-US, V20, P6881, DOI 10.1021/bi00527a022; AYLING JE, 1968, BIOCHEMISTRY-US, V7, P4532; BAILEY G B, 1970, Federation Proceedings, V29, P857; BESMER P, 1969, CHIMIA, V23, P190; CARDINALE GJ, 1968, BIOCHEMISTRY-US, V7, P3979; CHANG CC, 1982, J BIOL CHEM, V257, P3564; CHOI SY, 1992, J BIOCHEM-TOKYO, V112, P139, DOI 10.1093/oxfordjournals.jbchem.a123853; DUNATHAN HC, 1971, ADV ENZYMOL RAMB, V35, P79; DUNATHAN HC, 1974, P NATL ACAD SCI USA, V71, P3888, DOI 10.1073/pnas.71.10.3888; FARACI WS, 1988, BIOCHEMISTRY-US, V27, P3267, DOI 10.1021/bi00409a022; FLOSS HG, 1982, STEREOCHEMISTRY, P161; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3991, DOI 10.1021/bi00066a020; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3981, DOI 10.1021/bi00066a019; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HENDERSON LL, 1976, BIOCHEM BIOPH RES CO, V68, P793, DOI 10.1016/0006-291X(76)91215-8; INAGAKI K, 1987, AGR BIOL CHEM TOKYO, V51, P173, DOI 10.1080/00021369.1987.10867978; KANDA M, 1989, J BIOCHEM-TOKYO, V105, P653, DOI 10.1093/oxfordjournals.jbchem.a122720; KUO DJ, 1987, BIOCHEMISTRY-US, V26, P7589, DOI 10.1021/bi00398a009; KURAMITSU S, 1985, J BIOCHEM-TOKYO, V97, P993, DOI 10.1093/oxfordjournals.jbchem.a135176; LIM YH, 1993, J BACTERIOL, V175, P4213, DOI 10.1128/JB.175.13.4213-4217.1993; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; MARTINEZCARRION M, 1985, TRANSAMINASES, P308; MEHTA PK, 1993, EUR J BIOCHEM, V211, P373, DOI 10.1111/j.1432-1033.1993.tb19907.x; NAKAJIMA N, 1986, AGR BIOL CHEM TOKYO, V50, P2823, DOI 10.1080/00021369.1986.10867827; REYNOLDS K, 1991, J BASIC MICROB, V31, P177, DOI 10.1002/jobm.3620310304; RUNICK G, 1975, BIOCHEMISTRY-US, V14, P4515; SAWADA S, 1994, BIOSCI BIOTECH BIOCH, V58, P807, DOI 10.1271/bbb.58.807; Shaw JP, 1997, BIOCHEMISTRY-US, V36, P1329, DOI 10.1021/bi961856c; SHEN S, 1983, J CHEM SOC CHEM COMM, V82; SHOSTAK K, 1988, BIOCHEMISTRY-US, V27, P8007, DOI 10.1021/bi00421a006; SODA K, 1971, METHODS ENZYMOL    B, V17, P629; SODA K, 1986, COENZYMES COFACTOR B, V1, P223; SUKHAREV.BS, 1971, FEBS LETT, V15, P241, DOI 10.1016/0014-5793(71)80321-6; TANIZAWA K, 1988, BIOCHEMISTRY-US, V27, P1311, DOI 10.1021/bi00404a033; VOET JG, 1973, J BIOL CHEM, V248, P841; WISEMAN JS, 1984, J BIOL CHEM, V259, P8907; YAMAUCHI T, 1992, J BIOL CHEM, V267, P18361; YORIFUJI T, 1971, J BIOL CHEM, V246, P5085; YORIFUJI T, 1971, J BIOL CHEM, V246, P5093; YOSHIMURA T, 1993, J AM CHEM SOC, V115, P3897, DOI 10.1021/ja00063a007; Yoshimura Tohru, 1994, P147, DOI 10.1002/9783527615971.ch8	43	13	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4001	4005		10.1074/jbc.273.7.4001	http://dx.doi.org/10.1074/jbc.273.7.4001			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461589	hybrid			2022-12-25	WOS:000072048400031
J	Danner, S; Frank, M; Lohse, MJ				Danner, S; Frank, M; Lohse, MJ			Agonist regulation of human beta(2)-adrenergic receptor mRNA stability occurs via a specific AU-rich element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; RNA-BINDING-PROTEIN; MESSENGER-RNA; BETA-2-ADRENERGIC RECEPTOR; INDUCED DESTABILIZATION; MAMMALIAN-CELLS; GENE; DEGRADATION; AUUUA; SEQUENCE	Prolonged agonist stimulation of beta(2)-adrenergic receptors results in receptor down-regulation, which is closely associated with a reduction of the corresponding mRNA, an effect mediated in part by changes in mRNA stability. Transfection experiments with human beta(2)-adrenergic receptor cDNAs bearing or lacking the untranslated regions suggested that the essential agonist sensitivity of the mRNA resides within the 3'-untranslated region. The importance of this region was further confirmed in gel shift experiments; cytosolic preparations hom agonist-stimulated DDT1-MF2 smooth muscle cells caused a shift of beta(2)-adrenergic receptor mRNAs containing the 3'-untranslated region. Progressive 3'-terminal truncations of the receptor cDNA led to the identification of an AU-rich element at positions 329-337 of the 3'-untranslated region as the responsible cis-acting element. Substitution of this motif by cytosine residues almost completely abolished mRNA down-regulation and inhibited the formation of the RNA-protein complex. Even though the beta(2)-adrenergic receptor AU-rich element showed two U --> A transitions compared with the recently proposed AU-rich element consensus sequence, it revealed an almost identical destabilizing potency. Fusion of the beta(2)-adrenergic receptor 3' untranslated region to the beta-globin coding sequence dramatically reduced the half-life of the chimeric transcript in an agonist-and cAMP-dependent manner. This suggests that the agonist-induced beta(2)-adrenergic receptor mRNA destabilization is regulated by cAMP-dependent RNA-binding protein(s) via a specific AU-rich element.	Univ Wurzburg, Inst Pharmacol, D-97078 Wurzburg, Germany	University of Wurzburg	Lohse, MJ (corresponding author), Univ Wurzburg, Inst Pharmacol, Versbacher Str 9, D-97078 Wurzburg, Germany.		Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				BAEYENS DA, 1995, J CELL PHYSIOL, V163, P305, DOI 10.1002/jcp.1041630211; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Brown CY, 1996, P NATL ACAD SCI USA, V93, P13721, DOI 10.1073/pnas.93.24.13721; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS S, 1990, J BIOL CHEM, V265, P19330; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; Danner S, 1997, EUR J PHARMACOL, V331, P73, DOI 10.1016/S0014-2999(97)01022-4; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HADCOCK JR, 1993, J NEUROCHEM, V60, P1, DOI 10.1111/j.1471-4159.1993.tb05816.x; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HUANG LY, 1993, J BIOL CHEM, V268, P25769; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LAZARWESLEY E, 1991, ENDOCRINOLOGY, V129, P1116, DOI 10.1210/endo-129-2-1116; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MALBON CC, 1988, BIOCHEM BIOPH RES CO, V154, P676, DOI 10.1016/0006-291X(88)90192-1; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; PORT JD, 1992, J BIOL CHEM, V267, P24103; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; THOLANIKUNNEL BG, 1995, J BIOL CHEM, V270, P12787, DOI 10.1074/jbc.270.21.12787; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	36	59	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3223	3229		10.1074/jbc.273.6.3223	http://dx.doi.org/10.1074/jbc.273.6.3223			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452435	hybrid			2022-12-25	WOS:000071822300020
J	Furuta, M; Carroll, R; Martin, S; Swift, HH; Ravazzola, M; Orci, L; Steiner, DF				Furuta, M; Carroll, R; Martin, S; Swift, HH; Ravazzola, M; Orci, L; Steiner, DF			Incomplete processing of proinsulin to insulin accompanied by elevation of des-31,32 proinsulin intermediates in islets of mice lacking active PC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPROTEIN CONVERTASES; BETA-CELL; CONVERSION; RAT; CLEAVAGE; NIDDM; SITE	The prohormone convertases PC2 (SPC2) and PC3/PC1 (SPC3) are the major precursor processing endoproteases in a wide variety of neural and endocrine tissues. Both enzymes are normally expressed in the islet beta cells and participate in proinsulin processing. Recently we generated mice lacking active PC2 due to a disruption of the PC2 gene (Furuta, M., Yano, H., Zhou, A., Rouille, Y., Hoist, J. J., Carroll, R. J., Ravazzola, M., Orci, L., Furuta, H., and Steiner, D. F. (1997) Proc. Natl. Acad. Sci. U.S. A. 94, 6646-6651). Here we report that these PC2 mutant mice have elevated circulating proinsulin, comprising 60% of immunoreactive insulin-like components. Acid ethanol extractable proinsulin from pancreas is also significantly elevated, representing about 35% of total immunoreactive insulin-like components. These increased amounts of proinsulin are mainly stored in secretory granules, giving rise to an altered appearance on electron microscopy. In pulse-chase experiments, the mutant islets incorporate lesser amounts of isotopic amino acids into insulin-related components than normal islets. In both wild-type and mutant islets, proinsulin I was processed more rapidly to insulin, reflecting the preference of both PC2 and PC3 for substrates having a basic amino acid positioned four residues upstream of the cleavage site. The overall half-time for the conversion of proinsulin to insulin is increased approximately 3-fold in the mutant islets and is associated with a 4-5-fold greater elevation of des-31,32 proinsulin, an intermediate that is formed by the preferential cleavage of proinsulin at the B chain-C-peptide junction by PC3 and is C-terminally processed to remove Arg(31) and Arg(32) by carboxypeptidase E. The constitutive release of newly synthesized proinsulin from both mutant and wild-type islets during the first 1-2 h of chase was normal (<2% of total). These results demonstrate that PC2 plays an essential role in proinsulin processing in vivo, but is quantitatively less important in this regard than PC3, and that its absence does not influence the efficient sorting of proinsulin into the regulated secretory pathway.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Geneva, Dept Morphol, CH-1211 Geneva 4, Switzerland	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Geneva	Steiner, DF (corresponding author), Univ Chicago, Howard Hughes Med Inst, 5841 S Maryland Ave,MC 1028, Chicago, IL 60637 USA.				NIDDK NIH HHS [DK 20595, DK 13914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013914, P60DK020595, P30DK020595, R01DK013914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAN SJ, 1992, P NATL ACAD SCI USA, V89, P6678, DOI 10.1073/pnas.89.15.6678; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; HALES CN, 1996, DIABETES REV, V4, P320; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Kaufmann JE, 1997, DIABETES, V46, P978, DOI 10.2337/diabetes.46.6.978; LERNMARK A, 1976, J CELL BIOL, V71, P606, DOI 10.1083/jcb.71.2.606; LIPKIND G, 1995, J BIOL CHEM, V270, P13277, DOI 10.1074/jbc.270.22.13277; MADSEN OD, 1983, ENDOCRINOLOGY, V113, P2135, DOI 10.1210/endo-113-6-2135; MAXWELL MH, 1978, J MICROSC-OXFORD, V112, P253, DOI 10.1111/j.1365-2818.1978.tb01174.x; MICHAEL J, 1987, J BIOL CHEM, V262, P16531; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NEERMANARBEZ M, 1994, BIOCHEM J, V300, P57, DOI 10.1042/bj3000057; ORAHILLY S, 1995, NEW ENGL J MED, V333, P1386, DOI 10.1056/NEJM199511233332104; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; OSTREGA D, 1995, DIABETES, V44, P437, DOI 10.2337/diabetes.44.4.437; RHODES CJ, 1994, DIABETES, V43, P511, DOI 10.2337/diabetes.43.4.511; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SIZONENKO S, 1993, DIABETES, V42, P933, DOI 10.2337/diabetes.42.6.933; SIZONENKO SV, 1991, BIOCHEM J, V278, P621, DOI 10.1042/bj2780621; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; Steiner D., 1995, ENDOCRINOLOGY, P1296; STEINER DF, 1973, NATURE, V243, P528, DOI 10.1038/243528a0; TAGER HS, 1975, METHODS ENZYMOLOGY; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; WENTWORTH BM, 1986, J MOL EVOL, V23, P305, DOI 10.1007/BF02100639; WROBLEWSKI VJ, 1993, DIABETES, V42, P1407, DOI 10.2337/diabetes.42.10.1407; YOSHIDA H, 1995, DIABETES, V44, P389, DOI 10.2337/diabetes.44.4.389	29	153	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3431	3437		10.1074/jbc.273.6.3431	http://dx.doi.org/10.1074/jbc.273.6.3431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452465	hybrid			2022-12-25	WOS:000071822300050
J	Rousset, R; Fabre, S; Desbois, C; Bantignies, F; Jalinot, P				Rousset, R; Fabre, S; Desbois, C; Bantignies, F; Jalinot, P			The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins	ONCOGENE			English	Article						HTLV-1; Tax; PDZY; two-hybrid	VIRUS TYPE-I; COMPLETE NUCLEOTIDE-SEQUENCE; NMDA RECEPTOR SUBUNITS; NF-KAPPA-B; LEUKEMIA-VIRUS; TRANSGENIC MICE; TRANSCRIPTION FACTORS; TRANSACTIVATOR TAX; GUANYLATE KINASES; GENE	Infection by HTLV-1 has been correlated with the appearance of various proliferative or degenerative diseases. Some of these disorders have been observed in transgenic mice expressing the Tax protein, which is known to transactivate various viral and cellular promoters through interactions with several transcription factors. In this study we show that the C-terminus of this viral oncoprotein represents a motif permitting binding of Tax to the PDZ domains of several cellular proteins. A two-hybrid screen with Tax as bait indeed yielded complementary DNAs coding for six proteins including PDZ domains. Two of them correspond to truncated forms of the PSD-95 and beta 1-syntrophin proteins, another clone codes for a protein homologous to the product of the C. elegans gene lin-7. The other three clones code for new human members of the PDZ family of cellular proteins. The interaction of Tax with the products of these clones was confirmed by immunoprecipitation assays in mammalian cells, and analysis of various mutants of Tax established the importance of the C-terminal amino acids for several of these interactions. These data suggest that Tax could perturb the normal function of targeted cellular proteins by strongly interacting with their PDZ domains.	Ecole Normale Super Lyon, Lab Biol Mol & Cellulaire, CNRS, UMR 49, F-69364 Lyon 07, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Jalinot, P (corresponding author), Ecole Normale Super Lyon, Lab Biol Mol & Cellulaire, CNRS, UMR 49, 46 Allee Italie, F-69364 Lyon 07, France.		Fabre, Stéphane/ABC-1483-2020; Morris, Christelle/M-8168-2014; Rousset, Raphael/E-5908-2017; FABRE, Stéphane/AAQ-8400-2020	Morris, Christelle/0000-0003-1575-4609; Rousset, Raphael/0000-0002-4999-403X; FABRE, Stéphane/0000-0001-7350-9500				AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BENVENISTY N, 1992, ONCOGENE, V7, P2399; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CRENON I, 1993, ONCOGENE, V8, P867; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FURUTA Y, 1989, J VIROL, V63, P3185, DOI 10.1128/JVI.63.7.3185-3189.1989; GESSAIN A, 1993, J VIROL, V67, P1015, DOI 10.1128/JVI.67.2.1015-1023.1993; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; Harlow E., 1988, ANTIBODIES LAB MANUA, P447; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LAURANCE ME, 1997, J BIOL CHEM, V272, P24646; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MALIK KTA, 1988, J GEN VIROL, V69, P1695, DOI 10.1099/0022-1317-69-7-1695; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Miller J.H., 1972, EXPT MOL GENETICS; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERENBERG MI, 1989, AM J PATHOL, V135, P1025; Niethammer M, 1996, J NEUROSCI, V16, P2157; Ozden S, 1996, J ACQ IMMUN DEF SYND, V13, pS154, DOI 10.1097/00042560-199600001-00024; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; PFEFFER U, 1995, BIOTECHNIQUES, V18, P204; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUBEN S M, 1989, New Biologist, V1, P275; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TSUJIMOTO A, 1988, MOL BIOL MED, V5, P29; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 1996, J ACQ IMMUN DEF SYND, V13, pS63, DOI 10.1097/00042560-199600001-00012	63	162	175	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					643	654		10.1038/sj.onc.1201567	http://dx.doi.org/10.1038/sj.onc.1201567			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482110				2022-12-25	WOS:000071816600009
J	Inoue, Y; Tsujimoto, Y; Kimura, A				Inoue, Y; Tsujimoto, Y; Kimura, A			Expression of the glyoxalase I gene of Saccharomyces cerevisiae is regulated by high osmolarity glycerol mitogen-activated protein kinase pathway in osmotic stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; YAP-1 TRANSCRIPTIONAL REGULATION; SIGNAL-TRANSDUCTION PATHWAY; TRIOSEPHOSPHATE ISOMERASE; METHYLGLYOXAL SYNTHASE; PLEIOTROPIC DRUG; ELEMENT STRE; TARGET GENE; YEAST; IDENTIFICATION	Methylglyoxal is a cytotoxic metabolite derived from dihydroxyacetone phosphate, an intermediate of glycolysis, Detoxification of methylglyoxal is performed by glyoxalase I, Expression of the structural gene of glyoxalase I (GLO1) of Saccharomyces cerevisiae under several stress conditions was investigated using the GLO1-lacZ fusion gene, and expression of the GLO1 gene was found to be specifically induced by osmotic stress, The Hog1p is one of the mitogen-activated protein kinases (MAPKs) in S. cerevisiae, and both Msn2p and Msn4p are the transcriptional regulators that are thought to be under the control of Hog1p-MAPK. Expression of the GLO1 gene under osmotic stress was completely repressed in hog1 Delta disruptant and was repressed approximately 80 and 50% in msn2 Delta and msn4 Delta disruptants, respectively, A double mutant of the MSN2 and MSN4 gene was unable to induce expression of the GLO1 gene under highly osmotic conditions, Glucose consumption increased approximately 30% during the adaptive period in osmotic stress in the wild type strain, On the contrary, it was reduced by 15% in the hog1 Delta mutant, When the yeast cell is exposed to highly osmotic conditions, glycerol is synthesized as a compatible solute, Glycerol is synthesized from glucose, and a rate-limiting enzyme in glycerol biosynthesis is glycerol-3-phosphate dehydrogenase (GPD1 gene product), which catalyzes reduction of dihydroxyacetone phosphate to glycerol 3-phosphate. Expression of the GPD1 gene is also under the control of Hog1p-MAPK. Methylglyoxal is also synthesized from dihydroxyacetone phosphate; therefore, induction of the GLO1 gene expression by osmotic stress was thought to scavenge methylglyoxal, which in creased during glycerol production for adaptation to osmotic stress.	Kyoto Univ, Food Sci Res Inst, Kyoto 6110011, Japan	Kyoto University	Inoue, Y (corresponding author), Kyoto Univ, Food Sci Res Inst, Kyoto 6110011, Japan.		kimura, akira/D-1215-2010					Alarco AM, 1997, J BIOL CHEM, V272, P19304, DOI 10.1074/jbc.272.31.19304; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; COHEN G, 1988, EUR J BIOCHEM, V176, P159; COOPER RA, 1974, EUR J BIOCHEM, V44, P81, DOI 10.1111/j.1432-1033.1974.tb03459.x; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; FORST SA, 1994, RES MICROBIOL, V145, P363, DOI 10.1016/0923-2508(94)90083-3; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HIRATA D, 1994, MOL GEN GENET, V242, P250, DOI 10.1007/BF00280413; HOPPER DJ, 1972, BIOCHEM J, V128, P321, DOI 10.1042/bj1280321; HUSSAIN M, 1991, GENE, V101, P149, DOI 10.1016/0378-1119(91)90238-7; Inoue Y, 1995, Adv Microb Physiol, V37, P177, DOI 10.1016/S0065-2911(08)60146-0; INOUE Y, 1987, J BIOCHEM-TOKYO, V102, P583, DOI 10.1093/oxfordjournals.jbchem.a122091; Inoue Y, 1996, J BIOL CHEM, V271, P25958, DOI 10.1074/jbc.271.42.25958; IYENGAR R, 1981, BIOCHEMISTRY-US, V20, P1223, DOI 10.1021/bi00508a026; Izawa S, 1996, BIOCHEM J, V320, P61, DOI 10.1042/bj3200061; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MAGER WH, 1993, MOL MICROBIOL, V10, P253, DOI 10.1111/j.1365-2958.1993.tb01951.x; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Miller JH., 1972, EXPT MOL GENETICS; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; Norbeck J, 1996, J BIOL CHEM, V271, P13875, DOI 10.1074/jbc.271.23.13875; NORBECK J, 1997, J BIOL CHEM, V272, P55454; OHTAKE Y, 1991, YEAST, V7, P953, DOI 10.1002/yea.320070907; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Pratt L., 1995, 2 COMPONENT SIGNAL T, P105; RAY S, 1981, J BIOL CHEM, V256, P6230; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; ROGGENKAMP R, 1974, FEBS LETT, V41, P283, DOI 10.1016/0014-5793(74)81230-5; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; SHAPIRO R, 1969, BIOCHEMISTRY-US, V8, P238, DOI 10.1021/bi00829a034; SIKORSKI RS, 1989, GENETICS, V122, P19; TSAI PK, 1976, J BIOL CHEM, V251, P364; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; VANDERJAGT DL, 1993, BIOCHEM SOC T, V21, P522, DOI 10.1042/bst0210522; Varela JCS, 1996, MICROBIOL-SGM, V142, P721, DOI 10.1099/00221287-142-4-721; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	53	86	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2977	2983		10.1074/jbc.273.5.2977	http://dx.doi.org/10.1074/jbc.273.5.2977			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446611	hybrid			2022-12-25	WOS:000071736600066
J	Tsuji, Y; Torti, SV; Torti, FM				Tsuji, Y; Torti, SV; Torti, FM			Activation of the ferritin H enhancer, FER-1, by the cooperative action of members of the AP1 and Sp1 transcription factor families	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; HEAVY-CHAIN; FACTOR-ALPHA; GENE-EXPRESSION; MESSENGER-RNA; MUSCLE-CELLS; PROMOTER; AP-1; JUN	We have previously reported that the adenovirus E1A oncogene represses the transcription of the H subunit of the mouse ferritin gene, Subsequent analyses defined FER-1, a 37-nucleotide sequence located 4.1 kilobases proximal to the start site of transcription, as the target of E1A-mediated transcriptional repression and as an enhancer of the ferritin H gene, FER-1 is composed of an API-like sequence followed by an element with dyed symmetry. To achieve maximal enhancer activity and transcriptional repression by E1A, both elements were essential, Using gel retardation assays, we now demonstrate that the binding complex for the AP1-like sequence of FER-1 contains JunD, FosB, and ATF1. Furthermore, JunD and FosB were able to activate FER-1 enhancer activity by transient cotransfection with ferritin H-chloramphenicol acetyltransferase reporter constructs, This augmented enhancer activity was inhibited by E1A. In addition, we have defined the minimal sequence in the dyad element of FER-1 required for protein interaction, This was determined to be a C-rich sequence to which Sp1 and Sp3 bind, Experiments with recombinant proteins indicate that members of both transcription factor families simultaneously bind FER-1, Taken together, these results elucidate molecular mechanisms involved in the transcriptional regulation of a pivotal gene in iron metabolism and provide insights into the contribution of the Sp1 family to the activation of AP1-dependent enhancers.	Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University	Tsuji, Y (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA.	ytsuji@bgsm.edu			NCI NIH HHS [CA12197] Funding Source: Medline; NIDDK NIH HHS [DK-42412] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042412, R37DK042412] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHAZENBALK GD, 1990, MOL ENDOCRINOL, V4, P1117, DOI 10.1210/mend-4-8-1117; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; IMLER JL, 1988, NUCLEIC ACIDS RES, V16, P3005, DOI 10.1093/nar/16.7.3005; JAIN SK, 1985, J BIOL CHEM, V260, P1762; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KWAK EL, 1995, J BIOL CHEM, V270, P15285, DOI 10.1074/jbc.270.25.15285; KWAK EL, 1990, GENE, V94, P255, DOI 10.1016/0378-1119(90)90396-9; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIAU G, 1991, J BIOL CHEM, V266, P18819; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; MODJTAHEDI N, 1992, EXP CELL RES, V201, P74, DOI 10.1016/0014-4827(92)90349-D; Moffat GJ, 1996, J BIOL CHEM, V271, P1054, DOI 10.1074/jbc.271.2.1054; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; Noti JD, 1996, MOL CELL BIOL, V16, P2940; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SUZUKI M, 1995, MOL CELL BIOL, V15, P5423; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TSUJI Y, 1991, J BIOL CHEM, V266, P7257; TSUJI Y, 1993, J IMMUNOL, V150, P1897; TSUJI Y, 1993, J BIOL CHEM, V268, P7270; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6; Ye JP, 1996, MOL CELL BIOL, V16, P157	38	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2984	2992		10.1074/jbc.273.5.2984	http://dx.doi.org/10.1074/jbc.273.5.2984			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446612	hybrid			2022-12-25	WOS:000071736600067
J	Meiners, S; Brinkmann, V; Naundorf, H; Birchmeier, W				Meiners, S; Brinkmann, V; Naundorf, H; Birchmeier, W			Role of morphogenetic factors in metastasis of mammary carcinoma cells	ONCOGENE			English	Review						HGF; neuregulin; E-cadherin; metastasis; morphogenesis; epithelial-mesenchymal transition	HEPATOCYTE GROWTH-FACTOR; E-CADHERIN EXPRESSION; C-MET RECEPTOR; HUMAN PANCREATIC-CANCER; HUMAN BREAST-CANCER; SCATTER FACTOR; BETA-CATENIN; EPITHELIAL-CELLS; TYROSINE KINASE; TUMOR PROGRESSION	We have analysed the role of the morphogenetic factors hepatocyte growth factor/scatter factor (HGF), neuregulin and E-cadherin in the process of metastasis and morphogenesis of mammary carcinoma cells. The cDNAs for HGF, neuregulin and E-cadherin were stably expressed in anaplastic human MDA MB 435 carcinoma cells. The altered cells were then injected into the mammary fat pads of nude mice, where they form tumors which can spontaneously metastasize to the lungs. We found that expression of HGF or neuregulin promoted metastasis whereas expression of the cell adhesion molecule E-cadherin was inhibitory. Moreover, expression of E-cadherin reconstituted the ability of the cells to form morphogenetic structures in matrigel cultures in response to HGF. These data demonstrate that HGF and neuregulin, which control branching or lobulo-alveolar morphogenesis of normal breast epithelium, do have metastasis-promoting effects on breast carcinoma cells. Moreover, our results suggest that the differential activities of the two factors can be explained by the degree of epithelial differentiation: induction of morphogenesis requires an intact epithelial adhesion and differentiation system, whereas induction of metastasis is observed when the cells have lost their epithelial characteristics.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Birchmeier, W (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.		Brinkmann, Volker/A-6015-2009					ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BECKER KF, 1994, CANCER RES, V54, P3845; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Boyer B, 1996, CURR TOP MICROBIOL, V213, P179; BRINGUIER PP, 1993, CANCER RES, V53, P3241; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; DANIEL CW, 1995, DEV BIOL, V169, P511, DOI 10.1006/dbio.1995.1165; DIRENZO MF, 1995, CANCER RES, V55, P1129; DORUDI S, 1993, AM J PATHOL, V142, P981; EBERT M, 1994, CANCER RES, V54, P5775; FERRACINI R, 1995, ONCOGENE, V10, P739; FIDLER IJ, 1990, CANCER RES, V50, P6130; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GAMALLO C, 1993, AM J PATHOL, V142, P987; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Gunthert U, 1996, CURR TOP MICROBIOL, V213, P271; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; HUMPHREY PA, 1995, AM J PATHOL, V147, P386; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Jeffers M, 1996, ONCOGENE, V13, P853; JOSEPH A, 1995, J NATL CANCER I, V87, P372, DOI 10.1093/jnci/87.5.372; KANDA H, 1993, ONCOGENE, V8, P3047; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Krane IM, 1996, ONCOGENE, V12, P1781; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LEONE A, 1993, ONCOGENE, V8, P2325; LIOTTA LA, 1988, CANCER SURV, V7, P631; MAYER B, 1993, CANCER RES, V53, P1690; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOLL R, 1993, AM J PATHOL, V143, P1731; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAIDU YM, 1994, P NATL ACAD SCI USA, V91, P5281, DOI 10.1073/pnas.91.12.5281; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; NIEMANN C, 1997, UNPUB J CELL BIOL; OTTO T, 1994, CANCER RES, V54, P3120; OYAMA T, 1994, CANCER RES, V54, P6282; PARK JB, 1989, CANCER RES, V49, P6605; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Powell WC, 1996, CURR TOP MICROBIOL, V213, P1; PRESS MF, 1994, CANCER RES, V54, P5675; PRICE JE, 1990, CANCER RES, V50, P717; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; REICHMANN E, 1994, SEMIN CANCER BIOL, V5, P157; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; RONG S, 1995, CANCER RES, V55, P1963; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; Silletti S, 1996, CURR TOP MICROBIOL, V213, P137; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SORIANO JV, 1995, J CELL SCI, V108, P413; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; UMBAS R, 1994, CANCER RES, V54, P3929; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zschiesche W, 1997, ANTICANCER RES, V17, P561	105	97	106	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	1998	16	1					9	20		10.1038/sj.onc.1201486	http://dx.doi.org/10.1038/sj.onc.1201486			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467938				2022-12-25	WOS:000071236800002
J	Corey, S; Krapivinsky, G; Krapivinsky, L; Clapham, DE				Corey, S; Krapivinsky, G; Krapivinsky, L; Clapham, DE			Number and stoichiometry of subunits in the native atrial G-protein-gated K(+) channel, I(KACh)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; ACETYLCHOLINE RECEPTORS; NEUROMUSCULAR-JUNCTIONS; VENTRICULAR MYOCYTES; CROSS-LINKING; SHAKER; GIRK1; DROSOPHILA; ACTIVATE; CURRENTS	The G-protein-regulated, inwardly rectifying K(+) (GIRK) channels are critical for functions as diverse as heart rate modulation and neuronal post-synaptic inhibition. GIRK channels are distributed predominantly throughout the heart, brain, and pancreas. In recent years, GIRK channels have received a great deal of attention for their direct G-protein beta gamma (G(beta gamma)) regulation. Native cardiac I(KACh) is composed of GIRK1 and GIRK4 subunits (Krapivinsky, G., Gordon, E. A., Wickman, K. A., Velimirovic, B., Krapivinsky, L., and Clapham, D. E. (1995) Nature 374, 135-141). Here, we examine the quaternary structure of I(KACh) using a variety of complementary approaches. Complete cross-linking of purified atrial I(KACh) protein formed a single adduct with a total molecular weight that was most consistent with a tetramer. In addition, partial cross-linking of purified I(KACh) produced subsets of molecular weights consistent with monomers, dimers, trimers, and tetramers. Within the presumed protein dimers, GIRK1-GIRK1 and GIRK4-GIRK4 adducts were formed, indicating that the tetramer was composed of two GIRK1 and two GIRK4 subunits. This 1:1 GIRK1 to GIRK4 stoichiometry was confirmed by two independent means, including densitometry of both silver-stained and Western-blotted native atrial I(KACh). Similar experimental results could potentially be obtained if GIRK1 and GIRK4 subunits assembled randomly as 2:2 and equally sized populations of 3:1 and 1:3 tetramers. We also show that GIRK subunits may form homotetramers in expression systems, although the evidence to date suggests that GIRK1 homotetramers are not functional. We conclude that the inwardly rectifying atrial K(+) channel, I(KACh), a prototypical GIRK channel, is a heterotetramer and is most likely composed of two GIRK1 subunits and two GIRK4 subunits.	Childrens Hosp, Howard Hughes Med Inst, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Mayo Clin & Mayo Fdn, Neurosci Program, Rochester, MN 55905 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Mayo Clinic	Clapham, DE (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Div Cardiovasc, 1309 Enders,320 Longwood Ave, Boston, MA 02115 USA.	clapham@rascal.med.harvard.edu	Clapham, David/R-5974-2019; Clapham, David/S-1123-2019	Clapham, David/0000-0002-4459-9428				ARIS JP, 1983, J BIOL CHEM, V258, P4599; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; FERTUCK HC, 1976, J CELL BIOL, V69, P144, DOI 10.1083/jcb.69.1.144; GAFFNEY BJ, 1985, BIOCHIM BIOPHYS ACTA, V822, P289, DOI 10.1016/0304-4157(85)90012-7; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Huang DH, 1997, BIOTECHNIQUES, V22, P454, DOI 10.2144/97223bm18; Inanobe A, 1995, BIOCHEM BIOPH RES CO, V217, P1238, DOI 10.1006/bbrc.1995.2901; ITO H, 1995, N-S ARCH PHARMACOL, V351, P610; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; Kennedy ME, 1996, NEUROPHARMACOLOGY, V35, P831, DOI 10.1016/0028-3908(96)00132-3; KOUMI SI, 1994, AM J PHYSIOL, V266, pH1812, DOI 10.1152/ajpheart.1994.266.5.H1812; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; LAND BR, 1980, P NATL ACAD SCI-BIOL, V77, P3736, DOI 10.1073/pnas.77.6.3736; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MATTHEWSBELLINGER J, 1978, J PHYSIOL-LONDON, V279, P197, DOI 10.1113/jphysiol.1978.sp012340; MCCORMACK K, 1992, BIOPHYS J, V63, P1406, DOI 10.1016/S0006-3495(92)81703-4; Mourrain P, 1997, P NATL ACAD SCI USA, V94, P10034, DOI 10.1073/pnas.94.19.10034; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; Pessia M, 1996, EMBO J, V15, P2980, DOI 10.1002/j.1460-2075.1996.tb00661.x; PETERS K, 1977, ANNU REV BIOCHEM, V46, P523, DOI 10.1146/annurev.bi.46.070177.002515; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; Silverman SK, 1996, J BIOL CHEM, V271, P30524, DOI 10.1074/jbc.271.48.30524; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; Tucker SJ, 1996, AM J PHYSIOL-HEART C, V271, pH379, DOI 10.1152/ajpheart.1996.271.1.H379; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7	39	91	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5271	5278		10.1074/jbc.273.9.5271	http://dx.doi.org/10.1074/jbc.273.9.5271			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478984	hybrid			2022-12-25	WOS:000072310400068
J	Gan, WN; La Celle, M; Rhoads, RE				Gan, WN; La Celle, M; Rhoads, RE			Functional characterization of the internal ribosome entry site of eIF4G mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCEPHALOMYOCARDITIS VIRUS-RNA; EUKARYOTIC PROTEIN-SYNTHESIS; 5' NONTRANSLATED REGION; TRACT-BINDING-PROTEIN; SYNTHESIS INITIATION FACTOR-EIF-4-GAMMA; CAP-INDEPENDENT TRANSLATION; MESSENGER-RNA; POLIOVIRUS RNA; IN-VITRO; NONCODING REGION	The eIF4 group initiation factors are required for cap-dependent translation initiation. Infection of mammalian cells by picornaviruses results in proteolytic cleavage of one of these factors, eIF4G, which severely restricts cap-dependent initiation but permits cap independent initiation to proceed from an internal ribosome entry site (IRES) in picornaviral RNAs. The first 357 nucleotides (nt) of the 5'-untranslated region of eIF4G mRNA also contains an IRES, Using bicistronic constructs for expression in K562 cells, we have now shown that progressive deletions of the 5'-untranslated region can have either stimulatory or inhibitory effects. Furthermore, a 101-nt segment exhibits full IRES activity, and an 81-nt segment exhibits detectable IRES activity. A polypyrimidine tract (PPT) at the 3' terminus is essential for internal initiation, a property which is characteristic of picornaviral IRESs but not the other host cellular IRESs studied to date. IRES activity does not require sequences beyond 357 nt. Out-of-frame AUGs have no effect on IRES-driven luciferase expression when introduced upstream of the PPT but markedly decrease expression when introduced at sites between the PPT and the authentic initiation codon at nt 369. These results suggest that the ribosomal subunit enters at or near the PPT and then scans downstream for the initiation codon.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Rhoads, RE (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.				NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLIOZ C, 1995, J VIROL, V69, P2214, DOI 10.1128/JVI.69.4.2214-2222.1995; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BORMAN AM, 1994, EMBO J, V13, P3149, DOI 10.1002/j.1460-2075.1994.tb06613.x; Borman AM, 1997, RNA, V3, P186; BOROVJAGIN A, 1994, FEBS LETT, V351, P299, DOI 10.1016/0014-5793(94)00848-5; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BROWN EA, 1994, J VIROL, V68, P1066, DOI 10.1128/JVI.68.2.1066-1074.1994; CHOMCYNSKI P, 1991, CURRENT PROTOCOLS MO; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; ETCHISON D, 1985, J VIROL, V54, P634, DOI 10.1128/JVI.54.2.634-638.1985; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; EVSTAFIEVA AG, 1991, NUCLEIC ACIDS RES, V19, P665, DOI 10.1093/nar/19.3.665; FUKUSHI S, 1994, BIOCHEM BIOPH RES CO, V199, P425, DOI 10.1006/bbrc.1994.1246; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; GLASS MJ, 1993, VIROLOGY, V193, P842, DOI 10.1006/viro.1993.1193; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; Kaminski A, 1995, RNA, V1, P924; KAMINSKI A, 1994, EMBO J, V13, P1673, DOI 10.1002/j.1460-2075.1994.tb06431.x; KINGSTON RE, 1994, CURRENT PROTOCOLS MO; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUGE S, 1989, J MOL BIOL, V207, P175, DOI 10.1016/0022-2836(89)90448-8; KUGE S, 1987, J VIROL, V61, P1478, DOI 10.1128/JVI.61.5.1478-1487.1987; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; LIU DX, 1992, J VIROL, V66, P6143, DOI 10.1128/JVI.66.10.6143-6154.1992; LLOYD RE, 1988, J VIROL, V62, P4216, DOI 10.1128/JVI.62.11.4216-4223.1988; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MADER S, 1995, MOL CELL BIOL, V15, P4990; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; NICHOLSON R, 1991, J VIROL, V65, P5886, DOI 10.1128/JVI.65.11.5886-5894.1991; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; PESTOVA TV, 1991, J VIROL, V65, P6194, DOI 10.1128/JVI.65.11.6194-6204.1991; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; PILIPENKO EV, 1994, J MOL BIOL, V241, P398, DOI 10.1006/jmbi.1994.1516; POYRY T, 1992, J VIROL, V66, P5313; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELDEN RF, 1994, CURRENT PROTOCOLS MO; SVITKIN YV, 1994, J VIROL, V68, P1544, DOI 10.1128/JVI.68.3.1544-1550.1994; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; Titus DE, 1991, PROMEGA PROTOCOLS AP; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; WHETTER LE, 1994, J VIROL, V68, P5253, DOI 10.1128/JVI.68.8.5253-5263.1994; YAN RQ, 1992, J BIOL CHEM, V267, P23226; Ye X, 1997, MOL CELL BIOL, V17, P1714, DOI 10.1128/MCB.17.3.1714; ZHANG Y, 1989, J BIOL CHEM, V264, P10679	57	68	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5006	5012		10.1074/jbc.273.9.5006	http://dx.doi.org/10.1074/jbc.273.9.5006			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478948	hybrid			2022-12-25	WOS:000072310400032
J	Lee, YJ; Galoforo, SS; Berns, CM; Chen, JC; Davis, BH; Sim, JE; Corry, PM; Spitz, DR				Lee, YJ; Galoforo, SS; Berns, CM; Chen, JC; Davis, BH; Sim, JE; Corry, PM; Spitz, DR			Glucose deprivation-induced cytotoxicity and alterations in mitogen-activated protein kinase activation are mediated by oxidative stress in multidrug-resistant human breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASES; HYDROGEN-PEROXIDE; C-FOS; GROWTH; PHOSPHORYLATION; SUPEROXIDE; PATHWAY; ACID; EXPRESSION; METABOLISM	We previously observed that glucose deprivation induces cell death in multidrug-resistant human breast carcinoma cells (MCF-7/ADR), As a follow up we wished to test the hypothesis that metabolic oxidative stress was the causative process or at least the link between causative processes behind the cytotoxicity. In the studies described here, we demonstrate that mitogen-activated protein kinase (MAPK) was activated within 3 min of being in glucose-free medium and remained activated for 3 h, Glucose deprivation for 2-4 h also caused oxidative stress as evidenced by a 3-fold greater steady state concentration of oxidized glutathione and a 3-fold increase in pro-oxidant production, Glucose and glutamate treatment rapidly suppressed MAPK activation and rescued cells from cytotoxicity, Glutamate and the peroxide scavenger, pyruvate, rescued the cells from cell killing as well as suppressed pro-oxidant production, In addition the thiol antioxidant, N-acetyl-L-cysteine, rescued cells from glucose deprivation-induced cytotoxicity and suppressed MAPK activation, These results suggest that glucose deprivation-induced cytotoxicity and alterations in MAPK signal transduction are mediated by oxidative stress in MCF-7/ADR. These results also support the speculation that a common mechanism of glucose deprivation-induced cytotoxicity in mammalian cells may involve metabolic oxidative stress.	William Beaumont Hosp, Dept Radiat Oncol, Res Labs, Royal Oak, MI 48073 USA; William Beaumont Hosp, Dept Clin Pathol, Royal Oak, MI 48073 USA; Washington Univ, Sch Med, Radiat Oncol Ctr, Sect Canc Biol, St Louis, MO 63108 USA	Beaumont Health; Beaumont Health; Washington University (WUSTL)	Lee, YJ (corresponding author), William Beaumont Hosp, Dept Radiat Oncol, Res Labs, 3601 W 13 Mile Rd, Royal Oak, MI 48073 USA.			Spitz, Douglas/0000-0002-1254-8765	NATIONAL CANCER INSTITUTE [R01CA044550, R37CA044550, R01CA048000] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051469] Funding Source: NIH RePORTER; NCI NIH HHS [CA48000, CA44550] Funding Source: Medline; NHLBI NIH HHS [HL51469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson ME, 1985, HDB METHODS OXYGEN R, P317; AVERILLBATES DA, 1994, ARCH BIOCHEM BIOPHYS, V312, P52, DOI 10.1006/abbi.1994.1279; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOVERIS A, 1975, FEBS LETT, V54, P311, DOI 10.1016/0014-5793(75)80928-8; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; CHENG B, 1995, J NEUROSCI, V15, P7095; COHEN JS, 1987, ANN NY ACAD SCI, V508, P216, DOI 10.1111/j.1749-6632.1987.tb32906.x; Crawford DR, 1996, FREE RADICAL BIO MED, V21, P521, DOI 10.1016/0891-5849(96)00160-8; EIGENBRODT E, 1985, REGULATION CARBOHYDR, V2, P141; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FORREST VJ, 1994, FREE RADICAL BIO MED, V16, P675, DOI 10.1016/0891-5849(94)90182-1; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Gupta AK, 1997, MOL CELL BIOCHEM, V170, P23, DOI 10.1023/A:1006890316102; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Lee YJ, 1997, J CELL SCI, V110, P681; Liu X, 1997, J BIOL CHEM, V272, P11690, DOI 10.1074/jbc.272.18.11690; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MERRALL NW, 1993, BIOCHEM J, V295, P351, DOI 10.1042/bj2950351; MUINDI JRF, 1986, P AM ASSOC CANC RES, V27, P272; NATH KA, 1995, AM J PHYSIOL, V26, pC227; OBERLEY LW, 1984, J THEOR BIOL, V106, P403, DOI 10.1016/0022-5193(84)90038-9; OBERLEY LW, 1981, MED HYPOTHESES, V7, P21, DOI 10.1016/0306-9877(81)90018-9; OLIVER BL, 1995, P SOC EXP BIOL MED, V210, P162; Pennisi E, 1997, SCIENCE, V275, P1567, DOI 10.1126/science.275.5306.1567; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; STEVENSON MA, 1994, CANCER RES, V54, P12; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Walker J M, 1984, Methods Mol Biol, V1, P57, DOI 10.1385/0-89603-062-8:57; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	42	198	201	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5294	5299		10.1074/jbc.273.9.5294	http://dx.doi.org/10.1074/jbc.273.9.5294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478987	hybrid			2022-12-25	WOS:000072310400071
J	Moallem, E; Kilav, R; Silver, J; Naveh-Many, T				Moallem, E; Kilav, R; Silver, J; Naveh-Many, T			RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; MESSENGER-RNA; IN-VITRO; NUCLEOTIDE-SEQUENCE; POSTTRANSCRIPTIONAL REGULATION; EXTRACELLULAR CALCIUM; UNTRANSLATED REGION; PTH SECRETION; RAT; CELLS	Parathyroid hormone (PTH) regulates serum calcium and phosphate levels, which, in turn, regulate PTH secretion and mRNA levels, PTH mRNA levels are markedly increased in rats fed low calcium diets and decreased after low phosphate diets, and this effect is posttranscriptional. Protein-PTH mRNA binding studies, with parathyroid cytosolic proteins, showed three protein-RNA bands, This binding was to the 3'-untranslated region (UTR) of the PTH mRNA and was dependent upon the terminal 60 nucleotides. Parathyroid proteins from hypocalcemic rats showed increased binding, and proteins from hypophosphatemic rats decreased binding, correlating with PTH mRNA levels, There is no parathyroid cell line; however, a functional role was provided by an in vitro degradation assay. Parathyroid proteins from control rats incubated with a PTH mRNA probe led to an intact transcript for 40 min; the transcript was intact with hypocalcemic proteins for 180 min and with hypophosphatemic proteins only for 5 min, A PTH mRNA probe without the 3'-UTR, or just the terminal 60 nucleotides, incubated with hypophosphatemic proteins, showed no degradation at all, indicating that the sequences in the 3'-UTR determine PTH mRNA degradation, Hypocalcemia and hypophosphatemia regulate PTH gene expression post-transcriptionally, This correlates with binding of proteins to the PTR mRNA 3'-UTR, which determines its stability.	Hadassah Univ Hosp, Serv Nephrol, Minerva Ctr Calcium & Bone Metab, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Silver, J (corresponding author), Hadassah Univ Hosp, Serv Nephrol, Minerva Ctr Calcium & Bone Metab, POB 12000, IL-91120 Jerusalem, Israel.							Agy MB, 1996, VIROLOGY, V217, P158, DOI 10.1006/viro.1996.0103; Almaden Y, 1996, J BONE MINER RES, V11, P970; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CARRAZANA EJ, 1988, MOL CELL BIOL, V8, P2267, DOI 10.1128/MCB.8.6.2267; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DODSON RE, 1994, MOL CELL BIOL, V14, P3130, DOI 10.1128/MCB.14.5.3130; HAWA NS, 1993, J MOL ENDOCRINOL, V10, P43, DOI 10.1677/jme.0.0100043; KEMPER B, 1986, CRIT REV BIOCHEM MOL, V19, P353, DOI 10.3109/10409238609082545; KILAV R, 1995, J CLIN INVEST, V96, P327, DOI 10.1172/JCI118038; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KRIKORIAN CR, 1991, J VIROL, V65, P112, DOI 10.1128/JVI.65.1.112-122.1991; KRONENBERG HM, 1979, P NATL ACAD SCI USA, V76, P4981, DOI 10.1073/pnas.76.10.4981; LEEDMAN PJ, 1995, MOL ENDOCRINOL, V9, P375, DOI 10.1210/me.9.3.375; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; NAVEHMANY T, 1992, J CLIN INVEST, V90, P2434, DOI 10.1172/JCI116134; NAVEHMANY T, 1990, J CLIN INVEST, V86, P1313, DOI 10.1172/JCI114840; Nielsen PK, 1996, NEPHROL DIAL TRANSPL, V11, P1762; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; OKAZAKI T, 1992, J CLIN INVEST, V89, P1268, DOI 10.1172/JCI115711; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; SCHMELZER HJ, 1987, NUCLEIC ACIDS RES, V15, P6740, DOI 10.1093/nar/15.16.6740; SILVER J, 1996, PRINCIPLES BONE BIOL; Slatopolsky E, 1996, J CLIN INVEST, V97, P2534, DOI 10.1172/JCI118701; THEIL EC, 1994, BIOCHEM J, V304, P1; Vadher S, 1996, J BONE MINER RES, V11, P746; VASICEK TJ, 1983, P NATL ACAD SCI-BIOL, V80, P2127, DOI 10.1073/pnas.80.8.2127	29	212	220	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5253	5259		10.1074/jbc.273.9.5253	http://dx.doi.org/10.1074/jbc.273.9.5253			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478982	hybrid			2022-12-25	WOS:000072310400066
J	Park, K; Debyser, Z; Tabor, S; Richardson, CC; Griffith, JD				Park, K; Debyser, Z; Tabor, S; Richardson, CC; Griffith, JD			Formation of a DNA loop at the replication fork generated by bacteriophage T7 replication proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAGGING-STRAND SYNTHESIS; NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; COORDINATED LEADING-STRAND; RNA PRIMER SYNTHESIS; ESCHERICHIA-COLI; GENE-4 PROTEIN; DEOXYRIBONUCLEIC-ACID; PRIMASE-HELICASE; BINDING-PROTEIN; POLYMERASE ACTIVITY	Intermediates in the replication of circular and linear M13 double-stranded DNA by bacteriophage T7 proteins have been examined by electron microscopy. Synthesis generated double-stranded DNA molecules containing a single replication fork with a linear duplex tail, A complex presumably consisting of T7 DNA polymerase and gene 4 helicase/primase molecules was present at the fork together with a variable amount of single-stranded DNA sequestered by gene 2.5 single-stranded DNA binding protein, Analysis of the length distribution of Okazaki fragments formed at different helicase/primase concentrations was consistent with coupling of leading and lagging strand replication, Fifteen to forty percent of the templates engaged in replication have a DNA loop at the replication fork, The loops are fully double-stranded with an average length of similar to 1 kilobase, Labeling with biotinylated dCTP showed that the loops consist of newly synthesized DNA, and synchronization experiments using a linear template with a G-less cassette demonstrated that the loops are formed by active displacement of the lagging strand, A long standing feature of models for coupled leading/lagging strand replication has been the presence of a DNA loop at the replication fork, This study provides the first direct demonstration of such loops.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Harvard Medical School	Griffith, JD (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline; NIGMS NIH HHS [GM 31819] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1975, DNA SYNTHESIS ITS RE, P241; ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHASE JW, 1980, NUCLEIC ACIDS RES, V8, P3215, DOI 10.1093/nar/8.14.3215; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; EISENBERG S, 1977, P NATL ACAD SCI USA, V74, P3198, DOI 10.1073/pnas.74.8.3198; ENGLER MJ, 1983, J BIOL CHEM, V258, P1197; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HUBER HE, 1987, J BIOL CHEM, V262, P16224; HUBER HE, 1988, CANCER CELL, V6, P11; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15022; KOLODNER R, 1978, J BIOL CHEM, V253, P566; Kong DC, 1996, EMBO J, V15, P2010, DOI 10.1002/j.1460-2075.1996.tb00552.x; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MODRICH P, 1975, J BIOL CHEM, V250, P5508; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9818; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; NOSSAL NG, 1983, BACTERIOPHAGE T, V4, P71; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; REGISTER JC, 1986, P NATL ACAD SCI USA, V83, P624, DOI 10.1073/pnas.83.3.624; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; SELICK HE, 1987, DNA REPLICATION RECO, V47, P183; SINHA NK, 1980, J BIOL CHEM, V255, P4290; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	51	50	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5260	5270		10.1074/jbc.273.9.5260	http://dx.doi.org/10.1074/jbc.273.9.5260			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478983	Green Published, hybrid			2022-12-25	WOS:000072310400067
J	Xing, S; Furminger, TL; Tong, Q; Jhiang, SM				Xing, S; Furminger, TL; Tong, Q; Jhiang, SM			Signal transduction pathways activated by RET oncoproteins in PC12 pheochromocytoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; NERVE GROWTH-FACTOR; TRANSFORMING ACTIVITY; RET/PTC ONCOGENE; ADAPTER PROTEINS; PROMOTER REGION; PROTOONCOGENE; GENE; ASSOCIATION; EXPRESSION	Gene alterations in the ret proto-oncogene, which encodes a receptor tyrosine kinase, have been found to associate with several human diseases. In this study, we showed that induction of the vgf promoter activity is a good molecular indicator for RET activation in PC12 cells, a rat pheochromocytoma cell line. We demonstrated that all forms of RET oncoprotein, including RET chimeric oncoproteins found in human papillary thyroid carcinomas (RET/PTC) as well as RET oncoproteins found in patients with multiple endocrine neoplasia type 2A and 2B (2A/RET and 2B/RET) can induce vgf promoter activity in PC12 cells. In contrast, a RET mutant found in a patient with Hirschsprung's disease, as well as a RET/PTC1 mutant with deletion of the dimerization domain, failed to induce vgf promoter activity in PC12 cells. We further determined that the signaling events mediated by phosphorylated Tyr(294) and phosphorylated Tyr(451) binding sites are essential for RET/PTC1 to induce vgf promoter activity in PC12 cells. We also showed that RET/PTC1, 2A/RET, and 2B/RET induce ELK-, cAMP-responsive element binding protein (CREB), or JUN-mediated gene expression in PC12 cells, and these three signaling events are mediated by phosphorylated Tyr(294) and phosphorylated Tyr(451) binding sites in RET/PTC1.	Ohio State Univ, Dept Physiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Grad Program, Columbus, OH 43210 USA	Ohio State University; Ohio State University; Ohio State University	Jhiang, SM (corresponding author), Ohio State Univ, Dept Physiol, 302 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.				NCI NIH HHS [R29 CA60074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; BURRY RW, 1993, J NEUROSCI RES, V36, P241, DOI 10.1002/jnr.490360302; CALIFANO D, 1995, ONCOGENE, V11, P107; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; ITOH F, 1989, Tumor Research, V24, P1; Iwashita T, 1996, ONCOGENE, V12, P481; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; TONG Q, 1995, ONCOGENE, V10, P1781; Tong Q, 1997, J BIOL CHEM, V272, P9043; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Xing SH, 1996, ENDOCRINOLOGY, V137, P1512, DOI 10.1210/en.137.5.1512	41	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4909	4914		10.1074/jbc.273.9.4909	http://dx.doi.org/10.1074/jbc.273.9.4909			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478934	hybrid			2022-12-25	WOS:000072310400018
J	Boylan, JM; Gruppuso, PA				Boylan, JM; Gruppuso, PA			Uncoupling of hepatic, epidermal growth factor-mediated mitogen-activated protein kinase activation in the fetal rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; INSULIN; DESENSITIZATION; HEPATOCYTES; GRB2-SOS; CASCADE; 3CH134; STRESS; CELLS	Stimulation of cell proliferation by mitogens involves tyrosine phosphorylation of proteins at the cell membrane by receptor tyrosine kinases. This promotes formation of multi-protein complexes that can activate the small G-protein, Ras. Activation of Ras, in turn, leads to sequential activation of the following three serine-threonine kinases: Raf, extracellular signal-regulated kinase kinase (MEK), and members of the family of mitogen-activated protein (MAP) kinases. Prior studies have shown that intraperitoneal injection of epidermal growth factor (EGF) leads to rapid activation of hepatic MAP kinases in adult rats but not in late gestation (E19) fetal rats (Boylan, J. M., and Gruppuso, P. A. (1996) Cell Growth & Differ. 7, 1261-1269). The present studies were undertaken to determine the mechanism for this "uncoupling" of the MAP kinase pathway. E19 fetal rats and adult male rats were injected with EGF (0.5 mu g/g body weight, intraperitoneally) or with saline. After 15 min, livers were removed and prepared for kinase analyses, EGF injection led to a rapid and marked activation of hepatic Raf and MEK in both fetal and adult rats, whereas MAP kinase activation was minimal in fetal as opposed to adult rats. Examination of the ontogeny of this dissociation of MAP kinase activation from MEK activation showed gradual acquisition of intact signaling as an adult hepatocyte phenotype was attained during the first 4 postnatal weeks. Over this period, MAP kinase content as determined by Western immunoblotting was constant, Recombination experiments using partially purified fetal and adult rat liver MEK and MAP kinase showed intact MAP kinase activation in vitro, indicating that neither enzyme was irreversibly altered in the fetus, In studies using primary cultures of E19 fetal rat hepatocytes, uncoupling of MAP kinase activation from MEK activation could be induced by incubation of fetal hepatocytes for 24 h with a potent fetal hepatocyte mitogen, transforming growth factor-alpha. These findings indicate that a novel negative feedback mechanism for MAP kinase regulation may be active in developing rat hepatocytes.	Rhode Isl Hosp, Dept Pediat, Div Pediat Endocrinol & Metab, Providence, RI 02903 USA; Brown Univ, Providence, RI 02903 USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University	Gruppuso, PA (corresponding author), Rhode Isl Hosp, Dept Pediat, Div Pediat Endocrinol & Metab, 593 Eddy St, Providence, RI 02903 USA.	Philip_Gruppuso@brown.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD024455] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD011343, P01HD011343] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24455, HD11343] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOYLAN JM, 1994, AM J PHYSIOL-GASTR L, V267, pG1078, DOI 10.1152/ajpgi.1994.267.6.G1078; Boylan JM, 1996, CELL GROWTH DIFFER, V7, P1261; BUDAY L, 1995, ONCOGENE, V11, P1327; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CURRAN TR, 1993, EXP CELL RES, V209, P53, DOI 10.1006/excr.1993.1284; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRUPPUSO PA, 1994, ENDOCRINOLOGY, V134, P769, DOI 10.1210/en.134.2.769; GRUPPUSO PA, 1989, AM J PHYSIOL, V256, pE49, DOI 10.1152/ajpendo.1989.256.1.E49; GRUPPUSO PA, 1995, J CELL BIOCHEM, V58, P65, DOI 10.1002/jcb.240580109; GRUPPUSO PA, 1992, PERINATAL BIOCH, P194; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KRAUTWALD S, 1995, ONCOGENE, V10, P1187; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Lipeski LE, 1996, BIOCHEM MOL BIOL INT, V39, P975; NAEYE RL, 1965, PEDIATRICS, V35, P980; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	28	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3784	3790		10.1074/jbc.273.6.3784	http://dx.doi.org/10.1074/jbc.273.6.3784			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452512	hybrid			2022-12-25	WOS:000071822300097
J	Decoster, E; Vanhaesebroeck, B; Boone, E; Plaisance, S; De Vos, K; Haegeman, G; Grooten, J; Fiers, W				Decoster, E; Vanhaesebroeck, B; Boone, E; Plaisance, S; De Vos, K; Haegeman, G; Grooten, J; Fiers, W			Induction of unresponsiveness to tumor necrosis factor (TNF) after autocrine TNF expression requires TNF membrane retention	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA PRECURSOR; CELL-LINE; FACTOR RECEPTORS; RESISTANCE; INHIBITOR; PROTEIN; CYTOTOXICITY; VECTORS; LIGAND; GROWTH	Tumor necrosis factor (TNF) has a specific gene-inducing activity on many cell types and exerts a cytotoxic effect on a number of tumor cell lines. However, several tumor cell types are resistant to TNF-induced effects, and some of these produce TNF. We previously demonstrated that introduction of an exogenous TNF gene in the TNF-sensitive cell line L929sA induced autocrine TNF production and unresponsiveness to the cytotoxic activity of TNF, This resistance required biologically active TNF and was correlated with complete down-modulation of the TNF receptors on the cell surface. We have now characterized this process in more detail. The role of expression of the membrane-bound TNF preform and its subsequent proteolytic processing in the induction of TNF unresponsiveness was investigated. Exchange of the TNF presequence for the signal sequence of interleukin-6 resulted in production of secreted TNF, but not in induction of TNF resistance. On the other hand, expression of non-secretable, membrane-bound TNF generated complete TNF unresponsiveness. To explore whether the requirement for anchoring reflected a specific functional role of the TNF presequence, the latter was replaced by the membrane anchor of trimeric chicken hepatic lectin. Expression of this construct induced complete TNF unresponsiveness. Hence, the role of the TNF presequence in the induction of TNF unresponsiveness only involves its function as a membrane anchor, which permits oligomerization of the TNF molecule into a biologically active homotrimer.	Flanders Interuniv Inst Biotechnol, Mol Biol Lab, B-9000 Ghent, Belgium; State Univ Ghent, B-9000 Ghent, Belgium	Ghent University	Fiers, W (corresponding author), Flanders Interuniv Inst Biotechnol, Mol Biol Lab, KL Ledeganckstr 35, B-9000 Ghent, Belgium.		De Vos, Kurt/D-8380-2011; Plaisance, Stephane/ABI-6307-2020; Plaisance, Stephane/B-3488-2009	De Vos, Kurt/0000-0003-2161-6309; Plaisance, Stephane/0000-0002-1651-241X; Plaisance, Stephane/0000-0002-1651-241X				Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BEYAERT R, 1993, CANCER RES, V53, P2623; CHIACCHIA KB, 1984, J BIOL CHEM, V259, P5440; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; DING AH, 1989, J BIOL CHEM, V264, P3924; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; Fiers W, 1995, BIOL THERAPY CANC, P295; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HIMENO T, 1990, CANCER RES, V50, P4941; HUYLEBROECK D, 1988, GENE, V66, P163, DOI 10.1016/0378-1119(88)90354-X; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LLEONART R, 1990, BIO-TECHNOL, V8, P1263, DOI 10.1038/nbt1290-1263; LUCAS R, 1994, SCIENCE, V263, P814, DOI 10.1126/science.8303299; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MELLOW TE, 1988, J BIOL CHEM, V263, P5468; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; NAKAMURA S, 1991, AGR BIOL CHEM TOKYO, V55, P53, DOI 10.1080/00021369.1991.10870533; OKAMOTO T, 1992, CANCER RES, V52, P5278; PATESTOS NP, 1993, BIOCHIMIE, V75, P1007, DOI 10.1016/0300-9084(93)90153-J; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; ROSEJOHN S, 1993, J BIOL CHEM, V268, P22084; RUBIN BY, 1986, J EXP MED, V164, P1350, DOI 10.1084/jem.164.4.1350; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPRIGGS D, 1987, P NATL ACAD SCI USA, V84, P6563, DOI 10.1073/pnas.84.18.6563; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STEER CJ, 1990, J BIOL CHEM, V265, P3744; STEVENSON FT, 1992, J EXP MED, V176, P1053, DOI 10.1084/jem.176.4.1053; Tang P, 1996, BIOCHEMISTRY-US, V35, P8216, DOI 10.1021/bi952182t; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VANHAESEBROECK B, 1991, CANCER RES, V51, P2469; VANHAESEBROECK B, 1992, J IMMUNOL, V148, P2785; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H	38	14	14	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3271	3277		10.1074/jbc.273.6.3271	http://dx.doi.org/10.1074/jbc.273.6.3271			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452442	hybrid			2022-12-25	WOS:000071822300027
J	Johansson, J; Gudmundsson, GH; Rottenberg, ME; Berndt, KD; Agerberth, B				Johansson, J; Gudmundsson, GH; Rottenberg, ME; Berndt, KD; Agerberth, B			Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; EPITHELIAL-CELLS; PIG INTESTINE; BONE-MARROW; PROTEIN; PR-39; ANTIBIOTICS; NEUTROPHILS; EXPRESSION; DEFENSINS	The influence of ion composition, pH, and peptide concentration on the conformation and activity of the 37-residue human antibacterial peptide LL-37 has been studied. At micromolar concentration in water, LL-37 exhibits a circular dichroism spectrum consistent with a disordered structure. The addition of 15 mM HCO3-, SO42-, or CF3CO2- causes the peptide to adopt a helical structure, with approximately equal efficiency, while 160 mM Cl- is less efficient, A cooperative transition from disordered to helical structure is observed as the peptide concentration is increased, consistent with formation of an oligomer, The extent of alpha-helicity correlates with the antibacterial activity of LL-37 against both Gram-positive and Gram-negative bacteria. Two homologous peptides, FF-33 and SK-29, containing 4 and 8 residue deletions at the N terminus, respectively, require higher concentrations of anions for helix formation and are less active than LL 37 against Escherichia coli D21. Below pH 5, the helical content of LL-37 gradually decreases, and at pH 2 it is entirely disordered, In contrast, the helical structure is retained at pH over 13. The minimal inhibitory concentration of LL-37 against E. coli is 5 mu M, and at 13-25 mu M the peptide is cytotoxic against several eukaryotic cells, In solutions containing the ion compositions of plasma, intracellular fluid, or interstitial fluid, LL-37 is helical, and hence it could pose a danger to human cells upon release. However, in the presence of human serum, the antibacterial and the cytotoxic activities of LL-37 are inhibited.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Agerberth, B (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Doktorsringen 9A3, S-17177 Stockholm, Sweden.		Berndt, Kurt/J-8574-2015; Gudmundsson, Gudmundur H/K-9178-2015	Berndt, Kurt/0000-0002-3049-967X; Gudmundsson, Gudmundur H/0000-0001-5793-0565; Rottenberg, Martin/0000-0003-0514-7434; Johansson, Jan/0000-0002-8719-4703				AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; Baldwin RL, 1996, BIOPHYS J, V71, P2056, DOI 10.1016/S0006-3495(96)79404-3; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1993, INFECT IMMUN, V61, P2978, DOI 10.1128/IAI.61.7.2978-2984.1993; CABIAUX V, 1994, EUR J BIOCHEM, V224, P1019, DOI 10.1111/j.1432-1033.1994.01019.x; CREIGHTON TE, 1993, PROTEINS STRUCTURE M, P262; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; FERNLUND P, 1991, LAURELLS KLINISK KEM, P59; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GREENFIELD N, 1969, BIOCHEMISTRY-US, V8, P108; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; HOLTZER ME, 1992, BIOPOLYMERS, V32, P1675, DOI 10.1002/bip.360321209; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; MORRISET.JD, 1973, BIOCHEMISTRY-US, V12, P1290, DOI 10.1021/bi00731a008; NORDEN MA, 1995, J CLIN MICROBIOL, V33, P1231, DOI 10.1128/JCM.33.5.1231-1237.1995; PANYUTICH A, 1991, AM J RESP CELL MOL, V5, P101, DOI 10.1165/ajrcmb/5.2.101; Popsueva AE, 1996, FEBS LETT, V391, P5, DOI 10.1016/0014-5793(96)00692-8; ROMEO D, 1988, J BIOL CHEM, V263, P9573; SCHLUESENER HJ, 1993, J NEUROIMMUNOL, V47, P199, DOI 10.1016/0165-5728(93)90030-3; Scholtz J. Martin, 1995, P171, DOI 10.1016/B978-012310920-0/50005-X; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; Skerlavaj B, 1996, J BIOL CHEM, V271, P28375, DOI 10.1074/jbc.271.45.28375; STEINER H, 1988, BIOCHIM BIOPHYS ACTA, V939, P260, DOI 10.1016/0005-2736(88)90069-7; TALIAFERRO WH, 1955, J INFECT DIS, V96, P199, DOI 10.1093/infdis/96.3.199; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4	37	495	522	0	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3718	3724		10.1074/jbc.273.6.3718	http://dx.doi.org/10.1074/jbc.273.6.3718			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452503	hybrid			2022-12-25	WOS:000071822300088
J	Nicol, R; Stavnezer, E				Nicol, R; Stavnezer, E			Transcriptional repression by v-Ski and c-Ski mediated by a specific DNA binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; COMPLEX-FORMATION; ONCOGENE ENCODES; PROTEIN; SEQUENCE; CELLS; DOMAIN; ACTIVATION; ENHANCER; FAMILY	The Ski oncoprotein has been shown to bind DNA and activate transcription in conjunction with other cellular factors, Because tumor cells or myogenic cells were used for those studies, it is not clear that those activities of Ski are related to its transforming ability, In this study, we use a nuclear extract of c-ski-transformed cells to identify a specific DNA binding site for Ski with the consensus sequence GTCTAGAC. We demonstrate that both c-Ski and v-Ski in nuclear extracts are components of complexes that bind specifically to this site. By evaluating the features of the sequence that are critical for binding, we show that binding is cooperative. Although Ski cannot bind to this sequence on its own, we use cross-linking with ultraviolet light to show that Ski binds to this site along with several unidentified cellular proteins, Furthermore, we find that Ski represses transcription either through upstream copies of this element or when brought to the promoter by a heterologous DNA binding domain. This is the first demonstration that Ski acts as a repressor rather than an activator and could provide new insights into regulation of gene expression by Ski.	Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	Case Western Reserve University; University System of Ohio; University of Cincinnati	Stavnezer, E (corresponding author), 10900 Euclid Ave, Cleveland, OH 44106 USA.	exs44@po.cwru.edu			NCI NIH HHS [CA-43600] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043600] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; ENGERT JC, 1995, NUCLEIC ACIDS RES, V23, P2988, DOI 10.1093/nar/23.15.2988; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KELDER B, 1998, IN PRESS GENE AMST; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; LARSEN J, 1992, ONCOGENE, V7, P1903; LARSEN J, 1993, ONCOGENE, V8, P3221; Liang SD, 1996, MOL CELL BIOL, V16, P3773; MERTZ LM, 1994, ANAL BIOCHEM, V221, P160, DOI 10.1006/abio.1994.1392; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SMITH GH, 1986, ANAL BIOCHEM, V156, P17, DOI 10.1016/0003-2697(86)90147-8; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; Tarapore P, 1997, NUCLEIC ACIDS RES, V25, P3895, DOI 10.1093/nar/25.19.3895; WILLIAMS KR, 1991, METHOD ENZYMOL, V208, P516; WOLFFE AP, 1997, ANTURE, V387, P16; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; Zheng GX, 1997, ONCOGENE, V15, P459, DOI 10.1038/sj.onc.1201205; Zhong HL, 1997, J BIOL CHEM, V272, P8402, DOI 10.1074/jbc.272.13.8402; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995	48	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3588	3597		10.1074/jbc.273.6.3588	http://dx.doi.org/10.1074/jbc.273.6.3588			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452486	hybrid			2022-12-25	WOS:000071822300071
J	Noguchi, Y; Nakamura, S; Yasuda, T; Kitagawa, M; Kohn, LD; Saito, Y; Hirai, A				Noguchi, Y; Nakamura, S; Yasuda, T; Kitagawa, M; Kohn, LD; Saito, Y; Hirai, A			Newly synthesized Rho A, not Ras, is isoprenylated and translocated to membranes coincident with progression of the G(1) to S phase of growth-stimulated rat FRTL-5 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; GDP DISSOCIATION INHIBITOR; COENZYME-A REDUCTASE; REGULATORY PROTEIN; CYCLE PROGRESSION; C-TERMINUS; THYROTROPIN; TRANSITION; EXPRESSION; FARNESYL	Ras and Rho are involved in the regulation of signal transduction events governing cell growth and cell proliferation. Protein prenylation is essential for the activation and/or the translocation of these small GTPases; however, protein geranylgeranylation rather than farnesylation is required for G(1)/S transition. We studied prenylation and translocation of Ras and Rho A during G(1)/S progression in growth-stimulated rat thyroid FRTL-5 cells. Immunoblot analysis revealed that both Ras and Rho A were detected in membrane fractions at G(0). Rho A was eliminated from the membrane fraction during G(1) and was not detected on the membrane at mid-G(1). Translocation of Rho A from the cytoplasm back to the membranes was observed during late G(1) phase. In contrast, Ras remains in the membrane fraction through the cell cycle progression from G(1) to S phase. The immunoprecipitation of Rho A from the membrane fraction demonstrated that newly synthesized Rho A, labeled by pulsing cells with [S-35]methionine and [S-35]cysteine, was geranylgeranylated and associated with the membrane in late G(1). These results indicate that Rho A, not Ras, was eliminated from membrane fraction during G(1) progression and that newly synthesized Rho A is geranylgeranylated and translocated to membranes during G(1)/S progression in growth-stimulated FRTL-5 cells.	Chiba Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Chiba 260, Japan; Okayama Univ, Sch Med, Inst Cellular & Mol Biol, Dept Cell Chem, Okayama 700, Japan; Kyusyu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 81282, Japan; NIDDK, Cell Regulat Sect, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	Chiba University; Okayama University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hirai, A (corresponding author), Chiba Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 1-8-1 Inohana Cho, Chiba 260, Japan.	aizan@med.m.chiba-u.ac.jp						ARAKI S, 1990, J BIOL CHEM, V265, P13007; ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHAKRABARTI R, 1991, J BIOL CHEM, V266, P12216; FARRELL FX, 1993, BIOCHEM J, V289, P349, DOI 10.1042/bj2890349; FUJIYAMA A, 1990, J BIOL CHEM, V265, P3362; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GRIECO D, 1990, J BIOL CHEM, V265, P19343; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hirai A, 1997, J BIOL CHEM, V272, P13; HIRAI A, 1994, J CLIN INVEST, V94, P2215, DOI 10.1172/JCI117583; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; ISOMURA M, 1991, ONCOGENE, V6, P119; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; OLOFSSON B, 1988, ONCOGENE, V3, P321; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OMER CA, 1994, MOL MICROBIOL, V11, P219, DOI 10.1111/j.1365-2958.1994.tb00302.x; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TSAI LH, 1993, ONCOGENE, V8, P1593; TSUJITA Y, 1986, BIOCHIM BIOPHYS ACTA, V877, P50, DOI 10.1016/0005-2760(86)90117-7; Vogt A, 1996, ONCOGENE, V13, P1991; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Yamamoto K, 1996, ENDOCRINOLOGY, V137, P2036, DOI 10.1210/en.137.5.2036; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	31	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3649	3653		10.1074/jbc.273.6.3649	http://dx.doi.org/10.1074/jbc.273.6.3649			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452494	hybrid			2022-12-25	WOS:000071822300079
J	Paciucci, R; Tora, M; Diaz, VM; Real, FX				Paciucci, R; Tora, M; Diaz, VM; Real, FX			The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro	ONCOGENE			English	Article						tissue-type plasminogen activator; urokinase-type plasminogen activator; urokinase receptor; annexin II; invasion; pancreas cancer	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; ENDOTHELIAL-CELL RECEPTOR; UROKINASE-RECEPTOR; ANNEXIN-II; EXTRACELLULAR-MATRIX; GENE-TRANSCRIPTION; CARCINOMA-CELLS; GLYCOSYL-PHOSPHATIDYLINOSITOL; COLON ADENOCARCINOMAS	Plasminogen activators (PAs) play an important role in tumor cell invasion, We have analysed the expression of tissue-type PA (t-PA), urokinase-type PA (u-PA), and their respective receptors, annexin II and u-PAR, in normal and neoplastic cultures of pancreatic cells, as well as in pancreatic tissues, and have examined their role in tumor invasiveness in vitro. Using Northern blotting, Western blotting, and ELISA, t-PA is detected in cultured pancreas cancer cells displaying a well differentiated phenotype but it is undetectable in less differentiated cells and in normal pancreatic cultures, In contrast, u-PA transcripts, protein, and enzymatic activity are detected both in cancer cells and in normal cultures, Higher levels of u-PAR and annexin II are present in cancer cells than in normal cultures and, in SK-PC-1 cells, both receptors are localized in the basolateral membrane, In vitro invasion assays indicate that both t-PA and u-PA contribute to the invasiveness of SK-PC-1 cells through reconstituted extracellular matrix, To determine the relevance of these studies to pancreas cancer, immunohistochemical assays have been used to examine the expression of t-PA, u-PA, and their receptors in normal and neoplastic tissues, t-PA is absent from normal pancreas and from tumor associated pancreatitis, whereas it is detected in the majority of pancreas cancer tissues (16/17), Annexin II is also overexpressed in some tumors (5/13), u-PAR is overexpressed in most tumor samples examined (14/15), while u-PA is weakly detected in a low number of cases (3/14); both u-PAR and u-PA are overexpressed in areas of tumor associated pancreatitis, Indirect evidences indicate that K-ras and p53 mutated proteins can regulate the expression of PAs, In pancreatic cancer we have found an association between codon 12 K-ras mutations and t-PA expression (P=0.04). These results support the contention that, in the exocrine pancreas, activation of t-PA is more specifically associated to neoplastic transformation and to the invasive phenotype, whereas the induction of u-PA/u-PAR system might be more relevant to inflammatory or non-neoplastic events.	Inst Municipal Invest Med, Unit Biol Cellular & Mol, E-08003 Barcelona, Spain		Paciucci, R (corresponding author), Inst Municipal Invest Med, Unit Biol Cellular & Mol, E-08003 Barcelona, Spain.		Arribas, Francisco X Real/H-5275-2015; Díaz, Víctor Manuel/F-5013-2016; Paciucci, Rosanna/AGP-3844-2022	Arribas, Francisco X Real/0000-0001-9501-498X; Díaz, Víctor Manuel/0000-0001-8561-7576; Paciucci, Rosanna/0000-0001-5651-5933				AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BERROZPE G, 1994, INT J CANCER, V58, P185, DOI 10.1002/ijc.2910580207; Blasi Francesco, 1996, Seminars in Thrombosis and Hemostasis, V22, P513, DOI 10.1055/s-2007-999053; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CALDAS C, 1994, CANCER RES, V54, P3568; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARRATO C, 1994, GASTROENTEROLOGY, V107, P160, DOI 10.1016/0016-5085(94)90073-6; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Davis RG, 1995, J IMMUNOL METHODS, V188, P91, DOI 10.1016/0022-1759(95)00207-3; DEVRIES TJ, 1994, AM J PATHOL, V144, P70; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIESS H, 1996, PANCREATIC CANC MOL, P51; GRESS TM, 1995, INT J CANCER, V62, P407, DOI 10.1002/ijc.2910620409; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOORENS A, 1993, AM J PATHOL, V143, P685; HSU DW, 1995, AM J PATHOL, V147, P114; JANKUN J, 1991, CANCER RES, V51, P1221; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KALTHOFF H, 1993, ONCOGENE, V8, P289; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; LIMONGI P, 1995, FEBS LETT, V369, P207, DOI 10.1016/0014-5793(95)00742-R; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; LUND LR, 1991, EMBO J, V10, P3399, DOI 10.1002/j.1460-2075.1991.tb04904.x; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Malats N, 1997, INT J CANCER, V70, P661, DOI 10.1002/(SICI)1097-0215(19970317)70:6<661::AID-IJC6>3.0.CO;2-T; MARS WM, 1993, AM J PATHOL, V143, P949; MEDCALF RL, 1991, MOL ENDOCRINOL, V5, P1773, DOI 10.1210/mend-5-12-1773; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MOSER TL, 1994, INT J CANCER, V56, P552, DOI 10.1002/ijc.2910560415; Moss SE, 1997, TRENDS CELL BIOL, V7, P87, DOI 10.1016/S0962-8924(96)10049-0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Nielsen BS, 1996, LAB INVEST, V74, P168; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; Paciucci R, 1996, FEBS LETT, V385, P72, DOI 10.1016/0014-5793(96)00352-3; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; PARKKINEN J, 1991, J BIOL CHEM, V266, P16730; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PITTMAN RN, 1995, J NEUROCHEM, V64, P566; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; PYKE C, 1995, CANCER RES, V55, P4132; PYKE C, 1991, AM J PATHOL, V138, P1059; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STURZEBECHER J, 1988, FIBRINOLYSIS, V2, P49; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VERSPAGET HW, 1995, EUR J CANCER, V31A, P1105, DOI 10.1016/0959-8049(95)00170-N; Vila Maya R., 1994, Zentralblatt fuer Pathologie, V140, P225; VILA MR, 1994, LAB INVEST, V71, P423; VILA MR, 1995, LAB INVEST, V72, P395; VILA MR, 1995, LAB INVEST, V73, P409; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; WANG Y, 1994, FEBS LETT, V353, P138, DOI 10.1016/0014-5793(94)01032-3; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILSON EL, 1983, BLOOD, V61, P568; WILSON EL, 1987, J EXP MED, V165, P1609, DOI 10.1084/jem.165.6.1609	78	64	65	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					625	633		10.1038/sj.onc.1201564	http://dx.doi.org/10.1038/sj.onc.1201564			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482108				2022-12-25	WOS:000071816600007
J	Kimball, SR; Heinzinger, NK; Horetsky, RL; Jefferson, LS				Kimball, SR; Heinzinger, NK; Horetsky, RL; Jefferson, LS			Identification of interprotein interactions between the subunits of eukaryotic initiation factors eIF2 and eIF2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; POLYPEPTIDE-CHAIN INITIATION; PROTEIN-SYNTHESIS; TRANSLATION INITIATION; RAT-LIVER; FACTOR-II; MECHANISM; PHOSPHORYLATION; PURIFICATION; INHIBITION	Modulation of protein/protein interaction is an important mechanism involved in regulation of translation initiation. Specifically, regulation of the interaction of eIF2 with the guanine nucleotide exchange factor, eIF2B, is a key mechanism for controlling translation under a variety of conditions, Phosphorylation of the alpha-subunit of eIF2 converts the protein into a competitive inhibitor of eIF2B by causing an increase in the binding affinity of eIF2B for eIF2, Consequently, it has been assumed that the a subunit of eIF2 is directly involved in binding to eIF2B, In the present study, eIF2 was found to bind only to the delta- and epsilon-subunits of eIF2B, and eIF2B was shown to bind only to the beta-subunit of eIF2 by far-Western blot analysis, The binding site on eIF2 beta for either the eIF2B holoprotein, or the isolated delta- or epsilon-subunits of eIF2B was shown to be located within approximately 70 amino acids of the C terminus of the protein, Phosphorylation of the alpha-subunit of eIF2 did not promote binding of eIF2B to the isolated subunit, However, it did cause an increase in the affinity of eIF2B for eIF2, Finally, phosphorylation by protein kinase A of the beta-subunit of elF2 in the C-terminal portion of the protein increased the guanine nucleotide exchange activity of eIF2B, whereas phosphorylation by casein kinase II or protein kinase C was without effect.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kimball, SR (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, POB 850, Hershey, PA 17033 USA.				NIDDK NIH HHS [DK07684, DK13499, DK15658] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013499, T32DK007684, R01DK015658, R01DK013499] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DEALDANA CRV, 1994, MOL CELL BIOL, V14, P3208, DOI 10.1128/MCB.14.5.3208; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P546; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; GOSS DJ, 1984, J BIOL CHEM, V259, P7374; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; KIMBALL SR, 1987, J BIOL CHEM, V262, P2220; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; KIMBALL SR, 1989, AM J PHYSIOL, V256, pC28, DOI 10.1152/ajpcell.1989.256.1.C28; KIMBALL SR, 1994, BBA-GEN SUBJECTS, V1201, P473, DOI 10.1016/0304-4165(94)90079-5; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; OLDFIELD S, 1992, EUR J BIOCHEM, V208, P73, DOI 10.1111/j.1432-1033.1992.tb17160.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; WELSH GI, 1994, BIOCHEM BIOPH RES CO, V201, P1279, DOI 10.1006/bbrc.1994.1843; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625	16	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3039	3044		10.1074/jbc.273.5.3039	http://dx.doi.org/10.1074/jbc.273.5.3039			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446619	hybrid			2022-12-25	WOS:000071736600074
J	Albertoni, M; Daub, DM; Arden, KC; Viars, CS; Powell, C; Van Meir, EG				Albertoni, M; Daub, DM; Arden, KC; Viars, CS; Powell, C; Van Meir, EG			Genetic instability leads to loss of both p53 alleles in a human glioblastoma	ONCOGENE			English	Article						glioma; brain tumour; PCR diagnosis; p53	WILD-TYPE P53; CELL-CYCLE; HUMAN CANCERS; EXPRESSION; AMPLIFICATION; LINES; DNA; CHECKPOINT; CYTOMETRY; MUTATIONS	Little is known about the relationship between genetic recombination mechanisms and loss of tumour suppressor genes in solid tumours. Here, we demonstrate deletion and truncation of both p53 alleles in a primary human glioblastoma and a derived cell line as the combined result of a t(17;20) reciprocal translocation and a 1.1 Mbp genomic deletion on chromosome 17p, starting in intron 4 of the p53 gene and ending at the telomeric CA-repeat marker D17S960. These results (i) suggest that genetic instability can lead to loss of tumour suppressor function in solid cancers, (ii) provide mapping of one such recombination event at the nucleotide level, and (iii) establish the orientation of the p53 gene on chromosome 17 as: centromere 5'-3'-telomere.	CHU Vaudois BH19 109, Dept Neurosurg, Lab Tumour Biol & Genet, CH-1011 Lausanne, Switzerland; Ludwig Inst Canc Res, San Diego, CA 92093 USA; LabCorp, Mol Biol & Pathol, Res Triangle Pk, NC 27709 USA	Ludwig Institute for Cancer Research	Van Meir, EG (corresponding author), CHU Vaudois BH19 109, Dept Neurosurg, Lab Tumour Biol & Genet, CH-1011 Lausanne, Switzerland.			Van Meir, Erwin G./0000-0003-2444-7707				BERMINGHAM JR, 1995, GENOMICS, V29, P70, DOI 10.1006/geno.1995.1216; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BOUFFLER SD, 1995, CANCER RES, V55, P3883; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Di Leonardo A, 1997, CANCER RES, V57, P1013; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1991, CANCER RES, V51, P3075; LUZI P, 1994, CYTOMETRY, V18, P79, DOI 10.1002/cyto.990180205; MAKOSWALES M, 1995, NAT MED, V1, P570; Marchevsky A, 1996, CYTOMETRY, V26, P101; MCPHERSON MJ, 1991, PCR PRACTICAL APPROA, P137; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MEYN MS, 1994, INT J RADIAT BIOL, V66, P141; MILLER CW, 1990, CANCER RES, V50, P7950; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PELTOMAKI P, 1993, CANCER RES, V53, P5853; POGRIBNY IP, 1995, CANCER RES, V55, P1894; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; STUDER A, 1985, ACTA NEUROPATHOL, V66, P208, DOI 10.1007/BF00688585; VAN MEIR EG, 1995, P NATL ACAD SCI USA, V92, P1008, DOI 10.1073/pnas.92.4.1008; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; VAN MEIR EG, 1994, CANCER RES, V54, P649; VANMEYEL DJ, 1994, JNCI-J NATL CANCER I, V86, P1011, DOI 10.1093/jnci/86.13.1011; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	33	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					321	326		10.1038/sj.onc.1201544	http://dx.doi.org/10.1038/sj.onc.1201544			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467957				2022-12-25	WOS:000071582100004
J	Sohda, M; Misumi, Y; Yano, A; Takami, N; Ikehara, Y				Sohda, M; Misumi, Y; Yano, A; Takami, N; Ikehara, Y			Phosphorylation of the vesicle docking protein p115 regulates its Association with the Golgi membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT; BINDING; COMPLEX; USO1P; CELLS	The vesicle docking protein p115 was found to be phosphorylated in a cell cycle-specific manner; it was found phosphorylated in interphase but not in mitotic cells, During interphase, however, two forms of p115 were detected in the cells; the phosphorylated form was found exclusively in cytosol, whereas the unphosphorylated form was associated with membranes, mostly of the Golgi complex, The latter form was released from the membranes upon phosphorylation. Mutational analysis revealed that the phosphorylation site of p115 was the Ser(942) residue in the C-terminal acidic domain, A mutant with a single substitution of Ser(942) --> Ata markedly increased its association with the Golgi membrane, Another mutant with Ser(942) --> Asp was able to associate with the membrane, although at a decreased level, indicating that the dissociation of p115 from the membrane is not simply due to the negative charge of phosphorylated Ser(942), Taken together, these results suggest that the phosphorylation of Ser(942) at the C-terminal acidic domain regulates the interaction of p115 with the Golgi membrane, possibly taking part in the regulatory mechanism of vesicular transport.	Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 81480, Japan; Fukuoka Univ, Sch Med, Radioisotope Lab, Jonan Ku, Fukuoka 81480, Japan	Fukuoka University; Fukuoka University	Ikehara, Y (corresponding author), Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 81480, Japan.							AMES GFL, 1976, BIOCHEMISTRY-US, V15, P616, DOI 10.1021/bi00648a026; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; FEATHERSTONE C, 1985, J CELL BIOL, V101, P2036, DOI 10.1083/jcb.101.6.2036; Haruta T, 1997, BIOCHEM J, V325, P455, DOI 10.1042/bj3250455; Levine TP, 1996, J BIOL CHEM, V271, P17304, DOI 10.1074/jbc.271.29.17304; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Misumi Y, 1997, J BIOL CHEM, V272, P23851, DOI 10.1074/jbc.272.38.23851; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; SUPRYNOWICZ FA, 1986, J CELL BIOL, V103, P2073, DOI 10.1083/jcb.103.6.2073; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015	22	43	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5385	5388		10.1074/jbc.273.9.5385	http://dx.doi.org/10.1074/jbc.273.9.5385			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478999	hybrid			2022-12-25	WOS:000072310400083
J	Menard, R; Carmona, E; Takebe, S; Dufour, E; Plouffe, C; Mason, P; Mort, JS				Menard, R; Carmona, E; Takebe, S; Dufour, E; Plouffe, C; Mason, P; Mort, JS			Autocatalytic processing or recombinant human procathepsin L - Contribution of both intermolecular and unimolecular events in the processing of procathepsin L in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-L; IN-VITRO; CYSTEINE PROTEINASES; CELLS; IDENTIFICATION; PURIFICATION; ACTIVATION; PRECURSOR; PAPAIN; PROPEPTIDE	The autocatalytic processing of procathepsin L was investigated in vitro using purified recombinant proenzyme expressed in Pichia pastoris. Pure intermolecular processing was studied by incubating the mutant procathepsin L (C25S), which cannot autoactivate with a small amount of mature active cathepsin L. The results clearly establish that, contrary to recent reports, intermolecular processing of procathepsin L is possible. The main cleavage sites are located at or near the N terminus of the mature enzyme, in an accessible portion of the proregion, which contains sequences corresponding to the known substrate specificity of cathepsin L. Contrary to procathepsins B, K, and S, autocatalytic processing of procathepsin L can generate the natural mature form the enzyme. A continuous assay using the substrate benzyloxycarbonyl-Phe-Arg 4-methylcoumarinyl-7-amide hydrochloride has also been used to obtain information on the nature of the steps involved in the autocatalytic processing of wild-type procathepsin L. Processing is initiated by decreasing the pH from 8.0 to 5.3. The influence of proenzyme concentration on the rate of processing indicates the existence of both unimolecular and biomolecular steps in the mechanism of processing. The nature of the unimolecular event that triggers processing remains elusive. Circular dichroism and fluorescence measurements indicate the absence of large scale conformational change in the structure of procathepsin L on reduction of pH. However, the bimolecular reaction can be attributed to intermolecular processing of the zymogen.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Shriners Hosp Crippled Children, Joint Dis Lab, Montreal, PQ H3G 1A6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3G 1A6, Canada	National Research Council Canada; McGill University; McGill University	Menard, R (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.		Dufour, Eric/T-8774-2019; Dufour, Eric/F-8008-2012	Dufour, Eric/0000-0002-8267-9656				Baker KC, 1996, PROTEIN ENG, V9, P525, DOI 10.1093/protein/9.6.525; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; BOUJRAD N, 1995, SCIENCE, V268, P1609, DOI 10.1126/science.7777858; BROMME D, 1993, J BIOL CHEM, V268, P4832; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; ESSER RE, 1994, ARTHRITIS RHEUM, V37, P236, DOI 10.1002/art.1780370213; Fujishima A, 1997, FEBS LETT, V407, P47, DOI 10.1016/S0014-5793(97)00216-0; Ishidoh K, 1995, BIOCHEM BIOPH RES CO, V217, P624, DOI 10.1006/bbrc.1995.2820; ISHIDOH K, 1994, FEBS LETT, V352, P281, DOI 10.1016/0014-5793(94)00924-4; KAKEGAWA H, 1993, FEBS LETT, V321, P247, DOI 10.1016/0014-5793(93)80118-E; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P193; KOGA H, 1990, J BIOCHEM-TOKYO, V108, P976, DOI 10.1093/oxfordjournals.jbchem.a123324; KOMINAMI E, 1988, FEBS LETT, V231, P225, DOI 10.1016/0014-5793(88)80736-1; MACH L, 1994, J BIOL CHEM, V269, P13030; MACH L, 1993, BIOCHEM J, V293, P437, DOI 10.1042/bj2930437; MACIEWICZ RA, 1988, BIOCHEM SOC T, V16, P1056, DOI 10.1042/bst0161056; MASON RW, 1992, BIOCHEM BIOPH RES CO, V189, P1659, DOI 10.1016/0006-291X(92)90268-P; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; MASON RW, 1989, BIOCHEM J, V257, P125, DOI 10.1042/bj2570125; MCDONALD JK, 1995, ARCH BIOCHEM BIOPHYS, V323, P409, DOI 10.1006/abbi.1995.0062; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; McQueney MS, 1997, J BIOL CHEM, V272, P13955, DOI 10.1074/jbc.272.21.13955; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V263, P107, DOI 10.1016/0003-9861(88)90618-2; Nomura T, 1997, BIOCHEM BIOPH RES CO, V230, P143, DOI 10.1006/bbrc.1996.5905; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SHEAHAN K, 1989, CANCER RES, V49, P3809; SMITH SM, 1989, BIOCHEM J, V262, P931, DOI 10.1042/bj2620931; STORER AC, 1994, METHOD ENZYMOL, V244, P486; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; TRABANDT A, 1990, MATRIX, V10, P349, DOI 10.1016/S0934-8832(11)80142-3; VERNET T, 1991, J BIOL CHEM, V266, P21451; YAGEL S, 1989, CANCER RES, V49, P3553; ZABLUDOFF SD, 1990, BIOL REPROD, V43, P25, DOI 10.1095/biolreprod43.1.25	34	123	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4478	4484		10.1074/jbc.273.8.4478	http://dx.doi.org/10.1074/jbc.273.8.4478			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468501	hybrid, Green Published			2022-12-25	WOS:000072115000029
J	Yen, YM; Wong, B; Johnson, RC				Yen, YM; Wong, B; Johnson, RC			Determinants of DNA binding and bending by the Saccharomyces cerevisiae high mobility group protein NHP6A that are important for its biological activities - Role of the unique N terminus and putative intercalating methionine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONHISTONE CHROMOSOMAL PROTEIN; SEX-DETERMINING REGION; LINKER HISTONES B4; HMG-BOX; TRANSCRIPTION FACTOR; NUCLEAR-LOCALIZATION; NUCLEOPROTEIN STRUCTURES; DROSOPHILA-MELANOGASTER; ARCHITECTURAL ELEMENTS; SEQUENCE SPECIFICITY	The non-histone proteins 6A/B (NHP6A/B) of Saccharomyces cerevisiae are high mobility group proteins that bind and severely bend DNA of mixed sequence. They exhibit high affinity for linear DNA and even higher affinity for microcircular DNA. The 16-amino acid basic segment located N-terminal to the high mobility group domain is required for stable complex formation on both linear and microcircular DNA. Although mutants lacking the N terminus are able to promote microcircle formation and Hin invertasome assembly at high protein concentrations, they are unable to form stable complexes with DNA, co-activate transcription, and complement the growth defect of Delta nhp6a/b mutants. A basic patch between amino acids 13 and 16 is critical for these activities, and a second basic patch between residues 8 and 10 is required for the formation of monomeric complexes with linear DNA. Mutational analysis suggests that proline 18 may direct the path of the N-terminal arm to facilitate DNA binding, whereas the conserved proline at position 21, tyrosine 28, and phenylalanine 31 function to maintain the tertiary structure of the high mobility group domain. Methionine 29, which may intercalate into DNA, is essential for NHP6A-induced micro-circle formation of 75-bp but not 98-bp fragments in vitro, and for full growth complementation of Delta nhp6a/b mutants in vivo.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Johnson, RC (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.				NIGMS NIH HHS [GM08042, GM38509, GM07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038509, T32GM008042, R01GM038509] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1019, DOI 10.1093/nar/23.6.1019; BIANCHI ME, 1991, GENE, V104, P271, DOI 10.1016/0378-1119(91)90261-9; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BONNEANDREA C, 1986, BIOL CELL, V58, P185, DOI 10.1111/j.1768-322X.1986.tb00505.x; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; COSTIGAN C, 1994, MOL CELL BIOL, V14, P2391, DOI 10.1128/MCB.14.4.2391; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; DURRIN LK, 1992, MOL CELL BIOL, V12, P1621, DOI 10.1128/MCB.12.4.1621; Farid RS, 1996, TOXICOL APPL PHARM, V141, P532, DOI 10.1006/taap.1996.0319; GE H, 1994, J BIOL CHEM, V269, P17136; GRASSER KD, 1995, PLANT J, V7, P185, DOI 10.1046/j.1365-313X.1995.7020185.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; Hardman CH, 1995, BIOCHEMISTRY-US, V34, P16596, DOI 10.1021/bi00051a007; HAYASHI T, 1989, J BIOCHEM-TOKYO, V105, P577, DOI 10.1093/oxfordjournals.jbchem.a122707; HAYKINSON MJ, 1993, EMBO J, V12, P2503, DOI 10.1002/j.1460-2075.1993.tb05905.x; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; Johns E.W., 1982, HMG CHROMOSOMAL PROT, P1; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; Kirov NC, 1996, EMBO J, V15, P7079, DOI 10.1002/j.1460-2075.1996.tb01099.x; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; KUEHL L, 1984, J CELL BIOL, V99, P648, DOI 10.1083/jcb.99.2.648; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LAVOIE BD, 1994, J BIOL CHEM, V269, P15571; LnenicekAllen M, 1996, NUCLEIC ACIDS RES, V24, P1047, DOI 10.1093/nar/24.6.1047; LOCKER D, 1995, J MOL BIOL, V246, P243, DOI 10.1006/jmbi.1994.0079; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Lu J, 1996, J BIOL CHEM, V271, P33678, DOI 10.1074/jbc.271.52.33678; MAEDA Y, 1992, EMBO J, V11, P3695, DOI 10.1002/j.1460-2075.1992.tb05454.x; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; Nightingale K, 1996, EMBO J, V15, P548, DOI 10.1002/j.1460-2075.1996.tb00387.x; OHASHI Y, 1994, MOL CELL BIOL, V14, P2731, DOI 10.1128/MCB.14.4.2731; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; Paull TT, 1996, GENE DEV, V10, P2769, DOI 10.1101/gad.10.21.2769; PAULL TT, 1995, J BIOL CHEM, V270, P8744, DOI 10.1074/jbc.270.15.8744; PAVET D, 1997, J MOL BIOL, V266, P66; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; POULAT F, 1995, J CELL BIOL, V128, P737, DOI 10.1083/jcb.128.5.737; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; Rose MD., 1990, METHODS YEAST GENETI; SCHULMAN IG, 1991, MOL CELL BIOL, V11, P166, DOI 10.1128/MCB.11.1.166; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SIKORSKI RS, 1989, GENETICS, V122, P19; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SREERAMA N, 1993, ANAL BIOCHEM, V209, P33; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; TEO SH, 1995, EMBO J, V14, P3844, DOI 10.1002/j.1460-2075.1995.tb00054.x; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; Ura K, 1996, EMBO J, V15, P4959, DOI 10.1002/j.1460-2075.1996.tb00876.x; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; vanHoute LPA, 1995, J BIOL CHEM, V270, P30516, DOI 10.1074/jbc.270.51.30516; WAGNER CR, 1992, MOL CELL BIOL, V12, P1915, DOI 10.1128/MCB.12.5.1915; WAGNER JP, 1995, J BIOL CHEM, V270, P7394, DOI 10.1074/jbc.270.13.7394; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Wisniewski JR, 1997, EUR J BIOCHEM, V243, P151, DOI 10.1111/j.1432-1033.1997.0151a.x	76	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4424	4435		10.1074/jbc.273.8.4424	http://dx.doi.org/10.1074/jbc.273.8.4424			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468494	hybrid			2022-12-25	WOS:000072115000022
J	Black, MW; Boothroyd, JC				Black, MW; Boothroyd, JC			Development of a stable episomal shuttle vector for Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTONOMOUS REPLICATION; DNA; TRANSFORMATION; EXPRESSION; GENE; LEISHMANIA; MARKER	The rapid developments in the molecular genetics of Toxoplasma gondii have far reaching implications in treatment and vaccination strategies far this as well as closely related pathogens such as Plasmodium. Although stable transformation of this parasite through homologous and illegitimate genomic integration has provided many of the tools necessary for genetic analysis, subsequent manipulations of the DNA have proven laborious, This report-describes the selection and subsequent characterization of a Toxoplasma sequence that permits the episomal maintenance of bacterial plasmids in this parasite, This sequence was isolated from the Toxoplasma. genome through selection for episomal stability of a pUC19-based library in the absence of a selectable marker, A 500-base pair fragment was determined to possess the stabilization activity. Transformations of Toxoplasma using vectors possessing this fragment, referred to as EMS (episomal maintenance sequence), demonstrated an elevated stable transformation frequency compared with the vector alone, Mutants deficient in hyploxanthine-xanthine-guanine phosphoribosyltransferase activity were used as a test to see if this gene could be selected from a genomic library using a vector containing the EMS. The success of this test demonstrates the utility of EMS-containing vectors in complementation strategies and the ability of such constructs bearing large? fragments of the Toxoplasma genome to be maintained episomally.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University	Boothroyd, JC (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.			Boothroyd, John C./0000-0001-9719-745X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021423, R01AI021423] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 30230, AI 21423] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1995, CURRENT PROTOCOLS MO, V1; Boothroyd John C., 1995, MBL (Marine Biology Laboratory) Lectures in Biology, V12, P211; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; DONALD RGK, 1994, MOL BIOCHEM PARASIT, V63, P243, DOI 10.1016/0166-6851(94)90060-4; DONALD RGK, 1993, P NATL ACAD SCI USA, V90, P11703, DOI 10.1073/pnas.90.24.11703; GODBERG J, 1990, NUCLEIC ACIDS RES, V18, P5515; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; KIM K, 1993, CLIN RES, V41, pA209; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; OSSORIO PN, 1991, J MOL BIOL, V222, P525, DOI 10.1016/0022-2836(91)90494-Q; PAPADOPOULOU B, 1994, MOL BIOCHEM PARASIT, V65, P39, DOI 10.1016/0166-6851(94)90113-9; PFEFFERKORN ER, 1976, EXP PARASITOL, V36, P365, DOI 10.1016/0014-4894(76)90040-0; PFEFFERKORN ER, 1978, EXP PARASITOL, V44, P26, DOI 10.1016/0014-4894(78)90077-2; PFEFFERKORN ER, 1979, J PARASITOL, V65, P364, DOI 10.2307/3280274; PFEFFERKORN ER, 1994, EXP PARASITOL, V79, P374, DOI 10.1006/expr.1994.1099; ROOS DS, 1993, J BIOL CHEM, V268, P6269; ROOS DS, 1994, METHOD CELL BIOL, V45, P28; Sabin AB, 1941, J AMER MED ASSOC, V116, P801, DOI 10.1001/jama.1941.02820090001001; SIBLEY LD, 1994, P NATL ACAD SCI USA, V91, P5508, DOI 10.1073/pnas.91.12.5508; SOLDATI D, 1995, MOL CELL BIOL, V15, P87, DOI 10.1128/MCB.15.1.87; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; STINCHCOMB DT, 1980, P NATL ACAD SCI-BIOL, V77, P4559, DOI 10.1073/pnas.77.8.4559; WARE PL, 1987, INFECT IMMUN, V55, P778, DOI 10.1128/IAI.55.3.778-783.1987	23	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3972	3979		10.1074/jbc.273.7.3972	http://dx.doi.org/10.1074/jbc.273.7.3972			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461585	hybrid			2022-12-25	WOS:000072048400027
J	Torella, C; Mattingly, JR; Artigues, A; Iriarte, A; Martinez-Carrion, M				Torella, C; Mattingly, JR; Artigues, A; Iriarte, A; Martinez-Carrion, M			Insight into the conformation of protein folding intermediate(s) trapped by GroEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; CHAPERONIN GROEL; ALPHA-LACTALBUMIN; ESCHERICHIA-COLI; MASS-SPECTROMETRY; BINDING PROTEIN; CENTRAL CAVITY; PRECURSOR; POLYPEPTIDE; CLEAVAGE	Many aspects of the mechanism by which the GroEL/ES chaperonins mediate protein folding are still unclear, including the amount of structure present in the substrate bound to GroEL. To address this issue we have analyzed the susceptibility to limited proteolysis and to alkylation of cysteine residues of mitochondrial aspartate aminotransferase (mAAT) bound to GroEL. Several regions of the N-terminal portion of GroEL-bound mAAT are highly susceptible to proteolysis, whereas a large core of about 200 residues containing the C-terminal half of the polypeptide chain is protected in the complex, This protection does not extend to the mAAT sulfhydryl groups which in the GroEL-mAAT complex have similar reactivity as in fully unfolded mAAT, These results suggest that the mAAT species bound to GroEL represent folding intermediates with a conformation that is substantially more disorganized than that of the native state. The N-terminal half of the molecule is more flexible and lies exposed at the mouth of the central cavity of GroEL, The more compact C-terminal section of mAAT, which contains residues located at the subunit interface in the native dimer, appears to be hidden in the central cavity of GroEL, Thus, the bulk of the interactions in the GroEL-mAAT complex seems to involve residues from the more compact C-terminal section of the substrate.	Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Martinez-Carrion, M (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA.				NHLBI NIH HHS [HL-38412] Funding Source: Medline; NIGMS NIH HHS [GM-38341] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI F, 1989, J BIOL CHEM, V264, P4782; Artigues A, 1997, J BIOL CHEM, V272, P16852, DOI 10.1074/jbc.272.27.16852; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BEREZOV A, 1994, J BIOL CHEM, V269, P22222; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; DELAURETO PP, 1995, BIOCHEMISTRY-US, V34, P12596, DOI 10.1021/bi00039a015; DOONAN S, 1975, BIOCHEM J, V149, P497, DOI 10.1042/bj1490497d; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; Gervasoni P, 1996, P NATL ACAD SCI USA, V93, P12189, DOI 10.1073/pnas.93.22.12189; Goldberg MS, 1997, P NATL ACAD SCI USA, V94, P1080, DOI 10.1073/pnas.94.4.1080; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; KHISTY VJ, 1995, J BIOL CHEM, V270, P25920, DOI 10.1074/jbc.270.43.25920; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LILIE H, 1995, P NATL ACAD SCI USA, V92, P8100, DOI 10.1073/pnas.92.18.8100; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTINEZCARRION M, 1990, ANN NY ACAD SCI, V585, P346, DOI 10.1111/j.1749-6632.1990.tb28067.x; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MATTINGLY JR, 1995, J BIOL CHEM, V270, P1138, DOI 10.1074/jbc.270.3.1138; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; REYES AM, 1993, J BIOL CHEM, V268, P22281; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; ROSPERT S, 1993, P NATL ACAD SCI USA, V90, P10967, DOI 10.1073/pnas.90.23.10967; SANDMEIER E, 1980, J BIOL CHEM, V255, P284; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0	46	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3915	3925		10.1074/jbc.273.7.3915	http://dx.doi.org/10.1074/jbc.273.7.3915			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461576	hybrid			2022-12-25	WOS:000072048400018
J	Gao, Z; Garbers, DL				Gao, Z; Garbers, DL			Species diversity in the structure of zonadhesin, a sperm-specific membrane protein containing multiple cell adhesion molecule-like domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; TYROSINE-PHOSPHATASE; EXTRACELLULAR-MATRIX; VONWILLEBRAND-FACTOR; MAM DOMAIN; RECEPTOR; CLONING; FAMILY; IDENTIFICATION; EXPRESSION	A hallmark of gamete interactions at fertilization is relative or absolute species specificity, A pig sperm protein that binds to the extracellular matrix of the egg in a species-specific manner was recently identified and named zonadhesin (Hardy, D, M,, and Garbers, D, L, (1995) J. Biol. Chen, 270, 26025-26028), We have now cloned a cDNA for mouse zonadhesin (16.4 kb), and it demonstrates a large species variation in the numbers and arrangements of domains, Expression of mouse zonadhesin mRNA is evident only within the testis, and the protein is found exclusively on the apical region of the sperm head, There are 20 partial D-domains, found as tandem repeats, inserted between two of the four full D-domains and an additional partial D-domain, These domains are homologous to the D-domains of von Willebrand factor and alpha-tectorin. A region at the N terminus of the mouse cDNA contains three tandem repeats homologous to MAM domains, These are domains comprised of about 160 amino acids that are present in transmembrane proteins such as the meprins and receptor protein-tyrosine phosphatases, where they appear to function in cell/cell interactions, Additionally, mouse zonadhesin contains a mucin-like domain and a domain homologous to epidermal growth factor (EGF), A putative single transmembrane segment separates a short carboxyl tail from the extracellular region, The existence of MAM, mucin, D-, and EGF domains suggest that mouse zonadhesin functions in multiple cell adhesion processes, where binding to the extracellular matrix of the egg is but one of the functions of this sperm-specific membrane protein.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Garbers, DL (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD010254] Funding Source: NIH RePORTER; NICHD NIH HHS [HD10254] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS C G, 1990, New Biologist, V2, P410; DAVIS LG, 1986, BASIC METHODS MOL BI, P139; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; FUJISAWA T, 1991, EUR J BIOCHEM, V196, P673, DOI 10.1111/j.1432-1033.1991.tb15864.x; Gao Z, 1997, GENOMICS, V41, P119, DOI 10.1006/geno.1997.4620; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUM JR, 1994, J BIOL CHEM, V269, P2440; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HARDY DM, 1994, J BIOL CHEM, V269, P19000; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; Joba W, 1997, J BIOL CHEM, V272, P1805, DOI 10.1074/jbc.272.3.1805; KOTANI E, 1995, BBA-GENE STRUCT EXPR, V1260, P245, DOI 10.1016/0167-4781(94)00202-E; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE SL, 1994, BIOTECHNOL APPL BIOC, V19, P31; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MEYER D, 1993, THROMB HAEMOSTASIS, V70, P99; OHMORI H, 1994, J BIOL CHEM, V269, P17833; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMIZU Y, 1993, NATURE, V366, P630, DOI 10.1038/366630a0; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wang HY, 1996, ONCOGENE, V12, P2555; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	36	87	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3415	3421		10.1074/jbc.273.6.3415	http://dx.doi.org/10.1074/jbc.273.6.3415			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452463	hybrid			2022-12-25	WOS:000071822300048
J	Johnson, BD; Schumacher, RJ; Ross, ED; Toft, DO				Johnson, BD; Schumacher, RJ; Ross, ED; Toft, DO			Hop modulates hsp70/hsp90 interactions in protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RETICULOCYTE LYSATE; HEAT-SHOCK PROTEINS; PROGESTERONE-RECEPTOR COMPLEXES; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; HSP90; HSP70; DNAJ; BINDING; GRPE	Hop is a 60-kDa protein characterized by its ability to bind the two chaperones, hsp70 and hsp90. We have tested the function of Hop using an assay for the refolding of denatured firefly luciferase. We show that Hop is involved in the process of refolding thermally denatured firefly luciferase in rabbit reticulocyte lysate. Hop also stimulates refolding by hsp70 and Ydj-1 in a purified refolding system. Hsp90 can also stimulate refolding, and optimal refolding is observed in the presence of both Hop and hsp90. Similar stimulation was observed when Hop was replaced by its yeast homolog Sti1. In assays of the binding of Hop to hsp70 and hsp90, Hop preferentially forms a complex with ADP-bound hsp70, and this process is unaffected by the presence of hsp90. Hop does not alter the ATPase activity or the rate of ADP dissociation of hsp70. Hop also appears to bind to the ADP-bound form of hsp90, blocking the ATP-dependent conversion of hsp90 to a form capable of interacting with p23. Conversely, once p23 is bound to hsp90, Hop binding is diminished. These results confirm that Hop provides a physical link between hsp70 and hsp90 and also indicate that Hop modulates the activities of both of these chaperone proteins.	Mayo Grad Sch, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	Mayo Clinic; Yale University; Howard Hughes Medical Institute; Yale University	Toft, DO (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	toft@mayo.edu		Ross, Eric/0000-0002-6473-9977	NICHD NIH HHS [HD 09140] Funding Source: Medline; NIDDK NIH HHS [DK 46249] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046249] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Gao BC, 1996, J BIOL CHEM, V271, P16792, DOI 10.1074/jbc.271.28.16792; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Gross M, 1996, J BIOL CHEM, V271, P16833, DOI 10.1074/jbc.271.28.16833; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hofeld J., 1995, CELL, V83, P589; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; PALLEROS DR, 1993, NATURE, V365, P6624; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Thulasiraman V, 1996, BIOCHEMISTRY-US, V35, P13443, DOI 10.1021/bi9615396	47	281	293	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3679	3686		10.1074/jbc.273.6.3679	http://dx.doi.org/10.1074/jbc.273.6.3679			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452498	hybrid			2022-12-25	WOS:000071822300083
J	Luo, YQ; Umegaki, H; Wang, XT; Abe, R; Roth, GS				Luo, YQ; Umegaki, H; Wang, XT; Abe, R; Roth, GS			Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; DOMINANT-NEGATIVE MUTANT; CENTRAL-NERVOUS-SYSTEM; X-RAY-MICROANALYSIS; C-JUN; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; PC12 CELLS; MOLECULAR MECHANISMS; SYMPATHETIC NEURONS	Dopamine (DA) is a neurotransmitter, but it also exerts a neurotoxic effect under certain pathological conditions, including age-related neurodegeneration such as Parkinson's disease. By using both the 293 cell line and primary neonatal rat postmitotic striatal neuron cultures, we show here that DA induces apoptosis in a time-and concentration-dependent manner. Concomitant with the apoptosis, DA activates the JNK pathway, including increases in JNK activity, phosphorylation of c-Jun, and subsequent increase in c-Jun protein. This DA-induced JNK activation precedes apoptosis and is persistently sustained during the process of apoptosis. Transient expression of a dominant negative mutant SEK1(Lys --> Arg), an upstream kinase of JNK, prevents both DA-induced JNK activation and apoptosis. A dominant negative c-Jun mutant FLAG Delta 169 also reduces DA-induced apoptotic cell death. Anti-oxidants N-acetylcysteine and catalase, which serve as scavengers of reactive oxygen species generated by metabolic DA oxidation, effectively block DA-induced JNK activation and subsequent apoptosis. Thus, our data suggest that DA triggers an apoptotic death program through an oxidative stress-involved JNK activation signaling pathway. Given the fact that the anti-oxidative defense system declines during aging, this molecular event may be implicated in the age-related striatal neuronal cell loss and age-related dopaminergic neurodegenerative disorders, such as Parkinson's and Huntington's diseases.	NIA, Gerontol Res Ctr, Mol Physiol & Genet Sect, NIH, Baltimore, MD 21224 USA; NIA, Gerontol Res Ctr, Gene Express & Aging Sect, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Luo, YQ (corresponding author), NIA, Gerontol Res Ctr, Mol Physiol & Genet Sect, NIH, 4940 Eastern Ave,4E02, Baltimore, MD 21224 USA.	luoyq@helix.nih.gov						ABAD F, 1995, EUR J PHARM-ENVIRON, V293, P55, DOI 10.1016/0926-6917(95)90018-7; ADAMS JD, 1991, FREE RADICAL BIO MED, V10, P161, DOI 10.1016/0891-5849(91)90009-R; AKIYAMA Y, 1991, J NEUROCHEM, V57, P997, DOI 10.1111/j.1471-4159.1991.tb08249.x; Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; BENZI G, 1992, NEUROBIOL AGING, V13, P361, DOI 10.1016/0197-4580(92)90109-B; Berman SB, 1996, J NEUROCHEM, V67, P593; BOSSI SR, 1993, NEUROREPORT, V4, P73, DOI 10.1097/00001756-199301000-00019; BROWN PH, 1994, ONCOGENE, V9, P791; BUISSON A, 1992, J NEUROCHEM, V59, P1153, DOI 10.1111/j.1471-4159.1992.tb08358.x; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Cheng NN, 1996, BRAIN RES, V743, P278, DOI 10.1016/S0006-8993(96)01056-6; COHEN G, 1974, J BIOL CHEM, V249, P2447; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Drukarch B, 1996, J NEUROSCI, V16, P6038; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FILLOUX F, 1991, SYNAPSE, V8, P281, DOI 10.1002/syn.890080406; FORNSTEDT B, 1989, J NEURAL TRANSM-PARK, V1, P279, DOI 10.1007/BF02263482; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAN Z, 1989, BRAIN RES, V498, P299, DOI 10.1016/0006-8993(89)91108-6; HASTINGS TG, 1995, J NEUROCHEM, V64, P919; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; HIRSCH EC, 1991, J NEUROCHEM, V56, P446, DOI 10.1111/j.1471-4159.1991.tb08170.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JELLINGER K, 1992, J NEUROCHEM, V59, P1168, DOI 10.1111/j.1471-4159.1992.tb08362.x; JENNER P, 1993, ACTA NEUROL SCAND, V87, P6; JONSSON G, 1971, PROGR HISTOCHEM CYTO, V2, P299; KASTNER A, 1993, J NEUROCHEM, V61, P1024, DOI 10.1111/j.1471-4159.1993.tb03616.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAI H, 1987, NEUROBIOL AGING, V8, P45, DOI 10.1016/0197-4580(87)90056-X; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MADISON DV, 1982, NATURE, V299, P636, DOI 10.1038/299636a0; Masserano JM, 1996, MOL PHARMACOL, V50, P1309; MESCO ER, 1992, J NEUROSCI RES, V31, P341, DOI 10.1002/jnr.490310216; MICHEL PP, 1990, J NEUROSCI RES, V26, P428, DOI 10.1002/jnr.490260405; ODELL SJ, 1991, BRAIN RES, V564, P256, DOI 10.1016/0006-8993(91)91461-9; OFFEN D, 1995, BBA-MOL CELL RES, V1268, P171, DOI 10.1016/0167-4889(95)00075-4; OLANOW CW, 1994, CURR OPIN NEUROL, V7, P548, DOI 10.1097/00019052-199412000-00013; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; ROTH GS, 1994, ANN NY ACAD SCI, V719, P129, DOI 10.1111/j.1749-6632.1994.tb56824.x; Rubin Lee L., 1994, Current Opinion in Neurobiology, V4, P696, DOI 10.1016/0959-4388(94)90012-4; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; SCHLINGENSIEPEN KH, 1993, DEV GENET, V14, P305, DOI 10.1002/dvg.1020140408; SCHMIDT CJ, 1985, J PHARMACOL EXP THER, V233, P539; Shinkai T, 1997, J NEUROSCI RES, V47, P393; Simantov R, 1996, NEUROSCIENCE, V74, P39, DOI 10.1016/0306-4522(96)00102-9; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; TODD RD, 1992, BIOL PSYCHIAT, V31, P794, DOI 10.1016/0006-3223(92)90311-M; VALERIO A, 1994, J NEUROCHEM, V62, P1260; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WALKINSHAW G, 1994, NEUROSCIENCE, V63, P975, DOI 10.1016/0306-4522(94)90566-5; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN CYI, 1995, J BIOL CHEM, V270, P26827, DOI 10.1074/jbc.270.45.26827; ZHANG L, 1995, BRAIN RES, V677, P177, DOI 10.1016/0006-8993(95)00197-X; ZilkhaFalb R, 1997, CELL MOL NEUROBIOL, V17, P101, DOI 10.1023/A:1026333222008; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	69	283	291	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3756	3764		10.1074/jbc.273.6.3756	http://dx.doi.org/10.1074/jbc.273.6.3756			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452508	hybrid			2022-12-25	WOS:000071822300093
J	Mayer, B; Pfeiffer, S; Schrammel, A; Koesling, D; Schmidt, K; Brunner, F				Mayer, B; Pfeiffer, S; Schrammel, A; Koesling, D; Schmidt, K; Brunner, F			A new pathway of nitric oxide cyclic GMP signaling involving S-nitrosoglutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLYL CYCLASE; NO-CENTER-DOT; BIOLOGICAL-ACTIVITY; SUPEROXIDE-DISMUTASE; ENDOTHELIAL-CELLS; AQUEOUS-SOLUTION; SYNTHASE; GLUTATHIONE; KINETICS; PEROXYNITRITE	Nitric oxide (NO), a physiologically important activator of soluble guanylyl cyclase (sGC), is synthesized from L-arginine and O-2 in a reaction catalyzed by NO synthases (NOS), Previous studies with purified NOS failed to detect formation of free NO, presumably due to a fast inactivation of NO by simultaneously produced superoxide (O-2(radical anion)). To characterize the products involved in NOS-induced sGC activation, we measured the formation of cyclic 3',5'-guanosine monophosphate (cGMP) by purified sGC incubated in the absence and presence of GSH (1 mM) with drugs releasing different NO-related species or with purified neuronal NOS. Basal sGC activity was 0.04 +/- 0.01 and 0.19 +/- 0.06 mu mol of cGMP x mg(-1) x min(-1) without and with 1 mM GSH, respectively. The NO donor DEA/NO activated sGC in a GSH-independent manner, Peroxynitrite had no effect in the absence of GSH but significantly stimulated the enzyme in the presence of the thiol (3.45 a 0.60 mu mol of cGMP x mg(-1) x min(-1)). The NO/O-2(radical anion) donor SIN-1 caused only a slight accumulation of cGMP in the absence of GSH but was almost as effective as DEA/NO in the presence of the thiol, The profile of sGC activation by Ca2+/calmodulin-activated NOS resembled that of SIN-1; at a maximally active concentration of 200 ng/0.1 ml, NOS increased sGC activity to 1.22 +/- 0.12 and 8.51 +/- 0.88 mu mol of cGMP x mg(-1) x min(-1) in the absence and presence of GSH, respectively, The product of NOS and GSH was identified as the thionitrite GSNO, which activated sGC through Cu+-catalyzed release of free NO. In contrast to S-nitrosation by peroxynitrite, the novel NO/O-2(radical anion)-triggered pathway was very efficient (25-45% GSNO) and insensitive to CO2. Cu+-specific chelators inhibited bradykinin-induced cGMP release from rat isolated hearts but did not interfere with the direct activation of cardiac sGC, suggesting that thionitrites may occur as intermediates of NO/cGMP signaling in mammalian tissues.	Graz Univ, Inst Pharmakol & Toxikol, A-8010 Graz, Austria; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	University of Graz; Free University of Berlin	Mayer, B (corresponding author), Graz Univ, Inst Pharmakol & Toxikol, Univ Pl 2, A-8010 Graz, Austria.	mayer@kfunigraz.ac.at	Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494				Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BRUNNER F, 1995, J MOL CELL CARDIOL, V27, P1953, DOI 10.1016/0022-2828(95)90017-9; Butler AR, 1997, ANAL BIOCHEM, V249, P1; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEVION M, 1993, P NATL ACAD SCI USA, V90, P1102, DOI 10.1073/pnas.90.3.1102; CULCASI M, 1994, J BIOL CHEM, V269, P12589; DAVIS MD, 1988, EUR J BIOCHEM, V173, P345, DOI 10.1111/j.1432-1033.1988.tb14004.x; Davisson RL, 1996, HYPERTENSION, V28, P354, DOI 10.1161/01.HYP.28.3.354; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Dicks AP, 1996, J CHEM SOC PERK T 2, P481, DOI 10.1039/p29960000481; Dierks EA, 1996, BIOCHEM PHARMACOL, V51, P1593, DOI 10.1016/0006-2952(96)00078-0; Feelisch M., 1989, J CARDIOVASC PHARM, V14, P13; FERRARI R, 1991, AM J MED, V91, pS95, DOI 10.1016/0002-9343(91)90291-5; FREEDMAN JE, 1995, J CLIN INVEST, V96, P394, DOI 10.1172/JCI118047; Friebe A, 1996, NATURE, V382, P120, DOI 10.1038/382120a0; FUKUTO JM, 1993, BIOCHEM BIOPH RES CO, V196, P707, DOI 10.1006/bbrc.1993.2307; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GOLDSTEIN S, 1995, J AM CHEM SOC, V117, P12078, DOI 10.1021/ja00154a007; GORDGE MP, 1995, BRIT J PHARMACOL, V114, P1083, DOI 10.1111/j.1476-5381.1995.tb13317.x; Gordge MP, 1996, BRIT J PHARMACOL, V119, P533, DOI 10.1111/j.1476-5381.1996.tb15704.x; Gorren ACF, 1997, BIOCHEMISTRY-US, V36, P4360, DOI 10.1021/bi962381s; Gorren ACF, 1996, ARCH BIOCHEM BIOPHYS, V330, P219, DOI 10.1006/abbi.1996.0247; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; HARTENECK C, 1994, BIOCHEM J, V304, P683, DOI 10.1042/bj3040683; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; Hogg N, 1997, BIOCHEM J, V323, P477, DOI 10.1042/bj3230477; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Hou YC, 1996, BIOCHEM BIOPH RES CO, V228, P88, DOI 10.1006/bbrc.1996.1620; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLUGE I, 1995, SAT S 4 INT BRAIN RE; Lipton SA, 1996, TRENDS PHARMACOL SCI, V17, P186, DOI 10.1016/0165-6147(96)20028-8; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; MAYER B, 1994, NEUROPHARMACOLOGY, V33, P1253, DOI 10.1016/0028-3908(94)90024-8; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MAYER B, 1995, J BIOL CHEM, V270, P17355, DOI 10.1074/jbc.270.29.17355; Mayer Bernd, 1995, P21, DOI 10.1016/B978-012721985-1/50004-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; MURPHY ME, 1991, P NATL ACAD SCI USA, V88, P10860, DOI 10.1073/pnas.88.23.10860; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; PACE GW, 1995, FREE RADICAL BIO MED, V19, P523, DOI 10.1016/0891-5849(95)00047-2; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; POU S, 1992, J BIOL CHEM, V267, P24173; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1991, J BIOL CHEM, V266, P4244; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; Schrammel A, 1996, MOL PHARMACOL, V50, P1; Schultz G., 1984, METHOD ENZYMAT AN, P379; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; VENTURINI CM, 1993, J PHARMACOL EXP THER, V266, P1497; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; WINTERBOURN CC, 1990, FREE RADICAL RES COM, V8, P287, DOI 10.3109/10715769009053361; Zhang HW, 1997, ARCH BIOCHEM BIOPHYS, V339, P183, DOI 10.1006/abbi.1996.9863	74	172	178	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3264	3270		10.1074/jbc.273.6.3264	http://dx.doi.org/10.1074/jbc.273.6.3264			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452441	hybrid			2022-12-25	WOS:000071822300026
J	White, RR; Kwon, YG; Taing, M; Lawrence, DS; Edelman, AM				White, RR; Kwon, YG; Taing, M; Lawrence, DS; Edelman, AM			Definition of optimal substrate recognition motifs of Ca2+-calmodulin-dependent protein kinases IV and II reveals shared and distinctive features	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT MULTIPROTEIN KINASE; GLYCOGEN-SYNTHASE KINASE; ACETYL-COA CARBOXYLASE; PHOSPHORYLATION SITES; MOLECULAR-CLONING; CA-2+ CALMODULIN; STRUCTURAL BASIS; GENE-EXPRESSION; BINDING PROTEIN; RAT-BRAIN	The substrate recognition determinants of Ca2+-calmodulin-dependent protein kinase (CaMK) TV and CaMKII alpha were investigated using peptide substrates modeled on the amino acid sequence encompassing Ser-g of synapsin I, For both kinases, hydrophobic residues (Leu or Phe) at the -5 position, are well tolerated, whereas non-hydrophobic residues (Arg, Ala, or Asp) decrease V-max/K-m,,, by 55- to >4000-fold., At the -3 position, substitution of Ala for Arg leads to decreases of 99- and 343- fold in V-max/K-m,, for CaMKIV and CaMKII alpha, respectively, For both kinases, the nature of the residues occupying the -4, -1, and + 4 positions exerts relatively little influence on phosphorylation kinetics, CaMKIV and CaMKII alpha respond differently to substitutions at the -2 and +1 positions, Substitution of Arg at the -2 position with non-basic residues (Gin or Ala) leads to a-fold decreases in V-max/K-m,,JK, for CaMKIV, but 17-28-fold increases for CaMKII alpha., Additionally, peptides containing Leu, Asp, or Ala at the +1 position are phosphorylated with similar efficiencies by CaMKIV, whereas the Leu-substituted peptide is preferred by CaMKII alpha (by a factor of 5.8-9.7-fold), Thus, CaMKIV and CaMKII alpha preferentially phosphorylate substrates with the motifs: Hyd-X-Arg-X-X-Ser*/Thr*, and Hyd-X-Arg-NB-X-Ser*/Thr*-Hyd, respectively, where Hyd represents a hydrophobic, X any, and NE a non-basic amino acid residue. The different specificities of the two kinases may contribute to their targeting to distinct physiological substrates during Ca2+-dependent cellular events.	SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Chem, Buffalo, NY 14214 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Yeshiva University; Albert Einstein College of Medicine	Edelman, AM (corresponding author), SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA.	aedelman@ubmede.buffalo.edu			NIGMS NIH HHS [GM45989] Funding Source: Medline; NINDS NIH HHS [NS24738] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024738, R29NS024738] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO S, 1991, BIOCHEM BIOPH RES CO, V175, P955, DOI 10.1016/0006-291X(91)91658-Y; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; CAMPBELL DG, 1986, J BIOL CHEM, V261, P489; CLARKE PR, 1990, FEBS LETT, V269, P213, DOI 10.1016/0014-5793(90)81157-J; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DOSKELAND AP, 1984, EUR J BIOCHEM, V145, P31, DOI 10.1111/j.1432-1033.1984.tb08518.x; EDELMAN AM, 1990, MOL CELL BIOCHEM, V97, P87; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FINEMESSER RL, 1996, ONCOGENE, V12, P2725; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARDIE DG, 1986, EUR J BIOCHEM, V157, P553, DOI 10.1111/j.1432-1033.1986.tb09702.x; HARDIE DG, 1995, PROTEIN KINASE FACTS, P128; HASHIMOTO Y, 1990, ARCH BIOCHEM BIOPHYS, V278, P41, DOI 10.1016/0003-9861(90)90228-Q; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P347, DOI 10.1111/j.1432-1033.1988.tb14203.x; IKEBE M, 1990, J BIOL CHEM, V265, P8975; IKEBE M, 1990, J BIOL CHEM, V265, P17607; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKLUND U, 1994, EUR J BIOCHEM, V225, P53, DOI 10.1111/j.1432-1033.1994.00053.x; MARTENSEN TM, 1989, BIOCHEMISTRY-US, V28, P9243, DOI 10.1021/bi00450a002; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MISRA RP, 1994, J BIOL CHEM, V269, P25483; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MOORE S, 1954, J BIOL CHEM, V211, P907; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; PATTON BL, 1990, J BIOL CHEM, V265, P11204; PAYNE ME, 1983, J BIOL CHEM, V258, P2376; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENOLIKAR S, 1988, BIOCHEM BIOPH RES CO, V151, P1332, DOI 10.1016/S0006-291X(88)80508-4; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SODERLING TR, 1986, BIOCHEM BIOPH RES CO, V139, P1017, DOI 10.1016/S0006-291X(86)80279-0; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; Stewart JM, 1984, SOLID PHASE PEPTIDE; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WOODGETT JR, 1983, EUR J BIOCHEM, V136, P481, DOI 10.1111/j.1432-1033.1983.tb07766.x	61	114	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3166	3172		10.1074/jbc.273.6.3166	http://dx.doi.org/10.1074/jbc.273.6.3166			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452427	hybrid			2022-12-25	WOS:000071822300012
J	Cuvillier, O; Rosenthal, DS; Smulson, ME; Spiegel, S				Cuvillier, O; Rosenthal, DS; Smulson, ME; Spiegel, S			Sphingosine 1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during Fas- and ceramide-mediated apoptosis in Jurkat T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; INTERLEUKIN-1-BETA CONVERTING ENZYME; CD95 FAS/APO-1; ICE/CED-3 PROTEASE; PATHWAY; KINASE; CPP32; BCL-2; SPHINGOMYELINASE; INVOLVEMENT	Ceramide, a sphingolipid generated by the hydrolysis of membrane-associated sphingomyelin, appears to play a role as a gauge of apoptosis. A further metabolite of ceramide, sphingosine 1-phosphate (SPP), prevents ceramide-mediated apoptosis, and it has been suggested that the balance between intracellular ceramide and SPP levels may determine the cell fate (Cuvillier, O., Pirianov, G, Kleuser, B., Vanek, P. G., Coso, O. A., Gut-kind, J. S., and Spiegel, S. (1996) Nature 381, 800-803). Here, we investigated the role of SPP and the protein kinase C activator, phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), in the caspase cascade leading to the proteolysis of poly(ADP-ribose) polymerase (PARP) and lamins. In Jurkat T cells, Fas ligation or addition of exogenous C-2-ceramide induced activations of caspase-3/CPP32 and caspase-7/Mch3 followed by PARP cleavage, effects that can be blocked either by SPP or TPA. Furthermore, both SPP and TPA inhibit the activation of caspase-6/Mch2 and subsequent lamin B cleavage. Ceramide, in contrast to Fas ligation, did not induce activation of caspase-8/FLICE and neither SPP nor TPA were able to prevent this activation. Thus, SPP, likely generated via protein kinase C-mediated activation of sphingosine kinase, suppresses the apoptotic pathway downstream of FLICE but upstream of the executioner caspases, caspase-3, -6, and -7.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University	Spiegel, S (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 353 Basic Sci Bldg,3900 Reservoir Rd NW, Washington, DC 20007 USA.		CUVILLIER, Olivier/B-2567-2009; Rosenthal, Dean S/J-2360-2014; CUVILLIER, Olivier/S-1631-2019	CUVILLIER, Olivier/0000-0003-3346-375X; CUVILLIER, Olivier/0000-0003-3346-375X; Rosenthal, Dean/0000-0002-7624-0209	NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880, R37GM043880] Funding Source: NIH RePORTER; NCI NIH HHS [CA61774] Funding Source: Medline; NIGMS NIH HHS [GM43880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chmura SJ, 1996, CANCER RES, V56, P2711; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; DUKE RC, 1992, CURRENT PROTOCOLS IM, V2; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Greidinger EL, 1996, FEBS LETT, V390, P299, DOI 10.1016/0014-5793(96)00678-3; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hasegawa J, 1996, CANCER RES, V56, P1713; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	46	235	247	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2910	2916		10.1074/jbc.273.5.2910	http://dx.doi.org/10.1074/jbc.273.5.2910			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446602	hybrid			2022-12-25	WOS:000071736600057
J	Goldfarb, AN; Lewandowska, K; Pennell, CA				Goldfarb, AN; Lewandowska, K; Pennell, CA			Identification of a highly conserved module in E proteins required for in vivo helix-loop-helix dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; IN-VIVO; NUCLEAR PHOSPHOPROTEIN; INHIBITORY DOMAIN; CRYSTAL-STRUCTURE; HLH PROTEINS; BHLH DOMAIN; ID-PROTEIN; GENE; MYOD	Basic helix-loop-helix (bHLH) transcription factors often function as heterodimeric complexes consisting of a tissue-specific factor such as SCL/tal or MyoD bound to a broadly expressed E protein. bHLH dimerization therefore appears to represent a key regulatory step in cell lineage determination and oncogenesis. Previous functional and structural studies have indicated that the well defined HLH domain is both necessary and sufficient for dimerization. Most of these studies, however, have employed in vitro systems for analysis of HLH dimerization, and their implications for the requirements for in vivo dimerization remain unclear. Using multiple approaches, we have analyzed bHLH dimerization in intact, living cells and have identified a novel domain in E proteins, domain C, which is required for in vivo dimerization. Domain C, which lies just carboxyl-terminal to helix 2 of the HLH domain, represents the most highly conserved region within E proteins and appears to influence the in vivo conformation of the adjacent HLH domain. These results suggest that HLH dimerization in vivo may represent a complex, regulated process that is distinct from HLH dimerization in vitro.	Case Western Reserve Univ, Sch Med, Inst Pathol, Dept Pathol, Cleveland, OH 44106 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	Case Western Reserve University; University of Minnesota System; University of Minnesota Twin Cities	Goldfarb, AN (corresponding author), Case Western Reserve Univ, Sch Med, Inst Pathol, Dept Pathol, Biomed Res Bldg,Rm 936,10900 Euclid Ave, Cleveland, OH 44106 USA.			Pennell, Christopher/0000-0002-2901-6554	NCI NIH HHS [1 R29 CA7204-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; BISHOP P, 1995, J AM CHEM SOC, V117, P8283, DOI 10.1021/ja00136a032; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FAIRMAN R, 1993, P NATL ACAD SCI USA, V90, P10429, DOI 10.1073/pnas.90.22.10429; Fairman R, 1997, PROTEIN SCI, V6, P175; Ferre d'Amare AR, 1993, NATURE, V363, P38; FINKEL T, 1993, J BIOL CHEM, V268, P5; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; GIBSON TJ, 1993, PROTEIN ENG, V6, P41, DOI 10.1093/protein/6.1.41; Goldfarb AN, 1996, J BIOL CHEM, V271, P2683, DOI 10.1074/jbc.271.5.2683; GOLDFARB AN, 1995, BLOOD, V85, P465; GOLDFARB AN, 1992, BLOOD, V80, P2858; GOLDFARB AN, 1994, EXP CELL RES, V214, P481, DOI 10.1006/excr.1994.1285; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Maleki SJ, 1997, BIOCHEMISTRY-US, V36, P6762, DOI 10.1021/bi970262m; Pauza ME, 1997, J IMMUNOL, V158, P3259; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; SHIRAKATA M, 1993, GENE DEV, V7, P2456, DOI 10.1101/gad.7.12a.2456; SHIRAKATA M, 1995, EMBO J, V14, P1766, DOI 10.1002/j.1460-2075.1995.tb07165.x; SHUE GL, 1994, J BIOL CHEM, V269, P2707; STAROVASNIK MA, 1992, BIOCHEMISTRY-US, V31, P9891, DOI 10.1021/bi00156a006; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; Wright WE, 1996, DEV GENET, V19, P131, DOI 10.1002/(SICI)1520-6408(1996)19:2<131::AID-DVG4>3.0.CO;2-A; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	40	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2866	2873		10.1074/jbc.273.5.2866	http://dx.doi.org/10.1074/jbc.273.5.2866			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446597	hybrid			2022-12-25	WOS:000071736600052
J	Schissel, SL; Jiang, XC; Tweedie-Hardman, J; Jeong, TS; Camejo, EH; Najib, J; Rapp, JH; Williams, KJ; Tabas, I				Schissel, SL; Jiang, XC; Tweedie-Hardman, J; Jeong, TS; Camejo, EH; Najib, J; Rapp, JH; Williams, KJ; Tabas, I			Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH - Implications for atherosclerotic lesion development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; APOLIPOPROTEIN-E; MACROPHAGE UPTAKE; AORTIC INTIMA; RECEPTOR; RABBIT; MICE; HYPERCHOLESTEROLEMIA; RETENTION	The subendothelial aggregation and retention of low density lipoprotein (LDL) are key events in atherogenesis, but the mechanisms in vivo are not known. Previous studies have shown that treatment of LDL with bacterial sphingomyelinase (SMase) in vitro leads to the formation of lesion-like LDL aggregates that become retained on extracellular matrix and stimulate macrophage foam cell formation. In addition, aggregated human lesional LDL, but not unaggregated lesional LDL or plasma LDL, shows evidence of hydrolysis by an arterial wall SMase in vivo, and several arterial wall cell types secrete a SMase (S-SMase). S-SMase, however, has a sharp acid pH optimum using a standard in vitro SM-micelle assay. Thus, a critical issue regarding the potential role of S-SMase in atherogenesis is whether the enzyme can hydrolyze lipoprotein-SM, particularly at neutral pH. We now show that S-SMase can hydrolyze and aggregate native plasma LDL at pH 5.5 but not at pH 7.4. Remarkably, LDL modified by oxidation, treatment with phospholipase A(2), or enrichment with apolipoprotein CIII, which are modifications associated with increased atherogenesis, is hydrolyzed readily by S-SMase at pH 7.4. In addition, lipoproteins from the plasma of apolipoprotein E knock-out mice, which develop extensive atherosclerosis, are highly susceptible to hydrolysis and aggregation by S-SMase at pH 7.4; a high SM:PC ratio in these lipoproteins appears to be an important factor in their susceptibility to S-SMase. Most importantly, LDL extracted from human atherosclerotic lesions, which is enriched in sphingomyelin compared with plasma LDL, is hydrolyzed by S-SMase at pH 7.4 10-fold more than same donor plasma LDL, suggesting that LDL is modified in the arterial wall to increase its susceptibility to S-SMase. In summary, atherogenic lipoproteins are excellent substrates for S-SMase, even at neutral pH, making this enzyme a leading candidate for the arterial wall SMase that hydrolyzes LDL-SM and causes subendothelial LDL aggregation.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA; Gothenburg Univ, Wallenberg Lab Cardiovasc Res, S-41345 Gothenburg, Sweden; Inst Pasteur, F-59019 Lille, France; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA; Thomas Jefferson Univ, Div Endocrinol Diabet & Metab Dis, Dorrance H Hamilton Res Labs, Philadelphia, PA 19107 USA	Columbia University; Columbia University; Columbia University; University of Gothenburg; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jefferson University	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.			Williams, Kevin Jon/0000-0002-0000-2159	NHLBI NIH HHS [HL57560, HL 21006, HL56984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057560, P50HL021006, P50HL056984] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD TY, 1986, BIOCHEMISTRY-US, V25, P4415, DOI 10.1021/bi00363a036; AHMAD TY, 1985, J LIPID RES, V26, P1160; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CALLAHAN JW, 1983, J NEUROSCI RES, V10, P151, DOI 10.1002/jnr.490100205; Camejo German, 1993, Current Opinion in Lipidology, V4, P385, DOI 10.1097/00041433-199310000-00007; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CLAVEY V, 1995, ARTERIOSCL THROM VAS, V15, P963, DOI 10.1161/01.ATV.15.7.963; DallingaThie GM, 1997, J CLIN INVEST, V99, P953, DOI 10.1172/JCI119260; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; Dzeletovic S, 1995, CHEM PHYS LIPIDS, V78, P119, DOI 10.1016/0009-3084(95)02489-6; ELSAADANI M, 1989, J LIPID RES, V30, P627; Goldberg IJ, 1996, J LIPID RES, V37, P693; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOFF HF, 1985, ANN NY ACAD SCI, V454, P183, DOI 10.1111/j.1749-6632.1985.tb11857.x; HOFF HF, 1990, EUR HEART J, V11, P105, DOI 10.1093/eurheartj/11.suppl_E.105; HOFF HF, 1983, HDB ELECTROPHORESIS, V3, P133; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P300, DOI 10.1161/01.ATV.17.2.300; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; IVANDIC B, 1996, CIRCULATION, V94, P152; KAARTINEN M, 1994, ARTERIOSCLER THROMB, V14, P966, DOI 10.1161/01.ATV.14.6.966; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; Kinscherf R, 1997, FEBS LETT, V405, P55, DOI 10.1016/S0014-5793(97)00157-9; KREUZER J, 1994, CHEM PHYS LIPIDS, V67-8, P175, DOI 10.1016/0009-3084(94)90137-6; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; MAROUDAS A, 1988, BIOPHYS CHEM, V32, P257, DOI 10.1016/0301-4622(88)87012-1; MasucciMagoulas L, 1997, SCIENCE, V275, P391, DOI 10.1126/science.275.5298.391; Menkin V, 1934, AM J PATHOL, V10, P193; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; PORTMAN OW, 1970, J LIPID RES, V11, P23; PREISS J, 1986, J BIOL CHEM, V261, P8597; PUHL H, 1994, METHOD ENZYMOL, V233, P425; RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767; Rigoli L, 1995, ACTA DIABETOL, V32, P251, DOI 10.1007/BF00576258; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Sartipy P, 1996, J BIOL CHEM, V271, P26307, DOI 10.1074/jbc.271.42.26307; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHNEIDER EG, 1976, BIOCHIM BIOPHYS ACTA, V441, P201, DOI 10.1016/0005-2760(76)90163-6; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P895, DOI 10.1161/01.ATV.9.6.895; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SMITH EB, 1979, ADV EXP MED BIOL, V115, P245; SPENCE MW, 1993, ADV LIPID RES, V26, P3; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; SRIPADA PK, 1987, J LIPID RES, V28, P710; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1993, J BIOL CHEM, V268, P20419; TAPPER H, 1992, BIOCHEM J, V281, P245, DOI 10.1042/bj2810245; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; Tsukamoto Y, 1996, J CLIN INVEST, V98, P1930, DOI 10.1172/JCI118994; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; XU XX, 1991, J BIOL CHEM, V266, P24849; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	70	256	266	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2738	2746		10.1074/jbc.273.5.2738	http://dx.doi.org/10.1074/jbc.273.5.2738			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446580	hybrid			2022-12-25	WOS:000071736600035
J	Nozaki, C; Asai, N; Murakami, H; Iwashita, T; Iwata, Y; Horibe, K; Klein, RD; Rosenthal, A; Takahashi, M				Nozaki, C; Asai, N; Murakami, H; Iwashita, T; Iwata, Y; Horibe, K; Klein, RD; Rosenthal, A; Takahashi, M			Calcium-dependent ret activation by GDNF and neurturin	ONCOGENE			English	Article						Ret; GDNF; neurturin; Ca2+ ion; neuroblastoma	MICE LACKING GDNF; NEUROBLASTOMA CELL-LINES; TYROSINE KINASE; PROTOONCOGENE PRODUCTS; TRANSMITTER SECRETION; HIRSCHSPRUNGS-DISEASE; DOPAMINERGIC-NEURONS; SEQUENCE SIMILARITY; NEUROTROPHIC FACTOR; MOTOR-NEURONS	Glial cell line-derived neurotrophic factor (GDNF) and neurturin (NTN) define a new family of neurotrophic factors that play crucial roles in survival and differentiation of various neurons. Recent studies demonstrated that GDNF and NTN use a multicomponent receptor system in which glycosyl-phosphatidylinositol (GPI)-linked cell surface proteins and Ret receptor tyrosine kinase function as the ligand-binding and signalling components, respectively. In the present study, we investigated the role of Ca2+ ions for biochemical and biological activities of Ret because Ret has a unique structure of the extracellular domain with the cadherin-like motif. The results demonstrated that Ca2+ ions might be required for the complex formation of Ret and GDNF or NTN that induces Ret oligomerization and autophosphorylation. Full morphological differentiation of neuroblastoma cells by these neurotrophic factors was also Ca2+-dependent. These findings thus suggested that, in addition to GPI-linked cell surface proteins, Ca2+ ions are components of the signal transducing complex formed by Ret and GDNF protein family.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 466, Japan; Nagoya Univ, Sch Med, Dept Pediat, Showa Ku, Nagoya, Aichi 466, Japan; Genentech Inc, Dept Neurosci, San Francisco, CA 94080 USA	Nagoya University; Nagoya University; Roche Holding; Genentech	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 466, Japan.		Takahashi, Masahide/AAN-4770-2020; ASAI, Naoya/I-7377-2014; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; 				ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Chakravarti A, 1996, HUM MOL GENET, V5, P303; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Ghosh A, 1996, CURR BIOL, V6, P130, DOI 10.1016/S0960-9822(02)00442-6; IKEDA I, 1990, ONCOGENE, V5, P1291; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Iwashita T, 1996, HUM MOL GENET, V5, P1577, DOI 10.1093/hmg/5.10.1577; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; KUMA K, 1993, MOL BIOL EVOL, V10, P539; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; McAllister AK, 1996, NEURON, V17, P1057, DOI 10.1016/S0896-6273(00)80239-1; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MORIMOTO T, 1995, NEURON, V15, P689, DOI 10.1016/0896-6273(95)90156-6; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1995, CRIT REV ONCOGENESIS, V6, P35, DOI 10.1615/CritRevOncog.v6.i1.30; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0	44	55	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					293	299		10.1038/sj.onc.1201548	http://dx.doi.org/10.1038/sj.onc.1201548			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467954				2022-12-25	WOS:000071582100001
J	Craig, C; Kim, M; Ohri, E; Wersto, R; Katayose, D; Li, ZW; Choi, YH; Mudahar, B; Srivastava, S; Seth, P; Cowan, K				Craig, C; Kim, M; Ohri, E; Wersto, R; Katayose, D; Li, ZW; Choi, YH; Mudahar, B; Srivastava, S; Seth, P; Cowan, K			Effects of adenovirus-mediated p16(INK4A) expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells	ONCOGENE			English	Article						adenovirus; gene therapy; breast cancer; p16; cyclin dependent kinase inhibitors	DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA SUSCEPTIBILITY GENE; TUMOR-SUPPRESSOR GENE; CDK INHIBITORS; POTENTIAL MEDIATOR; GROWTH SUPPRESSION; PRODUCT PRB; PROTEIN; P21; PHOSPHORYLATION	We constructed an adenoviral vector containing human p16 cDNA in order to evaluate the cytotoxic effects of exogenous p16 expression on cancer cell proliferation and to explore the potential use of p16 in cancer gene therapy, Following infection of human breast (MCF-7, MDA-MB-231, and BT549), osteosarcoma (U-2 OS and Saos-2), cervical (C33a), and lung cancer (H358) cell lines with the recombinant adenovirus Adp16, high levels of p16 expression were observed in all cell lines. Cancer cell lines which were mutant or null for p16 but wild-type for the retinoblastoma gene product (pRb) (MCF-7, MDA-MB-231, BT549 and U-2 OS) were 7-22-fold more sensitive to the cytotoxic effects of Adp16 than to a control virus, In contrast, cancer cell lines which were wild-type for p16 but mutant or null for pRb (Saos-2, C33a and H358) were <threefold more sensitive to Adp16 when compared to a control virus, Analysis of 5-bromodeoxyuridine incorporation into DNA following infection with Adp16 showed a loss of S phase in those cell lines which were null or mutant for p16 but expressed a functional pRb. This cell cycle arrest was associated with binding of the p16 protein to cyclin-dependent kinase 4 and dephosphorylation of pRb. In contrast, human cancer cell lines expressing a wild-type p16 and a mutant pRb or no pRb showed no substantial loss of S phase following Adp16 infection. Based on these studies, we conclude that p16-mediated cytotoxicity is tightly associated with the presence of functional pRb in human cancer cells, and that tumor cells which are mutant or null for p16 are candidates for Adp16 mediated cancer gene therapy.	NCI, Med Branch, NIH, Bethesda, MD 20892 USA; NCI, Pathol Branch, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Surg Branch, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA	Seth, P (corresponding author), NCI, Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.							AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; ARAP W, 1995, CANCER RES, V55, P1351; BARTEK J, 1992, ONCOGENE, V7, P101; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Costello JF, 1996, CANCER RES, V56, P2405; CRAIG C, 1997, ONCOGENE, V11, P110; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fueyo J, 1996, ONCOGENE, V12, P103; Geradts J, 1996, AM J PATHOL, V149, P15; GINSBERG HS, 1988, VIROLOGY, P147; GOTTESMAN MM, 1994, J NATL CANCER I, V86, P1277, DOI 10.1093/jnci/86.17.1277; GRAHAM FL, 1991, GENE TRANSFER EXPRES, P109, DOI DOI 10.1385/0-89603-178-0:109; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HERMAN JG, 1995, P AM ASSOC CANC RES, V36, P20; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIN XM, 1995, CANCER RES, V55, P3250; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; Katayose D, 1995, CLIN CANCER RES, V1, P889; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI Y, 1994, ONCOGENE, V9, P2261; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, ONCOGENE, V9, P2159; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SCHUTTE B, 1987, CYTOMETRY, V8, P372, DOI 10.1002/cyto.990080405; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Seth P, 1996, CANCER RES, V56, P1346; SETH P, 1986, VIRUS ATTACHMENT ENT, P191; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	58	111	120	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					265	272		10.1038/sj.onc.1201493	http://dx.doi.org/10.1038/sj.onc.1201493			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464545				2022-12-25	WOS:000071427100014
J	Kim, SK; Su, LK; Oh, Y; Kemp, BL; Hong, WK; Mao, L				Kim, SK; Su, LK; Oh, Y; Kemp, BL; Hong, WK; Mao, L			Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines	ONCOGENE			English	Article						SCLC; PTEN/MMAC1; PTH2; chromosome 9; tumor suppressor	HOMOZYGOUS DELETION; CARCINOMA; MUTATIONS; RB; PROTEIN; CDKN2	Loss of heterozygosity (LOH) at chromosome 10q23-q25 is frequent in small cell lung cancer (SCLC), indicating the presence of putative tumor suppressor genes, PTEN/MMAC1, a newly cloned candidate tumor suppressor gene at 10q23, was mutated in multiple human cancers, We investigated whether mutations of PTEN/MMAC1 play an important role in SCLC tumorigenesis, We examined 16 SCLC cell lines for PTEN/MMAC1 mRNA expression by reverse-transcriptase polymerase chain reaction (RT-PCR) and potential mutations by sequencing analysis of the PTEN/MMAC1 coding region, No mutation was observed in PTEN/MMAC1 cDNAs in 15 cell lines expressing PTEN/MMAC1, One SCLC cell line, DMS79, did not have detectable PTEN/MMAC1 expression, Importantly, we identified a novel homologue of PTEN/MMAC1, termed PTH2, localized to chromosome 9p21-q13 and containing only ten amino acid substitutions compared with the PTEN/MMAC1 coding region, However, because the putative initiation codon for PTEN/MMAC1 gene was changed to arginine in PTH2, the translational initiation site of PTH2 is very likely to differ from that of the PTEN/MMAC1, PTH2 was expressed in two normal lung tissues and two normal colon tissues, but in only four of 16 SCLC cell lines, A missense mutation in PTH2 was identified in a SCLC cell line that did not express PTEN/MMAC1 mRNA, Our data suggest that inactivation of PTEN/MMAC1 is a rare event in SCLC tumorigenesis, However, the PTEN/MMAC1 homologue PTH2 may play a role in SCLC tumorigenesis.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mao, L (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358	NATIONAL CANCER INSTITUTE [P50CA070907, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA 70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; FEARON ER, 1990, CELL, V61, P757; HOSOE S, 1994, CANCER RES, V54, P1787; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; Kim SK, 1997, CANCER RES, V57, P400; Kim SK, 1996, CANCER RES, V56, P2519; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MERLO A, 1994, CANCER RES, V54, P2322; MERLO A, 1994, CANCER RES, V54, P640; MILLER CW, 1992, CANCER RES, V52, P1695; MORI N, 1990, ONCOGENE, V5, P1713; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Ohta M, 1996, INT J CANCER, V65, P762, DOI 10.1002/(SICI)1097-0215(19960315)65:6<762::AID-IJC9>3.0.CO;2-X; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; RIED T, 1994, CANCER RES, V54, P1801; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Wiest JS, 1997, CANCER RES, V57, P1; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	26	54	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					89	93		10.1038/sj.onc.1201512	http://dx.doi.org/10.1038/sj.onc.1201512			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467947	Bronze			2022-12-25	WOS:000071236800011
J	Brenneisen, P; Wenk, J; Klotz, LO; Wlaschek, M; Briviba, K; Krieg, T; Sies, H; Scharffetter-Kochanek, K				Brenneisen, P; Wenk, J; Klotz, LO; Wlaschek, M; Briviba, K; Krieg, T; Sies, H; Scharffetter-Kochanek, K			Central role of ferrous/ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; MURINE SKIN FIBROBLASTS; FREE-RADICAL REACTIONS; EXPOSURE IN-VITRO; HYDROGEN-PEROXIDE; LIPID-PEROXIDATION; GENE-EXPRESSION; OZONE DEPLETION; TRANSCRIPTIONAL ACTIVATION; 5'-FLANKING REGION	Reactive oxygen species (ROS) are important second messengers for the induction of several genes in a variety of physiological and pathological conditions. Ultraviolet B (UVB) irradiation has recently been shown to generate lipid peroxidation products and hydroxyl radicals (HO.) with detrimental long term effects like cancer formation and premature aging of the skin, Here, we addressed the question of whether ferric/ferrous iron via the generation of ROS may mediate the UVB response, finally leading to connective tissue degradation, a hallmark in carcinogenesis and aging. Therefore, we studied the involvement of iron and ROS in the modulation of Jun N-terminal kinase 2 (JNK2) activity, c-jun and c-fos mRNA levels, key signaling steps in the transcriptional control of matrix-degrading metalloprotease (MMP)-1/interstitial collagenase and MMP-3/stromelysin-1 after-UVB irradiation of human dermal fibroblasts in vitro. The iron-driven generation of lipid peroxides and hydroxyl radicals were identified as early events in the downstream signaling pathway of the UVB response leading to a 15-fold increase in JNK2 activity, a 3.5-fold increase in c-jun, to a 6-fold increase in MMP-1, and a 3.8-fold increase in MMP-3 mRNA levels, while virtually no alteration of c-fos mRNA levels were observed. Diminished generation of reactive oxygen species resulted in a significant reduction of JNK2 activity, c-jun, MMP-1, and MMP-3 mRNA levels after WE irradiation compared with UVB-irradiated cells. Collectively, we have identified the iron-driven Fenton reaction and lipid peroxidation as possible central mechanisms underlying signal transduction of the UVB response.	Univ Cologne, Dept Dermatol, D-50924 Cologne, Germany; Univ Dusseldorf, Inst Physiol Chem 1, D-40225 Dusseldorf, Germany	University of Cologne; Heinrich Heine University Dusseldorf	Scharffetter-Kochanek, K (corresponding author), Univ Cologne, Dept Dermatol, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.		Sies, Helmut/B-7266-2008; Klotz, Lars Oliver/AAC-5051-2019; Sies, Helmut/ABE-7355-2020	Sies, Helmut/0000-0002-1000-3198; Klotz, Lars Oliver/0000-0002-1261-8911; Briviba, Karlis/0000-0003-3338-7515				Aalto K, 1996, TOXICOL LETT, V85, P93, DOI 10.1016/0378-4274(96)03645-4; Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; ALCANTARA O, 1994, BLOOD, V84, P3510; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1985, J CELL BIOCHEM, V29, P351, DOI 10.1002/jcb.240290408; Ariizumi K, 1996, J DERMATOL SCI, V12, P147, DOI 10.1016/0923-1811(95)00474-2; BABBS CF, 1990, FREE RADICAL BIO MED, V8, P471, DOI 10.1016/0891-5849(90)90060-V; BAYREUTHER K, 1992, ARCH GERONTOL GERIAT, P47, DOI 10.1016/S0167-4943(05)80006-8; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BIEMOND P, 1988, FREE RADICAL BIO MED, V4, P185, DOI 10.1016/0891-5849(88)90026-3; BISSETT DL, 1991, PHOTOCHEM PHOTOBIOL, V54, P215, DOI 10.1111/j.1751-1097.1991.tb02009.x; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; Brenneisen P, 1996, PHOTOCHEM PHOTOBIOL, V64, P649, DOI 10.1111/j.1751-1097.1996.tb03119.x; Brenneisen P, 1997, FREE RADICAL BIO MED, V22, P515, DOI 10.1016/S0891-5849(96)00404-2; BRENNEISEN P, 1994, EXP CELL RES, V211, P219, DOI 10.1006/excr.1994.1081; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x; BURDON RH, 1989, FREE RADICAL RES COM, V7, P149, DOI 10.3109/10715768909087937; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CERUTTI PA, 1994, LANCET, V344, P862, DOI 10.1016/S0140-6736(94)92832-0; CHEESEMAN KH, 1993, DNA FREE RADICALS, P109; CHOI HS, 1993, MOL ENDOCRINOL, V7, P1596, DOI 10.1210/me.7.12.1596; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; CRAWFORD HC, 1994, INVAS METAST, V14, P234; CRUTZEN PJ, 1992, NATURE, V356, P104, DOI 10.1038/356104a0; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; DEAN RT, 1994, FREE RADICAL RES, V20, P83, DOI 10.3109/10715769409147506; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fisher GJ, 1996, J INVEST DERMATOL, V107, P7; FLEISCHMAJER R, 1981, J INVEST DERMATOL, V76, P400, DOI 10.1111/1523-1747.ep12520933; GAIRE M, 1994, J BIOL CHEM, V269, P2032; Garmyn M, 1997, J PHOTOCH PHOTOBIO B, V37, P125, DOI 10.1016/S1011-1344(96)07340-X; GILCHREST BA, 1989, J AM ACAD DERMATOL, V21, P610, DOI 10.1016/S0190-9622(89)70227-9; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HANTZE MW, 1995, INDUCIBLE GENE EXPRE, V1, P241; Herrmann G, 1993, Exp Dermatol, V2, P92, DOI 10.1111/j.1600-0625.1993.tb00015.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IIZAWA O, 1994, ARCH DERMATOL RES, V286, P47, DOI 10.1007/BF00375843; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON RA, 1992, J PHOTOCH PHOTOBIO B, V14, P345, DOI 10.1016/1011-1344(92)85113-9; Lee SF, 1996, FREE RADICAL BIO MED, V21, P437, DOI 10.1016/0891-5849(96)00040-8; LIN F, 1993, ARCH BIOCHEM BIOPHYS, V300, P714, DOI 10.1006/abbi.1993.1099; LLOYD SA, 1993, LANCET, V342, P1156, DOI 10.1016/0140-6736(93)92130-L; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; MAJMUDAR G, 1994, MOL CARCINOGEN, V9, P17, DOI 10.1002/mc.2940090105; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MASAKI H, 1995, BIOCHEM BIOPH RES CO, V206, P474, DOI 10.1006/bbrc.1995.1067; MASAKI H, 1995, J DERMATOL SCI, V10, P25, DOI 10.1016/0923-1811(95)93711-9; MELEFORS O, 1993, BLOOD REV, V7, P251, DOI 10.1016/0268-960X(93)90012-S; MELLO AC, 1984, BIOCHIM BIOPHYS ACTA, V781, P56, DOI 10.1016/0167-4781(84)90123-4; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MINOTTI G, 1992, LIPIDS, V27, P219, DOI 10.1007/BF02536182; Muller JM, 1997, EUR J BIOCHEM, V244, P45, DOI 10.1111/j.1432-1033.1997.00045.x; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; OSHIRO S, 1994, J BIOCHEM-TOKYO, V115, P849, DOI 10.1093/oxfordjournals.jbchem.a124428; Perez S., 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P453; PETERSEN MJ, 1992, J INVEST DERMATOL, V99, P440, DOI 10.1111/1523-1747.ep12616142; PIETARINEN P, 1995, AM J RESP CELL MOL, V13, P434, DOI 10.1165/ajrcmb.13.4.7546773; RIAZULHAQ, 1995, EXP HEMATOL, V23, P428; Sawamura D, 1996, ARCH DERMATOL RES, V288, P628, DOI 10.1007/s004030050115; SCHAICH KM, 1992, LIPIDS, V27, P209, DOI 10.1007/BF02536181; SCHARFFETTER K, 1991, ARCH DERMATOL RES, V283, P506, DOI 10.1007/BF00371923; SCHARFFETTERKOC.K, 1992, ENV THREAT SKIN, P72; SCHARFFETTERKOCHANEK K, 1993, FEBS LETT, V331, P304, DOI 10.1016/0014-5793(93)80357-Z; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; SIRUM KL, 1989, BIOCHEMISTRY-US, V28, P8691, DOI 10.1021/bi00448a004; Slaper H, 1996, NATURE, V384, P256, DOI 10.1038/384256a0; Spear N, 1995, ARCH BIOCHEM BIOPHYS, V324, P111, DOI 10.1006/abbi.1995.9921; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VANLENTEN BJ, 1995, J CLIN INVEST, V95, P2104, DOI 10.1172/JCI117898; WLASCHEK M, 1995, J INVEST DERMATOL, V104, P194, DOI 10.1111/1523-1747.ep12612751; WLASCHEK M, 1994, PHOTOCHEM PHOTOBIOL, V59, P550, DOI 10.1111/j.1751-1097.1994.tb02982.x; ZENG LH, 1995, CORNEA, V14, P509	83	178	192	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5279	5287		10.1074/jbc.273.9.5279	http://dx.doi.org/10.1074/jbc.273.9.5279			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478985	hybrid			2022-12-25	WOS:000072310400069
J	Remy, E; de Rocquigny, H; Petitjean, P; Muriaux, D; Theilleux, V; Paoletti, J; Roques, BP				Remy, E; de Rocquigny, H; Petitjean, P; Muriaux, D; Theilleux, V; Paoletti, J; Roques, BP			The annealing of tRNA(3)(Lys) to human immunodeficiency virus type 1 primer binding site is critically dependent on the NCp7 zinc fingers structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 NUCLEOCAPSID PROTEIN; MURINE LEUKEMIA-VIRUS; GENOMIC RNA; H-1-NMR; ELEMENTS; RETROVIRUSES; DIMERIZATION; INFECTIVITY; SEQUENCE; PEPTIDES	The nucleocapsid protein NCp7 of the human immunodeficiency virus type 1 contains two zinc fingers of the CX2CX4HX4C type, flanked by several basic residues, and plays a major role in viral infectivity. Thus, NCp7 was shown to promote annealing of the tRNA(3)(Lys) to the primer binding site, a key step in reverse transcription. However; previous in vitro experiments were unable to clarify the role of the zinc fingers in this process, due to nucleic acid aggregation induced by the basic N- and C-terminal domains of NCp7. We show here that deletion of these sequences in (12-53)NCp7 strongly reduces the formation of aggregates and allows a direct visualization of the binary or ternary complexes between NCp7 and nucleic acids by gel electrophoresis. (12-53)NCp7 is able to induce hybridization of the P-33 tRNA(3)(Lys) and the human immunodeficiency virus type 1 viral RNA-(77-257), which contains the primer binding site. Modification of the proximal zinc finger conformation in Cys(23)(12-53)NCp7 led to a large reduction in this hybridization process, while replacement of Trp(37) by Leu in the distal zinc fingers resulted in a complete absence of annealing activity. These data account for the in vivo loss of viral infectivity following these mutations and emphasize the critical role of the structure of the zinc finger domain of NCp7. This could facilitate a rational approach to new antiviral agents directed toward NCp7.	UFR Sci Pharmaceut, CNRS, URA D1500,Dept Pharmacochim Mol & Struct, INSERM,U266,Unite Pharmacochim Mol & Struct, F-75270 Paris 06, France; Inst Gustave Roussy, CNRS, URA 147, Lab Pharmacol & Physicochim Macromol, F-94805 Villejuif, France; Inst Pasteur, Dept Biochim & Genet Mol, CNRS URA 487, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Roques, BP (corresponding author), UFR Sci Pharmaceut, CNRS, URA D1500,Dept Pharmacochim Mol & Struct, INSERM,U266,Unite Pharmacochim Mol & Struct, 4 Ave Observatoire, F-75270 Paris 06, France.							ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERKOWITZ RD, 1994, VIROLOGY, V202, P233, DOI 10.1006/viro.1994.1339; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; COFFIN JM, 1990, RETROVIRIDAE THEIR R, V51, P1437; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEMENE H, 1994, BIOCHEMISTRY-US, V33, P11707, DOI 10.1021/bi00205a006; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DORFMAN T, 1993, J VIROL, V67, P6159, DOI 10.1128/JVI.67.10.6159-6169.1993; GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990; GORELICK RJ, 1996, RETROVIRUSES 1996S R, P356; Huang Y, 1997, J VIROL, V71, P4378, DOI 10.1128/JVI.71.6.4378-4384.1997; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Khan R, 1996, NUCLEIC ACIDS RES, V24, P3568, DOI 10.1093/nar/24.18.3568; LAM WC, 1994, BIOCHEMISTRY-US, V33, P10693, DOI 10.1021/bi00201a017; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V21, P831; Li XG, 1996, J VIROL, V70, P4996, DOI 10.1128/JVI.70.8.4996-5004.1996; MELY Y, 1991, BIOPOLYMERS, V31, P899, DOI 10.1002/bip.360310709; Mely Y, 1996, BIOCHEMISTRY-US, V35, P5175, DOI 10.1021/bi952587d; MELY Y, 1995, J BIOL CHEM, V270, P1650, DOI 10.1074/jbc.270.4.1650; MERIC C, 1984, J MOL BIOL, V173, P531, DOI 10.1016/0022-2836(84)90396-6; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MORELLET N, 1994, J MOL BIOL, V235, P287, DOI 10.1016/S0022-2836(05)80033-6; MURIAUX D, 1995, J BIOL CHEM, V270, P8209, DOI 10.1074/jbc.270.14.8209; OTTMANN M, 1995, J VIROL, V69, P1778, DOI 10.1128/JVI.69.3.1778-1784.1995; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; Roques BP, 1997, BIOCHIMIE, V79, P673, DOI 10.1016/S0300-9084(97)83501-8; Stoylov SP, 1997, BIOPOLYMERS, V41, P301, DOI 10.1002/(SICI)1097-0282(199703)41:3&lt;301::AID-BIP5&gt;3.0.CO;2-W; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; SUROVOY A, 1993, J MOL BIOL, V229, P94, DOI 10.1006/jmbi.1993.1011; VANBEVEREN C, 1984, RNA TUMOR VIRUSES, V2, P559; VERONESE FD, 1987, AIDS RES HUM RETROV, V3, P253, DOI 10.1089/aid.1987.3.253; Yu QA, 1996, J VIROL, V70, P5791, DOI 10.1128/JVI.70.9.5791-5798.1996	36	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4819	4822		10.1074/jbc.273.9.4819	http://dx.doi.org/10.1074/jbc.273.9.4819			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478919	hybrid			2022-12-25	WOS:000072310400003
J	Zhu, XD; Sadowski, PD				Zhu, XD; Sadowski, PD			The role of single-stranded DNA in Flp-mediated strand exchanged	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; 2-MU-M CIRCLE PLASMID; SACCHAROMYCES-CEREVISIAE; TARGET SEQUENCE; HOLLIDAY JUNCTIONS; INTEGRASE FAMILY; BINDING DOMAIN; CHI-STRUCTURES; PROTEIN; LIGATION	The Flp recognition target site contains two inverted 13-base pair (bp) Flp binding sequences that surround an 8-bp core region. Flp recombinase has been shown to carry out strand ligation independently of its ability to execute strand cleavage. Using a synthetic activated DNA substrate bearing a S'-phosphotyrosine group, we have developed an assay to measure strand exchange by Flp proteins. We have shown that wild-type Flp protein was able to catalyze strand exchange using DNA substrates containing 8-bp duplex core sequences. Mutant Flp proteins that are defective in either DNA bending or DNA cleavage were also impaired in their abilities to carry out strand exchange. The inability of these mutant proteins to execute strand exchange could be overcome by providing a DNA substrate containing a single-stranded core sequence. This single-stranded core sequence could be as small as 3 nucleotides. Full activity of mutant Flp proteins in strand exchange was observed when both partner DNAs contained an 8-nucleotide single-stranded core region. Using suicide substrates, we showed that single-stranded DNA is also important for strand exchange reactions where Pip-mediated strand cleavage is required. These results suggest that the ability of Flp to induce DNA bending and strand cleavage may be crucial for strand, exchange. We propose that both DNA bending and strand cleavage may be required to separate the strands of the core region and that single-stranded DNA in the core region might be an intermediate in Pip-mediated DNA recombination.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto	Sadowski, PD (corresponding author), Univ Toronto, Dept Mol & Med Genet, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	P.Sadowski@utoronto.ca		Zhu, Xu-Dong/0000-0003-1859-3134				ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; AMIN AA, 1989, MOL CELL BIOL, V9, P1987, DOI 10.1128/MCB.9.5.1987; AMIN AA, 1990, J MOL BIOL, V214, P55, DOI 10.1016/0022-2836(90)90146-D; ANDREWS BJ, 1987, J MOL BIOL, V193, P345, DOI 10.1016/0022-2836(87)90223-3; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BEATTY LG, 1988, J MOL BIOL, V204, P283, DOI 10.1016/0022-2836(88)90576-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CameriniOtero RD, 1995, ANNU REV GENET, V29, P509, DOI 10.1146/annurev.genet.29.1.509; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; DIXON JE, 1995, MOL MICROBIOL, V18, P449, DOI 10.1111/j.1365-2958.1995.mmi_18030449.x; DIXON JE, 1994, J MOL BIOL, V243, P199, DOI 10.1006/jmbi.1994.1647; DIXON JE, 1993, J MOL BIOL, V234, P522, DOI 10.1006/jmbi.1993.1608; EVANS BR, 1990, J BIOL CHEM, V265, P18504; FUTCHER AB, 1986, J THEOR BIOL, V119, P197, DOI 10.1016/S0022-5193(86)80074-1; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P2320; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; JAYARAM M, 1985, P NATL ACAD SCI USA, V82, P5875, DOI 10.1073/pnas.82.17.5875; JAYARAM M, 1988, P NATL ACAD SCI USA, V85, P7902, DOI 10.1073/pnas.85.21.7902; JAYARAM M, 1994, TRENDS BIOCHEM SCI, V19, P78, DOI 10.1016/0968-0004(94)90039-6; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEE J, 1995, J BIOL CHEM, V270, P4042, DOI 10.1074/jbc.270.8.4042; Luetke KH, 1997, NUCLEIC ACIDS RES, V25, P4240, DOI 10.1093/nar/25.21.4240; MEYERLEON L, 1990, MOL CELL BIOL, V10, P235, DOI 10.1128/MCB.10.1.235; MEYERLEON L, 1988, MOL CELL BIOL, V8, P3784, DOI 10.1128/MCB.8.9.3784; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; PAN G, 1993, THESIS U TORONTO; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; PAN GH, 1992, J BIOL CHEM, V267, P12397; PAN GH, 1993, J BIOL CHEM, V268, P3683; PAN H, 1991, J BIOL CHEM, V266, P11347; PANIGRAHI GB, 1992, NUCLEIC ACIDS RES, V20, P5927, DOI 10.1093/nar/20.22.5927; PRASAD PV, 1987, P NATL ACAD SCI USA, V84, P2189, DOI 10.1073/pnas.84.8.2189; PROTEAU G, 1986, NUCLEIC ACIDS RES, V14, P4787, DOI 10.1093/nar/14.12.4787; REYNOLDS AE, 1987, MOL CELL BIOL, V7, P3566, DOI 10.1128/MCB.7.10.3566; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SADOWSKI PD, 1995, PROG NUCLEIC ACID RE, V51, P53, DOI 10.1016/S0079-6603(08)60876-4; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; VOLKERT FC, 1986, CELL, V46, P541, DOI 10.1016/0092-8674(86)90879-2; ZHU XD, 1995, J BIOL CHEM, V270, P11646, DOI 10.1074/jbc.270.19.11646; ZHU XD, 1995, J BIOL CHEM, V270, P23044, DOI 10.1074/jbc.270.39.23044	46	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4921	4927		10.1074/jbc.273.9.4921	http://dx.doi.org/10.1074/jbc.273.9.4921			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478936	hybrid			2022-12-25	WOS:000072310400020
J	Rodriguez-Villanueva, J; Greenhalgh, D; Wang, XJ; Bundman, D; Cho, S; Delehedde, M; Roop, D; McDonnell, TJ				Rodriguez-Villanueva, J; Greenhalgh, D; Wang, XJ; Bundman, D; Cho, S; Delehedde, M; Roop, D; McDonnell, TJ			Human keratin-1,bcl-2 transgenic mice aberrantly express keratin 6, exhibit reduced sensitivity to keratinocyte cell death induction, and are susceptible to skin tumor formation	ONCOGENE			English	Article						bcl-2; apoptosis; keratinocyte; skin cancer	IN-VIVO PATTERNS; WILD-TYPE P53; IMMUNOHISTOCHEMICAL ANALYSIS; EPIDERMAL DIFFERENTIATION; BCL-2 PROTEIN; HAIR FOLLICLE; APOPTOSIS; GENE; CARCINOGENESIS; LYMPHOMA	Nonmelanoma skin cancers (NMSC) are among the most common malignancies in the world. Typically, these neoplasms grow slowly and are comparatively indolent in their clinical behavior. The most frequent molecular alterations implicated in the pathogenesis of these neoplasms involve genes known to be regulators of cell death including p53, Ha-ras and bcl-2. In order to evaluate the significance cell death deregulation during skin carcinogenesis, we generated a transgenic mouse model (HK1.bcl-2) using the human keratin 1 promoter to target the expression of a human bcl-2 minigene to the epidermis. Transgenic HK1.bcl-2 protein was expressed at high levels specifically in the epidermis extending from the stratum basale through the stratum granulosum. The epidermis of HK1.bcl-2 mice exhibited multifocal hyperplasia without associated hyperkeratosis and aberrant expression of keratin 6. The rate of proliferation was similar in HK1.bcl-2 and control epidermis although suprabasal BrdUrd incorporating cells were present only in HK1.bcl-2 skin, Keratinocytes from the HK1.bcl-2 mice mere significantly more resistant to cell death induction by U.V.-B, DMBA, and TPA, compared to central keratinocytes. Furthermore, papillomas developed at a significantly greater frequency and shorter latency in the HK1.bcl-2 mice compared to control littermates following initiation with DMBA and promotion with TPA. Together these results support a role for bcl-2 in the pathogenesis of NMSC.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77077 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77077 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	McDonnell, TJ (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, 1515 Holcombe Blvd,Box 89, Houston, TX 77077 USA.			DELEHEDDE, Maryse/0000-0003-2724-143X	NATIONAL CANCER INSTITUTE [R01CA052607, P01CA068233] Funding Source: NIH RePORTER; NCI NIH HHS [CA52607, CA68233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARBEIT JM, 1996, SKIN CANC, P7; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BROWN K, 1995, CANCER METAST REV, V14, P113, DOI 10.1007/BF00665795; BURNS PA, 1991, ONCOGENE, V6, P2363; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DANNO K, 1987, PHOTOCHEM PHOTOBIOL, V45, P683, DOI 10.1111/j.1751-1097.1987.tb07401.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENHALG DA, 1995, SKIN CANC MECHANISMS, P317; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KANJILAL S, 1993, CANCER RES, V53, P2961; Krajewski S, 1996, CANCER RES, V56, P2849; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; MARIN MC, 1994, ONCOGENE, V9, P3107; MARTHINUSS J, 1995, CELL GROWTH DIFFER, V6, P239; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V9, P701; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; QUILAN RA, 1985, ANN NY ACAD, V455, P282; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RADY P, 1992, CANCER RES, V52, P3804; RODRIGUEZVILLANUEVA J, 1995, PATHOL RES PRACT, V191, P391, DOI 10.1016/S0344-0338(11)80724-7; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; ROTHNAGEL JA, 1990, J INVEST DERMATOL, V94, P573; ROTHNAGEL JA, 1991, CELL GROWTH DIFFER, V2, P107; SCHWEIZER J, 1982, CANCER RES, V42, P1517; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STARK HJ, 1987, DIFFERENTIATION, V35, P236, DOI 10.1111/j.1432-0436.1987.tb00174.x; STENN KS, 1994, J INVEST DERMATOL, V103, P107, DOI 10.1111/1523-1747.ep12391844; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WANG YS, 1993, ONCOGENE, V8, P3427; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; ZINKEL S, 1994, SEMIN CANCER BIOL, V5, P77	49	74	75	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					853	863		10.1038/sj.onc.1201610	http://dx.doi.org/10.1038/sj.onc.1201610			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484776				2022-12-25	WOS:000072053200004
J	Bochkareva, E; Frappier, L; Edwards, AM; Bochkarev, A				Bochkareva, E; Frappier, L; Edwards, AM; Bochkarev, A			The RPA32 subunit of human replication protein A contains a single-stranded DNA-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL DOMAINS; 70-KDA SUBUNIT; COMPLEX; PHOSPHORYLATION; EXPRESSION; POLYMERASE; INITIATION; KINASE; GENES	Replication protein A (RPA) is a conserved nuclear single-stranded DMA (ssDNA)-binding protein, Human RPA (hRPA) comprises three subunits of approximately 70, 32, and 14 kDa (hRPA70, hRPA32 and hRPA14), RPA is known to bind ssDNA through two ssDNA-binding domains in the RPA70 subunit. Here, we demonstrate that the complex of hRPA32 and hRPA14 has an ssDNA-binding domain, Limited proteolysis of the hRPA14.32 complex defined a cars dimes composed of the central region of hRPA32 (amino acids 43-171) and RPA14. The core dimes bound ssDNA with an affinity of approximately 10-50 mu M, which is at least 100-fold more avid than the DNA-binding affinity of the intact dimer. Analysis of the predicted secondary structure of hRPA32 suggests that amino acids 63-150 of hRPA32 form an ssDNA-binding domain similar in structure to each of those in hRPA70, The complex of hRPA14 and hRPA32-(43-171) in turn formed a trimeric complex with the C-terminal region of hRPA70 (amino acids 436-616), The ssDNA-binding affinity of this trimeric complex was 3 to 5-fold higher than hRPA14.32-(43-171) alone, suggesting a role far the C terminus of hRPA70 in ssDNA binding.	Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Toronto, ON M5G 1L6, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Frappier, L (corresponding author), Natl Canc Inst, Toronto, ON, Canada.	lori.frappier@utoronto.ca		Edwards, Aled/0000-0002-4782-6016				Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P5586, DOI 10.1021/bi9526995; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Iftode C, 1997, MOL CELL BIOL, V17, P3876, DOI 10.1128/MCB.17.7.3876; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LI L, 1995, MOL CELL BIOL, V15, P5396; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Pfuetzner RA, 1997, J BIOL CHEM, V272, P430; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; Raghunathan S, 1997, P NATL ACAD SCI USA, V94, P6652, DOI 10.1073/pnas.94.13.6652; Rost B, 1996, METHOD ENZYMOL, V266, P525; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yang C, 1997, NAT STRUCT BIOL, V4, P153, DOI 10.1038/nsb0297-153	35	96	100	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3932	3936		10.1074/jbc.273.7.3932	http://dx.doi.org/10.1074/jbc.273.7.3932			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461578	hybrid			2022-12-25	WOS:000072048400020
J	Mehta, VB; Connors, L; Wang, HCR; Chiu, IM				Mehta, VB; Connors, L; Wang, HCR; Chiu, IM			Fibroblast variants nonresponsive to fibroblast growth factor 1 are defective in its nuclear translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS; SIGNAL-TRANSDUCTION; MAP KINASE; FACTOR RECEPTOR; POINT MUTATION; MESODERM INDUCTION; MITOGEN; IMPORT; CELLS	Fibroblast growth factors (FGF) elicit biological effects by binding to high affinity cell-surface receptors and activation of receptor tyrosine kinase. We previously reported that two NIH/3T3 derivatives, NR31 and NR33 (NR cells), express high levels of full-length FGF-1 and exhibit a complete spectrum of transformed phenotype, In the present study, we report that NR cells respond to the mitogenic stimulation of truncated FGF-1 but not to the full-length FGF-1. Incubation of the NR cells with either form of FGF-1 resulted in its binding to cell-surface FGF receptors, activation of mitogen-activated protein (MAP) kinase, and induction of c-fos and c-myc, These data demonstrate that the FGF receptor-mediated, MAP kinase-dependent signaling pathway is not defective in the NR cells. Our data further suggest that the activation of MAP kinase in response to full-length FGF-1 is not sufficient for mitogenesis. Subcellular distribution of exogenously added FGF-1 demonstrated that full-length FGF-1 fails to translocate to the nuclei of NR31 cells, Although the full-length FGF-1 was detected in the nuclear fractions of both NIH/3T3 and NR33 cells, its half-life is much shortened in NR33 than in NIH/3T3 cells, These observations suggest that nonresponsiveness of the two NR cell lines may be due to defectiveness at different steps of nuclear translocation mechanism of FGF-1.	Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	Ohio State University; James Cancer Hospital & Solove Research Institute; Ohio State University	Chiu, IM (corresponding author), Ohio State Univ, Dept Internal Med, 480 W 9th Ave, Columbus, OH 43210 USA.	chiu.1@osu.edu	Chiu, Ing-Ming/B-1534-2008; Wang, Hwa-Chain/L-5646-2015	Wang, Hwa-Chain/0000-0001-5836-4120	NATIONAL CANCER INSTITUTE [R01CA045611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047506] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA45611] Funding Source: Medline; NIDDK NIH HHS [R01DK47506] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1993, ONCOGENE, V8, P2015; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Patrie KM, 1997, GROWTH FACTORS, V14, P39, DOI 10.3109/08977199709021509; PATRIE KM, 1995, J BIOL CHEM, V270, P29018, DOI 10.1074/jbc.270.48.29018; PELECH SL, 1993, CURR BIOL, V3, P513, DOI 10.1016/0960-9822(93)90043-N; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Renaud F, 1996, J BIOL CHEM, V271, P2801, DOI 10.1074/jbc.271.5.2801; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SETH A, 1991, J BIOL CHEM, V266, P23521; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; STURGILL TW, 1991, METHOD ENZYMOL, V200, P342; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270	52	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4197	4205		10.1074/jbc.273.7.4197	http://dx.doi.org/10.1074/jbc.273.7.4197			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461616	hybrid			2022-12-25	WOS:000072048400058
J	Mogridge, J; Mah, TF; Greenblatt, J				Mogridge, J; Mah, TF; Greenblatt, J			Involvement of boxA nucleotides in the formation of a stable ribonucleoprotein complex containing the bacteriophage lambda N protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ANTITERMINATION FACTORS; NUSA GENE PROTEIN; ESCHERICHIA-COLI; PHAGE-LAMBDA; RNA-POLYMERASE; ANTI-TERMINATION; RECOGNITION SITE; COLIPHAGE-LAMBDA; NUTL; SEQUENCE	The association of the transcriptional antitermination protein N of bacteriophage lambda with Escherichia coli RNA polymerase depends on nut site RNA (boxA + boxB) in the nascent transcript and the host protein, NusA. This ribonucleoprotein complex can transcribe through Rho dependent and intrinsic termination sites located up to several hundred base pairs downstream of nut. For antitermination to occur farther downstream, this core antitermination complex must be stabilized by the host proteins NusB, NusG, and ribosomal protein S10. Here, we show that the assembly of NusB, NusG, and S10 onto the core complex involves nucleotides 2-7 of lambda boxA (CGCUCUUACACA) and is a fully cooperative process that depends on the presence of all three proteins. This assembly of NusB, NusG, and S10 also requires the carboxyl-terminal region (amino acids 73-107) of N, which interacts directly with RNA polymerase. NusB and S10 assemble in the absence of NusG when lambda boxA is altered at nucleotides 8 and 9 to create a consensus version of boxA (CGCUCUUUAACA). These experiments suggest that multiple protein-protein and protein-RNA interactions are required to convert a core antitermination complex into a complete complex.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Greenblatt, J (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.							BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BARON J, 1992, J BACTERIOL, V174, P1983, DOI 10.1128/jb.174.6.1983-1989.1992; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; CHATTOPADHYAY S, 1995, P NATL ACAD SCI USA, V92, P4061, DOI 10.1073/pnas.92.9.4061; DAS A, 1984, CELL, V80, P5530; DEVITO J, 1994, P NATL ACAD SCI USA, V91, P8660, DOI 10.1073/pnas.91.18.8660; DOELLING JH, 1989, NUCLEIC ACIDS RES, V17, P5565, DOI 10.1093/nar/17.14.5565; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GODA Y, 1985, NUCLEIC ACIDS RES, V13, P2569, DOI 10.1093/nar/13.7.2569; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LI J, 1992, J BIOL CHEM, V267, P6012; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; MASON SW, 1992, J MOL BIOL, V223, P55, DOI 10.1016/0022-2836(92)90715-V; MASON SW, 1992, J BIOL CHEM, V267, P19418; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; MOGRIDGE J, 1998, IN PRESS MOL CELL; NODWELL JR, 1993, CELL, V72, P261, DOI 10.1016/0092-8674(93)90665-D; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; OLSON ER, 1984, J MOL BIOL, V180, P1053, DOI 10.1016/0022-2836(84)90270-5; OLSON ER, 1982, CELL, V31, P61, DOI 10.1016/0092-8674(82)90405-6; PATTERSON TA, 1994, J MOL BIOL, V236, P217, DOI 10.1006/jmbi.1994.1131; PELTZ SW, 1985, SCIENCE, V228, P91, DOI 10.1126/science.3156406; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; ROSENBERG M, 1978, NATURE, V272, P414, DOI 10.1038/272414a0; SALSTROM JS, 1978, J MOL BIOL, V124, P195, DOI 10.1016/0022-2836(78)90156-0; SULLIVAN SL, 1992, J BACTERIOL, V174, P1339, DOI 10.1128/jb.174.4.1339-1344.1992; SWINDLE J, 1988, J BIOL CHEM, V263, P10229; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; WARD DF, 1983, J MOL BIOL, V168, P73, DOI 10.1016/S0022-2836(83)80323-4; WHALEN W, 1988, P NATL ACAD SCI USA, V85, P2494, DOI 10.1073/pnas.85.8.2494; WHALEN W A, 1990, New Biologist, V2, P975; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4514, DOI 10.1073/pnas.84.13.4514	37	33	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4143	4148		10.1074/jbc.273.7.4143	http://dx.doi.org/10.1074/jbc.273.7.4143			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461609	hybrid			2022-12-25	WOS:000072048400051
J	Souri, M; Aoyama, T; Cox, GF; Hashimoto, T				Souri, M; Aoyama, T; Cox, GF; Hashimoto, T			Catalytic and FAD-binding residues of mitochondrial very long chain acyl-coenzyme A dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; BETA-OXIDATION ENZYMES; COA DEHYDROGENASE; A DEHYDROGENASE; MOLECULAR-CLONING; PIG-KIDNEY; DEFICIENCY; PURIFICATION; IDENTIFICATION; SITE	Very long-chain acyl-CoA dehydrogenase (VLCAD) is one of four flavoproteins which catalyze the initial step of the mitochondrial beta-oxidation spiral, By sequence comparison with other acyl-CoA dehydrogenases, Glu-422 of VLCAD has been presumed to be the catalytic residue that abstracts the a-proton in the alpha beta-dehydrogenation reaction. Replacing Glu-422 with glutamine (E422Q) caused a loss of enzyme activity by preventing the formation of a charge transfer complex between VLCAD and palmitoyl-CoA. This result provides further evidence for Glu-422 being part of the active site of VLCAD, F418L is a disease-causing mutation in human VLCAD deficiency, Unlike wild-type VLCAD, F418L and F418V contained no bound FAD when expressed at extremely high levels in the baculovirus expression system, Although F418T and F418Y bound FAD at a level similar to that of wild type VLCAD, both showed reduced V-max,, values toward palmitoyl-CoA, most likely due to a decrease in the rate of enzyme-bound FAD reduction, These data suggest that Phe-418 is involved in the binding and subsequent reduction of FAD, FAD-deficient VLCADs (F418L, F418V, and apo-VLCAD) showed increased sensitivity to trypsinization. Loss of FAD may change the folding of VLCAD subunit.	Shinshu Univ, Sch Med, Dept Biochem, Nagano 390, Japan; Childrens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA	Shinshu University; Harvard University; Boston Children's Hospital	Souri, M (corresponding author), Yamagata Univ, Sch Med, Dept Mol Pathobiochem, Iida Nishi 2-2-2, Yamagata 99023, Japan.	msouri@med.id.yamagata-u.ac.jp						Andresen BS, 1996, HUM MOL GENET, V5, P461, DOI 10.1093/hmg/5.4.461; AOYAMA T, 1994, J BIOL CHEM, V269, P19088; AOYAMA T, 1995, J CLIN INVEST, V95, P2465, DOI 10.1172/JCI117947; AOYAMA T, 1995, AM J HUM GENET, V57, P273; AOYAMA T, 1993, BIOCHEM BIOPH RES CO, V191, P1369, DOI 10.1006/bbrc.1993.1368; AOYAMA T, 1994, BIOCHEM BIOPH RES CO, V198, P1113, DOI 10.1006/bbrc.1994.1158; Battaile KP, 1996, BIOCHEMISTRY-US, V35, P15356, DOI 10.1021/bi961113r; BERTRAND C, 1993, BIOCHIM BIOPHYS ACTA, V1180, P327, DOI 10.1016/0925-4439(93)90058-9; BROSS P, 1990, J BIOL CHEM, V265, P7116; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DJORDJEVIC S, 1994, BIOCHEMISTRY-US, V33, P4258, DOI 10.1021/bi00180a021; FURUTA S, 1981, J BIOCHEM, V90, P1739, DOI 10.1093/oxfordjournals.jbchem.a133651; GHISLA S, 1984, BIOCHEMISTRY-US, V23, P3154, DOI 10.1021/bi00309a008; IKEDA Y, 1985, BIOCHEMISTRY-US, V24, P7192, DOI 10.1021/bi00346a027; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; IZAI K, 1992, J BIOL CHEM, V267, P1027; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; Kobayashi A, 1996, J BIOCHEM-TOKYO, V119, P775, DOI 10.1093/oxfordjournals.jbchem.a021307; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; NADA MA, 1995, J BIOL CHEM, V270, P530, DOI 10.1074/jbc.270.2.530; OGILVIE I, 1994, NEUROLOGY, V44, P467, DOI 10.1212/WNL.44.3_Part_1.467; SAIJO T, 1995, J BIOL CHEM, V270, P1899, DOI 10.1074/jbc.270.4.1899; Souri M, 1996, AM J HUM GENET, V58, P97; STRAUSS AW, 1995, P NATL ACAD SCI USA, V92, P10496, DOI 10.1073/pnas.92.23.10496; THORPE C, 1995, FASEB J, V9, P718, DOI 10.1096/fasebj.9.9.7601336; THORPE C, 1979, BIOCHEMISTRY-US, V18, P331, DOI 10.1021/bi00569a016; THORPE C, 1981, EUR J BIOCHEM, V118, P279; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; WIELAND T, 1953, ANGEW CHEM-GER EDIT, V65, P186, DOI 10.1002/ange.19530650706; YAMAGUCHI S, 1993, PEDIATR RES, V34, P111, DOI 10.1203/00006450-199307000-00025	31	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4227	4231		10.1074/jbc.273.7.4227	http://dx.doi.org/10.1074/jbc.273.7.4227			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461620	hybrid			2022-12-25	WOS:000072048400062
J	Davis-Smyth, T; Presta, LG; Ferrara, N				Davis-Smyth, T; Presta, LG; Ferrara, N			Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor placenta growth factor receptor Flt-1 required for binding and structural stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TYROSINE KINASE; FACTOR VEGF; HUMAN CD4; IN-VIVO; ANGIOGENESIS; ANTIBODIES; SITE; VASCULOGENESIS; DETERMINANTS	Flt-1 is one of two receptor tyrosine kinases through which the angiogenic factor vascular endothelial growth factor (VEGF) functions. Placenta growth factor (P1GF) is an additional ligand for Flt-1. The second immunoglobulin-like domain in the extracellular domain of Flt-1 has previously been identified as the region containing the critical ligand-binding determinants, We analyzed the contribution of charged residues within the first three domains of Flt-1 to ligand binding by alanine scanning mutagenesis. Domain 2 residues Arg(159), Glu(208) and His(223)-Arg(224) (together) affect both VEGF and P1GF binding, while Glu(137), Lys(171), His(223), and Arg(224) affect P1GF but not VEGF. Several charged residues, especially Asp(187), are important in maintaining the structural integrity of domain 2. In addition, some residues in domain 3 contribute to binding (Asp(231)) or provide for additional discrimination between ligands (Arg(280)-Asp(283)).	Genentech Inc, Dept Cardiovasc Res, San Francisco, CA 94080 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Ferrara, N (corresponding author), Genentech Inc, Dept Cardiovasc Res, 1 DNA Way, San Francisco, CA 94080 USA.							Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Barleon B, 1997, J BIOL CHEM, V272, P10382; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Binnerts ME, 1996, J BIOL CHEM, V271, P9962, DOI 10.1074/jbc.271.17.9962; BLECHMAN JM, 1993, STEM CELLS, V11, P12; Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V231, P596, DOI 10.1006/bbrc.1997.6156; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NANDURI J, 1994, J NEUROSCI RES, V37, P433, DOI 10.1002/jnr.490370402; PARK JE, 1994, J BIOL CHEM, V269, P25646; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; SU W, 1991, P NATL ACAD SCI USA, V88, P10870, DOI 10.1073/pnas.88.23.10870; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0	42	45	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3216	3222		10.1074/jbc.273.6.3216	http://dx.doi.org/10.1074/jbc.273.6.3216			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452434	hybrid			2022-12-25	WOS:000071822300019
J	Du, LL; Collins, RN; Novick, PJ				Du, LL; Collins, RN; Novick, PJ			Identification of a Sec4p GTPase-activating protein (GAP) as a novel member of a Rab GAP family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; PURIFICATION; HYDROLYSIS; CLONING; BINDING	A yeast open reading frame sharing homology with the two known yeast Rab GTPase-activating proteins (GAPs), Gyp6p and Gyp7p, was found in a data base search. We have named the gene containing this open reading frame GYP1. Recombinant Gyp1p showed GAP activity on Sec4p, increasing both its steady-state rate and single turnover GTPase activity. Gyp1p also stimulated the GTPase activity of several other yeast Rab proteins including Ypt1p, Ypt7p, and Ypt51p but showed no GAP activity on Ypt6p and Ypt32p. Deletion of the GYP1 gene or overexpression of Gyp1p did not alter the growth rate of yeast. However, overexpression of Gyp1p was inhibitory in combination with a subset of secretory mutants including sec4-8 and several ypt1 mutants. This effect is probably due to the increase in GAP activity, which can be observed in a lysate from cells overexpressing Gyp1p. The finding that yeast Rab GAPs share homology with proteins in other species, such as Caenorhabditis elegans and human, suggests the existence of a conserved Rab GAP family.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University; Yale University	Novick, PJ (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, Sterling Hall Med,POB 208002, New Haven, CT 06520 USA.			Du, Li-Lin/0000-0002-1028-7397	NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; Collins RN, 1997, J BIOL CHEM, V272, P18281, DOI 10.1074/jbc.272.29.18281; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; Mallet L, 1996, YEAST, V12, P1351, DOI 10.1002/(SICI)1097-0061(199610)12:13<1351::AID-YEA24>3.0.CO;2-6; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P243, DOI 10.1016/S0968-0004(97)01073-6; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; STAHL B, 1994, J BIOL CHEM, V269, P24770; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; TAN TJ, 1991, FEBS LETT, V291, P322, DOI 10.1016/0014-5793(91)81312-V; VOLLMER P, 1995, METHOD ENZYMOL, V257, P118; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017	20	69	70	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3253	3256		10.1074/jbc.273.6.3253	http://dx.doi.org/10.1074/jbc.273.6.3253			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452439	hybrid			2022-12-25	WOS:000071822300024
J	Morris, NJ; Ross, SA; Lane, WS; Moestrup, SK; Petersen, CM; Keller, SR; Lienhard, GE				Morris, NJ; Ross, SA; Lane, WS; Moestrup, SK; Petersen, CM; Keller, SR; Lienhard, GE			Sortilin is the major 110-kDa protein in GLUT4 vesicles from adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED MEMBRANE AMINOPEPTIDASE; INSULIN-STIMULATED TRANSLOCATION; RAT ADIPOSE-CELLS; GROWTH FACTOR-II; 3T3-L1 ADIPOCYTES; SUBCELLULAR TRAFFICKING; GLUCOSE TRANSPORTERS; TRANSFERRIN RECEPTORS; SURFACE	Vesicles containing the glucose transporter GLUT4 from rat adipocytes contain a major protein of 110 kDa, We have isolated this protein, obtained the sequences of peptides, and cloned a large portion of its cDNA, This revealed that the protein is sortilin, a novel membrane protein that was cloned in another context from a human source while this work was in progress. Subcellular fractionation of rat and 3T3-L1 adipocytes, together with GLUT4 vesicle isolation, showed that sortilin was primarily located in the low density microsomes in vesicles containing GLUT4, Insulin caused a 1.7-fold increase in the amount of sortilin at the plasma membranes of 3T3-L1 adipocytes, as assessed by cell surface biotinylation, The expression of sortilin in 3T3-L1 cells occurred only upon differentiation. Previous characterization of sortilin has led to the suggestion that it functions to sort lumenal proteins from the trans Golgi. The significance of its insulin stimulated increase at the cell surface and of its expression upon differentiation will require definitive delineation of its function.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Harvard Univ, Dept Mol & Cellular Biol, Harvard Microchem Facil, Cambridge, MA 02138 USA; Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark	Dartmouth College; Harvard University; Aarhus University	Lienhard, GE (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.	gustav.e.lienhard@dartmouth.edu	Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019	Moestrup, Søren Kragh/0000-0003-3862-2107; Morris, Nicholas/0000-0002-8389-7508	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK025336, R56DK025336, R01DK025336, F32DK009401] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09401, DK25336] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CORVERA S, 1989, J BIOL CHEM, V264, P10133; Fisher MD, 1996, J BIOL CHEM, V271, P11806, DOI 10.1074/jbc.271.20.11806; FROST SC, 1985, J BIOL CHEM, V260, P2646; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1997, AM J PHYSIOL, V271, pE1; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Malide D, 1997, FEBS LETT, V409, P461, DOI 10.1016/S0014-5793(97)00563-2; Martin S, 1997, J CELL SCI, V110, P2281; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; Morris NJ, 1997, J BIOL CHEM, V272, P9388; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; SATOH S, 1993, J BIOL CHEM, V268, P17820; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; TANNER LI, 1987, J BIOL CHEM, V262, P8975; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; WEBER TM, 1988, RECEPTOR BIOCH METHO, P171; YANG J, 1993, J BIOL CHEM, V268, P4600; YANG J, 1992, J BIOL CHEM, V267, P10393	30	116	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3582	3587		10.1074/jbc.273.6.3582	http://dx.doi.org/10.1074/jbc.273.6.3582			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452485	hybrid			2022-12-25	WOS:000071822300070
J	Olson, DP; Sun, BL; Koenig, RJ				Olson, DP; Sun, BL; Koenig, RJ			Thyroid hormone response element architecture affects corepressor release from thyroid hormone receptor dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL CO-REPRESSOR; ACTIVATION; DOMAIN; IDENTIFICATION; DISSECTION; SEQUENCES; COMPLEX	Thyroid hormone receptors are ligand-modulated transcription factors that can repress or activate transcription depending upon the absence or presence of thyroid hormone and the nature of the hormone response element to which the receptors are bound. The ability of thyroid hormone receptors to repress transcription in the absence of ligand is thought to be due to associations with nuclear hormone receptor corepressors. Ligand binding by the thyroid hormone receptor is believed to dissociate these corepressors and recruit coactivators to promote transcription from target promoters. We hypothesize that variations in response element architecture may influence both the association and dissociation of corepressors from DNA-bound thyroid hormone receptors. Using a chimeric corepressor, we find that ligand alone does not fully relieve corepressor-mediated repression, particularly in the presence of thyroid hormone receptor and its heterodimerization partner, the retinoid X receptor, Interestingly, the steroid receptor coactivator 1 together with ligand is able to mediate full release of corepression, but this relief is dependent upon the architecture of the response element to which the nuclear receptor dimer-corepressor complex is bound. These studies suggest that other cellular factors in addition to ligand may be required for the release of corepressors from thyroid hormone receptor dimers.	Univ Michigan, Med Ctr, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Koenig, RJ (corresponding author), Univ Michigan, Med Ctr, Div Endocrinol & Metab, 1500 W Med Ctr Dr,5560 MSRB 2, Ann Arbor, MI 48109 USA.				NIDDK NIH HHS [DK44155] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044155] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BRENT G A, 1989, New Biologist, V1, P329; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; HALL BL, 1993, P NATL ACAD SCI USA, V90, P6929, DOI 10.1073/pnas.90.15.6929; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NGY L, 1997, CELL, V89, P373; OHASHI H, 1991, BIOCHEM BIOPH RES CO, V178, P1167, DOI 10.1016/0006-291X(91)91015-5; Olson DP, 1997, J BIOL CHEM, V272, P9907; ONATE SA, 1995, SCIENCE, V270, P1354; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; UPPALURI R, 1995, MOL CELL BIOL, V15, P1499; Walfish PG, 1997, P NATL ACAD SCI USA, V94, P3697, DOI 10.1073/pnas.94.8.3697; Williams Graham R., 1995, P217; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zamir I, 1996, MOL CELL BIOL, V16, P5458	27	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3375	3380		10.1074/jbc.273.6.3375	http://dx.doi.org/10.1074/jbc.273.6.3375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452457	hybrid			2022-12-25	WOS:000071822300042
J	Yoon, JW; Liu, CZ; Yang, JT; Swart, R; Iannaccone, P; Walterhouse, D				Yoon, JW; Liu, CZ; Yang, JT; Swart, R; Iannaccone, P; Walterhouse, D			GLI activates transcription through a herpes simplex viral protein 16-like activation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; CUBITUS-INTERRUPTUS; KRUPPEL FAMILY; GENE; DROSOPHILA; SEQUENCES; BINDING; IDENTIFICATION; EXPRESSION; INITIATION	Three proteins have been identified in mammals, GLI, GLI2, and GLI3, which share a highly conserved zinc finger domain with Drosophila Cubitus interruptus and are believed to function as transcription factors in the vertebrate Sonic hedgehog-Patched signaling pathway, To understand the role GLI plays in the Sonic hedgehog-Patched pathway and mechanisms of GLI-induced transcriptional regulation, we have characterized its transcriptional regulatory properties and contributions of specific domains to transcriptional regulation, We have demonstrated that GLI activates expression of reporter constructs in HeLa cells in a concentration-dependent manner through the GLI consensus binding motif and that a GAL4 binding domain-GLI fusion protein activates reporter expression through the GAIA DNA binding site, GLI-induced transcriptional activation requires the carboxyl-terminal amino acids 1020-1091, which includes an 18-amino acid region highly similar to the alpha-helical herpes simplex viral protein 16 activation domain, including the consensus recognition element for the human TFIID TATA box-binding protein-associated factor TAF(II)31 and conservation of all three amino acid residues believed to contact directly chemically complementary residues in TAF(II)31. The presence of this region in the GLI activation domain provides a mechanism for GLI-induced transcriptional regulation.	Northwestern Univ, Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Sch Med,Div Hematol Oncol, Chicago, IL 60614 USA; Northwestern Univ, Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Sch Med,Dept Pediat, Chicago, IL 60614 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	Walterhouse, D (corresponding author), Northwestern Univ, Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Sch Med,Div Hematol Oncol, Box 30,2300 Childrens Plaza, Chicago, IL 60614 USA.			Liu, Cheng/0000-0002-2219-1018	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028992] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K08CA064395] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64395] Funding Source: Medline; NICHD NIH HHS [HD-28992] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; ARUGA J, 1994, J NEUROCHEM, V63, P1880; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Biesecker LG, 1996, J MED GENET, V33, P585, DOI 10.1136/jmg.33.7.585; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEBONO M, 1995, GENE DEV, V9, P155, DOI 10.1101/gad.9.2.155; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Jan E, 1997, EMBO J, V16, P6301, DOI 10.1093/emboj/16.20.6301; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; LIU CZ, 1998, IN PRESS GENE AMST; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Mo R, 1997, DEVELOPMENT, V124, P113; RADKE F, 1995, NUCLEIC ACIDS RES, V23, P2277; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROBERTS WM, 1989, CANCER RES, V49, P5407; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VORTKAMP A, 1995, DNA CELL BIOL, V14, P629, DOI 10.1089/dna.1995.14.629; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; Yang JT, 1997, MOL MED, V3, P826, DOI 10.1007/BF03401719	35	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3496	3501		10.1074/jbc.273.6.3496	http://dx.doi.org/10.1074/jbc.273.6.3496			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452474	hybrid			2022-12-25	WOS:000071822300059
J	Hadman, M; Lin, W; Bush, L; Bos, TJ				Hadman, M; Lin, W; Bush, L; Bos, TJ			Apolipoprotein A-1 is a negative target of v-Jun overexpression	ONCOGENE			English	Article						Jun; apolipoprotein A-1; regulation	A-I-GENE; HIGH-DENSITY LIPOPROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; C-JUN; GLUCOCORTICOID RECEPTOR; DNA-BINDING; TRANSCRIPTIONAL REGULATION; FUNCTIONAL ANTAGONISM; EMBRYO FIBROBLASTS; COLLAGENASE GENE	The product of the Jun oncogene influences a variety of processes including cell proliferation and differentiation. Jun exerts its influence by binding to the promoter and enhancer regions of a number of different target genes resulting in their activation or repression. We describe here the isolation and characterization of a gene differentially downregulated upon overexpression of v-Jun but not c-Jun. DNA and amino acid homology search analysis revealed this gene to be identical to chicken apolipoprotein A-1, the major component of high density lipoprotein (HDL). The half life of apolipoprotein A-1 RNA remains constant in the presence or absence of v-Jun overexpression suggesting downregulation by v-Jun is at the level of promoter-activity. Consistent with this hypothesis, apolipoprotein A-1 upstream promoter fragments active in normal and c-Jun expressing CEF are inactive in v-Jun transformed CEF. Analysis of expression of apolipoprotein A-1 in CEF overexpressing other oncogenes revealed a similar downregulation by Myc and v-Src but not c-Fos, v-Ha-Ras, c-Src or c-Ski. Our findings point to a potential regulatory affect on cholesterol metabolism by v-Jun, as a result of altered levels of apolipoprotein A-1 message expression.	Eastern Virginia Med Sch, Dept Microbiol & Immunol, Norfolk, VA 23501 USA	Eastern Virginia Medical School	Bos, TJ (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Immunol, POB 1980, Norfolk, VA 23501 USA.				NCI NIH HHS [R01 CA 51982, R29 CA 51982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051982, R01CA051982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BARONI S, 1994, LEUKEMIA RES, V18, P643, DOI 10.1016/0145-2126(94)90047-7; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BHATTACHARYYA N, 1993, DNA CELL BIOL, V12, P597, DOI 10.1089/dna.1993.12.597; BHATTACHARYYA N, 1991, GENE, V104, P163, DOI 10.1016/0378-1119(91)90246-8; BHATTACHARYYA N, 1993, GENE, V137, P315, DOI 10.1016/0378-1119(93)90027-Z; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; EISENBERG S, 1984, J LIPID RES, V25, P1017; FOLIN M, 1993, HAEMATOLOGICA, V78, P277; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GAUDET F, 1995, J BIOL CHEM, V270, P29916; GE RW, 1994, J BIOL CHEM, V269, P13185; GIZANGGINSBERG E, 1990, GENE DEV, V4, P447; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Hadman M, 1996, ONCOGENE, V12, P135; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KILBOURNE EJ, 1995, J BIOL CHEM, V270, P7004, DOI 10.1074/jbc.270.12.7004; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAMONFAVA S, 1992, J LIPID RES, V33, P831; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MILNER JN, 1992, GENE DEV, V6, P2491; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; RAJAVASHISTH TB, 1987, J BIOL CHEM, V262, P7058; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; RONNEMAA T, 1989, AM J EPIDEMIOL, V130, P632, DOI 10.1093/oxfordjournals.aje.a115385; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Scribano D, 1996, HAEMATOLOGICA, V81, P343; SPIEGEL RJ, 1982, AM J MED, V72, P775, DOI 10.1016/0002-9343(82)90543-5; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Taylor AH, 1996, J LIPID RES, V37, P2232; TOURAY M, 1991, ONCOGENE, V6, P1227; VARMA VK, 1992, METABOLISM, V41, P1075, DOI 10.1016/0026-0495(92)90288-L; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; VOGT PK, 1990, CANCER BIOL, V1, P27; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WONG WY, 1992, ONCOGENE, V7, P2077; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	55	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					655	660		10.1038/sj.onc.1201574	http://dx.doi.org/10.1038/sj.onc.1201574			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482111				2022-12-25	WOS:000071816600010
J	Mahony, D; Parry, DA; Lees, E				Mahony, D; Parry, DA; Lees, E			Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells	ONCOGENE			English	Article						Cdk6; cell-cycle	CYCLIN-DEPENDENT KINASES; RETINOBLASTOMA-PROTEIN; GENE-EXPRESSION; G1 PHASE; G(1); INHIBITION; D1; PROGRESSION; IDENTIFICATION; OVEREXPRESSION	We have performed biochemical analyses of cdk6 complexes in T cells. By gel filtration chromatography we observed at least three cdk6 containing complexes in the cell, the most abundant eluting at 450 kDa and 50-70 kDa and a minor complex eluting at 170 kDa. Cyclin D was present in the minor 170 kDa complex which coeluted with the peak of cdk associated in vitro Rb kinase activity, Analysis of proteins that co-immunoprecipitated with cdk6 showed that the 450 kDa complex contained both Hsp90 and CDC37. The 50-70 kDa complex was made up of two moieties, a 66 kDa complex containing cdk6 bound to p19(INK4d) and monomeric cdk6. The subcellular localisation of the cdk6 complexes was analysed by preparing cytoplasmic and nuclear extracts. The 450 kDa complex was shown to be predominantly cytoplasmic, whereas the 170 kDa cyclin D/cdk6 and the 50-70 kDa complexes were present in both nuclear and cytoplasmic compartments. When these same extracts were assayed for cdk6 associated kinase activity, only the nuclear cdk6 complexes were active. These data suggest that even though there are cdk6/cyclin D complexes detectable in both the cytoplasm and nucleus, only the cdk6 that is in the nucleus is active.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Mahony, D (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, 901 Calif Ave, Palo Alto, CA 94304 USA.							AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BATES S, 1994, ONCOGENE, V9, P71; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hirai H, 1996, MOL CELL BIOL, V16, P6457; HORI T, 1987, BLOOD, V70, P1069; JIANG W, 1993, ONCOGENE, V8, P3447; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LUCAS JJ, 1995, J IMMUNOL, V154, P6275; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, ONCOGENE, V10, P2125; Lukas J, 1996, MOL CELL BIOL, V16, P6917; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEVINS JR, 1992, SCIENCE, V258, P424; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	42	80	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	1998	16	5					603	611		10.1038/sj.onc.1201570	http://dx.doi.org/10.1038/sj.onc.1201570			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482106				2022-12-25	WOS:000071816600005
J	Blagoveshchenskaya, AD; Norcott, JP; Cutler, DF				Blagoveshchenskaya, AD; Norcott, JP; Cutler, DF			Lysosomal targeting of P-selectin is mediated by a novel sequence within its cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GRANULE MEMBRANE-PROTEIN; REGULATED SECRETORY PATHWAY; WEIBEL-PALADE BODIES; DI-LEUCINE MOTIF; INTERNALIZATION SIGNAL; RECEPTOR COMPLEXES; ENDOTHELIAL-CELLS; ACID-PHOSPHATASE; HORSERADISH-PEROXIDASE	Signals controlling the intracellular targeting of many membrane proteins are present as short sequences within their cytoplasmic domains, P-selectin is a type I membrane protein receptor for leukocytes, acting during the inflammation response. Heterologous expression experiments have demonstrated that its 35-residue cytoplasmic tail contains signals for targeting to synaptic-like microvesicles, dense-cored granules, and lysosomes, We have examined the lysosomal targeting information present within the cytoplasmic tail by site-directed mutagenesis of horseradish peroxidase-P-selectin chimeras followed by transient transfection in H.Ep.2 cells. Assaying lysosomal targeting by subcellular fractionation as well as intracellular proteolysis, we have discovered a novel lysosomal targeting signal, KCPL, located within the C1 domain of the cytoplasmic tail, Alanine substitution of this tetrapeptide reduced lysosomal targeting to the level of a tailless horseradish peroxidase-P-selectin chimera, which was previously found to be deficient in both internalization and delivery to lysosomes, A proline residue within this lysosomal targeting signal makes a major contribution to the efficiency of lysosomal targeting, A diaminobenzidine density shift procedure established that chimeras with an inactivated KCPL sequence are present within transferrin-positive compartments, Such a mutant also displays an increased level of expression at the plasma membrane. Our results indicate that the sequence KCPL within the cytoplasmic tail of P-selectin is a structural element that mediates sorting from endosomes to lysosomes.	Univ London Univ Coll, Mol Cell Biol Lab, MRC, London WC1E 6BT, England; Univ London Univ Coll, Dept Biochem, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Cutler, DF (corresponding author), Univ London Univ Coll, Mol Cell Biol Lab, MRC, Gower St, London WC1E 6BT, England.	d.cutler@ucl.ac.uk		Cutler, Daniel/0000-0002-4288-7530	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AJIOKA RS, 1987, J CELL BIOL, V104, P77, DOI 10.1083/jcb.104.1.77; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BONFANTI R, 1989, BLOOD, V73, P1109; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BREMNES B, 1994, J CELL SCI, V107, P2021; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CONNOLLY CN, 1994, J CELL BIOL, V127, P641, DOI 10.1083/jcb.127.3.641; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; FUTTER CE, 1989, J CELL SCI, V94, P685; GHOSH RN, 1994, J CELL SCI, V107, P2177; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HAMBURGER SA, 1990, BLOOD, V75, P550; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; KORNILOVA ES, 1992, ONCOGENE, V7, P511; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MASTERSON WJ, 1992, PROTEIN TARGETING PR, P242; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCEVER RP, 1995, AGENT ACTION SUPPL, V47, P117; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MCEVER RP, 1993, STRUCTURE, FUNCTION, AND REGULATION OF MOLECULES INVOLVED IN LEUKOCYTE ADHESION, P135; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MILLER K, 1986, J CELL BIOL, V102, P500, DOI 10.1083/jcb.102.2.500; NABI IR, 1993, MOL BIOL CELL, V4, P627, DOI 10.1091/mbc.4.6.627; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; Norcott JP, 1996, J CELL BIOL, V134, P1229, DOI 10.1083/jcb.134.5.1229; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SETIADI H, 1995, J BIOL CHEM, V270, P26818, DOI 10.1074/jbc.270.45.26818; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; SUBRAMANIAM M, 1993, MOL BIOL CELL, V4, P791, DOI 10.1091/mbc.4.8.791; Subtil A, 1997, J CELL BIOL, V136, P583, DOI 10.1083/jcb.136.3.583; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANDEURS B, 1993, EUR J CELL BIOL, V61, P208; VANDEURS B, 1995, EUR J CELL BIOL, V66, P309; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WILEY HS, 1982, J BIOL CHEM, V257, P4222; Zwart DE, 1996, J BIOL CHEM, V271, P907, DOI 10.1074/jbc.271.2.907	63	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2729	2737		10.1074/jbc.273.5.2729	http://dx.doi.org/10.1074/jbc.273.5.2729			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446579	hybrid			2022-12-25	WOS:000071736600034
J	Mandal, M; Bandyopadhyay, D; Goepfert, TM; Kumar, R				Mandal, M; Bandyopadhyay, D; Goepfert, TM; Kumar, R			Interferon-induces expression of cyclin-dependent kinase-inhibitors p21(WAF1) and p27(Kip1) that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK)	ONCOGENE			English	Article						interferons; cell cycle; CDK; CDK-inhibitors; CDK-activating kinase	SENSITIVE HEMATOPOIETIC-CELLS; DAUDI CELLS; RETINOBLASTOMA PROTEIN; ALPHA-INTERFERON; INTERLEUKIN-6 SUPPRESS; GROWTH ARREST; 3T3 CELLS; GENES; P21; G1	To understand the mechanism of interferon (IFN)-mediated suppression of cell cycle progression, we have earlier shown that IFN-alpha enhances the expression of underphosphorylated retinoblastoma protein by inhibiting the cyclin-dependent kinase-2 (CDK-2) activity (Kumar and Atlas, Proc. Natl, Acad, Sci. 89, 6599-6603, 1992; Zhang and Kumar, Biochem. Biophysi. Res. Comm., 200, 522-528, 1994), In the studies presented here, we investigated the mechanism of inhibition of CDKs in IFN-treated cells by delineating the potential role(s) of CDK-inhibitors (CKIs) and CDK-activating kinase (CAK). We report that IFN-alpha inhibits the H-1 kinase activity associated with CDK-4 or CDK-2 due to induction of expression of CDK-inhibitor p21(WAF1) (but not p27(Kip1)) as its immunodepletion from IFN-treated extracts restored the CDK-associated H-1 kinase activity, In addition, we also show that IFN-gamma induces expression of CDK-inhibitors p21(WAF1) and p27(Kip1) and inhibited the H-1 kinase activity associated with CDK-2 or CDK-4, The observed IFN-gamma-mediated inhibition of CDK-2 and CDK-4 kinase activity was due to enhanced interactions with p21(WAF1) and p27(Kip1), respectively, We also demonstrated that IFN-induced CKIs prevent CAK from activating the CDK-2 as immunodepletion of induced CKIs from the inhibitory extracts resulted in the restoration of CAK-mediated activation of CDK-2.	Univ Texas, Md Anderson Canc Ctr, Dept Clin Invest, Cell Growth Regulat Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Clin Invest, Cell Growth Regulat Lab, Cell Growth Regulat Lab, Houston, TX 77030 USA.		Mandal, Mahitosh/GMW-6195-2022	Mandal, Mahitosh/0000-0003-3861-3323	NCI NIH HHS [CA56564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; BURKE LC, 1992, ONCOGENE, V7, P783; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; CLARKE PR, 1995, CURR BIOL, V5, P40, DOI 10.1016/S0960-9822(95)00013-3; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1993, CELL, V75, P805; Harvat BL, 1996, CELL GROWTH DIFFER, V7, P289; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Korutla L, 1996, ANTICANCER RES, V16, P2789; KUMAR R, 1994, J BIOL CHEM, V269, P25437; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; KUMAR R, 1989, CANCER RES, V49, P5180; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MOORE RN, 1984, SCIENCE, V223, P178, DOI 10.1126/science.6606850; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Peng D, 1996, CANCER RES, V56, P3666; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; SEROZ T, 1995, CURR OPIN GENET DEV, V5, P217, DOI 10.1016/0959-437X(95)80011-5; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOKAWA Y, 1977, NATURE, V268, P236, DOI 10.1038/268236a0; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMADA H, 1994, MOL CELL BIOCHEM, V136, P117, DOI 10.1007/BF00926071; Yamada H, 1995, MOL CELL BIOCHEM, V152, P149, DOI 10.1007/BF01076077; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	42	86	89	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					217	225		10.1038/sj.onc.1201529	http://dx.doi.org/10.1038/sj.onc.1201529			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464540				2022-12-25	WOS:000071427100009
J	Veldhoen, N; Stewart, J; Brown, R; Milner, J				Veldhoen, N; Stewart, J; Brown, R; Milner, J			Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog	ONCOGENE			English	Article						therapy-induced p53 mutation; canine p53 germ line mutation; canine lymphoma	CHRONIC MYELOCYTIC-LEUKEMIA; P-GLYCOPROTEIN EXPRESSION; BREAST-CANCER; DNA DAMAGE; CLONAL EVOLUTION; FREE-RADICALS; MUTANT-CELLS; THERAPY; DOXORUBICIN; RESISTANCE	Mutations of the p53 gene are associated with a number of non-lymphoid cancers of the dog. The present study investigates the p53 gene status within canine patients treated for primary and secondary lymphoma. Three out of eight patients exhibited p53 gene mutations, These included one patient with a germ line mutation and two patients with de novo p53 mutations associated with the secondary lymphoma. Allelic loss of the p53 gene was also observed within primary and secondary tumours of the three canine patients. The results indicate that germ line p53 mutations exist in dogs and may be involved in the known predisposition of some breeds to cancer, The presence of therapy-related p53 point mutations was found to be associated with chemoresistant secondary lymphomas. A causative role for DNA-damaging chemotherapy in de novo mutation of the p53 gene is discussed, Characterization of p53 inactivation in canine tumorigenesis may provide a valuable clinical model for assessing the efficacy and optimal therapeutic regimens of anti-cancer agents.	Univ York, Dept Biol, YCRC Res Grp P53, York YO1 5DD, N Yorkshire, England; Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland	University of York - UK; Beatson Institute; University of Glasgow	Veldhoen, N (corresponding author), Univ York, Dept Biol, YCRC Res Grp P53, York YO1 5DD, N Yorkshire, England.							Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AKMAN SA, 1992, BIOCHEMISTRY-US, V31, P3500, DOI 10.1021/bi00128a026; BARTKOWIAK D, 1992, CANCER CHEMOTH PHARM, V30, P189, DOI 10.1007/BF00686310; CARTER RF, 1986, CAN J VET RES, V50, P154; CERVANTES A, 1988, CANCER LETT, V41, P169, DOI 10.1016/0304-3835(88)90113-9; CHANG H, 1994, BLOOD, V83, P452; DEVILEE P, 1994, ANTICANCER RES, V14, P2039; Doroshaw J., 1996, CANC CHEMOTHERAPY BI, P409; ELROUBY S, 1993, BLOOD, V82, P3452; Felix CA, 1996, BLOOD, V87, P4376, DOI 10.1182/blood.V87.10.4376.bloodjournal87104376; FREBOURG T, 1995, AM J HUM GENET, V56, P608; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; FULTON R, 1987, NATURE, V326, P190, DOI 10.1038/326190a0; GREENLEE PG, 1990, CANCER-AM CANCER SOC, V66, P480, DOI 10.1002/1097-0142(19900801)66:3&lt;480::AID-CNCR2820660314&gt;3.0.CO;2-X; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hoffmann L, 1995, ANN ONCOL, V6, P781, DOI 10.1093/oxfordjournals.annonc.a059316; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; KAPPUS H, 1986, BIOCHEM PHARMACOL, V35, P1, DOI 10.1016/0006-2952(86)90544-7; KATZ JP, 1990, J VIROL, V64, P4288, DOI 10.1128/JVI.64.9.4288-4295.1990; KEIZER HG, 1990, PHARMACOL THERAPEUT, V47, P219, DOI 10.1016/0163-7258(90)90088-J; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAEGEL SA, 1995, CANCER LETT, V92, P181, DOI 10.1016/0304-3835(95)03779-V; KUROSAWA M, 1994, BLOOD, V83, P2750; Lee JJ, 1996, CANCER, V77, P1892, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1892::AID-CNCR20>3.0.CO;2-U; Liu PK, 1996, ONCOGENE, V12, P2267; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MACVEAN DW, 1978, VET PATHOL, V15, P700, DOI 10.1177/030098587801500602; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MAYR B, 1994, BRIT VET J, V150, P81, DOI 10.1016/S0007-1935(05)80099-5; MCBRIDE TJ, 1991, BIOCHEMISTRY-US, V30, P207, DOI 10.1021/bi00215a030; MUINDI J, 1985, MOL PHARMACOL, V27, P356; ONIONS DE, 1984, JNCI-J NATL CANCER I, V72, P909; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; PEDERSENBJERGAARD J, 1992, J CLIN ONCOL, V10, P1444, DOI 10.1200/JCO.1992.10.9.1444; PREUDHOMME C, 1993, LEUKEMIA, V7, P1888; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SQUIRE RA, 1973, JNCI-J NATL CANCER I, V51, P565; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; TURNER MJ, 1990, FREE RADICAL BIO MED, V9, P415, DOI 10.1016/0891-5849(90)90018-E; vanLeeuwen IS, 1997, CANCER LETT, V111, P173, DOI 10.1016/S0304-3835(96)04529-6; vanLeeuwen IS, 1996, ANTICANCER RES, V16, P3737; Varley JM, 1997, ONCOGENE, V14, P865, DOI 10.1038/sj.onc.1201041; WADA H, 1994, LEUKEMIA, V8, P53; WISHART GC, 1990, BRIT J CANCER, V62, P758, DOI 10.1038/bjc.1990.373	49	55	56	1	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					249	255		10.1038/sj.onc.1201489	http://dx.doi.org/10.1038/sj.onc.1201489			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464543				2022-12-25	WOS:000071427100012
J	Hoshino, M; Izumi, T; Shimizu, T				Hoshino, M; Izumi, T; Shimizu, T			Leukotriene D-4 activates mitogen-activated protein kinase through a protein kinase C alpha Raf-1-dependent pathway in human monocytic leukemia THP-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LUNG; MAP KINASE; SIGNAL TRANSDUCTION; HUMAN NEUTROPHILS; RECEPTOR; PHOSPHORYLATION; WORTMANNIN; ANTAGONIST; EOSINOPHIL; INHIBITION	Leukotriene D-4 (LTD4) is a major lipid mediator involved in inflammatory and allergic disorders including bronchial asthma. Despite its potent biological activity, little is known about the receptor and intracellular signaling pathways. Here we analyzed the signal transduction mechanisms through LTD4 receptors using human monocytic leukemia THP-1 cells. When these cells were stimulated with LTD4, intracellular calcium concentration was increased and mitogen-activated protein kinase (MAP kinase) was activated severalfold, This activation was inhibited by staurosporine or GF109203X treatment or abolished by protein kinase C depletion. Cytosolic protein kinase C alpha was translocated to the membrane, and Raf-l was activated by LTD, treatment in a similar time course. LTD4-induced Raf-l activation was diminished by protein kinase C depletion in the cells. A chemotactic response of THP-1 cells toward LTD, was observed which was inhibited by pertussis toxin (PTX) pretreatment. Thus, LTD4 has at least two distinct signaling pathways in THP-1 cells, a PTX-insensitive mitogen-activated protein kinase activation through protein kinase Ca and Raf-l and a PTX-sensitive chemotactic response. This cellular signaling can explain in part the versatile activities of LTD4 in macrophages under inflammatory and allergic conditions.	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Shimizu, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Hongo 7-3-1, Tokyo 113, Japan.							ALEXANDER SPH, 1997, TRENDS PHARM SCI S, V18, P50; CHAN CC, 1990, EUR J PHARMACOL, V191, P273; CHAN CC, 1994, J PHARMACOL EXP THER, V269, P891; DELLAROCCA GJ, 1997, J BIOL CHEM, V272, P19215; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FERBY IM, 1994, J BIOL CHEM, V269, P30485; GOTOH Y, 1994, ONCOGENE, V9, P1891; Hartmann K, 1997, BLOOD, V89, P2863, DOI 10.1182/blood.V89.8.2863; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HONDA Z, 1994, J BIOL CHEM, V269, P2307; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KRUMP E, 1995, BIOCHEM J, V310, P681, DOI 10.1042/bj3100681; Kuang YN, 1996, J BIOL CHEM, V271, P3975; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; METTERS KM, 1993, J BIOL CHEM, V268, P6487; NAKAGAWA N, 1992, JPN J PHARMACOL, V60, P217, DOI 10.1254/jjp.60.217; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OBATA T, 1992, JPN J PHARMACOL, V60, P227, DOI 10.1254/jjp.60.227; ROCHETTE C, 1993, BIOCHIM BIOPHYS ACTA, V1177, P2383; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SPADA CS, 1994, J LEUKOCYTE BIOL, V55, P183, DOI 10.1002/jlb.55.2.183; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Waga I, 1996, J IMMUNOL METHODS, V190, P71, DOI 10.1016/0022-1759(95)00266-9; WATANABE T, 1990, J BIOL CHEM, V265, P21237; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227; Yen HH, 1997, J LEUKOCYTE BIOL, V61, P529, DOI 10.1002/jlb.61.4.529; YOKOMIZO T, 1997, NATURE, V387, P6320	34	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4878	4882		10.1074/jbc.273.9.4878	http://dx.doi.org/10.1074/jbc.273.9.4878			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478929	hybrid			2022-12-25	WOS:000072310400013
J	Chaillan-Huntington, CE; Patston, PA				Chaillan-Huntington, CE; Patston, PA			Influence of the P-5 residue on alpha(1)-proteinase inhibitor mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-PROTEINASE INHIBITOR; CRYSTAL-STRUCTURE; PROTEINASE-INHIBITORS; REACTIVE LOOP; ALPHA(1)-ANTITRYPSIN; COMPLEX; CHYMOTRYPSIN; ALPHA(1)-ANTICHYMOTRYPSIN; CONFORMATION; SERPIN	The reactive center loop of native alpha(1)-proteinase inhibitor has been reported to be in a helical conformation and in a beta-strand conformation by two different studies. In the beta-strand loop structure the P-5 glutamic acid plays a unique role by stabilizing the loop in the predicted optimal conformation for the interaction with target proteinases and insertion into beta-sheet A. We hypothesize here that disrupting the interactions that stabilize the beta-strand conformation of the loop would result in changes in the inhibitory properties of the serpin. In addition, our earlier studies on reactive center loop mutants of alpha(1)-proteinase inhibitor suggested that the P-5 residue was important in stabilizing the alpha(1)-proteinase inhibitor-proteinase complexes. To address these issues we made mutants of alpha(1)-proteinase inhibitor with glycine, glutamine, or lysine at the P-5 position and measured the rates and stoichiometries of inhibition with trypsin and human neutrophil elastase and the stabilities of the resulting complexes, In most cases the rate of inhibition was reduced by about half and the stoichiometry increased between 2- and 4-fold, The only exception was for trypsin with the lysine variant where the P, was now the favored site of cleavage, These data show that the P-5 Glu is important in maintaining the reactive center loop in a conformation optimal for interaction with the proteinase and for a fast rate of loop insertion. The complexes formed with trypsin and the variant serpins were less stable than that formed with wild-type serpin and resulted in up to 33% regeneration of trypsin activity over a period of 6 days, compared with 17% with wild type, Thus, the P-5 residue of alpha(1)-proteinase inhibitor is important in all steps of the inhibitory mechanism in a manner consistent with the structural role played by this residue in the beta-strand loop structure of native alpha(1)-proteinase inhibitor.	Univ Illinois, Coll Dent, Dept Oral Med & Diagnost Sci MC 838, Chicago, IL 60612 USA; Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Patston, PA (corresponding author), Univ Illinois, Coll Dent, Dept Oral Med & Diagnost Sci MC 838, 801 S Paulina St, Chicago, IL 60612 USA.				NHLBI NIH HHS [HL-49242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049242, R29HL049242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATTY K, 1984, H-S Z PHYSIOL CHEM, V365, P731, DOI 10.1515/bchm2.1984.365.2.731; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; ChaillanHuntington CE, 1997, BIOCHEMISTRY-US, V36, P9562, DOI 10.1021/bi970651g; Ciaccia AV, 1997, J BIOL CHEM, V272, P888, DOI 10.1074/jbc.272.2.888; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; Dan JH, 1997, J BIOL CHEM, V272, P8243, DOI 10.1074/jbc.272.13.8243; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Eriksson S, 1996, CHEST, V110, pS237, DOI 10.1378/chest.110.6_Supplement.237S; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; JANIN J, 1990, J BIOL CHEM, V265, P16027; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; KWON KS, 1995, BBA-PROTEIN STRUCT M, V1247, P179, DOI 10.1016/0167-4838(94)00224-5; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; ODA K, 1977, BIOCHEM BIOPH RES CO, V76, P1062, DOI 10.1016/0006-291X(77)90964-0; OLSON ST, 1995, J BIOL CHEM, V270, P9717, DOI 10.1074/jbc.270.17.9717; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; PATSTON PA, 1994, SEMIN THROMB HEMOST, V20, P410, DOI 10.1055/s-2007-1001929; Patston PA, 1996, FEBS LETT, V383, P87, DOI 10.1016/0014-5793(96)00231-1; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Song HK, 1995, FEBS LETT, V377, P150; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; Stone SR, 1997, J MOL BIOL, V265, P344, DOI 10.1006/jmbi.1996.0727; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354	31	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4569	4573		10.1074/jbc.273.8.4569	http://dx.doi.org/10.1074/jbc.273.8.4569			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468513	hybrid			2022-12-25	WOS:000072115000041
J	Sidhu, JS; Omiecinski, CJ				Sidhu, JS; Omiecinski, CJ			Protein synthesis inhibitors exhibit a nonspecific effect on phenobarbital-inducible cytochome P450 gene expression in primary rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED INDUCTION; LIVER; CYCLOHEXIMIDE; TRANSCRIPTION; ACTIVATION; CYTOCHROME-P-450B; PHOSPHORYLATION; SUPERINDUCTION; CULTURES; ELEMENT	Previous investigations have indicated that de novo protein synthesis is a critical requirement for phenobarbital (PB) induction, We reexamined this issue in PB-responsive primary rat hepatocyte cultures using a broader array of protein synthesis inhibitors and experimental end points. Anisomycin, cycloheximide, emetine, puromycin, and puromycin aminonucleoside, a negative analog, were evaluated for their respective effects on protein synthesis and the PR-induction process, All of the inhibitors effectively repressed de novo protein synthesis in the cells in a concentration-dependent manner, However, anisomycin only minimally effected PB induction, ascertained though the measure of CYP2B1, CYP2B2, and CYP3A1 mRNA levels, The inactive agent, puromycin aminonucleoside, produced marked repression of the PB induction response, Results from further experiments demonstrated that these protein synthesis inhibitors stimulated rapid and differential phosphorylation of the stress-activated protein kinase/c-Jun kinase (SAP/JNK) pathway, indicating nonselective actions on cellular processes, Puromycin aminonucleoside was without effect on these pathways, despite its efficacy as an inhibitor of PB induction, These results demonstrate that de novo protein synthesis is not a requirement for PB induction, nor is activation of the SAPK/JNK kinase cascade responsible for down-regulating PB responsiveness in primary hepatocytes.	Univ Washington, Dept Environm Hlth, Seattle, WA 98105 USA	University of Washington; University of Washington Seattle	Omiecinski, CJ (corresponding author), Univ Washington, Dept Environm Hlth, 4225 Roosevelt Way NE 100, Seattle, WA 98105 USA.	cjo@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032281] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32281] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGER HJ, 1990, ARCH BIOCHEM BIOPHYS, V281, P204, DOI 10.1016/0003-9861(90)90433-Y; CHIANALE J, 1988, HEPATOLOGY, V8, P327, DOI 10.1002/hep.1840080223; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW SC, 1995, EXP CELL RES, V216, P149, DOI 10.1006/excr.1995.1019; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DOGRA SC, 1993, ARCH BIOCHEM BIOPHYS, V300, P531, DOI 10.1006/abbi.1993.1073; HARDWICK JP, 1983, J BIOL CHEM, V258, P8081; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; Honkakoski P, 1996, J BIOL CHEM, V271, P9746, DOI 10.1074/jbc.271.16.9746; HONKAKOSKI P, 1989, ARCH BIOCHEM BIOPHYS, V273, P42, DOI 10.1016/0003-9861(89)90160-4; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; LUSSKA A, 1992, J BIOL CHEM, V267, P15146; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; NIMS RW, 1994, J BIOCHEM TOXICOL, V9, P279, DOI 10.1002/jbt.2570090602; Nirodi CS, 1996, ARCH BIOCHEM BIOPHYS, V331, P79, DOI 10.1006/abbi.1996.0285; OMIECINSKI CJ, 1985, J BIOL CHEM, V260, P3247; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; Seglen P., 1976, METHODS BIOL, V13, P433; Shu JY, 1996, ONCOGENE, V13, P2421; Sidhu J. S., 1994, In Vitro Toxicology, V7, P225; SIDHU JS, 1995, J BIOL CHEM, V270, P12762, DOI 10.1074/jbc.270.21.12762; Sidhu JS, 1996, J PHARMACOL EXP THER, V276, P238; Sidhu JS, 1997, J PHARMACOL EXP THER, V282, P1122; SIDHU JS, 1995, PHARMACOGENETICS, V5, P24, DOI 10.1097/00008571-199502000-00003; SIDHU JS, 1993, ARCH BIOCHEM BIOPHYS, V301, P103, DOI 10.1006/abbi.1993.1121; Sommer KM, 1996, PHARMACOGENETICS, V6, P369, DOI 10.1097/00008571-199608000-00012; TEILFELD RM, 1989, DNA NY, V8, P329; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370	30	43	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4769	4775		10.1074/jbc.273.8.4769	http://dx.doi.org/10.1074/jbc.273.8.4769			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468541	hybrid			2022-12-25	WOS:000072115000069
J	Broos, J; Hoeve-Duurkens, RT; Robillard, GT				Broos, J; Hoeve-Duurkens, RT; Robillard, GT			A mechanism to alter reversibly the oligomeric state of a membrane-bound protein demonstrated with Escherichia coli EIImtl in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHOTRANSFERASE SYSTEM; MANNITOL TRANSPORT PROTEIN; SITE-SPECIFIC MUTAGENESIS; ENZYME-II; PHOSPHORYLATION; PERMEASE; MUTANTS; IIMTL; COMPLEMENTATION; ENZYME-II(MTL)	This paper reports that the aggregation state of a membrane protein can be changed reversibly without the use of chaotropic agents or denaturants by altering the attractive interactions between micelles of polyethylene glycol-based detergents, This has been documented using mannitol permease of Escherichia coli (EIImtl), a protein whose activity is dependent on the dimerization of its membrane-embedded domains, We show that the driving force for the hydrophobic interactions responsible for the dimerization can be decreased by bringing the protein into a less polar environment, This can be done simply and reversibly by increasing the micelle cluster size of the solubilizing detergent since the micropolarity in the micelle decreases upon clustering and is directly related to the cluster size. The micelle cluster size was varied at a fixed temperature by adding sodium phosphate or a second detergent with a distinct clustering behavior, and the changes were quantified by quasi elastic light scattering and by determining the cloud point or demixing temperature (T-d) of the detergent, Maximal EIImtl activity was found when no micelle clustering occurred, but the activity gradually decreased down to 5% of the maximal activity with increasing cluster size, The inactivation was found to be completely reversible, The kinetics of heterodimer formation were also significantly affected by changes in the micelle cluster size as expected, Increasing the cluster size resulted in faster formation of functional heterodimers by increasing the rate of homodimer dissociation. This phenomenon should be generally applicable to controlling the oligomeric state of membrane-bound proteins or even water-soluble proteins if their subunit association is dominated by hydrophobic forces.	Univ Groningen, Dept Biochem, NL-9747 AG Groningen, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, GBB, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Robillard, GT (corresponding author), Univ Groningen, Dept Biochem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	g.t.robillard@chem.rug.nl						BOER H, 1994, J BIOL CHEM, V269, P17863; Boer H, 1996, BIOCHEMISTRY-US, V35, P12901, DOI 10.1021/bi9611016; BOER H, 1996, THESIS U GRONINGEN N; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CORTI M, 1981, J PHYS CHEM-US, V85, P1442, DOI 10.1021/j150610a033; CORTI M, 1982, PHYS REV LETT, V48, P1617, DOI 10.1103/PhysRevLett.48.1617; Dijkstra DS, 1996, BIOCHEMISTRY-US, V35, P6628; DOOIJEWAARD G, 1979, BIOCHEMISTRY-US, V18, P2990, DOI 10.1021/bi00581a013; HAYTER JB, 1982, COLLOID POLYM SCI, V260, P1023, DOI 10.1007/BF01451649; KHANDEKAR SS, 1989, J CELL BIOCHEM, V39, P207, DOI 10.1002/jcb.240390212; KomaromyHiller G, 1996, LANGMUIR, V12, P916, DOI 10.1021/la950535j; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10120, DOI 10.1021/bi00495a016; LOLKEMA JS, 1993, J BIOL CHEM, V268, P17844; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P1396, DOI 10.1021/bi00057a002; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10659, DOI 10.1021/bi00499a012; LOLKEMA JS, 1992, NEW COMPR BIOCH, V21, P135; MITCHELL DJ, 1983, J CHEM SOC FARAD T 1, V79, P975, DOI 10.1039/f19837900975; NILSSON PG, 1983, J PHYS CHEM-US, V87, P4756, DOI 10.1021/j100246a041; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5520, DOI 10.1021/bi00415a020; PAS HH, 1987, BIOCHEMISTRY-US, V26, P6689, DOI 10.1021/bi00395a019; ROBILLARD GT, 1987, BIOCHEMISTRY-US, V26, P5796, DOI 10.1021/bi00392a032; ROBILLARD GT, 1979, BIOCHEMISTRY-US, V18, P2984, DOI 10.1021/bi00581a012; ROOSSIEN FF, 1986, FEBS LETT, V196, P284, DOI 10.1016/0014-5793(86)80264-2; ROOSSIEN FF, 1984, BIOCHEMISTRY-US, V23, P5682, DOI 10.1021/bi00319a003; SAIER MH, 1980, J SUPRAMOL STR CELL, V14, P281, DOI 10.1002/jss.400140303; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P4046, DOI 10.1021/bi00362a009; VANDIJK AA, 1990, BIOCHEMISTRY-US, V29, P8164, DOI 10.1021/bi00487a026; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1768, DOI 10.1021/bi00221a006; WENG QP, 1992, J BIOL CHEM, V267, P19529; ZULAUF M, 1983, J PHYS CHEM-US, V87, P856, DOI 10.1021/j100228a032; ZULAUF M, 1991, CRYSTALLIZATION MEMB, P53	31	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3865	3870		10.1074/jbc.273.7.3865	http://dx.doi.org/10.1074/jbc.273.7.3865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461568	hybrid, Green Published			2022-12-25	WOS:000072048400010
J	Casanueva, OI; Garcia-Huidobro, T; Campos, EO; Aldunate, R; Garrido, J; Inestrosa, NC				Casanueva, OI; Garcia-Huidobro, T; Campos, EO; Aldunate, R; Garrido, J; Inestrosa, NC			A major portion of synaptic basal lamina acetylcholinesterase is detached by high salt- and heparin-containing buffers from rat diaphragm muscle and Torpedo electric organ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-TAILED ACETYLCHOLINESTERASE; EXTRACELLULAR-MATRIX; ASYMMETRIC ACETYLCHOLINESTERASE; NEUROMUSCULAR-JUNCTION; CELLULAR-LOCALIZATION; MOLECULAR-FORMS; CELLS; ASSOCIATION; BINDING; 16S-ACETYLCHOLINESTERASE	Collagen-tailed asymmetric acetylcholinesterase (AChE) forms are believed to be anchored to the synaptic basal lamina via electrostatic: interactions involving proteoglycans. However, it was recently found that in avian and rat muscles, high ionic strength or polyanionic buffers could not detach AChE: from cell-surface clusters and that these buffers solubilized intracellular non-junctional asymmetric AChE rather than synaptic: forms of the enzyme. In the present study, asymmetric AChE forms were specifically solubilized by ionic buffers from sg synaptic basal! lamina-enriched fractions, largely devoid of intracellular material, obtained from the electric organ of Torpedo californica and the end plate regions of rat diaphragm muscle, Furthermore, foci of AChE activity were seen to diminish in size, number, and staining intensity when the rat synaptic basal lamina-enriched preparations were treated with the extraction buffers, Pn the case of Torpedo, almost all the AChE activity was removed from the pure basal lamina sheets. We therefore conclude that a major portion of extracellular collagen-tailed AChE is extractable from rat and Torpedo synaptic basal lamina by high ionic strength and heparin buffers,;although some non-extractable AChE activity remains associated with the junctional regions.	Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Santiago, Chile	Pontificia Universidad Catolica de Chile	Inestrosa, NC (corresponding author), Catholic Univ Chile, Mol Neurobiol Unit, POB 114-D, Santiago, Chile.			Aldunate, Rebeca/0000-0002-5540-3187				BAYNE EK, 1984, J CELL BIOL, V99, P1486, DOI 10.1083/jcb.99.4.1486; BETZ W, 1973, J PHYSIOL-LONDON, V230, P673, DOI 10.1113/jphysiol.1973.sp010211; Bowen DC, 1996, J NEUROCHEM, V66, P2580; BRANDAN E, 1985, J CELL BIOL, V101, P985, DOI 10.1083/jcb.101.3.985; BRANDAN E, 1984, BIOCHEM J, V221, P415, DOI 10.1042/bj2210415; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; DEPREZ PN, 1995, BBA-PROTEIN STRUCT M, V1252, P53, DOI 10.1016/0167-4838(95)00109-8; DEPREZ PN, 1995, J BIOL CHEM, V270, P11043, DOI 10.1074/jbc.270.19.11043; Eccles JC, 1942, J NEUROPHYSIOL, V5, P211, DOI 10.1152/jn.1942.5.3.211; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FERNANDEZ HL, 1984, NEUROCHEM RES, V9, P1213; GORDON H, 1989, DEV BIOL, V135, P675; HALL ZW, 1973, J NEUROBIOL, V4, P343, DOI 10.1002/neu.480040404; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HALL ZW, 1971, NATURE-NEW BIOL, V232, P62, DOI 10.1038/newbio232062a0; INESTROSA NC, 1983, CELL BIOCHEM FUNCT, V1, P41, DOI 10.1002/cbf.290010108; INESTROSA NC, 1984, BIOCHEM J, V217, P377, DOI 10.1042/bj2170377; INESTROSA NC, 1985, J NEUROCHEM, V45, P86, DOI 10.1111/j.1471-4159.1985.tb05478.x; INESTROSA NC, 1981, J NEUROSCI, V1, P1260; INESTROSA NC, 1983, EXP CELL RES, V147, P393, DOI 10.1016/0014-4827(83)90221-5; INESTROSA NC, 1990, J MEMBRANE BIOL, V118, P1, DOI 10.1007/BF01872200; INESTROSA NC, 1982, CELL, V29, P71, DOI 10.1016/0092-8674(82)90091-5; INESTROSA NC, 1988, NERVE MUSCLE CELL TR, P147; INESTROSA NC, 1988, NEUROSCI LETT, V90, P185; INESTROSA NC, 1992, MULTIDISCIPLINARY AP, P51; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KOENIG J, 1979, BIOL CELLULAIRE, V35, P147; LEE SL, 1982, J BIOL CHEM, V257, P2292; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; MENDEZ B, 1984, CELL MOL NEUROBIOL, V4, P125, DOI 10.1007/BF00711000; PERELMAN A, 1990, J BIOL CHEM, V265, P214; PEREZTUR J, 1991, FEBS LETT, V286, P25, DOI 10.1016/0014-5793(91)80932-S; Rossi SG, 1996, J BIOL CHEM, V271, P1979, DOI 10.1074/jbc.271.4.1979; ROSSI SG, 1993, J BIOL CHEM, V268, P19152; ROTUNDO RL, 1984, P NATL ACAD SCI-BIOL, V81, P479, DOI 10.1073/pnas.81.2.479; Rotundo RL, 1997, J CELL BIOL, V136, P367, DOI 10.1083/jcb.136.2.367; SANES JR, 1979, J CELL BIOL, V83, P357, DOI 10.1083/jcb.83.2.357; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; TORRES JC, 1983, FEBS LETT, V154, P265, DOI 10.1016/0014-5793(83)80162-8; VIGNY M, 1983, J BIOL CHEM, V258, P8794; YOUNKIN SG, 1982, J BIOL CHEM, V257, P13630	42	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4258	4265		10.1074/jbc.273.7.4258	http://dx.doi.org/10.1074/jbc.273.7.4258			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461624	hybrid			2022-12-25	WOS:000072048400066
J	Finn, JP; Edwards, RH				Finn, JP; Edwards, RH			Multiple residues contribute independently to differences in ligand recognition between vesicular monoamine transporters 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINE TRANSPORTER; ENDOCRINE-CELLS; LOCALIZATION; EXPRESSION; CLONING; TETRABENAZINE; SENSITIVITY; INHIBITORS; ISOFORMS; NEURONS	The two closely related vesicular monoamine trans porters (VMATs) 1 and 2 differ substantially in ligand recognition. The neuronal VMAT2 exhibits a higher affinity for monoamine substrates and in particular for histamine as well as a greater sensitivity to the inhibitor tetrabenazine than the nonneuronal VMAT1, The analysis of chimeric transport proteins has previously shown that two major domains, one spanning transmembrane domains (TMDs) 5-8 (TMD5-8) and the other, TMDs 9-12 (TMD9-12), are required for the high affinity interactions characteristic of VMAT2. Using site-directed mutagenesis to replace residues in TMD5-8 of VMAT2 with the equivalent residues from VMAT1, we now show that the sensitivity of VMAT2 to tetrabenazine requires Ala-315, and this interaction occurs independently of the interaction with residues in TMD9-12, The ability to recognize histamine as a substrate depends on Pro-237, and the contribution of TMD9-12 to histamine recognition appears to involve a common mechanism, In contrast, the replacement of many residues in TMD5-8 of VMAT2 with equivalent residues from VMAT1 improves the recognition of both serotonin and tryptamine, and these mutations show a dominant effect on the recognition of both tryptamine and serotonin over mutations in TMD9-12. The results indicate that different ligands interact through distinct mechanisms with the VMATs and that the recognition of each ligand involves multiple, independent interactions with the transport protein.	Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Edwards, RH (corresponding author), Univ Calif San Francisco, Sch Med, Dept Neurol, 3rd & Parnassus St, San Francisco, CA 94143 USA.	edwards@itsa.ucsf.edu						ERICKSON JD, 1993, J NEUROCHEM, V61, P2314, DOI 10.1111/j.1471-4159.1993.tb07476.x; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Finn JP, 1997, J BIOL CHEM, V272, P16301, DOI 10.1074/jbc.272.26.16301; HOWELL M, 1994, FEBS LETT, V338, P16, DOI 10.1016/0014-5793(94)80108-8; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MERICKEL A, 1995, NEUROPHARMACOLOGY, V34, P1543, DOI 10.1016/0028-3908(95)00148-Y; Peter D, 1996, J BIOL CHEM, V271, P2979, DOI 10.1074/jbc.271.6.2979; PETER D, 1993, GENOMICS, V18, P720, DOI 10.1016/S0888-7543(05)80383-0; PETER D, 1994, J BIOL CHEM, V269, P7231; PETER D, 1995, J NEUROSCI, V15, P6179; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SURRATT CK, 1993, FEBS LETT, V318, P325, DOI 10.1016/0014-5793(93)80539-7; WEIHE E, 1994, J MOL NEUROSCI, V5, P149, DOI 10.1007/BF02736730	15	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3943	3947		10.1074/jbc.273.7.3943	http://dx.doi.org/10.1074/jbc.273.7.3943			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461580	hybrid			2022-12-25	WOS:000072048400022
J	Tsoi, M; Rhee, KH; Bungard, D; Li, XF; Lee, SL; Auer, RN; Lytton, J				Tsoi, M; Rhee, KH; Bungard, D; Li, XF; Lee, SL; Auer, RN; Lytton, J			Molecular cloning of a novel potassium-dependent sodium-calcium exchanger from rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; SARCOLEMMAL NA+-CA2+ EXCHANGER; SARCOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; MESSENGER-RNAS; SMOOTH-MUSCLE; K+; PHOTORECEPTORS; NEURONS; INITIATION	We have isolated a novel cDNA clone from rat cerebral cortex encoding a protein of 670 amino acids (NCKX2) that has significant similarity to the 1199-amino acid-long Na/Ca-K exchanger of bovine rod outer segment (NCKX1), NCKX2 transcripts are 10.5 kilobase pairs in length and are expressed abundantly in neurons throughout the brain and with much lower abundance in selected other tissues, The predicted topology of the rat NCKX2 protein is very similar to that of bovine NCKX1, beginning with a solitary transmembrane segment (MO), which is removed as a "signal peptide" in bovine NCKX1, an extracellular loop, a cluster of five transmembrane spanning segments (Mi to M5), a long cytoplasmic loop, and a final hydrophobic cluster (M6 to M11), Within the hydrophobic clusters, rat NCKX2 shares 80% identity and 91% similarity with bovine NCKX1, The two larger hydrophilic loops are much shorter in NCKX2 than in NCKX1, accounting largely for the difference in length between the two proteins, and are dissimilar in sequence except for a 32-amino acid stretch with 69% identity in the cytosolic loop. NCKX2 was epitope-tagged in the extracellular domain and was shown to be expressed at the surface of transfected HEK cells. Analysis of NCKX2 function by fluorescent imaging of fura-a-loaded transfected cells demonstrated that NCKX2 is a potassium-dependent sodium/calcium exchanger.	Univ Calgary, Hlth Sci Ctr, Dept Med Biochem, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Neurosci, Calgary, AB T2N 4N1, Canada; Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Tsoi, M (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Med Biochem, Rm 2518,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	jlytton@acs.ucalgary.ca	Auer, Roland/F-6661-2017	Auer, Roland/0000-0001-9044-3419; Lytton, Jonathan/0000-0003-4770-2512				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BREITSCHOPF H, 1996, NONRADIOACTIVE IN SI, P136; Carpenter M.B, 1991, CORE TEXT NEUROANATO; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CONDRESCU M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P198, DOI 10.1016/0005-2736(90)90226-E; DAHAN D, 1991, J BIOL CHEM, V266, P2067; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; FRIEDEL U, 1991, BIOCHIM BIOPHYS ACTA, V1061, P247, DOI 10.1016/0005-2736(91)90290-O; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HYRSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35; Juhaszova M, 1996, ANN NY ACAD SCI, V779, P318, DOI 10.1111/j.1749-6632.1996.tb44804.x; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KIMURA M, 1993, J BIOL CHEM, V268, P6874; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lederer WJ, 1996, ANN NY ACAD SCI, V779, P7, DOI 10.1111/j.1749-6632.1996.tb44764.x; LI ZP, 1991, J BIOL CHEM, V266, P1014; LI ZP, 1994, J BIOL CHEM, V269, P17434; LYTTON J, 1992, J BIOL CHEM, V267, P14483; Lytton J, 1996, ANN NY ACAD SCI, V779, P58, DOI 10.1111/j.1749-6632.1996.tb44770.x; MARLIER LNJL, 1993, MOL BRAIN RES, V20, P21, DOI 10.1016/0169-328X(93)90107-Z; MOORE EDW, 1993, NATURE, V365, P657, DOI 10.1038/365657a0; Navangione A, 1997, BIOPHYS J, V73, P45, DOI 10.1016/S0006-3495(97)78046-9; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NIGGLI E, 1991, NATURE, V349, P621, DOI 10.1038/349621a0; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Paxinos G., 1996, RAT BRAIN STEREOTAXI; REEVES JP, 1983, J BIOL CHEM, V258, P3178; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; Rispoli G, 1996, ANN NY ACAD SCI, V779, P346, DOI 10.1111/j.1749-6632.1996.tb44806.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHNETKAMP PPM, 1989, PROG BIOPHYS MOL BIO, V54, P1, DOI 10.1016/0079-6107(89)90007-2; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; SCHNETKAMP PPM, 1995, CELL CALCIUM, V18, P322, DOI 10.1016/0143-4160(95)90028-4; Schulze DH, 1996, ANN NY ACAD SCI, V779, P46, DOI 10.1111/j.1749-6632.1996.tb44769.x; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; ZEINER M, 1994, BIOTECHNIQUES, V17, P1051	45	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4155	4162		10.1074/jbc.273.7.4155	http://dx.doi.org/10.1074/jbc.273.7.4155			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461611	hybrid			2022-12-25	WOS:000072048400053
J	Yuan, ZM; Huang, YY; Ishiko, T; Nakada, S; Utsugisawa, T; Kharbanda, S; Wang, R; Sung, P; Shinohara, A; Weichselbaum, R; Kufe, D				Yuan, ZM; Huang, YY; Ishiko, T; Nakada, S; Utsugisawa, T; Kharbanda, S; Wang, R; Sung, P; Shinohara, A; Weichselbaum, R; Kufe, D			Regulation of Rad51 function by c-Abl in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NUCLEAR TYROSINE KINASE; ESCHERICHIA-COLI RECA; HOMOLOGOUS RECOMBINATION; IONIZING-RADIATION; STRESS-RESPONSE; STRAND EXCHANGE; P53; REPAIR; GROWTH	The Rad51 protein, a homolog of bacterial RecA, functions in DNA double-strand break repair and genetic recombination. Whereas Rad51 catalyzes ATP-dependent pairing and strand exchange between homologous DNA molecules, regulation of this function is unknown. The c-Abl tyrosine kinase is activated by ionizing radiation and certain other DNA-damaging agents. Here we demonstrate that c-Abl interacts constitutively with Rad51. We show that c-Abl phosphorylates Rad51 on Tyr-54 in vitro. The results also show that treatment of cells with ionizing radiation induces c-Abl dependent phosphorylation of Rad51. Phosphorylation of Rad51 by c-Abl inhibits the binding of Rad51 to DNA and the function of Rad51 in ATP-dependent DNA strand exchange reactions. These findings represent the first demonstration that Rad51 is regulated by phosphorylation and support a functional role for c-Abl in regulating Rad51-dependent recombination in the response to DNA damage.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Canc Pharmacol, Boston, MA 02115 USA; Rockefeller Univ, Mass Spectrometry Ctr, New York, NY 10021 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Ctr Mol Med, San Antonio, TX 78245 USA; Osaka Univ, Fac Sci, Dept Biol, Osaka 560, Japan; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Rockefeller University; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Osaka University; University of Chicago	Yuan, ZM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Canc Pharmacol, 44 Binney St, Boston, MA 02115 USA.		Utsugisawa, Taiju/ABD-7059-2021; Wang, Rong/A-8721-2009					Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GOGA A, 1995, ONCOGENE, V11, P791; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAESHIMA K, 1995, GENE, V160, P195, DOI 10.1016/0378-1119(95)00148-Y; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	40	170	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3799	3802		10.1074/jbc.273.7.3799	http://dx.doi.org/10.1074/jbc.273.7.3799			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461559	hybrid			2022-12-25	WOS:000072048400001
J	Bajzar, L; Nesheim, M; Morser, J; Tracy, PB				Bajzar, L; Nesheim, M; Morser, J; Tracy, PB			Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; PROTEIN-C; PLASMINOGEN-ACTIVATOR; HUMAN-PLASMA; FACTOR-V; PROTHROMBIN ACTIVATION; PROCARBOXYPEPTIDASE-B; CARBOXYPEPTIDASE-U; INACTIVATION; COAGULATION	Thrombin-activable fibrinolysis inhibitor (TAFI) is a recently described plasma zymogen that can be activated by thrombin to an enzyme with carboxypeptidase B-like activity, The enzyme, TAFIa, potently attentuates fibrinolysis, TAFI activation, like protein C activation, is augmented about 1250-fold by thrombomodulin (TM), In this work, the effects of both soluble and cellular forms of TM on TAFI activation-dependent suppression of fibrinolysis were investigated, Soluble TM included in clots formed from purified components, barium citrate-adsorbed plasma, or normal human plasma maximally increased the tissue plasminogen activator-induced lysis time PS-fold, with saturation occurring at 5, 10, and 1 nM TM in the three respective systems. Soluble TM did not effect lysis in the system of purified components lacking TAFI or in plasmas immunodepleted of TAFI, In addition, the antifibrinolytic effect of TM was negated by monoclonal antibodies against either TAFI or TM, The inhibition of fibrinolysis by cellular TM was assessed by forming clots in dialyzed, barium citrate-adsorbed, or normal plasma over cultured human umbilical vein endothelial cells (HUVECs), Tissue plasminogen activator-induced lysis time was increased 2-fold, with both plasmas, in the presence of HUVECs, The antifibrinolytic effect of HUVECs was abolished 66% by specific anti-TAFI or anti-TM monoclonal antibodies, A newly developed functional assay demonstrated that HUVECs potentiate the thrombin-catalyzed. TM-dependent formation of activated TAFI, Thus, endothelial cell TRI, in vitro at least, appears to participate in the regulation of not only coagulation but also fibrinolysis.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA; Berlex Biosci, Cardiovasc Dept, Richmond, CA 94804 USA	Queens University - Canada; Queens University - Canada; University of Vermont	Nesheim, M (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	nesheimm@post.queensu.ca			NHLBI NIH HHS [HLP01-46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASTRUP T, 1991, SEMIN THROMB HEMOST, V17, P161, DOI 10.1055/s-2007-1002606; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; Bajzar L., 1996, Fibrinolysis, V10, P81; BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Broze GJ, 1996, BLOOD, V88, P3815, DOI 10.1182/blood.V88.10.3815.bloodjournal88103815; BUTENAS S, 1995, ANAL BIOCHEM, V225, P231, DOI 10.1006/abio.1995.1148; COLLEN D, 1991, BLOOD, V78, P3114; COTE HCF, 1994, J BIOL CHEM, V269, P11374; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; EATON DL, 1991, J BIOL CHEM, V266, P21833; ESMON CT, 1991, ANN NY ACAD SCI, V614, P30, DOI 10.1111/j.1749-6632.1991.tb43689.x; ESMON CT, 1984, SEMIN THROMB HEMOST, V10, P122, DOI 10.1055/s-2007-1004414; FULCHER CA, 1984, BLOOD, V63, P486; GRIFFIN JH, 1984, SEMIN THROMB HEMOST, V10, P162, DOI 10.1055/s-2007-1004419; HEMKER HC, 1993, THROMB HAEMOSTASIS, V70, P617; HOOGENDOORN H, 1990, BLOOD, V75, P2164; ISHII H, 1985, J CLIN INVEST, V76, P2178, DOI 10.1172/JCI112225; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KODAMA S, 1990, CLIN CHIM ACTA, V192, P191, DOI 10.1016/0009-8981(90)90221-D; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEVIN EG, 1986, THROMB HAEMOSTASIS, V56, P115; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; SCHLEEF RR, 1990, J CELL BIOL, V110, P155, DOI 10.1083/jcb.110.1.155; SHATOS MA, 1990, J BIOL CHEM, V265, P20443; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; SUZUKI K, 1988, J BIOCHEM-TOKYO, V104, P628, DOI 10.1093/oxfordjournals.jbchem.a122523; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TAKAHASHI Y, 1995, THROMB HAEMOSTASIS, V73, P805; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; TANS G, 1991, J BIOL CHEM, V266, P21864; VondemBorne PAK, 1997, J CLIN INVEST, V99, P2323, DOI 10.1172/JCI119412; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WANG W, 1994, J BIOL CHEM, V269, P15937	39	96	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2792	2798		10.1074/jbc.273.5.2792	http://dx.doi.org/10.1074/jbc.273.5.2792			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446587	hybrid			2022-12-25	WOS:000071736600042
J	Naito, M; Ohara, N; Matsumoto, S; Yamada, T				Naito, M; Ohara, N; Matsumoto, S; Yamada, T			The novel fibronectin-binding motif and key residues of mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-INTERFERON PRODUCTION; BACILLUS CALMETTE-GUERIN; BOVIS-BCG; ALPHA-ANTIGEN; EXTRACELLULAR PROTEINS; PROTECTIVE IMMUNITY; KANSASII INFECTION; SECRETED PROTEIN; IMMUNOGLOBULIN-G; TUBERCULOSIS	The binding motifs of the immunodominant antigen (Ag) alpha-Ag (Ag 85 complex B) of Mycobacterium kansasii for human fibronectin were examined using digested fragments. We defined two fibronectin-binding epitopes on 27 amino acids from 84 to 110 and on 20 amino acids from 211 to 230, The epitopes were almost conserved in the closely related Ag 85 complex of other mycobacteria species. Inhibition of fibronectin binding to intact alpha-Ag molecules was observed with peptide-(84-110), but not with peptide-(211-230). Peptide (84-110) could also inhibit fibronectin binding to all components of the Ag 85 complex of Bacillus Calmette-Guerin (Ag 85A, Ag 85B, and Ag 85C). Further study with synthetic peptides defined 11 residues from 98 to 108 as the minimum motif. Six residues ((98)FEWYYQ(103)) were critical for interacting with fibronectin. The motif revealed no homology to other known prokaryotic and eukaryotic fibronectin-binding proteins. The defined motif of alpha-Ag is novel and unique for mycobacteria.	Nagasaki Univ, Sch Dent, Dept Oral Bacteriol, Nagasaki 852, Japan	Nagasaki University	Naito, M (corresponding author), Nagasaki Univ, Sch Dent, Dept Oral Bacteriol, 1-7-1 Sakamoto, Nagasaki 852, Japan.		OHARA, Naoya/B-2481-2011	NAITO, Mariko/0000-0003-0769-7747; Matsumoto, Sohkichi/0000-0002-6106-7538				ABOUZEID C, 1988, INFECT IMMUN, V56, P3046, DOI 10.1128/IAI.56.12.3046-3051.1988; ABOUZEID C, 1988, J GEN MICROBIOL, V134, P531; ANDERSEN P, 1994, INFECT IMMUN, V62, P2536, DOI 10.1128/IAI.62.6.2536-2544.1994; Aung H, 1996, J CLIN INVEST, V98, P1261, DOI 10.1172/JCI118910; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; BREATHNACH A, 1995, CLIN INFECT DIS, V20, P812, DOI 10.1093/clinids/20.4.812; CONTENT J, 1991, INFECT IMMUN, V59, P3205, DOI 10.1128/IAI.59.9.3205-3212.1991; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530; HUYGEN K, 1988, INFECT IMMUN, V56, P3196, DOI 10.1128/IAI.56.12.3196-3200.1988; HUYGEN K, 1988, SCAND J IMMUNOL, V27, P187, DOI 10.1111/j.1365-3083.1988.tb02338.x; JANICKI BW, 1971, AM REV RESPIR DIS, V104, P602; KITAURA H, 1993, BIOCHEM BIOPH RES CO, V196, P1466, DOI 10.1006/bbrc.1993.2417; MATSUO K, 1990, INFECT IMMUN, V58, P550, DOI 10.1128/IAI.58.2.550-556.1990; MATSUO K, 1988, J BACTERIOL, V170, P3847, DOI 10.1128/jb.170.9.3847-3854.1988; MATSUO K, 1990, INFECT IMMUN, V58, P4049, DOI 10.1128/IAI.58.12.4049-4054.1990; NAGAI S, 1991, INFECT IMMUN, V59, P372, DOI 10.1128/IAI.59.1.372-382.1991; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHARA N, 1993, INFECT IMMUN, V61, P1173, DOI 10.1128/IAI.61.4.1173-1179.1993; OHARA N, 1995, SCAND J IMMUNOL, V41, P433, DOI 10.1111/j.1365-3083.1995.tb03589.x; ORME IM, 1988, INFECT IMMUN, V56, P3310, DOI 10.1128/IAI.56.12.3310-3312.1988; PAL PG, 1992, INFECT IMMUN, V60, P4781, DOI 10.1128/IAI.60.11.4781-4792.1992; PEAKE P, 1993, INFECT IMMUN, V61, P4828, DOI 10.1128/IAI.61.11.4828-4834.1993; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; RAMBUKKANA A, 1993, INFECT IMMUN, V61, P1835, DOI 10.1128/IAI.61.5.1835-1845.1993; RATLEDGE C, 1989, BIOL MYCOBACTERIA, V3, P511; RATLIFF TL, 1988, J GEN MICROBIOL, V134, P1307; ROCHE PW, 1994, INFECT IMMUN, V62, P5319, DOI 10.1128/IAI.62.12.5319-5326.1994; SALATA RA, 1991, J LAB CLIN MED, V118, P589; SHAFER RW, 1992, CLIN INFECT DIS, V15, P161, DOI 10.1093/clinids/15.1.161; SNIDER DJ, 1992, NEW ENGL J MED, V32, P703; SUZUKI Y, 1987, J BACTERIOL, V169, P839, DOI 10.1128/jb.169.2.839-843.1987; TAKANO M, 1994, SCAND J IMMUNOL, V40, P165, DOI 10.1111/j.1365-3083.1994.tb03446.x; THOLE JER, 1992, MOL MICROBIOL, V6, P153, DOI 10.1111/j.1365-2958.1992.tb01996.x; TURNEER M, 1988, J CLIN MICROBIOL, V26, P1714, DOI 10.1128/JCM.26.9.1714-1719.1988; WAYNE LG, 1992, CLIN MICROBIOL REV, V5, P1; WEINROTH SE, 1994, CLIN INFECT DIS, V18, P261, DOI 10.1093/clinids/18.2.261; WIKER HG, 1990, AM REV RESPIR DIS, V141, P830, DOI 10.1164/ajrccm/141.4_Pt_1.830; WIKER HG, 1992, SCAND J IMMUNOL, V36, P307, DOI 10.1111/j.1365-3083.1992.tb03104.x; WIKER HG, 1986, INT ARCH ALLER A IMM, V81, P307, DOI 10.1159/000234154; WOLINSKY E, 1992, CLIN INFECT DIS, V15, P1, DOI 10.1093/clinids/15.1.1	42	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2905	2909		10.1074/jbc.273.5.2905	http://dx.doi.org/10.1074/jbc.273.5.2905			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446601	hybrid			2022-12-25	WOS:000071736600056
J	Zhang, F; Anderson, D				Zhang, F; Anderson, D			In vitro selection of bacteriophage phi 29 prohead RNA aptamers for prohead binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-RNA; DNA; DNA-GP3; PRNA	Prohead RNA (pRNA) of the Bacillus subtilis bacteriophage phi 29 is needed for in vitro packaging of DNA-gene product 3 (DNA-gp3). Residues 22-84 of the 174-base pRNA bind the portal vertex of the prohead, the site of DNA packaging, To define the nucleotides of pRNA needed for prohead binding and DNA-gp3 packaging and to seek biologically active variants of pRNA, segments of pRNA were randomized to obtain vast repertoires of RNA molecules, RNA aptamers, ligands best suited for prohead binding, were obtained by multiple rounds of in vitro selection, Evolution of pRNA aptamers was followed by a competition binding assay and nucleotide sequencing, and mutants were tested for DNA-gp3 packaging, Aptamers selected following randomization of the E stem and loop and a part of the C-E loop that were active in DNA-gp3 packaging were invariably wild-type. DNA-gp3 packaging activity also required nucleo tides G(82) and G(83) that form base pairs intermolecularly with C-47 and C-48 to produce a novel hexameric oligomer of pRNA, The only mutant aptamers that retained full DNA-gp(3) packaging activity showed changes of the U residues at positions 81, 84, and 85 of the D loop. Thus, the in vitro selections essentially recapitulated the natural evolution of pRNA.	Univ Minnesota, Dept Oral Sci, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Genet & Cell Biol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Anderson, D (corresponding author), Univ Minnesota, Dept Oral Sci, 18-246 Moos Hlth Sci Tower,515 Delaware St SE, Minneapolis, MN 55455 USA.				NIDCR NIH HHS [DE03606] Funding Source: Medline; NIGMS NIH HHS [GM39931] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE003606, R01DE003606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039931] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1990, J BIOL CHEM, V265, P22365; GRIMES S, 1990, J MOL BIOL, V215, P559, DOI 10.1016/S0022-2836(05)80168-8; GRIMES S, 1989, J MOL BIOL, V209, P101, DOI 10.1016/0022-2836(89)90173-3; Grimes S, 1997, J MOL BIOL, V266, P901, DOI 10.1006/jmbi.1996.0843; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; GUO PX, 1986, P NATL ACAD SCI USA, V83, P3505, DOI 10.1073/pnas.83.10.3505; LONGEL J, 1992, BIOTECHNIQUES, V13, P604; REID RJD, 1994, J BIOL CHEM, V269, P18656; REID RJD, 1994, J BIOL CHEM, V269, P9084; REID RJD, 1994, J BIOL CHEM, V269, P5157; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WICHITWECHKARN J, 1989, NUCLEIC ACIDS RES, V17, P3459, DOI 10.1093/nar/17.9.3459; WICHITWECHKARN J, 1992, J MOL BIOL, V223, P991, DOI 10.1016/0022-2836(92)90257-K; ZHANG CL, 1994, VIROLOGY, V201, P77, DOI 10.1006/viro.1994.1267; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	15	17	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2947	2953		10.1074/jbc.273.5.2947	http://dx.doi.org/10.1074/jbc.273.5.2947			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446607	hybrid			2022-12-25	WOS:000071736600062
J	Botelho, FM; Edwards, DR; Richards, CD				Botelho, FM; Edwards, DR; Richards, CD			Oncostatin M stimulates c-fos to bind a transcriptionally responsive AP-1 element within the tissue inhibitor of metalloproteinase-1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-FIBROBLASTS; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; HEPG2 CELLS; EXPRESSION; PROTEINS; TIMP-1; INTERLEUKIN-6; COLLAGENASE; ACTIVATION	Tissue inhibitor of metalloproteinases-1 (TIMP-1) can be regulated by gp130 cytokines such as IL-6 and oncostatin M (OSM). Polymerase chain reaction deletion analysis of the murine TIMP-1 proximal promoter in chloramphenicol acetyltransferase reporter gene constructs identified an AP-1 element (-59/-53) that allows maximal responsiveness to OSM in HepG2 cells. Fos and Jun nuclear factors bound constitutively to this site as identified by supershift analysis in electrophoretic mobility shift assays, and oncostatin M (but not IL-6) induced an additional "complex 2" that contained c-Fos and JunD. OSM stimulated a rapid and transient increase in c-Fos mRNA and nuclear protein that coincided with complex 2 formation. Phorbol 13-myristate 12-acetate could also induce c-Fos but could not regulate the TIMP-1 reporter gene constructs. Transfection studies also showed that 3'-deletion of sequences downstream of the transcriptional start site (+1/+47) markedly reduced OSM -fold induction. Nuclear factors bound to SP1 and Ets sequences were detected, but were not altered upon OSM stimulation. Although OSM and IL-6 induced STAT (signal transducers and activators of transcription) factors to bind a high affinity Sis-inducible element DNA probe, binding to homologous TIMP-1 promoter sequences was not detected. Thus, OSM (but not IL-6) stimulates c-Fos, which participates in maximal activation of TIMP-1 transcription, likely in cooperation with other factors such as SP1 or as yet unidentified mechanisms involving the +1 to +47 region of the promoter.	McMaster Univ, Hlth Sci Ctr, Dept Pathol, Mol Virol & Immunol Program, Hamilton, ON L8N 3Z5, Canada; Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB T2N 4N1, Canada	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary	Richards, CD (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Pathol, Mol Virol & Immunol Program, Rm 4H17,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.		Edwards, Dylan R/B-4734-2009	Edwards, Dylan R/0000-0002-3292-2064; Richards, Carl/0000-0002-0081-2231				AMARAL MC, 1993, J CLIN INVEST, V92, P848, DOI 10.1172/JCI116659; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BROWN TJ, 1987, J IMMUNOL, V139, P2977; BROWN TJ, 1990, MOL BIOL CARDIOVASC, V131, P195; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; CAWSTON TE, 1990, BIOCHEM J, V269, P183, DOI 10.1042/bj2690183; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SD, 1987, J CLIN INVEST, V80, P1280, DOI 10.1172/JCI113203; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; GEARING DP, 1992, NEW BIOL, V4, P61; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; GROVE RI, 1991, J BIOL CHEM, V266, P18194; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; KUMAR G, 1994, J IMMUNOL, V153, P4436; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LIU JW, 1992, CELL GROWTH DIFFER, V3, P307; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MURPHY G, 1985, J BIOL CHEM, V260, P3079; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; RICHARDS CD, 1993, J IMMUNOL, V150, P5596; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; ROEB E, 1994, FEBS LETT, V349, P45, DOI 10.1016/0014-5793(94)00636-9; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SHIMADA Y, 1992, BLOOD, V79, P2423; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOLDI R, 1994, ONCOGENE, V9, P2253; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; ULISSE S, 1994, ENDOCRINOLOGY, V135, P2479, DOI 10.1210/en.135.6.2479; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	47	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5211	5218		10.1074/jbc.273.9.5211	http://dx.doi.org/10.1074/jbc.273.9.5211			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478976	hybrid			2022-12-25	WOS:000072310400060
J	Joshi, AK; Rangan, VS; Smith, S				Joshi, AK; Rangan, VS; Smith, S			Differential affinity labeling of the two subunits of the homodimeric animal fatty acid synthase allows isolation of heterodimers consisting of subunits that have been independently modified	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MAMMARY-GLAND; MULTIFUNCTIONAL ENZYME; MOLECULAR-CLONING; ESCHERICHIA-COLI; ACTIVE-CENTERS; SYNTHETASE; SITE; THIOESTERASE; DOMAIN; CDNA	To explore the domain interactions that are required for catalytic activity of the multifunctional, homodimeric fatty acid synthase (FAS), we have formulated a strategy that allows isolation of modified dimers containing independently mutated subunits, Either a hexahistidine or a FLAG octapeptide tag was incorporated into the FAS at either the amino terminus, within an internal noncatalytic domain, or at the carboxyl terminus, The presence of the tags had no effect on the activity of the wild-type FAS. His-tagged dimers were mixed with FLAG-tagged dimers, and the subunits were randomized to produce a mixture of His-tagged homodimers, FLAG-tagged homodimers, and doubly tagged heterodimers. The doubly tagged heterodimers could be purified to homogeneity by chromatography on an anti-FLAG immunoaffinity column followed by a metal ion chelating column, This procedure for isolation of FAS heterodimers was utilized to determine whether the two centers for fatty acid synthesis in the FAS dimer can function independently of each other, Doubly tagged heterodimers, consisting of one wild-type subunit and one subunit in which the thioesterase activity had been eliminated, either by mutation or by treatment with phenylmethanesulfonyl fluoride, have 50% of the wild-type thioesterase activity and, in the presence of substrates, accumulate a long chain fatty acyl moiety on the modified subunit, thus blocking further substrate turnover at this center, Nevertheless, the ability of the heterodimer to synthesize fatty acids is also 50% of the wild-type FAS, demonstrating that an individual center for fatty acid synthesis has the same activity when paired with either a functional or nonfunctional catalytic center.	Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	Smith, S (corresponding author), Childrens Hosp, Oakland Res Inst, 747 52nd St, Oakland, CA 94609 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 16073] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; CHANG SI, 1990, ACCOUNTS CHEM RES, V23, P363, DOI 10.1021/ar00179a003; CHANG SI, 1988, BIOCHEMISTRY-US, V27, P4753, DOI 10.1021/bi00413a026; HARDIE DG, 1986, MULTIDOMAIN PROTEINS, P229; HOLZER KP, 1989, P NATL ACAD SCI USA, V86, P4387, DOI 10.1073/pnas.86.12.4387; JOSHI AK, 1993, BIOCHEM J, V296, P143, DOI 10.1042/bj2960143; JOSHI AK, 1993, J BIOL CHEM, V268, P22508; Joshi AK, 1997, BIOCHEMISTRY-US, V36, P2316, DOI 10.1021/bi9626968; JOSHI AK, 1998, IN PRESS BIOCHEMISTR; KUMAR S, 1973, BIOCHEM BIOPH RES CO, V53, P334, DOI 10.1016/0006-291X(73)91438-1; KYUSHIKI H, 1989, BIOCHEM BIOPH RES CO, V164, P434, DOI 10.1016/0006-291X(89)91738-5; LIBERTINI LJ, 1979, ARCH BIOCHEM BIOPHYS, V192, P47, DOI 10.1016/0003-9861(79)90070-5; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MCCARTHY AD, 1982, FEBS LETT, V147, P256, DOI 10.1016/0014-5793(82)81054-5; MIKKELSEN J, 1985, BIOCHEM J, V227, P21, DOI 10.1042/bj2270021; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; POULOSE AJ, 1984, ARCH BIOCHEM BIOPHYS, V230, P117, DOI 10.1016/0003-9861(84)90092-4; POULOSE AJ, 1981, BIOCHEM BIOPH RES CO, V103, P377, DOI 10.1016/0006-291X(81)90463-0; SCHWEIZER M, 1989, NUCLEIC ACIDS RES, V17, P567, DOI 10.1093/nar/17.2.567; SINGH N, 1984, J BIOL CHEM, V259, P3605; Smith S, 1975, Methods Enzymol, V35, P65, DOI 10.1016/0076-6879(75)35139-2; Smith S, 1981, Methods Enzymol, V71 Pt C, P181, DOI 10.1016/0076-6879(81)71026-7; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SMITH S, 1985, EUR J BIOCHEM, V152, P547, DOI 10.1111/j.1432-1033.1985.tb09230.x; SMITH S, 1979, ARCH BIOCHEM BIOPHYS, V197, P379, DOI 10.1016/0003-9861(79)90259-5; SMITH S, 1971, J BIOL CHEM, V246, P6428; STERN A, 1982, J BIOL CHEM, V257, P799; STOOPS JK, 1982, J BIOL CHEM, V257, P3230; STOOPS JK, 1981, J BIOL CHEM, V256, P5128; TSUKAMOTO Y, 1983, J BIOL CHEM, V258, P5312; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WANG YS, 1984, J BIOL CHEM, V259, P3644; Witkowski A, 1996, BIOCHEMISTRY-US, V35, P10569, DOI 10.1021/bi960910m; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x; YUAN ZY, 1985, J BIOL CHEM, V260, P3532	36	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4937	4943		10.1074/jbc.273.9.4937	http://dx.doi.org/10.1074/jbc.273.9.4937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478938	hybrid			2022-12-25	WOS:000072310400022
J	Jiang, F; Kelly, BL; Hagopian, K; Greenberg, ML				Jiang, F; Kelly, BL; Hagopian, K; Greenberg, ML			Purification and characterization of phosphatidylglycerolphosphate synthase from Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; MIXED MICELLAR ANALYSIS; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEINS; ESCHERICHIA-COLI; PHOSPHATIDYLINOSITOL SYNTHASE; CYTOCHROME-OXIDASE; CONTACT SITES; CARDIOLIPIN; REQUIREMENT	The enzyme CDP-diacylglycerol:sn-glycerol-3-phosphate 3-phosphatidyltransferase (phosphatidylglycerolphosphate synthase; PGPS(4); EC 2.7.8.5) is located in the mitochondrial inner membrane and catalyzes the committed step in the cardiolipin branch of phospholipid synthesis. Previous studies revealed that PGPS is the most highly regulated enzyme in cardiolipin biosynthesis in both Saccharomyces cerevisiae and Schizosaccharomyces pombe, In this work, we report the purification to homogeneity of PGPS from S. pombe, The enzyme was solubilized from the mitochondrial membrane of S. pombe with Triton X-100. The solubilized enzyme, together with the associated detergent and intrinsic lipids, had a molecular mass of 120 kDa, as determined by gel filtration. The enzyme was further purified using salt-induced phase separation, gel filtration, and ionic exchange, hydroxylapatite, and affinity chromatographies, The procedure yielded a homogeneous protein preparation, evidenced by both SDS-polyacrylamide gel electrophoresis (PAGE) and agarose isoelectric focusing under nondenaturing conditions. The purified enzyme had an apparent molecular mass of 60 kDa as determined by SDS-PAGE. The enzyme showed a strong dependence on lipid cofactors for activity in vitro. While both phosphatidic acid and CDP-diacylglycerol appeared to be activators, the most significant activation was observed with cardiolipin, The possible physiological significance of the lipid cofactor effect is discussed, This is the first purification of a eucaryotic PGPS enzyme to date, and the first purification of a phospholipid biosynthetic enzyme from S. pombe.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.	MLGREEN@sun.science.wayne.edu			NIGMS NIH HHS [GM37723] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037723] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEDO JC, 1993, ELECTROPHORESIS, V14, P88, DOI 10.1002/elps.1150140116; AMES GFL, 1976, BIOCHEMISTRY-US, V15, P616, DOI 10.1021/bi00648a026; ANDREWS P, 1964, BIOCHEM J, V91, P222, DOI 10.1042/bj0910222; ANTONSSON BE, 1994, BIOCHEM J, V297, P517, DOI 10.1042/bj2970517; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; AWASTHI YC, 1971, BIOCHIM BIOPHYS ACTA, V226, P42, DOI 10.1016/0005-2728(71)90176-9; BAELEE MS, 1984, J BIOL CHEM, V259, P857; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMAN GM, 1983, CAN J MICROBIOL, V29, P1452, DOI 10.1139/m83-222; CONVERSE CA, 1975, SCIENCE, V189, P469, DOI 10.1126/science.1154021; COUSMINER JJ, 1982, J BACTERIOL, V151, P1372, DOI 10.1128/JB.151.3.1372-1379.1982; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; DUTT A, 1985, BIOCHEMISTRY-US, V24, P1074, DOI 10.1021/bi00326a001; EATON BR, 1976, ARCH BIOCHEM BIOPHYS, V176, P604, DOI 10.1016/0003-9861(76)90204-6; ENDO T, 1988, EMBO J, V7, P1153, DOI 10.1002/j.1460-2075.1988.tb02925.x; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; FRY M, 1980, BIOCHEM BIOPH RES CO, V93, P1238, DOI 10.1016/0006-291X(80)90622-1; GAYNOR PM, 1991, J BACTERIOL, V173, P6124, DOI 10.1128/jb.173.19.6124-6131.1991; GAYNOR PM, 1992, J BACTERIOL, V174, P5711, DOI 10.1128/JB.174.17.5711-5718.1992; GREENBERG ML, 1988, MOL CELL BIOL, V8, P4773, DOI 10.1128/MCB.8.11.4773; HAJRA AK, 1968, J BIOL CHEM, V243, P3458; HAJRA AK, 1978, J NEUROCHEM, V31, P125, DOI 10.1111/j.1471-4159.1978.tb12440.x; HIRABAYASHI T, 1976, BIOCHEMISTRY-US, V15, P5205, DOI 10.1021/bi00669a002; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; HOFFMANN B, 1994, J BIOL CHEM, V269, P1940; KARKHOFFSCHWEIZER RR, 1991, J BACTERIOL, V173, P6132, DOI 10.1128/jb.173.19.6132-6138.1991; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON TJ, 1976, BIOCHEMISTRY-US, V15, P974, DOI 10.1021/bi00650a005; LARSON TJ, 1976, BIOCHEMISTRY-US, V15, P5212, DOI 10.1021/bi00669a003; OU WJ, 1988, J BIOCHEM-TOKYO, V103, P589, DOI 10.1093/oxfordjournals.jbchem.a122312; PARISH CR, 1986, ANAL BIOCHEM, V156, P495, DOI 10.1016/0003-2697(86)90284-8; RIDGWAY ND, 1987, J BIOL CHEM, V262, P17231; RIETVELD A, 1983, EMBO J, V2, P907, DOI 10.1002/j.1460-2075.1983.tb01520.x; RIGHETTI PG, 1979, RECENT DEV CHROMATOG, P1; SANDERMANN H, 1986, PROGR PROTEIN LIPID, P197; SCHEIDELER MA, 1989, J BIOL CHEM, V264, P12455; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SNOW PM, 1984, J IMMUNOL, V133, P2058; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WARLOW RS, 1990, ELECTROPHORESIS, V11, P53, DOI 10.1002/elps.1150110112; WHITAKER JR, 1963, ANAL CHEM, V35, P1950, DOI 10.1021/ac60205a048	44	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4681	4688		10.1074/jbc.273.8.4681	http://dx.doi.org/10.1074/jbc.273.8.4681			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468529	hybrid			2022-12-25	WOS:000072115000057
J	Ma, TH; Yang, BX; Gillespie, A; Carlson, EJ; Epstein, CJ; Verkman, AS				Ma, TH; Yang, BX; Gillespie, A; Carlson, EJ; Epstein, CJ; Verkman, AS			Severely impaired urinary concentrating ability in transgenic mice lacking aquaporin-1 water channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY; CHIP28; MEMBRANE; RECONSTITUTION; LOCALIZATION; LIPOSOMES; CLONING; PROTEIN; TUBULE	Water channel aquaporin-1 (AQP1) is strongly ex pressed in kidney in proximal tubule and descending limb of Henle epithelia and, in vasa recta endothelia, The grossly normal phenotype in human subjects deficient in AQP1 (Colton null blood group) and in AQP4 knockout mice has suggested that aquaporins (other than the vasopressin-regulated water channel AQP2) may not be important in mammalian physiology, We have generated transgenic mice lacking detectable AQP1. by targeted gene disruption, In kidney proximal tubule membrane vesicles from knockout mice, osmotic water permeability was reduced 8-fold compared with vesicles from wild-type mice, Although the knockout mice were grossly normal In terms of survival, physical appearance, and organ morphology, they became severely dehydrated and lethargic after water deprivation for 36 h, Body weight decreased by 35 +/- 2%, serum osmolality increased to >500 mOsm, and urinary osmolality (657 +/- 59 mOsm) did not change from that before water deprivation. In contrast, wild-type and heterozygous mice remained active after water deprivation, body weight decreased by 20-22%, serum osmolality remained normal (810-330 mOsm), and urine osmolality rose to >2500 mOsm, Urine [Na+] in water-deprived knockout mice was <10 mM, and urine osmolality was slot increased by the V2 agonist DDAVP, The results suggest that AQP1 knockout mice are unable to create a hypertonic medullary interstitium by countercurrent multiplication, AQP1 is thus required for the formation of a concentrated urine by the kidney.	Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu		Ma, Tonghui/0000-0001-9338-1030	NHLBI NIH HHS [HL51854, HL42368] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368, R01HL051854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; Booth A G, 1974, Biochem J, V142, P575; CHOU CL, 1995, AM J PHYSIOL-RENAL, V269, pF70, DOI 10.1152/ajprenal.1995.269.1.F70; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HASEGAWA H, 1994, AM J PHYSIOL, V266, pC893, DOI 10.1152/ajpcell.1994.266.4.C893; JEN JF, 1994, B MATH BIOL, V56, P491, DOI 10.1007/BF02460468; Knepper MA, 1997, AM J PHYSIOL-RENAL, V272, pF3, DOI 10.1152/ajprenal.1997.272.1.F3; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Pallone TL, 1997, AM J PHYSIOL-RENAL, V272, pF587, DOI 10.1152/ajprenal.1997.272.5.F587; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VANOS CH, 1994, BBA-REV BIOMEMBRANES, V1197, P291; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; VERKMAN AS, 1985, AM J PHYSIOL, V248, pF650, DOI 10.1152/ajprenal.1985.248.5.F650; Verkman AS, 1996, AM J PHYSIOL-CELL PH, V270, pC12, DOI 10.1152/ajpcell.1996.270.1.C12; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	24	451	471	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4296	4299		10.1074/jbc.273.8.4296	http://dx.doi.org/10.1074/jbc.273.8.4296			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468475	hybrid			2022-12-25	WOS:000072115000003
J	Patturajan, M; Schulte, RJ; Sefton, BM; Berezney, R; Vincent, M; Bensaude, O; Warren, SL; Corden, JL				Patturajan, M; Schulte, RJ; Sefton, BM; Berezney, R; Vincent, M; Bensaude, O; Warren, SL; Corden, JL			Growth-related changes in phosphorylation of yeast RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TRANSCRIPTION FACTOR TFIIH; CDK-ACTIVATING KINASE; TATA-BINDING PROTEIN; LARGEST SUBUNIT; SACCHAROMYCES-CEREVISIAE; NONPHOSPHORYLATED FORM; HEPTAPEPTIDE REPEAT; SPLICING COMPLEXES; STATIONARY-PHASE	The largest subunit of RNA polymerase II contains a unique C-terminal domain (CTD) consisting of tandem repeats of the consensus heptapeptide sequence Tyr(1)-Ser(2)-Pro(3)-Thr(4)-Ser(5)Pro(6)-Ser(7). Two forms of the largest subunit can be separated by SDS-polyacrylamide gel electrophoresis. The faster migrating form termed IIA contains little or no phosphate on the CTD, whereas the slower migrating II0 form is multiply phosphorylated. CTD kinases with different phosphoryl acceptor specificities are able to convert IIA to II0 in vitro, and different phosphoisomers have been identified in vivo. In this paper we report the binding specificities of a set of monoclonal antibodies that recognize different phosphoepitopes on the CTD. Monoclonal antibodies like H5 recognize phosphoserine in position 2, whereas monoclonal antibodies like H14 recognize phosphoserine in position 5. The relative abundance of these phosphoepitopes changes when growing yeast enter stationary phase or are heat-shocked. These results indicate that phosphorylation of different CTD phosphoacceptor sites are independently regulated in response to environmental signals.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Salk Inst Biol Studies, San Diego, CA 92186 USA; Nexstar Pharmaceut, Boulder, CO 80301 USA; SUNY Buffalo, Dept Sci Biol, Buffalo, NY 14260 USA; Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada; Rech Sci Vie & Sante, Quebec City, PQ G1K 7P4, Canada; ENS, F-75230 Paris 05, France	Johns Hopkins University; Salk Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Laval University; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Corden, JL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.			Bensaude, Olivier/0000-0002-0259-6608				Akhtar A, 1996, EMBO J, V15, P4654, DOI 10.1002/j.1460-2075.1996.tb00842.x; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; BREGMAN DB, 1994, J CELL SCI, V107, P387; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CAGAS PM, 1995, PROTEINS, V21, P149, DOI 10.1002/prot.340210209; CHABOT B, 1995, NUCLEIC ACIDS RES, V23, P3206, DOI 10.1093/nar/23.16.3206; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; Dobbins JR, 1996, INT J PEPT PROT RES, V47, P260; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; HARDING MM, 1992, J MED CHEM, V35, P4658, DOI 10.1021/jm00103a002; KANG ME, 1993, J BIOL CHEM, V268, P25033; KANG ME, 1995, J BIOL CHEM, V270, P23390, DOI 10.1074/jbc.270.40.23390; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PIPER P, 1990, ANTON LEEUW INT J G, V58, P195, DOI 10.1007/BF00548933; Rickert P, 1996, ONCOGENE, V12, P2631; SCHULTE RJ, UNPUB; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; Seydoux G, 1997, DEVELOPMENT, V124, P2191; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SMITH DB, 1995, CURRENT PROTOCOLS MO, V2; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; Steinmetz EJ, 1996, MOL CELL BIOL, V16, P6993, DOI 10.1128/mcb.16.12.6993; STONE N, 1992, J BIOL CHEM, V267, P6353; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; THIBODEAU A, 1991, EXP CELL RES, V195, P145, DOI 10.1016/0014-4827(91)90510-2; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TRIGON S, 1995, J BIOL CHEM, V270, P13091, DOI 10.1074/jbc.270.22.13091; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; Voellmy R, 1996, EXS, V77, P121; WARREN SL, 1992, J CELL SCI, V103, P381; WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WEST ML, 1995, GENETICS, V140, P1223; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; Yuryev A, 1996, GENETICS, V143, P661; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHANG J, 1991, J BIOL CHEM, V266, P2290; [No title captured]	78	212	212	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4689	4694		10.1074/jbc.273.8.4689	http://dx.doi.org/10.1074/jbc.273.8.4689			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468530	hybrid			2022-12-25	WOS:000072115000058
J	Chaffanet, M; Popovici, C; Leroux, D; Jacrot, M; Adelaide, J; Dastugue, N; Gregoire, MJ; Hagemeijer, A; Lafage-Pochitaloff, M; Birnbaum, D; Pebusque, MJ				Chaffanet, M; Popovici, C; Leroux, D; Jacrot, M; Adelaide, J; Dastugue, N; Gregoire, MJ; Hagemeijer, A; Lafage-Pochitaloff, M; Birnbaum, D; Pebusque, MJ			t(6;8), t(8;9) and t(8;13) translocations associated with stem cell myeloproliferative disorders have close or identical breakpoints in chromosome region 8p11-12	ONCOGENE			English	Article						FGFR1 gene; leukemia; lymphoma; human chromosome pairs 6, 8, 9, 13; translocation; fluorescence in situ hybridization; stem cell; hematopoiesis	ACUTE MONOCYTIC LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE MONOBLASTIC LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; T-CELL; CLINICOPATHOLOGICAL ENTITY; RECIPROCAL TRANSLOCATION; MYELOMONOCYTIC LEUKEMIA; RECEPTOR GENES; SHORT ARM	A stem-cell myeloproliferative disorder involving T- and B-cell, and myeloid lineages, is associated with three different translocations with a breakpoint in region p11-12 of chromosome 8: t(6;8)(q27;p11), t(8;9)(p11;q33), and t(8;13)(p12;q12), respectively. Using fluorescence in situ hybridization (FISH), we have analysed blood cells from a series of five patients carrying these different translocations. We have identified cosmids from chromosome region 8p11-12 that span the breakpoint in all the cases. They are specific for the FGFR1 gene that encodes a receptor for members of the FGF family. The breakpoint was further detected by Southern and pulsed-field gel electrophoresis analyses with probes from the FGFR1 locus.	Inst Cancerol & Immunol Marseille, INSERM, U119, Oncol Mol Lab, F-13009 Marseille, France; Inst J Paoli I Calmettes, Lab Biol Tumeurs, F-13009 Marseille, France; Univ Grenoble 1, Inst Albert Bonniot, Grp Rech Lymphomes, Grenoble, France; Hop Purpan, Lab Hematol Genet Hemopathies, Toulouse, France; Ctr Hosp Univ, Genet Lab, Nancy, France; Univ Leuven, Ctr Human Genet, Louvain, Belgium; IPC, Dept Hematol, Lab Cytogenet, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU de Toulouse; CHU de Nancy; KU Leuven; UNICANCER; Institut Paoli-Calmette (IPC)	Pebusque, MJ (corresponding author), Inst Cancerol & Immunol Marseille, INSERM, U119, Oncol Mol Lab, 27 Bd Roure, F-13009 Marseille, France.		CHAFFANET, Max/AAU-5743-2020; POPOVICI, Cornel/A-2027-2009; Leroux, Dominique/G-7309-2014; ADELAIDE, José JA/O-4390-2017	POPOVICI, Cornel/0000-0001-8226-3127; ADELAIDE, José JA/0000-0003-4364-9857; CHAFFANET, Max/0000-0002-2344-1488				AGUIAR RCT, 1995, BLOOD, V86, P834, DOI 10.1182/blood.V86.2.834.bloodjournal862834; BEHRINGER D, 1995, LEUKEMIA, V9, P988; BELLOMO MJ, 1992, BRIT J HAEMATOL, V81, P307, DOI 10.1111/j.1365-2141.1992.tb08225.x; BERNSTEIN R, 1987, CANCER GENET CYTOGEN, V24, P213, DOI 10.1016/0165-4608(87)90101-4; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Chaffanet M, 1996, CYTOGENET CELL GENET, V72, P63, DOI 10.1159/000134164; DIB A, 1995, ONCOGENE, V10, P995; DREXLER HG, 1995, LEUKEMIA, V9, P480; Elsner S., 1994, British Journal of Haematology, V87, P124; FAGAN K, 1993, CANCER GENET CYTOGEN, V65, P71, DOI 10.1016/0165-4608(93)90062-Q; FRIEDHOFF F, 1983, CANCER GENET CYTOGEN, V9, P391, DOI 10.1016/0165-4608(83)90088-2; HEIM S, 1987, BRIT J HAEMATOL, V66, P323, DOI 10.1111/j.1365-2141.1987.tb06917.x; INHORN RC, 1995, BLOOD, V85, P1881, DOI 10.1182/blood.V85.7.1881.bloodjournal8571881; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEMPSKI H, 1995, GENE CHROMOSOME CANC, V12, P283, DOI 10.1002/gcc.2870120408; LAFAGE M, 1992, GENE CHROMOSOME CANC, V5, P40, DOI 10.1002/gcc.2870050107; LAI JL, 1992, CANCER GENET CYTOGEN, V60, P180, DOI 10.1016/0165-4608(92)90013-X; LAI JL, 1987, CANCER GENET CYTOGEN, V27, P101, DOI 10.1016/0165-4608(87)90265-2; LESLIE J, 1994, BRIT J HAEMATOL, V86, P876, DOI 10.1111/j.1365-2141.1994.tb04847.x; LEWIS JP, 1983, AM J PEDIAT HEMATOL, V5, P265; MACDONALD D, 1995, LEUKEMIA, V9, P1628; MACDONALD D, 1994, BRIT J HAEMATOL, V86, P879, DOI 10.1111/j.1365-2141.1994.tb04848.x; Michaux L, 1996, BLOOD, V87, P1658, DOI 10.1182/blood.V87.4.1658.bloodjournal8741658; MITELMAN F, 1992, GENE CHROMOSOME CANC, V5, P57, DOI 10.1002/gcc.2870050109; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; NAEEM R, 1995, GENE CHROMOSOME CANC, V12, P148, DOI 10.1002/gcc.2870120210; Nakayama H, 1996, BRIT J HAEMATOL, V92, P692, DOI 10.1046/j.1365-2141.1996.00386.x; OSCIER DG, 1985, J MED GENET, V22, P398, DOI 10.1136/jmg.22.5.398; PEBUSQUE MJ, 1993, GENE CHROMOSOME CANC, V8, P119, DOI 10.1002/gcc.2870080209; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RUTA M, 1988, ONCOGENE, V3, P9; Sainati L, 1996, PEDIATR HEMAT ONCOL, V13, P151, DOI 10.3109/08880019609030805; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SLOVAK ML, 1991, CANCER GENET CYTOGEN, V56, P237, DOI 10.1016/0165-4608(91)90176-U; Soenen V, 1996, GENE CHROMOSOME CANC, V15, P191, DOI 10.1002/(SICI)1098-2264(199603)15:3<191::AID-GCC9>3.0.CO;2-Y; STARK B, 1995, LEUKEMIA RES, V19, P367, DOI 10.1016/0145-2126(94)00150-9; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; vandenBerg H, 1996, LEUKEMIA, V10, P1252; VANNIER JP, 1984, LEUKEMIA RES, V8, P647, DOI 10.1016/0145-2126(84)90013-4; Velloso ERP, 1996, LEUKEMIA LYMPHOMA, V21, P137, DOI 10.3109/10428199609067591; ZELEZNIKLE NJ, 1995, SEMIN HEMATOL, V32, P201	42	55	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					945	949		10.1038/sj.onc.1201601	http://dx.doi.org/10.1038/sj.onc.1201601			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484786				2022-12-25	WOS:000072053200014
J	Hermesh, O; Kalderon, B; Bar-Tana, J				Hermesh, O; Kalderon, B; Bar-Tana, J			Mitochondria uncoupling by a long chain fatty acyl analogue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; OXIDATIVE-PHOSPHORYLATION; ENERGY-METABOLISM; OXYGEN-CONSUMPTION; ADP/ATP CARRIER; INNER MEMBRANE; ACIDS; MECHANISM; TRANSPORT; PERMEABILITY	Mitochondria uncoupling by fatty acids in vivo is still questionable, being confounded by their dual role as substrates for oxidation and as putative genuine uncouplers of oxidative phosphorylation, To dissociate between substrate and the uncoupling activity of fatty acids in oxidative phosphorylation, the uncoupling effect was studied here using a nonmetabolizable long chain fatty acyl analogue, beta,beta'-Methyl-substituted hexadecane alpha,omega-dioic acid (MEDICA 16) is reported here to induce in freshly isolated liver cells a saturable oligomycin-insensitive decrease in mitochondrial proton motive force with a concomitant increase in cellular respiration, Similarly, MEDICA 16 induced a saturable decrease in membrane potential, proton gradient, and proton motive force in isolated liver and heart mitochondria accompanied by an increase in mitochondrial respiration, Uncoupling by MEDICA 16 in isolated mitochondria was partially suppressed by added atractyloside. Hence, fatty acids may act as genuine uncouplers of cellular oxidative phosphorylation by interacting with specific mitochondrial proteins, including the adenine nucleotide translocase.	Hebrew Univ Jerusalem, Fac Med, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Bar-Tana, J (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Human Nutr & Metab, POB 12272, IL-91120 Jerusalem, Israel.	bartanaj@yam-suff.cc.huji.ac.il						ANDREYEV AY, 1989, EUR J BIOCHEM, V182, P585, DOI 10.1111/j.1432-1033.1989.tb14867.x; BARTANA J, 1985, J BIOL CHEM, V260, P8404; BERRY MN, 1991, LABORATORY TECHNIQUE, V21, P15; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BRAND MD, 1986, BIOCHEM SOC T, V14, P1200, DOI 10.1042/bst0141200; BRUSTOVETSKY N, 1994, J BIOL CHEM, V269, P27329; Cho JH, 1997, BIOCHEM J, V324, P971, DOI 10.1042/bj3240971; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; DEBEER LJ, 1974, EUR J BIOCHEM, V47, P591, DOI 10.1111/j.1432-1033.1974.tb03730.x; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; FAHN S, 1966, J BIOL CHEM, V241, P1882; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; HASSINEN I, 1990, BIOCHIM BIOPHYS ACTA, V1019, P73, DOI 10.1016/0005-2728(90)90126-O; HERTZ R, 1991, BIOCHEM J, V274, P745, DOI 10.1042/bj2740745; Hertz R, 1996, BIOCHEM J, V319, P241, DOI 10.1042/bj3190241; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; Jezek P, 1997, FEBS LETT, V408, P161, DOI 10.1016/S0014-5793(97)00334-7; KALDERON B, 1992, ENDOCRINOLOGY, V131, P1629, DOI 10.1210/en.131.4.1629; KALDERON B, 1995, ENDOCRINOLOGY, V136, P3552, DOI 10.1210/en.136.8.3552; KINGSLEYHICKMAN PB, 1990, J BIOL CHEM, V265, P1545; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; Krauth J, 1988, DISTRIBUTION FREE ST; Liu GY, 1996, J BIOL CHEM, V271, P25338, DOI 10.1074/jbc.271.41.25338; LUVISETTO S, 1987, BIOCHEMISTRY-US, V26, P7332, DOI 10.1021/bi00397a021; LUVISETTO S, 1990, J BIOENERG BIOMEMBR, V22, P635, DOI 10.1007/BF00809068; Mayorek N, 1997, DIABETES, V46, P1958, DOI 10.2337/diabetes.46.12.1958; Mela L, 1979, Methods Enzymol, V55, P39; NOBES CD, 1990, J BIOL CHEM, V265, P12910; NOBES CD, 1990, J BIOL CHEM, V265, P12903; PIETROBON D, 1987, BIOCHEMISTRY-US, V26, P7339, DOI 10.1021/bi00397a022; PLOMP PJAM, 1985, FEBS LETT, V193, P243, DOI 10.1016/0014-5793(85)80161-7; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; ROTTENBERG H, 1986, BIOCHEMISTRY-US, V25, P1747, DOI 10.1021/bi00355a045; Rottenberg H, 1979, Methods Enzymol, V55, P547; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1018, P1, DOI 10.1016/0005-2728(90)90103-B; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; SCHOLZ R, 1984, EUR J BIOCHEM, V141, P223, DOI 10.1111/j.1432-1033.1984.tb08179.x; SCHONFELD P, 1988, BIOCHIM BIOPHYS ACTA, V936, P280, DOI 10.1016/0005-2728(88)90003-5; SCHONFELD P, 1990, FEBS LETT, V264, P246, DOI 10.1016/0014-5793(90)80259-L; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; SOBOLL S, 1984, EUR J BIOCHEM, V141, P231, DOI 10.1111/j.1432-1033.1984.tb08180.x; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y; WOJTCZAK L, 1976, J BIOENERG BIOMEMBR, V8, P293; WOJTCZAK L, 1974, FEBS LETT, V44, P25, DOI 10.1016/0014-5793(74)80298-X	45	59	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3937	3942		10.1074/jbc.273.7.3937	http://dx.doi.org/10.1074/jbc.273.7.3937			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461579	hybrid			2022-12-25	WOS:000072048400021
J	Parenti, A; Morbidelli, L; Cui, XL; Douglas, JG; Hood, JD; Granger, HJ; Ledda, F; Ziche, M				Parenti, A; Morbidelli, L; Cui, XL; Douglas, JG; Hood, JD; Granger, HJ; Ledda, F; Ziche, M			Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase(1/2) activation in postcapillary endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TYROSINE KINASE; MAP KINASE; PERMEABILITY FACTOR; TUMOR-GROWTH; CELL GROWTH; IN-VITRO; RECEPTOR; BOVINE; DIFFERENTIATION	We recently demonstrated that nitric oxide (NO) significantly contributes to the mitogenic effect of vascular endothelial growth factor (VEGF), suggesting a role for the NO pathway in the signaling cascade following kinase-derivative receptor activation in vascular endothelium. The aim of this study was to investigate the intracellular pathways linked to VEGF/NO-induced endothelial cell proliferation, We assessed the activity of the mitogen-activated protein kinase (MAPK) that is specifically activated by growth factors, extracellular-regulated kinase (ERK1/2), on cultured microvascular endothelium isolated from coronary postcapillary venules, ERK1/2 was immunoprecipitated, and its activity was assessed with an immunocomplex kinase assay. in endothelial cells exposed for 5 min to the NO donor drug sodium nitroprusside at a concentration of 100 mu M, ERK1/2 activity significantly increased. VEGF produced a time-and concentration-dependent activation of ERK1/2. Maximal activity was obtained after 5 min of stimulation at a concentration of 10 ng/ml., The specific MAPK kinase inhibitor PD 98059 abolished ERK1/2 activation and endothelial cell proliferation in a concentration-dependent manner in response to VEGF and sodium nitroprusside. The NO synthase inhibitor N-omega-monomethyl-L-arginine, as well as the guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one blocked the activation of ERK1/2 induced by VEGF, suggesting that NO and cGMP contributed to the VEGF-dependent ERK1/2 activation, These results demonstrate for the first time that kinase-derivative receptor activation triggers the NO synthase/guanylate cyclase pathway to activate the MAPK cascade and substantiates the hypothesis that the activation of ERK1/2 is necessary for VEGF-induced endothelial cell proliferation.	Univ Florence, Dept Preclin & Clin Pharmacol, I-50134 Florence, Italy; Case Western Reserve Univ, Sch Med, Div Hypertens, Cleveland, OH 44106 USA; Texas A&M Univ, Hlth Sci Ctr, Microcirculat Res Inst, College Stn, TX 77843 USA; Texas A&M Univ, Hlth Sci Ctr, Dept Med Physiol, College Stn, TX 77843 USA	University of Florence; Case Western Reserve University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Ziche, M (corresponding author), Univ Florence, Dept Preclin & Clin Pharmacol, Viale Morgagni 65, I-50134 Florence, Italy.	ziche@stat.ds.unifi.it	Morbidelli, Lucia/AAC-7858-2020; Morbidelli, Lucia/K-4053-2016	Morbidelli, Lucia/0000-0001-8148-7049; Parenti, Astrid/0000-0002-7980-6853	NHLBI NIH HHS [HL-21498] Funding Source: Medline; PHS HHS [41618] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021498, R37HL021498] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER H, 1995, J IMMUNOL, V154, P4710; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bates DO, 1996, AM J PHYSIOL-HEART C, V271, pH2520, DOI 10.1152/ajpheart.1996.271.6.H2520; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BREIER G, 1992, DEVELOPMENT, V114, P521; BROCK TA, 1991, AM J PATHOL, V138, P213; BUGA GM, 1991, HYPERTENSION, V17, P187, DOI 10.1161/01.HYP.17.2.187; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GOTO F, 1993, LAB INVEST, V69, P508; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; LEIBOVICH SJ, 1994, P NATL ACAD SCI USA, V91, P4190, DOI 10.1073/pnas.91.10.4190; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Pearce MJ, 1996, BIOCHEM BIOPH RES CO, V218, P500, DOI 10.1006/bbrc.1996.0089; PIPILISYNETOS E, 1995, BRIT J PHARMACOL, V116, P1829, DOI 10.1111/j.1476-5381.1995.tb16670.x; RANJAN V, 1995, AM J PHYSIOL-HEART C, V269, pH550, DOI 10.1152/ajpheart.1995.269.2.H550; SCHELLING ME, 1988, AM J PHYSIOL, V254, pH1211, DOI 10.1152/ajpheart.1988.254.6.H1211; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu HM, 1996, AM J PHYSIOL-HEART C, V271, pH2735, DOI 10.1152/ajpheart.1996.271.6.H2735; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZICHE M, 1993, AM J PHYSIOL, V265, pH569, DOI 10.1152/ajpheart.1993.265.2.H569; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; Ziche M, 1997, CIRC RES, V80, P845, DOI 10.1161/01.res.80.6.845; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557; ZICHE M, 1993, BIOCHEM BIOPH RES CO, V192, P1198, DOI 10.1006/bbrc.1993.1543	45	389	404	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4220	4226		10.1074/jbc.273.7.4220	http://dx.doi.org/10.1074/jbc.273.7.4220			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461619	hybrid			2022-12-25	WOS:000072048400061
J	Scotto, C; Mely, Y; Ohshima, H; Garin, J; Cochet, C; Chambaz, E; Baudier, J				Scotto, C; Mely, Y; Ohshima, H; Garin, J; Cochet, C; Chambaz, E; Baudier, J			Cysteine oxidation in the mitogenic S100B protein leads to changes in phosphorylation by catalytic CKII-alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; NITRIC-OXIDE; BINDING PROPERTIES; NEURITE EXTENSION; CALCIUM-BINDING; IONS BINDING; BOVINE BRAIN; CELLS; S100-ALPHA-ALPHA; PEROXYNITRITE	The glial-derived calcium-binding protein S100B can be secreted to act as a neurotrophic factor or a mitogen, stimulating proliferation of glial cells, The extracellular S100B activities rely on the oxidation of the protein cysteine residues (Kligman, D., and Marshak, D. R. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 7136-7139; Winningham-Major, F., Staecker, J, L., Barger, S, W., Coats, S., and Van Eldik, L. J. (1989) J. Cell Biol, 109, 3063-3071), Here we show that oxidation of the S100B cysteine residues, Cys-68 and Cys-84, induces a conformational change in the protein structure, unmasking a canonical CKII phosphorylation site located within the typical EF-hand calcium-binding site II beta, Intrasubunit disulfide-bridged S100B monomer and disulfide-bonded S100B dimer are phosphorylated by the catalytic CKII-alpha subunit on Ser-62 with a K-m of 0.5 mu M and a V-max of 10 pmol/min/100 pmol of S100B, Oxidized S100B is the best in vitro CKII-alpha substrate identified so far, Next we show that intrasubunit disulfide-bridged S100B monomer is the most potent S100B species to stimulate [H-3]thymidine uptake by C6 glial cells in culture, In addition, the phosphorylated intrasubunit disulfide-bridged S100B monomer retains apparent mitogenic activity toward C6 glial cells, and hence, P-32-labeled S100B should be a useful probe for characterizing the mechanisms by which extracellular oxidized S100B functions, Finally, we show that formation of intrasubunit disulfide-bridged S100B monomer is stimulated by peroxynitrite anion, suggesting that production of mitogenic S100B species could be enhanced in neuropathology associated with peroxynitrite anion production.	CEN Grenoble, BRCE, Dept Biol Mol & Struct, INSERM U244, F-38054 Grenoble 9, France; CEN Grenoble, BRCE, Dept Biol Mol & Struct, INSERM U244, F-38054 Grenoble, France; CEA, Dept Biol Mol & Struct, F-38054 Grenoble, France; CEN Grenoble, CP, Dept Biol Mol & Struct, Lab Chim Prot, F-38054 Grenoble, France; UFR Sci Pharmaceut, Biophys Lab, F-69372 Lyon, France; Ctr Int Rech Canc, F-69372 Lyon, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA; CEA; World Health Organization; International Agency for Research on Cancer (IARC)	Baudier, J (corresponding author), CEN Grenoble, BRCE, Dept Biol Mol & Struct, INSERM U244, 17 Rue Martyrs, F-38054 Grenoble 9, France.		Ohshima, Hiroshi/E-8044-2010; Baudier, Jacques/O-2183-2016	Cochet, Claude/0000-0002-1772-4270; jacques, baudier/0000-0001-8427-4444				Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; ALLORE R, 1988, SCIENCE, V239, P1311, DOI 10.1126/science.2964086; BARGER SW, 1992, BIOCHIM BIOPHYS ACTA, V1160, P105, DOI 10.1016/0167-4838(92)90043-D; BARGER SW, 1992, J BIOL CHEM, V267, P9689; BAUDIER J, 1986, J BIOL CHEM, V261, P8204; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BAUDIER J, 1986, BIOCHEMISTRY-US, V25, P6934, DOI 10.1021/bi00370a029; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BIDWAI AP, 1993, ARCH BIOCHEM BIOPHYS, V300, P265, DOI 10.1006/abbi.1993.1037; FILHOL O, 1992, J BIOL CHEM, V267, P20577; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HEIZMANN CW, 1992, TRENDS NEUROSCI, V15, P259, DOI 10.1016/0166-2236(92)90067-I; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; Hu JG, 1996, J BIOL CHEM, V271, P2543, DOI 10.1074/jbc.271.5.2543; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; Mahoney CW, 1996, J BIOL CHEM, V271, P28798, DOI 10.1074/jbc.271.46.28798; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1987, FEBS LETT, V215, P241, DOI 10.1016/0014-5793(87)80154-0; MELY Y, 1990, J NEUROCHEM, V55, P1100, DOI 10.1111/j.1471-4159.1990.tb03111.x; POU S, 1992, J BIOL CHEM, V267, P24173; QUADRONI M, 1994, J BIOL CHEM, V269, P16116; RADI R, 1991, J BIOL CHEM, V266, P4244; REED JW, 1974, J AM CHEM SOC, V96, P1248, DOI 10.1021/ja00811a062; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDTSPANIOL I, 1993, CELL MOL BIOL RES, V39, P761; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SENDTNER M, 1994, CURR BIOL, V4, P1036, DOI 10.1016/S0960-9822(00)00237-2; SHASHOUA VE, 1984, J NEUROCHEM, V42, P1536, DOI 10.1111/j.1471-4159.1984.tb12739.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Snapes Dr., 1991, GIRLFRENZY; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063	35	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3901	3908		10.1074/jbc.273.7.3901	http://dx.doi.org/10.1074/jbc.273.7.3901			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461574	hybrid			2022-12-25	WOS:000072048400016
J	Fanger, GR; Widmann, C; Porter, AC; Sather, S; Johnson, GL; Vaillancourt, RR				Fanger, GR; Widmann, C; Porter, AC; Sather, S; Johnson, GL; Vaillancourt, RR			14-3-3 proteins interact with specific MEK kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; 14-3-3-PROTEINS; ACTIVATION; RAF-1; PATHWAYS; YEAST; ERK; RAS; PHOSPHORYLATION; ASSOCIATION	MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase kinase) kinases (MEKKs) regulate c-Jun N-terminal kinase and extracellular response kinase pathways. The 14-3-3 zeta and 14-3-3 epsilon isoforms were isolated in a two-hybrid screen for proteins interacting with the N-terminal regulatory domain of MEKK3. 14-3-3 proteins bound both the N-terminal regulatory and C-terminal kinase domains of MEKK3. The binding affinity of 14-3-3 for the MEKK3 N terminus was 90 nM, demonstrating a high affinity interaction. 14-3-3 proteins also interacted with MEKK1 and MEKK2, but not MEKK4. Endogenous 14-3-3 protein and MEKK1 and MEKK2 were similarly distributed in the cell, consistent with their in vitro interactions. MEKK1 and 14-3-3 proteins colocalized using two color digital confocal immunofluorescence. Binding of 14-3-3 proteins mapped to the N-terminal 393 residues of 196-kDa MEKK1. Unlike MEKK2 and MEKK3, the C-terminal kinase domain of MEKK1 demonstrated little or no ability to interact with 14-3-3 proteins. MEKK1, but not MEKK2, -3 or -4, is a caspase-3 substrate that when cleaved releases the kinase domain from the N-terminal regulatory domain. Functionally, caspase-3 cleavage of MEKK1 releases the kinase domain from the N-terminal 14-3-3-binding region, demonstrating that caspases can selectively alter protein kinase interactions with regulatory proteins. With regard to MEKK1, -2 and -3, 14-3-3 proteins do not appear to directly influence activity, but rather function as "scaffolds" for protein-protein interactions.	Univ Arizona, Coll Pharm, Dept Pharmacol Toxicol, Tucson, AZ 85721 USA; Natl Jewish Med & Res Ctr, Div Basic Sci, Program Mol Signal Transduct, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	University of Arizona; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Vaillancourt, RR (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol Toxicol, Tucson, AZ 85721 USA.	vaillancourt@pharmacy.arizona.edu	Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363	NIDDK NIH HHS [DK37871, DK48845] Funding Source: Medline; NIGMS NIH HHS [GM18643-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048845, R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018643] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Banik U, 1997, J BIOL CHEM, V272, P26219, DOI 10.1074/jbc.272.42.26219; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kockel L, 1997, GENE DEV, V11, P1140, DOI 10.1101/gad.11.9.1140; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRINTEN JA, 1994, GENETICS, V138, P609; RAGHAVAN M, 1995, STRUCTURE, V3, P331, DOI 10.1016/S0969-2126(01)00164-2; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Siow YL, 1997, J BIOL CHEM, V272, P7586, DOI 10.1074/jbc.272.12.7586; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; YAN MH, 1994, NATURE, V372, P798; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281	45	132	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3476	3483		10.1074/jbc.273.6.3476	http://dx.doi.org/10.1074/jbc.273.6.3476			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452471	hybrid			2022-12-25	WOS:000071822300056
J	Ono, S; Benian, GM				Ono, S; Benian, GM			Two Caenorhabditis elegans actin depolymerizing factor/cofilin proteins, encoded by the unc-60 gene, differentially regulate actin filament dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN SKELETAL-MUSCLE; ACANTHAMOEBA-CASTELLANII; BINDING PROTEINS; ADP-ACTIN; F-ACTIN; COFILIN; PURIFICATION; TROPOMYOSIN; ACTOPHORIN; BRAIN	The Caenorhabditis elegans unc-60 gene encodes two actin depolymerizing factor/cofilin proteins which are implicated in the regulation of actin filament assembly in body wall muscle. We examined the interaction of recombinant UNC-60A and B proteins with actin and found that they differentially regulate actin filament dynamics. Co-pelleting assays with F-actin showed that UNC-60A depolymerized but did not remain bound to F-actin, whereas UNC-60B bound to but did not depolymerize F-actin. In the pH range of 6.8-8.0, the apparent activities of UNC-60A and B did not change although UNC-60A showed greater actin-depolymerizing activity at higher pH. These activities were further confirmed by a light scattering assay and electron microscopy. The effects of these proteins on actin polymerization were quite different. UNC-60A inhibited polymerization in a concentration dependent manner. On the other hand, UNC-60B strongly inhibited the nucleation process but accelerated the following elongation step, However, an excess amount of UNC-60B increased the amount of unpolymerized actin. These results indicate that UNC-60A depolymerizes actin filaments and inhibits actin polymerization, whereas UNC-60B strongly binds to F-actin without depolymerizing it and, through binding to G-actin, changes the rate of actin polymerization depending on the UNC-60B:actin ratio. These data suggest that the two UNC-60 isoforms play differential roles in regulating actin filament dynamics in, vivo.	Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Ono, S (corresponding author), Emory Univ, Dept Pathol, Woodruff Mem Bldg 7007A, Atlanta, GA 30322 USA.		Ono, Shoichiro/A-6475-2015	Ono, Shoichiro/0000-0002-4763-0398				ABE H, 1989, J BIOCHEM-TOKYO, V106, P696, DOI 10.1093/oxfordjournals.jbchem.a122919; Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; ABE H, 1989, J BIOCHEM-TOKYO, V106, P172, DOI 10.1093/oxfordjournals.jbchem.a122810; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIER MF, 1988, J BIOL CHEM, V263, P817; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; COOPER JA, 1986, J BIOL CHEM, V261, P477; Fedorov AA, 1997, NAT STRUCT BIOL, V4, P366, DOI 10.1038/nsb0597-366; GIULIANO KA, 1988, BIOCHEMISTRY-US, V27, P8931, DOI 10.1021/bi00425a009; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; HIGASHI S, 1965, J MOL BIOL, V12, P843, DOI 10.1016/S0022-2836(65)80332-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; MABUCHI I, 1983, J CELL BIOL, V97, P1612, DOI 10.1083/jcb.97.5.1612; MACIVER SK, 1994, FEBS LETT, V347, P251, DOI 10.1016/0014-5793(94)00552-4; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; MATSUMURA F, 1983, J BIOL CHEM, V258, P6636; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MCKIM KS, 1994, MOL GEN GENET, V242, P346, DOI 10.1007/BF00280425; MCKIM KS, 1988, GENETICS, V118, P49; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; Nagaoka R, 1996, J MUSCLE RES CELL M, V17, P463, DOI 10.1007/BF00123362; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; OHSHIMA S, 1989, J BIOCHEM-TOKYO, V105, P855, DOI 10.1093/oxfordjournals.jbchem.a122765; ONO S, 1994, J BIOL CHEM, V269, P15280; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; SHIMIZU N, 1986, J BIOCHEM-TOKYO, V99, P751, DOI 10.1093/oxfordjournals.jbchem.a135534; WATERSTON RH, 1980, DEV BIOL, V77, P271, DOI 10.1016/0012-1606(80)90475-3; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410	35	82	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3778	3783		10.1074/jbc.273.6.3778	http://dx.doi.org/10.1074/jbc.273.6.3778			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452511	hybrid			2022-12-25	WOS:000071822300096
J	Satoh, A; Nakanishi, H; Obaishi, H; Wada, M; Takahashi, K; Satoh, K; Hirao, K; Nishioka, H; Hata, Y; Mizoguchi, A; Takai, Y				Satoh, A; Nakanishi, H; Obaishi, H; Wada, M; Takahashi, K; Satoh, K; Hirao, K; Nishioka, H; Hata, Y; Mizoguchi, A; Takai, Y			Neurabin-II/spinophilin - An actin filament-binding protein with one PDZ domain localized at cadherin-based cell-cell adhesion sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; COMPLEX; JUNCTIONS; CATENIN; MODEL	In a preceding paper, we reported a novel actin filament (F-actin)-binding protein, named neurabin, which was specifically expressed in neural tissue and implicated in neurite formation, We purified from rat brain another F-actin-binding protein, which had a domain organization similar to that of neurabin but was ubiquitously expressed, and named it neurabin-II, The original neurabin, renamed neurabin-I, had 1095 amino acids and a calculated M-r of 122,729, whereas neurabin-II had 817 amino acids and a calculated M-r of 89,642. Both neurabin-I and -II had one F-actin-binding domain at the N-terminal region, one PDZ domain at the middle region, a domain known to interact with transmembrane proteins, and domains predicted to form coiled-coil structures at the C-terminal region, Both neurabin-I and -II bound along the sides of F-actin and showed F-actin-cross-linking activity. The subcellular distribution analysis indicated that neurabin-II was enriched at the postsynaptic density fraction in rat brain and the adherens junction fraction in rat liver, Immunofluorescence microscopic analysis revealed that neurabin-II was highly concentrated at the synapse in primary cultured rat hippocampal neurons and at the cadherin-based cell-cell adhesion sites in Madin-Darby canine kidney cells, Neurabin-II turned out to be the same as a recently reported protein phosphatase 1-binding protein named spinophilin, These results suggest that neurabin-II/spinophilin plays an important role in linking the actin cytoskeleton to the plasma membrane.	JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project, Kobe, Hyogo 65122, Japan; Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 565, Japan; Kyoto Univ, Grad Sch, Dept Anat & Neurobiol, Kyoto 60601, Japan	Japan Science & Technology Agency (JST); Osaka University; Kyoto University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Osaka 565, Japan.			Nakanishi, Hiroyuki/0000-0002-9765-0266				Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bretscher A, 1993, CURR OPIN CELL BIOL, V5, P653, DOI 10.1016/0955-0674(93)90136-E; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; FRASER AB, 1975, BIOCHEMISTRY-US, V14, P2207, DOI 10.1021/bi00681a025; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; Serres M, 1997, EXP CELL RES, V231, P163, DOI 10.1006/excr.1996.3443; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TSUKITA S, 1989, J CELL BIOL, V108, P31, DOI 10.1083/jcb.108.1.31; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767	30	186	192	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3470	3475		10.1074/jbc.273.6.3470	http://dx.doi.org/10.1074/jbc.273.6.3470			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452470	hybrid			2022-12-25	WOS:000071822300055
J	Schalinske, KL; Chen, OS; Eisenstein, RS				Schalinske, KL; Chen, OS; Eisenstein, RS			Iron differentially stimulates translation of mitochondrial aconitase and ferritin mRNAs in mammalian cells - Implications for iron regulatory proteins as regulators of mitochondrial citrate utilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; SYNTHASE MESSENGER-RNA; RESPONSIVE ELEMENT; TRANSFERRIN RECEPTOR; CYTOSOLIC ACONITASE; RAT HEPATOCYTES; HIGH-AFFINITY; REGION; PHOSPHORYLATION; IDENTIFICATION	Utilization of mRNAs containing iron-responsive elements (IREs) is modulated by iron-regulated RNA-binding proteins (iron regulatory proteins). We examine herein whether iron differentially affects translation of ferritin and mitochondrial aconitase (m-Acon) mRNAs because they contain a similar but not identical IRE in their 5'-untranslated regions. First, we demonstrate that m-Acon synthesis is iron-regulated in mammalian cells. In HL-60 cells, hemin (an iron source) stimulated m-Acon synthesis 3-fold after 4 h compared with cells treated with an iron chelator (Desferal). Furthermore, hemin stimulated m-Acon synthesis 2-4-fold in several cell lines. Second, me show that iron modulates the polysomal association of m-Acon mRNA. We observed m-Acon mRNA in both ribonucleoprotein and polyribosomal fractions of HL-60 cells. Hemin significantly increased the polyribosomal association and decreased the ribonucleoprotein abundance of m-Acon mRNA in HL-60 cells. Third, our results indicate that iron differentially regulates translation of m-Acon and ferritin mRNAs. A dose response to hemin in HL-60 cells elicited a 2-2.4-fold increase in m-Acon synthesis within 5 h compared with untreated cells, whereas ferritin synthesis was stimulated 20-100-fold. We conclude that iron modulates m-Acon synthesis at the translational level and that iron regulatory proteins appear to differentially affect translation of IRE-containing mRNAs.	Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Eisenstein, RS (corresponding author), Univ Wisconsin, Dept Nutr Sci, 1415 Linden Dr, Madison, WI 53706 USA.	eisenste@nutrisci.wisc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047219, R29DK047219] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47219] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AISEN P, 1968, BIOCHEM BIOPH RES CO, V32, P220, DOI 10.1016/0006-291X(68)90372-0; AZIZ N, 1986, NUCLEIC ACIDS RES, V14, P915, DOI 10.1093/nar/14.2.915; BAKER E, 1985, AM J PHYSIOL, V248, pG93, DOI 10.1152/ajpgi.1985.248.1.G93; BAKER E, 1981, BRIT J HAEMATOL, V47, P493, DOI 10.1111/j.1365-2141.1981.tb02678.x; BARTON HA, 1990, J BIOL CHEM, V265, P7000; Beaumont C, 1996, J BIOL CHEM, V271, P7923, DOI 10.1074/jbc.271.14.7923; BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; BEUTLER E, 1959, J CLIN INVEST, V38, P1605, DOI 10.1172/JCI103939; BHASKER CR, 1993, J BIOL CHEM, V268, P12699; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; Chen O. S., 1997, FASEB Journal, V11, pA444; Chen OS, 1997, J NUTR, V127, P238, DOI 10.1093/jn/127.2.238; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DIX DJ, 1992, BIOCHEMISTRY-US, V31, P2818, DOI 10.1021/bi00125a024; DIX DJ, 1993, J MOL BIOL, V231, P230, DOI 10.1006/jmbi.1993.1278; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; EISENSTEIN RS, 1997, METAL IONS GENE REGU, P157; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; GROOTVELD M, 1989, J BIOL CHEM, V264, P4417; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HARRIS DC, 1973, BIOCHIM BIOPHYS ACTA, V329, P156, DOI 10.1016/0304-4165(73)90019-6; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; HENDERSON BR, 1995, J BIOL CHEM, V270, P20509, DOI 10.1074/jbc.270.35.20509; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; Kim HY, 1996, J BIOL CHEM, V271, P24226, DOI 10.1074/jbc.271.39.24226; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOLD EA, 1990, NUCLEIC ACIDS RES, V18, P1819, DOI 10.1093/nar/18.7.1819; MARTIN RB, 1986, J INORG BIOCHEM, V28, P181, DOI 10.1016/0162-0134(86)80081-2; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; OHIRA Y, 1987, AM J PHYSIOL, V253, pC639, DOI 10.1152/ajpcell.1987.253.5.C639; PAGE MA, 1984, AM J PHYSIOL, V246, pG26, DOI 10.1152/ajpgi.1984.246.1.G26; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schalinske KL, 1997, BIOCHEMISTRY-US, V36, P3950, DOI 10.1021/bi9624447; Schalinske KL, 1996, J BIOL CHEM, V271, P7168, DOI 10.1074/jbc.271.12.7168; SHULL GE, 1982, J BIOL CHEM, V257, P4187; THEIL EC, 1994, BIOCHEM J, V304, P1; Thorp HH, 1996, INORG CHEM, V35, P2773, DOI 10.1021/ic951094u; TREFFRY A, 1979, BIOCHEM J, V181, P709, DOI 10.1042/bj1810709; WALDEN WE, 1986, BIOCHEMISTRY-US, V25, P2033, DOI 10.1021/bi00356a030; ZHENG LM, 1992, ARCH BIOCHEM BIOPHYS, V299, P356, DOI 10.1016/0003-9861(92)90287-7; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	52	66	68	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3740	3746		10.1074/jbc.273.6.3740	http://dx.doi.org/10.1074/jbc.273.6.3740			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452506	hybrid			2022-12-25	WOS:000071822300091
J	Xu, SJ; Wang, YP; Roe, B; Pearson, WR				Xu, SJ; Wang, YP; Roe, B; Pearson, WR			Characterization of the human class Mu glutathione S-transferase gene cluster and the GSTM1 deletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG-CANCER RISK; MAMMALIAN-CELLS; BLADDER-CANCER; HOMOLOGY REQUIREMENTS; NULL GENOTYPE; ALU REPEATS; M1 GSTM1; SUSCEPTIBILITY; SEQUENCES; CLONING	A partial physical map has been constructed of the human class Mu glutathione S-transferase genes on chromosome 1p13.3. The glutathione S-transferase genes in this cluster are spaced about 20 kilobase pairs (kb) apart, and arranged as 5'-GSTM4-GSTM2-GSTM1-GSTM5-3'. This map has been used to localize the end points of the polymorphic GSTM1 deletion, The left repeated region is 5 kb downstream from the 3'-end of the GSTM2 gene and 5 kb upstream from the beginning of the GSTM1 gene; the right repeated region is 5 kb downstream from the 5'-end of the GSTM1 and 10 kb upstream from the 5'-end of the GSTM5 gene. The GSTM1-0 deletion produces a novel 7.4-kb HindIII fragment with the loss of 10.3- and 11.4-kb HindIII fragments. The same novel fragment was seen in 13 unrelated individuals (20 null alleles), suggesting that most GSTM1-0 deletions involve recombinations between the same two regions. We have cloned and sequenced the deletion junction that is produced at the GSTM1-null locus; the 5'- and 5'-flanking regions are more than 99% identical to each other and to the deletion junction sequence over 2.3 kb. Because of the high sequence identity between the left repeat, right repeat, and deletion junction regions, the crossing over cannot be localized within the 2.3-kb region, The 2.3-kb repeated region contains a reverse class IV Alu repetitive element near one end of the repeat.	Univ Virginia, Dept Biochem, Charlottesville, VA 22908 USA; Univ Oklahoma, Dept Chem, Norman, OK 73019 USA	University of Virginia; University of Oklahoma System; University of Oklahoma - Norman	Pearson, WR (corresponding author), Univ Virginia, Dept Biochem, Box 440 Jordan Hall, Charlottesville, VA 22908 USA.	wrp@virginia.edu	Pearson, William/K-4908-2019	Pearson, William/0000-0002-0727-3680	NHGRI NIH HHS [R01 HG00313] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000313] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AYARES D, 1986, P NATL ACAD SCI USA, V83, P5199, DOI 10.1073/pnas.83.14.5199; Batzer MA, 1996, J MOL EVOL, V42, P3, DOI 10.1007/BF00163204; BATZER MA, 1991, GENOMICS, V9, P481, DOI 10.1016/0888-7543(91)90414-A; BELL DA, 1993, J NATL CANCER I, V85, P1159, DOI 10.1093/jnci/85.14.1159; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; BRITTEN RJ, 1989, P NATL ACAD SCI USA, V86, P3718, DOI 10.1073/pnas.86.10.3718; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COMSTOCK KE, 1993, J BIOL CHEM, V268, P16958; DALY AK, 1993, BRIT MED J, V307, P481, DOI 10.1136/bmj.307.6902.481; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; Heagerty A, 1996, BRIT J CANCER, V73, P44, DOI 10.1038/bjc.1996.8; HEAGERTY AHM, 1994, LANCET, V343, P266, DOI 10.1016/S0140-6736(94)91115-0; HIGGS DR, 1980, NATURE, V284, P632, DOI 10.1038/284632a0; HIRVONEN A, 1993, CARCINOGENESIS, V14, P1479, DOI 10.1093/carcin/14.7.1479; HWU HR, 1986, P NATL ACAD SCI USA, V83, P3875, DOI 10.1073/pnas.83.11.3875; LAFUENTE A, 1995, BRIT J CANCER, V72, P324, DOI 10.1038/bjc.1995.332; LIN HJ, 1994, CARCINOGENESIS, V15, P1077, DOI 10.1093/carcin/15.5.1077; LISKAY RM, 1987, GENETICS, V115, P161; LONDON SJ, 1995, J NATL CANCER I, V87, P1246, DOI 10.1093/jnci/87.16.1246; MCWILLIAMS JE, 1995, CANCER EPIDEM BIOMAR, V4, P589; METZENBERG AB, 1991, GENETICS, V128, P143; PAN HQ, 1994, GENET ANAL-BIOMOL E, V11, P181; PEARSON WR, 1988, J BIOL CHEM, V263, P13324; PEARSON WR, 1993, AM J HUM GENET, V53, P220; Pearson WR, 1996, METHOD ENZYMOL, V266, P227; PEMBLE S, 1994, BIOCHEM J, V300, P271, DOI 10.1042/bj3000271; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; ROSS VL, 1993, BIOCHEM J, V294, P373, DOI 10.1042/bj2940373; RUBNITZ J, 1984, MOL CELL BIOL, V4, P2253, DOI 10.1128/MCB.4.11.2253; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCOTT AF, 1984, MOL BIOL EVOL, V1, P371; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; SEIDEGARD J, 1990, CARCINOGENESIS, V11, P33, DOI 10.1093/carcin/11.1.33; SINNOTT P, 1990, P NATL ACAD SCI USA, V87, P2107, DOI 10.1073/pnas.87.6.2107; Smit AFA, 1996, P NATL ACAD SCI USA, V93, P1443, DOI 10.1073/pnas.93.4.1443; SUZUKI T, 1987, ANN HUM GENET, V51, P95, DOI 10.1111/j.1469-1809.1987.tb01051.x; TAYLOR JB, 1991, BIOCHEM J, V274, P587, DOI 10.1042/bj2740587; VNENCAKJONES CL, 1990, SCIENCE, V250, P1745, DOI 10.1126/science.1980158; VORACHEK WR, 1991, P NATL ACAD SCI USA, V88, P4443, DOI 10.1073/pnas.88.10.4443; WALDMAN AS, 1988, MOL CELL BIOL, V8, P5350, DOI 10.1128/MCB.8.12.5350; XU S, 1996, P INT ISSX WORKSH GL, P227; [No title captured]	43	163	173	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3517	3527		10.1074/jbc.273.6.3517	http://dx.doi.org/10.1074/jbc.273.6.3517			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452477	hybrid			2022-12-25	WOS:000071822300062
J	Grigoryev, SA; Woodcock, CL				Grigoryev, SA; Woodcock, CL			Chromatin structure in granulocytes - A link between tight compaction and accumulation of a heterochromatin-associated protein (MENT)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLTRANSFERASE; HISTONE H1; NUCLEOSOME; BINDING; CELLS; DNA; CONDENSATION; DOMAIN; STAGE; MODEL	To study the mechanism of heterochromatin formation in vertebrate cells, we isolated nuclei from chicken polymorphonuclear granulocytes and examined the chromatin organization. me found granulocyte chromatin to remain insoluble after nuclease digestion and to be resistant to swelling in low salt/high pH media, Both insolubility and resistance to swelling were lost after washing with 0.3 M NaCl, a procedure that released two abundant tissue-specific proteins from granulocyte nuclei, One of them (42 kDa) is identified as MENT, a protein previously shown to be associated with repressed chromatin from mature chicken erythrocytes. We show that MENT is immunolocalized in granulocyte heterochromatin, where it is one of the most abundant chromatin proteins (similar to 2 molecules/200 base pairs of DNA). MENT is the first nuclear protein structurally related to the serine protease inhibitor family. The other abundant protein is similar to or identical with mim-1, a myeloid-specific protein that is known to be stored in cell granules and to associate with isolated nuclei. MENT (but not mim-1) binds chromatin and free DNA, and, at its physiological protein/DNA ratio, enhances compaction and the reversible Mg2+-dependent self-association of nucleosome arrays. MENT appears to promote the formation of heterochromatin by acting as a "glue" within and between chains of nucleosomes.	Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Grigoryev, SA (corresponding author), Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.	sergei@bio.umass.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043786, R55GM051352] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43786, GM-51352] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; COLE RD, 1987, INT J PEPT PROT RES, V30, P433; COUTELLE C, 1974, EXP CELL RES, V88, P15, DOI 10.1016/0014-4827(74)90612-0; DAVIES HG, 1975, J CELL SCI, V17, P263; di Padua Mathieu D, 1981, J Cell Biol, V91, P135, DOI 10.1083/jcb.91.1.135; Edwards S.L., 1994, BIOCH PHYSL NEUTROPH; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; ERICKSON PA, 1993, METHOD CELL BIOL, V37, P283, DOI 10.1016/S0091-679X(08)60255-1; ERLANGER BF, 1964, BIOCHEMISTRY-US, V3, P1880, DOI 10.1021/bi00900a015; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GRIGORYEV SA, 1992, EXP CELL RES, V198, P268, DOI 10.1016/0014-4827(92)90379-M; GRIGORYEV SA, 1993, EXP CELL RES, V206, P335, DOI 10.1006/excr.1993.1154; HANSEN JC, 1989, ANAL BIOCHEM, V179, P167, DOI 10.1016/0003-2697(89)90219-4; Harlow E., 1988, ANTIBODIES LAB MANUA, V2nd, P479; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LABHART P, 1981, EUR J CELL BIOL, V25, P19; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOENING UE, 1967, BIOCHEM J, V102, P251, DOI 10.1042/bj1020251; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; MISHIMA K, 1991, J BIOCHEM-TOKYO, V110, P388, DOI 10.1093/oxfordjournals.jbchem.a123591; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Pennisi E, 1997, SCIENCE, V275, P155, DOI 10.1126/science.275.5297.155; Pinkoski MJ, 1996, J BIOL CHEM, V271, P10225, DOI 10.1074/jbc.271.17.10225; POSTNIKOV YV, 1991, NUCLEIC ACIDS RES, V19, P717, DOI 10.1093/nar/19.4.717; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PrymakowskaBosak M, 1996, P NATL ACAD SCI USA, V93, P10250, DOI 10.1073/pnas.93.19.10250; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; ROWLEY AF, 1988, VERTEBRATE BLOOD CEL, P257; RUIZCARRILLO A, 1980, BIOCHEMISTRY-US, V19, P2544, DOI 10.1021/bi00553a002; SCALA C, 1992, J HISTOCHEM CYTOCHEM, V40, P1799, DOI 10.1177/40.11.1431065; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SIROTKIN AM, 1995, P NATL ACAD SCI USA, V92, P6434, DOI 10.1073/pnas.92.14.6434; SUN JM, 1989, SCIENCE, V245, P68, DOI 10.1126/science.2740916; TRAVIS J, 1981, METHOD ENZYMOL, V80, P754; van Holde KE., 1989, SPRINGER SERIES MOL; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; VERREAULT A, 1993, COLD SPRING HARB SYM, V58, P15, DOI 10.1101/SQB.1993.058.01.005; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; Wolffe A., 1995, CHROMATIN STRUCTURE; WOODCOCK CL, 1997, METHOD CELL BIOL, V53, P167; YAMADA K, 1992, FEBS LETT, V311, P203, DOI 10.1016/0014-5793(92)81102-R; ZLATANOVA J, 1992, J CELL SCI, V103, P889	60	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3082	3089		10.1074/jbc.273.5.3082	http://dx.doi.org/10.1074/jbc.273.5.3082			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446625	hybrid			2022-12-25	WOS:000071736600080
J	Ni, AG; Chao, L; Chao, J				Ni, AG; Chao, L; Chao, J			Transcription factor nuclear factor kappa B regulates the inducible expression of the human B-1 receptor gene in inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; BRADYKININ RECEPTORS; PHARMACOLOGICAL CHARACTERIZATION; GROWTH-FACTORS; CLONING; ACTIVATION; PROTEIN; DES-ARG9-BRADYKININ; KININS; RNA	Expression of the bradykinin B-1 receptor gene is upregulated in vascular smooth muscle cells (VSMCs) in response to a variety of inflammatory stimuli. We isolated the 5'-flanking region of the human bradykinin B-1 receptor gene and examined its promoter activity by transient transfection analysis. This region (-2582 to +34) showed promoter activity inducible by lipopolysaccharide (LPS), tumor necrosis factor alpha (TNF-alpha), and interleukin-1 beta (IL-1 beta) in VSMCs. Further deletion analysis revealed that constructs containing 111 base pairs of 5'-flanking sequence were sufficient for transcriptional induction. Mutagenesis of a nuclear factor ICE (NF-KB)like site at -64 to -55 abolished most of the LPS, TNF-alpha; and IL-1 beta inducibility, whereas a mutation of a cyclic AMP response element at -50 to -43 markedly reduced the basal promoter activity, and a mutation of the activator protein 1 (AP-1) site at -78 to -72 had minimal effects. Nuclear extracts from LPS, TNF-alpha, and IL-1 beta-treated VSMCs, IL-1 beta-treated human hepatoma HepG(2), and human lung fibroblast IMR-90 cells showed strong. inducible binding activity to the NF-kappa B-like site by gel shift assays. These results demonstrated that NF-kappa B-like nuclear factor was involved in the inducible expression of the human bradykinin B-1 receptor gene during inflammatory processes.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Chao, J (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.				NHLBI NIH HHS [HL 29397, HL 52196] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052196, R01HL029397] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Austin CE, 1997, J BIOL CHEM, V272, P11420; Bachvarov DR, 1995, J PHARMACOL EXP THER, V275, P1623; Bachvarov DR, 1996, GENOMICS, V33, P374, DOI 10.1006/geno.1996.0213; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P439; BATHON JM, 1991, ANNU REV PHARMACOL, V31, P129; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chai KX, 1996, GENOMICS, V31, P51, DOI 10.1006/geno.1996.0008; COGSWELL JP, 1994, J IMMUNOL, V153, P712; DEBLOIS D, 1989, IMMUNOPHARMACOLOGY, V17, P187, DOI 10.1016/0162-3109(89)90047-7; DEBLOIS D, 1988, BRIT J PHARMACOL, V93, P969, DOI 10.1111/j.1476-5381.1988.tb11487.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAY A, 1993, TRENDS NEUROSCI, V16, P99, DOI 10.1016/0166-2236(93)90133-7; GOLDSTEIN RH, 1984, J BIOL CHEM, V259, P9263; GORDON D, 1986, CIRC RES, V59, P633, DOI 10.1161/01.RES.59.6.633; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HESS JF, 1994, MOL PHARMACOL, V45, P1; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LAWRENCE R, 1994, J BIOL CHEM, V269, P28913; LEVESQUE L, 1993, BRIT J PHARMACOL, V109, P1254, DOI 10.1111/j.1476-5381.1993.tb13757.x; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LIBBY P, 1986, J CLIN INVEST, V78, P1432, DOI 10.1172/JCI112732; MACNEIL T, 1995, BBA-GENE STRUCT EXPR, V1264, P223, DOI 10.1016/0167-4781(95)00152-7; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Pesquero JB, 1996, BIOCHEM BIOPH RES CO, V220, P219, DOI 10.1006/bbrc.1996.0384; PESQUERO JB, 1997, KALLIKREIN KININ SYS; REGOLI D, 1980, PHARMACOL REV, V32, P1; Rupniak NMJ, 1997, PAIN, V71, P89, DOI 10.1016/S0304-3959(97)03343-5; Sardi SP, 1997, EUR J PHARMACOL, V321, P33, DOI 10.1016/S0014-2999(96)00927-2; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SMITH JAM, 1995, MOL PHARMACOL, V47, P525; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; WILKBLASZCZAK MA, 1994, NEURON, V13, P1215, DOI 10.1016/0896-6273(94)90059-0; Yang XH, 1996, BIOCHEM BIOPH RES CO, V222, P718, DOI 10.1006/bbrc.1996.0810	44	118	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2784	2791		10.1074/jbc.273.5.2784	http://dx.doi.org/10.1074/jbc.273.5.2784			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446586	hybrid			2022-12-25	WOS:000071736600041
J	Valgeirsdottir, S; Paukku, K; Silvennoinen, O; Heldin, CH; Claesson-Welsh, L				Valgeirsdottir, S; Paukku, K; Silvennoinen, O; Heldin, CH; Claesson-Welsh, L			Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF beta-receptor juxtamembrane and kinase insert domains	ONCOGENE			English	Article						PDGF; receptor; Stat; JAK; phosphorylation, binding sites	SIGNAL-TRANSDUCTION PATHWAYS; COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASES; DNA-BINDING ACTIVITY; PHOSPHOLIPASE-C-GAMMA; AUTOPHOSPHORYLATION SITES; TARGETED DISRUPTION; MOUSE-LIVER; IDENTIFICATION; GENE	Signal transducers and activators of transcription (Stats) are known to transduce signals from the cell surface to the nucleus in cytokine receptor signaling. We examined the capacity of platelet-derived gron th factor (PDGF) receptor to interact with and activate Stat molecules. Activation of the PDGF beta-receptor led to tyrosine phosphorylation of Stat1, Stat3 and Stat5, which was accompanied by specific DNA-binding activities, These events were only weakly stimulated by the activated PDGF alpha-receptor. In cells expressing PDGF beta-receptors mutated at Tyr579, Tyr581 or Tyr775, tyrosine phosphorylation as well as DNA-binding activity of Stat5 was reduced. Immobilized peptides containing phosphorylated Tyr579, Tyr581 or Tyr775 bound Stat5, suggesting direct binding of Stat5 to these tyrosine residues of the PDGF beta-receptor. Members of the Janus kinase family were also shown to interact with the PDGF beta-receptor, and to a lesser extent with the alpha-receptor, but their importance for PDGF-induced Stat activation remains to be determined.	Biomed Ctr, Dept Med & Physiol Chem, S-75123 Uppsala, Sweden; Biomed Ctr, Ludwig Inst Canc Res, Uppsala, Sweden; Univ Helsinki, Dept Virol, Haartman Inst, Helsinki, Finland; Tampere Univ, Inst Med Technol, FIN-33101 Tampere, Finland	Ludwig Institute for Cancer Research; University of Helsinki; Tampere University	Claesson-Welsh, L (corresponding author), Biomed Ctr, Dept Med & Physiol Chem, Box 575, S-75123 Uppsala, Sweden.							ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Heldin CH., 1996, MOL CELLULAR BIOL WO, P249; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Novak U, 1996, J BIOL CHEM, V271, P18350, DOI 10.1074/jbc.271.31.18350; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Raines E.W., 1990, PEPTIDE GROWTH FACTO, DOI [10.1007/978-3-642-49295-2_5, DOI 10.1007/978-3-642-49295-2_5]; RAZ R, 1994, J BIOL CHEM, V269, P24391; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; VALGEIRSDOTTIR S, 1995, J BIOL CHEM, V270, P10161, DOI 10.1074/jbc.270.17.10161; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEIMA SM, 1990, EXP CELL RES, V186, P324, DOI 10.1016/0014-4827(90)90312-X; WENNSTROM S, 1994, ONCOGENE, V9, P651; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	54	63	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					505	515		10.1038/sj.onc.1201555	http://dx.doi.org/10.1038/sj.onc.1201555			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484840				2022-12-25	WOS:000071739400009
J	Harris, TM; Rogler, LE; Rogler, CE				Harris, TM; Rogler, LE; Rogler, CE			Reactivation of the maternally imprinted IGF2 allele in TGF alpha induced hepatocellular carcinomas in mice	ONCOGENE			English	Article						IGF2; imprinting; DEN; hepatocellular carcinoma; transgenic mice	GROWTH-FACTOR-II; INSULIN-RECEPTOR SUBSTRATE-1; HEPATITIS-VIRUS CARRIERS; TRANSGENIC MICE; DIFFERENTIAL EXPRESSION; MESSENGER-RNA; GENE-EXPRESSION; LIVER-TUMORS; OVEREXPRESSION; APOPTOSIS	The Insulin like growth factor 2 (IGF2) gene is expressed in several types of tumors in humans and mice and has been implicated as an important growth factor in tumor progression. IGF2 expression in the TGF alpha transgenic mice was analysed in liver and tumors from animals which also contained one or two functional IGF2 alleles. In a two by two mating experiment using transgenic mice containing either a TGF alpha transgene or a IGF2 gene knockout, we have investigated whether IGF2 imprinting is reversed during hepatocarcinogenesis and the consequences of IGF2 expression for tumor growth. We observed that: (1) 100% of the hepatocellular carcinomas expressed IGF2 (2) the normally imprinted maternal allele is active in the tumors in which the paternal allele is knocked out and (3) all three of the murine IGF2 promoters upstream of the reactivated maternal alleles are transcriptionally active in tumors. We also observed that the total tumor burden of animals with two wild type IGF-2 alleles (paternal and maternal) was the same as the tumor burden in animals which contained only a single reactivated maternal allele. The 100% incidence of reactivation of the imprinted maternal allele suggests that IGF2 expression is selected during murine hepatocarcinogenesis and can substitute for the paternal allele when it is inactivated.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Rogler, LE (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Marion Bessin Liver Res Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NCI NIH HHS [CA56076] Funding Source: Medline; NIDDK NIH HHS [T32 DK 07218] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007218] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; CARIANI E, 1988, CANCER RES, V48, P6844; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COLLIER JD, 1993, LIVER, V13, P151; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DEMOOR CH, 1994, EUR J BIOCHEM, V226, P1039; DEMOOR CH, 1995, BIOCHEM J, V307, P225, DOI 10.1042/bj3070225; DEPAGTERHOLTHUIZEN P, 1988, BIOCHIM BIOPHYS ACTA, V950, P282, DOI 10.1016/0167-4781(88)90124-8; FLORINI JR, 1993, ADV EXP MED BIOL, V343, P319; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; FURUSAKA A, 1994, CANCER LETT, V84, P85, DOI 10.1016/0304-3835(94)90361-1; GREENBLATT MS, 1994, CANCER RES, V54, P4855; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JIRTLE R, 1995, LIVER REGENERATION C, P199; KAUFMANN WK, 1992, CARCINOGENESIS, V13, P1481, DOI 10.1093/carcin/13.8.1481; KIESS W, 1994, HORM RES, V41, P66, DOI 10.1159/000183963; LAUTERIO TJ, 1992, ADV EXP MED BIOL, V321, P31; LEE GH, 1992, CANCER RES, V52, P5162; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; OHLSSON R, 1989, DEVELOPMENT, V106, P555; Pimentel E., 1994, HDB GROWTH FACTORS, VII, P55; PINTAR JE, 1991, ADV EXP MED BIOL, V293, P325; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; Rossetti L, 1996, J BIOL CHEM, V271, P203, DOI 10.1074/jbc.271.1.203; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; SCHIRMACHER P, 1992, CANCER RES, V52, P2549; SHINAR DM, 1993, ENDOCRINOLOGY, V132, P1158, DOI 10.1210/en.132.3.1158; SINGER C, 1995, CANCER RES, V55, P2448; Steinmetz KL, 1996, TOXICOL APPL PHARM, V140, P131, DOI 10.1006/taap.1996.0206; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TAKAGI H, 1992, CANCER RES, V52, P5171; Tanaka S, 1996, J CLIN INVEST, V98, P2100, DOI 10.1172/JCI119016; Tanaka S, 1996, CANCER RES, V56, P3391; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; WAKIYAMA M, 1992, NUCL ACIDS S SERIES, V27, P159; YANG D, 1993, CANCER RES, V53, P2020; Yang DY, 1996, J VIROL, V70, P6260, DOI 10.1128/JVI.70.9.6260-6268.1996; YANG DY, 1991, CARCINOGENESIS, V12, P1893, DOI 10.1093/carcin/12.10.1893; Yun K, 1996, AM J PATHOL, V148, P1081; Zhang N, 1997, HEPATOLOGY, V25, P900, DOI 10.1002/hep.510250419	45	36	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					203	209		10.1038/sj.onc.1201519	http://dx.doi.org/10.1038/sj.onc.1201519			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464538				2022-12-25	WOS:000071427100007
J	Maguer-Satta, V; Burl, S; Liu, L; Damen, J; Chahine, H; Krystal, G; Eaves, A; Eaves, C				Maguer-Satta, V; Burl, S; Liu, L; Damen, J; Chahine, H; Krystal, G; Eaves, A; Eaves, C			BCR-ABL accelerates C2-ceramide-induced apoptosis	ONCOGENE			English	Article						CML; BCR-ABL; ceramide; apoptosis; tyrosine phosphorylation	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; HUMAN HEMATOPOIETIC-CELLS; ACTIVATED PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE-ACTIVITY; RAS SIGNALING PATHWAY; LONG-TERM CULTURE; HUMAN BONE-MARROW	In patients with chronic myeloid leukemia (CML), the neoplastic (BCR-ABL(+)) progenitor cells are characterized by an increased proliferative activity, Whether these cells are also resistant to apoptosis and if so, under what conditions remains controversial, We now show that highly purified populations of very primitive neoplastic progenitor cells obtained directly from CML patients survive and proliferate in vitro for several weeks in the absence of any added growth factors (except insulin), In contrast, purified primary normal progenitors maintained under the same conditions die rapidly, Nevertheless, both primary CML cells and BCR-ABL(+) BAF3 cells show the same dose-dependent sensitivity to TNF-alpha or ceramide-induced apoptosis as their respective normal counterparts, In fact, time course studies demonstrated an even faster onset of apoptosis in ceramide-treated BCR-ABL(+) BAF3 cells as compared to normal controls, BCR-ABL(+) cells treated with ceramide also showed a rapid and sequential increase in the tyrosine phosphorylation of p210(BCR-ABL), p46-56(SHC) and p120(Cbl), These findings suggest growth factor deprivation and treatment with TNF-alpha or ceramide trigger different initial events both of which can lead to apoptosis in factor-dependent hematopoietic cells, However, in the first case, activation of apoptosis is blocked by the basal activity of p210(BCR-ABL), whereas in the second, the presence of p210(BCR-ABL) appears to accelerate the onset of apoptosis by a mechanism that may involve an activation of its kinase function.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Expt Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; Univ Victor Segalen, Lab Greffe de Moelle, CNRS, UMR 5540, Bordeaux, France; Univ British Columbia, Dept Med, Vancouver, BC, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University of British Columbia; University of British Columbia	Eaves, C (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.		Maguer-Satta, Veronique/U-8857-2019	Maguer-Satta, Veronique/0000-0002-1556-068X; Krystal, Gerald/0000-0002-1961-6281				AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Albrecht T, 1996, BRIT J HAEMATOL, V95, P501, DOI 10.1046/j.1365-2141.1996.d01-1934.x; AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CARLESSO N, 1994, ONCOGENE, V9, P149; CASHMAN JD, 1992, LEUKEMIA, V6, P886; Chacko GW, 1996, J IMMUNOL, V157, P2234; CHEN M, 1995, CANCER RES, V55, P991; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; EAVES AC, 1986, P NATL ACAD SCI USA, V83, P5306, DOI 10.1073/pnas.83.14.5306; Eaves C J, 1987, Baillieres Clin Haematol, V1, P931, DOI 10.1016/S0950-3536(87)80033-1; EAVES CJ, 1993, P NATL ACAD SCI USA, V90, P12015, DOI 10.1073/pnas.90.24.12015; FIALKOW PJ, 1981, BLOOD, V58, P158, DOI 10.1182/blood.V58.1.158.158; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Hariharan I K, 1988, Oncogene Res, V3, P387; HAWLEY RG, 1994, GENE THER, V1, P136; Hogge DE, 1996, BLOOD, V88, P3765, DOI 10.1182/blood.V88.10.3765.bloodjournal88103765; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIM MY, 1991, J BIOL CHEM, V266, P484; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Kitanaka A, 1996, BLOOD, V88, P590, DOI 10.1182/blood.V88.2.590.bloodjournal882590; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LANSDORP PM, 1992, J EXP MED, V175, P1501, DOI 10.1084/jem.175.6.1501; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MaguerSatta V, 1996, BLOOD, V88, P1796; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nishii K, 1996, ONCOGENE, V13, P2225; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Petzer AL, 1996, J EXP MED, V183, P2551, DOI 10.1084/jem.183.6.2551; Petzer AL, 1996, BLOOD, V88, P2162, DOI 10.1182/blood.V88.6.2162.bloodjournal8862162; Petzer AL, 1997, BLOOD, V90, P64; PONCHIO L, 1995, BLOOD, V86, P3314, DOI 10.1182/blood.V86.9.3314.bloodjournal8693314; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SANTUCCI MA, 1993, INT J RADIAT ONCOL, V26, P831, DOI 10.1016/0360-3016(93)90498-K; Sattler M, 1996, ONCOGENE, V12, P839; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Selleri C, 1997, BLOOD, V89, P957, DOI 10.1182/blood.V89.3.957; SIRARD C, 1994, BLOOD, V83, P1575; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; STRIFE A, 1988, CANCER RES, V48, P1035; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SUTHERLAND HJ, 1991, BLOOD, V78, P666, DOI 10.1182/blood.V78.3.666.bloodjournal783666; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TOKER A, 1994, J BIOL CHEM, V269, P32358; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; UDOMSAKDI C, 1992, P NATL ACAD SCI USA, V89, P6192, DOI 10.1073/pnas.89.13.6192; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WIEDEMANN LM, 1988, BLOOD, V71, P349; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	85	41	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	1998	16	2					237	248		10.1038/sj.onc.1201533	http://dx.doi.org/10.1038/sj.onc.1201533			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464542				2022-12-25	WOS:000071427100011
J	Wang, QJ; Acs, P; Goodnight, JA; Blumberg, PM; Mischak, H; Mushinski, JF				Wang, QJ; Acs, P; Goodnight, JA; Blumberg, PM; Mischak, H; Mushinski, JF			The catalytic domain of PKC-epsilon, in reciprocal PKC-delta and -epsilon chimeras, is responsible for conferring tumorgenicity to NIH3T3 cells, whereas both regulatory and catalytic domains of PKC-epsilon contribute to in vitro transformation	ONCOGENE			English	Article						chimeric PKC; PKC-epsilon; PKC-delta; transformation; tumorgenicity; NIH3T3	PROTEIN-KINASE-C; FIBROBLASTS; NUCLEAR; ISOFORM; RAS	Protein kinase C-epsilon (PKC-epsilon) has been shown to increase growth and cause malignant transformation when overexpressed in NIH3T3 cells, whereas PKC-delta reduced fibroblast growth, Two reciprocal chimeric proteins (PKC-epsilon delta and PKC-delta epsilon were constructed by exchanging the regulatory and catalytic domains of PKC-delta and -epsilon and were stably overexpressed in NIH3T3 cells, Fibroblasts that overexpressed either chimera showed maximum cell density and morphology that were intermediate between cells overexpressing PKC-delta and those that overexpressed PKC-epsilon, Moreover, all lines that expressed chimeras were capable of anchorage-independent growth in the presence of TPA, which indicated that both the regulatory and catalytic domains of PKC-epsilon could independently induce NIH3T3 transformation, although the combination of both domains, as found in PKC-epsilon, was the most active form, In contrast, the translocation pattern and ability to induce tumors in nude mice was attributable to the catalytic domains exclusively, In particular, cells that expressed PKC-delta epsilon retained PKC-epsilon's full potency of tumorgenicity when injected into nude mice, In sum, our findings not only reinforce the concept that only certain PKC isozymes contribute to carcinogenesis but also show that different domains of PKCs mediate the physiologically distinguishable events of transformation and tumorgenesis.	NCI, Genet Lab, Bethesda, MD 20892 USA; NCI, Cellular Carcinogenesis & Tumor Promot Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mushinski, JF (corresponding author), NCI, Genet Lab, Bethesda, MD 20892 USA.		Wang, Qiming Jane/B-6064-2012; Mischak, Harald/E-8685-2011	Wang, Qiming Jane/0000-0002-9502-4851; Mischak, Harald/0000-0003-0323-0306				Borgatti P, 1996, EXP CELL RES, V224, P72, DOI 10.1006/excr.1996.0112; CACACE AM, 1993, ONCOGENE, V8, P2095; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; Wang WJ, 1997, J BIOL CHEM, V272, P76; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; ZUALI G, 1996, BRIT J HAEMATOL, V92, P530	15	18	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	1998	16	1					53	60		10.1038/sj.onc.1201507	http://dx.doi.org/10.1038/sj.onc.1201507			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467942				2022-12-25	WOS:000071236800006
J	Wu, Y; Liu, JX; Arlinghaus, RB				Wu, Y; Liu, JX; Arlinghaus, RB			Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase	ONCOGENE			English	Article						Bcr serine/threonine kinase; Bcr tyrosine residues; tyrosine phosphorylation of Bcr; inhibition of Bcr serine kinase by Bcr-Ab1; kinase role of Bcr tyrosines 328 and 360	MUSCLE PYRUVATE-KINASE; ABL ONCOPROTEINS; GENE ENCODES; P160 BCR; PHOSPHORYLATION; LEUKEMIA; CELLS	Bcr is a novel serine/threonine protein kinase that is believed to require two cysteine pairs for activity (Maru and Witte, Cell, 67, 459, 1991), Tyrosine phosphorylated Bcr has dramatically reduced kinase activity, and tyrosine 360 of Bcr, which is one of the sites of phosphorylation by the Bcr - Abl oncoprotein, is required for transkinase activity (Liu et al., Mel. Cell Biol,, 16, 998, 1996), Results presented here indicate that Bcr tyrosine 328 is also phosphorylated within Bcr-Abl expressing cells and is required for Bcr's serine/threonine kinase activity, Bcr Y328F, like Bcr Y360F, had defective transkinase activity but can autophosphorylate. However, the Y328F/Y360F double mutant of Bcr is defective in both trans-and autokinase activities, Taken together with the kinase inhibitory effects of tyrosine phosphorylation of Bcr by Bcr-Abl, our studies with tyrosine to phenylalanine Bcr mutants indicate that the hydroxyl residues of tyrosines 328 and 360 play crucial roles in Bcr's kinase activity.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA65611, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065611, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNAMALAI AE, 1981, J BIOL CHEM, V256, P276; CAMPBELL ML, 1991, ADV CANCER RES, V57, P227; CAMPBELL ML, 1990, ONCOGENE, V5, P773; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; LI WJ, 1989, ONCOGENE, V4, P127; LIFSHITZ B, 1988, ONCOGENE, V2, P113; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LU D, 1993, BLOOD, V82, P1257; Ma GZ, 1997, ONCOGENE, V14, P2367, DOI 10.1038/sj.onc.1201053; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TOMICH JM, 1981, BIOCHEMISTRY-US, V20, P6711, DOI 10.1021/bi00526a029	18	18	18	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	1998	16	1					141	146		10.1038/sj.onc.1201524	http://dx.doi.org/10.1038/sj.onc.1201524			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467953				2022-12-25	WOS:000071236800017
J	Bazhenova, EN; Deryabina, YI; Eriksson, O; Zvyagilskaya, RA; Saris, NEL				Bazhenova, EN; Deryabina, YI; Eriksson, O; Zvyagilskaya, RA; Saris, NEL			Characterization of a high capacity calcium transport system in mitochondria of the yeast Endomyces magnusii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; PERMEABILITY TRANSITION PORE; ADENINE-NUCLEOTIDES; SACCHAROMYCES-CEREVISIAE; CA-2+ TRANSPORT; ALLOSTERIC ACTIVATOR; HEART-MITOCHONDRIA; BRAIN MITOCHONDRIA; VACUOLAR MEMBRANE; MATING PHEROMONE	The Ca2+ transport system of Endomyces magnusii mitochondria has been shown previously to be activated by spermine. Here we report it tea be regulated also by low, physiological ADP concentrations, by the intramitochondrial NADH/NAD(+) ratio, and by Ca2+ ions. The combination of all these physiological modulators induced high initial rates of Ca2+ uptake and high Ca2+-buffering capacity of yeast mitochondria, enabling them to lower the medium [Ca2+] to similar to 0.2 mu M. The mechanisms of stimulation by these agents are discussed.	Univ Helsinki, Inst Biomed, Dept Med Chem, FIN-00014 Helsinki, Finland; Russian Acad Sci, Bach Inst Biochem, Lab Biol Oxidat, Moscow 117071, Russia	University of Helsinki; Research Center of Biotechnology RAS; Russian Academy of Sciences	Saris, NEL (corresponding author), Univ Helsinki, Inst Biomed, Dept Med Chem, POB 8, FIN-00014 Helsinki, Finland.	saris@penger.helsinki.fi	Eriksson-Rosenberg, Ove/GVU-6692-2022					AKERMAN KEO, 1983, BIOCHEM BIOPH RES CO, V114, P1176, DOI 10.1016/0006-291X(83)90686-1; BALCAVAG.WX, 1973, BIOCHIM BIOPHYS ACTA, V305, P41, DOI 10.1016/0005-2728(73)90229-6; BAZHENOVA EN, 1998, IN PRESS BIOCH BIOPH; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALVERT CM, 1995, J BIOL CHEM, V270, P7272, DOI 10.1074/jbc.270.13.7272; Fersht A., 1985, ENZYME STRUCTURE MEC; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; IIDA H, 1990, J BIOL CHEM, V265, P13391; JACKSON SL, 1993, MICROBIOL REV, V57, P367, DOI 10.1128/MMBR.57.2.367-382.1993; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KRONER H, 1986, ARCH BIOCHEM BIOPHYS, V251, P525, DOI 10.1016/0003-9861(86)90360-7; KRONER H, 1988, ARCH BIOCHEM BIOPHYS, V267, P205, DOI 10.1016/0003-9861(88)90024-0; LAPIDUS RG, 1994, J BIOL CHEM, V269, P18931; LEIKIN YN, 1987, BIOKHIMIYA, V52, P676; MANON S, 1993, J BIOENERG BIOMEMBR, V25, P671; MCCORMACK JG, 1993, BIOCHEM SOC T, V21, P793, DOI 10.1042/bst0210793; MOORE CL, 1971, BIOCHEM BIOPH RES CO, V42, P298, DOI 10.1016/0006-291X(71)90102-1; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1016, P87, DOI 10.1016/0005-2728(90)90010-2; ROTTENBERG H, 1989, FEBS LETT, V247, P483, DOI 10.1016/0014-5793(89)81396-1; SARIS NEL, 1990, J BIOENERG BIOMEMBR, V22, P81, DOI 10.1007/BF00762847; Scarpa A, 1972, Methods Enzymol, V24, P343; Scarpa A, 1979, Methods Enzymol, V56, P301; Sordahl L A, 1978, Ann N Y Acad Sci, V307, P238, DOI 10.1111/j.1749-6632.1978.tb41952.x; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; TACHIKAWA T, 1987, AGR BIOL CHEM TOKYO, V51, P1209, DOI 10.1080/00021369.1987.10868161; Tanida I, 1996, FEBS LETT, V379, P38, DOI 10.1016/0014-5793(95)01478-0; TONINELLO A, 1983, BIOCHEM BIOPH RES CO, V111, P792, DOI 10.1016/0006-291X(83)91368-2; VOTYAKOVA TV, 1990, FEBS LETT, V261, P139, DOI 10.1016/0014-5793(90)80655-3; VOTYAKOVA TV, 1993, J BIOENERG BIOMEMBR, V25, P569, DOI 10.1007/BF01108413; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZVJAGILSKAYA RA, 1983, DOKL AKAD NAUK SSSR, V269, P1233; ZVYAGIL'SKAYA R A, 1981, Biokhimiya, V46, P3; ZVYAGILSKAYA RA, 1991, FUNCTIONAL ACTIVITY, V36; ZVYAGILSKAYA RA, 1995, YEAST, V11, pS469; ZVYAGILSKAYA RA, 1996, BIOCHIM BIOPHYS ACTA, V9, P193; ZVYAGILSKAYA RA, 1982, DOKL AKAD NAUK SSSR, V263, P491	42	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4372	4377		10.1074/jbc.273.8.4372	http://dx.doi.org/10.1074/jbc.273.8.4372			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468487	hybrid			2022-12-25	WOS:000072115000015
J	Farah, S; Agazie, Y; Ohan, N; Ngsee, JK; Liu, XJ				Farah, S; Agazie, Y; Ohan, N; Ngsee, JK; Liu, XJ			A rho-associated protein kinase, ROK alpha, binds insulin receptor substrate-1 and modulates insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; XENOPUS-OOCYTE MATURATION; MAP KINASE; IRS-1; PHOSPHORYLATION; ACTIVATION; DISTINCT; TRANSDUCTION; CYTOSKELETON; INVOLVEMENT	Insulin receptor substrate-1 (IRS-1) is physphorylated on multiple tyrosine residues by ligand-activated insulin receptors. These tyrosine phosphorylation sites serve to dock several Src homology 2-containing signaling proteins, In addition, IRS-1 contains a pleckstrin homology domain and a phosphotyrosine binding domain (PTB) implicated in protein-protein and protein-lipid interactions, In a yeast two-hybrid screening using Xenopus IRS-1 (xIRS-1) pleekstrin homology-PTB domains as bait, we identified a Xenopus homolog of Rho-associated kinase alpha (xROK alpha) as a potential xIRS-1-binding protein, The original clone contained. the carboxyl terminus of xROK alpha (xROK-C) including the putative Rho binding domain but lacking the amino-terminal kinase domain. Further analyses in yeast indicated that xROK-C bound to the putative PTB domain of xIRS-1. Binding of xROK-C to xIRS-1 was confirmed in Xenopus oocytes after microinjection of mRNA corresponding to xROK-C. Furthermore, microinjection of xROK-C mRNA inhibited insulin-induced mitogen-activated protein kinase activation with a concomitant inhibition of oocyte maturation. In contrast, microinjection of xROK-C mRNA did not inhibit mitogen-activated protein kinase activation or oocyte maturation induced by progesterone or by microinjection of viral. Ras (v-Ras) mRNA, These results suggest that xROK alpha may play a role in insulin signaling via a direct interaction with xIRS-1.	Ottawa Civic Hosp, Loeb Res Inst, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Biochem, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Obstet & Gynecol, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa	Liu, XJ (corresponding author), Ottawa Civic Hosp, Loeb Res Inst, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.	johne@civich.ottawa.on.ca		Liu, X. Johne/0000-0003-3381-5030				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BORK P, 1995, CELL, V80, P687; CIRCIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514; Craparo A, 1997, J BIOL CHEM, V272, P11663; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KasusJacobi A, 1997, J BIOL CHEM, V272, P17166, DOI 10.1074/jbc.272.27.17166; KAVANAUGH WM, 1994, SCIENCE, V266, P819; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; LIU XJ, 1995, MOL CELL BIOL, V15, P3563; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SMITH LD, 1991, METHOD CELL BIOL, V36, P45; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YAMASAKI H, 1992, J BIOL CHEM, V267, P20953; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	52	58	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4740	4746		10.1074/jbc.273.8.4740	http://dx.doi.org/10.1074/jbc.273.8.4740			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468537	hybrid			2022-12-25	WOS:000072115000065
J	Mesnildrey, S; Agou, F; Karlsson, A; Bonne, DD; Veron, M				Mesnildrey, S; Agou, F; Karlsson, A; Bonne, DD; Veron, M			Coupling between catalysis and oligomeric structure in nucleoside diphosphate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; X-RAY STRUCTURE; CRYSTAL-STRUCTURE; ACTIVE-SITE; NM23 GENE; STABILITY; BINDING; ENZYME; DROSOPHILA; RESOLUTION	A dimeric Dictyostelium nucleoside diphosphate kinase has been stabilized by the double mutation P100S-N150stop which targets residues involved in the trimer interface (Karlsson, A, Mesnildrey S., Xu, Y., Morera, S., Janin, J., and Vernon, M. (1996) J, Biol. Chem. 271, 19928-19934), The reassociation of this dimeric form into a hexamer similar to the wild-type enzyme is induced by the presence of a nucleotide substrate, Equilibrium sedimentation and gel filtration experiments, as well as enzymatic activity measurements, show that reactivation of the enzyme closely parallels its reassociation, A phosphorylatable intermediate with low activity participates ist the association pathway while the dimeric form is shown totally devoid of enzymatic activity, Our results support the hypothesis that different oligomeric species of nucleoside diphosphate kinase are involved in different cellular processes where the enzymatic activity is not required.	Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, CNRS URA 1149, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Veron, M (corresponding author), Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, CNRS URA 1149, 25 Rue Dr Roux, F-75724 Paris 15, France.	mveron@pasteur.fr	Karlsson, Anna/E-7945-2018; , AGOU/GXA-2760-2022	Karlsson, Anna/0000-0001-6843-6685				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DevilleBonne D, 1996, BIOCHEMISTRY-US, V35, P14643, DOI 10.1021/bi960945m; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; Giartosio A, 1996, J BIOL CHEM, V271, P17845, DOI 10.1074/jbc.271.30.17845; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; Jaenicke R, 1986, Methods Enzymol, V131, P218; Karlsson A, 1996, J BIOL CHEM, V271, P19928, DOI 10.1074/jbc.271.33.19928; LASCU I, 1993, J BIOL CHEM, V268, P20268; Lascu I, 1997, J BIOL CHEM, V272, P15599, DOI 10.1074/jbc.272.25.15599; LASCU I, 1992, J BIOL CHEM, V267, P12775; LASCU I, 1994, J BIOL CHEM, V269, P7046; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lu Q, 1996, J BIOL CHEM, V271, P32886, DOI 10.1074/jbc.271.51.32886; Mesnildrey S, 1997, FEBS LETT, V418, P53, DOI 10.1016/S0014-5793(97)01292-1; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; MORERA S, 1994, J MOL BIOL, V243, P373; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; SEGEL IH, 1975, ENZYME KINETICS, P608; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STURTEVANT AH, 1956, GENETICS, V41, P118; TEPPER AD, 1994, J BIOL CHEM, V269, P32175; Timmons L, 1997, ADV GENET, V35, P207, DOI 10.1016/S0065-2660(08)60451-4; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673	37	40	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4436	4442		10.1074/jbc.273.8.4436	http://dx.doi.org/10.1074/jbc.273.8.4436			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468495	Green Published, hybrid			2022-12-25	WOS:000072115000023
J	Spurkland, A; Brinchmann, JE; Markussen, G; Pedeutour, F; Munthe, E; Lea, T; Vartdal, E; Aasheim, HC				Spurkland, A; Brinchmann, JE; Markussen, G; Pedeutour, F; Munthe, E; Lea, T; Vartdal, E; Aasheim, HC			Molecular cloning of a T cell-specific adapter protein (TSAd) containing an Src homology (SH) 2 domain and putative SH3 and phosphotyrosine binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TYROSINE KINASE; CYTOPLASMIC PROTEIN; LYMPHOCYTES-B; EXPRESSION; PEPTIDES; GENE; IDENTIFICATION; HYBRIDIZATION; VIRUS	Adapter proteins link catalytic signaling proteins to cell surface receptors or downstream effector proteins. In this paper, we present the cDNA sequence F2771, isolated from an activated CD8+ T cell cDNA library. The F2771 cDNA encodes a novel putative adapter protein. The predicted amino acid sequence includes an SH2 domain as well as putative SH3 and phosphotyrosine binding interaction motifs, but lacks any known catalytic domains, The expression of the gene is limited to tissues of the immune system and, in particular, activated T cells. The protein expressed by F2771 cDNA in transfected COS cells is localized in the cytoplasm. A polyclonal antiserum raised against an F2771-encoded peptide reacts with a tyrosine-phosphorylated 52-kDa protein expressed in phytohemagglutinin-stimulated peripheral blood mononuclear cells. The gene is localized to chromosome 1q21, a region often found to be aberrant in lymphomas. The T cell-specific expression and the rapid induction of mRNA expression upon receptor binding, as well as the lack of catalytic domains in the presence of protein interaction domains, indicate that the F2771 gene encodes a novel T cell-specific adapter protein (TSAd) involved in the control of T cell activation.	Natl Hosp Norway, Inst Transplantat Immunol, N-0027 Oslo, Norway; Natl Hosp Norway, Inst Immunol & Rheumatol, N-0027 Oslo, Norway; Norwegian Radium Hosp, Dept Immunol, N-0310 Oslo, Norway; Fac Med Nice, CNRS, URA, Nice, France	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Oslo; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Spurkland, A (corresponding author), Natl Hosp Norway, Inst Transplantat Immunol, N-0027 Oslo, Norway.		Spurkland, Anne/L-3369-2019; Munthe, Else/O-3576-2017	Spurkland, Anne/0000-0003-4421-0766; Munthe, Else/0000-0003-3859-1582				Aasheim Hans-Christian, 1996, V69, P115; AASHEIM HC, 1994, BIOTECHNIQUES, V16, P716; BRINCHMANN JE, 1989, J VIROL METHODS, V25, P293, DOI 10.1016/0166-0934(89)90056-6; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Coligan J, 1995, CURRENT PROTOCOLS IM; COOKE M P, 1989, New Biologist, V1, P66; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; FUHLBRIGGE RC, 1987, J IMMUNOL, V138, P3799; FUNDERUD S, 1990, EUR J IMMUNOL, V20, P201, DOI 10.1002/eji.1830200129; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAMBERT KN, 1993, NUCLEIC ACIDS RES, V21, P775, DOI 10.1093/nar/21.3.775; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Margolis B, 1996, J LAB CLIN MED, V128, P235, DOI 10.1016/S0022-2143(96)90022-0; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Omri B, 1996, J NEUROCHEM, V67, P1360; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEDEUTOUR F, 1994, GENOMICS, V19, P31, DOI 10.1006/geno.1994.1008; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PRATT JC, 1996, IMMUNOLOGIST, V4, P122; RASMUSSEN AM, 1992, J IMMUNOL METHODS, V146, P195, DOI 10.1016/0022-1759(92)90228-L; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Takaki S, 1997, J BIOL CHEM, V272, P14562, DOI 10.1074/jbc.272.23.14562; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WHANGPENG J, 1995, BLOOD, V85, P203, DOI 10.1182/blood.V85.1.203.bloodjournal851203; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZENNER G, 1995, BIOESSAYS, V17, P967, DOI 10.1002/bies.950171110	49	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4539	4546		10.1074/jbc.273.8.4539	http://dx.doi.org/10.1074/jbc.273.8.4539			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468509	hybrid			2022-12-25	WOS:000072115000037
J	Heikinheimo, L; Somerharju, P				Heikinheimo, L; Somerharju, P			Preferential decarboxylation of hydrophilic phosphatidylserine species in cultured cells - Implications of the mechanism of transport to mitochondria and cellular aminophospholipid species compositions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN-2; HAMSTER OVARY CELLS; RAT-LIVER MITOCHONDRIA; LIPID TRANSFER PROTEIN; PERFORMANCE LIQUID-CHROMATOGRAPHY; PERMEABILIZED ANIMAL-CELLS; PHOSPHOLIPID TRANSFER; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; LIPOPROTEIN SECRETION	In baby hamster kidney and other cultured cells the majority of phosphatidylethanolamine (PE) is synthesized from phosphatidylserine (PS) in a process which involves transport of PS from the endoplasmic reticulum to mitochondria and decarboxylation therein by PS decarboxylase. To study the mechanism of this transport process, we first determined the molecular species composition of PE and PS from baby hamster kidney and Chinese hamster ovary cells. Interestingly, the hydrophilic diacyl molecular species were found to be much more abundant in PE than in PS, suggesting that hydrophilic PS species may be more readily transported to mitochondria than the hydrophobic ones. To study this, me compared the rates of decarboxylation of different PS molecular species in these cells. The cells were pulse labeled with [H-3]serine whereafter the distribution of the labels among PS and PE molecular species was determined by reverse phase high performance liquid chromatography and liquid scintillation counting. The hydrophilic PE species contained relatively much more H-3 label than those of PS, which indicates that they are more readily decarboxylated than the hydrophobic ones. Control experiments showed that differences in [H-3]PS and -PE molecular species profiles are not due to (i) incorporation of H-3 label to some PE species via alternative pathways, (ii) differences in degradation or remodeling among species, or (iii) selective decarboxylation of PS molecular species by the enzyme. Therefore, hydrophilic PS species are indeed decarboxylated faster than the hydrophobic ones. The rate of decarboxylation decreased systematically with hydrophobicity, strongly suggesting that formation of so called activated monomers, i.e. lipid molecules perpendicularly displaced from the membrane (Jones, J. D., and Thompson, T. E. (1990) Biochemistry 29, 1593-1600), is the rate-limiting step in the transport of PS from the endoplasmic reticulum to mitochondria. The formation of activated monomers and thus the rate of transfer is probably greatly enhanced by frequent collisions between the two membranes which tend to be closely associated. The present data also provides a feasible explanation why hydrophilic molecular species in these cells are much more abundant in PE as compared with PS, its immediate precursor.	Univ Helsinki, Dept Med Chem, Inst Biomed, Helsinki 00014, Finland	University of Helsinki	Somerharju, P (corresponding author), Univ Helsinki, Dept Med Chem, Inst Biomed, POB 8, Helsinki 00014, Finland.	pentti.somerharju@helsinki.fi						ACHLEITNER G, 1995, J BIOL CHEM, V270, P29836; Allan D, 1996, MOL MEMBR BIOL, V13, P81, DOI 10.3109/09687689609160580; ARDAIL D, 1993, J BIOL CHEM, V268, P25985; ARTHUR G, 1993, BIOCHEM J, V293, P125, DOI 10.1042/bj2930125; BJERVE KS, 1985, BIOCHIM BIOPHYS ACTA, V833, P396, DOI 10.1016/0005-2760(85)90096-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORKENHAGEN L, 1961, J BIOL CHEM, V236, pPC28; CHEN H, 1993, J LIPID RES, V34, P2159; Christie W., 1989, GAS CHROMATOGRAPHY L; COMFURIUS P, 1990, J LIPID RES, V31, P1719; CRAIN RC, 1980, BIOCHIM BIOPHYS ACTA, V620, P37, DOI 10.1016/0005-2760(80)90182-4; DENNIS EA, 1972, J LIPID RES, V13, P263; DERZKO Z, 1980, BIOCHEMISTRY-US, V19, P6050, DOI 10.1021/bi00567a016; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; DYGAS A, 1989, ACTA BIOCHIM POL, V36, P131; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2857, DOI 10.1021/bi00333a007; FRANKE WW, 1971, PROTOPLASMA, V73, P35, DOI 10.1007/BF01286409; GAIGG B, 1996, BIOCHIM BIOPHYS ACTA, V1234, P214; GURD FRN, 1960, LIPID CHEM, P208; Han XL, 1995, J AM SOC MASS SPECTR, V6, P1202, DOI 10.1016/1044-0305(95)00568-4; HANADA K, 1992, J BIOL CHEM, V267, P23527; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; HOVIUS R, 1992, J BIOL CHEM, V267, P16790; HULLIN F, 1989, J LIPID RES, V30, P1963; JASINSKA R, 1993, BIOCHIM BIOPHYS ACTA, V1152, P161, DOI 10.1016/0005-2736(93)90243-S; JONES JD, 1990, BIOCHEMISTRY-US, V29, P1593, DOI 10.1021/bi00458a034; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KOBAYASHI T, 1991, J CELL BIOL, V113, P235, DOI 10.1083/jcb.113.2.235; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1986, J BIOL CHEM, V261, P5795; MASSEY JB, 1984, BIOCHIM BIOPHYS ACTA, V794, P274, DOI 10.1016/0005-2760(84)90156-5; MASSEY JB, 1982, BIOCHEMISTRY-US, V21, P3630, DOI 10.1021/bi00258a016; MEDLOCK KA, 1988, BIOCHEMISTRY-US, V27, P7079, DOI 10.1021/bi00418a061; MEGLI FM, 1986, BIOCHIM BIOPHYS ACTA, V861, P463, DOI 10.1016/0005-2736(86)90455-4; MENDISHANDAGAMA SMLC, 1995, TISSUE CELL, V27, P483, DOI 10.1016/S0040-8166(05)80056-4; MILLER MA, 1986, J BIOL CHEM, V261, P9753; NICHOLS JW, 1983, J BIOL CHEM, V258, P5368; NICHOLS JW, 1988, BIOCHEMISTRY-US, V27, P3925, DOI 10.1021/bi00411a006; PATTON GM, 1990, METHOD ENZYMOL, V187, P195; PATTON GM, 1982, J LIPID RES, V23, P190; POWNALL HJ, 1991, BIOCHEMISTRY-US, V30, P5696, DOI 10.1021/bi00237a009; SAMBORSKI RW, 1993, BIOCHIM BIOPHYS ACTA, V1167, P15, DOI 10.1016/0005-2760(93)90211-Q; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; SHIAO YJ, 1995, BIOCHEM J, V310, P673, DOI 10.1042/bj3100673; SILVIUS JR, 1993, BIOCHEMISTRY-US, V32, P13318, DOI 10.1021/bi00211a045; VANAMERONGEN A, 1989, BIOCHIM BIOPHYS ACTA, V1004, P36, DOI 10.1016/0005-2760(89)90209-9; VANCE JE, 1986, J BIOL CHEM, V261, P4486; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1991, J BIOL CHEM, V266, P89; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANCE JE, 1988, BIOCHIM BIOPHYS ACTA, V963, P70, DOI 10.1016/0005-2760(88)90339-6; VANHAREN L, 1992, BIOCHIM BIOPHYS ACTA, V1124, P288; VANHEUSDEN GPH, 1990, J BIOL CHEM, V265, P4105; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WIMLEY WC, 1991, BIOCHEMISTRY-US, V30, P1702, DOI 10.1021/bi00220a036; XU ZL, 1991, J BIOL CHEM, V266, P2143; YOREK MA, 1985, J BIOL CHEM, V260, P2930; ZBOROWSKI J, 1983, FEBS LETT, V157, P179, DOI 10.1016/0014-5793(83)81141-7; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	65	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3327	3335		10.1074/jbc.273.6.3327	http://dx.doi.org/10.1074/jbc.273.6.3327			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452450	hybrid			2022-12-25	WOS:000071822300035
J	Kemppainen, RJ; Behrend, EN				Kemppainen, RJ; Behrend, EN			Dexamethasone rapidly induces a novel Ras superfamily member-related gene in AtT-SO cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITION; PROTEINS; FAMILY; MOTIFS	Differential display was used to identify a new Ras superfamily gene (Dexras1) induced by dexamethasone (Dex) in AtT-20 cells. Treatment of AtT-20 cells with Dex for 30 min resulted in increased mRNA for Dexras1; the highest concentrations appeared after 2 h of treatment, The gene was also identified in mouse heart, brain, liver, and kidney and furthermore was induced in these tissues after Dex treatment, The deduced protein shows regions of homology characteristic of members of the Ras superfamily of small GTPases, Highest homology (36% identity, 57% positives) was found with human Rap-ab, followed closely by a number of other Ras subfamily members, suggesting that Dexras1 is probably a member of the Ras subfamily of GTPases (members include Ras and Rap). Dexras1 is the first Ras superfamily member identified that is induced in response to steroids. The function of this gene is unknown; however, its wide distribution and rapid induction by Dex suggests the possibility of a role in glucocorticoid action in a variety of tissues.	Auburn Univ, Coll Vet Med, Dept Physiol & Pharmacol, Auburn, AL 36849 USA	Auburn University System; Auburn University	Kemppainen, RJ (corresponding author), Auburn Univ, Coll Vet Med, Dept Physiol & Pharmacol, 213 Greene Hall, Auburn, AL 36849 USA.		Behrend, Ellen N/C-3215-2018; Kemppainen, Robert/X-9105-2019	Behrend, Ellen N/0000-0002-5010-2983; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R15DK047975, K08DK002400] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47975, K08 DK02400] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CLARK TP, 1994, AM J PHYSIOL, V267, pR463, DOI 10.1152/ajpregu.1994.267.2.R463; DelVillar K, 1996, BIOCHEM SOC T, V24, P709; DSilva NJ, 1997, J HISTOCHEM CYTOCHEM, V45, P965, DOI 10.1177/002215549704500706; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Orth DN, 1992, WILLIAMS TXB ENDOCRI, P489; SHIPSTON MJ, 1995, TRENDS ENDOCRIN MET, V6, P261, DOI 10.1016/1043-2760(95)00149-2; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WOODS MD, 1992, ENDOCRINOLOGY, V131, P2873, DOI 10.1210/en.131.6.2873; ZERIAL M, 1995, GUIDEBOOK SMALL GTPA; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	16	133	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3129	3131		10.1074/jbc.273.6.3129	http://dx.doi.org/10.1074/jbc.273.6.3129			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452419	hybrid			2022-12-25	WOS:000071822300004
J	Stanley, P; Hogg, N				Stanley, P; Hogg, N			The I domain of integrin LFA-1 interacts with ICAM-1 domain 1 at residue Glu-34 but not Gln-73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; INTERCELLULAR-ADHESION MOLECULE-3; BINDING-SITE; CONTAINS; ALPHA-4-BETA-1; ARRANGEMENT; RECEPTOR; DISTINCT; LIGANDS	Using a solid phase assay, we show that isolated LFA-1 I domain binds ICAM-1 in a Mg2+-dependent manner and is blocked by anti-I domain monoclonal antibodies. This activity mirrors that of the intact receptor (Dransfield, I., Cabanas, C., Craig, A., and Hogg, N. (1992) J. Cell Biob. 116, 219-226) and suggests that the I domain controls divalent cation-dependent receptor function. In ICAM-1, domain 1 residues Glu-34 and Gln-73 have been identified as critical for binding of LFA-1 as an intact receptor (Staunton, D. E., Dustin, M. L., Erickson, H. P., and Springer, T. A. (1990) Cell 61, 243-254). For the first time, we show that isolated I domain binds to domain 1 of ICAM-1 and that this interaction is inhibited partially by mutation of Glu-34 but not by Gln-73. The anti-ICAM-1 monoclonal antibody RR1/1, which maps to Gln-73 (Staunton, D. E., Dustin, M. L., Erickson, H. P., and Springer, T. A. (1990) Cell 61, 243-254), enhances I domain binding, suggesting potential allosteric control or coordinate binding by this region. Finally, I domain binding inhibited by Glu-34 ICAM-1 mutation correlates with divalent cation dependence, indicating that this residue might be in direct contact with the metal ion-dependent adhesion site. Thus, we describe the interaction between the LFA-1 I domain and ICAM-1, an event that controls the function of the intact receptor but includes only part of the complete ligand binding site.	Imperial Canc Res Fund, Leukocyte Adhes Lab, London WC2A 3PX, England	Cancer Research UK	Hogg, N (corresponding author), Imperial Canc Res Fund, Leukocyte Adhes Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.							BEBBINGTON CR, 1992, BIO-TECHNOL, V10, P169, DOI 10.1038/nbt0292-169; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BERGELSON JM, 1995, CURR BIOL, V5, P615, DOI 10.1016/S0960-9822(95)00124-2; Casasnovas JM, 1997, NATURE, V387, P312, DOI 10.1038/387312a0; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Fisher KL, 1997, MOL BIOL CELL, V8, P501, DOI 10.1091/mbc.8.3.501; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; GRAVES BJ, 1995, NAT STRUCT BIOL, V2, P181, DOI 10.1038/nsb0395-181; Hogg Nancy, 1994, Trends in Cell Biology, V4, P379, DOI 10.1016/0962-8924(94)90044-2; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; JAKUBOWSKI A, 1995, CELL ADHES COMMUN, V3, P131, DOI 10.3109/15419069509081282; KAMATA T, 1994, J BIOL CHEM, V269, P26006; Klickstein LB, 1996, J BIOL CHEM, V271, P23920, DOI 10.1074/jbc.271.39.23920; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; LOFTUS JC, 1997, J CLIN INVEST, V99, P23025; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RANDI AM, 1994, J BIOL CHEM, V269, P12395; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; SADHU C, 1994, CELL ADHES COMMUN, V2, P429, DOI 10.3109/15419069409004453; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Welply JK, 1996, PROTEINS, V26, P262, DOI 10.1002/(SICI)1097-0134(199611)26:3<262::AID-PROT3>3.0.CO;2-G	30	47	53	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3358	3362		10.1074/jbc.273.6.3358	http://dx.doi.org/10.1074/jbc.273.6.3358			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452454	hybrid			2022-12-25	WOS:000071822300039
J	Antonyak, MA; Moscatello, DK; Wong, AJ				Antonyak, MA; Moscatello, DK; Wong, AJ			Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; EGF RECEPTOR; STRESS; PATHWAY; ERK; JNK; TRANSFORMATION	Epidermal growth factor receptor (EGF) variant type III (EGFRvIII) is a constitutively active, naturally occurring mutation of the EGF receptor that is found in many types of human tumors. When overexpressed in NIH3T3 fibroblasts, EGFRvIII induces transformation by enhancing cell growth and reducing apoptosis, Analysis of downstream signaling pathways has revealed that extracellular signal-regulated kinase activity is down-regulated, raising doubt as to the significance of this pathway in promoting transformation, We investigated whether the c-Jun N-terminal kinase (JNK) pathway was affected by EGFRvIII. NIH3T3 cells expressing EGFRvIII exhibited a high basal level of JNK activity, which was not present in cells overexpressing the normal EGF receptor, Treatment of cells overexpressing EGFRvIII with inhibitors of the EGF receptor or phosphatidylinositol 3-kinase resulted in the down-regulation of JNK activity. Furthermore, the down-regulation of JNK activity was associated with a loss of properties related to transformation, and there was no evidence for JNK activity in the promotion of apoptosis in these cells. These findings implicate constitutive activation of the JNK pathway in transformation by EGFRvIII.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Wong, AJ (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.	a_wong@lac.jci.tju.edu			NCI NIH HHS [CA69495, CA51093] Funding Source: Medline; NIDDK NIH HHS [5-T32-DK07705-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051093, R01CA069495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007705] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; Greulich H, 1996, ONCOGENE, V12, P1689; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HARRIS AL, 1992, NATL CANC I MONOGR, V11, P181; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOBAYASHI M, 1997, J BIOL CHEM, V272, P1608; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHLEGEL J, 1994, INT J CANCER, V56, P72; Stofega MR, 1997, CELL GROWTH DIFFER, V8, P113; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	42	138	142	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2817	2822		10.1074/jbc.273.5.2817	http://dx.doi.org/10.1074/jbc.273.5.2817			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446590	hybrid			2022-12-25	WOS:000071736600045
J	Legesse-Miller, A; Sagiv, Y; Porat, A; Elazar, Z				Legesse-Miller, A; Sagiv, Y; Porat, A; Elazar, Z			Isolation and characterization of a novel low molecular weight protein involved in intra-Golgi traffic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; ENDOPLASMIC-RETICULUM; N-ACETYLGLUCOSAMINE; FUSION PROTEIN; GENE-PRODUCT; YEAST; VESICLES; NSF; PURIFICATION; MEMBRANE	Analysis of the cytosolic requirements for in vitro intra-Golgi transport led to the characterization of three proteins: N-ethylmaleimide-sensitive fusion protein (NSF), soluble NSF attachment protein (SNAP), and p115, all involved in the docking and fusion of transport vesicles to their target membranes, In the course of determining the minimal cytosolic requirements for intra-Golgi transport in vitro, we identified three additional factors that are sufficient to replace crude cytosol, We describe here the purification and characterization of one of these factors, a novel 16-kDa protein, p16, an essential factor for intra-Golgi protein transport, Based on transport activity, this purification procedure resulted in similar to 1,400-fold enrichment of pie to apparent homogeneity. The activity of pie could be observed in the absence of vesicle formation, suggesting that it may participate in the docking and fusion processes.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elazar, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	bmzevi@weizmann.weizmann.ac.il						BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BLOCK MR, 1992, METHOD ENZYMOL, V219, P300; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Mayer T, 1996, J BIOL CHEM, V271, P16097, DOI 10.1074/jbc.271.27.16097; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; ORCI L, 1991, CELL, V64, P1183; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PEREZ M, 1985, J BIOL CHEM, V260, P4671; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SZTUL E, 1993, J BIOL CHEM, V268, P1876; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	34	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3105	3109		10.1074/jbc.273.5.3105	http://dx.doi.org/10.1074/jbc.273.5.3105			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446628	hybrid			2022-12-25	WOS:000071736600083
J	Sugihara, T; Wadhwa, R; Kaul, SC; Mitsui, Y				Sugihara, T; Wadhwa, R; Kaul, SC; Mitsui, Y			A novel alternatively spliced form of murine vascular endothelial growth factor, VEGF 115	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCED EXPRESSION; TUMOR-GROWTH; IDENTIFICATION; ANGIOGENESIS; FIBROBLASTS; CELLS; IMMORTALIZATION; FAMILY; INVIVO	Murine immortal fibroblasts express a form of vascular endothelial growth factor (VEGF) that was cloned, characterized and named VEGF 115, It differs from VEGF 120 by 37 amino acids at the carboxyl terminus, VEGF 115-specific sequence reacted to a single transcript in mouse tissues, Reverse transcription-polymerase chain reaction was performed in mouse tissues and in fibroblasts of normal and immortal divisional phenotypes. The data from mouse tissues suggested that VEGF 115 is not a tissue-specific isoform of VEGF 120, whereas a functional relevance with immortalization is indicated from the latter, The novel cDNA was expressed in Escherichia coli, and the His-tagged VEGF 115 (17.2 kDa) thus obtained was recognized by anti-VEGF antibody, A mammalian expression plasmid, pCMV(neo+), encoding for VEGF 115 was transfected to NIH 3T3 cells, and the conditioned medium of stable transfectants was found to have fibroblast growth factor-replacing activity for human umbilical vein endothelial cells. Two independent genomic PI clonings with primers specific for VEGF 164 and VEGF 115, respectively, resulted in isolation of identical P1 clones, We analyzed these three P1 clones on Southern blots with common and specific probes for VEGF 164 and VEGF 115. The results support the hypothesis that VEGF 115 is a new alternatively spliced form of mouse VEGF.	Agcy Ind Sci & Technol, Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan; Chugai Res Inst Mol Med, Niihari, Ibaraki 30041, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Sugihara, T (corresponding author), Agcy Ind Sci & Technol, Natl Inst Biosci & Human Technol, 1-1 Higashi, Tsukuba, Ibaraki 305, Japan.		Wadhwa, Renu/L-8898-2018; Kaul, Sunil C/L-8671-2018	Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916				BACIC M, 1995, GROWTH FACTORS, V12, P11, DOI 10.3109/08977199509003209; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; ENOMOTO T, 1994, BIOCHEM BIOPH RES CO, V202, P1716, DOI 10.1006/bbrc.1994.2133; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; KAUL SC, 1994, BBA-GEN SUBJECTS, V1201, P389, DOI 10.1016/0304-4165(94)90067-1; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KONDO S, 1995, BBA-GEN SUBJECTS, V1243, P195, DOI 10.1016/0304-4165(94)00150-V; KUMAZAKI T, 1993, EXP CELL RES, V205, P396, DOI 10.1006/excr.1993.1103; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; Sambrook J., 2002, MOL CLONING LAB MANU; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; SUGIHARA T, 1994, BBA-MOL CELL RES, V1224, P365, DOI 10.1016/0167-4889(94)90269-0; TAKAHASHI A, 1994, CANCER RES, V54, P4233; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WHEELER T, 1995, PLACENTA, V16, P289, DOI 10.1016/0143-4004(95)90115-9; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213	26	40	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3033	3038		10.1074/jbc.273.5.3033	http://dx.doi.org/10.1074/jbc.273.5.3033			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446618	hybrid			2022-12-25	WOS:000071736600073
J	Kao, MC; Liu, GY; Chuang, TC; Lin, YS; Wuu, JA; Law, SL				Kao, MC; Liu, GY; Chuang, TC; Lin, YS; Wuu, JA; Law, SL			The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene	ONCOGENE			English	Article						HER-2/neu; SV30 large T antigen; p185; cancer gene therapy	E1A GENE-PRODUCTS; LARGE TUMOR-ANTIGEN; VIRUS-40 LARGE-T; NEU ONCOGENE; OVARIAN-CANCER; PROTO-ONCOGENE; EGF RECEPTOR; TRANSCRIPTIONAL REPRESSION; C-ERBB-2 GENE; BREAST-CANCER	The deregulation of the HER-2/neu protooncogene was demonstrated in a wide variety of human cancers and shown to be correlated with the progress of malignancy and metastasis in animal models. Repression of HER-2/neu overexpression suppressed the malignant phenotypes of HER-2/neu-overexpressing cancer cells. This suggested that HER-2/neu may be a good target for developing anti-cancer drugs, We found a deletion mutant of simian virus 40 (SV40) large T antigen (LT) suppresses the Her-2/neu oncogene expression at the transcriptional level, PCR clones of this mutant SV40LT, named LT425, which contains the N-terminal region of amino acid residues 1-178 of SV40LT, were subcloned and stably transfected into the HER-2/neu-overexpressing human ovarian cancer SKOV3.ip1 cells. These LT425 clones were found to be able to down-regulate the endogenous production of p185(HER-2/neu). In addition, the LT425-expressing stable transfectants showed reduced growth rate, low soft agarose colony forming ability, and low tumorigenic potential as compared with the parental line. These data suggested that the N-terminal 178 amino acids domain only of SV40LT may act as a transforming repressor of HER-2/neu oncogene.	Natl Def Med Ctr, Dept Biochem, Taipei 10764, Taiwan; Cheng Hsin Phys Med & Rehabil Ctr, Taipei, Taiwan; Vet Gen Hosp, Dept Med Res, Taipei 11217, Taiwan	National Defense Medical Center	Kao, MC (corresponding author), Natl Def Med Ctr, Dept Biochem, Taipei 10764, Taiwan.		Liu, Gary/A-6200-2009					Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERCHUCK A, 1990, CANCER RES, V50, P4087; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; CHUANG TC, 1996, THESIS NATL DEFENSE; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Cozen SD, 1995, ONCOGENE, V11, P2295; DEMILIA J, 1989, ONCOGENE, V4, P1233; Eckner R, 1996, MOL CELL BIOL, V16, P3454; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; GANNON JV, 1991, NATURE, V349, P802; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gu KF, 1996, CANCER LETT, V99, P185, DOI 10.1016/0304-3835(95)04061-7; HOU L, 1992, CANCER LETT, V65, P215, DOI 10.1016/0304-3835(92)90234-M; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; HUNG MC, 1986, BIOCH MOL EPIDEMIOL, V40, P391; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LOVELAND BE, 1992, BIOCHEM INT, V27, P501; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; MATIN A, 1993, CELL GROWTH DIFFER, V4, P1; MILLER SJ, 1994, INT J ONCOL, V4, P965; MITRA AB, 1994, CANCER RES, V54, P637; Monier R., 1986, PAPOVAVIRIDAE, V1, P247; Mymryk JS, 1996, ONCOGENE, V13, P1581; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PARK JB, 1989, CANCER RES, V49, P6605; REDDY VB, 1978, SCIENCE, V200, P494, DOI 10.1126/science.205947; ROBB JA, 1972, J VIROL, V9, P562, DOI 10.1128/JVI.9.3.562-563.1972; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SALZMAN NP, 1986, PAPOVAVIRIDAE, P27; SAWAI ET, 1994, VIROLOGY, V189, P782; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINER DB, 1990, CANCER RES, V50, P421; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; YOKOTA J, 1988, ONCOGENE, V2, P283; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZHANG X, 1989, ONCOGENE, V4, P985; ZHAU HE, 1990, MOL CARCINOGEN, V3, P254, DOI 10.1002/mc.2940030503	63	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					547	554		10.1038/sj.onc.1201513	http://dx.doi.org/10.1038/sj.onc.1201513			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484845				2022-12-25	WOS:000071739400014
J	Li, CD; Larsson, C; Futreal, A; Lancaster, J; Phelan, C; Aspenblad, U; Sundelin, B; Liu, Y; Ekman, P; Auer, G; Bergerheim, USR				Li, CD; Larsson, C; Futreal, A; Lancaster, J; Phelan, C; Aspenblad, U; Sundelin, B; Liu, Y; Ekman, P; Auer, G; Bergerheim, USR			Identification of two distinct deleted regions on chromosome 13 in prostate cancer	ONCOGENE			English	Article						prostate cancer; chromosome 13; BRCA2; Rb1; pRb; DBM	RETINOBLASTOMA SUSCEPTIBILITY GENE; COMPARATIVE GENOMIC HYBRIDIZATION; ALLELIC LOSS; IN-SITU; BREAST; BRCA2; HETEROZYGOSITY; CARCINOMA; MUTATIONS; PROTEIN	Aberrations of 13q occur frequently in prostate cancer and this chromosome contains two known tumor suppressor genes, BRCA2 and Rb1. This study analysed 13q LOH, DNA ploidy, BRCA2 mutation and pRb expression in prostate cancers, In total, 13q deletions were found in 18 of 36 tumors but did not correlate with histological grade, stage or DNA ploidy. Two smallest regions of overlapping deletions were defined: one flanked by D13S218 and D13S153; the other flanked by D13S31 and D13S137. BRCA2 was less frequently deleted ,whereas Rb1 did have a high frequency of deletion. None of the two genes was located in any of these two regions, Furthermore, BRCA2 mutation was not found in the five tumors where deletions had involved the BRCA2 locus, Neither did the Rb1 deletion correlate with absent pRb expression. In addition, tetraploidy was found in 14 out of 25 tumors analysed and correlated with aberrant pRb expression. Our results indicate that 13q deletion is an early non-random event, Tumor suppressor genes other than BRCA2 or Rb1 may be the target of 13q deletions. Aberrant pRb expression was not reflect the tyro-hit Rb1 inactivation but may be involved in the tetraploidization of prostate cancer cells.	Karolinska Hosp, Dept Urol, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Mol Med, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Pathol, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Oncol, S-17176 Stockholm, Sweden; Duke Univ, Med Ctr, Dept Surg, Div Gynecol Oncol, Durham, NC 27710 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Duke University	Li, CD (corresponding author), Karolinska Hosp, Dept Urol, S-17176 Stockholm, Sweden.			Auer, Gert/0000-0003-3911-0285; Li, Chunde/0000-0003-4331-079X	NCI NIH HHS [P50-CA68438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA068438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; Cher ML, 1996, CANCER RES, V56, P3091; CLETONJANSEN AM, 1995, BRIT J CANCER, V72, P1241, DOI 10.1038/bjc.1995.493; Cooney KA, 1996, CANCER RES, V56, P1142; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Herzog H, 1996, GENOME RES, V6, P858, DOI 10.1101/gr.6.9.858; HSIEH CL, 1990, SOMAT CELL MOLEC GEN, V16, P567, DOI 10.1007/BF01233097; JEWITT HJ, 1975, UROL CLIN N AM, V2, P105; Kubota Y, 1995, PROSTATE, V27, P314, DOI 10.1002/pros.2990270604; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEONARDO AD, 1997, CANCER RES, V57, P1013; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; Maestro R, 1996, CANCER RES, V56, P1146; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MOSTOFI FK, 1980, 10 WHO INT HIST CLAS; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Pearce SHS, 1996, CLIN ENDOCRINOL, V45, P195, DOI 10.1046/j.1365-2265.1996.d01-1561.x; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; PHILLIPS SMA, 1994, BRIT J CANCER, V70, P1252, DOI 10.1038/bjc.1994.482; RADFORD DM, 1995, CANCER RES, V55, P3399; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; STEINBECK RG, 1994, ANAL QUANT CYTOL, V16, P196; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; Tricoli JV, 1996, GENE CHROMOSOME CANC, V15, P108, DOI 10.1002/(SICI)1098-2264(199602)15:2<108::AID-GCC5>3.0.CO;2-7; VISAKORPI T, 1995, CANCER RES, V55, P342; Whitmore Jr WF, 1956, AM J MED, V21, P697; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YANGFENG TL, 1992, INT J CANCER, V52, P575, DOI 10.1002/ijc.2910520414; ZHANG X, 1994, CANCER RES, V54, P4177	34	71	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					481	487		10.1038/sj.onc.1201554	http://dx.doi.org/10.1038/sj.onc.1201554			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484837				2022-12-25	WOS:000071739400006
J	Pyles, RB; Santoro, IM; Groden, J; Parysek, LM				Pyles, RB; Santoro, IM; Groden, J; Parysek, LM			Novel protein isoforms of the APC tumor suppressor in neural tissue	ONCOGENE			English	Article						APC; tumor suppressor; neural tissue; protein isoforms	MULTIPLE INTESTINAL NEOPLASIA; COLORECTAL-CANCER; BRAIN-TUMORS; GENE-PRODUCT; WILD-TYPE; ASSOCIATION; COLI; IDENTIFICATION; EXPRESSION; MUTATIONS	The conventional protein isoform of the APC tumor suppressor is 310 kD and is encoded by exons 1-15 of the APC gene, Other RNAs are expressed from the APC gene and include one form that contains an exon upstream of exon 1, designated BS, but this transcript does not include exon 1, This transcript recently has been shown to be enriched in non-dividing, terminally-differentiated cells (Santoro and Groden, 1997). To determine if the BS-containing transcript encoded an alternate APC protein isoform, we generated and affinity-purified a polyclonal antibody directed to protein sequence predicted by exon BS, The BS antibody labeled a band of similar to 300 kD on immunoblots of cerebral and cerebellar tissue from adult human, baboon, rat and mouse, These same tissue lysates also contained prominent BS-reactive proteins of 290 kD, 200 kD and 150 kD, Lysates from mitotically active cells did not contain these APC isoforms, To verify that BS-reactive proteins were APC isoforms, BS-immunoprecipitates were blotted and labeled with commercially available APC antibodies, All four high molecular weight BS-antibody-precipitated proteins were recognized by antibodies directed against epitopes encoded by APC exons 2 and 15. BS isoforms were not, however, labeled with antibodies to an epitope encoded by APC exon 1, consistent with the prediction that BS-APC isoforms lack the domain encoded by these sequences, Like conventional APC, at least one of the four BS-APC protein isoforms also interacts with beta-catenin. BS-APC isoforms that lack exon 1-encoded sequences are incapable of dimerization with the conventional form of APC, yet retain the ability to bind beta-catenin, Such isoforms are likely to be functionally distinct from the conventional APC protein.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Neurobiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Anat, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Pyles, RB (corresponding author), Childrens Hosp Res Fdn, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NCI NIH HHS [CA-63507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063507, R01CA063507] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHAT RV, 1994, J NEUROSCI, V14, P3059; CARRARO U, 1983, BIOCHEM BIOPH RES CO, V116, P793, DOI 10.1016/S0006-291X(83)80212-5; GRODEN J, 1995, CANCER RES, V55, P1531; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRODEN J, 1995, NEW ENGL J MED, V332, P884, DOI 10.1056/NEJM199503303321310; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Harlow E., 1988, ANTIBODIES LAB MANUA; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kraus C, 1996, INT J CANCER, V65, P383, DOI 10.1002/(SICI)1097-0215(19960126)65:3<383::AID-IJC18>3.3.CO;2-U; LUONGO C, 1994, CANCER RES, V54, P5947; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MIYASHIRO I, 1995, ONCOGENE, V11, P89; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Santoro IM, 1997, CANCER RES, V57, P488; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1993, CANCER RES, V53, P2728; SULEKOVA Z, 1995, INT J CANCER, V63, P435, DOI 10.1002/ijc.2910630323; TAINER JA, 1984, NATURE, V312, P127, DOI 10.1038/312127a0; THLIVERIS A, 1994, CANCER RES, V54, P2991; Yamamoto H, 1996, CANCER RES, V56, P3605	31	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					77	82		10.1038/sj.onc.1201505	http://dx.doi.org/10.1038/sj.onc.1201505			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467945				2022-12-25	WOS:000071236800009
J	Baugh, RJ; Broze, GJ; Krishnaswamy, S				Baugh, RJ; Broze, GJ; Krishnaswamy, S			Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TICK ANTICOAGULANT PEPTIDE; HUMAN FACTOR-VII; COAGULATION INHIBITOR; PROTHROMBINASE COMPLEX; BLOOD-COAGULATION; CELL-SURFACES; STUART FACTOR; ACTIVATION; BINDING; MECHANISM	Tissue factor (TF) pathway inhibitor (TFPI) regulates factor X activation through the sequential inhibition of factor Xa and the VIIa.TF complex, Factor Xa formation was studied in a purified, reconstituted system, at plasma concentrations of factor X and TFPI, saturating concentrations of factor VIIa, and increasing concentrations of TF reconstituted into phosphatidylcholine: phosphatidylserine membranes (TF/PCPS) or PC membranes (TF/PC). The initial rate of factor Xa formation was equivalent in the presence or absence of 2.4 nM TFPI, However, reaction extent was small (<20%) relative to that observed in the absence of TFPI, implying the rapid inhibition of VIIa.TF during factor X activation, Initiation of factor Xa formation using increasing concentrations of TF/PCPS or TF/PC in the presence of TFPI yielded families of progress curves where both initial rate and reaction extent were linearly proportional to the concentration VIIa.TF. These observations were consistent with a kinetic model in which the rate-limiting step represents the initial inhibition of newly formed factor Xa. Numerical analyses of progress curves yielded a rate constant for inhibition of VIIa.TF by Xa.TFPI (>10(8) M-1.s(-1)) that was substantially greater than the value (7.34 +/- 0.8 x 10(6) M-1.s(-1)) directly measured. Thus, VIIa.TF is inhibited at near diffusion-limited rates by Xa.TFPI formed during catalysis which cannot be explained by studies of the isolated reaction, We propose that the predominant inhibitory pathway during factor X activation may involve the initial inhibition of factor Xa either bound to or in the near vicinity of VIIa.TF on the membrane surface. As a result, VIIa.TF inhibition is unexpectedly rapid, and the concentration of active factor Xa that escapes regulation is linearly dependent on the availability of TF.	Emory Univ, Dept Med, Div Hematol Oncol, Atlanta, GA 30322 USA; Washington Univ, Jewish Hosp, Div Hematol, St Louis, MO 63110 USA	Emory University; Barnes-Jewish Hospital; Washington University (WUSTL)	Krishnaswamy, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, 310 Abramson,324 S 34th St, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047465, R01HL034462] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-34462, R01 HL-47465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Bevington PR, 1969, DATA REDUCTION ERROR; BROZE GJ, 1985, J CLIN INVEST, V76, P937, DOI 10.1172/JCI112093; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1995, ANNU REV MED, V46, P103, DOI 10.1146/annurev.med.46.1.103; CALLANDER NS, 1992, J BIOL CHEM, V267, P876; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DAVID GS, 1972, BIOCHEM BIOPH RES CO, V48, P464, DOI 10.1016/S0006-291X(72)80074-3; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; GENTRY R, 1995, BIOPHYS J, V69, P362, DOI 10.1016/S0006-3495(95)79908-8; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GIRARD TJ, 1993, METHOD ENZYMOL, V222, P195; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HUANG ZF, 1993, J BIOL CHEM, V268, P26950; JESTY J, 1994, BIOCHEMISTRY-US, V33, P12686, DOI 10.1021/bi00208a020; JORDAN SP, 1992, BIOCHEMISTRY-US, V31, P5374, DOI 10.1021/bi00138a019; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; KRISHNASWAMY S, 1994, BIOCHEMISTRY-US, V33, P7897, DOI 10.1021/bi00191a017; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCHE Y, 1994, BIO-TECHNOL, V12, P1119, DOI 10.1038/nbt1194-1119; LAWSON JH, 1993, METHOD ENZYMOL, V222, P177; LINDHOUT T, 1994, BIOCHEM J, V297, P131, DOI 10.1042/bj2970131; LINDHOUT T, 1995, THROMB HAEMOSTASIS, V74, P910; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; MANN KG, 1990, BLOOD, V76, P1; Mason J T, 1978, Ann N Y Acad Sci, V308, P29, DOI 10.1111/j.1749-6632.1978.tb22012.x; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NEMERSON Y, 1992, SEMIN HEMATOL, V29, P170; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; NOVOTNY WF, 1991, BLOOD, V78, P394; NOVOTNY WF, 1991, BLOOD, V78, P387; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; RAO LVM, 1995, BLOOD, V85, P121, DOI 10.1182/blood.V85.1.121.bloodjournal851121; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; WALKER RK, 1994, J BIOL CHEM, V269, P27441; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WILLIAMS JW, 1979, BIOCHEMISTRY-US, V18, P2567, DOI 10.1021/bi00579a021	51	174	185	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4378	4386		10.1074/jbc.273.8.4378	http://dx.doi.org/10.1074/jbc.273.8.4378			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468488	hybrid			2022-12-25	WOS:000072115000016
J	Sharma, B; Iozzo, RV				Sharma, B; Iozzo, RV			Transcriptional silencing of perlecan gene expression by interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; FIBROBLAST GROWTH-FACTOR; COLON CARCINOMA-CELLS; BASEMENT-MEMBRANES; DOMAIN-III; BINDING; LOCALIZATION; MATRICES; MOLECULE; RECEPTOR	Perlecan, a heparan sulfate proteoglycan of basement membranes and cell surfaces, has been implicated in the control of tumor cell growth and metastasis because of its ability to bind and store growth factors and its activity as an inducer of angiogenesis. Because interferon-gamma (IFN-gamma), a cytokine with known antiproliferative and antitumoral activity, binds with known anti high affinity to the heparan sulfate side chains of perlecan, we investigate the activity of IFN-gamma on perlecan gene expression and cell growth in colon carcinoma cells. We found that IFN-gamma rapidly and efficiently blocked perlecan gene expression with concurrent growth suppression, a phenomenon that was independent of a functional p21(WAF1/CIP1). These effects were transcriptionally mediated, did not require new protein synthesis, and were fully reversible. Moreover, we found these IFN-gamma-induced effects to generalizable because they could be reproduced in a variety of cells with various histogenetic backgrounds. The transcriptional repression of the perlecan gene required intact Stat1 protein, and these effects were likely mediated by Stat1-binding sites in the distal promoter region. Thus, the IFN-gamma-mediated transcriptional repression of perlecan may represent a novel antitumoral effect of this cytokine through which it eliminates a powerful angiogenic stimulus.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, JAH, Philadelphia, PA 19107 USA	Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, JAH, Rm 249,1020 Locust St, Philadelphia, PA 19107 USA.	Iozzo@lac.jci.tju.edu	Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aviezer D, 1997, MOL CELL BIOL, V17, P1938, DOI 10.1128/MCB.17.4.1938; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BORNSTEIN P, 1989, PROG NUCLEIC ACID RE, V37, P67; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; CHEN TR, 1987, CANCER GENET CYTOGEN, V27, P125, DOI 10.1016/0165-4608(87)90267-6; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COHEN IR, 1994, CANCER RES, V54, P5771; COUCHMAN JR, 1995, J HISTOCHEM CYTOCHEM, V43, P955, DOI 10.1177/43.9.7543915; COUCHMAN JR, 1993, CELL SURFACE EXTRACE, P33; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Friedl A, 1997, AM J PATHOL, V150, P1443; GRASSEL S, 1995, MOL CELL BIOCHEM, V145, P61, DOI 10.1007/BF00925714; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; IOZZO RV, 1989, ARCH BIOCHEM BIOPHYS, V269, P239, DOI 10.1016/0003-9861(89)90105-7; Iozzo RV, 1997, J BIOL CHEM, V272, P5219, DOI 10.1074/jbc.272.8.5219; IOZZO RV, 1984, J CELL BIOL, V99, P403, DOI 10.1083/jcb.99.2.403; IOZZO RV, 1998, IN PRESS ANN REV BIO; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LORTAT-JACOB H, 1991, FEBS LETT, V280, P152, DOI 10.1016/0014-5793(91)80225-R; LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093; Mathiak M, 1997, CANCER RES, V57, P2130; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; Praillet C, 1996, FEBS LETT, V387, P109, DOI 10.1016/0014-5793(96)00468-1; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; TIMAR J, 1992, AM J PATHOL, V141, P467; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; WALDMAN T, 1995, CANCER RES, V55, P5187; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079	32	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4642	4646		10.1074/jbc.273.8.4642	http://dx.doi.org/10.1074/jbc.273.8.4642			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468523	hybrid			2022-12-25	WOS:000072115000051
J	Zhang, YL; Yu, NJ; Spremulli, LL				Zhang, YL; Yu, NJ; Spremulli, LL			Mutational analysis of the roles of residues in Escherichia coli elongation factor Ts in the interaction with elongation factor Tu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-EF-TU; CRYSTAL-STRUCTURE; COMPLEX	The crystal structure of the Escherichia coli elongation factor (EF)-Tu.Ts complex indicates that there are extensive contacts between EF-Tu and EF-Ts. To determine the importance of these contacts in the interaction between E. coli EF-Ta and EF-Ts, residues in EF-Ts at the interface of these two proteins were mutated, The binding constants governing the interaction of the resulting EF-Ts variants with E, coti EF-Tu were determined, The effects of these mutations on the ability of EF-Ts to stimulate GDP exchange with EF-Tu.GDP and on its ability to stimulate the activity of EF-Tu in polymerization were tested. The results indicate that Arg-12, Met-19, and Met-20 in the N-terminal domain of EF-Ts and His-147 and Lys-166 and/or His-167 in subdomain C of EF-Ts are crucial in the interaction between EF-Tu and EF-Ts. Lys-23, Val-234, Met-235, and the C-terminal helix his are less important, The binding constants of the EF-Ts variants governing their interactions with EF-Tu correlate well with their activities in stimulating GDP exchange with EF-Tu, Mutations prepared in EF-Tu indicate that His-19 and Gln-114 but not Glu-348 in EF-Tu are moderately important for its interaction with EF-Ts.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Res Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Spremulli, LL (corresponding author), Univ N Carolina, Dept Chem, Campus Box 3290, Chapel Hill, NC 27599 USA.	Linda_Spremulli@une.edu			NIGMS NIH HHS [GM32734] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOSCH L, 1983, PROG NUCLEIC ACID RE, V30, P91; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Clark BFC, 1997, CURR OPIN STRUC BIOL, V7, P110, DOI 10.1016/S0959-440X(97)80014-0; FOX L, 1980, J BIOL CHEM, V255, P6018; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, CURR BIOL, V1, P35; LI XM, 1993, NUCLEIC ACIDS RES, V21, P3745, DOI 10.1093/nar/21.16.3745; MILLER DL, 1970, BIOCHEM BIOPH RES CO, V38, P1016, DOI 10.1016/0006-291X(70)90341-4; MILLER DL, 1970, ARCH BIOCHEM BIOPHYS, V141, P26, DOI 10.1016/0003-9861(70)90102-5; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; RAVEL JM, 1969, COLD SPRING HARB SYM, V34, P321, DOI 10.1101/SQB.1969.034.01.039; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schwartzbach C J, 1996, Methods Enzymol, V264, P248, DOI 10.1016/S0076-6879(96)64025-7; Tsai CJ, 1996, CRIT REV BIOCHEM MOL, V31, P127, DOI 10.3109/10409239609106582; XIN H, 1995, J BIOL CHEM, V270, P17243, DOI 10.1074/jbc.270.29.17243; Xin H., 1997, BIOCHIM BIOPHYS ACTA, V1352, P101; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712; Zhang YL, 1996, FEBS LETT, V391, P330, DOI 10.1016/0014-5793(96)00789-2; Zhang YL, 1997, J BIOL CHEM, V272, P21956, DOI 10.1074/jbc.272.35.21956	21	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4556	4562		10.1074/jbc.273.8.4556	http://dx.doi.org/10.1074/jbc.273.8.4556			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468511	hybrid, Green Published			2022-12-25	WOS:000072115000039
J	Gemma, A; Hagiwara, K; Vincent, F; Ke, Y; Hancock, AR; Nagashima, M; Bennett, WP; Harris, CC				Gemma, A; Hagiwara, K; Vincent, F; Ke, Y; Hancock, AR; Nagashima, M; Bennett, WP; Harris, CC			hSmad5 gene, a human hSmad family member: its full length cDNA, genomic structure, promoter region and mutation analysis in human tumors	ONCOGENE			English	Article						transforming growth factor-beta; cDNA; genomic structure; PCR-SSCP	GROWTH-FACTOR-BETA; MAD-RELATED PROTEIN; II RECEPTOR GENE; TGF-BETA; SIGNALING PATHWAYS; CELL-GROWTH; CLONING; CANCER; INHIBITION; KINASE	hSmad (mothers against decapentaplegic)-related proteins are important messengers within the Transforming Growth Factor-beta(1) (TGF-beta(1)) superfamily signal transduction pathways. To further characterize a member of this family, we obtained a full length cDNA of the human hSmad5 (hSmad5) gene by rapid amplification of cDNA ends (RACE) and then determined the genomic structure of the gene. There are eight exons and two alternative transcripts; the shorter transcript lacks exon 2. We identified the hSmad5 promoter region from a human genomic YAC clone by obtaining the nucleotide sequence extending 1235 base pairs upstream of the 5' end of the cDNA. We found a CpG island consistent with a promoter region, and we demonstrated promoter activity in a 1232 bp fragment located upstream of the transcription initiation site. To investigate the frequency of somatic hSmad5 mutations in human cancers, we designed intron-based primers to examine coding regions by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis. Neither homozygous deletions or point mutations were found in 40 primary gastric tumors and 51 cell lines derived from diverse types of human cancer including 20 cell lines resistant to the growth inhibitory effects of TGF-beta(1). These results suggest that the hSmad5 gene is not commonly mutated and that other genetic alterations mediate the loss of TGF-beta(1) responsiveness in human cancers.	NCI, Human Carcinogenesis Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; IFREMER, Lab Ecotoxicol, F-44311 Nantes 03, France; Beijing Med Univ, Sch Oncol, Beijing 100034, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ifremer; Peking University	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA.			VINCENT-HUBERT, Francoise/0000-0002-2266-9237				ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gemma A, 1997, CANCER RES, V57, P1435; Gemma A, 1996, INT J CANCER, V68, P605, DOI 10.1002/(SICI)1097-0215(19961127)68:5<605::AID-IJC9>3.0.CO;2-2; Hagiwara K, 1996, NUCLEIC ACIDS RES, V24, P2460, DOI 10.1093/nar/24.12.2460; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LECHNER JF, 1983, CANCER RES, V43, P5915; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Riggins GJ, 1997, CANCER RES, V57, P2578; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; Tamura G, 1996, CANCER RES, V56, P612; VINCENT F, 1997, IN PRESS ONCOGENE; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	30	35	38	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					951	956		10.1038/sj.onc.1201614	http://dx.doi.org/10.1038/sj.onc.1201614			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484787				2022-12-25	WOS:000072053200015
J	Kagan, J; Liu, JH; Stein, JD; Wagner, SS; Babkowski, R; Grossman, BH; Katz, RL				Kagan, J; Liu, JH; Stein, JD; Wagner, SS; Babkowski, R; Grossman, BH; Katz, RL			Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer	ONCOGENE			English	Article						chromosome 10; LOH; microsatellite; bladder cancer; tumor suppressor gene (TSG)	TUMOR-SUPPRESSOR GENES; TRANSITIONAL CELL-CARCINOMA; HUMAN PROSTATE-CANCER; LONG ARM; HETEROZYGOSITY; DELETIONS; GLIOMAS; MARKERS	A limited number of previous studies have indicated a low frequency of chromosome 10 allele losses and deletions in bladder cancers. We investigated the involvement of chromosome 10 in advanced bladder cancers. Loss of heterozygosity (LOH) was analysed in 19 microsatellite loci in 20 grade III invasive transitional cell carcinomas. Nine (45%) of the 20 tumors had at least one allele loss on the long arm of chromosome 10. The short arm of chromosome 10 was not affected, The most frequent LOH occurred at D10S215, where four (29%) of 14 of the informative cases had an allele loss. The minimal region with allele losses was located between the centromeric marker D10S1644 and the telomeric marker D10S541, which are separated by 2.52 cM. The results strongly suggest the existence within that region of a tumor suppressor gene or genes for advanced bladder cancer.	Univ Texas, MD Anderson Cancer Ctr, Div Lab Med, Sect Expt Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Urol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kagan, J (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Div Lab Med, Sect Expt Lab Med, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [U01CA056973] Funding Source: NIH RePORTER; NCI NIH HHS [UO1 CA-56973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albarosa R, 1996, AM J HUM GENET, V58, P1260; BABU VR, 1987, CANCER RES, V47, P6800; Beahrs O. H., 1992, MANUAL STAGING CANC, V4th; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GIBAS Z, 1984, CANCER RES, V44, P1257; GRAY IC, 1995, CANCER RES, V55, P4800; ISSHIKI K, 1993, GENE CHROMOSOME CANC, V8, P178, DOI 10.1002/gcc.2870080307; Ittmann MM, 1996, PROSTATE, V28, P275; KAGAN J, 1995, ONCOGENE, V11, P2121; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; KNOWLES MA, 1994, CANCER RES, V54, P531; Lacombe L, 1996, INT J CANCER, V69, P110, DOI 10.1002/(SICI)1097-0215(19960422)69:2<110::AID-IJC7>3.0.CO;2-3; LEVINE AJ, 1992, CANCER SURV, V12, P1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Nagase S, 1996, BRIT J CANCER, V74, P1979, DOI 10.1038/bjc.1996.663; PARKER SL, 1997, J CLIN, V47, P5; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Raskind WH, 1996, GENE CHROMOSOME CANC, V16, P138, DOI 10.1002/(SICI)1098-2264(199606)16:2<138::AID-GCC8>3.0.CO;2-0; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA, P805; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Trybus TM, 1996, CANCER RES, V56, P2263; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; WANG MR, 1994, CANCER GENET CYTOGEN, V73, P8, DOI 10.1016/0165-4608(94)90175-9; Zedenius J, 1996, HUM GENET, V97, P299, DOI 10.1007/BF02185758	27	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					909	913		10.1038/sj.onc.1201606	http://dx.doi.org/10.1038/sj.onc.1201606			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484782				2022-12-25	WOS:000072053200010
J	Cao, Y; Stafforini, DM; Zimmerman, GA; McIntyre, TM; Prescott, SM				Cao, Y; Stafforini, DM; Zimmerman, GA; McIntyre, TM; Prescott, SM			Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; SIGNAL TRANSDUCERS; MACROPHAGE LINEAGE; MOUSE MACROPHAGES; INTERFERON-GAMMA; EPITHELIAL-CELLS; SYNTHASE GENE; MYELOID CELLS; DIFFERENTIATION; SECRETION	Platelet-activating factor (PAF) is a potent phospholipid with diverse physiological and pathological actions, and it is inactivated by PAF acetylhydrolase, In this study, we analyzed the tissue distribution of the plasma PAF acetylhydrolase mRNA in humans. We isolated a 3,5-kilobase fragment containing the 5' genomic sequence of the plasma PAF acetylhydrolase gene and fun-ther characterized the promoter activity, We detere mined the transcriptional initiation site by primer extension. We then prepared constructs containing various lengths of 5' genomic fragments fused to a luciferase reporter gene and transfected these constructs into COS-7 cells, We found that there is more than one region in the 1.3-kilobase 5' genomic sequence conferring promoter activity and that a very short 5'-flanking region (72 base pairs) is sufficient for more than 65% of the basal activity. in parallel, we examined the regulation of expression of the PAF acetylhydrolase gene, We found that interferon-gamma (IFN gamma) and lipopolysaccharide (LPS) significantly inhibited synthesis of PAF acetylhydrolase, whereas other cytokines, including IFN alpha, interleukin (IE) 1 alpha, IL4, IL6, tumor necrosis factor-alpha, granulocyte/macrophage colony-stimulating factor, and macrophage colony-stimulating factor, had a smaller or no effect in human monocyte-derived macrophages. Furthermore, transfection of the promoter/reporter construct into macrophage RAW264.7 cells revealed that IFN gamma and LPS decreased the promoter activity by 35% and 50%, respectively, whereas PAF stimulated it by 52% via its receptor, The promoter activity was much lower in monocytic U937 cells compared with the basal level in COS-7 cells, wile the activities in P388DI and RAW264.7 macrophagic cells were considerably higher than the basal level in COS-7 cells. There are multiple regions in the PAF acetylhydrolase promoter that contain responsive elements for signal transducer and activators of transcription-related proteins, and also for myeloid-specific transcription factors. Our data indicate that the opposite of mRNA expression in monocytes versus macrophages is due to inhibition of the promoter activity in the former and activation in the latter cells.	Univ Utah, Huntsman Canc Inst, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Prescott, SM (corresponding author), Univ Utah, Huntsman Canc Inst, Program Human Mol Biol & Genet, 15 N 2030 E,Suite 4220, Salt Lake City, UT 84112 USA.	steve.prescott@genetics.utah.edu			NHLBI NIH HHS [1F32HL09775, HL 35828, HL 50153] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035828, F32HL009775, P50HL050153] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI H, 1994, J BIOL CHEM, V269, P24557; Barahmandpour F, 1996, CURR TOP MICROBIOL, V211, P121; BARAHMANDPOUR F, 1995, FEBS LETT, V360, P29, DOI 10.1016/0014-5793(95)00072-H; BAZAN HEP, 1993, P NATL ACAD SCI USA, V90, P8678, DOI 10.1073/pnas.90.18.8678; BAZAN NG, 1994, P NATL ACAD SCI USA, V91, P5252, DOI 10.1073/pnas.91.12.5252; BENNETT SAL, 1993, CARCINOGENESIS, V14, P1289, DOI 10.1093/carcin/14.7.1289; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; CHAO W, 1990, BIOCHEM J, V292, P617; CHOW BKC, 1991, J BIOL CHEM, V266, P18927; Deng WL, 1996, CELL IMMUNOL, V170, P20, DOI 10.1006/cimm.1996.0129; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; ELSTAD MR, 1989, J BIOL CHEM, V264, P8467; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; HAMILTON TA, 1992, MACROPHAGE PATHOGEN, P83; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; Howard KM, 1997, J BIOL CHEM, V272, P27543, DOI 10.1074/jbc.272.44.27543; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; NARAHARA H, 1993, AM J OBSTET GYNECOL, V169, P531, DOI 10.1016/0002-9378(93)90614-O; NARAHARA H, 1993, ARCH BIOCHEM BIOPHYS, V301, P275, DOI 10.1006/abbi.1993.1144; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; PANG JHS, 1995, J BIOL CHEM, V270, P14123, DOI 10.1074/jbc.270.23.14123; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SATOH K, 1991, J CLIN INVEST, V87, P476, DOI 10.1172/JCI115020; SATOH K, 1993, METABOLISM, V42, P672, DOI 10.1016/0026-0495(93)90231-C; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; SHELLEY CS, 1993, P NATL ACAD SCI USA, V90, P5364, DOI 10.1073/pnas.90.11.5364; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; SNYDER F, 1995, BIOCHEM J, V305, P689, DOI 10.1042/bj3050689; SNYDER F, 1995, BBA-LIPID LIPID MET, V1254, P231, DOI 10.1016/0005-2760(94)00192-2; SQUINTO SP, 1990, J MOL NEUROSCI, V2, P79, DOI 10.1007/BF02876914; SQUINTO SP, 1989, J NEUROSCI RES, V24, P558, DOI 10.1002/jnr.490240414; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; STAFFORINI DM, 1991, LIPIDS, V26, P979, DOI 10.1007/BF02536488; STAFFORINI DM, 1990, J BIOL CHEM, V265, P9682; STAFFORINI DM, 1990, METHOD ENZYMOL, V187, P344; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; TARBET EB, 1991, J BIOL CHEM, V266, P16667; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; VENABLE ME, 1993, J LIPID RES, V34, P691; Wang H, 1997, BIOCHEM J, V322, P603, DOI 10.1042/bj3220603; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; YASUDA K, 1992, ENDOCRINOLOGY, V130, P708, DOI 10.1210/en.130.2.708	52	95	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4012	4020		10.1074/jbc.273.7.4012	http://dx.doi.org/10.1074/jbc.273.7.4012			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461591	hybrid			2022-12-25	WOS:000072048400033
J	Gasson, MJ; Kitamura, Y; McLauchlan, WR; Narbad, A; Parr, AJ; Lindsay, E; Parsons, H; Payne, J; Rhodes, MJC; Walton, NJ				Gasson, MJ; Kitamura, Y; McLauchlan, WR; Narbad, A; Parr, AJ; Lindsay, E; Parsons, H; Payne, J; Rhodes, MJC; Walton, NJ			Metabolism of ferulic acid to vanillin - A bacterial gene of the enoyl-SCoA hydratase/isomerase superfamily encodes an enzyme for the hydration and cleavage of a hydroxycinnamic acid SCoA thioester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHRORHIZON CELL-CULTURES; PARA-HYDROXYBENZOIC ACID; BETA-OXIDATION ENZYMES; LARGE ALPHA-SUBUNIT; PARA-COUMARIC ACID; COENZYME-A LYASE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; MULTIENZYME COMPLEX; ACTIVE-SITE	A gene encoding a novel enoyl-SCoA hydratase/lyase enzyme for the hydration and nonoxidative cleavage of feruloyl-SCoA to vanillin and acetyl-SCoA was isolated and characterized from a strain of Pseudomonas fluorescens. Feruloyl-SCoA is the CoASH thioester of ferulic acid (4-hydroxy-3-methoxy-trans-cinnamic acid), an abundant constituent of plant cell walls and a degradation product of lignin. The gene was isolated by a combination of mutant complementation and biochemical approaches, and its function was demonstrated by heterologous expression in Escherichia coli under the control of a T7 RNA polymerase promoter. The gene product is a member of the enoyl-SCoA hydratase/isomerase superfamily.	Inst Food Res, Norwich Lab, Dept Genet & Microbiol, Norwich NR4 7UA, Norfolk, England; Inst Food Res, Norwich Lab, Dept Biochem, Norwich NR4 7UA, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Walton, NJ (corresponding author), Inst Food Res, Norwich Lab, Dept Genet & Microbiol, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.	nicholas.walton@BBSRC.ac.uk						ANDERSON DH, 1989, J BACTERIOL, V171, P6468, DOI 10.1128/jb.171.12.6468-6472.1989; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; DORDINE RL, 1994, BIOCHEMISTRY-US, V33, P14733, DOI 10.1021/bi00253a011; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FRENCH CJ, 1976, PHYTOCHEMISTRY, V15, P564, DOI 10.1016/S0031-9422(00)88979-7; GUHNEMANNSCHAFER K, 1994, EUR J BIOCHEM, V226, P909, DOI 10.1111/j.1432-1033.1994.t01-1-00909.x; HAGEDORN S, 1994, ANNU REV MICROBIOL, V48, P773, DOI 10.1146/annurev.micro.48.1.773; HAGEL P, 1975, FEBS LETT, V59, P120, DOI 10.1016/0014-5793(75)80355-3; HARTLEY RD, 1977, PHYTOCHEMISTRY, V16, P1531, DOI 10.1016/0031-9422(77)84017-X; He XY, 1996, BIOCHEMISTRY-US, V35, P9625, DOI 10.1021/bi960374y; He XY, 1997, BIOCHEMISTRY-US, V36, P11044, DOI 10.1021/bi970901t; HRUZ PW, 1992, BIOCHEMISTRY-US, V31, P6842, DOI 10.1021/bi00144a026; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; LOFFELHARDT W, 1975, H-S Z PHYSIOL CHEM, V356, P487, DOI 10.1515/bchm2.1975.356.1.487; LOSCHER R, 1994, PLANT PHYSIOL, V106, P271, DOI 10.1104/pp.106.1.271; MULLERNEWEN G, 1995, EUR J BIOCHEM, V228, P68, DOI 10.1111/j.1432-1033.1995.tb20230.x; MULLERNEWEN G, 1993, BIOCHEMISTRY-US, V32, P11405; NARBAD A, 1997, Patent No. 00809; NARBAD A, 1996, Patent No. 96061874; OSUMI T, 1985, J BIOL CHEM, V260, P8905; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PREISIGMULLER R, 1994, J BIOL CHEM, V269, P20475; Priefert H, 1997, J BACTERIOL, V179, P2595, DOI 10.1128/JB.179.8.2595-2607.1997; Rabenhorst J, 1996, APPL MICROBIOL BIOT, V46, P470, DOI 10.1007/s002530050846; Rosazza JPN, 1995, J IND MICROBIOL, V15, P457, DOI 10.1007/BF01570016; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO S, 1992, J BIOCHEM-TOKYO, V111, P8, DOI 10.1093/oxfordjournals.jbchem.a123722; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNITZLER JP, 1992, PLANTA, V188, P594, DOI 10.1007/BF00197054; SEMLER U, 1987, Z NATURFORSCH C, V42, P1070; SHARMA V, 1992, J BACTERIOL, V174, P5057, DOI 10.1128/JB.174.15.5057-5062.1992; Shriner R. L., 1942, ORG REACT, V1, P1; STASKAWICZ B, 1987, J BACTERIOL, V169, P5789, DOI 10.1128/jb.169.12.5789-5794.1987; TADASA K, 1977, AGR BIOL CHEM TOKYO, V41, P925, DOI 10.1080/00021369.1977.10862621; TADASA K, 1983, AGR BIOL CHEM TOKYO, V47, P2639, DOI 10.1080/00021369.1983.10866004; TOMS A, 1970, BIOCHEMISTRY-US, V9, P337, DOI 10.1021/bi00804a021; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; WHETTEN R, 1995, PLANT CELL, V7, P1001, DOI 10.2307/3870053; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X; Wu WJ, 1997, BIOCHEMISTRY-US, V36, P2211, DOI 10.1021/bi962549+; YANG SY, 1995, BIOCHEMISTRY-US, V34, P6441, DOI 10.1021/bi00019a025; YANG SY, 1993, J BIOL CHEM, V268, P6588; YANG XYH, 1991, BIOCHEMISTRY-US, V30, P6788, DOI 10.1021/bi00241a023; YAZAKI K, 1991, PHYTOCHEMISTRY, V30, P2233, DOI 10.1016/0031-9422(91)83620-Z; ZENK MH, 1980, ANAL BIOCHEM, V101, P182, DOI 10.1016/0003-2697(80)90058-5; ZENK MH, 1979, RECENT ADV PHYTOCHEM, V12, P139	50	177	189	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4163	4170		10.1074/jbc.273.7.4163	http://dx.doi.org/10.1074/jbc.273.7.4163			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461612	hybrid			2022-12-25	WOS:000072048400054
J	Noda, T; Ohsumi, Y				Noda, T; Ohsumi, Y			Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; SIGNAL-TRANSDUCTION; MAMMALIAN PROTEIN; VACUOLAR PROTEIN; RAPAMYCIN; PATHWAY; FKBP12-RAPAMYCIN; MECHANISMS	Autophagy is a bulk protein degradation process that is induced by starvation, The control mechanism for induction of autophagy is not well understood, We found that Tor, a phosphatidylinositol kinase homologue, is involved in the control of autophagy in the yeast, Sac charomyces cerevisiae, When rapamycin, an inhibitor of Tor function, is added, autophagy is induced even in cells growing in nutrient-rich medium, A temperature-sensitive tor mutant also leads to induction of autophagy at a nonpermissive temperature. These results indicate that Tor negatively regulates the induction of autophagy, Tor is the first molecule that is identified as a pivotal player in the starvation-signaling pathway of autophagy, Furthermore, we found that a high concentration of cAMP is inhibitory for induction of autophagy, APG gene products are involved in autophagy induced by starvation, Autophagy was not induced in apg mutants in the presence of rapamycin, indicating that the site of action of Tor is upstream of those of Apg proteins, In nutrient-rich medium, Apg proteins are involved also in the transport of aminopeptidase I from the cytosol to the vacuole, Tor may act to switch Apg function between autophagy and transport of aminopeptidase I.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 444, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Ohsumi, Y (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, Nishigonaka 38, Okazaki, Aichi 444, Japan.	yohsumi@nibb.ac.jp	Noda, Takeshi/B-7240-2008; Ohsumi, Yoshinori/C-6449-2009	Noda, Takeshi/0000-0003-3581-7961; Ohsumi, Yoshinori/0000-0003-2384-2166				BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; BAEDET NB, 1996, MOL BIOL CELL, V7, P25; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Funakoshi T, 1997, GENE, V192, P207, DOI 10.1016/S0378-1119(97)00031-0; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HOLEN I, 1991, BIOMED BIOCHIM ACTA, V50, P389; Kametaka S, 1996, GENE, V178, P139, DOI 10.1016/0378-1119(96)00354-X; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; KOVACS AL, 1981, EXP CELL RES, V133, P431, DOI 10.1016/0014-4827(81)90336-0; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; MATSUURA A, 1997, GENE, V192, P240; MEIJER AJ, 1985, EUR J BIOCHEM, V148, P189, DOI 10.1111/j.1432-1033.1985.tb08824.x; MITSUZAWA H, 1993, GENETICS, V135, P321; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Nothwehr SF, 1996, MOL CELL BIOL, V16, P2700; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; SEGLEN PO, 1984, J CELL BIOL, V99, P435, DOI 10.1083/jcb.99.2.435; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; Zheng XF, 1997, P NATL ACAD SCI USA, V94, P3070, DOI 10.1073/pnas.94.7.3070	39	997	1032	1	60	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3963	3966		10.1074/jbc.273.7.3963	http://dx.doi.org/10.1074/jbc.273.7.3963			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461583	hybrid			2022-12-25	WOS:000072048400025
J	Sekkai, D; Aillet, F; Israel, N; Lepoivre, M				Sekkai, D; Aillet, F; Israel, N; Lepoivre, M			Inhibition of NF-kappa B and HIV-1 long terminal repeat transcriptional activation by inducible nitric oxide synthase 2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; VASCULAR ENDOTHELIAL-CELLS; ANTIMICROBIAL ACTIVITY; VIRAL REPLICATION; GENE-EXPRESSION; IFN-GAMMA; IN-VITRO; TYPE-1; MACROPHAGES	In the human lymphoblastoid T cell line JJhan-5.1, stably transfected with a human immunodeficiency virus-1 long terminal repeat luciferase vector, the level of luciferase activity is dependent on activation of the nuclear factor kappa B (NF-kappa B) transcription factor, Tumor necrosis factor-induced luciferase activity was not modified in JJhan-5.1 cells co-cultivated with murine adenocarcinoma EMT-B cells but was strongly decreased when nitric oxide (NO) synthase 2 expression was induced in these cells, Two NO synthase inhibitors counteracted this inhibitory effect, Tumor necrosis factor-cu binding to JJhan-5.1 cells was not modified after incubation with EMT-6 cells, Viability and protein synthesis in JJhan-5.1 cells were also unchanged, Induction of NF-kappa B DNA binding activity was inhibited when EMT-6 cells expressed NO synthase 2 activity, Aminoguanidine, which completely abolished nitrite production, prevented this inhibition. NF-kappa B activation was also strongly inhibited by S-nitrosoglutathione but was marginally affected by N-(2-aminoethyl)-N-(2-hydroxy-2-nitrosohydrazino)-1,2-ethylenediamine. Taken together, these results indicated that NO-related species, released by EMT-6 effector cells and probably different from NO itself, inhibited NF-kappa B activation in human lymphoblastoid target cells, Consequently, transcriptional activity of a long terminal repeat-driven luciferase gene construct was markedly diminished.	Univ Paris Sud, CNRS, ERS 571, Unite 571, F-91405 Orsay, France; Inst Pasteur, Unite Biol Retrovirus, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Lepoivre, M (corresponding author), Univ Paris Sud, CNRS, ERS 571, Unite 571, Bat 430, F-91405 Orsay, France.	michel.lepoivre@bbmpc.u-psud.fr	Lepoivre, Michel/J-8578-2013					AKARID K, 1995, J VIROL, V69, P7001, DOI 10.1128/JVI.69.11.7001-7005.1995; Albina JE, 1995, J LEUKOCYTE BIOL, V58, P643, DOI 10.1002/jlb.58.6.643; ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAGLIONI C, 1985, J BIOL CHEM, V260, P3395; BAUD L, 1990, J IMMUNOL, V145, P556; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; Chao CC, 1996, GLIA, V16, P276, DOI 10.1002/(SICI)1098-1136(199603)16:3<276::AID-GLIA10>3.0.CO;2-X; CHEN F, 1995, BIOCHEM BIOPH RES CO, V214, P839, DOI 10.1006/bbrc.1995.2363; CHENAIS B, 1994, INT J IMMUNOPHARMACO, V16, P401, DOI 10.1016/0192-0561(94)90028-0; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; DAWSON VL, 1993, P NATL ACAD SCI USA, V90, P3256, DOI 10.1073/pnas.90.8.3256; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HIBBS JB, 1991, RES IMMUNOL, V142, P565, DOI 10.1016/0923-2494(91)90103-P; ISRAEL N, 1992, J IMMUNOL, V149, P3386; Janabi N, 1996, J IMMUNOL, V157, P2129; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; Khan BV, 1996, P NATL ACAD SCI USA, V93, P9114, DOI 10.1073/pnas.93.17.9114; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; KOKA P, 1995, J EXP MED, V182, P941, DOI 10.1084/jem.182.4.941; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1993, J IMMUNOL, V150, P1509; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; Liu J, 1996, J IMMUNOL, V157, P3569; LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634; Lowenstein CJ, 1996, J CLIN INVEST, V97, P1837, DOI 10.1172/JCI118613; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; MIRZA UA, 1995, J BIOL CHEM, V270, P17185, DOI 10.1074/jbc.270.29.17185; MOORADIAN DL, 1995, J CARDIOVASC PHARM, V25, P674, DOI 10.1097/00005344-199504000-00023; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sriskandan S, 1996, J IMMUNOL, V156, P2430; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Torre D, 1996, CLIN INFECT DIS, V22, P650, DOI 10.1093/clinids/22.4.650; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; ZEIHER AM, 1995, CIRC RES, V76, P980, DOI 10.1161/01.RES.76.6.980	46	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3895	3900		10.1074/jbc.273.7.3895	http://dx.doi.org/10.1074/jbc.273.7.3895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461573	hybrid			2022-12-25	WOS:000072048400015
J	Batt, DB; Roberts, TM				Batt, DB; Roberts, TM			Cell density modulates protein-tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SWISS 3T3 CELLS; GROWTH-FACTOR; SERINE-PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CROSS-TALK; PAXILLIN; INTEGRIN; SRC; PATHWAYS	The growth of normal cells is arrested at saturating cell density in a process termed contact inhibition. An understanding of how cells communicate their contact with one another is critical for determining how cancers develop and spread. Because the molecular details of how fibroblasts communicate density changes are unclear, we examined cell density itself as a source of signaling events rather than examine specific receptors. A technique was developed to measure tyrosine phosphorylation acutely as a function of cell. density. The tyrosine phosphorylation of a number of proteins was found to be modified in response to cell density. Three of these proteins were identified as Src, paxillin, and focal adhesion kinase (FAK), all of which show an increase in their tyrosine phosphate levels with increasing density. All of these proteins are found in focal adhesions, and both FAK and paxillin are believed to be localized exclusively in focal adhesions. Thus, changing cell density alters tyrosine phosphorylation of focal adhesion components.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Roberts, TM (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 44 Binney St, Boston, MA 02115 USA.	thomas_roberts@dfci.harvard.edu			NCI NIH HHS [CA43803] Funding Source: Medline; NIGMS NIH HHS [GM18214-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018214] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRYANT PJ, 1993, DEVELOPMENT, P239; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; GRADL G, 1995, CURR BIOL, V5, P526, DOI 10.1016/S0960-9822(95)00105-9; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUMBINER BM, 1993, J CELL SCI, P155; HATAI M, 1994, FEBS LETT, V350, P113, DOI 10.1016/0014-5793(94)00745-4; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kobayashi S, 1997, J BIOL CHEM, V272, P16262, DOI 10.1074/jbc.272.26.16262; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; Leventhal PS, 1996, J BIOL CHEM, V271, P5957, DOI 10.1074/jbc.271.11.5957; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; REBUTBONNETON C, 1993, J CELL SCI, V105, P629; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Saito Y, 1996, BIOCHEM BIOPH RES CO, V224, P23, DOI 10.1006/bbrc.1996.0978; Sakamoto M, 1996, LAB INVEST, V74, P199; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	35	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3408	3414		10.1074/jbc.273.6.3408	http://dx.doi.org/10.1074/jbc.273.6.3408			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452462	hybrid			2022-12-25	WOS:000071822300047
J	Evdokimova, VM; Kovrigina, EA; Nashchekin, DV; Davydova, EK; Hershey, JWB; Ovchinnikov, LP				Evdokimova, VM; Kovrigina, EA; Nashchekin, DV; Davydova, EK; Hershey, JWB; Ovchinnikov, LP			The major core protein of messenger ribonucleoprotein particles (p50) promotes initiation of protein biosynthesis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTES; CYTOPLASMIC MRNP; ESCHERICHIA-COLI; RNA TRANSLATION; SOMATIC-CELLS; RABBIT RETICULOCYTES; BINDING-PROTEINS; MASKING; INHIBITION; FAMILY	The major core protein of cytoplasmic messenger ribonucleoprotein particles (p50) has been shown previously to inhibit protein synthesis in vitro and in vivo, Furthermore, p50 is highly homologous to the Y-box-binding transcription factor family of proteins, binds DNA containing the Y-box motif, and thus may have a dual function in cells as a regulator of both transcription and translation, Here we show that binding or removal of p50 from rabbit reticulocyte lysate by monospecific antibodies to p50 strongly inhibits translation of endogenous and exogenous globin mRNAs as well as prokaryotic beta-galactosidase mRNA in a rabbit reticulocyte cell-free system, Thus, depending on the conditions, p50 not only may act as a translational repressor, but may also be required for protein synthesis, Translation inhibition with anti-p50 antibodies is not a result of mRNA degradation or its functional inactivation, The inhibition does not change the ribosome transit time, and therefore, it does not affect elongation/termination of polypeptide chains. The inhibition with anti-p50 antibodies is followed by a decay of polysomes and accumulation of the 48 S preinitiation complex, These results suggest that p50 participates in initiation of protein biosynthesis, Although uninvolved in the formation of the 48 S preinitiation complex, p50 is necessary either for attachment of the 60 S ribosomal subunit or for previous 5'-untranslated region scanning by the 43 S preinitiation complex.	Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	Russian Academy of Sciences; University of California System; University of California Davis	Ovchinnikov, LP (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia.	ovchinn@sun.ipr.serpukhov.su	Ovchinnikov, Lev/L-2397-2015	Nashchekin, Dmitry/0000-0001-7372-0752				ANTHONY DD, 1992, J BIOL CHEM, V267, P1554; AUERBACH S, 1975, BIOCHEM BIOPH RES CO, V63, P149, DOI 10.1016/S0006-291X(75)80023-4; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BRADDOCK M, 1994, NUCLEIC ACIDS RES, V22, P5255, DOI 10.1093/nar/22.24.5255; Davydova EK, 1997, NUCLEIC ACIDS RES, V25, P2911, DOI 10.1093/nar/25.14.2911; DE SA MFG, 1988, EUR J BIOCHEM, V176, P521; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; EY PL, 1978, BIOCHEMISTRY-US, V15, P429; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; HENTZE MW, 1995, CURR OPIN CELL BIOL, V7, P393, DOI 10.1016/0955-0674(95)80095-6; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JAIN SK, 1979, FEBS LETT, V97, P84, DOI 10.1016/0014-5793(79)80058-7; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; KOZAK M, 1980, CELL, V22, P459, DOI 10.1016/0092-8674(80)90356-6; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; MARELLO K, 1992, NUCLEIC ACIDS RES, V20, P5593, DOI 10.1093/nar/20.21.5593; MATHEWS MB, 1996, TRANSLATIONAL CONTRO, P505; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MINICH WB, 1993, EUR J BIOCHEM, V212, P633, DOI 10.1111/j.1432-1033.1993.tb17701.x; MINICH WB, 1990, MOL BIOL REP, V14, P65, DOI 10.1007/BF00360418; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; MINICH WB, 1989, FEBS LETT, V257, P257, DOI 10.1016/0014-5793(89)81547-9; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; ROUAULT TA, 1996, TRANSLATIONAL CONTRO, P335; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SMAILOV SK, 1990, FEBS LETT, V275, P99, DOI 10.1016/0014-5793(90)81448-W; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; SPIRIN AS, 1994, MOL REPROD DEV, V38, P107, DOI 10.1002/mrd.1080380117; SPIRIN AS, 1996, TRANSLATIONAL CONTRO, P319; Svitkin YV, 1996, EMBO J, V15, P7147, DOI 10.1002/j.1460-2075.1996.tb01106.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Ustinov VA, 1996, BIOCHEMISTRY-MOSCOW+, V61, P414; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	40	93	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3574	3581		10.1074/jbc.273.6.3574	http://dx.doi.org/10.1074/jbc.273.6.3574			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452484	hybrid			2022-12-25	WOS:000071822300069
J	Payne, AS; Gitlin, JD				Payne, AS; Gitlin, JD			Functional expression of the Menkes disease protein reveals common biochemical mechanisms among the copper-transporting P-type ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE GENE; HISTIDINE TREATMENT; IRON UPTAKE; MUTATIONS; YEAST; ENCODES; CELLS; AMPLIFICATION; ORGANIZATION; FIBROBLASTS	Menkes disease is a fatal neurodegenerative disorder of childhood caused by the absence or dysfunction of a putative P-type ATPase encoded on the X chromosome. To elucidate the function of the Menkes disease protein, a plasmid containing the open reading frame of the human Menkes disease gene was constructed and used to transform a strain of Saccharomyces cerevisiae deficient in CCC2, the yeast Menkes/Wilson disease gene homologue. ccc2 Delta yeast are deficient in copper transport into the secretory pathway, and expression of a wild type human Menkes cDNA complemented this defect, as evidenced by the restoration of copper incorporation into the multicopper oxidase Fet3p. Site-directed mutagenesis demonstrated the essential role of four specific amino acids in this process, including a conserved histidine, which is the site of the most common disease mutation in the homologous Wilson disease protein. The expression of Menkes cDNAs with successive mutations of the conserved cysteine residues in the six amino-terminal MXCXXC metal binding domains confirmed the essential role of these cysteine residues in copper transport but revealed that each of these domains is not functionally equivalent. These data demonstrate that the Menkes disease protein functions to deliver copper into the secretory pathway of the cell and that this process involves biochemical mechanisms common to previously characterized members of this P-type ATPase family.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL)	Gitlin, JD (corresponding author), St Louis Childrens Hosp, Dept Pediat, 1 Childrens Pl, St Louis, MO 63110 USA.	gitlin@kidsa1.wustl.edu			NIDDK NIH HHS [DK44464] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044464, R37DK044464] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; CAMAKARIS J, 1980, BIOCHEM GENET, V18, P117, DOI 10.1007/BF00504364; CAMAKARIS J, 1995, HUM MOL GENET, V4, P2117, DOI 10.1093/hmg/4.11.2117; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; DANKS DM, 1972, PEDIATRICS, V50, P188; DAS S, 1994, AM J HUM GENET, V55, P883; Dierick HA, 1997, HUM MOL GENET, V6, P409, DOI 10.1093/hmg/6.3.409; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; GOKA TJ, 1976, P NATL ACAD SCI USA, V73, P604, DOI 10.1073/pnas.73.2.604; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaler SG, 1996, NAT GENET, V13, P21, DOI 10.1038/ng0596-21; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Kuo YM, 1997, HUM MOL GENET, V6, P1043, DOI 10.1093/hmg/6.7.1043; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MENKES JH, 1962, PEDIATRICS, V29, P764; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; ROYCE PM, 1980, BIOCHEM J, V192, P579, DOI 10.1042/bj1920579; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambongi Y, 1997, J BIOCHEM-TOKYO, V121, P1169, DOI 10.1093/oxfordjournals.jbchem.a021711; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; Tumer Z, 1997, AM J HUM GENET, V60, P63; Tumer Z, 1996, NAT GENET, V12, P11, DOI 10.1038/ng0196-11; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; Yang XL, 1997, BIOCHEM J, V326, P897, DOI 10.1042/bj3260897; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	38	134	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3765	3770		10.1074/jbc.273.6.3765	http://dx.doi.org/10.1074/jbc.273.6.3765			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452509	hybrid			2022-12-25	WOS:000071822300094
J	Yu, MH; Zhang, LL; Rishi, AK; Khadeer, M; Inesi, G; Hussain, A				Yu, MH; Zhang, LL; Rishi, AK; Khadeer, M; Inesi, G; Hussain, A			Specific substitutions at amino acid 256 of the sarcoplasmic/endoplasmic reticulum Ca2+ transport ATPase mediate resistance to thapsigargin in thapsigargin-resistant hamster cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CA2+-ATPASE; GENE; PHOSPHORYLATION; SITE	High levels of resistance to thapsigargin (TG), a specific inhibitor of intracellular Ca2+ transport ATPases (SERCAs), can be developed in culture by stepwise exposure of mammalian cells to increasing concentrations of TG. We have identified, in two independently selected TG-resistant hamster cell lines of different lineages, mutant forms of SERCA. In the TG-resistant Chinese hamster lung fibroblast cell line DC-3F/TG, a T --> C change at nucleotide 766 introduces a Phe(256) --> Leu alteration within the first cytosolic loop of the SERCA. In contrast, in the TG-resistant Syrian hamster smooth muscle cell line DDT/TG 4 mu M, a T --> C change at nucleotide 767 introduces a Phe(256) --> Ser mutation at that position. When these specific mutations are introduced into a wild-type full-length avian SERCA1 cDNA, transfection experiments reveal that Ca2+ transport function and ATP hydrolytic activity are not altered by such mutations, However, a 4-5-fold resistance to TG inhibition of Ca2+ transport function occurs upon the introduction of either the Phe(256) --> Leu or the Phe(256) --> Ser mutation into wild-type SERCA1, These specific mutations also render the hydrolytic activity of the ATPase resistant to inhibition by TG, Our results not only implicate amino acid 256 in TG-SERCA interactions, but also demonstrate that specific mutations within SERCA can mediate resistance to TG.	Univ Maryland, Greenebaum Canc Ctr, Dept Med, Div Oncol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Biol Chem, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center	Hussain, A (corresponding author), Univ Maryland, Greenebaum Canc Ctr, Dept Med, Div Oncol, 655 W Baltimore St,Bressler Res Bldg,Rm 9-047, Baltimore, MD 21201 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL27867] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIEDLER JL, 1970, CANCER RES, V30, P1174; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; GUTHEIL JC, 1994, J BIOL CHEM, V269, P7976; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUSSAIN A, 1995, J BIOL CHEM, V270, P12140, DOI 10.1074/jbc.270.20.12140; HUSSAIN A, 1992, ARCH BIOCHEM BIOPHYS, V296, P539, DOI 10.1016/0003-9861(92)90608-Y; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MELERA PW, 1991, SEMINARS CANC BIOL, P245; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; RISHI A, 1992, AM J PHYSIOL, V262, pL566, DOI 10.1152/ajplung.1992.262.5.L566; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Sambrook J., 2002, MOL CLONING LAB MANU; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SMITH RG, 1984, J STEROID BIOCHEM, V20, P227; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; YU MH, 1993, CANCER RES, V53, P6031; ZHANG Z, 1995, J BIOL CHEM, V270, P16283	20	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3542	3546		10.1074/jbc.273.6.3542	http://dx.doi.org/10.1074/jbc.273.6.3542			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452480	hybrid			2022-12-25	WOS:000071822300065
J	Englaro, W; Derijard, B; Ortonne, JP; Ballotti, R				Englaro, W; Derijard, B; Ortonne, JP; Ballotti, R			Solar ultraviolet light activates extracellular signal-regulated kinases and the ternary complex factor in human normal keratinocytes	ONCOGENE			English	Article						ultraviolets A and B; ERKs; SAPKs; TCF/SRF; AP1	SERUM RESPONSE ELEMENT; GROWTH-FACTOR; TYROSINE KINASES; PHOSPHORYLATION; RADIATION; ERK; MECHANISMS; INDUCTION; RECEPTORS; PATHWAYS	Exposure to ultraviolet radiation of solar light is responsible for inflammation, premature skin aging and is the main cause of human skin carcinogenesis. While the noxious consequences of U.V. exposure are known, the molecular events triggered by this radiation are poorly understood. We observed that U.V.-A and U.V.-B irradiation of human keratinocytes induces the activation of tyrosine kinase pathways leading to the tyrosine phosphorylation of several cellular proteins. We also observed a stimulation of the Stress Activated Protein kinases (SAPKs), p38 and JNK, and an activation of the transcription factors AP-1 in response to U.V.-A and U.V.-B radiation. Furthermore, we clearly demonstrated that physiological U.V. doses are able to activate the Extracellular signal-Regulated Kinases, ERK1 and ERK2, which could explain the activation of the Ternary Complex Factor. Thus, in human keratinocytes, solar U.V. light activates multiple signalling pathways that could be involved in skin inflammation following U.V. induced skin injury or in U.V.-induced skin carcinogenesis.	Fac Med Nice, INSERM, U385, F-06107 Nice 2, France; Univ Nice, CNRS, Ctr Biochim, F-06018 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Ballotti, R (corresponding author), Fac Med Nice, INSERM, U385, Ave Valombrose, F-06107 Nice 2, France.		BALLOTTI, Robert/F-8825-2013	BALLOTTI, Robert/0000-0002-7322-4908				ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; DELUCA HF, 1982, BIOCHEM SOC T, V10, P147, DOI 10.1042/bst0100147; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DHANWADA KR, 1995, ONCOGENE, V11, P1947; DjavaheriMergny M, 1996, FEBS LETT, V384, P92, DOI 10.1016/0014-5793(96)00294-3; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HOLICK MF, 1980, SCIENCE, V210, P203, DOI 10.1126/science.6251551; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; JEANMOUGIN M, 1983, PHOTODERMATOSES PHOT, P11; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; PENTLAND AP, 1990, J CLIN INVEST, V86, P566, DOI 10.1172/JCI114746; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	28	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					661	664		10.1038/sj.onc.1201536	http://dx.doi.org/10.1038/sj.onc.1201536			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482112				2022-12-25	WOS:000071816600011
J	Krebs, B; Griffin, H; Winter, G; Rose-John, S				Krebs, B; Griffin, H; Winter, G; Rose-John, S			Recombinant human single chain Fv antibodies recognizing human interleukin-6 - Specific targeting of cytokine-secreting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY; AFFINITY HUMAN-ANTIBODIES; PHAGE DISPLAY LIBRARIES; HUMAN MYELOMA CELLS; RECEPTOR ANTAGONIST; HUMAN IL-6; SYNTHETIC REPERTOIRES; GP130 ACTIVATION; ESCHERICHIA-COLI; AMINO-ACIDS	A human antibody library was displayed on the surface of filamentous bacteriophage and screened for binding to human interleukin-6 (IL-6). Two antibody-bearing phages were selected that bound IL-6. The complementary-determining region 3 loops of the variable heavy chains of these two antibodies differed in length and sequence and recognized two distinct epitopes. One of the single chain Fv fragments isolated (H1) was found to bind human (but not murine) IL-6 with an affinity comparable to that of the human IL-6 receptor. HI also recognized newly synthesized human IL-6 intracellularly, as shown by indirect immunofluorescence. H1 did not neutralize human IL-6, and the H1 epitope was mapped to a region of IL-6 not involved in interactions with IL-6, IL-6 receptor, or the signal-transducing protein gp130. To target IL-6-secreting cells, we then constructed a bispecific antibody fragment (a diabody) comprising H1 and the antigen binding site of the T-cell activating monoclonal antibody OKT3. The diabody led to T-cell-mediated killing of cells secreting IL-6.	Johannes Gutenberg Univ Mainz, Dept Med, Sect Pathophysiol, D-55101 Mainz, Germany; Univ Cambridge, Ctr Prot Engn, MRC, Cambridge CB2 2QH, England	Johannes Gutenberg University of Mainz; University of Cambridge	Rose-John, S (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med, Sect Pathophysiol, Obere Zahlbacher Str 63, D-55101 Mainz, Germany.	rose@mzdmza.zdv.uni-mainz.de	Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279				AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; Ackermann B, 1997, J INFECT DIS, V175, P1121, DOI 10.1086/516451; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; BAUER J, 1991, ANN HEMATOL, V62, P203, DOI 10.1007/BF01729833; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1989, J IMMUNOL, V143, P1175; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; CASTELL J, 1990, EUR J BIOCHEM, V189, P113, DOI 10.1111/j.1432-1033.1990.tb15466.x; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; DEHON FD, 1994, J EXP MED, V180, P2395, DOI 10.1084/jem.180.6.2395; EHLERS M, 1994, J IMMUNOL, V153, P1744; EHLERS M, 1995, J BIOL CHEM, V270, P8158, DOI 10.1074/jbc.270.14.8158; EHLERS M, 1996, J INTERFORM CYTOKINE, V16, P599; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; Holliger P, 1996, PROTEIN ENG, V9, P299, DOI 10.1093/protein/9.3.299; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; JOHNSON KS, 1996, ANTIBODY ENG; Kallen K J, 1997, Expert Opin Investig Drugs, V6, P237, DOI 10.1517/13543784.6.3.237; KLEIN B, 1991, BLOOD, V78, P1198; KRUTTGEN A, 1990, FEBS LETT, V273, P95, DOI 10.1016/0014-5793(90)81059-W; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; MARKS JD, 1992, J BIOL CHEM, V267, P16007; NEURATH AR, 1992, J EXP MED, V176, P1561, DOI 10.1084/jem.176.6.1561; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROSEJOHN S, 1993, J BIOL CHEM, V268, P22084; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; Sporeno E, 1996, BLOOD, V87, P4510, DOI 10.1182/blood.V87.11.4510.bloodjournal87114510; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; Toniatti C, 1996, EMBO J, V15, P2726, DOI 10.1002/j.1460-2075.1996.tb00633.x; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; Vollmer P, 1996, J IMMUNOL METHODS, V199, P47, DOI 10.1016/S0022-1759(96)00163-9; Ward LD, 1996, J BIOL CHEM, V271, P20138, DOI 10.1074/jbc.271.33.20138; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WENDLING D, 1993, J RHEUMATOL, V20, P259; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	46	24	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2858	2865		10.1074/jbc.273.5.2858	http://dx.doi.org/10.1074/jbc.273.5.2858			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446596	hybrid			2022-12-25	WOS:000071736600051
J	Sakatsume, M; Stancato, LF; David, M; Silvennoinen, O; Saharinen, P; Pierce, J; Larner, AC; Finbloom, DS				Sakatsume, M; Stancato, LF; David, M; Silvennoinen, O; Saharinen, P; Pierce, J; Larner, AC; Finbloom, DS			Interferon gamma activation of Raf-1 is Jak1-dependent and p21(ras)-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; SERINE THREONINE KINASE; PROTEIN-TYROSINE KINASE; GENE-EXPRESSION; HUMAN-MONOCYTES; CELL-LINES; RECEPTOR; PHOSPHORYLATION; RAS; BINDING	Signal transduction through the interferon gamma (IFN gamma) receptor involves the formation of a ligand-dependent multimolecular association of receptor chains (alpha and beta), Janus tyrosine kinases (Jak1 and Jak2), and the transcription factor (signal transducers and activators of transcription 1 alpha (STAT1 alpha)) in addition to activation of mitogen-activated protein kinases (MAPK), Interactions between components of the Jak/STAT cascade and the p21(ras)/Raf-1/MAPK cascade are unexplored, Treatment of HeLa cells with IFN gamma resulted in the rapid and transient activation of Raf-1 and MAPK. Parallel activation of cells resulted in essentially no enhancement of p21(ras) activation despite marked enhancement after treatment with epidermal growth factor, In HeLa (E1C3) and fibrosarcoma (U4A) cell lines, both of which are deficient in Jak1 kinase, Raf-1 activation by IFN gamma was absent. Reconstitution of Raf-1 activity was observed only with kinase active Jak1 in both cell lines. In COS cells, transient expression of wild type or kinase-inactive Jak1 coimmunoprecipitated with Raf-1, but activation of Raf-1 activity was only observed in cells expressing kinase-active Jak1. These observations suggest that a kinase-active Jak1 is required for IFN gamma activation of Raf-1 that is p21(ras)-independent.	US FDA, Ctr Biol Evaluat & Res, Div Cytokine Biol, Bethesda, MD 20892 USA; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tampere University	Finbloom, DS (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Cytokine Biol, HFM-505,29 Lincoln Dr, Bethesda, MD 20892 USA.	Finbloom@A1.cbef.fda.gov	Saharinen, Pipsa I/C-9601-2016	Saharinen, Pipsa I/0000-0003-2652-0584				Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CATLING AD, 1994, J BIOL CHEM, V269, P30014; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FINBLOOM DS, 1995, CELL SIGNAL, V7, P739, DOI 10.1016/0898-6568(95)02004-7; FINBLOOM DS, 1985, J IMMUNOL, V135, P300; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LIU MK, 1994, INFECT IMMUN, V62, P2722, DOI 10.1128/IAI.62.7.2722-2731.1994; LOH JE, 1994, MOL CELL BIOL, V14, P2170, DOI 10.1128/MCB.14.3.2170; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; LUONG H, 1994, BIOCHEM J, V299, P799, DOI 10.1042/bj2990799; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MASLINSKI W, 1992, J BIOL CHEM, V267, P15281; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; Popik W, 1996, MOL CELL BIOL, V16, P6532; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Sakatsume M, 1996, J IMMUNOL, V156, P4160; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	41	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3021	3026		10.1074/jbc.273.5.3021	http://dx.doi.org/10.1074/jbc.273.5.3021			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446616	hybrid			2022-12-25	WOS:000071736600071
J	Medema, RH; Klompmaker, R; Smits, VAJ; Rijksen, G				Medema, RH; Klompmaker, R; Smits, VAJ; Rijksen, G			p21(waf1) can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases	ONCOGENE			English	Article						p21; cyclin B; PCNA; growth inhibition; tetracycline	WILD-TYPE P53; DEPENDENT KINASES; TERMINAL DIFFERENTIATION; RETINOBLASTOMA PROTEIN; GROWTH SUPPRESSION; GENE AMPLIFICATION; CDK INHIBITORS; P21; EXPRESSION; ARREST	p21(waf1) has been shown to mediate the p53-dependent growth arrest induced by DNA-damaging agents, Several functions have been ascribed to p21(waf1) that could be involved in this growth arrest, For one, p21(waf1) is an efficient inhibitor of cyclin-dependent kinases (CDKs). Also, p21(waf1) can interact with proliferating cell nuclear antigen (PCNA), and as such inhibit in vitro DNA-replication. Finally, p21(waf1) has been reported to inhibit stress-activated protein kinases (SAPKs). In order to study these multiple functions of p21(waf1) we have established U2OS-derived cell lines, in which the expression of p21(waf1) can be regulated by the concentration of tetracycline in the culture medium, We observed a virtually complete, but reversible inhibition of cell growth upon induction of p21(waf1)-expression. Both [H-3]thymidine-incorporation and CDK2-activity were strongly inhibited by p21(waf1). Upon induction of p21(waf1) cells accumulated with a 2N or 4N DNA content suggesting events in G1 and G2 can be inhibited by p21(waf1). Indeed, kinase activity associated with cyclin B was reduced dramatically upon induction of p21(waf1), although cyclin B continues to be expressed, In contrast, p21(waf1) does not seem to inhibit the function of PCNA in ongoing DNA replication, since cells expressing high levels of p21(waf1) apparently progressed normally through S-phase. Also, the activity of SAPKs was not substantially affected by the high levels of p21(waf1). We conclude that, at least in these U2OS-derived cells, p21(waf1) functions as an inhibitor of CDK-activity in G1 and G2, but not as an inhibitor of PCNA or SAPKs.	Univ Utrecht Hosp, Dept Haematol, Jordan Lab, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Medema, RH (corresponding author), Univ Utrecht Hosp, Dept Haematol, Jordan Lab, POB 85500, NL-3508 GA Utrecht, Netherlands.		Medema, Rene H/E-2981-2013; Smits, Veronique A.J./R-2302-2019; Medema, Rene H/G-5415-2011	Smits, Veronique A.J./0000-0002-9160-4525; Medema, Rene/0000-0002-6754-0381	NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER; NCI NIH HHS [CA39826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MICHIELI P, 1994, CANCER RES, V54, P3391; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Savio M, 1996, ONCOGENE, V13, P1591; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; STEINMAN RA, 1994, ONCOGENE, V9, P3389; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wyllie FS, 1996, ONCOGENE, V12, P1077; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	57	151	154	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					431	441		10.1038/sj.onc.1201558	http://dx.doi.org/10.1038/sj.onc.1201558			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484832				2022-12-25	WOS:000071739400001
J	Fang, XJ; Jin, XM; Xu, HJ; Liu, L; Peng, HQ; Hogg, D; Roth, JA; Yu, YH; Xu, FJ; Bast, RC; Mills, GB				Fang, XJ; Jin, XM; Xu, HJ; Liu, L; Peng, HQ; Hogg, D; Roth, JA; Yu, YH; Xu, FJ; Bast, RC; Mills, GB			Expression of p16 induces transcriptional downregulation of the RB gene	ONCOGENE			English	Article						p16; RB; expression; ovarian cancer	TUMOR-SUPPRESSOR GENE; CANCER CELL-LINES; KINASE-4 INHIBITOR GENE; RETINOBLASTOMA-PROTEIN; CDK4 AMPLIFICATION; SQUAMOUS-CELL; CYCLE CONTROL; MTS1 GENE; P16(INK4); INACTIVATION	The RE and p16(INK4A) tumor suppressor genes function in the same pathway of cell cycle control. Previous evidence indicates that the p16(INK4A) gene is transcriptionally repressed by the RE gene product, pRB. In this study using human ovarian cancer cell lines, we found that RE protein and mRNA were expressed at higher levels in cell lines lacking p16 than in those with normal p16. Since this suggests a potential role of p16 in regulating the cellular level of pRB, we studied the effect of wild-type p16(INK4A) on expression of the RE gene. Introduction of p16(INK4A), carried by an adenovirus vector,;into p16-negative cell lines dramatically decreased expression of RE protein and mRNA. Nuclei run-off assays demonstrated that p16 expression induced transcriptional downregulation of the RE gene. These results indicate that expression of RE is inversely regulated by p16. The findings reveal a new dimension of pRB-p16 interaction and should have implications for p16(INK4A)-mediated gene therapy.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Div Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Toronto, Dept Med, Toronto, ON M5G 1L7, Canada; Toronto Gen Hosp, Toronto, ON M5G 1L7, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Mills, GB (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Div Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NATIONAL CANCER INSTITUTE [P01CA064602] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAST RC, 1983, CANCER RES, V43, P1395; BERCHUCK A, 1992, AM J OBSTET GYNECOL, V166, P676, DOI 10.1016/0002-9378(92)91697-9; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BUICK RN, 1985, CANCER RES, V45, P3668; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DODSON MK, 1994, CANCER RES, V54, P610; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; GREENBERG ME, 1992, SHORT PROTOCOLS MOL; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; Hengstschlager M, 1996, ONCOGENE, V12, P1635; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JEN J, 1994, CANCER RES, V54, P6353; JIANG W, 1992, CANCER RES, V52, P2980; JIN XM, 1995, CANCER RES, V55, P3250; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P430; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAMMIE GA, 1991, ONCOGENE, V6, P439; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MORI T, 1994, CANCER RES, V54, P3396; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OSWALD F, 1994, ONCOGENE, V9, P2029; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PALES E, 1993, EMBO J, V12, P961; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PENG HQ, 1993, CANCER RES, V53, P3574; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHULZE A, 1994, ONCOGENE, V9, P3475; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SHAPIRO GI, 1995, CANCER RES, V55, P505; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; Ueki K, 1996, CANCER RES, V56, P150; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XU HJ, 1991, CANCER RES, V51, P2735; XU HJ, 1991, ONCOGENE, V6, P1139; XU L, 1994, CANCER RES, V54, P5262; ZHOU XL, 1994, ONCOGENE, V9, P3737	52	73	87	1	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					1	8		10.1038/sj.onc.1201525	http://dx.doi.org/10.1038/sj.onc.1201525			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467937				2022-12-25	WOS:000071236800001
J	He, LM; Cui, HM; Walsh, C; Mattsson, R; Lin, WL; Anneren, G; Pfeifer-Ohlsson, S; Ohlsson, R				He, LM; Cui, HM; Walsh, C; Mattsson, R; Lin, WL; Anneren, G; Pfeifer-Ohlsson, S; Ohlsson, R			Hypervariable allelic expression patterns of the imprinted IGF2 gene in tumor cells	ONCOGENE			English	Article						genomic imprinting; epigenetic; choriocarcinoma; activation; silencing	GROWTH FACTOR-II; H19 GENE; CHORIOCARCINOMA	The IGF2 gene, which encodes a growth factor, is subject to genomic imprinting, The frequently observed loss of IGF2 imprinting in a variety of tumors has been suggested to contribute to neoplasia, Since these reports have not documented the imprinting status of IGF2 at the cellular level, it cannot be excluded that the imprinting status might vary within the tumor, The possibility that loss of IGF2 imprinting in neoplastic cells reflects random imprinting patterns, was therefore addressed, We show here that individual cell populations of the JEG-3 choriocarcinoma cell line display heterogenous imprinting patterns of both IGF2 and H19, In addition, a lack of correlation between IGF2 and H19 imprinting status suggests that any regional parental imprint has been functionally lost, This notion is reinforced by the observation that JEG-3 cell subclones display a range of promoter-specific IGF2 allele usage, Moreover, we observed that the imprinting status of H19 and IGF2 were differentially modulated in JEG-3-derived tumors generated in nude mice, The results suggest that allele-specific expression of IGF2 operates in the absence of a parental imprint, Finally, our observations urge caution with respect to the general interpretation of biallelic expression as 'loss of imprinting'.	Uppsala Univ, Dept Anim Dev & Genet, S-75236 Uppsala, Sweden; Columbia Univ, Dept Genet & Dev, New York, NY USA; Univ Uppsala Hosp, Dept Paediat, S-75185 Uppsala, Sweden	Uppsala University; Columbia University; Uppsala University; Uppsala University Hospital	Ohlsson, R (corresponding author), Uppsala Univ, Dept Anim Dev & Genet, Norbyvagen 18A, S-75236 Uppsala, Sweden.		Walsh, Colum/ABD-7013-2020; Cui, Hengmi/A-2598-2008	Walsh, Colum/0000-0001-9921-7506; 				Adam GIR, 1996, DEVELOPMENT, V122, P839; Barletta JM, 1997, CANCER RES, V57, P48; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; DOUCRASY S, 1996, ONCOGENE, V12, P324; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; FEINBERG AP, 1994, COLD SPRING HARB SYM, V59, P357, DOI 10.1101/SQB.1994.059.01.040; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LYON MF, 1995, GENOMIC IMPRINTING C, P129; Mannens M, 1997, NAT GENET, V15, P113, DOI 10.1038/ng0297-113; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1989, EMBO J, V8, P1993, DOI 10.1002/j.1460-2075.1989.tb03606.x; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; OHLSSON R, 1995, GENOMIC IMPRINTING C, P1; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; TYCKO B, 1994, AM J PATHOL, V144, P431; ZHANG YH, 1993, AM J HUM GENET, V53, P113	20	18	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					113	119		10.1038/sj.onc.1201501	http://dx.doi.org/10.1038/sj.onc.1201501			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467950				2022-12-25	WOS:000071236800014
J	Wells, KM; Abercrombie, RF				Wells, KM; Abercrombie, RF			Luminal Ca2+ protects against thapsigargin inhibition in neuronal endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM POOLS; ADRENAL CHROMAFFIN CELLS; SARCOPLASMIC-RETICULUM; MG-2+-DEPENDENT ATPASE; FUNCTIONAL COMPARISONS; PC12 CELLS; STORES; IDENTIFICATION; PUMPS; CA-2+-ATPASE	Thapsigargin is a specific and potent inhibitor of sarco/endoplasmic reticulum Ca2+-ATPases, However, in whole rat brain microsomes, 1 mu M thapsigargin had no significant effect on the 10-min time course of ATP-dependent Ca2+ uptake in the absence of the luminal Ca2+ chelator oxalate, In contrast, 50 mM oxalate resolved a thapsigargin-sensitive Ca2+ uptake rate (IC50 similar or equal to 1 nM thapsigargin) five times that of a thapsigargin-insensitive rate. This remaining similar to 20% of the total ATP-dependent accumulation was insensitive to thapsigargin (up to 10 mu M), slightly less sensitive to vanadate inhibition, and unresponsive to 5 mu M inositol 1,4,5-trisphosphate or 10 nM caffeine. Measuring both 12-min Ca2+ uptake and initial Ca2+ uptake rates, the apparent thapsigargin sensitivity increased as oxalate concentrations increased from 10 to 50 mM, corresponding to a range of luminal free Ca2+ concentrations of similar to 300 down to 60 nM. Addition of oxalate during steady-state Ca-45 accumulation rapidly resolved the aforementioned thapsigargin sensitivity, These results strongly suggest that luminal Ca2+ may protect a large portion of neuronal endoplasmic reticulum Ca2+ pumps against thapsigargin inhibition, Although high [Ca2+] has been previously shown to protect against thapsigargin inhibition in several reticular membrane preparations, our results suggest that luminal Ca2+ alone is responsible for mediating this effect in neurons.	Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA	Emory University	Abercrombie, RF (corresponding author), Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA.				NINDS NIH HHS [NS19194] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019194] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIAN JH, 1991, J BIOL CHEM, V266, P8801; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; Caspersen C, 1995, FEBS LETT, V377, P31, DOI 10.1016/0014-5793(95)01304-0; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; Favre CJ, 1996, J BIOL CHEM, V271, P14925, DOI 10.1074/jbc.271.25.14925; KAPRIELIAN Z, 1989, MOL BRAIN RES, V6, P55, DOI 10.1016/0169-328X(89)90028-4; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MICHAELIS EK, 1983, J BIOL CHEM, V258, P6101; Moore JE, 1996, AM J PHYSIOL-CELL PH, V270, pC628, DOI 10.1152/ajpcell.1996.270.2.C628; Pizzo P, 1997, J CELL BIOL, V136, P355, DOI 10.1083/jcb.136.2.355; POULSEN JCJ, 1995, BIOCHEM J, V307, P749, DOI 10.1042/bj3070749; Rooney E, 1996, J BIOL CHEM, V271, P29304, DOI 10.1074/jbc.271.46.29304; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; TANAKA Y, 1993, BIOCHEMISTRY-US, V32, P12062, DOI 10.1021/bi00096a017; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; TRIBE RM, 1994, P NATL ACAD SCI USA, V91, P5908, DOI 10.1073/pnas.91.13.5908; VERMA A, 1990, CELL REGUL, V1, P781, DOI 10.1091/mbc.1.10.781; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; Wells KM, 1996, AM J PHYSIOL-CELL PH, V271, pC1472, DOI 10.1152/ajpcell.1996.271.5.C1472; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; Witcome M., 1992, BIOCHEM J, V283, P525; WU K, 1995, AM J PHYSIOL, V268, pC775	30	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5020	5025		10.1074/jbc.273.9.5020	http://dx.doi.org/10.1074/jbc.273.9.5020			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478950	hybrid			2022-12-25	WOS:000072310400034
J	Enami, I; Kamo, M; Ohta, H; Takahashi, S; Miura, T; Kusayanagi, M; Tanabe, S; Kamei, A; Motoki, A; Hirano, M; Tomo, T; Satoh, K				Enami, I; Kamo, M; Ohta, H; Takahashi, S; Miura, T; Kusayanagi, M; Tanabe, S; Kamei, A; Motoki, A; Hirano, M; Tomo, T; Satoh, K			Intramolecular cross-linking of the extrinsic 33-kDa protein leads to loss of oxygen evolution but not its ability of binding to photosystem II and stabilization of the manganese cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							33 KDA PROTEIN; 16-KDA PROTEINS; 12-KDA PROTEIN; CALCIUM-IONS; SPINACH; MN; RECONSTITUTION; POLYPEPTIDE; PARTICLES; COMPLEX	The extrinsic 33-kDa protein of photosystem II (PSII) was intramolecularly cross-linked by a zero-length cross-linker, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. The resulting cross linked 33-kDa protein rebound to urea/NaCl-washed PSII membranes, which stabilized the binding of manganese as effectively as the untreated 33-kDa protein, In contrast, the oxygen evolution was not restored by binding of the cross-linked protein, indicating that the binding and manganese stabilizing capabilities of the 33-kDa protein are retained but its reactivating ability is lost by intramolecular cross-linking of the protein, From measurements of CD spectra at high temperatures, the secondary structure of the intramolecularly cross-linked 33-kDa protein was found to be stabilized against heat treatment at temperatures 20 degrees C higher than that of the untreated 33-kDa protein, suggesting that structural flexibility of the 33-kDa protein was much decreased by the intramolecular cross-linking, The rigid structure is possibly responsible for the loss of the reactivating ability of the 33-kDa protein, which implies that binding of the 33-kDa protein to PSII is accompanied by a conformational change essential for the reactivation of oxygen evolution. Peptide mapping, N-terminal sequencing, and mass spectroscopic analysis of protease-digested products of the intramolecularly cross-linked 33-kDa protein revealed that cross-linkings occurred between the amino group of Lys(48) and the carboxyl group of Glu(246), and between the carboxyl group of Glu(10) and the amino group of Lys(14). These cross-linked amino acid residues are thus closely associated with each other through electrostatic interactions.	Sci Univ Tokyo, Fac Sci, Dept Biol, Shinjuku Ku, Tokyo 162, Japan	Tokyo University of Science	Enami, I (corresponding author), Sci Univ Tokyo, Fac Sci, Dept Biol, Shinjuku Ku, Kagurazaka 1-3, Tokyo 162, Japan.	enami@rs.noda.sut.ac.jp	Tomo, Tatsuya/K-7680-2012; Kamo, Masaharu/S-1280-2019	Tomo, Tatsuya/0000-0002-9369-1941; Kamo, Masaharu/0000-0001-6791-8754				AKERLUND HE, 1982, BIOCHIM BIOPHYS ACTA, V681, P1, DOI 10.1016/0005-2728(82)90271-7; ANDERSSON B, 1984, BIOCHIM BIOPHYS ACTA, V766, P21, DOI 10.1016/0005-2728(84)90212-3; ANDERSSON B, 1984, FEBS LETT, V168, P113, DOI 10.1016/0014-5793(84)80217-3; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Betts SD, 1996, BBA-BIOENERGETICS, V1274, P135, DOI 10.1016/0005-2728(96)00023-0; Betts SD, 1996, BIOCHEMISTRY-US, V35, P6302, DOI 10.1021/bi953066t; BRICKER TM, 1992, BIOCHEMISTRY-US, V31, P4623, DOI 10.1021/bi00134a012; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; BURNAP RL, 1994, BIOCHEMISTRY-US, V33, P13712, DOI 10.1021/bi00250a023; CHEN CG, 1995, BIOCHEMISTRY-US, V34, P13511, DOI 10.1021/bi00041a031; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; EATONRYE JJ, 1989, BIOCHIM BIOPHYS ACTA, V977, P219, DOI 10.1016/S0005-2728(89)80075-1; ENAMI I, 1991, BIOCHIM BIOPHYS ACTA, V1060, P224, DOI 10.1016/S0005-2728(09)91010-6; ENAMI I, 1994, BBA-BIOENERGETICS, V1186, P52, DOI 10.1016/0005-2728(94)90134-1; ENAMI I, 1989, BIOCHIM BIOPHYS ACTA, V977, P33, DOI 10.1016/S0005-2728(89)80006-4; ENAMI I, 1994, BBA-BIOENERGETICS, V1185, P75, DOI 10.1016/0005-2728(94)90195-3; Enami I, 1995, BBA-BIOENERGETICS, V1232, P208, DOI 10.1016/0005-2728(95)00122-0; ENAMI L, 1997, BIOCHIM BIOPHYS ACTA, V1320, P17; FRANZEN LG, 1984, BIOCHIM BIOPHYS ACTA, V765, P166, DOI 10.1016/0005-2728(84)90010-0; GHANOTAKIS DF, 1985, PHOTOSYNTH RES, V7, P97, DOI 10.1007/BF00037001; GHANOTAKIS DF, 1984, FEBS LETT, V170, P169, DOI 10.1016/0014-5793(84)81393-9; KUWABARA T, 1985, BIOCHIM BIOPHYS ACTA, V806, P283, DOI 10.1016/0005-2728(85)90107-0; KUWABARA T, 1983, PLANT CELL PHYSIOL, V24, P741, DOI 10.1093/oxfordjournals.pcp.a076571; KUWABARA T, 1986, BIOCHIM BIOPHYS ACTA, V850, P146, DOI 10.1016/0005-2728(86)90019-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIURA K, 1993, BIOCHIM BIOPHYS ACTA, V1172, P357, DOI 10.1016/0167-4781(93)90232-3; Miura T, 1997, J BIOL CHEM, V272, P3788, DOI 10.1074/jbc.272.6.3788; MIYAO M, 1984, FEBS LETT, V168, P118, DOI 10.1016/0014-5793(84)80218-5; MIYAO M, 1985, FEBS LETT, V180, P303, DOI 10.1016/0014-5793(85)81091-7; MIYAO M, 1984, FEBS LETT, V170, P350, DOI 10.1016/0014-5793(84)81342-3; MIYAO M, 1986, PHOTOSYNTH RES, V10, P489, DOI 10.1007/BF00118315; MIYAO M, 1989, BIOCHIM BIOPHYS ACTA, V977, P315, DOI 10.1016/S0005-2728(89)80086-6; MIYAO M, 1987, TOPICS PHOTOSYNTHESI, V9, P289; MOTOKI A, 1992, RES PHOTOSYNTHESIS, V2, P413; OHTA H, 1995, PHOTOSYNTHESIS LIGHT, V2, P361; ONO T, 1984, FEBS LETT, V168, P281, DOI 10.1016/0014-5793(84)80263-X; ONO T, 1984, FEBS LETT, V166, P381, DOI 10.1016/0014-5793(84)80117-9; ONO TA, 1983, FEBS LETT, V164, P255, DOI 10.1016/0014-5793(83)80297-X; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Seidler A, 1996, BBA-BIOENERGETICS, V1277, P35, DOI 10.1016/S0005-2728(96)00102-8; SHEN JR, 1991, PLANT CELL PHYSIOL, V32, P453, DOI 10.1093/oxfordjournals.pcp.a078101; SHEN JR, 1992, FEBS LETT, V301, P145, DOI 10.1016/0014-5793(92)81235-E; SHEN JR, 1993, BIOCHEMISTRY-US, V32, P1825, DOI 10.1021/bi00058a017; Shutova T, 1997, BIOCHEMISTRY-US, V36, P6350, DOI 10.1021/bi963115h; TANAKA S, 1989, BIOCHEMISTRY-US, V28, P7188, DOI 10.1021/bi00444a009; TANAKA S, 1988, PHOTOSYNTH RES, V17, P255, DOI 10.1007/BF00035452; VASS I, 1992, BIOCHIM BIOPHYS ACTA, V1102, P195, DOI 10.1016/0005-2728(92)90100-G; VASS I, 1987, BIOCHIM BIOPHYS ACTA, V892, P224, DOI 10.1016/0005-2728(87)90178-2; XU Q, 1994, BBA-BIOENERGETICS, V1188, P427, DOI 10.1016/0005-2728(94)90065-5	49	61	64	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4629	4634		10.1074/jbc.273.8.4629	http://dx.doi.org/10.1074/jbc.273.8.4629			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468521	hybrid			2022-12-25	WOS:000072115000049
J	Gong, WH; Howard, OMZ; Turpin, JA; Grimm, MC; Ueda, H; Gray, PW; Raport, CJ; Oppenheim, JJ; Wang, JM				Gong, WH; Howard, OMZ; Turpin, JA; Grimm, MC; Ueda, H; Gray, PW; Raport, CJ; Oppenheim, JJ; Wang, JM			Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; MULTIPLE LEUKOCYTE RECEPTORS; CHEMOKINE RECEPTORS; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; UNIQUE RECEPTORS; MCP3 INTERACTS; RANTES; MIP-1-ALPHA; MIP-1-BETA	Human immunodeficiency virus, type I (HIV-1) cell-type tropism is dictated by chemokine receptor usage: T-cell line tropic viruses use CXCR4, whereas monocyte tropic viruses primarily use CCR5 as fusion coreceptors. CC chemokines macrophage inflammatory protein (MIP)-1 alpha, MIP-1 beta, and RANTES (regulated on activation normal T cell expressed and secreted) inhibit CD4/CCR5-mediated HIV-1 cell fusion, MCP-2 is also a member of the CC chemokine subfamily and has the capacity to interact with at least two receptors including CCR-1 and CCR2B. In an effort to further characterize the binding properties of MCP-2 on leukocytes, we observed that MCP-2, but not MCP-1, effectively competed with MIP-1 beta for binding to monocytes, suggesting that MCP-2 may interact with CCR5, As predicted, MCP-2 competitively inhibited MIP-1 beta binding to HEK293 cells stably transfected with CCR5 (CCR5/293 cells). MCP-2 also bound to and induced chemotaxis of CCR5/293 cells with a potency comparable with that of MIP-1 beta. Confocal microscopy indicates that MCP-2 caused remarkable and dose-dependent internalization of CCR5 in CCR5/ 293 cells. Furthermore, MCP-2 inhibited the entry/replication of HIV-1ADA in CCR5/293 cells coexpressing CD4. These results indicated that MCP-2 uses CCR5 as one of its functional receptors and is an additional potent natural inhibitor of HIV-1.	NCI, Frederick Canc Res & Dev Ctr, LMI, DBS, Frederick, MD 21702 USA; SAIC, Intramural Res Support Program, Frederick, MD USA; SAIC, Intramural Res Support Program, Frederick, MD USA; SAIC, Dev Therapeut Program, Frederick, MD USA; ICOS Corp, Bothell, WA 98021 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); SAIC-Frederick; Icos Corporation	Wang, JM (corresponding author), NCI, Frederick Canc Res & Dev Ctr, LMI, DBS, Bldg 560,Rm 31-19, Frederick, MD 21702 USA.		Howard, O M Zack/B-6117-2012	Howard, O M Zack/0000-0002-0505-7052; Grimm, Michael/0000-0001-9426-3917				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; DECOCK B, 1990, BIOCHEM BIOPH RES CO, V167, P904, DOI 10.1016/0006-291X(90)90609-Q; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FRANCI C, 1995, J IMMUNOL, V154, P6511; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; HOWARD OMZ, 1995, BIOCHEM J, V306, P217, DOI 10.1042/bj3060217; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; OBERLIN E, 1996, NATURE, V382, P333; Oppenheim Joost J., 1996, P187; Proost P, 1996, J LEUKOCYTE BIOL, V59, P67, DOI 10.1002/jlb.59.1.67; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SOZZANI S, 1994, J IMMUNOL, V152, P3615; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; WANG JM, 1993, J IMMUNOL, V150, P3022; XU LL, 1995, EUR J IMMUNOL, V25, P2612, DOI 10.1002/eji.1830250931; Xu LL, 1996, J LEUKOCYTE BIOL, V60, P365, DOI 10.1002/jlb.60.3.365; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	31	108	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4289	4292		10.1074/jbc.273.8.4289	http://dx.doi.org/10.1074/jbc.273.8.4289			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468473	hybrid			2022-12-25	WOS:000072115000001
J	Luo, WS; Chu, GX; Sato, Y; Zhou, ZP; Kadambi, VJ; Kranias, EG				Luo, WS; Chu, GX; Sato, Y; Zhou, ZP; Kadambi, VJ; Kranias, EG			Transgenic approaches to define the functional role of dual site phospholamban phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC STIMULATION; CARDIAC SARCOPLASMIC-RETICULUM; GUINEA-PIG VENTRICLES; CA-2+ TRANSPORT; MECHANISMS; HEARTS; INHIBITORS; MICE; GENE	Phospholamban is a critical regulator of the sarcoplasmic reticulum Ca2+-ATPase activity and myocardial contractility, Phosphorylation of phospholamban occurs on both Ser(16) and Thr(17) during isoproterenol stimulation, To determine the physiological significance of dual site phospholamban phosphorylation, we generated transgenic models expressing either wild-type or the Ser(16) --> Ala mutant phospholamban in the cardiac compartment of the phospholamban knockout mice. Transgenic lines with similar levels of mutant or wild-type phospholamban were studied in parallel, Langendorff perfusion indicated that the basal hyperdynamic cardiac function of the knockout mouse was reversed to the same extent by reinsertion of either wild-type or mutant phospholamban, However, isoproterenol stimulation was associated with much lower responses in the contractile parameters of mutant phospholamban compared with wild-type hearts, These attenuated responses were due to lack of phosphorylation of mutant phospholamban, assessed in P-32 labelin, a perfusion experiments, The lack of phospholamban phosphorylation in vivo was not due to conversion of Ser(16) to Ala, since the mutated phospholamban form could serve as substrate for the calcium-calmodulin-dependent protein kinase in vitro. These findings indicate that phosphorylation of Ser(16) is a prerequisite for Thr(17) phosphorylation in phospholamban, and prevention of phosphoserine formation results in attenuation of the beta-agonist stimulatory responses in the mammalian heart.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Bethesda Ave,POB 670575, Cincinnati, OH 45267 USA.				NHLBI NIH HHS [HL26057, HL22619, HL52318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, R37HL026057, P50HL052318, R01HL026057] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSANI RA, 1995, AM J PHYSIOL-HEART C, V268, pH703, DOI 10.1152/ajpheart.1995.268.2.H703; BILEZIKJIAN LM, 1981, CIRC RES, V49, P1356, DOI 10.1161/01.RES.49.6.1356; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; COLYER J, 1991, J BIOL CHEM, V266, P17486; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; Hulme JT, 1997, PFLUG ARCH EUR J PHY, V434, P475, DOI 10.1007/s004240050423; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Kiss E, 1997, AM J PHYSIOL-HEART C, V272, pH785, DOI 10.1152/ajpheart.1997.272.2.H785; KRANIAS EG, 1985, BIOCHIM BIOPHYS ACTA, V844, P193, DOI 10.1016/0167-4889(85)90090-4; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; LINDEMANN JP, 1985, J BIOL CHEM, V260, P3122; LINDEMANN JP, 1985, J BIOL CHEM, V260, P4516; Luo WS, 1996, CIRC RES, V78, P839, DOI 10.1161/01.RES.78.5.839; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MATTIAZZI A, 1994, AM J PHYSIOL, V267, pH812, DOI 10.1152/ajpheart.1994.267.2.H812; MundinaWeilenmann C, 1996, AM J PHYSIOL-CELL PH, V270, pC107, DOI 10.1152/ajpcell.1996.270.1.C107; MundinaWeilenmann C, 1996, J BIOL CHEM, V271, P33561, DOI 10.1074/jbc.271.52.33561; NAPOLITANO R, 1992, J MOL CELL CARDIOL, V24, P387, DOI 10.1016/0022-2828(92)93193-N; RAEYMAEKERS L, 1988, BIOCHEM J, V252, P269, DOI 10.1042/bj2520269; RAPUNDALO ST, 1989, CIRC RES, V64, P104, DOI 10.1161/01.RES.64.1.104; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TALOSI L, 1993, AM J PHYSIOL, V264, pH791; VITTONE L, 1993, MOL CELL BIOCHEM, V124, P33, DOI 10.1007/BF01096379; VITTONE L, 1990, AM J PHYSIOL, V258, pH318, DOI 10.1152/ajpheart.1990.258.2.H318; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; Wolska BM, 1996, AM J PHYSIOL-CELL PH, V271, pC391, DOI 10.1152/ajpcell.1996.271.1.C391	27	88	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4734	4739		10.1074/jbc.273.8.4734	http://dx.doi.org/10.1074/jbc.273.8.4734			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468536	hybrid			2022-12-25	WOS:000072115000064
J	Venkateswarlu, K; Lamb, DC; Kelly, DE; Manning, NJ; Kelly, SL				Venkateswarlu, K; Lamb, DC; Kelly, DE; Manning, NJ; Kelly, SL			The N-terminal membrane domain of yeast NADPH-cytochrome P450 (CYP) oxidoreductase is not required for catalytic activity in sterol biosynthesis or in reconstitution of CYP activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; P-450 REDUCTASE; CANDIDA-ALBICANS; ERGOSTEROL BIOSYNTHESIS; GENE; 14-ALPHA-DEMETHYLASE; PURIFICATION; KETOCONAZOLE; FLUCONAZOLE; INHIBITION	The disruption of Saccharomyces cerevisiae NADPH-cytochrome P450 oxidoreductase (CPR) gene resulted in a viable strain accumulating approximately 25% of the ergosterol observed in a sterol wild-type parent. The associated phenotypes could be reversed in transformants after expression of native CPR and a mutant lacking the N-terminal 33 amino acids, which localized in the cytosol. This indicated availability of the CPR in each case to function with the monooxygenases squalene epoxidase, CYP51, and CYP61 in the ergosterol biosynthesis pathway. Purification of the cytosolic mutant CPR indicated properties identical to native CPR and an ability to reconstitute ergosterol biosynthesis when added to a cell-free system, as well as to allow reconstitution of activity with purified CYP61, sterol 22-desaturase. This was also observed for purified Candida albicans and human CYP51 in reconstituted systems. The ability of the yeast enzyme to function in a soluble form differed from human CPR, which is shown to be inactive in reconstituting CYP activity.	Univ Wales, Inst Biol Sci, Aberystwyth SY23 3DA, Dyfed, Wales; Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomolec Res, Sheffield S10 2UH, S Yorkshire, England; Sheffields Childrens Hosp, Neonatal Screening Lab, Sheffield S10 2UH, S Yorkshire, England	Aberystwyth University; University of Sheffield; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital	Kelly, SL (corresponding author), Univ Wales, Inst Biol Sci, Aberystwyth SY23 3DA, Dyfed, Wales.		Kanamarlapudi, Venkateswarlu/A-9864-2011	Kanamarlapudi, Venkateswarlu/0000-0002-8739-1483				AOYAMA Y, 1978, ARCH BIOCHEM BIOPHYS, V185, P362, DOI 10.1016/0003-9861(78)90178-9; AOYAMA Y, 1989, J BIOL CHEM, V264, P18502; BLACK SD, 1982, J BIOL CHEM, V257, P5929; DJORDJEVIC S, 1995, P NATL ACAD SCI USA, V92, P3214, DOI 10.1073/pnas.92.8.3214; HATA S, 1987, AGR BIOL CHEM TOKYO, V51, P1349, DOI 10.1080/00021369.1987.10868199; IMAI Y, 1981, J BIOCHEM-TOKYO, V89, P351, DOI 10.1093/oxfordjournals.jbchem.a133209; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KALB VF, 1987, DNA-J MOLEC CELL BIO, V6, P529, DOI 10.1089/dna.1987.6.529; Kelly SL, 1995, FEBS LETT, V377, P217, DOI 10.1016/0014-5793(95)01342-3; Kelly SL, 1997, J BIOL CHEM, V272, P9986, DOI 10.1074/jbc.272.15.9986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb DC, 1997, J BIOL CHEM, V272, P5682, DOI 10.1074/jbc.272.9.5682; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; QUAIL MA, 1993, PHYTOCHEMISTRY, V32, P273, DOI 10.1016/S0031-9422(00)94980-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEVRIOUKOVA IF, 1995, BIOCHIMIE, V77, P562, DOI 10.1016/0300-9084(96)88172-7; SHEN AL, 1989, J BIOL CHEM, V264, P7584; Shyadehi AZ, 1996, J BIOL CHEM, V271, P12445, DOI 10.1074/jbc.271.21.12445; Skaggs BA, 1996, GENE, V169, P105, DOI 10.1016/0378-1119(95)00770-9; SUTTER TR, 1989, BIOCHEM BIOPH RES CO, V160, P1257, DOI 10.1016/S0006-291X(89)80139-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUN G, 1994, GENE, V149, P123; VENKATESWARLU K, 1995, FEMS MICROBIOL LETT, V131, P337, DOI 10.1111/j.1574-6968.1995.tb07797.x; Venkateswarlu K, 1996, ANTIMICROB AGENTS CH, V40, P1382, DOI 10.1128/AAC.40.6.1382; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; VERMILION JL, 1981, J BIOL CHEM, V256, P266; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WEETE JD, 1989, ADV LIPID RES, V23, P115; YABUSAKI Y, 1988, J BIOCHEM-TOKYO, V103, P1004, DOI 10.1093/oxfordjournals.jbchem.a122370; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701; Yoshida Y, 1988, Curr Top Med Mycol, V2, P388	31	51	56	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4492	4496		10.1074/jbc.273.8.4492	http://dx.doi.org/10.1074/jbc.273.8.4492			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468503	hybrid			2022-12-25	WOS:000072115000031
J	Guo, YL; Baysal, K; Kang, B; Yang, LJ; Williamson, JR				Guo, YL; Baysal, K; Kang, B; Yang, LJ; Williamson, JR			Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factor-alpha in rat mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B; JNK ACTIVATION; IN-VITRO; STRESS; DEATH; PROLIFERATION; SUPPRESSION; FIBROBLASTS; INVITRO; PATHWAY	Rat mesangial cells are normally resistant to tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis, In this report we show that the cells can be made susceptible to the apoptotic effect of TNF-alpha when pretreated with actinomycin D, cycloheximide, or vanadate. c-Jun N-terminal protein kinase (JNK) has been thought to mediate apoptotic processes elicited by some stimuli, but its involvement in TNF-alpha-induced apoptosis has been controversial, JNK activation was investigated under conditions where the mesangial cells were either resistant or susceptible to TNF-alpha-induced apoptosis, TNF-alpha alone stimulated a single transient JNK activity peak, However, when the cells were pretreated with actinomycin D or cycloheximide, TNF-alpha stimulated a second sustained JNK activity peak. When the cells were pretreated with the phosphatase inhibitor vanadate, TNF-alpha-induced JNK activation was greatly prolonged, In all three cases, a sustained JNK activation was associated with the initiation of apoptosis. Our data suggest that a sustained activation of JNK induced by these reagents may be associated with blocking the expression of a phosphatase that inactivates JNK, Further studies reveal that the expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) was induced by TNF-alpha, indicating that MKP-1 may be involved in protecting the cells from apoptosis by preventing a prolonged activation of JNK under normal conditions. Additional studies showed that extracellular signal-regulated protein kinase activation stimulated by TNF-alpha was unlikely to contribute to the resistance of mesangial cells to TNF-alpha cytotoxicity.	Univ Penn, Dept Biochem & Biophys, Goddard Labs 601, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Williamson, JR (corresponding author), Univ Penn, Dept Biochem & Biophys, Goddard Labs 601, Sch Med, 37th & Hamilton Walk, Philadelphia, PA 19104 USA.	johnrwil@mail.med.upenn.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048493, R01DK015120] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-48493, DK-15120, DK-07314] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal V. R., 1997, CURR BIOL, V7, P94; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cosulich S, 1996, CURR BIOL, V6, P1586, DOI 10.1016/S0960-9822(02)70779-3; DAVIES M, 1994, KIDNEY INT, V45, P320, DOI 10.1038/ki.1994.41; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; GINES P, 1995, HEPATOLOGY, V22, P1296, DOI 10.1002/hep.1840220440; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GUO YL, 1990, PLANT PHYSIOL, V94, P143, DOI 10.1104/pp.94.1.143; Han YQ, 1997, J BIOL CHEM, V272, P9825; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KREISBERG JI, 1978, KIDNEY INT, V14, P21, DOI 10.1038/ki.1978.86; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEIST M, 1994, J IMMUNOL, V153, P1778; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; Li YC, 1997, J BIOL CHEM, V272, P20646, DOI 10.1074/jbc.272.33.20646; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Liu ZH, 1996, AM J PHYSIOL-CELL PH, V270, pC1595, DOI 10.1152/ajpcell.1996.270.6.C1595; LUBINUS M, 1994, J BIOL CHEM, V269, P9822; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; SKEHAN P, 1995, CELL GROWTH APOPTOSI, P179; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	50	236	240	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4027	4034		10.1074/jbc.273.7.4027	http://dx.doi.org/10.1074/jbc.273.7.4027			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461593	hybrid			2022-12-25	WOS:000072048400035
J	Orr, MS; Reinhold, W; Yu, LJ; Schreiber-Agus, N; O'Connor, PM				Orr, MS; Reinhold, W; Yu, LJ; Schreiber-Agus, N; O'Connor, PM			An important role for the retinoblastoma protein in staurosporine-induced G(1) arrest in murine embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; INHIBITOR STAUROSPORINE; POTENT INHIBITOR; G1 PHASE; 2 POINTS; PROGRESSION; CANCER; P21; PHOSPHORYLATION	In this study, we investigated the molecular basis of the ability of staurosporine to induce G(1) arrest in murine embryonic fibroblasts (MEFs), We used MEFs from transgenic mice lacking several negative regulators of the G(1)/S phase transition including cells from mice lacking p53, p21, retinoblastoma (Rb), or p16 genes. We found that p53 function was not essential for staurosporine-induced G(1) arrest. In contrast, MEFs from mice lacking Rb genes showed approximately a 70% reduced capacity to arrest in the G(1) phase following staurosporine treatment, In support of a role for Rb in staurosporine-induced G(1) arrest, rat embryonic fibroblasts stably overexpressing cyclin D1/Cdk4(R24C) exhibited approximately a 50% reduced G(1) arrest response to staurosporine. The role of Rb in determining the degree of staurosporine-induced G(1) arrest did not depend on the function of the cyclin-dependent kinase inhibitors p16 or p21 because MEFs lacking either of these genes were still capable of undergoing G(1) arrest following staurosporine exposure. Our studies provide evidence of an important role for the Rb protein in determining the degree of staurosporine-induced G(1) arrest in the first cell cycle.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 11724 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Yeshiva University; Albert Einstein College of Medicine	O'Connor, PM (corresponding author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bldg 37,Rm 5D09, Bethesda, MD 20892 USA.	po18c@nih.gov	Reinhold, William/J-6704-2017	Reinhold, William/0000-0001-5513-9323				AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1995, CANCER RES, V55, P1649; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KASTAN MB, 1991, CANCER RES, V51, P6304; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kwon TK, 1996, CELL GROWTH DIFFER, V7, P1305; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MICHIELI P, 1994, CANCER RES, V54, P3391; NEVINS JR, 1992, SCIENCE, V258, P424; OCONNOR PM, 1993, CANCER RES, V53, P4776; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; SCHNIER JB, 1994, CANCER RES, V54, P5959; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; TAM SW, 1994, ONCOGENE, V9, P2663; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	36	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3803	3807		10.1074/jbc.273.7.3803	http://dx.doi.org/10.1074/jbc.273.7.3803			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461560	hybrid			2022-12-25	WOS:000072048400002
J	Sims, CE; Allbritton, NL				Sims, CE; Allbritton, NL			Metabolism of inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate by the oocytes of Xenopus laevis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TRIS-TETRAKISPHOSPHATE PATHWAY; BRUTONS TYROSINE KINASE; SECRETING RINM5F CELLS; HUMAN-PLATELETS; RAT-BRAIN; OVARIAN FOLLICLES; 3-KINASE ACTIVITY; CA2+ RELEASE; TRISPHOSPHATE	The pathway and kinetics of inositol 4,4,5-trisphosphate (IP3) metabolism were measured in Xenopus laevis oocytes and cytoplasmic extracts of oocytes, Degradation of microinjected IP,in intact oocytes was similar to that in the extracts containing comparable concentrations of IP3 ([IP3]). The rate and route of metabolism of IP3 depended on the [IP3] and the intracellular free Ca2+ concentration ([Ca2+]), At low [IP3] (100 nM) and high [Ca2+] (greater than or equal to 1 mu M), IP3 was metabolized predominantly by inositol 1,4,5-trisphosphate 3-kinase (3-kinase) with a half-life of 60 s, As the [IP](3) was increased, inositol polyphosphate 5-phosphatase (5-phosphatase) degraded progressively more IP3. At a [IP3] of 8 mu M or greater, the dephosphorylation of IP3 was the dominant mode of IP3 removal irrespective of the [Ca2+]. At low [IP3] and low [Ca2+] (both less than or equal to 400 nM), the activities of the 5-phosphatase and 5-kinase were comparable. The calculated range of action of IP3 in the oocyte was similar to 300 mu M suggesting that IP3 acts as a global messenger in oocytes. in contrast to IP3 inositol 1,3,4,5-tetrakisphosphate (IP4) was metabolized very slowly. The half-life of IP4 (100 nM) was 20 min and independent of the [Ca2+]. IP4 may act to sustain Ca2+ signals initiated by IP3. The half-life of both IP3 and IP4 in Xenopus oocytes was are order of magnitude or greater than that in small mammalian cells.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Allbritton, NL (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.				NIMH NIH HHS [MH45324] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045324] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIDEN TJ, 1988, BIOCHEM J, V251, P435, DOI 10.1042/bj2510435; BIDEN TJ, 1987, J BIOL CHEM, V262, P3567; BIDEN TJ, 1986, J BIOL CHEM, V261, P1931; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BURGESS GM, 1985, BIOCHEM J, V232, P237, DOI 10.1042/bj2320237; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CONNOLLY TM, 1987, J BIOL CHEM, V262, P2146; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; CRANK J, 1989, MATH DIFFUSION, P29; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DANIEL JL, 1988, BIOCHEM J, V253, P789, DOI 10.1042/bj2530789; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; FERGUSON JE, 1991, EXP CELL RES, V192, P352, DOI 10.1016/0014-4827(91)90052-V; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, P511; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1995, BIOCHEM SOC T, V23, P27, DOI 10.1042/bst0230027; JOHANSON RA, 1988, J BIOL CHEM, V263, P7465; KING WG, 1989, J BIOL CHEM, V264, P6070; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LIN AN, 1990, BIOCHEM BIOPH RES CO, V170, P1371, DOI 10.1016/0006-291X(90)90546-Y; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; LoomisHusselbee JW, 1996, BIOCHEM J, V314, P811, DOI 10.1042/bj3140811; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MCINTOSH RP, 1990, BIOCHEM J, V268, P141, DOI 10.1042/bj2680141; MCINTOSH RP, 1990, BIOCHEM BIOPH RES CO, V166, P380, DOI 10.1016/0006-291X(90)91956-S; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; MORRIS AJ, 1987, BIOCHEM J, V248, P489, DOI 10.1042/bj2480489; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NUCCITELLI R, 1993, DEV BIOL, V158, P200, DOI 10.1006/dbio.1993.1179; PARKER I, 1991, J PHYSIOL-LONDON, V433, P207, DOI 10.1113/jphysiol.1991.sp018422; RYU SH, 1987, FASEB J, V1, P388, DOI 10.1096/fasebj.1.5.2824270; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SEGEL IH, 1975, BIOCH CALCULATIONS, P225; Shapira Hagit, 1992, Journal of Basic and Clinical Physiology and Pharmacology, V3, P119; SHAYMAN JA, 1988, BIOCHEM BIOPH RES CO, V151, P114, DOI 10.1016/0006-291X(88)90566-9; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; SIM SS, 1990, J BIOL CHEM, V265, P10367; SULPICE JC, 1990, METHODS INOSITIDE RE, P45; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; WALKER JW, 1987, NATURE, V327, P429; WANG SSH, 1995, J GEN PHYSIOL, V105, P149, DOI 10.1085/jgp.105.1.149; WREGGETT KA, 1987, BIOCHEM J, V245, P933, DOI 10.1042/bj2450933; YAMAGUCHI K, 1987, BIOCHEM J, V244, P787, DOI 10.1042/bj2440787; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	53	80	81	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4052	4058		10.1074/jbc.273.7.4052	http://dx.doi.org/10.1074/jbc.273.7.4052			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461597	hybrid			2022-12-25	WOS:000072048400039
J	Aeschlimann, D; Koeller, MK; Allen-Hoffmann, BL; Mosher, DF				Aeschlimann, D; Koeller, MK; Allen-Hoffmann, BL; Mosher, DF			Isolation of a cDNA encoding a novel member of the transglutaminase gene family from human keratinocytes - Detection and identification of transglutaminase gene products based on reverse transcription polymerase chain reaction with degenerate primers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; COAGULATION FACTOR-XIII; AMINO-ACID-SEQUENCE; TISSUE TRANSGLUTAMINASE; CROSS-LINKING; MEMBRANE-PROTEIN; MOLECULAR-CLONING; ERYTHROCYTE PROTEIN-4.2; LAMELLAR ICHTHYOSIS; MESSENGER-RNA	We developed a method using a single set of degenerate oligonucleotide primers for amplification of the conserved active site of transglutaminases by reverse transcription-polymerase chain reaction (RT-PCR) and identification of the PCR products by cleavage with diagnostic restriction enzymes. We demonstrate amplification of tissue transglutaminase (TG(C)), keratinocyte transglutaminase (TG(K)), prostate transglutaminase (TG(P)), the a-subunit of factor XIII, and band 4.2 protein from different human cells or tissues, Analysis of normal human keratinocytes revealed expression of a transglutaminase different from the expected and characterized transglutaminase gene products. A full-length cDNA for the novel transglutaminase (TG(X)) was obtained by anchored PCR. The deduced amino acid sequence encoded a protein with 720 amino acids and a molecular mass of similar to 81 kDa. A comparison of TG(X) to the other members of the gene family revealed that the domain structure and the residues required for enzymatic activity and Ca2+ binding are conserved and showed an overall sequence identity of about 35%. Two transcripts with an apparent size of 2.2 and 2.8 kilobases were detected with a specific probe for TG(X) on Northern blots of human foreskin keratinocyte mRNA, indicating the presence of alternatively spliced mRNAs. cDNA sequencing revealed a shorter TG(X) transcript lacking the sequence homologous to that encoded by exon III of other transglutaminase genes. TG(X) expression increased severalfold when keratinocyte cultures were induced to differentiate by suspension or growth to postconfluency, suggesting that TG(X) contributes to the formation of the cornified envelope.	Univ Wisconsin, Div Orthoped Surg, Clin Sci Ctr F4312, Madison, WI 53792 USA; Univ Wisconsin, Dept Med, Madison, WI 53792 USA; Univ Wisconsin, Dept Pathol, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Aeschlimann, D (corresponding author), Univ Wisconsin, Div Orthoped Surg, Clin Sci Ctr F4312, 600 Highland Ave, Madison, WI 53792 USA.			Aeschlimann, Daniel/0000-0003-0930-7706	NHLBI NIH HHS [HL21644] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ALLENHOFFMANN BL, 1984, P NATL ACAD SCI-BIOL, V81, P7802, DOI 10.1073/pnas.81.24.7802; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; COHEN CM, 1993, SEMIN HEMATOL, V30, P119; Dubbink HJ, 1996, BIOCHEM J, V315, P901, DOI 10.1042/bj3150901; Esposito C, 1996, J BIOL CHEM, V271, P27416, DOI 10.1074/jbc.271.44.27416; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FRAIJ BM, 1992, J BIOL CHEM, V267, P22616; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GENTILE V, 1991, J BIOL CHEM, V266, P478; GRANT FJ, 1994, BIOCHEM BIOPH RES CO, V203, P1117, DOI 10.1006/bbrc.1994.2298; GREENBERG CS, 1988, BIOCHEM J, V256, P1013, DOI 10.1042/bj2561013; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; GRUNDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024, DOI 10.1073/pnas.83.21.8024; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; HO KC, 1992, J BIOL CHEM, V267, P12660; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM IG, 1994, J INVEST DERMATOL, V103, P137, DOI 10.1111/1523-1747.ep12392470; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KORSGREN C, 1991, P NATL ACAD SCI USA, V88, P4840, DOI 10.1073/pnas.88.11.4840; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LICHTI U, 1985, J BIOL CHEM, V260, P1422; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MARTINEZ J, 1994, BIOCHEMISTRY-US, V33, P2538, DOI 10.1021/bi00175a024; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nurminskaya M, 1996, DEV DYNAM, V206, P260, DOI 10.1002/(SICI)1097-0177(199607)206:3<260::AID-AJA4>3.0.CO;2-G; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; POON MC, 1989, J CLIN INVEST, V84, P787, DOI 10.1172/JCI114237; Raghunath M, 1996, J CLIN INVEST, V98, P1174, DOI 10.1172/JCI118901; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RISINGER MA, 1992, J BIOL CHEM, V267, P5680; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; RYBICKI AC, 1994, MAMM GENOME, V5, P438, DOI 10.1007/BF00357005; SCHENKER T, 1996, APOPTOSIS, V1, P126; SOTTILE J, 1989, THROMB HAEMOSTASIS, V62, P1100; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; SUNG LPA, 1992, BLOOD, V79, P2763; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; UPCHURCH HF, 1987, IN VITRO CELL DEV B, V23, P795; WERAARCHAKULBOONMARK N, 1992, P NATL ACAD SCI USA, V89, P9804, DOI 10.1073/pnas.89.20.9804; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Yee Vivien C., 1996, Seminars in Thrombosis and Hemostasis, V22, P377, DOI 10.1055/s-2007-999035	57	82	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3452	3460		10.1074/jbc.273.6.3452	http://dx.doi.org/10.1074/jbc.273.6.3452			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452468	hybrid, Green Accepted			2022-12-25	WOS:000071822300053
J	Matsushita, O; Jung, CM; Minami, J; Katayama, S; Nishi, N; Okabe, A				Matsushita, O; Jung, CM; Minami, J; Katayama, S; Nishi, N; Okabe, A			A study of the collagen-binding domain of a 116-kDa Clostridium histolyticum collagenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; INDIVIDUAL COLLAGENASES; NUCLEOTIDE-SEQUENCE; SECONDARY-STRUCTURE; III COLLAGENS; CLASS-I; GENE; PURIFICATION; PROPELLER; PROTEINS	gThe Clostridium histolyticum 116-kDa collagenase consists of four segments, S1, S2a, S2b, and S3. A 98-kDa gelatinase, which can degrade denatured but not native collagen, lacks the C-terminal fragment containing a part of S2b and S3. In this paper we have investigated the function of the C-terminal segments using recombinant proteins, Full-length collagenase degraded both native type I collagen and a synthetic substrate, Pz-peptide, while an 88-kDa protein containing only S1 and S2a (S1S2a) degraded only Pt-peptide. Unlike the full-length enzyme, S1S2a did not bind to insoluble type I collagen. To determine the molecular determinant of collagen binding activity, various C-terminal regions were fused to the C terminus of glutathione S-transferase. S3 as well as S2bS3 conferred collagen binding, However, a glutathione S-transferase fusion protein with a region shorter than S3 exhibited reduced collagen binding activity. S3 liberated from the fusion protein also showed collagen binding activity, but not S2aS2b or S2b. S1 had 100% of the Pz-peptidase activity but only 5% of the collagenolytic activity of the full-length collagenase. These results indicate that S1 and S3 are the catalytic and binding domains, respectively, and that S2a and S2b form an interdomain structure.	Kagawa Med Univ, Fac Med, Dept Microbiol, Kagawa 7610793, Japan; Kagawa Med Univ, Fac Med, Dept Endocrinol, Kagawa 7610793, Japan	Kagawa University; Kagawa University	Okabe, A (corresponding author), Kagawa Med Univ, Fac Med, Dept Microbiol, 1750-1 Miki Cho, Kagawa 7610793, Japan.	microbio@kms.ac.jp		Nishi, Nozomu/0000-0001-7050-3226				Bethesda Research Laboratories, 1986, FOCUS, V8, P9; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BOND MD, 1984, BIOCHEMISTRY-US, V23, P3077, DOI 10.1021/bi00308a035; BOND MD, 1984, BIOCHEMISTRY-US, V23, P3085, DOI 10.1021/bi00308a036; BOND MD, 1984, BIOCHEMISTRY-US, V23, P3092, DOI 10.1021/bi00308a037; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; FRENCH MF, 1992, J PROTEIN CHEM, V11, P83, DOI 10.1007/BF01025095; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Henderson RM, 1996, P NATL ACAD SCI USA, V93, P8756, DOI 10.1073/pnas.93.16.8756; Jin F, 1996, INFECT IMMUN, V64, P230, DOI 10.1128/IAI.64.1.230-237.1996; Jung CM, 1996, MICROBIOL IMMUNOL, V40, P923, DOI 10.1111/j.1348-0421.1996.tb01161.x; KAWAMURA F, 1984, J BACTERIOL, V160, P442, DOI 10.1128/JB.160.1.442-444.1984; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; MALLYA SK, 1992, J PROTEIN CHEM, V11, P99, DOI 10.1007/BF01025096; MATSUSHITA O, 1994, J BACTERIOL, V176, P149, DOI 10.1128/JB.176.1.149-156.1994; Mayne R., 1987, STRUCTURE FUNCTION C; Mookhtiar K A, 1992, Matrix Suppl, V1, P116; MURZIN AG, 1992, PROTEINS, V14, P191, DOI 10.1002/prot.340140206; PETERKOFSKY B, 1982, METHOD ENZYMOL, V82, P453; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; STEINBRINK DR, 1985, J BIOL CHEM, V260, P2771; TAKEUCHI H, 1992, BIOCHEM J, V281, P703, DOI 10.1042/bj2810703; TRIEUCUOT P, 1991, GENE, V102, P99, DOI 10.1016/0378-1119(91)90546-N; VANWART HE, 1985, BIOCHEMISTRY-US, V24, P6520, DOI 10.1021/bi00344a032; Worthington C.C., 1988, WORTHINGTON ENZYME M; YOSHIHARA K, 1994, J BACTERIOL, V176, P6489, DOI 10.1128/JB.176.21.6489-6496.1994	29	109	117	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3643	3648		10.1074/jbc.273.6.3643	http://dx.doi.org/10.1074/jbc.273.6.3643			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452493	hybrid			2022-12-25	WOS:000071822300078
J	Patel, S; Santra, M; McQuillan, DJ; Iozzo, RV; Thomas, AP				Patel, S; Santra, M; McQuillan, DJ; Iozzo, RV; Thomas, AP			Decorin activates the epidermal growth factor receptor and elevates cytosolic Ca2+ in A431 carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SUPPRESSION; INHIBITION; INDUCTION	Several independent lines of evidence have implicated decorin, a small leucine-rich proteoglycan, in the inhibition of cell proliferation. However, the mechanism by which decorin mediates its effect on cell proliferation is unclear. Here we report, for the first time, decorin-mediated increases in intracellular Ca2+ levels of single A431 cells. The effects of decorin persisted in the absence of extracellular Ca2+ but were blocked by AG1478, an epidermal growth factor (EGF)-specific tyrosine kinase inhibitor, and by down-regulation of the EGF receptor. The effects of decorin were not mimicked by the structurally homologous protein, biglycan. Our results indicate a novel action of decorin on the EGF receptor, which results in mobilization of intracellular Ca2+ providing a possible mechanism by which decorin causes growth suppression.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Texas A&M Univ, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Texas A&M University System; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020; Thomas, Andrew/C-6755-2013; Patel, Sandip/O-9591-2015	Thomas, Andrew/0000-0002-9026-7467; Patel, Sandip/0000-0001-7247-2013; Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038422] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline; NIDDK NIH HHS [R01 DK38422] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADANY R, 1990, J BIOL CHEM, V265, P11389; BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MOSCATELLO DK, 1997, IN PRESS J CLIN INVE; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767	24	111	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3121	3124		10.1074/jbc.273.6.3121	http://dx.doi.org/10.1074/jbc.273.6.3121			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452417	hybrid			2022-12-25	WOS:000071822300002
J	Wang, Q; Driouch, K; Courtois, S; Champeme, MH; Bieche, I; Treilleux, I; Briffod, M; Rimokh, R; Magaud, JP; Curmi, P; Lidereau, R; Puisieux, A				Wang, Q; Driouch, K; Courtois, S; Champeme, MH; Bieche, I; Treilleux, I; Briffod, M; Rimokh, R; Magaud, JP; Curmi, P; Lidereau, R; Puisieux, A			Low frequency of TSG101/CC2 gene alterations in invasive human breast cancers	ONCOGENE			English	Article						human breast cancer; TSG101/CC2; rearrangement; mutation	HETEROZYGOSITY; CHROMOSOME-11; PHOSPHORYLATION; ADENOCARCINOMA; PHOSPHOPROTEIN; ONCOPROTEIN-18; INSTABILITY; PROGRESSION; EXPRESSION; STATHMIN	Large intragenic deletions of the TSG101/CC2 gene were recently reported in seven of 15 primary metastatic breast cancers. Although the number of samples was small, this observation suggested that TSG101/CC2 alterations were a major event in breast carcinogenesis. To study the frequency of these deletions in invasive breast cancers we analysed 189 primary invasive breast tumours and 59 breast cancer metastases. We detected intragenic rearrangements in only three samples (two primary tumours and one metastasis). Northern blot analysis of 43 tumours without rearrangements failed to detect any abnormalities. Furthermore, we studied TSG101/CC2 in 11 human breast adenocarcinoma cell lines by Southern blot, RT-PCR and sequencing of the entire coding region of the gene, and detected no abnormalities. These results show that genetic alteration of TSG101/CC2 is a rare event in breast cancer.	Ctr Leon Berard, Unite Oncol Mol, INSERM, U453, F-69373 Lyon 08, France; Ctr Rene Huguenin, Lab Oncogenet, F-92210 St Cloud, France; Ctr Leon Berard, Dept Anat & Cytol Pathol, F-69373 Lyon 08, France; Ctr Rene Huguenin, Lab Anatomocytopathol, F-92210 St Cloud, France; INSERM, U440, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Rene Huguenin Hospital; UNICANCER; Centre Leon Berard; Rene Huguenin Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm)	Puisieux, A (corresponding author), Ctr Leon Berard, Unite Oncol Mol, INSERM, U453, F-69373 Lyon 08, France.		Bièche, Ivan/O-7399-2017; CURMI, Patrick/G-4036-2013; Rimokh, Ruth/G-7506-2014	Bièche, Ivan/0000-0002-2430-5429; CURMI, Patrick A./0000-0001-5045-8501; PUISIEUX, Alain/0000-0002-9938-3798				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Baffa R, 1996, CANCER RES, V56, P268; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; BRATTSAND G, 1993, LEUKEMIA, V7, P569; CHENG KC, 1993, ADV CANCER RES, V60, P121; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FRIEDRICH B, 1995, PROSTATE, V27, P102, DOI 10.1002/pros.2990270207; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; HANASH SM, 1988, J BIOL CHEM, V263, P12813; KARNIK P, 1995, HUM MOL GENET, V4, P1889, DOI 10.1093/hmg/4.10.1889; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Lu KH, 1997, CANCER RES, V57, P387; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; Tran YK, 1996, CANCER RES, V56, P2916; WEBER JL, 1989, AM J HUM GENET, V44, P388; WINQVIST R, 1995, CANCER RES, V55, P2660	24	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					677	679		10.1038/sj.onc.1201563	http://dx.doi.org/10.1038/sj.onc.1201563			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482115				2022-12-25	WOS:000071816600014
J	Fushinobu, S; Ohta, T; Matsuzawa, H				Fushinobu, S; Ohta, T; Matsuzawa, H			Homotropic activation via the subunit interaction and allosteric symmetry revealed on analysis of hybrid enzymes of L-lactate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIFIDOBACTERIUM-LONGUM; ASPARTATE TRANSCARBAMOYLASE; LIGAND-BINDING; SITE; MECHANISM	L-Lactate dehydrogenase from Bifidobacterium lon-gum shows homotropic activation by pyruvate as well as heterotropic activation by fructose 1,6-bisphosphate, Hybrid enzymes were produced from the wild-type subunit and a mutant subunit, whose substrate specificity was altered to that of malate dehydrogenase, and separated to analyze the substrate-induced homotropic activation mechanism, Oxamate, a competitive inhibitor of L-lactate dehydrogenase, was used to mimic the substrate-induced activation of the wild-type subunit as "a regulatory subunit," The malate dehydrogenase activity of the mutant subunit as "the catalytic subunit" of the hybrid enzymes was measured, and the activity of the mutant subunit was activated on the addition of oxamate, Thus, we directly observed the inter-subunit homotropic activation transmitted from the wild-type to the mutant subunit, Moreover, "isomeric" hybrid enzymes that have different structural subunit arrangements but identical subunit compositions showed identical kinetic natures, This indicates that the enzyme maintains its subunit symmetry during the allosteric transition.	Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Matsuzawa, H (corresponding author), Univ Tokyo, Dept Biotechnol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.		Wood, David W/B-2992-2012; Fushinobu, Shinya/E-4987-2011	Fushinobu, Shinya/0000-0003-1346-6435				ACKERS GK, 1993, TRENDS BIOCHEM SCI, V18, P385, DOI 10.1016/0968-0004(93)90095-5; BLOOM CR, 1995, J MOL BIOL, V245, P324, DOI 10.1006/jmbi.1994.0027; Dixon M., 1979, ENZYMES, P400; EVENTOFF W, 1977, P NATL ACAD SCI USA, V74, P2677, DOI 10.1073/pnas.74.7.2677; FOOTE J, 1985, J MOL BIOL, V186, P175, DOI 10.1016/0022-2836(85)90267-0; Fushinobu S, 1996, J BIOL CHEM, V271, P25611, DOI 10.1074/jbc.271.41.25611; GARVIE EI, 1980, MICROBIOL REV, V44, P106, DOI 10.1128/MMBR.44.1.106-139.1980; GERHART JC, 1962, J BIOL CHEM, V237, P891; Holbrook JJ., 1975, ENZYMES, P191; IWATA S, 1989, AGR BIOL CHEM TOKYO, V53, P3365, DOI 10.1080/00021369.1989.10869841; IWATA S, 1994, NAT STRUCT BIOL, V1, P176, DOI 10.1038/nsb0394-176; IWATA S, 1993, J MOL BIOL, V230, P21, DOI 10.1006/jmbi.1993.1122; IWATA S, 1989, J BIOCHEM-TOKYO, V106, P558, DOI 10.1093/oxfordjournals.jbchem.a122894; Mattevi A, 1996, CURR OPIN STRUC BIOL, V6, P824, DOI 10.1016/S0959-440X(96)80013-3; Mattevi A, 1996, FEBS LETT, V389, P15, DOI 10.1016/0014-5793(96)00462-0; MINOWA T, 1989, GENE, V85, P161, DOI 10.1016/0378-1119(89)90476-9; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OHTA T, 1992, FARADAY DISCUSS, V93, P153, DOI 10.1039/fd9929300153; PERUTZ MF, 1989, MECH COOPERATIVITY A; ROSSMANN MG, 1973, J MOL BIOL, V76, P533, DOI 10.1016/0022-2836(73)90491-9; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; YANG YR, 1980, P NATL ACAD SCI-BIOL, V77, P5187, DOI 10.1073/pnas.77.9.5187; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	23	17	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2971	2976		10.1074/jbc.273.5.2971	http://dx.doi.org/10.1074/jbc.273.5.2971			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446610	hybrid			2022-12-25	WOS:000071736600065
J	Ikuta, T; Eguchi, H; Tachibana, T; Yoneda, Y; Kawajiri, K				Ikuta, T; Eguchi, H; Tachibana, T; Yoneda, Y; Kawajiri, K			Nuclear localization and export signals of the human aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED TRANSCRIPTION FACTOR; PORE-TARGETING COMPLEX; AMINO-ACID-SEQUENCE; AH-RECEPTOR; PROTEIN IMPORT; DNA-BINDING; DIOXIN RECEPTOR; HUMAN HOMOLOG; IDENTIFICATION; TRANSPORT	The aryl hydrocarbon receptor (Ahr) is a ligand activated transcription factor that binds DNA in the form of a heterodimer with the Ahr nuclear translocator (hypoxia-inducible factor 1 beta). We found in this study that Ahr contains both nuclear localization and export sig nals in the NH2-terminal region. A fusion protein composed of beta-galactosidase and full-length Ahr translocates from the cytoplasm to the nucleus in a ligand-dependent manner. However, a fusion protein lacking the PAS (Per-Ahr nuclear translocator-Sim homology) domain of the Ahr showed strong nuclear localization activity irrespective of the presence or absence of ligand. A minimum bipartite Ahr nuclear localization signal (NLS) consisting of amino acid residues 13-39 was identified by microinjection of fused proteins with glutathione S-transferase-green fluorescent protein, A NLS having mutations in bipartite basic amino acids lost nuclear translocation activity completely, which may explain the reduced binding activity to the NLS receptor, PTAC58. A 21-amino acid peptide (residues 55-75) containing the Ahr nuclear export signal is sufficient to direct nuclear export of a microinjected complex of glutathione S-transferase-Ahr-green fluorescent protein. These findings strongly suggest that Ahr act as a ligand- and signal-dependent nucleocytoplasmic shuttling protein.	Saitama Canc Ctr, Res Inst, Dept Biochem, Ina, Saitama 362, Japan; Osaka Univ, Sch Med, Dept Anat & Cell Biol, Osaka 562, Japan	Osaka University	Kawajiri, K (corresponding author), Saitama Canc Ctr, Res Inst, Dept Biochem, 818 Komuro, Ina, Saitama 362, Japan.	kawajiri@saitama-cc.go.jp	Eguchi, Hiromi/GWC-5633-2022					ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHEN HS, 1994, J BIOL CHEM, V269, P27554; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DENISON MS, 1986, J BIOL CHEM, V261, P3987; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; Eberhart DE, 1996, HUM MOL GENET, V5, P1083, DOI 10.1093/hmg/5.8.1083; Eguchi H, 1997, J BIOL CHEM, V272, P17640, DOI 10.1074/jbc.272.28.17640; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FUJIIKURIYAMA Y, 1994, EXP CLIN IMMUNOGENET, V11, P65; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORD NG, 1994, MOL PHARMACOL, V46, P618; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kawajiri K., 1996, CYTOCHROMES P450 MET, P77; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	53	202	204	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2895	2904		10.1074/jbc.273.5.2895	http://dx.doi.org/10.1074/jbc.273.5.2895			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446600	hybrid			2022-12-25	WOS:000071736600055
J	Kangas, AL; Nicholson, DW; Holtta, E				Kangas, AL; Nicholson, DW; Holtta, E			Involvement of CPP32/Caspase-3 in c-Myc-induced apoptosis	ONCOGENE			English	Article						apoptosis; CPP32/Caspase-3; c-Myc; ODC	PROGRAMMED CELL-DEATH; WILD-TYPE P53; ORNITHINE DECARBOXYLASE ACTIVITY; CRMA-INHIBITABLE PROTEASE; TUMOR-SUPPRESSOR P53; POLY(ADP-RIBOSE) POLYMERASE; GRANZYME-B; CYCLE ARREST; CONVERTING-ENZYME; GENE-EXPRESSION	c-Myc is a transcriptional activator implicated in the control of cell proliferation, differentiation and transformation, but is also involved in the regulation of programmed cell death, apoptosis. Despite intensive research, the molecular mechanisms by which c-Myc triggers and executes cell death remain still elusive. Here, we made use of Rat 1A MycER cells expressing a conditionally active c-Myc protein and tested first the hypothesis that ornithine decarboxylase (ODC), which is a transcriptional target of c-Myc, were a mediator of c-Myc-induced apoptosis. However, our results show that the activity of ODC is not required for the c-Myc-mediated apoptosis to occur in these cells. We also found that the expression of p53, p21(waf1/cip1), Bcl-2, Bax, Bcl-x(L), Bad and cyclins D1, E, A and B did not show any significant changes following c-Myc induction. But, our studies revealed that the c-Myc induced apoptosis is associated with a specific cleavage of poly(ADPribose) polymerase (PARP), suggesting that a cysteine protease of the ICE/CED-3 family is involved. Moreover, we found that the cysteine protease CPP32/Caspase-3, which is known to cleave PARR, is processed from its inactive form to an active protease composed of 17 and 12 kDa subunits; whilst Ich-1/Caspase-2 belonging to another subset of this protease family was not processed/activated following c-Myc activation. The activation of CPP32 and apoptotic cell death were inhibited by addition of Z-VAD-fmk, a universal inhibitor of ICE-like proteases. Further, a selective inhibitor of CPP32-like proteases (Z-DEVD-fmk) partly inhibited apoptosis. These results provide evidence that the ICE/CED3-family proteases, CPP32 and likely others, play a critical role in the execution of a nuclear proto-oncogene, c-Myc-induced apoptosis.	Univ Helsinki, Dept Pathol, Haartman Inst, FIN-00014 Helsinki, Finland; Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Dorval, PQ H9R 4P8, Canada	University of Helsinki; Merck & Company	Holtta, E (corresponding author), Univ Helsinki, Dept Pathol, Haartman Inst, POB 21 Haartmaninkatu 3, FIN-00014 Helsinki, Finland.							AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; ASKEW DS, 1991, ONCOGENE, V6, P1915; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CLIFFORD A, 1995, CANCER RES, V55, P1680; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DESIDERIO MA, 1995, CELL GROWTH DIFFER, V6, P505; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERNANDESALNEMR.F, 1996, P NATL ACAD SCI USA, V93, P7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MEGOSH L, 1995, CANCER RES, V55, P4205; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOSHIER JA, 1993, CANCER RES, V53, P2618; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENA A, 1993, J BIOL CHEM, V268, P27277; POHJANPELTO P, 1985, MOL CELL BIOL, V5, P1385, DOI 10.1128/MCB.5.6.1385; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; POULIN R, 1995, BIOCHEM J, V311, P723, DOI 10.1042/bj3110723; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Sakamuro D, 1995, ONCOGENE, V11, P2411; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TOBIAS KE, 1995, CELL GROWTH DIFFER, V6, P1279; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	89	60	64	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					387	398		10.1038/sj.onc.1201779	http://dx.doi.org/10.1038/sj.onc.1201779			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467964				2022-12-25	WOS:000071582100011
J	O'Hagan, RC; Hassell, JA				O'Hagan, RC; Hassell, JA			The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase	ONCOGENE			English	Article						PEA3; Ets; breast cancer; c-ErbB-2/HER2/Neu; tumorigenesis; metastasis	HUMAN-BREAST-CANCER; ACTIVATED PROTEIN-KINASE; MAP KINASE; NEU ONCOGENE; POINT MUTATION; EWINGS-SARCOMA; DNA-BINDING; CHROMOSOME-TRANSLOCATION; SIGNALING PATHWAY; MOLECULAR-CLONING	The HER2/neu gene, which is overexpressed in 20-30% of human breast tumors, encodes a receptor tyrosine kinase that functions through multiple signaling pathways to regulate the activity of nuclear transcription factors. We have reported that PEAS, an Ets family transcription factor, is overexpressed in HER2/Neu-induced breast tumors and their metastases. To account for the increased levels of PEA3 in these turners we have suggested that HER2/Neu enhances PEAS transcriptional activity, which then acts to stimulate expression of the PEAS gene. This hypothesis is consistent with the occurrence of PEAS binding sites in the PEAS promoter and with the ability of PEA3 to transactivate this promoter. To learn whether HER2/Neu indeed regulates PEAS activity we measured the capacity of constitutively-activated HER2/Neu to affect PEAS-dependent reporter gene expression. Coexpression of PEA3 and HER2/Neu stimulated PEA3-dependent reporter gene expression to a much greater extent than did either protein alone suggesting that HER2/Neu upregulates the transcriptional activity of PEAS. To define the pathway whereby HER2/Neu functions we employed dominant-negative mutants of signaling proteins known to be downstream of HER2/Neu. Overexpression of Rap1a, a Pas-related protein capable of antagonizing Pas function, completely inhibited the ability of HER2/Neu to stimulate PEAS-dependent gene expression. Pas is known to stimulate at least two mitogen-activated protein kinase (MAPK) cascades, the extracellular-regulated kinase (ERK) cascade and the stress-activated kinase (SAPK) or Jun kinase (JNK) cascade. Similarly, HER2/Neu activated both ERKs and SAPKs/JNKs in a Pas-dependent fashion. Dominant-inhibitory mutants in either the ERK or SAPK/JNK cascades partially inhibited HER2/Neu activation of PEAS-dependent gene expression. These findings suggest that HER2/Neu regulates PEA3 activity through two different Ras-dependent MAPK pathways.	McMaster Univ, Inst Mol Biol & Biotechnol, Canc Res Grp, Hamilton, ON L8S 4K1, Canada	McMaster University	Hassell, JA (corresponding author), McMaster Univ, Inst Mol Biol & Biotechnol, Canc Res Grp, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.							BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENZ CC, 1997, IN PRESS ONCOGENE; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IGLEHART JD, 1990, CANCER RES, V50, P6701; JANES PW, 1994, ONCOGENE, V9, P3601; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Kaya M, 1996, ONCOGENE, V12, P221; KING CR, 1989, CANCER RES, V49, P4185; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU E, 1992, ONCOGENE, V7, P1027; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATRISIAN LM, 1994, ANN NY ACAD SCI, V91, P10129; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MONTE D, 1994, ONCOGENE, V9, P1397; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; OHagan RC, 1996, ONCOGENE, V13, P1323; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RICCI A, 1995, ONCOGENE, V11, P1519; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITE MRA, 1992, ONCOGENE, V7, P677; XIE YM, 1995, ONCOGENE, V10, P2409; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAN MH, 1994, NATURE, V372, P798; ZHANG S, 1995, MOL CELL BIOL, V15, P4623	69	64	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					301	310		10.1038/sj.onc.1201547	http://dx.doi.org/10.1038/sj.onc.1201547			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467955				2022-12-25	WOS:000071582100002
J	Kerkhoff, E; Houben, R; Loffler, S; Troppmair, J; Rapp, UR				Kerkhoff, E; Houben, R; Loffler, S; Troppmair, J; Rapp, UR			Regulation of c-myc expression by Ras/Raf signalling	ONCOGENE			English	Article						raf; signal transduction; myc	NIH 3T3 CELLS; RAF; ACTIVATION; PROTEIN; GROWTH; FOS; TRANSFORMATION; ONCOGENES; KINASE; GENE	The c-myc gene is induced upon growth factor stimulation of arrested cells, The interaction of a mitogen with a transmembrane receptor triggers a variety of parallel signal transduction cascades. In order to analyse the role of the Ras/Raf cascade in the regulation of c-myc expression we have established fibroblast cell lines harboring conditional systems activating or inhibiting this pathway, Fusion of the c-Raf-1 kinase domain with the hormone binding domain of the estrogen receptor (c-Raf-1-BxB-ER(TM)) provides a 4-hydroxytamoxifen regulated form of the oncogenic c-Raf-1 kinase, We have generated NIH3T3 cells stably expressing the chimeric Raf protein (N-BxB-ER(TM)). 4-hydroxytamoxifen mediated activation of the fusion protein in serum starved N-BxB-ER(TM) induces the expression of the c-myc gene within 2-6 h, Deletion of the c-Raf-1 kinase domain generates a mutant c-Raf-1 protein (c-Raf-1-C4B), which can directly interact with the effector domain of the Ras protein and thereby block Ras mediated signalling, We have established a NIH3T3 based cell line expressing the c-Raf-1-C4B protein under the control of a tetracycline responsive promoter (N-C4B-tet), Serum starved cells expressing the c-Raf-1-C4B protein exhibit a significantly reduced induction of c-myc expression following serum stimulation compared to the same cells not expressing the Ras inhibitor, The induction of c-myc mRNA following the activation of the isolated Raf/Mek/Erk cascade in addition to the partial inhibition of serum mediated induction of c-myc expression in the presence of the Ras inactivating c-Raf-1-C4B mutant strongly indicates an involvement of the Ras/Raf pathway in the regulation of c-myc expression.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Verbacher Str 5, D-97078 Wurzburg, Germany.			Troppmair, Jakob/0000-0002-0611-3837; Houben, Roland/0000-0003-4538-2324				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BORTNER DM, 1992, INT J ONCOL, V1, P221; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cooper G.M., 1995, ONCOGENES; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Markowitz D G, 1988, Trans Assoc Am Physicians, V101, P212; MCCHARTY SA, 1997, MOL CELL BIOL, V17, P2401; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORSE HC, 1988, CELLULAR ONCOGENE AC, P335; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; RAPP UR, 1994, ONCOGENE, V9, P3493; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WATERS CM, 1991, ONCOGENE, V6, P797; Yang BS, 1996, MOL CELL BIOL, V16, P538	34	113	115	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					211	216		10.1038/sj.onc.1201520	http://dx.doi.org/10.1038/sj.onc.1201520			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464539				2022-12-25	WOS:000071427100008
J	Moir, RD; Lynch, T; Bush, AI; Whyte, S; Henry, A; Portbury, S; Multhaup, G; Small, DH; Tanzi, RE; Beyreuther, K; Masters, CL				Moir, RD; Lynch, T; Bush, AI; Whyte, S; Henry, A; Portbury, S; Multhaup, G; Small, DH; Tanzi, RE; Beyreuther, K; Masters, CL			Relative increase in Alzheimer's disease of soluble forms of cerebral A beta amyloid protein precursor containing the Kunitz protease inhibitory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; NEURITIC PLAQUE DENSITY; NORMAL HUMAN-BRAIN; AGED HUMAN BRAIN; TRANSGENIC MICE; RAT-BRAIN; DIFFERENTIAL EXPRESSION; INSITU HYBRIDIZATION; CEREBROSPINAL-FLUID; CULTURED-CELLS	Although a number of studies have examined amyloid precursor protein (APP) mRNA levels in Alzheimer's disease (AD), no clear consensus has emerged as to whether the levels of transcripts for isoforms containing a Kunitz protease inhibitory (KPI)-encoded region are increased or decreased in AD, Here we compare AD and control brain for the relative amounts of APP protein containing KPI to APP protein lacking this domain. APP protein was purified from the soluble subcellular fraction and Triton X-100 membrane pellet extract of one hemisphere of AD (n = 10), normal (n = 7), and neurological control (n = 5) brains, The amount of KPI-containing APP in the purified protein samples was determined using two independent assay methods, The first assay exploited the inhibitory action of KPI-containing APP on trypsin. The second assay employed reflectance analysis of Western blots, The proportion of KPI-containing forms of APP in the soluble subcellular fraction of AD brains is significantly elevated (p < 0.01) compared with controls, Species containing a HPI domain comprise 32-41 and 76-77% of purified soluble APP from control and AD brains, respectively, For purified membrane-associated APP, 72-77 and 65-82% of control and AD samples, respectively, contain a KPI domain. Since KPI-containing species of APP may be more amyloidogenic (Ho, L., Fukuchi, K., and Yonkin, S. G. (1996) J. Biol. Chem. 271, 30929-30934), our findings support an imbalance of isoforms as one possible mechanism for amyloid deposition in sporadic AD.	Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Genet & Aging Unit, Boston, MA 02114 USA; Univ Heidelberg, Ctr Mol Biol, D-6900 Heidelberg, Germany	University of Melbourne; Harvard University; Harvard Medical School; Massachusetts General Hospital; Ruprecht Karls University Heidelberg	Masters, CL (corresponding author), Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia.		Bush, Ashley/Y-2457-2019; Tanzi, Rudolph/AAE-9622-2019; Bush, Ashley I/A-1186-2007; Moir, Robert D./M-7612-2017	Bush, Ashley/0000-0001-8259-9069; Tanzi, Rudolph/0000-0002-7032-1454; Bush, Ashley I/0000-0001-8259-9069; Moir, Robert D./0000-0001-5431-3553; Portbury, Stuart/0000-0002-5470-6100				ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; BAHMANYAR S, 1987, SCIENCE, V237, P77, DOI 10.1126/science.3299701; BUSH AI, 1992, ANN NEUROL, V32, P57, DOI 10.1002/ana.410320110; BUSH AI, 1994, J BIOL CHEM, V269, P26618; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CARD JP, 1988, NEURON, V1, P835, DOI 10.1016/0896-6273(88)90131-6; CITRON M, 1993, NEUROBIOL AGING, V14, P571, DOI 10.1016/0197-4580(93)90041-9; COHEN ML, 1988, P NATL ACAD SCI USA, V85, P1227, DOI 10.1073/pnas.85.4.1227; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOEDERT M, 1987, EMBO J, V6, P3627, DOI 10.1002/j.1460-2075.1987.tb02694.x; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HEASE L, 1994, FEBS LETT, V349, P109; HIGGINS GA, 1988, P NATL ACAD SCI USA, V85, P1297, DOI 10.1073/pnas.85.4.1297; HIGGINS GA, 1990, P NATL ACAD SCI USA, V87, P3032, DOI 10.1073/pnas.87.8.3032; HIGGINS LS, 1995, REV NEUROSCIENCE, V6, P87; HIGGINS LS, 1993, ANN NY ACAD SCI, V695, P224, DOI 10.1111/j.1749-6632.1993.tb23056.x; HIGGINS LS, 1995, P NATL ACAD SCI USA, V92, P4402, DOI 10.1073/pnas.92.10.4402; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Ho LB, 1996, J BIOL CHEM, V271, P30929, DOI 10.1074/jbc.271.48.30929; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; HYMAN BT, 1993, MOL BRAIN RES, V18, P253, DOI 10.1016/0169-328X(93)90197-W; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; JACOBSEN JS, 1991, NEUROBIOL AGING, V12, P585, DOI 10.1016/0197-4580(91)90090-7; Johnson D, 1996, CONTROL ENG, V43, P85; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; JOHNSON SA, 1989, NEUROBIOL AGING, V10, P267, DOI 10.1016/0197-4580(89)90061-4; JOHNSON SA, 1988, EXP NEUROL, V102, P264, DOI 10.1016/0014-4886(88)90104-5; JOHNSON SA, 1996, MOL BRAIN RES, V43, P77; JOHNSTON JA, 1994, FEBS LETT, V354, P274, DOI 10.1016/0014-5793(94)01137-0; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kawarabayashi T, 1996, NEUROBIOL AGING, V17, P215, DOI 10.1016/0197-4580(95)02061-6; KITAGUCHI N, 1990, BIOCHIM BIOPHYS ACTA, V1038, P105, DOI 10.1016/0167-4838(90)90017-A; KITAGUCHI N, 1990, BIOCHEM BIOPH RES CO, V166, P1453, DOI 10.1016/0006-291X(90)91030-V; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; KONIG G, 1991, MOL BRAIN RES, V9, P259, DOI 10.1016/0169-328X(91)90010-U; KONIG G, 1992, J BIOL CHEM, V267, P10804; KOO EH, 1994, J BIOL CHEM, V269, P17386; KOO EH, 1990, NEURON, V2, P97; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LEWIS DA, 1988, P NATL ACAD SCI USA, V85, P1691, DOI 10.1073/pnas.85.5.1691; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MITA S, 1989, AM J PATHOL, V134, P1253; MOIR RD, 1992, J NEUROCHEM, V59, P1490, DOI 10.1111/j.1471-4159.1992.tb08465.x; MORGAN PM, 1995, P NATL ACAD SCI USA, V92, P5341; MOYA KL, 1994, J NEUROCHEM, V63, P1971; NAKAMURA S, 1992, ACTA NEUROPATHOL, V84, P244; Neve RL, 1996, NEUROBIOL AGING, V17, P191, DOI 10.1016/0197-4580(95)02074-8; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; OHYAGI Y, 1992, J NEUROL SCI, V111, P33, DOI 10.1016/0022-510X(92)90109-X; OKADA A, 1994, DEMENTIA, V5, P55, DOI 10.1159/000106697; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; OYAMA F, 1991, J NEUROPATH EXP NEUR, V50, P560, DOI 10.1097/00005072-199109000-00004; OYAMA F, 1992, J NEUROCHEM, V59, P1117, DOI 10.1111/j.1471-4159.1992.tb08354.x; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PALMERT MR, 1990, NEUROLOGY, V40, P1028, DOI 10.1212/WNL.40.7.1028; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; Schmechel D E, 1988, Alzheimer Dis Assoc Disord, V2, P96, DOI 10.1097/00002093-198802020-00002; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMALL DH, 1994, J NEUROSCI, V14, P2117; SOLA C, 1993, MOL BRAIN RES, V17, P41, DOI 10.1016/0169-328X(93)90071-V; SPILLANTINI MG, 1989, MOL BRAIN RES, V6, P143, DOI 10.1016/0169-328X(89)90048-X; TANAKA S, 1989, BIOCHEM BIOPH RES CO, V165, P1406, DOI 10.1016/0006-291X(89)92760-5; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANAKA S, 1992, MOL BRAIN RES, V15, P303, DOI 10.1016/0169-328X(92)90122-R; TANAKA S, 1993, NEUROSCI LETT, V163, P19, DOI 10.1016/0304-3940(93)90219-B; TANZI RE, 1993, MOL BRAIN RES, V18, P246, DOI 10.1016/0169-328X(93)90196-V; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TATEOSTROFF B, 1989, P NATL ACAD SCI USA, V86, P745, DOI 10.1073/pnas.86.2.745; VANNOSTRAND WE, 1987, J BIOL CHEM, V262, P8508; VANNOSTRAND WE, 1991, P NATL ACAD SCI USA, V88, P10302, DOI 10.1073/pnas.88.22.10302; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WILLOUGHBY DA, 1992, EXP NEUROL, V118, P332, DOI 10.1016/0014-4886(92)90191-R; ZHAN SS, 1995, CLIN NEUROPATHOL, V14, P142	87	93	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5013	5019		10.1074/jbc.273.9.5013	http://dx.doi.org/10.1074/jbc.273.9.5013			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478949	hybrid			2022-12-25	WOS:000072310400033
J	Silvestre, JS; Robert, V; Heymes, C; Aupetit-Faisant, B; Mouas, C; Moalic, JM; Swynghedauw, B; Delcayre, C				Silvestre, JS; Robert, V; Heymes, C; Aupetit-Faisant, B; Mouas, C; Moalic, JM; Swynghedauw, B; Delcayre, C			Myocardial production of aldosterone and corticosterone in the rat - Physiological regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; RIBONUCLEIC-ACID LEVELS; ANGIOTENSIN-II; MESSENGER-RNAS; CARDIAC FIBROSIS; GENE-EXPRESSION; DIETARY-SODIUM; CYP11B GENES; BIOSYNTHESIS; SYNTHASE	Increasing evidence suggests that mineralo- and glucocorticoids modulate cardiovascular homeostasis via the effects of circulating components generated within the adrenals but also through local synthesis, The aim of this study was to assess the existence of such a steroidogenic system in heart, Using the quantitative reverse transcriptase-polymerase chain reaction, the terminal enzymes of corticosterone and aldosterone synthesis (11 beta-hydroxylase and aldosterone synthase, respectively) were detected in the rat heart, This pathway was shown to be physiologically active, since production of aldosterone, corticosterone, and their precursor, deoxycorticosterone, was detected in both the homogenate and perfusate of isolated rat hearts using radioimmunoassay after Celite column chromatography, Perfusion of angiotensin II or adrenocorticotropin for 3 h increased aldosterone and corticosterone production and decreased deoxycorticosterone, suggesting that aldosterone and corticosterone are formed within the isolated heart from a locally present substrate, Chronic regulation of this intracardiac system was then examined, As in adrenals cardiac 11 beta-hydroxylase and aldosterone-synthase mRNAs were independently regulated by 1 week's treatment with either low sodium and high potassium diet (which increased aldosterone synthase mRNA level only), angiotensin II (which raised level of both mRNAs), or adrenocorticotropin (which stimulated the 11 beta-hydroxylase gene exclusively). Changes in cardiac steroid levels during treatment were not directly related to their plasma levels suggesting independent regulating mechanisms, This study, therefore, provides the first evidence for the existence of an endocrine cardiac steroidogenic system in rat heart and emphasizes its potential physiological and pathological relevance.	Hop Lariboisiere, INSERM, U127, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Delcayre, C (corresponding author), Hop Lariboisiere, INSERM, U127, 41 Bd Chapelle, F-75475 Paris 10, France.	claude.delcayre@inserm.lrb.ap-hop-paris.f	Silvestre, Jean-Sebastien/K-7695-2017; Heymes, Christophe/Y-9368-2019	Silvestre, Jean-Sebastien/0000-0003-3962-2205; Heymes, Christophe/0000-0002-6666-6193				ADLER GK, 1993, ENDOCRINOLOGY, V133, P2235, DOI 10.1210/en.133.5.2235; AGARWAL MK, 1979, J MOL CELL CARDIOL, V11, P115, DOI 10.1016/0022-2828(79)90457-7; AGUILERA G, 1981, ENDOCRINOLOGY, V108, P522, DOI 10.1210/endo-108-2-522; AUPETIT B, 1993, BIOCHIM BIOPHYS ACTA, V752, P73; AUPETITFAISANT B, 1993, J CLIN ENDOCR METAB, V76, P38, DOI 10.1210/jc.76.1.38; BIGLIERI EG, 1987, ANN NY ACAD SCI, V512, P426, DOI 10.1111/j.1749-6632.1987.tb24978.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILLA CG, 1990, CIRC RES, V67, P1355, DOI 10.1161/01.RES.67.6.1355; CAMPBELL SE, 1993, AM J HYPERTENS, V6, P487, DOI 10.1093/ajh/6.6.487; CASEY ML, 1982, ENDOCR REV, V3, P396, DOI 10.1210/edrv-3-4-396; Clyne CD, 1996, ENDOCR RES, V22, P485, DOI 10.1080/07435809609043735; CURNOW KM, 1991, MOL ENDOCRINOL, V5, P1513, DOI 10.1210/mend-5-10-1513; DANSER AHJ, 1994, HYPERTENSION, V24, P37, DOI 10.1161/01.HYP.24.1.37; DELCAYRE C, 1992, AM J PHYSIOL, V263, pH1537, DOI 10.1152/ajpheart.1992.263.5.H1537; DELLABRUNA R, 1995, J HYPERTENS, V13, P763; DellItalia LJ, 1997, J CLIN INVEST, V100, P253, DOI 10.1172/JCI119529; DZAU VJ, 1988, CIRCULATION, V77, P4; Fardella CE, 1996, ANNU REV NUTR, V16, P443, DOI 10.1146/annurev.nu.16.070196.002303; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; FUNDER JW, 1973, ENDOCRINOLOGY, V93, P1300, DOI 10.1210/endo-93-6-1300; HATAKEYAMA H, 1994, J BIOL CHEM, V269, P24316; HAYASHI T, 1991, AM J PHYSIOL, V261, pC106, DOI 10.1152/ajpcell.1991.261.1.C106; HEYMES C, 1994, CIRCULATION, V90, P1328, DOI 10.1161/01.CIR.90.3.1328; HOLLAND OB, 1993, ENDOCRINOLOGY, V132, P2666, DOI 10.1210/en.132.6.2666; Huang MH, 1996, J CLIN INVEST, V98, P1298, DOI 10.1172/JCI118916; HUET M, 1974, LAB INVEST, V30, P154; IKEDA U, 1991, J BIOL CHEM, V266, P12058; KNOX JR, 1969, J ENDOCRINOL, V43, P315, DOI 10.1677/joe.0.0430315; KORICHNEVA I, 1995, J MOL CELL CARDIOL, V27, P2521, DOI 10.1006/jmcc.1995.0239; LINDPAINTNER K, 1990, CIRC RES, V67, P564, DOI 10.1161/01.RES.67.3.564; LOMBES M, 1992, CIRC RES, V71, P503, DOI 10.1161/01.RES.71.3.503; MALEE MP, 1991, P NATL ACAD SCI USA, V88, P4731, DOI 10.1073/pnas.88.11.4731; MELLON SH, 1993, BRAIN RES, V629, P283, DOI 10.1016/0006-8993(93)91332-M; MELLON SH, 1995, J BIOL CHEM, V270, P1643, DOI 10.1074/jbc.270.4.1643; MUKAI K, 1991, BIOCHEM BIOPH RES CO, V180, P1187, DOI 10.1016/S0006-291X(05)81321-X; MUKAI K, 1993, J BIOL CHEM, V268, P9130; NOMURA M, 1993, J BIOCHEM-TOKYO, V113, P144, DOI 10.1093/oxfordjournals.jbchem.a124018; ROBERT V, 1994, HYPERTENSION, V24, P30, DOI 10.1161/01.HYP.24.1.30; ROBERT V, 1995, HYPERTENSION, V26, P971, DOI 10.1161/01.HYP.26.6.971; SHIBATA H, 1991, ENDOCRINOLOGY, V128, P2534, DOI 10.1210/endo-128-5-2534; Takeda Y, 1996, J CLIN ENDOCR METAB, V81, P2797, DOI 10.1210/jc.81.8.2797; TAKEDA Y, 1994, ENDOCRINOLOGY, V135, P2283, DOI 10.1210/en.135.5.2283; TAKEDA Y, 1995, HYPERTENSION, V25, P170, DOI 10.1161/01.HYP.25.2.170; TREMBLAY A, 1991, J BIOL CHEM, V266, P2245; TREMBLAY A, 1992, ENDOCRINOLOGY, V130, P3152, DOI 10.1210/en.130.6.3152; ULLIAN ME, 1992, HYPERTENSION, V20, P67, DOI 10.1161/01.HYP.20.1.67; WALKER BR, 1991, ENDOCRINOLOGY, V129, P3305, DOI 10.1210/endo-129-6-3305; WEHLING M, 1995, CIRC RES, V76, P973, DOI 10.1161/01.RES.76.6.973; YOUNG M, 1994, J CLIN INVEST, V93, P2578, DOI 10.1172/JCI117269; ZHAO HF, 1991, J BIOL CHEM, V266, P583	50	385	402	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4883	4891		10.1074/jbc.273.9.4883	http://dx.doi.org/10.1074/jbc.273.9.4883			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478930	hybrid			2022-12-25	WOS:000072310400014
J	He, ZN; Crist, M; Yen, HC; Duan, XQ; Quiocho, FA; Gimble, FS				He, ZN; Crist, M; Yen, HC; Duan, XQ; Quiocho, FA; Gimble, FS			Amino acid residues in both the protein splicing and endonuclease domains of the PI-SceI intein mediate DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORV RESTRICTION-ENDONUCLEASE; SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; RECOGNITION; CLEAVAGE	A structure-based model describing the interaction of the two-domain PI-SceI endonuclease with its 31-base pair DNA substrate suggests that the endonuclease domain (domain II) contacts the cleavage site region of the substrate, while the protein splicing domain (domain I) interacts with a distal region that is sufficient for high affinity binding, To support this model, alanine-scanning mutagenesis was used to assemble a set of 49 PI-SceI mutant proteins that were purified and assayed for their DNA binding and cleavage properties, Fourteen mutant proteins were 4- to >500-fold less active than wild-type PI-SceI in cleavage assays, and one mutant (T225A) was 3-fold more active, Alanine substitution at two positions in domain I reduces overall binding >60-fold by perturbing the interaction of PI-SceI with the minimal binding region. Conversely, mutations in domain II have little effect on binding, reduce binding to the cleavage site region only, or affect binding to both regions, Interestingly, substitutions at Lys(301), which is part of the endonucleolytic active site, eliminate binding to the cleavage site region but permit contact with the minimal binding region, This experimental evidence demonstrates that the protein splicing domain as well as the endonuclease domain is involved in binding of a DNA substrate with the requisite length.	Texas A&M Univ, Ctr Macromol Design, Inst Biosci & Technol, Houston, TX 77030 USA; Texas A&M Univ, Dept Biochem & Biophys, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Struct & Computat Biol & Mol Biophys Program, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University System; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Gimble, FS (corresponding author), Texas A&M Univ, Ctr Macromol Design, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.		Wood, David W/B-2992-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008280, R29GM050815] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08280, GM50815] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; BROWN BM, 1994, NAT STRUCT BIOL, V1, P164, DOI 10.1038/nsb0394-164; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gimble FS, 1996, J MOL BIOL, V263, P163, DOI 10.1006/jmbi.1996.0567; GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GIMBLE FS, 1993, J BIOL CHEM, V268, P21844; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; Heath PJ, 1997, NAT STRUCT BIOL, V4, P468, DOI 10.1038/nsb0697-468; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hwang JS, 1997, J BACTERIOL, V179, P1051, DOI 10.1128/jb.179.4.1051-1058.1997; MUELLER JE, 1993, NUCLEASES, P111; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6089, DOI 10.1021/bi00141a019; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1701, DOI 10.1021/bi952391d; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1712, DOI 10.1021/bi9523926; Wende W, 1996, NUCLEIC ACIDS RES, V24, P4123, DOI 10.1093/nar/24.21.4123	20	52	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4607	4615		10.1074/jbc.273.8.4607	http://dx.doi.org/10.1074/jbc.273.8.4607			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468518	hybrid			2022-12-25	WOS:000072115000046
J	Kuniyasu, A; Itagaki, K; Shibano, T; Iino, M; Kraft, G; Schwartz, A; Nakayama, H				Kuniyasu, A; Itagaki, K; Shibano, T; Iino, M; Kraft, G; Schwartz, A; Nakayama, H			Photochemical identification of transmembrane segment IVS6 as the binding region of semotiadil, a new modulator for the L-type voltage-dependent Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BI CALCIUM CHANNELS; SKELETAL-MUSCLE; ALPHA-1 SUBUNIT; 1,4-DIHYDROPYRIDINE SENSITIVITY; PHARMACOLOGICAL PROFILE; MOLECULAR DETERMINANTS; ANTAGONIST; BENZOTHIAZINE; SD-3211; FUMARATE	To identify the binding domain of a new Ca2+ antagonist semotiadil on L-type Ca2+ channels from skeletal muscle, photolabeling was carried out by using an azi dophenyl derivative of [H-3]semotiadil, Photoincorporation was observed in several polypeptides of membrane triad preparations; the only specific photoincorporation was in the alpha 1 subunit of the Ca2+ channel, After solubilization and purification, the photolabeled alpha(1) subunit was subjected to proteolytic and CNBr cleavage followed by antibody mapping, Specific labeling was associated solely with the region of transmembrane segment S6 in repeat IV. Quantitative immunoprecipitation was found in the tryptic and the Lys-C/Glu-C fragments of 6.6 and 6.1 kDa, respectively, Further CNBr cleavage of the Lys-C digests produced two smaller fragments of 3.4 and 1.8 kDa that were included in the tryptic and Lys-C/Glu-C fragments. The smallest labeled fragments were: Tyr(1350)-Met(1366) and Leu(1367)-Met(1381) containing IVS6, a possible pore forming region, The data suggest that semotiadil binds to a region that is overlapped with but not identical to those for phenylalkylamines, dihydropyridines and benzothiazepines. The present study also provides evidence that region IV represents an important component of a binding pocket for Ca2+ antagonists.	Kumamoto Univ, Fac Pharmaceut Sci, Kumamoto 862, Japan; NIEHS, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA; Daiichi Pharmaceut Co Ltd, New Prod Res Labs 2, Edogawa Ku, Tokyo 134, Japan; Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA	Kumamoto University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Daiichi Sankyo Company Limited; University of Cincinnati	Nakayama, H (corresponding author), Kumamoto Univ, Fac Pharmaceut Sci, 5-1 Oe Honmachi, Kumamoto 862, Japan.	jin@gpo.kumamoto-u.ac.jp	Itagaki, Kiyoshi/M-5501-2015	Itagaki, Kiyoshi/0000-0002-6033-1122	NHLBI NIH HHS [P01 HL22619] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; FUJITA M, 1990, J MED CHEM, V33, P1898, DOI 10.1021/jm00169a011; GALIZZI JP, 1986, P NATL ACAD SCI USA, V83, P7513, DOI 10.1073/pnas.83.19.7513; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; He M, 1997, J BIOL CHEM, V272, P2629, DOI 10.1074/jbc.272.5.2629; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, J BIOL CHEM, V272, P18759, DOI 10.1074/jbc.272.30.18759; KOJICPRODIC B, 1984, HELV CHIM ACTA, V67, P916, DOI 10.1002/hlca.19840670333; Kraus R, 1996, J BIOL CHEM, V271, P20113, DOI 10.1074/jbc.271.33.20113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; MIYAWAKI N, 1991, LIFE SCI, V48, P1903, DOI 10.1016/0024-3205(91)90222-W; MORI T, 1995, BRIT J PHARMACOL, V116, P1668, DOI 10.1111/j.1476-5381.1995.tb16389.x; NAGAO T, 1973, CHEM PHARM BULL, V21, P92; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; NAKAYAMA K, 1994, J CARDIOVASC PHARM, V23, P731, DOI 10.1097/00005344-199405000-00007; NAKAYAMA K, 1992, J CARDIOVASC PHARM, V20, P380, DOI 10.1097/00005344-199209000-00007; Nakayama K, 1996, CARDIOVASC DRUG REV, V14, P97, DOI 10.1111/j.1527-3466.1996.tb00222.x; OTA A, 1993, CHEM PHARM BULL, V41, P1681, DOI 10.1248/cpb.41.1681; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; QAR J, 1988, MOL PHARMACOL, V33, P363; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; WATANABE T, 1993, FEBS LETT, V334, P261, DOI 10.1016/0014-5793(93)80690-V; Watanabe Y, 1996, BIOORG MED CHEM LETT, V6, P1923, DOI 10.1016/0960-894X(96)00338-1	34	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4635	4641		10.1074/jbc.273.8.4635	http://dx.doi.org/10.1074/jbc.273.8.4635			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468522	hybrid			2022-12-25	WOS:000072115000050
J	Zimmer, DB; Cornwall, EH; Reynolds, PD; Donald, CM				Zimmer, DB; Cornwall, EH; Reynolds, PD; Donald, CM			S100A1 regulates neurite organization, tubulin levels, and proliferation in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; OUTGROWTH; FAMILY; BINDING; GAP-43; GENES; OVEREXPRESSION; TRANSFECTION; INVOLVEMENT; MORPHOLOGY	As a first step in determining what cellular processes are regulated by the calcium-modulated protein S100A1 isoform in neurons, the effects of ablated S100A1 expression on neurite organization and microtubule/tubulin levels in PC12 cells were examined. A mammalian expression vector containing the rat S100A1 cDNA in the antisense orientation with respect to a cytomegalovirus promoter was constructed and transfected into PC12 cells, Indirect immunofluorescence microscopy confirmed decreased S100A1 protein levels in all three stable transfectants (pAntisense clones) that expressed exogenous S100A1 antisense mRNA, In response to nerve growth factor, pAntisense clones extended significantly more neurites than control cells (4.01 +/- 0.16 versus 2.93 +/- 0.16 neurites/cell), This increase in neurite number was accompanied by an increase in total alpha-tubulin levels in untreated (4.0 +/- 0.6 versus 1.76 +/- 0.4 ng of alpha-tubulin/mg of total protein) and nerve growth factor-treated pAntisense clones (4.15 +/- 0.4 versus 2.04 +/- 0.5 ng of alpha-tubulin/mg of total protein) when compared with control cells. At high cell densities, pAntisense clones exhibited a significant decrease in anchorage-dependent growth, In soft agar, pAntisense clones formed significantly more colonies (153 +/- 8%) than control cells (116 +/- 5%), However, the pAntisense soft agar colonies were significantly smaller than those observed in control cells (40.6 +/- 3.0 versus 59.5 +/- 1.2 mu m). These data suggest that cell density inhibits both anchorage-independent and -dependent growth of pAntisense clones. In summary, ablation of S100A1 expression in PC12 cells results in increased tubulin levels, altered neurite organization, and decreased cell growth, Thus, S100A1 may directly link the cytoskeleton and calcium signal transduction pathways to cell proliferation.	Univ S Alabama, Dept Pharmacol, Sch Med, Mobile, AL 36688 USA	University of South Alabama	Zimmer, DB (corresponding author), Univ S Alabama, Dept Pharmacol, Sch Med, MSB 3130, Mobile, AL 36688 USA.	dzimmer@jaguar1.usouthal.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030660] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 30660] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Bonfoco E, 1996, J NEUROCHEM, V67, P2484; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandt PC, 1996, P NATL ACAD SCI USA, V93, P13843, DOI 10.1073/pnas.93.24.13843; BURKE WJ, 1994, LIFE SCI, V55, pPL313, DOI 10.1016/0024-3205(94)90074-4; CAPPELLETTI G, 1995, CELL BIOL INT, V19, P687, DOI 10.1006/cbir.1995.1118; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; ESMAELIAZAD B, 1994, J CELL SCI, V107, P869; Graham ME, 1997, MOL BIOL CELL, V8, P431, DOI 10.1091/mbc.8.3.431; GRIBKOFF VK, 1995, MOL BRAIN RES, V30, P29; Gupta RP, 1997, MOL CHEM NEUROPATHOL, V30, P223, DOI 10.1007/BF02815100; HANEMAAIJER R, 1991, J NEUROSCI RES, V30, P163, DOI 10.1002/jnr.490300117; IVINS KJ, 1993, J NEUROCHEM, V60, P626, DOI 10.1111/j.1471-4159.1993.tb03194.x; LAKSHMI MS, 1993, ANTICANCER RES, V13, P299; MARK MD, 1995, J CELL BIOL, V130, P701, DOI 10.1083/jcb.130.3.701; MASIAKOWSKI P, 1990, J NEUROSCI RES, V27, P264, DOI 10.1002/jnr.490270304; Meiri KF, 1996, J NEUROBIOL, V29, P213, DOI 10.1002/(SICI)1097-4695(199602)29:2<213::AID-NEU7>3.0.CO;2-D; NIELANDER HB, 1993, NEUROSCI LETT, V162, P46, DOI 10.1016/0304-3940(93)90556-Z; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; SELINFREUND RH, 1990, J CELL BIOL, V111, P2021, DOI 10.1083/jcb.111.5.2021; Takenaga K, 1997, ONCOGENE, V14, P331, DOI 10.1038/sj.onc.1200820; Tashima K, 1996, J NEUROCHEM, V66, P57; Wicki R, 1996, BIOCHEM BIOPH RES CO, V227, P594, DOI 10.1006/bbrc.1996.1551; Wicki R, 1996, CELL CALCIUM, V20, P459, DOI 10.1016/S0143-4160(96)90087-1; XIE RP, 1995, DEV BRAIN RES, V87, P77, DOI 10.1016/0165-3806(95)00061-H; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; Zimmer DB, 1996, BBA-MOL CELL RES, V1313, P229, DOI 10.1016/0167-4889(96)00094-8; ZIMMER DB, 1991, BRAIN RES BULL, V27, P157, DOI 10.1016/0361-9230(91)90061-N; ZIMMER DB, 1995, J NEUROCHEM, V64, P2727	32	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4705	4711		10.1074/jbc.273.8.4705	http://dx.doi.org/10.1074/jbc.273.8.4705			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468532	hybrid			2022-12-25	WOS:000072115000060
J	Geurts, JMW; Schoenmakers, EFPM; Roijer, E; Astrom, AK; Stenman, G; van de Ven, WJM				Geurts, JMW; Schoenmakers, EFPM; Roijer, E; Astrom, AK; Stenman, G; van de Ven, WJM			Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas	ONCOGENE			English	Article						NFIB; pleomorphic adenoma of the salivary glands; HMGIC	NUCLEAR FACTOR-I; SALIVARY-GLAND TUMORS; DNA-BINDING; PROTEINS; TRANSCRIPTION; PROMOTER; BREAKPOINT; CARCINOMA; CLONING; LIPOMAS	Approximately 12% of all pleomorphic adenomas of the salivary glands are characterized by chromosome aberrations involving the chromosome segment 12q13-15. Several chromosomes have been found as translocation partners of chromosome 12, and some of these recurrently. Recently, the HMGIC gene was identified as the target gene affected by the 12q13-15 aberrations. Here, me report the identification and characterization of a new translocation partner gene of HMGIC in pleomorphic adenomas, 3'-RACE analysis of a primary adenoma with an apparently normal karyotype revealed an HMGIC fusion transcript containing ectopic sequences derived from the human NFIB gene, previously mapped to chromosome band 9p24.1. The HMGIC NFIB fusion transcript was also confirmed by RT-PCR, Since the chromosome segment 9p12-24 is repeatedly involved as translocation partner of chromosome 12q13-15 in pleomorphic adenomas, we tested whether NFIB might be a recurrent partner of HMGIC, RT-PCR analysis of a second adenoma with an ins(9;12)(p23;q12q15) as the sole anomaly, revealed that also in this tumor an HMGIC/NFIB hybrid transcript was present, The reciprocal NFIB/HMGIC fusion transcript, however, could not be detected in any of these tumors, Nucleotide sequence analysis of the fusion transcripts indicated that the genetic aberration in both tumors resulted in the replacement of a carboxy-terminal segment of HMGIC by the last five amino acids of NFIB. In conclusion, our results reveal the recurrent involvement of the NFIB gene as translocation partner gene of HMGIC in pleomorphic adenomas.	Univ Leuven, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, Mol Oncol Lab, B-3000 Louvain, Belgium; Gothenburg Univ, Sahlgrens Hosp, Canc Genet Lab, S-41345 Gothenburg, Sweden	KU Leuven; Sahlgrenska University Hospital; University of Gothenburg	van de Ven, WJM (corresponding author), Univ Leuven, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium.							APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; ASHAR HR, 1995, CELL, V82, P57; BULLERDIEK J, 1993, CANCER GENET CYTOGEN, V65, P27, DOI 10.1016/0165-4608(93)90054-P; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; Fejzo MS, 1996, GENE CHROMOSOME CANC, V17, P1, DOI 10.1002/(SICI)1098-2264(199609)17:1<1::AID-GCC1>3.0.CO;2-0; Geurts JMW, 1997, CANCER RES, V57, P13; Geurts JMW, 1997, CANCER GENET CYTOGEN, V95, P198, DOI 10.1016/S0165-4608(96)00411-6; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; INOUE T, 1990, J BIOL CHEM, V265, P19065; KAZMIERCZAK B, 1995, CANCER RES, V55, P6038; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NORDKVIST A, 1994, GENE CHROMOSOME CANC, V10, P115, DOI 10.1002/gcc.2870100206; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; QIAN F, 1995, GENOMICS, V28, P66, DOI 10.1006/geno.1995.1107; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; Roijer E, 1996, GENE CHROMOSOME CANC, V17, P166; ROULET E, 1995, MOL CELL BIOL, V15, P5552; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SANDROS J, 1990, CANCER GENET CYTOGEN, V44, P153, DOI 10.1016/0165-4608(90)90042-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENMAKERS EFPM, 1995, GENOMICS, V29, P665, DOI 10.1006/geno.1995.9952; SCHOENMAKERS EFPM, 1994, GENOMICS, V20, P210, DOI 10.1006/geno.1994.1155; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SHAH JP, 1990, CURR PROB SURG, V27, P779, DOI 10.1016/0011-3840(90)90032-Z; STENMAN G, 1994, CHROMOSOME 12 ABERRA, P3; TIJAN R, 1994, CELL, V77, P5; Tkachenko A, 1997, CANCER RES, V57, P2276; Waldron CA., 1991, SURG PATHOLOGY SALIV, P165; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0; ZORBAS H, 1992, J BIOL CHEM, V267, P8478	36	115	118	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					865	872		10.1038/sj.onc.1201609	http://dx.doi.org/10.1038/sj.onc.1201609			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484777				2022-12-25	WOS:000072053200005
J	Meili, R; Cron, P; Hemmings, BA; Ballmer-Hofer, K				Meili, R; Cron, P; Hemmings, BA; Ballmer-Hofer, K			Protein kinase B/Akt is activated by polyomavirus middle-T antigen via a phosphatidylinositol 3-kinase-dependent mechanism	ONCOGENE			English	Article						middle-T; PI 3-kinase; protein kinase B/Akt; polyomavirus	TUMOR-ANTIGEN; PHOSPHOINOSITIDE 3-KINASE; PHOSPHORYLATION; TRANSFORMATION; ASSOCIATION; PP60C-SRC; BINDING; AKT; PHOSPHATASE-2A; INTERACTS	The middle tumor antigen (middle-T) of mouse polyomavirus is responsible for the transforming potential of this virus, Middle-T has been shown to interact with a variety of cellular proteins known to mediate mitogenic signaling, like phosphatase-2A, Src family kinases, phosphatidylinositol 3-kinase (PI3-kinase), the adapter protein SHC, phospholipase C gamma-1 and 14-3-3 family proteins, Association with SHC and PI 3-kinase, respectively, stimulates two independent signaling pathways that are indispensible for viral oncogenicity. SHC activates the Ras/MAPK pathway via Grb2/SOS resulting in changes in early gene expression, The downstream targets of PI 3-kinase are less well studied but seem to impinge on serum response factor (SRF) which is also involved in regulating early gene expression, Recently, the protein kinase B/Akt (PKB/Akt) has been identified as a target of PI 3-kinase in receptor tyrosine kinase signaling, Here we show that PKB/Akt is a target of wild type middle-T, but not of mutants unable to activate PI 3-kinase, These data were confirmed using inhibitors of PI 3-kinase as well as dominant-negative alleles of the catalytic subunit of this lipid kinase, In addition, mutants of PKB/Akt lacking a pleckstrin homology domain and therefore unable to bind to D3 phospatidylinositides were not activated by middle-T, Taken together these data suggest that middle-T activates PKB/Akt in a PI 3-kinase-dependent manner, Furthermore, direct association with D3 phosphatidylinositides seems to be essential for activation of PKB/Akt.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Ballmer-Hofer, K (corresponding author), Inst Med Radiobiol, CH-5232 Villigen, Switzerland.			Ballmer-Hofer, Kurt/0000-0002-3800-9129				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; COURTNEIDGE SA, 1989, ONCOGENE RES, V4, P75; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dahl J, 1996, MOL CELL BIOL, V16, P2728; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KIEFER F, 1994, ADV CANCER RES, V64, P125, DOI 10.1016/S0065-230X(08)60837-4; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	37	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					903	907		10.1038/sj.onc.1201605	http://dx.doi.org/10.1038/sj.onc.1201605			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484781				2022-12-25	WOS:000072053200009
J	Ulrich, E; Duwel, A; Kauffmann-Zeh, A; Gilbert, C; Lyon, D; Rudkin, B; Evan, G; Martin-Zanca, D				Ulrich, E; Duwel, A; Kauffmann-Zeh, A; Gilbert, C; Lyon, D; Rudkin, B; Evan, G; Martin-Zanca, D			Specific TrkA survival signals interfere with different apoptotic pathways	ONCOGENE			English	Article						survival signals; signal transduction; Akt; TrK	NERVE-GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; PC12 CELLS; ACTIVATION; FIBROBLASTS; RECEPTORS; PROTOONCOGENE; TRANSDUCTION; REQUIREMENT	Survival signalling by ligand-activated tyrosine kinase receptors plays a crucial role in maintaining the balance between cell viability and apoptosis in multicellular organisms. To identify receptor domains and pathways involved in survival signalling, the nerve growth factor receptor TrkA was expressed in Rat-1/MycER(TM) fibroblasts. We demonstrate that wt-TrkA receptor delays c-Myc-, U.V.- and Cycloheximide-induced apoptosis and activates targets such as the mitogen-activated protein kinase (MAPK) Erk2 and the serine/threonine kinase Akt/PKB, both of which have been implicated in survival signalling. TrkA mutated within its SHC binding site (Y490F) delays c-Myc-induced apoptosis without activating endogenous Akt/PKB. In contrast, the TrkA Y490F mutant receptor does not delay U.V.-induced apoptosis whilst TrkA mutated at its PLC-gamma binding site (Y785F) is capable of protecting from apoptosis induced by c-Myc or U.V. treatment. The double mutant TrkA YY490/785FF fails to block either of these two apoptotic stimuli. While PI3-kinase inhibitors LY294002 and Wortmannin competely block survival signalling following U.V. treatment, neither drug affects the ability of TrkA to block c-Myc-induced apoptosis. We show that the Akt/PKB pathway is essential for NGF stimulated TrkA survival signalling in the case of U.V.-induced apoptosis, but that apoptosis induced by c-Myc is also blocked by a novel, Akt/PKB-independent, pathway. These observations suggest that TrkA can activate different survival signalling pathways, which can interfere with specific apoptotic pathways.	Imperial Canc Res Fund Labs, London WC2A 3PX, England; Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain; Ecole Normale Super Lyon, Lab Cell & Mol Biol, Lyon, France	Cancer Research UK; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; Ecole Normale Superieure de Lyon (ENS de LYON)	Evan, G (corresponding author), Imperial Canc Res Fund Labs, 44 Lincolns Inn Fields, London WC2A 3PX, England.			RUDKIN, Brian B./0000-0003-3700-1982				BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; CARTER AN, 1992, J BIOL CHEM, V267, P14563; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; D'Mello SR, 1997, J NEUROSCI, V17, P1548; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P4086, DOI 10.1073/pnas.94.8.4086; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Minshall C, 1996, J IMMUNOL, V156, P939; MITRA G, 1991, ONCOGENE, V6, P2237; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; Parrizas M, 1997, J BIOL CHEM, V272, P154; Price BD, 1996, CANCER RES, V56, P246; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SMEYNE RJ, 1994, NATURE, V368, P245; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; Spear N, 1997, J NEUROCHEM, V69, P53; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Virdee K, 1996, J NEUROCHEM, V67, P1801; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YOUNG AR, 1987, PHOTODERMATOLOGY, V4, P127; Zhai S, 1996, EXP CELL RES, V224, P335, DOI 10.1006/excr.1996.0143	44	56	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					825	832		10.1038/sj.onc.1201842	http://dx.doi.org/10.1038/sj.onc.1201842			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484773				2022-12-25	WOS:000072053200001
J	Lee, GF; Kelley, RF				Lee, GF; Kelley, RF			A novel soluble tissue factor variant with an altered factor VIIa binding interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOVALENT PHAGE DISPLAY; KUNITZ DOMAIN INHIBITORS; SUBSTRATE RECOGNITION; CRYSTAL-STRUCTURE; FACTOR-X; RESIDUES; COMPLEX; SITE; IDENTIFICATION; SELECTION	Tissue factor (TF) residues Lys(20) and Asp(58) form part of a binding epitope previously shown by alanine scanning to be critical for high affinity interactions with factor VIIa (FVIIa), To explore the possibility of enhancing the affinity of a TF-based antagonist for FVIIa, we created libraries in which residues at 20, 58, and adjacent positions were varied in constructs containing the soluble extracellular domain of TF (sTF) fused to the bacteriophage M13 tail coat protein, TF variants monovalently displayed on phage were then sorted on the basis of binding to FVIIa, Sorting of preliminary libraries, in which position 58 and/or 20 and surrounding residues were randomized, led to the selection of TF proteins of essentially wild-type sequence, Therefore, we devised a strategy wherein TF position 20 was held fixed as alanine and 5 specific residues near to, and including, position 58 were randomized to effectively obtain alternative sequences at this interface, The consensus sequence reached with this library included wild-type residues at positions 61, 62, 65, and 66 but exclusively tryptophan at position 58, Analyses of the soluble K20A,D58W (A20W58) TF protein indicated that it binds FVIIa with an affinity comparable with wild-type sTF but is defective as a cofactor for FVIIa-dependent factor X activation, Further experiments designed to elucidate the mechanism of binding suggest that the new binding interactions involve more than the simple addition of hydrophobic surface area.	Genentech Inc, Dept Prot Engn, S San Francisco, CA 94080 USA	Roche Holding; Genentech	Kelley, RF (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, S San Francisco, CA 94080 USA.							BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BIETH J, 1974, PROTEINASE INHIBITOR, P463; BROZE GJ, 1994, HAEMOSTASIS THROMBOS, P349; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; DENNIS MS, 1994, J BIOL CHEM, V269, P22129; DENNIS MS, 1994, J BIOL CHEM, V269, P22137; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; KELLEY RF, 1995, BIOCHEMISTRY-US, V34, P10383, DOI 10.1021/bi00033a009; Kelley RF, 1997, BLOOD, V89, P3219, DOI 10.1182/blood.V89.9.3219; Kelly CR, 1997, J BIOL CHEM, V272, P17467, DOI 10.1074/jbc.272.28.17467; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee GF, 1997, BIOCHEMISTRY-US, V36, P5607, DOI 10.1021/bi970388j; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; Lowman HB., 1991, METHODS COMPANION ME, V3, P205; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; ROY S, 1991, J BIOL CHEM, V266, P22063; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1992, J BIOL CHEM, V267, P22206; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANFORD C, 1980, HYDROPHOBIC EFFECT; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; Williams J W, 1979, Methods Enzymol, V63, P437	33	11	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4149	4154		10.1074/jbc.273.7.4149	http://dx.doi.org/10.1074/jbc.273.7.4149			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461610	hybrid			2022-12-25	WOS:000072048400052
J	Niemela, R; Natunen, J; Majuri, ML; Maaheimo, H; Helin, J; Lowe, JB; Renkonen, O; Renkonen, R				Niemela, R; Natunen, J; Majuri, ML; Maaheimo, H; Helin, J; Lowe, JB; Renkonen, O; Renkonen, R			Complementary acceptor and site specificities of Fuc-TIV and Fuc-TVII allow effective biosynthesis of sialyl-TriLex and related polylactosamines present on glycoprotein counterreceptors of selectins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; MILK FUCOSYL-TRANSFERASE; LEWIS-X; MOLECULAR-CLONING; P-SELECTIN; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; LEUKOCYTE TRAFFICKING; DETERMINES EXPRESSION; CARBOHYDRATE LIGANDS; BETA-GALACTOSIDASE	The P-selectin counterreceptor PSGL-1 is covalently modified by mono alpha 2,3-sialylated, multiply alpha 1,3-fucosylated polylactosamines. These glycans are required for the adhesive interactions that allow this adhesion receptor-counterreceptor pair to facilitate leukocyte extravasation, To begin to understand the biosynthesis of these glycans, we have characterized the acceptor and site specificities of the two granulocyte alpha 1,3-fucosyltransferases, Fuc-TIV and Fuc-TVII, using recombinant forms of these two enzymes and a panel of synthetic polylactosamine-based accepters. We find that Fuc-TIV can transfer fucose effectively to all N-acetyllactosamine (LN) units in neutral polylactosamines, and to the "inner" LN units of alpha 2,3-sialylated accepters but is ineffective in transfer to the distal alpha 2,3-sialylated LN unit in alpha 2,3-sialylated accepters, Fuc-TVII, by contrast, effectively fucosylates only the distal alpha 2,3-sialylated LN unit in alpha 2,3-sialylated accepters and thus exhibits an acceptor site-specificity that is complementary to Fuc-TIV, Furthermore, the consecutive action of Fuc-TIV and Fuc-TVII, in vitro, can convert the long chairs sialoglycan SA alpha 2-3'LN beta 1-3'LN beta 1-3'LN (where SA is sialic acid) into the trifucosylated molecule SA alpha 2-3'Lex beta 1-3'Lex beta 1-3'Lex (where Lex is the trisaccharide Gal beta 1-4(Fuc alpha 1-3)GlcNAc) known to decorate PSGL-1, The complementary in vitro acceptor site-specificities of Fuc-TIV and Fuc-TVII imply that these enzymes cooperate in vivo in the biosynthesis of monosialylated, multifucosylated polylactosamine components of selectin counterreceptors on human leukocytes.	Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Helsinki; University of Helsinki; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Renkonen, R (corresponding author), Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, POB 21, FIN-00014 Helsinki, Finland.				NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA71932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKAWA M, 1974, J BIOCHEM, V75, P707, DOI 10.1093/oxfordjournals.jbchem.a130443; BEVILACQUA MP, 1994, ANNU REV MED, V45, P361, DOI 10.1146/annurev.med.45.1.361; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Clarke JL, 1996, J BIOL CHEM, V271, P10317, DOI 10.1074/jbc.271.17.10317; DEVRIES T, 1994, BIOCHEMISTRY-US, V33, P9937, DOI 10.1021/bi00199a016; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DEVRIES T, 1993, EUR J BIOCHEM, V216, P769, DOI 10.1111/j.1432-1033.1993.tb18197.x; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; Hiraiwa N, 1996, J BIOL CHEM, V271, P31556, DOI 10.1074/jbc.271.49.31556; HOLMES EH, 1993, ARCH BIOCHEM BIOPHYS, V301, P190, DOI 10.1006/abbi.1993.1132; JEZEQUELCUER M, 1993, BIOCHIM BIOPHYS ACTA, V1157, P252, DOI 10.1016/0304-4165(93)90107-J; JOHNSON PH, 1992, GLYCOCONJUGATE J, V9, P251, DOI 10.1007/BF00731137; JOHNSON PH, 1985, BIOCHEM SOC T, V13, P1119, DOI 10.1042/bst0131119; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LEPPANEN A, 1991, BIOCHEMISTRY-US, V30, P9287, DOI 10.1021/bi00102a022; LEY K, 1995, J IMMUNOL, V155, P525; LOWE JB, 1991, J BIOL CHEM, V266, P17467; Maaheimo H, 1997, CARBOHYD RES, V297, P145, DOI 10.1016/S0008-6215(96)00259-5; MAAHEIMO H, 1995, EUR J BIOCHEM, V234, P616, DOI 10.1111/j.1432-1033.1995.616_b.x; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NIEMELA R, 1995, GLYCOCONJUGATE J, V12, P36, DOI 10.1007/BF00731866; Niemela R, 1995, CARBOHYD RES, V279, P331, DOI 10.1016/0008-6215(95)00299-5; PATEL TP, 1994, BIOCHEMISTRY-US, V33, P14815, DOI 10.1021/bi00253a021; RABINA J, 1998, IN PRESS CARBOHYDR R; RENKONEN O, 1989, GLYCOCONJUGATE J, V6, P129, DOI 10.1007/BF01047895; RENKONEN O, 1990, BIOCHEM CELL BIOL, V68, P1032, DOI 10.1139/o90-152; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SARNESTO A, 1992, J BIOL CHEM, V267, P2745; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Seppo A, 1996, GLYCOBIOLOGY, V6, P65, DOI 10.1093/glycob/6.1.65; SEPPO A, 1990, BIOCHEM CELL BIOL, V68, P44, DOI 10.1139/o90-006; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P770, DOI 10.1021/bi952461g; SUEYOSHI S, 1994, J BIOL CHEM, V269, P32342; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; WATKINS WM, 1995, ADV EXP MED BIOL, V376, P83; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732	48	79	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4021	4026		10.1074/jbc.273.7.4021	http://dx.doi.org/10.1074/jbc.273.7.4021			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461592	hybrid			2022-12-25	WOS:000072048400034
J	Ohkuma, M; Zimmer, T; Iida, T; Schunck, WH; Ohta, A; Takagi, M				Ohkuma, M; Zimmer, T; Iida, T; Schunck, WH; Ohta, A; Takagi, M			Isozyme function of n-alkane-inducible cytochromes P450 in Candida maltosa revealed by sequential gene disruption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-VECTOR SYSTEM; MULTIGENE FAMILY; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; CYP52; IDENTIFICATION; TROPICALIS; YEAST; PURIFICATION; CONSTRUCTION	An n-alkane-assimilating yeast Candida maltosa contains multiple n-alkane-inducible forms of cytochromes P450 (P450alk), which can be assumed to catalyze terminal hydroxylation of n-alkanes in the assimilation pathway. Eight structurally related P450alk genes have been identified, In the present study, the function off four major isoforms of P450alk (encoded by ALK1, ALK2, ALK3, and ALK5 genes) was investigated by sequential gene disruption. Auxotrophic markers used for the selection of disrupted strains were regenerated repeatedly through either mitotic recombination between heterozygous alleles of the diploid genome or directed deletion of the marker gene, to allow sequential gene disruptions within a single strain, The strain depleted of all four isoforms could not utilize n-alkanes for growth, providing direct evidence that P450alk is essential for n-alkane assimilation, Growth properties of a series of intermediate disrupted strains, plasmid-based complementation, and enzyme assays after heterologous expression of single isoforms revealed (i) that each of the four individual isoforms is alone sufficient to allow growth on long chain n-alkane; (ii) that the ALK1-encoding isoform is the mesh; versatile and efficient P450alk form, considering both its enzymatic activity and its ability to confer growth on n-alkanes of different chain length; and (iii) that the ALK5-encoding isoform exhibits a rather narrow substrate specificity and thus cannot support the utilization of short chain n-alkanes.	Univ Tokyo, Lab Cellular Genet, Dept Biotechnol, Bunkyo Ku, Tokyo 113, Japan; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	University of Tokyo; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Takagi, M (corresponding author), Univ Tokyo, Lab Cellular Genet, Dept Biotechnol, Bunkyo Ku, Tokyo 113, Japan.		Iida, Toshiya/D-2804-2017; Ohkuma, Moriya/A-8100-2011					HIKIJI T, 1989, CURR GENET, V16, P261, DOI 10.1007/BF00422112; HONECK H, 1982, BIOCHEM BIOPH RES CO, V106, P1318, DOI 10.1016/0006-291X(82)91257-8; KAWAI S, 1991, AGR BIOL CHEM TOKYO, V55, P59, DOI 10.1080/00021369.1991.10870559; KELLY R, 1987, MOL CELL BIOL, V7, P199, DOI 10.1128/MCB.7.1.199; KELLY R, 1988, MOL GEN GENET, V214, P24, DOI 10.1007/BF00340174; Masuda Y, 1995, GENE, V167, P157, DOI 10.1016/0378-1119(95)00655-9; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OHKUMA M, 1995, DNA CELL BIOL, V14, P163, DOI 10.1089/dna.1995.14.163; OHKUMA M, 1991, DNA CELL BIOL, V10, P271, DOI 10.1089/dna.1991.10.271; OHKUMA M, 1995, BIOSCI BIOTECH BIOCH, V59, P1328, DOI 10.1271/bbb.59.1328; OHKUMA M, 1993, CURR GENET, V23, P205, DOI 10.1007/BF00351497; OHKUMA M, 1991, AGR BIOL CHEM TOKYO, V55, P1757, DOI 10.1080/00021369.1991.10870878; Ohkuma M, 1995, MOL GEN GENET, V249, P447, DOI 10.1007/BF00287107; PICATAGGIO S, 1992, BIO-TECHNOL, V10, P894, DOI 10.1038/nbt0892-894; PICATAGGIO S, 1991, MOL CELL BIOL, V11, P4333, DOI 10.1128/MCB.11.9.4333; Scheller U, 1996, ARCH BIOCHEM BIOPHYS, V328, P245, DOI 10.1006/abbi.1996.0170; SCHUNCK WH, 1989, BIOCHEM BIOPH RES CO, V161, P843, DOI 10.1016/0006-291X(89)92677-6; SCHUNCK WH, 1991, EUR J CELL BIOL, V55, P336; SCHUNCK WH, 1987, ARCH MICROBIOL, V147, P240, DOI 10.1007/BF00463482; SEGHEZZI W, 1992, DNA CELL BIOL, V11, P767, DOI 10.1089/dna.1992.11.767; TAKAGI M, 1989, AGR BIOL CHEM TOKYO, V53, P2217, DOI 10.1080/00021369.1989.10869646; TAKAGI M, 1986, J BACTERIOL, V167, P551, DOI 10.1128/jb.167.2.551-555.1986; Zimmer T, 1996, BIOCHEM BIOPH RES CO, V224, P784, DOI 10.1006/bbrc.1996.1100; ZIMMER T, 1995, DNA CELL BIOL, V14, P619, DOI 10.1089/dna.1995.14.619	24	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3948	3953		10.1074/jbc.273.7.3948	http://dx.doi.org/10.1074/jbc.273.7.3948			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461581	hybrid			2022-12-25	WOS:000072048400023
J	Matsuyama, S; Ueda, T; Crain, PF; McCloskey, JA; Watanabe, K				Matsuyama, S; Ueda, T; Crain, PF; McCloskey, JA; Watanabe, K			A novel wobble rule found in starfish mitochondria - Presence of 7-methylguanosine at the anticodon wobble position expands decoding capability of tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-CODE; TRANSFER-RNA; NUCLEOTIDE-SEQUENCE; MODIFIED NUCLEOSIDES; MASS-SPECTROMETRY; ASCARIS-SUUM; ORGANIZATION; DNA; EVOLUTION; GENOME	In the starfish mitochondrial (mt) genome, codons AGA and AGG (in addition to AGU and AGC) have been considered to be translated as serine. There is, however, only a single candidate mt tRNA gene responsible for translating these codons and it has a GCT anticodon sequence, but guanosine at the first position of the anticodon should base pair only with pyrimidines according to the conventional wobble rule. To solve this enigma, the mt tRNA(GCU)(ser) was purified, and sequence determination in combination with electrospray Liquid chromatography/mass spectrometry revealed that 7-methylguanosine is located at the first position of the anticodon. This is the first case in which a tRNA has been found to have 7-methylguanosine at the wobble position. It is suggested that methylation at N-7 of wobbling guanosine endows the tRNA with the capability of forming base pairs with all four nucleotides, A, U, G, and C, and expands the repertoire of codon-anticodon interaction. This finding indicates that a nonuniversal genetic code in starfish has been generated by base modification in the tRNA anticodon.	Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 113, Japan; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84112 USA	University of Tokyo; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Watanabe, K (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Hongo 7-3-1, Tokyo 113, Japan.		Ueda, Takuya/K-5217-2014	Ueda, Takuya/0000-0002-7760-8271	NIGMS NIH HHS [GM29812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029812] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ASAKAWA S, 1995, GENETICS, V140, P1047; BANKS JF, 1994, ANAL CHEM, V66, P406, DOI 10.1021/ac00075a015; BARRELL BG, 1980, P NATL ACAD SCI-BIOL, V77, P3164, DOI 10.1073/pnas.77.6.3164; CANTATORE P, 1989, J BIOL CHEM, V264, P10965; CLARY DO, 1985, J MOL EVOL, V22, P252, DOI 10.1007/BF02099755; CRAIN PF, 1990, METHOD ENZYMOL, V193, P782, DOI 10.1016/0076-6879(90)93450-Y; DEBRUIJN MHL, 1983, NATURE, V304, P234, DOI 10.1038/304234a0; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; GROSJEAN H, 1995, BIOCHIMIE, V77, P139, DOI 10.1016/0300-9084(96)88117-X; HECKMAN JE, 1980, P NATL ACAD SCI-BIOL, V77, P3159, DOI 10.1073/pnas.77.6.3159; HIMENO H, 1987, GENE, V56, P219; JACOBS HT, 1988, J MOL BIOL, V202, P185, DOI 10.1016/0022-2836(88)90452-4; KEITH G, 1995, BIOCHIMIE, V77, P142, DOI 10.1016/0300-9084(96)88118-1; KONDO A, 1996, NUCL ACIDS S SER, V35, P279; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; MARTIN RP, 1990, BIOCHEMISTRY-US, V29, P956, DOI 10.1021/bi00456a016; MORIYA J, 1994, BIOCHEMISTRY-US, V33, P2234, DOI 10.1021/bi00174a033; OKIMOTO R, 1992, GENETICS, V130, P471; OSAWA S, 1989, J MOL EVOL, V29, P202, DOI 10.1007/BF02100203; OSAWA S, 1992, MICROBIOL REV, V56, P229, DOI 10.1128/MMBR.56.1.229-264.1992; Osawa S., 1995, EVOLUTION GENETIC CO; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; Sprinzl M, 1996, NUCLEIC ACIDS RES, V24, P68, DOI 10.1093/nar/24.1.68; Suzuki T, 1996, FEBS LETT, V381, P195, DOI 10.1016/0014-5793(96)00107-X; WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P345; Watanabe Kimitsuna, 1995, P225; WATANABE YI, 1994, J BIOL CHEM, V269, P22902; WINTERMEYER W, 1970, FEBS LETT, V11, P160, DOI 10.1016/0014-5793(70)80518-X; WOLSTENHOLME DR, 1985, GENETICS, V109, P725; YOKOBORI S, 1993, J MOL EVOL, V36, P1, DOI 10.1007/BF02407301	31	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3363	3368		10.1074/jbc.273.6.3363	http://dx.doi.org/10.1074/jbc.273.6.3363			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452455	hybrid			2022-12-25	WOS:000071822300040
J	Medema, JP; Scaffidi, C; Krammer, PH; Peter, ME				Medema, JP; Scaffidi, C; Krammer, PH; Peter, ME			Bcl-x(L) acts downstream of caspase-8 activation by the CD95 death-inducing signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; APOPTOTIC CELL-DEATH; PROTEASE; BCL-2; FAS; FAS/APO-1; RECEPTOR; INVOLVEMENT; INTERACTS; DOMAIN	The Bcl-2 family member Bcl-x(L) has often been correlated with apoptosis resistance, We have shown recently that in peripheral human T cells resistance to CD95-mediated apoptosis is characterized by a lack of caspase-8 recruitment to the CD95 death-inducing sig naling complex (DISC) and by increased expression of Bcl-x(L) (Peter, M. E., Kischkel, F. C., Scheuerpflug, C. G., Medema, J. P., Debatin, K.-M., and Krammer, P. H. (1997) Eur. J. Immunol. 27, 1207-1212), This raises the possibility that Bcl-x(L) directly prevents caspase-8 activation by the DISC, To test this hypothesis a cell line in which CD95 signaling was inhibited by overexpression of Bcl-x(L) was used, In these MCF7-Fas-bcl-x(L) cells Bcl-x(L) had no effect on the recruitment of caspase-8 to the DISC, It did not affect the activity of the DISC nor the generation of the caspase-8 active subunits p18 and p10, In contrast, cleavage of a typical substrate for caspase-3-like proteases, poly(ADP-ribose) polymerase, was inhibited in comparison with the control-transfected CD95-sensitive MCF7-Fas cells, To test whether Bcl-x(L) would inhibit active caspase-8 subunits in the cytoplasm, a number of immunoprecipitation experiments were performed, Using monoclonal antibodies directed against different domains of caspase-8, anti-Bcl-x(L) antibodies, or fusion proteins of glutathione S-transferase with different domains of caspase-8, no evidence for a direct or indirect physical interaction between caspase-8 and Bcl-x(L) was found, Moreover, overexpression of Bcl-x(L) did not inhibit the activity of the caspase-8 active subunits p18/p10, Therefore, in this cell line that has become resistant to CD95-induced apoptosis due to overexpression of Bcl-x(L), Bcl-x(L) acts independently and downstream of caspase-8.	German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Peter, ME (corresponding author), German Canc Res Ctr, Tumor Immunol Program, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	m.peter@dkfz-heidelberg.de	Watzl, Carsten/B-4911-2013	Watzl, Carsten/0000-0001-5195-0995; Peter, Marcus Ernst/0000-0003-3216-036X; Medema, Jan Paul/0000-0003-3045-2924				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Bauer MKA, 1997, FEBS LETT, V402, P256, DOI 10.1016/S0014-5793(96)01497-4; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Estoppey S, 1997, CELL DEATH DIFFER, V4, P34, DOI 10.1038/sj.cdd.4400205; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MENON SD, 1995, J BIOL CHEM, V270, P18881; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Perry DK, 1997, CELL DEATH DIFFER, V4, P29, DOI 10.1038/sj.cdd.4400200; PETER ME, 1995, CELL DEATH DIFFER, V2, P163; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Shimizu S, 1996, ONCOGENE, V12, P2251; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	40	100	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3388	3393		10.1074/jbc.273.6.3388	http://dx.doi.org/10.1074/jbc.273.6.3388			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452459	hybrid			2022-12-25	WOS:000071822300044
J	Su, TZ; Wang, MH; Syu, LJ; Saltiel, AR; Oxender, DL				Su, TZ; Wang, MH; Syu, LJ; Saltiel, AR; Oxender, DL			Regulation of system A amino acid transport in 3T3-L1 adipocytes by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; SELECTIVE INHIBITOR WORTMANNIN; STIMULATED GLUCOSE-TRANSPORT; HAMSTER OVARY CELLS; PHOSPHOINOSITIDE 3-KINASE; GLYCOGEN-SYNTHASE; GLUT4 TRANSLOCATION; SIGNALING PATHWAYS; GENE-EXPRESSION	The insulin-stimulated uptake of 2-(methylamino) isobutyric acid (MeAIB), a nonmetabolizable substrate for system A, in 3T3-L1 adipocytes was investigated. As cells took on a more adipogenic phenotype, the insulin-stimulated versus the saturable basal MeAIB uptake increased by 5-fold. The induced transport activity showed properties characteristic of system A, with a K-m value of 190 mu M. The half-life of the induced system A activity was independent of de novo mRNA and protein synthesis and was not accelerated by ambient amino acids, therefore, it was mechanistically distinct from the previously described adaptive and hormonal regulation of system A. Inhibition of mitogen-activated protein kinase kinase by PD98059, Ras farnesylation by PD152440 and B581, p70(S6K) by rapamycin, and phosphatidylinositol 3-kinase (PI 3'-K) by wortmannin and LY294002 revealed that only wortmannin and LY294002 inhibited the insulin-induced MeAIB uptake with IC50 values close to that previously reported for inhibition of PI 3'-K. These results suggest that the Ras/mitogen-activated protein kinase and pp70(S6K) insulin signaling pathways are neither required nor sufficient for insulin stimulation of MeAIB uptake, and activation of PI 3'-K or a wortmanninn/LY294002-sensitive pathway may play an important role in regulation of system A transport by insulin in 3T3-L1 cells.	Parke Davis Pharmaceut Res Div, Dept Mol Biol, Ann Arbor, MI 48105 USA; Parke Davis Pharmaceut Res Div, Dept Cell Biol, Ann Arbor, MI 48105 USA	Pfizer; Pfizer	Su, TZ (corresponding author), Parke Davis Pharmaceut Res Div, Dept Mol Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; BRACY DS, 1986, J BIOL CHEM, V261, P1514; Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; COLLARINI EJ, 1987, ANNU REV NUTR, V7, P75, DOI 10.1146/annurev.nu.07.070187.000451; Conricode KM, 1995, BIOCHEM MOL BIOL INT, V36, P835; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GRUNFELD C, 1983, ENDOCRINOLOGY, V113, P1763, DOI 10.1210/endo-113-5-1763; HANDLOGTEN ME, 1984, J BIOL CHEM, V259, P3519; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Ho LKF, 1997, BIOCHEM BIOPH RES CO, V235, P130, DOI 10.1006/bbrc.1997.6747; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; JONES M, 1994, P NATL ACAD SCI USA, V91, P858, DOI 10.1073/pnas.91.3.858; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KILBERG MS, 1985, CURR TOP CELL REGUL, V25, P133; KILBERG MS, 1986, TRENDS BIOCHEM SCI, V11, P183, DOI 10.1016/0968-0004(86)90138-6; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MARSHALL S, 1989, J BIOL CHEM, V264, P2037; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; MOFFETT J, 1987, P NATL ACAD SCI USA, V84, P8040, DOI 10.1073/pnas.84.22.8040; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Obata T, 1996, CIRC RES, V79, P1167, DOI 10.1161/01.RES.79.6.1167; OKADA T, 1994, J BIOL CHEM, V269, P3568; OXENDER DL, 1963, J BIOL CHEM, V238, P3686; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; RUIZMONTASELL B, 1994, P NATL ACAD SCI USA, V91, P9569, DOI 10.1073/pnas.91.20.9569; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Su TZ, 1997, BRAIN RES, V757, P69, DOI 10.1016/S0006-8993(97)00139-X; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; TADROS LB, 1993, AM J PHYSIOL, V265, pE135, DOI 10.1152/ajpendo.1993.265.1.E135; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729	58	26	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3173	3179		10.1074/jbc.273.6.3173	http://dx.doi.org/10.1074/jbc.273.6.3173			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452428	hybrid			2022-12-25	WOS:000071822300013
J	Toke, DA; Bennett, WL; Dillon, DA; Wu, WI; Chen, XM; Ostrander, DB; Oshiro, J; Cremesti, A; Voelker, DR; Fischl, AS; Carman, GM				Toke, DA; Bennett, WL; Dillon, DA; Wu, WI; Chen, XM; Ostrander, DB; Oshiro, J; Cremesti, A; Voelker, DR; Fischl, AS; Carman, GM			Isolation and characterization of the Saccharomyces cerevisiae DPP1 gene encoding diacylglycerol pyrophosphate phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; PHOSPHOLIPID BIOSYNTHESIS; PHOSPHATIDYLSERINE DECARBOXYLASE; POLYVINYLIDENE DIFLUORIDE; INOSITOL LIPIDS; SHUTTLE VECTORS; NULL ALLELE; YEAST; PROTEIN	Diacylglycerol pyrophosphate (DGPP) is involved in a putative novel lipid signaling pathway, DGPP phosphatase (DGPP phosphohydrolase) is a membrane-associated 34-kDa enzyme from Saccharomyces cerevisiae which catalyzes the dephosphorylation of DGPP to yield phosphatidate (PA) and then catalyzes the dephosphorylation of PA to yield diacylglycerol, Amino acid sequence information derived from DGPP phosphatase was used to identify and isolate the DPP1 (diacylglycerol pyrophosphate phosphatase) gene encoding the enzyme. Multicopy plasmids containing the DPP1 gene directed a 10-fold overexpression of DGPP phosphatase activity in S. cerevisiae. The heterologous expression of the S. cerevisiae DPP1 gene in Sf-9 insect cells resulted in a 500-fold overexpression of DGPP phosphatase activity over that expressed in wild-type S. cerevisiae. DGPP phosphatase possesses a Mg2+-independent PA phosphatase activity, and its expression correlated with the overexpression of DGPP phosphatase activity in S. cerevisiae and in insect cells. DGPP phosphatase was predicted to be an integral membrane protein with six transmembrane-spanning domains. The enzyme contains a novel phosphatase sequence motif found in a superfamily of phosphatases. A dpp1 Delta mutant was constructed by deletion of the chromosomal copy of the DPP1 gene. The dpp1 Delta mutant was viable and did not exhibit any obvious growth defects. The mutant was devoid of DGPP phosphatase activity and accumulated (4-fold) DGPP. Analysis of the mutant showed that the DPP1 gene was not responsible for all of the Mg2+-independent PA phosphatase activity in S. cerevisiae.	Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, New Brunswick, NJ 08903 USA; Natl Jewish Ctr Immunol & Resp Med, Lord & Taylor Lab Lung Biochem, Denver, CO 80206 USA; Natl Jewish Ctr Immunol & Resp Med, Anna Perahia Adatto Clin Res Ctr, Denver, CO 80206 USA; Univ Rhode Isl, Dept Food Sci & Nutr, W Kingston, RI 02892 USA	Rutgers State University New Brunswick; National Jewish Health; National Jewish Health; University of Rhode Island	Carman, GM (corresponding author), Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, New Brunswick, NJ 08903 USA.	carman@aesop.rutgers.edu	Oshiro, June/ACF-4163-2022	Oshiro, June/0000-0003-1134-5023; Bennett, Wendy/0000-0001-9828-0706	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453, R01GM032453, R29GM049214] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-32453, GM-49214] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLANCEY CJ, 1993, J BIOL CHEM, V268, P24580; CULBERTSON MR, 1975, GENETICS, V80, P23; Dillon DA, 1997, J BIOL CHEM, V272, P10361; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; EXTON JH, 1990, J BIOL CHEM, V265, P1; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; HANSON BA, 1980, J LIPID RES, V21, P309; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; Innis MA, 1990, PCR PROTOCOLS GUIDE, P1, DOI [10.1016/0167-7799(90)90215-J, DOI 10.1016/0167-7799(90)90215-J]; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jacq C, 1997, NATURE, V387, P75, DOI 10.1038/387s075; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LIN YP, 1989, J BIOL CHEM, V264, P8641; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGEE TP, 1994, J BACTERIOL, V176, P6861, DOI 10.1128/JB.176.22.6861-6868.1994; MICHELL RH, 1992, TRENDS BIOCHEM SCI, V17, P274, DOI 10.1016/0968-0004(92)90433-A; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; O'Reilly D., 1992, BACULOVIRUS EXPRESSI, P109; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; Riedel B, 1997, PLANT SCI, V128, P1, DOI 10.1016/S0168-9452(97)00120-9; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Stukey J, 1997, PROTEIN SCI, V6, P469; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WISSING JB, 1993, PLANT PHYSIOL, V102, P1243, DOI 10.1104/pp.102.4.1243; WISSING JB, 1993, FEBS LETT, V315, P95, DOI 10.1016/0014-5793(93)81141-L; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0	57	100	107	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3278	3284		10.1074/jbc.273.6.3278	http://dx.doi.org/10.1074/jbc.273.6.3278			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452443	Green Published, hybrid			2022-12-25	WOS:000071822300028
J	Johnston, D; Hatzis, D; Sunday, ME				Johnston, D; Hatzis, D; Sunday, ME			Expression of v-Ha-ras driven by the calcitonin/calcitonin gene-related peptide promoter: a novel transgenic murine model for medullary thyroid carcinoma	ONCOGENE			English	Article						C-cells; RT-PCR; immunohistochemistry; thyroglobulin; cell lineage; dense-core granules	ONCOGENE INDUCES DIFFERENTIATION; CELL LUNG-CANCER; THYROGLOBULIN IMMUNOREACTIVITY; C-CELLS; MICE; PROTEIN; PHEOCHROMOCYTOMAS; TUMORS; ORIGIN; ENTITY	v-Ha-ras has been demonstrated previously to induce neuroendocrine differentiation of medullary thyroid carcinoma (MTC, malignant C cell tumor) cell lines. The potential role of ras mediated signaling in neuroendocrine cells in vivo has been investigated by expressing v-Ha-ras under control of the neural/neuroendocrine specific calcitonin/calcitonin gene-related peptide (CGRP) promoter. Five independent mouse lineages were derived following germ line insertion of the transgene. Four of the five lineages consistently express the transgene; neuroendocrine expression is found in three of the five lineages as both spliced and full length messages. Phenotypically, the mice expressing rascal have shortened lifespans primarily due to the high incidence of MTCs between 6 months to a year of age. C-cell hyperplasia is demonstrated in several mice in the absence of gross evidence of tumor formation. Histopathological and ultrastructural analyses demonstrate typical features of MTCs including prominent immunohistochemical staining for calcitonin and dense-core neurosecretory-type granules. In addition, four of 22 tumors co-express thyroglobulin (a non-neuroendocrine follicular epithelial cell marker) and calcitonin (a neuroendocrine marker) in a subset of the tumor cells. The rascal transgenic mouse provides a unique model for investigating the sequential pathogenesis of MTC and possibly also for elucidating the relationship between MTC and mixed medullary-follicular carcinomas.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Sunday, ME (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.			Sunday, Mary E./0000-0002-6788-1469	NHLBI NIH HHS [R01-HL44984, R01-HL50045] Funding Source: Medline; NICHD NIH HHS [N01-HD02911] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002911] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044984, R01HL050045] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMARA SG, 1984, MOL CELL BIOL, V4, P2151, DOI 10.1128/MCB.4.10.2151; BAETSCHER M, 1991, ONCOGENE, V6, P1133; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENNETT MM, 1992, ANN NY ACAD SCI, V657, P36, DOI 10.1111/j.1749-6632.1992.tb22755.x; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BOS JL, 1989, CANCER RES, V49, P4682; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; CUTHBERTSON RA, 1988, LAB INVEST, V58, P484; DAVIS LG, 1986, BASIC METHODS MOL BI, P1; DeLellis RA, 1994, PATHOBIOLOGY AGING R, P285; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; GLASSER SW, 1994, AM J PHYSIOL-LUNG C, V267, pL489, DOI 10.1152/ajplung.1994.267.5.L489; HARVEY M, 1995, CANCER RES, V55, P1146; HOLM R, 1987, LAB INVEST, V57, P258; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KOSTROUCH Z, 1991, ENDOCRINOLOGY, V129, P2202, DOI 10.1210/endo-129-4-2202; KOVACS CS, 1994, CANCER-AM CANCER SOC, V74, P928, DOI 10.1002/1097-0142(19940801)74:3<928::AID-CNCR2820740321>3.0.CO;2-E; LEBLANC B, 1990, VET PATHOL, V27, P445, DOI 10.1177/030098589902700610; LJUNGBERG O, 1985, VET PATHOL, V22, P95, DOI 10.1177/030098588502200201; LJUNGBERG O, 1983, CANCER, V52, P1053, DOI 10.1002/1097-0142(19830915)52:6<1053::AID-CNCR2820520621>3.0.CO;2-Q; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MABRY M, 1989, J CLIN INVEST, V84, P194, DOI 10.1172/JCI114140; MANENTI G, 1994, EUR J CANCER, V30A, P987, DOI 10.1016/0959-8049(94)90130-9; MANGUES R, 1990, ONCOGENE, V5, P1491; MOLEY JF, 1991, CANCER RES, V51, P1596; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; POLAK JM, 1974, HISTOCHEMISTRY, V40, P209, DOI 10.1007/BF00501955; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; SANTELLI G, 1993, CANCER RES, V53, P5523; SCHULZ N, 1992, CANCER RES, V52, P450; SOBRINHOSIMOES M, 1985, ULTRASTRUCT PATHOL, V8, pR3; SUNDAY ME, 1988, ENDOCRINOLOGY, V122, P1551, DOI 10.1210/endo-122-4-1551; SUNDAY ME, 1994, LAB INVEST, V70, P875; SUNDAY ME, 1991, METHODS NEUROSCI, V5, P123; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WILLIAMS ED, 1989, J PATHOL, V159, P135, DOI 10.1002/path.1711590208	39	29	29	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	1998	16	2					167	177		10.1038/sj.onc.1201478	http://dx.doi.org/10.1038/sj.onc.1201478			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464534				2022-12-25	WOS:000071427100003
J	Donato, NJ; Perez, M				Donato, NJ; Perez, M			Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAF1 proteolysis in ME-180 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; NUCLEOTIDE EXCISION-REPAIR; FAS-MEDIATED APOPTOSIS; KAPPA-B ACTIVATION; CARCINOMA-CELLS; POLY(ADP-RIBOSE) POLYMERASE; SUPPRESSOR GENE; FACTOR-ALPHA; DEATH; PROTEIN	Tumor necrosis factor (TNF)-mediated apoptotic signaling has been characterized by activation of specific protease or protein kinase cascades that regulate the onset of apoptosis, TNF has also been shown to induce oxidative or genotoxic stress in some cell types, and apoptotic potential may be determined by the cellular response to this stress, To determine the role of genotoxic stress in TNF-mediated apoptosis, we examined cellular accumulation of p53 in TNF-treated ME-180 cells selected for apoptotic sensitivity (ME-180S) or resistance (ME-180R) to TNF, Although TNF was able to activate receptor-mediated signaling in either cell line, p53 accumulation was measurable only in apoptotically sensitive ME-180S cells. TNF-induced changes in p53 levels were detected Ih after treatment, and peak levels were measurable 4-8 h after TNF exposure. TNF was unable to induce p21WAF1 in either cell line but affected the stability of this protein in apoptotically responsive ME-180S cells, Evidence of p21WAF1 proteolysis was detected by monitoring the appearance of a 16-kDa immunoblottable p21WAF1 fragment, which became detectable 4 h after TNF addition and increased in content before the onset of DNA fragmentation (16-24 h), The kinetics of p21WAF1 proteolysis closely paralleled those of poly(ADP-ribose) polymerase, suggesting cleavage of p21WAF1. by activation of an apoptotic protease, Pretreatment of ME-180S cells with the apoptotic protease inhibitor YVAD blocked TNF-induced apoptosis and prevented both poly(ADP-ribose) polymerase and p21WAF1 degradation but did not affect p53 induction. These results provide evidence for the early onset of genotoxic stress in cells committed to TNF-mediated apoptosis and for divergence in propagation of this signal in non-responsive cells. In addition, TNF-induced p21WAF1 proteolysis may be mediated by an apoptotic protease and may contribute to the apoptotic process by disrupting p53 signaling, altering cell cycle inhibition, and limiting cellular recovery from genotoxic stress.	Univ Texas, MD Anderson Cancer Ctr, Dept Bioimmunotherapy & Drug Carriers, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Donato, NJ (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Bioimmunotherapy & Drug Carriers, Box 44,1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA48906, CA73018] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073018, R29CA048906, R01CA048906] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTEK J, 1990, ONCOGENE, V5, P893; BELIZARIO JE, 1991, CANCER RES, V51, P2379; BELLOMO G, 1992, CANCER RES, V52, P1342; BELLUCCO T, 1995, INTERNET WORLD, V6, P8; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CLARK HM, 1992, J PATHOL, V166, P129, DOI 10.1002/path.1711660208; DARZYNKIEWICZ Z, 1984, CANCER RES, V44, P83; DONATO NJ, 1993, CELL GROWTH DIFFER, V4, P411; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; HARPER JW, 1993, CELL, V75, P805; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; HOLSTEIN M, 1991, SCIENCE, V253, P49; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; ITOH N, 1993, J BIOL CHEM, V268, P10932; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Martin Seamus J., 1994, Current Opinion in Oncology, V6, P616, DOI 10.1097/00001622-199411000-00015; MCDONNELL TJ, 1995, SEMIN CANCER BIOL, V6, P53, DOI 10.1006/scbi.1995.0007; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NISHIKAWA K, 1994, LYMPHOKINE CYTOK RES, V13, P37; NISHIKAWA K, 1992, CANCER RES, V52, P4758; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Perez M, 1996, J INTERF CYTOK RES, V16, P307, DOI 10.1089/jir.1996.16.307; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHEPARD HM, 1988, J CLIN IMMUNOL, V8, P333, DOI 10.1007/BF00917148; Shih SC, 1996, CANCER RES, V56, P1591; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Stoian I, 1996, BIOCHEM MOL MED, V59, P93, DOI 10.1006/bmme.1996.0072; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YonishRouach E, 1996, EXPERIENTIA, V52, P1001, DOI 10.1007/BF01920109; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang W, 1995, CLIN CANCER RES, V1, P1051; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	57	82	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5067	5072		10.1074/jbc.273.9.5067	http://dx.doi.org/10.1074/jbc.273.9.5067			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478957	hybrid			2022-12-25	WOS:000072310400041
J	Pummill, PE; Achyuthan, AM; DeAngelis, PL				Pummill, PE; Achyuthan, AM; DeAngelis, PL			Enzymological characterization of recombinant Xenopus DG42, a vertebrate hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATED TERATOCARCINOMA CELLS; STREPTOCOCCUS-PYOGENES; OLIGODENDROGLIOMA CELLS; SYNTHESIZE HYALURONAN; MOLECULAR-CLONING; GENE; SYNTHETASE; PROTEIN; ACID; IDENTIFICATION	We have characterized the hyaluronan (HA) synthase activity of the Xenopus DG42 gene product in vitro, The recombinant enzyme produced in yeast does not possess a nascent HA chain and, therefore, is an ideal model system for kinetic studies of the synthase's glycosyl transferase activity, The enzymatic rate was optimal from pH 7.6 to 8.1, Only the authentic sugar nucleotide precursors, UDP-glucuronic acid (UDP-GlcA) and UDP-N-acetylglucosamine (UDP-GlcNAc), were utilized to produce a large molecular weight polymer, UDP-glucose or the galactose epimers of the normal substrates did not substitute, The Michaelis constant, K-m, of recombinant DG42 in membranes was 60 +/- 20 and 235 +/- 40 mu M for UDP-GlcA and UDP-GlcNAc, respectively, which is comparable to values obtained previously from membranes derived from vertebrate cells, The apparent energy of activation for HA elongation is about 15 kilocalories/mol. DG42 polymerizes HA at average rates of about 80 to 110 monosaccharides/s in vitro, The resulting HA polysaccharide possessed molecular weights spanning 2 x 10(6)-10(7) Da, corresponding to about 10(4) sugar residues, This is the first report characterizing a defined eukaryotic enzyme that can produce a glycosaminoglycan.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA.	Paul-DeAngelis@OUHSC.edu			NIGMS NIH HHS [R01-GM56497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPEL A, 1979, J BIOL CHEM, V254, P2199; ATKINSON EM, 1992, MOL PLANT MICROBE IN, V5, P439, DOI 10.1094/MPMI-5-439; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; DeAngelis PL, 1996, BIOCHEMISTRY-US, V35, P9768, DOI 10.1021/bi960154k; DETERMAN HD, 1968, GEL CHROMATOGRAPHY; ISHIMOTO N, 1966, J BIOL CHEM, V241, P2052; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; MALINOWSKI NM, 1995, BIOCHEM MOL BIOL INT, V35, P1123; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; NG KF, 1989, J BIOL CHEM, V264, P11776; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945	25	30	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4976	4981		10.1074/jbc.273.9.4976	http://dx.doi.org/10.1074/jbc.273.9.4976			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478944	hybrid			2022-12-25	WOS:000072310400028
J	Gao, MX; Rychlik, W; Rhoads, RE				Gao, MX; Rychlik, W; Rhoads, RE			Cloning and characterization of human eIF4E genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; EUKARYOTIC PROTEIN-SYNTHESIS; CAP-BINDING-PROTEIN; SITE-DIRECTED MUTAGENESIS; RAT EMBRYO FIBROBLASTS; GLOBIN MESSENGER-RNA; TRANSLATION INITIATION; FACTOR EIF-4E; INCREASED EXPRESSION; ELEVATED LEVELS	Two human eukaryotic initiation factor 4E (eIF4E) genes were isolated and characterized from placental and chromosome 4-specific genomic libraries. One of the genes (EIF4E1) contained six introns, but the other gene (EIF4E2) was intronless, flanked by Alu sequences and 14-base pair (bp) direct repeats, and terminated by a short poly(A) stretch, all characteristics of retrotransposons, Numerous additional intronless eIF4E pseudogenes were found, but unlike EIF4E2, all contained premature in-frame stop codons. The entire EIF4E1 gene spanned >50 kilobase pahs, The coding regions of these two genes differed in four nucleotide residues, resulting in two amino acid differences in the predicted proteins, The promoter of EIF4E1 has been characterized previously. The putative promoter of EIF4E2 contained no TATA box but did contain a transcription initiator region (Inr) and numerous other sequence motifs characteristic of regulated promoters. EIF4E2 contained only tyro of the three polyadenylation signals present in EIF4E1. Evidence for transcription of both genes was obtained from primer extension, SI mapping, ribonuclease protection, and reverse transcriptase-polymerase chain reaction experiments, Transcription was found to initiate 19 bp upstream of the translational initiation codon in the case of EIF4E1 and 80 bp in the case of EIF4E2. The two genes were differentially expressed in four human cell lines, Wish, Chang, K562, and HeLa.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Rhoads, RE (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1501 Kings Hwy, Shreveport, LA 71130 USA.	rrhoad@lsumf.edu			PHS HHS [20818] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; ALTMANN M, 1988, J BIOL CHEM, V263, P17229; ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; Anthony B, 1996, INT J CANCER, V65, P858, DOI 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z; BHANDARI B, 1991, J BIOL CHEM, V266, P7784; BOMMER UA, 1994, CELL MOL BIOL RES, V40, P633; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHOMCYNSKI P, 1991, CURRENT PROTOCOLS MO; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; EDERY I, 1983, J BIOL CHEM, V258, P1398; FAGAN RJ, 1991, J BIOL CHEM, V266, P16518; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; GOSS DJ, 1990, BIOCHEMISTRY-US, V29, P5008, DOI 10.1021/bi00473a002; GRAFF JR, 1995, INT J CANCER, V60, P255; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAMANN KJ, 1990, GENOMICS, V7, P535, DOI 10.1016/0888-7543(90)90197-3; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; Hershey JWB, 1996, TRANSLATIONAL CONTRO; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; ISHIDA T, 1991, J CHEM SOC PERK T 1, P1847, DOI 10.1039/p19910001847; JARAMILLO M, 1991, J BIOL CHEM, V266, P10446; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li BDL, 1997, CANCER-AM CANCER SOC, V79, P2385; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; MADER S, 1995, MOL CELL BIOL, V15, P4990; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; MARINO MW, 1991, J BIOL CHEM, V266, P2685; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; Methot N, 1996, MOL CELL BIOL, V16, P5328; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; Morino S, 1996, EUR J BIOCHEM, V239, P597, DOI 10.1111/j.1432-1033.1996.0597u.x; Nathan CAO, 1997, ONCOGENE, V15, P579, DOI 10.1038/sj.onc.1201216; PELLETIER J, 1991, GENOMICS, V10, P1079, DOI 10.1016/0888-7543(91)90203-Q; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STOLTZFUS A, 1994, SCIENCE, V265, P202, DOI 10.1126/science.8023140; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; Teraoka Y, 1996, BIOCHEM BIOPH RES CO, V228, P704, DOI 10.1006/bbrc.1996.1720; UEDA H, 1991, FEBS LETT, V280, P207, DOI 10.1016/0014-5793(91)80294-D	59	27	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4622	4628		10.1074/jbc.273.8.4622	http://dx.doi.org/10.1074/jbc.273.8.4622			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468520	hybrid			2022-12-25	WOS:000072115000048
J	Hryciw, DH; Rychkov, GY; Hughes, BP; Bretag, AH				Hryciw, DH; Rychkov, GY; Hughes, BP; Bretag, AH			Relevance of the D13 region to the function of the skeletal muscle chloride channel, ClC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT MYOTONIA-CONGENITA; MOLECULAR-BASIS; MUTATIONS; THOMSEN; GENE	Although hydropathy analysis of the skeletal muscle chloride channel protein, ClC-1, initially predicted 13 potential membrane spanning domains (D1 to D13), later topological studies have suggested that domain D4 is extracellular and that D13, conserved in all eukaryotic ClC channels, is located within the extensive cytoplasmic tail that makes up the carboxyl terminus of the protein, We have examined the effect of deleting D13 (Delta D13) and the function of the carboxyl tail by removing the final 72 (fs923X), 100 (fs895X), 125 (L869X), 398 (N596X), and 420 (Q574X) amino acids from rat ClC-1. Appropriate cDNA constructs were prepared and expressed using the baculovirus Sf9 insect cell system, Patch clamp analysis of chloride currents in Sf9 cells showed that only relatively insubstantial changes could be attributed to the expressed fs923X, fs895X, and Delta D13 mutants compared with wild type rat ClC-1, For N596X and Q574X, however, adequate mRNA could be detected, but neither patch clamp nor polyacrylamide gel electrophoresis showed corresponding protein production, By contrast, expression of L869X. was demonstrable by polyacrylamide gel electrophoresis, but no chloride conductance attributable to it could be detected, Overall, our results indicate that the domain D13 is dispensable, as are the final 100 amino adds, but not the final 125 amino acids or more, of the carboxyl tail. Some essential. region of unknown significance, therefore, appears to reside in the 18 amino acids after D13, from Lys(877) to Arg(894).	Univ S Australia, Sch Pharm & Med Sci, Ctr Adv Biomed Studies, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Physiol, Adelaide, SA 5005, Australia	University of South Australia; University of Adelaide	Bretag, AH (corresponding author), Univ S Australia, Sch Pharm & Med Sci, Ctr Adv Biomed Studies, N Terrace, Adelaide, SA 5000, Australia.		Hryciw, Deanne/P-2642-2019; hughes, bernard p/D-1407-2009	Hryciw, Deanne/0000-0003-1697-8890; Rychkov, Grigori/0000-0002-2788-2977; Hughes, Bernard/0000-0002-4850-6794				Astill DS, 1996, BBA-BIOMEMBRANES, V1280, P178, DOI 10.1016/0005-2736(95)00281-2; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Beck CL, 1996, P NATL ACAD SCI USA, V93, P11248, DOI 10.1073/pnas.93.20.11248; GAUDETTE MF, 1991, NUCLEIC ACIDS RES, V19, P1879, DOI 10.1093/nar/19.8.1879; GEORGE AL, 1994, HUM MOL GENET, V3, P2071; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; Lloyd SE, 1997, J CLIN INVEST, V99, P967, DOI 10.1172/JCI119262; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; LORENZ C, 1994, HUM MOL GENET, V3, P941, DOI 10.1093/hmg/3.6.941; MEYERKLEINE C, 1995, AM J HUM GENET, V57, P1325; Ponting CP, 1997, J MOL MED-JMM, V75, P160; Possee RD., 1992, BACULOVIRUS EXPRESSI; Rychkov GY, 1996, J PHYSIOL-LONDON, V497, P423, DOI 10.1113/jphysiol.1996.sp021778; Rychkov GY, 1997, J PHYSIOL-LONDON, V501, P355, DOI 10.1111/j.1469-7793.1997.355bn.x; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; SchmidtRose T, 1997, J BIOL CHEM, V272, P20515, DOI 10.1074/jbc.272.33.20515; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x	19	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4304	4307		10.1074/jbc.273.8.4304	http://dx.doi.org/10.1074/jbc.273.8.4304			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468477	hybrid			2022-12-25	WOS:000072115000005
J	Allen, PB; Kwon, YG; Nairn, AC; Greengard, P				Allen, PB; Kwon, YG; Nairn, AC; Greengard, P			Isolation and characterization of PNUTS, a putative protein phosphatase 1 nuclear targeting subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; TYPE-1; PHOSPHORYLATION; IDENTIFICATION; ENCODES; GENE; MECHANISM; AFFINITY; SEQUENCE; MITOSIS	Protein phosphatase 1 (PP1) is found in the cell nucleus and has been implicated in several aspects of nuclear function. We report here the cloning and initial characterization of a novel protein similar to named phosphatase 1 nuclear targeting Subunit (PNUTS). This protein interacts with PP1 in a yeast two-hybrid assay, is found in a stable complex with PP1 in mammalian cell lysates, and exhibits a potent modulation of PP1 catalytic activity toward exogenous substrate in vitro. PNUTS is a ubiquitously expressed protein that exhibits a discreet nuclear compartmentalization and is colocalized with chromatin at distinct phases during mitosis. The subcellular localization of PP1 and the activity toward substrates involved in many aspects of cell physiology have previously been shown to be regulated by association with noncatalytic targeting subunits. The properties of PNUTS are consistent with its role as a targeting subunit for the regulation of nuclear PP1 function.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Hallym Univ, Hallym Acad Sci, Inst Environm & Life Sci, Chunchon 200703, Kangwon Do, South Korea	Rockefeller University; Hallym University	Allen, PB (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10021 USA.	allenp@rockvax.rockefeller.edu		Nairn, Angus/0000-0002-7075-0195	NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044] Funding Source: NIH RePORTER; NIDA NIH HHS [P01 DA010044] Funding Source: Medline; NIMH NIH HHS [MH 40899] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; CARDINALI B, 1994, FEBS LETT, V352, P276, DOI 10.1016/0014-5793(94)00973-2; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COHEN P, 1988, METHOD ENZYMOL, V159, P390; da Cruz e Silva E.F., 1995, J NEUROSCI, V15, P3375; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; DURFEE T, 1993, GENE DEV, V7, P55; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Ishii K, 1996, EMBO J, V15, P6629, DOI 10.1002/j.1460-2075.1996.tb01053.x; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kreivi JP, 1997, FEBS LETT, V420, P57, DOI 10.1016/S0014-5793(97)01485-3; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; Totaro A, 1996, GENOMICS, V31, P319, DOI 10.1006/geno.1996.0054; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x	38	133	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4089	4095		10.1074/jbc.273.7.4089	http://dx.doi.org/10.1074/jbc.273.7.4089			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461602	hybrid			2022-12-25	WOS:000072048400044
J	Trifa, Y; Privat, I; Gagnon, J; Baeza, L; Lerbs-Mache, S				Trifa, Y; Privat, I; Gagnon, J; Baeza, L; Lerbs-Mache, S			The nuclear RPL4 gene encodes a chloroplast protein that co-purifies with the T7-like transcription complex as well as plastid ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; TATA-BINDING PROTEIN; ESCHERICHIA-COLI; COMPLETE SEQUENCE; ANTITERMINATION FACTORS; NUCLEOTIDE-SEQUENCE; GENOME; DNA; SPINACH; OPERON	We have cloned and sequenced the cDNA and the gene coding for plastid ribosomal protein L4 (RPL4) from two higher plant species, spinach and Arabidopsis thaliana. Ribosomal protein L4 is one of the ribosomal proteins far which extraribosomal functions in transcriptional regulation has been demonstrated in prokaryotes, Sequence comparison of the two plant cDNAs and genes shows that the RPL4 gene has acquired a remarkable 3' extension during evolutionary transfer to the nuclear genome. This extension harbors an intron and codes for a glutamic and aspartic acid-rich amino acid sequence that resembles highly acidic C-terminal tails of same transcription factors, Co-purification of ribosomal protein L4 with plastid RNA polymerase and transcription factor CDF2 using different purification protocols as well as the surprising amino acid sequence of the L4 protein make it a likely candidate to play a role in plastid transcriptional regulation.	Univ Grenoble 1, Lab Genet Mol Plantes, F-38041 Grenoble, France; CNRS, F-38041 Grenoble, France; Inst Biol Struct JP Ebel, F-38027 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Lerbs-Mache, S (corresponding author), Univ Grenoble 1, Lab Genet Mol Plantes, BP 53, F-38041 Grenoble, France.		Gagnon, Jean/C-3136-2008	Gagnon, Jean/0000-0002-0177-824X				Allison LA, 1996, EMBO J, V15, P2802, DOI 10.1002/j.1460-2075.1996.tb00640.x; BAEZA L, 1991, NUCLEIC ACIDS RES, V19, P3577, DOI 10.1093/nar/19.13.3577; BAUMGARTNER BJ, 1993, PLANT PHYSIOL, V101, P781, DOI 10.1104/pp.101.3.781; DESARO FJL, 1995, J MOL BIOL, V252, P189, DOI 10.1006/jmbi.1995.0487; DORNE AM, 1984, MOL GEN GENET, V193, P129, DOI 10.1007/BF00327425; EISERMANN A, 1990, EMBO J, V9, P3981, DOI 10.1002/j.1460-2075.1990.tb07619.x; FRANZETTI B, 1992, J BIOL CHEM, V267, P19075; FRIEDMAN DI, 1981, P NATL ACAD SCI-BIOL, V78, P1115, DOI 10.1073/pnas.78.2.1115; HALLICK RB, 1993, NUCLEIC ACIDS RES, V21, P3537, DOI 10.1093/nar/21.15.3537; HARRAK H, 1995, PLANT PHYSIOL, V108, P685, DOI 10.1104/pp.108.2.685; HARRIS EH, 1994, MICROBIOL REV, V58, P700, DOI 10.1128/MMBR.58.4.700-754.1994; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; Hedtke B, 1997, SCIENCE, V277, P809, DOI 10.1126/science.277.5327.809; HERMANNLEDENMAT S, 1994, J MOL BIOL, V240, P1; HESS WR, 1993, EMBO J, V12, P563, DOI 10.1002/j.1460-2075.1993.tb05688.x; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; INOSTROZA JA, 1992, CELL, V70, P477; IRATNI R, 1994, GENE DEV, V8, P2928, DOI 10.1101/gad.8.23.2928; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Kowallik KV, 1995, PLANT MOL BIOL REP, V13, P336, DOI 10.1007/BF02669188; Kudla J, 1996, EMBO J, V15, P7137, DOI 10.1002/j.1460-2075.1996.tb01105.x; LERBS S, 1988, MOL GEN GENET, V211, P459, DOI 10.1007/BF00425701; LERBSMACHE S, 1993, P NATL ACAD SCI USA, V90, P5509, DOI 10.1073/pnas.90.12.5509; LINDAHL L, 1983, CELL, V33, P241, DOI 10.1016/0092-8674(83)90353-7; MAIER RM, 1995, J MOL BIOL, V251, P614, DOI 10.1006/jmbi.1995.0460; MASON SW, 1992, J MOL BIOL, V223, P55, DOI 10.1016/0022-2836(92)90715-V; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; MOSRIN C, 1990, MOL CELL BIOL, V10, P4737, DOI 10.1128/MCB.10.9.4737; NODWELL JR, 1993, CELL, V72, P261, DOI 10.1016/0092-8674(93)90665-D; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; Payet D, 1997, J MOL BIOL, V266, P66, DOI 10.1006/jmbi.1996.0782; POSNO M, 1984, CURR GENET, V8, P147, DOI 10.1007/BF00420227; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; SHA YZ, 1995, J MOL BIOL, V245, P474, DOI 10.1006/jmbi.1994.0039; SHI X, 1966, MOL CELL BIOL, V16, P669; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; Stirewalt VL, 1995, PLANT MOL BIOL REP, V13, P327, DOI 10.1007/BF02669186; TASHEVA ES, 1995, GENE DEV, V9, P304, DOI 10.1101/gad.9.3.304; THUILLIER V, 1995, EMBO J, V14, P351, DOI 10.1002/j.1460-2075.1995.tb07009.x; VOIT R, 1995, NUCLEIC ACIDS RES, V23, P2593, DOI 10.1093/nar/23.14.2593; Wakasugi T, 1997, P NATL ACAD SCI USA, V94, P5967, DOI 10.1073/pnas.94.11.5967; WAKASUGI T, 1994, P NATL ACAD SCI USA, V91, P9794, DOI 10.1073/pnas.91.21.9794; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; WOLFE KH, 1992, P NATL ACAD SCI USA, V89, P10648, DOI 10.1073/pnas.89.22.10648; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; Yoon JB, 1996, MOL CELL BIOL, V16, P1; ZENGEL JM, 1990, P NATL ACAD SCI USA, V87, P2675, DOI 10.1073/pnas.87.7.2675; ZENGEL JM, 1980, CELL, V21, P523, DOI 10.1016/0092-8674(80)90490-0; ZENGEL JM, 1993, NUCLEIC ACIDS RES, V21, P2429, DOI 10.1093/nar/21.10.2429; ZENGEL JM, 1992, GENE DEV, V6, P2655, DOI 10.1101/gad.6.12b.2655	51	36	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3980	3985		10.1074/jbc.273.7.3980	http://dx.doi.org/10.1074/jbc.273.7.3980			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461586	hybrid			2022-12-25	WOS:000072048400028
J	Budinger, GRS; Duranteau, J; Chandel, NS; Schumacker, PT				Budinger, GRS; Duranteau, J; Chandel, NS; Schumacker, PT			Hibernation during hypoxia in cardiomyocytes - Role of mitochondria as the O-2 sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEASURING OXYGEN CONCENTRATION; DOWN-REGULATION; CONTRACTION; ADAPTATION; DEPENDENCE; ISCHEMIA; CELLS; RAT	During myocardial hibernation, decreases in coronary perfusion elicit inhibition of contraction, suggesting that energy demand is attenuated. We previously found an inhibition of contraction and O-2 consumption during hypoxia (3% O-2; PO2 = 20 torr for >2 h) in cardiomyocytes, which was reversible after reoxygenation. This study sought to determine whether mitochondria function as cellular O-2 sensors mediating this response. Embryonic cardiomyocytes were studied under controlled O-2 conditions. Hypoxia produced no acute decrease in mitochondrial potential as assessed using tetramethylrhodamine ethylester (TMRE). Cellular [ATP] was preserved throughout hypoxia, as assessed using the probe Magnesium Green. Thus, ATP synthesis and utilization remained closely coupled. Cells adapted to hypoxia for >2 h exhibited a 4% increase in mitochon drial potential upon reoxygenation, suggesting that a partial inhibition of cytochrome c oxidase had existed. To test whether the oxidase serves as an O-2 sensor, azide was administered (1 mM) to simulate the effects of hypoxia by lowering the V-max of the oxidase. The effects of azide on contraction and mitochondrial potential mimicked the response to hypoxia. We conclude that partial inhibition of cytochrome oxidase during hypoxia allows mitochondria to function as the O-2 sensor mediating the decreases in ATP utilization and O-2 consumption during hypoxia.	Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Schumacker, PT (corresponding author), Univ Chicago, Dept Med, MC6026,5841 S Maryland Ave, Chicago, IL 60637 USA.			Schumacker, Paul T/0000-0001-9591-2034	NHLBI NIH HHS [HL32646, HL35440] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035440, R01HL032646, R55HL032646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI AE, 1995, CIRCULATION, V92, P244, DOI 10.1161/01.CIR.92.2.244; ARAI AE, 1991, CIRC RES, V69, P1458, DOI 10.1161/01.RES.69.6.1458; BARRY WH, 1980, AM J PHYSIOL, V239, pH651, DOI 10.1152/ajpheart.1980.239.5.H651; BUDINGER GRS, 1996, AM J PHYSIOL, V14, pL37; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CHANDEL N, 1995, AM J PHYSIOL-LUNG C, V268, pL918, DOI 10.1152/ajplung.1995.268.6.L918; Chandel NS, 1996, J BIOL CHEM, V271, P18672, DOI 10.1074/jbc.271.31.18672; Chandel NS, 1997, J BIOL CHEM, V272, P18808, DOI 10.1074/jbc.272.30.18808; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; FARKAS DL, 1989, BIOPHYS J, V56, P1053, DOI 10.1016/S0006-3495(89)82754-7; Heusch G, 1996, J MOL CELL CARDIOL, V28, P2359, DOI 10.1006/jmcc.1996.0229; ITO BR, 1995, CIRCULATION, V91, P2058, DOI 10.1161/01.CIR.91.7.2058; Laderoute KR, 1997, CIRC RES, V80, P336, DOI 10.1161/01.RES.80.3.336; LEE SC, 1993, CARDIOVASC RES, V27, P1542, DOI 10.1093/cvr/27.8.1542; Leyssens A, 1996, J PHYSIOL-LONDON, V496, P111, DOI 10.1113/jphysiol.1996.sp021669; Lo LW, 1996, ANAL BIOCHEM, V236, P153, DOI 10.1006/abio.1996.0144; MARBAN E, 1991, CIRCULATION, V83, P681, DOI 10.1161/01.CIR.83.2.681; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; Opie LH, 1996, J MOL CELL CARDIOL, V28, P2403, DOI 10.1006/jmcc.1996.0233; PETERSEN LC, 1977, BIOCHIM BIOPHYS ACTA, V460, P299, DOI 10.1016/0005-2728(77)90216-X; ROSS J, 1991, CIRCULATION, V83, P1076, DOI 10.1161/01.CIR.83.3.1076; RUMSEY WL, 1990, J BIOL CHEM, V265, P15392; Silverman HS, 1997, CIRC RES, V80, P699, DOI 10.1161/01.RES.80.5.699; WILSON DF, 1988, J BIOL CHEM, V263, P2712	24	123	126	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3320	3326		10.1074/jbc.273.6.3320	http://dx.doi.org/10.1074/jbc.273.6.3320			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452449	hybrid			2022-12-25	WOS:000071822300034
J	Henke, B; Girzalsky, W; Berteaux-Lecellier, V; Erdmann, R				Henke, B; Girzalsky, W; Berteaux-Lecellier, V; Erdmann, R			IDP3 encodes a peroxisomal NADP-dependent isocitrate dehydrogenase required for the beta-oxidation of unsaturated fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; 3-OXOACYL-COA THIOLASE; NUCLEOTIDE-SEQUENCE; CANDIDA-TROPICALIS; TARGETING SIGNAL; SHUTTLE VECTORS; PROTEIN IMPORT; YEAST GENES; OLEIC-ACID; IDENTIFICATION	In Saccharomyces cerevisiae the metabolic degradation of saturated fatty acids is exclusively confined to peroxisomes. In addition to a functional beta-oxidation system, the degradation of unsaturated fatty acids requires auxiliary enzymes, including a Delta 2,Delta 3-enoyl-CoA isomerase and an NADPH-dependent 2,4-dienoyl-CoA reductase. We found both enzymes to be present in yeast peroxisomes. The impermeability of the peroxisomal membrane for pyrimidine nucleotides led to the question of how the NADPH needed by the reductase is regenerated in the peroxisomal lumen. We report the identification and functional analysis of the IDP3 gene product, which is a yeast peroxisomal NADP-dependent isocitrate dehydrogenase. The newly identified peroxisomal protein is homologous to the mitochondrial Idp1p and cytosolic Idp2p, which both are yeast NADP-dependent isocitrate dehydrogenases. Yeast cells lacking Idp3p grow normally on saturated fatty acids, but growth is impaired on unsaturated fatty acids, indicating that the peroxisomal Idp3p is involved in their metabolic utilization. The data presented are consistent with the assumption that peroxisomes of S. cerevisiae contain the enzyme equipment needed for the degradation of unsaturated fatty acids, including an NADP-dependent isocitrate dehydrogenase, a putative constituent of a peroxisomal NADPH-regenerating redox system.	Ruhr Univ Bochum, Inst Physiol Chem, Dept Physiol Chem, D-44780 Bochum, Germany	Ruhr University Bochum	Erdmann, R (corresponding author), Ruhr Univ Bochum, Inst Physiol Chem, Dept Physiol Chem, Univ Str 150, D-44780 Bochum, Germany.	Ralf.Erdmann@rz.ruhr-uni-bochum.de	BERTEAUX-LECELLIER, Veronique/P-6456-2019; Berteaux-Lecellier, Veronique/O-4767-2018	BERTEAUX-LECELLIER, Veronique/0000-0003-2152-6231; Berteaux-Lecellier, Veronique/0000-0003-2152-6231				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Binstock J F, 1981, Methods Enzymol, V71 Pt C, P403; Blobel F, 1996, EUR J BIOCHEM, V240, P468, DOI 10.1111/j.1432-1033.1996.0468h.x; COOPER TG, 1969, J BIOL CHEM, V244, P3514; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DAIGNANFORNIER B, 1994, MOL GEN GENET, V243, P575, DOI 10.1007/BF00284206; DELAGARZA MM, 1985, EUR J BIOCHEM, V148, P285, DOI 10.1111/j.1432-1033.1985.tb08837.x; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; ERDMANN R, 1994, YEAST, V10, P1173, DOI 10.1002/yea.320100905; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P569; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; HARLOW E, 1988, ANTIBODIES; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HE XY, 1995, BIOCHEM BIOPH RES CO, V215, P15, DOI 10.1006/bbrc.1995.2428; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KUNAU WH, 1978, EUR J BIOCHEM, V91, P533, DOI 10.1111/j.1432-1033.1978.tb12707.x; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LOFTUS TM, 1994, BIOCHEMISTRY-US, V33, P9661, DOI 10.1021/bi00198a035; Maniatis T., 1982, MOL CLONING LAB MANU; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; OPPERDOES FR, 1988, TRENDS BIOCHEM SCI, V13, P255, DOI 10.1016/0968-0004(88)90158-2; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; STOFFEL W, 1965, H-S Z PHYSIOL CHEM, V341, P76, DOI 10.1515/bchm2.1965.341.1.76; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; TSERNG KY, 1991, J BIOL CHEM, V266, P11614; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; YAMAMOTO S, 1995, ARCH MICROBIOL, V163, P104, DOI 10.1007/BF00381783	53	79	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3702	3711		10.1074/jbc.273.6.3702	http://dx.doi.org/10.1074/jbc.273.6.3702			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452501	hybrid			2022-12-25	WOS:000071822300086
J	O'Handley, SF; Frick, DN; Dunn, CA; Bessman, MJ				O'Handley, SF; Frick, DN; Dunn, CA; Bessman, MJ			Orf186 represents a new member of the Nudix hydrolases, active on adenosine(5 ')triphospho(5 ')adenosine, ADP-ribose, and NADH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHOHYDROLASE; ESCHERICHIA-COLI; MUTAGENIC SUBSTRATE; DNA-SYNTHESIS; MUTATOR GENE; MUTT ENZYME; FHIT GENE; PROTEINS; CLONING; PURIFICATION	orf186, a new member of the Nudix hydrolase family of genes, has been cloned and expressed, and the protein has been purified and identified as an enzyme highly specific for compounds of ADP. Its three major substrates are adenosine(5') triphospho(5') adenosine, ADP-ribose, and NADH, all implicated in a variety of cellular regulatory processes, supporting the notion that the function of the Nudix hydrolases is to monitor the concentrations of reactive nucleoside diphosphate derivatives and to help modulate their accumulation during cellular metabolism.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Bessman, MJ (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.	zoot@jhu.edu		Frick, David/0000-0002-2434-7223; O'Handley, Suzanne/0000-0001-8373-0065; Dunn, Christopher/0000-0001-7899-0110	NIGMS NIH HHS [GM18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMES BN, 1960, J BIOL CHEM, V235, P769; Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BAXI MD, 1995, J PHARMACOL TOX MET, V33, P121, DOI 10.1016/1056-8719(94)00127-P; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BHATNAGAR SK, 1990, J BACTERIOL, V172, P2802, DOI 10.1128/jb.172.5.2802-2803.1990; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; Bucala R, 1992, Adv Pharmacol, V23, P1; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; CervantesLaurean D, 1996, J BIOL CHEM, V271, P10461, DOI 10.1074/jbc.271.18.10461; Cleland W W, 1979, Methods Enzymol, V63, P103; Fernandez A, 1996, BBA-GEN SUBJECTS, V1290, P121, DOI 10.1016/0304-4165(96)00019-0; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; GLASER L, 1965, BIOCHIM BIOPHYS ACTA, V101, P6, DOI 10.1016/0926-6534(65)90025-4; GURANOWSKI A, 1992, AP4A OTHER DINUCLEOS, P81; Hankin S, 1997, INT J BIOCHEM CELL B, V29, P317, DOI 10.1016/S1357-2725(96)00153-7; HURTADO C, 1987, J BACTERIOL, V169, P1718, DOI 10.1128/jb.169.4.1718-1723.1987; JACOBSON EL, 1994, MOL CELL BIOCHEM, V138, P207, DOI 10.1007/BF00928463; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KAMIYA H, 1995, J BIOL CHEM, V270, P19446, DOI 10.1074/jbc.270.33.19446; Kaneto H, 1996, BIOCHEM J, V320, P855, DOI 10.1042/bj3200855; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; LAZEWSKA D, 1993, PROTEIN EXPRES PURIF, V4, P45, DOI 10.1006/prep.1993.1007; Lin J, 1996, BIOCHEMISTRY-US, V35, P6715, DOI 10.1021/bi953071x; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MARKHAM R, 1952, BIOCHEM J, V52, P552, DOI 10.1042/bj0520552; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MCCREANOR GM, 1983, BIOCHIM BIOPHYS ACTA, V759, P222, DOI 10.1016/0304-4165(83)90316-1; MCDONALD LJ, 1994, MOL CELL BIOCHEM, V138, P221, DOI 10.1007/BF00928465; McLennan AG., 1992, AP4A OTHER DINUCLEOS; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; MOSS J, 1994, MOL CELL BIOCH, V138; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; OLIVERA BM, 1989, ADP RIBOSE TRANSFER, P353; RIORDAN JF, 1977, SCIENCE, V195, P884, DOI 10.1126/science.190679; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SONNINO S, 1966, ARCH BIOCHEM BIOPHYS, V116, P26, DOI 10.1016/0003-9861(66)90007-5; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; WEBER DJ, 1992, J BIOL CHEM, V267, P16939; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274; ZAMECNIK PC, 1966, BIOCHEM BIOPH RES CO, V24, P91, DOI 10.1016/0006-291X(66)90415-3	53	69	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3192	3197		10.1074/jbc.273.6.3192	http://dx.doi.org/10.1074/jbc.273.6.3192			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452430	hybrid			2022-12-25	WOS:000071822300015
J	Collins, MA; Zou, JY; Neafsey, EJ				Collins, MA; Zou, JY; Neafsey, EJ			Brain damage due to episodic alcohol exposure in vivo and in vitro: furosemide neuroprotection implicates edema-based mechanism	FASEB JOURNAL			English	Article						ethanol; neurodegeneration; excitotoxicity; binge intoxication; entorhinal cortex; dentate gyrus; dizocilpine maleate; olfactory bulb; cell swelling; intracranial pressure	ORGANOTYPIC HIPPOCAMPAL CULTURES; EPILEPTIFORM BURSTS; ARACHIDONIC-ACID; ETHANOL EXPOSURE; CELL LOSS; RAT; WITHDRAWAL; NEURONS; CEREBELLAR; SEIZURE	Adult rats intubated with a single dose of ethanol (alcohol; similar to 5 g/kg) for 5 to 10 successive days incur neurodegeneration in the entorhinal cortex, dentate gyrus, and olfactory bulbs accompanied by cerebrocortical edema and electrolyte (Na+, K+) accumulation. The brain damage is not lessened by cotreatment with the NMDA receptor antagonist MK-801; also, as reported elsewhere, MK-801 as well as non-NMDA receptor and Ca2+ channel antagonists are not neuroprotective in a similar, but more compressed, intoxication protocol. However, cotreatment with the electrolyte transport inhibitor/diuretic furosemide reduces alcohol-dependent cerebrocortical damage by 75-85% while preventing brain hydration and electrolyte elevations; olfactory bulb neurodegeneration is not attenuated. in parcel in vitro studies, rat organotypic entorhinal/hippocampal slice cultures exposed to alcohol (50-200 mM) 15 h/day for 6 days, mirroring episodic intoxication in vivo, demonstrate concentration-related release of the cytotoxic indicator, lactate dehydrogenase. Analogous to the in vivo findings, furosemide blocks this alcohol-induced in vitro cytotoxicity. Our results showing neuroprotection by furosemide indicate that brain edema and swelling are essential events in the brain damage induced by episodic alcohol exposure. Furosemide and related agents might be useful as neuroprotective agents in alcohol abuse. We suggest that the neurodegeneration is elicited in part by edema-dependent oxidative stress, but the regional selectivity of the damage may be best explained by physical (mechanical) compression of the limbic cortex against the adjacent tympanic bulla and subsequent neuronal cytoskeletal collapse. A scheme for these apparently nonexcitotoxic metabolic and mechanical pathways initiated by repeated alcohol exposure is proposed.	Loyola Univ, Stritch Sch Med, Dept Mol & Cellular Biochem, Maywood, IL 60153 USA; Loyola Univ, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago	Neafsey, EJ (corresponding author), Loyola Univ, Stritch Sch Med, Dept Mol & Cellular Biochem, Maywood, IL 60153 USA.	mcollin@luc.edu	Neafsey, Edward J./ABG-3419-2021					ADAMS H, 1972, INTRACRANIAL PRESSUR, P250; AHERN KV, 1994, NEUROSCI LETT, V165, P211; ANDREW RD, 1991, J NEUROL SCI, V101, P7, DOI 10.1016/0022-510X(91)90013-W; ASANO T, 1989, MOL CHEM NEUROPATHOL, V10, P101, DOI 10.1007/BF03159717; BAHR BA, 1995, J NEUROSCI RES, V42, P294, DOI 10.1002/jnr.490420303; Bazan N G, 1980, Adv Neurol, V28, P197; BEARD JD, 1968, J AMER MED ASSOC, V204, P135, DOI 10.1001/jama.204.2.135; Becker HC, 1996, ALCOHOL CLIN EXP RES, V20, pA121, DOI 10.1111/j.1530-0277.1996.tb01760.x; Beltramino C A, 1993, NIDA Res Monogr, V136, P101; Bruce AJ, 1996, P NATL ACAD SCI USA, V93, P2312, DOI 10.1073/pnas.93.6.2312; CHAN PH, 1983, ANN NEUROL, V13, P625, DOI 10.1002/ana.410130608; CHANDLER LJ, 1993, J NEUROCHEM, V60, P1578, DOI 10.1111/j.1471-4159.1993.tb03326.x; CLIFFORD DB, 1990, EPILEPSIA, V31, P382, DOI 10.1111/j.1528-1157.1990.tb05492.x; Collins MA, 1996, ALCOHOL CLIN EXP RES, V20, P284, DOI 10.1111/j.1530-0277.1996.tb01641.x; CORSO TD, 1997, IN PRESS ALCOHOL CLI; de Olmos J.S., 1981, NEUROANATOMICAL TRAC, P117, DOI [10.1007/978-1-4613-3189-6_4, DOI 10.1007/978-1-4613-3189-6_4]; Diekmann S, 1994, J Neural Transm Suppl, V44, P61; DUDEK FE, 1990, NEUROSCI LETT, V120, P267, DOI 10.1016/0304-3940(90)90056-F; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122, DOI 10.1152/ajplegacy.1949.157.1.122; Fix AS, 1996, TOXICOL PATHOL, V24, P291, DOI 10.1177/019262339602400305; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P504, DOI 10.1007/BF00310027; GROSS L, 1985, MUCH IS TOO MUCH EFF; HEATON MB, 1994, J NEUROSCI RES, V39, P305, DOI 10.1002/jnr.490390308; HOCHMAN DW, 1995, SCIENCE, V270, P99, DOI 10.1126/science.270.5233.99; HUNT WA, 1993, ALCOHOL, V10, P559, DOI 10.1016/0741-8329(93)90083-Z; HUNT WA, 1993, NIH PUBLICATION; KIMELBERG HK, 1993, J NEUROCHEM, V60, P1682, DOI 10.1111/j.1471-4159.1993.tb13391.x; KNOTT DH, 1968, SO MED J, V62, P485; LAMBIE DG, 1985, MED HYPOTHESES, V16, P377, DOI 10.1016/0306-9877(85)90058-1; LANCASTER FE, 1995, METAB BRAIN DIS, V10, P125, DOI 10.1007/BF01991860; LERMA J, 1992, MOL PHARMACOL, V41, P217; LOVINGER DM, 1993, ALCOHOL CLIN EXP RES, V17, P19, DOI 10.1111/j.1530-0277.1993.tb00720.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lundqvist C, 1995, ALCOHOL ALCOHOLISM, V30, P737; MACVICAR BA, 1991, J NEUROSCI, V11, P1458; MANDER AJ, 1989, DRUG ALCOHOL DEPEN, V24, P23; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; MCCOWN TJ, 1990, ALCOHOL CLIN EXP RES, V14, P394, DOI 10.1111/j.1530-0277.1990.tb00492.x; Meldrum B S, 1994, Neurology, V44, pS14; MENZANO E, 1994, ALCOHOL CLIN EXP RES, V18, P895, DOI 10.1111/j.1530-0277.1994.tb00057.x; MURPHY VA, 1987, ANAL BIOCHEM, V161, P144, DOI 10.1016/0003-2697(87)90664-6; NICHOLS JM, 1993, ALCOHOL, V10, P269, DOI 10.1016/0741-8329(93)90004-8; OLSON JE, 1990, ANN EMERG MED, V19, P1113, DOI 10.1016/S0196-0644(05)81514-8; PANTAZIS NJ, 1993, ALCOHOL CLIN EXP RES, V17, P1014, DOI 10.1111/j.1530-0277.1993.tb05657.x; PAULABARBOSA MM, 1991, ALCOHOL CLIN EXP RES, V15, P834, DOI 10.1111/j.1530-0277.1991.tb00610.x; ROPER SN, 1992, ANN NEUROL, V31, P81, DOI 10.1002/ana.410310115; SATO N, 1991, AM J PHYSIOL, V260, pE946, DOI 10.1152/ajpendo.1991.260.6.E946; SmithSwintosky VL, 1996, J CEREBR BLOOD F MET, V16, P585, DOI 10.1097/00004647-199607000-00008; Snyder AK, 1996, ROLE GLIA NEUROTOXIC, P111; SNYDER H, 1992, Journal of Emergency Medicine, V10, P129, DOI 10.1016/0736-4679(92)90205-8; SPARENBORG S, 1992, NEUROPHARMACOLOGY, V31, P357, DOI 10.1016/0028-3908(92)90068-Z; STAUB F, 1994, J CEREBR BLOOD F MET, V14, P1030, DOI 10.1038/jcbfm.1994.135; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Switzer R. C., 1982, ANAT REC, V202, p186A; SWITZER RC, 1993, ANN NY ACAD SCI, V679, P341, DOI 10.1111/j.1749-6632.1993.tb18319.x; TAVARES MA, 1982, EXP NEUROL, V78, P574, DOI 10.1016/0014-4886(82)90075-9; TRABERT W, 1992, ACTA PSYCHIAT SCAND, V85, P376, DOI 10.1111/j.1600-0447.1992.tb10322.x; TSAI GC, 1995, AM J PSYCHIAT, V152, P332; UNTERBERG A, 1990, ACT NEUR S, V51, P104; UNTERBERG A, 1990, ADV NEUROL, V52, P55; Vallett M, 1997, ALCOHOL CLIN EXP RES, V21, P275; Veatch LM, 1996, ALCOHOL CLIN EXP RES, V20, P262, DOI 10.1111/j.1530-0277.1996.tb01638.x; VORNOV JJ, 1991, EXP NEUROL, V114, P11, DOI 10.1016/0014-4886(91)90079-R; WALKER DW, 1980, SCIENCE, V209, P711, DOI 10.1126/science.7394532; WASTERLAIN CG, 1993, EPILEPSIA, V34, pS37, DOI 10.1111/j.1528-1157.1993.tb05905.x; Zou JY, 1996, ALCOHOL CLIN EXP RES, V20, P1406, DOI 10.1111/j.1530-0277.1996.tb01141.x	66	87	94	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1998	12	2					221	230		10.1096/fasebj.12.2.221	http://dx.doi.org/10.1096/fasebj.12.2.221			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472987	Bronze			2022-12-25	WOS:000071848400010
J	Muzio, M; Stockwell, BR; Stennicke, HR; Salvesen, GS; Dixit, VM				Muzio, M; Stockwell, BR; Stennicke, HR; Salvesen, GS; Dixit, VM			An induced proximity model for caspase-8 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; SIGNAL-TRANSDUCTION; TNF RECEPTOR; PROTEASE; APOPTOSIS; INHIBITION; DOMAIN	The assembly of the CD-95 (Fas/Apo-1) receptor death-inducing signaling complex occurs in a hierarchical manner; the death domain of CD-95 binds to the corresponding domain in the adapter molecule Fas-associated death domain (FADD) Mort-l, which in turn recruits the zymogen form of the death protease caspase-8 (FLICE/Mach-1) by a homophilic interaction involving the death effector domains. Immediately after recruitment, the single polypeptide FLICE zymogen is proteolytically processed to the active dimeric species composed of large and small catalytic subunits. Since all caspases cleave their substrates after Asp residues and are themselves processed from the single-chain zymogen to the two-chain active enzyme by cleavage at internal Asp residues, it follows that an upstream caspase can process a downstream zymogen. However, since FLICE represents the most apical caspase in the Fas pathway, its mode of activation has been enigmatic. We hypothesized that the FLICE zymogen possesses intrinsic enzymatic activity such that when approximated, it autoprocesses to the active protease. Support for this was provided by (i) the synthesis of chimeric F(pk)3FLICE molecules that can be oligomerized in vivo by the synthetic cell-permeable dimerizer FK1012H2. Cells transfected with F(pk)3FLICE underwent apoptosis after exposure to FR1012H2; (ii) the creation of a nonprocessable zymogen form of FLICE that retained low but detectable protease activity.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Harvard Univ, Howard Hughes Med Inst, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Burnham Inst, La Jolla, CA 92037 USA	University of Michigan System; University of Michigan; Harvard University; Howard Hughes Medical Institute; Sanford Burnham Prebys Medical Discovery Institute	Dixit, VM (corresponding author), Genentech Inc, 1 DNA Way, S San Francisco, CA 94080 USA.		Muzio, Marta/J-9360-2018; dixit, vishva m/A-4496-2012; Stockwell, Brent R/AAE-7200-2019	Muzio, Marta/0000-0002-7761-759X; dixit, vishva m/0000-0001-6983-0326; Stockwell, Brent R/0000-0002-3532-3868	NIGMS NIH HHS [GM-52067] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052067] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Clayton LK, 1997, EMBO J, V16, P2282, DOI 10.1093/emboj/16.9.2282; HEGUY A, 1992, J BIOL CHEM, V267, P2605; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Spencer DM, 1996, CURR BIOL, V6, P839, DOI 10.1016/S0960-9822(02)00607-3; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	23	837	873	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2926	2930		10.1074/jbc.273.5.2926	http://dx.doi.org/10.1074/jbc.273.5.2926			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446604	hybrid			2022-12-25	WOS:000071736600059
J	Schafer, SL; Lin, RT; Moore, PA; Hiscott, J; Pitha, PM				Schafer, SL; Lin, RT; Moore, PA; Hiscott, J; Pitha, PM			Regulation of type I interferon gene expression by interferon regulatory factor-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BINDING-PROTEIN; IFN-BETA-GENE; NF-KAPPA-B; HUMAN IMMUNODEFICIENCY VIRUS; ALPHA PROMOTER REGION; TRANSCRIPTION FACTOR; FACTOR FAMILY; INDUCIBLE GENES; VIRAL INDUCTION; NUCLEAR FACTOR	The genes of the family of interferon (IFN) regulatory factors (IRF) encode DNA binding transcriptional factors that are involved in modulation of transcription of IFN and interferon-induced genes (ISG), The presence of IRF binding sites in the promoter region of IFNA and IFNB genes indicates that IRF factors recognizing these sites play an important role in the virus-mediated induction of these genes, We have described a novel human gene of this family, IRF-3, that is constitutively expressed in a variety of cell types, IRF-3 binds to the interferon-sensitive response element (ISRE) present in the ISG15 gene promoter and activates its transcriptional activity, In the present study, we examined whether IRF-3 can modulate transcriptional activity of IFNA and IFNB promoter regions, Our results demonstrate that IRF-3 can bind to the IRF-like binding sites present in the virus-inducible region of the IFNA4 promoter and to the PRDIII region of the IFNB promoter but cannot alone stimulate their transcriptional activity in the human cell line, 293, However, the fusion protein generated from the IRF-3 binding domain and the RelA(p65) activation domain effectively activates both IFNA4 and IFNB promoters. Cotransfection of IRF-3 and RelA(p65) expression plasmids activates the IFNB gene promoter but not the promoter of IFNA4 gene that does not contain the NF-kB binding site. Surprisingly, activation of the IFNA4 gene promoter by virus and IRF-1 in these cells was inhibited by IRF-3, These data indicate that in 293 cells IRF-3 does not stimulate expression of IFN genes but can cooperate with RelA(p65) to stimulate the IFNB promoter.	Johns Hopkins Univ, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Dept Mol Biol & Genet, Baltimore, MD 21231 USA; McGill Univ, Dept Microbiol & Immunol, Quebec City, PQ H3T 1E2, Canada; Human Genome Sci Inc, Rockville, MD 20850 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; McGill University; GlaxoSmithKline; Human Genome Sciences Inc	Pitha, PM (corresponding author), Johns Hopkins Univ, Ctr Oncol, 418 N Bond St, Baltimore, MD 21231 USA.	parowe@welchlink.welch.jhu.edu	Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503	NCI NIH HHS [CA09071] Funding Source: Medline; NIAID NIH HHS [AI 19737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI019737, R01AI019737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AU WC, 1993, J BIOL CHEM, V268, P24032; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIAZ MO, 1994, GENOMICS, V22, P540, DOI 10.1006/geno.1994.1427; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; Genin P, 1995, NUCLEIC ACIDS RES, V23, P5055; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; Harada H, 1996, GENES CELLS, V1, P995, DOI 10.1046/j.1365-2443.1996.870287.x; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HISCOTT J, 1995, SEMIN VIROL, V6, P161, DOI 10.1006/smvy.1995.0021; HISCOTT J, 1984, NUCLEIC ACIDS RES, V12, P3727, DOI 10.1093/nar/12.9.3727; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LIN RT, 1994, J BIOL CHEM, V269, P17542; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MANIATIS T, 1992, TRANSCRIPTION REGULA; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOSCA JD, 1987, NATURE, V325, P67, DOI 10.1038/325067a0; NAF D, 1991, P NATL ACAD SCI USA, V88, P1369, DOI 10.1073/pnas.88.4.1369; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; Nonkwelo C, 1997, J VIROL, V71, P6887, DOI 10.1128/JVI.71.9.6887-6897.1997; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PITHA PM, 1995, SEMIN VIROL, V6, P151, DOI 10.1006/smvy.1995.0020; RAJ NBK, 1989, J BIOL CHEM, V264, P11149; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; RONCO LV, 1997, J INTERFERON RES S2, V17, P1; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; RYALS J, 1985, CELL, V41, P495; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHARF R, 1995, J BIOL CHEM, V270, P13063, DOI 10.1074/jbc.270.22.13063; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WEISZ A, 1992, J BIOL CHEM, V267, P25589; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748	55	255	259	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2714	2720		10.1074/jbc.273.5.2714	http://dx.doi.org/10.1074/jbc.273.5.2714			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446577	hybrid			2022-12-25	WOS:000071736600032
J	Sanchez-Perez, I; Murguia, JR; Perona, R				Sanchez-Perez, I; Murguia, JR; Perona, R			Cisplatin induces a persistent activation of JNK that is related to cell death	ONCOGENE			English	Article						cisplatin; JNK1; phosphatases; DNA damage	TERNARY COMPLEX-FORMATION; C-JUN; PROTEIN-KINASE; PLATINUM(II) COMPOUNDS; OXIDATIVE STRESS; GAMMA-RADIATION; MAP-KINASES; DNA; PHOSPHORYLATION; APOPTOSIS	Genotoxic stress triggers signalling pathways that either mediate cell killing or protection of affected cells. While induction of p53 is observed for most of the genotoxins, activation of MAPK/SAPK cascades is not a general response. The role of MAPK/SAPK activation on cell fate, seems to be dependent, in some systems, on the balanced response among both cascades. We have here examined the effect of cis and trans-DDP on the activation of ERK and JNK activities. While no significant induction of ERK was observed with the compounds, both of them are able to strongly activate JNK. Trans-DDP response is rapid and transient while the cis-DDP one is slow and persistent. In contrast with the observed nuclear translocation of JNK in response to U.V. light, none of the platinum compounds induces translocation, on the contrary, activation of JNK occurs in both the nuclear and cytoplasmic compartments, Inhibition of tyrosine phosphatases by orthovanadate pretreatment prolongs the time of JNK induction in response to both platinum compounds, The positive modulation of JNK activation correlates with an increase in toxicity that, for cis-DDP corresponds to a tenfold decrease in the IC50. A strong increase in MKP-1 levels was observed only in response to trans-DDP suggesting the involvement of this activity in the downregulation of JNK activity in response to this compound, Altogether the results suggest that the prolonged activation of JNK in response to cis-DDP contributes to cell death induction.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Perona, R (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Sánchez-Pérez, Isabel/R-4107-2016; Murguia, Jose R./H-4419-2015	Sánchez-Pérez, Isabel/0000-0002-4829-201X; Murguia, Jose R./0000-0001-9364-4603				ALAZARD R, 1982, MUTAT RES, V93, P327, DOI 10.1016/0027-5107(82)90148-8; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BRUHN SL, 1990, PROG INORG CHEM, V38, P477; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EASTMAN A, 1983, BIOCHEMISTRY-US, V22, P6058; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KASTAN MB, 1991, CANCER RES, V51, P6304; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; PASCOE JM, 1974, BIOCHEM PHARMACOL, V23, P1345, DOI 10.1016/0006-2952(74)90354-2; PINTO AL, 1985, P NATL ACAD SCI USA, V82, P4616, DOI 10.1073/pnas.82.14.4616; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; WANG HG, 1994, ONCOGENE, V9, P2751; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	52	216	222	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	1998	16	4					533	540		10.1038/sj.onc.1201578	http://dx.doi.org/10.1038/sj.onc.1201578			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484843				2022-12-25	WOS:000071739400012
J	Vande Pol, SB; Brown, MC; Turner, CE				Vande Pol, SB; Brown, MC; Turner, CE			Association of Bovine Papillomavirus Type 1 E6 oncoprotein with the focal adhesion protein paxillin through a conserved protein interaction motif	ONCOGENE			English	Article						integrin; transformation; cytoskeleton; phosphotyrosine	TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; BINDING PROTEIN; CELLS; IDENTIFICATION; KINASE; EXPRESSION; VINCULIN; SYSTEM; GENE	We have found that the E6 oncoprotein of Bovine Papillomavirus Type 1 (BE6) as well as the E6 protein of the cancer associated HPV-16 (16E6) interact with the focal adhesion protein paxillin. Mutational analysis of paxillin revealed that BE6 binds paxillin through small protein interaction motifs called LD motifs that have been previously identified as important in regulating association of paxillin with vinculin and focal adhesion kinase (FAK), and that BE6 can interact with at least two separate binding sites on paxillin. The LD motifs of paxillin that bind BE6 share homology with the E6 binding site of E6-AP, a ubiquitin ligase that together with 16E6 targets the degradation of the p53 tumor suppressor. Paxillin binding to BE6 excludes simultaneous binding to E6-AP. Mutational analysis of BE6 can distinguish the interaction of BE6 with E6-AP compared to paxillin and revealed that the interaction of BE6 with paxillin may be necessary for the induction of anchorage independent growth of cells by BE6.	Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA; SUNY Syracuse, Dept Anat & Cell Biol, Syracuse, NY USA	Case Western Reserve University; State University of New York (SUNY) System	Vande Pol, SB (corresponding author), Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA.		Pol, Scott Vande/AAO-1068-2020	Pol, Scott Vande/0000-0002-0587-4802	NATIONAL CANCER INSTITUTE [R29CA069292, R01CA069292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607, R29GM047607] Funding Source: NIH RePORTER; NCI NIH HHS [CA69292, R29 CA069292] Funding Source: Medline; NIGMS NIH HHS [GM47607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HARLOW E, 1990, CIBA F SYMP, V150, P262; HELLERHARRISON RA, 1989, BIOCHEMISTRY-US, V28, P9053, DOI 10.1021/bi00449a014; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Howley P M, 1991, Princess Takamatsu Symp, V22, P239; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; MEYERS C, 1992, J VIROL, V66, P1655, DOI 10.1128/JVI.66.3.1655-1664.1992; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Moore DD, 1995, GLOB MOB SURV; Ned R, 1997, J VIROL, V71, P4866, DOI 10.1128/JVI.71.6.4866-4870.1997; ROMANCZUK H, 1991, J VIROL, V65, P2739, DOI 10.1128/JVI.65.5.2739-2744.1991; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SIKORSKI RS, 1989, GENETICS, V122, P19; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Trujillo JM, 1996, VIROLOGY, V220, P1, DOI 10.1006/viro.1996.0279; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; VANDEPOL SB, 1995, J VIROL, V69, P395, DOI 10.1128/JVI.69.1.395-402.1995; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WOOD CK, 1994, J CELL SCI, V107, P709; YAN MH, 1994, J BIOL CHEM, V269, P19067; YANG YC, 1985, P NATL ACAD SCI USA, V82, P1030, DOI 10.1073/pnas.82.4.1030	54	114	117	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	1998	16	1					43	52		10.1038/sj.onc.1201504	http://dx.doi.org/10.1038/sj.onc.1201504			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467941				2022-12-25	WOS:000071236800005
J	Mellor, H; Flynn, P; Nobes, CD; Hall, A; Parker, PJ				Mellor, H; Flynn, P; Nobes, CD; Hall, A; Parker, PJ			PRK1 is targeted to endosomes by the small GTPase, RhoB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-N; PKN; LOCALIZATION	RhoB has been shown to be an endosomal GTPase both by immunocytochemistry and electron microscopy, however, its role in endocytosis is unknown. Elucidation of the cellular roles of other members of this superfamily of signaling proteins has come with the identification of their downstream partners. We show here that the recently isolated serine/threonine kinase PRK1 is targeted to the endosomal compartment by RhoB. This is established both through immunofluorescence and cell fractionation. PRK1 is shown to interact with activated RhoB in cells and is localized to endosomes through its Rho-binding HR1 domain. Translocation of PRK1 to the endosomal compartment by RhoB is accompanied by a shift in the electrophoretic mobility of the kinase indicative of an accompanying activation.	Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England; Univ London Univ Coll, Mol Cell Biol Lab, MRC, Oncogene & Signal Transduct Grp,Canc Res Campaign, London WC1E 6BT, England; Univ London Univ Coll, Dept Biochem, London WC1E 6BT, England	Cancer Research UK; University of London; University College London; University of London; University College London	Mellor, H (corresponding author), Imperial Canc Res Fund, Prot Phosphorylat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Parker, Peter j/D-5192-2013	Mellor, Harry/0000-0003-3894-0623; parker, peter/0000-0002-6218-2933				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; GORVEL JP, 1995, J BIOL CHEM, V270, P2741, DOI 10.1074/jbc.270.6.2741; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Moorman JP, 1996, J IMMUNOL, V156, P4146; Mukai H, 1996, J BIOL CHEM, V271, P9816, DOI 10.1074/jbc.271.16.9816; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Peng B, 1996, J BIOL CHEM, V271, P32233, DOI 10.1074/jbc.271.50.32233; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; ROBERTSON D, 1995, J HISTOCHEM CYTOCHEM, V43, P471, DOI 10.1177/43.5.7537292; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645	13	98	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4811	4814		10.1074/jbc.273.9.4811	http://dx.doi.org/10.1074/jbc.273.9.4811			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478917	hybrid			2022-12-25	WOS:000072310400001
J	Li, JX; Gao, EW; Mendelson, CR				Li, JX; Gao, EW; Mendelson, CR			Cyclic AMP-responsive expression of the surfactant protein-A gene is mediated by increased DNA binding and transcriptional activity of thyroid transcription factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT FETAL LUNG; FACTOR-I TTF-1; PULMONARY SURFACTANT; MESSENGER-RNA; FUNCTIONAL-CHARACTERIZATION; FAMILY MEMBERS; PHORBOL ESTER; SP-A2 GENES; APOPROTEIN; PROMOTER	Surfactant protein (SP)-A gene transcription is stimulated by factors that increase cyclic AMP. In the present study, we observed that three thyroid transcription factor-1 (TTF-1) binding elements (TBEs) located within a 255 base pair region flanking the 5'-end of the baboon SP-A2 (bSP-A2) gene are required for maximal cyclic AMP induction of bSP-A2 promoter activity. We found that TTF-I DNA binding activity was increased in nuclear extracts of pulmonary type II cells cultured in the presence of cyclic AMP. By contrast, the levels of immunoreactive TTF-1 protein were similar in nuclear extracts of control and cyclic AMP-treated type II cells. The incorporation of [P-32]orthophosphate into immunoprecipitated TTF-1 protein also was markedly increased by cyclic AMP treatment. Moreover, exposure of nuclear extracts from cyclic AMP-treated type II cells either to potato acid phosphatase or alkaline phosphatase abolished the cyclic AMP-induced increase in TTF-1 DNA-binding activity. Interestingly, the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), known to activate protein kinase C, also enhanced incorporation of [P-32]orthophosphate into TTF-I protein; however, the DNA binding activity of TTF-I was decreased in nuclear extracts of TPA-treated type II cells, Expression vectors encoding TTF-1 and the catalytic subunit of protein kinase A (PKA-cat) were cotransfected into A549 lung adenocarcinoma cells together with an SPA:human growth hormone fusion gene (255 base pairs of 5'-flanking DNA from the baboon SP-A2 gene. linked to human ,growth hormone, as reporter) containing TBEs, or with a reporter gene construct containing three tandem TBEs fused upstream of the bSP-A2 gene TATA box and the transcription initiation site, Coexpression of TTF-I and PKA-cat increased fusion gene expression 3-4-fold as compared with expression of TTF-I in the absence of PKA-cat, Moreover, the transcriptional! activity of TTF-1 tvas suppressed by cotransfection of a dominant negative form of PKA regulatory subunit RI alpha. We suggest that a PICA-induced increase of TTF-1 phosphorylation and TEE binding activity mediates cyclic AMP-induced expression of the SP-A gene in lung type II cells.	Univ Texas, SW Med Ctr, Dept Biochem, Cecil H & Ida Green Ctr Reprod Biol Sci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Obstet Gynecol, Cecil H & Ida Green Ctr Reprod Biol Sci, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mendelson, CR (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Cecil H & Ida Green Ctr Reprod Biol Sci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Mendelson, Carole Ruth/0000-0003-1696-9791	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL052647] Funding Source: NIH RePORTER; NHLBI NIH HHS [U10-HL-52647] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALCORN JL, 1993, MOL ENDOCRINOL, V7, P1072, DOI 10.1210/me.7.8.1072; Alcorn JL, 1997, AM J RESP CELL MOL, V17, P672, DOI 10.1165/ajrcmb.17.6.2858; AUTEN RL, 1990, AM J RESP CELL MOL, V3, P491, DOI 10.1165/ajrcmb/3.5.491; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BENSON B, 1985, P NATL ACAD SCI USA, V82, P6379, DOI 10.1073/pnas.82.19.6379; BOGGARAM V, 1988, J BIOL CHEM, V263, P19060; BOGGARAM V, 1988, J BIOL CHEM, V263, P2939; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CLEMENTS JA, 1976, BIOCH BASIS PULMONAR, P363; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; FISHER JH, 1988, BIOCHIM BIOPHYS ACTA, V950, P338, DOI 10.1016/0167-4781(88)90130-3; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GAO E, 1993, J BIOL CHEM, V268, P19697; Gao EW, 1997, J BIOL CHEM, V272, P23398, DOI 10.1074/jbc.272.37.23398; Gao EW, 1996, AM J PHYSIOL-LUNG C, V271, pL617, DOI 10.1152/ajplung.1996.271.4.L617; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HAWGOOD S, 1991, ANNU REV PHYSIOL, V53, P375, DOI 10.1146/annurev.ph.53.030191.002111; KATYAL SL, 1992, AM J RESP CELL MOL, V6, P446, DOI 10.1165/ajrcmb/6.4.446; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; KORFHAGEN TR, 1992, AM J PHYSIOL, V263, pL546, DOI 10.1152/ajplung.1992.263.5.L546; Kumar AS, 1997, J BIOL CHEM, V272, P20764, DOI 10.1074/jbc.272.33.20764; LAZZARO D, 1991, DEVELOPMENT, V113, P1095; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MCCORMICK SM, 1994, AM J PHYSIOL, V266, pL367, DOI 10.1152/ajplung.1994.266.4.L367; MCCORMICK SM, 1994, AM J PHYSIOL, V266, pL354, DOI 10.1152/ajplung.1994.266.4.L354; MENDELSON CR, 1991, ANNU REV PHYSIOL, V53, P415, DOI 10.1146/annurev.ph.53.030191.002215; MENDELSON CR, 1986, J BIOL CHEM, V261, P9938; Michael LF, 1996, MOL ENDOCRINOL, V10, P159, DOI 10.1210/me.10.2.159; MIZUNO K, 1991, MOL CELL BIOL, V11, P4927, DOI 10.1128/MCB.11.10.4927; ODOM MJ, 1987, ENDOCRINOLOGY, V121, P1155, DOI 10.1210/endo-121-3-1155; PRYHUBER GS, 1990, J BIOL CHEM, V265, P20822; Ray MK, 1996, MOL CELL BIOL, V16, P2056; Seidner SR, 1996, AM J PHYSIOL-LUNG C, V271, pL609, DOI 10.1152/ajplung.1996.271.4.L609; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; SMITH BT, 1977, AM REV RESPIR DIS, V115, P285; WHITSETT JA, 1992, AM J PHYSIOL, V262, pL688, DOI 10.1152/ajplung.1992.262.6.L688; WOHLFORDLENANE CL, 1992, AM J RESP CELL MOL, V7, P335, DOI 10.1165/ajrcmb/7.3.335; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Young PP, 1997, MOL ENDOCRINOL, V11, P1082, DOI 10.1210/me.11.8.1082; YOUNG PP, 1996, AM J PHYSIOL, V271, P6287; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249	45	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4592	4600		10.1074/jbc.273.8.4592	http://dx.doi.org/10.1074/jbc.273.8.4592			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468516	hybrid			2022-12-25	WOS:000072115000044
J	Srinivasan, A; Li, F; Wong, A; Kodandapani, L; Smidt, R; Krebs, JF; Fritz, LC; Wu, JC; Tomaselli, KJ				Srinivasan, A; Li, F; Wong, A; Kodandapani, L; Smidt, R; Krebs, JF; Fritz, LC; Wu, JC; Tomaselli, KJ			Bcl-x(L) functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; MEDIATED APOPTOSIS; ICE/CED-3 PROTEASE; DEATH; BCL-2; ICE; PATHWAY; INVOLVEMENT; REQUIREMENT; ACTIVATION	Stimulation of the Fas or tumor necrosis factor receptor 1 (TNFR1) cell surface receptors leads to the activation of the death effector protease, caspase-8, and subsequent apoptosis. In some cells, Bcl-x(L) overexpression can inhibit anti-Fas-and tumor necrosis factor (TNF)-alpha-induced apoptosis, To address the effect of Bcl-x(L) on caspase-8 processing, Fas-and TNFR1-mediated apoptosis were studied in the MCF7 breast carcinoma cell line stably transfected with human Fas cDNA (MCF7/F) or double transfected with Fas and human Bcl-x(L) cDNAs (MCF7/FB). Bcl-x(L) strongly inhibited apoptosis induced by either anti-Fas or TNF-alpha. In addition, Bcl-x(L) prevented the change in cytochrome c immunolocalization induced by anti-Fas or TNF-alpha treatment, Using antibodies that recognize the p20 and p10 subunits of active caspase-8, proteolytic processing of caspase-8 was detected in MCF7/F cells following anti-Fas or TNF-alpha, but not during UV-induced apoptosis, In MCF7/FB cells, caspase-8 was processed normally while processing of the downstream caspase-7 was markedly attenuated, Moreover, apoptosis induced by direct microinjection of recombinant, active caspase-8 was completely inhibited by Bcl-x(L). These data demonstrate that Bcl-x(L) can exert an anti-apoptotic function in cells in which caspase-8 is activated, Thus, at least in some cells, caspase-8 signaling in response to Fas or TNFR1 stimulation is regulated by a Bcl-x(L)-inhibitable step.	IDUN Pharmaceut Inc, Cell Biol, La Jolla, CA 92037 USA		Tomaselli, KJ (corresponding author), IDUN Pharmaceut Inc, Cell Biol, 11085 N Torrey Pines Rd,Suite 300, La Jolla, CA 92037 USA.	ktomasel@idun.com						Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Darmon AJ, 1996, J BIOL CHEM, V271, P21699, DOI 10.1074/jbc.271.36.21699; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HARLOW E, 1988, ANTIBODIES LAB MANUA, P285; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee RK, 1996, INT IMMUNOL, V8, P991, DOI 10.1093/intimm/8.7.991; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MINASCHEK G, 1989, EXP CELL RES, V183, P434, DOI 10.1016/0014-4827(89)90402-3; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	47	151	158	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4523	4529		10.1074/jbc.273.8.4523	http://dx.doi.org/10.1074/jbc.273.8.4523			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468507	hybrid			2022-12-25	WOS:000072115000035
J	Howes, R; Wasserman, JD; Freeman, M				Howes, R; Wasserman, JD; Freeman, M			In vivo analysis of argos structure-function - Sequence requirements for inhibition of the Drosophila epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; FACTOR EGF RECEPTOR; FAINT-LITTLE-BALL; FACTOR-ALPHA; GENE ENCODES; TGF-ALPHA; SIGNAL-TRANSDUCTION; CELL DETERMINATION; SECRETED PROTEIN; HIGH-AFFINITY	The Drosophila Argos protein is the only known extracellular inhibitor of the epidermal growth factor receptor (EGFR), It is structurally related to the activating ligands, in that it is a secreted protein with a single epidermal growth factor (EGF) domain, To understand the mechanism of Argos inhibition, we have investigated which regions of the protein are essential, A series of deletions were made and tested in vivo; furthermore, by analyzing chimeric proteins between Argos and the activating ligand, Spitz (a transforming growth factor-alpha-like factor), we have examined what makes one inhibitory and the other activating, Our results reveal that Argos has structural requirements that differ from all known EGFR activating ligands; domains flanking the EGF domain are essential for its function, We have also defined the important regions of the atypical Argos EGF domain, The extended B-loop is necessary, whereas the C-loop can be replaced with the equivalent Spitz region without substantially affecting Argos function, Comparison of the argos genes from Drosophila melanogaster and the housefly, Musca domestica, supports our structure-function analysis, These studies are a prerequisite for understanding how Argos inhibits the Drosophila EGFR and provide a basis for designing mammalian EGFR inhibitors.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Freeman, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	mf1@mrc-lmb.cam.ac.uk	Wasserman, JD/AAF-8145-2019; Wasserman, Jonathan D/M-4298-2013	Wasserman, JD/0000-0001-7088-8146; Wasserman, Jonathan D/0000-0001-7088-8146; Freeman, Matthew/0000-0003-0410-5451				AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CAMPION SR, 1994, PROG NUCLEIC ACID RE, V49, P353; CAMPION SR, 1990, BIOCHEMISTRY-US, V29, P9988, DOI 10.1021/bi00494a032; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; CHERBAS L, 1994, DROSOPHILA MELANOGAS, P161; CHIA CM, 1995, DEVELOPMENT, V121, P299; CLIFFORD R, 1992, DEVELOPMENT, V115, P853; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FREEMAN M, 1994, DEVELOPMENT, V120, P2297; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; FREEMAN M, 1994, MECH DEVELOP, V48, P25, DOI 10.1016/0925-4773(94)90003-5; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; Harlow E., 1988, ANTIBODIES LAB MANUA; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hennig W., 1981, INSECT PHYLOGENY; HOEPRICH PD, 1989, J BIOL CHEM, V264, P19086; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HOPPE BL, 1992, BIOTECHNIQUES, V12, P679; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOMORIYA A, 1984, P NATL ACAD SCI-BIOL, V81, P1351, DOI 10.1073/pnas.81.5.1351; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; KRETZSCHMAR D, 1992, EMBO J, V11, P2531, DOI 10.1002/j.1460-2075.1992.tb05318.x; LEE DC, 1995, PHARMACOL REV, V47, P51; LEJEUNE S, 1993, CANCER RES, V53, P3597; LIN YZ, 1991, BIOCHEMISTRY-US, V30, P3310, DOI 10.1021/bi00227a020; Lohmeyer M, 1997, INT J ONCOL, V10, P677; MACIAS A, 1989, ANTICANCER RES, V9, P177; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MATSUNAMI RK, 1990, FEBS LETT, V264, P105, DOI 10.1016/0014-5793(90)80776-F; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; OKANO H, 1992, DIFFERENTIATION, V52, P1, DOI 10.1111/j.1432-0436.1992.tb00494.x; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; RAZ E, 1992, DEVELOPMENT, V114, P113; RICHTER A, 1992, BIOCHEMISTRY-US, V31, P9546, DOI 10.1021/bi00155a006; RICHTER A, 1995, J BIOL CHEM, V270, P1612, DOI 10.1074/jbc.270.4.1612; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHEJTER ED, 1986, CELL, V46, P1091, DOI 10.1016/0092-8674(86)90709-9; Schnepp B, 1996, GENE DEV, V10, P2302, DOI 10.1101/gad.10.18.2302; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thompson SA, 1996, J BIOL CHEM, V271, P17927, DOI 10.1074/jbc.271.30.17927; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; vandePoll MLM, 1997, BIOCHEMISTRY-US, V36, P7425, DOI 10.1021/bi970227f; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; vanZoelen EJJ, 1996, PATHOL RES PRACT, V192, P761, DOI 10.1016/S0344-0338(96)80098-7; WADSWORTH SC, 1985, NATURE, V314, P178, DOI 10.1038/314178a0; WILEY LM, 1995, BIOESSAYS, V17, P839, DOI 10.1002/bies.950171005; WOLFF T, 1991, DEVELOPMENT, V113, P841	69	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4275	4281		10.1074/jbc.273.7.4275	http://dx.doi.org/10.1074/jbc.273.7.4275			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461626	hybrid			2022-12-25	WOS:000072048400068
J	Tsai, AL; Palmer, G; Xiao, GS; Swinney, DC; Kulmacz, RJ				Tsai, AL; Palmer, G; Xiao, GS; Swinney, DC; Kulmacz, RJ			Structural characterization of arachidonyl radicals formed by prostaglandin H synthase-2 and prostaglandin H synthase-1 reconstituted with mangano protoporphyrin IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; HIGHER OXIDATION-STATE; ENDOPEROXIDE SYNTHASE; TYROSYL RADICALS; CYCLOOXYGENASE CATALYSIS; SELECTIVE-INHIBITION; FATTY-ACIDS; PROTEIN; PURIFICATION; LIPOXYGENASE	A tyrosyl radical generated in the peroxidase cycle of prostaglandin H synthase-1 (PGHS-1) can serve as the initial oxidant for arachidonic acid (AA) in the cyclooxygenase reaction, Peroxides also induce radical formation in prostaglandin H synthase-2 (PGHS-2) and in PGHS-1 reconstituted with mangano, protoporphyrin IX (MnPGHS-1), but the EPR spectra of these radicals are distinct from the initial tyrosyl radical in PGHS-1, We have examined the ability of the radicals in PGHS-2 and MnPGHS-1 to oxidize AA, using single-turnover EPR studies. One wide singlet tyrosyl radical with an overall EPR line width of 29-31 gauss (G) was generated by reaction of PGHS-2 with ethyl hydroperoxide. Anaerobic additions of AA to PGHS-2, immediately after formation of this radical led to its disappearance and emergence of an AA radical (AA.) with a 7-line EPR, substantiated by experiments using octadeuterated AA. Subsequent addition of oxygen resulted in regeneration of the tyrosyl radical, In contrast, the peroxide-generated radical (a 21G narrow singlet) in a Y371F PGHS-2 mutant lacking cyclooxygenase activity failed to react with AA. The peroxide-generated radical in MnPGHS-1 exhibited a line width of 36-38G, but was also able to convert AA to an AA. with an EPR spectrum similar to that found with PGHS-2. These results indicate that the peroxide-generated radicals in PGHS-2 and MnPGHS-1 can each serve as immediate oxidants of AA to form the same carbon-centered fatty acid radical that subsequently reacts with oxygen to form a hydroperoxide, The EPR data for the AA-derived radical formed by PGHS-2 and MnPGHS-1 could be accounted for by a planar pentadienyl radical with two strongly interacting beta-protons at C10 of AA. These results support a functional role for peroxide-generated radicals in cyclooxygenase catalysis by both PGHS isoforms and provide important structural characterization of the carbon-centered AA..	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77030 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA; Roche Biosci, Inflammatory Dis Unit, Palo Alto, CA 94304 USA	University of Texas System; University of Texas Health Science Center Houston; Rice University; Roche Holding	Tsai, AL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, 6431 Fannin St, Houston, TX 77030 USA.				NIGMS NIH HHS [GM21337, GM52170, GM44911] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052170, R01GM021337, R37GM021337] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; BASCETTA E, 1982, 4 CHE7 S3C CHE7 C377, P110; DAVIES AG, 1981, J CHEM SOC PERK T 2, P633, DOI 10.1039/p29810000633; DIETZ R, 1988, EUR J BIOCHEM, V171, P821; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; GRAFF G, 1990, ANAL BIOCHEM, V188, P38, DOI 10.1016/0003-2697(90)90525-E; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HINCHLIFFE A, 1974, J MOL STRUCT, V23, P273, DOI 10.1016/0022-2860(74)85041-6; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; HSI LC, 1994, BIOCHEM BIOPH RES CO, V202, P1592, DOI 10.1006/bbrc.1994.2114; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1991, MOL PHARMACOL, V40, P833; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1994, BIOCHEMISTRY-US, V33, P5428, DOI 10.1021/bi00184a011; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; KULMACZ RJ, 1987, PROSTAGLANDINS RELAT, P207; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; NELSON MJ, 1994, BIOCHEMISTRY-US, V33, P4966, DOI 10.1021/bi00182a027; ODENWALLER R, 1992, J BIOL CHEM, V267, P13863; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STRIEDER S, 1992, J BIOL CHEM, V267, P13870; TSAI AL, 1994, J BIOL CHEM, V269, P5085; TSAI AL, 1992, J BIOL CHEM, V267, P17753; Tsai AL, 1997, J BIOL CHEM, V272, P8885; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u	33	78	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3888	3894		10.1074/jbc.273.7.3888	http://dx.doi.org/10.1074/jbc.273.7.3888			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461572	hybrid			2022-12-25	WOS:000072048400014
J	von Willebrand, M; Williams, S; Saxena, M; Gilman, J; Tailor, P; Jascur, T; Amarante-Mendes, GP; Green, DR; Mustelin, T				von Willebrand, M; Williams, S; Saxena, M; Gilman, J; Tailor, P; Jascur, T; Amarante-Mendes, GP; Green, DR; Mustelin, T			Modification of phosphatidylinositol 3-kinase SH2 domain binding properties by Abl- or Lck-mediated tyrosine phosphorylation at Tyr-688	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; CHRONIC MYELOGENOUS LEUKEMIA; TCR-ZETA-CHAIN; KINASE-ACTIVITY; BCR-ABL; PHILADELPHIA-CHROMOSOME; SIGNAL TRANSDUCTION; CATALYTIC SUBUNIT; INSULIN-RECEPTOR; PROTEIN-KINASE	In cells expressing the oncogenic Bcr-Abl tyrosine kinase, the regulatory p85 subunit of phosphatidylinositol 3-kinase is phosphorylated on tyrosine residues. We report that this phosphorylation event is readily catalyzed by the Abl and Lck protein-tyrosine kinases in vitro, by Bcr-Abl or a catalytically activated Lck-Y505F in cotransfected COS cells, and by endogenous kinases in transfected Jurkat T cells upon triggering of their T cen antigen receptor, Using these systems, we have mapped a major phosphorylation site to Tyr-688 in the C-terminal. SH2 domain of p85. Tyrosine phosphorylation of p85 in vitro or in vivo was not associated with detectable change in the enzymatic activity of the phosphatidylinositol 3-kinase heterodimer, but correlated with a strong reduction in the binding of same, but not all, phosphoproteins to the SH2 domains of p85, This provides tan additional candidate to the list of SH2 domains regulated by tyrosine phosphorylation and mag explain why association of phosphatidylinositol 3-kinase with same cellular ligands is transient or of lower stoichiometry than anticipated.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA	La Jolla Institute for Immunology; La Jolla Institute for Immunology	Mustelin, T (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA.	tomas_mustelin@liai.org	Mendes, Gustavo P Amarante/C-8187-2012; Green, Douglas R/N-8083-2018	Mendes, Gustavo P Amarante/0000-0002-7851-6205; Green, Douglas R/0000-0002-7332-1417; Mustelin, Tomas/0000-0001-5912-8840	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048960, R01GM052735, R37GM052735] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35603] Funding Source: Medline; NIGMS NIH HHS [GM52735, GM48960] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AmaranteMendes GP, 1997, CELL DEATH DIFFER, V4, P548, DOI 10.1038/sj.cdd.4400276; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; CARRERA AC, 1994, J BIOL CHEM, V269, P19435; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; Couture C, 1996, J BIOL CHEM, V271, P24294, DOI 10.1074/jbc.271.39.24294; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dennehy KM, 1997, EUR J IMMUNOL, V27, P679, DOI 10.1002/eji.1830270316; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; EXLEY M, 1994, J BIOL CHEM, V269, P15140; GOLD MR, 1992, J IMMUNOL, V148, P2012; GOTOH A, 1994, LEUKEMIA, V8, P115; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HSI ED, 1989, J BIOL CHEM, V264, P10836; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KARNITZ LM, 1994, J EXP MED, V179, P1799, DOI 10.1084/jem.179.6.1799; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; Lee DM, 1996, INT IMMUNOL, V8, P1195, DOI 10.1093/intimm/8.8.1195; LUO K, 1990, ONCOGENE, V5, P921; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Minshall C, 1996, J IMMUNOL, V156, P939; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSTELIN T, 1994, SRC FAMILY TYROSINE; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; REIF K, 1993, J BIOL CHEM, V268, P10780; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Stover DR, 1996, J BIOL CHEM, V271, P12481, DOI 10.1074/jbc.271.21.12481; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; Tailor P, 1996, EUR J BIOCHEM, V237, P736, DOI 10.1111/j.1432-1033.1996.0736p.x; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; Williams S, 1997, EUR J BIOCHEM, V245, P84, DOI 10.1111/j.1432-1033.1997.00084.x; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zenner G, 1996, J CELL BIOCHEM, V63, P94, DOI 10.1002/(SICI)1097-4644(199610)63:1<94::AID-JCB8>3.0.CO;2-V; ZHANG WG, 1993, P NATL ACAD SCI USA, V90, P11317, DOI 10.1073/pnas.90.23.11317; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	66	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3994	4000		10.1074/jbc.273.7.3994	http://dx.doi.org/10.1074/jbc.273.7.3994			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461588	hybrid			2022-12-25	WOS:000072048400030
J	Feron, O; Saldana, F; Michel, JB; Michel, T				Feron, O; Saldana, F; Michel, JB; Michel, T			The endothelial nitric-oxide synthase-caveolin regulatory cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; PALMITOYLATION; TRANSLOCATION; CELLS; ACYLATION; PROTEIN; M2	Nitric oxide production in the vascular endothelium is promoted by diverse agonists that transiently increase intracellular Ca2+ concentration and activate the endothelial nitric-oxide synthase (eNOS), a Ca2+/calmodulin-dependent enzyme. eNOS is acylated by the fatty acids myristate and palmitate and is targeted thereby to plasmalemmal signal-transducing domains termed caveolae., eNOS enzyme activity is markedly attenuated by its interactions with caveolin, the structural scaffolding protein of caveolae. Fire have discovered that in living cells, the eNOS-caveolin heteromeric complex undergoes cycles of dissociation and re-association modulated by Ca2+-mobilizing agonists. Calcium ionophore A23187 and the muscarinic cholinergic agonist carbachol both promote the dissociation of eNOS from caveolin in cultured cells, associated with translocation of eNOS from caveolae. As [Ca2+](i) returns to basal levels, eNOS reassociates with caveolin, and the inhibited enzyme complex is then restored to caveolae, a process accelerated by palmitoylation of the enzyme. These data establish an eNOS-caveolin regulatory cycle, wherein enzyme activation is modulated by reversible protein-protein interactions controlled by Ca2+/calmodulin and by enzyme palmitoylation. Alterations in this cycle are likely to have an important influence on nitric oxide-dependent signaling in the vascular wall.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Michel, T (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Cardiovasc, Thorn Bldg 1210A,75 Francis St, Boston, MA 02115 USA.	michel@calvin.bwh.harvard.edu	FERON, Olivier/AAM-6395-2020	FERON, Olivier/0000-0001-5360-0286				BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; DUDEK R, 1995, PHARMACOLOGY, V50, P257, DOI 10.1159/000139290; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FUKUDA S, 1995, BRAIN RES, V696, P30, DOI 10.1016/0006-8993(95)00704-T; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; ISHIZAKA N, 1995, PFLUG ARCH EUR J PHY, V429, P426, DOI 10.1007/BF00374159; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SASE K, 1997, TRENDS CARDIOVAS MED, V7, P25; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; VANHOUTTE PM, 1989, HYPERTENSION, V13, P658, DOI 10.1161/01.HYP.13.6.658; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Zhu X, 1996, P NATL ACAD SCI USA, V93, P2827, DOI 10.1073/pnas.93.7.2827	31	295	302	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3125	3128		10.1074/jbc.273.6.3125	http://dx.doi.org/10.1074/jbc.273.6.3125			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452418	hybrid			2022-12-25	WOS:000071822300003
J	Minegishi, N; Ohta, J; Suwabe, N; Nakauchi, H; Ishihara, H; Hayashi, N; Yamamoto, M				Minegishi, N; Ohta, J; Suwabe, N; Nakauchi, H; Ishihara, H; Hayashi, N; Yamamoto, M			Alternative promoters regulate transcription of the mouse GATA-2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; ZINC-FINGER PROTEIN; BETA-GLOBIN GENE; C-MYC; ERYTHROID-DIFFERENTIATION; XENOPUS GATA-2; HEMATOPOIETIC MESODERM; ENDOTHELIAL-CELLS; MESSENGER-RNA; STEM-CELLS	Transcription factor GATA-2 has been shown to be a key regulator in hematopoietic progenitor cells, To elucidate how the expression of the GATA-2 gene is controlled, we isolated the mouse GATA-2 (mGATA-2) gene. Transcription of mGATA-2 mRNAs was found to initiate from two distinct first exons, both of which encode entirely untranslated regions, while the remaining five exons are shared by each of the two divergent mRNAs. Reverse transcriptase-polymerase chain reaction analysis revealed that GATA-2 mRNA initiated at the upstream first exon (IS) in Sca-1(+)/c-kit(+) hematopoietic progenitor cells, whereas mRNA that initiates at the downstream first exon (IG) is expressed in all tissues and cell lines that express GATA-2. While the structure of the IG exon/promoter shows high similarity to those of the Xenopus and human GATA-2 genes, the IS exon/promoter has not been described previously, When we examined the regulation contributing to IS transcription using transient transfection assays, we found that sequences lying between -79 and -61 are critical for the cell type-specific activity of the IS promoter, DNase I footprinting experiments and electrophoretic mobility shift assays demonstrated the binding of transcription factors to this region, These data indicate that the proximal 80 base pair region of IS promoter is important for the generation of cell type-specific expression of mGATA-2 from the IS exon.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 305, Japan; Tohoku Univ, Sch Med, Dept Biochem, Aoba Ku, Sendai, Miyagi 98077, Japan	University of Tsukuba; University of Tsukuba; Tohoku University	Yamamoto, M (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305, Japan.	masiya@igaku.md.tsukuba.ac.jp	Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436				APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BREWER AC, 1995, EMBO J, V14, P757, DOI 10.1002/j.1460-2075.1995.tb07054.x; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; CHOI OR, 1986, NATURE, V323, P731, DOI 10.1038/323731a0; CROSS MA, 1994, ONCOGENE, V9, P3013; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; EMERSON BM, 1984, P NATL ACAD SCI-BIOL, V81, P95, DOI 10.1073/pnas.81.1.95; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Fleenor DE, 1996, GENE, V179, P219, DOI 10.1016/S0378-1119(96)00355-1; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Jippo T, 1996, BLOOD, V87, P993, DOI 10.1182/blood.V87.3.993.bloodjournal873993; KELLEY C, 1994, DEV BIOL, V165, P193, DOI 10.1006/dbio.1994.1246; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEONARD M, 1993, BLOOD, V82, P1071; MacNeill C, 1997, J BIOL CHEM, V272, P8396, DOI 10.1074/jbc.272.13.8396; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; Matsuzaki Y, 1997, BLOOD, V89, P853, DOI 10.1182/blood.V89.3.853; Meng AM, 1997, P NATL ACAD SCI USA, V94, P6267, DOI 10.1073/pnas.94.12.6267; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MORRIS JF, 1995, BLOOD, V86, P3640; MOUTHON MA, 1993, BLOOD, V81, P647; NAGAI T, 1994, BLOOD, V84, P1074, DOI 10.1182/blood.V84.4.1074.bloodjournal8441074; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; Onodera K, 1997, J BIOCHEM, V121, P251; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; ORLIC D, 1995, P NATL ACAD SCI USA, V92, P4601, DOI 10.1073/pnas.92.10.4601; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Partington GA, 1997, DEV BIOL, V181, P144, DOI 10.1006/dbio.1996.8432; PERROTTI D, 1995, MOL CELL BIOL, V15, P6075; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PISCHEDDA C, 1995, P NATL ACAD SCI USA, V92, P3511, DOI 10.1073/pnas.92.8.3511; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WALMSLEY ME, 1994, DEVELOPMENT, V120, P2519; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10642, DOI 10.1073/pnas.88.23.10642; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668; ZON LI, 1993, BLOOD, V81, P3234	54	99	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3625	3634		10.1074/jbc.273.6.3625	http://dx.doi.org/10.1074/jbc.273.6.3625			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452491	hybrid			2022-12-25	WOS:000071822300076
J	Ng, FWH; Shore, GC				Ng, FWH; Shore, GC			Bcl-X-L cooperatively associates with the Bap31 complex in the endoplasmic reticulum, dependent on procaspase-8 and Ced-4 adaptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PROTEASE	Bap31 is a polytopic integral membrane protein of the endoplasmic reticulum and forms a complex with Bcl-2/Bcl-X-L, and procaspase-8 (Ng, F., W., H.,, Nguyen, M.,, Kwan, T.,, Branton, P., E.,, Nicholson, W., D.,, Cromlish, J., A., and Shore, G., C., (1997) J., Cell Biol. 139, 327-338), In co-transfected human cells, procaspase-8 is capable of interacting with Ced-4, an important adaptor molecule in Caenorhabditis elegans that binds to and activates the C. elegans procaspase, proCed-3., Here, we show that the predicted death effector homology domain within the cytosolic region of Bap31 interacts with Ced-4 and contributes to recruitment of procaspase-8. Bcl-X-L,, which binds directly but weakly to the polytopic transmembrane region of Bap31, indirectly and cooperatively associates with the Bap31 cytosolic domain, dependent on the presence of procaspase-8 and Ced-4. Ced-4 Delta c does not interact with Bcl-X-L but rather displaces it from Bap31, suggesting that an endogenous Ced-4-like adaptor is a normal constituent of the Bap31 complex and is required for stable association of Bcl-X-L, with Bap31 in vivo., These findings indicate that Bap31 is capable of recruiting essential components of a core death regulatory machinery.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Shore, GC (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Schleiff E, 1997, J BIOL CHEM, V272, P17784, DOI 10.1074/jbc.272.28.17784; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	30	77	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3140	3143		10.1074/jbc.273.6.3140	http://dx.doi.org/10.1074/jbc.273.6.3140			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452422	hybrid			2022-12-25	WOS:000071822300007
J	Sleeman, MW; Donegan, NP; Heller-Harrison, R; Lane, WS; Czech, MP				Sleeman, MW; Donegan, NP; Heller-Harrison, R; Lane, WS; Czech, MP			Association of acyl-CoA synthetase-1 with GLUT4-containing vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 GLUCOSE-TRANSPORTER; INSULIN-SENSITIVE CELLS; RAT ADIPOSE-CELLS; SUBCELLULAR TRAFFICKING; 3T3-L1 ADIPOCYTES; FATTY-ACIDS; COENZYME-A; PROTEIN; INTERNALIZATION; KINETICS	GLUT4, the glucose transporter present in insulin-sensitive tissues, resides in intracellular vesicular structures and translocates to the cell surface in response to insulin, In an attempt to identify proteins present in these structures, GLUT4-enriched vesicles prepared from rat adipocytes treated with or without insulin were prepared by sucrose velocity gradient centrifugation and immunoadsorbed with anti-GLUT4 antibody, We report here the sequence identification by high performance liquid chromatography-ion trap mass spectrometry of a p75 protein band, long chain acyl-CoA synthetase-l, specifically present in immunoadsorbed GLUT4-containing vesicles but not in vesicles adsorbed by nonimmune serum. Acyl-CoA synthetase activity detected in GLUT4-enriched vesicles prepared by gradient centrifugation from insulin-treated adipocytes was decreased to about the same extent as GLUT4 protein. Additionally, immunoadsorbed GLUT4 vesicles were found to catalyze palmitoylation of proteins when incubated with labeled palmitate, a pathway that requires palmitate esterification with CoA. These data indicate that the insulin-sensitive membrane compartment that sequesters GLUT4 in fat cells contains long chain acyl-CoA synthetase-l and its product fatty acyl-CoA, shown previously to be required for budding and fusion in membrane trafficking processes.	Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Harvard Univ, Harvard Microchem Facil, Cambridge, MA 02318 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University	Czech, MP (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA.	Michael.Czech@banyan.ummed.edu		Donegan, Niles/0000-0002-8328-2044				CAIN CC, 1992, J BIOL CHEM, V267, P11681; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CORMONT MJ, 1993, ENDOCRINOLOGY, V129, P3343; CZECH MP, 1993, J BIOL CHEM, V268, P9187; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; ICHIHARA K, 1991, J LIPID RES, V32, P1709; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; MANGROO D, 1995, BIOCHEM CELL BIOL, V73, P223, DOI 10.1139/o95-027; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Mastick CC, 1997, ENDOCRINOLOGY, V138, P2391, DOI 10.1210/en.138.6.2391; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PESECKIS SM, 1993, J BIOL CHEM, V268, P5107; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; SATOH S, 1993, J BIOL CHEM, V268, P17820; Shibata H, 1996, J BIOL CHEM, V271, P9704, DOI 10.1074/jbc.271.16.9704; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STAGSTED J, 1993, J BIOL CHEM, V268, P22809; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; VOLCHUK A, 1994, BIOCHEM J, V304, P138; YANG J, 1993, J BIOL CHEM, V268, P4600	31	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3132	3135		10.1074/jbc.273.6.3132	http://dx.doi.org/10.1074/jbc.273.6.3132			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452420	hybrid			2022-12-25	WOS:000071822300005
J	Gagnebin, J; Kovar, H; Kajava, AV; Estreicher, A; Jug, G; Monnier, P; Iggo, R				Gagnebin, J; Kovar, H; Kajava, AV; Estreicher, A; Jug, G; Monnier, P; Iggo, R			Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity	ONCOGENE			English	Article						p53; gene therapy; transcription	DNA-BINDING; PROTEIN; MUTATIONS; GENE	p53 triple mutants (120N/121G/277H, 120H/121G/277H, 120S/121G/277H and 120H/121G/277Y) have altered sequence specificity in bandshift assays in vitro and transcription assays in vivo. These mutants activate transcription from the site TTT CATG AAA but not from wild type sites. The triple mutants activate more strongly than p53 with a single 277Y mutation. The TTT site matches the wild type p53 consensus at only 4/10 positions and is not recognised by wild type p53. 277Y mutations have been described in human tumours, and Ewing tumour cells expressing this mutant from the endogenous p53 locus selectively activate transcription from transfected luciferase reporters regulated by TTT-mutant p53 binding sites. p53 mutants with altered sequence specificity have potential advantages for cancer gene therapy: if used to activate transcription of conditionally toxic genes they would allow tumour-targeting by p53, which acts as a sensor for the malignant state, but place control over cell killing in the hands of the clinician. Rare tumours expressing such mutants from the endogenous p53 locus could be targeted directly with p53-regulated suicide vectors, but for most tumours both the p53 mutant and the reporter would need to be encoded by the virus.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; CHU Vaudois, Univ Hosp, Serv Otorhinolaryngol, CH-1011 Lausanne, Switzerland; St Anna Kinderspital, CCRI, A-1090 Vienna, Austria	Swiss Institute Experimental Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Saint Anna Children's Hospital	Iggo, R (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.		Kajava, Andrey V/E-1107-2014; Iggo, Richard/G-3546-2014	Kajava, Andrey V/0000-0002-2342-6886; Kovar, Heinrich/0000-0001-6873-9109; Estreicher, Anne/0000-0001-6828-2508				ABARZUA P, 1996, ONCOGENE, V13, P2447; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CULVER KW, 1992, SCIENCE, V256, P1500; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; EZZEDDINE ZD, 1991, NEW BIOL, V3, P608; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; FREIDLANDER P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KOVAR H, 1993, ONCOGENE, V8, P2683; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196	22	17	18	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					685	690		10.1038/sj.onc.1201568	http://dx.doi.org/10.1038/sj.onc.1201568			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482117				2022-12-25	WOS:000071816600016
J	Lannert, H; Gorgas, K; Meissner, I; Wieland, FT; Jeckel, D				Lannert, H; Gorgas, K; Meissner, I; Wieland, FT; Jeckel, D			Functional organization of the Golgi apparatus in glycosphingolipid biosynthesis - Lactosylceramide and subsequent glycosphingolipids are formed in the lumen of the late Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER GOLGI; ASPARAGINE-LINKED OLIGOSACCHARIDES; INTEGRAL MEMBRANE-PROTEIN; LOW-MOLECULAR-WEIGHT; BREFELDIN-A; GANGLIOSIDE BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; GLUCOSYLCERAMIDE SYNTHESIS; LYSOSOMAL-ENZYMES; PLASMA-MEMBRANE	Biosynthesis of plasma membrane sphingolipids involves the coordinate action of enzymes localized to individual compartments of the biosynthetic secretory pathway of proteins. These stations include the endoplasmic reticulum and the Golgi apparatus. Although a precise localization of all the enzymes that synthesize glycosphingolipids has not been achieved to date, it is assumed that the sequence of events in glycosphingolipid biosynthesis resembles that in glycoprotein biosynthesis, i.e. that early reactions occur in early stations (endoplasmic reticulum and cis/medial Golgi) of the pathway, and late reactions occur in late stations (trans Golgi/trans Golgi network). Using truncated analogues of ceramide and glucosylceramide that allow measurement of enzyme activities in intact membrane fractions, we have reinvestigated the localization of individual enzymes involved in glycosphingolipid biosynthesis and for the first time studied the localization of lactosylceramide synthase after partial separation of Golgi membranes as previously described (Trinchera, M., and Ghidoni, R. (1989) J. Biol. Chem. 264, 15766-15769). Here, we show that the reactions involved in higher glycosphingolipid biosynthesis, including lactosylceramide synthesis, all reside in the lumen of the late Golgi compartments from rat liver.	Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany; Univ Heidelberg, Inst Anat & Zellbiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Jeckel, D (corresponding author), Univ Heidelberg, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	CI1@ix.urz.uni-heidelberg.de						BARTLES JR, 1988, TRENDS BIOCHEM SCI, V13, P181, DOI 10.1016/0968-0004(88)90147-8; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BIEBERICH E, 1989, BIOL CHEM H-S, V370, P809, DOI 10.1515/bchm3.1989.370.2.809; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burger KNJ, 1996, J CELL BIOL, V133, P15, DOI 10.1083/jcb.133.1.15; CAMBRON LD, 1993, BIOCHEM BIOPH RES CO, V193, P585, DOI 10.1006/bbrc.1993.1664; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COLLINS RN, 1992, J BIOL CHEM, V267, P24906; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; DATTA SC, 1988, BIOCHEM BIOPH RES CO, V152, P155, DOI 10.1016/S0006-291X(88)80693-4; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1983, P NATL ACAD SCI-BIOL, V80, P3938, DOI 10.1073/pnas.80.13.3938; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; FRITZ VMR, 1995, J NEUROCHEM, V65, P1859; Fritz VMR, 1996, J NEUROCHEM, V67, P1393; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; HAKOMORI S, 1993, BIOCHEM SOC T, V21, P583, DOI 10.1042/bst0210583; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HARTELSCHENK S, 1991, EUR J BIOCHEM, V196, P349, DOI 10.1111/j.1432-1033.1991.tb15823.x; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; IBER H, 1991, EUR J BIOCHEM, V195, P115, DOI 10.1111/j.1432-1033.1991.tb15683.x; IBER H, 1992, J NEUROCHEM, V58, P1533, DOI 10.1111/j.1471-4159.1992.tb11375.x; IBER H, 1989, FEBS LETT, V248, P18, DOI 10.1016/0014-5793(89)80423-5; Jaskiewicz E, 1996, GLYCOCONJUGATE J, V13, P213, DOI 10.1007/BF00731496; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; KENDLER A, 1992, J NEUROSCI RES, V31, P205, DOI 10.1002/jnr.490310202; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOK JW, 1995, BIOCHEM J, V309, P905, DOI 10.1042/bj3090905; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANNERT H, 1994, FEBS LETT, V342, P91, DOI 10.1016/0014-5793(94)80591-1; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LUTZ MS, 1994, J BIOL CHEM, V269, P29227; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MARTINA JA, 1995, J NEUROCHEM, V64, P1274; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MOREAU P, 1993, BIOCHIM BIOPHYS ACTA, V1146, P9, DOI 10.1016/0005-2736(93)90332-T; Nakayama J, 1996, J BIOL CHEM, V271, P3684; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; POHLMANN R, 1982, J BIOL CHEM, V257, P5323; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; RANDERATH K, 1970, ANAL BIOCHEM, V34, P188, DOI 10.1016/0003-2697(70)90100-4; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; SCHNAAR R L, 1991, Glycobiology, V1, P477, DOI 10.1093/glycob/1.5.477; SCHULTE S, 1993, P NATL ACAD SCI USA, V90, P10265, DOI 10.1073/pnas.90.21.10265; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; SCHWEIZER A, 1994, J BIOL CHEM, V269, P4035; SHERWOOD AL, 1992, J BIOL CHEM, V267, P25328; SIMIONESCU N, 1976, J CELL BIOL, V70, P608, DOI 10.1083/jcb.70.3.608; TABAS I, 1979, J BIOL CHEM, V254, P1655; TRINCHERA M, 1990, J BIOL CHEM, V265, P18242; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; TRINCHERA M, 1991, BIOCHEMISTRY-US, V30, P2719, DOI 10.1021/bi00224a021; VAN HELVOORT A, 1994, J BIOL CHEM, V269, P1763; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VANHELVOORT A, 1995, FEBS LETT, V369, P18, DOI 10.1016/0014-5793(95)00616-H; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; WATTENBERG BW, 1990, J CELL BIOL, V111, P421, DOI 10.1083/jcb.111.2.421; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838	81	99	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2939	2946		10.1074/jbc.273.5.2939	http://dx.doi.org/10.1074/jbc.273.5.2939			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446606	hybrid			2022-12-25	WOS:000071736600061
J	Madamanchi, NR; Bukoski, RD; Runge, MS; Rao, GN				Madamanchi, NR; Bukoski, RD; Runge, MS; Rao, GN			Arachidonic acid activates Jun N-terminal kinase in vascular smooth muscle cells	ONCOGENE			English	Article						arachidonic acid; cytokines; growth factors; JNK1; signaling	CYTOSOLIC PHOSPHOLIPASE A(2); JNK/SAPK SIGNALING PATHWAY; BINDING PROTEINS RAC1; RAT MESANGIAL CELLS; C-JUN; MASTOCYTOMA-CELLS; GROWTH; LIPOXYGENASE; METABOLITES; EXPRESSION	We have previously demonstrated that arachidonic acid activates extracellular signal-regulated protein kinases (ERKs) group of mitogen-activated protein kinases (MAPKs) in vascular smooth muscle cells (VSMC). To understand the role of arachidonic acid in cellular signaling events, we have now studied its effect on jun N-terminal kinases (JNKs) group of MAPKs in VSMC. Arachidonic acid activated JNK1 in a time-and concentration-dependent manner with maximum effects at 10 min and 50 mu M. Induced activation of JNK1 by arachidonic acid is specific as other fatty acids such as linoleic and stearic acids had no such effect. Indomethacin and nordihydroguaiaretic acid (NDGA), potent inhibitors of the cyclooxygenase (COX) and the lipoxygenase (LOX)/monooxygenase (MOX) pathways, respectively, had no effect on arachidonic acid activation of JNK1 suggesting that the observed phenomenon is independent of its metabolism through either pathway. 12-hydroperoxyeicosatetraenoic acid (12-HpETE), the LOX metabolite of arachidonic acid significantly induced JNK1 activity. Protein kinase C (PKC) depletion by prolonged treatment of VSMC with phorbol 12-myristate 13-acetate (PMA) resulted in partial decrease in the responsiveness of JNK1 to arachidonic acid suggesting a role for both PKC-dependent and -independent mechanisms in the activation of JNK1 by this important fatty acid. On the other hand, the responsiveness of JNK1 to 12-HpETE was completely abolished in PKC-depleted cells, suggesting a major role for PKC in l2-HpETE-induced JNK1 activation. IL-1 beta and TNF-alpha activated JNK1 in a time-dependent manner with maximum effect at 10 min. Desensitization of JNK1 by arachidonic acid significantly reduced its responsiveness to both the cytokines. In addition, 4-bromophenacyl bromide (4-BPB), a potent and selective inhibitor of phospholipase A(2) (PLA(2)), significantly attenuated the cytokine-induced activation of JNK1. Together, these results show that (1) arachidonic acid and its LOX metabolite, 12-HpETE, activate JNK1 in VSMC, (2) PKC-dependent and -independent mechanisms play a role in the activation of JNK1 by arachidonic acid and 12-HpETE, and (3) arachidonic acid mediates, at least partially, the cytokine-induced activation of JNK1.	Univ Texas, Med Branch, Div Cardiol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sect Hypertens & Vasc Res, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Rao, GN (corresponding author), Univ Texas, Med Branch, Div Cardiol, Galveston, TX 77555 USA.			Madamanchi, Nageswara/0000-0003-0590-0908				ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P716, DOI 10.1073/pnas.90.2.716; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P4917, DOI 10.1073/pnas.90.11.4917; BUTCHER RD, 1993, CANCER RES, V53, P3405; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HANSSON A, 1986, BIOCHEM BIOPH RES CO, V134, P1215, DOI 10.1016/0006-291X(86)90380-3; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; JAATTELA M, 1995, ONCOGENE, V10, P2297; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIKKAWA U, 1988, PHILOS T ROY SOC B, V320, P313, DOI 10.1098/rstb.1988.0079; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; Knoepp SM, 1996, J BIOL CHEM, V271, P1678, DOI 10.1074/jbc.271.3.1678; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIN L, 1994, CIRC RES, V74, P197, DOI 10.1161/01.RES.74.2.197; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIU B, 1995, P NATL ACAD SCI USA, V92, P9323, DOI 10.1073/pnas.92.20.9323; Lu G, 1996, CIRC RES, V79, P611, DOI 10.1161/01.RES.79.3.611; MA YH, 1993, CIRC RES, V72, P126, DOI 10.1161/01.RES.72.1.126; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; NAKAO J, 1982, ATHEROSCLEROSIS, V44, P339, DOI 10.1016/0021-9150(82)90008-9; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; RALPH RK, 1990, CANCER LETT, V49, P181, DOI 10.1016/0304-3835(90)90156-R; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RAO GN, 1994, J BIOL CHEM, V269, P32586; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; Rizzo MT, 1996, BLOOD, V88, P3792, DOI 10.1182/blood.V88.10.3792.bloodjournal88103792; SAKATA A, 1987, J IMMUNOL, V138, P4353; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; SCHWARTZMAN ML, 1994, J BIOL CHEM, V269, P24321; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; YAN MH, 1994, NATURE, V372, P798; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	62	36	40	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					417	422		10.1038/sj.onc.1201551	http://dx.doi.org/10.1038/sj.onc.1201551			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467967				2022-12-25	WOS:000071582100014
J	Frederick, A; Rolfe, M; Chiu, MI				Frederick, A; Rolfe, M; Chiu, MI			The human UNP locus at 3p21.31 encodes two tissue-selective, cytoplasmic isoforms with deubiquitinating activity that have reduced expression in small cell lung carcinoma cell lines	ONCOGENE			English	Article						ubiquitin protease; small cell lung cancer; 3p21	FAT-FACETS GENE; PROTEIN-DEGRADATION; TRE ONCOGENE; ENZYME; CANCER; UBIQUITIN; PROTOONCOGENE; RECEPTORS; SUBUNIT; KINASE	The human Unp gene at 3p21.3 has sequence similarity to ubiquitin proteases and has been suggested to play a role in carcinogenesis of the lung (Gray et al., 1995). To investigate this possibility, we isolated cDNAs from several human tissue libraries and found evidence for two major isoforms, encoding proteins predicted to either contain an internal 47 amino acid segment or not. Both are functional in deubiquitination assays, and mutation of a critical conserved cysteine residue to alanine abolished activity. Unp specifies two closely-migrating transcripts whose relative abundance varies among human adult tissues. Antibodies specific to UNP confirm the presence of at least two endogenous protein isoforms of approximately 105-110 kDa in cell lysates, as predicted from the cDNA sequences. Cellular fractionation and immunocytochemistry revealed UNP expression localized primarily in the cytoplasm. When we examined a panel of lung-derived cell lines for both UNP mRNA and protein expression, we found reduced levels of UNP protein in all four small cell lung carcinoma cell lines tested. These findings directly contradict and offer alternative interpretations to a number of previously published observations on Unp.	Mitotix Inc, Cambridge, MA 02139 USA		Chiu, MI (corresponding author), Mitotix Inc, 1 Kendall Sq,Bldg 600, Cambridge, MA 02139 USA.							BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; GRAY DA, 1995, ONCOGENE, V10, P2179; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1994, ONCOGENE, V9, P611; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Jackers P, 1996, ONCOGENE, V13, P495; Kalderon D, 1996, CURR BIOL, V6, P662, DOI 10.1016/S0960-9822(09)00443-6; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NAKAMURA T, 1992, ONCOGENE, V7, P733; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Roche J, 1996, ONCOGENE, V12, P1289; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; TAM SW, 1994, CANCER RES, V54, P5816; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275; Zhu YA, 1997, J BIOL CHEM, V272, P51	37	46	49	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					153	165		10.1038/sj.onc.1201537	http://dx.doi.org/10.1038/sj.onc.1201537			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464533				2022-12-25	WOS:000071427100002
